﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Seddon, JM
   Reynolds, R
   Shah, HR
   Rosner, B
AF Seddon, Johanna M.
   Reynolds, Robyn
   Shah, Heeral R.
   Rosner, Bernard
TI Smoking, Dietary Betaine, Methionine, and Vitamin D in Monozygotic Twins
   with Discordant Macular Degeneration: Epigenetic Implications
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; FACTOR-H POLYMORPHISM; BODY-MASS INDEX;
   ENVIRONMENTAL ASSOCIATIONS; CIGARETTE-SMOKING; RISK-FACTORS; US TWIN;
   VARIANT; GENE; SUSCEPTIBILITY
AB Objective: We evaluated monozygotic twin pairs with discordant age-related macular degeneration (AMD) phenotypes to assess differences in behavioral and nutritional factors.
   Design: Case series.
   Participants: Caucasian male twin pairs from the United States Twin Study of Macular Degeneration.
   Methods: Twin pairs were genotyped to confirm monozygosity. Ocular characteristics were evaluated based on fundus photographs using the Wisconsin Grading System and a 5-grade Clinical Age-Related Maculopathy Staging System. We selected twin pairs discordant in each of the following phenotypic categories: Stage of AMD (n = 28), drusen area (n = 60), drusen size (n = 40), and increased pigment area (n = 56). The Wilcoxon signed-rank test and linear regression were used to assess associations between behavioral and nutritional characteristics and each phenotype within discordant twin pairs.
   Main Outcome Measures: Differences in smoking and dietary factors within twin pairs discordant for stage of AMD, drusen area, drusen size, and pigment area.
   Results: Representative fundus photographs depict the discordant phenotypes. Pack-years of smoking were higher for the twin with the more advanced stage of AMD (P = 0.05). Higher dietary intake of vitamin D was present in the twins with less severe AMD (P = 0.01) and smaller drusen size (P = 0.05) compared with co-twins, adjusted for smoking and age. Dietary intakes of betaine and methionine were significantly higher in the twin with lower stage of AMD (P = 0.009) and smaller drusen area (P = 0.03), respectively.
   Conclusions: The twin with the more advanced stage of AMD, larger drusen area, drusen size, and pigment area tended to be the heavier smoker. The twin with the earlier stage of AMD, smaller drusen size and area, and less pigment tended to have higher dietary vitamin D, betaine, or methionine intake. Results suggest that behavioral and nutritional factors associated with epigenetic mechanisms are involved in the etiology of AMD, in addition to genetic susceptibility.
C1 [Seddon, Johanna M.; Reynolds, Robyn] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Boston, MA 02111 USA.
   [Seddon, Johanna M.; Shah, Heeral R.] Tufts Med Ctr, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.; Shah, Heeral R.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Rosner, Bernard] Channing Labs, Boston, MA USA.
C3 Tufts Medical Center; Tufts Medical Center; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [R01-EY11309]; Massachusetts Lions Eye Research Fund Inc, New
   Bedford, Massachusetts; Research to Prevent Blindness, New York, NY;
   American Macular Degeneration Foundation, Northampton, Massachusetts; S.
   Elizabeth O'Brien Trust, Boston MA; Ophthalmic Epidemiology and Genetics
   Service, Tufts Medical Center, Tufts University School of Medicine,
   Boston, MA; NATIONAL EYE INSTITUTE [R01EY011309] Funding Source: NIH
   RePORTER
FX Supported by an anonymous donor to the research of JMS; National Eye
   Institute, National Institutes of Health, Bethesda, Maryland
   (R01-EY11309); Massachusetts Lions Eye Research Fund Inc, New Bedford,
   Massachusetts; Research to Prevent Blindness, New York, NY; The American
   Macular Degeneration Foundation, Northampton, Massachusetts; S.
   Elizabeth O'Brien Trust, Boston MA; Macular Degeneration Research Fund,
   Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center,
   Tufts University School of Medicine, Boston, MA.
CR AJANI UA, 1994, INVEST OPHTH VIS SCI, V35, P2725
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bailey LB, 2003, J NUTR, V133, p3748S, DOI 10.1093/jn/133.11.3748S
   CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338
   Chiuve SE, 2007, AM J CLIN NUTR, V86, P1073, DOI 10.1093/ajcn/86.4.1073
   Craig SAS, 2004, AM J CLIN NUTR, V80, P539
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706
   JABLON S, 1967, AM J HUM GENET, V19, P133
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Poulsen P, 2007, PEDIATR RES, V61, p38R, DOI 10.1203/pdr.0b013e31803c7b98
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wong AHC, 2005, HUM MOL GENET, V14, pR11, DOI 10.1093/hmg/ddi116
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zeisel SH, 2009, AM J CLIN NUTR, V89, pS1488, DOI 10.3945/ajcn.2009.27113B
NR 52
TC 76
Z9 79
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2011
VL 118
IS 7
BP 1386
EP 1394
DI 10.1016/j.ophtha.2010.12.020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 786JL
UT WOS:000292303000023
PM 21620475
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Told, R
   Reiter, GS
   Orsolya, A
   Mittermuller, TJ
   Eibenberger, K
   Schlanitz, FG
   Arikan, M
   Pollreisz, A
   Sacu, S
   Schmidt-Erfurth, U
AF Told, Reinhard
   Reiter, Gregor S.
   Orsolya, Angeli
   Mittermuller, Tamara J.
   Eibenberger, Katharina
   Schlanitz, Ferdinand G.
   Arikan, Mustafa
   Pollreisz, Andreas
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
TI SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY, FLUORESCEIN
   ANGIOGRAPHY, AND INDOCYANINE GREEN ANGIOGRAPHY COMPARISONS REVISITED
   Using a Novel Deep-Learning-Assisted Approach for Image Registration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE SSOCTA; ICGA; FA; nAMD; CNV; deep learning
ID CHOROIDAL NEOVASCULARIZATION; SPECTRAL-DOMAIN; OCT-ANGIOGRAPHY;
   VISUALIZATION; GUIDELINES; TYPE-1
AB Purpose: To compare area measurements between swept source optical coherence tomography angiography (SSOCTA), fluorescein angiography (FA), and indocyanine green angiography (ICGA) after applying a novel deep-learning-assisted algorithm for accurate image registration. Methods: We applied an algorithm for the segmentation of blood vessels in FA, ICGA, and SSOCTA images of 24 eyes with treatment-naive neovascular age-related macular degeneration. We trained a model based on U-Net and Mask R-CNN for each imaging modality using vessel annotations and junctions to estimate scaling, translation, and rotation. For fine-tuning of the registration, vessels and the elastix framework were used. Area, perimeter, and circularity measurements were performed manually using ImageJ. Results: Choroidal neovascularization lesion size, perimeter, and circularity delineations showed no significant difference between SSOCTA and ICGA (allP> 0.05). Choroidal neovascularization area showed excellent correlation between SSOCTA and ICGA (r = 0.992) and a Bland-Altman bias of -0.10 +/- 0.24 mm(2). There was no significant difference in foveal avascular zone size between SSOCTA and FA (P= 0.96) and an extremely small bias of 0.0004 +/- 0.04 mm(2)and excellent correlation (r = 0.933). Foveal avascular zone perimeter was not significantly different, but foveal avascular zone circularity was significantly different (P= 0.047), indicating that some small cavities or gaps may be missed leading to higher circularity values representing a more round-shaped foveal avascular zone in FA. Conclusion: We found no statistically significant differences between SSOCTA and FA and ICGA area measurements in patients with treatment-naive neovascular age-related macular degeneration after applying a deep-learning-assisted approach for image registration. These findings encourage a paradigm shift to using SSOCTA as a first-line diagnostic tool in neovascular age-related macular degeneration.
C1 [Told, Reinhard; Reiter, Gregor S.; Orsolya, Angeli; Mittermuller, Tamara J.; Eibenberger, Katharina; Schlanitz, Ferdinand G.; Pollreisz, Andreas; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Vienna Clin Trial Ctr VTC, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Orsolya, Angeli] Semmelweis Univ, Fac Med, Dept Ophthalmol, Budapest, Hungary.
   [Arikan, Mustafa] Med Univ Vienna, Dept Ophthal, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
C3 Medical University of Vienna; Semmelweis University; Medical University
   of Vienna
RP Told, R (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM reinhard.told@meduniwien.ac.at
RI Pollreisz, Andreas/AAJ-1538-2021
OI Told, Reinhard/0000-0003-2046-7081; Reiter, Gregor/0000-0001-7661-4015
CR AAO, 2015, AG REL MAC DEG PPP U
   Adhi M, 2013, OSLI RETINA, V44, pS40, DOI 10.3928/23258160-20131101-08
   Ang M, 2016, BRIT J OPHTHALMOL, V100, P1557, DOI 10.1136/bjophthalmol-2015-307706
   Babiuch AS, 2019, RETINA
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Chung CY, 2018, INT OPHTHALMOL, V38, P1119, DOI 10.1007/s10792-017-0570-y
   Cicinelli MV, 2019, RETINA
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Dollar K.H.G.G.P., 2017, IEEE I CONF COMP VIS, P2961, DOI [10.1109/CVPR.2014.81, DOI 10.1109/ICCV.2017.322]
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P3690, DOI 10.1167/iovs.17-21941
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Henke S, 2018, OPHTHALMOLOGE, V115, P941, DOI 10.1007/s00347-017-0605-9
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Klein S, 2010, IEEE T MED IMAGING, V29, P196, DOI 10.1109/TMI.2009.2035616
   LIM JI, 1995, INT OPHTHALMOL CLIN, V35, P59, DOI 10.1097/00004397-199503540-00006
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Peres MB, 2016, OSLI RETINA, V47, P1013, DOI 10.3928/23258160-20161031-05
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shamonin DP, 2014, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00050
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Told R, 2013, OPHTHALMOLOGE, V110, P960, DOI 10.1007/s00347-013-2813-2
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zhu LJ, 1998, OPTOMETRY VISION SCI, V75, P827, DOI 10.1097/00006324-199811000-00025
   Zotter S, 2011, OPT EXPRESS, V19, P1217, DOI 10.1364/OE.19.001217
NR 35
TC 10
Z9 11
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2020
VL 40
IS 10
BP 2010
EP 2017
DI 10.1097/IAE.0000000000002695
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NX9KP
UT WOS:000576020900027
PM 31800463
DA 2022-11-30
ER

PT J
AU Tuulonen, A
   Kataja, M
   Syvanen, U
   Miettunen, S
   Uusitalo, H
AF Tuulonen, Anja
   Kataja, Marko
   Syvanen, Ulla
   Miettunen, Sirpa
   Uusitalo, Hannu
TI Right services to right patients at right time in right setting in Tays
   Eye Centre
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE costs; efficiency; priority setting; segmentation; shared care;
   standardization
AB PurposeThe report describes the concepts behind procedures implemented in Tays Eye Centre to enable improved access to care and improved productivity.
   MethodsThe strategy was developed in 2009 after hospital district decided to construct a new eye hospital which was opened in 2012. The following principles were implemented: (i) identification of high-volume patient groups: the big four' eye diseases accounting for 70% of patient visits and costs: age-related macular degeneration (AMD), glaucoma, retinal diseases and cataract; (ii) stratification and prioritization of patient care based on risk of permanent visual disability; (iii) standardization of services for low-risk patients; (iv) maximization of productivity; and (v) shared care. The impact of the new strategy on access to care and productivity is reported for years 2011-2015.
   ResultsIn 2011-2015, the total number of services provided increased 46% while the work contribution increased 15%. The number of referrals increased 76% and the number of outpatient appointments increased 2.5-fold. Simultaneously, the number of delayed follow-up visits decreased to zero. Age-related macular degeneration (AMD) injections increased 1.8-fold. However, after 50% yearly increase in Age-related macular degeneration (AMD) injections, a plateau was reached in 2014 with a 3% decline in 2014-2015 with no changes in treatment indications. In the beginning of 2016, the number of injections has started to increase again (+9% compared to 2015). The total number of surgical procedures increased 98%. The annual number of cataract surgeries increased 64% and bilateral surgeries from 11% to 39%.
   ConclusionRevised operational concepts and new facilities together with a 15% increase in work contribution led to a 46% increase in overall productivity, improved access to care and the clearance of delayed services. Efforts continue to further refine cost-effective care and to define the appropriate levels of services.
C1 [Tuulonen, Anja; Kataja, Marko; Syvanen, Ulla; Miettunen, Sirpa; Uusitalo, Hannu] Tampere Univ Hosp, Tays Eye Ctr, POB 2000, FIN-33521 Tampere, Finland.
   [Uusitalo, Hannu] Univ Tampere, Dept Ophthalmol, Res & Dev Ctr Ophthalm Innovat SILK, Tampere, Finland.
C3 Tampere University; Tampere University Hospital; Tampere University
RP Tuulonen, A (通讯作者)，Tampere Univ Hosp, Tays Eye Ctr, POB 2000, FIN-33521 Tampere, Finland.
EM Anja.Tuulonen@pshp.fi
FU Competitive Research Funding of the Tampere University Hospital,
   Tampere, Finland [9P055]
FX This work was financially supported by the Competitive Research Funding
   of the Tampere University Hospital Grant 9P055, Tampere, Finland.
NR 0
TC 16
Z9 16
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2016
VL 94
IS 7
BP 730
EP 735
DI 10.1111/aos.13168
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EA5BI
UT WOS:000386631400047
PM 27422769
DA 2022-11-30
ER

PT J
AU Takayama, K
   Kaneko, H
   Kataoka, K
   Hattori, K
   Ra, E
   Tsunekawa, T
   Fukukita, H
   Haga, F
   Ito, Y
   Terasaki, H
AF Takayama, Kei
   Kaneko, Hiroki
   Kataoka, Keiko
   Hattori, Kyoko
   Ra, Eimei
   Tsunekawa, Taichi
   Fukukita, Hiroshi
   Haga, Fuminori
   Ito, Yasuki
   Terasaki, Hiroko
TI Comparison between 1-year outcomes of aflibercept with and without
   photodynamic therapy for polypoidal choroidal vasculopathy:
   Retrospective observation study
SO PLOS ONE
LA English
DT Article
ID SUBTENON TRIAMCINOLONE ACETONIDE; INTRAVITREAL RANIBIZUMAB; THICKNESS;
   COMBINATION; BEVACIZUMAB; MONOTHERAPY; INJECTIONS
AB Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like choroidal neovascularization and a branching vascular network. Intravitreal aflibercept injection (IAI) or photodynamic therapy (PDT) is used for treatment. We retrospectively compared the 1-year outcomes of IAI monotherapy and its combination with initial PDT for PCV. Twelve eyes with naive PCV received three IAIs and a single PDT after the first IAI and as needed injection (combination group); 11 eyes with naive PCV received three IAIs and as needed injections (IAI group). Significant improvements in visual acuity after 2 months and in CRT after 1 month were maintained at 12 months in both groups (both P < 0.05); groups did not differ significantly at any time point. CCT significantly reduced after 3 and 12 months in the combination group (both P < 0.05) but not in the IAI group. A mean of 3.7 +/- 0.9 and 5.6 +/- 2.0 injections was administered to the combination and IAI groups, respectively (P = 0.013). Within a 1-year period, combination therapy was found to yield similar visual acuity and retinal structure improvements and maintenance as IAI monotherapy while requiring fewer IAIs.
C1 [Takayama, Kei; Kaneko, Hiroki; Kataoka, Keiko; Hattori, Kyoko; Ra, Eimei; Tsunekawa, Taichi; Fukukita, Hiroshi; Haga, Fuminori; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
   [Takayama, Kei] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
C3 Nagoya University; National Defense Medical College - Japan
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Ito, Yasuki/M-4876-2014; Kaneko, Hiroki/AHA-2461-2022; Kaneko,
   Hiroki/O-7695-2015; Kataoka, Keiko/B-2806-2016
OI Ito, Yasuki/0000-0001-9219-9261; Kaneko, Hiroki/0000-0003-0731-6465;
   Kaneko, Hiroki/0000-0003-0731-6465; Takayama, Kei/0000-0002-1477-9014;
   Kataoka, Keiko/0000-0002-8795-6536
FU Chukyo longevity medical and promotion foundation [15H04994, 16K20313,
   17K16964]; Takeda Medical Research Foundation
FX The study was supported by a grant from the Grants-in-Aid for Scientific
   Research B (H. Terasaki, 15H04994), Grant-in-Aid for Young Scientists B
   (K. Kataoka, 16K20313), Grant-in-Aid for Young Scientists B (K.
   Takayama,17K16964), Chukyo longevity medical and promotion foundation
   (H. Kaneko), and Takeda Medical Research Foundation (H.Kaneko). There
   are no patents, products in development or marketed products to declare.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; The study was
   supported by a grant from the Grants-in-Aid for Scientific Research B
   (H. Terasaki, 15H04994), Grant-in-Aid for Young Scientists B (K.
   Kataoka, 16K20313), Grant-in-Aid for Young Scientists B (K.
   Takayama,17K16964), Chukyo longevity medical and promotion foundation
   (H. Kaneko), and Takeda Medical Research Foundation (H.Kaneko).
CR Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe
   Ho M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36870
   Imasawa M, 2009, JPN J OPHTHALMOL, V53, P588, DOI 10.1007/s10384-009-0732-1
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Ishikawa K, 2011, GRAEF ARCH CLIN EXP, V249, P273, DOI 10.1007/s00417-010-1548-x
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Kim H, 2015, GRAEFES ARCH CLIN EX
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumiya W, 2016, GRAEFES ARCH CLIN EX
   Nishide T, 2013, GRAEF ARCH CLIN EXP, V251, P2415, DOI 10.1007/s00417-013-2419-z
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189
   Sakurada Y, 2016, RETINA
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Takayama K, 2016, GRAEFES ARCH CLIN EX
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang WF, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004154
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 39
TC 15
Z9 16
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 3
PY 2017
VL 12
IS 5
AR e0176100
DI 10.1371/journal.pone.0176100
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ET9SB
UT WOS:000400647000035
PM 28467427
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Kubota, T
   Imasawa, M
   Mabuchi, F
   Tanabe, N
   Iijima, H
AF Sakurada, Yoichi
   Kubota, Takeo
   Imasawa, Mitsuhiro
   Mabuchi, Fumihiko
   Tanabe, Naohiko
   Iijima, Hiroyuki
TI ASSOCIATION OF LOC387715 A69S GENOTYPE WITH VISUAL PROGNOSIS AFTER
   PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; LOC387715 A69S; photodynamic therapy
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; GENE POLYMORPHISM; NO
   ASSOCIATION; LESION SIZE; VERTEPORFIN; CFH; NEOVASCULARIZATION;
   ANTIOXIDANTS; ZINC
AB Purpose: To investigate whether there is an association of the LOC387715 A69S genotype with visual prognosis after photodynamic therapy in eyes with polypoidal choroidal vasculopathy (PCV).
   Methods: Photodynamic therapy was repeated every 3 months until the disappearance of angiographic signs of active lesions in 71 eyes of 71 patients with PCV who were followed-up for at least 12 months. All patients were genotyped for LOC387715 A69S polymorphism (rs10490924, risk-allele T).
   Results: Although there was no statistically significant difference in the mean baseline visual acuity (P = 0.53) among the 3 genotypes, there was a statistically significant difference in the visual acuity both at the 12-month and final visits (P = 0.002 and P < 0.001, respectively) with the poorer acuity in patients with the higher "T-'' allele frequency. "T'' allele was more frequently observed in those with the recurred PCV lesions (odds ratio: 5.8, 95% confidential interval: 2.3-15.1, T vs. G).
   Conclusion: There is a pharmacogenetic association between the LOC387715 A69S variant and the long-term results after photodynamic therapy in eyes with PCV. The LOC387715 A69S genotype is of clinical importance to predict the visual prognosis after photodynamic therapy in eyes with PCV. These results should be confirmed or refuted by replication studies. RETINA 30:1616-1621, 2010
C1 [Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo Ku, Yamanashi 4093898, Japan.
   [Sakurada, Yoichi; Kubota, Takeo] Univ Yamanashi, Dept Epigenet Med, Fac Med, Yamanashi 4093898, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Iijima, H (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM hiijimar@yamanashi.ac.jp
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 28
TC 34
Z9 37
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2010
VL 30
IS 10
BP 1616
EP 1621
DI 10.1097/IAE.0b013e3181e587e3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 678HL
UT WOS:000284064600009
PM 20671585
DA 2022-11-30
ER

PT J
AU Chowdhury, AR
   Chatterjee, T
   Banerjee, S
AF Chowdhury, Amrita Roy
   Chatterjee, Tamojit
   Banerjee, Sreeparna
TI A Random Forest classifier-based approach in the detection of
   abnormalities in the retina
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Random Forest classifier; Naive Bayes classifier; Diabetic retinopathy
   images; Age-related macular degeneration; K-means clustering
ID DIABETIC-RETINOPATHY; AUTOMATIC DETECTION; SEGMENTATION; IMAGES;
   MICROANEURYSMS; LESIONS; DRUSEN
AB Classification of abnormalities from medical images using computer-based approaches is of growing interest in medical imaging. Timely detection of abnormalities due to diabetic retinopathy and age-related macular degeneration is required in order to prevent the prognosis of the disease. Computer-aided systems using machine learning are becoming interesting to ophthalmologists and researchers. We present here one such technique, the Random Forest classifier, to aid medical practitioners in accurate diagnosis of the diseases. A computer-aided diagnosis system is proposed for detecting retina abnormalities, which combines K means-based segmentation of the retina image, after due preprocessing, followed by machine learning techniques, using several low level and statistical features. Abnormalities in the retina that are classified are caused by age-related macular degeneration and diabetic retinopathy. Performance measures used in the analysis are accuracy, sensitivity, specificity, F-measure, and Mathew correlation coefficient. A comparison with another machine learning technique, the Naive Bayes classifier shows that the classification achieved by Random Forest classifier is 93.58% and it outperforms Naive Bayes classifier which yields an accuracy of 83.63%.
C1 [Chowdhury, Amrita Roy] Maulana Abul Kalam Azad Univ Technol, Comp Sci & Engn Dept, BF 142,Sect 1, Kolkata 700064, W Bengal, India.
   [Chatterjee, Tamojit] Calcutta Med Coll, Reg Inst Ophthalmol, Kolkata, W Bengal, India.
   [Banerjee, Sreeparna] Maulana Abul Kalam Azad Univ Technol, Dept Nat Sci & IEM, BF 142,Sect 1, Kolkata 700064, W Bengal, India.
C3 Maulana Abul Kalam Azad University of Technology; Maulana Abul Kalam
   Azad University of Technology
RP Banerjee, S (通讯作者)，Maulana Abul Kalam Azad Univ Technol, Dept Nat Sci & IEM, BF 142,Sect 1, Kolkata 700064, W Bengal, India.
EM amrita.me.cse@gmail.com; drtamojit@gmail.com; sreeparnab@hotmail.com
RI Chatterjee, Tamojit/ABC-2605-2021
FU Department of Biotechnology, Government of India
   [BT/PR4256/BID/7/393/2012]
FX The authors received support for this research from a grant from
   Department of Biotechnology, Government of India (No.
   BT/PR4256/BID/7/393/2012 dated 02.08.2012).
CR Abbadi NKE, 2013, IJCSI INT J COMPUTER, V10, P237
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Akila T., 2014, INT J EMERGING TECHN, V4, P24
   Akram MU, 2014, COMPUT BIOL MED, V45, P161, DOI 10.1016/j.compbiomed.2013.11.014
   American Academy of Ophthalmology, 2008, DIAB RET PREF PRACT
   Anitha J, 2013, NEURAL NETW WORLD, V23, P149, DOI 10.14311/NNW.2013.23.011
   [Anonymous], 1991, Ophthalmology, V98, P786
   BREIMAN L, 2001, MACH LEARN, V0045
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Decenciere E, 2013, IRBM, V34, P196, DOI 10.1016/j.irbm.2013.01.010
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Frame AJ, 1998, COMPUT BIOL MED, V28, P225, DOI 10.1016/S0010-4825(98)00011-0
   Jayakumari C., 2007, ASIAN J INFORM TECHN, V6, P842
   Jayanthi D., 2010, INT J COMPUT SCI INF, V7, P234
   Kauppi T, 2007, DIARETDB1 STANDARD D
   Kauppi T, 2007, DIARETDB0 STANDARD D
   Kavakiotis I, 2017, COMPUT STRUCT BIOTEC, V15, P104, DOI 10.1016/j.csbj.2016.12.005
   Lang A., 2013, P SPIE INT SOC OPTIC, V8869
   Liu DJ, 2009, HIS 2009: 2009 NINTH INTERNATIONAL CONFERENCE ON HYBRID INTELLIGENT SYSTEMS, VOL 1, PROCEEDINGS, P344, DOI 10.1109/HIS.2009.74
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Niemeijer M, 2009, IEEE T MED IMAGING, V28, P775, DOI 10.1109/TMI.2008.2012029
   Osareh A, 2003, BRIT J OPHTHALMOL, V87, P1220, DOI 10.1136/bjo.87.10.1220
   Rocha A, 2012, IEEE T BIO-MED ENG, V59, P2244, DOI 10.1109/TBME.2012.2201717
   Roychowdhury A, P INT C ADV COMP COM, V1, P168
   RoyChowdhury A, PREPRINT
   Roychowdhury S, 2014, IEEE J BIOMED HEALTH, V18, P1717, DOI 10.1109/JBHI.2013.2294635
   Saha R, 2016, LECT NOTES ARTIF INT, V9693, P734, DOI 10.1007/978-3-319-39384-1_65
   Saiprasad G, 2013, J DIGIT IMAGING, V26, P891, DOI 10.1007/s10278-012-9554-7
   Scherer R., 2012, MULTIPLE FUZZY CLASS, P228
   Sopharak A, 2008, COMPUT MED IMAG GRAP, V32, P720, DOI 10.1016/j.compmedimag.2008.08.009
   Spencer T, 1996, COMPUT BIOMED RES, V29, P284, DOI 10.1006/cbmr.1996.0021
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Welfer D, 2010, COMPUT BIOL MED, V40, P124, DOI 10.1016/j.compbiomed.2009.11.009
   Witten IH, 2011, MOR KAUF D, P3, DOI 10.1016/B978-0-12-374856-0.00001-8
   Zhang Z, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-80
NR 36
TC 30
Z9 31
U1 1
U2 18
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0140-0118
EI 1741-0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD JAN
PY 2019
VL 57
IS 1
BP 193
EP 203
DI 10.1007/s11517-018-1878-0
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Mathematical & Computational Biology;
   Medical Informatics
GA HF9FK
UT WOS:000454547600015
PM 30076537
DA 2022-11-30
ER

PT J
AU Akpek, EK
   Smith, RA
AF Akpek, Esen K.
   Smith, Roderick A.
TI Current Treatment Strategies for Age-Related Ocular Conditions
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID VEGF TRAP-EYE; INTRAOCULAR-PRESSURE; DRY EYE; TOPICAL CYCLOSPORINE;
   MACULAR DEGENERATION; RANIBIZUMAB; MEDICATIONS; AFLIBERCEPT;
   PROGRESSION; EFFICACY
AB Treatment for several major age-related ocular diseases has undergone a paradigm shift in recent years. Advances in basic science and clinical research have led to a more thorough understanding of the complex pathophysiology underlying common ocular diseases of aging, and to the development of highly effective new therapies for these conditions. The use of intraocular anti-angiogenic drugs, for example, has transformed the management of neovascular age-related macular degeneration and diabetic retinopathy. Many patients achieve impressive and durable gains in vision with these agents that were unattainable with older treatments. For glaucoma and dry eye disease, clinicians have a variety of pharmacologic and surgical options to choose from. However, significant challenges remain: not all patients respond to treatment, many older patients have difficulty complying with complex drug regimens, frequent office visits put a substantial strain on patients and caregivers, and therapies may cause unpleasant side effects. This article reviews the current treatment landscape for 4 major age-related ocular diseases: age-related macular degeneration, glaucoma, diabetic retinopathy, and dry eye.
C1 [Akpek, Esen K.] Johns Hopkins Sch Med, Wilmer Eye Inst, Ocular Surface Dis & Dry Eye Clin, Baltimore, MD USA.
   [Akpek, Esen K.] Johns Hopkins Sch Med, Wilmer Eye Inst, Div Cornea Cataract & External Dis, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Akpek, EK (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, Ocular Surface Dis & Dry Eye Clin, Baltimore, MD USA.
EM Esakpek@jhmi.edu
RI Akpek, Esen K/A-7054-2019
OI Akpek, Esen K/0000-0001-7700-207X
FU Allergan, Inc; Alcon
FX This activity is supported by an educational grant from Allergan, Inc.;
   Dr Akpek reports consultancy with Bausch & Lomb and research grants from
   Alcon and Allergan, Inc. Mr Smith has no relevant financial
   relationships with commercial interests to disclose.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Akpek EK, 2009, CORNEA, V28, P493, DOI 10.1097/ICO.0b013e31818d3846
   American Academy of Ophthalmology Cornea/External Disease Panel, 2011, DRY EYE SYNDR LTD RE
   [Anonymous], 2010, PREF PRACT PATT GUID
   Behrens A, 2006, CORNEA, V25, P900, DOI 10.1097/01.ico.0000214802.40313.fa
   Boland MV, 2012, AHRQ PUBLICATION, V12-EHC038-EF
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Caprioli J, 2008, OPHTHALMOLOGY, V115, P1123, DOI 10.1016/j.ophtha.2007.10.031
   Chang EE, 2012, OPHTHALMOLOGY, V119, P979, DOI 10.1016/j.ophtha.2011.11.003
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Friedman DS, 2007, INVEST OPHTH VIS SCI, V48, P5052, DOI 10.1167/iovs.07-0290
   Gedde SJ, 2009, AM J OPHTHALMOL, V148, P670, DOI 10.1016/j.ajo.2009.06.018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Jager RD, 2008, NEW ENGL J MED, V359, P1736
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lane SS, 2012, CORNEA, V31, P396, DOI 10.1097/ICO.0b013e318239aaea
   Lichter PR, 2001, OPHTHALMOLOGY, V108, P1943, DOI 10.1016/S0161-6420(01)00873-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maskin SL, 2010, CORNEA, V29, P1145, DOI 10.1097/ICO.0b013e3181d836f3
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Okeke CO, 2009, OPHTHALMOLOGY, V116, P2286, DOI 10.1016/j.ophtha.2009.05.026
   Perry HD, 2008, ARCH OPHTHALMOL-CHIC, V126, P1046, DOI 10.1001/archopht.126.8.1046
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Roberts CW, 2007, CORNEA, V26, P805, DOI 10.1097/ICO.0b013e318074e460
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sall K, 2000, OPHTHALMOLOGY, V107, P631, DOI 10.1016/S0161-6420(99)00176-1
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schulzer M, 1998, AM J OPHTHALMOL, V126, P487
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Singh K, 2011, ARCH OPHTHALMOL-CHIC, V129, P1080, DOI 10.1001/archophthalmol.2011.66
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Stewart WC, 2008, OPHTHALMOLOGY, V115, P1117, DOI 10.1016/j.ophtha.2007.10.004
NR 38
TC 6
Z9 6
U1 0
U2 13
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2013
VL 19
IS 5
SU S
BP S76
EP S84
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA 162VE
UT WOS:000320293300002
PM 23725499
DA 2022-11-30
ER

PT J
AU Simunovic, MP
AF Simunovic, Matthew P.
TI METAMORPHOPSIA AND ITS QUANTIFICATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE Amsler grid; epiretinal membrane; ForeseeHome device; macular
   degeneration; macular hole; metamorphopsia; preferential hyperacuity
   perimetry
ID PREFERENTIAL HYPERACUITY PERIMETER; OPTICAL COHERENCE TOMOGRAPHY;
   MACULAR PUCKER SURGERY; EPIRETINAL MEMBRANE; CHOROIDAL
   NEOVASCULARIZATION; RANDOMIZED-TRIAL; AMSLER CHART; FOVEAL PIT;
   FOLLOW-UP; EYE HOME
AB Purpose:To discuss and analyze the pathophysiologic mechanisms underlying metamorphopsia, the nature of adaptational mechanisms to this symptom, the development and clinical utility of tests of metamorphopsia, and to discuss the cost-effectiveness of screening populations at risk of exudative age-related macular degeneration using such tests.Methods:A primary literature search of PubMed and Web of Science was conducted for articles covering the mechanisms and/or tests of metamorphopsia.Results:A number of possible mechanisms of metamorphopsia were identified in addition to lateral photoreceptor displacement. These included disorders of image formation, changes in effective axial length, and pathology of the visual pathways and centers. The simplest tests of metamorphopsia rely on highly subjective assessments of regular patterns, as exemplified by Amsler grids. Such tests seem to offer poor sensitivity when used in real-life home-monitoring situations. Newer tests such as so-called preferential hyperacuity perimetry may offer more robust paradigms to assess the perception of distortion but suffer from an inherent disadvantage of being unable to precisely correlate function to structure. The recently published findings of the AREDS2-HOME trial suggest that formalized monitoring of visual function using a preferential hyperacuity perimetry task results in detection of exudative age-related macular degeneration when vision is better-preserved. A cost-benefit analysis using the data from the AREDS2-HOME trial suggests that the calculated cost of screening per letter gained/saved is $3,351 per year.Conclusion:Metamorphopsia is an important symptom in retinal disease and may occur through a variety of mechanisms. Although the human visual system is exquisitely sensitive to metamorphopsia, commonly used tests of this symptom may be unreliable in real-life conditions. Newer tests of metamorphopsia such as preferential hyperacuity perimetry may improve early detection rates of exudative age-related macular degeneration in at-risk populations.
C1 [Simunovic, Matthew P.] Univ Oxford, Nuffield Lab Ophthalmol, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England.
   [Simunovic, Matthew P.] Oxford Univ Hosp NHS Trust, Oxford Eye Hosp, Oxford, England.
   [Simunovic, Matthew P.] Moorfields Eye Hosp, London, England.
C3 University of Oxford; Oxford University Hospitals NHS Foundation Trust;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Simunovic, MP (通讯作者)，Univ Oxford, Oxford OX3 9DU, England.
EM mps23@cantab.net
RI Simunovic, Matthew/AAS-8946-2020
OI Simunovic, Matthew/0000-0003-0596-1356
CR Adams WJ, 2001, NAT NEUROSCI, V4, P1063, DOI 10.1038/nn729
   AJO A, 1947, ACTA PHYSIOL SCAND, V13, P130, DOI 10.1111/j.1748-1716.1947.tb00412.x
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   [Anonymous], 2001, OXFORD ENGLISH DICT
   Arimura E, 2007, ACTA OPHTHALMOL SCAN, V85, P55, DOI 10.1111/j.1600-0420.2006.00729.x
   Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Bouwens M, 2008, GRAEF ARCH CLIN EXP, V246, P1693, DOI 10.1007/s00417-008-0909-1
   Bouwens MD, 2003, GRAEF ARCH CLIN EXP, V241, P89, DOI 10.1007/s00417-002-0613-5
   CAMPOS EC, 1978, DOC OPHTHALMOL, V45, P381, DOI 10.1007/BF00161673
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Das R, 2009, RETINA, V29, P1013
   Dubis AM, 2009, BRIT J OPHTHALMOL, V93, P1223, DOI 10.1136/bjo.2008.150110
   Emsley HH, 1950, VISUAL OPTICS
   ENOCH JM, 1984, ARCH OPHTHALMOL-CHIC, V102, P1164, DOI 10.1001/archopht.1984.01040030942019
   ENOCH JM, 1995, OPHTHAL PHYSL OPT, V15, P339
   Faes L, 2014, EYE LOND
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Gibson JJ, 1933, J EXP PSYCHOL, V16, P1, DOI 10.1037/h0074626
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Gorrand JM, 1999, J OPT SOC AM A, V16, P1229, DOI 10.1364/JOSAA.16.001229
   HISADA H, 1992, Nippon Ganka Gakkai Zasshi, V96, P369
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   Jain A, 2013, OPHTHALMOL MANAGEMEN, V17, P26
   Kampmeier J, 2006, KLIN MONATSBL AUGENH, V223, P752, DOI 10.1055/s-2006-926880
   Klatt C, 2006, OPHTHALMOLOGE, V103, P945, DOI 10.1007/s00347-006-1381-0
   Knapp H., 1869, ARCH OPHTHALMOL-CHIC, V1, P377
   Kroyer K, 2010, INVEST OPHTH VIS SCI, V51, P6895, DOI 10.1167/iovs.10-5729
   LAKSHMINARAYANAN V, 1991, OPTOMETRY VISION SCI, V68, P942, DOI 10.1097/00006324-199112000-00005
   Legarreta JE, 2008, OPHTHAL SURG LAS IM, V39, pS43, DOI 10.3928/15428877-20080715-02
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Lotze RH, 1885, FORMS RECIPROCAL ACT
   Marmor MF, 2000, SURV OPHTHALMOL, V44, P343, DOI 10.1016/S0039-6257(99)00113-7
   Marmor MF, 2008, ARCH OPHTHALMOL-CHIC, V126, P907, DOI 10.1001/archopht.126.7.907
   Mathew R, 2012, EYE, V26, P389, DOI 10.1038/eye.2011.326
   Nijboer TCW, 2008, J NEUROPSYCHOL, V2, P287, DOI 10.1348/174866407X256563
   Nowomiejska K, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-13
   O'Leary DJ., 1985, CLIN EXPT OPTOMETRY, V68, P179
   Plenck JJ, 1782, DOCTRINA MORBIS OCUL
   POKORNY J, 1979, ARCH OPHTHALMOL-CHIC, V97, P867
   Reid T., 1764, INQUIRY HUMAN MIND P, P53
   Robison CD, 2011, BRIT J OPHTHALMOL, V95, P1419, DOI 10.1136/bjo.2010.194886
   Shinoda K, 2000, JPN J OPHTHALMOL, V44, P424, DOI 10.1016/S0021-5155(00)00173-8
   Simunovic MP, 2014, JAMA OPHTHALMOL, V132, P491, DOI 10.1001/jamaophthalmol.2013.5684
   SJOSTRAND J, 1986, ACTA OPHTHALMOL, V64, P425
   SMIDDY WE, 1989, ARCH OPHTHALMOL-CHIC, V107, P1469, DOI 10.1001/archopht.1989.01070020543036
   SNYDER AW, 1978, NATURE, V275, P127, DOI 10.1038/275127a0
   Ugarte M, 2005, BRIT J OPHTHALMOL, V89, P1576, DOI 10.1136/bjo.2005.077164
   Ugarte M, 2013, INDIAN J OPHTHALMOL, V61, P653, DOI 10.4103/0301-4738.117804
   Ugarte M, 2010, INVEST OPHTH VIS SCI, V51, P6894, DOI 10.1167/iovs.10-5483
   van Baelen M., 2005, INT C SER, V1282, P749
   Walls GL, 1937, ARCH OPHTHALMOL-CHIC, V18, P912
   Weinberger D, 1996, AM J OPHTHALMOL, V122, P864, DOI 10.1016/S0002-9394(14)70383-6
   WESTHEIMER G, 1975, INVEST OPHTH VISUAL, V14, P570
   Westheimer G, 2008, P ROY SOC B-BIOL SCI, V275, P2777, DOI 10.1098/rspb.2008.0712
   WILLIAMS RA, 1984, INVEST OPHTH VIS SCI, V25, P389
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 59
TC 23
Z9 23
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1285
EP 1291
DI 10.1097/IAE.0000000000000581
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600001
PM 26049620
DA 2022-11-30
ER

PT J
AU Krinsky, NI
   Landrum, JT
   Bone, RA
AF Krinsky, NI
   Landrum, JT
   Bone, RA
TI Biologic mechanisms of the protective role of lutein and zeaxanthin in
   the eye
SO ANNUAL REVIEW OF NUTRITION
LA English
DT Review
DE age-related macular degeneration; carotenoid action; macula; color;
   filter; antioxidant
ID MACULAR PIGMENT DENSITY; AGE-RELATED MACULOPATHY; CAROTENOID CATION
   RADICALS; OCULAR BLOOD-FLOW; BETA-CAROTENE; CATARACT-EXTRACTION;
   OPTICAL-DENSITY; DIETARY SUPPLEMENTATION; ABSOLUTE-CONFIGURATION; TISSUE
   CONCENTRATIONS
AB The macular region of the primate retina is yellow in color due to the presence of the macular pigment, composed of two dietary xanthophylls, lutein and zeaxanthin, and another xanthophyll, meso-zeaxanthin. The latter is presumably formed from either lutein or zeaxanthin in the retina. By absorbing blue-light, the macular pigment protects the underlying photoreceptor cell layer from light damage, possibly initiated by the formation of reactive oxygen species during a photosensitized reaction. There is ample epidemiological evidence that the amount of macular pigment is inversely associated with the incidence of age-related macular degeneration, an irreversible process that is the major cause of blindness in the elderly. The macular pigment can be increased in primates by either increasing the intake of foods that are rich in lutein and zeaxanthin, such as dark-green leafy vegetables, or by supplementation with lutein or zeaxanthin. Although increasing the intake of lutein or zeaxanthin might prove to be protective against the development of age-related macular degeneration, a causative relationship has yet to be experimentally demonstrated.
C1 Tufts Univ, Dept Biochem, Sch Med, Boston, MA 02111 USA.
   Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   Florida Int Univ, Dept Chem, Miami, FL 33199 USA.
   Florida Int Univ, Dept Phys, Miami, FL 33199 USA.
C3 Tufts University; Tufts University; United States Department of
   Agriculture (USDA); State University System of Florida; Florida
   International University; State University System of Florida; Florida
   International University
RP Krinsky, NI (通讯作者)，Tufts Univ, Dept Biochem, Sch Med, Boston, MA 02111 USA.
EM norman.krinsky@tufts.edu; landrumj@fiu.edu; bone@fiu.edu
RI Duarte, Graziela Biude Silva/Q-7728-2016
CR ABADI RV, 1992, INVEST OPHTH VIS SCI, V33, P494
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   ANDREWES AG, 1974, ACTA CHEM SCAND B, VB 28, P139, DOI 10.3891/acta.chem.scand.28b-0139
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1983, APPL OPTICS, V22, P775, DOI 10.1364/AO.22.000775
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BONE RA, 1984, VISION RES, V24, P103, DOI 10.1016/0042-6989(84)90094-4
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Bour LJ, 2002, INVEST OPHTH VIS SCI, V43, P1450
   BRINDLEY GS, 1952, J PHYSIOL-LONDON, V116, P350, DOI 10.1113/jphysiol.1952.sp004709
   Britton G., 1995, CAROTENOIDS B, V1B, P13
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   BUCHECKER R, 1978, HELV CHIM ACTA, V61, P1962, DOI 10.1002/hlca.19780610603
   Buchecker R, 1995, CAROTENOIDS, V1B, P63
   BURTON GW, 1989, J NUTR, V119, P109, DOI 10.1093/jn/119.1.109
   BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Compounds I. of M. (US) P. on D.A. and R., 2000, DIETARY REFERENCE IN
   COREN S, 1972, VISION RES, V12, P343, DOI 10.1016/0042-6989(72)90124-1
   CRAFT NE, 1992, METHOD ENZYMOL, V213, P185
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dagnelie G, 2000, Optometry, V71, P147
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   DEVRIES H, 1953, PHYSICA, V19, P419, DOI 10.1016/S0031-8914(53)80048-0
   DOREY CK, 1993, OPHTHALMOL VIS, V34, P1161
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922
   EAGLE RC, 1984, OPHTHALMOLOGY, V91, P613
   Eliel E.L., 1962, STEREOCHEMISTRY CARB
   ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x
   FOOTE CS, 1970, J AM CHEM SOC, V92, P5216, DOI 10.1021/ja00720a036
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gao G, 1996, J PHYS CHEM-US, V100, P5362, DOI 10.1021/jp9529230
   Gellermann W, 2002, OPT LETT, V27, P833, DOI 10.1364/OL.27.000833
   Goodman GE, 1998, CANCER EPIDEM BIOMAR, V7, P405
   Goodwin T., 1984, BIOCH CAROTENOIDS
   Goodwin T, 1980, BIOGEOCHEMISTRY CARO, P346
   GRANT JL, 1988, J AM CHEM SOC, V110, P2151, DOI 10.1021/ja00215a025
   Gruszecki WI, 1999, Z NATURFORSCH C, V54, P517
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   HALLIWELL B, 1995, FREE RADICAL BIO MED, V18, P125, DOI 10.1016/0891-5849(95)91457-3
   HAM WT, 1983, J OCCUP ENVIRON MED, V25, P101
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HANKINSON SE, 1992, BMJ-BRIT MED J, V305, P335, DOI 10.1136/bmj.305.6849.335
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   HILL TJ, 1995, J AM CHEM SOC, V117, P8322, DOI 10.1021/ja00137a004
   Jacques PF, 1999, INT J VITAM NUTR RES, V69, P198, DOI 10.1024/0300-9831.69.3.198
   JAFFE GJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P445
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   KAPLAN LA, 1990, CLIN PHYSIOL BIOCH, V8, P1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1992, ANAL CHEM, V64, P2111, DOI 10.1021/ac00042a016
   KHALED M, 1990, J PHYS CHEM-US, V94, P5164, DOI 10.1021/j100375a072
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Kohler B.E., 1995, CAROTENOIDS, V1B, P1
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Landrum JT, 1999, METHOD ENZYMOL, V299, P457
   LEMARCHAND L, 1995, INT J CANCER, V63, P18, DOI 10.1002/ijc.2910630105
   Liaaen-Jensen S., 1971, CAROTENOIDS, P61
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Mares-Perlman J.A., 1999, CRC MOD NUT, P181
   Mares-Perlman JA, 1999, AM J CLIN NUTR, V70, P431
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Martin HD, 1999, PURE APPL CHEM, V71, P2253, DOI 10.1351/pac199971122253
   McLellan JS, 2002, NATURE, V417, P174, DOI 10.1038/417174a
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Moreland JD, 1998, VISION RES, V38, P3241, DOI 10.1016/S0042-6989(98)00013-3
   Mortensen A, 2001, ARCH BIOCHEM BIOPHYS, V385, P13, DOI 10.1006/abbi.2000.2172
   NAYLOR EJ, 1954, J PHYSIOL-LONDON, V124, P543, DOI 10.1113/jphysiol.1954.sp005127
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   NORREN DV, 1974, VISION RES, V14, P1237, DOI 10.1016/0042-6989(74)90222-3
   NSOUKPOEKOSSI CN, 1988, BIOCHIM BIOPHYS ACTA, V940, P255, DOI 10.1016/0005-2736(88)90200-3
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   Okulski W, 2000, BBA-BIOMEMBRANES, V1509, P216, DOI 10.1016/S0005-2736(00)00298-4
   PALOZZA P, 1992, METHOD ENZYMOL, V213, P403
   Pauleikhoff D, 2001, OPHTHALMOLOGE, V98, P511, DOI 10.1007/s003470170110
   PEASE PL, 1983, AM J OPTOM PHYS OPT, V60, P667
   Pryor WA, 2000, NUTR REV, V58, P39
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Rautalahti M, 1997, CANCER LETT, V114, P235, DOI 10.1016/S0304-3835(97)04672-7
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   Ritenbaugh C, 1996, CANCER EPIDEM BIOMAR, V5, P907
   RUDDOCK K. H., 1963, VISION RES, V3, P417, DOI 10.1016/0042-6989(63)90093-2
   RUTTIMANN A, 1983, J HIGH RES CHROMATOG, V6, P612, DOI 10.1002/jhrc.1240061105
   SAMPLE PA, 1991, ACTA OPHTHALMOL, V69, P310
   SAMPLE PA, 1988, INVEST OPHTH VIS SCI, V29, P1306
   SCHALCH W, 1999, CRC MOD NUT, P215
   SCHIEDT K, 1991, PURE APPL CHEM, V63, P89, DOI 10.1351/pac199163010089
   SCHIEDT K, 1985, PURE APPL CHEM, V57, P685, DOI 10.1351/pac198557050685
   SCHIEDT K, 1989, CAROTENOIDS, P247
   SCHMITZ HH, 1993, METHOD ENZYMOL, V214, P102
   SCHMITZ HH, 1991, J NUTR, V121, P1613, DOI 10.1093/jn/121.10.1613
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   STRAUB O, 1987, KEY CAROTENOIDS
   Surai PF, 2000, EUR J CLIN NUTR, V54, P298, DOI 10.1038/sj.ejcn.1600939
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tabunoki H, 2002, J BIOL CHEM, V277, P32133, DOI 10.1074/jbc.M204507200
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Truscott TG, 1996, J PHOTOCH PHOTOBIO B, V35, P233, DOI 10.1016/S1011-1344(96)07299-5
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VANNORREN D, 1986, VISION RES, V26, P313, DOI 10.1016/0042-6989(86)90028-3
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   WALD G., 1949, DOCUMENTA OPHTHALMOL, V3, P94, DOI 10.1007/BF00162600
   WEALE RA, 1953, BRIT J OPHTHALMOL, V37, P148, DOI 10.1136/bjo.37.3.148
   Weedon B. C. L., 1971, CAROTENOIDS, P267
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P33, DOI 10.1016/S0304-4165(97)00006-8
   WOOTEN BR, 1973, J GEN PHYSIOL, V61, P125, DOI 10.1085/jgp.61.2.125
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
   Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149
   Zechmeister L, 1962, CIS T ISOMERIC CAROT, P63, DOI [10.1007/978-3-7091-5548-6_7, DOI 10.1007/978-3-7091-5548-6_7]
NR 165
TC 571
Z9 626
U1 2
U2 122
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0199-9885
EI 1545-4312
J9 ANNU REV NUTR
JI Annu. Rev. Nutr.
PY 2003
VL 23
BP 171
EP 201
DI 10.1146/annurev.nutr.23.011702.073307
PG 31
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 717ML
UT WOS:000185093400010
PM 12626691
DA 2022-11-30
ER

PT J
AU Cruz-Gonzalez, F
   Cabrillo-Estevez, L
   Lopez-Valverde, G
   Cieza-Borrella, C
   Hernandez-Galilea, E
   Gonzalez-Sarmiento, R
AF Cruz-Gonzalez, Fernando
   Cabrillo-Estevez, Lucia
   Lopez-Valverde, Gloria
   Cieza-Borrella, Clara
   Hernandez-Galilea, Emiliano
   Gonzalez-Sarmiento, Rogelio
TI Predictive value of VEGF A and VEGFR2 polymorphisms in the response to
   intravitreal ranibizumab treatment for wet AMD
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; Antiangiogenic treatment; Genetics; VEGFA; VEGFR; Polymorphisms
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; ASSOCIATION; GENE;
   ANGIOGENESIS; KDR
AB To determine whether gene polymorphisms of the vascular endothelial growth factor A (VEGF A) and its receptor (VEGFR) influence the response to a variable-dosing treatment regimen with ranibizumab for age-related macular degeneration.
   This prospective cohort study included 94 patients (94 eyes) with exudative age-related macular degeneration (AMD) treated with ranibizumab. Patients underwent a 1-year treatment as in the Study of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (SUSTAIN). Injections were administered monthly during 3 months to all the patients diagnosed of neovascular AMD; reinjections were made when a patient lost 5 letters on the Early Treatment Diabetic Retinopathy Study chart or gained 100 mu m in central subfield retinal thickness measured by OCT. Genotypes (VEGF A (rs 699947, rs833061) and VEGFR (rs 2071559)) were analyzed using TaqMan probes. Best-corrected visual acuity (BCVA), subjective improvement, and macular thickness measured with OCT values were compared with VEGF A and VEGFR genotypes. Multiple regression analysis was used to assess the statistical significance.
   We found statistically significant differences in allelic distribution of VEGF A rs833061 polymorphism in relation with the response to intravitreal ranibizumab regarding to visual acuity improvement [p = 0,.34; OR: 1.619 (1.098-2.386)]. Patients carrying "protector" genotype CC had higher probability of best corrected visual acuity improvement. When we analyzed VEGF A rs699947 polymorphism we found that patients expressing AA genotype had a higher chance of increasing their best corrected visual acuity [p:0,022; OR 1,532 (1,015-2,313)]. We did not find statistically significant differences reagarding VEGFR rs2071559 polymorphism and treatment response.
   Polymorphisms of VEGF A seem to influence the different response to antiangiogenic treatment in patients with AMD in our population, although further investigation is needed to know the mechanisms of this relationship.
C1 [Cruz-Gonzalez, Fernando; Cabrillo-Estevez, Lucia; Lopez-Valverde, Gloria; Hernandez-Galilea, Emiliano] Hosp Univ Salamanca, Dept Oftalmol, Salamanca, Spain.
   [Cieza-Borrella, Clara] Univ Salamanca, Dept Med, Unidad Med Mol, E-37008 Salamanca, Spain.
   [Cruz-Gonzalez, Fernando; Gonzalez-Sarmiento, Rogelio] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37008 Salamanca, Spain.
   [Cruz-Gonzalez, Fernando] Complejo Asistencial Univ Salamanca, Dept Oftalmol, Salamanca 37007, Spain.
C3 University of Salamanca; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer
   de Salamanca (IBMCC); University of Salamanca
RP Cruz-Gonzalez, F (通讯作者)，Complejo Asistencial Univ Salamanca, Dept Oftalmol, Paseo San Vicente 58, Salamanca 37007, Spain.
EM cruzgonzalez.fernando@gmail.com
RI Gonzalez-Sarmiento, Rogelio/V-5526-2019
OI Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Cieza-Borrella,
   Clara/0000-0003-2739-1040
CR Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Chang W, 2013, MOL VIS, V19, P702
   Pau ECD, 2009, CANCER-AM CANCER SOC, V115, P1701, DOI 10.1002/cncr.24193
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Forsti A, 2007, BREAST CANCER RES TR, V101, P83, DOI 10.1007/s10549-006-9265-1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P167
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Pabst S, 2010, CHEST, V137, P156, DOI 10.1378/chest.09-1003
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Stevens A, 2003, CANCER RES, V63, P812
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Veikkola T, 2000, CANCER RES, V60, P203
   Wang Y, 2007, J AM COLL CARDIOL, V50, P760, DOI 10.1016/j.jacc.2007.04.074
   Zeng GC, 2000, CANCER RES, V60, P6670
NR 20
TC 19
Z9 21
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2014
VL 252
IS 3
BP 469
EP 475
DI 10.1007/s00417-014-2585-7
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC5DM
UT WOS:000332541100014
PM 24522370
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Lee, DW
   Kim, CG
   Kim, JW
AF Kim, Jae Hui
   Chang, Young Suk
   Lee, Dong Won
   Kim, Chul Gu
   Kim, Jong Woo
TI Quantification of retinal changes after resolution of submacular
   hemorrhage secondary to polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Hemorrhage; Polypoidal choroidal
   vasculopathy; Outer nuclear layer; Photoreceptor layer
ID SUBRETINAL DRUSENOID DEPOSITS; MACULAR DEGENERATION; RETICULAR
   PSEUDODRUSEN; VISUAL IMPAIRMENT; PREVALENCE; EYES; PROGNOSIS; THICKNESS;
   BLINDNESS; THERAPY
AB To evaluate changes in the thickness of retinal layers after resolution of submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV).
   Retrospective, observational study.
   This study included 21 patients (21 eyes) who had been diagnosed with submacular hemorrhage secondary to PCV and treated using anti-vascular endothelial growth factor monotherapy. After the hemorrhage had resolved, the thicknesses of the retinal layers were measured on horizontal- and vertical-crosshair optical coherence tomography scan images. The thickness of each layer in the region affected by the hemorrhage was compared with the thickness of the layer in the corresponding region in the fellow eye, as well as between an unaffected region in the eye with the hemorrhage and the corresponding region in the fellow eye.
   Optical coherence tomography (OCT) was performed 5.5 +/- 2.8 months after diagnosis. In the horizontal OCT images, the outer plexiform layer (OPL) and outer nuclear layer (ONL) + photoreceptor layer (PRL) were significantly thinner in the affected region than in the corresponding region (P = 0.019 and P < 0.001, respectively). In the vertical OCT image, the ONL+PRL was significantly thinner in the affected region than in the corresponding region (P < 0.001). The thickness of the retinal layer in the unaffected region did not differ from that in the corresponding region of the fellow eye.
   The significant thinning of the outer retinal layers in the regions affected by submacular hemorrhage suggests that the hemorrhage induces marked damage in the outer retinal layers, explaining the poor visual prognosis of submacular hemorrhage.
C1 [Kim, Jae Hui; Lee, Dong Won; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Coll Med, Dept Ophthalmol, Kims Eye Hosp, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
   [Chang, Young Suk] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Coll Med, Dept Ophthalmol, Kims Eye Hosp, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
OI Lee, Darrall/0000-0002-6990-4441
FU Kim's Eye Hospital Research Center
FX This study received financial support from Kim's Eye Hospital Research
   Center for English proofreading.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bae K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168474
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Duan XR, 2010, OPHTHALMOLOGY, V117, P1585, DOI 10.1016/j.ophtha.2009.12.036
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kim JH, 2016, JPN J OPHTHALMOL, V60, P466, DOI 10.1007/s10384-016-0466-9
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim KM, 2016, SEMIN OPHTHALMOL, P1
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Pilat AV, 2014, BRIT J OPHTHALMOL, V98, P941, DOI 10.1136/bjophthalmol-2013-303119
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Terasaki H, 1997, AM J OPHTHALMOL, V123, P207, DOI 10.1016/S0002-9394(14)71037-2
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ueda-Arakawa N, 2012, JPN J OPHTHALMOL, V56, P589, DOI 10.1007/s10384-012-0191-y
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 36
TC 10
Z9 10
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2018
VL 62
IS 1
BP 54
EP 62
DI 10.1007/s10384-017-0549-2
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FS0JF
UT WOS:000419459500006
PM 29188462
DA 2022-11-30
ER

PT J
AU Pece, A
   Vadala, M
   Manzi, R
   Calori, G
AF Pece, A
   Vadala, M
   Manzi, R
   Calori, G
TI Back pain after photodynamic therapy with verteporfin
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INFUSION; CHEST
AB PURPOSE: To report the incidence of back pain after photodynamic therapy, which suggests methods for prevention that are related to its pathogenesis.
   DESIGN: Retrospective case series.
   METHODS: We retrospectively observed 548 patients who had undergone photodynamic therapy with verteporfin.
   RESULTS: Of 548 patients at the first treatment, 14 patients (2.6%) experienced pain during the infusion. Eleven patients were being treated for age-related macular degeneration; their mean age was 81 years, which significantly differed from the mean age of the overall age-related macular degeneration group (P =.003). The pain was mild in eight patients, moderate in four patients, and severe in two patients, with dyspnea and precordial pain. Five of the 14 patients had further courses of photodynamic therapy. After being treated prophylactically 60 minutes before photodynamic therapy, only one patient reported further mild pain.
   CONCLUSIONS: The biologic mechanisms of back pain may involve a high level of circulating thromboxanes that are induced by the liposomal composition of verteporfin. Prevention may include hydration, nonsteroidal anti,inflammatory drugs, and halving the infusion rate.
C1 Melegnano Hosp, Dept Ophthalmol, I-20077 Milan, Italy.
   Univ Palermo, NOOP Dept, Sez Oftalmol, Palermo, Italy.
   Ist Tumori, Anesthesiol ICU Dept, Milan, Italy.
   Osped San Raffaele, Clin Res Unit, Milan, Italy.
C3 University of Palermo; Vita-Salute San Raffaele University; IRCCS
   Ospedale San Raffaele
RP Pece, A (通讯作者)，Melegnano Hosp, Dept Ophthalmol, Via Pandina 1, I-20077 Milan, Italy.
EM pece.retina@mclink.it
RI Vadalà, Maria/AAT-1084-2021
OI VADALA', Maria/0000-0002-2726-698X
CR Borodoker N, 2002, AM J OPHTHALMOL, V133, P211, DOI 10.1016/S0002-9394(01)01341-1
   Cahill MT, 2002, AM J OPHTHALMOL, V134, P281, DOI 10.1016/S0002-9394(02)01475-7
   Hui YF, 2000, ANN PHARMACOTHER, V34, P810, DOI 10.1345/aph.19236
   LONGWORTH KE, 1992, J APPL PHYSIOL, V73, P2608, DOI 10.1152/jappl.1992.73.6.2608
   Szebeni J, 2000, AM J PHYSIOL-HEART C, V279, pH1319, DOI 10.1152/ajpheart.2000.279.3.H1319
   Walsh TJ, 2001, ANTIMICROB AGENTS CH, V45, P3487, DOI 10.1128/AAC.45.12.3487-3496.2001
   2004, RETINA, V24, P1
NR 7
TC 3
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2006
VL 141
IS 3
BP 593
EP 594
DI 10.1016/j.ajo.2005.10.042
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 022LS
UT WOS:000236057900039
PM 16490525
DA 2022-11-30
ER

PT J
AU Jeong, SY
   Sagong, M
AF Jeong, Seongyong
   Sagong, Min
TI Short-term efficacy of intravitreal aflibercept depending on
   angiographic classification of polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; VASCULAR HYPERPERMEABILITY; CLINICOPATHOLOGICAL
   CORRELATION; PHOTODYNAMIC THERAPY; OUTCOMES; RANIBIZUMAB; SUBTYPES;
   ARMS2
AB Background/aims To compare the short-term efficacy of intravitreal aflibercept treatment according to the subtypes of polypoidal choroidal vasculopathy (PCV) based on indocyanine green angiography (ICGA).
   Methods Twenty-nine patients (29 eyes) with treatment-naive subfoveal PCV were consecutively enrolled in this institutional study. The subjects were classified into two subtypes (type 1, polypoidal choroidal neovascularisation (CNV), 16 eyes; and type 2, idiopathic PCV, 13 eyes) based on the presence or absence of both feeder and draining vessels on ICGA. Intravitreal aflibercept was administered at baseline and at 1, 2 and 4 months. The primary outcome was the polyp regression percentage after 3 monthly injections. Changes in the best-corrected visual acuity and subfoveal choroidal thickness (CT) were evaluated at 3 and 6 months.
   Results The complete polyp regression percentage was higher in type 1 than type 2 patients after 3 monthly injections (81% vs 30%, p=0.008). Type 1 patients showed better visual improvement at 3 months (-0.34 vs -0.08 logarithm of the minimum angle of resolution (logMAR), p=0.050) and 6 months (-0.30 vs -0.10 logMAR, p=0.168) than type 2 patients. Although subfoveal CT was significantly decreased after injections in both groups, type 2 patients with a thicker choroid at baseline showed a greater decrease than type 1 patients (p=0.032).
   Conclusions There was a difference in early treatment response with aflibercept between two subtypes of PCV. Type 1 polypoidal CNV showed better visual improvement with a higher percentage of polyp regression than type 2 idiopathic PCV.
C1 [Jeong, Seongyong; Sagong, Min] Yeungnam Univ, Coll Med, Dept Ophthalmol, 170 Hyunchungro, Daegu 42415, South Korea.
C3 Yeungnam University
RP Sagong, M (通讯作者)，Yeungnam Univ, Coll Med, Dept Ophthalmol, 170 Hyunchungro, Daegu 42415, South Korea.
EM msagong@ynu.ac.kr
OI Jeong, SeongYong/0000-0001-9175-9642
FU Yeungnam University
FX This study was funded by the Yeungnam University Research Grant 2015.
CR Bessho H, 2011, MOL VIS, V17, P977
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JH, 2016, BR J OPHTHALMOL
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Mori K, 2005, RETINA-J RET VIT DIS, V25, P430, DOI 10.1097/00006982-200506000-00006
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 29
TC 20
Z9 21
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2017
VL 101
IS 6
BP 758
EP 763
DI 10.1136/bjophthalmol-2016-309144
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2ZG
UT WOS:000402363900014
PM 27597740
DA 2022-11-30
ER

PT J
AU Tanaka, K
   Mori, R
   Kawamura, A
   Nakashizuka, H
   Wakatsuki, Y
   Yuzawa, M
AF Tanaka, Koji
   Mori, Ryusaburo
   Kawamura, Akiyuki
   Nakashizuka, Hiroyuki
   Wakatsuki, Yu
   Yuzawa, Mitsuko
TI Comparison of OCT angiography and indocyanine green angiographic
   findings with subtypes of polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CLASSIFICATION; ASSOCIATIONS; GENOTYPES
AB Purpose To compare the findings of optical coherence tomography angiography (OCTA) with indocyanine green angiography (ICGA) in polypoidal choroidal vasculopathy (PCV) that was divided into two types: polypoidal choroidal neovascularisation (CNV) and typical PCV (type 2 PCV).
   Methods We studied a retrospective case series of 32 patients with treatment-naive PCV (24 men, eight women; mean age 65.4 years). PCV was categorised into polypoidal CNV (type 1 PCV) and type 2 PCV based on ICGA findings. OCTA was performed using the RTVue XR Avanti. Macular cubes (3x3 or 6x6 mm) were acquired. To evaluate the locations of polyps and branched vessel networks (BVNs), we used B-mode scan.
   Results OCTA clearly depicted only 17% of the type 1 PCV polyps and 46% of the type 2 PCV polyps which were detectable by ICGA. All type 1 PCV polyps detectable by OCTA were located just beneath the retinal pigment epithelium (RPE). On the other hand, type 2 PCV polyps were detected in various locations. All BVNs of type 1 PCV were located between the RPE and Bruch's membrane on OCTA images. However, the BVNs in type 2 PCV were located mainly under the RPE, though some were located in the choroid.
   Conclusions Polyps of type 1 PCV were more difficult to detect with OCTA than those of type 2 PCV. Polyps of type 1 PCV were located just beneath the RPE. The BVNs of type 1 PCV were located between the RPE and Bruch's membrane.
C1 [Tanaka, Koji; Mori, Ryusaburo; Kawamura, Akiyuki; Nakashizuka, Hiroyuki; Wakatsuki, Yu; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Nihon University
RP Mori, R (通讯作者)，Nihon Univ, Sch Med, Div Ophthalmol,Dept Visual Sci, Chiyoda Ku, 1-6 Kandasurugadai, Tokyo 1018309, Japan.
EM jikokoji.mori@gmail.com
RI Tanaka, Koji/H-3119-2019
OI Tanaka, Koji/0000-0003-3323-4148
FU Division of Companion Diagnostics, Department of Pathology and
   Microbiology, Nihon University School of Medicine
FX This work was funded in part by the Division of Companion Diagnostics,
   Department of Pathology and Microbiology, Nihon University School of
   Medicine.
CR Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 18
TC 46
Z9 52
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2017
VL 101
IS 1
BP 51
EP 55
DI 10.1136/bjophthalmol-2016-309264
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ6BP
UT WOS:000393303800010
PM 27913447
DA 2022-11-30
ER

PT J
AU Hu, J
   Leng, X
   Hu, YJ
   Atik, A
   Song, X
   Li, ZX
   Liu, YH
   Lu, L
AF Hu, Jie
   Leng, Xuan
   Hu, Yijun
   Atik, Alp
   Song, Xin
   Li, Zhixi
   Liu, Yuhua
   Lu, Lin
TI The Features of Inflammation Factors Concentrations in Aqueous Humor of
   Polypoidal Choroidal Vasculopathy
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE INJECTION;
   COMBINED PHOTODYNAMIC THERAPY; EPITHELIUM-DERIVED FACTOR;
   TUMOR-NECROSIS-FACTOR; MACULAR DEGENERATION; NEOVASCULARIZATION
   SECONDARY; PATHOLOGICAL MYOPIA; RISK-FACTORS; MEMBRANES
AB Purpose
   To investigate the cytokine concentrations in the aqueous humor of patients with refractory polypoidal choroidal vasculopathy (PCV).
   Methods
   Three separate groups of patients were studied refractory PCV (Group A, 41 eyes), stable PCV (Group B, 39 eyes) and senile cataract (Group C, 44 eyes). Aqueous humor samples were collected at two time points for Groups A and B before the first intravitreal ranibizumab injection and before the last injection. Aqueous humor samples were collected prior to phacoemulsification in Group C. The cytokine concentrations of interleukin 2, 6, and 8 (IL-2, IL-6, and IL-8), tumor necrosis factor a (TNF-a), monocyte chemotactic protein 1 (MCP-1), and vascular endothelial growth factor (VEGF) were measured by cytometric bead array and flow cytometry.
   Results
   Before the first treatment, the MCP-1, VEGF, and TNF-a levels in Group A were significantly higher than those in Group C (P < 0.05), and the MCP-1 and VEGF levels in Group A were significantly higher than those in Group B (P < 0.05). Significantly higher MCP-1 and VEGF levels were seen in Group B compared to Group C (P < 0.05). Before the final treatment, the MCP-1, VEGF, and TNF-a concentrations in Group A were significantly higher than those in Group B (P < 0.05) and Group C (P < 0.05). IL-2 levels were significantly lower in Group A compared to Group B (P < 0.05) and Group C (P < 0.05).
   Conclusion
   Inflammatory cytokines such as MCP-1, VEGF, and TNF-alpha may be associated with the pathogenesis of both stable and refractory PCV.
C1 [Hu, Jie; Leng, Xuan; Hu, Yijun; Song, Xin; Li, Zhixi; Liu, Yuhua; Lu, Lin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
   [Atik, Alp] Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 Sun Yat Sen University; Royal Victorian Eye & Ear Hospital
RP Hu, J (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
EM hehujie@126.com
RI Hu, Yijun/J-4044-2016
OI Hu, Yijun/0000-0002-6424-7905
FU National Natural Science Foundation of China [81271009]
FX This study was supported by the National Natural Science Foundation of
   China (81271009), JH. JH conceived and designed the experiments for this
   manuscript.
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan WM, 2007, BRIT J OPHTHALMOL, V91, P174, DOI 10.1136/bjo.2006.103606
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheng C, 2007, J CLIN INVEST, V117, P616, DOI 10.1172/JCI28180
   Chu WM, 2013, CANCER LETT, V328, P222, DOI 10.1016/j.canlet.2012.10.014
   FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341
   Fruebis J, 1997, ARTERIOSCL THROM VAS, V17, P1289, DOI 10.1161/01.ATV.17.7.1289
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lin JT, 2014, CURR PHARM DESIGN, V20, P4580, DOI 10.2174/1381612820666140522115801
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Miao H, 2012, MOL VIS, V18, P574
   Montero JA, 2007, BRIT J OPHTHALMOL, V91, P131, DOI 10.1136/bjo.2006.106526
   NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Selzman CH, 2002, AM J PHYSIOL-HEART C, V283, pH1455, DOI 10.1152/ajpheart.00188.2002
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097/IAE.0b013e318042d3b0
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 28
TC 10
Z9 11
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2016
VL 11
IS 1
AR e0147346
DI 10.1371/journal.pone.0147346
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DB6WB
UT WOS:000368655300098
PM 26799405
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Crooke, A
   Huete-Toral, F
   Colligris, B
   Pintor, J
AF Crooke, Almudena
   Huete-Toral, Fernando
   Colligris, Basilio
   Pintor, Jesus
TI The role and therapeutic potential of melatonin in age-related ocular
   diseases
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Review
DE aged-related ocular diseases; age-related macular degeneration; aging;
   cataract; diabetic retinopathy; glaucoma; melatonin
ID RETINAL-PIGMENT EPITHELIUM; NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL-DNA
   DAMAGE; NF-KAPPA-B; GANGLION-CELL DEATH; OPEN-ANGLE GLAUCOMA; TRABECULAR
   MESHWORK CELLS; NLRP3 INFLAMMASOME ACTIVATION; ERYTHROID 2-RELATED
   FACTOR-2; PREVENTS OXIDATIVE STRESS
AB The eye is continuously exposed to solar UV radiation and pollutants, making it prone to oxidative attacks. In fact, oxidative damage is a major cause of age-related ocular diseases including cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy. As the nature of lens cells, trabecular meshwork cells, retinal ganglion cells, retinal pigment epithelial cells, and photoreceptors is postmitotic, autophagy plays a critical role in their cellular homeostasis. In age-related ocular diseases, this process is impaired, and thus, oxidative damage becomes irreversible. Other conditions such as low-grade chronic inflammation and angiogenesis also contribute to the development of retinal diseases (glaucoma, age-related macular degeneration and diabetic retinopathy). As melatonin is known to have remarkable qualities such as antioxidant/antinitridergic, mitochondrial protector, autophagy modulator, anti-inflammatory, and anti-angiogenic, it can represent a powerful tool to counteract all these diseases. The present review analyzes the role and therapeutic potential of melatonin in age-related ocular diseases, focusing on nitro-oxidative stress, autophagy, inflammation, and angiogenesis mechanisms.
C1 [Crooke, Almudena; Huete-Toral, Fernando; Colligris, Basilio; Pintor, Jesus] Univ Complutense Madrid, Dept Biochem & Mol Biol 4, Grp Ocupharm, Fac Opt & Optometry, Madrid, Spain.
C3 Complutense University of Madrid
RP Pintor, J (通讯作者)，Univ Complutense Madrid, Dept Biochem & Mol Biol 4, Fac Opt & Optometry, Madrid, Spain.
EM jpintor@vet.ucm.es
RI Crooke, Almudena/Z-1516-2019
OI Crooke, Almudena/0000-0003-4360-1896; Pintor, Jesus/0000-0002-9191-7679;
   Colligris, Basilio/0000-0001-6907-3636; Huete Toral,
   Fernando/0000-0003-3166-411X
FU Universidad Complutense de Madrid [PR1/07-14890]; Ministerio de Sanidad,
   Servicios Sociales e Igualdad [REICS RD12/0034/0003]; Ministerio de
   Economia y Competitividad [SAF2013-44416-R, SAF2016-77084-R]
FX Universidad Complutense de Madrid, Grant/Award Number: PR1/07-14890;
   Ministerio de Sanidad, Servicios Sociales e Igualdad, Grant/Award
   Number: REICS RD12/0034/0003; Ministerio de Economia y Competitividad,
   Grant/Award Number: SAF2013-44416-R and SAF2016-77084-R
CR ABE M, 1994, J PINEAL RES, V17, P94, DOI 10.1111/j.1600-079X.1994.tb00119.x
   Acuna-Castroviejo D, 2003, ADV EXP MED BIOL, V527, P549
   Akbulut KG, 2009, J PINEAL RES, V47, P308, DOI 10.1111/j.1600-079X.2009.00715.x
   Akpek EK, 2013, AM J MANAG CARE, V19, pS67
   Alarma-Estrany P, 2008, J PINEAL RES, V45, P468, DOI 10.1111/j.1600-079X.2008.00618.x
   Alarma-Estrany P, 2007, PHARMACOL THERAPEUT, V113, P507, DOI 10.1016/j.pharmthera.2006.11.003
   Alarma-Estrany P, 2009, J PINEAL RES, V47, P201, DOI 10.1111/j.1600-079X.2009.00702.x
   Alcantara-Contreras S, 2011, NEUROSCI LETT, V494, P61, DOI 10.1016/j.neulet.2011.02.056
   Alkozi H, 2017, ACTA OPHTHALMOL, V95, pE185, DOI 10.1111/aos.13253
   ALVARADO J, 1984, OPHTHALMOLOGY, V91, P564
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Andersen LPH, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0052-2
   Aranda ML, 2016, J PINEAL RES, V60, P360, DOI 10.1111/jpi.12318
   Arendt J, 1998, REV REPROD, V3, P13, DOI 10.1530/ror.0.0030013
   ARMSTRONG SM, 1991, MED HYPOTHESES, V34, P300, DOI 10.1016/0306-9877(91)90046-2
   Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050
   Aslan M, 2006, FREE RADICAL RES, V40, P147, DOI 10.1080/10715760500456219
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Alkozi HA, 2017, EXP EYE RES, V154, P168, DOI 10.1016/j.exer.2016.11.019
   Babizhayev MA, 2016, AM J THER, V23, pE98, DOI 10.1097/MJT.0b013e3181ea31ff
   Babizhayev MA, 2011, FUND CLIN PHARMACOL, V25, P139, DOI 10.1111/j.1472-8206.2010.00829.x
   Bagnis A, 2012, EXP EYE RES, V103, P55, DOI 10.1016/j.exer.2012.07.011
   Bai J, 2013, FREE RADICAL RES, V47, P635, DOI 10.3109/10715762.2013.808743
   Bai N, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-34
   Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611
   Baptista FI, 2015, NEUROSCI LETT, V602, P56, DOI 10.1016/j.neulet.2015.06.044
   Bardak Y, 2000, CURR EYE RES, V20, P225, DOI 10.1076/0271-3683(200003)20:3;1-9;FT225
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Barton GP, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00352
   Baydas G, 2004, ACTA DIABETOL, V41, P123, DOI 10.1007/s00592-004-0155-x
   Belforte NA, 2010, J PINEAL RES, V48, P353, DOI 10.1111/j.1600-079X.2010.00762.x
   Berthoud VM, 2009, ANTIOXID REDOX SIGN, V11, P339, DOI 10.1089/ars.2008.2119
   BESHARSE JC, 1983, SCIENCE, V219, P1341, DOI 10.1126/science.6828862
   BESHARSE JC, 1977, SCIENCE, V196, P536, DOI 10.1126/science.300504
   Blasiak J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6819736
   Bogdan C, 2015, TRENDS IMMUNOL, V36, P161, DOI 10.1016/j.it.2015.01.003
   Bolanos JP, 1997, J NEUROCHEM, V68, P2227
   Bonnefont-Rousselot D, 2010, TOXICOLOGY, V278, P55, DOI 10.1016/j.tox.2010.04.008
   Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   Brosh I, 2009, LEARN MEMORY, V16, P413, DOI 10.1101/lm.1430809
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Buonfiglio DD, 2011, INVEST OPHTH VIS SCI, V52, P7416, DOI 10.1167/iovs.10-6756
   Burch JB, 2014, J GERONTOL A-BIOL, V69, pS1, DOI 10.1093/gerona/glu041
   Caballero B, 2009, MECH AGEING DEV, V130, P722, DOI 10.1016/j.mad.2009.09.001
   Cardinali DP, 2008, NEUROIMMUNOMODULAT, V15, P272, DOI 10.1159/000156470
   CARLBERG C, 1995, J PINEAL RES, V18, P171, DOI 10.1111/j.1600-079X.1995.tb00157.x
   Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje
   Carrillo-Vico A, 2013, INT J MOL SCI, V14, P8638, DOI 10.3390/ijms14048638
   Cavallini G, 2007, AUTOPHAGY, V3, P26, DOI 10.4161/auto.3268
   Cavet ME, 2014, INVEST OPHTH VIS SCI, V55, P5005, DOI 10.1167/iovs.14-14515
   Ceraulo L, 1999, J PINEAL RES, V26, P108, DOI 10.1111/j.1600-079X.1999.tb00570.x
   Chang HM, 2009, J PINEAL RES, V47, P211, DOI 10.1111/j.1600-079X.2009.00704.x
   Chen HQ, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00103
   Chen J, 2011, CLIN OPHTHALMOL, V5, P667, DOI 10.2147/OPTH.S15971
   Cheng XP, 2012, J PHARMACOL SCI, V119, P177, DOI 10.1254/jphs.11183FP
   Cheng Y, 2014, J NEUROIMMUNOL, V269, P38, DOI 10.1016/j.jneuroim.2014.02.001
   Cheng ZY, 2010, TRENDS ENDOCRIN MET, V21, P589, DOI 10.1016/j.tem.2010.06.005
   CHIOU GCY, 1984, OPHTHALMIC RES, V16, P302, DOI 10.1159/000265334
   Chiquet C, 2006, AM J OPHTHALMOL, V142, P325, DOI 10.1016/j.ajo.2006.03.040
   Choi SI, 2013, J PINEAL RES, V54, P361, DOI 10.1111/jpi.12039
   Chumboatong W, 2017, NEUROCHEM INT, V102, P114, DOI 10.1016/j.neuint.2016.12.011
   Chung SY, 2003, J PINEAL RES, V34, P95, DOI 10.1034/j.1600-079X.2003.00010.x
   Corriere M, 2013, CURR DIABETES REP, V13, P805, DOI 10.1007/s11892-013-0425-5
   Costello MJ, 2013, EXP EYE RES, V116, P141, DOI 10.1016/j.exer.2013.08.017
   Coto-Montes A, 2012, MOL CELL ENDOCRINOL, V361, P12, DOI 10.1016/j.mce.2012.04.009
   Coughlin L, 2015, INVEST OPHTH VIS SCI, V56, P1437, DOI 10.1167/iovs.14-16126
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   Crooke A, 2012, CURR MED CHEM, V19, P3508, DOI 10.2174/092986712801323234
   Crooke A, 2013, J PHARMACOL EXP THER, V346, P138, DOI 10.1124/jpet.112.202036
   Crooke A, 2012, J PINEAL RES, V52, P265, DOI 10.1111/j.1600-079X.2011.00938.x
   Crooke A, 2011, PHARMACOGENET GENOM, V21, P587, DOI 10.1097/FPC.0b013e32834910d1
   Csiszar A, 2009, AM J PHYSIOL-HEART C, V297, pH13, DOI 10.1152/ajpheart.00368.2009
   Cuesta S, 2011, MECH AGEING DEV, V132, P573, DOI 10.1016/j.mad.2011.10.005
   Cuesta S, 2010, EXP GERONTOL, V45, P950, DOI 10.1016/j.exger.2010.08.016
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De la Fuente M, 2009, CURR PHARM DESIGN, V15, P3003, DOI 10.2174/138161209789058110
   DelaPaz MA, 1996, INVEST OPHTH VIS SCI, V37, P1849
   DeMuro RL, 2000, J CLIN PHARMACOL, V40, P781, DOI 10.1177/00912700022009422
   Deng SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077100
   Deng WG, 2006, BLOOD, V108, P518, DOI 10.1182/blood-2005-09-3691
   Doganay S, 2006, CURR EYE RES, V31, P147, DOI 10.1080/02713680500514685
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Dragicevic N, 2011, J PINEAL RES, V51, P75, DOI 10.1111/j.1600-079X.2011.00864.x
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Duarte AI, 2005, FREE RADICAL BIO MED, V39, P876, DOI 10.1016/j.freeradbiomed.2005.05.002
   Dubocovich ML, 2010, PHARMACOL REV, V62, P343, DOI 10.1124/pr.110.002832
   DUBOCOVICH ML, 1988, FASEB J, V2, P2765, DOI 10.1096/fasebj.2.12.2842214
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Ellis DZ, 2010, INVEST OPHTH VIS SCI, V51, P5817, DOI 10.1167/iovs.09-5072
   Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa
   Escames G, 2004, J NEUROENDOCRINOL, V16, P929, DOI 10.1111/j.1365-2826.2004.01250.x
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Farajnia S, 2012, J NEUROSCI, V32, P5891, DOI 10.1523/JNEUROSCI.0469-12.2012
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fernandez-Durango R, 2008, INVEST OPHTH VIS SCI, V49, P2506, DOI 10.1167/iovs.07-1363
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Fu Y, 2012, FRONT BIOSCI-LANDMRK, V17, P1461, DOI 10.2741/3997
   Gabelt BT, 2005, PROG RETIN EYE RES, V24, P612, DOI 10.1016/j.preteyeres.2004.10.003
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Galano A, 2013, J PINEAL RES, V54, P245, DOI 10.1111/jpi.12010
   Gao JY, 2013, INVEST OPHTH VIS SCI, V54, P7174, DOI 10.1167/iovs.13-12593
   Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Gooneratne NS, 2012, J PINEAL RES, V52, P437, DOI 10.1111/j.1600-079X.2011.00958.x
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Grace MS, 1999, VISUAL NEUROSCI, V16, P909, DOI 10.1017/S0952523899165106
   GRIERSON I, 1987, EYE, V1, P204, DOI 10.1038/eye.1987.38
   Guo YC, 2010, J HUAZHONG U SCI-MED, V30, P1, DOI 10.1007/s11596-010-0101-9
   Gurler B, 2000, EYE, V14, P730, DOI 10.1038/eye.2000.193
   Gutierrez-Cuesta J, 2008, J PINEAL RES, V45, P497, DOI 10.1111/j.1600-079X.2008.00626.x
   Hardeland R, 2015, PROG NEUROBIOL, V127, P46, DOI 10.1016/j.pneurobio.2015.02.001
   Hardeland R, 2013, J PINEAL RES, V55, P325, DOI 10.1111/jpi.12090
   Hardeland R, 2009, BIOFACTORS, V35, P183, DOI 10.1002/biof.23
   HARDING JJ, 1970, BIOCHEM J, V117, P957, DOI 10.1042/bj1170957
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hasegawa K, 2008, BIOCHEM BIOPH RES CO, V372, P51, DOI 10.1016/j.bbrc.2008.04.176
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P4912, DOI 10.1167/iovs.08-2192
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P1447, DOI 10.1167/iovs.07-1361
   He Y, 2010, ADV EXP MED BIOL, V664, P165, DOI 10.1007/978-1-4419-1399-9_20
   He Z, 2011, CLIN EXP OPTOM, V94, P133, DOI 10.1111/j.1444-0938.2010.00564.x
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hikichi T, 2011, CLIN OPHTHALMOL, V5, P655, DOI 10.2147/OPTH.S19559
   Himori N, 2013, J NEUROCHEM, V127, P669, DOI 10.1111/jnc.12325
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2139
   Hori YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073875
   Hou XB, 2016, SCI REP-UK, V6, DOI 10.1038/srep38186
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Huang XQ, 2005, INVEST OPHTH VIS SCI, V46, P2503, DOI 10.1167/iovs.05-0154
   Huete-Toral F, 2015, J PHARMACOL EXP THER, V352, P119, DOI 10.1124/jpet.114.218263
   Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0
   IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27
   Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622
   Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516
   Ismail SA, 2009, ANESTH ANALG, V108, P1146, DOI 10.1213/ane.0b013e3181907ebe
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jenwitheesuk A, 2014, INT J MOL SCI, V15, P16848, DOI 10.3390/ijms150916848
   Ji YH, 2015, MOL CELL BIOCHEM, V401, P87, DOI 10.1007/s11010-014-2294-x
   Jiang TT, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3528274
   Jiang TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050661
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Johnson SC, 2015, AGING CELL, V14, P809, DOI 10.1111/acel.12362
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Ju KR, 2006, BRAIN RES, V1122, P209, DOI 10.1016/j.brainres.2006.09.022
   Ju WK, 2007, INVEST OPHTH VIS SCI, V48, P2145, DOI 10.1167/iovs.06-0573
   Ju WK, 2008, MOL VIS, V14, P2629
   Ju WK, 2009, INVEST OPHTH VIS SCI, V50, P707, DOI 10.1167/iovs.08-2499
   Jung KH, 2010, J PINEAL RES, V48, P239, DOI 10.1111/j.1600-079X.2010.00748.x
   Jung KH, 2009, J PINEAL RES, V47, P173, DOI 10.1111/j.1600-079X.2009.00698.x
   Jung-Hynes B, 2011, J PINEAL RES, V50, P140, DOI 10.1111/j.1600-079X.2010.00823.x
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kanki R, 2004, BRAIN RES, V1015, P73, DOI 10.1016/j.brainres.2004.04.044
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   Karslioglu I, 2005, J RADIAT RES, V46, P277, DOI 10.1269/jrr.46.277
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kato H, 2015, J PINEAL RES, V59, P267, DOI 10.1111/jpi.12259
   Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007
   Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kaur C, 2013, J PINEAL RES, V54, P190, DOI 10.1111/jpi.12016
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kergoat H, 2006, INVEST OPHTH VIS SCI, V47, P5423, DOI 10.1167/iovs.06-0602
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Khan RS, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-3
   Kimball SR, 2008, J PINEAL RES, V44, P379, DOI 10.1111/j.1600-079X.2007.00539.x
   Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107
   Ko ML, 2005, FREE RADICAL BIO MED, V39, P365, DOI 10.1016/j.freeradbiomed.2005.03.025
   Kojima T, 1997, CELL STRUCT FUNCT, V22, P347, DOI 10.1247/csf.22.347
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Korkmaz A, 2012, GENE, V503, P1, DOI 10.1016/j.gene.2012.04.040
   Kowluru RA, 1997, FREE RADICAL BIO MED, V22, P587, DOI 10.1016/S0891-5849(96)00347-4
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Kowluru RA, 2014, INVEST OPHTH VIS SCI, V55, P5653, DOI 10.1167/iovs.14-14383
   Kowluru RA, 2012, EXPERT OPIN INV DRUG, V21, P797, DOI 10.1517/13543784.2012.681043
   Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297
   Lau BWM, 2007, J MOL NEUROSCI, V32, P160, DOI 10.1007/s12031-007-0031-6
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Lee HJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/589365
   Lee JH, 2009, DIABETES, V58, P344, DOI 10.2337/db07-1795
   Leon J, 2000, MOL PHARMACOL, V58, P967, DOI 10.1124/mol.58.5.967
   Leon J, 2006, J NEUROCHEM, V98, P2023, DOI 10.1111/j.1471-4159.2006.04029.x
   Leon-Blanco MM, 2003, J PINEAL RES, V35, P204, DOI 10.1034/j.1600-079X.2003.00077.x
   Leske MC, 2007, OPHTHAL EPIDEMIOL, V14, P166, DOI 10.1080/09286580701501931
   Li WG, 2008, BIOCHEM PHARMACOL, V76, P1485, DOI 10.1016/j.bcp.2008.07.017
   Li ZR, 1997, J PINEAL RES, V22, P117, DOI 10.1111/j.1600-079X.1997.tb00312.x
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2001, NEUROREPORT, V12, P1011, DOI 10.1097/00001756-200104170-00029
   Lichtenstein A, 2011, J CELL SCI, V124, P910, DOI 10.1242/jcs.073072
   Lim HD, 2012, J PINEAL RES, V53, P225, DOI 10.1111/j.1600-079X.2012.00991.x
   Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin TJ, 2011, J CATARACT REFR SURG, V37, P1270, DOI 10.1016/j.jcrs.2011.02.027
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Liton PB, 2008, INVEST OPHTH VIS SCI, V49, P3961, DOI 10.1167/iovs.08-1915
   Liu B, 2000, GLIA, V30, P178, DOI 10.1002/(SICI)1098-1136(200004)30:2<178::AID-GLIA7>3.0.CO;2-C
   Liu L, 2003, J BIOL CHEM, V278, P31998, DOI 10.1074/jbc.M303553200
   LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193
   Luchetti F, 2009, FREE RADICAL BIO MED, V46, P339, DOI 10.1016/j.freeradbiomed.2008.09.017
   Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450
   De Bonis ML, 2014, STEM CELL REP, V2, P690, DOI 10.1016/j.stemcr.2014.03.002
   Madsen-Bouterse SA, 2010, FREE RADICAL RES, V44, P313, DOI 10.3109/10715760903494168
   Mammucari C, 2010, MECH AGEING DEV, V131, P536, DOI 10.1016/j.mad.2010.07.003
   Mao XB, 2017, BIOCHEM BIOPH RES CO, V482, P341, DOI 10.1016/j.bbrc.2016.11.065
   Marchiafava PL, 1999, J PINEAL RES, V26, P184, DOI 10.1111/j.1600-079X.1999.tb00582.x
   Markantonis SL, 2008, J CLIN PHARMACOL, V48, P240, DOI 10.1177/0091270007311112
   Martinez-Aguila A, 2016, J PHARMACOL EXP THER, V357, P293, DOI 10.1124/jpet.115.231456
   Martinez-Aguila A, 2013, EUR J PHARMACOL, V701, P213, DOI 10.1016/j.ejphar.2012.12.009
   Martinez-Campa CM, 2008, CANCER LETT, V268, P272, DOI 10.1016/j.canlet.2008.04.001
   Mauriz JL, 2007, J PINEAL RES, V42, P222, DOI 10.1111/j.1600-079X.2006.00409.x
   Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002
   McLaren JW, 2009, EXP EYE RES, V88, P641, DOI 10.1016/j.exer.2008.10.018
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Michael J Morgan, 2011, Cell Research, V21, P103
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   Mishra M, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15020
   Mistraletti G, 2010, J PINEAL RES, V48, P142, DOI 10.1111/j.1600-079X.2009.00737.x
   Mittag TW, 2000, INVEST OPHTH VIS SCI, V41, P3451
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6
   Mor M, 2010, EXPERT OPIN THER PAT, V20, P1059, DOI 10.1517/13543776.2010.496455
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Morishita H, 2013, J BIOL CHEM, V288, P11436, DOI 10.1074/jbc.M112.437103
   Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6
   Munemasa Y, 2009, GENE THER, V16, P17, DOI 10.1038/gt.2008.126
   Munemasa Y, 2015, PROG RETIN EYE RES, V47, P1, DOI 10.1016/j.preteyeres.2015.03.002
   Munemasa Y, 2010, J NEUROCHEM, V115, P1508, DOI 10.1111/j.1471-4159.2010.07057.x
   Naia L, 2015, MOL NEUROBIOL, V51, P331, DOI 10.1007/s12035-014-8735-4
   Narayanan SP, 2013, PROG RETIN EYE RES, V36, P260, DOI 10.1016/j.preteyeres.2013.06.002
   Neufeld AH, 1999, SURV OPHTHALMOL, V43, pS129, DOI 10.1016/S0039-6257(99)00010-7
   Neufeld AH, 1997, ARCH OPHTHALMOL-CHIC, V115, P497, DOI 10.1001/archopht.1997.01100150499009
   Ng F, 2013, J CELL PHYSIOL, V228, P2262, DOI 10.1002/jcp.24399
   Nguyen D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.117
   Nishida S, 2002, J PINEAL RES, V32, P26, DOI 10.1034/j.1600-079x.2002.10797.x
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   OBRIEN IAD, 1986, CLIN ENDOCRINOL, V24, P359, DOI 10.1111/j.1365-2265.1986.tb01639.x
   OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719
   Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694
   Osborne NN, 2006, BRIT J OPHTHALMOL, V90, P237, DOI 10.1136/bjo.2005.082230
   Ozdemir G, 2014, EYE, V28, P1020, DOI 10.1038/eye.2014.127
   Ozdemir G, 2014, CAN J OPHTHALMOL, V49, P443, DOI 10.1016/j.jcjo.2014.07.003
   Palacios JA, 2010, J CELL BIOL, V191, P1299, DOI 10.1083/jcb.201005160
   Pall Martin L., 2015, Shengli Xuebao, V67, P1
   Pall Martin L, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P1
   PANG SF, 1979, EXPERIENTIA, V35, P231, DOI 10.1007/BF01920634
   Park HYL, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.26
   Park Sang-Woo, 2012, Chonnam Med J, V48, P116, DOI 10.4068/cmj.2012.48.2.116
   Park YH, 2016, INVEST OPHTH VIS SCI, V57, P508, DOI 10.1167/iovs.15-18481
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peek CB, 2013, SCIENCE, V342, P591, DOI 10.1126/science.1243417
   Pescosolido N, 2015, OPHTHAL PHYSL OPT, V35, P201, DOI 10.1111/opo.12189
   Petrash JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12940
   Picinato MC, 2008, J PINEAL RES, V44, P88, DOI 10.1111/j.1600-079X.2007.00493.x
   Pintor J, 2003, BRIT J PHARMACOL, V138, P831, DOI 10.1038/sj.bjp.0705118
   Pintor J, 2001, EUR J PHARMACOL, V416, P251, DOI 10.1016/S0014-2999(01)00864-0
   Piras A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022514
   Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040
   Porter K, 2015, BBA-MOL BASIS DIS, V1852, P379, DOI 10.1016/j.bbadis.2014.11.021
   Porter K, 2013, AUTOPHAGY, V9, P581, DOI 10.4161/auto.23568
   Prada C, 2005, J NEUROPHYSIOL, V94, P968, DOI 10.1152/jn.01286.2004
   Pulliero A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098106
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Ramis MR, 2015, CURR MED CHEM, V22, P2690, DOI 10.2174/0929867322666150619104143
   Ramis MR, 2015, MECH AGEING DEV, V146, P28, DOI 10.1016/j.mad.2015.03.008
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200
   Ren Peng-Liang, 2014, Sichuan Da Xue Xue Bao Yi Xue Ban, V45, P572
   Ressmeyer AR, 2003, REDOX REP, V8, P205, DOI 10.1179/135100003225002709
   Reznick RM, 2007, CELL METAB, V5, P151, DOI 10.1016/j.cmet.2007.01.008
   Richter T, 2007, EXP GERONTOL, V42, P1039, DOI 10.1016/j.exger.2007.08.005
   Rivara S, 2015, EXPERT OPIN THER PAT, V25, P425, DOI 10.1517/13543776.2014.1001739
   Robeva R, 2008, J PINEAL RES, V44, P52, DOI 10.1111/j.1600-079X.2007.00527.x
   Rodrigues Gustavo B, 2016, Int J Retina Vitreous, V2, P26
   Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x
   Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Rohde B H, 1985, J Ocul Pharmacol, V1, P235, DOI 10.1089/jop.1985.1.235
   Rokicki W, 2015, MED SCI MONITOR, V21, P76, DOI 10.12659/MSM.891177
   Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241
   Rosen R, 2009, MOL VIS, V15, P1673
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saenz DA, 2004, FASEB J, V18, P1912, DOI 10.1096/fj.04-2062fje
   Salido EM, 2013, J PINEAL RES, V54, P179, DOI 10.1111/jpi.12008
   Salpea KD, 2010, ATHEROSCLEROSIS, V209, P42, DOI 10.1016/j.atherosclerosis.2009.09.070
   SAMPLES JR, 1988, CURR EYE RES, V7, P649, DOI 10.3109/02713688809033192
   Sansone L, 2013, J CELL PHYSIOL, V228, P1754, DOI 10.1002/jcp.24334
   Santos JM, 2012, FREE RADICAL BIO MED, V53, P1729, DOI 10.1016/j.freeradbiomed.2012.08.588
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Schneemann A, 2003, GRAEF ARCH CLIN EXP, V241, P321, DOI 10.1007/s00417-003-0638-4
   Schneemann A, 2002, GRAEF ARCH CLIN EXP, V240, P936, DOI 10.1007/s00417-002-0559-7
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schutt F, 2012, INVEST OPHTH VIS SCI, V53, P5354, DOI 10.1167/iovs.12-9845
   Schug TT, 2010, MOL CELL BIOL, V30, P4712, DOI 10.1128/MCB.00657-10
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Semkova I, 2010, EXP EYE RES, V90, P244, DOI 10.1016/j.exer.2009.10.012
   Serle JB, 2004, J GLAUCOMA, V13, P385, DOI 10.1097/01.ijg.0000133150.44686.0b
   Shakespeare TI, 2009, MOL BIOL CELL, V20, P2582, DOI 10.1091/mbc.E08-12-1257
   Shi HQ, 2015, BIOCHEM BIOPH RES CO, V463, P1071, DOI 10.1016/j.bbrc.2015.06.060
   SHIDA CS, 1994, J PINEAL RES, V16, P198, DOI 10.1111/j.1600-079X.1994.tb00102.x
   Shirazi A, 2011, CELL J, V13, P79
   SKENE DJ, 1990, BRAIN RES, V528, P170, DOI 10.1016/0006-8993(90)90214-V
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su WR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099719
   Sugawara T, 1998, INVEST OPHTH VIS SCI, V39, P2458
   Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014
   SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2
   Tajes M, 2009, J PINEAL RES, V47, P228, DOI 10.1111/j.1600-079X.2009.00706.x
   Tan DX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122124
   Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje
   Tapias V, 2009, J NEUROSCI RES, V87, P3002, DOI 10.1002/jnr.22123
   Taysi S, 2008, INT J RADIAT BIOL, V84, P803, DOI 10.1080/09553000802390932
   Teng YC, 2015, MOL NEUROBIOL, V52, P1015, DOI 10.1007/s12035-015-9250-y
   Tengan CH, 2012, INT J MOL SCI, V13, P17160, DOI 10.3390/ijms131217160
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Terman A, 1995, GERONTOLOGY, V41, P319
   Tezel G, 2005, INVEST OPHTH VIS SCI, V46, P3177, DOI 10.1167/iovs.05-0208
   Tezel G, 1998, INVEST OPHTH VIS SCI, V39, P2277
   Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511
   Tezel G, 2000, J NEUROSCI, V20, P8693
   Tezel G, 2012, INVEST OPHTH VIS SCI, V53, P4220, DOI 10.1167/iovs.11-9101
   Tezel G, 2011, EXP EYE RES, V93, P178, DOI 10.1016/j.exer.2010.07.009
   Tezel G, 2010, INVEST OPHTH VIS SCI, V51, P5071, DOI 10.1167/iovs.10-5289
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Tokarz P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060898
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   TOUITOU Y, 1981, J ENDOCRINOL, V91, P467, DOI 10.1677/joe.0.0910467
   Trump B F, 1996, New Horiz, V4, P139
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van Heemst D, 2010, AGING DIS, V1, P147
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Vincent L, 2010, J PINEAL RES, V48, P222, DOI 10.1111/j.1600-079X.2010.00746.x
   VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2007, ANN NY ACAD SCI, V1097, P64, DOI 10.1196/annals.1379.027
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang HB, 2016, MOL VIS, V22, P116
   Wang JY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101601
   Wang Y, 2014, MOL MED REP, V10, P1179, DOI 10.3892/mmr.2014.2346
   Webers CAB, 2008, DRUG AGING, V25, P729, DOI 10.2165/00002512-200825090-00002
   Wiechmann AF, 2004, EXP EYE RES, V79, P585, DOI 10.1016/j.exer.2004.07.004
   WIECHMANN AF, 1992, INVEST OPHTH VIS SCI, V33, P1894
   WIEDERHOLT M, 1994, INVEST OPHTH VIS SCI, V35, P2515
   Wiesenberg I, 1998, RESTOR NEUROL NEUROS, V12, P143
   Wilkinson-Berka JL, 2013, CLIN SCI, V124, P597, DOI 10.1042/CS20120212
   Woldemussie E, 2004, GLIA, V47, P109, DOI 10.1002/glia.20000
   Wood JPM, 2008, MOL VIS, V14, P334
   Xie MY, 2014, MOL VIS, V20, P921
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yagci R, 2006, CURR EYE RES, V31, P845, DOI 10.1080/02713680600899663
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang XJ, 2013, CHINESE MED J-PEKING, V126, P4358, DOI 10.3760/cma.j.issn.0366-6999.20131956
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yin F, 2013, BIOCHEM SOC T, V41, P101, DOI 10.1042/BST20120260
   Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3
   Zeng KH, 2016, NEUROCHEM RES, V41, P1050, DOI 10.1007/s11064-015-1793-9
   Zhang M, 2007, NEUROREPORT, V18, P1675, DOI 10.1097/WNR.0b013e3282f0b5a2
   Zhao WJ, 2010, J PHYSIOL-LONDON, V588, P2605, DOI 10.1113/jphysiol.2010.187641
   Zheng TY, 2011, CURR EYE RES, V36, P449, DOI 10.3109/02713683.2011.559301
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P3941, DOI 10.1167/iovs.13-11598
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
   Zhu HQ, 2008, J PINEAL RES, V45, P328, DOI 10.1111/j.1600-079X.2008.00595.x
   Zuo L, 2013, INVEST OPHTH VIS SCI, V54, P5097, DOI 10.1167/iovs.13-12157
NR 386
TC 44
Z9 45
U1 1
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD SEP
PY 2017
VL 63
IS 2
AR e12430
DI 10.1111/jpi.12430
PG 25
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA FC4AC
UT WOS:000406779800008
PM 28658514
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Liu, B
   Zhang, XZ
   Mi, L
   Peng, YT
   Wen, F
AF Liu, Bing
   Zhang, Xiongze
   Mi, Lan
   Peng, Yuting
   Wen, Feng
TI Choroidal structure in subtypes of polypoidal choroidal vasculopathy
   determined by binarization of optical coherence tomographic images
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE choroidal thickness; choroidal vascular hyperpermeability; choroidal
   vascularity index; optical coherence tomography; polypoidal choroidal
   vasculopathy
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; VASCULAR HYPERPERMEABILITY; HEALTHY EYES; THICKNESS
AB Importance Chorodial structure in subtypes of polypoidal choroidal vasculopathy (PCV). Background To evaluate choroidal vascularity in the eyes of patients with PCV with and without choroidal vascular hyperpermeability (CVH). Design A hospital-based retrospective study. Participants Fifty-eight PCV patients (28 with CVH; 30 without CVH) and 30 normal controls were included in this study. Methods All study subjects underwent spectral-domain optical coherence tomography with enhanced depth imaging, and the choroidal images were binarized into the luminal area and stromal area. Main Outcome Measures Choroidal vascularity index (CVI) and subfoveal choroidal thickness (SFCT). Results Compared to normal controls, patients with PCV showed no obvious difference in SFCT (P = 0.510), but significantly lower CVI (P = 0.003). Among PCV patients, the CVI in eyes with CVH was significantly greater than that in those without CVH (65.78 +/- 4.70 vs 62.28 +/- 3.90; P = 0.002), and a significant difference in SFCT was also found between the two subtypes of PCV (340.8 +/- 89.2 vs 250.4 +/- 67.7; P < 0.001). Conclusions and Relevance PCV eyes with CVH have a greater CVI and a thicker SFCT than those without CVH. The significant differences in choroidal vascularity between the two subtypes of PCV may broaden our understanding of the pathogenesis of this disease and contribute to significant improvements in treatment.
C1 [Liu, Bing; Zhang, Xiongze; Mi, Lan; Peng, Yuting; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
   [Liu, Bing] Shandong Univ, Dept Ophthalmol, Hosp 2, Jinan, Shandong, Peoples R China.
C3 Sun Yat Sen University; Shandong University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
FU Fundamental Research Funds of State Key Laboratory of Ophthalmology;
   National Natural Science Foundation of China [81870674]
FX Fundamental Research Funds of State Key Laboratory of Ophthalmology;
   National Natural Science Foundation of China, Grant Number: 81870674
CR Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   Agrawal R, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.4.7
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kinoshita T, 2017, BRIT J OPHTHALMOL, V101, P360, DOI 10.1136/bjophthalmol-2016-308594
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
NR 32
TC 14
Z9 15
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2019
VL 47
IS 5
BP 631
EP 637
DI 10.1111/ceo.13467
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA II9GP
UT WOS:000475504600009
PM 30663190
DA 2022-11-30
ER

PT J
AU Weng, HY
   Huang, TL
   Chang, PY
   Wang, JK
AF Weng, Hsin-Yu
   Huang, Tzu-Lun
   Chang, Pei-Yao
   Wang, Jia-Kang
TI One-year outcome of combination therapy with intravitreal aflibercept
   and photodynamic therapy for polypoidal choroidal vasculopathy
SO BMC PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
DE Intravitreal injection; Aflibercept; Photodynamic therapy; Polypoidal
   choroidal vasculopathy
ID RANIBIZUMAB; VERTEPORFIN
AB BackgroundTo investigate the one-year visual and anatomical outcomes of combination therapy with intravitreal aflibercept (IVA) and photodynamic therapy (PDT) for treating polypoidal choroidal vasculopathy (PCV).MethodsThis was a retrospective case-series study, including 30 eyes from 30 patients with treatment-naive PCV treated by combination therapy with IVA and PDT. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), complete polyp regression rate, and dry macula rate were recorded every 3months during 12-month follow-up. Clinical factors associated with final visual outcome and retreatment were investigated.ResultsThe mean LogMAR BCVA was significantly improved from 0.730.65 at baseline to 0.51 +/- 0.60 (p=0.01), and the mean CRT was also significantly improved from 339 +/- 96m at baseline to 244 +/- 43m at 12-month follow-up (p<0.001). Complete regression of polypoidal lesions was 76.7%, and dry macula rate was 100% at 12months. Better final BCVA was associated with younger age and better baseline BCVA (p=0.02 and p<0 001). The patients without complete polyp regression at 3-month follow-up were associated with retreatment (p=0.03).Conclusion p id=Par4 In this study, combination therapy with IVA and PDT had significant visual and anatomical improvements to PCV patients during one-year follow-up. Better baseline BCVA and younger age were found to be associated with better visual outcome.
C1 [Weng, Hsin-Yu; Huang, Tzu-Lun; Chang, Pei-Yao; Wang, Jia-Kang] Far Eastern Mem Hosp, Dept Ophthalmol, New Taipei, Taiwan.
   [Huang, Tzu-Lun; Wang, Jia-Kang] Yuan Ze Univ, Dept Elect Engn, Taoyuan, Taiwan.
   [Chang, Pei-Yao; Wang, Jia-Kang] Natl Taiwan Univ, Dept Med, Taipei, Taiwan.
   [Wang, Jia-Kang] Natl Yang Ming Univ, Dept Med, Taipei, Taiwan.
   [Wang, Jia-Kang] Oriental Inst Technol, Dept Healthcare Adm, New Taipei, Taiwan.
   [Wang, Jia-Kang] Oriental Inst Technol, Dept Nursing, New Taipei, Taiwan.
C3 Far Eastern Memorial Hospital; Yuan Ze University; National Taiwan
   University; National Yang Ming Chiao Tung University; Asia Eastern
   University of Science & Technology; Asia Eastern University of Science &
   Technology
RP Wang, JK (通讯作者)，Far Eastern Mem Hosp, Dept Ophthalmol, New Taipei, Taiwan.; Wang, JK (通讯作者)，Yuan Ze Univ, Dept Elect Engn, Taoyuan, Taiwan.; Wang, JK (通讯作者)，Natl Taiwan Univ, Dept Med, Taipei, Taiwan.; Wang, JK (通讯作者)，Natl Yang Ming Univ, Dept Med, Taipei, Taiwan.; Wang, JK (通讯作者)，Oriental Inst Technol, Dept Healthcare Adm, New Taipei, Taiwan.; Wang, JK (通讯作者)，Oriental Inst Technol, Dept Nursing, New Taipei, Taiwan.
EM jiakangw2158@gmail.com
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 17
TC 2
Z9 2
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2050-6511
J9 BMC PHARMACOL TOXICO
JI BMC Pharmacol. Toxicol.
PD MAY 14
PY 2019
VL 20
AR 29
DI 10.1186/s40360-019-0310-1
PG 5
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA HY5CJ
UT WOS:000468144600001
PM 31088543
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hernandez-Martinez, P
   Dolz-Marco, R
   Alonso-Plasencia, M
   Abreu-Gonzalez, R
AF Hernandez-Martinez, Pablo
   Dolz-Marco, Rosa
   Alonso-Plasencia, Marta
   Abreu-Gonzalez, Rodrigo
TI Aflibercept for inflammatory choroidal neovascularization with
   persistent fluid on intravitreal ranibizumab therapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; BEVACIZUMAB; UVEITIS
AB Choroidal neovascularization (CNV) is an important cause of severe central vision loss that may appear as a complication of infectious and noninfectious posterior uveitis. Inflammatory CNV is the third cause of CNV after age-related macular degeneration (AMD) and pathologic myopia [1]. The prevalence of inflammatory CNV in eyes with posterior uveitis is about 2 % at the time of initial presentation [2, 3]. Although most cases of inflammatory CNVrespond well to the intravitreal vascular endothelial growth factor (VEGF) inhibitors, bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA, USA) [4-6] and ranibizumab (Lucentis; Genentech, Inc.) [7], there is a proportion of cases that might be suboptimally responders [8]. Several authors have reported the outcomes of switching these VEGF inhibitors to aflibercept (VEGF-TrapEye, Eylea; Regeneron, Tarrytown, NY, USA) for CNV secondary to age-related macular degeneration (AMD) [9, 10]. However, little is known of this switch in indications other than neovascular AMD. Herein, we report the short-term efficacy of intravitreal aflibercept injections in three cases diagnosed with inflammatory CNV and persistent retinal fluid in spite of intravitreal ranibizumab injections.
C1 [Hernandez-Martinez, Pablo; Dolz-Marco, Rosa] Spain Polytech Hosp La Fe, Unit Macula, Dept Ophthalmol, Univ & Polytech Hosp La Fe, Valencia 46026, Spain.
   [Alonso-Plasencia, Marta; Abreu-Gonzalez, Rodrigo] Univ Hosp La Candelaria, Dept Ophthalmol, Tenerife, Spain.
RP Hernandez-Martinez, P (通讯作者)，Spain Polytech Hosp La Fe, Unit Macula, Dept Ophthalmol, Univ & Polytech Hosp La Fe, Bulevar Sur S-N, Valencia 46026, Spain.
EM pablooftalmologia@yahoo.es
OI Dolz-Marco, Rosa/0000-0002-2963-2541; Abreu-Gonzalez,
   Rodrigo/0000-0002-0354-4252
CR Arevalo JF, 2011, RETINA-J RET VIT DIS, V31, P353, DOI 10.1097/IAE.0b013e3181ed8cec
   Baxter SL, 2013, AM J OPHTHALMOL, V156, P468, DOI 10.1016/j.ajo.2013.04.040
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Mansour AM, 2012, CLIN OPHTHALMOL, V6, P1233, DOI 10.2147/OPTH.S34294
   Mansour AM, 2012, CAN J OPHTHALMOL, V47, P269, DOI 10.1016/j.jcjo.2012.03.042
   Neri P, 2009, MIDDLE EAST AFR J OP, V16, P245, DOI 10.4103/0974-9233.58422
   Perentes Y, 2005, OCUL IMMUNOL INFLAMM, V13, P219, DOI 10.1080/09273940490518883
   Rouvas A, 2011, RETINA-J RET VIT DIS, V31, P871, DOI 10.1097/IAE.0b013e3182003ca8
   Tran T, 2008, GRAEF ARCH CLIN EXP, V246, P1685, DOI 10.1007/s00417-008-0906-4
NR 10
TC 7
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2014
VL 252
IS 8
BP 1337
EP 1339
DI 10.1007/s00417-014-2634-2
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM4MX
UT WOS:000339829900021
PM 24789465
DA 2022-11-30
ER

PT J
AU Takeuchi, T
   Tagami, T
   Fukushige, K
   Ozeki, T
AF Takeuchi, Takao
   Tagami, Tatsuaki
   Fukushige, Kaori
   Ozeki, Tetsuya
TI Useful properties of siRNA-coated gold nanoparticles as a
   mini-nanocarrier platform for intraocular administration
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Age-related macular degeneration; Antiangiogenic therapy; Gold
   nanoparticle; Nanomedicine; Small interfering RNA (siRNA)
ID TOPICAL DELIVERY; RANIBIZUMAB; ANGIOGENESIS; AFLIBERCEPT; RNAS
AB Wet type age-related macular degeneration results in the reduction and loss of eyesight and is closely correlated with angiogenesis. Small interfering siRNA (siRNA) is a functional nucleic acid used as a knockdown tool to control target gene expression in a sequence-dependent manner. In contrast, siRNA can potently inhibit angiogenesis in an "independent" manner via its interaction with Toll-like receptor 3. In this study, siRNA was conjugated with ultra-small gold nanoparticles to prevent the distribution of siRNA outside the eye, and the usefulness of this mini-carrier with siRNA against angiogenesis was investigated. Thiolated siRNA (siRNA-hexaethyleneglycol-SH) was conjugated to the surface of gold nanoparticles through a coordinate bond. The nanoparticles were small (approximately 10 nm in diameter) and carried approximately 7.6 siRNA molecules oriented vertically. These nanoparticles suppressed luciferase gene expression in a cell line stably expressing luciferase. The siRNA-gold nanoparticles inhibited tube formation by human endothelial cells on Matrigel efficiently. These siRNA-gold nanoparticles may be useful for treating angiogenesis resulting from age-related macular degeneration.
C1 [Takeuchi, Takao; Tagami, Tatsuaki; Fukushige, Kaori; Ozeki, Tetsuya] Nagoya City Univ, Grad Sch Pharmaceut Sci, Drug Delivery & Nano Pharmaceut, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.
   [Fukushige, Kaori] Aichi Med Univ, Dept Anat, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.
C3 Nagoya City University; Aichi Medical University
RP Ozeki, T (通讯作者)，Nagoya City Univ, Grad Sch Pharmaceut Sci, Drug Delivery & Nano Pharmaceut, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.
EM ozekit@phar.nagoya-cu.ac.jp
CR Ako-Adounvo Ann-Marie, 2014, Recent Pat Drug Deliv Formul, V8, P193
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Chen PC, 2008, NANOTECHNOL SCI APPL, V1, P45
   Dykman LA, 2016, BIOMATERIALS, V108, P13, DOI 10.1016/j.biomaterials.2016.08.040
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fukushige K, 2017, J DRUG DELIV SCI TEC, V39, P435, DOI 10.1016/j.jddst.2017.03.024
   Guo JF, 2017, INT J NANOMED, V12, P6131, DOI 10.2147/IJN.S140772
   Hennig R, 2015, EUR J PHARM BIOPHARM, V95, P294, DOI 10.1016/j.ejpb.2015.02.027
   Hoshikawa A, 2017, J DRUG DELIV SCI TEC, V38, P45, DOI 10.1016/j.jddst.2017.01.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kobayashi H, 2016, BBA-GENE REGUL MECH, V1859, P71, DOI 10.1016/j.bbagrm.2015.08.007
   Kubowicz P, 2013, CURR MED CHEM, V20, P1801
   Kumar H, 2009, BIOCHEM J, V420, P1, DOI 10.1042/BJ20090272
   Lai TH, 2015, INT J NANOMED, V10, P5925, DOI 10.2147/IJN.S88514
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482
   Singh SK, 2011, PHARM RES-DORDR, V28, P873, DOI 10.1007/s11095-010-0343-z
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Souza JG, 2014, J PHARM PHARMACOL, V66, P507, DOI 10.1111/jphp.12132
   Tam C, 2017, APPL MICROBIOL BIOT, V101, P7091, DOI 10.1007/s00253-017-8433-z
   Tanetsugu Y, 2017, BIOL PHARM BULL, V40, P145, DOI 10.1248/bpb.b16-00437
   Wang JY, 2003, ANTI-CANCER DRUG, V14, P13, DOI 10.1097/00001813-200301000-00003
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V15, P1349, DOI 10.1517/14712598.2015.1057565
   Zheng D, 2012, P NATL ACAD SCI USA, V109, P11975, DOI 10.1073/pnas.1118425109
NR 26
TC 1
Z9 1
U1 3
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD OCT
PY 2018
VL 47
BP 411
EP 416
DI 10.1016/j.jddst.2018.06.009
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GU3FV
UT WOS:000445162500048
DA 2022-11-30
ER

PT J
AU Akpek, EK
   Smith, RA
AF Akpek, Esen K.
   Smith, Roderick A.
TI Overview of Age-Related Ocular Conditions
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID DRY EYE; MACULAR DEGENERATION; RISK-FACTORS; PREVALENCE; DISEASE;
   MECHANISMS
AB The United States is an aging society. The number of Americans 65 years or older is expected to more than double over the next 40 years, from 40.2 million in 2010 to 88.5 million in 2050, with aging baby boomers accounting for most of the increase. As the society ages, the prevalence of age-related diseases, including diseases of the eye, will continue to increase. By 2020, age-related macular degeneration, one of the leading causes of vision loss, is expected to affect 2.95 million individuals in the United States. Likewise, the prevalence of open-angle glaucoma, estimated at 2.2 million in 2000, is projected to increase by 50%, to 3.36 million by 2020. As the eye ages, it undergoes a number of physiologic changes that may increase susceptibility to disease. Environmental and genetic factors are also major contributors to the development of age-related ocular diseases. This article reviews the physiology of the aging eye and the epidemiology and pathophysiology of 4 major age-related ocular diseases: age-related macular degeneration, glaucoma, diabetic retinopathy, and dry eye.
C1 [Akpek, Esen K.] Johns Hopkins Sch Med, Wilmer Eye Inst, Ocular Surface Dis & Dry Eye Clin, Baltimore, MD USA.
   [Akpek, Esen K.] Johns Hopkins Sch Med, Wilmer Eye Inst, Div Cornea Cataract & External Dis, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Akpek, EK (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, Ocular Surface Dis & Dry Eye Clin, Baltimore, MD USA.
EM Esakpek@jhmi.edu
RI Akpek, Esen K/A-7054-2019
OI Akpek, Esen K/0000-0001-7700-207X
FU Allergan, Inc; Alcon
FX This activity is supported by an educational grant from Allergan, Inc.;
   Dr Akpek reports consultancy with Bausch St Lomb and research grants
   from Alcon and Allergan, Inc. Mr Smith has no relevant financial
   relationships with commercial interests to disclose.
CR Akpek EK, 2009, CORNEA, V28, P493, DOI 10.1097/ICO.0b013e31818d3846
   AMD Alliance International, 2010, GLOB EC COST VIS IMP
   [Anonymous], POPULATION ESTIMATES
   [Anonymous], AB SJOGR
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Behrens A, 2006, CORNEA, V25, P900, DOI 10.1097/01.ico.0000214802.40313.fa
   Chang EE, 2012, OPHTHALMOLOGY, V119, P979, DOI 10.1016/j.ophtha.2011.11.003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding J, 2012, EXP GERONTOL, V47, P483, DOI 10.1016/j.exger.2012.03.020
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Ehrlich R, 2009, GRAEF ARCH CLIN EXP, V247, P583, DOI 10.1007/s00417-008-1018-x
   Falcao M, 2010, OPEN CIRC VASC J, V3, P30, DOI DOI 10.2174/1877382601003020030
   Faragher RGA, 1997, BRIT J OPHTHALMOL, V81, P814, DOI 10.1136/bjo.81.10.814
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fraunfelder FT, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/285851
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Glaucoma Research Foundation, GLAUC FACTS STATS
   Harwerth RS, 2008, INVEST OPHTH VIS SCI, V49, P4437, DOI 10.1167/iovs.08-1753
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein R, 2010, OPHTHALMOLOGY, V117, P63, DOI 10.1016/j.ophtha.2009.06.051
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   Lemp MA, 2007, OCUL SURF, V5, P75
   Liew M, 2012, BRIT J OPHTHALMOL, V96, P1498, DOI 10.1136/bjophthalmol-2012-301767
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264
   National Institutes of Health, SUMM EYE DIS PREV DA
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Saydah SH, 2004, JAMA-J AM MED ASSOC, V291, P335, DOI 10.1001/jama.291.3.335
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 34
TC 28
Z9 33
U1 0
U2 9
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2013
VL 19
IS 5
SU S
BP S67
EP S75
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA 162VE
UT WOS:000320293300001
PM 23725498
DA 2022-11-30
ER

PT J
AU Omarova, S
   Charvet, CD
   Reem, RE
   Mast, N
   Zheng, WC
   Huang, S
   Peachey, NS
   Pikuleva, IA
AF Omarova, Saida
   Charvet, Casey D.
   Reem, Rachel E.
   Mast, Natalia
   Zheng, Wenchao
   Huang, Suber
   Peachey, Neal S.
   Pikuleva, Irina A.
TI Abnormal vascularization in mouse retina with dysregulated retinal
   cholesterol homeostasis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID DENSITY-LIPOPROTEIN RECEPTOR; AGE-RELATED MACULOPATHY; STEROL
   27-HYDROXYLASE GENE; BILE-ACID SYNTHESIS; MACULAR DEGENERATION;
   CEREBROTENDINOUS-XANTHOMATOSIS; ANGIOMATOUS PROLIFERATION; SUBRETINAL
   NEOVASCULARIZATION; CHOROIDAL NEOVASCULARIZATION; PIGMENT-EPITHELIUM
AB Several lines of evidence suggest a link between age-related macular degeneration and retinal cholesterol maintenance. Cytochrome P450 27A1 (CYP27A1) is a ubiquitously expressed mitochondrial sterol 27-hydroxylase that plays an important role in the metabolism of cholesterol and cholesterol-related compounds. We conducted a comprehensive ophthalmic evaluation of mice lacking CYP27A1. We found that the loss of CYP27A1 led to dysregulation of retinal cholesterol homeostasis, including unexpected upregulation of retinal cholesterol biosynthesis. Cyp27a1(-/-) mice developed retinal lesions characterized by cholesterol deposition beneath the retinal pigment epithelium. Further, Cyp27a1-null mice showed pathological neovascularization, which likely arose from both the retina and the choroid, that led to the formation of retinal-choroidal anastomosis. Blood flow alterations and blood vessel leakage were noted in the areas of pathology. The Cyp27a1(-/-) retina was hypoxic and had activated Muller cells. We suggest a mechanism whereby abolished sterol 27-hydroxylase activity leads to vascular changes and identify Cyp27a1(-/-) mice as a model for one of the variants of type 3 retinal neovascularization occurring in some patients with age-related macular degeneration.
C1 [Omarova, Saida; Charvet, Casey D.; Reem, Rachel E.; Mast, Natalia; Zheng, Wenchao; Huang, Suber; Pikuleva, Irina A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Huang, Suber] Univ Hosp Cleveland, Cleveland, OH 44106 USA.
   [Peachey, Neal S.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Peachey, Neal S.] Cleveland VA Med Ctr, Cleveland, OH USA.
   [Peachey, Neal S.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; University Hospitals of Cleveland;
   Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Case Western Reserve University; Louis
   Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve
   University; Cleveland Clinic Foundation
RP Pikuleva, IA (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, 2085 Adelbert Rd,R 303A, Cleveland, OH 44106 USA.
EM iap8@case.edu
RI Peachey, Neal/G-5533-2010
OI Peachey, Neal/0000-0002-4419-7226; Pikuleva, Irina/0000-0001-9742-6232
FU Visual Sciences Research Center Core Facility [P30 EY11373]; NIH
   [EY018383]; Visual Sciences Training Program [T32 EY07157]; Veterans
   Administration Office of Research and Development; Ohio Lions Eye
   Research Foundation; Foundation Fighting Blindness; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [R01EY018383, T32EY007157,
   P30EY011373] Funding Source: NIH RePORTER
FX The authors thank the Visual Sciences Research Center Core Facility
   (supported by P30 EY11373) for assistance with genotyping (Anna
   Yakubenko), tissue sectioning (Cathy Doller), and microscopy (Scott
   Howell). Many thanks to Timothy Kern and Alex Veenstra for help with FA
   techniques. This work was supported in part by grants from the NIH
   (EY018383 to I.A. Pikuleva), predoctoral and postdoctoral research
   training fellowships T32 EY07157 from the Visual Sciences Training
   Program (to C.D. Charvet and R.E. Reem, respectively), funds from the
   Veterans Administration Office of Research and Development (to N.S.
   Peachey), the Ohio Lions Eye Research Foundation, and the Foundation
   Fighting Blindness, and unrestricted grants from Research to Prevent
   Blindness. I.A. Pikuleva is a recipient of the Jules and Doris Stein
   Professorship from Research to Prevent Blindness.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Bavner A, 2010, J LIPID RES, V51, P2722, DOI 10.1194/jlr.M008326
   Bjorkhem I., 1995, METABOLIC MOL BASES, P2073
   Bjorkhem I, 2010, BIOCHEM BIOPH RES CO, V396, P46, DOI 10.1016/j.bbrc.2010.02.140
   Bojanic DD, 2010, J LIPID RES, V51, P169, DOI [10.1194/jlr.M900250-JLR200, 10.1194/M900250-JLR200]
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   CASTANHO MARB, 1992, J BIOL CHEM, V267, P204
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   CRUYSBERG JRM, 1995, AM J OPHTHALMOL, V120, P597, DOI 10.1016/S0002-9394(14)72206-8
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeBose-Boyd RA, 2008, CELL RES, V18, P609, DOI 10.1038/cr.2008.61
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dotti MT, 2001, J INHERIT METAB DIS, V24, P696, DOI 10.1023/A:1012981019336
   DREHER Z, 1992, J COMP NEUROL, V323, P59, DOI 10.1002/cne.903230106
   Dubrac S, 2005, J LIPID RES, V46, P76, DOI 10.1194/jlr.M400219-JLR200
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   Fliesler SJ, 1997, INT J BIOCHEM CELL B, V29, P877, DOI 10.1016/S1357-2725(97)00018-6
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Gass JD, 1997, ATLAS MACULAR DIS
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   GUARNERI P, 1994, J NEUROCHEM, V63, P86
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Heo GY, 2012, ARCH BIOCHEM BIOPHYS, V518, P119, DOI 10.1016/j.abb.2011.12.016
   Heo GY, 2011, J LIPID RES, V52, P1117, DOI 10.1194/jlr.M014217
   Honda A, 2001, J LIPID RES, V42, P291
   Hong C, 2010, J BIOL CHEM, V285, P19720, DOI 10.1074/jbc.M110.123729
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Jaliffa CO, 2005, J NEUROCHEM, V94, P1666, DOI 10.1111/j.1471-4159.2005.03321.x
   Jankovic B, 2006, CYTOM PART B-CLIN CY, V70B, P45, DOI 10.1002/cyto.b.20086
   Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172
   Kizaka-Kondoh S, 2009, ADV DRUG DELIVER REV, V61, P623, DOI 10.1016/j.addr.2009.01.006
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103
   Kuzmanovic M, 2003, INVEST OPHTH VIS SCI, V44, P3606, DOI 10.1167/iovs.02-1265
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Liao WL, 2011, J PROTEOME RES, V10, P241, DOI 10.1021/pr1008898
   Lin M, 2011, DIABETOLOGIA, V54, P1554, DOI 10.1007/s00125-011-2081-0
   Loewen N, 2009, EXP EYE RES, V88, P928, DOI 10.1016/j.exer.2008.11.037
   LUND E, 1989, SCAND J CLIN LAB INV, V49, P165, DOI 10.3109/00365518909105417
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MORGAN SJ, 1989, BRIT J OPHTHALMOL, V73, P1011, DOI 10.1136/bjo.73.12.1011
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7
   Pikuleva I, 2003, ARCH BIOCHEM BIOPHYS, V420, P35, DOI 10.1016/j.abb.2003.09.028
   Pikuleva IA, 2006, PHARMACOL THERAPEUT, V112, P761, DOI 10.1016/j.pharmthera.2006.05.014
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P165, DOI 10.1007/s00417-011-1804-8
   Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605
   Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805
   Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SHAW G, 1984, EUR J CELL BIOL, V33, P95
   Shen X, 2010, GRAEF ARCH CLIN EXP, V248, P1127, DOI 10.1007/s00417-010-1362-5
   Sirvent A, 2004, FEBS LETT, V566, P173, DOI 10.1016/j.febslet.2004.04.026
   Sobhanifar S, 2005, CANCER RES, V65, P7259, DOI 10.1158/0008-5472.CAN-04-4480
   Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
NR 95
TC 46
Z9 46
U1 0
U2 4
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 2012
VL 122
IS 8
BP 3012
EP 3023
DI 10.1172/JCI63816
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 983OM
UT WOS:000307128600036
PM 22820291
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Huber, M
   Wachtlin, J
AF Huber, Matthias
   Wachtlin, Joachim
TI Vitreous Levels of Proteins Implicated in Angiogenesis Are Modulated in
   Patients with Retinal or Choroidal Neovascularization
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Angiogenesis; Neovascularization;
   Proliferative diabetic retinopathy; Vitreous
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY; MYOCARDIAL-INFARCTION; FACTOR
   RECEPTOR; ANTI-VEGF; ANGIOPOIETIN-2; IDENTIFICATION; METABOLISM
AB Aim: The aim of this study was to investigate the levels of pigment epithelium-derived factor (PEDF), angiopoietin 2, vascular endothelial growth factor (VEGF), and soluble VEGF receptor 1 (sVEGFR-1) in vitreous samples of patients suffering from age-related macular degeneration with choroidal neovascularization or from proliferative diabetic retinopathy (PDR). Methods: Proteins in vitreous samples of 29 patients were quantified via enzyme-linked immunosorbent assays. Results: Vitreous levels of sVEGFR-1 were significantly higher in age-related macular degeneration with choroidal neovascularization (p = 0.005) and in PDR (p = 0.003) versus controls. In analogue comparisons, PEDF was significantly decreased (p < 0.01). PDR was associated with significantly increased angiopoietin 2 and VEGF levels (p = 0.001 for both). Conclusion: The vitreous in retinal or choroidal neovascularization revealed a pro-angiogenic potential indicated by decreased PEDF or increased angiopoietin 2 levels compared to controls. However, higher amounts of sVEGFR-1 were concomitant, pointing to activation of an endogenous anti-angiogenic system in the protein network. Copyright (c) 20125. Karger AG, Basel
C1 [Huber, Matthias] Charite, Inst Clin Pharmacol & Toxicol, DE-10117 Berlin, Germany.
   [Wachtlin, Joachim] St Gertrauden Hosp, Dept Ophthalmol, Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Huber, M (通讯作者)，Charite, Inst Clin Pharmacol & Toxicol, Charitepl 1, DE-10117 Berlin, Germany.
EM matthias.huber@charite.de
CR Afzal A, 2007, MICROVASC RES, V74, P131, DOI 10.1016/j.mvr.2007.04.011
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al-Shabrawey M, 2011, DIABETES, V60, P614, DOI 10.2337/db10-0008
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Borg ML, 2011, DIABETES, V60, P1458, DOI 10.2337/db10-0845
   Cai J, 2006, MICROVASC RES, V71, P20, DOI 10.1016/j.mvr.2005.10.004
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Ellis LM, 2008, CLIN CANCER RES, V14, P6371, DOI 10.1158/1078-0432.CCR-07-5287
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Feng YX, 2009, CELL PHYSIOL BIOCHEM, V23, P277, DOI 10.1159/000218174
   Habtemariam T, 2001, CELL MOL BIOL, V47, P1201
   Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104
   Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Ideno J, 2007, INT J MOL MED, V19, P75
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Lieb W, 2010, CIRC-CARDIOVASC GENE, V3, P300, DOI 10.1161/CIRCGENETICS.109.914556
   Manalo KB, 2011, EXPERT OPIN THER PAT, V21, P121, DOI 10.1517/13543776.2011.545347
   Matsunaga N, 2008, OPHTHALMOLOGY, V115, P1916, DOI 10.1016/j.ophtha.2008.06.025
   Notari L, 2006, J BIOL CHEM, V281, P38022, DOI 10.1074/jbc.M600353200
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Pfister F, 2010, ACTA DIABETOL, V47, P59, DOI 10.1007/s00592-009-0099-2
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong D, 2011, GRAEF ARCH CLIN EXP, V249, P161, DOI 10.1007/s00417-010-1574-8
   Woolf AS, 2010, CURR OPIN NEPHROL HY, V19, P20, DOI 10.1097/MNH.0b013e328333025e
   Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x
   Yao D, 2007, J BIOL CHEM, V282, P31038, DOI 10.1074/jbc.M704703200
NR 34
TC 14
Z9 15
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2012
VL 228
IS 3
BP 188
EP 193
DI 10.1159/000339952
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 010LU
UT WOS:000309096700009
PM 22868384
DA 2022-11-30
ER

PT J
AU Martinez-Alberquilla, I
   Gasull, X
   Perez-Luna, P
   Seco-Mera, R
   Ruiz-Alcocer, J
   Crooke, A
AF Martinez-Alberquilla, Irene
   Gasull, Xavier
   Perez-Luna, Patricia
   Seco-Mera, Ruben
   Ruiz-Alcocer, Javier
   Crooke, Almudena
TI Neutrophils and neutrophil extracellular trap components: Emerging
   biomarkers and therapeutic targets for age-related eye diseases
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Neutrophil; Neutrophil extracellular trap; Dry eye; Glaucoma;
   Age-related macular degeneration; Diabetic retinopathy
ID TO-LYMPHOCYTE RATIO; GLYCATION END-PRODUCTS; GANGLION-CELL LAYER;
   OPEN-ANGLE GLAUCOMA; HUMAN TRABECULAR MESHWORK; GENE-EXPRESSION PROFILE;
   AQUEOUS-HUMOR DYNAMICS; DIABETIC MACULAR EDEMA; VERSUS-HOST-DISEASE; DRY
   EYE
AB Age-related eye diseases, including dry eye, glaucoma, age-related macular degeneration, and diabetic retinopathy, represent a major global health issue based on their increasing prevalence and disabling action. Unraveling the molecular mechanisms underlying these diseases will provide novel opportunities to reduce the burden of age-related eye diseases and improve eye health, contributing to sustainable development goals achievement. The impairment of neutrophil extracellular traps formation/degradation processes seems to be one of these mechanisms. These traps formed by a meshwork of DNA and neutrophil cytosolic granule proteins may exacerbate the inflammatory response promoting chronic inflammation, a pivotal cause of age-related diseases. In this review, we describe current findings that suggest the role of neutrophils and their traps in the pathogenesis of the above-mentioned age-related eye diseases. Furthermore, we discuss why these cells and their constituents could be biomarkers and therapeutic targets for dry eye, glaucoma, age-related macular degeneration, and diabetic retinopathy. We also examine the therapeutic potential of some neutrophil function modulators and provide several recommendations for future research in age-related eye diseases.
C1 [Martinez-Alberquilla, Irene; Ruiz-Alcocer, Javier] Univ Complutense Madrid, Fac Opt & Optometry, Dept Optometry & Vis, Madrid, Spain.
   [Gasull, Xavier] Univ Barcelona, Med Sch, Inst Neurosci, Neurophysiol Lab,Dept Biomed, Barcelona, Spain.
   [Gasull, Xavier] Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain.
   [Perez-Luna, Patricia; Seco-Mera, Ruben; Crooke, Almudena] Univ Complutense Madrid, Fac Opt & Optometry, Dept Biochem & Mol Biol, C Arcos de Jalon 118, Madrid 28037, Spain.
   [Martinez-Alberquilla, Irene; Ruiz-Alcocer, Javier; Crooke, Almudena] Univ Complutense Madrid, Fac Opt & Optometry, Clin & Expt Eye Res Grp, UCM 971009, Madrid, Spain.
C3 Complutense University of Madrid; University of Barcelona; University of
   Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Complutense University
   of Madrid; Complutense University of Madrid
RP Crooke, A (通讯作者)，Univ Complutense Madrid, Fac Opt & Optometry, Dept Biochem & Mol Biol, C Arcos de Jalon 118, Madrid 28037, Spain.
EM acrooke@ucm.es
OI Crooke, Almudena/0000-0003-4360-1896
FU European Regional Development Fund (ERDF); European Union; Ministerio de
   Ciencia e Innovacion [FIS P17/00296, RD16/0008/0014]; Instituto de Salud
   Carlos III, Spain [FIS P17/00296, RD16/0008/0014]; Agencia Estatal de
   Investigacion (MICINN), Spain [PID2020-119305RB-I00, MDM-2017-0729];
   Generalitat de Catalunya, Spain [2017SGR737]; Universidad Complutense de
   Madrid, Spain [CT63/19-CT64/19]; Banco Santander, Spain
   [CT63/19-CT64/19]
FX This work was supported by European Regional Development Fund (ERDF),
   European Union, and Ministerio de Ciencia e Innovacion and Instituto de
   Salud Carlos III, Spain [FIS P17/00296 (X.G.) and RETICs Oftared
   RD16/0008/0014 (X.G.)]; Agencia Estatal de Investigaci ' on (MICINN),
   Spain [PID2020-119305RB-I00 (X.G.) and MDM-2017-0729 (to Institut de
   Neurociencies, Universitat de Barcelona)]; and Generalitat de Catalunya,
   Spain [2017SGR737 (X.G.)]. I.MA. holds a predoctoral fellowship from
   Universidad Complutense de Madrid and Banco Santander, Spain
   (CT63/19-CT64/19).
CR Akpek EK, 2013, AM J MANAG CARE, V19, pS67
   Alonso-Fernandez P, 2008, J AM GERIATR SOC, V56, P2244, DOI 10.1111/j.1532-5415.2008.02018.x
   ALVARADO J, 1984, OPHTHALMOLOGY, V91, P564
   Alves M, 2005, J ENDOCRINOL, V187, P159, DOI 10.1677/joe.1.06209
   An S, 2019, OCUL SURF, V17, P589, DOI 10.1016/j.jtos.2019.03.010
   AnandBabu K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216899
   Arafat SN, 2017, AM J OPHTHALMOL, V176, P46, DOI 10.1016/j.ajo.2016.12.026
   Aragona P., 2006, INVESTIG OPHTHALMOL, V47, P269
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Atalay Kursat, 2019, Med Hypothesis Discov Innov Ophthalmol, V8, P278
   Avni I, 2010, OPHTHALMOLOGY, V117, P1287, DOI 10.1016/j.ophtha.2009.11.029
   Azab B, 2012, RENAL FAILURE, V34, P571, DOI 10.3109/0886022X.2012.668741
   BALAZSI AG, 1984, AM J OPHTHALMOL, V97, P760, DOI 10.1016/0002-9394(84)90509-9
   Barkaway A, 2021, IMMUNITY, V54, P1494, DOI 10.1016/j.immuni.2021.04.025
   Barletta KE, 2012, ARTERIOSCL THROM VAS, V32, P856, DOI 10.1161/ATVBAHA.111.226845
   Bazan N.G, 2009, LIPOXIN A4 PROTECTIO
   Bazan N.G, 2010, LIPOXIN A4 PROTECTIO
   Bhattacharya SK, 2006, INVEST OPHTH VIS SCI, V47, P2508, DOI 10.1167/iovs.05-1499
   Bian C, 2010, HEART VESSELS, V25, P469, DOI 10.1007/s00380-010-0010-7
   Bian F, 2019, MUCOSAL IMMUNOL, V12, P897, DOI 10.1038/s41385-018-0127-z
   Blumberg D, 2015, PROG BRAIN RES, V221, P81, DOI 10.1016/bs.pbr.2015.04.007
   Boldea Radu C., 2001, International Ophthalmology, V24, P67, DOI 10.1023/A:1016361426238
   Bonilha VL, 2013, EXP EYE RES, V111, P71, DOI 10.1016/j.exer.2013.03.017
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Brennan EP, 2018, DIABETES, V67, P2657, DOI 10.2337/db17-1317
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Bron A J, 2004, Ocul Surf, V2, P149
   Bron AJ, 2017, OCUL SURF, V15, P438, DOI 10.1016/j.jtos.2017.05.011
   Bron AJ, 2009, OCUL SURF, V7, P78, DOI 10.1016/S1542-0124(12)70299-9
   Burch JB, 2014, J GERONTOL A-BIOL, V69, pS1, DOI 10.1093/gerona/glu041
   Burton MJ, 2021, LANCET GLOB HEALTH, V9, pE489, DOI 10.1016/S2214-109X(20)30488-5
   Caballero M, 2004, BIOCHEM BIOPH RES CO, V323, P1048, DOI 10.1016/j.bbrc.2004.08.195
   Caprioli J, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12716
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Cassatella MA, 2019, TRENDS IMMUNOL, V40, P648, DOI 10.1016/j.it.2019.05.003
   Charles BA, 2014, HANDBOOK OF NUTRITION, DIET, AND THE EYE, P525, DOI 10.1016/B978-0-12-401717-7.00053-8
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Chen M, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00205-w
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Cheng JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103222
   Cheon SY, 2019, EXP NEUROBIOL, V28, P643, DOI 10.5607/en.2019.28.6.643
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chirivi RGS, 2021, CELL MOL IMMUNOL, V18, P1528, DOI 10.1038/s41423-020-0381-3
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Choi W, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64048-7
   Chowdhury CS, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4579
   Chung JO, 2016, DIABETIC MED, V33, P1649, DOI 10.1111/dme.13141
   Chung TW, 2013, BBA-MOL CELL RES, V1833, P3386, DOI 10.1016/j.bbamcr.2013.10.011
   Ciudin A, 2010, EXP DIABETES RES, DOI 10.1155/2010/714108
   Clapp C, 2019, ACTA DIABETOL, V56, P1031, DOI 10.1007/s00592-019-01343-4
   Costa G, 2009, J NEUROSCI RES, V87, P1375, DOI 10.1002/jnr.21956
   Court H, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0181-7
   Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008
   Croft MA, 2017, EXP EYE RES, V158, P187, DOI 10.1016/j.exer.2016.07.007
   Crooke A, 2008, PHARMACOL THERAPEUT, V119, P55, DOI 10.1016/j.pharmthera.2008.04.002
   Crooke A, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12430
   Curtis TM, 2011, DIABETOLOGIA, V54, P690, DOI 10.1007/s00125-010-1971-x
   Das UN, 2013, NUTRITION, V29, P1, DOI 10.1016/j.nut.2012.02.003
   Das UN, 2012, MED SCI MONITOR, V18, pLE1, DOI 10.12659/MSM.882187
   De Groef L, 2016, INVEST OPHTH VIS SCI, V57, P5984, DOI 10.1167/iovs.16-19734
   De la Fuente M, 2009, CURR PHARM DESIGN, V15, P3003, DOI 10.2174/138161209789058110
   de Paiva Cintia S, 2017, Int Ophthalmol Clin, V57, P47, DOI 10.1097/IIO.0000000000000170
   de Souza RG, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e3
   DelaCruz JP, 1997, J PHARMACOL EXP THER, V280, P454
   DelaPaz MA, 1996, INVEST OPHTH VIS SCI, V37, P1849
   Delgado-Rizo V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00081
   Di Zazzo A, 2019, INVEST OPHTH VIS SCI, V60, P1769, DOI 10.1167/iovs.18-25822
   Dogru M, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23402
   Dorward DA, 2015, AM J PATHOL, V185, P1172, DOI 10.1016/j.ajpath.2015.01.020
   Dosch M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041222
   Drew W, 2018, EXP GERONTOL, V105, P70, DOI 10.1016/j.exger.2017.12.020
   Eshaq Randa S, 2017, Pathophysiology, V24, P229, DOI 10.1016/j.pathophys.2017.07.001
   Farid M, 2016, OCUL IMMUNOL INFLAMM, V24, P327, DOI 10.3109/09273948.2014.986581
   Fasanella V, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7432131
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng J, 2019, MOL MED REP, V20, P216, DOI 10.3892/mmr.2019.10236
   Fletcher EL, 2019, DRUG DISCOV TODAY, V24, P1598, DOI 10.1016/j.drudis.2019.03.029
   Floderer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101881
   Fonseca B, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00719
   Foulsham W, 2020, AM J PATHOL, V190, P1474, DOI 10.1016/j.ajpath.2020.03.016
   Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016
   Franceschi C, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00061
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Gabelt BT, 2005, PROG RETIN EYE RES, V24, P612, DOI 10.1016/j.preteyeres.2004.10.003
   Ganesalingam K, 2019, CLIN EXP OPTOM, V102, P446, DOI 10.1111/cxo.12849
   Gerhardinger C, 2005, INVEST OPHTH VIS SCI, V46, P349, DOI 10.1167/iovs.04-0860
   Ghosh S, 2020, CELL MOL LIFE SCI, V77, P835, DOI 10.1007/s00018-019-03423-8
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Giebel J, 2005, ACTA OPHTHALMOL SCAN, V83, P471, DOI 10.1111/j.1600-0420.2005.00472.x
   Gipson IK, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12840
   Grbic DM, 2012, INFLAMM BOWEL DIS, V18, P1456, DOI 10.1002/ibd.21931
   GRIERSON I, 1987, EYE, V1, P204, DOI 10.1038/eye.1987.38
   Gronert K, 2010, EXP EYE RES, V91, P478, DOI 10.1016/j.exer.2010.07.004
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Guo Y, 2011, INVEST OPHTH VIS SCI, V52, P1460, DOI 10.1167/iovs.10-5930
   Gupta T, 2017, J HISTOCHEM CYTOCHEM, V65, P567, DOI 10.1369/0022155417726507
   Gupta V, 2014, BBA-MOL BASIS DIS, V1842, P1567, DOI 10.1016/j.bbadis.2014.05.026
   Hagan S, 2016, EPMA J, V7, DOI 10.1186/s13167-016-0065-3
   Hamada K, 2021, BRIT J PHARMACOL, V178, P4552, DOI 10.1111/bph.15637
   Harman A, 2000, ANAT REC, V260, P124
   Hazeldine J, 2014, AGING CELL, V13, P690, DOI 10.1111/acel.12222
   Hofbauer T, 2017, ATHEROSCLEROSIS, V263, pE67, DOI 10.1016/j.atherosclerosis.2017.06.226
   Hollo G, 2014, EXPERT OPIN PHARMACO, V15, P1737, DOI 10.1517/14656566.2014.936850
   Hu CX, 2018, ONCOTARGETS THER, V11, P8099, DOI 10.2147/OTT.S181223
   Hu HL, 2010, EXP EYE RES, V91, P425, DOI 10.1016/j.exer.2010.06.017
   Ilhan N, 2015, OCUL IMMUNOL INFLAMM, V23, P287, DOI 10.3109/09273948.2014.921715
   Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516
   Jensen EL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082922
   Jha MK, 2015, NEUROSCI BIOBEHAV R, V49, P135, DOI 10.1016/j.neubiorev.2014.12.006
   Jin HL, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-112
   Jing-Xu, 2018, CELL PHYSIOL BIOCHEM, V48, P705, DOI 10.1159/000491897
   Johnson SC, 2015, AGING CELL, V14, P809, DOI 10.1111/acel.12362
   Ju KR, 2006, BRAIN RES, V1122, P209, DOI 10.1016/j.brainres.2006.09.022
   Kaeslin MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165314
   Kita M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40008-8
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   Kojima T, 2012, AM J PATHOL, V180, P1879, DOI 10.1016/j.ajpath.2012.01.019
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Kowluru RA, 2012, EXPERT OPIN INV DRUG, V21, P797, DOI 10.1517/13543784.2012.681043
   Kurtul BE, 2016, EYE, V30, P1045, DOI 10.1038/eye.2016.89
   Kurtul Bengi Ece, 2016, Korean J Ophthalmol, V30, P377
   Kwon J, 2020, OCUL SURF, V18, P80, DOI 10.1016/j.jtos.2019.10.004
   Lamoke F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139664
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Li L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00347
   Li Y, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0471-y
   Li ZY, 2016, AGING-US, V8, P2337, DOI 10.18632/aging.101050
   Liesenborghs I, 2020, ACTA OPHTHALMOL, V98, P48, DOI 10.1111/aos.14154
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liou Gregory I, 2011, J Ocul Biol Dis Infor, V4, P19, DOI 10.1007/s12177-011-9067-5
   Liou GI, 2008, INVEST OPHTH VIS SCI, V49, P5526, DOI 10.1167/iovs.08-2196
   Liu BY, 2018, SURV OPHTHALMOL, V63, P56, DOI 10.1016/j.survophthal.2017.06.007
   Liu HT, 2019, DIABETOLOGIA, V62, P2365, DOI 10.1007/s00125-019-04998-4
   Liu YT, 2013, INVEST OPHTH VIS SCI, V54, P6382, DOI 10.1167/iovs.13-12128
   Livne-Bar I, 2017, J CLIN INVEST, V127, P4403, DOI 10.1172/JCI77398
   Lu R.J., 2021, NAT AGING
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Mahajan A, 2019, J LEUKOCYTE BIOL, V105, P1087, DOI 10.1002/JLB.HI0718-249RR
   Malet F, 2014, ACTA OPHTHALMOL, V92, pE429, DOI 10.1111/aos.12174
   Mancini JE, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0332-7
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Markovskaya A, 2008, EUR J PHARMACOL, V579, P93, DOI 10.1016/j.ejphar.2007.10.040
   Mashaghi A, 2017, BRIT J OPHTHALMOL, V101, P1, DOI 10.1136/bjophthalmol-2015-307848
   Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023
   Medicine D., 2016, MAKING EYE HLTH POPU
   Micera A, 2016, ADV THER, V33, P252, DOI 10.1007/s12325-016-0285-x
   Minns D, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8968943
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mowen KA, 2014, NAT IMMUNOL, V15, P512, DOI 10.1038/ni.2873
   Mun C, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.10
   Murali A, 2020, EUR J OPHTHALMOL, V30, P1195, DOI 10.1177/1120672120919337
   Nag TC, 2021, EYE, V35, P2917, DOI 10.1038/s41433-021-01602-1
   Nag TC, 2011, ANN ANAT, V193, P205, DOI 10.1016/j.aanat.2011.02.004
   Nag TC, 2019, ANN ANAT, V226, P35, DOI 10.1016/j.aanat.2019.06.007
   Nattinen J, 2019, CLIN PROTEOM, V16, DOI 10.1186/s12014-019-9233-5
   Navarro A, 2008, ADV DRUG DELIVER REV, V60, P1534, DOI 10.1016/j.addr.2008.05.002
   Nelson JD, 2011, INVEST OPHTH VIS SCI, V52, P1930, DOI 10.1167/iovs.10-6997b
   Neufeld AH, 1999, SURV OPHTHALMOL, V43, pS129, DOI 10.1016/S0039-6257(99)00010-7
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nien CJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P462, DOI 10.1001/archophthalmol.2011.69
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Ohashi Y, 2020, ADV THER, V37, P707, DOI 10.1007/s12325-019-01188-x
   Ortak H, 2013, ACTA HISTOCHEM, V115, P382, DOI 10.1016/j.acthis.2012.09.013
   Ortmann W, 2018, CELL TISSUE RES, V371, P473, DOI 10.1007/s00441-017-2751-4
   Ozcan DO, 2022, OCUL IMMUNOL INFLAMM, V30, P588, DOI 10.1080/09273948.2020.1821899
   Ozgonul C, 2016, J GLAUCOMA, V25, pE815, DOI 10.1097/IJG.0000000000000392
   Park Cheul Ho, 2012, Korean J Ophthalmol, V26, P123, DOI 10.3341/kjo.2012.26.2.123
   Park JH, 2016, EXP CLIN ENDOCR DIAB, V124, P557, DOI 10.1055/s-0042-101792
   Parmar T, 2018, J IMMUNOL, V200, P3128, DOI 10.4049/jimmunol.1701573
   Pelegrin P, 2009, PURINERG SIGNAL, V5, P129, DOI 10.1007/s11302-009-9141-7
   Peters K.S., 2021, AM J OPHTHALMOL
   Peyman Gholam A, 2011, J Ophthalmic Vis Res, V6, P36
   Postnikoff CK, 2020, OCUL SURF, V18, P841, DOI 10.1016/j.jtos.2020.08.011
   Prata Larissa G P Langhi, 2018, Semin Immunol, V40, P101275, DOI 10.1016/j.smim.2019.04.003
   Purvis GSD, 2018, DIABETOLOGIA, V61, P482, DOI 10.1007/s00125-017-4469-y
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reyes NJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aas9164
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rios JD, 2005, EXP EYE RES, V80, P477, DOI 10.1016/j.exer.2004.10.012
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   Rocha LR, 2020, AGING CELL, V19, DOI 10.1111/acel.13089
   Roda M, 2020, EYE CONTACT LENS, V46, pS129, DOI 10.1097/ICL.0000000000000663
   Romano GL, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114199
   Rusciano D, 2018, OPHTHALMIC RES, V60, P94, DOI 10.1159/000489093
   Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366
   Santiago AR, 2020, PHARMACOL THERAPEUT, V210, DOI 10.1016/j.pharmthera.2020.107513
   Seen S, 2018, ACTA OPHTHALMOL, V96, pE412, DOI 10.1111/aos.13526
   Sekeryapan B, 2016, CORNEA, V35, P983, DOI 10.1097/ICO.0000000000000872
   Sharif U, 2019, J CELL MOL MED, V23, P405, DOI 10.1111/jcmm.13944
   Sharma A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/781683
   Shen MQ, 2016, BBA-PROTEINS PROTEOM, V1864, P787, DOI 10.1016/j.bbapap.2016.04.001
   Shikari H, 2013, SURV OPHTHALMOL, V58, P233, DOI 10.1016/j.survophthal.2012.08.004
   Shinozaki Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93456
   Shosha E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041215
   Sil P, 2017, J IMMUNOL, V198, P428, DOI 10.4049/jimmunol.1600766
   Silk E, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.52
   Silvestre-Roig C, 2019, NATURE, V569, P236, DOI 10.1038/s41586-019-1167-6
   Smith CP, 2007, EXP EYE RES, V85, P817, DOI 10.1016/j.exer.2007.08.017
   Sofoluwe A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53058-9
   Sonawane S, 2012, INVEST OPHTH VIS SCI, V53, P8253, DOI 10.1167/iovs.12-10430
   Soto D, 2005, J PHARMACOL EXP THER, V314, P1042, DOI 10.1124/jpet.105.085274
   Stapleton F, 2017, OCUL SURF, V15, P334, DOI 10.1016/j.jtos.2017.05.003
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Sugimoto MA, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8239258
   Sugiyama T, 2005, AM J PHYSIOL-CELL PH, V288, pC568, DOI 10.1152/ajpcell.00380.2004
   Sugiyama T, 2014, WORLD J DIABETES, V5, P141, DOI 10.4239/wjd.v5.i2.141
   Suk K, 2016, PROG NEUROBIOL, V144, P158, DOI 10.1016/j.pneurobio.2016.08.001
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Sundaresan Y, 2019, EYE VISION, V6, DOI 10.1186/s40662-019-0156-z
   Taichman NS, 1997, J LEUKOCYTE BIOL, V62, P397, DOI 10.1002/jlb.62.3.397
   Takagi H, 1998, DIABETES, V47, P1480, DOI 10.2337/diabetes.47.9.1480
   Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P1311
   Tang BH, 2020, OPHTHALMIC RES, V63, P413, DOI 10.1159/000504450
   Tang WY, 2018, CELL PHYSIOL BIOCHEM, V46, P375, DOI 10.1159/000488472
   Taurone S, 2020, CLIN ANAT, V33, P245, DOI 10.1002/ca.23488
   Taurone S, 2015, MOL MED REP, V11, P1384, DOI 10.3892/mmr.2014.2772
   Tektas OY, 2009, EXP EYE RES, V88, P769, DOI 10.1016/j.exer.2008.11.025
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Tezel G, 2000, J NEUROSCI, V20, P8693
   Tezel G, 2011, EXP EYE RES, V93, P178, DOI 10.1016/j.exer.2010.07.009
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tibrewal S, 2014, INVEST OPHTH VIS SCI, V55, P7961, DOI 10.1167/iovs.14-15332
   Tibrewal S, 2013, INVEST OPHTH VIS SCI, V54, P8051, DOI 10.1167/iovs.13-12844
   Toris CB, 1999, AM J OPHTHALMOL, V127, P407, DOI 10.1016/S0002-9394(98)00436-X
   Uchino Miki, 2013, Curr Ophthalmol Rep, V1, P51
   Ueno S, 2018, INVEST OPHTH VIS SCI, V59, P370, DOI 10.1167/iovs.17-22438
   Ulu SM, 2013, DIABETES TECHNOL THE, V15, P942, DOI 10.1089/dia.2013.0097
   UN Department of Economic and Social Affairs Population Division, 2019, STESASERA423 UN DEP, VII
   Vindeirinho J, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/4270301
   Wang AL, 2007, ANN NY ACAD SCI, V1097, P64, DOI 10.1196/annals.1379.027
   Wang H, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01462-5
   Wang LZY, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03076
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wang X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00399
   Wei AJ, 2011, CORNEA, V30, P1007, DOI 10.1097/ICO.0b013e31820ca468
   Wenisch C, 2000, J LEUKOCYTE BIOL, V67, P40, DOI 10.1002/jlb.67.1.40
   Wizeman J, 2014, INVEST OPHTH VIS SCI, V55
   Woldemussie E, 2004, GLIA, V47, P109, DOI 10.1002/glia.20000
   Yang XD, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0795-8
   Yang X, 2020, CHINESE MED J-PEKING, V133, P2586, DOI 10.1097/CM9.0000000000001015
   Yoon C.H., 2020, INT J MOL SCI, V21
   Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96
   Yue S, 2015, INT J ENV RES PUB HE, V12, P10009, DOI 10.3390/ijerph120810009
   Zheng Y, 2018, INT J OPHTHALMOL-CHI, V11, P196, DOI 10.18240/ijo.2018.02.03
   Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360
   Zhou YB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01200
   Zhu WQ, 2010, BRIT J OPHTHALMOL, V94, P1448, DOI 10.1136/bjo.2008.155820
NR 252
TC 5
Z9 5
U1 3
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD FEB
PY 2022
VL 74
AR 101553
DI 10.1016/j.arr.2021.101553
PG 14
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 0I0PL
UT WOS:000779130000008
PM 34971794
OA Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU MacKenzie, G
   Peng, DF
AF MacKenzie, Gilbert
   Peng, Defen
TI Interval-censored parametric regression survival models and the analysis
   of longitudinal trials
SO STATISTICS IN MEDICINE
LA English
DT Article
DE artificial precision; bias; interval censoring; longitudinal RCTs;
   parametric models; proportional hazards; nonproportional hazards; proxy
   likelihoods; survival models
ID PROPORTIONAL HAZARDS MODEL; FAILURE TIME DATA; MACULAR DEGENERATION;
   CONSISTENCY; LIKELIHOOD; TUTORIAL
AB This paper develops interval censoring likelihood methods in the context of parametric proportional hazard (PH) and non-PH regression models in the longitudinal study setting to reanalyze the medical research council's randomized controlled trial of teletherapy in age-related macular degeneration. We compare the performance of the interval censoring likelihood with proxy likelihoods that were used to analyze the original data. It is shown, analytically, that the use of such proxy likelihoods in selected PH models leads to biased estimators. Such estimators are artificially precise; further, the magnitude of their percentage bias is quantified in a data-directed simulation study. For non-PH models, we demonstrate that these results obtained from PH models do not hold uniformly and explain the implications of this finding for the reanalysis of proxy likelihood trial data. Our final analysis, of the age-related macular degeneration trial data, based on fitting PH and non-PH models, reassuringly confirms the published findings from the original trial. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [MacKenzie, Gilbert] ENSAI, Rennes, France.
   [MacKenzie, Gilbert; Peng, Defen] Univ Limerick, Dept Math & Stat, Ctr Biostat, Limerick, Ireland.
   [Peng, Defen] Zhongnan Univ Econ & Law, Wuhan, Peoples R China.
C3 Ecole Nationale de la Statistique et de l'Analyse de l'Information
   (ENSAI); University of Limerick; Zhongnan University of Economics & Law
RP MacKenzie, G (通讯作者)，ENSAI, Rennes, France.
EM gilbert.mackenzie@ul.ie
FU two Science Foundation Ireland (SFI); Mathematics Initiative, II, via
   the BIO-SI in the Centre of Biostatistics, University of Limerick,
   Ireland [07/MI/012]; SFI [05/RF/MAT 026]
FX The work in this paper was supported by two Science Foundation Ireland
   (SFI, www.sfi.ie) project grants. Professor MacKenzie was supported
   under the Mathematics Initiative, II, via the BIO-SI (www.ul.ie/bio-si)
   research program in the Centre of Biostatistics, University of Limerick,
   Ireland: grant number 07/MI/012. Dr. Peng is also supported via an SFI
   Research Frontiers Programme award: grant number 05/RF/MAT 026. We thank
   the associate editor and anonymous referees whose suggestions
   substantially improved the presentation of the paper.
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Bridgman SA, 2009, KNEE, V16, P216, DOI 10.1016/j.knee.2008.11.012
   BUCKLEY J, 1979, BIOMETRIKA, V66, P429
   Collett, 2003, MODELLING SURVIVAL D
   COX DR, 1975, BIOMETRIKA, V62, P269, DOI 10.2307/2335362
   COX DR, 1972, J R STAT SOC B, V34, P187
   FINKELSTEIN DM, 1986, BIOMETRICS, V42, P845, DOI 10.2307/2530698
   Gomez G, 2009, STAT MODEL, V9, P259, DOI 10.1177/1471082X0900900402
   Ha ID, 2010, STAT MODEL, V10, P315
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Henschel V, INTCOX COMPENDIUM AP
   Lam KF, 2010, STAT MED, V29, P680, DOI 10.1002/sim.3835
   Law G, 1992, STAT MED, V11, P1569
   Lawless JF, 2006, BIOMETRIKA, V93, P671, DOI 10.1093/biomet/93.3.671
   Lawless JF., 2003, STAT MODELS METHODS
   Lindsey JC, 1998, STAT MED, V17, P219, DOI 10.1002/(SICI)1097-0258(19980130)17:2<219::AID-SIM735>3.0.CO;2-O
   Lindsey JK, 1998, LIFETIME DATA ANAL, V4, P329, DOI 10.1023/A:1009681919084
   MacKenzie G, 2002, 17 INT WORKSH STAT M, P431
   MacKenzie G., 1999, 14 INT WORKSH STAT M, P259
   MacKenzie G, 1996, J ROYAL STAT SOC D, V45, P21
   ODELL PM, 1992, BIOMETRICS, V48, P951, DOI 10.2307/2532360
   Pan W, 1999, J COMPUT GRAPH STAT, V8, P109, DOI 10.2307/1390923
   Pan W, 1998, BIOMETRICS, V54, P1053, DOI 10.2307/2533856
   Pan W, 2002, BIOMETRICS, V58, P64, DOI 10.1111/j.0006-341X.2002.00064.x
   Peng D, 2009, THESIS MACMASTER U O
   Schick A, 2000, SCAND J STAT, V27, P45, DOI 10.1111/1467-9469.00177
   Sparling YH, 2006, BIOSTATISTICS, V7, P599, DOI 10.1093/biostatistics/kxj028
   Sun J., 2006, STAT ANAL INTERVAL C
   Sun JG, 1996, STAT MED, V15, P1387, DOI 10.1002/(SICI)1097-0258(19960715)15:13&lt;1387::AID-SIM268&gt;3.0.CO;2-R
   TURNBULL BW, 1976, J R STAT SOC B, V38, P290
   Yu QQ, 2000, SCAND J STAT, V27, P35, DOI 10.1111/1467-9469.00176
NR 32
TC 2
Z9 2
U1 0
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD JUL 20
PY 2013
VL 32
IS 16
BP 2804
EP 2822
DI 10.1002/sim.5721
PG 19
WC Mathematical & Computational Biology; Public, Environmental &
   Occupational Health; Medical Informatics; Medicine, Research &
   Experimental; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology; Public, Environmental &
   Occupational Health; Medical Informatics; Research & Experimental
   Medicine; Mathematics
GA 164HW
UT WOS:000320400900007
PM 23297174
DA 2022-11-30
ER

PT J
AU Xiang, DH
   Tian, HH
   Yang, XL
   Shi, F
   Zhu, WF
   Chen, HY
   Chen, XJ
AF Xiang, Dehui
   Tian, Haihong
   Yang, Xiaoling
   Shi, Fei
   Zhu, Weifang
   Chen, Haoyu
   Chen, Xinjian
TI Automatic Segmentation of Retinal Layer in OCT Images With Choroidal
   Neovascularization
SO IEEE TRANSACTIONS ON IMAGE PROCESSING
LA English
DT Article
DE Choroidal neovascularization; optical coherence tomography; neural
   network and graph search
ID OPTICAL COHERENCE TOMOGRAPHY; VESSEL SEGMENTATION; MACULAR EDEMA;
   CLASSIFICATION; DIFFUSION; LEVEL
AB Age-related macular degeneration is one of the main causes of blindness. However, the internal structures of retinas are complex and difficult to be recognized due to the occurrence of neovascularization. Traditional surface detection methods may fail in the layer segmentation. In this paper, a supervised method is reported for simultaneously segmenting layers and neovascularization. Three spatial features, seven gray-level-based features, and 14 layer-like features are extracted for the neural network classifier. The coarse surfaces of different optical coherence tomography (OCT) images can thus be found. To describe and enhance retinal layers with different thicknesses and abnormalities, multi-scale bright and dark layer detection filters are introduced. A constrained graph search algorithm is also proposed to accurately detect retinal surfaces. The weights of nodes in the graph are computed based on these layer-like responses. The proposed method was evaluated on 42 spectral-domain OCT images with age-related macular degeneration. The experimental results show that the proposed method outperforms state-of-the-art methods.
C1 [Xiang, Dehui; Tian, Haihong; Yang, Xiaoling; Shi, Fei; Zhu, Weifang; Chen, Xinjian] Soochow Univ, Sch Elect & Informat Engn, Suzhou 215006, Peoples R China.
   [Xiang, Dehui; Tian, Haihong; Yang, Xiaoling; Shi, Fei; Zhu, Weifang; Chen, Xinjian] Soochow Univ, State Key Lab Radiat Med & Protect, Sch Radiat Med & Protect, Suzhou 215006, Peoples R China.
   [Chen, Haoyu] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Chen, Haoyu] Chinese Univ Hong Kong, Shantou 515041, Peoples R China.
C3 Soochow University - China; Soochow University - China; Shantou
   University
RP Xiang, DH; Chen, XJ (通讯作者)，Soochow Univ, Sch Elect & Informat Engn, Suzhou 215006, Peoples R China.
EM xiangdehui@suda.edu.cn; xjchen@suda.edu.cn
RI Xiang, Dehui/B-1938-2016; Chen, Haoyu/A-7432-2013
OI Xiang, Dehui/0000-0001-7873-9778; Chen, Haoyu/0000-0003-0676-4610; Chen,
   Xinjian/0000-0002-0871-293X
FU National Basic Research Program of China (973 Program) [2014CB748600];
   National Natural Science Foundation of China (NSFC) [61401293, 81371629,
   61401294, 81401451, 81401472]; National Science Fund of Talented Young
   Scholars [61622114]
FX This work was supported in part by the National Basic Research Program
   of China (973 Program) under Grant 2014CB748600, in part by the National
   Natural Science Foundation of China (NSFC) under Grant 61401293, Grant
   81371629, Grant 61401294, Grant 81401451, and Grant 81401472, and in
   part by the National Science Fund of Talented Young Scholars under Grant
   61622114.
CR Chen HY, 2016, RETINA-J RET VIT DIS, V36, P1964, DOI 10.1097/IAE.0000000000001017
   Chen XJ, 2012, INVEST OPHTH VIS SCI, V53, P8042, DOI 10.1167/iovs.12-10083
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Gao ET, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128925
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Goodfellow IJ, 2014, ADV NEUR IN, V27, P2672
   GRAHAM RL, 1983, J ALGORITHM, V4, P324, DOI 10.1016/0196-6774(83)90013-5
   Hassan B, 2016, J OPT SOC AM A, V33, P455, DOI 10.1364/JOSAA.33.000455
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Li QL, 2016, IEEE T MED IMAGING, V35, P109, DOI 10.1109/TMI.2015.2457891
   Lu SJ, 2010, IEEE T BIO-MED ENG, V57, P2605, DOI 10.1109/TBME.2010.2055057
   Manniesing R, 2006, MED IMAGE ANAL, V10, P815, DOI 10.1016/j.media.2006.06.003
   Marin D, 2011, IEEE T MED IMAGING, V30, P146, DOI 10.1109/TMI.2010.2064333
   Morley D., 2017, CORR
   Mortazi Aliasghar, 2017, Medical Image Computing and Computer-Assisted Intervention, MICCAI 2017. 20th International Conference. Proceedings: LNCS 10434, P377, DOI 10.1007/978-3-319-66185-8_43
   Novosel J, 2016, I S BIOMED IMAGING, P702, DOI 10.1109/ISBI.2016.7493363
   Novosel J, 2015, MED IMAGE ANAL, V26, P146, DOI 10.1016/j.media.2015.08.008
   Roy A. G., 2017, RELAYNET RETINAL LAY
   Sabour S., 2017, P 31 C NEUR INF PROC
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Song Q, 2013, IEEE T MED IMAGING, V32, P376, DOI 10.1109/TMI.2012.2227120
   Tian J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133908
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
   Vermeer KA, 2011, BIOMED OPT EXPRESS, V2, P1743, DOI 10.1364/BOE.2.001743
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiang D., 2018, IEEE J BIOMED HEALTH, P1
   Xiang DH, 2017, MED IMAGE ANAL, V42, P257, DOI 10.1016/j.media.2017.06.010
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 37
TC 31
Z9 35
U1 5
U2 47
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1057-7149
EI 1941-0042
J9 IEEE T IMAGE PROCESS
JI IEEE Trans. Image Process.
PD DEC
PY 2018
VL 27
IS 12
BP 5880
EP 5891
DI 10.1109/TIP.2018.2860255
PG 12
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA GS9ET
UT WOS:000444019600012
PM 30059302
DA 2022-11-30
ER

PT J
AU Ye, Z
   Li, ZH
   He, SZ
AF Ye, Zi
   Li, Zhaohui
   He, Shouzhi
TI Long non-coding RNA associated-competing endogenous RNAs are induced by
   clusterin in retinal pigment epithelial cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE long non-coding RNA; competing endogenous RNA network; retinal pigment
   epithelial cells; clusterin
ID MACULAR DEGENERATION; COMPLEMENT; EXPRESSION; GENE; PATHOGENESIS;
   INFLAMMATION; CONSUMPTION; HYPOTHESIS
AB Age related macular degeneration is one of the most common causes of vision loss in the elderly. Long noncoding RNAs (lncRNAs) serve important roles in regulating gene expression by acting as competing endogenous RNAs (ceRNAs). However, the roles of specific lncRNAs and their associated ceRNA function induced by clusterin in cultured retinal pigment epithelial (RPE) cells remain to be fully elucidated. Based on high throughput sequencing data from RPE cells treated with or without clusterin, the present study identified differentially expressed mRNAs, lncRNAs and microRNAs (miRNAs). A lncRNA-mRNA-microRNA (miRNA) network (ceRNA network) was subsequently constructed based on the bioinformatic database miRanda and miRNA targets database miRTarBase. These results demonstrated the expression pattern of several lncRNAs, and a clear clusterin-associated ceRNA network in RPE cells, which included 75 lncRNAs and 32 miRNAs in RPE cells induced by clusterin. Collectively, the present study uncovered and characterized via bioinformatics the global properties of the ceRNA network in human RPE cells in response to clusterin. These results may aid in the elucidation of the molecular mechanisms of clusterin in age-related macular degeneration.
C1 [Ye, Zi; Li, Zhaohui; He, Shouzhi] Peoples Liberat Army Gen Hosp, Dept Ophthalmol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Li, ZH (通讯作者)，Peoples Liberat Army Gen Hosp, Dept Ophthalmol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM yezi201588@126.com
OI Li, Zhaohui/0000-0002-4132-658X
FU China Social Assistance Fund [BJ-LM2015001 J]
FX The current study was supported by the China Social Assistance Fund
   (grant no. BJ-LM2015001 J).
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bell JT, 2011, TRENDS GENET, V27, P116, DOI 10.1016/j.tig.2010.12.005
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen X, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-7-r78
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Guduric-Fuchs J, 2012, J CELL BIOCHEM, V113, P2098, DOI 10.1002/jcb.24084
   HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163
   JENNE DE, 1991, J BIOL CHEM, V266, P11030
   John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kociok N, 2010, GRAEF ARCH CLIN EXP, V248, P1145, DOI 10.1007/s00417-010-1371-4
   Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32
   Li YY, 2011, NEUROSCI LETT, V487, P94, DOI 10.1016/j.neulet.2010.09.079
   Li YY, 2011, NEUROSCI LETT, V499, P109, DOI 10.1016/j.neulet.2011.05.044
   Liu YR, 2016, CLIN CANCER RES, V22, P1653, DOI 10.1158/1078-0432.CCR-15-1555
   Pogue AI, 2011, J INORG BIOCHEM, V105, P1434, DOI 10.1016/j.jinorgbio.2011.05.012
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Pundir P, 2015, J IMMUNOL, V195, P2774, DOI 10.4049/jimmunol.1401348
   Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Su XP, 2014, ONCOTARGET, V5, P9864, DOI 10.18632/oncotarget.2454
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tsang FHC, 2015, LIVER INT, V35, P1597, DOI 10.1111/liv.12746
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215
   Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010
NR 47
TC 8
Z9 8
U1 1
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2017
VL 16
IS 6
BP 8399
EP 8405
DI 10.3892/mmr.2017.7606
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FQ3AM
UT WOS:000418229200066
PM 28944909
OA Bronze
DA 2022-11-30
ER

PT J
AU Yang, ZL
   Tong, ZZ
   Chorich, LJ
   Pearson, E
   Yang, X
   Moore, A
   Hunt, DM
   Zhang, K
AF Yang, Zhenglin
   Tong, Zongzhong
   Chorich, Louis J.
   Pearson, Erik
   Yang, Xian
   Moore, Anthony
   Hunt, David M.
   Zhang, Kang
TI Clinical characterization and genetic mapping of North Carolina macular
   dystrophy
SO VISION RESEARCH
LA English
DT Article
DE NCMD; NCDR1; fine mapping; interval
ID HONEYCOMB RETINAL DYSTROPHY; MULTILOCUS LINKAGE ANALYSIS; MALATTIA
   LEVENTINESE; RDS GENE; MAPS; DEGENERATION; DISEASE; MCDR1; PHENOTYPE;
   FAMILY
AB North Carolina macular dystrophy (NCMD) is an autosomal dominant macular disease, was mapped to 6q14-q16.2, the disease-causing gene has yet not been identified. It shares phenotypic similarity with age-related macular degeneration including drusen and choroidal neovascularization. We collected six families with NCMD including 75 members, and conducted clinical characterization and genetic mapping for these families. Forty-five patients were diagnosed as NCMD; all six NCMD families were mapped to MCDR1 locus using genetic linkage analysis. MCDR1 interval was refined to 3 cM (1.8mb) between D6S1716 to D6S1671 via fine mapping using microsatellite markers in these six families, all eleven annotated genes within the interval were analyzed by mutation screening in coding regions, no mutation was found, suggesting a potential novel gene or a new pathological mechanism causing NCMD. The refinement of MCDR1 locus will aid the disease-causing gene identification. Functional studies of NCMD genes should provide important insights into pathogenetic mechanisms of NCMD and age-related macular degeneration. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Yang, Zhenglin; Tong, Zongzhong; Pearson, Erik; Yang, Xian; Zhang, Kang] Univ Utah, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Yang, Zhenglin; Tong, Zongzhong; Pearson, Erik; Yang, Xian; Zhang, Kang] Univ Utah, Hlth Sci Ctr, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Salt Lake City, UT 84132 USA.
   [Chorich, Louis J.] Havener Eye Inst, Columbus, OH 43210 USA.
   [Moore, Anthony; Hunt, David M.] Inst Ophthalmol, London EC1V 9EL, England.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Ohio State University; University
   of London; University College London
RP Yang, ZL (通讯作者)，Univ Utah, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
EM zhenglin.yang@hmbg.utah.edu; zhang@hmbg.utah.edu
RI Hunt, David M/K-6024-2012; Zhang, Kang/Y-2740-2019
OI Hunt, David M/0000-0002-9264-3948; Zhang, Kang/0000-0002-4549-1697
FU NATIONAL EYE INSTITUTE [R01EY014448, R01EY014428] Funding Source: NIH
   RePORTER; NEI NIH HHS [R01EY14448, R01 EY014428, R01 EY014428-04, R01
   EY014428-03, R01 EY014428-01, R01 EY014448-03S1, R01 EY014448, R01
   EY014448-04, R01EY41128, R01 EY014448-03, R01 EY014448-01, R01
   EY014428-05A1S1, R01 EY014448-02, R01 EY014448-05S1, R01 EY014448-05,
   R01 EY014428-05A1, R01 EY014428-02] Funding Source: Medline
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Cameron DJ, 2007, INT J BIOL SCI, V3, P111
   CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295
   FRANK HR, 1974, AM J OPHTHALMOL, V78, P903, DOI 10.1016/0002-9394(74)90800-9
   Garibaldi DC, 1999, INT OPHTHALMOL CLIN, V39, P117, DOI 10.1097/00004397-199903940-00009
   Gregory CY, 1996, HUM MOL GENET, V5, P1055, DOI 10.1093/hmg/5.7.1055
   Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kniazeva M, 2000, AM J OPHTHALMOL, V130, P197, DOI 10.1016/S0002-9394(00)00585-7
   Kniazeva M, 1999, AM J HUM GENET, V64, P1394, DOI 10.1086/302377
   LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443
   LATHROP GM, 1985, AM J HUM GENET, V37, P482
   LEFLER WH, 1971, AM J OPHTHALMOL, V71, P224, DOI 10.1016/0002-9394(71)90394-1
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Rabb MF, 1998, AM J OPHTHALMOL, V125, P502, DOI 10.1016/S0002-9394(99)80191-3
   Reichel MB, 1998, BRIT J OPHTHALMOL, V82, P1162, DOI 10.1136/bjo.82.10.1162
   Sauer CG, 1997, J MED GENET, V34, P961, DOI 10.1136/jmg.34.12.961
   Small K W, 1997, Mol Vis, V3, P1
   SMALL KW, 1992, ARCH OPHTHALMOL-CHIC, V110, P515, DOI 10.1001/archopht.1992.01080160093040
   SMALL KW, 1992, GENOMICS, V13, P681, DOI 10.1016/0888-7543(92)90141-E
   SMALL KW, 1993, OPHTHALMIC PAED GEN, V14, P143, DOI 10.3109/13816819309042913
   Small KW, 1998, RETINA-J RET VIT DIS, V18, P448
   Small KW, 1999, MOL VIS, V5
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659
   Yang ZL, 2002, HUM MOL GENET, V11, P605, DOI 10.1093/hmg/11.5.605
   Yen H, 2000, SCIENCE, V289, P1890
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 34
TC 20
Z9 20
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD FEB
PY 2008
VL 48
IS 3
BP 470
EP 477
DI 10.1016/j.visres.2007.09.015
PG 8
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 272BG
UT WOS:000253832000018
PM 17976682
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Baek, J
   Cheung, CMG
   Jeon, S
   Lee, JH
   Lee, WK
AF Baek, Jiwon
   Cheung, Chui Ming Gemmy
   Jeon, Sohee
   Lee, Jae Hyung
   Lee, Won Ki
TI Polypoidal Choroidal Vasculopathy: Outer Retinal and Choroidal Changes
   and Neovascularization Development in the Fellow Eye
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; fellow eye study; RPE changes;
   pachyvessel; incidence
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CLINICAL
   CHARACTERISTICS; FEATURES; CHINESE; DRUSEN; RPE; CHORIOCAPILLARIS;
   LESIONS
AB PURPOSE. We investigated the outer retinal, RPE, and choroidal changes and the development of choroidal neovascularization (CNV) in fellow eyes of patients with unilateral polypoidal choroidal vasculopathy or aneurysmal type 1 neovascularization (PCV/AT1).
   METHODS. In this retrospective observational cohort study, 263 patients with unilateral PCV/AT1 were enrolled. Fundus photography, enhanced depth imaging optical coherence tomography, and indocyanine green angiography at baseline and follow-up were analyzed. Incidence and risk factors for the development of CNV were analyzed.
   RESULTS. In fellow eyes of unilateral PCV/AT1 cases, RPE and outer retinal abnormalities were observed in 222 (84%) eyes, and dilated Haller vessels (pachyvessel) were identified in the corresponding abnormality area in 157 (71%) eyes. Follow-up data were available for 233 patients. During a 27.6-month mean follow-up period, 20/233 (9%) eyes had CNV (12 PCV/AT1 and eight type 1 CNV). In 18 eyes (90%), CNV developed at the RPE or outer retinal abnormality areas accompanied by pachyvessel. A significantly higher risk for CNV was observed if RPE and outer retinal abnormalities were accompanied by pachyvessel (hazard ratio, 9.3; 95% confidence interval, 1.1-75.9, P = 0.037).
   CONCLUSIONS. RPE and outer retinal abnormalities were common in fellow eyes of patients presenting with unilateral PCV/AT1. CNV developed in fellow eyes of 9% of patients, frequently in the areas with RPE and outer retinal abnormality accompanied by pachyvessel.
C1 [Baek, Jiwon] Catholic Univ Korea, Coll Med, Bucheon St Marys Hosp, Dept Ophthalmol & Visual Sci, Bucheon, Gyeonggi Do, South Korea.
   [Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Duke NUS Grad Med Sch, Eye Acad Clin Program, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Jeon, Sohee] Keye Eye Ctr, Seoul, South Korea.
   [Lee, Jae Hyung; Lee, Won Ki] Catholic Univ Korea, Coll Med, St Marys Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Catholic University of Korea; Singapore National Eye Center; National
   University of Singapore; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; Catholic
   University of Korea; Catholic University Korea Hospital; Seoul St.
   Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Coll Med, Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul St,222 Banpo Daero, Seoul 06591, South Korea.
EM wklee@catholic.ac.kr
OI Cheung, Chui Ming Gemmy/0000-0003-3358-3516
CR Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Fujimoto H, 2008, OPHTHALMOLOGY, V115, P1494, DOI 10.1016/j.ophtha.2008.01.021
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Gupta Pawan, 2010, International Ophthalmology, V30, P175, DOI 10.1007/s10792-009-9302-2
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hayashi K, 2005, JPN J OPHTHALMOL, V49, P153, DOI 10.1007/s10384-004-0153-0
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim JW, 2011, J OPHTHALMOL, V25, P222
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1595, DOI 10.1167/iovs.15-18494
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 54
TC 10
Z9 10
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2019
VL 60
IS 2
BP 590
EP 598
DI 10.1167/iovs.18-24244
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HN0LZ
UT WOS:000459881100013
PM 30721925
OA gold
DA 2022-11-30
ER

PT J
AU Ma, WX
   Coon, S
   Zhao, L
   Fariss, RN
   Wong, WT
AF Ma, Wenxin
   Coon, Steven
   Zhao, Lian
   Fariss, Robert N.
   Wong, Wai T.
TI A2E accumulation influences retinal microglial activation and complement
   regulation
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Microglia; Retina; Lipofuscin; A2E; Aging; Age-related macular
   degeneration; Complement; Activation; Neuroprotection; Photoreceptors;
   Chemokine
ID PIGMENTED EPITHELIAL-CELLS; SUBRETINAL DRUSENOID DEPOSITS; LIGHT-INDUCED
   DAMAGE; MACULAR DEGENERATION; MOUSE RETINA; FACTOR-H; LIPOFUSCIN
   FLUOROPHORE; GENE-EXPRESSION; RPE LIPOFUSCIN; UNITED-STATES
AB Age-related macular degeneration is an outer retinal disease that involves aging and immune dysfunction. In the aging retina, microglia aggregate in the outer retina and acquire intracellular autofluorescent lipofuscin deposits. In this study, we investigated whether accumulation of A2E, a key bisretinoid constituent of ocular lipofuscin, alters the physiology of retinal microglia in pathologically relevant ways. Our findings show that sublethal accumulations of intracellular A2E in cultured retinal microglia increased microglial activation and decreased microglial neuroprotection of photoreceptors. Increased A2E accumulation also lowered microglial expression of chemokine receptors and suppressed microglial chemotaxis, suggesting that lipofuscin accumulation may potentiate subretinal microglial accumulation. Significantly, A2E accumulation altered microglial complement regulation by increasing complement factor B and decreasing complement factor H expression, favoring increased complement activation and deposition in the outer retina. Taken together, our findings highlight the role of microglia in the local control of complement activation in the retina and present the age-related accumulation of ocular lipofuscin in subretinal microglia as a cellular mechanism capable of driving outer retinal immune dysregulation in age-related macular degeneration pathogenesis. Published by Elsevier Inc.
C1 [Ma, Wenxin; Zhao, Lian; Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Coon, Steven] NICHHD, Sect Neuroendocrinol, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA.
   [Fariss, Robert N.] NEI, Biol Imaging Core, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Wong, WT (通讯作者)，NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bldg 6,Room 215, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Fariss, Robert/ABI-1771-2020; Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Fariss, Robert/0000-0003-3227-7170
FU NEI Intramural by the National Eye Institute Intramural Research
   Program; American Health Assistance Foundation (AHAF); NATIONAL EYE
   INSTITUTE [ZIAEY000463, ZICEY000459] Funding Source: NIH RePORTER
FX We are grateful to Dr. Maria M. Campos for her assistance with
   histopathology of aged and AMD eyes. This study was supported by the NEI
   Intramural by the National Eye Institute Intramural Research Program and
   a grant from the American Health Assistance Foundation (AHAF).
   Acknowledgement is made to the donors of ADR, a program of the American
   Health Assistance Foundation, for support of this research.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Biber K, 2008, J NEUROIMMUNOL, V198, P69, DOI 10.1016/j.jneuroim.2008.04.012
   Boehm Michael R. R., 2011, Inflammation & Allergy Drug Targets, V10, P283
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Czeh M, 2011, DEV NEUROSCI-BASEL, V33, P199, DOI 10.1159/000328989
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Ding XY, 2009, INVEST OPHTH VIS SCI, V50, P4957, DOI 10.1167/iovs.09-3381
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lei L, 2012, MOL VIS, V18, P103
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luo C, 2011, MOL VIS, V17, P1588
   Ma KN, 2010, INVEST OPHTH VIS SCI, V51, P6776, DOI 10.1167/iovs.10-5887
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Madinier A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008101
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Olah M, 2011, CNS NEUROL DISORD-DR, V10, P108, DOI 10.2174/187152711794488575
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park LCH, 2001, MECH AGEING DEV, V123, P21, DOI 10.1016/S0047-6374(01)00336-0
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Ransohoff RM, 2007, INT REV NEUROBIOL, V82, P187, DOI 10.1016/S0074-7742(07)82010-1
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Toku K, 1998, J NEUROSCI RES, V53, P415, DOI 10.1002/(SICI)1097-4547(19980815)53:4<415::AID-JNR3>3.0.CO;2-9
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuohy G, 2002, INVEST OPHTH VIS SCI, V43, P3583
   Vinet J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-27
   von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhao L, 2007, MOL VIS, V13, P873
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 79
TC 72
Z9 78
U1 0
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2013
VL 34
IS 3
BP 943
EP 960
DI 10.1016/j.neurobiolaging.2012.06.010
PG 18
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 065AF
UT WOS:000313117900025
PM 22819137
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lee, JH
   Lee, T
   Lee, SC
   Lee, CS
AF Lee, Ji Hwan
   Lee, Taekjune
   Lee, Sung Chul
   Lee, Christopher Seungkyu
TI Disappearance of soft drusen and subsequent development of choroidal
   neovascularization following macular hole surgery: a case report
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Drusen; Choroidal neovascularization; Macular hole; Surgery
ID DEGENERATION; RISK
AB Background: Drusen are important risk factor for neovascular age-related macular degeneration (AMD) and have a dynamic nature as they can enlarge, newly form, or disappear over time. There have been few reports on drusen regression or choroidal neovascularization (CNV) development after macular hole surgery.
   We report, to our knowledge, the first case of both drusen regression and subsequent CNV development within 7 months of successful macular hole surgery. Case presentation: A 73-year-old woman presented with a stage 3 full-thickness macular hole and large, confluent soft macular drusen in the right eye and a neovascular age-related macular degeneration (AMD) in the fellow eye. Four months after the successful macular hole surgery, significant regression of drusen was seen, especially in the temporal area to the fovea. Three months later, the patient developed CNV and her best-corrected visual acuity decreased to 20/100, despite further regression of macular drusen.
   Conclusions: Macular hole patients with macular soft drusen need to be carefully followed up after surgery for possible drusen regression and CNV development.
C1 [Lee, Ji Hwan; Lee, Taekjune; Lee, Sung Chul; Lee, Christopher Seungkyu] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Seoul 120749, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Lee, CS (通讯作者)，Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, 134 Shinchondong, Seoul 120749, South Korea.
EM sklee219@yuhs.ac
OI Lee, Christopher/0000-0001-5054-9470; , Sung Chul/0000-0001-9438-2385;
   Lee, Ji Hwan/0000-0003-1759-8195
CR Banker AS, 1997, OPHTHALMOLOGY, V104, P1442, DOI 10.1016/S0161-6420(97)30118-3
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Chaudhry NA, 2000, ARCH OPHTHALMOL-CHIC, V118, P131
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Dithmar S, 2013, EYE, V27, P779, DOI 10.1038/eye.2013.35
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, RETINA-J RET VIT DIS, V21, P184, DOI 10.1097/00006982-200104000-00018
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lehmann F, 2014, OPHTHALMOLO IN PRESS
   Oh HN, 2012, CLIN OPHTHALMOL, V6, P1287, DOI 10.2147/OPTH.S33650
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SEBAG M, 1991, ACTA OPHTHALMOL, V69, P603
   Tabandeh H, 2004, RETINA-J RET VIT DIS, V24, P714, DOI 10.1097/00006982-200410000-00005
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 14
TC 4
Z9 4
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 28
PY 2015
VL 15
AR 43
DI 10.1186/s12886-015-0029-8
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH5PB
UT WOS:000354086700001
PM 25928705
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Do, DV
AF Do, Diana V.
TI Detection of new-onset choroidal neovascularization
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   fluorescein angiography; optical coherence tomography
ID AMSLER; EYE
AB Purpose of review
   To highlight the most common methods that are used to detect new-onset choroidal neovascularization (CNV) as a result of age-related macular degeneration (AMD).
   Recent findings
   Numerous modalities are available to try to detect CNV. Amsler grid testing, preferential hyperacuity perimetry (PHP), optical coherence tomography (OCT), and fluorescein angiography are tools that may be used to detect CNV. The Age-Related Macular Degeneration: Detection of Onset of new Choroidal neovascularization Study (AMD DOC Study) evaluated the sensitivity of time domain OCT, relative to fluorescein angiography, in detecting new-onset neovascular AMD within a 2-year period. The sensitivity of each modality for detecting CNV was OCT 0.40 [(95% confidence interval (95% CI) (0.16-0.68), supervised Amsler grid 0.42 (95% CI 0.15-0.72), and PHP 0.50 (95% CI 0.23-0.77)].
   Summary
   Numerous modalities are available to try to detect CNV. The prospective AMD DOC Study demonstrated that fluorescein angiography still remains the best method to detect new-onset CNV.
C1 Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Carl Camras Ctr Innovat Clin Trials Ophthalmol, Omaha, NE USA.
C3 University of Nebraska System; University of Nebraska Medical Center
RP Do, DV (通讯作者)，Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Carl Camras Ctr Innovat Clin Trials Ophthalmol, Omaha, NE USA.
EM ddo@jhmi.edu
FU Genentech; Regeneron
FX Dr Do has received research funding from Genentech and Regeneron.
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lowenstein A, 2010, RETINA, V30, P1058
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   ROY MS, 1985, OPHTHALMOLOGICA, V191, P215, DOI 10.1159/000309590
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015
NR 11
TC 55
Z9 57
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2013
VL 24
IS 3
BP 244
EP 247
DI 10.1097/ICU.0b013e32835fd7dd
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ML
UT WOS:000317394000010
PM 23518615
DA 2022-11-30
ER

PT J
AU Penn, JS
   Madan, A
   Caldwell, RB
   Bartoli, M
   Caldwell, RW
   Hartnett, ME
AF Penn, J. S.
   Madan, A.
   Caldwell, R. B.
   Bartoli, M.
   Caldwell, R. W.
   Hartnett, M. E.
TI Vascular endothelial growth factor in eye disease
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE retina; angiogenesis; vascular endothelial growth factor; age-related
   macular degeneration; diabetic retinopathy; retinopathy of prematurity
ID RETINAL-PIGMENT EPITHELIUM; OXYGEN-INDUCED RETINOPATHY; INTRAVITREAL
   BEVACIZUMAB AVASTIN; COMPLEMENT FACTOR-H; OCCULT CHOROIDAL
   NEOVASCULARIZATION; HYPOXIA-INDUCIBLE FACTOR-1; GLYCATION END-PRODUCTS;
   NITRIC-OXIDE SYNTHASE; INDUCED TRANSCRIPTIONAL ACTIVATION;
   INTERCELLULAR-ADHESION MOLECULE-1
AB Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the US, for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Penn, J. S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Madan, A.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
   [Caldwell, R. B.; Bartoli, M.; Caldwell, R. W.] Med Coll Georgia, Augusta, GA 30912 USA.
   [Hartnett, M. E.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
C3 Vanderbilt University; Stanford University; University System of
   Georgia; Augusta University; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine
RP Penn, JS (通讯作者)，Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
EM john.penn@vanderbilt.edu
OI Caldwell, Ruth/0000-0003-0168-0354
FU RPB; VA Merit Review Award [EY04618, EY011766];  [EY007533];  [EY08126];
   [EY07135];  [EY015130];  [EY017011]; NATIONAL EYE INSTITUTE
   [R01EY004618, R01EY017011, P30EY008126, R01EY015130, R29EY007533,
   R01EY007533, R01EY011766, R56EY015130] Funding Source: NIH RePORTER
FX The authors are indebted to Susan E. Yanni for her contributions to the
   editing and processing of this review. its preparation was funded in
   part by EY007533, EY08126, EY07135 and support from RPB (JSP); EY04618,
   EY011766, VA Merit Review Award (RBC); EY015130, EY017011 (MEH).
CR Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032
   Abu El-Asrar AM, 2004, EYE, V18, P306, DOI 10.1038/sj.eye.6700642
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Alexandraki K, 2006, ANN NY ACAD SCI, V1084, P89, DOI 10.1196/annals.1372.039
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   ALSHABRAWEY M, 2008, INVEST OPHTHALM 0331
   ALSHABRAWEY M, 2006, OPHTHALMOL VIS SCI, V47
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson Christina G, 2004, J Perinatol, V24, P164, DOI 10.1038/sj.jp.7211067
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Antonetti D A, 1999, Semin Ophthalmol, V14, P240, DOI 10.3109/08820539909069543
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   ASHTON N, 1961, Trans Ophthalmol Soc U K, V81, P145
   ASHTON N, 1966, AM J OPHTHALMOL, V62, P412, DOI 10.1016/0002-9394(66)91322-5
   ASHTON N, 1968, BRIT J OPHTHALMOL, V52, P505
   ASHTON N, 1957, Br J Ophthalmol, V41, P449, DOI 10.1136/bjo.41.8.449
   ASHTON N, 1970, BRIT MED BULL, V26, P103, DOI 10.1093/oxfordjournals.bmb.a070758
   ASKIE LM, 2000, COCHRANE DB SYST REV, V12
   Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   BANCALARI E, 1987, PEDIATRICS, V79, P663
   Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561
   Barber AJ, 2005, INVEST OPHTH VIS SCI, V46, P2210, DOI 10.1167/iovs.04-1340
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200
   Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje
   Bates DO, 2002, J ANAT, V200, P581, DOI 10.1046/j.1469-7580.2002.00066.x
   Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687
   Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.3.CO;2-D
   Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853
   BEHZADIAN MA, 2004, OPHTHAMOL VIS SCI, V45
   BEHZADIAN MA, 2003, FASEB J, V19, P19
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Berkowitz BA, 2000, INVEST OPHTH VIS SCI, V41, P1925
   Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BLANKS JC, 1983, J COMP NEUROL, V221, P31, DOI 10.1002/cne.902210103
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Bock F, 2007, OPHTHALMOLOGE, V104, P336, DOI 10.1007/s00347-007-1512-2
   Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bornes S, 2004, J BIOL CHEM, V279, P18717, DOI 10.1074/jbc.M308410200
   BOULTON ME, 2007, INVEST OPHTHALMOL VI, V48
   Breen EC, 2007, J CELL BIOCHEM, V102, P1358, DOI 10.1002/jcb.21579
   BREIER G, 1992, DEVELOPMENT, V114, P521
   Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown LF, 1997, LAB INVEST, V76, P245
   Brown MS, 2006, J AAPOS, V10, P143, DOI 10.1016/j.jaapos.2005.09.005
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Bursell SE, 1999, DIABETES CARE, V22, P1245, DOI 10.2337/diacare.22.8.1245
   Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869
   Caballero S, 2007, DIABETES, V56, P960, DOI 10.2337/db06-1254
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Caldwell RB, 2005, CURR DRUG TARGETS, V6, P511, DOI 10.2174/1389450054021981
   Campbell F. W., 1951, T OPHTH SOC UK, V71, P287
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2007, J CELL PHYSIOL, V210, P575, DOI 10.1002/jcp.20893
   Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 1998, NATURE, V395, P525, DOI 10.1038/26791
   Ceriello A, 2001, DIABETOLOGIA, V44, P834
   Chan CK, 2005, LAB INVEST, V85, P721, DOI 10.1038/labinvest.3700277
   Chan-Ling T, 2004, INVEST OPHTH VIS SCI, V45, P2020, DOI 10.1167/iovs.03-1169
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   CHANLING T, 1990, CURR EYE RES, V9, P459, DOI 10.3109/02713689008999612
   CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201
   CHAO FC, 1982, THROMB HAEMOSTASIS, V47, P259
   CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1
   CHEN Z, 2007, MED RES REV
   Chong EWT, 2006, CLIN EXP OPHTHALMOL, V34, P464, DOI 10.1111/j.1442-9071.2006.01250.x
   Chow LC, 2003, PEDIATRICS, V111, P339, DOI 10.1542/peds.111.2.339
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Claxton S, 2003, EXP EYE RES, V77, P305, DOI 10.1016/S0014-4835(03)00153-2
   COGAN D G, 1963, Trans Ophthalmol Soc U K, V83, P465
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419
   Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015
   Das Arup, 2006, Semin Ophthalmol, V21, P23, DOI 10.1080/08820530500509366
   de Gooyer TE, 2006, INVEST OPHTH VIS SCI, V47, P5561, DOI 10.1167/iovs.06-0647
   Dejneka NS, 2004, MOL VIS, V10, P964
   Delbosc S, 2002, J CARDIOVASC PHARM, V40, P611, DOI 10.1097/00005344-200210000-00015
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Deng JX, 2007, CURR CANCER DRUG TAR, V7, P91, DOI 10.2174/156800907780006922
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dixelius J, 2003, J BIOL CHEM, V278, P40973, DOI 10.1074/jbc.M304499200
   Dor Y, 2001, AM J PHYSIOL-CELL PH, V280, pC1367, DOI 10.1152/ajpcell.2001.280.6.C1367
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dorey CK, 1996, ARCH OPHTHALMOL-CHIC, V114, P1210, DOI 10.1001/archopht.1996.01100140410008
   Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500
   Dorrell MI, 2006, PROG RETIN EYE RES, V25, P277, DOI 10.1016/j.preteyeres.2006.01.001
   DREHER B, 1988, BRAIN BEHAV EVOLUT, V31, P369, DOI 10.1159/000116602
   Du YP, 2003, FREE RADICAL BIO MED, V35, P1491, DOI 10.1016/j.freeradbiomed.2003.08.018
   Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x
   Dugel Pravin U, 2006, Int Ophthalmol Clin, V46, P131, DOI 10.1097/01.iio.0000212142.15794.30
   Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eichler W, 2004, NEUROREPORT, V15, P1633, DOI 10.1097/01.wnr.0000133071.00786.a4
   El-Remessy AB, 2007, FASEB J, V21, P2528, DOI 10.1096/fj.06-7854com
   El-Remessy AB, 2006, AM J PATHOL, V168, P235, DOI 10.2353/ajpath.2006.050500
   El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612
   El-Remessy AB, 2003, INVEST OPHTH VIS SCI, V44, P3135, DOI 10.1167/iovs.02-1022
   El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5
   Ellis EA, 1998, FREE RADICAL BIO MED, V24, P111, DOI 10.1016/S0891-5849(97)00202-5
   Ellis EA, 2000, FREE RADICAL BIO MED, V28, P91, DOI 10.1016/S0891-5849(99)00216-6
   Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273
   ENGERMAN RL, 1965, AM J OPHTHALMOL, V60, P628, DOI 10.1016/0002-9394(65)92251-8
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Esser P, 1995, Ger J Ophthalmol, V4, P269
   Fattal E, 2006, ADV DRUG DELIVER REV, V58, P1203, DOI 10.1016/j.addr.2006.07.020
   Feeney SA, 2003, INVEST OPHTH VIS SCI, V44, P839, DOI 10.1167/iovs.02-0040
   Feng YY, 1999, INVEST OPHTH VIS SCI, V40, P157
   Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   FLOWER RW, 1985, INVEST OPHTH VIS SCI, V26, P957
   FLYNN JT, 1987, OPHTHALMOLOGY, V94, P630
   Fons P, 2004, J CELL PHYSIOL, V200, P351, DOI 10.1002/jcp.20076
   Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Frank RN, 2002, AM J OPHTHALMOL, V133, P693, DOI 10.1016/S0002-9394(02)01321-1
   Fruttiger M, 1996, NEURON, V17, P1117, DOI 10.1016/S0896-6273(00)80244-5
   Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Fuh G, 2000, J BIOL CHEM, V275, P26690
   Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349
   Funatsu H, 2003, INVEST OPHTH VIS SCI, V44, P1042, DOI 10.1167/iovs.02-0374
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gariano RF, 1996, INVEST OPHTH VIS SCI, V37, P93
   Gariano RF, 2006, GENE EXPR PATTERNS, V6, P187, DOI 10.1016/j.modgep.2005.06.008
   GARIANO RF, 1994, INVEST OPHTH VIS SCI, V35, P3442
   Gariano RF, 2003, PROG RETIN EYE RES, V22, P295, DOI 10.1016/S1350-9462(02)00062-9
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Ghirlanda G, 1997, DIABETES METAB REV, V13, P15, DOI 10.1002/(SICI)1099-0895(199703)13:1<15::AID-DMR176>3.0.CO;2-M
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Gilbert RE, 1998, LAB INVEST, V78, P1017
   Gluzman-Poltorak Z, 2001, J BIOL CHEM, V276, P18688, DOI 10.1074/jbc.M006909200
   Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262
   Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096
   GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355
   GOLE GA, 1982, AUST J OPHTHALMOL, V10, P223, DOI 10.1111/j.1442-9071.1982.tb01621.x
   Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684
   Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Graier WF, 1996, DIABETES, V45, P1386, DOI 10.2337/diabetes.45.10.1386
   Graier WF, 1997, HORM METAB RES, V29, P622, DOI 10.1055/s-2007-979113
   Graier WF, 1999, DIABETES RES CLIN PR, V45, P153, DOI 10.1016/S0168-8227(99)00045-5
   GRANT MB, 1993, ANN NY ACAD SCI, V692, P230
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu XL, 2003, AM J PHYSIOL-CELL PH, V285, pC546, DOI 10.1152/ajpcell.00424.2002
   Gu XL, 2002, INVEST OPHTH VIS SCI, V43, P496
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Gupta K, 2005, POSTGRAD MED J, V81, P236, DOI 10.1136/pgmj.2004.023309
   Guthrie SM, 2005, BLOOD, V105, P1916, DOI 10.1182/blood-2004-09-3415
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401
   Han Y, 2004, ARCH OPHTHALMOL-CHIC, V122, P1809, DOI 10.1001/archopht.122.12.1809
   HANKS SK, 1991, METHOD ENZYMOL, V200, P38
   Harhaj NS, 2006, INVEST OPHTH VIS SCI, V47, P5106, DOI 10.1167/iovs.06-0322
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Hashimoto T, 2006, DEVELOPMENT, V133, P2201, DOI 10.1242/dev.02385
   HATA Y, 1995, VIRCHOWS ARCH, V426, P479
   He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130
   Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hellstrom A, 2003, PEDIATRICS, V112, P1016, DOI 10.1542/peds.112.5.1016
   Hirai FE, 2008, AM J OPHTHALMOL, V145, P700, DOI 10.1016/j.ajo.2007.11.019
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6
   Hoffmann S, 2000, INVEST OPHTH VIS SCI, V41, P2389
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   HOLASH JA, 1993, BRAIN RES, V629, P218, DOI 10.1016/0006-8993(93)91323-K
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hollborn M, 2006, GRAEF ARCH CLIN EXP, V244, P732, DOI 10.1007/s00417-005-0154-9
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200
   Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178
   Horiuchi M, 2003, CIRCULATION, V107, P106, DOI 10.1161/01.CIR.0000043244.13596.20
   Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Huez I, 2001, MOL ENDOCRINOL, V15, P2197, DOI 10.1210/me.15.12.2197
   Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217
   Ida H, 2003, INVEST OPHTH VIS SCI, V44, P5430, DOI 10.1167/iovs.03-0609
   Ideno J, 2007, INT J MOL MED, V19, P75
   Igarashi K, 1998, BIOCHEM BIOPH RES CO, V251, P77, DOI 10.1006/bbrc.1998.9442
   IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Inoguchi T, 2003, J AM SOC NEPHROL, V14, pS227, DOI 10.1097/01.ASN.0000077407.90309.65
   Inoguchi T, 2003, CURR MED CHEM, V10, P1759, DOI 10.2174/0929867033457133
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Jain SK, 2006, FREE RADICAL BIO MED, V41, P1187, DOI 10.1016/j.freeradbiomed.2006.07.017
   JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848
   JALKH AE, 1990, OPHTHALMOLOGY, V97, P1614
   JIANG B, 1994, J CELL SCI, V107, P2499
   JIANG B, 1995, GLIA, V15, P1, DOI 10.1002/glia.440150102
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002
   Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kannan R, 2006, MOL VIS, V12, P1649
   Kao JC, 2005, J OCUL PHARMACOL TH, V21, P1, DOI 10.1089/jop.2005.21.1
   Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kelly Darren J, 2005, Diab Vasc Dis Res, V2, P76, DOI 10.3132/dvdr.2005.013
   Kent D, 2000, BRIT J OPHTHALMOL, V84, P542, DOI 10.1136/bjo.84.5.542
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kimura S, 2005, HYPERTENSION, V45, P860, DOI 10.1161/01.HYP.0000163462.98381.7f
   KING B, 2006, INVEST OPHTHALMOL VI
   KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764
   Kinose F, 2005, MOL VIS, V11, P366
   KINSEY VE, 1977, PEDIATRICS, V60, P655
   Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491
   Klein R, 1997, LANCET, V350, P197, DOI 10.1016/S0140-6736(97)04195-0
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   KLEIN R, 1995, NIH PUBL
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Konopatskaya O, 2006, MOL VIS, V12, P626
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kowluru RA, 2004, DIABETES, V53, P3233, DOI 10.2337/diabetes.53.12.3233
   Kowluru RA, 2003, DIABETES, V52, P818, DOI 10.2337/diabetes.52.3.818
   Kowluru RA, 2002, INVEST OPHTH VIS SCI, V43, P3287
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Kowluru RA, 2000, CURR EYE RES, V21, P814, DOI 10.1076/ceyr.21.4.814.5545
   KRANTZ SB, 1991, BLOOD, V77, P419
   Kretzer F L, 1988, Birth Defects Orig Artic Ser, V24, P147
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   KUNISAKI M, 1995, AM J PHYSIOL-ENDOC M, V269, pE239, DOI 10.1152/ajpendo.1995.269.2.E239
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015
   Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001
   LEAF AA, 1995, DEV MED CHILD NEUROL, V37, P814
   Lee IG, 2006, EYE, V20, P546, DOI 10.1038/sj.eye.6701920
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lee SB, 2006, J BIOL CHEM, V281, P36228, DOI 10.1074/jbc.M606702200
   Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746
   LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758
   Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liao JK, 2002, INT J CARDIOL, V86, P5, DOI 10.1016/S0167-5273(02)00195-X
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   LING TL, 1988, DEV BRAIN RES, V44, P73, DOI 10.1016/0165-3806(88)90119-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu KM, 2007, J MOL ENDOCRINOL, V38, P423, DOI 10.1677/JME-06-0015
   Lu M, 1999, INVEST OPHTH VIS SCI, V40, P1808
   LUCEY JF, 1984, PEDIATRICS, V73, P82
   Lutty GA, 1997, AM J PATHOL, V151, P707
   LUTTY GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P267, DOI 10.1001/archopht.1992.01080140123039
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Madan A, 2003, FRONT BIOSCI-LANDMRK, V8, pD1030, DOI 10.2741/1056
   Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Makowski GS, 1998, INFLAMMATION, V22, P287, DOI 10.1023/A:1022300216202
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Matsumoto K, 2002, DIABETES RES CLIN PR, V55, P131, DOI 10.1016/S0168-8227(01)00296-0
   Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709
   Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   McColm J, 2004, MOL VIS, V10, P512
   McFarlane S, 2005, BRIT J OPHTHALMOL, V89, P107, DOI 10.1136/bjo.2004.045914
   McLeod DS, 2006, DEV DYNAM, V235, P3336, DOI 10.1002/dvdy.20988
   McLeod DS, 1998, INVEST OPHTH VIS SCI, V39, P1918
   MCLEOD DS, 1987, MICROVASC RES, V33, P257, DOI 10.1016/0026-2862(87)90021-5
   McMullen ME, 2005, J BIOL CHEM, V280, P20995, DOI 10.1074/jbc.M407060200
   Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992
   Meleth AD, 2005, INVEST OPHTH VIS SCI, V46, P4295, DOI 10.1167/iovs.04-1057
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Miao HQ, 2006, BIOCHEM BIOPH RES CO, V345, P438, DOI 10.1016/j.bbrc.2006.04.119
   MICHAELSON IC, 1948, J ANAT, V82, P167
   MICHAELSON IC, 1954, BRIT J OPHTHALMOL, V38, P577, DOI 10.1136/bjo.38.10.577
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Misko TP, 1998, J BIOL CHEM, V273, P15646, DOI 10.1074/jbc.273.25.15646
   Mitamura Y, 2001, OPHTHALMOLOGICA, V215, P415, DOI 10.1159/000050900
   Miyahara S, 2004, AM J PATHOL, V164, P1697, DOI 10.1016/S0002-9440(10)63728-5
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   MORRISON DG, 2007, INVEST OPHTHALMOL VI, V48
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murata T, 1996, LAB INVEST, V74, P819
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   NAVARATNA D, 2007, INVEST OPHTHALMOL VI, V48
   Navaratna D, 2007, DIABETES, V56, P2380, DOI 10.2337/db06-1694
   Neagoe PE, 2005, J BIOL CHEM, V280, P9904, DOI 10.1074/jbc.M412017200
   Neu J, 2006, INVEST OPHTH VIS SCI, V47, P3151, DOI 10.1167/iovs.05-1473
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   NILAUSEN KARIN, 1958, ACTA OPHTHALMOL, V36, P65
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   NISHIMURA M, 1982, OPHTHALMOLOGICA, V185, P147, DOI 10.1159/000309237
   Noda K, 2005, INVEST OPHTH VIS SCI, V46, P3817, DOI 10.1167/iovs.04-1528
   Notari L, 2005, INVEST OPHTH VIS SCI, V46, P2736, DOI 10.1167/iovs.04-1489
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631
   Obrosova IG, 2005, DIABETES, V54, P234, DOI 10.2337/diabetes.54.1.234
   Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200
   Oh H, 2002, P NATL ACAD SCI USA, V99, P383, DOI 10.1073/pnas.012074399
   OHISSON A, 2006, COCHRANE DB SYST REV, V3
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Okamoto T, 2002, FASEB J, V16, P1928, DOI 10.1096/fj.02-0030fje
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI200111772
   PALMER EA, 1988, ARCH OPHTHALMOL-CHIC, V106, P471
   PALMER EA, 1991, OPHTHALMOLOGY, V98, P1628
   PATZ A, 1957, PEDIATRICS, V19, P504
   PATZ A, 1952, AM J OPHTHALMOL, V35, P1248, DOI 10.1016/0002-9394(52)91140-9
   PEER J, 1995, LAB INVEST, V72, P638
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P255, DOI 10.1007/BF00920031
   PENN JS, 1994, PEDIATR RES, V36, P724, DOI 10.1203/00006450-199412000-00007
   PENN JS, 1995, INVEST OPHTH VIS SCI, V36, P2063
   PENN JS, 1993, INVEST OPHTH VIS SCI, V34, P576
   Penn JS, 2000, INVEST OPHTH VIS SCI, V41, P4007
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   PHELPS DL, 1984, PEDIATRICS, V73, P1
   PHELPS DL, 1988, PEDIATR RES, V24, P106, DOI 10.1203/00006450-198807000-00024
   Phelps DL, 2000, PEDIATRICS, V105, P295
   PHELPS DL, 1987, PEDIATR RES, V22, P297, DOI 10.1203/00006450-198709000-00012
   PHELPS DL, 1990, INVEST OPHTH VIS SCI, V31, P2194
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Platt DH, 2005, FREE RADICAL BIO MED, V39, P1353, DOI 10.1016/j.freeradbiomed.2005.06.015
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   PROVIS JM, 1985, J COMP NEUROL, V233, P429, DOI 10.1002/cne.902330403
   Provis JM, 2000, INVEST OPHTH VIS SCI, V41, P2827
   Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200
   Rahimi N, 2006, EXP EYE RES, V83, P1005, DOI 10.1016/j.exer.2006.03.019
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rapisarda A, 2002, CANCER RES, V62, P4316
   Ratcliffe PJ, 2007, J CLIN INVEST, V117, P862, DOI 10.1172/JCI31750
   RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2
   Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROBBINS RA, 1991, AM J PHYSIOL, V260, pL254, DOI 10.1152/ajplung.1991.260.4.L254
   Robbins SG, 1997, GROWTH FACTORS, V14, P229, DOI 10.3109/08977199709021522
   Robbins SG, 1998, GROWTH FACTORS, V16, P1
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Romagnoli C, 2000, EUR J PEDIATR, V159, P627, DOI 10.1007/PL00008390
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102
   Salhia B, 2000, BRAIN RES, V883, P87, DOI 10.1016/S0006-8993(00)02825-0
   Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659
   Sandercoe TM, 1999, EXP EYE RES, V69, P511, DOI 10.1006/exer.1999.0730
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Scalia R, 2002, MICROCIRCULATION, V9, P431, DOI 10.1038/sj.mn.7800168
   Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263
   Schafer M, 2003, CIRC RES, V92, P1010, DOI 10.1161/01.RES.0000070882.81508.FC
   Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Shi Q, 2001, CANCER RES, V61, P4143
   Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59
   Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808
   Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Simpson DAC, 1999, BIOCHEM BIOPH RES CO, V262, P333, DOI 10.1006/bbrc.1999.1201
   Sjolie AK, 1997, OPHTHALMOLOGY, V104, P252, DOI 10.1016/S0161-6420(97)30327-3
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Sonta T, 2004, FREE RADICAL BIO MED, V37, P115, DOI 10.1016/j.freeradbiomed.2004.04.001
   Soriano FG, 2001, CIRC RES, V89, P684, DOI 10.1161/hh2001.097797
   Sowers JR, 2003, AM J CARDIOL, V91, p14B
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Sreekumar PG, 2006, BIOCHEM BIOPH RES CO, V346, P1200, DOI 10.1016/j.bbrc.2006.06.021
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Starita Carla, 2007, Dev Ophthalmol, V39, P122, DOI 10.1159/000098504
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Stitt AW, 1998, J PATHOL, V186, P306, DOI 10.1002/(SICI)1096-9896(1998110)186:3<306::AID-PATH183>3.0.CO;2-B
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290
   STONE J, 1987, J COMP NEUROL, V255, P35, DOI 10.1002/cne.902550104
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Storkebaum E, 2005, NAT NEUROSCI, V8, P85, DOI 10.1038/nn1360
   Sun FY, 2005, J NEUROSCI RES, V79, P180, DOI 10.1002/jnr.20321
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   TAILOI CL, 1992, INVEST OPHTH VIS SCI, V33, P2128
   Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016
   Takagi H, 2003, INVEST OPHTH VIS SCI, V44, P393, DOI 10.1167/iovs.02-0276
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V320, P372, DOI 10.1016/j.bbrc.2004.05.177
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   TAKAHASHI K, 2003, FASEB J, V28, P28
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   Takeda N, 2001, DIABETOLOGIA, V44, P1043, DOI 10.1007/s001250100588
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Taomoto M, 2000, INVEST OPHTH VIS SCI, V41, P230
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93
   Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106
   Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200
   Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78
   Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4
   Vinores SA, 2001, HISTOL HISTOPATHOL, V16, P1061, DOI 10.14670/HH-16.1061
   Vuorela P, 2000, OBSTET GYNECOL, V95, P353, DOI 10.1016/S0029-7844(99)00565-7
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   WATANABE T, 1988, NATURE, V332, P834, DOI 10.1038/332834a0
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev
   Werdich XQ, 2004, EXP EYE RES, V79, P623, DOI 10.1016/j.exer.2004.07.006
   West H, 2005, DEVELOPMENT, V132, P1855, DOI 10.1242/dev.01732
   Wilkinson-Berka JL, 2004, AM J PATHOL, V164, P1263, DOI 10.1016/S0002-9440(10)63214-2
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723
   Yamagishi S, 2006, J BIOL CHEM, V281, P20213, DOI 10.1074/jbc.M602110200
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   YANG J, 2007, INVEST OPHTHALMOL VI, V48
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yang XJ, 1996, J NEUROSCI, V16, P6089
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
   Yoo PS, 2006, WORLD J GASTROENTERO, V12, P4937, DOI 10.3748/wjg.v12.i31.4937
   York Jackie R, 2004, J Perinatol, V24, P82, DOI 10.1038/sj.jp.7211040
   Young T L, 1997, J AAPOS, V1, P105, DOI 10.1016/S1091-8531(97)90008-2
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05-4313fje
   Zhang YF, 1997, INVEST OPHTH VIS SCI, V38, P1653
   Zhong H, 2000, CANCER RES, V60, P1541
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231
NR 546
TC 466
Z9 501
U1 0
U2 69
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2008
VL 27
IS 4
BP 331
EP 371
DI 10.1016/j.preteyeres.2008.05.001
PG 41
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 345SU
UT WOS:000259017700001
PM 18653375
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Saito, M
   Iida, T
   Nagayama, D
AF Saito, Masaaki
   Iida, Tomohiro
   Nagayama, Dai
TI Cross-sectional and en face optical coherence tomographic features of
   polypoidal choroidal vasculopathy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; optical coherence tomography; retinal
   pigment epithelial detachment; OCT-ophthalmoscope; retinal pigment
   epithelium; fluorescein angiography; indocyanine green angiography;
   abnormal vascular network; B-scan; C-scan
ID PIGMENT EPITHELIAL DETACHMENT
AB Purpose: To correlate optical coherence tomography (OCT)-ophthalmoscope images with angiographic signs of polypoidal lesions and branching network vessels in eyes with polypoidal choroidal vasculopathy (PCV).
   Methods: The authors prospectively examined 50 consecutive eyes with PCV using the OCT-ophthalmoscope and fluorescein and indocyanine green angiography (ICGA).
   Results: ICGA showed polypoidal lesions in all eyes. In 18 of 22 eyes with a retinal pigment epithelial detachment (PED), OCT-ophthalmoscope cross-sectional B-scan images showed a central dome-shaped PED and a contiguous small PED corresponding to the polypoidal lesions on ICGA. Transverse C-scan images showed an irregularity or protrusion of the highly reflective retinal pigment epithelium (RIDE) line of the PED corresponding to the polypoidal lesions on ICGA in all 22 eyes. In 28 eyes without a PED, the B-scan images showed polypoidal lesions as anterior protrusions of a highly reflective RPE line in 26 of 28 eyes; in those 26 eyes, C-scan images showed distinctive rings of a highly reflective RPE line corresponding to the polypoidal lesions on ICGA. ICGA showed an abnormal vascular network in 41 of the 50 eyes that appeared as a highly reflective area on C-scan images in 32 of the 41 eyes. In 20 of the 41 eyes, B-scan images showed two separate highly reflective RPE lines at the area of the abnormal vascular network.
   Conclusions: The OCT-ophthalmoscope C-scan images of the irregularity and the protrusion in the PED and the distinctive bright rings in eyes without a PED may be diagnostically important as indicators of polypoidal lesions in eyes with PCV.
C1 [Saito, Masaaki; Iida, Tomohiro; Nagayama, Dai] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan.
C3 Fukushima Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350
CR GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Ikuno Y, 2005, AM J OPHTHALMOL, V139, P462, DOI 10.1016/j.ajo.2004.09.078
   Ishikawa H, 2000, OPHTHALMIC SURG LAS, V31, P223
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Koizumi H, 2006, AM J OPHTHALMOL, V142, P340, DOI 10.1016/j.ajo.2006.03.021
   MARUKO I, IN PRESS AM J OPHTHA
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Podoleanu AG, 2004, J BIOMED OPT, V9, P86, DOI 10.1117/1.1627778
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Van Velthoven MEJ, 2006, RETINA-J RET VIT DIS, V26, P129, DOI 10.1097/00006982-200602000-00001
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 40
Z9 42
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2008
VL 28
IS 3
BP 459
EP 464
DI 10.1097/IAE.0b013e318156db60
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 273SH
UT WOS:000253951500010
PM 18327139
DA 2022-11-30
ER

PT J
AU Choi, EY
   Park, SE
   Lee, SC
   Koh, HJ
   Kim, SS
   Byeon, SH
   Kim, M
   Lee, CS
AF Choi, Eun Young
   Park, Sung Eun
   Lee, Sung Chul
   Koh, Hyoung Jun
   Kim, Sung Soo
   Byeon, Suk Ho
   Kim, Min
   Lee, Christopher Seungkyu
TI Long-Term Incidence and Growth of Chorioretinal Atrophy in Patients with
   Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-vascular endothelialgrowth factor; Photodynamic therapy; Polypoidal
   choroidal vasculopathy; Chorioretinalatrophy; Retinal pigment epithelial
   atrophy; Geographic atrophy
ID INTRAVITREAL RANIBIZUMAB INJECTIONS; PIGMENT EPITHELIAL ATROPHY;
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY;
   NATURAL-HISTORY; THICKNESS; VERTEPORFIN; AFLIBERCEPT; OUTCOMES
AB Purpose: To investigate the long-term incidence and growth rate of chorioretinal atrophy (CRA) in patients with polypoidal choroidal vasculopathy (PCV) and determine the associated risk factors. Methods: The medical records of 88 patients with unilateral symptomatic PCV who received anti-vascular endothelial growth factor (anti-VEGF) injections with or without photodynamic therapy (PDT) were analyzed retrospectively. Near-infrared fundus imaging and spectral domain optical coherence tomography were used to measure the CRA area and growth rate. Kaplan-Meier survival analysis was performed to estimate the CRA incidence. Logistic and linear regression analyses were used to investigate risk factors (e.g., age, frequency of abnormal OCT findings, PDT history, total injection number, and choroidal thickness) associated with the CRA incidence and growth rate, respectively. Results: The overall CRA incidence was 40.8% at 5 years. The absence of subretinal fluid, the presence of intraretinal fluid, and a thin choroid were significant risk factors for CRA occurrence with a history of PDT. Overall 5-year CRA growth rate was 0.69 mm(2)/year. Faster CRA growth was significantly related to the presence of subretinal hyperreflective material and thin choroid. PDT history was not significantly related to CRA growth. Conclusions: Thin choroid may be a significant risk factor for long-term development and growth of CRA in eyes with PCV. Intraretinal fluid seems to promote the development of CRA, while subretinal fluid seems to be associated with CRA prevention. The history of PDT was significantly related to the occurrence of CRA, but not to the growth rate of CRA.
C1 [Choi, Eun Young; Park, Sung Eun; Kim, Min; Lee, Christopher Seungkyu] Yonsei Univ, Inst Vis Res, Gangnam Severance Hosp, Dept Ophthalmol,Coll Med, 211 Eonjuro Gangnam Gu, Seoul 06273, South Korea.
   [Lee, Sung Chul; Koh, Hyoung Jun; Kim, Sung Soo; Byeon, Suk Ho; Lee, Christopher Seungkyu] Yonsei Univ, Inst Vis Res, Severance Hosp, Dept Ophthalmol,Coll Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Lee, CS (通讯作者)，Yonsei Univ, Inst Vis Res, Gangnam Severance Hosp, Dept Ophthalmol,Coll Med, 211 Eonjuro Gangnam Gu, Seoul 06273, South Korea.
EM sklee219@yuhs.ac
RI ; Choi, Eun Young/Y-5204-2018
OI , Sung Chul/0000-0001-9438-2385; Lee, Christopher/0000-0001-5054-9470;
   Kim, Min/0000-0003-1873-6959; Choi, Eun Young/0000-0002-1668-6452;
   Byeon, suk ho/0000-0001-8101-0830; Kim, Sung Soo/0000-0002-0574-7993;
   Koh, Hyoung Jun/0000-0002-5932-8516
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hikichi T, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0237-x
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liu L, 2015, MOL VIS, V21, P1130
   Mantel I, 2018, BR J OPHTHALMOL
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Miyata M, 2018, BR J OPHTHALMOL, pbjophthalmol, DOI DOI 10.1136/BJOPHTHAL-MOL-2018-311963
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Pak KY, 2017, RETINA-J RET VIT DIS, V37, P561, DOI 10.1097/IAE.0000000000001195
   Pokroy R, 2017, RETINA
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3
   Sakurada Y, 2016, RETINA
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
NR 57
TC 3
Z9 3
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAR
PY 2020
VL 243
IS 2
BP 136
EP 144
DI 10.1159/000501724
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE6EW
UT WOS:000526817700008
PM 31454801
DA 2022-11-30
ER

PT J
AU Kim, IK
   Lee, K
   Park, JH
   Baek, J
   Lee, WK
AF Kim, In Ki
   Lee, Kook
   Park, Jae Hyun
   Baek, Jiwon
   Lee, Won Ki
TI Classification of pachychoroid disease on ultrawide-field indocyanine
   green angiography using auto-machine learning platform
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; EXTEND REGIMEN;
   VIDEOANGIOGRAPHY; NEOVASCULOPATHY; AFLIBERCEPT; VALIDATION; IMAGES
AB Aims
   Automatic identification of pachychoroid maybe used as an adjunctive method to confirm the condition and be of help in treatment for macular diseases. This study investigated the feasibility of classifying pachychoroid disease on ultra-widefield indocyanine green angiography (UWF ICGA) images using an automated machine-learning platform.
   Methods
   Two models were trained with a set including 783 UWF ICGA images of patients with pachychoroid (n=376) and non-pachychoroid (n=349) diseases using the AutoML Vision (Google). Pachychoroid was confirmed using quantitative and qualitative choroidal morphology on multimodal imaging by two retina specialists. Model 1 used the original and Model 2 used images of the left eye horizontally flipped to the orientation of the right eye to increase accuracy by equalising the mirror image of the right eye and left eye. The performances were compared with those of human experts.
   Results
   In total, 284, 279 and 220 images of central serous chorioretinopathy, polypoidal choroidal vasculopathy and neovascular age-related maculopathy were included. The precision and recall were 87.84% and 87.84% for Model 1 and 89.19% and 89.19% for Model 2, which were comparable to the results of the retinal specialists (90.91% and 95.24%) and superior to those of ophthalmic residents (68.18% and 92.50%).
   Conclusions
   Auto machine-learning platform can be used in the classification of pachychoroid on UWF ICGA images after careful consideration for pachychoroid definition and limitation of the platform including unstable performance on the medical image.
C1 [Kim, In Ki; Park, Jae Hyun; Baek, Jiwon] Catholic Univ Korea, Dept Ophthalmol, Bucheon St Marys Hosp, Coll Med, Gyeonggi Do, South Korea.
   [Lee, Kook] Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Coll Med, Seoul, South Korea.
   [Lee, Won Ki] Nune Eye Ctr, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital
RP Baek, J (通讯作者)，Catholic Univ Korea, Dept Ophthalmol, Bucheon St Marys Hosp, Coll Med, 327 Sosa Ro, Bucheon 14647, Gyeonggi Do, South Korea.
EM md.jiwon@gmail.com
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute - Ministry of Health and Welfare, Republic of
   Korea [HI17C2012030018]
FX This work was supported by a grant from the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute, funded
   by the Ministry of Health and Welfare, Republic of Korea (grant no:
   HI17C2012030018).
CR Baek J, 2020, RETINA-J RET VIT DIS, V40, P2166, DOI 10.1097/IAE.0000000000002723
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P1668, DOI 10.1097/IAE.0000000000001773
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P957, DOI 10.1097/IAE.0000000000001655
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hirahara S, 2016, AM J OPHTHALMOL, V166, P103, DOI 10.1016/j.ajo.2016.03.040
   Hwang ES, 2018, OPHTHALMOLOGY, V125, P1862, DOI 10.1016/j.ophtha.2018.06.020
   Kim YD, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61519-9
   Klufas MA, 2015, RETINA-J RET VIT DIS, V35, P508, DOI 10.1097/IAE.0000000000000318
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuroda Y, 2016, AM J OPHTHALMOL, V169, P199, DOI 10.1016/j.ajo.2016.06.043
   Lee A, 2020, GRAEF ARCH CLIN EXP, V258, P1921, DOI 10.1007/s00417-020-04772-y
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Livingstone D, 2020, LARYNGOSCOPE, V130, P1408, DOI 10.1002/lary.28292
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Menchini U, 1997, INT OPHTHALMOL, V21, P57, DOI 10.1023/A:1005880129005
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Sakurada Y, 2018, RETINA-J RET VIT DIS, V38, P1977, DOI 10.1097/IAE.0000000000002294
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Yang J., 2019, GRAEFES ARCH CLIN EX, V258
   ZBL QV., 2016, NEURAL ARCHITECTURE
NR 44
TC 12
Z9 12
U1 4
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2021
VL 105
IS 6
BP 856
EP 861
DI 10.1136/bjophthalmol-2020-316108
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SH6KE
UT WOS:000654243300020
PM 32620684
DA 2022-11-30
ER

PT J
AU Fragiotta, S
   Abdolrahimzadeh, S
   Dolz-Marco, R
   Sakurada, Y
   Gal-Or, O
   Scuderi, G
AF Fragiotta, Serena
   Abdolrahimzadeh, Solmaz
   Dolz-Marco, Rosa
   Sakurada, Yoichi
   Gal-Or, Orly
   Scuderi, Gianluca
TI Significance of Hyperreflective Foci as an Optical Coherence Tomography
   Biomarker in Retinal Diseases: Characterization and Clinical
   Implications
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID DIABETIC MACULAR EDEMA; TYPE-3 NEOVASCULARIZATION; PIGMENT-EPITHELIUM;
   VISUAL OUTCOMES; CYSTOID SPACES; OUTER RETINA; FOLLOW-UP; DRUSEN
   CHARACTERISTICS; PREDICTIVE FACTORS; INTRARETINAL FOCI
AB Hyperreflective foci (HRF) is a term coined to depict hyperreflective dots or roundish lesions within retinal layers visualized through optical coherence tomography (OCT). Histopathological correlates of HRF are not univocal, spacing from migrating retinal pigment epithelium cells, lipid-laden macrophages, microglial cells, and extravasated proteinaceous or lipid material. Despite this, HRF can be considered OCT biomarkers for disease progression, treatment response, and prognosis in several retinal diseases, including diabetic macular edema, age-related macular degeneration (AMD), retinal vascular occlusions, and inherited retinal dystrophies. The structural features and topographic location of HRF guide the interpretation of their significance in different pathological conditions. The presence of HRF less than 30 mu m with reflectivity comparable to the retinal nerve fiber layer in the absence of posterior shadowing in diabetic macular edema indicates an inflammatory phenotype with a better response to steroidal treatment. In AMD, HRF overlying drusen are associated with the development of macular neovascularization, while parafoveal drusen and HRF predispose to macular atrophy. Thus, HRF can be considered a key biomarker in several common retinal diseases. Their recognition and critical interpretation via multimodal imaging are vital to support clinical strategies and management.
C1 [Fragiotta, Serena; Abdolrahimzadeh, Solmaz; Scuderi, Gianluca] Univ Roma La Sapienza, S Andrea Hosp, Dept NESMOS, Ophthalmol Unit, Rome, Italy.
   [Dolz-Marco, Rosa] Oftalvist Clin, Unit Macula, Valencia, Spain.
   [Sakurada, Yoichi] Univ Yamanashi, Yamanashi, Japan.
   [Gal-Or, Orly] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of
   Yamanashi; Rabin Medical Center
RP Fragiotta, S (通讯作者)，Univ Roma La Sapienza, S Andrea Hosp, Dept NESMOS, Ophthalmol Unit, Rome, Italy.
EM serena.fragiotta@uniroma1.it; solmaz.abdolrahimzadeh@uniroma1.it;
   rosadolzmarco@gmail.com; sakurada@yamanashi.ac.jp; wataya@gmail.com;
   gianluca.scuderi@uniroma1.it
RI Fragiotta, Serena/I-5227-2016
OI Fragiotta, Serena/0000-0002-6214-6270; Sakurada,
   Yoichi/0000-0002-2894-0454; Scuderi, Gianluca/0000-0003-0744-0722;
   Dolz-Marco, Rosa/0000-0002-2963-2541
CR Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Agrawal R, 2018, INT OPHTHALMOL, V38, P993, DOI 10.1007/s10792-017-0549-8
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Ahn J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-55606-9
   Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Arrigo A, 2020, OPHTHALMOL THER, V9, P971, DOI 10.1007/s40123-020-00297-z
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Berasategui B, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0848-5
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Borrelli E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091271
   Busch C, 2020, ACTA OPHTHALMOL, V98, pE801, DOI 10.1111/aos.14390
   Chatziralli I, 2017, DIABETES THER, V8, P1393, DOI 10.1007/s13300-017-0332-x
   Chatziralli IP, 2016, RETINA-J RET VIT DIS, V36, P2319, DOI 10.1097/IAE.0000000000001070
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Choi MY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222364
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Chung YR, 2020, ACTA DIABETOL, V57, P861, DOI 10.1007/s00592-020-01495-8
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Couturier A, 2022, BRIT J OPHTHALMOL, V106, P540, DOI 10.1136/bjophthalmol-2020-317191
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Davoudi S, 2016, RETINA-J RET VIT DIS, V36, P1622, DOI 10.1097/IAE.0000000000001022
   De Benedetto U, 2015, RETINA-J RET VIT DIS, V35, P449, DOI 10.1097/IAE.0000000000000336
   Deak GG, 2010, OPHTHALMOLOGY, V117, P773, DOI 10.1016/j.ophtha.2009.09.027
   Do JR, 2021, RETINA-J RET VIT DIS, V41, P355, DOI 10.1097/IAE.0000000000002826
   Ebner C, 2021, WIEN KLIN WOCHENSCHR, V133, P123, DOI 10.1007/s00508-020-01718-6
   Echols BS, 2020, OPHTHALMOL RETINA, V4, P1059, DOI 10.1016/j.oret.2020.05.001
   Fayed AE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217109
   Feher J, 2018, INT J IMMUNOPATH PH, V31, DOI 10.1177/0394632017748841
   Fernandez-Avellaneda P, 2021, AM J OPHTHALMOL, V222, P112, DOI 10.1016/j.ajo.2020.09.003
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Fragiotta Serena, 2017, Int J Retina Vitreous, V3, P8, DOI 10.1186/s40942-017-0061-3
   Framme C, 2012, INVEST OPHTH VIS SCI, V53, P5814, DOI 10.1167/iovs.12-9950
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Frizziero L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113514
   Gobuty Marisa, 2016, Int J Retina Vitreous, V2, P9, DOI 10.1186/s40942-016-0034-y
   Grewal DS, 2017, AM J OPHTHALMOL, V177, P116, DOI 10.1016/j.ajo.2017.02.017
   Habot-Wilner Z, 2011, EYE, V25, P1064, DOI 10.1038/eye.2011.125
   Heng LZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126557
   Horu T, 2012, OPHTHALMOLOGY, V119, P1047, DOI 10.1016/j.ophtha.2011.10.030
   Hu XF, 2020, RETINA-J RET VIT DIS, V40, P1070, DOI 10.1097/IAE.0000000000002531
   Hu XT, 2019, BRIT J OPHTHALMOL, V103, P153, DOI 10.1136/bjophthalmol-2018-313311
   Kang JW, 2016, RETINA-J RET VIT DIS, V36, P1630, DOI 10.1097/IAE.0000000000000995
   Kang JW, 2014, GRAEF ARCH CLIN EXP, V252, P1413, DOI 10.1007/s00417-014-2595-5
   Kawaguchi Yuriya, 2016, Am J Ophthalmol Case Rep, V3, P25, DOI 10.1016/j.ajoc.2016.04.002
   Keane PA, 2013, JAMA OPHTHALMOL, V131, P341, DOI 10.1001/jamaophthalmol.2013.1724
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kim KT, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/3459164
   Kodjikian L, 2019, EUR J OPHTHALMOL, V29, P573, DOI 10.1177/1120672119857511
   Kuroda M, 2014, CLIN OPHTHALMOL, V8, P435, DOI 10.2147/OPTH.S58164
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Lee H, 2018, INVEST OPHTH VIS SCI, V59, P5367, DOI 10.1167/iovs.18-25825
   Lee H, 2018, INVEST OPHTH VIS SCI, V59, P715, DOI 10.1167/iovs.17-23042
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Li B, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/5639284
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Liu SL, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1168-0
   Massin P, 2006, ACTA OPHTHALMOL SCAN, V84, P466, DOI 10.1111/j.1600-0420.2006.00694.x
   Meduri A, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/6639418
   Michl M, 2021, ACTA OPHTHALMOL, V99, P418, DOI 10.1111/aos.14621
   Midena E, 2018, INVEST OPHTH VIS SCI, V59, P5366, DOI 10.1167/iovs.18-25611
   Milani P, 2016, CLIN OPHTHALMOL, V10, P1749, DOI 10.2147/OPTH.S108509
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Mugisho OO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202156
   Murakami T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27192-9
   Murakami T, 2018, JPN J OPHTHALMOL, V62, P292, DOI 10.1007/s10384-018-0575-8
   Murakami T, 2015, JPN J OPHTHALMOL, V59, P236, DOI 10.1007/s10384-015-0382-4
   Nagasaka Y, 2018, OPHTHALMOL RETINA, V2, P726, DOI 10.1016/j.oret.2017.07.020
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nishijima K, 2014, RETINA-J RET VIT DIS, V34, P732, DOI 10.1097/IAE.0000000000000005
   Niu SJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01733-0
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Ota T, 2013, CLIN OPHTHALMOL, V7, P237, DOI 10.2147/OPTH.S40079
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Ozsaygili C, 2020, RETINA-J RET VIT DIS, V40, P1044, DOI 10.1097/IAE.0000000000002537
   Oztas Z, 2018, TURK OFTALMOL DERG, V48, P66, DOI 10.4274/tjo.03780
   Paavo M, 2017, INVEST OPHTH VIS SCI, V58, P4769, DOI 10.1167/iovs.17-22338
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Panozzo G, 2020, EUR J OPHTHALMOL, V30, P8, DOI 10.1177/1120672119880394
   Park YG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56143-1
   Parodi MB, 2019, GRAEF ARCH CLIN EXP, V257, P41, DOI 10.1007/s00417-018-4167-6
   Pemp B, 2014, RETINA-J RET VIT DIS, V34, P2407, DOI 10.1097/IAE.0000000000000250
   Piri N, 2015, JAMA OPHTHALMOL, V133, P398, DOI 10.1001/jamaophthalmol.2014.5604
   Roy R, 2019, ASIA-PAC J OPHTHALMO, V8, P314, DOI 10.1097/APO.0000000000000249
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schreur V, 2020, RETINA-J RET VIT DIS, V40, P1565, DOI 10.1097/IAE.0000000000002626
   Schreur V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206482
   Schuerch K, 2016, RETINA-J RET VIT DIS, V36, pS147, DOI 10.1097/IAE.0000000000001256
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Silva N, 2020, CASE REP OPHTHALM, V11, P493, DOI 10.1159/000509139
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Tiosano L, 2020, GRAEF ARCH CLIN EXP, V258, P2353, DOI 10.1007/s00417-020-04837-y
   Turksever C, 2017, OPHTHALMOLOGICA, V238, P172, DOI 10.1159/000477856
   Uji A, 2018, RETINA-J RET VIT DIS, V38, P163, DOI 10.1097/IAE.0000000000001519
   Uji A, 2014, INVEST OPHTH VIS SCI, V55, P3361, DOI 10.1167/iovs.14-13948
   Uji A, 2014, AM J OPHTHALMOL, V157, P227, DOI 10.1016/j.ajo.2013.09.008
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
   Vujosevic S, 2017, RETINA-J RET VIT DIS, V37, P1092, DOI 10.1097/IAE.0000000000001304
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Weingessel B, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3082560
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yalcin NG, 2019, TURK OFTALMOL DERG, V49, P194, DOI 10.4274/tjo.galenos.2018.19616
   Yamada Y, 2013, RETINA-J RET VIT DIS, V33, P726, DOI 10.1097/IAE.0b013e3182753960
   Yoshitake S, 2014, EYE, V28, P439, DOI 10.1038/eye.2013.290
   Yoshitake S, 2014, OPHTHALMOLOGY, V121, P1036, DOI 10.1016/j.ophtha.2013.11.033
   Yoshitake T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57646-y
   Zur D, 2018, OPHTHALMOLOGY, V125, P267, DOI 10.1016/j.ophtha.2017.08.031
NR 121
TC 5
Z9 5
U1 2
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD DEC 17
PY 2021
VL 2021
AR 6096017
DI 10.1155/2021/6096017
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XY8TH
UT WOS:000737237400002
PM 34956669
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
   Kim, CG
   Lee, DW
   Kim, YJ
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
   Kim, Ye Ji
TI MORPHOLOGIC FEATURES ASSOCIATED WITH FIBROTIC SCARRING AFTER
   ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; hemorrhage; polypoidal choroidal vasculopathy; scar; subretinal
   hyperreflective material
ID SUBRETINAL HYPERREFLECTIVE MATERIAL; 2 ANGIOGRAPHIC SUBTYPES; FACTOR-H
   CFH; MACULAR DEGENERATION; NATURAL-HISTORY; INTRAVITREAL RANIBIZUMAB;
   SUBMACULAR HEMORRHAGE; OUTCOMES; CLASSIFICATION; VERTEPORFIN
AB Purpose: To investigate morphologic features associated with fibrotic scarring after anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy (PCV).
   Methods: This retrospective study included 293 patients who had been diagnosed with PCV and treated with anti-vascular endothelial growth factor monotherapy during a 12-month follow-up period. Associations of morphologic features, including type of PCV, location of the polypoidal lesion, greatest linear dimension, largest polyp diameter, choroidal vascular hyperpermeability, pigment epithelial detachment, intraretinal fluid, and subretinal hyperreflective material (SHRM) with fibrotic scar at 12 months were analyzed.
   Results: Fibrotic scars were noted in 15 eyes (5.1%). The incidence of fibrotic scars was higher in Type 1 PCV (8 of 76 eyes) than in Type 2 PCV (7 of 217 eyes, P = 0.028). The incidence was also higher in eyes with SHRM (14 of 124 eyes) than in eyes without SHRM (1 of 169 eyes, P < 0.001). In multivariate analysis, SHRM was associated with fibrotic scar (P = 0.005). Among the SHRM cases, the incidence of the scar was 12.9% in eyes with submacular hemorrhage and 8.5% in eyes without hemorrhage.
   Conclusion: Although fibrotic scar is an infrequent finding in PCV, the possibility of scarring should be considered in eyes with SHRM, particularly in submacular hemorrhage cases.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won; Kim, Ye Ji] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX Supported by Kim's Eye Hospital Research Center.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P272, DOI 10.3341/kjo.2016.30.4.272
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JH, 2016, JPN J OPHTHALMOL, V60, P466, DOI 10.1007/s10384-016-0466-9
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee JH, 2016, GRAEF ARCH CLIN EXP, V254, P645, DOI 10.1007/s00417-015-3092-1
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nakai S, 2017, OPHTHALMOLOGICA, V237, P123, DOI 10.1159/000455273
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 46
TC 7
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2018
VL 38
IS 11
BP 2168
EP 2176
DI 10.1097/IAE.0000000000001845
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VZ
UT WOS:000454007400008
PM 28930802
DA 2022-11-30
ER

PT J
AU Gomi, F
   Sawa, M
   Mitarai, K
   Tsujikawa, M
   Tano, Y
AF Gomi, Fumi
   Sawa, Miki
   Mitarai, Keiichi
   Tsujikawa, Motokazu
   Tano, Yasuo
TI Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine
   green and fluorescein angiography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; indocyanine green angiography;
   fluorescein angiography; lesion size; confocal SLO
ID SCANNING LASER OPHTHALMOSCOPE; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; VERTEPORFIN; NEOVASCULARIZATION; VIDEOANGIOGRAPHY; CAMERA
AB Background Before treating polypoidal choroidal vasculopathy (PCV), the extent of the lesion should be determined, but the angiographic lesion size of PCV is sometimes different when comparing indocyanine green angiography (ICGA) and fluorescein angiography (FA). The purpose of this study was to evaluate angiographic findings and compare the lesion sizes of PCV on ICGA and FA using confocal scanning laser ophthalmoscopy (SLO) and fundus camera.
   Methods Thirty-seven eyes of 37 patients with PCV were examined by ICGA and FA using confocal SLO and a fundus camera, and the findings and the lesion sizes were compared during the early, mid, and late-phases of ICGA and FA.
   Results The polyps with abnormal vessel networks were depicted on ICGA in all eyes and the lesion showed classic-type leakage on FA in 15 eyes. Ten eyes with a pigment epithelial detachment (PED) had the maximal lesion size on FA because hyperfluorescent areas involving PED were determined as the lesions; although on ICGA, a PED distinguished from abnormal vessels was not included in the lesion. In 27 eyes without a PED, the early-phase of ICGA using confocal SLO showed the maximal lesion size in 24 eyes (89%) and the late-phase in three eyes (11%), and the maximal size on ICGA agreed on FA. While FA depicted the maximal lesion sizes in 24 eyes (89%), another three eyes showed the maximal lesion size on early-phase ICGA on confocal SLO. The maximal lesion size on ICGA using a fundus camera was smaller than when using confocal SLO in seven eyes (19%).
   Conclusions The ICGA on confocal SLO could visualize the more detailed findings of the abnormal vasculature of PCV and the FA showed hyperfluorescent regions overlaying the lesions. To determine the maximal lesion size on angiograms, early-phase ICGA using confocal SLO and FA should be referred.
C1 Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, Rm E7,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gelisken F, 1998, RETINA-J RET VIT DIS, V18, P37
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Shiraki K, 2001, JPN J OPHTHALMOL, V45, P368, DOI 10.1016/S0021-5155(01)00362-8
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 21
TC 30
Z9 33
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2007
VL 245
IS 10
BP 1421
EP 1427
DI 10.1007/s00417-007-0564-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209RJ
UT WOS:000249405400002
PM 17347808
DA 2022-11-30
ER

PT J
AU Chang, YS
   Kim, JH
   Kim, KM
   Kim, JW
   Lee, TG
   Kim, CG
   Cho, SW
AF Chang, Young Suk
   Kim, Jae Hui
   Kim, Kyung Min
   Kim, Jong Woo
   Lee, Tae Gon
   Kim, Chul Gu
   Cho, Sung Won
TI Long-Term Outcomes of Anti-Vascular Endothelial Growth Factor Therapy
   for Polypoidal Choroidal Vasculopathy
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB INJECTIONS; VERTEPORFIN
AB Purpose: To investigate a clinical outcome after more than 4 years for polypoidal choroidal vasculopathy (PCV) treated with anti-vascular endothelial growth factor (VEGF) therapy and to investigate the factors predictive of long-term visual outcomes.
   Methods: This retrospective study included 31 eyes, with PCV treated with anti-VEGF therapy (either ranibizumab or bevacizumab, or both), and were followed up for 4 years or longer. The best-corrected visual acuity (BCVA) at baseline was compared with that measured at 3 months and at the final follow-up. Factors associated with final visual acuity were also analyzed.
   Results: The mean follow-up period was 53.0 +/- 4.3 months. During the follow-up period, the patients were treated with an average of 8.8 +/- 3.0 intravitreal anti-VEGF injections. BCVA at diagnosis at 12, 24, and 36 months, and at final follow-up was 0.52 +/- 0.35, 0.46 +/- 0.36, 0.57 +/- 0.45, 0.76 +/- 0.56, and 0.83 +/- 0.60, respectively. When compared to the baseline value, the BCVA was significantly improved at 3 months (P = 0.006), whereas the BCVA at final follow- up was significantly decreased compared to the baseline value (P = 0.018). Among the included eyes, 48.4% experienced deterioration of visual acuity and 51.6% showed stable vision. BCVA at 12 months was most strongly associated with visual acuity at final follow- up.
   Conclusions: Although the long-term treatment outcome of PCV is generally unfavorable, stable vision can be achieved in approximately half of the patients. Visual acuity at 12 months after the initial treatment is predictive of long-term visual outcomes.
C1 [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
   [Kim, Jae Hui; Kim, Kyung Min; Kim, Jong Woo; Lee, Tae Gon; Kim, Chul Gu; Cho, Sung Won] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by the Kim's Eye Hospital Research Center.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Chhablani JK, 2013, INDIAN J OPHTHALMOL, V61, P136, DOI 10.4103/0301-4738.109390
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Hikichi T, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0026-y
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kim JH, 2015, J OCUL PHARMACOL TH, V31, P241, DOI 10.1089/jop.2014.0145
   Lee JH, 2016, GRAEF ARCH CLIN EXP, V254, P645, DOI 10.1007/s00417-015-3092-1
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan CSH, 2013, INDIAN J OPHTHALMOL, V61, P684, DOI 10.4103/0301-4738.123149
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 24
TC 11
Z9 12
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD MAY
PY 2016
VL 32
IS 4
BP 219
EP 224
DI 10.1089/jop.2015.0073
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA DN9KB
UT WOS:000377397300008
PM 26991591
DA 2022-11-30
ER

PT J
AU Lin, TC
   Hwang, DK
   Lee, FL
   Chen, SJ
AF Lin, Tai-Chi
   Hwang, De-Kuang
   Lee, Fenq-Lih
   Chen, Shih-Jen
TI Visual prognosis of massive submacular hemorrhage in polypoidal
   choroidal vasculopathy with or without combination treatment
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE combination treatment; photodynamic therapy; polypoidal choroidal
   vasculopathy; submacular hemorrhage; vascular endothelial growth factor
   inhibitors
ID TISSUE-PLASMINOGEN ACTIVATOR; FACTOR-H CFH; PHOTODYNAMIC THERAPY;
   MACULAR DEGENERATION; PNEUMATIC DISPLACEMENT; FOLLOW-UP; SECONDARY;
   RANIBIZUMAB; MONOTHERAPY; MANAGEMENT
AB Background: Submacular hemorrhage associated with polypoidal choroidal vasculopathy (PCV) may cause severe visual loss. The purpose of this study is to report the visual prognosis of massive submacular hemorrhage in patients with PCV.
   Methods: Twenty patients with PCV and submacular hemorrhage who received either subretinal tissue plasminogen activator (TPA) with vitrectomy or intravitreal injection of TPA and gas to achieve pneumatic displacement of the hemorrhage were enrolled. Additionally, combination treatment with either photodynamic therapy (PDT) or intravitreal injection of vascular endothelial growth factor inhibitors (anti-VEGF) was performed to treat the underlying PCV.
   Results: Five patients received subretinal TPA with vitrectomy and 15 patients received intravitreal injection of TPA and gas to remove or displace the submacular hemorrhage. Combination treatment with PDT and intravitreal anti-VEGF was performed in three patients and intravitreal anti-VEGF injection alone in 13 patients. The mean logarithm of the minimal angle of resolution converted from the best corrected visual acuity (BCVA) were improved at 3 months, 6 months, and 12 months. Better initial BCVA, smaller size of submacular hemorrhage and younger age were statistically significant predictors for BCVA. Combination treatment with PDT showed significant efficacy in the improvement of BCVA.
   Conclusion: Combination treatment of submacular hemorrhage secondary to PCV may yield visual and anatomic improvements. Initial BCVA, the initial size of submacular hemorrhage and age were significant predictors for visual prognosis. Copyright (C) 2015, the Chinese Medical Association. Published by Elsevier Taiwan LLC.
C1 [Lin, Tai-Chi; Lee, Fenq-Lih; Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
   [Lin, Tai-Chi] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Hwang, De-Kuang] Taichung Vet Gen Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Hwang, De-Kuang] Natl Yang Ming Univ, Dept Publ Hlth, Taipei 112, Taiwan.
   [Hwang, De-Kuang] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.
   [Lee, Fenq-Lih; Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; Taichung Veterans General Hospital; National Yang Ming Chiao
   Tung University; National Yang Ming Chiao Tung University; National Yang
   Ming Chiao Tung University
RP Chen, SJ (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
EM sjchen@vghtpe.gov.tw
RI Hwang, DK De-Kuang/J-3931-2016
OI Hwang, DK De-Kuang/0000-0001-6346-8485
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Matsushita S, 2008, J MED INVESTIG, V55, P231, DOI 10.2152/jmi.55.231
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Oh IK, 2009, OPHTHALMOLOGICA, V223, P78, DOI 10.1159/000173715
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Rishi E, 2012, INDIAN J OPHTHALMOL, V60, P521, DOI 10.4103/0301-4738.103779
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 21
TC 9
Z9 10
U1 0
U2 0
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD MAR
PY 2016
VL 79
IS 3
BP 159
EP 165
DI 10.1016/j.jcma.2015.11.004
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DK3FY
UT WOS:000374803700010
PM 26775600
OA hybrid
DA 2022-11-30
ER

PT J
AU Gigon, A
   Vadala, M
   Bonfiglio, VME
   Reibaldi, M
   Eandi, CM
AF Gigon, Anthony
   Vadala, Maria
   Bonfiglio, Vincenza M. E.
   Reibaldi, Michele
   Eandi, Chiara M.
TI Early OCTA Changes of Type 3 Macular Neovascularization Following
   Brolucizumab Intravitreal Injections
SO MEDICINA-LITHUANIA
LA English
DT Article
DE neovascular age-related macular degeneration; type 3 neovascularization;
   retinal angiomatous proliferation; brolucizumab; optical coherence
   tomography angiography; intravitreal injection
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION;
   ANASTOMOSIS
AB Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3 neovascularization in neovascular age-related macular degeneration (nAMD), evaluated by optical coherence tomography angiography (OCTA). Materials and Methods: This is a bicentric retrospective case series. Patients with newly diagnosed type 3 MNV treated with brolucizumab IVI and at least 6 months follow-up were enrolled. OCTA en face images and B-scans were analyzed for lesions at baseline, 1 month, 3 months, and 6 months. Whenever detectable, lesion area on outer retina and choriocapillaris layers was measured. Results: Twelve eyes of 12 patients were included into the study. The most consistent OCTA sign at baseline was the presence of a vascular tuft in the outer retina (100%). The highest response was achieved at 3 months, with statistically significant decrease in lesion detection in the outer retina, in the choriocapillaris, and outer retinal lesion size. At 6 months, 58% of outer retinal lesions had disappeared. Conclusions: Brolucizumab IVI shows a good short-term efficacy for the treatment of type 3 neovascularizations. Further studies with greater number of patients and longer follow-up are warranted to confirm these findings.
C1 [Gigon, Anthony; Eandi, Chiara M.] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, CH-1004 Lausanne, Switzerland.
   [Vadala, Maria; Bonfiglio, Vincenza M. E.] Univ Palermo, Biomed Neurosci & Adv Diagnost BIND Dept, I-90133 Palermo, Italy.
   [Reibaldi, Michele; Eandi, Chiara M.] Univ Torino, Dept Surg Sci, I-10122 Turin, Italy.
C3 University of Lausanne; University of Palermo; University of Turin
RP Eandi, CM (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, CH-1004 Lausanne, Switzerland.; Eandi, CM (通讯作者)，Univ Torino, Dept Surg Sci, I-10122 Turin, Italy.
EM chiara.eandi@unito.it
OI Eandi, Chiara Maria/0000-0003-3656-1689; Gigon,
   Anthony/0000-0002-5457-7871; Reibaldi, Michele/0000-0003-1368-6729;
   VADALA', Maria/0000-0002-2726-698X
CR Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Querques G, 2012, RETINA-J RET VIT DIS, V32, P458, DOI 10.1097/IAE.0b013e3182205960
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 17
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD SEP
PY 2022
VL 58
IS 9
AR 1180
DI 10.3390/medicina58091180
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4R5SI
UT WOS:000856823200001
PM 36143855
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kokame, GT
   Liu, K
   Kokame, KA
   Kaneko, KN
   Omizo, JN
AF Kokame, Gregg T.
   Liu, Keke
   Kokame, Kelli A.
   Kaneko, Kyle N.
   Omizo, Jase N.
TI Clinical Characteristics of Polypoidal Choroidal Vasculopathy and
   Anti-Vascular Endothelial Growth Factor Treatment Response in Caucasians
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Indocyanine green angiography; Caucasian; Subretinal aneurysmal
   neovascularization
ID MACULAR DEGENERATION; DIAGNOSIS
AB Background/Aims: To identify the clinical characteristics of polypoidal choroidal vasculopathy (PCV) in Caucasian patients and assess the prevalence of anti-vascular endothelial growth factor (anti-VEGF) resistance. Methods: This involved a retrospective chart review of Caucasian patients diagnosed with PCV and utilizing indocyanine green angiography with the scanning laser ophthalmoscope. Data collected included patients' demographics, disease characteristics, and treatment response. Results: There were 54 eyes of 49 patients with PCV; 51.0% were male and 49.0% were female with a mean age of 72.9 years. Forty-four patients (89.8%) had PCV unilaterally and 10.2% (5 patients) had PCV bilaterally. PCV was located in the macula in 79.6%, in the peripapillary region in 16.7%, and in both regions in 3.7%. PCV commonly presents with serous detachment (66.7%), retinal pigment epithelial detachment (RPED) (51.9%) and subretinal hemorrhage (37.0%). Twenty-nine eyes were included in the treatment response analysis, with 18 eyes (62.1%) showing persistent disease activity after 3 initial injections of anti-VEGF treatment. Conclusion: PCV in Caucasian patients is more often unilateral and presents more commonly in the macular region than the peripapillary region. Serous detachment and RPED are the 2 most common findings. Resistance to current anti-VEGF treatment was noted frequently; it is thus extremely important to identify this subtype of type I subretinal neovascularization.
C1 [Kokame, Gregg T.] Univ Hawaii, Sch Med, Dept Surg, Div Ophthalmol, Honolulu, HI 96822 USA.
   [Kokame, Gregg T.; Liu, Keke; Kokame, Kelli A.; Kaneko, Kyle N.; Omizo, Jase N.] Retina Ctr Pali Momi, Aiea, HI USA.
   [Kokame, Gregg T.; Liu, Keke; Kokame, Kelli A.; Kaneko, Kyle N.; Omizo, Jase N.] Retina Consultants Hawaii, Aiea, HI USA.
   [Kokame, Gregg T.; Liu, Keke; Kokame, Kelli A.; Kaneko, Kyle N.; Omizo, Jase N.] Hawaii Macula & Retina Inst, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
   [Kokame, Gregg T.; Liu, Keke] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA.
C3 University of Hawaii System; University of Hawaii System
RP Kokame, GT (通讯作者)，Hawaii Macula & Retina Inst, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
EM retinahi@aol.com
OI Liu, Keke/0000-0002-1091-715X
CR Alasil Tarek, 2017, Int J Retina Vitreous, V3, P9, DOI 10.1186/s40942-017-0060-4
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Chen YFN, 2017, CAN J OPHTHALMOL, V52, P475, DOI 10.1016/j.jcjo.2017.02.014
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   METTU PS, 2016, INVEST OPHTH VIS SCI, V57
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
   Zarbin M, 2019, OPHTHALMOLOGY, V126, P849, DOI 10.1016/j.ophtha.2019.01.003
NR 31
TC 7
Z9 7
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2020
VL 243
IS 3
BP 178
EP 186
DI 10.1159/000503834
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LO2CU
UT WOS:000533434600003
PM 31707394
DA 2022-11-30
ER

PT J
AU Kim, KS
   Lee, WK
AF Kim, Kyu Seop
   Lee, Won Ki
TI Bevacizumab for serous changes originating from a persistent branching
   vascular network following photodynamic therapy for polypoidal choroidal
   vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Branching vascular network; Photodynamic therapy;
   Polypoidal choroidal vasculopathy
ID INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION; NEOVASCULARIZATION;
   VERTEPORFIN; AVASTIN
AB To report the efficacy of intravitreal bevacizumab for either recurrent or persistent serous changes originating from a persistent branching vascular network or secondary choroidal neovascularization after photodynamic therapy for polypoidal choroidal vasculopathy, despite regression of polypoidal lesions.
   Twenty eyes of 20 patients with at least 12 months of regular follow-up were retrospectively reviewed. Intravitreal bevacizumab was administered on an as-needed basis, guided by optical coherence tomography (OCT), after the first injection.
   Seventeen (85%) of 20 eyes showed resolution of macular fluid after a mean of 1.9 (range 1-3) consecutive injections; however, 15 (88%) of them had relapsing episodes of fluid collection. The mean number of injections needed was 4.2 (range 1-6) over a period of 12 months. At 12 months, 10 eyes (50%) had no fluid accumulation on OCT, while 10 eyes (50%) had some residual fluid. The mean central foveal thickness improved significantly from 280 +/- A 37 to 226 +/- A 62 mu m (P = 0.002). Visual acuity was maintained or improved in 16 eyes (80%).
   Intravitreal bevacizumab appears to be effective in resolving intraretinal and subretinal fluid originating from these lesions. However, the favorable effect was maintained for only a limited period of time and required repeated injections.
C1 [Kim, Kyu Seop; Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul 137701, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
NR 20
TC 16
Z9 16
U1 0
U2 0
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2011
VL 55
IS 4
BP 370
EP 377
DI 10.1007/s10384-011-0045-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 801YL
UT WOS:000293476400009
PM 21647565
DA 2022-11-30
ER

PT J
AU Byeon, SH
   Lew, YJ
   Lee, SC
   Kwon, OW
AF Byeon, Suk Ho
   Lew, Young Ju
   Lee, Sung Chul
   Kwon, Oh Woong
TI Clinical features and follow-up results of pulsating polypoidal
   choroidal vasculopathy treated with photodynamic therapy
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE haemorrhage; photodynamic therapy (PDT); polypoidal choroidal
   vasculopathy (PCV); pulsatile blood flow; pulsation
ID RETINAL ARTERIAL MACROANEURYSMS; MACULAR DEGENERATION; CASE SERIES;
   VERTEPORFIN; HEMORRHAGE
AB Purpose:
   To report on the clinical course of pulsating polypoidal choroidal vasculopathy (PCV) treated with photodynamic therapy (PDT).
   Methods:
   A total of 63 eyes of 58 consecutive patients diagnosed with PCV, treated with PDT and followed up for at least 6 months were enrolled. Best-corrected visual acuity (BCVA), fluorescein angiography and high-speed indocyanine green angiography (ICGA) using confocal scanning laser ophthalmoscopy (HRA) were performed.
   Results:
   Of the 63 PCV eyes, 14 eyes (22.2%) of 14 patients were classified as having pulsating PCV. The mean age of pulsating PCV patients was 60.6 +/- 7.0 years (48-69 years), which was younger than non-pulsating PCV patients (65.7 years, p = 0.035). The mean follow-up period was 23.9 +/- 10.7 months, and PDT was administered 1.6 +/- 0.9 times to pulsating PCV patients. The mean logMAR BCVAs were 0.85 +/- 0.47 at presentation and 0.71 +/- 0.52 at final examination. Extensive haemorrhagic events were more common in pulsating than in non-pulsating PCV patients (57.1% versus 26.5%, p = 0.032). However, the risk of haemorrhage within 3 months of PDT was similar for both pulsating PCV and the remaining patients (14.3% versus 20%, p = 0.723).
   Conclusion:
   Pulsating PCV showed distinctive features including a relatively younger patient age at presentation, and a haemorrhagic tendency (especially extensive). However, the use of PDT did not directly increase the risk of haemorrhage in pulsating PCV patients.
C1 [Byeon, Suk Ho; Lew, Young Ju; Lee, Sung Chul; Kwon, Oh Woong] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Kwon, OW (通讯作者)，Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, 134 Seodaemun Gu, Seoul 120752, South Korea.
EM owkwon0301@yuhs.ac
OI , Sung Chul/0000-0001-9438-2385; Byeon, suk ho/0000-0001-8101-0830
FU Yonsei University Medical School [6-2006-0088]
FX This research was supported by Yonsei University Medical School grant 6-
   2006-0088.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza Eriko, 2006, Nippon Ganka Gakkai Zasshi, V110, P288
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Jalali S, 2006, AM J OPHTHALMOL, V142, P608, DOI 10.1016/j.ajo.2006.05.055
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Parodi MB, 2007, ACTA OPHTHALMOL SCAN, V85, P50, DOI 10.1111/j.1600-0420.2006.00738.x
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schneider U, 1997, OPHTHALMOLOGICA, V211, P115, DOI 10.1159/000310775
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SHULTS WT, 1974, AM J OPHTHALMOL, V77, P304, DOI 10.1016/0002-9394(74)90734-X
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Townsend-Pico WA, 2000, AM J OPHTHALMOL, V129, P33, DOI 10.1016/S0002-9394(99)00337-2
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 38
TC 23
Z9 26
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2010
VL 88
IS 6
BP 660
EP 668
DI 10.1111/j.1755-3768.2009.01517.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 643PI
UT WOS:000281310000017
PM 19563374
OA Bronze
DA 2022-11-30
ER

PT J
AU Hosokawa, M
   Morizane, Y
   Hirano, M
   Kimura, S
   Kumase, F
   Shiode, Y
   Doi, S
   Toshima, S
   Hosogi, M
   Fujiwara, A
   Mitsuhashi, T
   Shiraga, F
AF Hosokawa, Mio
   Morizane, Yuki
   Hirano, Masayuki
   Kimura, Shuhei
   Kumase, Fumiaki
   Shiode, Yusuke
   Doi, Shinichiro
   Toshima, Shinji
   Hosogi, Mika
   Fujiwara, Atsushi
   Mitsuhashi, Toshiharu
   Shiraga, Fumio
TI One-year outcomes of a treat-and-extend regimen of intravitreal
   aflibercept for polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Polypoidal choroidal vasculopathy; Treat-and-extend regimen
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; VEGF-TRAP; JAPANESE
   PATIENTS; RANIBIZUMAB INJECTIONS; PREDICTIVE FACTORS; VERTEPORFIN;
   BEVACIZUMAB; RECURRENCE; PROTOCOL
AB To evaluate the 1-year treatment outcomes of intravitreal aflibercept injections (IVA) using a treat-and-extend regimen for polypoidal choroidal vasculopathy (PCV).
   Thirty-seven eyes with treatment-naive PCV treated with IVA using a treat-and-extend regimen for 1 year were reviewed retrospectively. The main outcome measures were changes in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the treatment interval at 1 year. The predictive factors for patients who could not continue to extend the treatment interval because of poor response to IVA or recurrence were analyzed.
   The mean logarithm of the minimum angle of resolution BCVA improved from 0.37 at baseline to 0.21 at 1 year (P < 0.001). The mean CRT decreased from 342.3 mu m at baseline to 196.6 mu m at 1 year (P < 0.001). The mean treatment interval was 9.7 weeks at 1 year (4 weeks in 11 eyes [29.7%], 6 weeks in 1 eye [2.7%], 8 weeks in 2 eyes [5.4%], 10 weeks in 1 eye [2.7%], and 12 weeks in 22 eyes [59.5%]). A larger number of polypoidal lesions at baseline was predictive for patients who could not continue to extend the treatment interval.
   IVA using a treat-and-extend regimen is effective for improving BCVA and CRT in eyes with PCV.
C1 [Hosokawa, Mio; Morizane, Yuki; Hirano, Masayuki; Kimura, Shuhei; Kumase, Fumiaki; Shiode, Yusuke; Doi, Shinichiro; Toshima, Shinji; Hosogi, Mika; Fujiwara, Atsushi; Shiraga, Fumio] Okayama Univ, Dept Ophthalmol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan.
   [Mitsuhashi, Toshiharu] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan.
C3 Okayama University; Okayama University
RP Morizane, Y (通讯作者)，Okayama Univ, Dept Ophthalmol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan.
EM moriza-y@okayama-u.ac.jp
FU Santen; Alcon; Byer; Novartis; Hoya; Senju; Topcon
FX M. Hosokawa, None; Y. Morizane, None; M. Hirano, None; S. Kimura, None;
   F. Kumase, None; Y. Shiode, None; S. Doi, None; S. Toshima, None; M.
   Hosogi, None; A. Fujiwara, None; T. Mitsuhashi, None; F. Shiraga, Grants
   (Santen), Board membership (Santen), Consultant fees (Alcon, Byer,
   Novartis, Santen), Lecture fees (Alcon, Hoya, Novartis, Santen, Senju,
   Topcon).
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Jeng KW, 2014, RETINA-J RET VIT DIS, V34, P1796, DOI 10.1097/IAE.0000000000000182
   Kang HM, 2016, GRAEF ARCH CLIN EXP, V254, P1519, DOI 10.1007/s00417-015-3241-6
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rahimy E, 2014, AM J OPHTHALMOL, V158, P345, DOI 10.1016/j.ajo.2014.05.013
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 36
TC 24
Z9 26
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2017
VL 61
IS 2
BP 150
EP 158
DI 10.1007/s10384-016-0492-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EN6RN
UT WOS:000396131200004
PM 27928695
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Komuku, Y
   Iwahashi, C
   Gomi, F
AF Komuku, Yuki
   Iwahashi, Chiharu
   Gomi, Fumi
TI Effectiveness of polypoidal lesion-selective photodynamic therapy with
   intravitreal antivascular endothelial growth factor for polypoidal
   choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Intravitreal antivascular endothelial
   growth factor; Photodynamic therapy; Polypoidal choroidal vasculopathy
ID MACULAR DEGENERATION; RANIBIZUMAB THERAPY; VERTEPORFIN; AFLIBERCEPT;
   NEOVASCULARIZATION; COMBINATION; THICKNESS; SINGLE
AB Purpose To evaluate the 24-month effectiveness of polypoidal lesion-selective photodynamic therapy (PDT) combined with antivascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV) with branching vascular networks (BVNs) involving the fovea with 1 or more polyps. Study design A retrospective case series. Patients and methods Twenty-six eyes from 25 PCV patients treated with polypoidal lesion-selective PDT combined with aflibercept were included in the study. The main outcome measure was change in best-corrected visual acuity (BCVA), and the secondary outcome measures were changes in central retinal thickness and subfoveal choroidal thickness on optical coherence tomography (OCT), status of exudation at 24 months, and number of additional treatments. Results Fourteen eyes of 14 patients showed treatment-naive PCV, and 12 eyes of 11 patients were switched from anti-VEGF monotherapy. The baseline mean logMAR BCVA was 0.43, and this had increased significantly, by 0.31, at 24 months (P = .034). The mean central retinal thickness (CRT) and central choroidal thickness (CCT) were significantly lower at all time points than those at baseline. The mean number of additional injections of aflibercept was 3.1 (range, 0-9), and that of additional PDT treatments was 0.5 (range, 0-2). Conclusion Polypoidal lesion-selective PDT with aflibercept was effective for relatively large, fovea-involved PCV, with significant visual improvement at 24 months.
C1 [Komuku, Yuki; Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, 1-1 Mukogawa cho, Nishinomiya, Hyogo 6638501, Japan.
   [Iwahashi, Chiharu; Gomi, Fumi] Sumitomo Hosp, Dept Ophthalmol, Osaka, Japan.
C3 Hyogo College of Medicine; Sumitomo Hospital
RP Gomi, F (通讯作者)，Hyogo Coll Med, Dept Ophthalmol, 1-1 Mukogawa cho, Nishinomiya, Hyogo 6638501, Japan.; Gomi, F (通讯作者)，Sumitomo Hosp, Dept Ophthalmol, Osaka, Japan.
EM fgomi@hyo-med.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Miyata M, 2018, BR J OPHTHALMOL
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P100, DOI 10.1007/s10384-018-0636-z
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Suzuki M, 2013, GRAEF ARCH CLIN EXP, V251, P2331, DOI 10.1007/s00417-013-2336-1
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 26
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2020
VL 64
IS 3
BP 265
EP 270
DI 10.1007/s10384-020-00734-3
EA MAR 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LP4QN
UT WOS:000521700400001
PM 32206935
DA 2022-11-30
ER

PT J
AU Jalali, S
   Parra, SL
   Majji, AB
   Hussain, N
   Shah, VA
AF Jalali, Subhadra
   Parra, Sandra L.
   Majji, Ajit B.
   Hussain, Nazimul
   Shah, Vinay A.
TI Ultrasonographic characteristics and treatment outcomes of surgery for
   vitreous hemorrhage in idiopathic polypoidal choroidal vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To describe the ultrasonographic characteristics and treatment outcomes of surgery in vitreous hemorrhage (VH) associated with idiopathic polypoidal choroidal vasculopathy (IPCV).
   DESIGN: Retrospective interventional and observational case series.
   METHODS: Clinical, ultrasound, and surgical data of 10 consecutive patients operated for VH due to IPCV in a tertiary eye institute was studied by chart review. Data were analyzed to determine the clinical features, ultrasonographic characteristics, and surgical outcomes. An additional five patients with IPCV without VH were evaluated by ultrasound in various stages of the disease.
   RESULTS: Between January 1998 and March 2005, 10 eyes of 10 patients underwent vitreous surgery for VH associated with IPCV. Characteristic ultrasonographic features that helped the diagnosis preoperatively included focal choroidal thickening without excavation or acoustic hollowing with associated low reflective echoes of dispersed VH, or diffuse choroidal thickening and low-intensity echoes of dispersed hemorrhage on either side of the retinal spike, often without vitreous detachment spike. Oral corticosteroids were provided preoperatively to patients with associated exudative retinal detachment. Indocyanine green angiography (ICGA) confirmed IPCV postoperatively. Focal lesions were treated with laser photocoagulation. Anatomical success was seen in nine of 10 eyes. Visual acuity improved in five of 10 eyes but was limited by macular pathology in other five eyes. The most common complication was iatrogenic tears. Some eyes had recurrent IPCV lesions in follow-up.
   CONCLUSIONS: Characteristic ultrasonographic features could identify IPCV in eyes with VH. Anatomical and visual outcomes of our management approach were encouraging and need further study.
C1 LV Prasad Eye Inst, Smt Kannuri Santhamma Retina Vitreous Ctr, Hyderabad 500034, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute
RP Jalali, S (通讯作者)，LV Prasad Eye Inst, Smt Kannuri Santhamma Retina Vitreous Ctr, LV Prasad Marg,Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.
EM subhadra@lvpei.org
RI Hussain, Nazimul/Q-7563-2019
OI Hussain, Nazimul/0000-0001-6920-5168
CR Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   YANNUZI LA, 2000, PRINCIPLES PRACTICE, V3, P2030
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 6
TC 10
Z9 14
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2006
VL 142
IS 4
BP 608
EP 619
DI 10.1016/j.ajo.2006.05.055
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 092LS
UT WOS:000241098900012
PM 17011853
DA 2022-11-30
ER

PT J
AU Ruamviboonsuk, P
   Tadarati, M
   Vanichvaranont, S
   Hanutsaha, P
   Pokawattana, N
AF Ruamviboonsuk, P.
   Tadarati, M.
   Vanichvaranont, S.
   Hanutsaha, P.
   Pokawattana, N.
TI Photodynamic therapy combined with ranibizumab for polypoidal choroidal
   vasculopathy: results of a 1-year preliminary study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; INTRAVITREAL BEVACIZUMAB; VERTEPORFIN; NEOVASCULARIZATION;
   EXPRESSION; VEGF
AB Background/aims To determine the potential efficacy and safety of combined verteporfin photodynamic therapy (PDT) with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV).
   Methods In this prospective, non-comparative, interventional study, 12 eyes from 12 patients that had active PCV were treated with PDT combined with three monthly intravitreal injections of ranibizumab. The patients were then monitored monthly with measurements of best-corrected visual acuity (BCVA) and central retinal thickness quantified by optical coherence tomography for 1 year. Indocyanine green angiography (ICGA) and fluorescein angiography were performed every 3 months. The eyes were re-treated with PDT and a ranibizumab injection, or with solely ranibizumab injection when indicated.
   Results At month 12, the mean BCVA change from baseline was + 12.3 letters (p = 0.04). Eight patients (58.3%, p = 0.02) had a BCVA gain of 15 letters or more. One patient (8.3%, p = 1.0) had a BCVA loss of 15 letters or more. All patients underwent regression of polyps without recurrence. One patient experienced an insignificant subretinal haemorrhage. No other adverse event that could be attributed to the treatment was observed.
   Conclusions This combination therapy showed encouraging results concerning improving vision, reducing the incidence of subretinal haemorrhage and reducing the recurrence of polyps when compared to previously published data that reported PDT monotherapy for PCV.
C1 [Ruamviboonsuk, P.; Tadarati, M.; Vanichvaranont, S.; Pokawattana, N.] Rangsit Univ, Rajavithi Hosp, Dept Ophthalmol, Fac Med, Bangkok 10400, Thailand.
   [Hanutsaha, P.] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Ophthalmol, Bangkok 10700, Thailand.
C3 Rajavithi Hospital; Rangsit University; Mahidol University
RP Ruamviboonsuk, P (通讯作者)，Rangsit Univ, Rajavithi Hosp, Dept Ophthalmol, Fac Med, Bangkok 10400, Thailand.
EM paisan@rajavithi.go.th
FU Rajavithi Hospital
FX Research funds of Rajavithi Hospital.
CR AIELLO LP, 2004, RETINA, V24, P3
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mitamura Y, 2009, EYE, V23, P67, DOI 10.1038/sj.eye.6702996
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 26
TC 48
Z9 50
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2010
VL 94
IS 8
BP 1045
EP 1051
DI 10.1136/bjo.2009.173120
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 634IX
UT WOS:000280575400018
PM 20530656
OA Bronze
DA 2022-11-30
ER

PT J
AU Mitry, D
   Patra, S
AF Mitry, Danny
   Patra, Sudeshna
TI Combination therapy with focal laser photocoagulation and intravitreal
   ranibizumab for polypoidal choroidal vasculopathy: a case series
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Photocoagulation; Polypoidal choroidal vasculopathy; Ranibizumab
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC
   THERAPY; FOLLOW-UP; MACULAR DEGENERATION; NEOVASCULARIZATION;
   VERTEPORFIN; BEVACIZUMAB; EFFICACY; FEATURES
AB PURPOSE. The study aim is to describe the clinical outcomes of patients with polypoidal choroidal vasculopathy (PCV) treated with focal argon laser photocoagulation and ranibizumab combination therapy.
   METHODS. This study is a retrospective case series of 6 patients (6 eyes) diagnosed with PCV who received combination therapy with argon laser photocoagulation and ranibizumab and have at least 12 months follow-up. Argon laser photocoagulation was applied directly to the polypoidal lesions as identified on indocyanine green angiography and followed by a course of intravitreal ranibizumab injections. The primary outcome measures were the mean change in logMAR visual acuity and the mean change in central macular thickness (CM?) at final follow-up.
   RESULTS. The mean (SD) duration of follow-up was 1.09 (0.22) years. At the final follow-up the difference (95% confidence interval [Cl]) in logMAF? acuity was 0.48 (0.10-0.74) (p=0.01) and the difference (95% CO in CMT was 207 pm (35-490) (p=0.02) on optical coherence tomography. The mean (SD) number of ranibizumab injections per eye was 4.83 (3.6). The mean (SD) number of laser treatments per eye was 1.16 (0.4).
   CONCLUSIONS. In this study, combination therapy with focal argon laser photocoagulation and intravitreal ranibizumab resulted in improved visual acuity and clinical outcomes for patients with PCV for up to 1 year.
C1 [Mitry, Danny] Whipps Cross Univ Hosp, Eye Treatment Ctr, London E11 1NR, England.
C3 University of London; Queen Mary University London
RP Mitry, D (通讯作者)，Whipps Cross Univ Hosp, Eye Treatment Ctr, London E11 1NR, England.
EM mitryd@gmail.com
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 30
TC 1
Z9 1
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2012
VL 22
IS 6
BP 1001
EP 1007
DI 10.5301/ejo.5000135
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 050HF
UT WOS:000312043200019
PM 22467591
DA 2022-11-30
ER

PT J
AU Suzuki, M
   Gomi, F
   Sawa, M
   Ueno, C
   Nishida, K
AF Suzuki, Mihoko
   Gomi, Fumi
   Sawa, Miki
   Ueno, Chikako
   Nishida, Kohji
TI Changes in fundus autofluorescence in polypoidal choroidal vasculopathy
   during 3 years of follow-up
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Indocyanine green angiography;
   Branching vascular networks; Autofluorescence
ID OPTICAL COHERENCE TOMOGRAPHY; BRANCHING VASCULAR NETWORKS; GEOGRAPHIC
   ATROPHY; RANIBIZUMAB; LESIONS
AB To investigate changes in fundus autofluorescence (FAF) during 3 years of follow-up in patients with polypoidal choroidal vasculopathy (PCV).
   Retrospective study.
   We retrospectively reviewed the charts of 48 eyes of 47 patients (35 men, 12 women; mean age, 69.9 +/- 7.1 years) with treatment-na < ve PCV for whom FAF and indocyanine green angiography (ICGA) images were available at baseline and at 3 years +/- 3 months follow-up examination. The main outcome measures were the FAF changes during 3 years of follow-up, and the correlation between them and polypoidal lesions and branching vascular networks on ICGA.
   The FAF of the polypoidal lesions showed three patterns at baseline and changes during 3 years of follow-up: confluent hypoautofluorescence surrounded by a hyperautofluorescent ring (86.1 % -> aEuro parts per thousand 51.4 %), confluent hypoautofluorescence without a ring (8.3 % -> aEuro parts per thousand 43.0 %), and no marked changes (5.6 % -> aEuro parts per thousand 5.6 %). The FAF in 96.2 % of resolved polypoidal lesions persisted on images with abnormal FAF during the 3 years of follow-up. The granular hypoautofluorescence at the branching vascular networks at baseline became partially confluent hypoautofluorescence in 41 eyes (85.4 %). The mean area with confluent hypoautofluorescence that corresponded to the branching vascular network lesions increased significantly (P < 0.001) from 1.75 mm(2) to 5.10 mm(2) after 3 years of follow-up.
   The FAF changes in PCV during the 3 years of follow-up can indicate that FAF imaging is a useful and clinically beneficial tool for noninvasively evaluating the PCV lesions and disorders of the upper retinal pigment epithelium.
C1 [Suzuki, Mihoko; Sawa, Miki; Ueno, Chikako; Nishida, Kohji] Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan.
   [Gomi, Fumi] Sumitomo Hosp, Dept Ophthalmol, Kita Ku, Osaka 5300005, Japan.
C3 Osaka University; Sumitomo Hospital
RP Gomi, F (通讯作者)，Sumitomo Hosp, Dept Ophthalmol, Kita Ku, Osaka 5300005, Japan.
EM gomi.fumi@gmail.com
OI Gomi, Fumi/0000-0003-0807-8817; Nishida, Kohji/0000-0001-9069-3610
CR Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Ueno C, 2012, RETINA, V94, P297
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 20
TC 11
Z9 13
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2013
VL 251
IS 10
BP 2331
EP 2337
DI 10.1007/s00417-013-2336-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 220PW
UT WOS:000324598500005
PM 23604513
DA 2022-11-30
ER

PT J
AU Soman, M
   Nair, I
   Sheth, JU
   Nair, U
AF Soman, Manoj
   Nair, Indu
   Sheth, Jay U.
   Nair, Unnikrishnan
TI Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal
   Vasculopathy: Real-World Evidence
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Biosimilars; Ranibizumab;
   Razumab; Safety profile
ID VERTEPORFIN
AB Introduction: To analyze the efficacy and safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab (R) (Intas Pharmaceuticals, Ahmedabad, India; BRm; Razumab (R)) and the innovator ranibizumab drug (IRm; LUCENTIS (R)) in Indian patients with polypoidal choroidal vasculopathy (PCV) under real-world conditions.
   Methods: This was a retrospective study of treatment-naive and previously treated PCV eyes undergoing intravitreal therapy with either BRm or IRm from January 2019 to September 2020 as three loading doses followed by a pro-re-nata (PRN) regimen. Changes in the best-corrected visual acuity (BCVA), subretinal fluid (SRF), intraretinal fluid (IRF), SRF height, and subfoveal choroidal thickness (SFCT) and the safety profiles were assessed at weeks 12, 24, and 52, respectively.
   Results: A total of 22 eyes received IRm and 19 eyes underwent BRm therapy, respectively. Both the groups were comparable in age (P = 0.41) and gender distribution, although the BRm arm had significantly more eyes that were previously treated (P < 0.00001) with a greater median number of injections (P < 0.0001). At week 52, both groups had similar gains in visual acuity (P = 0.19), SRF resolution (P = 0.8), IRF resolution (P = 0.47), and SRF height (P = 0.71). The IRm eyes exhibited a significant improvement in BCVA (P = 0.001) at all visits with a greater mean number of injections (IRm: 5.41 +/- 0.94; BRm: 4 +/- 1.45; P = 0.0004), while the BRm eyes showed a similar increase in BCVA but did not reach statistical significance until week 52. The SFCT decreased significantly in the BRm arm at week 52 (P = 0.045). One eye (5.26%) in the BRm arm experienced mild anterior uveitis, which was treated with topical corticosteroids. In either arm, no other ocular or systemic adverse effects were observed.
   Conclusions: Our real-world data demonstrated the ranibizumab biosimilar Razumab to have comparable visual acuity outcomes to the innovator ranibizumab molecule with an adequate safety profile in the management of PCV. Although these encouraging results support its use as a viable alternative to the innovator molecule, further prospective studies in a diverse patient population are needed to validate our findings.
C1 [Soman, Manoj; Nair, Indu; Sheth, Jay U.; Nair, Unnikrishnan] Chaithanya Eye Hosp & Res Inst, Vitreoretinal Serv, Trivandrum 695004, Kerala, India.
   [Soman, Manoj; Sheth, Jay U.; Nair, Unnikrishnan] Chaithanya Innovat Technol & Eyecare Res, Trivandrum, Kerala, India.
RP Sheth, JU (通讯作者)，Chaithanya Eye Hosp & Res Inst, Vitreoretinal Serv, Trivandrum 695004, Kerala, India.
EM drjay009@gmail.com
OI Nair, Indu/0000-0002-7681-6714
CR Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sharma A, 2022, EYE, V36, P1106, DOI 10.1038/s41433-021-01616-9
   Sharma A, 2020, EYE, V34, P1006, DOI 10.1038/s41433-019-0722-6
   Sharma S., 2018, INT J OPHTHALMOL EYE, V6, P377
   Sharma S, 2020, OPHTHALMOL THER, V9, P103, DOI 10.1007/s40123-019-00228-7
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Woo SJ, 2021, JAMA OPHTHALMOL, V139, P68, DOI 10.1001/jamaophthalmol.2020.5053
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 17
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD JUN
PY 2022
VL 11
IS 3
BP 1175
EP 1186
DI 10.1007/s40123-022-00507-w
EA APR 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1I2EU
UT WOS:000781706900002
PM 35412266
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kang, SW
   Kim, TH
   Kim, SJ
   Ahn, J
AF Kim, Jae Hui
   Kang, Se Woong
   Kim, Tae-Hyup
   Kim, Sang Jin
   Ahn, Jeeyun
TI Structure of Polypoidal Choroidal Vasculopathy Studied by Colocalization
   Between Tomographic and Angiographic Lesions
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CLINICOPATHOLOGICAL CORRELATION; VASCULAR HYPERPERMEABILITY; FEATURES;
   PATTERN
AB PURPOSE: To investigate the structure of polypoidal choroidal vasculopathy (PCV) by tomographic localization of the branching vascular network and late geographic hyperfluorescence.
   DESIGN: Observational case series.
   METHODS: We examined 34 eyes with PCV by simultaneous indocyanine green angiography (ICGA) and spectral-domain optical coherence tomography (OCT) imaging. The margin of the branching vascular network and the late geographic hyperfluorescence on ICGA was colocalized on OCT, in a point-to-point manner, using innate software. The large vessels within the branching vascular network were also colocalized on OCT.
   RESULTS: Late geographic hyperfluorescence on ICGA was noted in 30 eyes. The extent of late geographic hyperfluorescence was larger than that of branching vascular network in 12 eyes. In the remaining eyes, the extent was the same. A double-layer sign on OCT, which consisted of two hyper-reflective lines, representing the retinal pigment epithelium and Bruch membrane, was noted in 29 eyes. In all 28 eyes exhibiting both late geographic hyperfluorescence and the double-layer sign, the extent of late geographic hyperfluorescence matched exactly the extent of double-layer sign on OCT. In 7 of 34 eyes, the thickness of the subretinal pigment epithelial space over the Bruch membrane was too thin to accommodate the large vessels of the branching vascular network. Although the double-layer sign showed mild reduction in area after photodynamic therapy, its general configuration was maintained.
   CONCLUSIONS: Late geographic hyperfluorescence on ICGA corresponds with the double-layer sign on OCT in eyes with PCV. Our observations suggest that the double-layer sign consists mainly of fibrous tissue harbored by the branching vascular network, and late geographic hyperfluorescence may originate from the staining of tissue. (C) 2013 by Elsevier Inc. All rights reserved.
C1 [Kim, Jae Hui] Konyang Univ, Dept Ophthalmol, Kims Eye Hosp, Myung Gok Eye Res Inst,Coll Med, Seoul, South Korea.
   [Kang, Se Woong; Kim, Tae-Hyup; Kim, Sang Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
   [Ahn, Jeeyun] Boramae Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital; Sungkyunkwan University
   (SKKU); Samsung Medical Center; Seoul National University (SNU); Seoul
   National University Hospital
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
OI Ahn, Jeeyun/0000-0001-9017-1652
CR Abe S, OPHTHALMIC IN PRESS
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 19
TC 32
Z9 33
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2013
VL 156
IS 5
BP 974
EP 980
DI 10.1016/j.ajo.2013.06.013
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 250NJ
UT WOS:000326859200016
PM 23958701
DA 2022-11-30
ER

PT J
AU Takayama, K
   Kaneko, H
   Kataoka, K
   Ueno, S
   Chang-Hua, P
   Ito, Y
   Terasaki, H
AF Takayama, Kei
   Kaneko, Hiroki
   Kataoka, Keiko
   Ueno, Shinji
   Chang-Hua, Piao
   Ito, Yasuki
   Terasaki, Hiroko
TI Short-term focal macular electroretinogram of eyes treated by
   aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Focal macular electroretinogram;
   Photodynamic therapy; Aflibercept
ID INTRAVITREAL RANIBIZUMAB; DEGENERATION; THICKNESS
AB To compare short-term outcomes of intravitreal aflibercept injection (IAI) with or without initial photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) using focal macular electroretinography (FMERG).
   Observation case series.
   Twelve patients (6 males, 6 females; 12 eyes) with na < ve PCV received 3 initial IAIs and a single session of PDT 3 days after the first IAI (combination group), and 13 patients (7 males, 6 females; 13 eyes) with na < ve PCV received 3 initial IAIs only (IAI group) were retrospectively observed. Changes in visual acuity, central retinal thickness (CRT), central choroidal thickness (CCT), and FMERG parameters (FMERGs) were compared.
   The combination group showed improved visual acuity after the second and third IAI (P = 0.040, 0.019, respectively); both groups showed reduced CRT after the first IAI (P < 0.01, each). Only the combination group showed reduced CCT after the third IAI (P = 0.031). The FMERGs of the IAI group showed improved amplitudes of a-waves after the third IAI (P = 0.026) and of b-waves after the first and third IAI (P = 0.034, < 0.01, respectively); the combination group did not show improvement. The implicit times of the a- and b-waves were not changed in either group.
   Combination therapy and IAI monotherapy each improved visual acuity and retinal structure to a similar degree; combination therapy reduced choroidal thickness but did not improve FMERGs in the short term.
C1 [Takayama, Kei; Kaneko, Hiroki; Kataoka, Keiko; Ueno, Shinji; Chang-Hua, Piao; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Kaneko, H (通讯作者)，Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Ito, Yasuki/M-4876-2014; Kaneko, Hiroki/O-7695-2015; Kaneko,
   Hiroki/AHA-2461-2022; Kataoka, Keiko/B-2806-2016
OI Ito, Yasuki/0000-0001-9219-9261; Kaneko, Hiroki/0000-0003-0731-6465;
   Kaneko, Hiroki/0000-0003-0731-6465; Kataoka, Keiko/0000-0002-8795-6536;
   Takayama, Kei/0000-0002-1477-9014
FU Chukyo Longevity Medical and Promotion Foundation; Takeda Medical
   Research Foundation;  [15H04994];  [16 K11320];  [16 K20313]
FX This work was partially supported by Grants-in-Aid for Scientific
   Research B (H.T.; 15H04994), Grant-in-Aid for Scientific Research C
   (S.U.; 16 K11320), Grant-in-Aid for Young Scientists B (K.K.; 16
   K20313), Chukyo Longevity Medical and Promotion Foundation (H.K.),
   Takeda Medical Research Foundation (H.K.). These sponsors had no role in
   the design or conduct of this research.
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Ishikawa K, 2011, GRAEF ARCH CLIN EXP, V249, P273, DOI 10.1007/s00417-010-1548-x
   Ishikawa K, 2009, RETINA-J RET VIT DIS, V29, P803, DOI 10.1097/IAE.0b013e31819c631a
   Kim H, 2015, GRAEFES ARCH CLIN EX, P1
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   MIYAKE Y, 1989, INVEST OPHTH VIS SCI, V30, P1743
   MIYAKE Y, 1988, INVEST OPHTH VIS SCI, V29, P1631
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Pirozzi E, 2006, ACTA OPHTHALMOL SCAN, V84, P27, DOI 10.1111/j.1600-0420.2005.00529.x
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Terasaki H, 2001, Nagoya J Med Sci, V64, P1
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
NR 24
TC 5
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2017
VL 255
IS 3
BP 449
EP 455
DI 10.1007/s00417-016-3468-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM0CO
UT WOS:000394986600002
PM 27538907
DA 2022-11-30
ER

PT J
AU Matsumiya, W
   Honda, S
   Otsuka, K
   Miki, A
   Nagai, T
   Imai, H
   Kusuhara, S
   Nakamura, M
AF Matsumiya, Wataru
   Honda, Shigeru
   Otsuka, Keiko
   Miki, Akiko
   Nagai, Takayuki
   Imai, Hisanori
   Kusuhara, Sentaro
   Nakamura, Makoto
TI One-year outcome of combination therapy with intravitreal aflibercept
   and verteporfin photodynamic therapy for polypoidal choroidal
   vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Combination therapy; One-year outcome; Polypoidal choroidal
   vasculopathy; Polypoidal lesion; Verteporfin photodynamic therapy
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; VEGF TRAP; JAPANESE
   PATIENTS; PLUS RANIBIZUMAB; BEVACIZUMAB; NEOVASCULARIZATION; DIAGNOSIS;
   RESISTANT
AB The purpose of the study was to evaluate the 1-year visual and anatomical outcomes of combination therapy with intravitreal aflibercept (IVA) and verteporfin photodynamic therapy (vPDT) for polypoidal choroidal vasculopathy (PCV), and to determine the predictors of a good visual outcome.
   This was a prospective case-series study. Twenty eyes from 20 treatment-na < ve PCV patients were treated with combination therapy with IVA and vPDT. Best-corrected visual acuity (BCVA) and morphological parameters including polypoidal lesions in indocyanine green angiography (ICGA) were evaluated over 12 months of follow-up.
   The mean logMAR BCVA was significantly improved from 0.30 at baseline to 0.20 at 3 months and 0.18 at 12 months. The mean central retinal thickness was also significantly improved at 3 months and at 12 months. In ICGA, complete regression of polypoidal lesions was found in 14 out of 20 eyes (70 %) at 3 months and in 14 out of 18 eyes (78 %) at 12 months although no ICGA were done on two eyes. In the multivariate logistic regression analyses, the baseline greatest linear dimension was found as a significant predictive factor for good visual improvement (ae 0.3 LogMAR units improvement from baseline) at 12 months.
   In this study, combination therapy with IVA and vPDT gave visual and anatomical improvements to treatment-na < ve PCV patients over 12 months of follow-up period.
C1 [Matsumiya, Wataru; Honda, Shigeru; Otsuka, Keiko; Miki, Akiko; Nagai, Takayuki; Imai, Hisanori; Kusuhara, Sentaro; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Matsumiya, W (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM ytkmatsu@hotmail.com
RI Honda, Shigeru/W-4761-2019
OI Imai, Hisanori/0000-0001-8879-3604; Nakamura,
   Makoto/0000-0002-6464-4302; Kusuhara, Sentaro/0000-0002-6458-539X
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Oh IK, 2009, OPHTHALMOLOGICA, V223, P78, DOI 10.1159/000173715
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 29
TC 14
Z9 14
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2017
VL 255
IS 3
BP 541
EP 548
DI 10.1007/s00417-016-3500-1
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM0CO
UT WOS:000394986600012
PM 27687988
DA 2022-11-30
ER

PT J
AU Yehoshua, Z
   Rosenfeld, PJ
   Albini, TA
AF Yehoshua, Zohar
   Rosenfeld, Philip J.
   Albini, Thomas A.
TI Current Clinical Trials in Dry AMD and the Definition of Appropriate
   Clinical Outcome Measures
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE drusen; geographic atrophy; age-related macular degeneration; clinical
   trials
ID AGE-RELATED MACULOPATHY; VISUAL-ACUITY LOSS; GEOGRAPHIC ATROPHY; MACULAR
   DEGENERATION; DISEASE PROGRESSION; POTENTIAL THERAPY; SEVERITY SCALE;
   EYE DISEASE; COMPLEMENT; DRUSEN
AB Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.
C1 [Yehoshua, Zohar; Rosenfeld, Philip J.; Albini, Thomas A.] Univ Miami, Bascom Palmer Eye Inst, Miller Sch Med, Dept Ophthalmol, Miami, FL 33136 USA.
   [Yehoshua, Zohar] Hebrew Univ Jerusalem, Kaplan Med Ctr, Dept Ophthalmol, Rehovot, Israel.
C3 Bascom Palmer Eye Institute; University of Miami; Hebrew University of
   Jerusalem; Kaplan Medical Center
RP Albini, TA (通讯作者)，Univ Miami, Bascom Palmer Eye Inst, Miller Sch Med, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM talbini@med.miami.edu
OI Albini, Thomas/0000-0003-2199-9047
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beltran WA, 2003, INVEST OPHTH VIS SCI, V44, P3642, DOI 10.1167/iovs.02-0763
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   GREGORI G, 2011, OPHTHALMOLOGY
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HOLERS, 2009, 51 ANN M AM SOC HEM
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   KUBOTA R, 2009, INVEST OPHTHALMOL VI, V50
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lujan BJ, 2008, OPHTHAL SURG LAS IM, V39, pS15, DOI 10.3928/15428877-20080715-01
   Lutty G, 1999, MOL VIS, V5
   Mata NL, 2010, CURR OPIN OPHTHALMOL, V21, P190, DOI 10.1097/ICU.0b013e32833866c8
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Ralston PG, 2010, INVEST OPHTH VIS SCI, V51
   RISITANO, 2009, 51 ANN M AM SOC HEM
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   STERNBERG P, 2010, INVEST OPHTHALMOL VI, V51
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 72
TC 38
Z9 42
U1 0
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 167
EP 180
DI 10.3109/08820538.2011.577132
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200013
PM 21609230
DA 2022-11-30
ER

PT J
AU Song, JH
   Byeon, SH
   Lee, SC
   Koh, HJ
   Kwon, OW
AF Song, Ji Hun
   Byeon, Suk Ho
   Lee, Sung Chul
   Koh, Hyoung Jun
   Kwon, Oh Woong
TI Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab
   Injection for the Management of Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Choroidal neovascularization;
   Vascular endothelial growth factor; Bevacizumab; Intravitreal injection
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; LASER PHOTOCOAGULATION; PHOTODYNAMIC THERAPY;
   NEOVASCULARIZATION; AVASTIN; PENETRATION; CANCER
AB Aims: To evaluate the short-term safety and efficacy of a single intravitreal bevacizumab injection in patients with polypoidal choroidal vasculopathy (PCV). Methods: The records of patients treated with intravitreal bevacizumab for PCV were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fluorescein and indocyanine green angiography. Changes in visual acuity and central retinal thickness (CRT) over 3 months were the main outcome measures. Results: Nineteen eyes of 18 patients were included. No serious ocular or systemic adverse events were observed. The median baseline visual acuity and CRT were 20/100 and 230 mu m, respectively. After 1 month, there was no significant improvement in median visual acuity (20/80(+1); p = 0.055), but median CRT had decreased significantly (160 mu m; p < 0.001). After 3 months (data available for 17 eyes), both median visual acuity (20/63(-2); p = 0.001) and CRT (190 mu m; p = 0.007) showed significant improvements over baseline values. Conclusions: Intravitreal bevacizumab therapy for PCV was well tolerated over the 3-month follow-up period. Shortterm results are promising, but further studies are necessary to evaluate long-term efficacy. Copyright (C) 2008 S. Karger AG, Basel
C1 [Song, Ji Hun; Byeon, Suk Ho; Lee, Sung Chul; Koh, Hyoung Jun; Kwon, Oh Woong] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Kwon, OW (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Sodaemungu Shinchondong 134, Seoul 120752, South Korea.
EM owkwon0301@yuhs.ac
OI , Sung Chul/0000-0001-9438-2385; Byeon, suk ho/0000-0001-8101-0830; Koh,
   Hyoung Jun/0000-0002-5932-8516
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Han Dennis P, 2004, Trans Am Ophthalmol Soc, V102, P305
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vedantham V, 2005, EYE, V19, P915, DOI 10.1038/sj.eye.6701666
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 30
TC 35
Z9 35
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2009
VL 223
IS 2
BP 85
EP 92
DI 10.1159/000175312
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 407HY
UT WOS:000263355400003
PM 19023226
DA 2022-11-30
ER

PT J
AU Wang, TA
   Chan, WC
   Tsai, SH
   Chen, LJ
AF Wang, Te-An
   Chan, Wei-Chun
   Tsai, Shawn H.
   Chen, Lee-Jen
TI Clinical features of pachyvessels associated with polypoidal choroidal
   vasculopathy in chronic central serous chorioretinopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID THICKNESS; EYES
AB To investigate the association between clinical features of chronic central serous chorioretinopathy (CSC) and subsequent development of polypoidal choroidal vasculopathy (PCV). Characteristics and treatment response of PCV secondary to CSC were described. This retrospective observational study included 18 patients with chronic CSC (18 eyes) with subsequent PCV and 36 controls (36 eyes) with chronic CSC without PCV development during follow-up. Clinical features were compared between the two groups. A logistic regression model was used to evaluate the risk factor of PCV formation. Treatments for PCV included anti-vascular endothelial growth factor (VEGF) monotherapy, photodynamic therapy (PDT), or PDT and anti-VEGF combination treatment. Subretinal fluid on optical coherence tomography images were assessed after treatments. Significant between-group differences were observed in best-corrected visual acuity after disease resolution and presence of pachyvessels (P=.001 and P=.003, respectively). The presence of pachyvessels in chronic CSC was associated with subsequent PCV (odds ratio=6.00; 95% CI, 1.74-20.68; P=.005). CSC recurrence and subfoveal choroidal thickness (SFCT) were not significantly associated with subsequent PCV development (P=.393 and P=.911, respectively). The mean age of PCV diagnosis was 51 years, and the mean time from CSC diagnosis to PCV confirmation was 77.8 months. The mean (range) SFCT of PCV was 327.7 (134-599) mu m. Nine patients received anti-VEGF monotherapy and 5 had disease remission. Four patients received PDT and anti-VEGF combination treatment and all of the 4 had disease remission. In chronic CSC, pachyvessel characteristics are associated with subsequent PCV development. This result will assist clinicians to evaluate CSC in clinical practice and provide insights into the pathogenesis of PCV.
C1 [Wang, Te-An; Chan, Wei-Chun; Tsai, Shawn H.; Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, 92 Sec 2,Zhongshan Rd, Taipei 10449, Taiwan.
   [Tsai, Shawn H.] Mackay Jr Coll Med Nursing & Management, Dept Optometry, Taipei, Taiwan.
C3 Mackay Memorial Hospital; Mackay Junior College of Medicine, Nursing &
   Management
RP Chen, LJ (通讯作者)，Mackay Mem Hosp, Dept Ophthalmol, 92 Sec 2,Zhongshan Rd, Taipei 10449, Taiwan.
EM chen.leejen@msa.hinet.net
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Baek J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42052-w
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sartini F, 2020, INT OPHTHALMOL, V40, P3577, DOI 10.1007/s10792-020-01522-1
   Sartini F, 2019, EYE, V33, P1035, DOI 10.1038/s41433-019-0381-7
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P679, DOI 10.1097/IAE.0000000000002988
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Uppugunduri SR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193324
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Yang HS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227718
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 27
TC 0
Z9 0
U1 0
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 6
PY 2021
VL 11
IS 1
AR 13867
DI 10.1038/s41598-021-93476-2
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TI3SS
UT WOS:000672717200002
PM 34230584
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lee, WK
   Lee, PY
   Lee, SK
AF Lee, Won Ki
   Lee, Phil Young
   Lee, Sang Kyu
TI Photodynamic therapy for polypoidal choroidal vasculopathy:
   Vaso-occlusive effect on the branching vascular network and origin of
   recurrence
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE branching vascular network; photodynamic therapy; polypoidal choroidal
   vasculopathy; recurrence; vaso-occlusion
ID PIGMENT EPITHELIAL DETACHMENTS; CLINICOPATHOLOGICAL CORRELATION; MACULAR
   DEGENERATION; VERTEPORFIN
AB Purpose: To determine whether photodynamic therapy (PDT) has a vaso-occlusive effect on the branching vascular network in polypoidal choroidal vasculopathy (PCV) and whether PDT can prevent future recurrence.
   Methods: We analyzed pre- and post-PDT indocyanine green angiography (ICGA) results of 27 patients (27 eyes) who were diagnosed with PCV and who had shown clinical improvement accompanied by occlusion of polypoidal lesions after PDT. We also investigated the recurrent events in these patients and the origin of the recurrences.
   Results: The branching vascular network persisted, at least in part, in 20 (87%) of 23 eyes undergoing one PDT session and in two (50%) of four eyes undergoing two PDT sessions. In the remaining five eyes, we could not determine definitively whether the branching vessels were occluded completely. Recurrent serous changes occurred in nine eyes (33%) 14-48 months after the last PDT. ICGA revealed that these changes were caused by new polypoidal lesions that originated from further-grown branches of the persistent branching vascular network. Diffuse leakage from undetermined sources seemed to coexist in two eyes.
   Conclusions: PDT cannot induce complete occlusion of the branching vascular network. PDT does not prevent future recurrence, because new active polypoidal lesions may develop from the persistent branching vessels in the network.
C1 [Lee, Won Ki; Lee, Phil Young; Lee, Sang Kyu] Catholic Univ Korea, Kangnam St Marys Hosp, Dept Ophthalmol, Seoul 137701, South Korea.
C3 Catholic University of Korea; Catholic University Korea Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Kangnam St Marys Hosp, Dept Ophthalmol, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Breslow R, 1999, ORG LETT, V1, P117, DOI 10.1021/ol990037s
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 20
TC 36
Z9 39
U1 0
U2 1
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD APR
PY 2008
VL 52
IS 2
BP 108
EP 115
DI 10.1007/s10384-007-0501-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 331AY
UT WOS:000257986300005
PM 18626733
DA 2022-11-30
ER

PT J
AU Hsia, Y
   Chan, LW
   Yang, CH
   Yang, CM
   Hsieh, YT
AF Hsia, Yun
   Chan, Li-Wei
   Yang, Chang-Hao
   Yang, Chung-May
   Hsieh, Yi-Ting
TI Prognostic factors for combined ranibizumab and prompt verteporfin
   photodynamic therapy for polypoidal choroidal vasculopathy
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Photodynamic therapy; Ranibizumab;
   Verteporfin; Recurrent hemorrhage; Polyp regression
ID INTRAVITREAL RANIBIZUMAB; HEMORRHAGIC COMPLICATIONS; MACULAR
   DEGENERATION; COMBINATION THERAPY; RISK-FACTORS; INJECTIONS;
   MONOTHERAPY; BEVACIZUMAB; AFLIBERCEPT; EFFICACY
AB Purpose: To investigate the prognostic factors for the combined therapy of ranibizumab and prompt verteporfin photodynamic therapy (vPDT) for eyes with polypoidal choroidal vasculopathy (PCV).
   Methods: Sixty-two PCV eyes of 62 patients that received the initial treatment of intravitreal ranibizumab followed by vPDT within 1 week plus a 2nd intravitreal ranibizumab 1 month later in one single medical center were retrospectively enrolled. Best-corrected visual acuity (BCVA) and parameters obtained from optical coherence tomography at baseline, 3 months, 6 months and 1 year were measured and compared. Factors associated with polyp regression, recurrent hemorrhage and visual improvement were analyzed.
   Results: After the loading treatment, complete and partial polyp regression was achieved in 53.6% and 39.3% of cases, respectively at Month 3. The mean logarithm of the minimum angle of resolution of BCVA improved from 0.64 +/- 0.38 to 0.55 +/- 0.46 (P = 0.008) at Month 12. Recurrent hemorrhage (P = 0.001) and previous antivascular endothelial growth factor (VEGF) treatment (P = 0.017) were associated with poorer visual improvement at Month 12. Incomplete polyp regression (P = 0.038) and previous anti-VEGF treatment (P = 0.005) were associated with a higher risk of recurrent hemorrhage.
   Conclusions: Recurrent hemorrhage was associated with poor visual improvement after combined ranibizumab and vPDT for PCV. Complete polyp eradication was associated with a lower risk of recurrent hemorrhage. Patients who had previously received anti-VEGF were associated with recurrent hemorrhage and poor visual improvement; more frequent follow-ups and more aggressive subsequent treatments may be needed for these cases.
C1 [Hsia, Yun; Chan, Li-Wei; Yang, Chang-Hao; Yang, Chung-May; Hsieh, Yi-Ting] Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Zhongshan S Rd, Taipei 10002, Taiwan.
   [Chan, Li-Wei] Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Ophthalmol, New Taipei, Taiwan.
   [Yang, Chang-Hao; Yang, Chung-May] Natl Taiwan Univ, Coll Med, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   Buddhist Tzu Chi General Hospital; Taipei Tzu Chi Hospital; National
   Taiwan University
RP Hsieh, YT (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Zhongshan S Rd, Taipei 10002, Taiwan.
EM ythyth@gmail.com
RI Yang, Chang-Hao/AAR-3759-2021
OI Hsia, Yun/0000-0001-6972-7732; YANG, CHUNG-MAY/0000-0003-4082-420X;
   YANG, CHANG-HAO/0000-0002-4328-8716
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Han LH, 2017, INT J OPHTHALMOL-CHI, V10, P1280, DOI 10.18240/ijo.2017.08.16
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Jain P, 2018, INDIAN J OPHTHALMOL, V66, P1119, DOI 10.4103/ijo.IJO_1222_17
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee JB, 2018, IEEE T POWER ELECTR, V33, P10419, DOI 10.1109/TPEL.2018.2799726
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Liu L, 2017, PHOTODIAGN PHOTODYN, V20, P215, DOI 10.1016/j.pdpdt.2017.09.008
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Rishi P, 2017, INDIAN J OPHTHALMOL, V65, P712, DOI 10.4103/ijo.IJO_174_17
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Wong IY, 2018, RETINA-J RET VIT DIS, V38, P725, DOI 10.1097/IAE.0000000000001614
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhao M, 2017, INT J OPHTHALMOL-CHI, V10, P413, DOI 10.18240/ijo.2017.03.14
NR 40
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2019
VL 27
BP 227
EP 233
DI 10.1016/j.pdpdt.2019.06.004
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IW3HH
UT WOS:000484870600040
PM 31195145
DA 2022-11-30
ER

PT J
AU de Carlo, TE
   Kokame, GT
   Kaneko, KN
   Lian, R
   Lai, JC
   Wee, R
AF de Carlo, Talisa E.
   Kokame, Gregg T.
   Kaneko, Kyle N.
   Lian, Rebecca
   Lai, James C.
   Wee, Raymond
TI SENSITIVITY AND SPECIFICITY OF DETECTING POLYPOIDAL CHOROIDAL
   VASCULOPATHY WITH EN FACE OPTICAL COHERENCE TOMOGRAPHY AND OPTICAL
   COHERENCE TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; age-related macular degeneration; anti-VEGF resistance;
   bevacizumab; indocyanine green angiography; optical coherence
   tomography; polypoidal choroidal vasculopathy; ranibizumab
ID MACULAR DEGENERATION
AB Purpose: Determine sensitivity and specificity of polypoidal choroidal vasculopathy (PCV) diagnosis with structural en face optical coherence tomography (OCT) and OCT angiography (OCTA).
   Methods: Retrospective review of the medical records of eyes diagnosed with PCV by indocyanine green angiography with review of diagnostic testing with structural en face OCT and OCTA by a trained reader. Structural en face OCT, cross-sectional OCT angiograms alone, and OCTA in its entirety were reviewed blinded to the findings of indocyanine green angiography and each other to determine if they could demonstrate the PCV complex. Sensitivity and specificity of PCV diagnosis was determined for each imaging technique using indocyanine green angiography as the ground truth.
   Results: Sensitivity and specificity of structural en face OCT were 30.0% and 85.7%, of OCT angiograms alone were 26.8% and 96.8%, and of the entire OCTA were 43.9% and 87.1%, respectively. Sensitivity and specificity were improved for OCT angiograms and OCTA when looking at images taken within 1 month of PCV diagnosis.
   Conclusion: Sensitivity of detecting PCV was low using structural en face OCT and OCTA but specificity was high. Indocyanine green angiography remains the gold standard for PCV detection.
C1 [de Carlo, Talisa E.] Univ Hawaii, Dept Med, Transit Residency Program, Sch Med, Honolulu, HI 96822 USA.
   [de Carlo, Talisa E.; Kokame, Gregg T.; Lian, Rebecca; Lai, James C.; Wee, Raymond] Univ Hawaii, John A Burns Sch Med, Sch Med, Honolulu, HI 96822 USA.
   [de Carlo, Talisa E.; Kokame, Gregg T.; Kaneko, Kyle N.; Lai, James C.; Wee, Raymond] Retina Ctr Pali Momi, Aiea, HI USA.
   [de Carlo, Talisa E.; Kokame, Gregg T.; Kaneko, Kyle N.; Lai, James C.; Wee, Raymond] Retina Consultants Hawaii, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
   [de Carlo, Talisa E.; Kokame, Gregg T.; Kaneko, Kyle N.; Lai, James C.; Wee, Raymond] Hawaii Macula & Retina Inst, Aiea, HI USA.
   [Kokame, Gregg T.; Lai, James C.; Wee, Raymond] Univ Hawaii, Dept Surg, Div Ophthalmol, Sch Med, Honolulu, HI 96822 USA.
C3 University of Hawaii System; University of Hawaii System; University of
   Hawaii System
RP Kokame, GT (通讯作者)，Retina Consultants Hawaii, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
EM retinahi@aol.com
CR Agarwal N, 2012, OBSTET MED, V5, P176, DOI 10.1258/om.2011.110024
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2016, 10 APVRS C BANK THAI
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kokame GT, 2015, OPHTHAL SURG LAS IM, V47, P737
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 24
TC 17
Z9 17
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2019
VL 39
IS 7
BP 1343
EP 1352
DI 10.1097/IAE.0000000000002139
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ5AA
UT WOS:000480761900013
PM 29561386
DA 2022-11-30
ER

PT J
AU Lai, TYY
   Lam, CPS
   Luk, FOJ
   Chan, RPS
   Chan, WM
   Liu, DTL
   Lam, DSC
AF Lai, Timothy Y. Y.
   Lam, Carol P. S.
   Luk, Fiona O. J.
   Chan, Rose P. S.
   Chan, Wai-Man
   Liu, David T. L.
   Lam, Dennis S. C.
TI Photodynamic Therapy With or Without Intravitreal Triamcinolone
   Acetonide for Symptomatic Polypoidal Choroidal Vasculopathy
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID TREATED RAT MODEL; MACULAR DEGENERATION; NEOVASCULAR MEMBRANES; RETINAL
   TOXICITY; VERTEPORFIN; INJECTION; EXPRESSION; RABBITS; KENALOG; CELLS
AB Purpose: To evaluate the outcome of verteporfin photodynamic therapy (PDT) with or without intravitreal triamcinolone acetonide (IVTA) for the treatment of symptomatic polypoidal choroidal vasculopathy (PCV).
   Methods: Retrospective analysis of PCV patients who underwent PDT with or without IVTA with follow-up of 2 or more years. Changes in best-corrected visual acuity (BCVA), proportion of eyes with moderate visual loss (3 or more lines), and complications were compared between patients with or without IVTA.
   Results: Twenty-seven eyes of 27 patients were analyzed, with 12 eyes treated by PDT monotherapy and 15 eyes treated by combined PDT with IVTA. The baseline characteristics of both groups were similar. At 1 year, the mean logMAR BCVA for the PDT monotherapy group improved from 0.74 to 0.58 (P = 0.011), whereas the combined PDT and IVTA group improved from 0.84 to 0.74 (P = 0.17). At 2 years, the mean logMAR BCVA for the monotherapy and combined treatment groups were 0.62 and 0.84, respectively, and the changes compared with baseline were not statistically significant. No significant difference was found in the mean logMAR BCVA, the mean line of visual changes, and the mean number of PDT treatments between the 2 groups at 1 and 2 years. One (8.3%) and 4 (26.7%) eyes in the monotherapy and the combined groups lost 3 or more lines at 2 years, respectively. Patients who had combined PDT with IVTA were more likely to develop cataract requiring surgery and ocular hypertension (P = 0.043 and 0.046, respectively).
   Conclusions: PDT reduced the risks of visual loss in patients with symptomatic PCV in the short term but the effect might not be sustained after 1 year. The adjunctive use of IVTA during PDT did not appear to result in additional benefit for treating PCV.
C1 [Lai, Timothy Y. Y.; Lam, Carol P. S.; Luk, Fiona O. J.; Chan, Rose P. S.; Chan, Wai-Man; Liu, David T. L.; Lam, Dennis S. C.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 3-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Lai, Timothy Y Y/AAC-2120-2020; Lam, Dennis/AAL-1211-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428; 
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lang YR, 2007, RETINA-J RET VIT DIS, V27, P778, DOI 10.1097/IAE.0b013e318030c517
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee YA, 2009, EYE, V23, P645, DOI 10.1038/eye.2008.17
   Luttrull JK, 2007, RETINA-J RET VIT DIS, V27, P688, DOI 10.1097/IAE.0b013e318030e999
   Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761
   Mitamura Y, 2009, EYE, V23, P67, DOI 10.1038/sj.eye.6702996
   Morrison VL, 2006, RETINA-J RET VIT DIS, V26, P339, DOI 10.1097/00006982-200603000-00014
   Oner A, 2005, DOC OPHTHALMOL, V111, P107, DOI 10.1007/s10633-005-4608-5
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
NR 40
TC 21
Z9 23
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD FEB
PY 2010
VL 26
IS 1
BP 91
EP 95
DI 10.1089/jop.2009.0073
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 562JT
UT WOS:000275047000012
PM 20148658
DA 2022-11-30
ER

PT J
AU Ogino, K
   Tsujikawa, A
   Yamashiro, K
   Ooto, S
   Oishi, A
   Nakata, I
   Miyake, M
   Yoshimura, N
AF Ogino, Ken
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Ooto, Sotaro
   Oishi, Akio
   Nakata, Isao
   Miyake, Masahiro
   Yoshimura, Nagahisa
TI Intravitreal Injection of Ranibizumab for Recovery of Macular Function
   in Eyes With Subfoveal Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; electroretinography; age related
   macular degeneration; microperimetry; ranibizumab
ID ANGIOGRAPHIC FINDINGS; PHOTODYNAMIC THERAPY; ELECTRORETINOGRAMS;
   MICROPERIMETRY; VERTEPORFIN; BEVACIZUMAB
AB PURPOSE. To evaluate changes in macular function in eyes with polypoidal choroidal vasculopathy (PCV) after intravitreal ranibizumab (IVR) treatment.
   METHODS. Twenty-three eyes from 23 patients with treatment-naive subfoveal PCV received three monthly injections of IVR, followed by as-needed injections. Visual acuity (VA); retinal thickness (measured with optical coherence tomography); macular sensitivity (measured with microperimetry); and focal macular electroretinograms (fmERGs) were evaluated both before the initiation of therapy and after 3 and 12 months.
   RESULTS. Before treatment, cystoid macular edema was observed in five eyes, serous retinal detachments in 13 eyes, and serosanguinous pigment epithelial detachments in 18 eyes. IVR treatment resulted in substantial morphological improvements and consequent marked reductions in foveal thickness (P = 0.008). Although logarithm of the minimum angle of resolution (logMAR) VA did not improve significantly over the 12-month study period (P = 0.623), the amplitude of the fmERG photopic negative response and macular sensitivity within 4 degrees had increased significantly at 3 months (P = 0.004, P = 0.026, respectively). This trend persisted until the end of the 12-month monitoring period. Among the eyes with preexisting serous retinal detachments, those in which the detachments had resolved completely at 3 months also exhibited greater increases in fmERG a-wave amplitudes (P = 0.048).
   CONCLUSIONS. IVR therapy resulted in morphological improvements and the partial recovery of macular function in eyes with subfoveal PCV. This therapy may improve photoreceptor function by resolving serous retinal detachments.
C1 [Ogino, Ken; Tsujikawa, Akitaka; Yamashiro, Kenji; Ooto, Sotaro; Oishi, Akio; Nakata, Isao; Miyake, Masahiro; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; Miyake, Masahiro/V-1261-2019
OI Oishi, Akio/0000-0002-0977-9458; Miyake, Masahiro/0000-0001-7410-3764;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Grants-in-Aid for Scientific Research [24791848] Funding Source: KAKEN
CR Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Cho HJ, 2011, EYE LOND, V24, P483
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Iwata E, 2012, INVEST OPHTH VIS SCI, V53, P4185, DOI 10.1167/iovs.11-9335
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Miyake Y, 1998, Nagoya J Med Sci, V61, P79
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Ogino K, 2011, INVEST OPHTH VIS SCI, V52, P8047, DOI 10.1167/iovs.11-8143
   Ogino K, 2011, INVEST OPHTH VIS SCI, V52, P3514, DOI 10.1167/iovs.10-7142
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sa Ho-Seok, 2005, Korean J Ophthalmol, V19, P275
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Terasaki H, 2001, INVEST OPHTH VIS SCI, V42, P229
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
NR 33
TC 15
Z9 16
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2013
VL 54
IS 5
BP 3771
EP 3779
DI 10.1167/iovs.12-11494
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 173YC
UT WOS:000321118300079
PM 23661367
DA 2022-11-30
ER

PT J
AU Asano, S
   Azuma, K
   Shimizu, K
   Yamamoto, R
   Lee, J
   Murata, H
   Inoue, T
   Asaoka, R
   Obata, R
AF Asano, Shotaro
   Azuma, Keiko
   Shimizu, Kimiko
   Yamamoto, Risako
   Lee, Jinhee
   Murata, Hiroshi
   Inoue, Tatsuya
   Asaoka, Ryo
   Obata, Ryo
TI Choroidal structure as a biomarker for visual acuity in intravitreal
   aflibercept therapy for polypoidal choroidal vasculopathy
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; HEALTHY EYES; RANIBIZUMAB;
   THICKNESS; OUTCOMES; HYPERPERMEABILITY; BINARIZATION; AMD
AB Purpose
   To investigate the relationship between choroidal structure and visual acuity after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy (PCV).
   Methods
   We conducted a retrospective, single-centre and observational study including 18 eyes of 18 patients with PCV (73.8 +/- 10.2 years of age) who were treated with three monthly intravitreal aflibercept injections followed by additional treatments in a treat-and-extend protocol. The cross-sectional images of the macula were obtained with enhanced depth imaging optical coherence tomography at baseline, at 3 months, and at 12 months. The choroidal layer was divided into luminal or stromal segments by applying binarization processing to calculate these areas. The relationships between age, spherical equivalent, best-corrected visual acuity (BCVA), baseline value, or changes in the luminal or the stromal areas, and the BCVA change at 12 months were analysed using multiple regression analyses and model selection procedures.
   Results
   Both stromal and luminal areas were decreased at 3 and 12 months compared to baseline areas (5% and 9% at 3 months, 6% and 12% at 12 months, p < 0.0001, p < 0.0001, p < 0.0001 and p < 0.0001, respectively). Greater improvement of visual acuity (VA) at 12 months was significantly associated with younger age, greater spherical equivalent, worse baseline BCVA, greater baseline luminal area, and smaller baseline stromal area.
   Conclusions
   Choroidal structure might be useful as a new biomarker for potential Visual outcomes after intravitreal aflibercept therapy for PCV.
C1 [Asano, Shotaro; Azuma, Keiko; Shimizu, Kimiko; Yamamoto, Risako; Murata, Hiroshi; Inoue, Tatsuya; Asaoka, Ryo; Obata, Ryo] Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Tokyo, Japan.
   [Asano, Shotaro; Azuma, Keiko; Shimizu, Kimiko; Yamamoto, Risako; Murata, Hiroshi; Inoue, Tatsuya; Asaoka, Ryo; Obata, Ryo] Univ Tokyo, Fac Med, Tokyo, Japan.
   [Lee, Jinhee] Miyata Eye Hosp, Miyazaki, Japan.
C3 University of Tokyo; University of Tokyo
RP Obata, R (通讯作者)，Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Tokyo, Japan.; Obata, R (通讯作者)，Univ Tokyo, Fac Med, Tokyo, Japan.
EM robata-tky@umin.ac.jp
FU JSPS KAKENHI [JP16K11260]
FX This study was done under JSPS KAKENHI Grant Number JP16K11260. The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cicchetti DV., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]
   Daizumoto E, 2017, BRIT J OPHTHALMOL, V101, P56, DOI 10.1136/bjophthalmol-2016-309694
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Goodenough AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034338
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Mallows CL, 2000, TECHNOMETRICS, V42, P87, DOI 10.2307/1271437
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Sonoda S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157190
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Tibshirani RJ, 2012, ANN STAT, V40, P1198, DOI 10.1214/12-AOS1003
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   TORNQUIST P, 1979, ACTA PHYSIOL SCAND, V106, P351, DOI 10.1111/j.1748-1716.1979.tb06409.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhang Z., 2016, ANN TRANSLATIONAL ME, V4
NR 44
TC 4
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 10
PY 2018
VL 13
IS 5
AR e0197042
DI 10.1371/journal.pone.0197042
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GF3JM
UT WOS:000431851700059
PM 29746511
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Ma, ST
   Huang, CH
   Chang, YC
   Lai, TT
   Hsieh, YT
   Ho, TC
   Yang, CM
   Cheng, CG
   Yang, CH
AF Ma, Shang-Te
   Huang, Chu-Hsuan
   Chang, Yun-Chia
   Lai, Tso-Ting
   Hsieh, Yi-Ting
   Ho, Tzyy-Chang
   Yang, Chung-May
   Cheng, Cheng-Guo
   Yang, Chang-Hao
TI Clinical features and prognosis of polypoidal choroidal vasculopathy
   with different morphologies of branching vascular network on optical
   coherence tomography angiography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; CLASSIFICATION;
   RANIBIZUMAB; OUTCOMES
AB This study highlights the clinical features and treatment response of polypoidal choroidal vasculopathy (PCV) among three different branching vascular network (BVN) morphologies in optical coherence tomography angiography (OCTA), and further correlates the BVN features with those under fluorescent angiography (FA) and indocyanine green angiography (ICGA). In total, we reviewed 70 eyes with PCV followed up for > 12 months. OCTA, ICGA and FA images were obtained at baseline and post-treatments. BVN was assessed using OCTA and divided into three types by a previously described BVN classification: type 1 (trunk), type 2 (glomeruli), and type 3 (stick). At baseline, type 1 BVN had the poorest vision and thinnest subfoveal choroidal thickness (SFCT), whereas type 3 had the best vision and thickest SFCT. The aforementioned trend sustained after treatments. Each BVN morphology in OCTA showed typical features in FA + ICGA and encompassed significant correlation (p = 0.004). In conclusion, OCTA is an innovative imaging tool for the detection and classification of BVN in PCV. Furthermore, OCTA has advantages of being noninvasive and free of systemic toxicities. The BVN can be divided into three types based on morphological characteristics in OCTA, which play crucial roles in clinical presentations and treatment outcomes.
C1 [Ma, Shang-Te] Taipei Med Univ, Dept Ophthalmol, Shuang Ho Hosp, New Taipei, Taiwan.
   [Ma, Shang-Te; Lai, Tso-Ting; Hsieh, Yi-Ting; Ho, Tzyy-Chang; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Huang, Chu-Hsuan] Cathay Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chang, Yun-Chia; Cheng, Cheng-Guo] Shin Kong Wu Ho Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hsieh, Yi-Ting; Ho, Tzyy-Chang; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ, Dept Ophthalmol, Coll Med, Taipei, Taiwan.
C3 Taipei Medical University; Shuang Ho Hospital; National Taiwan
   University; National Taiwan University Hospital; Cathay General
   Hospital; Shin Kong Wu Ho Su Memorial Hospital; National Taiwan
   University
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.; Yang, CH (通讯作者)，Natl Taiwan Univ, Dept Ophthalmol, Coll Med, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
RI Chang, Yunchia/ABD-2506-2021
OI YANG, CHUNG-MAY/0000-0003-4082-420X; YANG, CHANG-HAO/0000-0002-4328-8716
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Chen LJ, 2020, J FORMOS MED ASSOC, V119, P569, DOI 10.1016/j.jfma.2019.04.012
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Desmettre T, 2000, J FR OPHTALMOL, V23, P821
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   MARCUS DF, 1984, ARCH OPHTHALMOL-CHIC, V102, P825
   Olsen TW, 1996, ARCH OPHTHALMOL-CHIC, V114, P97, DOI 10.1001/archopht.1996.01100130093018
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P614, DOI 10.1111/ceo.13464
   Tan CS, 2018, INVEST OPHTH VIS SCI, V59, P889, DOI 10.1167/iovs.17-22683
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 38
TC 1
Z9 1
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 8
PY 2021
VL 11
IS 1
AR 17848
DI 10.1038/s41598-021-97340-1
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UN3CJ
UT WOS:000693895300006
PM 34497317
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chaikitmongkol, V
   Chaovisitsaree, T
   Patikulsila, D
   Kunavisarut, P
   Phasukkijwatana, N
   Watanachai, N
   Choovuthayakorn, J
   Isipradit, S
   Boonyot, P
   Sangkaew, A
   Ingviya, T
   Bressler, SB
   Bressler, NM
AF Chaikitmongkol, Voraporn
   Chaovisitsaree, Thanaphat
   Patikulsila, Direk
   Kunavisarut, Paradee
   Phasukkijwatana, Nopasak
   Watanachai, Nawat
   Choovuthayakorn, Janejit
   Isipradit, Sirawit
   Boonyot, Pawinee
   Sangkaew, Apisara
   Ingviya, Thammasin
   Bressler, Susan B.
   Bressler, Neil M.
TI Optical Coherence Tomography Features for Identifying Posttreatment
   Complete Polypoidal Regression in Polypoidal Choroidal Vasculopathy
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy;
   complete polypoidal regression; optical coherence tomography;
   indocyanine green angiography
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; RANIBIZUMAB;
   COMBINATION; DIAGNOSIS; EFFICACY; EVEREST; SAFETY
AB Purpose: To determine accuracy and relative risk (RR) of posttreatment optical coherence tomography (OCT) features in identifying complete or incomplete polypoidal regression in polypoidal choroidal vasculopathy (PCV). Design: Validity analysis. Methods: Treatment-naive PCV eyes undergoing OCT and indocyanine green angiography (ICGA) at baseline and posttreatment were included. Two graders confirmed diagnosis and identified posttreatment complete or incomplete regression on ICGA. Two other graders classified OCT characteristics of pigment epithelial detachment (PED) (polypoidal lesion) based on 5 prespecified features: "A," no PED; "B," PED with internal homogeneous reflectivity with predominant "BUN" (blended retinal pigment epithelium with underlying structure) sign; "C," PED with internal homogeneous reflectivity with minimal "BUN"; "D," heterogeneous PED; and "E," PED with hyporeflectivity. Results: Among 130 polypoidal lesions (65 pretreatment and 65 posttreatment) of 39 PCV eyes (39 patients; 54% female; mean age +/- SD: 64.6 +/- 8.2), all pretreatment lesions showed feature D on OCT. Posttreatment lesions with complete regression (31 lesions) showed OCT features A, B, C, D, and E in 32%, 45%, 13%, 10%, and 0%, respectively. Posttreatment lesions with incomplete regression (34 lesions) showed OCT features A, B, C, D, and E in 0%, 6%, 15%, 79%, and 0%, respectively. Presence of either feature A or B had highest accuracy (86%; 95% confidence interval: 75%-93%); 77% sensitivity; 94% specificity; RR 5.0 (3.5-7.1, P<0.001) for complete regression. Presence of feature D had highest accuracy (85%; 95% confidence interval: 74%-92%); 79% sensitivity; 90% specificity; RR 4.6 (3.0-6.9, P<0.001) for incomplete regression. Conclusions: Without ICGA, OCT features could provide high accuracy in identifying posttreatment complete or incomplete polypoidal regression in PCV.
C1 [Chaikitmongkol, Voraporn; Patikulsila, Direk; Kunavisarut, Paradee; Watanachai, Nawat; Choovuthayakorn, Janejit] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Retina Div, Chiang Mai, Thailand.
   [Chaovisitsaree, Thanaphat; Isipradit, Sirawit; Sangkaew, Apisara] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Chiang Mai, Thailand.
   [Phasukkijwatana, Nopasak] Mahidol Univ, Fac Med, Dept Ophthalmol, Retina Div,Siriraj Hosp, Bangkok, Thailand.
   [Boonyot, Pawinee] Srinakharinwirot Univ, Fac Med, Bangkok, Thailand.
   [Ingviya, Thammasin] Prince Songkla Univ, Fac Med, Dept Family Med & Prevent Med, Hat Yai, Thailand.
   [Bressler, Susan B.; Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
C3 Chiang Mai University; Chiang Mai University; Mahidol University;
   Srinakharinwirot University; Prince of Songkla University; Johns Hopkins
   University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, 600 North Wolfe St,Maumenee 752, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
CR [Anonymous], 2018, DATA UNOFFICIAL SURV
   Bhoomibunchoo C, 2017, CLIN OPHTHALMOL, V11, P317, DOI 10.2147/OPTH.S126226
   Chaikitmongkol Voraporn, 2021, Asia Pac J Ophthalmol (Phila), V10, P507, DOI 10.1097/APO.0000000000000445
   Chaikitmongkol V, 2020, ASIA-PAC J OPHTHALMO, V9, P260, DOI 10.1097/01.APO.0000656992.00746.48
   Chaikitmongkol V, 2018, OPHTHALMOL RETINA, V2, P170, DOI 10.1016/j.oret.2017.06.006
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Deddens JA, 2004, AM J EPIDEMIOL, V159, P213, DOI 10.1093/aje/kwh022
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Invernizzi A, 2020, ASIA-PAC J OPHTHALMO, V9, P335, DOI 10.1097/APO.0000000000000307
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Morizane-Hosokawa M, 2018, ACTA MED OKAYAMA, V72, P379, DOI 10.18926/AMO/56175
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Teo KYC, 2021, OPHTHALMOL RETINA, V5, P945, DOI 10.1016/j.oret.2021.04.002
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD SEP-OCT
PY 2022
VL 11
IS 5
BP 408
EP 416
DI 10.1097/APO.0000000000000551
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4X8FJ
UT WOS:000861071300003
PM 36179334
OA gold
DA 2022-11-30
ER

PT J
AU Wong, IY
   Shi, X
   Gangwani, R
   Iu, LP
   Fung, N
   Li, Q
   Ng, ALK
   Li, XX
AF Wong, Ian Y.
   Shi, Xuan
   Gangwani, Rita
   Iu, Lawrence P.
   Fung, Nicholas
   Li, Qing
   Ng, Alex L. K.
   Li, Xiaoxin
TI ONE-YEAR RESULTS OF HALF- VERSUS STANDARD-DOSE PHOTODYNAMIC THERAPY
   COMBINED WITH RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; age-related macular degeneration;
   photodynamic therapy; verteporfin; ranibizumab; half-dose; half-fluence
ID CENTRAL SEROUS CHORIORETINOPATHY; INTRAVITREAL BEVACIZUMAB; FLUENCE
AB Purpose: To explore the efficacy of half-dose verteporfin photodynamic therapy (hd-PDT) and standard-dose photodynamic therapy (sd-PDT), when combined with ranibizumab in the treatment of polypoidal choroidal vasculopathy.
   Methods: Subjects were allocated to either the hd-PDT arm or the sd-PDT arm. All subjects received an injection of ranibizumab and PDT treatment (dosage according to allocation) at baseline. Subjects were followed up monthly for 12 months, and re-treatment were given at each visit if criteria were met.
   Results: There were 26 subjects in the hd-PDT arm and 32 in the sd-PDT arm. Overall mean age was 69.3 +/- 9.4 years. Baseline demographics and ocular features did not differ significantly between the two arms. Improvement in vision and reduction in central retinal thickness were similar between the two arms. When presenting, visual acuity was better than 20/50 (logarithm of the minimum angle of resolution 0.4), or when there were three or less polyps angiogram, those treated with hd-PDT tended to perform better than those treated with sd-PDT.
   Conclusion: In general, hd-PDT was able to produce similar results as sd-PDT. Subgroup analysis revealed superior results with hd-PDT when baseline vision was 20/50 or better, or when there were three or less polyps on indocyanine green angiography.
C1 [Wong, Ian Y.; Gangwani, Rita; Iu, Lawrence P.; Fung, Nicholas; Li, Qing; Ng, Alex L. K.] Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Shi, Xuan; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.
C3 University of Hong Kong; Peking University
RP Wong, IY (通讯作者)，FRCOphth, Room 301,Level 3,Block B,Cyberport 4, Pokfulam, Hong Kong, Peoples R China.
EM ianyhwong@gmail.com
RI Ng, Alex Lap-Ki/O-1468-2019; Iu, Lawrence/K-7441-2019
OI Ng, Alex Lap-Ki/0000-0002-8321-5634; Iu, Lawrence/0000-0001-6898-5043
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Byon IS, 2014, OSLI RETINA, V45, P534, DOI 10.3928/23258160-20141118-08
   Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koh AH, 2016, ANN M AM AC OPHTH OC
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Nicolo M, 2014, AM J OPHTHALMOL, V157, P1033, DOI 10.1016/j.ajo.2014.01.022
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
NR 19
TC 6
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2018
VL 38
IS 4
BP 725
EP 730
DI 10.1097/IAE.0000000000001614
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2BD
UT WOS:000440623400017
PM 28333878
DA 2022-11-30
ER

PT J
AU Suzuki, M
   Nagai, N
   Shinoda, H
   Uchida, A
   Kurihara, T
   Tomita, Y
   Kamoshita, M
   Iyama, C
   Tsubota, K
   Ozawa, Y
AF Suzuki, Misa
   Nagai, Norihiro
   Shinoda, Hajime
   Uchida, Atsuro
   Kurihara, Toshihide
   Tomita, Yohei
   Kamoshita, Mamoru
   Iyama, Chigusa
   Tsubota, Kazuo
   Ozawa, Yoko
TI Distinct Responsiveness to Intravitreal Ranibizumab Therapy in
   Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; IDIOPATHIC DISEASE; BEVACIZUMAB; EFFICACY; CLASSIFICATION;
   COMBINATION; VERTEPORFIN; SUBTYPES
AB PURPOSE: To understand the prognosis of polypoidal choroidal vasculopathy (PCV) by evaluating the responsiveness to intravitreal ranibizumab (IVR) monotherapy according to the presence of a single or multiple polyps.
   DESIGN: Retrospective case series.
   METHODS: We included 48 treatment-naive eyes of 48 patients who received IVR monotherapy at the Medical Retina Division Clinic, Keio University Hospital between March 2009 and January 2013 and attended the clinic for at least 12 months. All patients received 3 monthly IVR injections followed by pro re nata injections and were divided into single polyp and multiple polyps groups according to indocyanine green angiography and optical coherence tomography (OCT) findings. The outcome measures included changes in best corrected visual acuity (BCVA) and OCT findings over 2 years after initial IVR.
   RESULTS: At baseline, the multiple polyps group exhibited a poorer BCVA, larger greatest linear dimension, and higher prevalence of fibrovascular pigment epithelial detachment compared with the single polyp group. Over 2 years, the multiple polyps group showed no improvement in BCVA, although the central retinal thickness (CRT) decreased in both groups. The multiple polyps group exhibited a significantly greater CRT at 1 year and required more injections in the first year compared with the single polyp group; furthermore, it included a higher number of nonresponders judged either by BCVA or fundus findings at 1 year and fundus findings at 2 years.
   CONCLUSIONS: We propose that the stratification of PCV lesions according to the presence of single or multiple polyps may be valuable to understand the prognosis. (C) 2016 The Authors. Published by Elsevier Inc.
C1 [Suzuki, Misa; Nagai, Norihiro; Shinoda, Hajime; Uchida, Atsuro; Kurihara, Toshihide; Tomita, Yohei; Kamoshita, Mamoru; Iyama, Chigusa; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Kurihara, Toshihide/ABA-7058-2020; Ozawa, Yoko/AAH-9888-2020; Tomita,
   Yohei/AAC-6968-2021; Tomita, Yohei/AGR-6793-2022; Uchida,
   Atsuro/GVT-8593-2022
OI Kurihara, Toshihide/0000-0002-5457-2720; Uchida,
   Atsuro/0000-0002-1378-7151; Tomita, Yohei/0000-0003-1013-5737
FU Alcon Research LTD.; Japanese Retina and Vitreous Society; International
   Myopia Conference (IMC); Keio University School of Medicine Alumni
   Association (Sanshikai); ARVO/Alcon Foundation; Keystone Symposia;
   Ministry of Agriculture, Forestry, and Fisheries of Japan; Alcon
   Research LTD; OPHTECS Co, Ltd; ROHTO Pharmaceutical Co, Ltd; Dai Nippon
   Printing Co, Ltd; Santen Pharmaceutical Co Ltd; QD Laser, Inc; R-Tech
   Ueno, Ltd; Tsubota Laboratory, Inc; Plaza Eye Co, Ltd; Ogura Co, Ltd;
   TAKATAOPTICAL CO, LTD; Otsuka Pharmaceutical Co, Ltd; Kowa Company, Ltd;
   JIN CO, LTD; Wakamoto Pharmaceutical Co, Ltd; Toray Industries, Inc;
   Meiji Co, Ltd; Yamada Bee Farm Co, Ltd; Pfizer Inc; Kissei
   Pharmaceutical Co, Ltd; White Medical Co Ltd; Wakasa Seikatsu Co, Ltd;
   Senju Pharmaceuticals Co, Ltd; Ministry of Agriculture, Forestry, and
   Fisheries of Japan [24592647]; JINS Co, Ltd; Novartis Pharmaceuticals
   Japan; Bayer AG
FX MISA SUZUKI: PFIZER JAPAN INC, NOVARTIS Pharmaceuticals Japan. Norihiro
   Nagai: Santen Pharmaceutical Co Ltd, Bayer AG. Hajime Shinoda: Alcon
   Research LTD. Atsuro Uchida: award from Alcon Research LTD. Toshihide
   Kurihara: Ministry of Education, Culture, Sports, Science, and
   Technology in Japan (MEXT) KAKENHI, Charitable Trust Fund for Ophthalmic
   Research in Commemoration of Santen Pharmaceutical's Founder, Uehara
   Memorial Foundation, Takeda Science Foundation, Tsubota Laboratory, Inc,
   Fuji Xerox Co, Ltd, Kirin Company, Ltd, Novartis Pharmaceuticals Japan,
   Santen Pharmaceutical Co Ltd, and Otuka Pharmaceutical Co, Ltd; awards
   from the Japanese Retina and Vitreous Society, International Myopia
   Conference (IMC), Keio University School of Medicine Alumni Association
   (Sanshikai), ARVO/Alcon Foundation, and Keystone Symposia. Kazuo
   Tsubota: grant-in-aid "A Scheme to Revitalize Agriculture and Fisheries
   in Disaster Area through Deploying Highly Advanced Technology" from the
   Ministry of Agriculture, Forestry, and Fisheries of Japan; Alcon
   Research LTD, OPHTECS Co, Ltd, ROHTO Pharmaceutical Co, Ltd, Dai Nippon
   Printing Co, Ltd, Santen Pharmaceutical Co Ltd, QD Laser, Inc, R-Tech
   Ueno, Ltd, Tsubota Laboratory, Inc, Plaza Eye Co, Ltd, Ogura Co, Ltd,
   TAKATAOPTICAL CO, LTD, Otsuka Pharmaceutical Co, Ltd, Kowa Company, Ltd,
   JIN CO, LTD, Wakamoto Pharmaceutical Co, Ltd, Toray Industries, Inc,
   Meiji Co, Ltd, Yamada Bee Farm Co, Ltd, Pfizer Inc, Kissei
   Pharmaceutical Co, Ltd, White Medical Co Ltd, Wakasa Seikatsu Co, Ltd,
   Senju Pharmaceuticals Co, Ltd. Yoko Ozawa: Grant-in-Aid for Scientific
   Research, JSPS KAKENHI (24592647), Grant-in-Aid, "A Scheme to Revitalize
   Agriculture and Fisheries in Disaster Area through Deploying Highly
   Advanced Technology," from the Ministry of Agriculture, Forestry, and
   Fisheries of Japan, Wakasa Seikatsu Co, Ltd, JINS Co, Ltd, Santen
   Pharmaceutical Co Ltd, Novartis Pharmaceuticals Japan, Alcon Research
   LTD, Bayer AG, Senju Pharmaceuticals Co, Ltd. The following authors have
   no disclosures: Yohei Tomita, Mamoru Kamoshita, and Chigusa Iyama. All
   authors attest that they meet the current ICMJE criteria for authorship.
CR Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2015, INVEST OPHTH VIS SCI, V56, P3998, DOI 10.1167/iovs.15-17207
NR 29
TC 15
Z9 17
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2016
VL 166
BP 52
EP 59
DI 10.1016/j.ajo.2016.03.024
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO2QD
UT WOS:000377624000010
PM 27017997
OA hybrid
DA 2022-11-30
ER

PT J
AU Lin, WY
   Yang, SC
   Chen, SJ
   Tsai, CL
   Du, SZ
   Lim, TH
AF Lin, Wei-Yang
   Yang, Sheng-Chang
   Chen, Shih-Jen
   Tsai, Chia-Ling
   Du, Shuo-Zhao
   Lim, Tock-Han
TI Automatic Segmentation of Polypoidal Choroidal Vasculopathy from
   Indocyanine Green Angiography Using Spatial and Temporal Patterns
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; indocyanine green angiography;
   computer-aided diagnostic tool
ID PHOTODYNAMIC THERAPY; VERTEPORFIN
AB Purpose: To develop a computer-aided diagnostic tool for automated detection and quantification of polypoidal regions in indocyanine green angiography (ICGA) images.
   Methods: The ICGA sequences of 59 polypoidal choroidal vasculopathy (PCV) treatment-naiive patients from five Asian countries (Hong Kong, Singapore, South Korea, Taiwan, and Thailand) were provided by the EVEREST study. The ground truth was provided by the reading center for the presence of polypoidal regions. The proposed detection algorithm used both temporal and spatial features to characterize the severity of polypoidal lesions in ICGA sequences. Leave-one-out cross validation was carried out so that each patient was used once as the validation sample. For each patient, a fixed detection threshold of 0.5 on the severity was applied to obtain sensitivity, specificity, and balanced accuracy with respect to the ground truth.
   Results: Our system achieved an average accuracy of 0.9126 (sensitivity = 0.9125, specificity = 0.9127) for detection of polyps in the 59 ICGA sequences. Among the total of 222 features extracted from ICGA sequence, the spatial variances exhibited best discriminative power in distinguishing between polyp and nonpolyp regions. The results also indicated the importance of combining spatial and temporal features to further improve detection accuracy.
   Conclusions: The developed software provided a means of detecting and quantifying polypoidal regions in ICGA images for the first time.
   Translational Relevance: This preliminary study demonstrated a computer-aided diagnostic tool, which enables objective evaluation of PCV and its progression. Ophthalmologists can easily visualize the polypoidal regions and obtain quantitative information about polyps by using the proposed system.
C1 [Lin, Wei-Yang; Yang, Sheng-Chang; Du, Shuo-Zhao] Natl Chung Cheng Univ, Dept Comp Sci & Informat Engn, Chiayi 621, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei 11217, Taiwan.
   [Tsai, Chia-Ling] Iona Coll, Dept Comp Sci, New Rochelle, NY USA.
   [Lim, Tock-Han] Tan Tock Seng Hosp, Inst Eye, Natl Healthcare Grp, Singapore, Singapore.
C3 National Chung Cheng University; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University; Iona College; Tan Tock Seng
   Hospital
RP Chen, SJ (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
EM sjchen@vghtpe.gov.tw
FU Ministry of Science and Technology, Taiwan [102-2221-E-194-056]
FX The authors thank the investigators in the EVEREST trial for sharing the
   image data: Adrian Koh, Won Ki Lee, Lee-Jen Chen, Hakyoung Kim, Timothy
   Lai, and Paisan Ruamviboonsuk. Supported by grants from the Ministry of
   Science and Technology, Taiwan (Grant No. 102-2221-E-194-056).
CR Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Domingo C, 2000, P 13 ANN C COMP LEAR, P180
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Recktenwald G., 2000, NUMERICAL METHODS MA
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Tsai CL, 2011, INVEST OPHTH VIS SCI, V52, P2767, DOI 10.1167/iovs.10-6048
   Tsai CL, 2010, IEEE T MED IMAGING, V29, P636, DOI 10.1109/TMI.2009.2030324
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 14
TC 6
Z9 6
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2015
VL 4
IS 2
AR 7
DI 10.1167/tvst.4.2.7
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED1DF
UT WOS:000388583500007
PM 25806144
OA Green Published
DA 2022-11-30
ER

PT J
AU Wang, JJ
   Klein, R
   Smith, W
   Klein, BEK
   Tomany, S
   Mitchell, P
AF Wang, JJ
   Klein, R
   Smith, W
   Klein, BEK
   Tomany, S
   Mitchell, P
TI Cataract surgery and the 5-year incidence of late-stage age-related
   maculopathy - Pooled findings from the Beaver Dam and Blue Mountains Eye
   Studies
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT PROJECT; CAUSE-SPECIFIC PREVALENCE; QUALITY-OF-LIFE;
   MACULAR DEGENERATION; RETINAL-DETACHMENT; INTRAOCULAR-LENS; GRADING
   SYSTEM; OCULAR FACTORS; FELLOW EYES; EXTRACTION
AB Purpose: To assess whether cataract surgery in older persons increases risk for the development of late-stage age-related maculopathy (ARM).
   Design: Combined analysis of longitudinal data from two population-based cohorts, the Beaver Dam Eye Study and Blue Mountains Eye Study.
   Participants: The Beaver Dam Eye Study examined 4926 persons aged 43 years or older at baseline and re-examined 3684 after 5 years. The Blue Mountains Eye Study examined 3654 persons aged 49 years or older at baseline and re-examined 2335 after 5 years.
   Methods: The two studies used similar protocols for retinal photography and photographic grading. We defined incident late-stage ARM as the development of neovascular ARM or geographic atrophy in eyes without either lesion type at baseline that was confirmed by consensus between the study investigators. Nonphakic eyes included eyes that were aphakic or pseudophakic at baseline. Eye-specific data were analyzed. Age- and study site-adjusted relative risks were calculated using the Cochran-Mantel-Haenszel method. Multivariate-adjusted odds ratios (ORs) were also estimated using generalized estimating equation models.
   Results. Of the 6019 participants examined after 5 years, 11,391 eyes were considered at risk for developing late-stage ARM, including 315 nonphakic and 11,076 phakic eyes. Late-state ARM (either neovascular ARM or geographic atrophy) developed in 6.0% to 7.5% of nonphakic eyes (10 of 168 right and 11 of 147 left eyes), compared with 0.7% of phakic eyes (40 of 5504 right and 37 of 5572 left eyes) during the 5-year period. Age- and study site-adjusted 5-year relative risks were 2.8 (95% confidence interval [Cl], 1.6-5.1) for right and 3.7 (95% Cl, 2.1-6.4) for left eyes. After further adjustment for gender, smoking, and the presence of indistinct or reticular drusen or pigmentary abnormalities at baseline, nonphakic eyes had a substantially higher risk for developing either late-stage ARM lesion compared with phakic eyes, OR = 5.7 (95% Cl, 2.4-13.6).
   Conclusions: Pooled findings from these two large population-based cohorts support the hypothesis that cataract surgery in older persons may be associated with an increased subsequent risk for developing late-stage ARM, particularly neovascular ARM. (C) 2003 by the American Academy of Ophthalmology.
C1 Univ Sydney, Dept Ophthalmol, Westmead Millennium & Save Sight Inst, Westmead, NSW 2145, Australia.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   Univ Newcastle, Ctr Biostat & Epidemiol, Newcastle, NSW 2308, Australia.
C3 University of Sydney; University of Wisconsin System; University of
   Wisconsin Madison; University of Newcastle
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Westmead Millennium & Save Sight Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
FU NEI NIH HHS [EY 06594] Funding Source: Medline
CR Ambrecht AM, 1999, BRIT J OPHTHALMOL, V83, P253
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   EDWARDS MG, 1994, AM J OPHTHALMOL, V118, P440, DOI 10.1016/S0002-9394(14)75793-9
   GLYNN RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P381, DOI 10.1001/archopht.1992.01080150079033
   Hawkins WR, 1997, OPHTHALMOLOGY, V104, P900, DOI 10.1016/S0161-6420(97)30212-7
   Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159
   JAVITT JC, 1994, OPHTHALMOLOGY, V101, P100
   KATZ J, 1994, INVEST OPHTH VIS SCI, V35, P2461
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein BEK, 1997, OPHTHALMOLOGY, V104, P573, DOI 10.1016/S0161-6420(97)30267-X
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   LeClaire JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P1404
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Norregaard JC, 1998, ARCH OPHTHALMOL-CHIC, V116, P1095, DOI 10.1001/archopht.116.8.1095
   Norregaard JC, 1997, BRIT J OPHTHALMOL, V81, P102, DOI 10.1136/bjo.81.2.102
   Norregaard JC, 1996, BRIT J OPHTHALMOL, V80, P689, DOI 10.1136/bjo.80.8.689
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 45
TC 169
Z9 189
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2003
VL 110
IS 10
BP 1960
EP 1967
DI 10.1016/S0161-6420(03)00816-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 726TF
UT WOS:000185615400017
PM 14522772
DA 2022-11-30
ER

PT J
AU Rajeswaren, V
   Wong, JO
   Yabroudi, D
   Nahomi, RB
   Rankenberg, J
   Nam, MH
   Nagaraj, RH
AF Rajeswaren, Vivian
   Wong, Jeffrey O.
   Yabroudi, Dana
   Nahomi, Rooban B.
   Rankenberg, Johanna
   Nam, Mi-Hyun
   Nagaraj, Ram H.
TI Small Heat Shock Proteins in Retinal Diseases
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Review
DE small heat shock proteins; glaucoma; diabetic retinopathy; age-related
   macular degeneration; retina
ID ALPHA-B-CRYSTALLIN; ELEVATED INTRAOCULAR-PRESSURE; GANGLION-CELLS;
   CHAPERONE ACTIVITY; A-CRYSTALLIN; PIGMENT EPITHELIUM;
   HEAT-SHOCK-PROTEIN-27 EXPRESSION; NEUROPROTECTIVE PROPERTIES;
   MESENCHYMAL TRANSITION; DIABETIC-RETINOPATHY
AB This review summarizes the latest findings on small heat shock proteins (sHsps) in three major retinal diseases: glaucoma, diabetic retinopathy, and age-related macular degeneration. A general description of the structure and major cellular functions of sHsps is provided in the introductory remarks. Their role in specific retinal diseases, highlighting their regulation, role in pathogenesis, and possible use as therapeutics, is discussed.
C1 [Rajeswaren, Vivian; Wong, Jeffrey O.; Yabroudi, Dana; Nahomi, Rooban B.; Rankenberg, Johanna; Nam, Mi-Hyun; Nagaraj, Ram H.] Sue Anschutz Rodgers Eye Ctr, Sch Med, Dept Ophthalmol, Aurora, CO 80045 USA.
   [Nagaraj, Ram H.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Nam, MH; Nagaraj, RH (通讯作者)，Sue Anschutz Rodgers Eye Ctr, Sch Med, Dept Ophthalmol, Aurora, CO 80045 USA.; Nagaraj, RH (通讯作者)，Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO 80045 USA.
EM Mi-hyun.nam@cuanschutz.edu; ram.nagaraj@cuanschutz.edu
FU Department of Ophthalmology, University of Colorado.
FX We thank the Research to Prevent Blindness, NY for an unrestricted grant
   to the Department of Ophthalmology, University of Colorado.
CR Abu El-Asrar AM, 2012, MIDDLE EAST AFR J OP, V19, P70, DOI 10.4103/0974-9233.92118
   Ahmad MF, 2008, J MOL BIOL, V375, P1040, DOI 10.1016/j.jmb.2007.11.019
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Anders F, 2018, CURR EYE RES, V43, P1267, DOI 10.1080/02713683.2018.1485950
   Anders F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112418
   Bakthisaran R, 2016, BBA-GEN SUBJECTS, V1860, P167, DOI 10.1016/j.bbagen.2015.09.017
   Bakthisaran R, 2015, BBA-PROTEINS PROTEOM, V1854, P291, DOI 10.1016/j.bbapap.2014.12.019
   Bartelt-Kirbach B, 2014, CELL STRESS CHAPERON, V19, P145, DOI [10.1007/s12192-013-0465-4, 10.1007/s12192-013-0452-9]
   Batulan Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00285
   Baughman HER, 2020, P NATL ACAD SCI USA, V117, P2923, DOI 10.1073/pnas.1915099117
   Boehm N, 2012, BRAIN BEHAV IMMUN, V26, P96, DOI 10.1016/j.bbi.2011.07.241
   Boelens WC, 2020, CELL STRESS CHAPERON, V25, P581, DOI 10.1007/s12192-020-01093-1
   Carra S, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2011.0409
   Chen DH, 2018, J CELL MOL MED, V22, P3215, DOI 10.1111/jcmm.13602
   Chen HH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05681-9
   Chen W, 2017, CLIN EXP OPHTHALMOL, V45, P379, DOI 10.1111/ceo.12891
   CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391
   Chidlow G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114838
   Comes N, 2009, PHYSIOL GENOMICS, V38, P205, DOI 10.1152/physiolgenomics.90261.2008
   Cordonnier T, 2015, INT J CANCER, V136, pE496, DOI 10.1002/ijc.29122
   Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841
   Dong YK, 2016, INT J OPHTHALMOL-CHI, V9, P1100, DOI 10.18240/ijo.2016.08.03
   Dukay B, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-020-02070-2
   Ecroyd H, 2007, BIOCHEM J, V401, P129, DOI 10.1042/BJ20060981
   Edwards HV, 2012, BIOCHEM SOC T, V40, P210, DOI 10.1042/BST20110673
   Erni ST, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00570
   Feng Y, 2014, ACTA DIABETOL, V51, P211, DOI 10.1007/s00592-013-0488-4
   Fort PE, 2009, MOL CELL PROTEOMICS, V8, P767, DOI 10.1074/mcp.M800326-MCP200
   Freilich R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07012-4
   Ge HZ, 2017, CANCER BIOL THER, V18, P552, DOI 10.1080/15384047.2017.1345382
   Grotegut P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020513
   Grotegut P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020549
   Guo Y, 2010, INVEST OPHTH VIS SCI, V51, P3003, DOI 10.1167/iovs.09-4663
   Han L, 2018, ONCOL LETT, V16, P5309, DOI 10.3892/ol.2018.9286
   Hebb MO, 2006, BRAIN RES, V1073, P146, DOI 10.1016/j.brainres.2005.12.038
   Heise EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082520
   Heise Erich A, 2011, J Ocul Biol Dis Infor, V4, P62, DOI 10.1007/s12177-011-9073-7
   Huang W, 2007, INVEST OPHTH VIS SCI, V48, P4129, DOI 10.1167/iovs.06-0606
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934
   Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200
   Jaya N, 2009, P NATL ACAD SCI USA, V106, P15604, DOI 10.1073/pnas.0902177106
   Joachim SC, 2007, CURR EYE RES, V32, P501, DOI 10.1080/02713680701375183
   Joachim SC, 2009, INVEST OPHTH VIS SCI, V50, P4734, DOI 10.1167/iovs.08-3144
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Jovcevski B, 2015, CHEM BIOL, V22, P186, DOI 10.1016/j.chembiol.2015.01.001
   Kalesnykas G, 2007, NEUROSCIENCE, V150, P692, DOI 10.1016/j.neuroscience.2007.09.078
   Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2
   Kappe G, 2010, CELL STRESS CHAPERON, V15, P457, DOI 10.1007/s12192-009-0155-4
   Kase S, 2011, INT J MOL MED, V28, P505, DOI 10.3892/ijmm.2011.708
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kim YH, 2012, DIABETOLOGIA, V55, P2835, DOI 10.1007/s00125-012-2625-y
   Klopstein A, 2012, J NEUROSCI, V32, P14478, DOI 10.1523/JNEUROSCI.0923-12.2012
   Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200
   Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003
   Kriehuber T, 2010, FASEB J, V24, P3633, DOI 10.1096/fj.10-156992
   Krueger-Naug AMR, 2002, NEUROSCIENCE, V110, P653, DOI 10.1016/S0306-4522(01)00453-5
   Krueger-Naug AMR, 2003, NEUROSCIENCE, V116, P49, DOI 10.1016/S0306-4522(02)00582-1
   Kurnellas MP, 2012, J BIOL CHEM, V287, P36423, DOI 10.1074/jbc.M112.371229
   Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930, DOI 10.1152/ajplung.1997.273.5.L930
   Lee YJ, 2012, ANGIOGENESIS, V15, P229, DOI 10.1007/s10456-012-9255-3
   Lelj-Garolla B, 2006, J BIOL CHEM, V281, P8169, DOI 10.1074/jbc.M512553200
   Li QH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182588
   Li Y, 2003, INVEST OPHTH VIS SCI, V44, P1299, DOI 10.1167/iovs.02-0235
   Lim EMF, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02108-z
   Losiewicz MK, 2011, INVEST OPHTH VIS SCI, V52, P5034, DOI 10.1167/iovs.10-6931
   Maksimiuk M, 2020, ANN AGR ENV MED, V27, P326, DOI 10.26444/aaem/111759
   MEHLEN P, 1995, J IMMUNOL, V154, P363
   Mellier G, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.413
   Miyara N, 2008, JPN J OPHTHALMOL, V52, P84, DOI 10.1007/s10384-007-0507-5
   Mrugacz M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030458
   Munemasa Y, 2009, INVEST OPHTH VIS SCI, V50, P3869, DOI 10.1167/iovs.08-3138
   Mymrikov EV, 2017, J BIOL CHEM, V292, P672, DOI 10.1074/jbc.M116.760413
   Mymrikov EV, 2011, PHYSIOL REV, V91, P1123, DOI 10.1152/physrev.00023.2010
   Nagaraj RH, 2016, BBA-GEN SUBJECTS, V1860, P252, DOI 10.1016/j.bbagen.2015.03.012
   Nagaraj RH, 2012, BBA-MOL BASIS DIS, V1822, P120, DOI 10.1016/j.bbadis.2011.11.011
   Nagaraj RH, 2012, AMINO ACIDS, V42, P1205, DOI 10.1007/s00726-010-0778-x
   Nahomi RB, 2020, EXP EYE RES, V190, DOI 10.1016/j.exer.2019.107864
   Nahomi RB, 2014, BBA-MOL BASIS DIS, V1842, P164, DOI 10.1016/j.bbadis.2013.11.011
   Nahomi RB, 2013, BIOCHEMISTRY-US, V52, P8126, DOI 10.1021/bi400638s
   Nahomi RB, 2013, BBA-MOL BASIS DIS, V1832, P195, DOI 10.1016/j.bbadis.2012.08.015
   Nandi SK, 2019, EXP EYE RES, V182, P1, DOI 10.1016/j.exer.2019.02.024
   Nandi SK, 2019, BIOCHEMISTRY-US, V58, P1260, DOI 10.1021/acs.biochem.8b01053
   Nath M, 2022, ENEURO, V9, DOI 10.1523/ENEURO.0045-22.2022
   Nath M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112384
   O'Reilly AM, 2010, MOL NEUROBIOL, V42, P124, DOI 10.1007/s12035-010-8143-3
   Pangratz-Fuehrer S, 2011, EYE, V25, P809, DOI 10.1038/eye.2011.42
   Park YH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39141-1
   Pasupuleti N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.3
   Pinach S, 2013, ACTA DIABETOL, V50, P579, DOI 10.1007/s00592-011-0346-1
   Piri N, 2013, MOL NEUROBIOL, V48, P819, DOI 10.1007/s12035-013-8470-2
   Pons M, 2010, AM J PATHOL, V177, P1198, DOI 10.2353/ajpath.2010.091108
   Rada CC, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abc1044
   Raju M, 2016, BBA-GEN SUBJECTS, V1860, P246, DOI 10.1016/j.bbagen.2015.06.010
   Rao NA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033582
   Reddy VS, 2013, INVEST OPHTH VIS SCI, V54, P7674, DOI 10.1167/iovs.13-12715
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947
   Rothbard JB, 2012, J BIOL CHEM, V287, P9708, DOI 10.1074/jbc.M111.337691
   Ruebsam A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97919
   Rusmini P, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00176
   Sakai M, 2003, JPN J OPHTHALMOL, V47, P42, DOI 10.1016/S0021-5155(02)00627-5
   Schmidt T, 2016, CELL STRESS CHAPERON, V21, P167, DOI 10.1007/s12192-015-0650-8
   Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767
   Shemetov AA, 2008, BIOCHEMISTRY-MOSCOW+, V73, P200, DOI 10.1134/S0006297908020120
   Shemetov AA, 2011, MOL CELL BIOCHEM, V355, P47, DOI 10.1007/s11010-011-0837-y
   Shi CB, 2017, BIOCHEM BIOPH RES CO, V489, P369, DOI 10.1016/j.bbrc.2017.05.070
   Shi YJ, 2017, P NATL ACAD SCI USA, V114, pE1243, DOI 10.1073/pnas.1621174114
   Shiota M, 2013, CANCER RES, V73, P3109, DOI 10.1158/0008-5472.CAN-12-3979
   Sreekumar PG, 2022, EXP EYE RES, V215, DOI 10.1016/j.exer.2021.108918
   Sreekumar PG, 2018, J CONTROL RELEASE, V283, P94, DOI 10.1016/j.jconrel.2018.05.014
   Stankowska DL, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0194-2
   Steele MR, 2006, INVEST OPHTH VIS SCI, V47, P977, DOI 10.1167/iovs.05-0865
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   SWAMY MS, 1992, EXP EYE RES, V54, P337, DOI 10.1016/0014-4835(92)90046-U
   Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114
   Tao XY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017799
   Taylor RP, 2005, J MOL CELL CARDIOL, V38, P433, DOI 10.1016/j.yjmcc.2004.12.014
   Tezel G, 1998, INVEST OPHTH VIS SCI, V39, P2277
   Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511
   Tezel G, 2000, J NEUROSCI, V20, P3552, DOI 10.1523/JNEUROSCI.20-10-03552.2000
   Thanos S, 2014, PROG RETIN EYE RES, V42, P145, DOI 10.1016/j.preteyeres.2014.06.004
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vahatupa M, 2018, INVEST OPHTH VIS SCI, V59, P3294, DOI 10.1167/iovs.18-23831
   Wang W, 2014, J CONTROL RELEASE, V191, P4, DOI 10.1016/j.jconrel.2014.04.028
   Wang WJ, 2018, ANN CLIN LAB SCI, V48, P594
   Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008
   Wax MB, 1998, ARCH OPHTHALMOL-CHIC, V116, P993, DOI 10.1001/archopht.116.8.993
   Wax MB, 2001, OPHTHALMOLOGY, V108, P296, DOI 10.1016/S0161-6420(00)00525-X
   Webster JM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01047
   Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200
   Wettstein G, 2012, INT J BIOCHEM CELL B, V44, P1680, DOI 10.1016/j.biocel.2012.05.024
   Windisch BK, 2009, CLIN EXP OPHTHALMOL, V37, P299, DOI 10.1111/j.1442-9071.2009.02032.x
   Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049
   Wu D, 2022, IN VIVO, V36, P132, DOI 10.21873/invivo.12684
   Wu N, 2014, LIFE SCI, V94, P17, DOI 10.1016/j.lfs.2013.10.034
   Wu ZH, 2012, NEURAL REGEN RES, V7, P1493, DOI 10.3969/j.issn.1673-5374.2012.19.008
   Xi JH, 2003, MOL VIS, V9, P410
   Xu WM, 2019, MUCOSAL IMMUNOL, V12, P1291, DOI 10.1038/s41385-019-0198-5
   Yan H, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7205408
   Yokoyama A, 2001, INVEST OPHTH VIS SCI, V42, P3283
   Zhang XW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032765
   Zhu ZH, 2018, NEUROCHEM INT, V115, P69, DOI 10.1016/j.neuint.2018.02.006
NR 145
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD APR 11
PY 2022
VL 9
AR 860375
DI 10.3389/fmolb.2022.860375
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 1B4FQ
UT WOS:000792393500001
PM 35480891
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nandakumar, N
   Buzney, S
   Weiter, JJ
AF Nandakumar, Namrata
   Buzney, Sheldon
   Weiter, John J.
TI Lipofuscin and the Principles of Fundus Autofluorescence: A Review
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Fundus autofluorescence; Age-related macular degeneration; Geographic
   atrophy; Lipofuscin
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY; CONE PHOTOPIGMENT;
   MACULAR PIGMENT; HUMAN RPE; MELANIN; PHAGOCYTOSIS; FLUORESCENCE;
   PRODUCTS; CELLS
AB Fundus autofluorescence is a non-invasive imaging modality that measures lipofuscin that has accumulated in the retinal pigment epithelium (RPE). Excessive lipofuscin in the RPE is a common pathway found in several diseases including Stargardt's disease and age-related macular degeneration. This review discusses the role of photooxidative damage in the development of lipofuscin and the principles of fundus autofluorescence.
C1 [Nandakumar, Namrata; Buzney, Sheldon; Weiter, John J.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary
RP Nandakumar, N (通讯作者)，243 Charles St, Boston, MA 02114 USA.
CR BARR FE, 1983, MED HYPOTHESES, V11, P1, DOI 10.1016/0306-9877(83)90122-6
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   Chen SF, 2001, CURR EYE RES, V23, P422, DOI 10.1076/ceyr.23.6.422.6963
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Feeney-Burns L, 1980, Curr Top Eye Res, V2, P119
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Franceschetti A, 1965, Arch Ophtalmol Rev Gen Ophtalmol, V25, P505
   HERMAN KG, 1982, INVEST OPHTH VIS SCI, V23, P277
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   KATZ ML, 1989, ADV EXP MED BIOL, V266, P109
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KLIEN BA, 1967, AM J OPHTHALMOL, V64, P3, DOI 10.1016/0002-9394(67)93339-9
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Sliney DH, 1999, J EPIDEMIOL, V9, P22
   Sohol RS, 1981, AGE PIGMENTS, p[317, 102]
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   STEINBERG RH, 1977, PHILOS T ROY SOC B, V277, P459, DOI 10.1098/rstb.1977.0028
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wing GL, ARVO ABSTR
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   Zigman S, 2000, J OCUL PHARMACOL TH, V16, P161, DOI 10.1089/jop.2000.16.161
NR 41
TC 17
Z9 21
U1 1
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD SEP-NOV
PY 2012
VL 27
IS 5-6
BP 197
EP 201
DI 10.3109/08820538.2012.711415
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 041SD
UT WOS:000311420600017
PM 23163276
DA 2022-11-30
ER

PT J
AU Hikichi, T
AF Hikichi, Taiichi
TI Individualized ranibizumab therapy strategies in year 3 after as-needed
   treatment for polypoidal choroidal vasculopathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Individualized therapy; Polypoidal choroidal vasculopathy; Ranibizumab
ID VISUAL-FUNCTION-QUESTIONNAIRE; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; TRIAL; NEOVASCULARIZATION; RESPONSIVENESS; VERTEPORFIN;
   GUIDELINES; REGIMENS; OUTCOMES
AB Background: To investigate the third-year results of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV) in individualized treatment regimens based on the outcomes during 2 years.
   Methods: One hundred seventy-two consecutive eyes of 163 prospective treatment-naive patients with PCV were treated with three monthly intravitreal ranibizumab injections followed by as-needed reinjections and completed a 2-year follow-up. Treatment regimens during the third year were selected individually based on their outcomes from the following treatment regimens: as-needed injections based on quarterly examinations, as-needed injections based on monthly examinations, a monthly ranibizumab injection schedule, and the treat-and-extend schedule. Visual acuity (VA) and foveal thickness at the end of the third year and the prevalence of discontinuous follow-up examinations during the third year were evaluated.
   Results: Of 163 patients, 35 (21%) patients were excluded; nine patients had discontinuous follow-up examinations during the third year. In 128 eyes of 128 patients studied during the third year, the significant improvements in VA and foveal thickness 2 years after the first injection compared to baseline were maintained at the end of the third year. Six (18%, 6/34) patients treated with as-needed injections based on quarterly examinations had discontinuous follow-up examinations, the prevalence of which differed significantly (P = 0.025) from the other groups.
   Conclusions: The individualized treatment strategies in the third year based on each patient's outcomes during 2 years maintained the improved VA and avoided discontinuation of follow-up during the third year.
C1 Ohtsuka Eye Hosp, Kita Ku, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Kita Ku, Kita 16 Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
FU Novartis Pharma K.K.; Bayer Yakuhin Ltd.; Santen Pharmaceutical Co. Ltd;
   Kowa Pharmaceutical Co. Ltd; Abbott Japan Ltd.; Otsuka Pharmaceutical
   Co. Ltd.; Senjyu Pharmaceutical Co. Ltd.
FX Dr. Hikichi has received lecture fees from Novartis Pharma K.K., Bayer
   Yakuhin Ltd., Santen Pharmaceutical Co. Ltd, Kowa Pharmaceutical Co.
   Ltd, Abbott Japan Ltd., Otsuka Pharmaceutical Co. Ltd., and Senjyu
   Pharmaceutical Co. Ltd. There are no non-financial competing interests.
CR Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
NR 32
TC 7
Z9 7
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 10
PY 2015
VL 15
AR 37
DI 10.1186/s12886-015-0026-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CF5MW
UT WOS:000352602300001
PM 25881324
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Karan, G
   Lillo, C
   Yang, Z
   Cameron, DJ
   Locke, KG
   Zhao, Y
   Thirumalaichary, S
   Li, C
   Birch, DG
   Vollmer-Snarr, HR
   Williams, DS
   Zhang, K
AF Karan, G
   Lillo, C
   Yang, Z
   Cameron, DJ
   Locke, KG
   Zhao, Y
   Thirumalaichary, S
   Li, C
   Birch, DG
   Vollmer-Snarr, HR
   Williams, DS
   Zhang, K
TI Lipofuscin accumulation, abnormal electrophysiology, and photoreceptor
   degeneration in mutant ELOVL4 transgenic mice: A model for macular
   degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE phagosome; Stargardt disease; photoreceptor; retinal pigment epithelium
ID DOCOSAHEXAENOIC ACID; RETINITIS-PIGMENTOSA; GENE; FLUOROPHORES;
   PHENOTYPE; DYSTROPHY; MUTATION; PROTEIN
AB Macular degeneration is a heterogeneous group of disorders characterized by photoreceptor degeneration and atrophy of the retinal pigment epithelium (RIPE) in the central retina. An autosomal dominant form of Stargardt macular degeneration (STGD) is caused by mutations in ELOVL4, which is predicted to encode an enzyme involved in the elongation of long-chain fatty acids. We generated transgenic mice expressing a mutant form of human ELOVL4 that causes STGD. In these mice, we show that accumulation by the RIPE of undigested phagosomes and lipofuscin, including the fluorophore, 2-[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,7E-octatetraenyl]-1-(2-hyydroxyethyl)-4-[4-methyl-6-(2,6,6,-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E-hexatrienyl]-pyridinium (A2E) is followed by RPE atrophy. Subsequently, photoreceptor degeneration occurs in the central retina in a pattern closely resembling that of human STGD and age-related macular degeneration. The ELOVL4 transgenic mice thus provide a good model for both STGD and dry age-related macular degeneration, and represent a valuable tool for studies on therapeutic intervention in these forms of blindness.
C1 Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   Univ Utah, Program Human Mol Biol & Genet, Eccles Inst Human Genet, Salt Lake City, UT 84132 USA.
   Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA.
   Univ Calif San Diego, Sch Med, Dept Pharmacol, San Diego, CA 92093 USA.
   Univ Calif San Diego, Sch Med, Dept Neurosci, San Diego, CA 92093 USA.
   Retina Fdn SW, Dallas, TX 75231 USA.
   Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah; University of California System; University of
   California San Diego; University of California System; University of
   California San Diego; Retina Foundation of the Southwest; Brigham Young
   University
RP Williams, DS (通讯作者)，Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
EM dswilliams@ucsd.edu; hrvs@chem.byu.edu
RI Zhang, Kang/Y-2740-2019; Lillo, Concepcion/A-6321-2009
OI Zhang, Kang/0000-0002-4549-1697; Lillo, Concepcion/0000-0001-5814-9826;
   Birch, David/0000-0002-6594-2897; Vollmer-Snarr,
   Heidi/0000-0002-7312-4907
FU NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [P30EY012598, R01EY007042, R01EY013408,
   R01EY014448, R01EY014428, R01EY005235] Funding Source: NIH RePORTER;
   NCRR NIH HHS [M01-RR00064, M01 RR000064] Funding Source: Medline; NEI
   NIH HHS [P30EY12598, R01 EY005235, R01EY05235, R01 EY007042, R01EY14428,
   R01EY13408, P30 EY012598, R01 EY014428, R01EY14448, R01 EY014448, R01
   EY013408] Funding Source: Medline
CR Anderson RE, 2002, MOL VIS, V8, P351
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   BIRCH DG, 1995, INVEST OPHTH VIS SCI, V36, P1603
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A
   CONVERSE CA, 1983, T OPHTHAL SOC UK, V103, P508
   Edwards AO, 2001, INVEST OPHTH VIS SCI, V42, P2652
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HOFFMAN DR, 1995, INVEST OPHTH VIS SCI, V36, P1009
   HOOD DC, 1993, VISION RES, V33, P1605, DOI 10.1016/0042-6989(93)90027-T
   HUBBARD AF, 2005, IN PRESS ARCH OPHTHA
   LIOU GI, 1990, J BIOL CHEM, V265, P8373
   LOCKE K, 2004, J OPHTHAL PHOTOGR, V26, P81
   MacDonald IM, 2004, BRIT J OPHTHALMOL, V88, P305, DOI 10.1136/bjo.2003.024299
   Mandal MNA, 2004, GENOMICS, V83, P626, DOI 10.1016/j.ygeno.2003.09.020
   MARMOR MF, 1989, DOC OPHTHALMOL, V73, P299, DOI 10.1007/BF00154485
   Maugeri A, 2004, INVEST OPHTH VIS SCI, V45, P4263, DOI 10.1167/iovs.04-0078
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zhang XM, 2003, MOL VIS, V9, P301
NR 27
TC 145
Z9 172
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 15
PY 2005
VL 102
IS 11
BP 4164
EP 4169
DI 10.1073/pnas.0407698102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 907PT
UT WOS:000227731000051
PM 15749821
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kabedi, NN
   Kayembe, DL
   Mwanza, JC
AF Kabedi, Nelly N.
   Kayembe, David L.
   Mwanza, Jean-Claude
TI Vision-Related Quality of Life, Anxiety and Depression in Congolese
   Patients with Polypoidal Choroidal Vasculopathy
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Quality of life; Anxiety; Depression;
   Congolese
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; AGE; MULTICENTER; OUTCOMES;
   ILLNESS; BURDEN; IMPACT; ACUITY; AMD
AB Objective To assess the impact of polypoidal choroidal vasculopathy (PCV) on quality of life (QoL) and mental health in a cohort of Congolese patients. Methods Fifteen PCV patients and 26 age-matched controls completed the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) and the Hospital Anxiety and Depression Scale (HADS) questionnaire. Outcome measures were QoL and HADS scores, frequency of anxiety and depression, correlations between best-corrected distance visual acuity (BCDVA) and QoL and HADS scores. Risk factors for anxiety and depression were also determined. Results The QoL composite score was (54.9 +/- 24.2) in patients and (94.5 +/- 4.5) in controls,p<.001. Patients scored higher on HADS-A (9.5 +/- 3.4) and HADS-D (6.7 +/- 4.7) than controls (3.0 +/- 2.7 and 1.5 +/- 2.6), allp<.001. Anxiety and depression were present in 73.3% and 46.7% of patients, respectively, versus 1% each of controls (p<.001). Every unit improvement in best eye's BCDVA increased QoL composite score by 24.3, but decreased HADS-D by 5.9. Macular lesions decreased QoL by 34.5 while increasing HADS-A and HADS-D scores by 4.2 and 4.4, respectively. A history of stroke also increased the HADS-A score by 5.9. Conclusions PCV impairs the QoL and induces both anxiety and depression in Congolese PCV patients. Screening for QoL, anxiety and depression in PCV patients at first presentation will help detect those in need of psychological support.
C1 [Kabedi, Nelly N.; Kayembe, David L.; Mwanza, Jean-Claude] Univ Kinshasa, Dept Ophthalmol, Kinshasa, DEM REP CONGO.
   [Mwanza, Jean-Claude] Univ North Carolina Chapel Hill, Sch Med, Dept Ophthalmol, Chapel Hill, NC USA.
C3 Universite de Kinshasa; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine
RP Mwanza, JC (通讯作者)，Univ North Carolina Chapel Hill, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
EM jean-claude_mwanza@med.unc.edu
RI Mwanza, Jean-Claude/L-4235-2017
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Evans J. D., 1996, STRAIGHTFORWARD STAT
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Ghoshal R, 2018, SAINS MALAYS, V47, P2447, DOI 10.17576/jsm-2018-4710-21
   Gomi F, 2019, JPN J OPHTHALMOL, V63, P437, DOI 10.1007/s10384-019-00687-2
   Guyomarch J, 2008, J FR OPHTALMOL, V31, P579, DOI 10.1016/S0181-5512(08)75458-5
   Hawkins BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P78, DOI 10.1001/archopht.123.1.78
   Inan S, 2019, SAO PAULO MED J, V137, P25, DOI 10.1590/1516-3180.2018.0195071218
   Jacob Louis, 2017, Ger Med Sci, V15, pDoc19, DOI 10.3205/000260
   Jelin E, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1203-0
   Kabedi NN, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4103871
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim Joon-Bom, 2017, Curr Ophthalmol Rep, V5, P176, DOI 10.1007/s40135-017-0137-0
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Olson D., 2019, J VITREORETIN DIS, V3, P211, DOI [10.1177/2474126419849199, DOI 10.1177/2474126419849199]
   Oluleye TS, 2013, CLIN OPHTHALMOL, V7, P1373, DOI 10.2147/OPTH.S47511
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Picoto Maria, 2015, Rev. bras.oftalmol., V74, P216, DOI 10.5935/0034-7280.20150044
   Rafsten L, 2018, J REHABIL MED, V50, P769, DOI 10.2340/16501977-2384
   Ramalho R, 2018, EOFTALMO, V4, P100
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Schippert AC, 2018, GERONTOL GERIATR MED, V4, DOI 10.1177/2333721418801601
   Siaudvytyte L, 2012, MEDICINA-LITHUANIA, V48, P109, DOI 10.3390/medicina48020015
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Tan CS, 2018, INVEST OPHTH VIS SCI, V59, P889, DOI 10.1167/iovs.17-22683
   Tarita-Nistor L, 2006, VISION RES, V46, P2487, DOI 10.1016/j.visres.2006.01.035
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597
   Zheng YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46453
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 41
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD APR 2
PY 2020
VL 35
IS 3
BP 156
EP 163
DI 10.1080/08820538.2020.1774623
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MF5IT
UT WOS:000545376500002
PM 32507004
DA 2022-11-30
ER

PT J
AU Spaide, RF
   Ooto, S
   Curcio, CA
AF Spaide, Richard F.
   Ooto, Sotaro
   Curcio, Christine A.
TI Subretinal drusenoid deposits AKA pseudodrusen
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; drusen;
   geographic atrophy; optical coherence tomography; outer retinal atrophy;
   pseudodrusen; reticular pseudodrusen; reticular drusen; reticular
   macular disease; subretinal drusenoid deposit
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; AGE-RELATED
   MACULOPATHY; MACULAR DEGENERATION FINDINGS; RETINITIS PUNCTATA
   ALBESCENS; LIPOPROTEIN-LIKE PARTICLES; MEDIATED DARK-ADAPTATION;
   RETICULAR PSEUDODRUSEN; GEOGRAPHIC-ATROPHY; FELLOW-EYES
AB A distinction between conventional drusen and pseudodrusen was first made in 1990, and more recently knowledge of pseudodrusen, more accurately called subretinal drusenoid deposits (SDDs), has expanded. Pseudodrusen have a bluish-white appearance by biomicroscopy and color fundus photography. Using optical coherence tomography, pseudodrusen were found to be accumulations of material internal to the retinal pigment epithelium that could extend internally through the ellipsoid zone. These deposits are more commonly seen in older eyes with thinner choroids. Histologic evaluation of these deposits revealed aggregations of material in the subretinal space between photoreceptors and retinal pigment epithelium. SDDs contain some proteins in common with soft drusen but differ in lipid composition. Many studies reported that SDDs are strong independent risk factors for late age-related macular degeneration. Geographic atrophy and type 3 neovascularization are particularly associated with SDD. Unlike conventional drusen, eyes with SDD show slow dark adaptation and poor contrast sensitivity. Outer retinal atrophy develops in eyes with regression of SDD, a newly recognized form of late age-related macular degeneration. Advances in imaging technology have enabled many insights into this condition, including associated photoreceptor, retinal pigment epithelium, and underlying choroidal changes. (C) 2018 Published by Elsevier Inc.
C1 [Spaide, Richard F.; Ooto, Sotaro] Manhattan Eye Ear & Throat Hosp, Vitreous Retina Macula Consultants New York, New York, NY 10021 USA.
   [Spaide, Richard F.; Ooto, Sotaro] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Ooto, Sotaro] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Kyoto, Japan.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
C3 Manhattan Eye Ear & Throat Hospital; Vitreous Retina Macula Consultants
   of New York; Manhattan Eye Ear & Throat Hospital; Kyoto University;
   University of Alabama System; University of Alabama Birmingham
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@gmail.com
RI Spaide, Richard/ABD-7368-2020
FU Topcon Medical Systems; Heidelberg Engineering, Inc.; Novartis; Alcon
   Japan; NEI [EY1R01EY027948]; Heidelberg Engineering; Hoffman La Roche;
   Research to Prevent Blindness, NY; Macula Foundation; International
   Retinal Research Foundation
FX Richard F. Spaide, MD is a consultant in Topcon Medical Systems and
   received royalties from Topcon Medical Systems and DORC. He also
   received consulting fees from Topcon Medical Systems, Heidelberg
   Engineering, Inc., and Novartis. Sotaro Ooto, MD receives grant from
   Alcon Japan. Christine A. Curcio, PhD receives grant from NEI
   (EY1R01EY027948), research funding from Heidelberg Engineering and
   Hoffman La Roche, departmental support from Research to Prevent
   Blindness, NY, grant from Macula Foundation, and grant from
   International Retinal Research Foundation.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ajmal M, 2012, MOL VIS, V18, P1558
   Albert AD, 2005, PROG LIPID RES, V44, P99, DOI 10.1016/j.plipres.2005.02.001
   Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Badal J, 2018, INT OPHTHALMOL, V38, P199, DOI 10.1007/s10792-017-0448-z
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bandyopadhyay A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010365
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   CARTERDAWSON L, 1979, INVEST OPHTH VIS SCI, V18, P437
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Chang TY, 2017, J LIPID RES, V58, P2239, DOI 10.1194/jlr.R075630
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cho HJ, 2015, AM J OPHTHALMOL, V19
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   Dessalces E, 2013, JAMA OPHTHALMOL, V131, P1314, DOI 10.1001/jamaophthalmol.2013.4476
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Elfandi S, 2016, OPHTHALMOLOGY, V123, P2205, DOI 10.1016/j.ophtha.2016.06.052
   Elison JR, 2004, DOC OPHTHALMOL, V109, P279, DOI 10.1007/s10633-004-4119-9
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Farjo KM, 2009, INVEST OPHTH VIS SCI, V50, P5089, DOI 10.1167/iovs.09-3797
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fishman GA, 2004, ARCH OPHTHALMOL-CHIC, V122, P70, DOI 10.1001/archopht.122.1.70
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Gifford S R, 1939, Trans Am Ophthalmol Soc, V37, P195
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Heiferman MJ, 2015, RETINA-J RET VIT DIS, V35, P2593, DOI 10.1097/IAE.0000000000000666
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hu ZH, 2017, NEUROPHOTONICS, V4, DOI 10.1117/1.NPh.4.1.011012
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Hulke JW, 1859, OPHTHAL HOSP REP J R, V1, P180
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132013
   Kamami-Levy C, 2014, J FR OPHTALMOL, V37, P780, DOI 10.1016/j.jfo.2014.06.003
   KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Kovach JL, 2016, OPHTHALMOLOGY, V123, P921, DOI 10.1016/j.ophtha.2015.10.036
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Loeffler KU, 1998, BRIT J OPHTHALMOL, V82, P1104, DOI 10.1136/bjo.82.10.1104
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Muller H., 1856, ARCH OPHTHALMOL-CHIC, V2, P1
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Olsen TW, 2015, T AM OPHTHAL SOC, V113, P1
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pichi F, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/634351
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pilgrim M, 2017, INVEST OPHTH VIS SCI, V58
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Pras E, 2012, MOL VIS, V18, P1712
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Ravera V, 2016, RETINA-J RET VIT DIS, V36, P2274, DOI 10.1097/IAE.0000000000001152
   Roberts PK, 2017, BRIT J OPHTHALMOL, V101, P1361, DOI 10.1136/bjophthalmol-2016-310004
   ROBISON WG, 1980, INVEST OPHTH VIS SCI, V19, P1030
   Rones B, 1937, ARCH OPHTHALMOL-CHIC, V18, P388
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudnew A, 1871, BOSTON MED SURG J, V9, P106
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schaal KB, 2017, OPHTHALMOLOGY, V124, P205, DOI 10.1016/j.ophtha.2016.10.009
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schatz P, 2011, OPHTHALMOLOGY, V118, P888, DOI 10.1016/j.ophtha.2010.09.005
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   SEBAG M, 1991, ACTA OPHTHALMOL, V69, P603
   Sergouniotis PI, 2011, OPHTHALMOLOGY, V118, P1661, DOI 10.1016/j.ophtha.2010.12.031
   Shijo T, 2017, GRAEF ARCH CLIN EXP, V255, P1125, DOI 10.1007/s00417-017-3622-0
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   SORSBY A, 1966, NATURE, V210, P1011, DOI 10.1038/2101011a0
   Spaide RF, 2004, RETINA-J RET VIT DIS, V24, P301, DOI 10.1097/00006982-200404000-00019
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2017, RETINA, V38, P891
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2006, OPHTHALMOLOGY, V113, P1392, DOI 10.1016/j.ophtha.2006.03.023
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Switzer DW, 2011, EYE, V25, P1379, DOI 10.1038/eye.2011.162
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Vachali PP, 2013, ARCH BIOCHEM BIOPHYS, V539, P181, DOI 10.1016/j.abb.2013.07.008
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VINE AK, 1980, AM J OPHTHALMOL, V89, P680, DOI 10.1016/0002-9394(80)90288-3
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vongkulsiri S, 2014, AM J OPHTHALMOL, V158, P710, DOI 10.1016/j.ajo.2014.07.009
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang NK, 2012, DOC OPHTHALMOL, V125, P51, DOI 10.1007/s10633-012-9336-z
   Wedl C, 1854, GRUNDZUGE PATHOLOGIS
   Wilde C, 2016, EUR J OPHTHALMOL, V26, P128, DOI 10.5301/ejo.5000661
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Ying GS, 2016, PLOS ONE, V11, P229
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zhou Q, 2017, ACTA OPHTHALMOL, V95, pE518, DOI 10.1111/aos.13398
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 243
TC 116
Z9 117
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD NOV-DEC
PY 2018
VL 63
IS 6
BP 782
EP 815
DI 10.1016/j.survophthal.2018.05.005
PG 34
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GY5PU
UT WOS:000448633800004
PM 29859199
DA 2022-11-30
ER

PT J
AU Vinores, SA
AF Vinores, SA
TI Technology evaluation: Pegaptanib, Eyetech/Pfizer
SO CURRENT OPINION IN MOLECULAR THERAPEUTICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; BLOOD-RETINAL BARRIER; MACULAR DEGENERATION;
   CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; APTAMER NX1838;
   EXPRESSION; VERTEPORFIN; CELLS; PHARMACOKINETICS
AB Eyetech Pharmaceuticals and Pfizer are co-developing the anti-vascular endothelial growth factor aptamer, pegaptanib, as an angiogenesis inhibitor for the potential treatment of age-related macular degeneration and diabetic macular edema, in addition to other ocular diseases. Gilead was previously investigating the aptamer for the potential treatment of cancer, however, no data have been published for this indication since 1999.
C1 Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Vinores, SA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, 825 Maumenee,600 N Wolfe St, Baltimore, MD 21287 USA.
EM svinores@jhmi.edu
OI Lima, Emilly/0000-0001-5297-7364
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   AMIN RH, 1977, INVEST OPHTH VIS SCI, V38, P36
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P271
   ARCHER DB, 1983, INT OPHTHALMOL, V6, P171, DOI 10.1007/BF00127646
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bell C, 1999, FASEB J, V13, pA35
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   DELAEY JJ, 1983, DOC OPHTHALMOL, V55, P91, DOI 10.1007/BF00140466
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   *EYET PHARM INC, 2002, HAMBR QUIST S   0107, P41
   *EYET PHARM INC, 2002, PRESS RELEASE   0807
   Famulok M, 1998, CURR OPIN CHEM BIOL, V2, P320, DOI 10.1016/S1367-5931(98)80004-5
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   *GIL SCI INC, 2002, CO WORLD WID WE 0123
   *GIL SCI INC, 2000, GIL SCI INC PRE 0405
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   *INH THER SYST INC, 2002, PRESS RELEASE   0226
   *IOMED INC, 2001, IOMED INC PRESS 0208
   *IOMED INC, 2000, IOMED INC PRESS 1109
   *IS PHARM INC, 1998, IS PHARM INC PR 1221
   *IS PHARM INC, 2002, IS PHARM INC PR 0107
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   JACKSONMATTHEWS.D, 2002, IDDB M REPORT   0506
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mathews MK, 1997, INVEST OPHTH VIS SCI, V38, P2729
   MOUSA SA, 1999, IDDB M REPORT   1101
   Murata T, 1996, LAB INVEST, V74, P819
   *NEXST PHARM INC, 1998, NEXST PHARM INC 0722
   *NEXST PHARM INC, 1998, NEXST PHARM INC 0827
   Nishiwaki H, 2002, PHOTOCHEM PHOTOBIOL, V75, P149, DOI 10.1562/0031-8655(2002)075<0149:LTPOOR>2.0.CO;2
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   PATZ A, 1977, T AM ACAD OPHTHALMOL, V83, P468
   Patz A, 1973, T AM ACAD OPHTHALMOL, V77, P34
   PEER J, 1995, LAB INVEST, V72, P638
   *PFIZ INC, 2003, CO PRES         0617
   *PFIZ INC, 2003, PRESS REL       0617
   *PFIZ INC, 2002, PRESS REL       1218
   *PFIZ INC, 2003, PRESS REL       1022
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   SAGATIES MJ, 1987, INVEST OPHTH VIS SCI, V28, P2000
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   STEWART PA, 1994, J COMP NEUROL, V340, P566, DOI 10.1002/cne.903400409
   Sun SG, 2000, CURR OPIN MOL THER, V2, P100
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   TOMKINSON B, 1999, P ANN M AM ASS CANC, V40, P4097
   TOUT S, 1993, NEUROSCIENCE, V55, P291, DOI 10.1016/0306-4522(93)90473-S
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   Vinores SA, 1997, HISTOL HISTOPATHOL, V12, P99
   VINORES SA, 1995, HISTOL HISTOPATHOL, V10, P141
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
NR 66
TC 37
Z9 41
U1 0
U2 9
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1464-8431
EI 2040-3445
J9 CURR OPIN MOL THER
JI Curr. Opin. Mol. Ther.
PD DEC
PY 2003
VL 5
IS 6
BP 673
EP 679
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 763MP
UT WOS:000188090000014
PM 14755895
DA 2022-11-30
ER

PT J
AU Wen, XF
   Hu, X
   Miao, L
   Ge, XF
   Deng, YH
   Bible, PW
   Wei, L
AF Wen, Xiaofeng
   Hu, Xiao
   Miao, Li
   Ge, Xiaofei
   Deng, Yuhua
   Bible, Paul W.
   Wei, Lai
TI Epigenetics, microbiota, and intraocular inflammation: New paradigms of
   immune regulation in the eye
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Epigenetics; Uveitis; Age-related macular degeneration; Intraocular
   microbiota; Gut microbiota; Epigenetic therapy
ID MACULAR DEGENERATION; DNA METHYLATION; RECEPTOR POLYMORPHISMS; NLRP3
   INFLAMMASOME; GENE-EXPRESSION; IL17RC PROMOTER; HERITABILITY;
   ACTIVATION; MECHANISMS; DISEASE
AB Sight threatening immune responses that damage the eye characterize intraocular inflammatory diseases. These diseases including uveitis and age-related macular degeneration are worryingly common and quality of life shattering. Genetic studies in past decades significantly advanced our understanding of the etiology of these devastating diseases. Unfortunately, patient genetics alone failed to adequately explain disease origin, susceptibility, and progression. Non-genetic factors such as the epigenetic regulation of ocular diseases and the environmental factors triggering intraocular inflammation offer new insight into intraocular inflammatory disorders. Importantly, mounting evidence is signaling that dysbiosis of human microbiota leads to rapid epigenomic reprograming of host cells and results in the onset of many diseases. In this review, we discuss how epigenetic mechanisms and microbiota may cooperate to initiate and perpetuate ocular inflammation. Lastly, we propose that the discovery of intraocular microbiota presents a significant shift in thought affecting current approaches to the diagnosis, treatment, and prevention of intraocular inflammatory diseases such as uveitis and age-related macular degeneration. The geographical and genetic background difference in both disease presentation and genetic association of intraocular inflammatory diseases may be due to the variation of intraocular microbiota.
C1 [Wen, Xiaofeng; Hu, Xiao; Miao, Li; Ge, Xiaofei; Deng, Yuhua; Bible, Paul W.; Wei, Lai] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wei, L (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM weil9@mail.sysu.edu.cn
OI Hu, Xiao/0000-0001-7589-2769
FU National Natural Science Foundation of China [81570828]; National Basic
   Research Program of China [2015CB964601]
FX This work was supported by the National Natural Science Foundation of
   China 81570828 and the National Basic Research Program of China
   2015CB964601 to LW.
CR Abd A.J., 2017, DRUG DISCOV TODAY, V3, P30375
   Ahmadi M, 2017, BIOMED PHARMACOTHER, V87, P596, DOI 10.1016/j.biopha.2016.12.072
   Allis CD, 2006, EPIGENETICS, P23
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Ashford NA, 2015, SCIENCE, V347, P727, DOI 10.1126/science.aaa6246
   Avichezer D, 2003, J AUTOIMMUN, V21, P185, DOI 10.1016/j.jaut.2003.08.004
   Bae Jae-Bum, 2013, Genomics & Informatics, V11, P7, DOI 10.5808/GI.2013.11.1.7
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Baslan T, 2014, CURR OPIN GENET DEV, V26, P59, DOI 10.1016/j.gde.2014.06.004
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Bordenstein SR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002226
   Bradbury J, 2003, PLOS BIOL, V1, P316, DOI 10.1371/journal.pbio.0000082
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]
   Capuano F, 2014, ANAL CHEM, V86, P3697, DOI 10.1021/ac500447w
   Caspi RR, 2008, OPHTHAL RES, V40, P169, DOI 10.1159/000119871
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Cheung KC, 2017, SCAND ACTUAR J, P1, DOI 10.1080/03461238.2015.1054303
   Cho H, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0515-z
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/nmeth.4396, 10.1038/NMETH.4396]
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dai LZ, 2014, NAT CHEM BIOL, V10, P365, DOI [10.1038/NCHEMBIO.1497, 10.1038/nchembio.1497]
   Davatchi F, 2017, EXPERT REV CLIN IMMU, V13, P57, DOI 10.1080/1744666X.2016.1205486
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dupont C, 2009, SEMIN REPROD MED, V27, P351, DOI 10.1055/s-0029-1237423
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Elkon R, 2017, NAT BIOTECHNOL, V35, P732, DOI 10.1038/nbt.3863
   Eskandarpour M, 2017, J IMMUNOL, V198, P1093, DOI 10.4049/jimmunol.1600735
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fazila Asmar A. S., 2015, EPIGENETIC CANC THER
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Forrester JV, 2013, INT REV IMMUNOL, V32, P76, DOI 10.3109/08830185.2012.747524
   FORRESTER JV, 1989, BRIT J OPHTHALMOL, V73, P155, DOI 10.1136/bjo.73.2.155
   Foster KR, 2017, NATURE, V548, P43, DOI 10.1038/nature23292
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Galeone Massimiliano, 2012, Patholog Res Int, V2012, P595380, DOI 10.1155/2012/595380
   Gauthier AC, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5712341
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Gilbert JA, 2016, NATURE, V535, P94, DOI 10.1038/nature18850
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Goldstein I., 2017, WILEY INTERDISCIP RE, V22
   Guo F, 2017, CELL RES, V27, P967, DOI 10.1038/cr.2017.82
   Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112
   Hammond C. J., 2001, INVEST OPHTH VIS SCI, V42, P1212
   Hammond CJ, 2000, NEW ENGL J MED, V342, P1786, DOI 10.1056/NEJM200006153422404
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hammond CJ, 2001, INVEST OPHTH VIS SCI, V42, P601
   He SK, 2013, MOL VIS, V19, P665
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   HOLLIDAY R, 1990, PHILOS T ROY SOC B, V326, P329, DOI 10.1098/rstb.1990.0015
   Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Hughes T, 2014, ARTHRITIS RHEUMATOL, V66, P1648, DOI 10.1002/art.38409
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Hyun K, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.11
   Ichiyama K, 2015, IMMUNITY, V42, P613, DOI 10.1016/j.immuni.2015.03.005
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jabs D. A., 2017, OPHTHALMOLOGY, V20, P31557
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kattan OM, 2008, J IMMUNOL, V181, P1399, DOI 10.4049/jimmunol.181.2.1399
   Kersten E., 2017, SURV OPHTHALMOL, V6257, P30262
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kowarsky M, 2017, P NATL ACAD SCI USA, V114, P9623, DOI 10.1073/pnas.1707009114
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Kumar DKV, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1059
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Li Wendy, 2016, Yale Journal of Biology and Medicine, V89, P597
   Lim DH, 2015, INVEST OPHTH VIS SCI, V56, P3919, DOI 10.1167/iovs.14-15763
   Liu MM, 2013, CURR GENOMICS, V14, P166, DOI 10.2174/1389202911314030002
   Markowiak P, 2017, NUTRIENTS, V9, DOI 10.3390/nu9091021
   Marmorstein R, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018762
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Morton LT, 2016, CURR OPIN RHEUMATOL, V28, P39, DOI 10.1097/BOR.0000000000000234
   Nabel CS, 2011, SCIENCE, V333, P1229, DOI 10.1126/science.1211917
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Pennington KL, 2015, J EXP NEUROSCI, V9, P51, DOI 10.4137/JEN.S25513
   Qureshi IA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0506
   Rama-doss M., 2017, DRUG DISCOV TODAY, V22, P30464
   Rhee HS, 2011, CELL, V147, P1408, DOI 10.1016/j.cell.2011.11.013
   Rhein M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00182
   Riggs, 1996, EPIGENETIC MECH GENE
   Rosenbaum JT, 2016, JPN J OPHTHALMOL, V60, P1, DOI 10.1007/s10384-015-0416-y
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Sakabe K, 2010, P NATL ACAD SCI USA, V107, P19915, DOI 10.1073/pnas.1009023107
   Sanfilippo PG, 2010, SURV OPHTHALMOL, V55, P561, DOI 10.1016/j.survophthal.2010.07.003
   Schep AN, 2017, NAT METHODS, V14, P975, DOI [10.1038/NMETH.4401, 10.1038/nmeth.4401]
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shapiro E, 2013, NAT REV GENET, V14, P618, DOI 10.1038/nrg3542
   Sharma A., 2017, CLIN GENET, V13, P13136
   Shechter R, 2013, NAT REV IMMUNOL, V13, P206, DOI 10.1038/nri3391
   Singh B, 2010, MOL MICROBIOL, V78, P545, DOI 10.1111/j.1365-2958.2010.07373.x
   Singh U, 2016, TUMOR BIOL, V37, P14427, DOI 10.1007/s13277-016-5308-3
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Soon WW, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.61
   St Leger AJ, 2017, IMMUNITY, V47, P148, DOI 10.1016/j.immuni.2017.06.014
   Stelzer Y, 2015, CELL, V163, P218, DOI 10.1016/j.cell.2015.08.046
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   SZANTO E, 1991, CLIN RHEUMATOL, V10, P395, DOI 10.1007/BF02206659
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tan MJ, 2011, CELL, V146, P1015, DOI 10.1016/j.cell.2011.08.008
   Tan QH, 2015, J EXP BIOL, V218, P134, DOI 10.1242/jeb.107151
   TEIKARI JM, 1991, HUM HERED, V41, P151, DOI 10.1159/000153994
   TEIKARI JM, 1987, ACTA OPHTHALMOL, V65, P715
   TEIKARI JM, 1992, SCAND J SOC MED, V20, P73
   Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847
   Thion M. S., 2017, CELL, V21, P31432
   Tomasetti C, 2017, SCIENCE, V355, P1330, DOI 10.1126/science.aaf9011
   Tropini C, 2017, CELL HOST MICROBE, V21, P433, DOI 10.1016/j.chom.2017.03.010
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vatanen T, 2016, CELL, V165, P842, DOI 10.1016/j.cell.2016.04.007
   Vehof J, 2014, INVEST OPHTH VIS SCI, V55, P7278, DOI 10.1167/iovs.14-15200
   VESTAL KP, 1990, OPHTHALMIC PLAST REC, V6, P265, DOI 10.1097/00002341-199012000-00007
   Waddington C.H, 1968, BASIC IDEAS BIOL, P1
   Wang JY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101601
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wen L., 2017, MOL ASPECT MED, V21, P30062
   Wolf T, 2018, CURR OPIN MICROBIOL, V42, P7, DOI 10.1016/j.mib.2017.09.001
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Woo V, 2017, CURR OPIN IMMUNOL, V44, P52, DOI 10.1016/j.coi.2016.12.001
   Wu CT, 2001, SCIENCE, V293, P1103, DOI 10.1126/science.293.5532.1103
   Wu XJ, 2017, NAT REV GENET, V18, P517, DOI 10.1038/nrg.2017.33
   Xiao L, 2015, NAT BIOTECHNOL, V33, P1103, DOI 10.1038/nbt.3353
   Xie X, 2017, CURR OPIN GENET DEV, V46, P104, DOI 10.1016/j.gde.2017.07.003
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yonova-Doing E, 2016, OPHTHALMOLOGY, V123, P1237, DOI 10.1016/j.ophtha.2016.01.036
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang Q, 2015, NATURE, V525, P389, DOI 10.1038/nature15252
   Zhang XY, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0167-1
   Zhou F, 2016, NATURE, V533, P487, DOI 10.1038/nature17997
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zuo T, 2009, EPIGENOMICS-UK, V1, P331, DOI 10.2217/epi.09.31
NR 158
TC 37
Z9 40
U1 1
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2018
VL 64
BP 84
EP 95
DI 10.1016/j.preteyeres.2018.01.001
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GK9AV
UT WOS:000436529700005
PM 29357307
OA hybrid
DA 2022-11-30
ER

PT J
AU Azuma, K
   Okubo, A
   Nomura, Y
   Zhou, HP
   Terao, R
   Hashimoto, Y
   Asano, KS
   Azuma, K
   Inoue, T
   Obata, R
AF Azuma, Keiko
   Okubo, Atsushi
   Nomura, Yoko
   Zhou, Hanpeng
   Terao, Ryo
   Hashimoto, Yohei
   Asano, Kimiko Shimizu
   Azuma, Kunihiro
   Inoue, Tatsuya
   Obata, Ryo
TI Association between pachychoroid and long-term treatment outcomes of
   photodynamic therapy with intravitreal ranibizumab for polypoidal
   choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; CLINICAL CHARACTERISTICS; CLASSIFICATION;
   VERTEPORFIN; AFLIBERCEPT
AB We investigated long-term treatment responses in patients with treatment-naive polypoidal choroidal vasculopathy (PCV) undergoing photodynamic therapy (PDT) with intravitreal ranibizumab (IVR). The medical charts of 14 patients with treatment-naive PCV who underwent PDT with IVR were retrospectively reviewed. Patients were followed up and treated with additional IVR for >= 3 years. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), greatest linear dimension (GLD) on angiography, polyp regression and central choroidal thickness (CCT) were assessed. Associations between these functional or anatomic outcomes with age, baseline CCT, baseline GLD or choroidal vascular hyperpermeability (CVH) were investigated using univariate and multivariate analysis. Mean logMAR BCVA improved significantly at 3 years (0.34 +/- 0.24 to 0.12 +/- 0.29, p=0.003). Greater BCVA improvement and longer time to first recurrence was significantly associated with CVH. Fewer number of IVR retreatment within 3 years was associated with thicker baseline CCT. Mean CCT significantly decreased at 3 years (217 +/- 33 mu m to 197 +/- 48 mu m, p=0.003). Greater decrease of CCT was significantly associated both with greater number of IVR retreatment within 3 years and absence of CVH. These results showed that pachychoroid characteristics at baseline was associated long-term functional and anatomic outcomes in patients with treatment-naive PCV who had undergone combination PDT and IVR.
C1 [Azuma, Keiko; Okubo, Atsushi; Nomura, Yoko; Zhou, Hanpeng; Terao, Ryo; Hashimoto, Yohei; Asano, Kimiko Shimizu; Azuma, Kunihiro; Inoue, Tatsuya; Obata, Ryo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan.
   [Azuma, Keiko; Okubo, Atsushi; Nomura, Yoko; Zhou, Hanpeng; Terao, Ryo; Hashimoto, Yohei; Asano, Kimiko Shimizu; Azuma, Kunihiro; Inoue, Tatsuya; Obata, Ryo] Univ Tokyo, Fac Med, Tokyo 1138655, Japan.
C3 University of Tokyo; University of Tokyo
RP Obata, R (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan.
EM robata-tky@umin.ac.jp
RI Terao, Ryo/AAV-3334-2020
OI Terao, Ryo/0000-0001-6182-4343
FU JSPS KAKENHI [JP16K11260]
FX This study was done under JSPS KAKENHI grant no. JP16K11260. The
   sponsoring organisation had no role in study design; in the collection,
   analysis, and interpretation of the data; in the writing of the report;
   or in the decision to submit the article for publication.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Burnham KP, 2014, ECOLOGY, V95, P627, DOI 10.1890/13-1066.1
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hiroe T, 2018, OPHTHALMOL RETINA, V2, P152, DOI 10.1016/j.oret.2017.05.013
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kishi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206646
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Liu L, 2018, PHOTODIAGN PHOTODYN, V24, P372, DOI 10.1016/j.pdpdt.2018.10.019
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Tibshirani RJ, 2012, ANN STAT, V40, P1198, DOI 10.1214/12-AOS1003
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Tsujikawa A, 2018, JPN J OPHTHALMOL, V62, P127, DOI 10.1007/s10384-017-0556-3
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 41
TC 7
Z9 7
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 20
PY 2020
VL 10
IS 1
AR 8337
DI 10.1038/s41598-020-65346-w
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LY3XN
UT WOS:000540462600029
PM 32433551
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Newport, A
   Lockwood, B
AF Newport, Amy
   Lockwood, Brian
TI Non-carotenoid nutraceuticals for treatment of eye diseases
SO AGRO FOOD INDUSTRY HI-TECH
LA English
DT Article
ID MACULAR DEGENERATION; FATTY-ACIDS; TRIAL; N-3
AB There is increasing prevalence of eye disorders, particularly in the elderly Many of these are caused by oxidative stress. Four non-carotenoid nutraceuticals, pycnogenol, docosahexaenoic acid, alpha lipoic acid and bilberry, have been evaluated for possible benefits in diseases such as age related macular degeneration (AMD), diabetic retinopathy, dry eye syndrome and retinitis pigmentosa, and for improvement of night vision.
C1 [Newport, Amy; Lockwood, Brian] Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England.
C3 University of Manchester
RP Lockwood, B (通讯作者)，Sch Pharm & Pharmaceut Sci, Stopford Bldg,Room 2-27,Oxford Rd, Manchester M13 9PT, Lancs, England.
CR Arora S, 2004, EYE, V18, P470, DOI 10.1038/sj.eye.6700700
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bryhn M, 2007, AGRO FOOD IND HI TEC, V18, P6
   Canter PH, 2004, SURV OPHTHALMOL, V49, P38, DOI 10.1016/j.survophthal.2003.10.006
   CHALLEN JJ, 2002, J ORTHOMOL MED, V17, P209
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   Hoffman D. R., 2000, Fatty acids in foods and their health implications., P817
   Miljanovic B, 2005, AM J CLIN NUTR, V82, P887, DOI 10.1093/ajcn/82.4.887
   Nakaishi H, 2000, Altern Med Rev, V5, P553
   Packer L., 1999, ENV NUTR INTERACT, V3, P47
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SCHONLAU F, 2002, INT OPHTHALMOL, V24, P161
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spadea L, 2001, PHYTOTHER RES, V15, P219, DOI 10.1002/ptr.853
   Trevithick JR, 2000, INT OPHTHALMOL CLIN, V40, P59, DOI 10.1097/00004397-200010000-00005
NR 18
TC 0
Z9 0
U1 1
U2 6
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1722-6996
EI 2035-4606
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi-Tech
PD MAR-APR
PY 2008
VL 19
IS 2
BP 47
EP 49
PG 3
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 309DD
UT WOS:000256440000010
DA 2022-11-30
ER

PT J
AU Chen, XJ
   Niemeijer, M
   Zhang, L
   Lee, K
   Abramoff, MD
   Sonka, M
AF Chen, Xinjian
   Niemeijer, Meindert
   Zhang, Li
   Lee, Kyungmoo
   Abramoff, Michael D.
   Sonka, Milan
TI Three-Dimensional Segmentation of Fluid-Associated Abnormalities in
   Retinal OCT: Probability Constrained Graph-Search-Graph-Cut
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Age-related macular degeneration; graph cut; graph search; retinal layer
   segmentation; symptomatic exudate-associated derangement (SEAD)
ID OPTICAL COHERENCE TOMOGRAPHY; IMAGE SEGMENTATION; RANIBIZUMAB;
   BEVACIZUMAB; SURFACES
AB An automated method is reported for segmenting 3-D fluid-associated abnormalities in the retina, so-called symptomatic exudate-associated derangements (SEAD), from 3-D OCT retinal images of subjects suffering from exudative age-related macular degeneration. In the first stage of a two-stage approach, retinal layers are segmented, candidate SEAD regions identified, and the retinal OCT image is flattened using a candidate-SEAD aware approach. In the second stage, a probability constrained combined graph search-graph cut method refines the candidate SEADs by integrating the candidate volumes into the graph cut cost function as probability constraints. The proposed method was evaluated on 15 spectral domain OCT images from 15 subjects undergoing intravitreal anti-VEGF injection treatment. Leave-one-out evaluation resulted in a true positive volume fraction (TPVF), false positive volume fraction (FPVF) and relative volume difference ratio (RVDR) of 86.5%, 1.7%, and 12.8%, respectively. The new graph cut-graph search method significantly outperformed both the traditional graph cut and traditional graph search approaches (p < 0.01, p < 0.04) and has the potential to improve clinical management of patients with choroidal neovascularization due to exudative age-related macular degeneration.
C1 [Chen, Xinjian; Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Dept Biomed Engn, Iowa City, IA 52242 USA.
   [Niemeijer, Meindert; Abramoff, Michael D.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] VA Med Ctr, Iowa City, IA 52246 USA.
   [Sonka, Milan] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care
   System; University of Iowa
RP Chen, XJ (通讯作者)，Univ Iowa, Dept Elect & Comp Engn, Dept Biomed Engn, Iowa City, IA 52242 USA.
EM xinjian-chen@uiowa.edu; mniemeij@healthcare.uiowa.edu;
   li-zhang-1@uiowa.edu; kyungmle@engineering.uiowa.edu;
   michael-abramoff@uiowa.edu; milan-sonka@uiowa.edu
RI Abramoff, Michael D/A-5836-2009; Chen, Xinjian/E-8592-2016
OI Abramoff, Michael D/0000-0002-3490-0037; Chen,
   Xinjian/0000-0002-0871-293X
FU National Institutes of Health [EY017066, EB004640]; Research to Prevent
   Blindness; Veterans Administration Center of Excellence for Prevention
   and Treatment of Visual Loss; NATIONAL EYE INSTITUTE [R01EY017066,
   R01EY018853, R01EY019112] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB004640] Funding
   Source: NIH RePORTER
FX This work was supported in part by the National Institutes of Health
   under Grant EY017066, Grant EB004640, by Research to Prevent Blindness
   and the Veterans Administration Center of Excellence for Prevention and
   Treatment of Visual Loss. Asterisk indicates corresponding author.
CR Abramoff MD, 2007, INVEST OPHTH VIS SCI, V48, P1665, DOI 10.1167/iovs.06-1081
   Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Appleton B, 2006, IEEE T PATTERN ANAL, V28, P106, DOI 10.1109/TPAMI.2006.12
   Arya S, 1998, J ACM, V45, P891, DOI 10.1145/293347.293348
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Boykov Y, 2004, IEEE T PATTERN ANAL, V26, P1124, DOI 10.1109/TPAMI.2004.60
   Boykov Y, 2006, INT J COMPUT VISION, V70, P109, DOI 10.1007/s11263-006-7934-5
   Boykov YY, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL I, PROCEEDINGS, P105, DOI 10.1109/ICCV.2001.937505
   Chen XJ, 2011, MED PHYS, V38, P4610, DOI 10.1118/1.3602070
   Chen XJ, 2010, MED PHYS, V37, P6390, DOI 10.1118/1.3515751
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Christopher M., 2012, RETINA
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cox DR., 1974, THEORETICAL STAT
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Delong A., 2009, P IEEE INT C COMP VI
   Dolejsi M, 2010, BIOSIG BRNO, P27
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Freedman D, 2005, PROC CVPR IEEE, P755
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Kolmogorov V, 2004, IEEE T PATTERN ANAL, V26, P147, DOI 10.1109/TPAMI.2004.1262177
   Krzanowski W.J., 1988, PRINCIPLES MULTIVARI
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Li K, 2004, PROC SPIE, V5370, P620, DOI 10.1117/12.537048
   Malcolm J, 2007, IEEE IMAGE PROC, P2061
   Markus M., 2010, OPT EXP, V1, P1358
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M., ARVO 2012 UNPUB
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Snyman J., 2005, PRACTICAL MATH OPTIM
   Song Q., 2011, P 22 BIENN INT C INF
   Udupa JK, 2006, COMPUT MED IMAG GRAP, V30, P75, DOI 10.1016/j.compmedimag.2005.12.001
   Veksler O, 2008, LECT NOTES COMPUT SC, V5304, P454, DOI 10.1007/978-3-540-88690-7_34
   Vu N., 2008, P IEEE COMP SOC C CO, P1
   Wu XD, 2002, LECT NOTES COMPUT SC, V2380, P1029
   Yin Y, 2010, IEEE T MED IMAGING, V29, P2023, DOI 10.1109/TMI.2010.2058861
NR 46
TC 143
Z9 150
U1 1
U2 20
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD AUG
PY 2012
VL 31
IS 8
BP 1521
EP 1531
DI 10.1109/TMI.2012.2191302
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 983LK
UT WOS:000307120600002
PM 22453610
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bottoni, F
   Romano, M
   Massacesi, A
   Bergamini, F
AF Bottoni, Ferdinando
   Romano, Mary
   Massacesi, Amedeo
   Bergamini, Fulvio
TI Remodeling of the vascular channels in retinal angiomatous
   proliferations treated with intravitreal triamcinolone acetonide and
   photodynamic therapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; retinal angiomatous proliferation;
   triamcinolone acetonide; photodynamic therapy
ID MACULAR DEGENERATION; EXPRESSION; CELLS
AB The objective was to describe the remodeling of the vascular channels in stage II retinal angiomatous proliferation (RAP) treated by intravitreal injections of triamcinolone acetonide (TA) and subsequent photodynamic therapy (PDT).
   Stage II RAP secondary to age-related macular degeneration was documented by dynamic digital fluorescein and indocyanine green angiography in 3 consecutive patients (3 eyes). All eyes were treated with intravitreal injection of TA (4 mg, 0.1 ml) followed by PDT 5-10 days later.
   Indocyanine green angiography (ICGA) revealed a complete remodeling of the vascular structure of the three RAPs after treatment. The feeding retinal artery, which shunted a major part of the blood flow from the original arteriole toward the intraretinal neovascular complex before treatment, regained a normal appearance after treatment. With RAP closure, the blood flow was again directed through the original retinal arteriole, and the connection to the RAP was no longer visible.
   Stage II RAPs are difficult lesions to treat. A real remodeling of the vascular lesion is achieved with the combined use of intravitreal TA and PDT. This finding corroborates the need for randomized clinical trials currently under way to evaluate this combination treatment in wet, age-related macular degeneration.
C1 San Giuseppe Hosp, Dept Ophthalmol, Milan, Italy.
   Univ Naples 2, Inst Ophthalmol, Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Bottoni, F (通讯作者)，Via Andrea Verga 8, I-20144 Milan, Italy.
EM ferdinando.bottoni@fastwebnet.it
OI ROMANO, Mary/0000-0002-1344-8467
CR Bandi N, 2001, EUR J PHARMACOL, V425, P109, DOI 10.1016/S0014-2999(01)01192-X
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   GRISANTI S, 2004, CLUB JUL GON 24 M AT
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
NR 12
TC 12
Z9 17
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2006
VL 244
IS 11
BP 1528
EP 1533
DI 10.1007/s00417-006-0311-9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 103PL
UT WOS:000241899100021
PM 16609904
DA 2022-11-30
ER

PT J
AU Du, XL
   Li, WB
   Hu, BJ
AF Du, Xue-Li
   Li, Wen-Bo
   Hu, Bo-Jie
TI Application of artificial intelligence in ophthalmology
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE artificial intelligence; deep learning; machine learning; images
   processing; ophthalmology
ID RETINAL VEIN OCCLUSION; DIABETIC-RETINOPATHY; RISK-FACTORS; MACULAR
   DEGENERATION; AUTOMATED DETECTION; VISUAL IMPAIRMENT; EYE DISEASES; PLUS
   DISEASE; PREMATURITY; GLAUCOMA
AB Artificial intelligence is a general term that means to accomplish a task mainly by a computer, with the least human beings participation, and it is widely accepted as the invention of robots. With the development of this new technology, artificial intelligence has been one of the most influential information technology revolutions. We searched these English-language studies relative to ophthalmology published on PubMed and Springer databases. The application of artificial intelligence in ophthalmology mainly concentrates on the diseases with a high incidence, such as diabetic retinopathy, age-related macular degeneration, glaucoma, retinopathy of prematurity, age-related or congenital cataract and few with retinal vein occlusion. According to the above studies, we conclude that the sensitivity of detection and accuracy for proliferative diabetic retinopathy ranged from 75% to 91.7%, for non-proliferative diabetic retinopathy ranged from 75% to 94.7%, for age-related macular degeneration it ranged from 75% to 100%, for retinopathy of prematurity ranged over 95%, for retinal vein occlusion just one study reported ranged over 97%, for glaucoma ranged 63.7% to 93.1%, and for cataract it achieved a more than 70% similarity against clinical grading.
C1 [Du, Xue-Li; Li, Wen-Bo; Hu, Bo-Jie] Tianjin Med Univ, Eye Hosp, 251 Fukang Rd, Tianjin 300384, Peoples R China.
C3 Tianjin Medical University
RP Hu, BJ (通讯作者)，Tianjin Med Univ, Eye Hosp, 251 Fukang Rd, Tianjin 300384, Peoples R China.
EM bhu07@tmu.edu.cn
RI li, wenbo/GZM-8930-2022
CR Akyol K, 2016, COMPUT MATH METHOD M, V2016, DOI 10.1155/2016/6814791
   Nguyen A, 2015, PROC CVPR IEEE, P427, DOI 10.1109/CVPR.2015.7298640
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Ataer-Cansizoglu E, 2015, METHOD INFORM MED, V54, P93, DOI 10.3414/ME13-01-0081
   Ataer-Cansizoglu E, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.6.5
   Ataer-Cansizoglu E, 2014, PATTERN RECOGN LETT, V38, P120, DOI 10.1016/j.patrec.2013.11.022
   Bek T, 2006, ACTA OPHTHALMOL SCAN, V84, P16, DOI 10.1111/j.1600-0420.2005.00574.x
   Bengio Y, 2013, IEEE T PATTERN ANAL, V35, P1798, DOI 10.1109/TPAMI.2013.50
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Bolon-Canedo V, 2015, COMPUT METH PROG BIO, V122, P1, DOI 10.1016/j.cmpb.2015.06.004
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Campbell JP, 2016, JAMA OPHTHALMOL, V134, P651, DOI 10.1001/jamaophthalmol.2016.0611
   Cerentini A, 2017, STUD HEALTH TECHNOL, V245, P318, DOI 10.3233/978-1-61499-830-3-318
   Chaum E, 2008, RETINA-J RET VIT DIS, V28, P1463, DOI 10.1097/IAE.0b013e31818356dd
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   DAMMS T, 1993, INVEST OPHTH VIS SCI, V34, P2246
   Darcy AM, 2016, JAMA-J AM MED ASSOC, V315, P551, DOI 10.1001/jama.2015.18421
   Doi K, 2007, COMPUT MED IMAG GRAP, V31, P198, DOI 10.1016/j.compmedimag.2007.02.002
   Doi K, 2006, PHYS MED BIOL, V51, pR5, DOI 10.1088/0031-9155/51/13/R02
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Farabet C, 2013, IEEE T PATTERN ANAL, V35, P1915, DOI 10.1109/TPAMI.2012.231
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleming AD, 2006, INVEST OPHTH VIS SCI, V47, P1120, DOI 10.1167/iovs.05-1155
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gautam D, 2018, INT J NUMER METH BIO, V34, DOI 10.1002/cnm.2953
   Gelman R, 2007, J AAPOS, V11, P532, DOI 10.1016/j.jaapos.2007.09.005
   Gilbert C, 2005, PEDIATRICS, V115, pE518, DOI 10.1542/peds.2004-1180
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   Gillner M, 2014, Z MED PHYS, V24, P104, DOI 10.1016/j.zemedi.2013.07.002
   Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684
   Hamet P, 2017, METABOLISM, V69, pS36, DOI 10.1016/j.metabol.2017.01.011
   Heidary Fatemeh, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P43
   Imani E, 2015, COMPUT MED IMAG GRAP, V43, P78, DOI 10.1016/j.compmedimag.2015.03.004
   Jiang F, 2017, STROKE VASC NEUROL, V2, P230, DOI 10.1136/svn-2017-000101
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Klein R, 2000, T AM OPHTHAL SOC, V98, P133
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Kose C, 2012, COMPUT METH PROG BIO, V107, P274, DOI 10.1016/j.cmpb.2011.06.007
   Krause J, 2018, OPHTHALMOLOGY, V125, P1264, DOI 10.1016/j.ophtha.2018.01.034
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lee A, 2017, OPHTHALMOLOGY, V124, P1726, DOI 10.1016/j.ophtha.2017.08.046
   Lee JG, 2017, KOREAN J RADIOL, V18, P570, DOI 10.3348/kjr.2017.18.4.570
   Lim LL, 2008, BRIT J OPHTHALMOL, V92, P1316, DOI 10.1136/bjo.2008.140640
   Liu WW, 2007, OPHTHALMOLOGY, V114, P1795, DOI 10.1016/j.ophtha.2007.03.010
   Liu XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168606
   Mirsharif Q, 2013, COMPUT MED IMAG GRAP, V37, P607, DOI 10.1016/j.compmedimag.2013.06.003
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Muhammad H, 2017, J GLAUCOMA, V26, P1086, DOI 10.1097/IJG.0000000000000765
   Murff HJ, 2011, JAMA-J AM MED ASSOC, V306, P848, DOI 10.1001/jama.2011.1204
   Musch DC, 2011, OPHTHALMOLOGY, V118, P1766, DOI 10.1016/j.ophtha.2011.01.047
   Niemeijer M, 2009, MED IMAGE ANAL, V13, P859, DOI 10.1016/j.media.2009.08.003
   Obermeyer Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMp1606181
   Oddone F, 2016, OPHTHALMOLOGY, V123, P939, DOI 10.1016/j.ophtha.2015.12.041
   Ohnell H, 2016, OPHTHALMOLOGY, V123, P1173, DOI 10.1016/j.ophtha.2016.01.039
   Omodaka K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190012
   Paulus J, 2010, INT J COMPUT ASS RAD, V5, P557, DOI 10.1007/s11548-010-0479-7
   Rogers SL, 2010, OPHTHALMOLOGY, V117, P1094, DOI 10.1016/j.ophtha.2010.01.058
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Sevik U, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.4.046006
   Suzuki K, 2017, RADIOL PHYS TECHNOL, V10, P257, DOI 10.1007/s12194-017-0406-5
   Tandon R, 2016, OPHTHALMOLOGY, V123, pE4, DOI 10.1016/j.ophtha.2015.05.032
   Taylor HR, 2001, BRIT J OPHTHALMOL, V85, P261, DOI 10.1136/bjo.85.3.261
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Vega R, 2015, COMPUT BIOL MED, V58, P20, DOI 10.1016/j.compbiomed.2014.12.016
   Venkata G, 2005, BRIT J OPHTHALMOL, V89, P257, DOI 10.1136/bjo.2004.056937
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Yasuda M, 2010, INVEST OPHTH VIS SCI, V51, P3205, DOI 10.1167/iovs.09-4453
   Yazid H, 2012, J MED SYST, V36, P1997, DOI 10.1007/s10916-011-9659-4
   Yun WL, 2008, INFORM SCIENCES, V178, P106, DOI 10.1016/j.ins.2007.07.020
   Zhao RQ, 2015, C P IEEE
NR 75
TC 26
Z9 29
U1 2
U2 23
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2018
VL 11
IS 9
BP 1555
EP 1561
DI 10.18240/ijo.2018.09.21
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT3OB
UT WOS:000444411700021
PM 30225234
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kang, HM
   Koh, HJ
AF Kang, Hae Min
   Koh, Hyoung Jun
TI Long-term Visual Outcome and Prognostic Factors After Intravitreal
   Ranibizumab Injections for Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; FLUENCE PHOTODYNAMIC THERAPY; ENDOTHELIAL
   GROWTH-FACTOR; MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION;
   JAPANESE PATIENTS; ASIAN PATIENTS; NEOVASCULARIZATION; BEVACIZUMAB;
   VERTEPORFIN
AB PURPOSE: To evaluate long-term visual outcome and investigate the prognostic factors after anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective study.
   METHODS: Analyses were done among 36 eyes (36 patients) with naive PCV that were treated with intravitreal ranibizumab injections and completed at least 3-year follow-up. All clinical data, including baseline characteristics; imaging data from fluorescein angiography, indocyanine green angiography, and optical coherence tomography; presence of recurrence; and best-corrected-visual acuity (BCVA) were investigated.
   RESULTS: During mean follow-up of 42.58 +/- 12.59 months, mean numbers of anti-VEGF injection were 11.45 +/- 7.81. Twenty-four eyes (66.7%) showed at least 1 recurrence during follow-up. Mean baseline BCVA was 0.68 +/- 0.43 logMAR (20/95 Snellen equivalent), and 0.78 +/- 0.53 logMAR (20/120 Snellen equivalent) at 36 months (P = .307). Mean BCVA was significantly improved at 1 month (P = .018), and improvement was maintained until 12 months (P = .044), then deteriorated. Among baseline characteristics, greatest lesion diameter (B = 0.219, P = .001) and pigment epithelial detachment (B = 0.362, P = .025) were significantly correlated with long-term visual outcome. Recurrence during follow-up (B = 0.371, P = .024) was also significantly correlated with long-term visual outcome.
   CONCLUSION: Significant visual improvement by anti-VEGF therapy was maintained during the first year of initial treatment; however, vision then deteriorated during long-term follow-up. Smaller lesion size, absence of pigment epithelial detachment at baseline, and no recurrence during follow-up were significantly correlated with better long-term visual outcome. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Kang, Hae Min; Koh, Hyoung Jun] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, 134 Sinchon Dong, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Koh A, 2011, SINGAP MED J, V52, P232
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 63
Z9 68
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2013
VL 156
IS 4
BP 652
EP 660
DI 10.1016/j.ajo.2013.05.038
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 231VT
UT WOS:000325447200003
PM 23891333
DA 2022-11-30
ER

PT J
AU Sistiabudi, R
   Ivanisevic, A
AF Sistiabudi, Rizaldi
   Ivanisevic, Albena
TI Dip-Pen Nanolithography of Bioactive Peptides on Collagen-Terminated
   Retinal Membrane
SO ADVANCED MATERIALS
LA English
DT Article
ID PIGMENT EPITHELIUM; BRUCHS MEMBRANE; LAYERS
AB Dip-pen nanolithography is used to directly modify freshly dissected eye tissues with biologically active collagen-binding peptide molecules. The results address the challenge of surface heterogeneity and utilize dip-pen nanolithography to control the localization and concentration of molecules on a collagen-terminated tissue-derived surface. This method can allow the development of scaffolds for treatment of age-related macular degeneration.
C1 [Sistiabudi, Rizaldi; Ivanisevic, Albena] Purdue Univ, Weldon Sch Biomed Engn, Dept Chem, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Purdue University West
   Lafayette Campus
RP Ivanisevic, A (通讯作者)，Purdue Univ, Weldon Sch Biomed Engn, Dept Chem, 260 S Martin Jischke Dr, W Lafayette, IN 47907 USA.
EM albena@purdue.edu
RI Sistiabudi, Rizaldi/AAR-6668-2020
CR Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2000, INVEST OPHTH VIS SCI, V41, pS858
   Huck WTS, 2007, ANGEW CHEM INT EDIT, V46, P2754, DOI 10.1002/anie.200604819
   Jegadesan S, 2007, J NANOSCI NANOTECHNO, V7, P2172, DOI 10.1166/jnn.2007.789
   Jung H, 2004, NANO LETT, V4, P2171, DOI 10.1021/nl048705c
   Kinsella JM, 2006, NANOSCI TECHNOL, P1
   LIM JH, 2003, ANGEW CHEM, V115, P2411
   MARCU L, 2003, HDB BIOMEDICAL FLUOR, P412
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Nam JM, 2004, ANGEW CHEM INT EDIT, V43, P1246, DOI 10.1002/anie.200353203
   Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661
   Salaita K, 2007, NAT NANOTECHNOL, V2, P145, DOI 10.1038/nnano.2007.39
   Sistiabudi R, 2008, LANGMUIR, V24, P1591, DOI 10.1021/la703561d
   Sistiabudi R, 2007, J PHYS CHEM C, V111, P11676, DOI 10.1021/jp072757j
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tinazli A, 2007, NAT NANOTECHNOL, V2, P220, DOI 10.1038/nnano.2007.63
NR 16
TC 27
Z9 27
U1 4
U2 17
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD OCT 2
PY 2008
VL 20
IS 19
BP 3678
EP +
DI 10.1002/adma.200800950
PG 5
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 359YJ
UT WOS:000260023900019
DA 2022-11-30
ER

PT J
AU Nakata, I
   Tsujikawa, A
   Yamashiro, K
   Otani, A
   Ooto, S
   Akagi-Kurashige, Y
   Ueda-Arakawa, N
   Iwama, D
   Yoshimura, N
AF Nakata, Isao
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Otani, Atsushi
   Ooto, Sotaro
   Akagi-Kurashige, Yumiko
   Ueda-Arakawa, Naoko
   Iwama, Daisuke
   Yoshimura, Nagahisa
TI Two-year outcome of photodynamic therapy combined with intravitreal
   injection of bevacizumab and triamcinolone acetonide for polypoidal
   choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Photodynamic therapy;
   Polypoidal choroidal vasculopathy; Triamcinolone acetonide
ID MACULAR DEGENERATION; CLINICAL CHARACTERISTICS; JAPANESE PATIENTS;
   RANIBIZUMAB; VERTEPORFIN; VEGF; NEOVASCULARIZATION; IMPROVEMENT;
   EXPRESSION; AVASTIN
AB To compare the 2-year results after photodynamic therapy (PDT) alone and PDT combined with intravitreal injections of bevacizumab and triamcinolone acetonide (triple therapy) for polypoidal choroidal vasculopathy (PCV).
   We retrospectively reviewed the medical records of 40 consecutive patients (40 eyes) with subfoveal PCV. Of these 40 eyes, 16 were treated with PDT alone and 24 were treated with triple therapy.
   The change in visual acuity in the triple therapy group was significantly better than that in the PDT group (P < 0.001). At 24 months, improvement in visual acuity was seen in only two eyes (12.5 %) of the PDT group, while it was seen in ten eyes (41.7 %) of the triple therapy group. Retreatment was given to 12 eyes (75.0 %) in the PDT group and to nine eyes (37.5 %) in the triple therapy group, although the retreatment-free period was significantly longer in the triple therapy group than in the PDT group (P < 0.001). Post-treatment vitreous hemorrhage was seen in only two eyes (12.5 %), all of which were in the PDT group.
   Compared with PDT alone, triple therapy appears to reduce the postoperative hemorrhagic complications and recurrences of PCV and to improve the 2-year visual outcomes of PCV.
C1 [Nakata, Isao; Tsujikawa, Akitaka; Yamashiro, Kenji; Otani, Atsushi; Ooto, Sotaro; Akagi-Kurashige, Yumiko; Ueda-Arakawa, Naoko; Iwama, Daisuke; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto 6068507, Japan.
   [Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University; Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
OI Tsujikawa, Akitaka/0000-0003-0779-7799; Yamashiro,
   Kenji/0000-0001-9354-8558
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [21592256]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX This study was supported in part by the Japan Society for the Promotion
   of Science (JSPS), Tokyo, Japan (Grant-in-Aid for Scientific Research,
   no. 21592256), and by the Japan National Society for the Prevention of
   Blindness, Tokyo, Japan. We thank the following clinicians at Kyoto
   University Hospital for their assistance in gathering the treatment
   histories for our study: Hiroshi Tamura, MD, Hideo Nakanishi, MD, Hisako
   Hayashi, MD, Satoko Nakagawa, MD, Kohei Takayama, MD, Yumiko Ojima, MD,
   and Takahiro Horii, MD.
CR Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Koh A, 2012, RETINA
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mukai R, 2010, OPHTHALMOLOGICA, V224, P267, DOI 10.1159/000287348
   Obata R, 2007, BRIT J OPHTHALMOL, V91, P100, DOI 10.1136/bjo.2006.098004
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 34
TC 16
Z9 21
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2013
VL 251
IS 4
BP 1073
EP 1080
DI 10.1007/s00417-012-2137-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114RD
UT WOS:000316759000004
PM 22923282
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Wolf, AT
   Harris, A
   Oddone, F
   Siesky, B
   Vercellin, AV
   Ciulla, TA
AF Wolf, Amber T.
   Harris, Alon
   Oddone, Francesco
   Siesky, Brent
   Vercellin, Alice Verticchio
   Ciulla, Thomas A.
TI Disease progression pathways of wet AMD: opportunities for new target
   discovery
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Article
DE Age-related macular degeneration; integrins; therapy; treatment; VEGF;
   tyrosine kinase inhibitors
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB; BEVACIZUMAB; INJECTION; MODEL; EYE
AB Introduction Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among people age 60 years or older in developed countries. Current standard-of-care anti-vascular endothelial growth factor (VEGF) therapy, which inhibits angiogenesis and vascular permeability, has been shown to stabilize choroidal neovascularization and increase visual acuity in neovascular AMD. However, therapeutic limitations of anti-VEGF therapy include limited durability with consequent need for frequent intravitreal injections, and a ceiling of efficacy. Current strategies under investigation include targeting VEGF-C and VEGF-D, integrins, tyrosine kinase receptors, and the Tie2/angiopoietin-2 pathway. A literature search was conducted through November 30, 2021 on PubMed, Medline, Google Scholar, and associated digital platforms with the following keywords: wet macular degeneration, age-related macular degeneration, therapy, VEGF-A, VEGF-C, VEGF-D, integrins, Tie2/Ang2, and tyrosine kinase inhibitors. Areas covered The authors provide a comprehensive review of AMD disease pathways and mechanisms involved in wet AMD as well as novel targets for future therapies. Expert opinion With novel targets and advancements in drug delivery, there is potential to address treatment burden and to improve outcomes for patients afflicted with neovascular AMD.
C1 [Wolf, Amber T.; Harris, Alon; Siesky, Brent; Vercellin, Alice Verticchio] Mt Sinai Hosp, Icahn Sch Med, Dept Ophthalmol, New York, NY 10029 USA.
   [Oddone, Francesco] Fdn Bietti, Glaucoma Unit, Rome, Italy.
   [Ciulla, Thomas A.] Midwest Eye Inst, Retina Dept, Indianapolis, IN USA.
   [Ciulla, Thomas A.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Ciulla, Thomas A.] Clearside Biomed, Med Dept, Alpharetta, GA USA.
C3 Icahn School of Medicine at Mount Sinai; IRCCS - Fondazione "G.B.
   Bietti" per lo Studio e la Ricerca in Oftalmologia; Indiana University
   System; Indiana University Bloomington
RP Harris, A (通讯作者)，Icahn Sch Med Mt Sinai, Mt Sinai Hosp, Ophthalmol, 1468 Madison Ave,Annenberg 22-86, New York, NY 10029 USA.; Harris, A (通讯作者)，Icahn Sch Med Mt Sinai, Mt Sinai Hosp, Int Res & Acad Affairs, 1468 Madison Ave,Annenberg 22-86, New York, NY 10029 USA.; Harris, A (通讯作者)，Icahn Sch Med Mt Sinai, Mt Sinai Hosp, Ophthalm Vasc Diagnost & Res Program, 1468 Madison Ave,Annenberg 22-86, New York, NY 10029 USA.
EM palonharris@gmail.com
OI Ciulla, Thomas/0000-0001-5557-6777
FU NIH [R01EY030851]; NSF DMS [1853222/2021192]; Research to Prevent
   Blindness, NY
FX A Harris is supported by the NIH grant (R01EY030851), NSF DMS
   (1853222/2021192), and in part by a Challenge Grant award from Research
   to Prevent Blindness, NY.
CR Adverum, 2021, ADV PRES 2 YEAR OPTI
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   [Anonymous], 2021, GRAYBUG VISION
   Arepalli S, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00325-5
   Avery RL WJ., 2020, SUBJECTS NEOVASCULAR
   Baek SU, 2016, CUTAN OCUL TOXICOL, V35, P310, DOI 10.3109/15569527.2015.1124886
   Bantseev V, 2021, TOXICOL PATHOL, V49, P663, DOI 10.1177/0192623320968079
   Bhatt P, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1474-0
   Bracha P, 2018, SURV OPHTHALMOL, V63, P281, DOI 10.1016/j.survophthal.2017.08.008
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Chandrasekaran PR, 2021, THER ADV OPHTHALMOL, V13, DOI 10.1177/25158414211027708
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Daniel E, 2017, INVEST OPHTH VIS SCI, V58
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   EyePoint Pharma, 2021, EYEPOINT PHARM PIP
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Gelfman CM, 2021, J OCUL PHARMACOL TH, V37, P181, DOI 10.1089/jop.2021.0001
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirasawa M, 2016, J BIOL CHEM, V291, P7373, DOI 10.1074/jbc.M115.710186
   Homayouni Mansour, 2009, J Ophthalmic Vis Res, V4, P105
   Hu TT, 2019, EXP EYE RES, V180, P43, DOI 10.1016/j.exer.2018.11.022
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Kansara VS, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.7.19
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Kunzmann K., 2021, VOROLANIB VIA DURASE
   Lieu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077117
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Nguyen QD, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00250-z
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Roche, 2020, ROCH PORT DEL SYST R
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   SciFluor Life Sciences, 2017, SCIFLUOR ANN POS TOP
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Surace EM, 2008, VISION RES, V48, P353, DOI 10.1016/j.visres.2007.07.027
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Tsujinaka H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14340-x
   Van Hove I, 2021, PROG RETIN EYE RES, V85, DOI 10.1016/j.preteyeres.2021.100966
   Wan CR, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020288
   Wang WQ, 2016, MOL PHARMACEUT, V13, P2881, DOI 10.1021/acs.molpharmaceut.6b00056
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xue K, 2019, BIOMATER SCI-UK, V7, P4603, DOI 10.1039/c9bm01049a
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zhang BY, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107972
NR 55
TC 0
Z9 0
U1 5
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD JAN 2
PY 2022
VL 26
IS 1
BP 5
EP 12
DI 10.1080/14728222.2022.2030706
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ZT7JO
UT WOS:000769328200002
PM 35060431
DA 2022-11-30
ER

PT J
AU Biro, A
   Prohaszka, Z
   Fust, G
   Blasko, B
AF Biro, Adrienn
   Prohaszka, Zoltan
   Fuest, George
   Blasko, Bernadett
TI Determination of complement factor H functional polymorphisms (V62I,
   Y402H, and E936D) using sequence-specific primer PCR and restriction
   fragment length polymorphisms
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; MACULAR DEGENERATION; MUTATIONS; DISEASE;
   PROTEIN; ACTIVATION; REGULATOR; CLUSTER; FAMILY; GENES
AB Background: Complement factor H (CFH; HF) is an essential regulatory protein that plays a critical role in the homeostasis of the complement system in plasma. Several polymorphisms and mutations in the complement factor H gene (CFH, HF1) have been identified. These have revealed interesting associations with hemolytic-uremic syndrome and age-related macular degeneration.
   Methods and Results: The aim of this study was to develop a rapid and reliable assay for determining genotypic variants of the CFH gene. Sequence-specific primer PCR and restriction fragment length polymorphism techniques were chosen for the analysis of CFH polymorphisms. The assays detected the following published single nucleotide polymorphisms of CFH in our Caucasian population (n = 271): rs800292, 257G-->A (V62I); rs1061170, 1277T-->C (Y402H); and rs1065489, 288IG-->T (E936D). The allele frequencies (257G = 0.850, 1277T = 0.574, and 2881G = 0.839) that we obtained from a healthy Hungarian population were consistent with previously published results.
   Conclusion: These analytical methods are simple, reliable, and rapid to perform, and are amenable to automation. Therefore, they could facilitate large-scale genotypic analyses of the CFH gene in various diseases, such as hemolytic-uremic syndrome, age-related macular degeneration, and cardiovascular diseases.
C1 Semmelweis Univ, Fac Med, Dept Internal Med 3, Szentagothai Janos Knowledge Ctr, H-1125 Budapest, Hungary.
C3 Semmelweis University
RP Blasko, B (通讯作者)，Semmelweis Univ, Fac Med, Dept Internal Med 3, Szentagothai Janos Knowledge Ctr, Kutvolgyi Ut 4, H-1125 Budapest, Hungary.
EM blasko@kut.sote.hu
RI Prohászka, Zoltán/F-2191-2010
OI Prohászka, Zoltán/0000-0003-1761-7982
CR Caprioli J, 2005, CURR OPIN CRIT CARE, V11, P487, DOI 10.1097/01.ccx.0000176688.10810.30
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5
   DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   *EUR BIOINF I, CLUSTALW SUBM FORM
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   ROSS GD, 1982, J IMMUNOL, V129, P2051
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WEIS JH, 1987, J IMMUNOL, V138, P312
   Ying LH, 1999, AM J HUM GENET, V65, P1538, DOI 10.1086/302673
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
   Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6
   Zipfel PF, 2001, INT IMMUNOPHARMACOL, V1, P461, DOI 10.1016/S1567-5769(00)00047-3
   ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4
   [No title captured]
NR 27
TC 6
Z9 6
U1 0
U2 1
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 1177-1062
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PY 2006
VL 10
IS 5
BP 303
EP 310
DI 10.1007/BF03256205
PG 8
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 105HI
UT WOS:000242020600004
PM 17022693
DA 2022-11-30
ER

PT J
AU Ow, V
   Loh, XJ
AF Ow, Valerie
   Loh, Xian Jun
TI Recent developments of temperature-responsive polymers for ophthalmic
   applications
SO JOURNAL OF POLYMER SCIENCE
LA English
DT Review
DE biomaterials; drug delivery; hydrogels; ophthalmic; stimuli-responsive
ID DRUG-DELIVERY SYSTEM; INJECTABLE THERMOSENSITIVE HYDROGEL;
   BLOCK-COPOLYMER HYDROGELS; THERMOGELLING COPOLYMERS;
   DIABETIC-RETINOPATHY; SUSTAINED DELIVERY; POLY(ETHYLENE GLYCOL);
   POLY(ESTER URETHANE)S; CONTROLLED-RELEASE; IN-VIVO
AB Blindness is one of the most feared disabilities. From cataracts and glaucoma to age-related macular degeneration and retinal vascular diseases, ocular diseases have adverse impacts on patients and pose a huge burden to the healthcare system. The World Health Organization estimates that out of 2.2 billion people with visual impairment, almost half of the cases can be prevented or has yet to be addressed. This presents an urgent clinical and societal need to be met. Temperature-sensitive hydrogels are one of the most biocompatible materials, which can be applied into the eye. By exploiting physiological temperature as a stimulus for in situ gel formation, control of the mechanical properties, rate of drug release, and biomechanical interactions can be tuned. They are very versatile and have immense potential in ocular applications by acting as vitreous substitutes in retinal surgery or topical eye drops and lenses for ocular discomfort and inflammation. In this article, we provide a review of the recent developments in temperature-responsive polymers in ophthalmic therapy in the past 5 years including retinal detachment, retinal vascular diseases, dry eyes, cataracts, age-related macular degeneration, and glaucoma.
C1 [Ow, Valerie; Loh, Xian Jun] ASTAR, Inst Mat Res & Engn, 2 Fusionopolis Way,Innovis,08-03, Singapore 138634, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Institute of
   Materials Research & Engineering (IMRE)
RP Loh, XJ (通讯作者)，ASTAR, Inst Mat Res & Engn, 2 Fusionopolis Way,Innovis,08-03, Singapore 138634, Singapore.
EM lohxj@imre.a-star.edu.sg
RI Loh, Xian Jun/H-6260-2013
OI Loh, Xian Jun/0000-0001-8118-6502
FU A*STAR (Singapore) IAF-PP [H17/01/a0/013]; OculaR Biomaterials and
   Device
FX This study was supported by an A*STAR (Singapore) IAF-PP (HMBS Domain)
   grant H17/01/a0/013 (OrBID): OculaR Biomaterials and Device.
CR Afshin A, 2019, LANCET, V393, P1958, DOI 10.1016/S0140-6736(19)30041-8
   Al-Kinani AA, 2018, ADV DRUG DELIVER REV, V126, P113, DOI 10.1016/j.addr.2017.12.017
   Ameeduzzafar, 2016, DRUG DELIV, V23, P710, DOI 10.3109/10717544.2014.923065
   [Anonymous], 1992, LANCET, V339, P1389
   Appel EA, 2012, CHEM COMMUN, V48, P9843, DOI 10.1039/c2cc35131e
   Awwad S, 2020, EUR J PHARM BIOPHARM, V153, P130, DOI 10.1016/j.ejpb.2020.05.005
   Awwad S, 2019, EUR J PHARM SCI, V137, DOI 10.1016/j.ejps.2019.104993
   Awwad S, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201700255
   Baker AEG, 2021, BIOMATERIALS, V271, DOI 10.1016/j.biomaterials.2021.120750
   Balachandra A, 2019, DRUG DELIV, V26, P343, DOI 10.1080/10717544.2019.1587042
   Barouti G, 2016, CHEM-EUR J, V22, P10501, DOI 10.1002/chem.201601404
   Burton MJ, 2021, LANCET GLOB HEALTH, V9, pE489, DOI 10.1016/S2214-109X(20)30488-5
   Buwalda SJ, 2017, BIOMACROMOLECULES, V18, P316, DOI 10.1021/acs.biomac.6b01604
   Caccavo D, 2018, CHEM SOC REV, V47, P2357, DOI 10.1039/c7cs00638a
   Cally O, 2019, BIOMATER SCI SER, V2, P1
   Chan BQY, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10010089
   Chen Y, 2020, J MATER CHEM B, V8, P980, DOI 10.1039/c9tb02523e
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Ciolino JB, 2014, BIOMATERIALS, V35, P432, DOI 10.1016/j.biomaterials.2013.09.032
   Huynh CT, 2011, MACROMOLECULES, V44, P6629, DOI 10.1021/ma201261m
   Huynh CT, 2011, ACTA BIOMATER, V7, P3123, DOI 10.1016/j.actbio.2011.05.004
   Craig JP, 2017, OCUL SURF, V15, P802, DOI 10.1016/j.jtos.2017.08.003
   Deguchi S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102171
   Delplace V, 2019, J CONTROL RELEASE, V293, P10, DOI 10.1016/j.jconrel.2018.11.012
   Dimatteo R, 2018, ADV DRUG DELIVER REV, V127, P167, DOI 10.1016/j.addr.2018.03.007
   Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.21, 10.1038/natrevmats.2016.71]
   DiPasquale SA, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202101263
   Dou QQ, 2014, ADV HEALTHC MATER, V3, P977, DOI 10.1002/adhm.201300627
   Dou QQ, 2016, J POLYM SCI POL CHEM, V54, P2837, DOI 10.1002/pola.28191
   Egbu R, 2018, EUR J PHARM BIOPHARM, V124, P95, DOI 10.1016/j.ejpb.2017.12.019
   Fan XS, 2016, ACS APPL MATER INTER, V8, P33351, DOI 10.1021/acsami.6b09110
   Fedorchak MV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09379-8
   Gan LH, 2001, POLYMER, V42, P65, DOI 10.1016/S0032-3861(00)00296-2
   Guo SS, 2017, MAT SCI ENG C-MATER, V70, P1163, DOI 10.1016/j.msec.2016.03.074
   Han Y, 2022, BIOACT MATER, V9, P77, DOI 10.1016/j.bioactmat.2021.07.027
   Hayashi K, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-017-0044
   He BB, 2021, BIOACT MATER, V6, P3085, DOI 10.1016/j.bioactmat.2021.02.029
   He CL, 2008, J CONTROL RELEASE, V127, P189, DOI 10.1016/j.jconrel.2008.01.005
   Hong JH, 2017, ACS APPL MATER INTER, V9, P11568, DOI 10.1021/acsami.7b02488
   Hu BH, 2020, ADV MATER, V32, DOI 10.1002/adma.201907030
   Huynh DP, 2009, J CONTROL RELEASE, V137, P20, DOI 10.1016/j.jconrel.2009.02.021
   Ilochonwu BC, 2020, J CONTROL RELEASE, V326, P419, DOI 10.1016/j.jconrel.2020.07.031
   Jeong B, 1999, MACROMOLECULES, V32, P7064, DOI 10.1021/ma9908999
   Jeong B, 2002, ADV DRUG DELIVER REV, V54, P37, DOI 10.1016/S0169-409X(01)00242-3
   Jeong B, 2000, J CONTROL RELEASE, V63, P155, DOI 10.1016/S0168-3659(99)00194-7
   Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218
   Jimenez J, 2021, DRUG DELIV TRANSL RE, V11, P2224, DOI 10.1007/s13346-020-00890-6
   Joo MK, 2009, J MATER CHEM, V19, P5891, DOI 10.1039/b902208b
   Karim AA, 2016, CHEM-ASIAN J, V11, P1300, DOI 10.1002/asia.201501434
   Kim YJ, 2017, J MATER CHEM B, V5, P4307, DOI 10.1039/c7tb00157f
   Lai JY, 2020, CHEM ENG J, V402, DOI 10.1016/j.cej.2020.126190
   Li XY, 2013, INT J PHARMACEUT, V448, P96, DOI 10.1016/j.ijpharm.2013.03.024
   Li XZ, 2016, ACS APPL MATER INTER, V8, P5148, DOI 10.1021/acsami.5b12212
   Li ZB, 2015, CHEM SOC REV, V44, P2865, DOI 10.1039/c5cs00089k
   Li ZB, 2012, BIOMACROMOLECULES, V13, P3977, DOI 10.1021/bm3012506
   Lim HK, 2019, BIOMATER SCI SER, V2, P76
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin QY, 2021, ACCOUNTS MATER RES, V2, P881, DOI 10.1021/accountsmr.1c00128
   Lin QY, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120547
   Lin T, 2018, BIOMATER SCI-UK, V6, P3160, DOI 10.1039/c8bm01047a
   Liow SS, 2017, SMALL, V13, DOI 10.1002/smll.201603404
   Liow SS, 2017, BIOMACROMOLECULES, V18, P886, DOI 10.1021/acs.biomac.6b01777
   Liow SS, 2016, ACS BIOMATER SCI ENG, V2, P295, DOI 10.1021/acsbiomaterials.5b00515
   Liu H, 2018, ACTA BIOMATER, V73, P103, DOI 10.1016/j.actbio.2018.04.035
   Liu WQ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.12
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Liu ZP, 2019, NAT BIOMED ENG, V3, P598, DOI 10.1038/s41551-019-0382-7
   Liu ZP, 2016, INVEST OPHTH VIS SCI, V57
   Loh XJ, 2008, POLYMER, V49, P5084, DOI 10.1016/j.polymer.2008.08.061
   Loh XJ, 2008, BIOMATERIALS, V29, P3185, DOI 10.1016/j.biomaterials.2008.04.015
   Loh XJ, 2008, BIOMATERIALS, V29, P2164, DOI 10.1016/j.biomaterials.2008.01.016
   Loh XJ, 2007, BIOMATERIALS, V28, P4113, DOI 10.1016/j.biomaterials.2007.05.016
   Loh XJ, 2007, BIOMACROMOLECULES, V8, P585, DOI 10.1021/bm0607933
   Loh XJ, 2013, MAT SCI ENG C-MATER, V33, P4545, DOI 10.1016/j.msec.2013.07.011
   Loh XJ, 2013, POLYM CHEM-UK, V4, P2564, DOI 10.1039/c3py00096f
   Loh XJ, 2012, J MATER CHEM, V22, P21249, DOI 10.1039/c2jm33777k
   Loh XJ, 2012, J BIOMED MATER RES A, V100A, P2686, DOI 10.1002/jbm.a.34198
   Loh XJ, 2011, J MATER CHEM, V21, P2246, DOI 10.1039/c0jm03051a
   Loh XJ, 2010, J MATER CHEM, V20, P10634, DOI 10.1039/c0jm01461c
   Loh XJ, 2009, MACROMOL BIOSCI, V9, P1069, DOI 10.1002/mabi.200900081
   Loh XJ, 2009, J PHYS CHEM B, V113, P11822, DOI 10.1021/jp903984r
   Luo LJ, 2020, MAT SCI ENG C-MATER, V115, DOI 10.1016/j.msec.2020.111095
   Luo LJ, 2020, J CONTROL RELEASE, V317, P246, DOI 10.1016/j.jconrel.2019.11.038
   Luo LJ, 2018, CARBOHYD POLYM, V197, P375, DOI 10.1016/j.carbpol.2018.06.020
   Ma MS, 2020, CARBOHYD POLYM, V236, DOI 10.1016/j.carbpol.2020.116096
   Mohammadi M, 2018, ACTA BIOMATER, V73, P90, DOI 10.1016/j.actbio.2018.04.037
   Moon HJ, 2012, CHEM SOC REV, V41, P4860, DOI 10.1039/c2cs35078e
   Nguyen VPN, 2011, SOFT MATTER, V7, P2150, DOI 10.1039/c0sm00764a
   Parikh BH, 2021, INVEST OPHTH VIS SCI, V62
   Patel M, 2018, BIOMATERIALS, V159, P91, DOI 10.1016/j.biomaterials.2018.01.001
   Peppas N.A., 2013, BIOMATERIALS SCI, P166
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Phan VHG, 2016, SCI REP-UK, V6, DOI 10.1038/srep29978
   Prasanna A, 2018, REACT FUNCT POLYM, V124, P40, DOI 10.1016/j.reactfunctpolym.2018.01.001
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rajasekaran A., 2010, INT J PHARMTECH RES, V2, P668, DOI DOI 10.1517/17425247.2011.548801
   Rhee MK, 2017, OPHTHALMOLOGY, V124, pS14, DOI 10.1016/j.ophtha.2017.08.029
   Rong XF, 2019, INT J NANOMED, V14, P45, DOI 10.2147/IJN.S184574
   Ross AE, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119285
   Seah I, 2020, EYE, V34, P1341, DOI 10.1038/s41433-020-0770-y
   Seliktar D, 2012, SCIENCE, V336, P1124, DOI 10.1126/science.1214804
   Shi K, 2016, SCI REP-UK, V6, DOI 10.1038/srep19077
   Shim WS, 2006, BIOMATERIALS, V27, P5178, DOI 10.1016/j.biomaterials.2006.05.038
   Shim WS, 2005, BIOMACROMOLECULES, V6, P2930, DOI 10.1021/bm050521k
   Solomon SD, 2017, DIABETES CARE, V40, P412, DOI 10.2337/dc16-2641
   Stein JD, 2021, JAMA-J AM MED ASSOC, V325, P164, DOI 10.1001/jama.2020.21899
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Su WY, 2011, J BIOMAT SCI-POLYM E, V22, P1777, DOI 10.1163/092050610X522729
   Su XY, 2018, INVEST OPHTH VIS SCI, V59
   Su XY, 2015, BIOMACROMOLECULES, V16, P3093, DOI 10.1021/acs.biomac.5b01091
   Sun JG, 2017, J MATER CHEM B, V5, P6400, DOI 10.1039/c7tb01556a
   Sun JG, 2017, ACS APPL MATER INTER, V9, P7990, DOI 10.1021/acsami.6b16509
   Tan GX, 2017, INT J BIOL MACROMOL, V103, P941, DOI 10.1016/j.ijbiomac.2017.05.132
   Tao Y, 2013, ACTA BIOMATER, V9, P5022, DOI 10.1016/j.actbio.2012.09.026
   Thai MDL, 2018, BIOMACROMOLECULES, V19, P3536, DOI 10.1021/acs.biomac.8b00819
   Thambi T, 2019, NEW J CHEM, V43, P18979, DOI 10.1039/c9nj03687c
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Topete A, 2019, INT J PHARMACEUT, V558, P43, DOI 10.1016/j.ijpharm.2018.12.028
   Tsubota K, 2017, OCUL SURF, V15, P65, DOI 10.1016/j.jtos.2016.09.003
   Turabee MH, 2018, BIOMATER SCI-UK, V6, P661, DOI 10.1039/c7bm00980a
   Vashist A, 2014, J MATER CHEM B, V2, P147, DOI 10.1039/c3tb21016b
   Wang S, 2021, CARBOHYD POLYM, V256, DOI 10.1016/j.carbpol.2020.117519
   Wang XY, 2018, MOLECULES, V23, DOI 10.3390/molecules23030553
   Wee CY, 2017, MACROMOL CHEM PHYS, V218, DOI 10.1002/macp.201700196
   Wu YL, 2016, ADV HEALTHC MATER, V5, P2679, DOI 10.1002/adhm.201600723
   Wu YL, 2016, RSC ADV, V6, P44506, DOI 10.1039/c6ra08022g
   Xiang YG, 2017, DRUG DISCOV TODAY, V22, P1318, DOI 10.1016/j.drudis.2017.04.001
   Xue K, 2020, ACS APPL BIO MATER, V3, P9043, DOI 10.1021/acsabm.0c01266
   Xue K, 2020, BIOMATER SCI-UK, V8, P926, DOI 10.1039/c9bm01603a
   Xue K, 2019, BIOMATER SCI-UK, V7, P4603, DOI 10.1039/c9bm01049a
   Xue K, 2018, CHEM REC, V18, P1517, DOI 10.1002/tcr.201800015
   Yan TY, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80476-x
   Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k
   Yu Z, 2020, J BIOMED MATER RES A, V108, P2435, DOI 10.1002/jbm.a.36995
   Zhang KW, 2021, GELS-BASEL, V7, DOI 10.3390/gels7030077
   Zhang SH, 2021, ADV THER-GERMANY, V4, DOI 10.1002/adtp.202100088
   Zhang YB, 2019, BIOMACROMOLECULES, V20, P1478, DOI 10.1021/acs.biomac.9b00043
   Zhang YB, 2018, ACTA BIOMATER, V77, P63, DOI 10.1016/j.actbio.2018.07.021
   Zhao XX, 2022, ADV MATER, V34, DOI 10.1002/adma.202108360
   Zheng CH, 2017, MAT SCI ENG C-MATER, V74, P110, DOI 10.1016/j.msec.2017.02.005
   Zhu YN, 2020, INT J PHARMACEUT, V587, DOI 10.1016/j.ijpharm.2020.119688
NR 142
TC 1
Z9 1
U1 13
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2642-4150
EI 2642-4169
J9 J POLYM SCI
JI J. Polym. Sci.
PD MAY 1
PY 2022
VL 60
IS 9
BP 1429
EP 1447
DI 10.1002/pol.20210907
EA JAN 2022
PG 19
WC Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Polymer Science
GA 0X0AR
UT WOS:000747285700001
DA 2022-11-30
ER

PT J
AU Hasegawa, E
   Sonoda, KH
   Shichita, T
   Morita, R
   Sekiya, T
   Kimura, A
   Oshima, Y
   Takeda, A
   Yoshimura, T
   Yoshida, S
   Ishibashi, T
   Yoshimura, A
AF Hasegawa, Eiichi
   Sonoda, Koh-Hei
   Shichita, Takashi
   Morita, Rimpei
   Sekiya, Takashi
   Kimura, Akihiro
   Oshima, Yuji
   Takeda, Atsunobu
   Yoshimura, Takeru
   Yoshida, Shigeo
   Ishibashi, Tatsuro
   Yoshimura, Akihiko
TI IL-23-Independent Induction of IL-17 from gamma delta T Cells and Innate
   Lymphoid Cells Promotes Experimental Intraocular Neovascularization
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; INFLAMMATION; ACTIVATION; DIFFERENTIATION; ANGIOGENESIS;
   EXPRESSION; SENTINELS; CYTOKINES
AB Choroidal neovascularization (CNV) is a characteristic of age-related macular degeneration. Genome-wide association studies have provided evidence that the immune system is involved in the pathogenesis of age-related macular degeneration; however, the role of inflammatory cytokines in CNV has not been established. In this study, we demonstrated that IL-17 had a strong potential for promoting neovascularization in a vascular endothelial growth factor-independent manner in laser-induced experimental CNV in mice. Infiltrated gamma delta T cells and Thy-1(+) innate lymphoid cells, but not Th17 cells, were the main sources of IL-17 in injured eyes. IL-23 was dispensable for IL-17 induction in the eye. Instead, we found that IL-1 beta and high-mobility group box 1 strongly promoted IL-17 expression by gamma delta T cells. Suppression of IL-1 beta and high-mobility group box 1, as well as depletion of gamma delta T cells, reduced IL-17 levels and ameliorated experimental CNV. Our findings suggest the existence of a novel inflammatory cytokine network that promotes neovascularization in the eye. The Journal of Immunology, 2013, 190: 1778-1787.
C1 [Hasegawa, Eiichi; Shichita, Takashi; Morita, Rimpei; Sekiya, Takashi; Kimura, Akihiro; Yoshimura, Akihiko] Keio Univ, Dept Microbiol & Immunol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan.
   [Hasegawa, Eiichi; Shichita, Takashi; Morita, Rimpei; Sekiya, Takashi; Kimura, Akihiro; Yoshimura, Akihiko] Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Chiyoda Ku, Tokyo 1020075, Japan.
   [Hasegawa, Eiichi; Oshima, Yuji; Takeda, Atsunobu; Yoshimura, Takeru; Yoshida, Shigeo; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan.
   [Sonoda, Koh-Hei] Yamaguchi Univ, Dept Ophthalmol, Grad Sch Med, Ube, Yamaguchi 7558505, Japan.
C3 Keio University; Japan Science & Technology Agency (JST); Kyushu
   University; Yamaguchi University
RP Yoshimura, A (通讯作者)，Keio Univ, Dept Microbiol & Immunol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM yoshimura@a6.keio.jp
RI Yoshimura, Akihiko/K-5515-2013
OI Yoshida, Shigeo/0000-0003-1049-8909; Kimura, Akihiro/0000-0001-5614-8547
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Program for the Promotion of Fundamental Studies in Health Science of
   the National Institute of Biomedical Innovation; SENSIN Medical Research
   Foundation; Mochida Memorial Foundation; Uehara Memorial Foundation;
   Takeda Science Foundation; Grants-in-Aid for Scientific Research
   [22590438, 23689071] Funding Source: KAKEN
FX This work was supported by special grants-in-aid from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan; the Program
   for the Promotion of Fundamental Studies in Health Science of the
   National Institute of Biomedical Innovation; the SENSIN Medical Research
   Foundation; the Mochida Memorial Foundation; the Uehara Memorial
   Foundation; and the Takeda Science Foundation.
CR Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200
   Arimura N, 2009, LAB INVEST, V89, P278, DOI 10.1038/labinvest.2008.165
   Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949
   Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800
   Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355
   Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Han GC, 2011, IMMUNOLOGY, V133, P340, DOI 10.1111/j.1365-2567.2011.03445.x
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   Hijioka K, 2008, BIOCHEM BIOPH RES CO, V374, P38, DOI 10.1016/j.bbrc.2008.06.080
   Ichiyama K, 2008, J BIOL CHEM, V283, P17003, DOI 10.1074/jbc.M801286200
   Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   Izcue A, 2008, IMMUNITY, V28, P559, DOI 10.1016/j.immuni.2008.02.019
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin Q, 2011, ARTERIOSCL THROM VAS, V31, P1024, DOI 10.1161/ATVBAHA.111.224048
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020
   Michel ML, 2008, P NATL ACAD SCI USA, V105, P19845, DOI 10.1073/pnas.0806472105
   Moran EM, 2011, ARTHRITIS RHEUM-US, V63, P3263, DOI 10.1002/art.30582
   Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6
   Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Pickens SR, 2010, J IMMUNOL, V184, P3233, DOI 10.4049/jimmunol.0903271
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Ryu S, 2006, CLIN RHEUMATOL, V25, P16, DOI 10.1007/s10067-005-1081-1
   Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749
   Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999
   Su ZL, 2011, EUR J IMMUNOL, V41, P3586, DOI 10.1002/eji.201141879
   Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tanaka K, 2008, J IMMUNOL, V180, P3746, DOI 10.4049/jimmunol.180.6.3746
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
NR 42
TC 66
Z9 70
U1 0
U2 8
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2013
VL 190
IS 4
BP 1778
EP 1787
DI 10.4049/jimmunol.1202495
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 088HS
UT WOS:000314825400041
PM 23319736
OA Bronze
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Kitamei, H
   Shioya, S
   Higuchi, M
   Matsushita, T
   Kosaka, S
   Matsushita, R
   Takami, K
   Ohtsuka, H
AF Hikichi, Taiichi
   Kitamei, Hirokuni
   Shioya, Shoko
   Higuchi, Makoto
   Matsushita, Takuro
   Kosaka, Shoko
   Matsushita, Reiko
   Takami, Kimitaka
   Ohtsuka, Hideo
TI Relation between changes in foveal choroidal thickness and 1-year
   results of ranibizumab therapy for polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   MACULAR DEGENERATION; VASCULAR HYPERPERMEABILITY; HEALTHY-SUBJECTS
AB Aim To determine a correlation between changes in the subfoveal choroidal thickness and outcomes 1 year after ranibizumab therapy for polypoidal choroidal vasculopathy (PCV).
   Methods We prospectively studied 89 consecutive eyes with treatment-nave symptomatic PCV and 1 year of follow-up after treatment. The choroidal thickness was measured monthly by optical coherence tomography using enhanced-depth imaging and the correlation between the changes in the choroidal thickness and outcomes 1 year after treatment was analysed.
   Results 86 eyes followed for 1 year were ultimately analysed. The mean logarithm of the minimum angle of resolution visual acuity (0.33 +/- 0.35) 1 year after the first injection significantly (p=0.001) improved compared to baseline (0.42 +/- 0.37). The mean choroidal and foveal retinal thicknesses decreased significantly (p=0.001 for both comparisons) from 271 and 347 mu m to 212 and 203 mu m, respectively. The amplitude of the change in the subfoveal choroidal thickness during the 1-year follow-up in eyes in which the polypoidal lesions resolved 1 year after the first injection (89 +/- 94 mu m) was significantly (p=0.022) greater than in eyes in which the polypoidal lesions remained (45 +/- 109 mu m).
   Conclusions The subfoveal choroidal thickness decreased during ranibizumab therapy, which was associated with resolved polypoidal lesions and foveal retinal thickness, and may be associated with PCV activity.
C1 [Hikichi, Taiichi; Kitamei, Hirokuni; Shioya, Shoko; Higuchi, Makoto; Matsushita, Takuro; Kosaka, Shoko; Matsushita, Reiko; Takami, Kimitaka; Ohtsuka, Hideo] Ohtsuka Eye Hosp, Dept Ophthalmol, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Kita Ku, Kita 16 Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
FU Novartis Pharma Japan; Bayer. Japan; Santen; Alcon Japan
FX TH received lecture fees from Novartis Pharma Japan, Bayer. Japan,
   Santen, and Alcon Japan. HK received lecture fee from Novartis Pharma
   Japan. SS received lecture fees from Novartis Pharma Japan and Bayer.
   Japan.
CR Brown JS, 2009, INVEST OPHTH VIS SCI, V50, P5, DOI 10.1167/iovs.08-1779
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim JH, 2013, EYE LOND, V27, P807
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Michel JB, 1998, PATHOL BIOL, V46, P181
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Shao L, 2013, INVEST OPHTH VIS SCI, V54, P230, DOI 10.1167/iovs.12-10351
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Usui S, 2012, AM J OPHTHALMOL, V153, P10, DOI 10.1016/j.ajo.2011.05.037
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 16
Z9 17
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2014
VL 98
IS 9
BP 1201
EP 1204
DI 10.1136/bjophthalmol-2013-304555
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN3QW
UT WOS:000340504400010
PM 24723615
DA 2022-11-30
ER

PT J
AU Singh, RP
   Sears, JE
AF Singh, Rishi P.
   Sears, Jonathan E.
TI Retinal pigment epithelial tears after pegaptanib injection for
   exudative age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY
AB PURPOSE: To report two cases of retinal pigment epithelium (RPE) tears following intravitreal pegaptanib injections for occult choroidal neovascularization. DESIGN: Noncomparative case series.
   METHODS: The charts of two patients with pigment epithelial tears after receiving intravitreal pegaptanib were reviewed. Approval from the institutional review board and informed consent were obtained before chart review. Fundus photos, intravenous fluorescein angio grams, and optical coherence tomography (OCT) were obtained before and after therapy confirmed the diagnosis.
   RESULTS: Two patients had turbid pigment epithelial detachments (PEDs) and occult choroidal neovascular membranes (CNVMs) treated with intravitreal pegaptanib. Both patients developed RPE tears weeks following one intravitreal pegaptanib injection.
   CONCLUSIONS: This report describes the development of RPE tears after intravitreal pegaptanib injection. Caution should be taken in cases of turbid pigment epithelial detachments in the monocular patient when treatment with intravitreal pegaptanib is entertained. Future studies should be performed to evaluate which subtypes of lesions are most susceptible to this devastating visual complication.d
C1 Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Cole Eye Ctr, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Cole Eye Inst, Retina Serv, Cole Eye Ctr, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation
RP Sears, JE (通讯作者)，Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Cole Eye Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM searsj@ccf.org
CR GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   GHASSEMIFAR R, 2005, CELL TISSUE RES, V15, P1
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   Srivastava SK, 2002, RETINA-J RET VIT DIS, V22, P669, DOI 10.1097/00006982-200210000-00027
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 7
TC 56
Z9 60
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2006
VL 142
IS 1
BP 160
EP 162
DI 10.1016/j.ajo.2006.03.051
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064HF
UT WOS:000239079100026
PM 16815269
DA 2022-11-30
ER

PT J
AU Sethna, S
   Scott, PA
   Giese, APJ
   Duncan, T
   Jian, XY
   Riazuddin, S
   Randazzo, PA
   Redmond, TM
   Bernstein, SL
   Riazuddin, S
   Ahmed, ZM
AF Sethna, Saumil
   Scott, Patrick A.
   Giese, Arnaud P. J.
   Duncan, Todd
   Jian, Xiaoying
   Riazuddin, Sheikh
   Randazzo, Paul A.
   Redmond, T. Michael
   Bernstein, Steven L.
   Riazuddin, Saima
   Ahmed, Zubair M.
TI CIB2 regulates mTORC1 signaling and is essential for autophagy and
   visual function
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; INTRAVITREAL
   SIROLIMUS; GEOGRAPHIC ATROPHY; HIGH-RISK; AGE; RHEB; ACTIVATION;
   MECHANISMS; DISEASE
AB Age-related macular degeneration (AMD) is a multifactorial neurodegenerative disorder. Although molecular mechanisms remain elusive, deficits in autophagy have been associated with AMD. Here we show that deficiency of calcium and integrin binding protein 2 (CIB2) in mice, leads to age-related pathologies, including sub-retinal pigment epithelium (RPE) deposits, marked accumulation of drusen markers APOE, C3, A beta, and esterified cholesterol, and impaired visual function, which can be rescued using exogenous retinoids. Cib2 mutant mice exhibit reduced lysosomal capacity and autophagic clearance, and increased mTORC1 signaling-a negative regulator of autophagy. We observe concordant molecular deficits in dry-AMD RPE/choroid post-mortem human tissues. Mechanistically, CIB2 negatively regulates mTORC1 by preferentially binding to 'nucleotide empty' or inactive GDP-loaded Rheb. Upregulated mTORC1 signaling has been implicated in lymphangioleiomyomatosis (LAM) cancer. Over-expressing CIB2 in LAM patient-derived fibroblasts downregulates hyperactive mTORC1 signaling. Thus, our findings have significant implications for treatment of AMD and other mTORC1 hyperactivity-associated disorders. Age-related macular degeneration (AMD) has been connected to deficits in autophagy. Here, the authors demonstrate, in mice and dry-AMD patient samples, that calcium and integrin binding protein 2 (CIB2) regulates Rheb-mTORC1 signaling axis, and subsequently autophagy.
C1 [Sethna, Saumil; Giese, Arnaud P. J.; Riazuddin, Saima; Ahmed, Zubair M.] Univ Maryland, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA.
   [Scott, Patrick A.] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
   [Duncan, Todd; Redmond, T. Michael] NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Jian, Xiaoying; Randazzo, Paul A.] NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Riazuddin, Sheikh] Univ Hlth Sci, Allama Iqbal Med Coll, Lahore, Pakistan.
   [Bernstein, Steven L.; Ahmed, Zubair M.] Univ Maryland, Sch Med, Dept Ophthalmol & Visual Sci, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University of Louisville; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); National Institutes of Health (NIH) - USA;
   NIH National Cancer Institute (NCI); University of Health Science -
   Pakistan; University System of Maryland; University of Maryland
   Baltimore
RP Ahmed, ZM (通讯作者)，Univ Maryland, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA.; Ahmed, ZM (通讯作者)，Univ Maryland, Sch Med, Dept Ophthalmol & Visual Sci, Baltimore, MD 21201 USA.
EM zmahmed@som.umaryland.edu
OI Randazzo, Paul/0000-0001-5349-0881; Bernstein,
   Steven/0000-0001-7758-0136; Redmond, T. Michael/0000-0002-1813-5291;
   Duncan, Todd/0000-0003-2901-6340
FU NIDCD/NIH [R01DC012564, R01DC016295, R56DC011803]; Loris Rich
   Postdoctoral fellowship, International Retinal Research Foundation, AL,
   USA; Research to Prevent Blindness
FX We thank Drs. M. Johnson, M. Matthews, and Ms. S. Riaz and D. Gomes for
   technical assistance; Drs. S. Miller, and J. Duniaef for mouse strains,
   Dr. E. Henske for cell lines, and the UMSOM core facility for access to
   the Zeiss-710 confocal and Nikon W1 microscopes. We also thank Drs. T.B.
   Friedman, R. Hertzano, C. Mueller, G. Frolenkov, and Ms. M. Ahmed for
   critically reading the manuscript. This work was supported by NIDCD/NIH
   grants R01DC012564, R01DC016295 (Z.M.A.), R56DC011803 (S.R.), and partly
   by the Loris Rich Postdoctoral fellowship, International Retinal
   Research Foundation, AL, USA (S.S.), and Research to Prevent Blindness
   Award (P.A.S. and Z.M.A.).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Barabas P, 2013, P NATL ACAD SCI USA, V110, P5181, DOI 10.1073/pnas.1214707110
   Bird JE, 2017, MOL BIOL CELL, V28, P463, DOI 10.1091/mbc.E16-08-0583
   Boada-Romero E, 2020, NAT REV MOL CELL BIO, V21, P398, DOI 10.1038/s41580-020-0232-1
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Fawal MA, 2015, DEV CELL, V33, P67, DOI 10.1016/j.devcel.2015.02.010
   Garwin GG, 2000, METHOD ENZYMOL, V316, P313
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Giese APJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00061-1
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   He LZ, 2014, AM J PATHOL, V184, P1660, DOI 10.1016/j.ajpath.2014.02.007
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Koenekoop RK, 2014, LANCET, V384, P1513, DOI 10.1016/S0140-6736(14)60153-7
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Leidal AM, 2018, NAT CELL BIOL, V20, P1338, DOI 10.1038/s41556-018-0235-8
   Leisner TM, 2016, FASEB J, V30, P2640, DOI 10.1096/fj.201500073R
   Li S, 2005, GENESIS, V41, P73, DOI 10.1002/gene.20097
   Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004
   Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053
   Maeda T, 2009, HUM MOL GENET, V18, P2277, DOI 10.1093/hmg/ddp163
   Mahoney SJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03035-z
   Martini-Stoica H, 2016, TRENDS NEUROSCI, V39, P221, DOI 10.1016/j.tins.2016.02.002
   Menon S, 2014, CELL, V156, P771, DOI 10.1016/j.cell.2013.11.049
   Michel V, 2017, EMBO MOL MED, V9, P1711, DOI 10.15252/emmm.201708087
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Parmar N, 2010, ENZYMES, V27, P39, DOI 10.1016/S1874-6047(10)27003-8
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Riazuddin S, 2012, NAT GENET, V44, P1265, DOI 10.1038/ng.2426
   RODIECK RW, 1972, VISION RES, V12, P773, DOI 10.1016/0042-6989(72)90003-X
   Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schneider JL, 2014, CURR OPIN GENET DEV, V26, P16, DOI 10.1016/j.gde.2014.04.003
   Scott PA, 2011, EXP EYE RES, V93, P513, DOI 10.1016/j.exer.2011.06.017
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sethna S, 2016, J BIOL CHEM, V291, P6494, DOI 10.1074/jbc.M115.687004
   Sethna Saumil, 2013, Methods Mol Biol, V935, P245, DOI 10.1007/978-1-62703-080-9_17
   Shields CL, 2012, ARCH OPHTHALMOL-CHIC, V130, P387, DOI 10.1001/archopthalmol.2011.1707
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Vallone R, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00274
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   WALD G, 1956, NATURE, V177, P174, DOI 10.1038/177174a0
   Wang YF, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00401
   Wolfson RL, 2017, CELL METAB, V26, P301, DOI 10.1016/j.cmet.2017.07.001
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wyant GA, 2017, CELL, V171, P642, DOI 10.1016/j.cell.2017.09.046
   Xue YL, 2015, J CLIN INVEST, V125, P727, DOI 10.1172/JCI79651
   Yang HJ, 2017, NATURE, V552, P368, DOI 10.1038/nature25023
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yu J, 2004, AM J PHYSIOL-LUNG C, V286, pL694, DOI 10.1152/ajplung.00204.2003
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhu WY, 2017, CANCER RES, V77, P4823, DOI 10.1158/0008-5472.CAN-17-0025
NR 73
TC 7
Z9 7
U1 1
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN 23
PY 2021
VL 12
IS 1
AR 3906
DI 10.1038/s41467-021-24056-1
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TC6RR
UT WOS:000668769000005
PM 34162842
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zheng, G
   Joo, J
   Zhang, C
   Geller, NL
AF Zheng, Gang
   Joo, Jungnam
   Zhang, Chun
   Geller, Nancy L.
TI Testing association for markers on the X chromosome
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; genome-wide association;
   Hardy-Weinberg equilibrium; trend test; X-linked markers
ID HARDY-WEINBERG EQUILIBRIUM; PREMATURE OVARIAN FAILURE; SAMPLE-SIZE;
   LINKAGE DISEQUILIBRIUM; GENETIC-MARKERS; POWER; DEVIATIONS; DISEASE
AB Test statistics for association between markers on autosomal chromosomes and a disease have been extensively studied. No research has been reported on performance of such test statistics for association on the X chromosome. With 100,000 or more single-nucleoticle polymorphisms (SNPs) available for genome-wide association studies, thousands of them come from the X chromosome. The X chromosome contains rich information about population history and linkage disequilibrium. To identify X-linked marker susceptibility to a disease, it is important to study properties of various statistics that can be used to test for association on the X chromosome. In this article, we compare performance of several approaches for testing association on the X chromosome, and examine how departure from Hardy-Weinberg equilibrium would affect type I error and power of these association tests using X-linked SNPs. The results are applied to the X chromosome of Klein et al. [2005], a genome-wide association study with 100K SNPs for age-related macular degeneration. We found that a SNP (rs10521496) covered by DIAPH2, known to cause premature ovarian failure (POF) in females, is associated with age-related macular degeneration.
C1 [Zheng, Gang; Joo, Jungnam; Geller, Nancy L.] NHLBI, Off Biostat Res, Bethesda, MD 20892 USA.
   [Zhang, Chun] Roche Palo Alto LLC, Palo Alto, CA USA.
C3 National Institutes of Health (NIH) - USA; NIH National Heart Lung &
   Blood Institute (NHLBI); Roche Holding
RP Zheng, G (通讯作者)，NHLBI, Off Biostat Res, 6701 Rockledge Dr, Bethesda, MD 20892 USA.
EM zhengg@nhlbi.nih.gov
CR Bione S, 2004, HUM REPROD, V19, P2759, DOI 10.1093/humrep/deh502
   Freidlin B, 2002, HUM HERED, V53, P146, DOI 10.1159/000064976
   Gillespie J. H., 2004, POPULATION GENETICS
   Hoh J, 2003, NAT REV GENET, V4, P701, DOI 10.1038/nrg1155
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laan M, 2005, EUR J HUM GENET, V13, P452, DOI 10.1038/sj.ejhg.5201340
   Leal SM, 2005, GENET EPIDEMIOL, V29, P204, DOI 10.1002/gepi.20086
   Li CC, 1976, 1 COURSE POPULATION
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Salanti G, 2005, EUR J HUM GENET, V13, P840, DOI 10.1038/sj.ejhg.5201410
   Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494
   Schaffner SF, 2004, NAT REV GENET, V5, P43, DOI 10.1038/nrg1247
   Schaid DJ, 2005, AM J HUM GENET, V76, P780, DOI 10.1086/429838
   Simpson JL, 1999, AM J MED GENET, V89, P186, DOI 10.1002/(SICI)1096-8628(19991229)89:4<186::AID-AJMG3>3.0.CO;2-5
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   Slager SL, 2001, HUM HERED, V52, P149, DOI 10.1159/000053370
   Smith JA, 2004, ARCH OPHTHALMOL-CHIC, V122, P151, DOI 10.1001/archopht.122.2.151
   Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046
   Wang T, 2007, AM J HUM GENET, V80, P353, DOI 10.1086/511312
   Weir B.S., 1996, GENETIC DATA ANAL
   Wellek S, 2004, BIOMETRICS, V60, P694, DOI 10.1111/j.0006-341X.2004.00219.x
   Wittke-Thompson JK, 2005, AM J HUM GENET, V76, P967, DOI 10.1086/430507
   ZHENG G, 2007, IN PRESS BMC GENET S
   Zou GY, 2006, ANN HUM GENET, V70, P923, DOI [10.1111/j.1469-1809.2006.0267.x, 10.1111/j.1469-1809.2006.00267.x]
NR 24
TC 66
Z9 67
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD DEC
PY 2007
VL 31
IS 8
BP 834
EP 843
DI 10.1002/gepi.20244
PG 10
WC Genetics & Heredity; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Mathematical & Computational Biology
GA 240GF
UT WOS:000251574600003
PM 17549761
DA 2022-11-30
ER

PT J
AU Bhutto, IA
   Baba, T
   Merges, C
   McLeod, DS
   Lutty, GA
AF Bhutto, Imran A.
   Baba, Takayuki
   Merges, Carol
   McLeod, D. Scott
   Lutty, Gerard A.
TI Low nitric oxide synthases (NOSs) in eyes with age-related macular
   degeneration (AMD)
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; nitric oxide synthases; retinal
   pigment epithelium; retinal endothelial cells; choriocapillaris; neurons
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL BLOOD-FLOW; NERVE-FIBERS; HUMAN
   RETINA; LOCALIZATION; CELLS; NEURONS; INNERVATION; ASTROCYTES;
   EXPRESSION
AB Nitric oxide (NO) production by vascular endothelium is important in regulation of blood flow. Reduced production of NO can adversely affect blood flow and other vascular functions. We investigated the expression of three nitric oxide synthase (NOS) isoforms in retina and choroid of aged human eyes and eyes with AMD. Alkaline phosphatase immunohistochemistry was performed using antibodies against inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NOSs on cryopreserved sections from aged control donor eyes (n = 13) and eyes with AMD (n = 22). CD34 antibody was used as an endothelial cell (EC) market. Three independent masked observers scored the intensity of the immunohistochemical reaction product. Mean scores from the aged control and AMD eyes were statistically compared. In aged control retinas, nNOS was in ganglion cells (RGCs) and neurons of both nuclear layers. in choroid, perivascular nerve fibers and retinal pigment epithelial (RPE) cells were nNOS(+). eNOS and iNOS were confined to the retinal and choroidal vascular ECs. Some cells presumably melanocytes or dendritic cells in choroid were also eNOS(+). In AMD eyes, nNOS was significantly lower in RGCs, neurons, retinal vessels and RPE (p <= 0.05) compared to the aged control eyes. iNOS and eNOS showed no significant differences between aged control and AMD eyes except that there was significantly less eNOS in choroidal arteries (p = 0.006) and choroidal cells (p = 0.03) of AMD eyes. Although NO was not measured directly, these findings suggest that there is less NO produced in AMD eyes. The decrease in retinal nNOS in AMD eyes is probably related to neuronal degeneration. The decrease in nNOS and eNOS in AMD choroid could be associated with vasoconstriction and hemodynamic changes. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Bhutto, Imran A.; Baba, Takayuki; Merges, Carol; McLeod, D. Scott; Lutty, Gerard A.] Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Dept Ophthalmol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 N Broadway, Baltimore, MD 21287 USA.
EM galutty@jhmi.edu
FU NIH [EY-01765, R01-EY016151]; Research to Prevent Blindness; Foundation
   Fighting Blindness; Altsheler Durell Foundation; NATIONAL EYE INSTITUTE
   [R01EY016151, P30EY001765] Funding Source: NIH RePORTER
FX This work was supported by NIH grants: EY-01765 (Wilmer) and
   R01-EY016151 (GL), Research to Prevent Blindness (Wilmer), the
   Foundation Fighting Blindness (GL), and Altsheler Durell Foundation.
   Gerard Lutty received an RPB senior scientific investigator award. The
   authors are grateful to the eye donors and their relatives for their
   generosity and also to Janet Sunness, MD, and Carol Applegate at the
   Great Baltimore Medical Center (Baltimore, MD for helping us acquire
   eyes from subjects with AMD.
CR Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergua A, 1996, ANAT EMBRYOL, V193, P239
   Bernatchez PN, 2005, P NATL ACAD SCI USA, V102, P761, DOI 10.1073/pnas.0407224102
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Boulanger CM, 1998, CIRC RES, V83, P1271, DOI 10.1161/01.RES.83.12.1271
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CIOFFI GA, 2002, OCULAR CIRCULATION
   Duda DG, 2004, TRENDS MOL MED, V10, P143, DOI 10.1016/j.molmed.2004.02.001
   FLUGEL C, 1994, INVEST OPHTH VIS SCI, V35, P592
   FLUGELKOCH C, 1994, INVEST OPHTH VIS SCI, V35, P4268
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Geyer O, 1997, GRAEF ARCH CLIN EXP, V235, P786, DOI 10.1007/BF02332864
   Gilchrist M, 2004, BLOOD, V104, P462, DOI 10.1182/blood-2003-08-2990
   Giordano A, 2002, FEBS LETT, V514, P135, DOI 10.1016/S0014-5793(02)02245-7
   Green W R, 1999, Mol Vis, V5, P27
   GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Ichihara A, 1998, AM J PHYSIOL-RENAL, V274, pF516, DOI 10.1152/ajprenal.1998.274.3.F516
   Jablonski MM, 2007, INVEST OPHTH VIS SCI, V48, P479, DOI 10.1167/iovs.06-0972
   Ju WK, 2001, NEUROREPORT, V12, P2405, DOI 10.1097/00001756-200108080-00024
   Kashiwagi S, 2002, CIRC RES, V91, pE55, DOI 10.1161/01.RES.0000047529.26278.4D
   Kiel JW, 1999, EXP EYE RES, V69, P413, DOI 10.1006/exer.1999.0717
   Kim IB, 2000, MICROSC RES TECHNIQ, V50, P112, DOI 10.1002/1097-0029(20000715)50:2<112::AID-JEMT3>3.0.CO;2-S
   Kim Ramasamy, 2007, Indian Journal of Ophthalmology, V55, P413
   Kugler P, 1996, GLIA, V16, P165, DOI 10.1002/(SICI)1098-1136(199602)16:2<165::AID-GLIA8>3.3.CO;2-X
   Lajoix AD, 2001, DIABETES, V50, P1311, DOI 10.2337/diabetes.50.6.1311
   LUNA LG, 1960, MANUAL HISTOLOGIC ST
   Lutjen-Drecoll E, 2006, EXP EYE RES, V82, P357, DOI 10.1016/j.exer.2005.09.015
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   MANN RM, 1995, INVEST OPHTH VIS SCI, V36, P925
   McLaren AT, 2007, AM J PHYSIOL-REG I, V292, pR403, DOI 10.1152/ajpregu.00403.2006
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MCLEOD DS, 2009, INVEST OPHTHALM 0408
   Meyer P, 1999, CURR EYE RES, V18, P375, DOI 10.1076/ceyr.18.5.375.5355
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P70, DOI 10.1038/jcbfm.1993.9
   Oyster CW., 1999, HUMAN EYE STRUCTURE
   PAGE C, 1992, AM J PATHOL, V141, P673
   PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200
   RUSKELL GL, 1971, EXP EYE RES, V12, P166, DOI 10.1016/0014-4835(71)90085-6
   Saini R, 2006, J LEUKOCYTE BIOL, V79, P519, DOI 10.1189/jlb.0605320
   SANDERS KM, 1992, AM J PHYSIOL, V262, pG379, DOI 10.1152/ajpgi.1992.262.3.G379
   Snyder S H, 1992, Curr Opin Neurobiol, V2, P323, DOI 10.1016/0959-4388(92)90123-3
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Toda N, 2003, PHARMACOL REV, V55, P271, DOI 10.1124/pr.55.2.3
   Tolias CM, 1999, FREE RADICAL BIO MED, V26, P99, DOI 10.1016/S0891-5849(98)00146-4
   Trivino A, 2002, ANAT EMBRYOL, V205, P417, DOI 10.1007/s00429-002-0257-6
   Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657
   YAMAMOTO R, 1993, NEUROSCIENCE, V54, P189, DOI 10.1016/0306-4522(93)90393-T
   Yuan ZR, 2004, LIFE SCI, V74, P3199, DOI 10.1016/j.lfs.2003.10.037
NR 56
TC 53
Z9 54
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2010
VL 90
IS 1
BP 155
EP 167
DI 10.1016/j.exer.2009.10.004
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 542SW
UT WOS:000273516500021
PM 19836390
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yong, M
   Zhou, MW
   Deng, GH
AF Yong, Meng
   Zhou, Minwen
   Deng, Guohua
TI Photodynamic therapy versus anti-vascular endothelial growth factor
   agents for polypoidal choroidal vasculopathy: A meta-analysis
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; photodynamic therapy; anti- vascular
   endothelial growth factor
ID INTRAVITREAL RANIBIZUMAB; FOLLOW-UP; CLINICAL CHARACTERISTICS;
   VERTEPORFIN; BEVACIZUMAB; HYPERPERMEABILITY; COMBINATION; MONOTHERAPY;
   EFFICACY; SAFETY
AB Background: The aim of this study was to evaluate the efficacy and tolerability of photodynamic therapy (PDT) compared to intravitreal vascular endothelial growth factor (VEGF) inhibitors in the treatment of polypoidal choroidal vasculopathy (PCV).
   Methods: Relevant studies were selected through an extensive search of the PubMed, EMBASE, Web of Science, and Cochrane Library databases. Outcomes of interest included visual outcomes, anatomic variables, and adverse events.
   Results: Six studies enrolling a total of 346 patients were included. The weighted mean differences (WMDs) of the mean changes in LogMAR VA when comparing PDT with anti-VEGF were -0.02 (95 % confidence interval [CI]: -0.12-0.08) at 3 months, 0.02 (95 % CI: -0.12-0.16) at 6 months, 0.02 (95 % CI: -0.15-0.18) at 12 months, and -0.17 (95 % CI: -0.90-0.55) at 24 months. There were no significant differences between the two groups at any of the time points. PDT was found to be associated with greater reduction of central retinal thickness (CRT) at six months (WMD: 44.94; 95 % CI: 16.44-73.44; P = 0.002), and it was superior to anti-VEGF therapy in achieving complete polyp regression (odd ratio, OR: 6.85; 95 % CI: 2.15-21.79; P = 0.001). Rates of adverse events did not differ significantly between the two treatments.
   Conclusions: PDT appeared to result in greater CRT reduction at six months and higher polyp regression rate. However, the two treatments appear to be comparable in terms of best corrected visual acuity change and adverse events.
C1 [Yong, Meng; Deng, Guohua] Third Peoples Hosp Changzhou, Div Opthalmol, Changzhou, Peoples R China.
   [Zhou, Minwen] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Ophthalmol, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University
RP Yong, M (通讯作者)，Third Peoples Hosp Changzhou, Div Opthalmol, Changzhou, Peoples R China.
FU Changzhou Health Bureau Science and Technology Medical Program
   [WZ201315]
FX This study was supported by Changzhou Health Bureau Science and
   Technology Medical Program (WZ201315).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 17
Z9 18
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 25
PY 2015
VL 15
AR 82
DI 10.1186/s12886-015-0064-5
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN4LZ
UT WOS:000358402900001
PM 26209516
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kohno, M
   Musashi, K
   Ikeda, HO
   Horibe, T
   Matsumoto, A
   Kawakami, K
AF Kohno, Masayuki
   Musashi, Kunihiro
   Ikeda, Hanako Ohashi
   Horibe, Tomohisa
   Matsumoto, Aki
   Kawakami, Koji
TI Oral administration of ferulic acid or ethyl ferulate attenuates retinal
   damage in sodium iodate-induced retinal degeneration mice
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HIGH-FAT DIET; MACULAR DEGENERATION; OXIDATIVE STRESS;
   PIGMENT-EPITHELIUM; GAMMA-ORYZANOL; ANTIOXIDANT; PROTECTION;
   NEUROPROTECTION; BIOAVAILABILITY; ASSOCIATIONS
AB Epidemiological studies indicate that the daily intake of antioxidants from a traditional Asian diet reduces the risk of developing age-related macular degeneration. Many of the phytochemicals that are abundant in whole grains exhibit a wide variety of biological activity such as antioxidant, anti-inflammatory, and neuroprotective effects. Ferulic acid (FA) is a phenolic acid found in vegetables and grains that has therapeutic potential for diabetes mellitus, Alzheimer's disease, and other diseases. We investigated the retinal protective effect of FA in a sodium iodate (NaIO3)-induced model of retinal degeneration. In a human retinal pigment epithelial cell line, FA attenuated H(2)O(2-)induced injury and lipopolysaccharide- or 7-ketocholesterol-induced inflammation. In mice, the oral administration of FA or its analog, ethyl ferulate, attenuated the morphological and functional features of NaIO3-induced retinal degeneration according to optical coherence tomography and electroretinography. Our results demonstrate that the oral administration of FA provides protective effects to the retina, suggesting that the intake of FA as a daily supplement or daily healthy diet containing rich vegetables and whole grains may prevent age-related macular degeneration.
C1 [Kohno, Masayuki; Horibe, Tomohisa; Matsumoto, Aki; Kawakami, Koji] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan.
   [Musashi, Kunihiro] Med Platform Co Ltd, Osaka, Japan.
   [Ikeda, Hanako Ohashi] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kyoto University; Kyoto University
RP Kawakami, K (通讯作者)，Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan.
EM kawakami.koji.4e@kyoto-u.ac.jp
RI Kawakami, Koji/GZA-6582-2022
FU Medical Platform Co., Ltd. [15K08587]; Japan Society for the Promotion
   of Science
FX We thank Ms. Mitsuko Tachi and Keiko Shimoura (Department of
   Pharmacoepidemiology, Graduate School of Medicine, Kyoto University) for
   providing technical assistance, and Dr. Tomoko Hasegawa, Ms. Sachiko
   Iwai, and Masami Suetsugu (Department of Ophthalmology and Visual
   Sciences, Graduate School of Medicine, Kyoto University) for support
   with ERG analysis, SD-OCT analysis, and animal maintenance,
   respectively. This study was supported by a grant from Medical Platform
   Co., Ltd. and a Grant-in-Aid for Scientific Research (C) (grant no.
   15K08587) from the Japan Society for the Promotion of Science.
CR Abe S, 2020, CLIN NUTR, V39, P298, DOI 10.1016/j.clnu.2019.02.010
   Ardiansyah, 2008, J AGR FOOD CHEM, V56, P2825, DOI 10.1021/jf072896y
   Bourne LC, 1998, BIOCHEM BIOPH RES CO, V253, P222, DOI 10.1006/bbrc.1998.9681
   Cheng CY, 2008, BRAIN RES, V1209, P136, DOI 10.1016/j.brainres.2008.02.090
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chowdhury S, 2016, FOOD CHEM TOXICOL, V97, P187, DOI 10.1016/j.fct.2016.09.011
   Costa C, 2017, FOOD CHEM TOXICOL, V110, P286, DOI 10.1016/j.fct.2017.10.023
   Cui LL, 2013, J ALZHEIMERS DIS, V37, P19, DOI 10.3233/JAD-130164
   Dysli C, 2016, EXP EYE RES, V153, P178, DOI 10.1016/j.exer.2016.10.018
   Ghosh S, 2017, FOOD CHEM TOXICOL, V103, P41, DOI 10.1016/j.fct.2017.02.028
   Hariri S, 2012, INVEST OPHTH VIS SCI, V53, P1982, DOI 10.1167/iovs.11-8395
   Hasegawa T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31184
   Hashizume K, 2013, FOOD SCI TECHNOL RES, V19, P705, DOI 10.3136/fstr.19.705
   Huber G, 2009, INVEST OPHTH VIS SCI, V50, P5888, DOI 10.1167/iovs.09-3724
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jang KH, 2019, EXP EYE RES, V180, P8, DOI 10.1016/j.exer.2018.11.026
   Joshi G, 2006, NEUROCHEM INT, V48, P318, DOI 10.1016/j.neuint.2005.11.006
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kanski J, 2002, J NUTR BIOCHEM, V13, P273, DOI 10.1016/S0955-2863(01)00215-7
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Kikuzaki H, 2002, J AGR FOOD CHEM, V50, P2161, DOI 10.1021/jf011348w
   Koh PO, 2012, NEUROSCI LETT, V507, P156, DOI 10.1016/j.neulet.2011.12.012
   Kozuka C, 2012, DIABETES, V61, P3084, DOI 10.2337/db11-1767
   Lee CC, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/678487
   Lin FL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41086
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Liu YX, 2017, J AGR FOOD CHEM, V65, P3179, DOI 10.1021/acs.jafc.7b00844
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Mancuso C, 2014, FOOD CHEM TOXICOL, V65, P185, DOI 10.1016/j.fct.2013.12.024
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mori T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055774
   Narasimhan A, 2015, APPL PHYSIOL NUTR ME, V40, P769, DOI 10.1139/apnm-2015-0002
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P994
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ono K, 2005, BIOCHEM BIOPH RES CO, V336, P444, DOI 10.1016/j.bbrc.2005.08.148
   Perez-Ternero C, 2017, FOOD FUNCT, V8, P2165, DOI [10.1039/c7fo00243b, 10.1039/C7FO00243B]
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sompong W, 2017, J PHYSIOL BIOCHEM, V73, P121, DOI 10.1007/s13105-016-0531-3
   TAMAGAWA M, 1992, FOOD CHEM TOXICOL, V30, P41, DOI 10.1016/0278-6915(92)90135-8
   Taofiq O, 2017, MOLECULES, V22, DOI 10.3390/molecules22020281
   Tsuruma K, 2012, J PHARMACOL SCI, V118, P351, DOI 10.1254/jphs.11110FP
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Xue HQ, 2018, INT J BIOL SCI, V14, P1232, DOI 10.7150/ijbs.24612
   Yan JJ, 2013, BIOL PHARM BULL, V36, P140, DOI 10.1248/bpb.b12-00798
   Yang YP, 2016, SCI REP-UK, V6, DOI 10.1038/srep29546
   Yin ZN, 2019, BIOMED ENVIRON SCI, V32, P11, DOI 10.3967/bes2019.002
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Zhao ZH, 2008, FOOD CHEM, V109, P691, DOI 10.1016/j.foodchem.2008.02.039
   Zheng RL, 1997, FREE RADICAL BIO MED, V22, P581, DOI 10.1016/S0891-5849(96)00272-9
   Zhu YD, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600852
NR 56
TC 12
Z9 12
U1 1
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 26
PY 2020
VL 10
IS 1
AR 8688
DI 10.1038/s41598-020-65673-y
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LY4AV
UT WOS:000540472300008
PM 32457394
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Alqudah, AM
AF Alqudah, Ali Mohammad
TI AOCT-NET: a convolutional network automated classification of multiclass
   retinal diseases using spectral-domain optical coherence tomography
   images
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Retina; Optical coherence tomography; Spectral domain; Classification;
   Deep learning
ID DIABETIC MACULAR EDEMA; ARTIFICIAL-INTELLIGENCE; DEGENERATION;
   DIAGNOSIS; OCT
AB Since introducing optical coherence tomography (OCT) technology for 2D eye imaging, it has become one of the most important and widely used imaging modalities for the noninvasive assessment of retinal eye diseases. Age-related macular degeneration (AMD) and diabetic macular edema eye disease are the leading causes of blindness being diagnosed using OCT. Recently, by developing machine learning and deep learning techniques, the classification of eye retina diseases using OCT images has become quite a challenge. In this paper, a novel automated convolutional neural network (CNN) architecture for a multiclass classification system based on spectral-domain optical coherence tomography (SD-OCT) has been proposed. The system used to classify five types of retinal diseases (age-related macular degeneration (AMD), choroidal neovascularization (CNV), diabetic macular edema (DME), and drusen) in addition to normal cases. The proposed CNN architecture with a softmax classifier overall correctly identified 100% of cases with AMD, 98.86% of cases with CNV, 99.17% cases with DME, 98.97% cases with drusen, and 99.15% cases of normal with an overall accuracy of 95.30%. This architecture is a potentially impactful tool for the diagnosis of retinal diseases using SD-OCT images.
C1 [Alqudah, Ali Mohammad] Yarmouk Univ, Dept Biomed Syst & Informat Engn, Irbid, Jordan.
C3 Yarmouk University
RP Alqudah, AM (通讯作者)，Yarmouk Univ, Dept Biomed Syst & Informat Engn, Irbid, Jordan.
EM ali_qudah@hotmail.com
RI Alqudah, Ali Mohamamd/A-1390-2017
OI Alqudah, Ali Mohamamd/0000-0002-5417-0043
CR Alqudah AM, 2018, J BIOMIM BIOMATER BI, V39, P40, DOI 10.4028/www.scientific.net/JBBBE.39.40
   Alsaih K, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0352-9
   Amil P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38136-8
   Awais M, 2017, IEEE I C SIGNAL IMAG, P489, DOI 10.1109/ICSIPA.2017.8120661
   Bakator Mihalj, 2018, Multimodal Technologies and Interaction, V2, DOI 10.3390/mti2030047
   Esteva A, 2019, NAT MED, V25, P24, DOI 10.1038/s41591-018-0316-z
   Fang LY, 2019, J VIS COMMUN IMAGE R, V59, P327, DOI 10.1016/j.jvcir.2019.01.022
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Gao F, 2017, COMPUT INTEL NEUROSC, V2017, DOI 10.1155/2017/3105053
   Gnanadurai D, 2005, INT J WAVELETS MULTI, V3, P141, DOI 10.1142/S0219691305000701
   Gu JX, 2018, PATTERN RECOGN, V77, P354, DOI 10.1016/j.patcog.2017.10.013
   Hinton GE, 2006, NEURAL COMPUT, V18, P1527, DOI 10.1162/neco.2006.18.7.1527
   Hussain MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198281
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Ji QG, 2018, ALGORITHMS, V11, DOI 10.3390/a11060088
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kingma J., 2014, ARXIV
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lemaitre G, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3298606
   Mehta P, 2018, MULTILABEL MULTICLAS
   Nugroho KA, 2018, 2018 2ND INTERNATIONAL CONFERENCE ON INFORMATICS AND COMPUTATIONAL SCIENCES (ICICOS), P141
   Perdomo O, 2018, I S BIOMED IMAGING, P1423, DOI 10.1109/ISBI.2018.8363839
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Reis ASC, 2012, INVEST OPHTH VIS SCI, V53, P1852, DOI 10.1167/iovs.11-9309
   Rong YB, 2019, IEEE J BIOMED HEALTH, V23, P253, DOI 10.1109/JBHI.2018.2795545
   Sajda P, 2006, ANNU REV BIOMED ENG, V8, P537, DOI 10.1146/annurev.bioeng.8.061505.095802
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2018, BR J OPHTHALMOL
NR 34
TC 44
Z9 44
U1 10
U2 26
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0140-0118
EI 1741-0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD JAN
PY 2020
VL 58
IS 1
BP 41
EP 53
DI 10.1007/s11517-019-02066-y
EA NOV 2019
PG 13
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Mathematical & Computational Biology;
   Medical Informatics
GA KH7NC
UT WOS:000499104700001
PM 31728935
DA 2022-11-30
ER

PT J
AU Coffey, PJ
   Gias, C
   McDermott, CJ
   Lundh, P
   Pickering, MC
   Sethi, C
   Bird, A
   Fitzke, FW
   Maass, A
   Chen, LL
   Holder, GE
   Luthert, PJ
   Salt, TE
   Moss, SE
   Greenwood, J
AF Coffey, Peter J.
   Gias, Carlos
   McDermott, Caroline J.
   Lundh, Peter
   Pickering, Matthew C.
   Sethi, Charanjit
   Bird, Alan
   Fitzke, Fred W.
   Maass, Annelie
   Chen, Li Li
   Holder, Graham E.
   Luthert, Philip J.
   Salt, Thomas E.
   Moss, Stephen E.
   Greenwood, John
TI Complement factor H deficiency in aged mice causes retinal abnormalities
   and visual dysfunction
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; innate immunity; retina
ID MACULAR DEGENERATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; FUNDUS
   AUTOFLUORESCENCE; DEPOSIT DISEASE; 2 PARTS; DRUSEN; VARIANT; RISK;
   MACULOPATHY; ACTIVATION
AB Age-related macular degeneration is the most common form of legal blindness in westernized societies, and polymorphisms in the gene encoding complement factor H (CFH) are associated with susceptibility to age-related macular degeneration in more than half of affected individuals. To investigate the relationship between complement factor H (CFH) and retinal disease, we performed functional and anatomical analysis in 2-year-old CFH-deficient (cfh(-/-)) mice. cfh(-1-) animals exhibited significantly reduced visual acuity and rod response amplitudes on electroretinography compared with age-matched controls. Retinal imaging by confocal scanning laser ophthalmoscopy revealed an increase in autofluorescent subretinal deposits in the cfh-1- mice, whereas the funclus and vasculature appeared normal. Examination of tissue sections showed an accumulation of complement C3 in the neural retina of the cfh-1- mice, together with a decrease in electron-dense material, thinning of Bruch's membrane, changes in the cellular distribution of retinal pigment epithelial cell organelles, and disorganization of rod photoreceptor outer segments. Collectively, these data show that, in the absence of any specific exogenous challenge to the innate immune system, CFH is critically required for the long-term functional health of the retina.
C1 UCL, Inst Ophthalmol, Div Cellular Therapy, London EC1V 9EL, England.
   UCL, Inst Ophthalmol, Div Pathol, London EC1V 9EL, England.
   UCL, Inst Ophthalmol, Div Visual Sci, London EC1V 9EL, England.
   UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England.
   Univ London Imperial Coll Sci Technol & Med, Mol Genet & Rheumatol Sect, London W12 0NN, England.
   Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; University of London; University College London; Imperial
   College London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust
RP Greenwood, J (通讯作者)，UCL, Inst Ophthalmol, Div Cellular Therapy, London EC1V 9EL, England.
EM j.greenwood@ucl.ac.uk
RI Fitzke, Fred/C-3535-2008; Salt, Thomas E/A-6405-2009; Mohammed,
   Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768; Luthert,
   Philip/0000-0001-7276-6898; Coffey, Peter/0000-0002-5427-2939;
   Greenwood, John/0000-0003-4496-2984; Pickering,
   Matthew/0000-0002-1153-0192
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278
   Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Prusky GT, 2003, EUR J NEUROSCI, V17, P167, DOI 10.1046/j.1460-9568.2003.02420.x
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Sethi CS, 2005, INVEST OPHTH VIS SCI, V46, P329, DOI 10.1167/iovs.03-0518
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 37
TC 157
Z9 166
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 16
PY 2007
VL 104
IS 42
BP 16651
EP 16656
DI 10.1073/pnas.0705079104
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 223MA
UT WOS:000250373400048
PM 17921253
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kang, HG
   Kang, H
   Byeon, SH
   Kim, SS
   Koh, HJ
   Lee, SC
   Kim, M
AF Kang, Hyun Goo
   Kang, Hyunseung
   Byeon, Suk Ho
   Kim, Sung Soo
   Koh, Hyoung Jun
   Lee, Sung Chul
   Kim, Min
TI Long-term visual outcomes for treatment of submacular haemorrhage
   secondary to polypoidal choroidal vasculopathy
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; choroid; macular degeneration; neovascularization; retina
ID TISSUE-PLASMINOGEN ACTIVATOR; EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL
   GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; PNEUMATIC
   DISPLACEMENT; VITRECTOMY; EVEREST
AB Importance There is no consensus on the optimal management of submacular haemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV). Background Design To compare the long-term outcome of three treatment strategies for PCV with SMH. Retrospective case series at two tertiary hospitals. Samples Methods A total of 48 consecutive eyes treated between July 2006 and March 2016. Patients were grouped according to the treatment received: 22 eyes with intravitreal bevacizumab (IVB), 14 with a combination of IVB and pneumatic displacement (PD) and 12 with IVB and vitrectomy (TPPV). Main Outcome Measures Results Change in best-corrected visual acuity (BCVA) at onset and up to 24 months. Secondary measures included demographic data, imaging data and complications. Comparing the mean BCVAs of the groups revealed significant differences only at month 1 (P = 0.005). Changes in the mean BCVA over time revealed no significance in the resulting final BCVA (P = 0.062), which was 20 out of 155 (logMAR 0.89 +/- 0.64) for IVB monotherapy, 20 out of 174 (0.94 +/- 1.04) for combined IVB + PD, and 20 out of 195 (0.99 +/- 0.90) for combined IVB + TPPV eyes. Sustained long-term improvement of over three Snellen lines was found in seven (31.82%) IVB monotherapy, 10 (71.43%) combined IVB + PD, and seven (58.33%) combined IVB + TPPV eyes (P = 0.043). SMH recurrence was observed in two eyes after IVB monotherapy and one eye after combined IVB + PD (P = 0.786). Conclusions and Relevance IVB monotherapy appears to be as effective as combination therapies for treating SMH secondary to PCV with regards to BCVA at 24 months, and may be a cost-effective strategy for long-term management.
C1 [Kang, Hyun Goo; Kang, Hyunseung; Kim, Min] Yonsei Univ, Dept Ophthalmol, Inst Vis Res, Gangnam Severance Hosp,Coll Med, 211 Eonjuro, Seoul 06273, South Korea.
   [Byeon, Suk Ho; Kim, Sung Soo; Koh, Hyoung Jun; Lee, Sung Chul] Yonsei Univ, Dept Ophthalmol, Inst Vis Res, Severance Hosp,Coll Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Kim, M (通讯作者)，Yonsei Univ, Dept Ophthalmol, Inst Vis Res, Gangnam Severance Hosp,Coll Med, 211 Eonjuro, Seoul 06273, South Korea.
EM minkim76@gmail.com
RI ; Kang, Hyun Goo/C-5569-2018
OI Byeon, suk ho/0000-0001-8101-0830; Kim, Sung Soo/0000-0002-0574-7993;
   Koh, Hyoung Jun/0000-0002-5932-8516; Kang, Hyun Goo/0000-0001-8359-9618;
   Kim, Min/0000-0003-1873-6959; , Sung Chul/0000-0001-9438-2385
FU Yonsei University College of Medicine [6-2017-0149]
FX This study was supported by a faculty research grant of Yonsei
   University College of Medicine (6-2017-0149).
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Hirashima T, 2015, RETINA-J RET VIT DIS, V35, P1969, DOI 10.1097/IAE.0000000000000574
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kitahashi M, 2014, CLIN OPHTHALMOL, V8, P485, DOI 10.2147/OPTH.S55413
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   Lee Jung Pil, 2016, Korean J Ophthalmol, V30, P192, DOI 10.3341/kjo.2016.30.3.192
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Liu EM, 2017, J VITREORETIN DIS, V1, P34
   Malik Farhan F, 2014, Int Ophthalmol Clin, V54, P51, DOI 10.1097/IIO.0000000000000018
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 5
Z9 6
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2018
VL 46
IS 8
BP 916
EP 925
DI 10.1111/ceo.13198
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HA2JT
UT WOS:000450064600011
PM 29652440
DA 2022-11-30
ER

PT J
AU Choe, S
   Kang, HG
   Park, KH
   Lee, CS
   Woo, SJ
AF Choe, Sooyeon
   Kang, Hyun Goo
   Park, Kyu Hyung
   Lee, Christopher Seungkyu
   Woo, Se Joon
TI Long-term outcomes of focal laser photocoagulation for the treatment of
   polypoidal choroidal vasculopathy
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE long-term efficacy; polypoidal choroidal vasculopathy; focal laser
   photocoagulation
ID PHOTODYNAMIC THERAPY; ARGON-LASER; DIAGNOSIS
AB AIM: To evaluate the long-term effect and safety of focal laser photocoagulation treatment in eyes with polypoidal choroidal vasculopathy (PCV)..
   METHODS: Medical records of 13 eyes of 13 patients with PCV were followed-up for more than 2y after focal laser photocoagulation treatment. The patients were diagnosed with PCV using indocyanine green angiography, and eyes with other comorbid ocular diseases were excluded. The measurement outcomes of the study were the post-treatment regression and recurrence of polyps, complications, and changes in visual acuities. Paired t-test was performed to compare visual outcome before and after the treatment.
   RESULTS: The mean age of the 13 patients was 70.2 +/- 5.5y, and the follow-up period was 72.3 +/- 31.0 (range, 25-118)mo. Three eyes had juxtafoveal polyps and 10 eyes had extrafoveal polyps. Of the 13 eyes, 9 eyes (69.2%) had regression of polyps 1.7 +/- 1.2 (range, 0.9-4)mo after focal laser photocoagulation. Five eyes (55.6%) showed recurrence of polyps during the follow-up periods, and the recurrence period was 12.8 +/- 18.9 (range, 1.9-48)mo. Mild subretinal hemorrhage occurred in two eyes (15.4%) 27 and 72d after laser treatment, respectively. There were no statistically significant differences in visual acuities at baseline; 1, 2, 3y post-treatment (all P>0.05); and last follow-up (0.63 +/- 0.5, 0.73 +/- 0.70, 0.67 +/- 0.57, 0.75 +/- 0.7, and 0.95 +/- 0.8 logMAR, respectively).
   CONCLUSION: Focal laser photocoagulation is beneficial for early regression of polyps in eyes with PCV and does not result in significant submacular hemorrhage during the long-term follow-up. Furthermore, it can be primarily considered in eyes with PCV with extrafoveal or juxtafoveal polyps to regress risky polyps as well as to maintain visual acuity without serious hemorrhagic complications.
C1 [Choe, Sooyeon] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Ophthalmol, Coll Med, Seoul 03080, South Korea.
   [Kang, Hyun Goo; Lee, Christopher Seungkyu] Yonsei Univ, Gangnam Severance Hosp, Inst Vis Res, Dept Ophthalmol,Coll Med, Seoul 06273, South Korea.
   [Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Seongnam 13620, South Korea.
   [Lee, Christopher Seungkyu] Yonsei Univ, Severance Hosp, Inst Vis Res, Dept Ophthalmol,Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Yonsei University; Yonsei University Health System; Seoul National
   University (SNU); Yonsei University; Yonsei University Health System
RP Lee, CS (通讯作者)，Yonsei Univ, Severance Hosp, Inst Vis Res, Dept Ophthalmol,Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.; Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 173-82 Gumi Ro, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM sklee219@yuhs.ac; sejoon1@snu.ac.kr
RI ; Kang, Hyun Goo/C-5569-2018
OI Lee, Christopher/0000-0001-5054-9470; Kang, Hyun Goo/0000-0001-8359-9618
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2020R1F1A1072795]
FX Supported by the National Research Foundation of Korea (NRF) grant
   funded by the Korea government (MSIT; No.2020R1F1A1072795).
CR Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Eris E, 2018, LASER MED SCI, V33, P1833, DOI 10.1007/s10103-018-2463-3
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kim Joon-Bom, 2017, Curr Ophthalmol Rep, V5, P176, DOI 10.1007/s40135-017-0137-0
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Mones Jordi, 2016, Retin Cases Brief Rep, V10, P100, DOI 10.1097/ICB.0000000000000174
   Sheth Jay, 2018, Am J Ophthalmol Case Rep, V9, P112, DOI 10.1016/j.ajoc.2018.01.031
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 17
TC 1
Z9 1
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2021
VL 14
IS 9
BP 1402
EP 1407
DI 10.18240/ijo.2021.09.16
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UK5WN
UT WOS:000692040000015
PM 34540617
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Hamoudi, H
   Sorensen, TL
AF Hamoudi, Hassan
   Sorensen, Torben Lykke
TI Effect of Intravitreal Ranibizumab in the Treatment of Peripapillary
   Choroidal Neovascularisation
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEVACIZUMAB; MEMBRANES
AB Intravitreal ranibizumab therapy is widely used in treatment of subfoveal choroidal neovascularisation (CNV) in age-related macular degeneration. We wanted to study the effect of intravitreal ranibizumab therapy in peripapillary CNV. A prospective recording of treatment outcomes in twelve eyes (12 patients) with peripapillary CNV with intravitreal injections of ranibizumab was performed. The patients received a series of 3 injections 4-6 weeks apart, and then a new ophthalmic examination was made including OCT and further therapy was given if the peripapillary CNV was still active. Nine patients had idiopathic peripapillary CNV, and in 3 patients it was associated to age-related macular degeneration. Followup had to be at least 6 months. The mean follow-up time was 15.9 (range 9-27) months and the mean number of injections 6.2 (3-10). In 10 patients treatment had resulted in an inactivation of the peripapillary CNV, but 3 of them had reactivation, while 2 patients had no inactivation. Currently, 5 patients are continuous to receive treatment. VA improved in 10 patients. Intravitreal ranibizumab therapy appears to be effective in patients with peripapillary CNV, but in some cases there is repeated reactivation or continuous activity of the peripapillary CNV.
C1 [Sorensen, Torben Lykke] Copenhagen Univ Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
   Univ Copenhagen, DK-4000 Roskilde, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Sorensen, TL (通讯作者)，Copenhagen Univ Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
EM torbenls@dadlnet.dk
RI Sørensen, Torben Lykke L/N-1417-2014
OI Sørensen, Torben Lykke L/0000-0002-6790-0199
CR Browning DJ, 2005, OPHTHALMOLOGY, V112, P1054, DOI 10.1016/j.ophtha.2004.11.062
   Figueroa MS, 2008, BRIT J OPHTHALMOL, V92, P1244, DOI 10.1136/bjo.2008.144196
   Hoeh AE, 2009, EUR J OPHTHALMOL, V19, P163, DOI 10.1177/112067210901900128
   Jutley G, 2011, EYE, V25, P675, DOI 10.1038/eye.2011.24
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   Nochez Y, 2009, J FR OPHTALMOL, V32, P25, DOI 10.1016/j.jfo.2008.10.002
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah SP, 2010, ACTA OPHTHALMOL, V88, pe243, DOI 10.1111/j.1755-3768.2009.01590.x
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spandau UHM, 2007, ACTA OPHTHALMOL SCAN, V85, P340, DOI 10.1111/j.1600-0420.2006.00832.x
   Waisbourd M, 2011, ACTA OPHTHALMOL, V89, P203, DOI 10.1111/j.1755-3768.2010.02010.x
   Wong TY, 2010, NEW ENGL J MED, V363, P2135, DOI 10.1056/NEJMcp1003934
NR 13
TC 5
Z9 5
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2011
VL 2011
AR 602729
DI 10.1155/2011/602729
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979BO
UT WOS:000306790100024
PM 22235362
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Puntel, A
   Maeda, A
   Golczak, M
   Gao, SQ
   Yu, GP
   Palczewski, K
   Lu, ZR
AF Puntel, Anthony
   Maeda, Akiko
   Golczak, Marcin
   Gao, Song-Qi
   Yu, Guanping
   Palczewski, Krzysztof
   Lu, Zheng-Rong
TI Prolonged prevention of retinal degeneration with retinylamine loaded
   nanoparticles
SO BIOMATERIALS
LA English
DT Article
DE Retina degeneration; Prevention; Retinylamine; Drug delivery;
   Nanoparticles
ID VISUAL CYCLE; DRUG-DELIVERY; POLYMER NANOPARTICLES; MICE; RETINOPATHY;
   INHIBITORS; TRANSPORT; POTENT; MODEL; EYE
AB Retinal degeneration impairs the vision of millions in all age groups worldwide. Increasing evidence suggests that the etiology of many retinal degenerative diseases is associated with impairment in biochemical reactions involved in the visual cycle, a metabolic pathway responsible for regeneration of the visual chromophore (11-cis-retinal). Inefficient clearance of toxic retinoid metabolites, especially all-trans-retinal, is considered responsible for photoreceptor cytotoxicity. Primary amines, including retinylamine, are effective in lowing the concentration of all-trans-retinal within the retina and thus prevent retina degeneration in mouse models of human retinopathies. Here we achieved prolonged prevention of retinal degeneration by controlled delivery of retinylamine to the eye from polylactic acid nanoparticles in Abca4(-/-)Rdh8(-/-) (DKO) mice, an animal model of Stargardt disease/age-related macular degeneration. Subcutaneous administration of the nanoparticles containing retinylamine provided a constant supply of the drug to the eye for about a week and resulted in effective prolonged prevention of light-induced retinal degeneration in DKO mice. Retinylamine nanoparticles hold promise for prolonged prophylactic treatment of human retinal degenerative diseases, including Stargardt disease and age-related macular degeneration. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Puntel, Anthony; Yu, Guanping; Lu, Zheng-Rong] Case Western Reserve Univ, Sch Engn, Dept Biomed Engn, Cleveland, OH 44140 USA.
   [Maeda, Akiko; Golczak, Marcin; Gao, Song-Qi; Palczewski, Krzysztof] Case Western Reserve Univ, Cleveland Ctr Membrane & Struct Biol, Sch Med, Dept Pharmacol, Cleveland, OH 44140 USA.
   [Maeda, Akiko] Case Western Reserve Univ, Sch Med, Dept Ophthalmol, Cleveland, OH 44140 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University
RP Lu, ZR (通讯作者)，Case Western Reserve Univ, Dept Biomed Engn, Wickenden Bldg,Room 427,10900 Euclid Ave, Cleveland, OH 44106 USA.
EM zxl125@case.edu
FU National Eye Institute of the National Institutes of Health (NIH)
   [R24EY021126]; NATIONAL EYE INSTITUTE [R01EY023948, R24EY021126] Funding
   Source: NIH RePORTER
FX This work was supported by grant R24EY021126 from the National Eye
   Institute of the National Institutes of Health (NIH). ZRL is M. Frank
   Rudy and Margaret Domiter Rudy Professor of Biomedical Engineering and
   KP is John H. Hord Professor of Pharmacology.
CR Alvarez Z, 2014, BIOMATERIALS, V35, P4769, DOI 10.1016/j.biomaterials.2014.02.051
   Chen Y, J BIOL CHEM, V287, P5059
   Deng D, 2014, BIOMATERIALS, V35, P8801, DOI 10.1016/j.biomaterials.2014.06.058
   Deng Y, 2014, BIOMATERIALS, V35, P6595, DOI 10.1016/j.biomaterials.2014.04.038
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Golczak M, 2005, J BIOL CHEM, V280, P42263, DOI 10.1074/jbc.M509351200
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200
   Kiser PD, CHEM REV, V114, P194
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kubota R, RETINA, V32, P183
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Ma XB, 2014, BIOMATERIALS, V35, P2878, DOI 10.1016/j.biomaterials.2013.12.045
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, PHOTOCHEM PHOTOBIOL, V88, P1309
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mathaes R, 2014, INT J PHARMACEUT, V465, P159, DOI 10.1016/j.ijpharm.2014.02.037
   Molday RS, 2006, ADV EXP MED BIOL, V572, P465
   Murdaugh LS, EXP EYE RES, V90, P564
   Palczewski K, J BIOL CHEM, V287, P1612
   Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, J LIPID RES, V51, P247
   Sun H, 2012, BBA-MOL CELL BIOL L, V1821, P99, DOI 10.1016/j.bbalip.2011.06.010
   Wolf G, 2002, NUTR REV, V60, P62, DOI 10.1301/00296640260085976
   Ye F, 2014, BIOMATERIALS, V35, P3885, DOI 10.1016/j.biomaterials.2014.01.041
   Yu GP, 2014, BIOMACROMOLECULES, V15, P4570, DOI 10.1021/bm501352s
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang XD, 2014, BIOMATERIALS, V35, P1932, DOI 10.1016/j.biomaterials.2013.10.034
NR 32
TC 15
Z9 15
U1 4
U2 35
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2015
VL 44
BP 103
EP 110
DI 10.1016/j.biomaterials.2014.12.019
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA CB6FV
UT WOS:000349723800010
PM 25617130
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Khan, MA
   Skidmore, K
   Ho, AC
AF Khan, M. Ali
   Skidmore, Keegan
   Ho, Allen C.
TI Perioperative retina evaluation of the cataract surgery patient
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; cataract surgery; diabetic
   retinopathy; pseudophakic retinal detachment; uveitis
ID INTRAOCULAR-LENS IMPLANTATION; DIABETIC MACULAR EDEMA; AGE-RELATED
   MACULOPATHY; POSTERIOR VITREOUS DETACHMENT; OPTICAL COHERENCE
   TOMOGRAPHY; BLUE MOUNTAINS EYE; INTRAVITREAL BEVACIZUMAB; RISK-FACTORS;
   BEAVER DAM; DEGENERATION
AB Purpose of review
   To describe recent evidence regarding cataract surgery in patients with coexisting retinal disease, focusing on factors that are important to the perioperative evaluation and treatment of this patient population.
   Recent findings
   Studies in patients with age-related macular degeneration have yielded good visual gains without progression of neovascular disease or increased need for intravitreal antivascular endothelial growth factor therapy. Uveitic patients similarly gain vision on average, and control of inflammation remains paramount. Perioperative treatment with intravitreal antivascular endothelial growth factor and corticosteroid help mitigate postoperative macular edema in patients with diabetic macular edema. Risk of retinal detachment is elevated postcataract surgery, but evidence regarding prophylactic treatment of peripheral retinal pathology is lacking. Intracameral antibiotics have reduced rates of postcataract surgery endophthalmitis in recent population-based retrospective studies.
   Summary
   Favorable visual acuity outcomes are possible following cataract surgery in patients with retinal disease, including uveitis, diabetic macular edema, and age-related macular degeneration. Perioperative control of retinal disease activity is desired, but level 1 evidence to guide best practices regarding optimal timing and nature of perioperative treatment remains limited. Prevention of postoperative retinal detachment and endophthalmitis is deserving of additional study.
C1 [Khan, M. Ali; Ho, Allen C.] Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA 19107 USA.
   [Skidmore, Keegan] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
C3 Jefferson University; Brown University
RP Ho, AC (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM acho@att.net
OI Ho, Allen/0000-0003-3921-608X; Khan, Mohammed/0000-0002-6985-2418
CR American Academy of Ophthalmology, 2013, UV CAT SURG
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Baker CW, 2013, JAMA OPHTHALMOL, V131, P870, DOI 10.1001/jamaophthalmol.2013.2313
   Barry P, 2007, J CATARACT REFR SURG, V33, P978, DOI 10.1016/j.jcrs.2007.02.032
   Belair ML, 2009, AM J OPHTHALMOL, V148, P128, DOI 10.1016/j.ajo.2009.02.029
   Bhagwandien ACE, 2006, OPHTHALMOLOGY, V113, P643, DOI 10.1016/j.ophtha.2005.10.056
   Bjerrum SS, 2013, OPHTHALMOLOGY, V120, P2573, DOI 10.1016/j.ophtha.2013.07.045
   Chae JB, 2014, RETINA-J RET VIT DIS, V34, P149, DOI 10.1097/IAE.0b013e3182979b9e
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chew EY, 1999, ARCH OPHTHALMOL-CHIC, V117, P1600
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Dowler JGF, 2000, OPHTHALMOLOGY, V107, P457, DOI 10.1016/S0161-6420(99)00136-0
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Grixti A, 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/417603.
   Hikichi T, 2012, OPHTHALMOLOGY, V119, P2102, DOI 10.1016/j.ophtha.2012.03.050
   Hilford D, 2009, EYE, V23, P1388, DOI 10.1038/eye.2008.273
   Ivastinovic D, 2012, AM J OPHTHALMOL, V153, P705, DOI 10.1016/j.ajo.2011.09.009
   JAFFE GJ, 1992, AM J OPHTHALMOL, V114, P448, DOI 10.1016/S0002-9394(14)71857-4
   Kim SJ, 2007, OPHTHALMOLOGY, V114, P881, DOI 10.1016/j.ophtha.2006.08.053
   Kim SY, 2008, J CATARACT REFR SURG, V34, P823, DOI 10.1016/j.jcrs.2008.01.018
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Krepler K, 2002, GRAEF ARCH CLIN EXP, V240, P735, DOI 10.1007/s00417-002-0530-7
   Lanzagorta-Aresti A, 2009, RETINA-J RET VIT DIS, V29, P530, DOI 10.1097/IAE.0b013e31819c6302
   Leung TG, 2014, COCHRANE DB SYST REV, V3
   Matsuura K, 2013, J CATARACT REFR SURG, V39, P1702, DOI 10.1016/j.jcrs.2013.05.036
   Mehta S, 2014, AM J OPHTHALMOL, V158, P676, DOI 10.1016/j.ajo.2014.06.018
   Modi YS, 2013, AM J OPHTHALMOL, V156, P454, DOI 10.1016/j.ajo.2013.04.038
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Olsen T, 2012, OPEN OPHTHALMOL J, V6, P79, DOI 10.2174/1874364101206010079
   Orlin A, 2014, RETINA-J RET VIT DIS, V34, P1969, DOI 10.1097/IAE.0000000000000214
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rahman I, 2005, EYE, V19, P191, DOI 10.1038/sj.eye.6701450
   Ram J, 2010, J CATARACT REFR SURG, V36, P1283, DOI 10.1016/j.jcrs.2010.02.019
   Ripandelli G, 2007, OPHTHALMOLOGY, V114, P692, DOI 10.1016/j.ophtha.2006.08.045
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Schimel AM, 2014, JAMA OPHTHALMOL
   Shorstein NH, 2013, J CATARACT REFR SURG, V39, P8, DOI 10.1016/j.jcrs.2012.07.031
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Takamura Y, 2009, OPHTHALMOLOGY, V116, P1151, DOI 10.1016/j.ophtha.2009.01.014
   Tielsch JM, 1996, OPHTHALMOLOGY, V103, P1537, DOI 10.1016/S0161-6420(96)30465-X
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 43
TC 3
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JAN
PY 2015
VL 26
IS 1
BP 39
EP 44
DI 10.1097/ICU.0000000000000115
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU9PB
UT WOS:000345925900008
PM 25333755
DA 2022-11-30
ER

PT J
AU Tuo, JS
   Pang, JJ
   Cao, XG
   Shen, DF
   Zhang, J
   Scaria, A
   Wadsworth, SC
   Pechan, P
   Boye, SL
   Hauswirth, WW
   Chan, CC
AF Tuo, Jingsheng
   Pang, Ji-Jing
   Cao, Xiaoguang
   Shen, Defen
   Zhang, Jun
   Scaria, Abraham
   Wadsworth, Samuel C.
   Pechan, Peter
   Boye, Sanford L.
   Hauswirth, William W.
   Chan, Chi-Chao
TI AAV5-mediated sFLT01 gene therapy arrests retinal lesions in
   Ccl2(-/-)/Cx3cr1(-/-) mice
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Soluble VEGF receptor-1; Age-related macular degeneration; Animal model;
   Ccl2; Cx3cr1; Adeno-associated virus; Gene therapy; Retina
ID ENDOTHELIAL GROWTH-FACTOR; LEBER CONGENITAL AMAUROSIS; MACULAR
   DEGENERATION; ADENOASSOCIATED VIRUS; PIGMENT EPITHELIUM; DEFICIENT MICE;
   NITRIC-OXIDE; MOUSE MODEL; FACTOR VEGF; RAT MODEL
AB To test the effects of adeno-associated virus encoding sFLT01 (AAV5.sFLT01) on the retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) mice, a model for age-related macular degeneration (AMD), AAV5.sFLT01 was injected into the subretinal space of the right eyes and the left eyes served as controls. Histology found no retinal toxicity due to the treatment after 3 months. The treated eyes showed lesion arrest compared with lesion progression in the left eyes by fundus monitoring monthly and histological evaluation 3 months after treatment. Retinal ultrastructure showed fewer lipofuscin and better preserved photoreceptors after the treatment. A2E, a major component of lipofuscin, was lower in the treated eyes than in the control eyes. Molecular analysis showed that AAV5.sFLT01 lowered retinal extracellular signal-regulated kinase (ERK) phosphorylation and inducible nitric oxide synthetase expression, which suggested the involvement of reactive nitrogen species in the retinal lesions of Ccl2(-/-)/Cx3cr1(-/-). We concluded that local delivery of AAV5.sFLT01 can stabilize retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) mice. The findings provide further support for the potential beneficial effects of sFLT01 gene therapy for age-related macular degeneration. Published by Elsevier Inc.
C1 [Tuo, Jingsheng; Cao, Xiaoguang; Shen, Defen; Zhang, Jun; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Pang, Ji-Jing; Boye, Sanford L.; Hauswirth, William W.] Univ Florida, Dept Ophthalmol, Gainesville, FL USA.
   [Cao, Xiaoguang] Beijing Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Scaria, Abraham; Wadsworth, Samuel C.; Pechan, Peter] Genzyme Corp, Dept Mol Biol, Framingham, MA 01701 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); State University System of Florida; University of Florida; Peking
   University; Sanofi-Aventis; Genzyme Corporation
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,Bldg 10,Rm 10 N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Zhang, Jun/K-2424-2012
OI Tuo, Jingsheng/0000-0002-1372-7810; Pechan, Peter/0000-0001-9663-8743;
   hauswirth, william/0000-0002-3244-4947
FU National Eye Institute, National Institutes of Health; NATIONAL EYE
   INSTITUTE [P30EY021721, ZIAEY000418, ZIAEY000222, ZICEY000461] Funding
   Source: NIH RePORTER
FX This research was supported by the Intramural Research Program of
   National Eye Institute, National Institutes of Health.
CR Basu A, 2010, J IMMUNOL, V184, P545, DOI 10.4049/jimmunol.0900397
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Buch PK, 2008, GENE THER, V15, P849, DOI 10.1038/gt.2008.66
   Caivano M, 1998, FEBS LETT, V429, P249, DOI 10.1016/S0014-5793(98)00578-X
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Carter BJ, 2005, HUM GENE THER, V16, P541, DOI 10.1089/hum.2005.16.541
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gora-Kupilas K, 2005, FOLIA NEUROPATHOL, V43, P31
   Grieger JC, 2005, ADV BIOCHEM ENG BIOT, V99, P119, DOI 10.1007/10_005
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Ideno J, 2007, INT J MOL MED, V19, P75
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jing P.J., 2011, MOL THER, V19, P234
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kim YS, 2009, J IMMUNOL, V183, P5113, DOI 10.4049/jimmunol.0901566
   Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105
   Liu M.M., 2010, BR J OPHTHALMOL, DOI [DOI 10.1136/BJO.2009.158832, 10.1136/bjo.2009.158832]
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618
   Narasimhan P, 2009, STROKE, V40, P1467, DOI 10.1161/STROKEAHA.108.534644
   Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001
   Pang JJ, 2005, MOL VIS, V11, P152
   Paques M, 2007, INVEST OPHTH VIS SCI, V48, P2769, DOI 10.1167/iovs.06-1099
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shimoji M, 2009, NEUROTOX RES, V16, P318, DOI 10.1007/s12640-009-9076-3
   Smith TC, 2007, AUST FAM PHYSICIAN, V36, P359
   Son SH, 2009, CANCER LETT, V280, P86, DOI 10.1016/j.canlet.2009.02.012
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Zhang XM, 2009, INT IMMUNOPHARMACOL, V9, P810, DOI 10.1016/j.intimp.2009.02.018
NR 44
TC 15
Z9 16
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD FEB
PY 2012
VL 33
IS 2
AR 433.e1
DI 10.1016/j.neurobiolaging.2011.01.009
PG 10
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 863NR
UT WOS:000298171800053
PM 21397984
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mackey, DA
   Hewitt, AW
AF Mackey, David A.
   Hewitt, Alex W.
TI Genome-wide association study success in ophthalmology
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; gene-environment interaction;
   keratoconus; myopia; primary open-angle glaucoma
ID OPEN-ANGLE GLAUCOMA; CENTRAL CORNEAL THICKNESS; FACTOR-H POLYMORPHISM;
   MACULAR DEGENERATION; REFRACTIVE ERROR; SUSCEPTIBILITY LOCUS;
   INTRAOCULAR-PRESSURE; HIGH MYOPIA; EDUCATION INFLUENCES; GENETIC
   ASSOCIATION
AB Purpose of review
   Much progress in our understanding of the genetic profile of many ophthalmic diseases has been made over the last decade. Identification of novel gene associations allows insight into the mechanisms of disease and potentially enables the identification of individuals at increased risk, as well as facilitating the development of new treatments. We highlight key recent discoveries using the genome-wide association study design.
   Recent findings
   Over the last 2 years, we have seen major international collaborations successfully conduct genome-wide association study to identify genetic pathways associated with eye diseases, such as myopia, age-related macular degeneration and glaucoma. Similarly other studies have identified and confirmed genes associated with ocular biometry or disease-specific endophenotypes.
   Summary
   Our understanding of the genetic architecture of common eye diseases, such as myopia, age-related macular degeneration and glaucoma, is rapidly expanding. With reducing costs of next-generation sequencing, we expect a transition to large-scale interrogation at the whole exome and genome level, which will enable the identification of rare variants which confer a level of sensitivity and specificity to predict risk that will allow us to further understand, predict and intervene in genetic-based eye diseases.
C1 [Mackey, David A.; Hewitt, Alex W.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Mackey, David A.; Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Mackey, David A.; Hewitt, Alex W.] Univ Tasmania, Menzies Res Inst Tasmania, Sch Med, Hobart, Tas, Australia.
C3 Lions Eye Institute; University of Western Australia; Centre for Eye
   Research Australia; Royal Victorian Eye & Ear Hospital; University of
   Melbourne; University of Tasmania; Menzies Institute for Medical
   Research
RP Mackey, DA (通讯作者)，Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.
EM David.Mackey@lei.org.au
RI Mackey, David A/H-5340-2014; Hewitt, Alex W/D-1936-2013
OI Mackey, David A/0000-0001-7914-4709; Hewitt, Alex W/0000-0002-5123-5999
FU National Health and Medical Research Council (NHMRC); Ophthalmic
   Research Institute of Australia (ORIA)
FX Funding: This work was supported by grants from National Health and
   Medical Research Council (NHMRC) and The Ophthalmic Research Institute
   of Australia (ORIA). The Centre for Eye Research Australia (CERA)
   receives operational infrastructure support from the Victorian
   government.
CR Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396
   Bosten JM, 2014, INVEST OPHTH VIS SCI, V55, P345, DOI 10.1167/iovs.13-12879
   Burdon KP, 2011, NAT GENET, V43, P574, DOI 10.1038/ng.824
   Cheng CY, 2013, AM J HUM GENET, V93, P264, DOI 10.1016/j.ajhg.2013.06.016
   Darnovsky Marcy, 2014, MLO Med Lab Obs, V46, P33
   Day AC, 2013, BRIT J OPHTHALMOL, V97, P704, DOI 10.1136/bjophthalmol-2012-302969
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donnelly P, 2013, HUM MOL GENET, V22, P4653, DOI 10.1093/hmg/ddt293
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fan Q, 2014, HUM MOL GENET, V23, P546, DOI 10.1093/hmg/ddt431
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao XY, 2013, INVEST OPHTH VIS SCI, V54, P2435, DOI 10.1167/iovs.13-11692
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Guggenheim JA, 2013, MOL VIS, V19, P243
   Bae HA, 2013, INVEST OPHTH VIS SCI, V54, P5132, DOI 10.1167/iovs.13-12377
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hysi PG, 2014, JAMA OPHTHALMOL, V132, P50, DOI 10.1001/jamaophthalmol.2013.6022
   Hysi PG, 2010, NAT GENET, V42, P902, DOI 10.1038/ng.664
   Jensen RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054232
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Khor CC, 2013, HUM MOL GENET, V22, P5288, DOI 10.1093/hmg/ddt385
   Kiefer AK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003299
   Kirin M, 2013, HUM MOL GENET, V22, P3174, DOI 10.1093/hmg/ddt169
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Li X, 2013, INVEST OPHTH VIS SCI, V54, P2696, DOI 10.1167/iovs.13-11601
   Li YZ, 2013, NAT GENET, V45, P1361, DOI 10.1038/ng.2779
   Liu F, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000934
   Liu YT, 2013, INVEST OPHTH VIS SCI, V54, P6248, DOI 10.1167/iovs.13-12779
   Lopes MC, 2013, INVEST OPHTH VIS SCI, V54, P1260, DOI 10.1167/iovs.12-10463
   Lu Y, 2013, NAT GENET, V45, P155, DOI 10.1038/ng.2506
   Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980
   Meng WH, 2012, INVEST OPHTH VIS SCI, V53, P7983, DOI 10.1167/iovs.12-10409
   Nag A, 2014, HUM MOL GENET, V23, P3343, DOI 10.1093/hmg/ddu050
   Nag A, 2013, INVEST OPHTH VIS SCI, V54, P3607, DOI 10.1167/iovs.13-11952
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Ng SK, 2014, CLIN EXP OPHTHALMOL, V42, P25, DOI 10.1111/ceo.12234
   Oishi M, 2013, INVEST OPHTH VIS SCI, V54, P7492, DOI 10.1167/iovs.13-12825
   Ozel AB, 2014, HUM GENET, V133, P41, DOI 10.1007/s00439-013-1349-5
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Sahebjada S, 2013, INVEST OPHTH VIS SCI, V54, P8224, DOI 10.1167/iovs.13-12982
   Sanfilippo PG, 2010, SURV OPHTHALMOL, V55, P561, DOI 10.1016/j.survophthal.2010.07.003
   Schache M, 2013, OPHTHALMOLOGY, V120, P292, DOI 10.1016/j.ophtha.2012.08.006
   Scheetz TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058657
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sherwin JC, 2013, EXPERT REV OPHTHALMO, V8, P63, DOI 10.1586/EOP.12.81
   Sheu WHH, 2013, HUM MOL GENET, V22, P3165, DOI 10.1093/hmg/ddt161
   Shi D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054115
   Shi HH, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/641596
   Shi Y, 2013, HUM MOL GENET, V22, P2325, DOI 10.1093/hmg/ddt066
   Sim X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065804
   Simpson CL, 2013, MOL VIS, V19, P2173
   Stambolian D, 2013, HUM MOL GENET, V22, P2754, DOI 10.1093/hmg/ddt116
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Venturini C, 2014, BRIT J OPHTHALMOL, V98, P562, DOI 10.1136/bjophthalmol-2013-304080
   Verhoeven VJM, 2013, EUR J EPIDEMIOL, V28, P973, DOI 10.1007/s10654-013-9856-1
   Verhoeven VJM, 2013, NAT GENET, V45, P314, DOI 10.1038/ng.2554
   Verhoeven VJM, 2012, HUM GENET, V131, P1467, DOI 10.1007/s00439-012-1176-0
   Wojciechowski R, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003442
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yazar S, 2013, MOL VIS, V19, P1238
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 67
TC 20
Z9 20
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD SEP
PY 2014
VL 25
IS 5
BP 386
EP 393
DI 10.1097/ICU.0000000000000090
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4NI
UT WOS:000340564300004
PM 25014751
DA 2022-11-30
ER

PT J
AU Singh, SR
   Sahoo, NK
   Goud, NR
   Chhablani, J
AF Singh, Sumit Randhir
   Sahoo, Niroj Kumar
   Goud, Nallamasa Rohit
   Chhablani, Jay
TI Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy
   in treatment-naive polypoidal choroidal vasculopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Intravitreal bevacizumab; intravitreal ziv-aflibercept; polypoidal
   choroidal vasculopathy
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; RANIBIZUMAB;
   EFFICACY; SAFETY; VEGF
AB Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was from January 2016 to March 2018. The inclusion criteria were treatment-naive PCV patients who were treated with either IVZ or BVZ monotherapy on pro re nata protocol and followed up monthly for 6 months. The change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and pigment epithelial detachment (PED) height was measured at baseline and 6 months. Results: A total of 16 eyes were studied. IVZ group had an improvement in BCVA by 0.15 logarithm of minimum angle of resolution (logMAR; approximately 1.5 lines) at 6 months, whereas BVZ group had a reduction in BCVA by 0.21 logMAR (approximately 2 lines) (P = 0.027). Five patients and one patient in IVZ and BVZ groups, respectively, had >= 5 letters gain of BCVA. IVZ group had significant reduction in PED height (P = 0.048), whereas the change in CMT was not significant at 6 months (P = 0.681). The mean number of injections (2.87 +/- 0.83 in IVZ and 2.25 +/- 0.89 BVZ group; P = 0.168) and longest treatment-free interval (3.00 +/- 2.20 months in IVZ and 2.12 +/- 1.96 months in BVZ group; P = 0.41) were not significantly different. Conclusion: The visual and anatomical outcomes in terms of PED reduction in treatment-naive PCV patients were better in IVZ group compared with BVZ. IVZ monotherapy is a viable, cost-effective alternative in these patients with good safety profile.
C1 [Singh, Sumit Randhir; Sahoo, Niroj Kumar; Goud, Nallamasa Rohit; Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Banjara Hills, Hyderabad 34, Telangana, India.
C3 L. V. Prasad Eye Institute
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Banjara Hills, Hyderabad 34, Telangana, India.
EM jay.chhablani@gmail.com
RI Sahoo, Niroj/AHD-3438-2022; Sahoo, Niroj Kumar/ABH-7604-2020; Sahoo,
   Niroj/AHD-3511-2022
OI Sahoo, Niroj Kumar/0000-0003-0011-2507; Chhablani,
   Jay/0000-0003-1772-3558
CR Ashraf M, 2017, OSLI RETINA, V48, P399, DOI 10.3928/23258160-20170428-06
   Braimah IZ, 2018, BRIT J OPHTHALMOL, V102, P91, DOI 10.1136/bjophthalmol-2017-310318
   Chan EW, 2018, ACTA OPHTHALMOL, V96, pe258, DOI 10.1111/aos.13533
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Chhablani JK, 2013, INDIAN J OPHTHALMOL, V61, P136, DOI 10.4103/0301-4738.109390
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Iida T., 2016, AS PAC VITR RET SOC
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Singh SR, 2017, ASIA-PAC J OPHTHALMO, V6, P561, DOI 10.22608/APO.2017263
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
NR 23
TC 4
Z9 4
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2019
VL 67
IS 7
BP 1114
EP 1118
DI 10.4103/ijo.IJO_638_18
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IG3FI
UT WOS:000473687700029
PM 31238423
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Querques, G
   Querques, L
   Martinelli, D
   Massamba, N
   Coscas, G
   Soubrane, G
   Souied, EH
AF Querques, Giuseppe
   Querques, Lea
   Martinelli, Domenico
   Massamba, Nathalie
   Coscas, Gabriel
   Soubrane, Gisele
   Souied, Eric H.
TI PATHOLOGIC INSIGHTS FROM INTEGRATED IMAGING OF RETICULAR PSEUDODRUSEN IN
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE autofluorescence; fluorescein angiography; infrared reflectance;
   reticular pseudodrusen; spectral domain optical coherence tomography
ID HIGH-RISK; AUTOFLUORESCENCE
AB Purpose: The purpose of this study was to analyze the integrated infrared reflectance, fundus autofluorescence, and fluorescein angiography (integrated confocal scanning laser ophthalmoscopy fundus imaging) features of reticular pseudodrusen and eye-tracked Spectralis high-resolution spectral domain optical coherence tomography (Spectralis SD-OCT; Heidelberg Engineering, Heidelberg, Germany).
   Methods: Twenty-two consecutive patients with reticular pseudodrusen were prospectively enrolled and evaluated regarding confocal scanning laser ophthalmoscopy fundus imaging and eye-tracked SD-OCT findings.
   Results: Integrated fundus imaging revealed a "target" aspect of most reticular pseudodrusen in the 42 included eyes (22 patients; 12 women, 10 men; mean age 81.38 +/- 6.47 years). On fundus autofluorescence and infrared reflectance, the center of most reticular pseudodrusen appeared as an area of isoautofluorescence/reflectance surrounded by halos of reduced autofluorescence/reflectance. Similarly, on fluorescein angiography, the center of reticular pseudodrusen appeared as an area of decreased fluorescence surrounded by a faint halo of increased fluorescence. Spectral domain optical coherence tomography showed a well-defined round or triangular hyperreflective deposit localized between, externally, the retinal pigment epithelium layer, and, internally, the external limiting membrane or the outer plexiform layer. Moreover, SD-OCT showed the loss of both outer segment/retinal pigment epithelium interface and inner segment/outer segment interface over the hyperreflective lesions, as well as an abrupt interruption of both these interfaces at the border of the hyperreflective lesions.
   Conclusion: The peculiar confocal scanning laser ophthalmoscopy fundus imaging and tracked SD-OCT of reticular pseudodrusen suggest the presence of central lipofuscin-like retinal deposits localized above the retinal pigment epithelium. These findings give insights to other possible aspects of age-related retinal changes. RETINA 31: 518-526, 2011
C1 [Querques, Giuseppe; Querques, Lea; Martinelli, Domenico; Massamba, Nathalie; Coscas, Gabriel; Soubrane, Gisele; Souied, Eric H.] Univ Paris 12, Ctr Hosp Intercommunal, Dept Ophthalmol, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Ctr Hosp Intercommunal, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581; Martinelli,
   Domenico/0000-0001-8028-3167
CR Arnold J, 1996, RETINA-J RET VIT DIS, V16, P168, DOI 10.1097/00006982-199616020-00020
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Querques G, 2008, AM J OPHTHALMOL, V146, P501, DOI 10.1016/j.ajo.2008.05.029
   Querques G, 2009, SURV OPHTHALMOL, V54, P311, DOI 10.1016/j.survophthal.2008.12.010
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 14
TC 87
Z9 90
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2011
VL 31
IS 3
BP 518
EP 526
DI 10.1097/IAE.0b013e3181f04974
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 722YW
UT WOS:000287472400013
PM 21150696
DA 2022-11-30
ER

PT J
AU Podbielski, DW
   Noble, J
AF Podbielski, Dominik W.
   Noble, Jason
TI Can you identify this condition? Answer to Ophthaproblem - Wet
   age-related macular degeneration
SO CANADIAN FAMILY PHYSICIAN
LA English
DT Article
ID RANIBIZUMAB
C1 [Podbielski, Dominik W.; Noble, Jason] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON M5S 1A1, Canada.
C3 University of Toronto
RP Podbielski, DW (通讯作者)，Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON M5S 1A1, Canada.
CR Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Raftery JP, 2007, BRIT MED J, V334, P381, DOI 10.1136/bmj.39128.708565.3A
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   RIORANEVA P, 2008, VAUGHAN ASBURYS GEN
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 11
TC 0
Z9 0
U1 0
U2 0
PU COLL FAMILY PHYSICIANS CANADA
PI MISSISSAUGA
PA 2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA
SN 0008-350X
J9 CAN FAM PHYSICIAN
JI Can. Fam. Phys.
PD OCT
PY 2008
VL 54
IS 10
BP 1395
EP 1398
PG 4
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 362EJ
UT WOS:000260180700016
PM 18854465
DA 2022-11-30
ER

PT J
AU Bee, YS
   Ma, YL
   Chen, J
   Tsai, PJ
   Sheu, SJ
   Lin, HC
   Huang, H
   Liu, GS
   Tai, MH
AF Bee, Youn-Shen
   Ma, Yi-Ling
   Chen, Jinying
   Tsai, Pei-Jhen
   Sheu, Shwu-Jiuan
   Lin, Hsiu-Chen
   Huang, Hu
   Liu, Guei-Sheung
   Tai, Ming-Hong
TI Inhibition of Experimental Choroidal Neovascularization by a Novel
   Peptide Derived from Calreticulin Anti-Angiogenic Domain
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE choroidal neovascularization; neovascular age-related macular
   degeneration; calreticulin anti-angiogenic domain
ID TUMOR-GROWTH; MACULAR DEGENERATION; TOPICAL APPLICATION;
   CYCLIC-PEPTIDES; GENE DELIVERY; VASOSTATIN; DISEASE; BEVACIZUMAB;
   FRAGMENT
AB Choroidal neovascularization (CNV) is a key pathological feature of several leading causes of vision loss including neovascular age-related macular degeneration. Here, we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including tube formation, migration of endothelial cells, and vascular sprouting from rat aortic ring explants. In a rat model of laser-induced CNV, we demonstrate that intravitreal injection of CAD27 significantly attenuated the formation of CNV lesions as measured via fundus fluorescein angiography and choroid flat-mounts (19.5% and 22.4% reductions at 10 g and 20 g of CAD27 injected, respectively). Similarly, the reduction of CNV lesions was observed in rats that had received topical applications of CAD27 (choroid flat-mounts: 17.9% and 32.5% reductions at 10 g/mL and 20 g/mL of CAD27 instilled, respectively). Retinal function was unaffected, as measured using electroretinography in both groups receiving interareal injection or topical applications of CAD27 for at least fourteen days. These findings show that CAD27 can be used as a potential therapeutic alternative for targeting CNV in diseases such as neovascular age-related macular degeneration.
C1 [Bee, Youn-Shen; Tsai, Pei-Jhen; Sheu, Shwu-Jiuan; Lin, Hsiu-Chen] Kaohsiung Vet Gen Hosp, Dept Ophthalmol, Kaohsiung 813, Taiwan.
   [Bee, Youn-Shen] Yuh Ing Jr Coll Hlth Care & Management, Kaohsiung 807, Taiwan.
   [Bee, Youn-Shen] Natl Def Med Ctr, Taipei 114, Taiwan.
   [Ma, Yi-Ling] Kaohsiung Vet Gen Hosp, Div Nephrol, Kaohsiung 813, Taiwan.
   [Chen, Jinying; Liu, Guei-Sheung] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas 7000, Australia.
   [Chen, Jinying; Liu, Guei-Sheung] Jinan Univ, Dept Ophthalmol, Guangzhou 510632, Guangdong, Peoples R China.
   [Sheu, Shwu-Jiuan] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Sheu, Shwu-Jiuan] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan.
   [Huang, Hu] Cent S Univ, Aier Eye Inst, Aier Sch Ophthalmol, Changsha 410083, Hunan, Peoples R China.
   [Liu, Guei-Sheung] Univ Melbourne, Dept Surg, Ophthalmol, East Melbourne, Vic 3002, Australia.
   [Tai, Ming-Hong] Natl Sun Yat Sen Univ, Dept Biomed Sci, Kaohsiung 804, Taiwan.
   [Tai, Ming-Hong] Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung 804, Taiwan.
   [Tai, Ming-Hong] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung 804, Taiwan.
   [Tai, Ming-Hong] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan.
C3 Kaohsiung Veterans General Hospital; National Defense Medical Center;
   Kaohsiung Veterans General Hospital; University of Tasmania; Menzies
   Institute for Medical Research; Jinan University; National Yang Ming
   Chiao Tung University; Kaohsiung Veterans General Hospital; Central
   South University; University of Melbourne; National Sun Yat Sen
   University; National Sun Yat Sen University; National Sun Yat Sen
   University; Kaohsiung Medical University
RP Liu, GS (通讯作者)，Univ Tasmania, Menzies Inst Med Res, Hobart, Tas 7000, Australia.; Liu, GS (通讯作者)，Jinan Univ, Dept Ophthalmol, Guangzhou 510632, Guangdong, Peoples R China.; Liu, GS (通讯作者)，Univ Melbourne, Dept Surg, Ophthalmol, East Melbourne, Vic 3002, Australia.; Tai, MH (通讯作者)，Natl Sun Yat Sen Univ, Dept Biomed Sci, Kaohsiung 804, Taiwan.; Tai, MH (通讯作者)，Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung 804, Taiwan.; Tai, MH (通讯作者)，Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung 804, Taiwan.; Tai, MH (通讯作者)，Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan.
EM ysbee@vghks.gov.tw; ylma0329@gmail.com; janechenjy0907@gmail.com;
   pjtasi@vghks.gov.tw; sjsheu@vghks.gov.tw; sclin@vghks.gov.tw;
   huanghu@aierchina.com; rickliu0817@gmail.com; minghongtai@gmail.com
RI Liu, Guei-Sheung/Q-6472-2018
OI Liu, Guei-Sheung/0000-0003-3379-724X
FU Kaohsiung Veterans General Hospital [VGHKS 101-056, 103-089]; National
   Health and Medical Research Council of Australia [1061912]; Ophthalmic
   Research Institute of Australia; Rebecca L. Cooper Medical Research
   Foundation
FX We thank Minh Thuan Nguyen Tran for critically reviewing the manuscript.
   This work was supported by grants from the Kaohsiung Veterans General
   Hospital (VGHKS 101-056, 103-089), the National Health and Medical
   Research Council of Australia (#1061912), the Ophthalmic Research
   Institute of Australia, and the Rebecca L. Cooper Medical Research
   Foundation.
CR Bee YS, 2010, MOL VIS, V16, P756
   Birke K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076766
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Chan LY, 2016, SCI REP-UK, V6, DOI 10.1038/srep35347
   Chan WM, 2007, OPHTHALMOLOGY, V114, P2190, DOI 10.1016/j.ophtha.2007.03.043
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1690, DOI 10.1016/j.ophtha.2017.04.028
   Cloutier F, 2012, INVEST OPHTH VIS SCI, V53, P1195, DOI 10.1167/iovs.11-9064
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Huegel R, 2007, J INVEST DERMATOL, V127, P65, DOI 10.1038/sj.jid.5700484
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   Lange-Asschenfeldt B, 2001, J INVEST DERMATOL, V117, P1036, DOI 10.1046/j.0022-202x.2001.01519.x
   Lee JH, 2019, PROG RETIN EYE RES, V68, P31, DOI 10.1016/j.preteyeres.2018.08.003
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468
   Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349
   Prea SM, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/201726
   Robbie SJ, 2013, INVEST OPHTH VIS SCI, V54, P1490, DOI 10.1167/iovs.12-10169
   Sheu SJ, 2009, MOL VIS, V15, P1897
   Sheu SJ, 2005, EXP EYE RES, V81, P673, DOI 10.1016/j.exer.2005.04.005
   Shu Q, 2014, INT J MOL SCI, V15, P6019, DOI 10.3390/ijms15046019
   Tu LL, 2018, ANGIOGENESIS, V21, P95, DOI 10.1007/s10456-017-9591-4
   Wang L, 2014, MOLECULES, V19, P15391, DOI 10.3390/molecules191015391
   Wu PC, 2005, MOL VIS, V11, P28
   Yao L, 2002, J LEUKOCYTE BIOL, V71, P47
NR 29
TC 5
Z9 6
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2018
VL 19
IS 10
AR 2993
DI 10.3390/ijms19102993
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GY9HB
UT WOS:000448951000148
PM 30274378
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Hosseini, HRJ
   Mosallaei, M
   Kalameh, ZA
AF Hosseini, H. R. Jahadi
   Mosallaei, M.
   Kalameh, Z. Asadi
TI The Effect of Nutrition and Supplements on Ocular Health
SO IRANIAN RED CRESCENT MEDICAL JOURNAL
LA English
DT Review
DE Nutrition; Supplement; Ocular health
ID AGE-RELATED MACULOPATHY; RETINAL METABOLIC ABNORMALITIES; 3RD
   NATIONAL-HEALTH; MACULAR DEGENERATION; VITAMIN-E; DIETARY LUTEIN; EYE
   DISEASE; FATTY-ACIDS; OLDER WOMEN; ZEAXANTHIN
AB Nutrition is a subject of interest in many fields of medicine. So ophthalmologists have also attempted to find possible ways to preserve vision through diet and supplements. Ocular disorders such as cataracts, age-related macular degeneration and glaucoma are the leading causes of visual impairment and blindness in the world, so most of the studies have focused on these major disorders and nutritions containing antioxidant such as vitamin C and E. Zexanthin/luteins and omega 3 have been the main substances studied in this relation. Although benefits of the regimens with high amounts of antioxidants were observed in reducing progression of cataract, age-related macular degeneration and so on, as many of these studies have been observational, the cause and effect relationship cannot be definitely concluded and multiple cohort prospective studies will be desired to evaluate the exact role of nutrition. Somehow, a healthy diet which means the diet which increases our health can be achieved in regimens with low saturated fatty acids and rich in fresh fruits, vegetables and fish. On the whole, even though they may not affect disease progression, they are generally good for overall health.
C1 [Hosseini, H. R. Jahadi] Shiraz Univ Med Sci, Poostchi Eye Res Ctr, Dept Ophthalmol, Shiraz, Iran.
C3 Shiraz University of Medical Science
RP Hosseini, HRJ (通讯作者)，Shiraz Univ Med Sci, Poostchi Eye Res Ctr, Dept Ophthalmol, Shiraz, Iran.
EM jahadih@sums.ac.ir
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Berendschot TTJM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1732, DOI 10.1001/archopht.120.12.1732
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Biousse V, 2008, J FR OPHTALMOL, V31, P111, DOI 10.1016/S0181-5512(08)70343-7
   Blades KJ, 2001, EUR J CLIN NUTR, V55, P589, DOI 10.1038/sj.ejcn.1601186
   Chen XX, 2000, CARCINOGENESIS, V21, P1531, DOI 10.1093/carcin/21.8.1531
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Coleman AL, 2008, AM J OPHTHALMOL, V145, P1081, DOI 10.1016/j.ajo.2008.01.022
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2007, FORUM NUTR, V60, P168, DOI 10.1159/000107176
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Fernandez MM, 2008, CURR OPIN OPHTHALMOL, V19, P66, DOI 10.1097/ICU.0b013e3282f2d7b6
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hammond BR, 2008, NUTR REV, V66, P695, DOI 10.1111/j.1753-4887.2008.00121.x
   Herm RJ, 2008, NEW ENGL J MED, V359, P1735
   Higgins GT, 2007, ACTA OPHTHALMOL SCAN, V85, P772, DOI 10.1111/j.1600-0420.2007.00944.x
   Hosseini HRJ, 2008, IRAN RED CRESCENT ME, V10, P281
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Jacques PF, 1999, INT J VITAM NUTR RES, V69, P198, DOI 10.1024/0300-9831.69.3.198
   Jampol LM, 2001, JAMA-J AM MED ASSOC, V286, P2466
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Kowluru RA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1266, DOI 10.1001/archopht.126.9.1266
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V294, P32, DOI 10.1001/jama.294.1.32
   Lakshminarayana R, 2007, J AGR FOOD CHEM, V55, P6395, DOI 10.1021/jf070482z
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Lornejad-Schafer MR, 2007, EUR J NUTR, V46, P79, DOI 10.1007/s00394-006-0635-6
   Lu M, 2007, J AM COLL NUTR, V26, P133, DOI 10.1080/07315724.2007.10719594
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   Mares JA, 2006, ARCH OPHTHALMOL-CHIC, V124, P1339, DOI 10.1001/archopht.124.9.1339
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   McFadden SA, 2006, EXP EYE RES, V83, P949, DOI 10.1016/j.exer.2006.05.002
   Miljanovic B, 2005, AM J CLIN NUTR, V82, P887, DOI 10.1093/ajcn/82.4.887
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Morris MS, 2007, OPHTHAL EPIDEMIOL, V14, P288, DOI 10.1080/09286580601186759
   Nguyen CTO, 2007, INVEST OPHTH VIS SCI, V48, P756, DOI 10.1167/iovs.06-0585
   Nykamp Diane, 2007, Consult Pharm, V22, P490, DOI 10.4140/TCP.n.2007.490
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Porter L, 2005, BRIT J OPHTHALMOL, V89, P1531, DOI 10.1136/bjo.2005.074195
   Preethi KC, 2008, INT J TOXICOL, V27, P1, DOI 10.1080/10915810701876265
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SCHUYLER D, 2008, EUROTIMES, V13, P10
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Singhal S, 2001, J Assoc Physicians India, V49, P327
   Son HY, 2007, J NUTR SCI VITAMINOL, V53, P324, DOI 10.3177/jnsv.53.324
   Strobel M, 2007, EUR J NUTR, V46, P1, DOI 10.1007/s00394-007-1001-z
   Talegawkar SA, 2008, PUBLIC HEALTH NUTR, V11, P989, DOI 10.1017/S1368980007001310
   Teichmann K D, 1997, Eur J Med Res, V2, P445
   Tomlinson A, 2001, OPHTHAL PHYSL OPT, V21, P9, DOI 10.1046/j.1475-1313.2001.00544.x
   Townend BS, 2007, AM J OPHTHALMOL, V143, P932, DOI 10.1016/j.ajo.2007.03.006
   Trumbo PR, 2006, AM J CLIN NUTR, V84, P971, DOI 10.1093/ajcn/84.5.971
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Weber U., 1993, Ophthalmologe, V90, P486
   Wright ME, 2007, CANCER, V109, P891, DOI 10.1002/cncr.22482
NR 74
TC 2
Z9 2
U1 0
U2 8
PU KOWSAR PUBL
PI HOENSBROEK
PA PATERSWEG 22,, HOENSBROEK, LIMBURG 6431 GC, NETHERLANDS
SN 2074-1804
EI 2074-1812
J9 IRAN RED CRESCENT ME
JI Iran. Red Crescent Med. J.
PD JAN
PY 2009
VL 11
IS 1
BP 10
EP 17
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 418DR
UT WOS:000264127900004
DA 2022-11-30
ER

PT J
AU Ruiz-Moreno, JM
   Montero, JA
   Amat, P
   Lugo, FL
AF Ruiz-Moreno, Jose M.
   Montero, Javier A.
   Amat, Pedro
   Lugo, Francisco L.
TI Secondary Elevated IOP and Cataracts After High-dose Intravitreal
   Triamcinolone and Photodynamic Therapy to Treat Choroidal
   Neovascularization
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE intravitreous triamcinolone; photodynamic therapy; intraocular pressure;
   age-related macular degeneration
ID RANDOMIZED CLINICAL-TRIAL; MACULAR DEGENERATION; INTRAOCULAR-PRESSURE;
   ACETONIDE; VERTEPORFIN; INJECTION; CORTICOSTEROIDS; INHIBITION;
   DISEASES; OCCULT
AB Purpose: To analyze the appearance and evolution of high intraocular pressure (IOP) and cataracts after high-dose intravitreous triamcinolone acetonide (TA) and photodviiamic therapy (PDT) to treat choroidal neovascularization associated with age-related macular degeneration.
   Patients and Methods: Retrospective. consecutive. nonrandomized, interventional case series. Filty-one consecutive eyes with subfoveal (all types) choroidal neovascularization associated to age-related macular degeneration were treated by PDT and intravitreal 19.4 +/- 2.1 mg/0.1 mL TA. Changes in IOP and lens were considered as primary outcome indicators. Optic disk changes were also considered.
   Results: Twenty nine of 49 eyes (59%) needed topical therapy for high IOP at month 12, and 11 of 47 (23%) at month 24. Cataracts appeared in 14 of 42 phakic eyes (33%) after 12 months follow-up and in 22 of 40 phakic eyes (55%) completing 24 months follow-up. One eye showed an increased cup-to-disk ratio.
   Conclusions: The use of high-dose intravitreal TA is associated with cataracts and IOP elevation in approximately 50% of cases. The need for topical treatment for high IOP decreases during the second year.
C1 [Ruiz-Moreno, Jose M.] Univ Castilla La Mancha, Albacete Med Sch, Dept Ophthalmol, Albacete, Spain.
   [Ruiz-Moreno, Jose M.; Montero, Javier A.; Amat, Pedro; Lugo, Francisco L.] Alicante Inst Ophthalmol, Vitreo Retinal Unit, Alicante, Spain.
C3 Universidad de Castilla-La Mancha
RP Ruiz-Moreno, JM (通讯作者)，Univ Castilla La Mancha, Albacete Med Sch, Dept Ophthalmol, Albacete, Spain.
EM jm.ruiz@umh.es
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788
CR Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   BAKRI SJ, 2007, EYE
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   KITAZAWA Y, 1976, AM J OPHTHALMOL, V82, P492, DOI 10.1016/0002-9394(76)90500-6
   MACHEMER R, 1979, T AM OPHTHAL SOC, V77, P177
   McLean JM., 1950, T AM OPHTHAL SOC, V48, P293
   MONTEROMORENO JA, 2006, STUDIUM OPHTHALMOL, V24, P91
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   RENFRO L, 1992, DERMATOL CLIN, V10, P505
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Tripathi RC, 1999, DRUG AGING, V15, P439, DOI 10.2165/00002512-199915060-00004
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 31
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD JAN
PY 2009
VL 18
IS 1
BP 69
EP 72
DI 10.1097/IJG.0b013e31816b3037
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 398VO
UT WOS:000262759800012
PM 19142138
DA 2022-11-30
ER

PT J
AU Ferroni, M
   Cereda, MG
   Boschetti, F
AF Ferroni, Marco
   Cereda, Matteo Giuseppe
   Boschetti, Federica
TI A Combined Approach for the Analysis of Ocular Fluid Dynamics in the
   Presence of Saccadic Movements
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Computational fluid dynamics; Vitreous; Saccades; Age-related macular
   degeneration; Scleral hydraulic conductivity
ID VITREOUS-HUMOR; DRUG-DELIVERY; HUMAN EYE; PERMEABILITY; THICKNESS;
   TRANSPORT; MOTION; FLOW
AB One of the main ocular diseases is age-related macular degeneration, actually treated with antibodies injections into the eye. This problem has been faced by computational approaches, taking into account either the influence of the tissues surrounding the vitreous, or the saccades. The aim of this work is to propose a combined fluid dynamic model of the vitreous chamber that analyses the impact of the saccades on the fluid dynamic mechanisms. The ocular vitreous humor was modeled considering liquefaction occurring in presence of age-related macular degeneration. We identified two kinds of boundary conditions, one related to the physiological environment outside the chamber, and one related to the saccades. The scleral hydraulic conductivity was evaluated by means of experimental permeability tests. An exponential decay was used to describe the trend of the scleral hydraulic conductivity with the acting pressure drop. The streamline analysis shows two main stagnant regions on the equatorial plane and peculiar fluid dynamics in absence of saccades. This study demonstrates the major role played by the saccades in determining the fluid dynamic mechanisms inside the vitreous chamber of the eye and represents a powerful tool to investigate vitreous dynamics and its relation to clinical issues.
C1 [Ferroni, Marco; Boschetti, Federica] Politecn Milan, Chem Mat & Chem Engn Dept Giulio Natta, LaBS, Piazza L da Vinci 32, I-20133 Milan, Italy.
   [Cereda, Matteo Giuseppe] Univ Milan, Sacco Hosp, Eye Clin, Dept Biomed & Clin Sci Luigi Sacco, Via GB Grassi 74, I-20157 Milan, Italy.
C3 Polytechnic University of Milan; University of Milan; Luigi Sacco
   Hospital
RP Ferroni, M (通讯作者)，Politecn Milan, Chem Mat & Chem Engn Dept Giulio Natta, LaBS, Piazza L da Vinci 32, I-20133 Milan, Italy.
EM marco.ferroni@polimi.it
OI Ferroni, Marco/0000-0002-5202-7163
CR Abouali O, 2012, MED ENG PHYS, V34, P681, DOI 10.1016/j.medengphy.2011.09.011
   Argento A, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027615
   Balachandran RK, 2008, PHARM RES-DORDR, V25, P2685, DOI 10.1007/s11095-008-9691-3
   Balachandran RK, 2011, PHARM RES-DORDR, V28, P1049, DOI 10.1007/s11095-010-0356-7
   Balazs EA, 1978, 3 INT C EYE RES
   Becker W, 1989, Rev Oculomot Res, V3, P13
   Bhisitkul RB, 2001, BRIT J OPHTHALMOL, V85, P1, DOI 10.1136/bjo.85.1.1
   Bonfiglio A, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0020-8
   Chan CM, 2006, RETINA-J RET VIT DIS, V26, P176, DOI 10.1097/00006982-200602000-00009
   Cima MJ, 2014, J CONTROL RELEASE, V190, P157, DOI 10.1016/j.jconrel.2014.04.049
   David T, 1998, PHYS MED BIOL, V43, P1385, DOI 10.1088/0031-9155/43/6/001
   FATT I, 1970, EXP EYE RES, V10, P243, DOI 10.1016/S0014-4835(70)80035-5
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Friedrich S, 1997, CURR EYE RES, V16, P663, DOI 10.1076/ceyr.16.7.663.5061
   Haghjou N., 2011, WAS ENG TECH, V77, P706
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jackson TL, 2006, INVEST OPHTH VIS SCI, V47, P4942, DOI 10.1167/iovs.06-0362
   LAI WM, 1981, J BIOMECH ENG-T ASME, V103, P61, DOI 10.1115/1.3138261
   LEE B, 1992, BIORHEOLOGY, V29, P521
   Loudon C, 1998, J THEOR BIOL, V191, P63, DOI 10.1006/jtbi.1997.0564
   Missel PJ, 2002, PHARMACEUT RES, V19, P1636, DOI 10.1023/A:1020940927675
   Modareszadeh A, 2013, BIOMECH MODEL MECHAN, V12, P281, DOI 10.1007/s10237-012-0398-3
   Repetto R, 2005, PHYS MED BIOL, V50, P4729, DOI 10.1088/0031-9155/50/19/021
   Repetto R, 2010, BIOMECH MODEL MECHAN, V9, P65, DOI 10.1007/s10237-009-0159-0
   Romano MR, 2013, CURR EYE RES, V38, P371, DOI 10.3109/02713683.2012.745160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135
   Sekuler R., 1982, DTIC DOCUMENT
   Stay MS, 2003, PHARM RES-DORDR, V20, P96, DOI 10.1023/A:1022207026982
   Stocchino A, 2007, PHYS MED BIOL, V52, P2021, DOI 10.1088/0031-9155/52/7/016
   Stocchino A, 2010, PHYS MED BIOL, V55, P453, DOI 10.1088/0031-9155/55/2/008
   Vaiano AS, 2017, RETINA-J RET VIT DIS, V37, P1400, DOI 10.1097/IAE.0000000000001367
   Vurgese S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029692
   Xu J, 2000, PHARMACEUT RES, V17, P664, DOI 10.1023/A:1007517912927
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
NR 37
TC 6
Z9 6
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090-6964
EI 1573-9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD DEC
PY 2018
VL 46
IS 12
BP 2091
EP 2101
DI 10.1007/s10439-018-02110-2
PG 11
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA HC7QU
UT WOS:000451997300012
PM 30088168
DA 2022-11-30
ER

PT J
AU Julien, S
   Schraermeyer, U
AF Julien, Sylvie
   Schraermeyer, Ulrich
TI Lipofuscin can be eliminated from the retinal pigment epithelium of
   monkeys
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Lipofuscin; Age-related macular degeneration; Retinal pigment
   epithelium; Cynomolgus monkey; Electron microscopy
ID MACULAR DEGENERATION; RPE LIPOFUSCIN; VISUAL CYCLE; COMPLEMENT
   ACTIVATION; GEOGRAPHIC ATROPHY; MOUSE MODEL; CENTROPHENOXINE; CELLS;
   ACCUMULATION; A2E
AB Lipofuscin is a cytologic hallmark of aging in metabolically active postmitotic cells including neurons, cardiac muscle cells, and the retinal pigment epithelium (RPE). High levels of lipofuscin are involved in the pathogenesis of age-related macular degeneration (AMD), the main cause of blindness in the elderly population in the western world. Degradation and exocytosis of lipofuscin by RPE cells have not been observed in vivo until now, and no drug is known to eliminate the intracellular amount of lipofuscin. Here, we show that in monkeys treated with a small molecule belonging to the tetrahydropyridoethers class (n = 36 of 48 monkeys), RPE cells significantly release lipofuscin. In 4 eyes, macrophages were detected which had taken up lipofuscin. They were located between the Bruch's membrane and the RPE, and in the choroid. The quantification of pigment granules was performed by transmission electron microscopy. Our findings open the way to develop therapeutic strategies to remove lipofuscin from RPE cells, which may have implications for the treatment of age-related macular degeneration in which lipofuscin accumulation in cells is a causative factor. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Julien, Sylvie; Schraermeyer, Ulrich] Ctr Ophthalmol, Sect Expt Vitreoretinal Surg, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Schraermeyer, U (通讯作者)，Ctr Ophthalmol, Sect Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM Ulrich.Schraermeyer@med.uni-tuebingen.de
OI Julien-Schraermeyer, Sylvie/0000-0002-2322-511X
CR ANDREWS LD, 1986, NEUROBIOL AGING, V7, P107, DOI 10.1016/0197-4580(86)90148-X
   Biesemeier A, 2011, EXP EYE RES, V93, P29, DOI 10.1016/j.exer.2011.04.004
   BOK D, 1993, J CELL SCI, P189
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   DYLEWSKI DP, 1983, NEUROBIOL AGING, V4, P89, DOI 10.1016/0197-4580(83)90059-3
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   KATZ ML, 1983, J GERONTOL, V38, P525, DOI 10.1093/geronj/38.5.525
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   NANDY K, 1966, NATURE, V210, P313, DOI 10.1038/210313a0
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   OHTANI R, 1983, EXP GERONTOL, V18, P105, DOI 10.1016/0531-5565(83)90003-7
   PATRO N, 1992, INDIAN J MED RES-B, V96, P192
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Terman A, 1998, MECH AGEING DEV, V100, P145, DOI 10.1016/S0047-6374(97)00129-2
   Terman A, 2006, ANN NY ACAD SCI, V1067, P27, DOI 10.1196/annals.1354.005
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wu YL, 2011, J AM CHEM SOC, V133, P849, DOI 10.1021/ja107195u
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 36
TC 23
Z9 26
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD OCT
PY 2012
VL 33
IS 10
BP 2390
EP 2397
DI 10.1016/j.neurobiolaging.2011.12.009
PG 8
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 996LG
UT WOS:000308088500015
PM 22244091
DA 2022-11-30
ER

PT J
AU Yamaoka, S
   Okada, AA
   Sugahara, M
   Hida, T
AF Yamaoka, Seijo
   Okada, Annabelle A.
   Sugahara, Michitaka
   Hida, Tetsuo
TI Clinical Features of Polypoidal Choroidal Vasculopathy and Visual
   Outcomes in the Absence of Classic Choroidal Neovascularization
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy,
   natural history; Visual acuity
ID PHOTODYNAMIC THERAPY; VERTEPORFIN
AB Background/Aims: To report on the clinical features of polypoidal choroidal vasculopathy (PCV) and to delineate visual outcomes in the absence of classic choroidal neovascularization (CNV). Methods: Records were retrospectively reviewed of 233 eyes of 215 patients diagnosed with 'definite' PCV using Japanese criteria. Results: Of patients with definite PCV, 72.1% were men and 91.6% had unilateral disease. A history of systemic hypertension was elicited in 18.1% of patients, and blood pressure measurement revealed possible hypertension in 27.4% of patients. At the initial evaluation, 28.3% of eyes had classic CNV as assessed by fluorescein angiography and were treated by photodynamic therapy or other means. Of 112 eyes with active exudation but no classic CNV and no recent decreased vision, best-corrected visual acuity (BCVA) at 3 months improved by >= 0.2 logarithm of the minimum angle of resolution (logMAR) in 17%, was unchanged in 72% and worsened by >= 0.2 logMAR in 11%. In 67 eyes of which 1-year data were available, BCVA improved in 19%, was unchanged in 64% and worsened in 16%. Conclusions: The majority of PCV patients were men, with a high rate of diagnosed or suspected hypertension. More than two thirds of eyes had no evidence of classic CNV, of which 89% had stable or improved vision at 3 months without specific treatment. Of eyes followed for 12 months, 83% had stable or improved vision. Copyright (C) 2009 S. Karger AG, Basel
C1 [Yamaoka, Seijo; Okada, Annabelle A.; Sugahara, Michitaka; Hida, Tetsuo] Kyorin Univ, Sch Med, Dept Ophthalmol, Tokyo 1818611, Japan.
C3 Kyorin University
RP Okada, AA (通讯作者)，Kyorin Univ, Sch Med, Dept Ophthalmol, 6-20-2 Shinkawa, Tokyo 1818611, Japan.
EM aokada@e23.jp
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   National Heart Lung and Blood Institute, 2004, 7 NAT HEART LUNG BLO
   Okada AA, 2004, BRIT J OPHTHALMOL, V88, P1097, DOI 10.1136/bjo.2003.039719
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 25
TC 11
Z9 12
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2010
VL 224
IS 3
BP 147
EP 152
DI 10.1159/000236040
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 513KU
UT WOS:000271322000003
PM 19738395
DA 2022-11-30
ER

PT J
AU Brar, VS
   Sharma, RK
   Murthy, RK
   Chalam, KV
AF Brar, Vikram S.
   Sharma, Rajesh K.
   Murthy, Ravi K.
   Chalam, K. V.
TI Bevacizumab neutralizes the protective effect of vascular endothelial
   growth factor on retinal ganglion cells
SO MOLECULAR VISION
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; OXIDATIVE STRESS;
   IN-VIVO; VEGF; EXPRESSION; SURVIVAL; DIFFERENTIATION
AB Purpose: Vascular endothelial growth factor (VEGF) is well known for its role in pathologic neovascularization, including wet age-related macular degeneration. However, a growing body of evidence indicates that VEGF is also neuroprotective of non-vascular cells in various animal models through reduction of oxidative stress. In light of the widespread use of intraocular anti-VEGF therapies for age-related macular degeneration (AMD), we evaluated the impact of anti-VEGF agents on the neuroprotective effect of VEGF on retinal ganglion cells.
   Methods: Staurosporine differentiated retinal ganglion cells were treated with increasing doses of VEGF in the presence of hydrogen peroxide. After optimization, an increasing concentration of bevacizumab was added to neutralize VEGF-mediated protection. The degree of oxidative damage was measured at various time points using buthionine sulfoxime (BSO), a glutathione reductase inhibitor. Cell viability was assessed using WST-1 and Crystal violet assays.
   Results: VEGF (200 ng/ml) protected differentiated retinal ganglion cells (RGC)-5 against H(2)O(2)-mediated oxidative stress. This effect was eliminated by co-treatment with bevacizumab (2.0 mg/ml), which by itself was not cytotoxic.
   Conclusions: These results indicate an important role for VEGF in the maintenance of retinal ganglion cells.
C1 [Brar, Vikram S.; Sharma, Rajesh K.; Murthy, Ravi K.; Chalam, K. V.] Univ Florida, Coll Med, Dept Ophthalmol, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of Florida
RP Chalam, KV (通讯作者)，Univ Florida, Coll Med, Dept Ophthalmol, 580 W 8th St,Tower 2,3rd Floor, Jacksonville, FL 32209 USA.
EM kchalam@jax.ufl.edu
RI Chalam, kakarla/K-7507-2019
OI Chalam, kakarla/0000-0001-9325-8665; Chalam, K V/0000-0002-0004-9416
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Castilla MA, 2000, LIFE SCI, V67, P1003, DOI 10.1016/S0024-3205(00)00693-7
   Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Frassetto LJ, 2006, INVEST OPHTH VIS SCI, V47, P427, DOI 10.1167/iovs.05-0340
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170
   Madhavan L, 2008, STEM CELLS, V26, P254, DOI 10.1634/stemcells.2007-0221
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Siner JM, 2007, FASEB J, V21, P1422, DOI 10.1096/fj.06-6661com
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Wang YM, 2007, J NEUROSCI, V27, P304, DOI 10.1523/JNEUROSCI.4433-06.2007
NR 22
TC 55
Z9 56
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 12
PY 2010
VL 16
IS 200-02
BP 1848
EP 1853
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 651BH
UT WOS:000281899100001
PM 21031022
DA 2022-11-30
ER

PT J
AU Tomita, K
   Tsujikawa, A
   Yamashiro, K
   Ooto, S
   Tamura, H
   Otani, A
   Nakayama, Y
   Yoshimura, N
AF Tomita, Kaoruko
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Ooto, Sotaro
   Tamura, Hiroshi
   Otani, Atsushi
   Nakayama, Yoshihito
   Yoshimura, Nagahisa
TI Treatment of Polypoidal Choroidal Vasculopathy With Photodynamic Therapy
   Combined With Intravitreal Injections of Ranibizumab
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; BEVACIZUMAB; EFFICACY; VERTEPORFIN; EXPRESSION; OUTCOMES;
   VEGF
AB PURPOSE: To evaluate the 1-year efficacy and safety of photodynamic therapy (PDT) combined with intravitreal injections of ranibizumab for polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective chart review.
   METHODS: We retrospectively reviewed the medical records of 63 consecutive patients (66 eyes) with subfoveal PCV who were treated with PDT combined with intravitreal injections of ranibizumab. Of the 66 eyes, 29 had no history of treatment for PCV, 10 had been treated previously with only intravitreal injections of anti vascular endothelial growth factor agents, and 27 had been treated previously with PDT. All eyes had a minimal follow-up of 12 months.
   RESULTS: The combined therapy reduced substantially the exudative change immediately after initiation of treatment. In treatment-naive eyes, mean VA before treatment (0.47 +/- 0.37 logarithm of the minimal angle of resolution [logMAR]) improved to 0.32 +/- 0.30 (P < .01) at 3 months and to 0.29 +/- 0.29 (P < .01) at 12 months. Polypoidal lesions were reduced in all eyes and disappeared completely in 79.1% of cases. In eyes treated previously with only anti vascular endothelial growth factor therapy, some visual improvement was achieved, but in eyes treated previously with PDT, mean visual acuity (0.61 +/- 0.45) deteriorated to 0.68 +/- 0.52 at 12 months. Of all 66 eyes, 5 showed extensive postoperative subretinal hemorrhage, in 2 of which a vitreous hemorrhage developed, necessitating pars plana vitrectomy.
   CONCLUSIONS: PDT combined with ranibizumab led to significant visual recovery in treatment-naive eyes with PCV, but not in eyes with PCV that had demonstrated recurrence after previous PDT. PDT in combination with ranibizumab still has a risk of the postoperative hemorrhagic complications. (Am J Ophthalmol 2012;153:68-80. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
   [Tomita, Kaoruko; Tamura, Hiroshi; Otani, Atsushi; Yoshimura, Nagahisa] Nakano Eye Clin, Kyoto, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamashiro, Kenji/0000-0001-9354-8558
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [21592256]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED IN PART BY GRANT-IN-AID FOR
   SCIENTIFIC RESEARCH 21592256 FROM THE Japan Society for the Promotion of
   Science (JSPS), Tokyo, Japan; and the Japan National Society for the
   Prevention of Blindness, Tokyo, Japan. The authors indicate no financial
   conflict of interest. Involved in Conception and design of the study
   (K.T., AT., K.Y., SO., N.Y.); Data collection (K.T., HT., O.A., Y.N.);
   Analysis and interpretation of data (K.T.,. A.T., K.Y., SO., H.T., O.A.,
   Y.N., N.Y.); Writing of the article (K.T., AT.); Critical revision of
   the article (K.Y., SO., H.T., O.A., Y.N., N.Y.); and Final approval of
   the article (K.T., AT., K.Y., S.O., H.T., O.A., Y.N., N.Y.). This study
   was approved by the Institutional Review Board at Kyoto University
   Graduate School of Medicine and adhered to the tenets of the Declaration
   of Helsinki. For treatment, written informed consent was obtained from
   each patient. According to the guidelines, it is not mandatory to obtain
   informed consent from the patients for a retrospective study in which
   the researchers review only medical records.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moon SW, 2011, OPHTHALMOLOGICA, V225, P169, DOI 10.1159/000323811
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pai SA, 2009, ACTA OPHTHALMOL, V87, P806, DOI 10.1111/j.1755-3768.2008.01330.x
   Romano MR, 2010, CLIN OPHTHALMOL, V4, P1237, DOI 10.2147/OPTH.S12577
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zuo CG, 2009, DOC OPHTHALMOL, V119, P29, DOI 10.1007/s10633-009-9166-9
NR 46
TC 48
Z9 57
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2012
VL 153
IS 1
BP 68
EP 80
DI 10.1016/j.ajo.2011.07.001
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 865LP
UT WOS:000298312700011
PM 21907965
OA Green Published
DA 2022-11-30
ER

PT J
AU Lujan, LML
   Dorschmann, P
   Seeba, C
   Thalenhorst, T
   Roider, J
   Assanga, SBI
   Ruiz, JCG
   Castro, TD
   Rosas-Burgos, EC
   Plascencia-Jatomea, M
   Brauer, JME
   Klettner, A
AF Lewis Lujan, Lidianys Maria
   Dorschmann, Philipp
   Seeba, Charlotte
   Thalenhorst, Tabea
   Roider, Johann
   Iloki Assanga, Simon Bernard
   Galvez Ruiz, Juan Carlos
   Del Castillo Castro, Teresa
   Carina Rosas-Burgos, Ema
   Plascencia-Jatomea, Maribel
   Ezquerra Brauer, Josafat Marina
   Klettner, Alexa
TI Properties of Cephalopod Skin Ommochromes to Inhibit Free Radicals, and
   the Maillard Reaction and Retino-Protective Mechanisms in Cellular
   Models Concerning Oxidative Stress, Angiogenesis, and Inflammation
SO ANTIOXIDANTS
LA English
DT Article
DE ommochromes; cephalopods; ferroptosis; glycative stress; retinal pigment
   epithelium; uveal melanoma; vascular endothelial growth factor;
   interleukin
ID ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS; MACULAR DEGENERATION;
   PIGMENT EPITHELIUM; LIPID-PEROXIDATION; INDUCED EXPRESSION; XANTHURENIC
   ACID; IN-VITRO; RPE; ACTIVATION
AB Ommochromes are pigments of invertebrates that exhibit oxidative stress protection. The aim of this study was to investigate ommochromes extracted from cephalopod's skin for their ability to inhibit age-related-macular degeneration (AMD)-related factors such as H2O2-induced and iron-dependent oxidative stress (ferroptosis and erastin), accumulation of advanced glycation end-products (AGEs), as well as vascular endothelial growth factor (VEGF), and inflammatory cytokines (interleukin 6 and interleukin 8) secretion. As cell systems, we used primary porcine retinal pigment epithelium (RPE), human retinal pigment epithelium cell line ARPE-19 and uveal melanoma cell line OMM-1. In vitro, ommochromes produced an antiglycation effect by the inhibition of fructosylation reaction. The ommochromes showed protective effects against erastin- induced cell death in ARPE-19. In addition, in long-term stimulation (7 days) ommochromes decreased constitutively secreted VEGF, as well as interleukin 6 and interleukin 8 induced by Poly I:C in primary RPE. No relevant effects were detected in OMM-1 cells. The effects are dependent on the cell system, time of exposition, and concentration. This substance is of interest for further research concerning age-related macular degeneration.
C1 [Lewis Lujan, Lidianys Maria; Carina Rosas-Burgos, Ema; Plascencia-Jatomea, Maribel; Ezquerra Brauer, Josafat Marina] Univ Sonora, Dept Invest & Posgrad Alimentos, Blvd Luis Encinas & Rosales S-N, Hermosillo 83000, Sonora, Mexico.
   [Dorschmann, Philipp; Seeba, Charlotte; Thalenhorst, Tabea; Roider, Johann; Klettner, Alexa] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
   [Iloki Assanga, Simon Bernard; Galvez Ruiz, Juan Carlos] Sonora Univ, Dept Biol Chem Sci, Blvd Luis Encinas & Rosales S-N, Hermosillo 83000, Sonora, Mexico.
   [Del Castillo Castro, Teresa] Sonora Univ, Dept Res Polymers & Mat, Blvd Luis Encinas & Rosales S-N, Hermosillo 83000, Sonora, Mexico.
C3 Universidad de Sonora; University of Kiel; Schleswig Holstein University
   Hospital; Universidad de Sonora; Universidad de Sonora
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
EM alexakarina.klettner@uksh.de
RI Iloki Assanga, Simon Bernard/GNP-3218-2022; del Castillo,
   Teresa/GRN-7723-2022; Plascencia-Jatomea, Maribel/G-2019-2018
OI Iloki Assanga, Simon Bernard/0000-0002-2058-5881; del Castillo,
   Teresa/0000-0001-7578-3124; Plascencia-Jatomea,
   Maribel/0000-0003-0339-3658; Galvez-Ruiz, Juan
   Carlos/0000-0002-4035-313X; Ezquerra-Brauer, Josafat
   Marina/0000-0001-6838-4395
FU National Council of Science and Technology (CONACYT) of Mexico [2174,
   I0000/230/2018]; DFG (German Research Foundation)
FX Project number 2174 (agreement: I0000/230/2018) of the National Council
   of Science and Technology (CONACYT) of Mexico and the DFG (German
   Research Foundation).
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Aubourg SP, 2016, EUR J LIPID SCI TECH, V118, P1293, DOI 10.1002/ejlt.201500356
   Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292
   Iloki-Assanga SB, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0765-6
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bonnard M, 2021, MOLECULES, V26, DOI 10.3390/molecules26237263
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Daniels EV, 2012, BIOCHEM SYST ECOL, V44, P161, DOI 10.1016/j.bse.2012.04.025
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Doerschmann P, 2021, MAR DRUGS, V19, DOI 10.3390/md19100557
   Dorschmann P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239272
   Dorschmann P, 2019, MAR DRUGS, V17, DOI 10.3390/md17050258
   Dontsov AE, 2020, BIOCHEMISTRY-MOSCOW+, V85, P668, DOI 10.1134/S0006297920060048
   Dontsov AE, 2020, APPL BIOCHEM MICRO+, V56, P91, DOI 10.1134/S0003683820010044
   Dontsov AE, 2012, RUSS CHEM B+, V61, P442, DOI 10.1007/s11172-012-0061-2
   Dontsov Alexander, 2016, World J Exp Med, V6, P63
   Dorschmann P, 2020, MAR DRUGS, V18, DOI 10.3390/md18060282
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edeas M, 2010, PATHOL BIOL, V58, P220, DOI 10.1016/j.patbio.2009.09.011
   Chan-Higuera JE, 2019, MOLECULES, V24, DOI 10.3390/molecules24193420
   Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008
   Figon F, 2019, BIOL REV, V94, P156, DOI 10.1111/brv.12441
   Figon F, 2020, INSECT BIOCHEM MOLEC, V124, DOI 10.1016/j.ibmb.2020.103403
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Green W R, 1999, Mol Vis, V5, P27
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Imai H, 2017, CURR TOP MICROBIOL, V403, P143, DOI 10.1007/82_2016_508
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kannan R, 2006, MOL VIS, V12, P1649
   Karlsson M, 2016, ACTA OPHTHALMOL, V94, P556, DOI 10.1111/aos.13076
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168387
   Klettner A, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108214
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Knobbe CA, 2017, MED HYPOTHESES, V109, P184, DOI 10.1016/j.mehy.2017.10.010
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   Krueger K, 2022, CRIT REV FOOD SCI, V62, P7518, DOI 10.1080/10408398.2021.1915242
   Kumar A, 2018, ACS APPL MATER INTER, V10, P43177, DOI 10.1021/acsami.8b14123
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Lange CAK, 2012, OPHTHALMOLOGICA, V227, P115, DOI 10.1159/000331418
   Lee IT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117911
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Luyten GPM, 1996, INT J CANCER, V66, P380, DOI 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F
   Ezquerra-Brauer JM, 2016, LWT-FOOD SCI TECHNOL, V72, P134, DOI 10.1016/j.lwt.2016.04.024
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Ostrovsky MA, 2018, BIOL BULL+, V45, P570, DOI 10.1134/S1062359018060109
   Riss T. L., 2004, CELL VIABILITY ASSAY
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Romero Y, 2015, J MOL MODEL, V21, DOI 10.1007/s00894-015-2773-3
   Rowan S, 2018, BBA-MOL BASIS DIS, V1864, P3631, DOI 10.1016/j.bbadis.2018.08.036
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591
   SUAREZ G, 1991, BIOCHIM BIOPHYS ACTA, V1075, P12, DOI 10.1016/0304-4165(91)90068-R
   Takeuchi M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030387
   Terheyden L, 2021, GRAEF ARCH CLIN EXP, V259, P413, DOI 10.1007/s00417-020-04930-2
   Teselkin YO, 1998, VOP MED KHIM, V44, P70
   Tode J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.2
   Ursini F, 2020, FREE RADICAL BIO MED, V152, P175, DOI 10.1016/j.freeradbiomed.2020.02.027
   Ushakova N, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090408
   Vistoli G, 2013, FREE RADICAL RES, V47, P3, DOI 10.3109/10715762.2013.815348
   Watkins WM, 2013, EXP EYE RES, V116, P240, DOI 10.1016/j.exer.2013.09.014
   Williams TL, 2016, LANGMUIR, V32, P3754, DOI 10.1021/acs.langmuir.6b00243
   Yakovleva MA, 2020, PHOTOCH PHOTOBIO SCI, V19, P920, DOI 10.1039/c9pp00406h
   Zhao TT, 2021, AGING DIS, V12, P529, DOI 10.14336/AD.2020.0912
NR 78
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD AUG
PY 2022
VL 11
IS 8
AR 1574
DI 10.3390/antiox11081574
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 4C4GO
UT WOS:000846414300001
PM 36009293
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ranjan, R
   Kayastha, AM
   Sinha, N
AF Ranjan, Renuka
   Kayastha, Arvind M.
   Sinha, Neeraj
TI Interactions between hydroxyapatite and cholesterol associated with
   calcification in age-related macular degeneration
SO BIOPHYSICAL CHEMISTRY
LA English
DT Article
DE Drusen; Hydroxyapatite; Cholesterol; Biomimetics; NMR; TEM
ID IN-VITRO SIMULATION; VASCULAR CALCIFICATION; CALCIUM PHOSPHATES;
   CRYSTALS; CRYSTALLIZATION; MECHANISMS; INSIGHT; BONE
AB Hydroxyapatite deposition and calcification occurs over cholesterol-containing lipid droplets between Bruch's membrane and sub-retinal pigment epithelium (sub - RPE) in the eyes of patients affected by age-related ma-cular degeneration (AMD) as spherules, nodules, and Bruch's membrane plaques. In the present study, an at-tempt has been made to prepare a composite containing hydroxyapatite and cholesterol to elucidate interactions involved in the formation of such organic-inorganic interphase. To understand the mechanism of hydroxyapatite deposition on cholesterol, we have applied various biophysical techniques such as dynamic light scattering (DLS) measurements, transmission electron microscopy (TEM) imaging, Fourier transform infrared (FTIR) spectro-scopy and solid-state nuclear magnetic resonance (ssNMR) spectroscopy on the prepared composite. Our results give molecular level insight into the mechanism of biocalcification in the disease system.
C1 [Ranjan, Renuka; Sinha, Neeraj] Ctr Biomed Res, SGPGIMS Campus,Raebareily Rd, Lucknow 226014, Uttar Pradesh, India.
   [Ranjan, Renuka; Kayastha, Arvind M.] Banaras Hindu Univ, Sch Biotechnol, Inst Sci, Varanasi 221005, Uttar Pradesh, India.
C3 Banaras Hindu University (BHU)
RP Sinha, N (通讯作者)，Ctr Biomed Res, SGPGIMS Campus,Raebareily Rd, Lucknow 226014, Uttar Pradesh, India.; Kayastha, AM (通讯作者)，Banaras Hindu Univ, Sch Biotechnol, Inst Sci, Varanasi 221005, Uttar Pradesh, India.
EM kayasthabhu@gmail.com; neeraj.sinha@cbmr.res.in
RI RANJAN, RENUKA/GPC-5766-2022
OI Kayastha, Arvind M./0000-0002-5090-7159; RANJAN,
   RENUKA/0000-0003-1452-4289
FU Council of Scientific and Industrial Research, New Delhi, India
   [09/916(0085)/2015-EMR-I]; SERB India [EMR/2015/001758]
FX RR acknowledges the Senior Research Fellowship from the Council of
   Scientific and Industrial Research, New Delhi, India, for funding (File
   no. 09/916(0085)/2015-EMR-I). NS acknowledges financial assistance from
   SERB India (Grant no. EMR/2015/001758). We thank Prof. Imre Lengyel for
   insightful discussions regarding the preparation of the material. We
   thank Jaideep Saha and Vandana Jaiswal for assistance in the preparation
   of cholesterol micelles at CBMR. Nishith Kumar Verma and Rishabh Anand
   Omar are thanked for performing FTIR measurements at the Department of
   Chemical Engineering, IIT Kanpur. We acknowledge contributions of Abhas
   Singh, Department of Civil Engineering, IIT Kanpur for performing DLS
   measurements. We thank Advanced Imaging Centre, IIT Kanpur, for TEM
   Imaging.
CR Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42
   Barr DP, 1932, PHYSIOL REV, V12, P0593, DOI 10.1152/physrev.1932.12.4.593
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Boskey AL, 2003, CONNECT TISSUE RES, V44, P5, DOI 10.1080/03008200390152007
   del Molino AG, 2018, PROCEEDINGS OF THE 2018 ACM MULTIMEDIA CONFERENCE (MM'18), P10, DOI 10.1145/3240508.3240624
   Dong HR, 2011, J HIGH ENERGY PHYS, DOI 10.1007/JHEP10(2011)141
   Dorozhkin SV, 2005, P I MECH ENG H, V219, P477, DOI 10.1243/095441105X63273
   Dorozhkin SV, 2004, CRYST GROWTH DES, V4, P389, DOI 10.1021/cg034066s
   Dorozhkina EI, 2003, KEY ENG MATER, V240-2, P529, DOI 10.4028/www.scientific.net/KEM.240-242.529
   Ferraz M P, 2004, J Appl Biomater Biomech, V2, P74
   Guo W, 2000, ARTERIOSCL THROM VAS, V20, P1630, DOI 10.1161/01.ATV.20.6.1630
   Gupta U, 2014, MATER FOCUS, V3, P211, DOI 10.1166/mat.2014.1161
   HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313
   HIRSCH D, 1993, CALCIFIED TISSUE INT, V52, P94, DOI 10.1007/BF00308315
   HIRSCH D, 1990, J CRYST GROWTH, V104, P759, DOI 10.1016/0022-0248(90)90099-7
   HIRSCH D, 1992, CALCIFIED TISSUE INT, V50, P261, DOI 10.1007/BF00296291
   Jayalakshmi K, 2009, SOLID STATE NUCL MAG, V36, P60, DOI 10.1016/j.ssnmr.2009.06.001
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   KOUTSOUKOS P, 1980, J AM CHEM SOC, V102, P1553, DOI 10.1021/ja00525a015
   Kucukbenli E, 2012, J PHYS CHEM A, V116, P3765, DOI 10.1021/jp3019974
   Laird DF, 2006, J COLLOID INTERF SCI, V295, P348, DOI 10.1016/j.jcis.2005.09.013
   Ranjan R, 2019, METHODS MOL BIOL, V2037, P231, DOI 10.1007/978-1-4939-9690-2_14
   Reid DG, 2012, J LIPID RES, V53, P1569, DOI 10.1194/jlr.M026088
   SARIG S, 1992, CELL MATER, V2, P339
   Shariffdeen RS, 2016, IEEE INT CONF CLOUD, P11, DOI 10.1109/CLOUD.2016.0012
   Srivastava M, 2008, HEPATOL RES, V38, P997, DOI 10.1111/j.1872-034X.2008.00356.x
   Teotia AK, 2017, ACS APPL MATER INTER, V9, P6816, DOI 10.1021/acsami.6b14782
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   TOMSON MB, 1978, SCIENCE, V200, P1059, DOI 10.1126/science.200.4345.1059
   TORCHIA DA, 1978, J MAGN RESON, V30, P613, DOI 10.1016/0022-2364(78)90288-3
   Veis A, 2005, SCIENCE, V307, P1419, DOI 10.1126/science.1109440
   Xu QG, 2007, BIOMATERIALS, V28, P2687, DOI 10.1016/j.biomaterials.2007.02.007
NR 32
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 0301-4622
EI 1873-4200
J9 BIOPHYS CHEM
JI Biophys. Chem.
PD OCT
PY 2020
VL 265
AR 106430
DI 10.1016/j.bpc.2020.106430
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA NK1AQ
UT WOS:000566472600002
PM 32693318
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Da Pozzo, S
AF Parodi, MB
   Da Pozzo, S
TI Hot spots after photodynamic therapy for choroidal neovascularization in
   age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID VERTEPORFIN
C1 Univ Trieste, Eye Clin, I-34127 Trieste, Italy.
C3 University of Trieste
RP Parodi, MB (通讯作者)，Univ Trieste, Eye Clin, Piazza Osped 1, I-34127 Trieste, Italy.
RI Parodi, Maurizio Battaglia/K-7876-2016
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Chen CJ, 1999, OPHTHALMOLOGY, V106, P925, DOI 10.1016/S0161-6420(99)00511-4
   Menchini U, 1998, RETINA-J RET VIT DIS, V18, P472, DOI 10.1097/00006982-199805000-00017
   Parodi MB, 2001, GRAEF ARCH CLIN EXP, V239, P900, DOI 10.1007/s00417-001-0387-1
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
NR 5
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2002
VL 22
IS 5
BP 671
EP 673
DI 10.1097/00006982-200210000-00028
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 604LC
UT WOS:000178621400028
PM 12441743
DA 2022-11-30
ER

PT J
AU Corbelli, E
   Parravano, M
   Sacconi, R
   Sarraf, D
   Yu, SY
   Kim, K
   Capuano, V
   Miere, A
   Souied, E
   Varano, M
   Boninfante, A
   Chae, B
   Carnevali, A
   Querques, L
   Bandello, F
   Querques, G
AF Corbelli, Eleonora
   Parravano, Mariacristina
   Sacconi, Riccardo
   Sarraf, David
   Yu, Seung-Young
   Kim, Kiyoung
   Capuano, Vittorio
   Miere, Alexandra
   Souied, Eric
   Varano, Monica
   Boninfante, Antonluca
   Chae, Bora
   Carnevali, Adrian
   Querques, Lea
   Bandello, Francesco
   Querques, Giuseppe
TI Prevalence and Phenotypes of Age-Related Macular Degeneration in Eyes
   With High Myopia
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; high myopia; drusen; pseudodrusen;
   geographic atrophy; choroidal neovascularization
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL RANIBIZUMAB; MACULOPATHY;
   CLASSIFICATION; PSEUDODRUSEN
AB PURPOSE. To analyze the frequency and phenotypic variation of AMD in subjects with high myopia (HM), and to describe the clinical course and response to treatment of neovascularization (NV).
   METHODS. Patients with HM were identified at five retina tertiary referral centers. Inclusion criteria were myopic patients aged 55 years or more with axial lengths equal or greater than 25.5 mm.
   RESULTS. A total of 874 eyes from 442 HM subjects older than 55 years were identified and 104 eyes of 54 patients (72 +/- 11 years) were included in the study and followed up for 23.5 +/- 19.5 months. The estimated AMD frequency in HM subjects over 55 years was 11.9% (95% confidence interval; 9.8%-14.0%). A total of 34 of 104 eyes were diagnosed with drusen, 22 with reticular pseudodrusen (RPD), 28 with both drusen and RPD, and 20 with geographic atrophy. Neovascularization was detected in 52 eyes (50%), and type 1 was the most frequent form (39 eyes, 75%). Overall, NV was treated with 4.6 +/- 2.6 anti-VEGF injections. Eyes with treatment-naive NV at baseline (n = 34) required 3.8 +/- 1.5 anti-VEGF injections during the first year of treatment. This exceeded the injection number in the purely myopic population (1.8 to 3.6 injections for the first year).
   CONCLUSIONS. This study provides evidence to suggest that older patients with HM are at a significant risk of the dry and neovascular forms of AMD. NV in eyes with HM and AMD required more injections in the first year compared to NV in HM eyes without AMD.
C1 [Corbelli, Eleonora; Sacconi, Riccardo; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS, Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
   [Parravano, Mariacristina; Varano, Monica; Boninfante, Antonluca] Fdn GB Bietti IRCCS, Rome, Italy.
   [Sacconi, Riccardo] Univ Verona, Dept Neurol, Biomed & Movement Sci, Eye Clin, Verona, Italy.
   [Sarraf, David; Chae, Bora] Univ Calif Los Angeles, Inst Stein Eye, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA USA.
   [Sarraf, David; Chae, Bora] Greater Angeles VA Healthcare Ctr, Los Angeles, CA USA.
   [Yu, Seung-Young; Kim, Kiyoung; Souied, Eric] Kyung Hee Univ, Dept Ophthalmol, Kyung Hee Univ Hosp, Seoul, South Korea.
   [Capuano, Vittorio; Miere, Alexandra] Univ Paris Est Creteil, Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Carnevali, Adrian] Magna Graecia Univ Catanzaro, Dept Ophthalmol, Catanzaro, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS
   - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia;
   University of Verona; University of California System; University of
   California Los Angeles; Kyung Hee University; Kyung Hee University
   Hospital; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Magna Graecia University of Catanzaro
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS, Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Corbelli, Eleonora/AAA-3186-2019; Varano, Monica/K-8573-2016; bandello,
   francesco/AAH-2405-2019; boninfante, antonluca/AAC-2198-2020; Miere,
   Alexandra/AIC-4074-2022; KIM, KIYOUNG/GWM-6103-2022
OI Corbelli, Eleonora/0000-0003-1658-1922; bandello,
   francesco/0000-0003-3238-9682; Miere, Alexandra/0000-0003-4123-8210;
   Varano, Monica/0000-0002-6530-1563; Sacconi,
   Riccardo/0000-0003-2891-2012; Querques, Giuseppe/0000-0002-3292-9581
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Brue C, 2016, EYE, V30, P139, DOI 10.1038/eye.2015.199
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Cohen SY, 2015, JPN J OPHTHALMOL, V59, P36, DOI 10.1007/s10384-014-0363-z
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   CURTIN BJ, 1971, AM J OPHTHALMOL, V71, P42, DOI 10.1016/0002-9394(71)91092-0
   FERREIRA A, 2015, PLOS ONE, V24
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Karagiannis D, 2017, CLIN OPHTHALMOL, V11, P1197, DOI 10.2147/OPTH.S135174
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leveziel N, 2013, AM J OPHTHALMOL, V155, P913, DOI 10.1016/j.ajo.2012.11.021
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P407, DOI 10.1097/IAE.0000000000000368
   Pece A, 2015, GRAEF ARCH CLIN EXP, V253, P1867, DOI 10.1007/s00417-014-2886-x
   Querques G, 2016, DEV OPHTHALMOL, V56, P101, DOI 10.1159/000442800
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Silva R, 2012, OPHTHALMOLOGICA, V228, P197, DOI 10.1159/000339893
   Silva RM, 2010, RETINA-J RET VIT DIS, V30, P407, DOI 10.1097/IAE.0b013e3181c9691e
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 37
TC 5
Z9 5
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2019
VL 60
IS 5
BP 1394
EP 1402
DI 10.1167/iovs.18-25534
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HW5VL
UT WOS:000466757300013
PM 30938774
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Scott, EN
   Thomas, AL
AF Scott, Edwina N.
   Thomas, Anne L.
TI Vatalanib succinate - Multikinase inhibitor, antiangiogenic agent,
   oncolytic, treatment of age-related macular degeneration.
SO DRUGS OF THE FUTURE
LA English
DT Article
DE PTK-787; ZK-222584
ID TYROSINE KINASE INHIBITOR; ADVANCED COLORECTAL-CANCER; PHASE-I; LIVER
   METASTASES; TUMOR-GROWTH; PTK787/ZK-222584; ANGIOGENESIS; PTK/ZK; POTENT
AB Vatalanib succinate (PTK-787/ZK-222584) is a potent tyrosine kinase inhibitor with good oral bioavailability and activity against the vascular endothelial growth factor receptor (VEGFR) family, plateletderived growth factor receptor beta (PDGFR beta) and c-Kit receptor kinases. Despite encouraging results in early clinical trials, the efficacy of vatalanib against colorectal cancer was not borne out in terms of meeting the primary objectives of the phase III CONFIRM 1 (Colorectal Oral Novel Therapy for the Inhibition of Angiogenesis and Retarding of Metastases) and CONFRIM 2 studies. Two important lessons, however, have emerged from the vatalanib trials. Firstly, a new mode of biological imaging to confirm the antiangiogenic effect of vatalanib, DCE-MRI, was validated against clinical effect in the phase 1/11 trials. Secondly, lactate dehydrogenase (LDH) was shown to be a predictive factor for response to chemotherapy and vatalanib in both of the phase III trials.
C1 Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 5WW, Leics, England.
C3 University of Leicester
RP Thomas, AL (通讯作者)，Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 5WW, Leics, England.
EM atl07@le.ac.uk
OI Thomas, Anne/0000-0003-1998-3134
CR ANDERSEN L, 1988, ACTA CHEM SCAND B, V42, P492, DOI 10.3891/acta.chem.scand.42b-0492
   Azuma M, 2006, J CLIN ONCOL, V24, p153S
   Bold G, 2002, DRUG FUTURE, V27, P43, DOI 10.1358/dof.2002.027.01.647609
   Bold G, 2000, J MED CHEM, V43, P2310, DOI 10.1021/jm9909443
   BOLD G, Patent No. 0970070
   Drevs J, 2005, ANN ONCOL, V16, P558, DOI 10.1093/annonc/mdi118
   Drevs J, 2002, CANCER RES, V62, P4015
   DRUEY J, Patent No. 1061788
   Favaro JP, 2005, EXPERT OPIN INV DRUG, V14, P1251, DOI 10.1517/13543784.14.10.1251
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   GAULER TC, 2006, 42 ANN M AM SOC CLIN
   GEORGE D, 2003, P AM SOC CLIN ONCOL, V22
   GEORGE D, 2004, P AM SOC CLIN ONCOL, V23
   Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047
   HECHT JR, 2005, 41 ANN M AM SOC CLIN
   Hess-Stumpp H, 2005, CHEMBIOCHEM, V6, P550, DOI 10.1002/cbic.200400305
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jost LM, 2006, DRUG METAB DISPOS, V34, P1817, DOI 10.1124/dmd.106.009944
   Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809
   KNOBLICH J, 2003, EUR J CANC S5, V1
   KOCH I, 2004, 41 ANN M AM SOC CLIN
   Koehne C, 2006, J CLIN ONCOL S, V24
   KOUKOURAKIS MI, 2006, J CLIN ONCOL, V24, P877
   LETOURNEUX Y, 1980, J HETEROCYCLIC CHEM, V17, P961
   MAJOR P, 2006, J CLIN ONCOL S, V24
   MANLY DG, 1958, J ORG CHEM, V23, P373, DOI 10.1021/jo01097a012
   Morgan B, 2006, BRIT J CANCER, V94, P1420, DOI 10.1038/sj.bjc.6603140
   Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092
   Mross K, 2005, EUR J CANCER, V41, P1291, DOI 10.1016/j.ejca.2005.03.005
   PAVEL M, 2005, EUR J CANC S, V3
   Scott EN, 2007, EXPERT OPIN INV DRUG, V16, P367, DOI 10.1517/13543784.16.3.367
   STEWARD WP, 2004, P AM SOC CLIN ONCOL, V23
   TEJPAR S, 2005, 41 ANN M AM SOC CLIN
   Thomas AL, 2005, J CLIN ONCOL, V23, P4162, DOI 10.1200/JCO.2005.09.034
   von Dobschuetz E, 2006, TRANSPLANTATION, V82, P543, DOI 10.1097/01.tp.0000229434.92523.99
   Wood JM, 2000, CANCER RES, V60, P2178
   Yang BP, 2006, J NEUROSURG-SPINE, V5, P9, DOI 10.3171/spi.2006.5.1.9
NR 37
TC 0
Z9 0
U1 1
U2 2
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD JUL
PY 2007
VL 32
IS 7
BP 607
EP 613
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 209VF
UT WOS:000249415400005
DA 2022-11-30
ER

PT J
AU Hedlich, C
   Barstow, E
   Vogtle, LK
AF Hedlich, Christina
   Barstow, Elizabeth
   Vogtle, Laura K.
TI Age-Related Macular Degeneration and Reading Performance: Does Font
   Style Make a Difference?
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
C1 [Hedlich, Christina] Assoc Blind & Visually Impaired, Dept Occupat Therapy, 456 Cherry St SE, Grand Rapids, MI 49503 USA.
   [Barstow, Elizabeth] Univ Alabama Birmingham, Dept Occupat Therapy, Occupat Therapy, 348 SHPB,1716 Univ Blvd, Birmingham, AL 35294 USA.
   [Vogtle, Laura K.] Univ Alabama Birmingham, Occupat Therapy, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Hedlich, C (通讯作者)，Assoc Blind & Visually Impaired, Dept Occupat Therapy, 456 Cherry St SE, Grand Rapids, MI 49503 USA.
EM chedlich@comcast.net; bbarstow@uab.edu; lvogtle@uab.edu
CR American Foundation for the Blind, TIPS MAK PRINT MOR R
   Canadian National Institute for the Blind, CLEAR PRINT ACC GUID
   Colenbrander A., 2018, LEA NUMBERS CHART VI
   Council of Citizens with Low Vision International, BEST PRACT GUID LARG
   Dandona L, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-7
   Driscoll D.L., 2007, ECOLOG ENV ANTHR, V3, P19
   Good-Lite Company, 2018, LEA NUMB LOW CONTR T
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Kitchel J. E., APH AM PRINTING HOUS
   Mansfield JS, 1996, INVEST OPHTH VIS SCI, V37, P1492
   National Eye Institute, 2015, AG REL MAC DEG
   PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x
   Regents of the University of Minnesota, 1994, MNREAD AC CHARTS
   Russell-Minda E, 2007, J VISUAL IMPAIR BLIN, V101, P402, DOI 10.1177/0145482X0710100703
   Smallfield S, 2013, AM J OCCUP THER, V67, P288, DOI 10.5014/ajot.2013.004929
   Tarita-Nistor L, 2013, CAN J OPHTHALMOL, V48, P57, DOI 10.1016/j.jcjo.2012.09.017
   Wright V, 1996, MORGAN LOW VISION RE
NR 17
TC 1
Z9 1
U1 0
U2 5
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD JUL-AUG
PY 2018
VL 112
IS 4
BP 398
EP 403
PG 6
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA HD4SF
UT WOS:000452517600007
DA 2022-11-30
ER

PT J
AU Querques, G
   Querques, L
   Forte, R
   Massamba, N
   Blanco, R
   Souied, EH
AF Querques, Giuseppe
   Querques, Lea
   Forte, Raimondo
   Massamba, Nathalie
   Blanco, Rocio
   Souied, Eric H.
TI PRECURSORS OF TYPE 3 NEOVASCULARIZATION A Multimodal Imaging Analysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   fluorescein angiography; fundus autofluorescence; indocyanine
   angiography; retinal angiomatous proliferation; retinal-choroidal
   anastomosis; scanning laser ophthalmoscopy; spectral-domain optical
   coherence tomography; Type 3 neovascularization
ID RETINAL ANGIOMATOUS PROLIFERATION; MACULAR DEGENERATION; CHOROIDAL
   ANASTOMOSIS; RANIBIZUMAB; EYE; RISK
AB Purpose: To study the advent of exudative age-related macular degeneration in uninvolved fellow eyes of patients with unilateral Type 3 neovascularization and to investigate the precursors at the site of lesion development.
   Methods: We studied 37 consecutive patients with the diagnosis of unilateral Type 3 neovascularization, for the advent of exudative age-related macular degeneration in uninvolved fellow eyes (study eyes). Looking for the precursors of Type 3 neovascularization, we reviewed the multimodal imaging (fundus autofluorescence, fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography) in the study eyes and interpreted the changes over time at the site of lesion development.
   Results: Of the 37 patients, 12 (32%) developed exudative age-related macular degeneration in the study eye, after a mean of 19.6 +/- 9.5 months (range, 9-36 months) from the diagnosis of Type 3 neovascularization in the first involved eye (baseline). All these patients (12 of 12 eyes; 100%) developed Type 3 neovascularization in the study eye. Retrospective analysis of the precursors of these lesions revealed, at baseline, a focal hyperautofluorescence (fundus autofluorescence) that turned to focal hypoautofluorescence over time. In all eyes, a focal hyperfluorescence (fluorescein angiography and indocyanine green angiography) appeared over time at the site of Type 3 neovascularization development. The corresponding spectral-domain optical coherence tomography showed a localized retinal pigment epithelial (RPE) elevation characterized by a focal disruption of the RPE and photo-receptors and by the overlying outer plexiform layer that progressively took contact with the RPE. Based on these findings, it seems that a small, localized RPE elevation might be the lesion before the development of Type 3 neovascularization. This precursor lesion progresses over time to focal atrophy of RPE and photoreceptor.
   Conclusion: Type 3 neovascularization presents a predictable symmetry and bilaterality. Identification of the precursors of Type 3 neovascularization looks particularly useful for clinicians to detect the earliest changes in the vasogenic process in the fellow eye.
C1 [Querques, Giuseppe; Forte, Raimondo; Massamba, Nathalie; Blanco, Rocio; Souied, Eric H.] Univ Paris 12, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Querques, Giuseppe; Querques, Lea] Univ Vita Salute San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University
RP Querques, G (通讯作者)，Univ Paris 12, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P1165, DOI 10.1007/s00417-009-1089-3
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Mahmood S, 2009, EYE, V23, P530, DOI 10.1038/eye.2008.101
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Querques G, 2012, RETINA-J RET VIT DIS, V32, P458, DOI 10.1097/IAE.0b013e3182205960
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 15
TC 39
Z9 39
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2013
VL 33
IS 6
BP 1241
EP 1248
DI 10.1097/IAE.0b013e31827b639e
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 151IU
UT WOS:000319454700022
PM 23508076
DA 2022-11-30
ER

PT J
AU Atarashi, T
   Tamaki, Y
   Inoue, Y
   Obata, R
   Muranaka, K
   Yanagi, Y
AF Atarashi, T
   Tamaki, Y
   Inoue, Y
   Obata, R
   Muranaka, K
   Yanagi, Y
TI Transpupillary thermotherapy for treatment of exudative age-related
   macular degeneration in Japanese patients
SO EYE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; CLINICAL-TRIALS;
   PHOTOCOAGULATION; VASCULOPATHY; LESIONS
AB Purpose To report the therapeutic outcome of transpupillary thermotherapy (TTT) for subfoveal choroidal neovascularizarion (CNV) in brown retina using a diode-laser with the setting of lower energy level compared to the previous studies on light-pigmented Caucasian patients.
   Methods A total of 19 subfoveal CNVs in 18 patients were treated with TTT. The power of diode-laser was set 160 mW for 1.2 mm beam, 270 mW for 2.0 mm beam, and 400 mW for 3.0 mm beam, and the laser was delivered for 1 min through a slit-lamp mounted-delivery system. Patients were followed up for a mean of 8.8 months ( 4 - 12 months). Visual acuity and the fundus change as judged by funduscopic examination and simultaneous fluorescein and indocyanine green angiography were evaluated. Visual acuity was measured by a Japanese standard Landolt visual acuity chart and converted to logarithm of the minimal angle resolution (logMAR) visual acuity for statistical analysis. Improvement or decline in vision was defined as change of more than 0.2 in logMAR visual acuity.
   Results In eyes with minimally classic or occult only CNV, visual acuity improved in two eyes (18%) stabilized in seven eyes (64%) and worsened in two eyes ( 18%). In eyes with predominantly classic CNV, visual acuity improved in two eyes (25%), stabilized in four eyes (50%) and worsened in two eyes ( 25%). In all, 15 (84%) eyes of all studied subjects had improvement in exudation. Two (11%) and one (5%) eye(s) were noted to have a significant post-treatment haemorrhage and retinal pigment epithelial tear, respectively.
   Conclusion In patients with brown retinal colour, the treatment outcome of TTT was comparable to that of light-pigmented Caucasian patients with approximately half the laser power energy. Further randomized control studies are warranted.
C1 Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Yanagi, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Obata, Ryo/0000-0002-1762-0797
CR Auer C, 2002, KLIN MONATSBL AUGENH, V219, P250, DOI 10.1055/s-2002-30649
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rogers AH, 2001, CURR OPIN OPHTHALMOL, V12, P212, DOI 10.1097/00055735-200106000-00012
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 11
TC 9
Z9 12
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2004
VL 18
IS 6
BP 615
EP 618
DI 10.1038/sj.eye.6700733
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 827EP
UT WOS:000221882200012
PM 14739926
OA Bronze
DA 2022-11-30
ER

PT J
AU Apte, RS
   Sung, JU
   DiBernardo, C
   Feuer-Greenberg, E
AF Apte, RS
   Sung, JU
   DiBernardo, C
   Feuer-Greenberg, E
TI Giant neurosensory detachments associated with disciform lesions in
   neovascular age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; PREVALENCE
C1 Johns Hopkins Univ, Wilmer Ophthalmol Inst, Sch Med, Vitreoretinal Div, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Sung, JU (通讯作者)，Johns Hopkins Univ, Wilmer Ophthalmol Inst, Sch Med, Vitreoretinal Div, Baltimore, MD 21287 USA.
CR BARTSCH DU, 1989, AM J OPHTHALMOL, V108, P277, DOI 10.1016/0002-9394(89)90118-9
   DIBERNARDO C, 1999, VITREORETINAL DIS ES, P65
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Jaakkola A, 1999, OPHTHALMOLOGY, V106, P274, DOI 10.1016/S0161-6420(99)90065-9
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 7
TC 0
Z9 0
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2003
VL 87
IS 6
BP 795
EP 796
DI 10.1136/bjo.87.6.795-a
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 683LH
UT WOS:000183149800039
PM 12770991
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Ramsden, CM
   da Cruz, L
   Coffey, PJ
AF Ramsden, Conor M.
   da Cruz, Lyndon
   Coffey, Peter J.
TI Stemming the Tide of Age-Related Macular Degeneration: New Therapies for
   Old Retinas
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE stem cell; age-related macular degeneration; clinical trial
ID TRANSPLANTATION; FUTURE; CELLS
C1 [Ramsden, Conor M.; da Cruz, Lyndon; Coffey, Peter J.] UCL, Inst Ophthalmol, Div Ocular Biol & Therapeut, London Project Cure Blindness, London, England.
   [Ramsden, Conor M.; da Cruz, Lyndon] NIHR, Biomed Res Ctr, Moorfields Eye Hosp, NHS Fdn Trust, London, England.
   [Ramsden, Conor M.; da Cruz, Lyndon] UCL, Inst Ophthalmol, London, England.
   [Coffey, Peter J.] Univ Calif Santa Barbara, Neurosci Res Unit NRI, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
C3 University of London; University College London; Oxford University
   Hospitals NHS Foundation Trust; University of London; King's College
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London;
   University of California System; University of California Santa Barbara
RP Coffey, PJ (通讯作者)，Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM p.coffey@ucl.ac.uk
OI Coffey, Peter/0000-0002-5427-2939
FU London Project to Cure Blindness; Medical Research Council (MRC) UK
   [G1000730]; California Institute of Regenerative Medicine (CIRM)
   [G1000730]; Fight for Sight UK [1755]; Lincy Foundation [P12761];
   Macular Society; National Institute for Health Research (NIHR)
   Biomedical Research Centre based at Moorfields Eye Hospital National
   Health Service (NHS) Foundation Trust and University College London
   Institute of Ophthalmology [BRC2_011]; MRC [G1000730, MR/L022842/1]
   Funding Source: UKRI; Medical Research Council [G1000730, MR/L022842/1]
   Funding Source: researchfish
FX Supported by funding from The London Project to Cure Blindness; the
   Medical Research Council (MRC) UK (G1000730); the California Institute
   of Regenerative Medicine (CIRM) (G1000730); Fight for Sight UK (1755);
   The Lincy Foundation (P12761); the Macular Society; and the National
   Institute for Health Research (NIHR) (BRC2_011) Biomedical Research
   Centre based at Moorfields Eye Hospital National Health Service (NHS)
   Foundation Trust and University College London Institute of
   Ophthalmology. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR, or the Department of Health.
CR Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Palomo ABA, 2015, FIBROGENESIS TISSUE, V8, DOI 10.1186/s13069-015-0026-9
   Chen FK, 2014, J CLIN MED, V3, P1511, DOI 10.3390/jcm3041511
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DiMasi JA, 2010, CLIN PHARMACOL THER, V87, P272, DOI 10.1038/clpt.2009.295
   Eandi CM, 2008, COCHRANE DB SYST REV, V4
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Salmikangas P, 2010, BUNDESGESUNDHEITSBLA, V53, P24, DOI 10.1007/s00103-009-0991-5
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Yvon C, 2015, COMPUT STRUCT BIOTEC, V13, P382, DOI 10.1016/j.csbj.2015.05.001
NR 13
TC 6
Z9 6
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 5
SI SI
DI 10.1167/iovs.15-18643
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO8NC
UT WOS:000378039300002
PM 27116659
OA gold
DA 2022-11-30
ER

PT J
AU Najafabadi, HS
   Daftarian, N
   Ahmadieh, H
   Soheili, ZS
AF Najafabadi, Hoda Shams
   Daftarian, Narsis
   Ahmadieh, Hamid
   Soheili, Zahra-Soheila
TI Pharmacologic Treatment of Wet Type Age-related Macular Degeneration;
   Current and Evolving Therapies
SO ARCHIVES OF IRANIAN MEDICINE
LA English
DT Review
DE Age-related macular degeneration; angiogenesis; anti-angiogenesis drugs;
   anti-inflammatory drugs; inflammation
ID ENDOTHELIAL GROWTH-FACTOR; DEXAMETHASONE INTRAVITREAL IMPLANT;
   RANDOMIZED CONTROLLED-TRIAL; NECROSIS-FACTOR-ALPHA; PAZOPANIB EYE DROPS;
   CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; TRIAMCINOLONE
   ACETONIDE; CLINICAL-EVALUATION; KETOROLAC EYEDROPS
AB Age-related macular degenera ion as the major cat of blindness in the elderly population has remained at the epicenter esearch in ophthalmology. This retinal disorder is characterized by the photoreceptor and retinal pigment epithelial cells loss, occurring ithin the macula. The disease represents a spectrum of clinical manifestations. It is a multifactorial disease resulting from a combination of genetic predispositions and environmental risk factors. AMD is classified into two different types, dry and wet. 'Wet AMD is in close relation with angiogenesis and inflammatory processes. A variety of anti-angiogenesis arid anti-inflammatory drugs have been proposed for the treatment of the disease. The purpose of this paper is to briefly review the pharmacological therapies of the wet form ofAMD and focus on new drugs that are currently in different stages of research and development,
C1 [Najafabadi, Hoda Shams; Soheili, Zahra-Soheila] Natl Inst Inst Genet Engn & Biotechnol, Km 15,Tehran Karaj Highway, Tehran 14965161, Iran.
   [Daftarian, Narsis] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
   [Ahmadieh, Hamid] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences
RP Soheili, ZS (通讯作者)，Natl Inst Inst Genet Engn & Biotechnol, Km 15,Tehran Karaj Highway, Tehran 14965161, Iran.
EM soheili@nigeb.ac.ir
RI Daftarian, Narsis/AAW-5803-2020; Ahmadieh, Hamid/M-4853-2017; Soheili,
   Zahra-Soheila/W-8316-2018
OI Daftarian, Narsis/0000-0001-5846-8739; Ahmadieh,
   Hamid/0000-0002-8139-2661; Soheili, Zahra-Soheila/0000-0003-1292-465X
CR A DM, 2013, NEW CLIN TRIAL SQUAL
   Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Adler FH, 2011, ADLERS PHYSL EYE ELS
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Ahfat FG, 2013, EYE, V27, P289, DOI 10.1038/eye.2013.1
   Ahmadieh H, 2011, RETINA-J RET VIT DIS, V31, P1819, DOI 10.1097/IAE.0b013e31820d58f2
   Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Akrami H, 2011, GRAEF ARCH CLIN EXP, V249, P537, DOI 10.1007/s00417-010-1567-7
   Apte RS, 2010, ADV EXP MED BIOL, V664, P15, DOI 10.1007/978-1-4419-1399-9_2
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Augustin A, 2006, CLIN INTERV AGING, V1, P237, DOI 10.2147/ciia.2006.1.3.237
   Avastin, 2004, OPHTHAL SURG LAS IM, V36, P331
   Aydin Kurna S, 2014, J OPHTHALMOL, V2014
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Bingaman DP, 2005, INVEST OPHTHALMOL, V46, P464
   Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Carrion M, 2005, ARVO ANN M, P1
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1249, DOI 10.2147/OPTH.S14092
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen X, 2013, DIABETES OBES METAB, V15, P224, DOI 10.1111/dom.12008
   Chen Z, 2007, INVEST OPHTH VIS SCI, V48, P1469
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Connolly Brian, 2006, Ophthalmol Clin North Am, V19, P381
   Coppin C, 2011, BJU INT, V108, P1556, DOI 10.1111/j.1464-410X.2011.10629.x
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417-013-2375-7
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Medeiros MD, 2013, INVEST OPHTH VIS SCI, V54, P3320, DOI 10.1167/iovs.12-11463
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Eter N, 2005, INVEST OPHTH VIS SCI, V46, P1389
   Nano ME, 2013, ARQ BRAS OFTALMOL, V76, P80, DOI 10.1590/S0004-27492013000200005
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Fernandez-Vega B, 2016, CASE REP OPHTHAL, V7, P154, DOI 10.1159/000445102
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   GALLEMORE RP, 2006, REV OPHTHALMOL, V13, P81
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Geltzer A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub2
   Goebel J, 2000, TRANSPL IMMUNOL, V8, P153, DOI 10.1016/S0966-3274(00)00021-6
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Griffin DR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/497178
   Group Adwvs, 2007, RETINA, V27, P693
   Hamilton MM, 2008, MOL VIS, V14, P2535
   HANNINK M, 1989, BIOCHIM BIOPHYS ACTA, V989, P1, DOI 10.1016/0304-419X(89)90031-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HO AC, 2002, DRUGS FUTURE, V27, P1039
   Hoyng C, 2005, INVEST OPHTH VIS SCI, V46, P2365
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Jost LM, 2006, DRUG METAB DISPOS, V34, P1817, DOI 10.1124/dmd.106.009944
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kudelka MR, 2013, EXPERT REV OPHTHALMO, V8, P475, DOI 10.1586/17469899.2013.840095
   Kumar B, 2012, J POSTGRAD MED, V58, P132, DOI 10.4103/0022-3859.97176
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li X, OPHTHALMOLOGY, V121, P1740
   Libondi T, 2010, ACTA OPHTHALMOL, V88, pe32, DOI 10.1111/j.1755-3768.2008.01491.x
   Liu E, 2007, J AM SOC NEPHROL, V18, P2094, DOI 10.1681/ASN.2006010075
   Liu K, 2012, INT J PHOTOENERGY, V2012, P9
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Machalinska A, 2011, J OCUL PHARMACOL TH, V27, P471, DOI 10.1089/jop.2011.0091
   Magdelaine-Beuzelin C, 2010, MABS-AUSTIN, V2, P176, DOI 10.4161/mabs.2.2.11205
   Mares JA, 2006, AM J CLIN NUTR, V83, P733, DOI 10.1093/ajcn/83.4.733
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Perkel JM, 2009, SCIENCE, V326, P454, DOI 10.1126/science.opms.p0900039
   Porte C., 2012, SUMJ, V1
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Rivera M LA, 2012, PHARMACOKINETICS VEG
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Russo A, 2013, BRIT J OPHTHALMOL, V97, P1273, DOI 10.1136/bjophthalmol-2013-303417
   Samiei S BA, 2011, 11 EUR C
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Shukla Dhananjay, 2007, Indian Journal of Ophthalmology, V55, P427
   Singh R, 2014, RETINA-J RET VIT DIS, V34, P1787, DOI 10.1097/IAE.0000000000000179
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Sweeney K, 2005, DRUG DISCOV TODAY, V10, P1346, DOI 10.1016/S1359-6446(05)03607-X
   Tay HW., 1875, R LOND OPHTHAL HOSP, V8, P231
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Thomson AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/nri2546
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Tsoumakidou M, 2008, AM J RESP CRIT CARE, V177, P1180, DOI 10.1164/rccm.200711-1727PP
   Tsurufuji S, 1981, MECHANISMS TREATMENT, P63
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wetzel SK, 2010, J MOL BIOL, V402, P241, DOI 10.1016/j.jmb.2010.07.031
   Wu L, 2013, J OCUL PHARMACOL TH, V29, P366, DOI 10.1089/jop.2012.0203
   Wygledowska-Promienska D, 2014, MED SCI MONITOR, V20, P1168, DOI 10.12659/MSM.890671
   Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zou LH, 2011, THERANOSTICS, V1, P395, DOI 10.7150/thno/v01p0395
NR 120
TC 3
Z9 3
U1 0
U2 7
PU ACAD MEDICAL SCIENCES I R IRAN
PI TEHRAN
PA PO BOX 19395-5655, TEHRAN, 00000, IRAN
SN 1029-2977
EI 1735-3947
J9 ARCH IRAN MED
JI Arch. Iran. Med.
PD AUG
PY 2017
VL 20
IS 8
BP 525
EP 537
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FF1LE
UT WOS:000408660200009
PM 28846017
DA 2022-11-30
ER

PT J
AU Marc, RE
   Jones, BW
   Watt, CB
   Vazquez-Chona, F
   Vaughan, DK
   Organisciak, DT
AF Marc, Robert E.
   Jones, B. W.
   Watt, C. B.
   Vazquez-Chona, F.
   Vaughan, D. K.
   Organisciak, D. T.
TI Extreme retinal remodeling triggered by light damage: implications for
   age related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID AMINO-ACID SIGNATURES; PIGMENT-EPITHELIUM; MOUSE MODEL;
   IMMUNOCYTOCHEMICAL LOCALIZATION; MOLECULAR CHARACTERIZATION; ARGININE
   METABOLISM; PLASMA-MEMBRANE; ANIMAL-MODELS; MULLER CELLS; RAT RETINAS
AB Purpose: Our objective was to comprehensively assess the nature and chronology of neural remodeling in retinal degenerations triggered by light-induced retinal damage (LIRD) in adult albino rodents. Our primary hypothesis is that all complete photoreceptor degenerations devolve to extensive remodeling. An hypothesis emergent from data analysis is that the LIRD model closely mimics late-stage atrophic age relared macular degeneration (AMD).
   Methods: Sprague-Dawley (SD) rats received intense light exposures of varied durations and survival times ranging from 0 to 240 days. Remodeling was visualized by computational molecular phenotyping (CMP) of a small molecule library: 4-aminobutyrate (.), arginine (R), aspartate (D), glutamate (E), glutamine (Q), glutathione (J), glycine (G), and taurine (t). This library was augmented by probes for key proteins such as rod opsin, cone opsin and cellular retinal binding protein (CRALBP). Quantitative CMP was used to profile 160 eyes from 86 animals in over 6,000 sections.
   Results: The onset of remodeling in LIRD retinas is rapid, with immediate signs of metabolic stress in photoreceptors, the retinal pigmented epithelium (RPE), the choriocapillaris, and Muller cells. In particular, anomalous elevated aspartate levels appear to be an early stress marker in photoreceptors. After the stress phase, LIRD progresses to focal photoreceptor degeneration within 14 days and extensive remodeling by 60 days. RPE and choriocapillaris losses parallel Muller cell distal seal formation, with progressive neuronal migration, microneuroma evolution, fluid channel formation, and slow neuronal death. The remaining retina in advanced light damage can be classified as survivor, light damage (LD), or decimated zones where massive Muller cell and neuronal emigration into the choroid leaves a retina depleted of neurons and Muller cells. These zones and their transitions closely resemble human geographic atrophy. Across these zones, Muller cells manifest extreme changes in the definitive Muller cell tau QE signature, as well as CRALBP and arginine signals.
   Conclusions: LIRD retinas manifest remodeling patterns of genetic retinal degeneration models, but involve no developmental complexities, and are ultimately more aggressive, devastating the remaining neural retina. The decimation of the neural retina via cell emigration through the perforated retina-choroid interface is a serious denouement. If focal remodeling in LIRD accurately profiles late stage atrophic age-related macular degenerations, it augurs poorly for simple molecular interventions. Indeed, the LIRD profile in the SD rat manifests more similarities to advanced human atrophic AMD than most genetically or immunologically induced murine models of AMD.
C1 [Marc, Robert E.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol, Salt Lake City, UT 84132 USA.
   [Vaughan, D. K.] Univ Wisconsin, Dept Biol, Oshkosh, WI 54901 USA.
   [Organisciak, D. T.] Wright State Univ, Petticrew Res Lab, Dept Biochem & Mol Biol, Dayton, OH 45435 USA.
C3 Utah System of Higher Education; University of Utah; University of
   Wisconsin System; University System of Ohio; Wright State University
   Dayton
RP Marc, RE (通讯作者)，Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol, 65 Med Dr, Salt Lake City, UT 84132 USA.
EM robert.marc@hsc.utah.edu
OI Merriman, Dana/0000-0003-2780-0772; Jones, Bryan/0000-0001-5527-6643
FU NATIONAL EYE INSTITUTE [R01EY015128, P30EY014800, R01EY001959,
   R01EY002576] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY002576,
   EY01959, R01 EY015128, EY014800, R01 EY001959, EY015128, P30 EY014800,
   EY02576] Funding Source: Medline
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Berkich DA, 2007, J NEUROSCI RES, V85, P3367, DOI 10.1002/jnr.21500
   Bhutto IA, 2001, ANAT RECORD, V264, P63, DOI 10.1002/ar.1102
   Boatright JH, 2006, MOL VIS, V12, P1706
   Bosco A, 2005, INVEST OPHTH VIS SCI, V46, P3869, DOI 10.1167/iovs.05-0385
   Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   Chen J, 2008, ADV EXP MED BIOL, V613, P53, DOI 10.1007/978-0-387-74904-4_5
   Clagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241
   CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216
   Darrow RA, 1997, CURR EYE RES, V16, P144, DOI 10.1076/ceyr.16.2.144.5092
   Dejneka NS, 2003, DEV OPHTHALMOL, V37, P188
   Duncan T, 2006, PHOTOCHEM PHOTOBIOL, V82, P741, DOI 10.1562/2005-10-05-RA-712
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gordon WC, 2002, INVEST OPHTH VIS SCI, V43, P3511
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P4529, DOI 10.1167/iovs.04-0919
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Iandiev I, 2006, NEUROSCI LETT, V408, P108, DOI 10.1016/j.neulet.2006.08.084
   Johnson J, 1996, J COMP NEUROL, V375, P212
   Joly S, 2007, INVEST OPHTH VIS SCI, V48, P2311, DOI 10.1167/iovs.06-1205
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kalloniatis M, 1996, J NEUROSCI, V16, P6807
   Kornyei Z, 2007, FASEB J, V21, P2496, DOI 10.1096/fj.06-7756com
   Kramer R, 1998, EXP PHYSIOL, V83, P259, DOI 10.1113/expphysiol.1998.sp004111
   Lane MA, 2005, PROG NEUROBIOL, V75, P275, DOI 10.1016/j.pneurobio.2005.03.002
   LEWIS GP, 1994, AM J OPHTHALMOL, V118, P368, DOI 10.1016/S0002-9394(14)72962-9
   Lewis GP, 2005, MOL VIS, V11, P491
   LEWIS GP, 1991, EXP EYE RES, V53, P629, DOI 10.1016/0014-4835(91)90223-2
   LI ZY, 1995, J NEUROSCI, V15, P5429
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Loewenstein JI, 2004, ARCH OPHTHALMOL-CHIC, V122, P587, DOI 10.1001/archopht.122.4.587
   LOMBARDINI JB, 1991, BRAIN RES REV, V16, P151, DOI 10.1016/0165-0173(91)90003-Q
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   Luo TL, 2006, J NEUROBIOL, V66, P677, DOI 10.1002/neu.20239
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Marc RE, 1998, INVEST OPHTH VIS SCI, V39, P1694
   Marc RE, 1998, INVEST OPHTH VIS SCI, V39, P1685
   MARC RE, 1990, J NEUROSCI, V10, P4006, DOI 10.1523/JNEUROSCI.10-12-04006.1990
   MARC RE, 1995, J NEUROSCI, V15, P5106
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2001, J NEUROCYTOL, V30, P593, DOI 10.1023/A:1016516818393
   Marc RE, 1999, J COMP NEUROL, V407, P47, DOI 10.1002/(SICI)1096-9861(19990428)407:1<47::AID-CNE4>3.0.CO;2-0
   Marc RE, 1999, J COMP NEUROL, V407, P65
   Marc RE, 2002, J NEUROSCI, V22, P413, DOI 10.1523/JNEUROSCI.22-02-00413.2002
   MARC RE, 2005, PLASTICITY VISUAL SY, P33
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   McCaffery PJ, 2003, EUR J NEUROSCI, V18, P457, DOI 10.1046/j.1460-9568.2003.02765.x
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Militante J, 2004, NEUROCHEM RES, V29, P151, DOI 10.1023/B:NERE.0000010444.97959.1b
   Molotkova N, 2007, DEV BIOL, V303, P601, DOI 10.1016/j.ydbio.2006.11.035
   Morris SM, 2007, J NUTR, V137, p1602S, DOI 10.1093/jn/137.6.1602S
   NIR I, 1986, INVEST OPHTH VIS SCI, V27, P836
   Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694
   Peng YW, 2000, NAT NEUROSCI, V3, P1121, DOI 10.1038/80639
   Peranzoni E, 2007, IMMUNOBIOLOGY, V212, P795, DOI 10.1016/j.imbio.2007.09.008
   Pignatelli V, 2004, J COMP NEUROL, V469, P351, DOI 10.1002/cne.11019
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   POW DV, 1994, NEUROSCIENCE, V60, P355, DOI 10.1016/0306-4522(94)90249-6
   Ranchon I, 2003, J NEUROSCI, V23, P6050, DOI 10.1523/JNEUROSCI.23-14-06050.2003
   Rascher K, 2004, VISION RES, V44, P2091, DOI 10.1016/j.visres.2004.03.027
   RAYBORN ME, 1982, OPHTHALMOLOGY, V89, P1441
   Rodriguez PC, 2007, BLOOD, V109, P1568, DOI 10.1182/blood-2006-06-031856
   Rubino FM, 2004, J AM SOC MASS SPECTR, V15, P288, DOI 10.1016/j.jasms.2003.10.013
   Sarthy VP, 2005, GLIA, V49, P184, DOI 10.1002/glia.20097
   Schaffer S, 2000, AMINO ACIDS, V19, P527, DOI 10.1007/s007260070004
   Scholl HPN, 2007, MOL VIS, V13, P196
   Sidoryk M, 2004, NEUROREPORT, V15, P575, DOI 10.1097/00001756-200403220-00001
   Strettoi E, 2003, VISION RES, V43, P867, DOI 10.1016/S0042-6989(02)00594-1
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1864, DOI 10.1167/iovs.06-1065
   Tomi M, 2007, MICROVASC RES, V73, P100, DOI 10.1016/j.mvr.2006.10.003
   Trauger SA, 2008, J PROTEOME RES, V7, P1027, DOI 10.1021/pr700609j
   Troilo D, 2006, INVEST OPHTH VIS SCI, V47, P1768, DOI 10.1167/iovs.05-0298
   Umekage S, 2006, FEBS LETT, V580, P1222, DOI 10.1016/j.febslet.2006.01.033
   USUKURA J, 1987, EXP EYE RES, V45, P501, DOI 10.1016/S0014-4835(87)80061-1
   Varela C, 2003, VISION RES, V43, P879, DOI 10.1016/S0042-6989(02)00493-5
   Vaughan DK, 2003, INVEST OPHTH VIS SCI, V44, P848, DOI 10.1167/iovs.02-0709
   Vaughan DK, 2002, PHOTOCHEM PHOTOBIOL, V75, P547, DOI 10.1562/0031-8655(2002)075<0547:EFACRO>2.0.CO;2
   Vinnakota S, 1997, J NEUROCHEM, V69, P2238
   Warskulat U, 2007, METHOD ENZYMOL, V428, P439, DOI 10.1016/S0076-6879(07)28025-5
   WATANABE S, 1991, J BIOL CHEM, V266, P20803
   Williams A, 2007, GLIA, V55, P1300, DOI 10.1002/glia.20546
   Xu Y, 2007, J NEUROCHEM, V101, P120, DOI 10.1111/j.1471-4159.2006.04349.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yeramian A, 2006, EUR J IMMUNOL, V36, P1516, DOI 10.1002/eji.200535694
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 97
TC 210
Z9 224
U1 0
U2 10
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 25
PY 2008
VL 14
IS 93-96
BP 782
EP U1
PG 25
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 320WB
UT WOS:000257264700002
PM 18483561
DA 2022-11-30
ER

PT J
AU Iwasaki, M
   Kobayashi, K
   Aoki, S
   Miyamoto, H
   Imaizumi, H
AF Iwasaki, Masanori
   Kobayashi, Kenji
   Aoki, Shuichiro
   Miyamoto, Hirotomo
   Imaizumi, Hiroko
TI Comparative analysis of polypoidal choroidal vasculopathy with and
   without hemorrhage treated by anti-VEGF monotherapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor monotherapy; Exudative
   polypoidal choroidal vasculopathy; Hemorrhagic pigment epithelium
   detachment; Hemorrhagic polypoidal choroidal vasculopathy; Neovascular
   age-related macular degeneration; Optical coherence tomography
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; CLINICOPATHOLOGICAL
   CORRELATION; RANIBIZUMAB; VERTEPORFIN; AFLIBERCEPT; THICKNESS; DIAGNOSIS
AB Purpose Visual function and treatment response after anti-vascular endothelial growth factor monotherapy were compared between polypoidal choroidal vasculopathy (PCV) with and without hemorrhage. Methods We conducted a retrospective, observational study (mean, 26 months) for 49 eyes of 49 treatment-naive patients with PCV. Patients were classified into PCV with hemorrhage (26 eyes) or without hemorrhage (23 eyes). PCV with massive hemorrhage subgroup has four or more disc-hemorrhagic areas and included five eyes. Results There were no significant differences in patient age, sex, systolic blood pressure, diastolic blood pressure, presence of choroidal vascular hyperpermeability, number of polyps, maximum polyp size, lesion area, and presence of pigment epithelium detachment (PED) between the two groups. Except for the course of PCV-related hemorrhage, treatment number and its response were similar between the groups. Best-corrected visual acuity at the last visit in PCV with hemorrhage was 0.33 +/- 0.51 logMAR (20/41) comparable with 0.28 +/- 0.41 logMAR (20/38) without hemorrhage at the last visit (p = 0.944). Maximum polyp size in massive hemorrhagic PCV was significantly larger (314.6 +/- 111.4 mu m) than that of small hemorrhagic PCV (229.0 +/- 119.1 mu m; p = 0.037). All PCV with massive hemorrhage was accompanied by large hemorrhagic PED. Conclusion There were no significant differences in the baseline characteristics, treatment intervention, or suppression of disease activity between PCV with and without hemorrhage. Final visual acuity of PCV did not differ with or without hemorrhage. Development of massive hemorrhaging in PCV may be associated with both large polyps and hemorrhagic PED.
C1 [Iwasaki, Masanori; Kobayashi, Kenji; Aoki, Shuichiro; Miyamoto, Hirotomo; Imaizumi, Hiroko] Sapporo City Gen Hosp, Dept Ophthalmol, Chuo Ku, 1-1 Kita 11 Jo Nishi 13 Chome, Sapporo, Hokkaido 0608604, Japan.
C3 Sapporo City General Hospital
RP Iwasaki, M (通讯作者)，Sapporo City Gen Hosp, Dept Ophthalmol, Chuo Ku, 1-1 Kita 11 Jo Nishi 13 Chome, Sapporo, Hokkaido 0608604, Japan.
EM iwasakicom@yahoo.co.jp
OI Iwasaki, Masanori/0000-0002-7397-8654
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Matsumoto H, 2020, JPN J OPHTHALMOL, V64, P203, DOI 10.1007/s10384-020-00722-7
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Seidel G, 2015, AM J OPHTHALMOL, V159, P365, DOI 10.1016/j.ajo.2014.11.002
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
NR 20
TC 0
Z9 0
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2021
VL 259
IS 7
BP 1741
EP 1750
DI 10.1007/s00417-020-05033-8
EA JAN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TI3LH
UT WOS:000605543600004
PM 33409679
DA 2022-11-30
ER

PT J
AU Brown, EE
   Ball, JD
   Chen, ZY
   Khurshid, GS
   Prosperi, M
   Ash, JD
AF Brown, Emily E.
   Ball, Jacob D.
   Chen, Zhaoyi
   Khurshid, Gibran S.
   Prosperi, Mattia
   Ash, John D.
TI The Common Antidiabetic Drug Metformin Reduces Odds of Developing
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; metformin; case controlled study
ID ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; NATIONAL-HEALTH;
   ASSOCIATION; RISK; BEVACIZUMAB; MORBIDITY; MECHANISM; DISEASE; MODEL
AB PURPOSE. AMD is the leading cause of irreversible blindness in older individuals in the Western world, and there are currently no therapies to halt disease progression. Studies suggest that the commonly prescribed antidiabetic drug, metformin, is associated with decreased risk of several ocular diseases, but no work has investigated the effect of metformin use on development of AMD. Thus, we aim to investigate whether metformin use is associated with decreased risk of developing AMD.
   METHODS. In this retrospective case-control study, we used medical records from patients older than 55 who have visited a University of Florida health clinic. Three controls were matched for every AMD case, defined by International Classification of Diseases, Ninth Revision code, based on the Charlson Comorbidity Index to ensure comparable baseline overall health status. Univariate and conditional multivariable logistic regressions were used to determine the association between a variety of covariates, including metformin use, and AMD diagnosis.
   RESULTS. Metformin use was associated with decreased odds of developing AMD, independently of the other covariates investigated, with an odds ratio of 0.58 and a 95% confidence interval of 0.43 to 0.79. Other medications assessed were not associated with decreased odds of developing AMD.
   CONCLUSIONS. Patients who had taken metformin had decreased odds of developing AMD, suggesting that metformin may have a therapeutic role in AMD development or progression in those who are at risk. Further work should include clinical trials to investigate prospectively whether metformin has a protective effect in those at risk for developing AMD.
C1 [Brown, Emily E.; Khurshid, Gibran S.; Ash, John D.] Univ Florida, Coll Med, Dept Ophthalmol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.
   [Brown, Emily E.] Univ Florida, Clin & Translat Sci Inst, Gainesville, FL 32610 USA.
   [Ball, Jacob D.; Chen, Zhaoyi; Prosperi, Mattia] Univ Florida, Dept Epidemiol, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32610 USA.
   [Ball, Jacob D.; Chen, Zhaoyi; Prosperi, Mattia] Univ Florida, Coll Med, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida
RP Ash, JD (通讯作者)，Univ Florida, Coll Med, Dept Ophthalmol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.
EM jash@ufl.edu
OI Brown, Emily/0000-0003-0658-074X
FU National Center for Advancing Translational Sciences of NIH
   [UL1TR001427]; Foundation Fighting Blindness; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [R01EY016459] Funding Source: NIH
   RePORTER
FX Supported by the National Center for Advancing Translational Sciences of
   NIH under Award Number UL1TR001427. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of NIH. Additional funding comes from the Foundation
   Fighting Blindness and an unrestricted grant from Research to Prevent
   Blindness. These funding organizations had no role in the design or
   conduct of this research.
CR Ahmed CM, 2016, MOL VIS, V22, P294
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Calabrese MF, 2014, STRUCTURE, V22, P1161, DOI 10.1016/j.str.2014.06.009
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085716, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0087752, 10.1371/journal.pone.0091830]
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Filipp SL, 2018, OBES SCI PRACT, V4, P308, DOI 10.1002/osp4.274
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   HO DE, 2011, J STAT SOFTW, V42, P1, DOI DOI 10.18637/JSS.V042.I08
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kooragayala K, 2015, INVEST OPHTH VIS SCI, V56, P8428, DOI 10.1167/iovs.15-17901
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Lin HC, 2015, JAMA OPHTHALMOL, V133, P915, DOI 10.1001/jamaophthalmol.2015.1440
   Lin TC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188136
   MA L, 2015, SCI REP UK, V5
   Malgorzata Figurska, 2010, Klin Oczna, V112, P213
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Samuel MA, 2014, NAT NEUROSCI, V17, P1190, DOI 10.1038/nn.3772
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   U. S. Centers for Medicare & Medicaid Services, 2018 ICD 10 CM AND G
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Villena JE, 2011, REV PANAM SALUD PUBL, V30, P408
   Wang J, 2016, P NATL ACAD SCI USA, V113, pE3764, DOI 10.1073/pnas.1521749113
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 44
TC 35
Z9 36
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2019
VL 60
IS 5
BP 1470
EP 1477
DI 10.1167/iovs.18-26422
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HW5VL
UT WOS:000466757300021
PM 30973575
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kenney, MC
   Atilano, SR
   Boyer, D
   Chwa, M
   Chak, G
   Chinichian, S
   Coskun, P
   Wallace, DC
   Nesburn, AB
   Udar, NS
AF Kenney, M. Cristina
   Atilano, Shari R.
   Boyer, David
   Chwa, Marilyn
   Chak, Garrick
   Chinichian, Sahmon
   Coskun, Pinar
   Wallace, Douglas C.
   Nesburn, Anthony B.
   Udar, Nitin S.
TI Characterization of Retinal and Blood Mitochondrial DNA from Age-Related
   Macular Degeneration Patients
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MTDNA CONTROL-REGION; OXIDATIVE STRESS; EPITHELIAL-CELLS; POINT
   MUTATION; HAPLOGROUPS; METABOLISM; DISEASES; IDENTIFICATION; DAMAGE
AB PURPOSE. To determine mitochondrial (mt)DNA variants in AMD and age-matched normal retinas.
   METHODS. Total DNA was isolated from retinas (AMD, n = 13; age-matched normal, n = 13), choroid (AMD, n = 3), and blood (AMD, n = 138; normal, n = 133). Long-extension-polymerase chain reaction amplified the full-length (similar to 16.2 kb) mtDNA genome. Retinal mtDNA was sequenced for nucleotide variants and length heteroplasmy. Pyrosequencing was performed on heteroplasmic mtDNA. PCR amplification and enzyme digestions were used to analyze for nucleotide changes.
   RESULTS. Retinal mtDNA had a greater number of rearrangements and deletions than did blood mtDNA in normal samples (9.3 +/- 1.78 vs. 3 +/- 1.18, P = 0.019), and AMD samples (14.33 +/- 1.96 vs. 5.2 +/- 0.80, P = 0.0031. Five (55%) of 9 AMD patients had unreported SNPs, and 2 (16.6%) of 12 of the normal group did. The mtDNA coding region had 20 SNPs that produced amino acid changes. The noncoding MT-Dloop region had nucleotide heteroplasmy and length heteroplasmy. There were more SNPs per person in the AMD population than in the older (P = 0.003) and younger (P = 0.05) normal subjects. The C12557T (T-I) in the MT-ND5 gene was present in two AMD subjects (2/138) but was absent in the normal (0/133). Common mutations for Leber's hereditary optic neuropathy (LHON: G11778A; T14484C; and G3460A) were not present in AMD samples.
   CONCLUSIONS. AMD subjects have high levels of large mtDNA deletions/rearrangements in the retinas, unreported and amino acid-changing SNPs in the coding genome, and a greater number of SNPs per person in the noncoding MT-Dloop region. These mtDNA variants could diminish energy production efficiency, alter the mtDNA copy numbers and/or impact transcription in AMD retinas. (Invest Ophthalmol Vis Sci. 2010; 51:4289-4297) DOI:10.1167/iovs.09-4778
C1 [Kenney, M. Cristina] Univ Calif Irvine, Dept Ophthalmol, Med Ctr, Orange, CA 92868 USA.
   [Coskun, Pinar; Wallace, Douglas C.] Univ Calif Irvine, Dept Biol Chem, Orange, CA 92868 USA.
   [Coskun, Pinar; Wallace, Douglas C.] Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Orange, CA 92868 USA.
   [Coskun, Pinar; Wallace, Douglas C.] Univ Calif Irvine, Dept Pediat, Orange, CA 92868 USA.
   [Coskun, Pinar; Wallace, Douglas C.] Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Orange, CA 92868 USA.
   [Boyer, David] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Amer Eye Inst, Los Angeles, CA 90048 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine; Retina
   Vitreous Associates Medical Group; Cedars Sinai Medical Center
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Ophthalmol, Med Ctr, 101 City Dr, Orange, CA 92868 USA.
EM mkenney@uci.edu
OI Atilano, Shari/0000-0002-7729-7864; Udar, Nitin/0000-0001-8533-9190
FU Discovery Eye Foundation; Lincy Foundation; Henry L. Guenther
   Foundation; Iris and B. Gerald Cantor Foundation; Gilbert Foundation;
   Research to Prevent Blindness
FX Supported by The Discovery Eye Foundation, the Lincy Foundation, the
   Henry L. Guenther Foundation, the Iris and B. Gerald Cantor Foundation,
   the Gilbert Foundation, and Research to Prevent Blindness.
CR Atilano SR, 2009, CORNEA, V28, P426, DOI 10.1097/ICO.0b013e31818c2c55
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   BENDALL KE, 1995, AM J HUM GENET, V57, P248
   Bendall KE, 1997, AM J HUM GENET, V61, P1303, DOI 10.1086/301636
   Bravo-Nuevo A, 2003, ADV EXP MED BIOL, V533, P241
   BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786
   FUTTERMAN S, 1959, J BIOL CHEM, V234, P723
   HAUSWIRTH WW, 1985, NUCLEIC ACIDS RES, V13, P8093, DOI 10.1093/nar/13.22.8093
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Nag TC, 2006, BRAIN RES BULL, V71, P224, DOI 10.1016/j.brainresbull.2006.09.007
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   TORRONI A, 1994, AM J HUM GENET, V55, P760
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   WANG AL, NEUROBIOL AGING
   WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667
NR 28
TC 36
Z9 38
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 4289
EP 4297
DI 10.1167/iovs.09-4778
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JT
UT WOS:000280194100063
PM 20357205
DA 2022-11-30
ER

PT J
AU Mahalingam, M
   Sachidanandam, R
   Verma, A
   Alagorie, AR
   Sen, P
AF Mahalingam, Maanasi
   Sachidanandam, Ramya
   Verma, Aditya
   Alagorie, Ahmed Roshdy
   Sen, Parveen
TI Choriocapillaris flow deficits in polypoidal choroidal vasculopathy
   using swept source optical coherence tomography angiography
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choriocapillaris; flow deficits; polypoidal choroidal vasculopathy
ID DISEASE
AB Purpose: To evaluate the choriocapillaris flow deficits (CCFD) on swept-source optical coherence tomography angiography (SS-OCTA) in eyes with unilateral polypoidal choroidal vasculopathy (PCV), fellow unaffected eyes, and to compare them with age-matched healthy controls. Methods: This study was a cross-sectional study which included treatment-naive eyes with unilateral PCV (group 1), fellow unaffected eyes of patients with PCV (group 2), and normal eyes (group 3). Using the SS-OCTA, the Choriocapillaris (CC) slab was segmented from the structural optical coherence tomography (OCT) and the corresponding flow map was multiplied after signal compensation. The resultant image was evaluated for CCFD in equidistant squares measuring 1 x 1 mm, 1.5 x 1.5 mm, 2 x 2 mm, 2.5 x 2.5 mm, 3 x 3 mm, and 6 x 6 mm centered on the fovea. Results: The percentage of flow deficits were significantly increased (one-way ANOVA, P = 0.003 and P = 0.049) in the eyes with PCV as compared to the fellow eyes, and age-matched healthy controls. In the multiple pairwise comparison using post hoc Bonferroni, CCFD of 1 mm in group 1 and 2 (P = 0.019), group 1 and 3 (P = 0.003), and CCFD of 1.5 mm in group 1 and 3 (P = 0.044) were statistically significant. Correlation analysis showed no significant correlation between CCFD, age, Best corrected visual acuity (BCVA), foveal thickness (FT), and subfoveal choroidal thickness (SFCT) in our study. Linear regression analysis showed that the CCFD was negatively correlated with the distance from the foveal center in group 1 (beta = -0.613, P = 0.046). Conclusion: Eyes with PCV demonstrated a significant flow impairment in the choriocapillaris layer as compared to the fellow unaffected eyes and age-matched healthy eyes.
C1 [Mahalingam, Maanasi; Sachidanandam, Ramya] Unit Med Res Fdn, Elite Sch Optometry, Sankara Nethralaya, Chennai, Tamil Nadu, India.
   [Verma, Aditya; Sen, Parveen] Med Res Fdn, Dept Vitreo Retinal Serv, Chennai, Tamil Nadu, India.
   [Alagorie, Ahmed Roshdy] Tanta Univ, Fac Med, Dept Ophthalmol, Tanta, Egypt.
C3 Egyptian Knowledge Bank (EKB); Tanta University
RP Sen, P (通讯作者)，Med Res Fdn, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
EM parveensen@gmail.com
OI Mahalingam, Maanasi/0000-0002-2881-3316
CR Alagorie AR, 2020, RETINA-J RET VIT DIS, V40, P2106, DOI 10.1097/IAE.0000000000002878
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Baek J, 2020, RETINA-J RET VIT DIS, V40, P2166, DOI 10.1097/IAE.0000000000002723
   Baek J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42052-w
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Chun LY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223142
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P2887, DOI 10.1007/s00417-021-05167-3
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Dai YN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243830
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Greig EC, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00262-9
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Luo MY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01386-0
   Lutty G, 1999, MOL VIS, V5
   Matet A, 2019, RETINA-J RET VIT DIS, V39, P2178, DOI 10.1097/IAE.0000000000002271
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miyata M, 2018, BRIT J OPHTHALMOL, V102, P1208, DOI 10.1136/bjophthalmol-2017-311313
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 24
TC 0
Z9 0
U1 2
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD AUG
PY 2022
VL 70
IS 8
BP 3002
EP 3007
DI 10.4103/ijo.IJO_2905_21
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4D6HV
UT WOS:000847240800048
PM 35918961
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pivovar, A
   Oellers, P
AF Pivovar, Andrew
   Oellers, Patrick
TI Peripheral Manifestations in Age Related Macular Degeneration: A Review
   of Imaging and Findings
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; peripheral; ultra-widefield;
   fluorescein autofluorescence; grid analysis
ID FUNDUS AUTOFLUORESCENCE; PREVALENCE; GENOTYPES; DRUSEN; EYES
AB Purpose: To review novel findings in research with ultra-widefield imaging for analysis of peripheral manifestations in macular degeneration (AMD). We introduce the evolving widefield imaging modalities while summarizing the analytical techniques used in data collection of peripheral retinal findings thus far. Our review provides a summary of advancements to date and a commentary on future direction for AMD research. Methods: This is a literature review of all significant publications focused on the relationship between AMD and the retinal periphery conducted within the last two decades. Results and Conclusion: Promising research has been undertaken to elucidate peripheral retinal manifestations in macular degeneration using novel methodology. Advancements in ultra-widefield imaging and fundus autofluorescence have allowed us to elucidate peripheral retinal pigmentary changes, drusen deposition, and much more. Novel grid overlay techniques have been introduced to aid in analyzing these changes for pattern recognition and grouping of findings. This review discusses these findings in detail, providing evidence for the pan-retinal manifestations of AMD. Inter-study discordance in analytical approach highlights a need for more systematic future study.
C1 [Pivovar, Andrew; Oellers, Patrick] SUNY Upstate Med Univ, Dept Ophthalmol & Visual Sci, Syracuse, NY 13202 USA.
   [Oellers, Patrick] Retina Vitreous Surg Cent New York, Liverpool, NY 13088 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Upstate Medical Center
RP Oellers, P (通讯作者)，SUNY Upstate Med Univ, Dept Ophthalmol & Visual Sci, Syracuse, NY 13202 USA.; Oellers, P (通讯作者)，Retina Vitreous Surg Cent New York, Liverpool, NY 13088 USA.
EM pivovara@upstate.edu; poellers@rvscny.com
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bae K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170526
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Choudhry N, 2019, OPHTHALMOL RETINA, V3, P843, DOI 10.1016/j.oret.2019.05.007
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Forshaw TRJ, 2019, OPHTHALMOL RETINA, V3, P734, DOI 10.1016/j.oret.2019.04.014
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Guduru A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177207
   Heussen FM, 2012, INVEST OPHTH VIS SCI, V53, P6526, DOI 10.1167/iovs.12-9909
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   JABS, 1992, CONTROL CLIN TRIALS, V13, P22
   Kucukiba K, 2020, TURK OFTALMOL DERG, V50, P6, DOI 10.4274/tjo.galenos.2019.00359
   Lains I, 2018, AM J OPHTHALMOL, V190, P113, DOI 10.1016/j.ajo.2018.03.035
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Matsui Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7436293
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Nomura Y, 2015, CLIN OPHTHALMOL, V9, P297, DOI 10.2147/OPTH.S78210
   Oellers P, 2017, CLIN OPHTHALMOL, V11, P1967, DOI 10.2147/OPTH.S143246
   Patel SN, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841419899495
   Quinn N, 2019, PROG RETIN EYE RES, V68, P83, DOI 10.1016/j.preteyeres.2018.10.001
   Reznicek L, 2012, INVEST OPHTH VIS SCI, V53, P2193, DOI 10.1167/iovs.11-8483
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sepah YJ, 2014, SAUDI J OPHTHALMOL, V28, P111, DOI 10.1016/j.sjopt.2014.03.008
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Suetsugu T, 2016, CLIN OPHTHALMOL, V10, P2497, DOI 10.2147/OPTH.S120402
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Tsunoda K, 2019, DOC OPHTHALMOL, V139, P171, DOI 10.1007/s10633-019-09705-7
   Witmer MT, 2012, ACTA OPHTHALMOL, V90, pe428, DOI 10.1111/j.1755-3768.2012.02434.x
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
NR 31
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2021
VL 10
IS 17
AR 3993
DI 10.3390/jcm10173993
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA UN9DP
UT WOS:000694307900001
PM 34501441
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mohan, RR
   Cabrera, AP
   Harrison, RES
   Gorham, RD
   Johnson, LV
   Ghosh, K
   Morikis, D
AF Mohan, Rohith R.
   Cabrera, Andrea P.
   Harrison, Reed E. S.
   Gorham, Ronald D., Jr.
   Johnson, Lincoln V.
   Ghosh, Kaustabh
   Morikis, Dimitrios
TI Peptide redesign for inhibition of the complement system: Targeting
   age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H POLYMORPHISM; COMPSTATIN; DESIGN;
   ACTIVATION; CELL; DRUSEN; INFLAMMATION; VARIANTS; DISEASE
AB Purpose: To redesign a complement-inhibiting peptide with the potential to become a therapeutic for dry and wet agerelated macular degeneration (AMD).
   Methods: We present a new potent peptide (Peptide 2) of the compstatin family. The peptide is developed by rational design, based on a mechanistic binding hypothesis, and structural and physicochemical properties derived from molecular dynamics (MD) simulation. The inhibitory activity, efficacy, and solubility of Peptide 2 are evaluated using a hemolytic assay, a human RPE cell-based assay, and ultraviolet (UV) absorption properties, respectively, and compared to the respective properties of its parent peptide (Peptide 1).
   Results: The sequence of Peptide 2 contains an arginine-serine N-terminal extension (a characteristic of parent Peptide 1) and a novel 8-polyethylene glycol (PEG) block C-terminal extension. Peptide 2 has significantly improved aqueous solubility compared to Peptide 1 and comparable complement inhibitory activity. In addition, Peptide 2 is more efficacious in inhibiting complement activation in a cell-based model that mimics the pathobiology of dry AMD.
   Conclusions: We have designed a new peptide analog of compstatin that combines N-terminal polar amino acid extensions and C-terminal PEGylation extensions. This peptide demonstrates significantly improved aqueous solubility and complement inhibitory efficacy, compared to the parent peptide. The new peptide overcomes the aggregation limitation for clinical translation of previous compstatin analogs and is a candidate to become a therapeutic for the treatment of AMD.
C1 [Mohan, Rohith R.; Cabrera, Andrea P.; Harrison, Reed E. S.; Gorham, Ronald D., Jr.; Ghosh, Kaustabh; Morikis, Dimitrios] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
   [Johnson, Lincoln V.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Riverside;
   University of California System; University of California Santa Barbara
RP Morikis, D (通讯作者)，Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
EM dmorikis@ucr.edu
RI Morikis, Dimitrios/L-8527-2013
OI Morikis, Dimitrios/0000-0003-0083-4665; Mohan,
   Rohith/0000-0002-9943-484X; Harrison, Reed/0000-0003-2512-4344; Gorham,
   Ronald/0000-0002-0261-6699
FU Macular Degeneration Research, a program of the BrightFocus Foundation
   [M2013106]; University of California, Riverside, Research and Economic
   Development Office; Carolyn K. McGillvray Memorial Award for Macular
   Degeneration Research
FX DM acknowledges the donors to Macular Degeneration Research, a program
   of the BrightFocus Foundation, for support of this research (Grant
   M2013106), and the University of California, Riverside, Research and
   Economic Development Office for support through the Proof of Concept
   program. DM is the 2013 recipient of the Carolyn K. McGillvray Memorial
   Award for Macular Degeneration Research, administered by the
   Bright-Focus Foundation. KG acknowledges initial complement support from
   the Bourns College of Engineering of the University of California,
   Riverside. DM and RDG are co-inventors in patent applications of
   compstatin peptides, and DM, KG, RRM, APC, RESH, and RDG are
   co-inventors in a patent application for the PEGylated peptide described
   in this paper. Dimitrios Morikis dmorikis@ucr.edu) and Kaustabh Ghosh
   (kghosh@engr.ucr.edu) are co-corresponding authors for this paper.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gorham RD, 2015, J MED CHEM, V58, P814, DOI 10.1021/jm501345y
   Gorham RD, 2013, EXP EYE RES, V116, P96, DOI 10.1016/j.exer.2013.07.023
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hu J, 2001, MOL VIS, V7, P14
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kang JS, 2009, EXPERT OPIN EMERG DR, V14, P363, DOI 10.1517/14728210902907847
   Katragadda M, 2006, J MED CHEM, V49, P4616, DOI 10.1021/jm0603419
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klepeis JL, 2003, J AM CHEM SOC, V125, P8422, DOI 10.1021/ja034846p
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Li WJ, 2013, PROG POLYM SCI, V38, P421, DOI 10.1016/j.progpolymsci.2012.07.006
   Liszewski MK, 2015, J INTERN MED, V277, P294, DOI 10.1111/joim.12338
   Lopez de Victoria A, 2011, CHEM BIOL DRUG DES, V77, P431, DOI 10.1111/j.1747-0285.2011.01111.x
   Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mohan RR, 2015, MOL IMMUNOL, V64, P112, DOI 10.1016/j.molimm.2014.11.006
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   Morikis D, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P317
   Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311
   Morikis D, 2004, BIOCHEM SOC T, V32, P28, DOI 10.1042/BST0320028
   Morikis D, 2002, BIOCHEM SOC T, V30, P1026, DOI 10.1042/BST0301026
   Morikis D, 2002, J BIOL CHEM, V277, P14942, DOI 10.1074/jbc.M200021200
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ricklin D, CURRENT TOPICS COMPL, P273
   Risitano AM, 2014, BLOOD, V123, P2094, DOI 10.1182/blood-2013-11-536573
   Sahu A, 1996, J IMMUNOL, V157, P884
   Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Tamamis P, 2012, CHEM BIOL DRUG DES, V79, P703, DOI 10.1111/j.1747-0285.2012.01324.x
   UGLIENGO P, 1993, Z KRISTALLOGR, V207, P9, DOI 10.1524/zkri.1993.207.Part-1.9
   Yang X, 2016, FASEB J, V30, P601, DOI 10.1096/fj.15-277962
   Yang X, 2014, INVEST OPHTH VIS SCI, V55, P3140, DOI 10.1167/iovs.13-13659
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 43
TC 6
Z9 7
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 26
PY 2016
VL 22
BP 1280
EP 1290
PG 11
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA EK4OZ
UT WOS:000393907800002
PM 27829783
DA 2022-11-30
ER

PT J
AU Schnabolk, G
   Rohrer, B
   Simpson, KN
AF Schnabolk, Gloriane
   Rohrer, Barbel
   Simpson, Kit N.
TI Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among
   Medicare Beneficiaries With Rheumatoid Arthritis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; dry AMD; wet AMD; MarketScan;
   rheumatoid arthritis
ID ANTITUMOR NECROSIS FACTOR; MONOCLONAL-ANTIBODY; TNF-ALPHA; CONCOMITANT
   METHOTREXATE; INTRAVITREAL INFLIXIMAB; COMPLEMENT PROTEINS; RISK;
   ETANERCEPT; PREVALENCE; EXPRESSION
AB PURPOSE. AMD is the leading cause of blindness in the United States. The role of secondary inflammatory disease on AMD progression is largely unknown. Here we investigate the association between AMD and rheumatoid arthritis (RA), using MarketScan data for patients aged >= 65 years on Medicare.
   METHODS. Baseline data were extracted for subjects with at least two International Classification, Ninth Revision (ICD-9) diagnosis codes of RA and control subjects (no RA) and were matched at baseline by propensity score. Matched cohort data were extracted post-baseline time and examined up to 4.5 years of follow-up for ICD-9 diagnosis code AMD records. Multivariable regression models compared risk of an AMD diagnosis post-baseline for RA subjects and matched controls. Days until first AMD diagnosis between RA patients and controls was examined using survival analysis.
   RESULTS. Risk of new AMD diagnosis was elevated in RA patients (odds ratio [OR] 2.08; 95% confidence interval [CI] 1.98-2.18), with an increase in nonexudative AMD patients (P < 0.0001). Risk was elevated in female (n = 27,548) (OR 1.11; 95% CI 1.05-1.17) compared with male (n = 9704; P < 0.001) patients. The time to first AMD diagnosis was shorter for RA subjects than controls (P < 0.0001).
   CONCLUSIONS. Our analysis provides support of association between RA diagnosis and increased nonexudative AMD diagnosis.
C1 [Schnabolk, Gloriane; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
   [Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA.
   [Simpson, Kit N.] Med Univ South Carolina, Dept Healthcare Leadership & Management, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center;
   Medical University of South Carolina
RP Schnabolk, G (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM faith@musc.edu
FU National Institutes of Health (NIH) Building Interdisciplinary Research
   Careers in Women's Health (BIRCWH) fellowship [K12HD055885]; NIH
   [R01EY019320]; Department of Veterans Affairs [RX000444, BX003050];
   South Carolina Smart State Endowment; CEDAR - Medical University of
   South Carolina Provost Office; NIH/National Center for Advancing
   Translational Sciences South Carolina Clinical and Translational
   Research Institute Grant [UL1 TR001450]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055885] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR001450] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health (NIH) K12HD055885
   Building Interdisciplinary Research Careers in Women's Health (BIRCWH)
   fellowship (GS). Funding for BR was provided in part by the NIH
   R01EY019320, the Department of Veterans Affairs RX000444, BX003050 (BR)
   and the South Carolina Smart State Endowment. Additional support was
   provided by the CEDAR Core funded by the Medical University of South
   Carolina Provost Office, and from resources provided by NIH/National
   Center for Advancing Translational Sciences South Carolina Clinical and
   Translational Research Institute Grant UL1 TR001450.
CR An EY, 2008, MOL VIS, V14, P2292
   Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942
   Ballanti E, 2011, AUTOIMMUN REV, V10, P617, DOI 10.1016/j.autrev.2011.04.012
   Barbour KE, 2017, MMWR-MORBID MORTAL W, V66, P246, DOI 10.15585/mmwr.mm6609e1
   BRODEUR JP, 1991, ARTHRITIS RHEUM, V34, P1531
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chiu SY, 2018, CLIN OPHTHALMOL, V12, P2261, DOI 10.2147/OPTH.S170789
   Crowson CS, 2011, ARTHRITIS RHEUM-US, V63, P633, DOI 10.1002/art.30155
   Deane KD, 2017, BEST PRACT RES CL RH, V31, P3, DOI 10.1016/j.berh.2017.08.003
   DOHERTY M, 1988, ANN RHEUM DIS, V47, P190, DOI 10.1136/ard.47.3.190
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fernandez-Vega B, 2016, CASE REP OPHTHAL, V7, P154, DOI 10.1159/000445102
   Foster CS, 2003, ARCH OPHTHALMOL-CHIC, V121, P437, DOI 10.1001/archopht.121.4.437
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Gleicher N, 2007, J AUTOIMMUN, V28, P1, DOI 10.1016/j.jaut.2006.12.004
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GUC D, 1993, RHEUMATOL INT, V13, P139, DOI 10.1007/BF00301260
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helmick CG, 2008, ARTHRITIS RHEUM-US, V58, P15, DOI 10.1002/art.23177
   Innala L, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4540
   Jin YZ, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1366-1
   JOSE PJ, 1990, ANN RHEUM DIS, V49, P747, DOI 10.1136/ard.49.10.747
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Konttinen YT, 1996, ANN RHEUM DIS, V55, P888, DOI 10.1136/ard.55.12.888
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0
   Makrides SC, 1998, PHARMACOL REV, V50, P59
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   McDermott MF, 2001, CELL MOL BIOL, V47, P619
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mirshahi Alireza, 2012, J Ophthalmic Vis Res, V7, P39
   Mitoma H, 2008, ARTHRITIS RHEUM-US, V58, P1248, DOI 10.1002/art.23447
   Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004
   Neumann E, 2002, ARTHRITIS RHEUM, V46, P934, DOI 10.1002/art.10183
   OLEESKY DA, 1991, CLIN EXP IMMUNOL, V84, P250
   PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721
   RUDDY S, 1974, NEW ENGL J MED, V290, P1284, DOI 10.1056/NEJM197406062902304
   Ruddy S, 1975, Rheumatology, V6, P17
   Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480
   Smith JA, 2005, ARTHRIT RHEUM-ARTHR, V53, P18, DOI 10.1002/art.20904
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tyree PT, 2006, AM J MED QUAL, V21, P269, DOI 10.1177/1062860606288774
   van Hagen PM, 2014, ACTA OPHTHALMOL, V92, pe691, DOI 10.1111/aos.12471
   Wang HB, 2016, MOL VIS, V22, P116
   Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697
   Wouters D, 2006, ARTHRITIS RHEUM, V54, P1143, DOI 10.1002/art.21729
   Wu L, 2013, J OCUL PHARMACOL TH, V29, P366, DOI 10.1089/jop.2012.0203
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 57
TC 6
Z9 6
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2019
VL 60
IS 10
BP 3520
EP 3526
DI 10.1167/iovs.18-26444
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IS2FS
UT WOS:000481969000030
PM 31412111
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gohil, R
   Crosby-Nwaobi, R
   Forbes, A
   Burton, B
   Hykin, P
   Sivaprasad, S
AF Gohil, Rishma
   Crosby-Nwaobi, Roxanne
   Forbes, Angus
   Burton, Ben
   Hykin, Phil
   Sivaprasad, Sobha
TI Caregiver Burden in Patients Receiving Ranibizumab Therapy for
   Neovascular Age Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID VISUAL IMPAIRMENT; OLDER-PEOPLE; CARE
AB Purpose
   To assess the caregiver burden and factors determining the burden in patients receiving ranibizumab therapy for neovascular AMD (nAMD).
   Methods
   This is a cross-sectional questionnaire survey of 250 matched patient caregiver dyads across three large ophthalmic treatment centres in United Kingdom. The primary outcome was the subjective caregiver burden measured using caregiver reaction assessment scale (CRA). Objective caregiver burden was determined by the caregiver tasks and level of care provided. The factors that may predict the caregiver burden such as the patient's visual acuity of the better eye and vision related quality of life, demographics, satisfaction and support provided by the healthcare and the health status of the dyads were also collected and assessed in a hierarchical regression model.
   Results
   The mean CRA score was 3.2 +/- 0.5, similar to the score reported by caregivers for atrial fibrillation who require regular hospital appointments for monitoring their thromboprophylaxis. Caregiver tasks including accompanying for hospital appointments for eye treatment and patient's visual acuity in the better eye were the biggest contributors to the caregiver burden hierarchical model explaining 18% and 11% of the variance respectively.
   Conclusion
   Ranibizumab therapy for nAMD is associated with significant caregiver burden. Both disease impact and treatment frequency contributed to the overall burden.
C1 [Gohil, Rishma; Crosby-Nwaobi, Roxanne; Forbes, Angus; Hykin, Phil; Sivaprasad, Sobha] NIHR Moorfields Biomed Res Ctr, London, England.
   [Gohil, Rishma; Crosby-Nwaobi, Roxanne; Sivaprasad, Sobha] Kings Coll London, London, England.
   [Burton, Ben] James Paget Univ Hosp, Great Yarmouth, England.
   [Crosby-Nwaobi, Roxanne; Sivaprasad, Sobha] Kings Coll Hosp London, London, England.
C3 University of London; King's College London; King's College Hospital NHS
   Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，NIHR Moorfields Biomed Res Ctr, London, England.
EM sobha.sivaprasad@moorfields.nhs.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Burton, Ben/0000-0001-9579-9078;
   Forbes, Angus/0000-0003-3331-755X
FU Macular Society, Hampshire [MDS 2012]; Bayer Plc Berkshire [ISS 16709]
FX SS: Macular Society, Hampshire, http://www.macularsociety.org/, Grant
   number: MDS 2012 Sivaprasad. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript. SS: Bayer Plc Berkshire,
   http://www.bayer.co.uk/scripts/pages/en/index.php, Grant number: ISS
   16709. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Attkisson C.G., 2004, USE PSYCHOL TESTING
   Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6
   Brouwer WBF, 2004, ARTHRIT RHEUM-ARTHR, V51, P570, DOI 10.1002/art.20528
   Buckle M, 2015, EYE, V29, P403, DOI 10.1038/eye.2014.296
   Buys L, 2008, AUST J RURAL HEALTH, V16, P33, DOI 10.1111/j.1440-1584.2007.00948.x
   Coleman CI, 2012, INT J CLIN PRACT, V66, P984, DOI 10.1111/j.1742-1241.2012.02996.x
   Evans JR, 2008, ARCH OPHTHALMOL-CHIC, V126, P1428, DOI 10.1001/archopht.126.10.1428
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Forbes A, 2007, CLIN REHABIL, V21, P563, DOI 10.1177/0269215507075035
   Freeman EE, 2005, INVEST OPHTH VIS SCI, V46, P4040, DOI 10.1167/iovs.05-0687
   Gitlin LN, 2005, J AGING HEALTH, V17, P148, DOI 10.1177/0898264304274184
   GIVEN CW, 1992, RES NURS HEALTH, V15, P271, DOI 10.1002/nur.4770150406
   Godwin KM, 2013, AGING MENT HEALTH, V17, P423, DOI 10.1080/13607863.2012.756457
   Hanly P, 2015, SUPPORT CARE CANCER, V23, P1941, DOI 10.1007/s00520-014-2551-2
   Jacobi CE, 2003, RHEUMATOLOGY, V42, P1226, DOI 10.1093/rheumatology/keg366
   Kay S, 2014, OPHTHAL EPIDEMIOL, V21, P66, DOI 10.3109/09286586.2014.888456
   Ke KM, 2007, BRIT J OPHTHALMOL, V91, P1279, DOI 10.1136/bjo.2006.113142
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Nijboer C, 1999, SOC SCI MED, V48, P1259, DOI 10.1016/S0277-9536(98)00426-2
   Viitanen O, 2014, CLIN OPHTHALMOL, V8, P1913, DOI 10.2147/OPTH.S69246
   Wang JJ, 1999, AUST NZ J PUBL HEAL, V23, P147, DOI 10.1111/j.1467-842X.1999.tb01225.x
NR 26
TC 44
Z9 44
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 9
PY 2015
VL 10
IS 6
AR e0129361
DI 10.1371/journal.pone.0129361
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA CK6PC
UT WOS:000356349000050
PM 26056840
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Garg, A
   Oll, M
   Yzer, S
   Chang, S
   Barile, GR
   Merriam, JC
   Tsang, SH
   Bearelly, S
AF Garg, Aakriti
   Oll, Maris
   Yzer, Suzanne
   Chang, Stanley
   Barile, Gaetano R.
   Merriam, John C.
   Tsang, Stephen H.
   Bearelly, Srilaxmi
TI Reticular Pseudodrusen in Early Age-Related Macular Degeneration Are
   Associated With Choroidal Thinning
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE reticular pseudodrusen; spectral-domain optical coherence tomography;
   choroidal layer; early age-related macular degeneration; retinal
   ischemia
ID HIGH-RISK; MACULOPATHY; PREVALENCE; AUTOFLUORESCENCE
AB PURPOSE. To compare choroidal thickness (CT) measurements in early AMD between patients with and without reticular pseudodrusen (RPD) using spectral-domain optical coherence tomography (SD-OCT).
   METHODS. This cross-sectional study examined 84 age-and sex-matched AMD patients (40 RPD [63 eyes], 44 non-RPD [75 eyes]). Fundus photographs and scanning laser ophthalmoscopy images were graded to identify RPD and non-RPD groups by three retinal specialists (MO, SY, SB) who were masked to corresponding SD-OCTs. CT at the fovea and 2400 to 3000 mu m superior and inferior to the fovea was measured on SD-OCT by a grader (AG) and reviewed by a retinal specialist (SB). Only images with a clear posterior choroidal margin were analyzed (six eyes excluded due to poor image quality), and enhanced depth imaging SD-OCT was used when available (20 of 138 eyes). Greatest retinal thickness (RT) on horizontal foveal SD-OCT was also recorded.
   RESULTS. Mean CTs in the superior, foveal, and inferior macula in RPD (191.3 mu m +/- 57.9 SD, 176.3 mu m +/- 60.5 SD, 179.7 mu m +/- 56.24 SD) were significantly less than that of non-RPD (228.0 mu m +/- 66.1 SD, 216.5 mu m +/- 70.3 SD, 224.4 mu m +/- 71.9 SD; P = 0.0010, P = 0.0005, P = 0.0001, respectively), as was greatest RT (P = 0.0301).
   CONCLUSIONS. CT was thinner throughout the macula in the RPD group as compared with the non-RPD group. The current analysis supports an association between RPD and a thinned choroidal layer and is consistent with a choroidal etiology of RPD. CT may be integral to understanding RPD, and may be helpful in stratifying AMD progression risk.
C1 [Garg, Aakriti; Oll, Maris; Yzer, Suzanne; Chang, Stanley; Merriam, John C.; Tsang, Stephen H.; Bearelly, Srilaxmi] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA.
   [Barile, Gaetano R.] Manhattan Eye Ear & Throat Hosp, Dept Ophthalmol, New York, NY 10021 USA.
   [Tsang, Stephen H.] Columbia Univ Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Columbia University; Manhattan Eye Ear & Throat Hospital; Columbia
   University
RP Bearelly, S (通讯作者)，Columbia Univ, Harkness Eye Inst, 635 W 165th St, New York, NY 10032 USA.
EM sb3179@columbia.edu
RI Yzer, Suzanne/ABB-6929-2020; Chang, Stanley/AAL-2741-2021
OI Garg Shukla, Aakriti/0000-0002-0765-8337
FU Doris Duke Charitable Foundation; Robert L. Burch III Fund Columbia
   University, New York, New York; New York Stem Cell Science [R01EY018213,
   N09G-302]; Foundation Fighting Blindness; Schneeweiss Stem Cell Fund;
   Tistou and Charlotte Kerstan Foundation; Crowley Family Fund; Joel
   Hoffman Scholarship; Barbara and Donald Jonas Family Fund; Professor
   Gertrude Rothschild Stem Cell Foundation; NATIONAL EYE INSTITUTE
   [R01EY018213] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [T35HL007616] Funding Source: NIH RePORTER
FX Supported by a grant from the Doris Duke Charitable Foundation to
   Columbia University (AG); the Robert L. Burch III Fund Columbia
   University, New York, New York (SB); and R01EY018213, N09G-302 from New
   York Stem Cell Science, the Foundation Fighting Blindness, Schneeweiss
   Stem Cell Fund, the Tistou and Charlotte Kerstan Foundation, Crowley
   Family Fund, Joel Hoffman Scholarship, Barbara and Donald Jonas Family
   Fund, and Professor Gertrude Rothschild Stem Cell Foundation (SHT).
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 27
TC 71
Z9 72
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2013
VL 54
IS 10
BP 7075
EP 7081
DI 10.1167/iovs.13-12474
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 246VI
UT WOS:000326567700072
PM 24071958
OA Green Published
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, K
   Lim, SH
   Kang, DH
   Kim, JW
AF Cho, Han Joo
   Kim, Kunhae
   Lim, Soo Hyun
   Kang, Dong Hyun
   Kim, Jong Woo
TI Retinal pigment epithelial atrophy after anti-vascular endothelial
   growth factor therapy for polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; RANIBIZUMAB INJECTIONS;
   RETICULAR PSEUDODRUSEN; RISK-FACTORS; AFLIBERCEPT; PREVALENCE;
   MORPHOLOGY; OUTCOMES; EYES
AB Background/aims To describe the risk factors for the development of retinal pigment epithelial (RPE) atrophy following intravitreal anti-vascular endothelial growth factor (VEGF) injection treatment for polypoidal choroidal vasculopathy (PCV).
   Methods We retrospectively included 162 eyes of 162 treatment-naive patients with PCV in this study. All patients were treated with an initial series of three monthly loading doses of anti-VEGF injections, followed by further injections as required. Baseline ocular characteristics and lesion features were assessed using fluorescein angiography, indocyanine green angiography and spectral domain optical coherence tomography, to determine and evaluate the potential risk factors for RPE atrophy through 2 years of follow-up.
   Results RPE atrophy had developed in 17 of 162 eyes (10.5%) after 2 years of anti-VEGF treatment. Nine cases (53.0%) of RPE atrophy occurred at branching vascular networks, and eight (47.0%) developed at locations with polyp or polyp-associated pigment epithelial detachment. Among the baseline characteristics, the mean subfoveal choroidal thickness was significantly thinner (192 +/- 98 vs 288 +/- 152; p=0.009) and presence of subretinal drusenoid deposits was significantly more frequent in eyes with RPE atrophy (11.8% vs 2.1%; p=0.028). Using multiple logistic regression analysis, the mean subfoveal choroidal thickness (OR 0.975; 95% CI 0.929 to 1.324; p=0.002) was identified as a significant risk factor for the development of RPE atrophy.
   Conclusions Approximately one-tenth of the patients with PCV developed RPE atrophy during the 24 months after intravitreal anti-VEGF injections. Subfoveal choroidal thinning at baseline is associated with increased risk of post-treatment RPE atrophy.
C1 [Cho, Han Joo; Kim, Kunhae; Lim, Soo Hyun; Kang, Dong Hyun; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Konyang Univ, Kims Eye Hosp, Myung Gok Eye Res Inst, Ophthalmol,Coll Med, Seoul 138240, South Korea.
EM chojoo@gmail.com
OI Cho, Han Joo/0000-0001-7336-5762
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2018, RETINA-J RET VIT DIS, V38, P2150, DOI 10.1097/IAE.0000000000001862
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hikichi T, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0237-x
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2019, BRIT J OPHTHALMOL, V103, P900, DOI 10.1136/bjophthalmol-2018-312430
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Miyata M, 2018, BR J OPHTHALMOL
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Zarubina AV, 2017, INVEST OPHTH VIS SCI, V58, P6038, DOI 10.1167/iovs.17-22378
NR 29
TC 8
Z9 8
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2020
VL 104
IS 10
BP 1443
EP 1447
DI 10.1136/bjophthalmol-2019-315496
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NW6ZV
UT WOS:000575166900019
PM 31896542
DA 2022-11-30
ER

PT J
AU Feely, M
   Vetere, A
   Myers, LB
AF Feely, Mary
   Vetere, Arlene
   Myers, Lynn B.
TI A qualitative analysis of reading rehabilitation of persons with
   age-related macular degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID LOW-VISION; OF-LIFE; EXPERIENCE
C1 UCL, Inst Ophthalmol, London EC1V 9EL, England.
   UCL, Ctr Behav & Social Sci Med, London EC1V 9EL, England.
   Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England.
   Brunel Univ, Sch Social Sci & Law, Psychol Grp, Uxbridge UB8 3PH, Middx, England.
C3 University of London; University College London; University of London;
   University College London; University of Surrey; Brunel University
RP Feely, M (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM m.feely@ucl.ac.uk; a.vetere@surrey.ac.uk; lynn.myers@brunel.ac.uk
CR Borglin G, 2005, J AGING STUD, V19, P201, DOI 10.1016/j.jaging.2004.04.001
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   COLLINS J, 1999, NEW BEACON, V83
   Conrod BE, 1998, J VISUAL IMPAIR BLIN, V92, P464, DOI 10.1177/0145482X9809200707
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mogk L., 2000, VISION REHABILITATIO, P663
   SCHUCHARD RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243
   Smith J.A., 2003, QUALITATIVE PSYCHOL, P51
   Smith JA, 1996, PSYCHOL HEALTH, V11, P261, DOI 10.1080/08870449608400256
   Stelmack JA, 2004, J REHABIL RES DEV, V41, P729, DOI 10.1682/JRRD.2003.08.0136
   TRUDEAU M, 1990, J VISUAL IMPAIR BLIN, V84, P204
   Tuttle D., 1996, SELF ESTEEM ADJUSTIN, V2nd
   WATSON G, 1990, J VISUAL IMPAIR BLIN, V84, P119
   *WHO, 2006, PREV BLINDN VIS IMP
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98, P629, DOI 10.1177/0145482X0409801007
   WRIGHT VW, 1995, LEARN USE YOUR VISIO
NR 18
TC 8
Z9 8
U1 0
U2 2
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD JAN
PY 2007
VL 101
IS 1
BP 44
EP 49
DI 10.1177/0145482X0710100106
PG 6
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 134MB
UT WOS:000244086200007
DA 2022-11-30
ER

PT J
AU Kuwada, SK
AF Kuwada, Scott K.
TI Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric
   monoclonal antibody
SO CURRENT OPINION IN MOLECULAR THERAPEUTICS
LA English
DT Article
ID SIGNAL-TRANSDUCTION; INTEGRINS; GROWTH; MODULATION; RECEPTORS
AB PDL Biopharma Inc ( formerly Eos Biotechnology Inc) and Biogen Idec Inc are developing volociximab, an angiogenesis-inhibiting chimeric mAb that targets AAB1, a component protein of alpha 5/beta 1 integrin, for the potential treatment of solid tumors, including renal cell carcinoma. Two phase II clinical trials evaluating volociximab in solid tumors are underway. Volociximab is also under investigation for the treatment of age-related macular degeneration.
C1 Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
C3 Huntsman Cancer Institute; Utah System of Higher Education; University
   of Utah
RP Kuwada, SK (通讯作者)，Univ Utah, Huntsman Canc Inst, Room 3243,2000 Circle Hope Dr, Salt Lake City, UT 84112 USA.
EM scott.kuwada@hsc.utah.edu
CR Aplin AE, 1998, PHARMACOL REV, V50, P197
   BHASKAR V, 2004, J IMMUNOTHER, V27, pS9
   BHASKAR V, 2005, P AM ASS CANC RES, V46
   BHASKAR V, 2006, V P AM ASS CANC RES, V47
   CLEVERLEY J, 2006, IDDB M REP JUN 02 06
   Costa C, 2004, APMIS, V112, P402, DOI 10.1111/j.1600-0463.2004.apm11207-0802.x
   CRANMER L, 2006, P AM SOC CLIN ONCOL, V25
   FIGLIN RA, 2006, P AM SOC CLIN ONCOL, V25
   Folkman J, 1992, Semin Cancer Biol, V3, P65
   Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   HO SK, 2004, P AM ASS CANC RES, V45
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918
   JAYSON GC, 2004, P AM SOC CLIN ONCOL, V23
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Masumoto A, 1999, HEPATOLOGY, V29, P68, DOI 10.1002/hep.510290146
   Munoz-Chapuli R, 2004, CELL MOL LIFE SCI, V61, P2224, DOI 10.1007/s00018-004-4070-7
   *PROT DES LABS INC, 2003, ANN REP
   RAMAKRISHNAN V, 2005, INVEST OPHTHALMOL  S, V46, P465
   RAMAKRISHNAN V, 2004, P AM SOC CLIN ONCOL, V23
   RICART A, 2004, EJC S, V2
   RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H
   Smyth SS, 2002, J CELL BIOL, V158, P17, DOI 10.1083/jcb.200202100
   Sottile J, 2004, BBA-REV CANCER, V1654, P13, DOI 10.1016/j.bbcan.2003.07.002
   Su JM, 2002, WORLD J GASTROENTERO, V8, P613, DOI 10.3748/wjg.v8.i4.613
   TAWBI H, 2005, IDDB M REP AUG 26 28
   VALLE JW, 2006, P AM SOC CLIN ONCOL, V25
   VANITHA BVR, 2006, EXP THER ONCOL, V5, P273
   VANITHA R, 2003, P AM ASS CANC RES, V44
   YAZJI S, 2006, EUR J CANC, V4
   ZHU Z, 2004, IDDB M REP JUL
   2006, IDDB M REP
NR 33
TC 44
Z9 52
U1 0
U2 3
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1464-8431
EI 2040-3445
J9 CURR OPIN MOL THER
JI Curr. Opin. Mol. Ther.
PD FEB
PY 2007
VL 9
IS 1
BP 92
EP 98
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 201ZG
UT WOS:000248870600011
PM 17330407
DA 2022-11-30
ER

PT J
AU Wang, JC
   Miller, JB
AF Wang, Jay C.
   Miller, John B.
TI Optical Coherence Tomography Angiography: Review of Current Technical
   Aspects and Applications in Chorioretinal Disease
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Imaging; optical coherence tomography angiography; optical coherence
   tomography; retina; review
ID FOVEAL AVASCULAR ZONE; RETINAL VEIN OCCLUSION; DIABETIC-RETINOPATHY;
   MACULAR DEGENERATION; NEOVASCULARIZATION SECONDARY; TYPE-1
   NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; THERAPY; EYES; FEATURES
AB Optical coherence tomography angiography (OCT-A) has enabled fast, non-invasive, high-resolution visualization of vasculature within the eye. In the past few years, it has become increasingly utilized for a range of disorders including age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and uveitis among others. This article reviews technical aspects of OCT-A, its applications in chorioretinal disease, and known limitations of the technology.
C1 [Wang, Jay C.; Miller, John B.] Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Miller, JB (通讯作者)，Harvard Med Sch, Mass Eye & Ear, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM john_miller@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
CR Abucham-Neto Julio Zaki, 2018, Int J Retina Vitreous, V4, P15, DOI 10.1186/s40942-018-0117-z
   Agemy SA, 2015, RETINA-J RET VIT DIS, V35, P2353, DOI 10.1097/IAE.0000000000000862
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Chidambara L, 2016, BRIT J OPHTHALMOL, V100, P1482, DOI 10.1136/bjophthalmol-2015-307941
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Conrath J, 2005, EYE, V19, P322, DOI 10.1038/sj.eye.6701456
   Coscas F, 2016, AM J OPHTHALMOL, V161, P160, DOI 10.1016/j.ajo.2015.10.008
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2016, OSLI RETINA, V47, P115, DOI 10.3928/23258160-20160126-03
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   de Salles MC, 2016, INVEST OPHTH VIS SCI, V57, pOCT242, DOI 10.1167/iovs.15-18819
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Diaz J Daniel, 2018, J Vitreoretin Dis, V2, P146, DOI 10.1177/2474126418771805
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Falavarjani KG, 2017, INVEST OPHTH VIS SCI, V58, P30, DOI 10.1167/iovs.16-20579
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Hasegawa N, 2016, INVEST OPHTH VIS SCI, V57, pOCT348, DOI 10.1167/iovs.15-18782
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   Kim AY, 2016, AM J OPHTHALMOL, V171, P101, DOI 10.1016/j.ajo.2016.08.035
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   Matsunaga DR, 2015, OSLI RETINA, V46, P796, DOI 10.3928/23258160-20150909-03
   Mendis KR, 2010, INVEST OPHTH VIS SCI, V51, P5864, DOI 10.1167/iovs.10-5333
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Parravano M, 2017, ACTA OPHTHALMOL, V95, pE425, DOI 10.1111/aos.13180
   Rispoli M, 2015, RETINA-J RET VIT DIS, V35, P2332, DOI 10.1097/IAE.0000000000000845
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P1920, DOI 10.1097/IAE.0000000000002289
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P424, DOI 10.1097/IAE.0000000000001344
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Takase N, 2015, RETINA-J RET VIT DIS, V35, P2377, DOI 10.1097/IAE.0000000000000849
   Tian M, 2019, BRIT J OPHTHALMOL, V103, P1289, DOI 10.1136/bjophthalmol-2018-313078
   Wang JC, 2017, OSLI RETINA, V48, P638, DOI 10.3928/23258160-20170802-06
   Wang JC, 2018, CLIN OPHTHALMOL, V12, P95
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
NR 47
TC 9
Z9 9
U1 1
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY 19
PY 2019
VL 34
IS 4
SI SI
BP 211
EP 217
DI 10.1080/08820538.2019.1620797
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IS6PV
UT WOS:000482274600004
PM 31131663
DA 2022-11-30
ER

PT J
AU Park, MM
   Rebhun, CB
   Cole, ED
   Louzada, RN
   Novais, EA
   Rifai, F
   Alibhai, AY
   Duker, JS
   Waheed, NK
AF Park, Michael M.
   Rebhun, Carl B.
   Cole, Emily D.
   Louzada, Ricardo N.
   Novais, Eduardo A.
   Rifai, Fareed
   Alibhai, A. Yasin
   Duker, Jay S.
   Waheed, Nadia K.
TI Diagnosing Choroidal Neovascularization in Asymptomatic Individuals
   Using Optical Coherence Tomography Angiography
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID GROWTH-FACTOR THERAPY; MACULAR DEGENERATION; TYPE-1 NEOVASCULARIZATION;
   OCT ANGIOGRAPHY
AB Optical coherence tomography angiography (OCTA) is a noninvasive, rapid imaging technique that generates angiographic images without intravenous dye injections. Cross-sectional studies have described the presence of asymptomatic choroidal neovascularization (CNV) in patients with intermediate age-related macular degeneration (AMD). This case report describes the OCT features on longitudinal follow-up of a patient who started with unilateral asymptomatic CNV and eventually developed symptomatic exudative AMD.
C1 [Park, Michael M.; Rebhun, Carl B.; Cole, Emily D.; Louzada, Ricardo N.; Novais, Eduardo A.; Rifai, Fareed; Alibhai, A. Yasin; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, New England Eye Ctr, Boston, MA 02116 USA.
   [Park, Michael M.; Rebhun, Carl B.; Cole, Emily D.; Louzada, Ricardo N.; Novais, Eduardo A.; Rifai, Fareed; Alibhai, A. Yasin; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, Tufts Med Ctr, Boston, MA 02116 USA.
   [Louzada, Ricardo N.] Univ Fed Goias, Ophthalm Ctr Reference CEROF, Goiania, Go, Brazil.
   [Novais, Eduardo A.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Rifai, Fareed] Univ S Alabama, Coll Med, Mobile, AL USA.
C3 Tufts University; Tufts Medical Center; Tufts University; Universidade
   Federal de Goias; Universidade Federal de Sao Paulo (UNIFESP);
   University of South Alabama
RP Waheed, NK (通讯作者)，Tufts Med Ctr, New England Eye Ctr, 260 Tremont St,Biewend Bldg,9-11th Floor, Boston, MA 02116 USA.
EM nadiakwaheed@gmail.com
FU Macula Vision Research Foundation Grant; CAPES Foundation, Ministry of
   Education of Brazil, Brasilia, DF, Brazil; Carl Zeiss Meditec; OptoVue;
   Topcon Medical Systems
FX This work was supported in part by a Macula Vision Research Foundation
   Grant. Drs. Novais and Louzada are researchers supported by CAPES
   Foundation, Ministry of Education of Brazil, Brasilia, DF, Brazil.; Dr.
   Duker is a consultant for and receives research support from Carl Zeiss
   Meditec, OptoVue, and Topcon Medical Systems. Dr. Waheed is a consultant
   for Regeneron and Genentech, is on the speakers bureau for Optovue and
   Nidek, and receives research support from Carl Zeiss Meditec. The
   remaining authors report no relevant financial disclosures.
CR de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
NR 20
TC 1
Z9 1
U1 1
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL
PY 2017
VL 48
IS 7
BP 596
EP 598
DI 10.3928/23258160-20170630-13
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA FF5ZE
UT WOS:000409080200014
PM 28728188
DA 2022-11-30
ER

PT J
AU Tsui, I
   Pan, CK
   Rahimy, E
   Schwartz, SD
AF Tsui, Irena
   Pan, Carolyn K.
   Rahimy, Ehsan
   Schwartz, Steven D.
TI Ocriplasmin for Vitreoretinal Diseases
SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
LA English
DT Review
ID PLASMIN-ASSISTED VITRECTOMY; ENDOGENOUS MATRIX METALLOPROTEINASE-2;
   POSTERIOR VITREOUS DETACHMENT; VITREOMACULAR TRACTION SYNDROME; INTERNAL
   LIMITING MEMBRANE; DIABETIC MACULAR EDEMA; AUTOLOGOUS-PLASMIN;
   PHARMACOLOGICAL VITREOLYSIS; INTRAVITREAL PLASMIN; HUMAN-EYE
AB Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.
C1 [Tsui, Irena; Pan, Carolyn K.; Rahimy, Ehsan; Schwartz, Steven D.] Univ Calif Los Angeles, Retina Div, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles
RP Tsui, I (通讯作者)，Univ Calif Los Angeles, Retina Div, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
EM itsui@jsei.ucla.edu
OI Rahimy, Ehsan/0000-0001-8446-7078; Pan, Carolyn/0000-0002-1031-7488
FU ThromboGenics
FX Dr. S. D. Schwartz receives research support from ThromboGenics.
CR Asami T, 2004, OPHTHALMOLOGY, V111, P231, DOI 10.1016/j.ophtha.2003.06.001
   Azzolini C, 2004, AM J OPHTHALMOL, V138, P560, DOI 10.1016/j.ajo.2004.05.024
   Brown DJ, 1996, CURR EYE RES, V15, P439, DOI 10.3109/02713689608995835
   Chang LK, 2008, AM J OPHTHALMOL, V146, P121, DOI 10.1016/j.ajo.2008.03.001
   Chen W, 2008, EYE, V22, P300, DOI 10.1038/sj.eye.6702931
   Chen W, 2009, CURR EYE RES, V34, P1057, DOI 10.3109/02713680903308487
   de Smet MD, 2009, OPHTHALMOLOGY, V116, P1349, DOI 10.1016/j.ophtha.2009.03.051
   de Smet MD, 2009, INVEST OPHTH VIS SCI, V50, P814, DOI 10.1167/iovs.08-2185
   Gandorfer A, 2008, EYE, V22, P1273, DOI 10.1038/eye.2008.29
   Gandorfer A, 2006, AM J OPHTHALMOL, V141, P784, DOI 10.1016/j.ajo.2005.12.034
   Gandorfer A, 2004, INVEST OPHTH VIS SCI, V45, P641, DOI 10.1167/iovs.03-0930
   Gandorfer A, 2002, AM J OPHTHALMOL, V133, P156, DOI 10.1016/S0002-9394(01)01252-1
   Gandorfer A, 2001, BRIT J OPHTHALMOL, V85, P6, DOI 10.1136/bjo.85.1.6
   Gandorfer A, 2009, DEV OPHTHALMOL, V44, P1, DOI 10.1159/000223938
   Goldenberg DT, 2011, RETINA-J RET VIT DIS, V31, P393, DOI 10.1097/IAE.0b013e3181e586b2
   Hermel M, 2010, CURR EYE RES, V35, P419, DOI 10.3109/02713680903572517
   Hermel M, 2009, GRAEF ARCH CLIN EXP, V247, P331, DOI 10.1007/s00417-008-1000-7
   Hikichi T, 1999, RETINA-J RET VIT DIS, V19, P55, DOI 10.1097/00006982-199901000-00009
   Hirata A, 2007, RETINA-J RET VIT DIS, V27, P1074, DOI 10.1097/IAE.0b013e3180592beb
   Kim Nam Ju, 2004, Korean J Ophthalmol, V18, P35
   KOHNO T, 1983, JPN J OPHTHALMOL, V27, P496
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P515
   Li XX, 2002, GRAEF ARCH CLIN EXP, V240, P56, DOI 10.1007/s004170100351
   LIOTTA LA, 1981, CANCER RES, V41, P4629
   Margherio AR, 1998, OPHTHALMOLOGY, V105, P1617, DOI 10.1016/S0161-6420(98)99027-3
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Monea S, 2002, J CELL PHYSIOL, V192, P160, DOI 10.1002/jcp.10126
   PAPP B, 1987, BIOCHIM BIOPHYS ACTA, V925, P241, DOI 10.1016/0304-4165(87)90188-7
   Plantner JJ, 1998, CURR EYE RES, V17, P132, DOI 10.1076/ceyr.17.2.132.5610
   Rizzo S, 2006, RETINA-J RET VIT DIS, V26, P792, DOI 10.1097/01.iae.0000244266.83395.16
   RUSSELL SR, 1991, INVEST OPHTH VIS SCI, V32, P1986
   Sakuma T, 2006, EUR J OPHTHALMOL, V16, P138, DOI 10.1177/112067210601600122
   Sakuma T, 2005, EUR J OPHTHALMOL, V15, P787, DOI 10.1177/112067210501500621
   Sakuma T, 2005, INVEST OPHTH VIS SCI, V46, P3295, DOI 10.1167/iovs.04-1517
   Schneider EW, 2011, CLIN OPHTHALMOL, V5, P1151, DOI 10.2147/OPTH.S14840
   SEBAG J, 1989, INVEST OPHTH VIS SCI, V30, P1867
   Sivak JM, 2002, PROG RETIN EYE RES, V21, P1, DOI 10.1016/S1350-9462(01)00015-5
   Staubach F, 2004, CURR EYE RES, V29, P261, DOI 10.1080/02713680490516747
   Takano A, 2005, AM J OPHTHALMOL, V140, P654, DOI 10.1016/j.ajo.2005.04.017
   Trese MT, 2000, OPHTHALMOLOGY, V107, P1607, DOI 10.1016/S0161-6420(00)00210-4
   Udaondo P, 2010, OPHTHALMOLOGY, V117, P1859, DOI 10.1016/j.ophtha.2010.06.004
   Uemura A, 2005, ARCH OPHTHALMOL-CHIC, V123, P209, DOI 10.1001/archopht.123.2.209
   VERSTRAETEN TC, 1993, ARCH OPHTHALMOL-CHIC, V111, P849, DOI 10.1001/archopht.1993.01090060139038
   Wij WC, 2007, RETINA-J RET VIT DIS, V27, P1079, DOI 10.1097/IAE.0b013e31806196d0
   WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292
   Wu WC, 2008, RETINA-J RET VIT DIS, V28, pS75, DOI 10.1097/IAE.0b013e318158ea0e
   Wu WC, 2007, AM J OPHTHALMOL, V144, P668, DOI 10.1016/j.ajo.2007.07.027
   Yamada N, 2005, AM J OPHTHALMOL, V139, P112, DOI 10.1016/j.ajo.2004.08.055
NR 49
TC 14
Z9 16
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1110-7243
EI 1110-7251
J9 J BIOMED BIOTECHNOL
JI J. Biomed. Biotechnol.
PY 2012
AR 354979
DI 10.1155/2012/354979
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 023JK
UT WOS:000310028500001
PM 23193358
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Wolff, B
   Vasseur, V
   Cahuzac, A
   Coscas, F
   Castelnovo, L
   Favard, C
   Michel, G
   Francais, C
   Salomon, L
   Mauget-Faysse, M
AF Wolff, Benjamin
   Vasseur, Vivien
   Cahuzac, Armelle
   Coscas, Florence
   Castelnovo, Laurent
   Favard, Catherine
   Michel, Guillaume
   Francais, Catherine
   Salomon, Laurence
   Mauget-Faysse, Martine
TI Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a
   Prospective Study in a Caucasian Population
SO OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Aflibercept; Optical coherent
   tomography; Indocyanine green angiography; Prospective study; Caucasian
   population
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB;
   EFFICACY; CLASSIFICATION; COMBINATION; OUTCOMES; SAFETY
AB Introduction: Polypoidal choroidal vasculopathy (PCV) is a choroidal pathology characterized by frequent occurrences of subretinal hemorrhages and resistance to monotherapies such as ranibizumab or bevacizumab intravitreal injections (IVT). The purpose of this study is to evaluate both the anatomical and functional efficacy of aflibercept IVT as a monotherapy in PCV in a Caucasian population. Methods: We conducted a prospective multicenter study in either treatment-naive patients with PCV or PVC patients who had not been treated with anti-VEGF within the previous 3 months or with photodynamic therapy (PDT) within the previous 6 months. All patients had been treated with 3 initial monthly loading doses of aflibercept followed by a Q8 regimen for 28 weeks in total. All patients underwent a complete ophthalmic examination including the measurement of best-corrected visual acuity (BCVA) before each IVT and after 28 weeks as well as an optical coherent tomography (OCT) of the macula. At baseline and 28 weeks, the polypoidal dilations were analyzed with indocyanine green angiography. Results: Thirty-four eyes of 34 patients were included in this study. All patients were followed for 28 weeks and received 5 aflibercept IVT. The mean baseline BCVA was 55 letters. After 28 weeks, significant +13 letters in BCVA and a regression of exudative signs on OCT in all patients were observed. In 62% of the cases, polyp disappearance was observed on indocyanine green angiography. Discussion: In this study on a Caucasian population, we showed that aflibercept as a monotherapy provided both a significant visual gain and the regression of polypoidal dilations. Aflibercept use in monotherapy may contribute to reduce the hemorrhagic risk and atrophy linked to PDT.
C1 [Wolff, Benjamin; Castelnovo, Laurent; Michel, Guillaume] Ophthalmol Ctr Maison Rouge, 6 Rue Eglise, FR-67000 Strasbourg, France.
   [Vasseur, Vivien; Cahuzac, Armelle; Salomon, Laurence; Mauget-Faysse, Martine] Adolphe Rothschild Fdn, CIC Dept, Paris, France.
   [Coscas, Florence; Favard, Catherine; Francais, Catherine] Odeon Ophthalmol Ctr, Paris, France.
C3 Fondation Adolphe de Rothschild
RP Wolff, B (通讯作者)，Ophthalmol Ctr Maison Rouge, 6 Rue Eglise, FR-67000 Strasbourg, France.
EM bwolff@hotmail.fr
OI wolff, benjamin/0000-0003-4709-692X
FU Bayer
FX This study was supported by Bayer.
CR Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Nakai S, 2017, OPHTHALMOLOGICA, V237, P123, DOI 10.1159/000455273
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 20
TC 3
Z9 5
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 240
IS 4
BP 208
EP 212
DI 10.1159/000488808
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HC3UH
UT WOS:000451727700004
PM 29804123
DA 2022-11-30
ER

PT J
AU Cotrim, CC
   Jorge, R
   de Oliveira, MC
   Pieroni, F
   Messias, AMV
   Siqueira, RC
AF Cotrim, Carina Costa
   Jorge, Rodrigo
   de Oliveira, Maria Carolina
   Pieroni, Fabiano
   Vieira Messias, Andre M.
   Siqueira, Rubens Camargo
TI Clinical studies using stem cells for treatment of retinal diseases:
   state of the art
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Review
DE Stem cells; Retinal progenitor cells; Embryonic stem cells; Induced
   pluripotent stem cells; Bone marrow-derived stem cells
ID INTRAVITREAL USE; MACULAR EDEMA; THERAPY; LINES; DIFFERENTIATION;
   GENERATION
AB Degenerative retinal diseases such as retinitis pigmentosa, Stargardt's macular dystrophy, and age-related macular degeneration are characterized by irreversible loss of vision due to director indirect photoreceptor damage. No effective treatments exist, but stem cell studies have shown promising results. Our aim with this review was to describe the types of stem cells that are under study, their effects, and the main clinical trials involving them.
C1 [Cotrim, Carina Costa; Jorge, Rodrigo; Vieira Messias, Andre M.; Siqueira, Rubens Camargo] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Ophthalmol Otorhinolaryngol & Head & Neck Su, Ribeirao Preto, SP, Brazil.
   [de Oliveira, Maria Carolina; Pieroni, Fabiano] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, Ribeirao Preto, SP, Brazil.
   [Siqueira, Rubens Camargo] Univ Estadual Sao Jose do Rio Preto, Fac Med, Sao Jose Do Rio Preto, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de
   Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP)
RP Cotrim, CC (通讯作者)，Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Ophthalmol Otorhinolaryngol & Head & Neck Su, Ribeirao Preto, SP, Brazil.
EM cariscotrim@hotmail.com
RI Rodrigues, Maria Carolina Oliveira/A-2302-2012
OI Rodrigues, Maria Carolina Oliveira/0000-0003-0691-2222; Siqueira,
   Rubens/0000-0003-4563-1570
CR Palomo ABA, 2015, FIBROGENESIS TISSUE, V8, DOI 10.1186/s13069-015-0026-9
   Bauer G, 2018, STEM CELL TRANSL MED, V7, P676, DOI 10.1002/sctm.17-0282
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cotrim CC, 2017, CLIN OPHTHALMOL, V11, P931, DOI 10.2147/OPTH.S133502
   Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Guo XL, 2015, INT J OPHTHALMOL-CHI, V8, P818, DOI 10.3980/j.issn.2222-3959.2015.04.31
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Kuppermann B., CYTE PRESENTS RESULT
   Lanza R, 2009, ESSENTIALS OF STEM CELL BIOLOGY, 2ND EDITION, pXV, DOI 10.1016/B978-0-12-374729-7.00073-1
   Leeper NJ, 2010, CIRCULATION, V122, P517, DOI 10.1161/CIRCULATIONAHA.109.881441
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Liu Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0661-8
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193
   Oner A, 2018, TURK OFTALMOL DERG, V48, P33, DOI 10.4274/tjo.89972
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Park SS, 2017, PROG RETIN EYE RES, V56, P148, DOI 10.1016/j.preteyeres.2016.10.002
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Pellegrini G, 2007, SEMIN CELL DEV BIOL, V18, P805, DOI 10.1016/j.semcdb.2007.09.011
   Pera MF, 2011, NATURE, V471, P46, DOI 10.1038/471046a
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Semo M, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.4.6
   Siqueira R., 2015, REV U VIS, V87, P48
   Siqueira RC, 2013, BONE MARROW TRANSPL, V48, P612, DOI 10.1038/bmt.2012.185
   Siqueira RC, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0020-6
   Siqueira RC, 2015, ACTA OPHTHALMOL, V93, pE174, DOI 10.1111/aos.12473
   Siqueira RC, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt91
   Siqueira RC, 2010, ARQ BRAS OFTALMOL, V73, P474, DOI 10.1590/S0004-27492010000500019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tibbetts MD, 2012, CURR OPIN OPHTHALMOL, V23, P226, DOI 10.1097/ICU.0b013e328352407d
   Vugler A, 2007, MECH DEVELOP, V124, P807, DOI 10.1016/j.mod.2007.08.002
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zarbin M, 2019, METHODS MOL BIOL, V1834, P367, DOI 10.1007/978-1-4939-8669-9_23
   Zhao Xing, 2006, V330, P401
NR 42
TC 4
Z9 4
U1 0
U2 8
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2020
VL 83
IS 2
BP 160
EP 167
DI 10.5935/0004-2749.20200037
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KU3GO
UT WOS:000519597600016
PM 32159599
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Murphy, AR
   Truong, YB
   O'Brien, CM
   Glattauer, V
AF Murphy, Ashley R.
   Truong, Yen B.
   O'Brien, Carmel M.
   Glattauer, Veronica
TI Bio-inspired human in vitro outer retinal models: Bruch's membrane and
   its cellular interactions
SO ACTA BIOMATERIALIA
LA English
DT Review
DE Retinal tissue engineering; Bruch's membrane; In vitro modelling;
   Electrospinning
ID PIGMENT EPITHELIAL-CELLS; PLURIPOTENT STEM-CELLS; EXTRACELLULAR-MATRIX;
   AMNIOTIC MEMBRANE; MACULAR DEGENERATION; SUBRETINAL IMPLANTATION;
   COMPLEMENT ACTIVATION; SULFATE PROTEOGLYCAN; ELASTIC PROPERTIES;
   BASEMENT-MEMBRANE
AB Retinal degenerative disorders, such as age-related macular degeneration (AMD), are one of the leading causes of blindness worldwide, however, treatments to completely stop the progression of these debilitating conditions are non-existent. Researchers require sophisticated models that can accurately represent the native structure of human retinal tissue to study these disorders. Current in vitro models used to study the retina are limited in their ability to fully recapitulate the structure and function of the retina, Bruch's membrane and the underlying choroid. Recent developments in the field of induced pluripotent stem cell technology has demonstrated the capability of retinal pigment epithelial cells to recapitulate AMD-like pathology. However, such studies utilise unsophisticated, bio-inert membranes to act as Bruch's membrane and support iPSC-derived retinal cells. This review presents a concise summary of the properties and function of the Bruch's membrane-retinal pigment epithelium complex, the initial pathogenic site of AMD as well as the current status for materials and fabrication approaches used to generate in vitro models of this complex tissue. Finally, this review explores required advances in the field of in vitro retinal modelling.
   Statement of significance
   Retinal degenerative disorders such as age-related macular degeneration are worldwide leading causes of blindness. Previous attempts to model the Bruch's membrane-retinal pigment epithelial complex, the initial pathogenic site of age-related macular degeneration, have lacked the sophistication to elucidate valuable insights into disease mechanisms. Here we provide a detailed account of the morphological, physical and chemical properties of Bruch's membrane which may aid the fabrication of more sophisticated and physiologically accurate in vitro models of the retina, as well as various fabrication techniques to recreate this structure. This review also further highlights some recent advances in some additional challenging aspects of retinal tissue modelling including integrated fluid flow and photoreceptor alignment. (C) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Murphy, Ashley R.; Truong, Yen B.; O'Brien, Carmel M.; Glattauer, Veronica] CSIRO Mfg, Res Way, Clayton, Vic 3168, Australia.
   [O'Brien, Carmel M.] Monash Univ, Australian Regenerat Med Inst, Sci Technol Res & Innovat Precinct, Clayton Campus,Wellington Rd, Clayton, Vic 3800, Australia.
C3 Commonwealth Scientific & Industrial Research Organisation (CSIRO);
   Australian Regenerative Medicine Institute; Monash University
RP Murphy, AR (通讯作者)，CSIRO Mfg, Res Way, Clayton, Vic 3168, Australia.
EM Ash.Murphy@csiro.au
RI Glattauer, Veronica/A-9435-2018; O'Brien, Carmel M/I-5664-2017
OI Glattauer, Veronica/0000-0001-9139-9720; O'Brien, Carmel
   M/0000-0001-6189-1343; Murphy, Ashley/0000-0002-7728-6698; Truong,
   Yen/0000-0003-2210-2414
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Akrami H, 2011, BIOCHEM GENET, V49, P313, DOI 10.1007/s10528-010-9409-1
   Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142-9612(02)00353-8
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ANDERSON DH, 1995, J COMP NEUROL, V360, P1, DOI 10.1002/cne.903600102
   [Anonymous], STRUCTURE FUNCTION P
   [Anonymous], INVEST OPHTHALMOL VI
   [Anonymous], LASERS IMAGING RETIN
   [Anonymous], STEM CELLS INT
   [Anonymous], CELL BIOL RETINAL PI
   [Anonymous], STRUCTURE FUNCTION P
   [Anonymous], EYE HLTH INF MAC DEG
   Arrizabalaga JH, 2018, ACS BIOMATER SCI ENG, V4, P2226, DOI 10.1021/acsbiomaterials.8b00015
   Baker R.W., 2012, MEMBRANE TECHNOLOGY
   Barar Jaleh, 2009, J Ophthalmic Vis Res, V4, P238
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Beutel J, 2007, GRAEF ARCH CLIN EXP, V245, P1469, DOI 10.1007/s00417-007-0566-9
   Bhardwaj N, 2010, BIOTECHNOL ADV, V28, P325, DOI 10.1016/j.biotechadv.2010.01.004
   Boochoon KS, 2014, J BIOMECH, V47, P3237, DOI 10.1016/j.jbiomech.2014.06.021
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cai H, 2018, JOVE-J VIS EXP, DOI 10.3791/57084
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Cao H, 2009, MAT SCI ENG C-MATER, V29, P2270, DOI 10.1016/j.msec.2009.05.012
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Chen LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03788-5
   Corydon TJ, 2016, CELL PHYSIOL BIOCHEM, V40, P1, DOI 10.1159/000452520
   da Silva GR, 2011, INT J ARTIF ORGANS, V34, P198, DOI 10.5301/IJAO.2011.6398
   Da Silva GR, 2015, EUR J PHARM SCI, V73, P9, DOI 10.1016/j.ejps.2015.03.003
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dong B, 2009, MACROMOL RAPID COMM, V30, P539, DOI 10.1002/marc.200800634
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Esch EW, 2015, NAT REV DRUG DISCOV, V14, P248, DOI 10.1038/nrd4539
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   Farjood F, 2018, LAB CHIP, V18, P3413, DOI 10.1039/c8lc00659h
   Farrokh-Siar L, 1999, CURR EYE RES, V19, P89, DOI 10.1076/ceyr.19.2.89.5331
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Fitzpatrick SD, 2010, BIOMACROMOLECULES, V11, P2261, DOI 10.1021/bm100299j
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   FRIBERG TR, 1988, EXP EYE RES, V47, P429, DOI 10.1016/0014-4835(88)90053-X
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Fujie T, 2014, ADV MATER, V26, P1699, DOI 10.1002/adma.201304183
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Ghaemmaghami AM, 2012, DRUG DISCOV TODAY, V17, P173, DOI 10.1016/j.drudis.2011.10.029
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   GOLDBAUM MH, 1982, BRIT J OPHTHALMOL, V66, P17, DOI 10.1136/bjo.66.1.17
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Heidari R, 2015, APPL BIOCHEM BIOTECH, V175, P2399, DOI 10.1007/s12010-014-1431-z
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huang L, 2001, J BIOMAT SCI-POLYM E, V12, P979, DOI 10.1163/156856201753252516
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Isaacson A, 2018, EXP EYE RES, V173, P188, DOI 10.1016/j.exer.2018.05.010
   Ito A, 2005, TISSUE ENG, V11, P489, DOI 10.1089/ten.2005.11.489
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin ZB, 2009, J GENET, V88, P417, DOI 10.1007/s12041-009-0063-5
   Jirsova K, 2017, CELL TISSUE BANK, V18, P193, DOI 10.1007/s10561-017-9618-5
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Jung YH, 2018, ADV MATER, V30, DOI 10.1002/adma.201803550
   Krishna Y, 2007, J BIOMED MATER RES A, V80A, P669, DOI 10.1002/jbm.a.30953
   Kubota A, 2006, BIOMATERIALS, V27, P3639, DOI 10.1016/j.biomaterials.2006.02.018
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Lai JY, 2014, CARBOHYD POLYM, V101, P203, DOI 10.1016/j.carbpol.2013.09.060
   Lai JY, 2013, J MATER SCI-MATER M, V24, P2201, DOI 10.1007/s10856-013-4961-y
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   Leng T, 2013, OPHTHAL SURG LAS IM, V44, P73, DOI 10.3928/23258160-20121221-16
   Lin T., 2018, NOVEL ASPECTS NANOFI
   LIN WL, 1992, INVEST OPHTH VIS SCI, V33, P2072
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 1999, BIOMATERIALS, V20, P2351, DOI 10.1016/S0142-9612(99)00164-7
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   Lynn SA, 2017, TISSUE CELL, V49, P447, DOI 10.1016/j.tice.2017.06.003
   Marmor M.F., 1998, FUNCT DIS, P103
   MARSHALL GE, 1993, BRIT J OPHTHALMOL, V77, P515, DOI 10.1136/bjo.77.8.515
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   McLenachan Samuel, 2017, Biochem Biophys Rep, V10, P178, DOI 10.1016/j.bbrep.2017.03.008
   McUsic AC, 2012, BIOMATERIALS, V33, P1396, DOI 10.1016/j.biomaterials.2011.10.083
   Molday RS, 2015, J CELL SCI, V128, P4039, DOI 10.1242/jcs.175687
   Moldow B, 2001, BRIT J OPHTHALMOL, V85, P592, DOI 10.1136/bjo.85.5.592
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Popelka S, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/4/045022
   Proulx S, 2003, MOL VIS, V9, P473
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Rahmani S, 2018, INT J POLYM MATER PO, V67, P27, DOI 10.1080/00914037.2017.1297939
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Rezai KA, 1999, INVEST OPHTH VIS SCI, V40, P1223
   RIZZOLO LJ, 1994, INVEST OPHTH VIS SCI, V35, P2567
   Santos-Ferreira TF, 2017, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00105
   Shadforth AMA, 2017, J TISSUE ENG REGEN M, V11, P1915, DOI 10.1002/term.2089
   Shadforth AMA, 2015, J FUNCT BIOMATER, V6, P946, DOI 10.3390/jfb6030946
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Shafaie S, 2016, BIORESEARCH OPEN ACC, V5, DOI 10.1089/biores.2016.0008
   Shokoohmand A, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700221
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Singh AK, 2014, J BIOMED MATER RES A, V102, P639, DOI 10.1002/jbm.a.34726
   Singh R, 2018, STEM CELL REV REP, V14, P463, DOI 10.1007/s12015-018-9802-4
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Singhal Shweta, 2005, Indian Journal of Ophthalmology, V53, P109
   Sorkio A, 2017, J TISSUE ENG REGEN M, V11, P3134, DOI 10.1002/term.2221
   Sorkio A, 2015, TISSUE ENG PT A, V21, P2301, DOI [10.1089/ten.tea.2014.0640, 10.1089/ten.TEA.2014.0640]
   Sorkio AE, 2015, BIOMATERIALS, V51, P257, DOI 10.1016/j.biomaterials.2015.02.005
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   Tan EYS, 2017, J MATER CHEM B, V5, P5616, DOI 10.1039/c7tb00376e
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Thieltges F, 2011, OPHTHALMIC RES, V46, P133, DOI 10.1159/000324045
   Thomson HAJ, 2011, BRIT J OPHTHALMOL, V95, P563, DOI 10.1136/bjo.2009.166728
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tian Y, 2017, ACS BIOMATER SCI ENG, V3, P890, DOI 10.1021/acsbiomaterials.6b00757
   TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x
   Treharne AJ, 2012, J BIOMED MATER RES A, V100A, P2358, DOI 10.1002/jbm.a.34178
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   TURKSEN K, 1985, J HISTOCHEM CYTOCHEM, V33, P665, DOI 10.1177/33.7.3159787
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   Vargis E, 2014, BIOMATERIALS, V35, P3999, DOI 10.1016/j.biomaterials.2014.01.016
   Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wang Pengrui, 2018, Bioprinting, V12, pe00029, DOI 10.1016/j.bprint.2018.e00029
   Wang XF, 2018, INVEST OPHTH VIS SCI, V59, P2808, DOI 10.1167/iovs.17-22069
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Wikstrom J, 2008, BIOMATERIALS, V29, P869, DOI 10.1016/j.biomaterials.2007.10.056
   Wiley LA, 2015, PROG RETIN EYE RES, V44, P15, DOI 10.1016/j.preteyeres.2014.10.002
   Williams RL, 2005, J MATER SCI-MATER M, V16, P1087, DOI 10.1007/s10856-005-4710-y
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu WC, 2014, KAOHSIUNG J MED SCI, V30, P1, DOI 10.1016/j.kjms.2013.06.002
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zeugolis DI, 2008, BIOMATERIALS, V29, P2293, DOI 10.1016/j.biomaterials.2008.02.009
   Zorlutuna P, 2008, J BIOMAT SCI-POLYM E, V19, P399, DOI 10.1163/156856208783720976
   Zorlutuna P, 2007, BIOMATERIALS, V28, P3489, DOI 10.1016/j.biomaterials.2007.04.013
NR 154
TC 10
Z9 10
U1 2
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 1
PY 2020
VL 104
BP 1
EP 16
DI 10.1016/j.actbio.2020.01.013
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA KR0ZF
UT WOS:000517348400001
PM 31945506
DA 2022-11-30
ER

PT J
AU Tan, CSH
   Ngo, WK
   Lim, LW
   Lim, TH
AF Tan, Colin S. H.
   Ngo, Wei Kiong
   Lim, Louis W.
   Lim, Tock Han
TI A novel classification of the vascular patterns of polypoidal choroidal
   vasculopathy and its relation to clinical outcomes
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; RANIBIZUMAB MONOTHERAPY;
   VERTEPORFIN
AB Purpose To propose a novel classification system for polypoidal choroidal vasculopathy (PCV), and compare the clinical outcomes among PCV subtypes.
   Methods Consecutive treatment-naive patients with symptomatic PCV were managed over 5 years. PCV subtypes were classified based on indocyanine green angiography (ICGA) and fluorescein angiography (FA) characteristics.
   Results Among 107 patients, 3 PCV subtypes were seen: Type A (interconnecting channels on ICGA) -22.4%; Type B (branching vascular network with no leakage) -24.3%; Type C (branching vascular network with late leakage on FA) -53.3%. The proportion of patients with best-corrected visual acuity (BCVA) >= 20/40 was highest in Type A, intermediate in Type B and lowest in Type C at all time points (80% vs 66.7% vs 7.7% at 5 years, p<0.001). The highest rate of moderate visual loss (loss of >= 3 lines) occurred in Type C PCV (57.7% vs 0% for Types B and A at 5 years, p<0.001). Risk factors for poor visual outcomes were PCV subtype (OR 53.7, p<0.001 for Type C and OR 13.7, p=0.023 for Type B compared to Type A) and age (OR 1.06, 95% CI 1.002 to 1.125, p=0.044).
   Conclusions The PCV subtype seen on initial presentation affects the long-term visual outcomes over a 5-year period.
C1 [Tan, Colin S. H.; Ngo, Wei Kiong; Lim, Louis W.; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
   [Tan, Colin S. H.; Lim, Tock Han] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
C3 Tan Tock Seng Hospital
RP Tan, CSH (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM Colintan_eye@yahoo.com.sg
RI Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690
FU National University of Singapore-National Healthcare Group Clinician
   Leadership in Research Grant [CLR-09006]; National Healthcare Group
   Clinician Scientist Career Scheme Grant [CSCS/12005]
FX This study was supported by the National University of
   Singapore-National Healthcare Group Clinician Leadership in Research
   Grant CLR-09006 (Dr Tan). Dr Tan also receives research funding from the
   National Healthcare Group Clinician Scientist Career Scheme Grant
   (CSCS/12005) and travel support from Bayer (South East Asia) Pte Ltd,
   Heidelberg Engineering and Novartis. Dr Tock Han Lim receives travel
   support from Novartis, Bayer and Heidelberg Engineering.
CR BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tan CSH, 2013, ACTA OPHTHALMOL, V91, pE578, DOI 10.1111/aos.12214
   Tan CSH, 2013, BRIT J OPHTHALMOL, V97, P1357, DOI 10.1136/bjophthalmol-2013-304046
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 25
TC 58
Z9 61
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2014
VL 98
IS 11
BP 1528
EP 1533
DI 10.1136/bjophthalmol-2014-305059
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS3FR
UT WOS:000344163200012
PM 24997181
DA 2022-11-30
ER

PT J
AU Luviano, DM
   Benz, MS
   Kim, RY
   Fish, RH
   Wong, TP
   Kegley, EN
   Brown, DM
AF Luviano, Damien M.
   Benz, Matthew S.
   Kim, Rosa Y.
   Fish, Richard H.
   Wong, Tien P.
   Kegley, Eric N.
   Brown, David M.
TI Selected clinical comparisons of spectral domain and time domain optical
   coherence tomography
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
AB The authors report four cases where spectral domain optical coherence tomography (SD-OCT) imaged pathology not captured by time domain optical coherence tomography (TD-OCT). These cases include one of angioid streaks, two of juxtafoveal telangiectasia, and one of age-related macular degeneration. In each case, the improved images provided by SD-OCT changed either the management of the patient or the counseling of their disease process.
C1 [Luviano, Damien M.; Benz, Matthew S.; Kim, Rosa Y.; Fish, Richard H.; Wong, Tien P.; Kegley, Eric N.; Brown, David M.] Vitreoretinal Consultants, Greater Houston Retina Res Ctr, Houston, TX USA.
RP Benz, MS (通讯作者)，Vitreoretinal Consultants, Greater Houston Retina Res Ctr, 6560 Fannin,Suite 750, Houston, TX USA.
CR Albini TA, 2006, OPHTHAL SURG LAS IM, V37, P120, DOI 10.3928/1542-8877-20060301-07
   Arvas S, 2002, EUR J OPHTHALMOL, V12, P473, DOI 10.1177/112067210201200605
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Paunescu LA, 2006, OPHTHALMOLOGY, V113, P48, DOI 10.1016/j.ophtha.2005.08.016
   Schocket LS, 2006, OPHTHALMOLOGY, V113, P666, DOI 10.1016/j.ophtha.2006.01.003
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
NR 8
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2008
VL 39
IS 4
SU S
BP S104
EP S107
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 335IC
UT WOS:000258283000018
DA 2022-11-30
ER

PT J
AU Afenyi-Annan, A
   Brecher, ME
   Bandarenko, N
AF Afenyi-Annan, Araba
   Brecher, Mark E.
   Bandarenko, Nicholas
TI Update on multi-center clinical trials in the United States
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE multi-center clinical trials; platelet; thrombocytopenia; thrombotic
   thrombocytopenia purpura; rituximab; inflammatory bowel disease;
   dendritic cell vaccine; antigen presenting cell; rheopheresis;
   age-related macular degeneration
ID PROSTATIC ACID-PHOSPHATASE; CLOPIDOGREL-ASSOCIATED TTP; MACULAR
   DEGENERATION; DENDRITIC CELLS; ULCERATIVE-COLITIS; MONOCYTE APHERESIS;
   CULTURE SYSTEM; NEW-GENERATION; 7-DAY STORAGE; IMMUNOTHERAPY
AB This article reviews numerous multi-center clinical trials, either ongoing or in planning stages, which involve diverse clinical applications and emerging technologies in apheresis and transfusion medicine. The investigations summarized herein involve the following specific areas: platelet dosing strategy, thrombotic thrombocytopenia purpura, inflammatory bowel disease, seven-day platelet storage, dendritic cell vaccines, and age-related macular degeneration. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ N Carolina Hosp, Chapel Hill, NC 27514 USA.
C3 University North Carolina Hospital
RP Afenyi-Annan, A (通讯作者)，Univ N Carolina Hosp, 101 Manning Dr,1021 E Wing,Blood Bank,CB 7525, Chapel Hill, NC 27514 USA.
EM araba_afenyi-annan@med.unc.edu
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072355, R01HL069717]
   Funding Source: NIH RePORTER; NHLBI NIH HHS [U01HL072355,
   R01HL0-69717-01A1] Funding Source: Medline
CR Almand B, 2000, CLIN CANCER RES, V6, P1755
   *AM ASS BLOOD BANK, 2004, STAND BLOOD BANKS TR
   *AM ASS BLOOD BANK, 2003, COMPR RE BLOOD COLL
   AuBuchon JP, 2002, TRANSFUSION, V42, P855, DOI 10.1046/j.1537-2995.2002.00136.x
   Bandarenko N, 2006, TRANSFUSION, V46, p29A
   Beinart Garth, 2005, Clin Prostate Cancer, V4, P55, DOI 10.3816/CGC.2005.n.013
   Brecher ME, 2005, CLIN MICROBIOL REV, V18, P195, DOI 10.1128/CMR.18.1.195-204.2005
   Brecher ME, 2001, TRANSFUSION, V41, P477, DOI 10.1046/j.1537-2995.2001.41040477.x
   Brecher ME, 2002, TRANSFUSION, V42, P774, DOI 10.1046/j.1537-2995.2002.00122.x
   Brecher ME, 2004, TRANSFUSION, V44, P359, DOI 10.1111/j.1537-2995.2003.00617.x
   BRECHER ME, 2002, ROSSIS PRINCIPLES TR, P789
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Burch PA, 2004, PROSTATE, V60, P197, DOI 10.1002/pros.20040
   Burch PA, 2000, CLIN CANCER RES, V6, P2175
   DAIBUTSU M, 1987, THER PLASMAPHERES, V7, P257
   Dumont LJ, 2003, TRANSFUSION, V43, P143, DOI 10.1046/j.1537-2995.2003.00286.x
   Dumont LJ, 2002, TRANSFUSION, V42, P847, DOI 10.1046/j.1537-2995.2002.00147.x
   Dzik WH, 2006, J CLIN APHERESIS, V21, P57, DOI 10.1002/jca.20092
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabrilovich DI, 1997, CLIN CANCER RES, V3, P483
   George JN, 2006, J CLIN APHERESIS, V21, P49, DOI 10.1002/jca.20091
   Hanai H, 2004, DIGESTION, V70, P36, DOI 10.1159/000080079
   Heckman KD, 1997, J CLIN ONCOL, V15, P1143, DOI 10.1200/JCO.1997.15.3.1143
   Hersh JK, 1998, TRANSFUSION, V38, P637, DOI 10.1046/j.1537-2995.1998.38798346631.x
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Lin AM, 2006, UROL ONCOL-SEMIN ORI, V24, P434, DOI 10.1016/j.urolonc.2005.08.010
   MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297
   Ortolano GA, 2003, TRANSFUSION, V43, P1276, DOI 10.1046/j.1537-2995.2003.00487.x
   Pineda AA, 2006, INFLAMM BOWEL DIS, V12, pS10, DOI 10.1097/01.MIB.0000195386.19268.b3
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Reddy P, 2005, ANN HEMATOL, V84, P232, DOI 10.1007/s00277-004-0964-6
   Rini BI, 2006, CANCER-AM CANCER SOC, V107, P67, DOI 10.1002/cncr.21956
   RUBELLA P, 1997, NEW ENGL J MED, V337, P1870
   Sandborn WJ, 2006, INFLAMM BOWEL DIS, V12, pS15, DOI 10.1097/01.MIB.0000195387.26892.22
   Saniabadi AR, 2003, THER APHER DIAL, V7, P48, DOI 10.1046/j.1526-0968.2003.00012.x
   Sawada K, 2003, CURR PHARM DESIGN, V9, P307, DOI 10.2174/1381612033391928
   Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183
   Shimoyama T, 2001, J CLIN APHERESIS, V16, P1
   Slichter SJ, 2006, J CLIN APHERESIS, V21, P78, DOI 10.1002/jca.20090
   Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894
   Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252
   Swartz M, 1999, INVEST OPHTH VIS SCI, V40, pS319
   TAKAYUKI Y, 2006, WORLD J GASTROENTERO, V12, P520
   Vesely SK, 2003, BLOOD, V102, P60, DOI 10.1182/blood-2003-01-0193
   Wandt H, 1998, BLOOD, V91, P3601
   YOMTOVIAN R, 2004, BR J HAEMOTOL, V80, P94
   Zakarija A, 2004, STROKE, V35, P533, DOI 10.1161/01.STR.0000109253.66918.5E
   ZAKARIJA A, 2005, J CLIN APHERESIS, V20, P6
   Zheng XL, 2004, BLOOD, V103, P4043, DOI 10.1182/blood-2003-11-4035
NR 49
TC 2
Z9 2
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD FEB
PY 2007
VL 36
IS 1
BP 5
EP 12
DI 10.1016/j.transci.2006.10.007
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 157FQ
UT WOS:000245704500002
PM 17276142
DA 2022-11-30
ER

PT J
AU Cho, JH
   Ryoo, NK
   Cho, KH
   Park, SJ
   Park, KH
   Woo, SJ
AF Cho, Joon Hee
   Ryoo, Na-Kyung
   Cho, Kwan Hyuk
   Park, Sang Jun
   Park, Kyu Hyung
   Woo, Se Joon
TI Incidence Rate of Massive Submacular Hemorrhage and its Risk Factors in
   Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB INJECTIONS; PHOTODYNAMIC THERAPY;
   PROGNOSTIC-FACTORS; NATURAL-HISTORY; COMPLICATIONS; BEVACIZUMAB;
   OUTCOMES; EVEREST
AB PURPOSE: To investigate the incidence rate of massive submacular hemorrhage (SMH) in patients with polypoidal choroidal vasculopathy (PCV) and analyze the associated risk factors.
   DESIGN: Retrospective cohort study.
   METHODS: Patients diagnosed with PCV from May 2003 to May 2014 were included. Two hundred forty-five eyes of 245 patients were enrolled. The time between the initial visit to the clinic with subjective visual symptoms and the date of massive SMH was recorded. SMH larger than 4 disc diameters was defined as massive SMH. Age; hypertension; visual acuity (VA); indocyanine green angiography findings, including the greatest linear dimension, largest polyp size, and PCV type (cluster vs non-cluster); and treatment methods were reviewed for risk factor analysis using Kaplan-Meier survival and Cox regression analyses.
   RESULTS: The incidence rate of massive SMH within 1 year after the initial visit was 2.45%. Massive SMH occurred within 3, 5, and 10 years after the first visit in 6.17%, 11.09%, and 29.85% of patients, respectively. Cox regression analysis revealed that the cluster type of PCV was significantly associated with massive SMH (hazard ratio {FIR], 3.418; P =.003). Photodynamic therapy followed by anti-vascular endothelial growth factor injection lowered the risk of massive SMH (HR =.242; P =.047]. Final VA in eyes with massive SMH was significantly lower than that in patients without massive SMH (1.34 +/- 0.66 vs 0.63 +/- 0.53 logMAR; P <.001).
   CONCLUSIONS: Patients with PCV who develop massive SMH experience severe vision loss. The incidence rate of massive SMH in PCV increases with time. The cluster type of polyp in PCV is a significant risk factor for massive SMH. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Cho, Joon Hee; Ryoo, Na-Kyung; Cho, Kwan Hyuk; Park, Sang Jun; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Songnam, South Korea.
C3 Seoul National University (SNU)
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 300 Gumi Dong, Songnam 463707, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr
RI Woo, Se Joon/I-7357-2013
OI Woo, Se Joon/0000-0003-3692-7169
FU National Research Council of Science and Technology, Seoul, South Korea
   [CCP-13-02-KIST]
FX THIS STUDY WAS SUPPORTED BY A GRANT (CCP-13-02-KIST) FROM THE
   CONVERGENCE COMMERCIALIZAtion Project of National Research Council of
   Science and Technology, Seoul, South Korea.
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Cho HJ, 2012, CAN J OPHTHALMOL, V47, P170, DOI 10.1016/j.jcjo.2012.01.005
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lin HC, 2014, EYE, V28, P797, DOI 10.1038/eye.2014.124
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 27
TC 27
Z9 30
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2016
VL 169
BP 79
EP 88
DI 10.1016/j.ajo.2016.06.014
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW4UA
UT WOS:000383637300009
PM 27318076
DA 2022-11-30
ER

PT J
AU Montorio, D
   Giordano, M
   Concilio, M
   Cennamo, G
AF Montorio, Daniela
   Giordano, Mariapaola
   Concilio, Marina
   Cennamo, Gilda
TI Structural and Vascular Changes of the Choroid in Polypoidal Choroidal
   Vasculopathy after Intravitreal Anti-VEGF Therapy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Ranibizumab; Optical coherence
   tomography angiography; Choriocapillaris; Vessel density; Subfoveal
   choroidal thickness
ID ENDOTHELIAL GROWTH-FACTOR; INDOCYANINE GREEN ANGIOGRAPHY; MACULAR
   DEGENERATION; THICKNESS; HYPERPERMEABILITY; AFLIBERCEPT
AB Introduction: This study aimed to identify the changes in vessel density (VD) of the choriocapillaris (CC) and in subfoveal choroidal thickness (SFCT) and to evaluate their correlation with functional response after 3 monthly intravitreal injections of ranibizumab (loading phase [LP]) in patients affected by polypoidal choroidal vasculopathy (PCV). Methods: A total of 30 eyes of 30 PCV patients and 30 eyes of 30 healthy subjects as the control group were enrolled in this prospective study. The best-corrected visual acuity (BCVA) was measured at baseline and after 1 month from the third intravitreal injection in each patient. The VD of CC was evaluated in the macular area by means of optical coherence tomography angiography (OCTA). Central macular thickness (CMT) and SFCT were analyzed by enhanced depth imaging (EDI)-OCT. Results: The VD of CC showed statistically lower values in PCV patients at baseline with respect to after LP and normal eyes (p < 0.001). CMT and SFCT revealed a statistically significant reduction after LP (p < 0.001). Multiple regression analysis revealed a significant negative correlation between the reduced SFCT and CMT at baseline and the improvement of BCVA after LP (p < 0.05). Conclusion: The close relationship between the thinner SFCT and better visual outcome after LP reveals the role of the EDI-OCT assessment of the choroid as a predictive biomarker of functional response to anti-VEGF therapy. This tool could provide a quantitative evaluation of structural features of the choroid avoiding mistakes of evaluation at OCTA.
C1 [Montorio, Daniela; Giordano, Mariapaola; Concilio, Marina] Univ Naples Federico II, Dept Neurosci Reprod Sci & Dent, Naples, Italy.
   [Cennamo, Gilda] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy.
C3 University of Naples Federico II; University of Naples Federico II
RP Cennamo, G (通讯作者)，Univ Naples Federico II, Dept Publ Hlth, Naples, Italy.
EM xgilda@hotmail.com
OI Montorio, Daniela/0000-0003-1423-9621
CR Baek J, 2020, RETINA-J RET VIT DIS, V40, P2166, DOI 10.1097/IAE.0000000000002723
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Cennamo G, 2020, OPHTHALMOL THER, V9, P77, DOI 10.1007/s40123-019-00221-0
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Fujita A, 2020, RETINA-J RET VIT DIS, V40, P2296, DOI 10.1097/IAE.0000000000002760
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Jeong A, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.29
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim K, 2020, AM J OPHTHALMOL, V217, P240, DOI 10.1016/j.ajo.2020.05.017
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee B, 2019, GRAEF ARCH CLIN EXP, V257, P2163, DOI 10.1007/s00417-019-04432-w
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Ryu G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75506-7
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
NR 33
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2022
VL 245
IS 2
BP 173
EP 178
DI 10.1159/000521071
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1D0PR
UT WOS:000793512700010
PM 34844252
DA 2022-11-30
ER

PT J
AU Cicinelli, MV
   Cavalleri, M
   Consorte, AC
   Rabiolo, A
   Sacconi, R
   Bandello, F
   Querques, G
AF Cicinelli, Maria Vittoria
   Cavalleri, Michele
   Consorte, Andrea Celestino
   Rabiolo, Alessandro
   Sacconi, Riccardo
   Bandello, Francesco
   Querques, Giuseppe
TI SWEPT-SOURCE AND SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
   ANGIOGRAPHY VERSUS DYE ANGIOGRAPHY IN THE MEASUREMENT OF TYPE 1
   NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE swept-source; spectral domain; age-related macular degeneration; optical
   coherence tomography angiography; Type 1 neovascularization
ID INDOCYANINE GREEN ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION
AB Purpose: To compare the area of Type 1 neovascularization in patients with age-related macular degeneration calculated on spectral domain optical coherence tomography angiography (SD-OCTA), swept-source OCTA, and indocyanine green angiography (ICGA). Methods: Cross-sectional study enrolling patients with neovascular age-related macular degeneration with Type 1 neovascularization. During the same visit, ICGA (Spectralis HRA, Heidelberg, Germany), 3 x 3-mm or 6 x 6-mm SD-OCTA (CIRRUS AngioPlex model 5000; Carl Zeiss Meditec, Inc, Dublin, OH), and 3 x 3-mm or 6 x 6-mm swept-source OCTA (Plex Elite 9000; Carl Zeiss Meditec, Inc) were performed. Neovascularization areas were compared among the three instruments. The degree of consistency between measurements was investigated through the two-way mixed intraclass correlation, whereas the intermethod agreement was expressed by the Bland-Altman analysis. Mean difference and 95% confidence intervals are provided. Results: Eighteen eyes of 14 white patients (10 females, 83.3%) were included in the study. The neovascularization area measured on ICGA was higher compared to that measured on both SD-OCTA (P = 0.008) and swept-source OCTA (P = 0.008), whereas no differences were found between the two OCTA. Similar results were achieved analyzing 3 x 3-mm and 6 x 6-mm scan separately. Lowest reliability resulted from the ICGA versus SD-OCTA pair (intraclass correlation = 0.786, confidence interval = 0.500-0.915). Spectral domain OCTA and swept-source OCTA exhibited an excellent agreement (mean difference = 0.2). Swept-source OCTA offered qualitatively better images of the neovascularization, compared with SD-OCTA. Conclusion: Better visualization of the extent of neovascularization is obtained using SS-OCT or SD-OCT compared with ICGA, which may be influenced by choroidal permeability and dye leakage. Neovascularization area on OCTA may become an objective parameter in the follow-up of age-related macular degeneration patients, along with traditional imaging techniques.
C1 [Cicinelli, Maria Vittoria; Cavalleri, Michele; Consorte, Andrea Celestino; Rabiolo, Alessandro; Sacconi, Riccardo; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Sacconi, Riccardo] Univ Verona, Univ Hosp Verona, Dept Ophthalmol, Verona, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Verona; Azienda Ospedaliera Universitaria Integrata Verona
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Cavalleri, Michele/AAS-2701-2020; cicinelli, maria vittoria/M-1611-2019;
   Rabiolo, Alessandro/J-2831-2019
OI Cavalleri, Michele/0000-0001-5308-1201; cicinelli, maria
   vittoria/0000-0003-2938-0409; Rabiolo, Alessandro/0000-0002-7772-5929;
   bandello, francesco/0000-0003-3238-9682; Querques,
   Giuseppe/0000-0002-3292-9581; Sacconi, Riccardo/0000-0003-2891-2012
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P3690, DOI 10.1167/iovs.17-21941
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gass J D, 1994, Trans Am Ophthalmol Soc, V92, P91
   Giavarina D, 2015, BIOCHEM MEDICA, V25, P141, DOI 10.11613/BM.2015.015
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Nikolopoulou E, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6724818
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Soomro T, 2018, EYE, V32, P662, DOI 10.1038/eye.2018.2
   Souedan V, 2018, INT OPHTHALMOL, V38, P1051, DOI 10.1007/s10792-017-0559-6
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
NR 33
TC 12
Z9 13
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2020
VL 40
IS 3
BP 499
EP 506
DI 10.1097/IAE.0000000000002452
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1RI
UT WOS:000523731700013
PM 30649078
DA 2022-11-30
ER

PT J
AU Sakai, T
   Okano, K
   Kohno, H
   Tsuneoka, H
AF Sakai, Tsutomu
   Okano, Kiichiro
   Kohno, Hideo
   Tsuneoka, Hiroshi
TI Three-year visual outcomes of intravitreal ranibizumab with or without
   photodynamic therapy for polypoidal choroidal vasculopathy
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE photodynamic therapy; polypoidal choroidal vasculopathy; ranibizumab;
   VEGF
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; INJECTIONS; BEVACIZUMAB; EFFICACY
AB PurposeTo compare 3-year visual outcomes after intravitreal ranibizumab (IVR) monotherapy and combination therapy of photodynamic therapy (PDT) with IVR for polypoidal choroidal vasculopathy (PCV).
   MethodsMedical records for 45 eyes in 45 patients (34 men, 11 women; mean age, 73.8years old; range, 62-86years old) with treatment-naive PCV were reviewed retrospectively. Of the 45 eyes, 20 were treated with IVR monotherapy and 25 with combination therapy. Mean change in best-corrected visual acuity, numbers of injections of IVR and length of treatment-free period from baseline at month 36 were observed. Adverse events were monitored.
   ResultsThe change in visual acuity after combination therapy was significantly better than that after IVR monotherapy (p=0.0399). At 36months, improvement in visual acuity was seen in five eyes (25.0%) in the IVR monotherapy group and 13 eyes (52.0%) in the combination therapy group. The treatment-free period was significantly longer in the combination therapy group (p=0.0008). Additional IVR therapy was required significantly more frequently in the IVR monotherapy group (p=0.0026). Post-treatment subretinal haemorrhage or retinal pigment epithelium tear occurred only in the IVR monotherapy group, in one eye (5.0%) and one eye (5.0%), respectively.
   ConclusionInitial therapy consisting of a single session of PDT combined with IVR improves vision in treatment-naive PCV. Compared with IVR monotherapy, this combination therapy may be more effective for PCV.
C1 [Sakai, Tsutomu; Okano, Kiichiro; Kohno, Hideo; Tsuneoka, Hiroshi] Jikei Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
C3 Jikei University
RP Sakai, T (通讯作者)，Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.
EM tstmski@jikei.ac.jp
CR Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yang LH, 2015, ACTA OPHTHALMOL, V93, pE512, DOI 10.1111/aos.12606
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 15
Z9 15
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2016
VL 94
IS 8
BP E765
EP E771
DI 10.1111/aos.13130
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED1AR
UT WOS:000388576400020
PM 27237048
DA 2022-11-30
ER

PT J
AU Watanabe, G
   Fujii, H
   Kishi, S
AF Watanabe, Goro
   Fujii, Hitoshi
   Kishi, Shoji
TI Imaging of choroidal hemodynamics in eyes with polypoidal choroidal
   vasculopathy using laser speckle phenomenon
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroidal circulation; choroidal vasculopathy; indocyanine green
   angiography; laser speckle flowgraphy; polypoidal choroidal vasculopathy
ID OPTIC-NERVE HEAD; BLOOD-FLOW; 2-DIMENSIONAL MEASUREMENT; RETINAL
   MICROCIRCULATION; CLINICAL CHARACTERISTICS; CIRCULATION; FLOWGRAPHY;
   VISUALIZATION; NONCONTACT; VELOCITY
AB Purpose: To compare the images of choroidal vasculature obtained by laser speckle flowgraphy (LSFG) and indocyanine green angiography (IA), and to evaluate the imaging of choroidal hemodynamics in eyes with polypoidal choroidal vasculopathy (PCV) using LSFG.
   Methods: We performed IA and wide-field LSFG, which measures the index of blood velocity (mean square blur rate; MBR) in 25 eyes with PCV. We constructed an MBR map of the sequential MBR images (600 x 280 pixels) from four or five pulsations during measurement (4.5 s). A grayscale composite map of a still image was obtained by averaging the cumulative sum of the MBR map. We compared the angiographic images of the grayscale composite map to IA results and evaluated the choroidal hemodynamics of 25 eyes with PCV in the MBR map.
   Results: The choroidal vasculature on the grayscale map had a resolution similar to the IA results. The grayscale map detected branching network vessels in 20 (80%) of the 25 eyes and polypoidal lesions in 11 (44%) eyes. The MBR map showed that the pulsations of the branching network vessels and polypoidal lesions were synchronized with the cardiac rhythm. The fluctuation rates of the PCV lesions during one pulsation ranged from 8.3% to 26.7% (mean, 13.6%) and from 7.3% to 24.6% (mean, 15.9%) for the intact choroid. The MBR map showed the watershed zone and highest signal intensity in the macula.
   Conclusions: Using an MBR map, wide-field LSFG revealed the pulsating choroidal hemodynamics of the posterior fundus. A grayscale composite map showed the fine choroidal vasculature whose resolution was comparable to that of IA. The branching network vessels of PCV showed that pulsation was synchronized with the choroidal vessels. Wide-field LSFG showed the highest choroidal blood flow in the macular area and the presence of a watershed zone.
C1 [Watanabe, Goro; Kishi, Shoji] Gunma Univ, Sch Med, Dept Ophthalmol, Gunma, Japan.
   [Fujii, Hitoshi] Kyushu Inst Technol, Dept Comp Sci & Elect, Fukuoka, Japan.
C3 Gunma University; Kyushu Institute of Technology
RP Kishi, S (通讯作者)，3-39-15 Showamachi, Gunma 3718511, Japan.
EM kishi@med.gunma-u.ac.jp
CR ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   *AM NAT STAND I IN, 1993, AM NAT STAND SAF US, P31
   FUJII H, 1994, MED BIOL ENG COMPUT, V32, P302, DOI 10.1007/BF02512526
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Isono H, 2003, ARCH OPHTHALMOL-CHIC, V121, P225
   ISONO H, 1999, J EYE, V16, P1731
   KONISHI N, 1995, OPT ENG, V34, P753, DOI 10.1117/12.195203
   Konishi N, 2002, OPT REV, V9, P163, DOI 10.1007/s10043-002-0163-4
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nagahara M, 1999, JPN J OPHTHALMOL, V43, P186, DOI 10.1016/S0021-5155(99)00005-2
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tamaki Y, 1997, JPN J OPHTHALMOL, V41, P49, DOI 10.1016/S0021-5155(96)00008-1
   TAMAKI Y, 1994, INVEST OPHTH VIS SCI, V35, P3825
   TAMAKI Y, 1995, EXP EYE RES, V60, P373, DOI 10.1016/S0014-4835(05)80094-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 17
TC 41
Z9 42
U1 0
U2 3
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2008
VL 52
IS 3
BP 175
EP 181
DI 10.1007/s10384-007-0521-7
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 330LP
UT WOS:000257943200005
PM 18661267
DA 2022-11-30
ER

PT J
AU Caras, IW
   Littman, N
   Abo, A
AF Caras, Ingrid W.
   Littman, Neil
   Abo, Arie
TI Proceedings: Debilitating Eye Diseases
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
ID MACULAR DEGENERATION; CELLS
AB Debilitating eye diseases such as age-related macular degeneration and retinitis pigmentosa currently represent a large unmet medical need that could potentially be addressed by stem cell therapy. A number of novel stem cell-based cellular therapies are now under development to treat a variety of eye diseases. The approaches being taken by the California Institute for Regenerative Medicine, together with its grantees, are discussed.
C1 [Caras, Ingrid W.; Littman, Neil; Abo, Arie] Calif Inst Regenerat Med, San Francisco, CA 94107 USA.
RP Caras, IW (通讯作者)，Calif Inst Regenerat Med, 210 King St, San Francisco, CA 94107 USA.
EM icaras@cirm.ca.gov
OI Caras, Ingrid/0000-0002-8902-808X
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Cyranoski D, NATURE NEWS, DOI 10.1038/nature.2014.15897
   Foundation Fighting Blindness, EYE CONDITIONS
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Lin TC, 2014, J CHIN MED
   Mei H, 2014, TISSUE ENG PART C-ME, V20, P393, DOI [10.1089/ten.TEC.2013.0246, 10.1089/ten.tec.2013.0246]
   Pellegrini G, 2014, CELL STEM CELL, V15, P121, DOI 10.1016/j.stem.2014.07.011
   Rama P, 2010, NEW ENGL J MED, V363, P147, DOI 10.1056/NEJMoa0905955
NR 8
TC 6
Z9 6
U1 0
U2 1
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD DEC
PY 2014
VL 3
IS 12
BP 1393
EP 1397
DI 10.5966/sctm.2014-0221
PG 5
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AW7QZ
UT WOS:000346460900013
PM 25378652
OA Green Published, gold
DA 2022-11-30
ER

PT S
AU Massengill, MT
   Ahmed, CM
   Lewin, AS
   Ildefonso, CJ
AF Massengill, Michael T.
   Ahmed, Chulbul M.
   Lewin, Alfred S.
   Ildefonso, Cristhian J.
BE Ash, JD
   Anderson, RE
   LaVail, MM
   Rickman, CB
   Hollyfield, JG
   Grimm, C
TI Neuroinflammation in Retinitis Pigmentosa, Diabetic Retinopathy, and
   Age-Related Macular Degeneration: A Minireview
SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY
SE Advances in Experimental Medicine and Biology
LA English
DT Review
CT 17th International Symposium on Retinal Degeneration (RD)
CY SEP 19-24, 2016
CL Kyoto, JAPAN
SP Fdn Fighting Blindness, BrightFocus Fdn, Pro Retina, Fritz Tobler Fdn, Harrington Discovery Inst
DE Inflammation; Microglia; Muller glia; Diabetic retinopathy; Retinitis
   pigmentosa; Age-related macular degeneration
ID RETINAL DEGENERATION; MICROGLIAL ACTIVATION; PHOTORECEPTOR DEGENERATION;
   INFLAMMATORY RESPONSE; GENE-THERAPY; MOUSE MODEL; PROTEIN; MICE;
   PHAGOCYTOSIS; RECRUITMENT
AB The eye is an immuno-privileged organ. However, certain diseases such as uveitis are intrinsically linked to inflammation. In several retinal degenerative diseases, there is a unique damage at the onset of the disease, but evidence suggests that chronic and low-grade inflammatory processes play an important role in their progression. Studies have identified similar signaling pathways and changes in resident immune cells within the retina among these diseases. Herein, we will discuss some of these studies and propose how understanding this inflammatory response could aid in the development of therapies.
C1 [Massengill, Michael T.; Ahmed, Chulbul M.; Lewin, Alfred S.] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA.
   [Ildefonso, Cristhian J.] Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Ildefonso, CJ (通讯作者)，Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.
EM ildefons@ufl.edu
RI Ildefonso, Cristhian/AAC-3576-2021
OI Ildefonso, Cristhian/0000-0001-6179-720X; Lewin,
   Alfred/0000-0002-4192-9727
FU National Eye Institute [EY026268]; BrightFocus Foundation; Research to
   Prevent Blindness Foundation; NATIONAL EYE INSTITUTE [P30EY001583,
   R01EY026268, F30EY027163] Funding Source: NIH RePORTER
FX This work was supported by a grant from the National Eye Institute
   (EY026268), a BrightFocus Foundation travel award, and a grant from the
   Research to Prevent Blindness Foundation.
CR Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Arroba AI, 2016, BBA-MOL BASIS DIS, V1862, P1663, DOI 10.1016/j.bbadis.2016.05.024
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Chakravarthy H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146829
   Coucha M, 2015, MIDDLE EAST AFR J OP, V22, P135, DOI 10.4103/0974-9233.154386
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071
   Ildefonso CJ, 2016, ADV EXP MED BIOL, V854, P59, DOI 10.1007/978-3-319-17121-0_9
   Ildefonso CJ, 2015, MOL THER, V23, P875, DOI 10.1038/mt.2015.30
   Ildefonso CJ, 2015, HUM GENE THER, V26, P59, DOI 10.1089/hum.2014.089
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   McVicar CM, 2015, DIABETOLOGIA, V58, P1129, DOI 10.1007/s00125-015-3523-x
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Rana T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.539
   Samardzija M, 2006, INVEST OPHTH VIS SCI, V47, P5181, DOI 10.1167/iovs.06-0556
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Syeda S, 2015, EXP NEUROL, V267, P1, DOI 10.1016/j.expneurol.2015.02.027
   Wang L, 2015, NEUROCHEM RES, V40, P713, DOI 10.1007/s11064-015-1517-1
   Wang MH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-173
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016
   Zeng H, 2014, NEUROSCIENCE, V275, P54, DOI 10.1016/j.neuroscience.2014.05.065
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
NR 28
TC 25
Z9 26
U1 0
U2 5
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0065-2598
EI 2214-8019
BN 978-3-319-75402-4; 978-3-319-75401-7
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2018
VL 1074
BP 185
EP 191
DI 10.1007/978-3-319-75402-4_23
PG 7
WC Cell Biology; Medicine, Research & Experimental; Ophthalmology
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Ophthalmology
GA BK8XP
UT WOS:000443968600024
PM 29721943
DA 2022-11-30
ER

PT J
AU Dilks, DD
   Julian, JB
   Peli, E
   Kanwisher, N
AF Dilks, Daniel D.
   Julian, Joshua B.
   Peli, Eli
   Kanwisher, Nancy
TI Reorganization of Visual Processing in Age-Related Macular Degeneration
   Depends on Foveal Loss
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE cortical reorganization; cortical plasticity; primary visual cortex;
   retinotopy; human; adult visual system
ID SCANNING LASER OPHTHALMOSCOPE; PREFERRED RETINAL LOCUS; SURFACE-BASED
   ANALYSIS; TOPOGRAPHIC REORGANIZATION; RESTRICTED DEAFFERENTATION;
   STRIATE CORTEX; CORTICAL MAPS; ADULT CAT; PLASTICITY; STABILITY
AB Purpose. When individuals with central vision loss due to macular degeneration (MD) view stimuli in the periphery, most of them activate the region of retinotopic cortex normally activated only by foveal stimuli-a process often referred to as reorganization. Why do some show this reorganization of visual processing whereas others do not? We reported previously that six individuals with complete bilateral loss of central vision showed such reorganization, whereas two with bilateral central vision loss but with foveal sparing did not, and we hypothesized that the effect occurs only after complete bilateral loss of foveal vision. Here, we conduct a stronger test of the dependence of reorganization of visual processing in MD on complete loss of foveal function, by bringing back one (called MD6) of the two participants who previously did not show reorganization and who showed foveal sparing. MD6 has now lost all foveal function, and we predicted that if large-scale reorganization of visual processing in MD individuals depends on complete loss of foveal input, then we will now see such reorganization in this individual.
   Methods. MD6 and two normally sighted control subjects were scanned. Stimuli were gray-scale photographs of objects presented at either the fovea or a peripheral retinal location (i.e., the MD participant's preferred retinal locus or the control participants' matched peripheral location).
   Results. In MD6, visual stimulation at the preferred retinal locus significantly activated not only the expected "peripheral'' retinotopic cortex but also the deprived "foveal'' cortex. Crucially, MD6 exhibited no such large-scale reorganization 5 years earlier when she had some foveal sparing. By contrast, in the control participants, stimulation at the matched peripheral location produced significant activation in peripheral retinotopic cortex only.
   Conclusions. We conclude that complete loss of foveal function may be a necessary condition for large-scale reorganization of visual processing in individuals with MD.
C1 [Dilks, Daniel D.] Emory Univ, Dept Psychol, Atlanta, GA 30332 USA.
   [Julian, Joshua B.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.
   [Peli, Eli] Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Eye & Ear, Boston, MA USA.
   [Kanwisher, Nancy] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
C3 Emory University; University of Pennsylvania; Harvard University;
   Harvard Medical School; Massachusetts Eye & Ear Infirmary; Schepens Eye
   Research Institute; Massachusetts Institute of Technology (MIT)
RP Dilks, DD (通讯作者)，Emory Univ, Dept Psychol, 36 Eagle Row,Room 469, Atlanta, GA 30332 USA.
EM dilks@emory.edu
OI Peli, Eli/0000-0002-1340-9257; Julian, Joshua/0000-0001-6944-5479
FU National Institutes of Health [EY016559, EY13455, EY05957]; NATIONAL EYE
   INSTITUTE [R01EY013455, R01EY016159, R01EY005957] Funding Source: NIH
   RePORTER
FX We express our sincere thanks to MD6. We also thank the Athinoula A.
   Martinos Imaging Center at the McGovern Institute for Brain Research,
   MIT, Cambridge, MA. This work was supported in part by National
   Institutes of Health grants EY016559 and EY13455 (NK) and EY05957 (EP).
   The authors have no conflicts of interest.
CR Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   Baseler HA, 2011, NAT NEUROSCI, V14, P649, DOI 10.1038/nn.2793
   CHINO YM, 1992, VISION RES, V32, P789, DOI 10.1016/0042-6989(92)90021-A
   Cox RW, 1999, MAGNET RESON MED, V42, P1014, DOI 10.1002/(SICI)1522-2594(199912)42:6<1014::AID-MRM4>3.0.CO;2-F
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395
   DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995
   DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0
   DAS A, 1995, J NEUROPHYSIOL, V74, P779, DOI 10.1152/jn.1995.74.2.779
   Dilks DD, 2007, J NEUROSCI, V27, P9585, DOI 10.1523/JNEUROSCI.2650-07.2007
   Dilks DD, 2009, J NEUROSCI, V29, P8960, DOI 10.1523/JNEUROSCI.1557-09.2009
   Dilks DD, 2009, J NEUROSCI, V29, P2768, DOI 10.1523/JNEUROSCI.5258-08.2009
   Dougherty RF, 2003, J VISION, V3, P586, DOI 10.1167/3.10.1
   Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396
   Fitzgibbon A, 1999, IEEE T PATTERN ANAL, V21, P476, DOI 10.1109/34.765658
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   KAPADIA MK, 1994, J NEUROSCI, V14, P451
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6
   Muhlnickel W, 1998, P NATL ACAD SCI USA, V95, P10340, DOI 10.1073/pnas.95.17.10340
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Schumacher EH, 2008, RESTOR NEUROL NEUROS, V26, P391
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Tailby C, 2004, VISUAL NEUROSCI, V21, P79, DOI 10.1017/S0952523804041082
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Wandell BA, 2009, NAT REV NEUROSCI, V10, P873, DOI 10.1038/nrn2741
   Woods RL, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3292015
NR 29
TC 36
Z9 37
U1 0
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP E199
EP E206
DI 10.1097/OPX.0000000000000325
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500001
PM 24978868
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Ijiri, S
   Sugiyama, K
AF Ijiri, Shigeyuki l
   Sugiyama, Kazuhisa
TI Short-term efficacy of intravitreal aflibercept for patients with
   treatment-na < ve polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Polypoidal choroidal vasculopathy; Treatment-naive;
   Indocyanine green angiography
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; GROWTH-FACTOR; VEGF TRAP;
   RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; RESISTANT; FLUID; EYES
AB To evaluate the short-term efficacy of aflibercept monotherapy for patients with treatment-na < ve polypoidal choroidal vasculopathy (PCV).
   Prospective, consecutive case series.
   Thirty-three consecutive eyes of 33 symptomatic PCV patients (17 men, 16 women, mean age 75 +/- 8.7 years), not treated previously, received an intravitreal injection of 2.0 mg of aflibercept monthly for 3 months. Changes in best-corrected visual acuity (BCVA), optical coherence tomography (OCT) findings, and indocyanine green angiography (ICGA) findings 3 months after initial injection were evaluated.
   Compared with baseline, mean BCVA at 3-month visit significantly improved (0.40 +/- 0.34 vs 0.22 +/- 0.20 log minimum angle of resolution [logMAR] unit, P < 12 0.001). Eight eyes (24 %) showed improvement in BCVA a parts per thousand yenaEuro parts per thousand 0.3 logMAR unit, and no eyes (0 %) showed a decrease in BCVA of a parts per thousand yenaEuro parts per thousand 0.3 logMAR unit. Mean foveal thickness improved significantly (348 +/- 184 mu m at baseline vs 194 +/- 32 mu m at 3-month visit, P < 15 0.001). At 3-month visit, 31 eyes (97 %) achieved dry macula evaluated on OCT. Polypoidal lesions disappeared completely on ICGA in 16 eyes (48 %), and the number and/or the size of polypoidal lesions decreased in nine eyes (27 %). The remaining eight eyes (24 %) had unchanged polypoidal lesions. A branching vascular network remained and was unchanged in diameter in all 27 eyes in which it was detected at baseline.
   Intravitreal aflibercept was well-tolerated in patients with treatment-na < ve PCV over the short-term.
C1 [Ijiri, Shigeyuki l; Sugiyama, Kazuhisa] Kanazawa Univ, Grad Sch Med Sci, Dept Ophthalmol, Kanazawa, Ishikawa 9208641, Japan.
C3 Kanazawa University
RP Ijiri, S (通讯作者)，Kanazawa Univ, Grad Sch Med Sci, Dept Ophthalmol, Kanazawa, Ishikawa 9208641, Japan.
EM ijiri@p1.coralnet.or.jp
CR Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P750, DOI 10.1097/IAE.0b013e31819ed6bd
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
NR 33
TC 25
Z9 26
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2015
VL 253
IS 3
BP 351
EP 357
DI 10.1007/s00417-014-2707-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC6WR
UT WOS:000350510200004
PM 25023147
DA 2022-11-30
ER

PT J
AU Shojaei, F
   Ferrara, N
AF Shojaei, Farbod
   Ferrara, Napoleone
TI Antiangiogenesis to treat cancer and intraocular neovascular disorders
SO LABORATORY INVESTIGATION
LA English
DT Article
DE tumor angiogenesis; VEGF; bevacizumab; neovascularization; ranibizumab;
   stromal cells
ID MACULAR DEGENERATION; ENDOTHELIAL-CELLS; TUMOR-GROWTH; ANGIOGENESIS;
   THERAPY; VEGF; BEVACIZUMAB; RANIBIZUMAB; VERTEPORFIN
AB Identification and characterization of several important regulators of angiogenesis, and FDA approval of the first anti-angiogenic drugs, has opened a new era in the therapy of cancer and neovascular age-related macular degeneration. This brief review focuses on the progress in targeting one of the major regulators of angiogenesis, VEGF-A, and also discusses potential cellular and molecular mechanisms underlying resistance to antiangiogenic treatments.
C1 Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gothert JR, 2004, BLOOD, V104, P1769, DOI 10.1182/blood-2003-11-3952
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Smith JK, 2004, ONCOL RES, V14, P175, DOI 10.3727/000000003772462298
   Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031
   Yu JL, 2002, DIFFERENTIATION, V70, P599, DOI 10.1046/j.1432-0436.2002.700913.x
NR 27
TC 48
Z9 56
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD MAR
PY 2007
VL 87
IS 3
BP 227
EP 230
DI 10.1038/labinvest.3700526
PG 4
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 142XX
UT WOS:000244685700001
PM 17259997
OA Bronze
DA 2022-11-30
ER

PT J
AU Canning, C
   Lotery, A
AF Canning, C.
   Lotery, A.
TI Bevacizumab: a new way of doing business?
SO EYE
LA English
DT Review
DE bevacizumab; age-related macular degeneration; avastin
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; INTRAVITREAL INJECTION; AVASTIN; TRANSLOCATION; SURGERY;
   THERAPY; IMPACT; EDEMA
AB This review highlights the history of the development of treatments for choroidal neovascularization (wct AMD). It examines how drug therapies have evolved for the management of age-related macular degeneration (AMD) and the value of randomised clinical trials in determining efficacy. Finally it examines the emerging practice of utilising bevacizumab for the treatment of choroidal neovascularization despite the lack of any phase III clinical trial data.
C1 Univ Southampton, Southampton Gen Hosp, Div Human Genet, Southampton SO16 6YD, Hants, England.
   Southampton Gen Hosp, Southampton Eye Unit, Southampton SO9 4XY, Hants, England.
C3 University of Southampton; University of Southampton
RP Lotery, A (通讯作者)，Univ Southampton, Southampton Gen Hosp, Div Human Genet, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Atebara NH, 1998, OPHTHALMOLOGY, V105, P1598, DOI 10.1016/S0161-6420(98)99024-8
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P1103, DOI 10.1136/bjo.83.10.1103
   Chaudhuri A, 2006, BMJ-BRIT MED J, V332, P416, DOI 10.1136/bmj.332.7538.416
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Machemer R, 1998, AM J OPHTHALMOL, V125, P698, DOI 10.1016/S0002-9394(98)00020-8
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Reichel E, 2005, OPHTHAL SURG LAS IM, V36, P270, DOI 10.3928/1542-8877-20050701-03
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
NR 23
TC 4
Z9 4
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2006
VL 20
IS 9
BP 985
EP 987
DI 10.1038/sj.eye.6702501
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 092EE
UT WOS:000241079000001
PM 16858443
OA Bronze
DA 2022-11-30
ER

PT J
AU Han, LH
   Yuan, LF
   Liang, X
   Jia, X
   Zhang, ML
AF Han, Long-Hui
   Yuan, Li-Fei
   Liang, Xu
   Jia, Xin
   Zhang, Ming-Lian
TI Combined therapy versus anti-vascular endothelial growth factor
   monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE vascular endothelial growth factor; photodynamic therapy; polypoidal
   choroidal vasculopathy
ID INTRAVITREAL BEVACIZUMAB INJECTION; VERTEPORFIN PHOTODYNAMIC THERAPY;
   EPITHELIUM-DERIVED FACTOR; COMBINATION THERAPY; RANIBIZUMAB; EFFICACY;
   EXPRESSION; SAFETY
AB AIM: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) combined with photodynamic therapy (PDT) versus anti-VEGF monotherapy for polypoidal choroidal vasculopathy (PCV).
   METHODS: We conducted a Meta-analysis of 9 studies to compare the efficacy and safety between combined therapy and anti-VEGF monotherapy for PCV. The programs of RevMan 5.3 and Stata 12.0 were used to analyze data.
   RESULTS: The best corrected visual acuity (BCVA) in combined therapy group were significantly better than those of anti-VEGF monotherapy group at 6, 24 and 36mo, with pooled weighted means differences (WMDs) of 0.12 (0.06, 0.18), 0.25 (0.12, 0.38) and 0.28 (0.13, 0.43), respectively. The central retinal thickness (CRT) reductions in combined therapy group were higher than that in antiVEGF monotherapy group at 1, 3, 6 and 9mo, with pooled WMDs of 63.90 (20.41, 107.38), 33.47 (4.69, 62.24), 30.57 (0.12, 60.01) and 28.00 (2.51, 53.49), respectively. The regression rate of polyps in combined therapy group was much higher than that in anti-VEGF monotherapy group [RD: 0.47 (0.26, 0.68); P<0.0001]. The adverse event retinal hemorrhage did not differ significantly between the two groups.
   CONCLUSION: Our findings clearly document that antiVEGF combined with PDT is a more effective therapy for PCV compared with anti-VEGF monotherapy. Furthermore, combined therapy does not increase the incidence of retinal hemorrhage.
C1 [Han, Long-Hui; Yuan, Li-Fei; Jia, Xin; Zhang, Ming-Lian] Hebei Prov Eye Hosp, Hebei Prov Eye Inst, 399 East Quanbei St, Xingtai 054001, Hebei, Peoples R China.
   [Liang, Xu] Tianjin Eye Hosp, Tianjin 300020, Peoples R China.
C3 Tianjin Medical University
RP Han, LH (通讯作者)，Hebei Prov Eye Hosp, Hebei Prov Eye Inst, 399 East Quanbei St, Xingtai 054001, Hebei, Peoples R China.
EM han-longhui@163.com
CR Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kikushima W, 2016, GRAEFES ARCH CLIN EX
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Liu L, 2015, MOL VIS, V21, P1130
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
NR 43
TC 4
Z9 4
U1 1
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD AUG 18
PY 2017
VL 10
IS 8
BP 1280
EP 1289
DI 10.18240/ijo.2017.08.16
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FD7IO
UT WOS:000407700000016
PM 28861356
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Ye, LH
   Cai, Y
   Shi, X
   Wong, IYH
   Qu, JF
   Zhao, MW
   Ying, X
   Li, XX
AF Ye, Lin-Hong
   Cai, Yi
   Shi, Xuan
   Wong, Ian Yat Hin
   Qu, Jin-Feng
   Zhao, Ming-Wei
   Ying, Xin
   Li, Xiao-Xin
TI One-year results of intravitreal conbercept in treatment-naive subjects
   with polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Conbercept; Intravitreal injection; Polypoidal choroidal vasculopathy;
   Polyp regression
ID VERTEPORFIN PHOTODYNAMIC THERAPY; PIGMENT EPITHELIAL DETACHMENT;
   SHORT-TERM EFFICACY; RANIBIZUMAB; AFLIBERCEPT; SAFETY; MONOTHERAPY
AB Purpose To evaluate the functional and structural outcomes of intravitreal conbercept monotherapy using a "3 + pro re nata (PRN)" regimen in treatment-naive subjects with polypoidal choroidal vasculopathy (PCV) up to 12 months. Methods Thirty subjects (30 eyes) with PCV participated in this interventional, retrospective study. All subjects received intravitreal injections of 0.5 mg (0.05 ml) conbercept using a "3 + PRN" regimen for 12 months. The changes in best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters, polyp lesion area, and regression rate were evaluated at baseline, month 3, and month 12. Results At the study end-point, BCVA improved significantly from 52.80 +/- 17.17 ETDRS letters at baseline to 62.20 +/- 18.96 letters (P < 0.001), with a mean gain of 9.40 +/- 14.97 letters. The central retinal thickness (CRT) significantly reduced from 454.93 +/- 147.31 mu m at baseline to 308.73 +/- 106.80 mu m (P < 0.001) at end-point, and the total macular volume (TMV) decreased from 9.51 +/- 1.04 mm(3) at baseline to 8.32 +/- 0.84 mm3 at end-point (P < 0.001). The mean volume of pigment epithelial detachment (PED) decreased from 0.73 +/- 0.97 mm(3) at baseline to 0.48 +/- 0.71 mm(3) (P < 0.05) at month 3. At month 12, the mean volume of PED was 0.57 +/- 0.80 mm(3) (P > 0.05 compared to baseline). After the 3-monthly loading injections, 6 eyes (20.0%) showed complete polyp regression, whereas a total of 19 eyes (63.5%) showed complete regression at month 12. The average injections given per subject were 7.70 +/- 1.81. Conclusion Intravitreal conbercept using the "3 + PRN" regimen was effective in the treatment of PCV.
C1 [Ye, Lin-Hong; Cai, Yi; Shi, Xuan; Qu, Jin-Feng; Zhao, Ming-Wei; Ying, Xin; Li, Xiao-Xin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Ye, Lin-Hong; Cai, Yi; Shi, Xuan; Qu, Jin-Feng; Zhao, Ming-Wei; Ying, Xin; Li, Xiao-Xin] Eye Dis & Optometry Inst, Beijing, Peoples R China.
   [Ye, Lin-Hong; Cai, Yi; Shi, Xuan; Qu, Jin-Feng; Zhao, Ming-Wei; Ying, Xin; Li, Xiao-Xin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
   [Ye, Lin-Hong; Cai, Yi; Shi, Xuan; Qu, Jin-Feng; Zhao, Ming-Wei; Ying, Xin; Li, Xiao-Xin] Peking Univ, Coll Optometry, Hlth Sci Ctr, Beijing, Peoples R China.
   [Wong, Ian Yat Hin] Hong Kong Sanat & Hosp, Dept Ophthalmol, Hong Kong, Peoples R China.
   [Li, Xiao-Xin] Xiamen Univ, Xiamen Eye Ctr, Xiamen, Fujian, Peoples R China.
C3 Peking University; Peking University; Xiamen University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.; Li, XX (通讯作者)，Eye Dis & Optometry Inst, Beijing, Peoples R China.; Li, XX (通讯作者)，Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.; Li, XX (通讯作者)，Peking Univ, Coll Optometry, Hlth Sci Ctr, Beijing, Peoples R China.; Li, XX (通讯作者)，Xiamen Univ, Xiamen Eye Ctr, Xiamen, Fujian, Peoples R China.
EM drlixiaoxin@163.com
FU National Natural Science Foundation of China [81970815]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No. 81970815).
CR Chae Ju Byung, 2011, Korean J Ophthalmol, V25, P98, DOI 10.3341/kjo.2011.25.2.98
   Chan EW, 2017, AM J OPHTHALMOL, V177, P195, DOI 10.1016/j.ajo.2016.12.008
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   de Oliveira Dias Joao Rafael, 2016, Int J Retina Vitreous, V2, P3, DOI 10.1186/s40942-016-0026-y
   Huang Z, 2019, RETINA-J RET VIT DIS, V39, P889, DOI 10.1097/IAE.0000000000002035
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Peng YT, 2018, DRUG DES DEV THER, V12, P339, DOI 10.2147/DDDT.S158368
   Qi HJ, 2019, INT J OPHTHALMOL-CHI, V12, P51, DOI 10.18240/ijo.2019.01.08
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1114, DOI 10.4103/ijo.IJO_638_18
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
NR 28
TC 2
Z9 2
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2021
VL 259
IS 6
BP 1455
EP 1462
DI 10.1007/s00417-020-04988-y
EA NOV 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SK9OI
UT WOS:000585749500004
PM 33146832
DA 2022-11-30
ER

PT J
AU Meleth, AD
   Wong, WT
   Chew, EY
AF Meleth, Annal D.
   Wong, Wai T.
   Chew, Emily Y.
TI Treatment for atrophic macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; atrophic macular degeneration;
   geographic atrophy; retina; retinal pigment epithelium
ID GEOGRAPHIC ATROPHY; THERAPY; TRIAL
AB Purpose of review
   To summarize ongoing and recently completed trials on geographic atrophy associated with age-related macular degeneration.
   Recent findings
   A large number of investigational agents are under development for treatment of geographic atrophy in both pre and early-phase clinical testing.
   Summary
   Therapies targeting all putative phases of pathogenesis in geographic atrophy are under development. Thus far, no therapies have been demonstrated to be effective.
C1 [Meleth, Annal D.; Wong, Wai T.; Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016
CR AMBATI J, PHASE 1 OPEN LABEL D
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   COLLIER RJ, 2010, INVEST OPHTHALMOL VI
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   FRANCIS PJ, 2010, PHASE 1 OPEN LABEL N
   IMPLANT B, SAFETY EFFICACY BRIM
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   MELETH AD, 2010, INVEST OPHTHALMOL VI
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   WANG Y, 2011, EYE LOND, V25, P126
   WILLIAMS GA, 2009, ASS RES VIS OPHTH FT
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   STUDY SAFET TOLERABI
   FOFD4514S STUDY SAFE
   CNTO2476 STUDY SAFET
NR 23
TC 23
Z9 24
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2011
VL 22
IS 3
BP 190
EP 193
DI 10.1097/ICU.0b013e32834594b0
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749YQ
UT WOS:000289508400009
PM 21427574
DA 2022-11-30
ER

PT J
AU Tsui, I
   Jain, A
   Shah, S
   Schwartz, SD
   McCannel, TA
AF Tsui, Irena
   Jain, Atul
   Shah, Sumit
   Schwartz, Steven D.
   McCannel, Tara A.
TI Ultra Wide Field Imaging of Peripheral Exudative Hemorrhagic
   Chorioretinopathy
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE peripheral exudative hemorrhagic lesion; chorioretinopathy; Optos; wide
   field imaging; choroidal lesion; age related macular degeneration
AB Age related macular degeneration usually affects the macular region, but there is a rare peripheral counterpart known as peripheral exudative hermorrhagic chorioretinopathy (PEHCR). We employed ultra wide field imaging techniques to follow four patients with PEHCR. Accurate photographic documentation may be helpful in monitoring growth in order to distinguish PEHCR from potentially treatable or life-threatening lesions such as choroidal metastatic tumors or primary choroidal melanoma.
C1 [Tsui, Irena; Jain, Atul; Shah, Sumit; Schwartz, Steven D.; McCannel, Tara A.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Ophthalm Oncol Ctr,Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP McCannel, TA (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Ophthalm Oncol Ctr,Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM tmccannel@jsei.ucla.edu
CR Annesley W H Jr, 1980, Trans Am Ophthalmol Soc, V78, P321
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Collaer N, 2007, B SOC BELGE OPHTALMO, V305, P23
   Kubicka-Trzaska Agnieszka, 2005, Klin Oczna, V107, P147
   SASSANI JW, 1994, RETINA-J RET VIT DIS, V14, P177, DOI 10.1097/00006982-199414020-00013
NR 5
TC 7
Z9 8
U1 0
U2 1
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2009
VL 24
IS 1
BP 25
EP 28
DI 10.1080/08820530802520178
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V18QY
UT WOS:000208020500007
PM 19241288
DA 2022-11-30
ER

PT J
AU Kang, HM
   Koh, HJ
   Lee, CS
   Lee, SC
AF Kang, Hae Min
   Koh, Hyoung Jun
   Lee, Christopher Seungkyu
   Lee, Sung Chul
TI Combined Photodynamic Therapy With Intravitreal Bevacizumab Injections
   for Polypoidal Choroidal Vasculopathy: Long-term Visual Outcome
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; TIME-DOMAIN;
   RANIBIZUMAB; VERTEPORFIN
AB PURPOSE: To evaluate the long-term visual outcome after combination therapy of photodynamic therapy (PDT) with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective observational study.
   METHODS: The medical records of 34 eyes (34 patients) with naive PCV who were treated with combination therapy were analyzed. All patients completed at least 3 years of follow-up. All clinical data, including age, best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution [logMARD, imaging data of fluorescein angiography, indocyanine green angiography, and optical coherence tomography, were investigated.
   RESULTS: During a mean follow-up period of 46.8 5.2 months, a mean of 1.4 0.71 times of PDT and 9.2 6.6 intravitreal bevacizumab injections were performed. During follow-up, 21 eyes (61.8%) showed at least 1 recurrence. Mean BCVA was 0.59 0.35 logMAR (20/77 Snellen equivalent) at baseline and 0.39 0.34 logMAR (20/49 Snellen equivalent) at 3 years (P = .004). At 3 years, 14 patients (41.2%) gained 0.3 logMAR or more BCVA and 4 patients (11.8%) lost 0.3 logMAR or more BCVA than baseline. Baseline polyp size (13 = .551; P = .005) and location of polyps (13 = .400; P = .033) were significantly correlated with long-term visual outcome after combination therapy for PCV.
   CONCLUSIONS: Combination therapy of PDT with intravitreal bevacizumab injections showed favorable visual outcomes, and significant visual improvement was maintained in PCV patients. A total of 88.2% of patients avoided visual loss at 3 years after treatments. Largest polyp size at baseline and location of polypoidal lesions were prognostic factors for long-term visual outcomes in these patients.
C1 [Kang, Hae Min; Koh, Hyoung Jun; Lee, Christopher Seungkyu; Lee, Sung Chul] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
   [Koh, Hyoung Jun] Incheon Int St Marys Hosp, Dept Ophthalmol, Inchon, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Lee, SC (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, 134 Sinchon Dong, Seoul 120752, South Korea.
EM sunglee@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516; , Sung Chul/0000-0001-9438-2385;
   Lee, Christopher/0000-0001-5054-9470
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Forte R, 2009, EYE, V23, P2071, DOI 10.1038/eye.2008.363
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Han IC, 2009, AM J OPHTHALMOL, V147, P847, DOI 10.1016/j.ajo.2008.11.019
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Lai TY, 2010, RETINA, V31, P1581
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 41
TC 22
Z9 23
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2014
VL 157
IS 3
BP 598
EP 606
DI 10.1016/j.ajo.2013.11.015
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC2QX
UT WOS:000332350100014
PM 24269378
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Higuchi, M
   Matsushita, T
   Kosaka, S
   Matsushita, R
   Takami, K
   Ohtsuka, H
   Kitamei, H
   Shioya, S
AF Hikichi, Taiichi
   Higuchi, Makoto
   Matsushita, Takuro
   Kosaka, Shoko
   Matsushita, Reiko
   Takami, Kimitaka
   Ohtsuka, Hideo
   Kitamei, Hirokuni
   Shioya, Shoko
TI Results of 2 years of treatment with as-needed ranibizumab reinjection
   for polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; FOLLOW-UP; VERTEPORFIN;
   OUTCOMES
AB Purpose To investigate the 2-year outcomes of three monthly intravitreal ranibizumab injections followed by as-needed reinjections to treat polypoidal choroidal vasculopathy (PCV).
   Methods Seventy-five consecutive eyes with naive symptomatic PCV with 2 years of follow-up after treatment were studied prospectively.
   Results The mean (+/- SD) numbers of injections were 4.2 +/- 1.3 that included three monthly injections in the loading phase and 1.6 +/- 1.7 during years 1 and 2, respectively (mean 2-year total, 5.6 +/- 1.9). The baseline logarithm of the minimum angle of resolution visual acuity (VA) was 0.59 +/- 0.51 that improved significantly (p=0.001 for both comparisons) to 0.37 +/- 0.33 and 0.41 +/- 0.40 at 1 and 2 years, respectively, after the first injection. Although no significant difference was found between years 1 and 2 after the first injection, the VA tended to decrease slightly during year 2. The improved foveal thickness was maintained during year 2. Thirty (40%) eyes and 19 (25%) eyes, respectively, at years 1 and 2 after the first injection had no polypoidal lesions on indocyanine green angiography. A branching vascular network (BVN) remained in all eyes 2 years after the first injection and tended to increase in size during year 2.
   Conclusions The 2-year outcomes showed significant VA and foveal thickness improvements in eyes with PCV. During year 2, the magnitude of the improvement was lower compared with year 1. An as-needed reinjection schedule might not prevent polypoidal lesions or BVNs from regrowing. Further investigations should establish a treatment strategy for PCV.
C1 [Hikichi, Taiichi; Higuchi, Makoto; Matsushita, Takuro; Kosaka, Shoko; Matsushita, Reiko; Takami, Kimitaka; Ohtsuka, Hideo; Kitamei, Hirokuni; Shioya, Shoko] Ohtsuka Eye Hosp, Dept Ophthalmol, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Dept Ophthalmol, Kita Ku, Kita 16 Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
FU Novartis Pharma Japan; Bayer. Japan; Santen; Alcon Japan
FX Dr Hikichi received lecture fees from Novartis Pharma Japan, Bayer.
   Japan, Santen and Alcon Japan.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iwama D, 2012, INVEST OPHTH VIS SCI, V53, P1576, DOI 10.1167/iovs.11-8103
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 40
Z9 47
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2013
VL 97
IS 5
BP 617
EP 621
DI 10.1136/bjophthalmol-2012-302652
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 126AG
UT WOS:000317582900017
PM 23428984
OA Green Submitted, hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Scanlan, JM
   Cuddeford, JE
AF Scanlan, JM
   Cuddeford, JE
TI Low vision rehabilitation: A comparison of traditional and extended
   teaching programs
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID QUALITY-OF-LIFE; MACULAR DEGENERATION; CONTINGENCY-TABLES; VISUAL
   FUNCTION; EVERYDAY LIFE; EXACT TESTS; DISEASE
AB The purpose of the study was to determine the outcomes of a low vision service that made use of an extended period of education when assisting clients with age-related macular degeneration to use low vision devices. Extended teaching time made a significant difference to the experimental group, not only in the ability to read, but in their overall perceptions of the quality of their lives.
C1 Univ Manitoba, Helen Glass Ctr Nursing, Fac Nursing, Grad Program, Winnipeg, MB R3T 2N3, Canada.
   Canadian Natl Inst Blind, Sight Enhancement Ctr, Manitoba Div, Winnipeg, MB R3G 3M3, Canada.
C3 University of Manitoba
RP Scanlan, JM (通讯作者)，Univ Manitoba, Helen Glass Ctr Nursing, Fac Nursing, Grad Program, Winnipeg, MB R3T 2N3, Canada.
EM judith_scanlan@umanitoba.ca; joan.cuddeford@cnib.ca
OI Scanlan, Judith/0000-0001-9995-0783
CR Bandura A, 1977, SOCIAL LEARNING THEO
   Bandura A, 1997, SELF EFFICACY EXERCI
   Bowling A., 1995, MEASURING DIS
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DANIEL E, 2002, AM J HLTH ED, V33, P109
   Dilorio C, 2000, NURS RES, V49, P208, DOI 10.1097/00006199-200007000-00004
   GOODRICH G, 2002, ASS ED REH BLIND VIS
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Hinds A, 2003, BRIT J OPHTHALMOL, V87, P1391, DOI 10.1136/bjo.87.11.1391
   LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009
   Lewis M.A., 2002, HLTH BEHAV HLTH ED T, V3
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   McDonald JW, 1998, STAT COMPUT, V8, P391, DOI 10.1023/A:1008841109893
   McIlwaine G G, 1991, Eye (Lond), V5 ( Pt 5), P607
   Munro BH., 2001, STAT METHODS HLTH CA, V4th ed, P97
   Nolan J, 2001, Br J Nurs, V10, P524
   Raasch T W, 1997, J Am Optom Assoc, V68, P287
   RUBINSTEIN MP, 2001, LOW VISION ASSESSMEN
   SHUTTLEWORTH GN, 1995, BRIT J OPHTHALMOL, V79, P719, DOI 10.1136/bjo.79.8.719
   Smith PWF, 1996, J ROY STAT SOC A STA, V159, P309, DOI 10.2307/2983177
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   VANDELAAR KEW, 2004, SCH INQUIRY NURSING, V15, P235
   Verezen CA, 1996, OPTOMETRY VISION SCI, V73, P413, DOI 10.1097/00006324-199606000-00009
   VIRTANEN P, 1991, ACTA OPHTHALMOL, V69, P484
   WATSON GR, 1995, PEPPER VISUAL SKILLS
   WATSON GR, 1995, LEARN USE YOUR VISIO
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
NR 31
TC 28
Z9 28
U1 0
U2 2
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD OCT
PY 2004
VL 98
IS 10
BP 601
EP 611
DI 10.1177/0145482X0409801005
PG 11
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 922IH
UT WOS:000228830100005
DA 2022-11-30
ER

PT J
AU Saito, M
   Iida, T
   Kano, M
   Itagaki, K
AF Saito, M.
   Iida, T.
   Kano, M.
   Itagaki, K.
TI Two-year results of intravitreal ranibizumab for polypoidal choroidal
   vasculopathy with recurrent or residual exudation
SO EYE
LA English
DT Article
DE polypoidal choroidal vasculopathy; ranibizumab; vascular endothelial
   growth factor; branching vascular network; photodynamic therapy;
   age-related macular degeneration
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; JAPANESE
   PATIENTS; FOLLOW-UP; EFFICACY
AB Aim To clarify the 2-year efficacy of ranibizumab for patients with polypoidal choroidal vasculopathy (PCV) with recurrent or residual exudation from branching vascular networks after previous photodynamic therapy (PDT).
   Methods We retrospectively reviewed 26 eyes of 26 Japanese patients (22 men, 4 women) in this pilot study. All eyes had PCV with complete regression of polypoidal lesions resulting from PDT detected by indocyanine green angiography (ICGA), but recurrent or residual leakage from branching vascular networks on fluorescein angiography and evidence of persistent fluid on optical coherence tomography (OCT). Three consecutive intravitreal injections of ranibizumab (0.5 mg/0.05 ml) were administered to all eyes.
   Results The mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly from 0.55 at baseline to 0.35 at 12 months (P<0.0001) and 0.43 at 24 months (P = 0.0012). The mean increases in the BCVA 12 and 24 months after baseline were 1.95 and 1.23 lines, respectively. The mean central retinal thickness significantly decreased from 295 mm at baseline to 189 mm at 12 months (P<0.0038) and 163 mm at 24 months (P<0.001). The mean numbers of intravitreal ranibizumab (IVR) injections at months 12 and 24, including the initial treatments, were 5.8 and 8.8, respectively. Five (19.2%) eyes had recurrent polypoidal lesions on ICGA at a mean of 15.7 months after baseline. At month 24, OCT showed no exudation in 17 (65.4%) of the 26 eyes. No adverse events developed.
   Conclusions IVR injections maintained or improved the VA and retinal thickness at 24 months in eyes with PCV with recurrent or residual exudation from branching vascular networks after previous PDT.
C1 [Saito, M.; Iida, T.; Kano, M.; Itagaki, K.] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan.
   [Iida, T.] Tokyo Womens Med Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Fukushima Medical University; Tokyo Women's Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Saito Masaaki, 2009, Nippon Ganka Gakkai Zasshi, V113, P792
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 28
TC 4
Z9 6
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2013
VL 27
IS 8
BP 931
EP 939
DI 10.1038/eye.2013.114
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 198AC
UT WOS:000322893000005
PM 23743532
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Chang, YS
   Kim, JH
   Kim, JW
   Lee, TG
   Kim, CG
   Cho, SW
AF Chang, Young Suk
   Kim, Jae Hui
   Kim, Jong Woo
   Lee, Tae Gon
   Kim, Chul Gu
   Cho, Sung Won
TI Polypoidal choroidal vasculopathy in patients aged less than 50 years:
   characteristics and 6-month treatment outcome
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Age-related macular degeneration;
   Young patients; Choroidal neovascularization; Anti-vascular endothelial
   growth factor; Hemorrhage
ID CENTRAL SEROUS CHORIORETINOPATHY; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; CLINICAL CHARACTERISTICS; SUBMACULAR HEMORRHAGE; SUBRETINAL
   HEMORRHAGE; NATURAL-HISTORY; RANIBIZUMAB; THICKNESS; VERTEPORFIN
AB To investigate the characteristics and 6-month treatment outcome of polypoidal choroidal vasculopathy (PCV) in patients aged < 50 years.
   This retrospective study included 22 eyes from 22 patients who were < 50 years old and had been diagnosed with treatment na < ve PCV. Analyses of treatment outcome were performed in eyes treated with anti-vascular endothelial growth factor (VEGF) therapy. Eyes that exhibited submacular hemorrhage of a parts per thousand yen1 disc diameter and involving the fovea were included in the hemorrhage group. The remaining eyes were included in the no-hemorrhage group. The baseline best-corrected visual acuity (BCVA) was compared with that at 6 months within each group.
   The mean age of the 22 patients was 46.5 +/- 1.8 (range, 43-49) years. Submacular hemorrhage was noted in ten eyes (45.5 %). The presence of drusen was noted in one eye and pseudodrusen was not noted in any of the eyes included. Treatment outcome was analyzed in 18 eyes. A mean number of 2.9 +/- 0.5 intravitreal anti-VEGF injections were administered during the 6-month follow-up period. In the no-hemorrhage group (n = 10), the BCVA at diagnosis and at 6 months was 0.55 +/- 0.32 and 0.35 +/- 0.22 respectively (P = 0.011). In the hemorrhage group (n = 8), the values were 0.99 +/- 0.45 and 0.74 +/- 0.63 respectively (P = 0.128).
   A relatively high proportion of young PCV patients exhibited submacular hemorrhage at initial presentation. In those without submacular hemorrhage, intravitreal anti-VEGF therapy was found to be beneficial.
C1 [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
   [Kim, Jae Hui; Kim, Jong Woo; Lee, Tae Gon; Kim, Chul Gu; Cho, Sung Won] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center; Kim's Eye Hospital (Seoul, South
   Korea)
FX Kim's Eye Hospital (Seoul, South Korea) provided financial support in
   the form of funding for English editing support. The sponsor had no role
   in the design or conduct of this research.; This study was supported by
   Kim's Eye Hospital Research Center.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee SW, 2014, RETINA-J RET VIT DIS, V34, P385, DOI 10.1097/IAE.0b013e3182993f29
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 40
TC 4
Z9 5
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2016
VL 254
IS 6
BP 1083
EP 1089
DI 10.1007/s00417-015-3173-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN4GR
UT WOS:000377022400008
PM 26384678
DA 2022-11-30
ER

PT J
AU Kwon, HJ
   Lee, JJ
   Park, SW
   Byon, IS
   Lee, JE
AF Kwon, Han Jo
   Lee, Jae Jung
   Park, Sung Who
   Byon, Ik Soo
   Lee, Ji Eun
TI Enlargement of polypoidal choroidal vasculopathy lesion without
   exudative findings assessed in en face optical coherence tomography
   images
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; En face optical coherence tomography;
   Anti-vascular endothelial growth factor; Non-exudative enlargement
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; ANGIOGRAPHY;
   NEOVASCULARIZATION; EFFICACY; OUTCOMES
AB Purpose This study aimed to investigate growth of polypoidal choroidal vasculopathy (PCV) without exudative findings assessed in en face optical coherence tomography (OCT) images and its clinical implications.
   Methods Fifty patients who were diagnosed with PCV and had no disease activity after treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF) were included. Patients were followed up for at least 12months. Measurement of best-corrected visual acuity and volume scan using swept-source OCT was performed at each visit. The neovascular area of PCV was assessed using en face OCT. Growth group comprised patients who showed increase in neovascular area in the en face images without exudative findings. The main outcome measure was relationship between growth of PCV and recurrence.
   Results Among 50 eyes of 50 patients with average age of 68.5 +/- 8.6 years, 25 (50%) eyes were included in the growth group. Exudative recurrence was noted more frequently in the growth group (18 eyes, 72%) than in the non-growth group (6 eyes, 24%, P=.002, odds ratio=8.143). More injections were performed in the growth group (4.7 +/- 2.1 vs. 1.9 +/- 2.4, P=.002), but there was no difference in visual acuity at 1year. After an exudative recurrence following the lesion growth, more frequent injections were required than before the recurrence to achieve no disease activity (P=.002).
   Conclusion PCV lesion growth without fluid preceded exudative recurrence and worsening of response to anti-VEGF treatment.
C1 [Kwon, Han Jo; Lee, Jae Jung; Park, Sung Who; Byon, Ik Soo; Lee, Ji Eun] Pusan Natl Univ, Dept Ophthalmol, Coll Med, Yangsan, South Korea.
   [Kwon, Han Jo; Byon, Ik Soo] Pusan Natl Univ, Res Inst Convergence Biomed Sci & Technol, Yangsan Hosp, Yangsan, South Korea.
   [Lee, Jae Jung; Park, Sung Who; Lee, Ji Eun] Pusan Natl Univ Hosp, Med Res Inst, 179 Gudeok Ro, Busan 49241, South Korea.
C3 Pusan National University; Pusan National University; Pusan National
   University Hospital; Pusan National University; Pusan National
   University Hospital
RP Lee, JE (通讯作者)，Pusan Natl Univ, Dept Ophthalmol, Coll Med, Yangsan, South Korea.; Lee, JE (通讯作者)，Pusan Natl Univ Hosp, Med Res Inst, 179 Gudeok Ro, Busan 49241, South Korea.
EM jlee@pusan.ac.kr
OI Han Jo, Kwon/0000-0003-2973-9725
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Byon IS, 2014, OSLI RETINA, V45, P534, DOI 10.3928/23258160-20141118-08
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee Ji Woong, 2007, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V48, P63
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P2433, DOI 10.1097/IAE.0000000000000761
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Simonett JM, 2017, OSLI RETINA, V48, P126, DOI 10.3928/23258160-20170130-06
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 0
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2019
VL 257
IS 8
BP 1621
EP 1629
DI 10.1007/s00417-019-04317-y
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IJ3MX
UT WOS:000475809900006
PM 31098753
DA 2022-11-30
ER

PT J
AU Yap, A
   Wang, N
   Squirrell, D
AF Yap, Aaron
   Wang, Nancy
   Squirrell, David
TI Ethnic differences on long term outcomes of polypoidal choroidal
   vasculopathy after predominantly bevacizumab monotherapy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Bevacizumab; Treatment outcomes;
   Real-world study; Long term
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; AGE; RANIBIZUMAB;
   ANGIOGRAPHY; DISEASE
AB Background A 3-year single-centre, retrospective, comparative, non-randomized cohort study to describe the long-term outcomes of treatment-naive, Caucasian and non-Caucasian eyes with polypoidal choroidal vasculopathy (PCV) after treatment with predominantly Bevacizumab monotherapy or in combination with rescue photodynamic therapy (PDT). Methods Demographics, visual outcomes, optical coherence tomography (OCT) and treatment data were collected up to 3 years after the first visit. Stratified analysis according to ethnicity and baseline vision was performed to identify factors predictive of long-term visual improvement and maintenance. Results A total of 89 eyes with PCV were identified, of which 14 received rescue verteporfin PDT. There was an equal distribution between Caucasian and non-Caucasian individuals. Non-Caucasians present at a younger age (67.3 vs. 76.0 years, p = 0.002), have a higher proportion of foveal involvement (80.9%, vs.54.2% p = 0.007), choroidal hyperpermeability (50% vs 25.8%, p = 0.013) and lower baseline visual acuity (53.1 vs. 63.3 letters, p = 0.008). Mean visual acuity (VA) gain was + 8.9 letters and + 5.0 letters at 1 and 3 years of follow-up, respectively. Non-Caucasian individuals had a lower mean final visual acuity (VA) (54.7 vs. 70.5, respectively; P < 0.001) and net gain in VA (+ 2.0 vs. + 7.6 letters, p = 0.581) compared to Caucasian individuals. The mean total number of injections given over 3 years was 14. Conclusions Most patients treated with predominantly Bevacizumab anti-vascular endothelial growth factor (VEGF) monotherapy achieved sustained visual acuity gains out to 3 years. Due to ethnic-specific differences in presenting PCV phenotypes, non-Caucasians presented with lower baseline VA and had poorer long-term visual outcomes.
C1 [Yap, Aaron; Wang, Nancy; Squirrell, David] Univ Auckland, Dept Ophthalmol, 85 Pk Rd, Auckland 1051, New Zealand.
   [Squirrell, David] Auckland Dist Hlth Board, Dept Ophthalmol, Auckland, New Zealand.
C3 University of Auckland; Auckland District Health Board
RP Yap, A (通讯作者)，Univ Auckland, Dept Ophthalmol, 85 Pk Rd, Auckland 1051, New Zealand.
EM aaron.yap8@gmail.com
FU University of Auckland; Auckland District Health Board
FX We would like to acknowledge the University of Auckland and Auckland
   District Health Board for their support of this research project.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Corvi F, 2022, AM J OPHTHALMOL, V234, P108, DOI 10.1016/j.ajo.2021.08.006
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   European Union Agency for Fundamental Rights, 2018, BIGDATA DISCR DAT SU
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Gharehbagh SS, 2018, ACTA OPHTHALMOL, V96, pE94, DOI 10.1111/aos.13461
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Milne V, 2014, INT J RHEUM DIS, V17, P19, DOI 10.1111/1756-185X.12126
   Ministry for the Environment Stats NZ, 2018, NZ ENV REP SER ENV A
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Ramke J, 2019, CLIN EXP OPHTHALMOL, V47, P937, DOI 10.1111/ceo.13528
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Stats NZ., 2005, ETHNICITY NZ STANDAR
   Talks J, 2019, SURV OPHTHALMOL, V64, P707, DOI 10.1016/j.survophthal.2019.02.008
   Teo KYC, 2022, BRIT J OPHTHALMOL, V106, P987, DOI 10.1136/bjophthalmol-2020-318354
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Dijk EHC, 2021, GRAEF ARCH CLIN EXP, V259, P351, DOI 10.1007/s00417-020-04844-z
   Wataru K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229231
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 49
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 28
PY 2022
VL 22
IS 1
AR 325
DI 10.1186/s12886-022-02551-3
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3I4YJ
UT WOS:000832724000001
PM 35902835
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhao, XY
   Xia, S
   Chen, YX
AF Zhao, Xinyu
   Xia, Song
   Chen, Youxin
TI Characteristic appearances of fundus autofluorescence in treatment-naive
   and active polypoidal choroidal vasculopathy: a retrospective study of
   170 patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Autofluorescence; Polypoidal choroidal vasculopathy; Treatment-naive;
   Active; Polypoidal lesion; Branching vascular network
ID PIGMENT EPITHELIAL ATROPHY; MACULAR DEGENERATION; CHINESE PATIENTS;
   LESIONS; OPHTHALMOSCOPE; SUBTYPES
AB Purpose To investigate the characteristic appearances of fundus autofluorescence (FAF) in patients with treatment-naive and active polypoidal choroidal vasculopathy (PCV).
   Method Cases with the diagnosis of treatment-naive and active PCV from November 2012 to May 2017 at Peking Union Medical College Hospital were retrospectively reviewed. All patients underwent comprehensive ophthalmologic examination. Autofluorescence (AF) findings were described at the retinal sites of the corresponding lesions identified and diagnosed using indocyanine green angiography and spectral-domain optical coherence tomography.
   Results One hundred seventy patients with 192 affected eyes were included. The logMAR BCVA of the patients were 0.53 +/- 0.28. The six AF patterns of 243 polypoidal lesions were confluent hypo-AF with hyper-AF ring (49.8%), confluent hypo-AF (22.6%), hyper-AF with hypo-AF ring (3.7%), granular hypo-AF (7.0%), blocked hypo-AF due to hemorrhage (8.6%), and polyps without apparent AF changes (8.2%). For 146 branching vascular networks (BVNs), 97.3% were granular hypo-AF, and others were blocked hypo-AF due to hemorrhage.
   Conclusion In eyes with treatment-naive and active PCV, the polypoidal lesions and BVNs induce characteristic FAF changes. FAF images provide reliable adjunct reference for the diagnosis of PCV.
C1 [Zhao, Xinyu; Xia, Song; Chen, Youxin] Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
EM 478252553@qq.com
CR DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Hikichi T, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0237-x
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Ozkok A, 2016, RETINA-J RET VIT DIS, V36, P2191, DOI 10.1097/IAE.0000000000001034
   Oztas Z, 2016, TURK OFTALMOL DERG, V46, P165, DOI 10.4274/tjo.54280
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Sho K, ARCH OPHTHALMOL, V121, P1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Suetsugu T, 2016, CLIN OPHTHALMOL, V10, P2497, DOI 10.2147/OPTH.S120402
   Suzuki M, 2013, GRAEF ARCH CLIN EXP, V251, P2331, DOI 10.1007/s00417-013-2336-1
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 7
Z9 8
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2018
VL 256
IS 6
BP 1101
EP 1110
DI 10.1007/s00417-018-3980-2
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GG1AY
UT WOS:000432412900008
PM 29656364
DA 2022-11-30
ER

PT J
AU Kang, HM
   Koh, HJ
AF Kang, Hae Min
   Koh, Hyoung Jun
TI Two-Year Outcome after Combination Therapy for Polypoidal Choroidal
   Vasculopathy: Comparison with Photodynamic Monotherapy and Anti-Vascular
   Endothelial Growth Factor Monotherapy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-vascular endothelial growth factor therapy; Combination therapy;
   Photodynamic therapy; Polypoidal choroidal vasculopathy
ID INTRAVITREAL BEVACIZUMAB INJECTION; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; JAPANESE PATIENTS; CLINICOPATHOLOGICAL CORRELATION;
   RANIBIZUMAB INJECTIONS; FOLLOW-UP; EFFICACY; NEOVASCULARIZATION
AB Purpose: To compare treatment outcomes of photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF) therapy and PDT combined with anti-VEGF therapy for polypoidal choroidal vasculopathy (PCV). Procedures: A total of 62 eyes of 62 patients who had completed at least 2 years of follow-up were retrospectively reviewed; 19 eyes received PDT only, 23 had anti-VEGF therapy only and 20 underwent combination therapy. Best-corrected visual acuity at baseline and each follow-up visit was investigated as a primary outcome measure. Results: At year 2, the PDT and combination groups maintained significant visual improvement (p = 0.041 and p = 0.021), whereas the anti-VEGF group failed to do so (p = 0.673) when compared with the baseline. The combination group showed better visual outcome during follow-up, and significantly better visual outcome than the PDT group (p = 0.038) and the anti-VEGF group (p = 0.012) at year 2. Conclusions: Combination therapy leads to significantly better visual outcome than PDT and anti-VEGF monotherapy and is therefore a superior method for treating PCV, with a favorable visual outcome. (C) 2013 S. Karger AG, Basel
C1 [Kang, Hae Min; Koh, Hyoung Jun] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR Ahlers C., 2008, OPHTHALMOLOGY, V115, P39, DOI [10.1016/j.ophtha.2008.05.0172-s2.0-48149084442, DOI 10.1016/J.OPHTHA.2008.05.0172-S2.0-48149084442]
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Shanmugam Mahesh P., 2005, Indian Journal of Ophthalmology, V53, P61
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 18
Z9 20
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 2
BP 86
EP 93
DI 10.1159/000354546
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296AE
UT WOS:000330156700004
PM 24135710
DA 2022-11-30
ER

PT J
AU Schlecht, A
   Wolf, J
   Boneva, S
   Prinz, G
   Braunger, BM
   Wieghofer, P
   Agostini, H
   Schlunck, G
   Lange, C
AF Schlecht, Anja
   Wolf, Julian
   Boneva, Stefaniya
   Prinz, Gabriele
   Braunger, Barbara M.
   Wieghofer, Peter
   Agostini, Hansjuergen
   Schlunck, Guenther
   Lange, Clemens
TI Transcriptional and Distributional Profiling of Microglia in Retinal
   Angiomatous Proliferation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE AMD; Mactel 2; macular neovascularization; MNV type 3; retinal
   angiomatous proliferation; RAP; microglia; RNA sequencing; Cx3cr1;
   CreERT2
ID GROWTH-FACTOR THERAPY; MACULAR DEGENERATION; MOUSE MODEL;
   NEOVASCULARIZATION; ANGIOGENESIS; RANIBIZUMAB
AB Macular neovascularization type 3, formerly known as retinal angiomatous proliferation (RAP), is a hallmark of age-related macular degeneration and is associated with an accumulation of myeloid cells, such as microglia (MG) and infiltrating blood-derived macrophages (MAC). However, the contribution of MG and MAC to the myeloid cell pool at RAP sites and their exact functions remain unknown. In this study, we combined a microglia-specific reporter mouse line with a mouse model for RAP to identify the contribution of MG and MAC to myeloid cell accumulation at RAP and determined the transcriptional profile of MG using RNA sequencing. We found that MG are the most abundant myeloid cell population around RAP, whereas MAC are rarely, if ever, associated with late stages of RAP. RNA sequencing of RAP-associated MG showed that differentially expressed genes mainly contribute to immune-associated processes, including chemotaxis and migration in early RAP and proliferative capacity in late RAP, which was confirmed by immunohistochemistry. Interestingly, MG upregulated only a few angiomodulatory factors, suggesting a rather low angiogenic potential. In summary, we showed that MG are the dominant myeloid cell population at RAP sites. Moreover, MG significantly altered their transcriptional profile during RAP formation, activating immune-associated processes and exhibiting enhanced proliferation, however, without showing substantial upregulation of angiomodulatory factors.
C1 [Schlecht, Anja; Wolf, Julian; Boneva, Stefaniya; Prinz, Gabriele; Agostini, Hansjuergen; Schlunck, Guenther; Lange, Clemens] Univ Freiburg, Fac Med, Eye Ctr, Med Ctr, D-79106 Freiburg, Germany.
   [Schlecht, Anja; Braunger, Barbara M.] Julius Maximilians Univ Wuerzburg, Inst Anat & Cell Biol, D-97070 Wurzburg, Germany.
   [Wieghofer, Peter] Univ Augsburg, Med Fac, Inst Theoret Med, Cellular Neuroanat, D-86159 Augsburg, Germany.
   [Lange, Clemens] St Franziskus Hosp Muenster, Ophtha Lab, Dept Ophthalmol, D-48145 Munster, Germany.
C3 University of Freiburg; University of Wurzburg; University of Augsburg;
   St. Franziskus-Hospital
RP Schlecht, A; Lange, C (通讯作者)，Univ Freiburg, Fac Med, Eye Ctr, Med Ctr, D-79106 Freiburg, Germany.; Schlecht, A (通讯作者)，Julius Maximilians Univ Wuerzburg, Inst Anat & Cell Biol, D-97070 Wurzburg, Germany.; Lange, C (通讯作者)，St Franziskus Hosp Muenster, Ophtha Lab, Dept Ophthalmol, D-48145 Munster, Germany.
EM anja.schlecht@uni-wuerzburg.de; julian.wolf@uniklinik-freiburg.de;
   stefaniya.boneva@uniklinik-freiburg.de;
   gabriele.prinz@uniklinik-freiburg.de; barbara.braunger@uni-wuerzburg.de;
   peter.wieghofer@medizin.uni-leipzig.de;
   hansjuergen.agostini@uniklinik-freiburg.de;
   guenther.schlunck@uniklinik-freiburg.de;
   clemens.lange@augen-franziskus.de
RI Wieghofer, Peter/AAV-9572-2020
OI Boneva, Stefaniya/0000-0002-9811-2160; Wolf, Julian/0000-0002-3470-9697;
   Schlecht, Anja/0000-0003-3336-9982
FU Novartis; Baden-Wuerttemberg Ministry of Science, Research and Art;
   University of Freiburg
FX This research was funded by Novartis. The APC was funded by the
   Baden-Wuerttemberg Ministry of Science, Research and Art and the
   University of Freiburg in the funding programme Open Access Publishing.
CR Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Boeck M, 2020, GLIA, V68, P1859, DOI 10.1002/glia.23810
   Boneva S, 2020, LAB INVEST, V100, P1345, DOI 10.1038/s41374-020-0446-z
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Kataoka K, 2011, INVEST OPHTH VIS SCI, V52, P1431, DOI 10.1167/iovs.10-5798
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2168, DOI 10.1097/IAE.0000000000001845
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lange C, 2007, EXP EYE RES, V85, P323, DOI 10.1016/j.exer.2007.05.007
   Lange C, 2016, EXP EYE RES, V147, P148, DOI 10.1016/j.exer.2016.05.007
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   O'Donnell SL, 2002, GLIA, V39, P85, DOI 10.1002/glia.10081
   Pepe G, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-1011-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schlecht A, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.618598
   Schlecht A, 2020, AM J PATHOL, V190, P1632, DOI 10.1016/j.ajpath.2020.04.004
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sun Y, 2017, J EXP MED, V214, P1753, DOI 10.1084/jem.20161645
   Tenbrock L, 2022, CELL TISSUE RES, V387, P361, DOI 10.1007/s00441-021-03514-8
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Usui-Ouchi A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137317
   van der Maaten L, 2014, J MACH LEARN RES, V15, P3221
   Wang C, 2022, OPHTHALMIC RES, V65, P68, DOI 10.1159/000513588
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wieghofer P, 2021, EMBO J, V40, DOI 10.15252/embj.2020105123
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yates AD, 2020, NUCLEIC ACIDS RES, V48, pD682, DOI 10.1093/nar/gkz966
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang PP, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02230-y
NR 47
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2022
VL 23
IS 7
AR 3443
DI 10.3390/ijms23073443
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0L8ZI
UT WOS:000781755500001
PM 35408803
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kimura, S
   Morizane, Y
   Matoba, R
   Hosokawa, M
   Shiode, Y
   Hirano, M
   Doi, S
   Toshima, S
   Takahashi, K
   Hosogi, M
   Fujiwara, A
   Shiraga, F
AF Kimura, Shuhei
   Morizane, Yuki
   Matoba, Ryo
   Hosokawa, Mio
   Shiode, Yusuke
   Hirano, Masayuki
   Doi, Shinichiro
   Toshima, Shinji
   Takahashi, Kosuke
   Hosogi, Mika
   Fujiwara, Atsushi
   Shiraga, Fumio
TI Retinal sensitivity after displacement of submacular hemorrhage due to
   polypoidal choroidal vasculopathy: effectiveness and safety of
   subretinal tissue plasminogen activator
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Microperimetry; Polypoidal choroidal vasculopathy; Submacular
   hemorrhage; Tissue plasminogen activator
ID MACULAR DEGENERATION; PNEUMATIC DISPLACEMENT; PHOTODYNAMIC THERAPY;
   MICROPERIMETRY; VITRECTOMY; RANIBIZUMAB; BEVACIZUMAB; VERTEPORFIN;
   COMBINATION; INJECTION
AB To investigate the effectiveness of displacement of submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV) by assessing retinal sensitivity using microperimetry.
   We retrospectively reviewed the medical records of 11 consecutive PCV patients with SMH. All patients underwent vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-air exchange, followed by antivascular endothelial growth factor therapy using a pro re nata regimen. The retinal sensitivity was measured by use of microperimetry before and after surgery.
   The mean (SD) age of the patients was 74.1 +/- 9.4 years. The mean SMH diameter was 6.8 +/- 5.2 disc diameters. The best-corrected visual acuity (BCVA), mean retinal sensitivity, and mean number of measure points with a sensitivity >= 10 dB before the surgery were 0.94 +/- 0.49, 4.2 +/- 4.5 dB, and 15.6 +/- 15.1 points, respectively. These had significantly improved 6 months after surgery (0.39 +/- 0.37, 15.6 +/- 7.3 dB, and 50.9 +/- 22.2 points, respectively; P < 0.05 for all outcome measures). The mean number of measure points with an absolute scotoma before surgery had decreased significantly 6 months after surgery (from 40.5 +/- 15.0 to 9.4 +/- 16.0 points; P < 0.001).
   Displacement of SMH effectively improves retinal sensitivity as well as BCVA.
C1 [Kimura, Shuhei; Morizane, Yuki; Matoba, Ryo; Hosokawa, Mio; Shiode, Yusuke; Hirano, Masayuki; Doi, Shinichiro; Toshima, Shinji; Takahashi, Kosuke; Hosogi, Mika; Fujiwara, Atsushi; Shiraga, Fumio] Okayama Univ, Dept Ophthalmol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
C3 Okayama University
RP Morizane, Y (通讯作者)，Okayama Univ, Dept Ophthalmol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
EM moriza-y@okayama-u.ac.jp
CR BENNER JD, 1991, ARCH OPHTHALMOL-CHIC, V109, P1731, DOI 10.1001/archopht.1991.01080120115039
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chang YS, 2016, GRAEFES ARCH CLIN EX, V254, P1
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kim JH, 2015, J OCUL PHARMACOL TH, V31, P241, DOI 10.1089/jop.2014.0145
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Lin TC, 2016, J CHIN MED ASSOC, V79, P159, DOI 10.1016/j.jcma.2015.11.004
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Okanouchi T, 2016, RETINA-J RET VIT DIS, V36, P1035, DOI 10.1097/IAE.0000000000001029
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Sato S, 2012, INVEST OPHTH VIS SCI, V54, P3046
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Seiple WH., 2012, OPTOM REP, V2, P11
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2606, DOI 10.1167/iovs.14-15977
NR 36
TC 7
Z9 8
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2017
VL 61
IS 6
BP 472
EP 478
DI 10.1007/s10384-017-0530-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL2QM
UT WOS:000414063500006
PM 28836011
DA 2022-11-30
ER

PT J
AU Sato, T
   Kishi, S
   Matsumoto, H
   Mukai, R
AF Sato, Taku
   Kishi, Shoji
   Matsumoto, Hidetaka
   Mukai, Ryo
TI Comparisons of Outcomes With Different Intervals Between Adjunctive
   Ranibizumab and Photodynamic Therapy for Polypoidal Choroidal
   Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; INTRAVITREAL RANIBIZUMAB; JAPANESE PATIENTS; VERTEPORFIN;
   BEVACIZUMAB; INJECTION; NEOVASCULARIZATION; EFFICACY
AB PURPOSE: To determine the optimal time for administration of intravitreal ranibizumab injections before photodynamic therapy (PDT) as combined therapy to treat polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective, comparative, interventional case series.
   METHODS: The study included 99 eyes (98 patients) with treatment-naive subfoveal PCV treated with an intravitreal ranibizumab injection followed by PDT. The combination therapy included 1 ranibizumab injection administered 7 days before PDT (7-day group) or 2 days before PDT (2-day group). All eyes were followed for over 12 months.
   RESULTS: Intravitreal ranibizumab was administered 7 days before PDT in 59 eyes and 2 days before PDT in 40 eyes. In the 7-day group, the best-corrected visual acuity (BCVA) did not improve significantly at 3 months (P = .086) or 12 months (P = .259) compared with baseline. In the 2-day group, BCVA improved significantly at 3 months (P < .001) and 12 months (P < .001). The polypoidal lesions regressed completely in 46 eyes (78.0%) in the 7-day group and in 34 eyes (85.0%) in the 2-day group; 38 eyes (64.4%) and 35 eyes (87.5%), respectively, did not require additional treatment, which differed significantly (P = .008) between the 2 groups. Subretinal hemorrhages did not develop in either group within 1 month after the combined therapy.
   CONCLUSIONS: Administration of an intravitreal ranibizumab injection 2 days before PDT achieves significantly better visual outcomes and requires fewer additional treatments compared with administration of the injection 7 days before PDT. (C) 2013 by Elsevier Inc. All rights reserved.
C1 [Sato, Taku; Kishi, Shoji; Matsumoto, Hidetaka; Mukai, Ryo] Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Sato, T (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM takusato@showa.gunma-u.ac.jp
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2012, KOREAN J OPHTHALMOL, V26, P157
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 43
TC 19
Z9 22
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2013
VL 156
IS 1
BP 95
EP 105
DI 10.1016/j.ajo.2013.02.006
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 179OT
UT WOS:000321531900016
PM 23628354
DA 2022-11-30
ER

PT J
AU Honda, S
   Bessho, H
   Kondo, N
   Kusuhara, S
   Tsukahara, Y
   Negi, A
AF Honda, Shigeru
   Bessho, Hiroaki
   Kondo, Naoshi
   Kusuhara, Sentaro
   Tsukahara, Yasutomo
   Negi, Akira
TI Positive association of CD36 gene variants with the visual outcome of
   photodynamic therapy in polypoidal choroidal vasculopathy
SO MOLECULAR VISION
LA English
DT Article
ID MACULAR DEGENERATION; AGE; GENOTYPE; POLYMORPHISMS; ANGIOGENESIS;
   MULTICENTER; LIPOPROTEIN; EXPRESSION; PHENOTYPE; MET72THR
AB Purpose: To clarify the association between cluster of differentiation 36 (CD36) gene polymorphisms and the response to photodynamic therapy (PDT) in polypoidal choroidal vasculopathy (PCV).
   Methods: One hundred and thirty-seven patients with PCV were enrolled. The patients were treated with PDT and followed up for more than 6 months. Retreatments were performed every 3 months as needed based on findings from angiography. Patients who showed an improvement in their best-corrected visual acuity at 6 months post-PDT were classified as PDT responders, and the others were defined as non-responders. For the 73 responders and 64 non-responders, 19 single nucleotide polymorphisms (SNPs) across the CD36 region were genotyped using the TaqMan assay. We analyzed the association between these variants and the visual outcomes of PDT.
   Results: The allelic frequencies of the SNPs rs3211851, rs3173798, and rs3211908 showed nominally significant differences between the PDT responders and non-responders. Genotype association analysis revealed a significant association of SNP rs3173798 with the visual outcome of PDT in a dominant model. The presence of the C allele in rs3173798 was significantly associated with a poor response to PDT after multivariate logistic regression analysis with clinical pre-PDT parameters. The mean best-corrected visual acuity in the group with the TT genotype of rs3173798 was significantly improved over 12 months of follow-up after the initial PDT.
   Conclusions: The coding variants in CD36 are possibly associated with the visual outcome of PDT in patients with PCV.
C1 [Honda, Shigeru] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science and Culture, Tokyo, Japan [23,592,567];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a Grant-in Aid (C) 23,592,567 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (S.H.), and by
   a grant from the Takeda Science Foundation, Osaka, Japan (S.H.). The
   funding organization had no role in the design or conduct of this
   research. The authors have no proprietary or commercial interest in any
   of the materials discussed in this article.
CR Bessho H, 2012, MOL VIS, V18, P121
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bessho H, 2011, MOL VIS, V17, P977
   Bessho H, 2009, MOL VIS, V15, P1107
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   Kuniyasu A, 2003, FEBS LETT, V537, P85, DOI 10.1016/S0014-5793(03)00096-6
   Li M, 2010, MOL VIS, V16, P231
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Love-Gregory L, 2008, HUM MOL GENET, V17, P1695, DOI 10.1093/hmg/ddn060
   Love-Gregory L, 2011, HUM MOL GENET, V20, P193, DOI 10.1093/hmg/ddq449
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Plafker SM, 2010, ADV EXP MED BIOL, V664, P447, DOI 10.1007/978-1-4419-1399-9_51
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   She HC, 2008, INVEST OPHTH VIS SCI, V49, P5008, DOI 10.1167/iovs.07-1154
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   Wu KF, 2012, CURR EYE RES, V37, P68, DOI 10.3109/02713683.2011.618289
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236
NR 41
TC 5
Z9 5
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 22
PY 2012
VL 18
IS 283-86
BP 2796
EP 2804
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 053AL
UT WOS:000312241700004
PM 23213279
DA 2022-11-30
ER

PT J
AU Chakraborty, D
   Maiti, A
   Sengupta, S
   Mondal, S
   Nandi, K
   Chakraborty, S
AF Chakraborty, Debdulal
   Maiti, Aniruddha
   Sengupta, Sabyasachi
   Mondal, Soumen
   Nandi, Krishnendu
   Chakraborty, Somnath
TI Initial experience in treating polypoidal choroidal vasculopathy with
   brolucizumab in Indian eyes - A multicenter retrospective study
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF; brolucizumab; polypoidal choroidal vasculopathy
ID DIAGNOSIS
AB Purpose: To report the initial experience of managing treatment-resistant and treatment-naive eyes with polypoidal choroidal vasculopathy (PCV) by using brolucizumab 6 mg. Methods: This was a retrospective multicentric series of all consecutive eyes with PCV treated with brolucizumab. Treatment resistance was defined as taking at least six prior anti-VEGF injections over the past 1 year and showing persistent disease activity in the form of intra (IRF) or subretinal fluid (SRF) or both. All patients were treated on a pro re nata (PRN) basis and followed up monthly. Retreatment was considered when either SRF or IRF were present at any time point during the study. Results: We included 21 eyes of 21 patients with PCV with a mean age of 65.1 +/- 9.9 years, of which 16 eyes (76%) were treatment-resistant. The mean follow-up period from receiving the first brolucizumab was 27.3 +/- 3.3 weeks. Of the 21 eyes, seven eyes (33%) received three injections during follow-up, 13 eyes (62%) received two injections, and one eye received one injection. The mean injection-free interval was 12 +/- 1.2 weeks. The median pretreatment vision was 0.6 logMAR (IQR = 0.47-1 logMAR) and improved to 0.3 logMAR (IQR = 0.25-0.6 logMAR), whereas the mean macular thickness improved from 443 +/- 60 mu m at baseline to 289 +/- 25 mu m (P < 0.001) at the last follow-up period. None of the eyes experienced any intraocular inflammation across 48 injection sessions. Conclusion: Brolucizumab is safe and effective in controlling PCV disease in both treatment-resistant and treatment-naive eyes.
C1 [Chakraborty, Debdulal; Mondal, Soumen] Disha Eye Hosp, Vitreo Retina Serv, Kolkata, W Bengal, India.
   [Maiti, Aniruddha; Nandi, Krishnendu] Netralayam Super Special Eye Care Ctr, Kolkata, W Bengal, India.
   [Sengupta, Sabyasachi] Future Vis Eye Care & Res Ctr, Vitreo Retina Serv, Mumbai, Maharashtra, India.
   [Chakraborty, Somnath] Retina Inst Bengal, Siliguri, W Bengal, India.
RP Chakraborty, D (通讯作者)，Disha Eye Hosp, Dept Vitreo Retinal Serv, 88 Ghosh Rd, Kolkata 700120, W Bengal, India.
EM devdc@rediffmail.com
CR Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fenner BJ, 2022, EYE, V36, P257, DOI 10.1038/s41433-021-01688-7
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Ogura Y, 2022, BRIT J OPHTHALMOL, V106, P994, DOI 10.1136/bjophthalmol-2021-319090
NR 13
TC 3
Z9 3
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD APR
PY 2022
VL 70
IS 4
BP 1295
EP 1299
DI 10.4103/ijo.IJO_2513_21
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2Q8DD
UT WOS:000820647600052
PM 35326038
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shimizu, Y
   Miyata, M
   Ooto, S
   Miyake, M
   Mori, Y
   Tamura, H
   Ueda-Arakawa, N
   Uji, A
   Muraoka, Y
   Takahashi, A
   Wakazono, T
   Yamashiro, K
   Hata, M
   Tsujikawa, A
AF Shimizu, Yuichiro
   Miyata, Manabu
   Ooto, Sotaro
   Miyake, Masahiro
   Mori, Yuki
   Tamura, Hiroshi
   Ueda-Arakawa, Naoko
   Uji, Akihito
   Muraoka, Yuki
   Takahashi, Ayako
   Wakazono, Tomotaka
   Yamashiro, Kenji
   Hata, Masayuki
   Tsujikawa, Akitaka
TI Pachychoroid-phenotype effects on 5-year visual outcomes of anti-VEGF
   monotherapy in polypoidal choroidal vasculopathy
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; anti-VEGF; pachychoroid; polypoidal choroidal vasculopathy;
   ranibizumab
ID AGE; NEOVASCULARIZATION; RANIBIZUMAB
AB Purpose To investigate whether the efficacy of anti-vascular endothelial growth factor (VEGF) monotherapy for polypoidal choroidal vasculopathy (PCV) differs between pachychoroid and non-pachychoroid phenotypes in the long term. Methods This retrospective longitudinal study included 115 treatment-naive eyes in 115 consecutive patients with symptomatic PCV who were treated with anti-VEGF monotherapy and were followed up for 5 years. Eligible eyes were assigned to either a pachy-PCV group, with a pachychoroid phenotype, or a non-pachy-PCV group, without a pachychoroid phenotype. Best-corrected visual acuity (BCVA) and other parameters over a 5-year period were compared between the groups. Results Forty-eight eyes and 67 eyes were classified into the pachy-PCV and non-pachy-PCV groups respectively. Baseline and 5-year BCVA (logarithm of the minimum angle of resolution) were 0.19 +/- 0.20 and 0.16 +/- 0.28 in the pachy-PCV group, respectively, and 0.25 +/- 0.26 and 0.26 +/- 0.36 in the non-pachy-PCV group respectively. BCVA did not change significantly in either group (p = 0.18 and 0.08 respectively). BCVA did not differ between the groups at any observation time-point. Subfoveal choroidal thickness (SFCT) at baseline and at 5 years was significantly higher in the pachy-PCV group than in the non-pachy-PCV group (both p < 0.001); however, the mean rate of decrease in SFCT did not differ in either group over the 5-year period (22% vs. 23%, p = 0.81). Conclusion Our findings suggest that anti-VEGF monotherapy was similarly effective for pachychoroid- and non-pachychoroid-phenotype eyes with PCV, for at least 5 years, although further studies are required.
C1 [Shimizu, Yuichiro; Miyata, Manabu; Ooto, Sotaro; Miyake, Masahiro; Mori, Yuki; Tamura, Hiroshi; Ueda-Arakawa, Naoko; Uji, Akihito; Muraoka, Yuki; Takahashi, Ayako; Wakazono, Tomotaka; Yamashiro, Kenji; Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
   [Yamashiro, Kenji] Red Cross Otsu Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Hata, Masayuki] Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Biochem & Mol Med, Montreal, PQ, Canada.
C3 Kyoto University; Universite de Montreal
RP Miyata, M (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto, Kyoto 6068507, Japan.
EM miyatam@kuhp.kyoto-u.ac.jp
RI Miyata, Manabu/U-9008-2018; TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Miyata, Manabu/0000-0002-7574-1749
FU Japan Society for the Promotion of Science, Tokyo, Japan [18K09444]
FX This work was supported in part by a grant-in-aid for scientific
   research (no. 18K09444) from the Japan Society for the Promotion of
   Science, Tokyo, Japan.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Azar G, 2017, ACTA OPHTHALMOL, V95, P421, DOI 10.1111/aos.13221
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Borrelli E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77566-1
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Itagaki K, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01542-6
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Takahashi Y, 2018, JPN J OPHTHALMOL, V62, P576, DOI 10.1007/s10384-018-0615-4
   Wakazono T, 2017, RETINA-J RET VIT DIS, V37, P2062, DOI 10.1097/IAE.0000000000001451
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wong TY, 2019, RETINA-J RET VIT DIS, V39, P537, DOI 10.1097/IAE.0000000000001986
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
NR 31
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2022
VL 100
IS 4
BP E943
EP E949
DI 10.1111/aos.15015
EA SEP 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1A9ZF
UT WOS:000696546000001
PM 34533280
DA 2022-11-30
ER

PT J
AU Mitamura, Y
   Kitahashi, M
   Kubota-Taniai, M
   Yamamoto, S
AF Mitamura, Yoshinori
   Kitahashi, Masayasu
   Kubota-Taniai, Mariko
   Yamamoto, Shuichi
TI Comparison of intravitreal bevacizumab to photodynamic therapy for
   polypoidal choroidal vasculopathy: Short-term results
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; intravitreal bevacizumab; optical
   coherence tomography; photodynamic therapy; polypoidal choroidal
   vasculopathy
ID MACULAR DEGENERATION; JAPANESE PATIENTS; NEOVASCULARIZATION;
   VERTEPORFIN; INJECTION; EFFICACY; AVASTIN; MANAGEMENT; SAFETY
AB Aims: To compare the short-term therapeutic effects of intravitreal bevacizumab (IVB) to those of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). Materials and Methods: Retrospective interventional case study. Eighty-nine eyes of 89 patients with symptomatic PCV were treated by IVB or PDT. Eighteen eyes were treated with a single injection of IVB (s-IVB group), 22 eyes with three consecutive monthly IVB injections (m-IVB group), and 49 eyes with PDT alone (PDT group). The best-corrected visual acuity (BCVA) and OCT-determined central foveal thickness (CFT) were evaluated before, and one and three months after the treatment. For statistical analyses, one-factor ANOVA and Chi-square test were used. Results: The differences in the BCVA and CFT among the three groups at the baseline were not significant (P=0.992, P=0.981, respectively). Three months after the treatment, the BCVA improved by >0.2 logMAR units in two out of 18 eyes (11%) in the s-IVB group, three out of 22 eyes (14%) in the m-IVB group, and 15 out of 49 eyes (31%) in the PDT group (P=0.124). A decrease in the CFT by >20% was achieved in six out of 18 eyes in the s-IVB group, ten eyes (46%) in the m-IVB group, and 35 eyes (71%) in the PDT group (P=0.009). The resolution of polyps was achieved in three out of 18 eyes in the s-IVB group, one eye (5%) in the m-IVB group and 35 eyes (71%) in the PDT group (P < 0.001). Conclusion: The better short-term therapeutic outcomes in the PDT group than in the s-IVB and m-IVB groups indicate that PDT may be more effective than IVB in short term after treatment for PCV.
C1 [Mitamura, Yoshinori] Univ Tokushima, Dept Ophthalmol, Inst Hlth Biosci, Grad Sch, Tokushima 7708503, Japan.
   [Mitamura, Yoshinori; Kitahashi, Masayasu; Kubota-Taniai, Mariko; Yamamoto, Shuichi] Chiba Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Chiba, Japan.
C3 Tokushima University; Chiba University
RP Mitamura, Y (通讯作者)，Univ Tokushima, Dept Ophthalmol, Inst Hlth Biosci, Grad Sch, 3-18-15 Kuramoto, Tokushima 7708503, Japan.
EM ymita@clin.med.tokushima-u.ac.jp
CR Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitamura Y, 2009, EYE, V23, P67, DOI 10.1038/sj.eye.6702996
   Pai SA, 2009, ACTA OPHTHALMOL, V87, P806, DOI 10.1111/j.1755-3768.2008.01330.x
   PEDERSEN KB, ACTA OPHTHA IN PRESS
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 16
Z9 19
U1 0
U2 1
PU ALL INDIA OPHTHALMOLOGICAL SOC
PI HYDERABAD
PA C/O L V PRASAD EYE INST, L V PRASAD MARG, BANJARA HILLS, HYDERABAD,
   ANDHRA PRADESH 00000, INDIA
SN 0301-4738
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL-AUG
PY 2010
VL 58
IS 4
BP 291
EP 296
DI 10.4103/0301-4738.64130
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 646YC
UT WOS:000281580600005
PM 20534918
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kitagawa, Y
   Shimada, H
   Mori, R
   Tanaka, K
   Wakatsuki, Y
   Onoe, H
   Kaneko, H
   Machida, Y
   Nakashizuka, H
AF Kitagawa, Yorihisa
   Shimada, Hiroyuki
   Mori, Ryusaburo
   Tanaka, Koji
   Wakatsuki, Yu
   Onoe, Hajime
   Kaneko, Hiroyuki
   Machida, Yumiko
   Nakashizuka, Hiroyuki
TI One-Year Outcome of Intravitreal Tissue Plasminogen Activator,
   Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal
   Choroidal Vasculopathy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE polypoidal choroidal vasculopathy; recombinant tissue plasminogen
   activator; ranibizumab; gas injections; aflibercept; central retinal
   thickness; univariate analyses; central pigment epithelial detachment
   thickness; multivariate analyses; recurrence; complications; submacular
   hemorrhage; pro re nata
ID PIGMENT EPITHELIAL DETACHMENT; MACULAR DEGENERATION; PNEUMATIC
   DISPLACEMENT; VITRECTOMY; RTPA; AFLIBERCEPT; AMD
AB This study investigated one-year outcomes of treatment with one session of intravitreal recombinant tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). An extended study of a previous prospective trial of this treatment modality in PCV patients was conducted in 64 patients (64 eyes). Early Treatment Diabetic Retinopathy Study (ETDRS) score, central retinal thickness (CRT), and central pigment epithelial detachment thickness (CPEDT) before and 1, 3, and 12 months after treatment were analyzed. Mean ETDRS score increased from 58 at baseline to 64 letters (p = 0.0122), CRT decreased from 543 to 192 mu m (p < 0.0001), and CPEDT decreased from 161 to 103 mu m (p = 0.0668) at 3 months and were maintained until 12 months. Complications requiring reoperation occurred within one month in four eyes. Recurrence was observed in 46 eyes (72%), and 1.6 +/- 1.5 (0-7) intravitreal aflibercept injections were given pro re nata. Univariate and multivariate analyses identified CPEDT as the pre- and post-treatment factor affecting 12-month ETDRS score (p < 0.0001). Improved visual acuity stabilized 3 months after treatment. Although 72% of patients experienced recurrence, an average of 1.6 aflibercept injections/patient maintained visual acuity up to 12 months. CPEDT was the most important factor associated with visual outcome.
C1 [Kitagawa, Yorihisa; Shimada, Hiroyuki; Mori, Ryusaburo; Tanaka, Koji; Wakatsuki, Yu; Onoe, Hajime; Kaneko, Hiroyuki; Machida, Yumiko; Nakashizuka, Hiroyuki] Nihon Univ, Sch Med, Dept Ophthalmol, Chiyoda Ku, 1-6 Surugadai, Tokyo 1018309, Japan.
   [Shimada, Hiroyuki] Nihon Univ Hosp, Dept Ophthalmol, Chiyoda Ku, 1-6 Surugadai, Tokyo 1018309, Japan.
C3 Nihon University; Nihon University
RP Shimada, H (通讯作者)，Nihon Univ, Sch Med, Dept Ophthalmol, Chiyoda Ku, 1-6 Surugadai, Tokyo 1018309, Japan.; Shimada, H (通讯作者)，Nihon Univ Hosp, Dept Ophthalmol, Chiyoda Ku, 1-6 Surugadai, Tokyo 1018309, Japan.
EM k.yorihisa@gmail.com; sshimada@olive.ocn.ne.jp; ryu-m@sa2.so-net.ne.jp;
   taijinagaoka@gmail.com; wakatsuki.yu@nihon-u.ac.jp;
   onoe.hajime@nihon-u.ac.jp; kaneko.hiroyuki@nihon-u.ac.jp;
   machida.yumiko@nihon-u.ac.jp; nkshizuk@gmail.com
OI Shimada, Hiroyuki/0000-0001-8298-3757; Tanaka, Koji/0000-0003-3323-4148;
   Nakashizuka, Hiroyuki/0000-0001-5801-8893
CR Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Fassbender JM, 2016, RETINA-J RET VIT DIS, V36, P1860, DOI 10.1097/IAE.0000000000001030
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Grohmann C, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00228-x
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Jeong S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103088
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kim H, 2015, OPHTHALMOLOGICA, V233, P146, DOI 10.1159/000380830
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Lee SH, 2021, EYE, V35, P3064, DOI 10.1038/s41433-020-01383-z
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Shimada H, 2013, GRAEF ARCH CLIN EXP, V251, P1885, DOI 10.1007/s00417-013-2274-y
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tranos P, 2021, INT OPHTHALMOL, V41, P4037, DOI 10.1007/s10792-021-01976-x
   Treumer F, 2017, GRAEF ARCH CLIN EXP, V255, P1115, DOI 10.1007/s00417-017-3620-2
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 35
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2022
VL 11
IS 8
AR 2175
DI 10.3390/jcm11082175
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0R2WM
UT WOS:000785462000001
PM 35456268
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pawlak, AM
   Beattie, JR
   Glenn, JV
   Stitt, AW
   McGarvey, JJ
AF Pawlak, Anna M.
   Beattie, J. Renwick
   Glenn, Josephine V.
   Stitt, Alan W.
   McGarvey, John J.
TI Raman spectroscopy of advanced glycation end products (AGEs), possible
   markers for progressive retinal dysfunction
SO JOURNAL OF RAMAN SPECTROSCOPY
LA English
DT Article
DE confocal Raman microscopy; advanced glycation endproducts; lipid
   peroxidation products; ageing; age-related macular degeneration
ID MACULAR DEGENERATION; BRUCHS MEMBRANE; MAILLARD REACTION; IN-VIVO;
   ADVANCED GLYCOSYLATION; PROTEIN GLYCATION; LIPID OXIDATION; BONE TISSUE;
   ACID; LOCALIZATION
AB Raman microscopy is used to investigate the spectral features of selected compounds known to be involved in the development of the eye disease age-related macular degeneration (AMD). Diagnostic features were identified in synthetic samples of these compounds and in a biological matrix. The study demonstrates the potential of Raman microscopy for the development of diagnostic markers of the onset of AMD. Copyright (C) 2008 John Wiley & Sons, Ltd.
C1 [McGarvey, John J.] Queens Univ Belfast, Sch Chem & Chem Engn, Belfast BT9 5AG, Antrim, North Ireland.
   [Pawlak, Anna M.; Glenn, Josephine V.; Stitt, Alan W.] Queens Univ Belfast, Ctr Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [Beattie, J. Renwick; McGarvey, John J.] Queens Univ Belfast, Ctr Clin Raman Microscopy, Belfast BT12 6BA, Antrim, North Ireland.
   [Beattie, J. Renwick] Queens Univ Belfast, Resp Res Grp, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast; Queens University
   Belfast; Queens University Belfast
RP McGarvey, JJ (通讯作者)，Queens Univ Belfast, Sch Chem & Chem Engn, Belfast BT9 5AG, Antrim, North Ireland.
EM j.mcgarvey@qub.ac.uk
RI Pawlak, Anna/A-7904-2016; Beattie, James Renwick/I-4506-2015; Stitt,
   Alan/A-9842-2009
OI Pawlak, Anna/0000-0002-2911-6125; Beattie, James
   Renwick/0000-0002-0205-717X; Stitt, Alan/0000-0002-8647-9918
FU U.K. Medical Research Council [C0600053]; Leverhulme Trust
   [EM/2006/0049]; Biotechnology and Biological Sciences Research Council
   [18471]; Research and Development Office of the Northern Ireland NHS
   [SPI/2384/03]; MRC [G0600053] Funding Source: UKRI; Medical Research
   Council [G0600053] Funding Source: researchfish
FX AAA was provided by Prof. Vincent Monnier, Case Western Reserve
   University, Cleveland, USA. Prof. Koij Uchida, Nagoya University, Japan,
   is acknowledged for the gift of HNE. The research was supported by the
   U.K. Medical Research Council (Grant No. C0600053), The Leverhulme Trust
   (Grant No. EM/2006/0049, Emeritus Research Fellowship to JJM), The
   Biotechnology and Biological Sciences Research Council (Grant No.18471)
   and the Research and Development Office of the Northern Ireland NHS
   (Grant No SPI/2384/03).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ames JM, 2007, MOL NUTR FOOD RES, V51, P1085, DOI 10.1002/mnfr.200600304
   Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8
   Baynes JW, 2003, CLIN CHEM LAB MED, V41, P1159, DOI 10.1515/CCLM.2003.179
   Beattie JR, 2007, LIPIDS, V42, P679, DOI 10.1007/s11745-007-3059-z
   Beattie JR, 2007, FASEB J, V21, P766, DOI 10.1096/fj.06-7028com
   Beattie JR, 2006, LIPIDS, V41, P287, DOI 10.1007/s11745-006-5099-1
   Beattie JR, 2005, MOL VIS, V11, P825
   Beattie JR, 2004, LIPIDS, V39, P897, DOI 10.1007/s11745-004-1312-5
   Beattie JR, 2004, LIPIDS, V39, P407, DOI 10.1007/s11745-004-1245-z
   BOESZEBATTAGLIA K, 1989, EXP EYE RES, V49, P699, DOI 10.1016/S0014-4835(89)80064-8
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Carden A, 2003, CALCIFIED TISSUE INT, V72, P166, DOI 10.1007/s00223-002-1039-0
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Erckens RJ, 2001, LASER MED SCI, V16, P236, DOI 10.1007/PL00011360
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Gillery P, 2006, ANN BIOL CLIN-PARIS, V64, P309
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Goh SY, 2008, J CLIN ENDOCR METAB, V93, P1143, DOI 10.1210/jc.2007-1817
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hidalgo FJ, 2005, ANN NY ACAD SCI, V1043, P319, DOI 10.1196/annals.1333.039
   HIRAOKA BY, 1980, J BIOCHEM-TOKYO, V88, P373, DOI 10.1093/oxfordjournals.jbchem.a132982
   Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Huang ZW, 2005, PHOTOCHEM PHOTOBIOL, V81, P1219, DOI 10.1562/2005-02-24-RA-449
   Huang ZW, 2003, INT J CANCER, V107, P1047, DOI 10.1002/ijc.11500
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Karlsson S, 2001, J PHYS CHEM B, V105, P7944, DOI 10.1021/jp010727p
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kimura T, 1998, PATHOL INT, V48, P575, DOI 10.1111/j.1440-1827.1998.tb03953.x
   Koyama H, 2007, MOL MED, V13, P625, DOI 10.2119/2007-00087.Koyama
   Ling X, 1998, LAB INVEST, V78, P1591
   Mallick SB, 2006, ANAL BIOANAL CHEM, V386, P652, DOI 10.1007/s00216-006-0538-7
   Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207
   McCreadie BR, 2006, BONE, V39, P1190, DOI 10.1016/j.bone.2006.06.008
   Monnier VM, 2003, ARCH BIOCHEM BIOPHYS, V419, P1, DOI 10.1016/j.abb.2003.08.014
   Muik B, 2005, CHEM PHYS LIPIDS, V134, P173, DOI 10.1016/j.chemphyslip.2005.01.003
   Munch G, 1998, J NEURAL TRANSM, V105, P439, DOI 10.1007/s007020050069
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48
   Pudney PDA, 2007, APPL SPECTROSC, V61, P804, DOI 10.1366/000370207781540042
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Sailer K, 1997, BBA-BIOMEMBRANES, V1329, P259, DOI 10.1016/S0005-2736(97)00113-2
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sayre LM, 2006, DRUG METAB REV, V38, P651, DOI 10.1080/03602530600959508
   Schleicher E, 2007, KIDNEY INT, V72, pS17, DOI 10.1038/sj.ki.5002382
   Schraermeyer U, 1998, OPHTHALMOLOGE, V95, P291, DOI 10.1007/s003470050275
   Sell DR, 2007, BIOCHEM J, V404, P269, DOI 10.1042/BJ20061645
   Stewart S, 1999, SPECTROCHIM ACTA A, V55, P1615, DOI 10.1016/S1386-1425(98)00293-5
   Swain RJ, 2007, BIOCHEM SOC T, V35, P544, DOI 10.1042/BST0350544
   Taleb A, 2006, J PHYS CHEM B, V110, P19625, DOI 10.1021/jp061981q
   Thoreson R, 2007, NATION, V285, P6
   Thornalley PJ, 2005, ANN NY ACAD SCI, V1043, P111, DOI 10.1196/annals.1333.014
   Thornalley PJ, 2005, PEDIATR NEPHROL, V20, P1515, DOI 10.1007/s00467-005-2011-9
   Ton ALY, 2007, SEMIN NEPHROL, V27, P130, DOI 10.1016/j.semnephrol.2007.01.006
   Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1
   Van Nguyen C, 2006, MOL NUTR FOOD RES, V50, P1140, DOI 10.1002/mnfr.200600144
   Vlassara H, 2002, J INTERN MED, V251, P87, DOI 10.1046/j.1365-2796.2002.00932.x
   Vlassara H, 2002, P NATL ACAD SCI USA, V99, P15596, DOI 10.1073/pnas.242407999
   VLASSARA H, 1994, LAB INVEST, V70, P138
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yamagishi SI, 2007, CURR PHARM DESIGN, V13, P2832, DOI 10.2174/138161207781757051
   YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   YIN DZ, 1991, MECH AGEING DEV, V61, P99, DOI 10.1016/0047-6374(91)90009-O
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 67
TC 20
Z9 20
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0377-0486
EI 1097-4555
J9 J RAMAN SPECTROSC
JI J. Raman Spectrosc.
PD NOV
PY 2008
VL 39
IS 11
BP 1635
EP 1642
DI 10.1002/jrs.2011
PG 8
WC Spectroscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Spectroscopy
GA 376TP
UT WOS:000261206200018
DA 2022-11-30
ER

PT J
AU Lim, LW
   Tan, CS
   Ting, DS
AF Lim, Louis W.
   Tan, Colin S.
   Ting, Dominic S.
TI Comparison of Polypoidal Choroidal Vasculopathy Lesion Sizes Measured on
   Multicolor Imaging and Indocyanine Green Angiography
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; multicolour; indocynanine green
   angiography; retina; imaging
AB Purpose:To evaluate the areas of lesion components of polypoidal choroidal vasculopathy (PCV) measured using multicolor imaging compared to indocyanine green angiography (ICGA). Methods: In a prospective study of 50 consecutive treatment-na?ve PCV patients, multicolor imaging and ICGA were performed. The images were independently graded by reading center-certified retinal specialists to confirm the diagnosis of PCV and identify lesion components. The areas of the respective lesion components were compared. Results: The mean age of the participants was 67.8 years. PCV was diagnosed in 96% of eyes using multicolor imaging. The mean numbers of polypoidal lesions identified using ICGA and multicolor were 4.0 and 2.1, respectively (P < 0.001), with mean total polypoidal lesion areas of 0.32 mm2 versus 0.30 mm2 (P = 0.727). The area of the branching vascular network (BVN) on ICGA was 7.8 mm2 compared to 5.7 mm2 on multicolor imaging (P = 0.289). Patients with four or more polypoidal lesions on ICGA had larger differences in total lesion area between ICGA and multicolor imaging (4.07 vs. ?0.70 mm2, p = 0.039). Those with total lesion area ? 2.0 mm2 on ICGA had larger differences in mean polypoidal lesion number compared to those with smaller areas (2.2 vs. 0.5; P = 0.026). Conclusions: Multicolor imaging is a useful, noninvasive adjunct for detecting PCV lesion components, revealing lesion areas similar to but generally smaller than those seen on ICGA. This is important to consider when making treatment decisions with different imaging modalities Translational Relevance: New features seen on multicolor imaging can aid in the diagnosis and treatment of PCV.
C1 [Lim, Louis W.; Tan, Colin S.; Ting, Dominic S.] Tan Tock Seng Hosp, Natl Healthcare Grp, Inst Eye, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Tan, Colin S.] Tan Tock Seng Hosp, Natl Healthcare Grp, Inst Eye, Fundus Image Reading Ctr, Singapore, Singapore.
   [Tan, Colin S.] Duke NUS Med Sch, Singapore, Singapore.
C3 Tan Tock Seng Hospital; Tan Tock Seng Hospital; National University of
   Singapore
RP Tan, CS (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp, Inst Eye, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM colintan_eye@yahoo.com.sg
RI Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690
FU National Medical Research Council [NMRC/TA/0039/2015]; National
   Healthcare Group
FX Supported by grants from the National Medical Research Council
   (NMRC/TA/0039/2015, CST) and National Healthcare Group.
CR Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Graham KW, 2018, RETINA-J RET VIT DIS, V38, P1751, DOI 10.1097/IAE.0000000000001777
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan CS, 2019, OPHTHALMOL RETINA, V3, P400, DOI 10.1016/j.oret.2019.01.009
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P614, DOI 10.1111/ceo.13464
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P621, DOI 10.1111/ceo.13462
   Tan CS, 2018, INVEST OPHTH VIS SCI, V59, P889, DOI 10.1167/iovs.17-22683
   Tan CS, 2018, OSLI RETINA, V49, P4, DOI 10.3928/23258160-20171215-01
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, OSLI RETINA, V46, P786, DOI 10.3928/23258160-20150909-02
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2021
VL 10
IS 2
DI 10.1167/tvst.10.2.35
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RG2SX
UT WOS:000635394600005
PM 34003920
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, YH
   Chung, YR
   Kim, C
   Lee, K
   Lee, WK
AF Kim, Young Ho
   Chung, Yoo-Ri
   Kim, Chungwoon
   Lee, Kihwang
   Lee, Won Ki
TI The Association of Pachydrusen Characteristics with Choroidal Thickness
   and Patient's Age in Polypoidal Choroidal Vasculopathy versus Central
   Serous Chorioretinopathy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE central serous chorioretinopathy; choroid; pachydrusen; polypoidal
   choroidal vasculopathy
AB We investigated the relationship between pachydrusen and choroidal thickness and age in eyes with polypoidal choroidal vasculopathy (PCV) and fellow eyes, compared to eyes with central serous chorioretinopathy (CSC). This retrospective study included 89 eyes with PCV and 146 eyes with CSC. The number, location, and shape of the pachydrusen and their association with choroidal thickness and age were analyzed. PCV eyes showed pachydrusen more frequently than eyes with CSC (52% vs. 20%, p < 0.001). Large solitary type and clustered type were more frequent in PCV eyes compared to CSC eyes (p = 0.003 and p = 0.001, respectively). Subfoveal choroidal thickness was associated with pachydrusen in eyes with PCV (odds ratio [OR] 1.006, 95% confidence interval [CI] 1.001-1.011, p = 0.027), while age was associated with pachydrusen in CSC eyes (OR 1.137, 95% CI, 1.073-1.205; p < 0.001). Pachydrusen were localized directly over the pachyvessel on optical coherence tomographic findings in approximately two thirds of PCV eyes and fellow eyes (62% and 67%, respectively). Risk factors for pachydrusen differ according to diseases. The presence of pachydrusen was associated with choroidal thickness in PCV, while the association with age was more prominent in CSC.
C1 [Kim, Young Ho] Korea Univ, Dept Ophthalmol, Coll Med, Seoul 02841, South Korea.
   [Chung, Yoo-Ri; Kim, Chungwoon; Lee, Kihwang] Ajou Univ, Dept Ophthalmol, Sch Med, Suwon 16499, South Korea.
   [Lee, Won Ki] Nune Eye Hosp, Retina Ctr, Seoul 06198, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Ajou
   University
RP Lee, K (通讯作者)，Ajou Univ, Dept Ophthalmol, Sch Med, Suwon 16499, South Korea.
EM kimyh54067@naver.com; cyr216@hanmail.net; chungwoon92@aumc.ac.kr;
   kie114@hanmail.net; wklee0921@gmail.com
RI Kim, Young Ho/ABH-7801-2020
OI Kim, Young Ho/0000-0002-5281-1185; Lee, Won Ki/0000-0001-7039-1762
CR Baek J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42052-w
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chung YR, 2016, RETINA-J RET VIT DIS, V36, P1652, DOI 10.1097/IAE.0000000000000998
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jordan-Yu JM, 2021, RETINA-J RET VIT DIS, V41, P1084, DOI 10.1097/IAE.0000000000002966
   Jung CH, 2021, DIABETES METAB J, V45, P1, DOI 10.4093/dmj.2020.0254
   Kang HG, 2021, GRAEF ARCH CLIN EXP, V259, P2391, DOI 10.1007/s00417-021-05180-6
   Karska-Basta I, 2020, J PHYSIOL PHARMACOL, V71, P235, DOI 10.26402/jpp.2020.2.07
   Karska-Basta I, 2021, ACTA OPHTHALMOL, V99, pE222, DOI 10.1111/aos.14547
   Kong M, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.16
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Lee HH, 2021, KOREAN CIRC J, V51, P495, DOI 10.4070/kcj.2021.0097
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Singh SR, 2020, INDIAN J OPHTHALMOL, V68, P118, DOI 10.4103/ijo.IJO_528_19
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1121, DOI 10.4103/ijo.IJO_1757_18
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
NR 28
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2022
VL 23
IS 15
AR 8353
DI 10.3390/ijms23158353
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 3R7JH
UT WOS:000839083900001
PM 35955481
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lee, WK
   Kim, KS
   Kim, W
   Lee, SB
   Jeon, S
AF Lee, Won Ki
   Kim, Kyu Seop
   Kim, Wungjae
   Lee, Seung Bum
   Jeon, Sohee
TI Responses to Photodynamic Therapy in Patients With Polypoidal Choroidal
   Vasculopathy Consisting of Polyps Resembling Grape Clusters
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BRANCHING VASCULAR NETWORK; FOLLOW-UP; MACULAR DEGENERATION;
   INTRAVITREAL RANIBIZUMAB; JAPANESE PATIENTS; VERTEPORFIN; BEVACIZUMAB
AB PURPOSE: To investigate the responses to photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV) that show large aneurysmal dilation with internal angio-architecture consisting of diverse patterns of curvilinear vessels and polyps resembling grape clusters.
   DESIGN: Retrospective, interventional case series.
   METHODS: Twenty-two eyes of 22 patients were included. All patients initially received PDT monotreatment. The main outcome measures were the rates of complete polyp regression on indocyanine green angiography and initial favorable responses observed clinically. Also, the rates of recurrent exudative changes were evaluated at the 2-year follow-up. We focused on changes in the vascular features and their clinical association.
   RESULTS: Complete regression of polypoidal lesions was observed in 21 eyes (95%) after a mean of 1.7 PDTs. However, favorable clinical responses were achieved in only 9 eyes (41%), and 6 of them had recurrent exudation. Main vessels, previously consisting of the polypoidal lesion frame, persisted. Additionally, aberrant vessels with a thin radiating or tortuous configuration were observed in the area where large aneurysmal dilation was present. Leakage from this vascular complex or an expanded vascular complex was observed in a total of 14 eyes (64%) during the 2-year follow-up, contributing to persistent (8 eyes) or recurrent (6 eyes) exudation. This seemed 1:0 represent secondary choroidal neovascularization (CNV). In another 4 eyes (18%), fibrous changes developed immediately after PDT. Polyps recurred in 8 eyes (38%).
   CONCLUSIONS: This PCV pattern frequently evolved into typical CNV after PDT, resulting in persistent or recurrent exudation despite the disappearance of polypoidal structures. (Am J Ophthalmol 2012;154:355-365. (c) 2012 by Elsevier Inc. All rights reserved.)
C1 [Lee, Won Ki; Kim, Kyu Seop; Kim, Wungjae; Lee, Seung Bum; Jeon, Sohee] Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Coll Med, Seoul 137701, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   KUSASHIGE Y, 2008, AM J OPHTHALMOL, V146, P513
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 39
TC 33
Z9 35
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2012
VL 154
IS 2
BP 355
EP 365
DI 10.1016/j.ajo.2012.02.019
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 983XT
UT WOS:000307152700020
PM 22541658
DA 2022-11-30
ER

PT J
AU Alasil, T
   Ferrara, D
   Adhi, M
   Brewer, E
   Kraus, MF
   Baumal, CR
   Hornegger, J
   Fujimoto, JG
   Witkin, AJ
   Reichel, E
   Duker, JS
   Waheed, NK
AF Alasil, Tarek
   Ferrara, Daniela
   Adhi, Mehreen
   Brewer, Erika
   Kraus, Martin F.
   Baumal, Caroline R.
   Hornegger, Joachim
   Fujimoto, James G.
   Witkin, Andre J.
   Reichel, Elis
   Duker, Jay S.
   Waheed, Nadia K.
TI En Face Imaging of the Choroid in Polypoidal Choroidal Vasculopathy
   Using Swept-Source Optical Coherence Tomography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; CLINICOPATHOLOGICAL CORRELATION; MACULAR
   DEGENERATION; CLINICAL CHARACTERISTICS; JAPANESE PATIENTS; FEATURES;
   ANGIOGRAPHY; LESIONS; IPCV
AB OBJECTIVE: To define morphologic features of polypoidal choroidal vasculopathy (PCV) using en face images from swept-source optical coherence tomography (SS OCT).
   DESIGN: Prospective cross-sectional study.
   METHODS: The study included 10 eyes from 6 patients with PCV and 10 eyes from 5 age-matched normal subjects. All subjects were prospectively scanned with a prototype SS OCT system. A motion correction algorithm was applied to correct and merge scans into a single volumetric dataset. En face images were generated at intervals of 4.13 mu m (1 pixel) relative to the Bruch membrane.
   RESULTS: Age +/- standard deviation for the normal group was 62.4 (+/- 12.1) years and for the PCV group was 68.3 (+/- 5.2) years. En face SS OCT imaging of PCV eyes demonstrated the relationship between larger pigment epithelial detachments (PEDs) and small adjoining PEDs that correlated with the polypoidal lesions seen on indocyanine green angiography in all PCV eyes. En face SS OCT demonstrated choroidal vascular abnormalities in 7 out of 7 eyes with PCV, and in 2 out of 3 enrolled fellow eyes in patients with unilateral PCV. Out of 7 PCV eyes, focal choroidal vascular dilation was noted in 3 eyes and diffuse choroidal vascular dilation was noted in 1 eye. In addition, a branching vascular network was noted above the Bruch membrane in 1 eye, below the Bruch membrane within the choriocapillaris in 1 eye, and in the larger choroidal vascular layer in 1 eye.
   CONCLUSIONS: En face SS OCT provides an in vivo tool to visualize the pathologic features and the choroidal vasculature in PCV. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Alasil, Tarek; Ferrara, Daniela; Adhi, Mehreen; Brewer, Erika; Baumal, Caroline R.; Witkin, Andre J.; Reichel, Elis; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Kraus, Martin F.; Hornegger, Joachim] Univ Erlangen Nurnberg, Pattern Recognit Lab, D-91054 Erlangen, Germany.
   [Kraus, Martin F.; Hornegger, Joachim] Univ Erlangen Nurnberg, Sch Adv Opt Technol, D-91054 Erlangen, Germany.
   [Kraus, Martin F.; Fujimoto, James G.] MIT, Dept Elect Engn, Cambridge, MA 02139 USA.
   [Kraus, Martin F.; Fujimoto, James G.] MIT, Dept Comp Sci, Cambridge, MA 02139 USA.
   [Kraus, Martin F.; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
C3 Tufts University; University of Erlangen Nuremberg; University of
   Erlangen Nuremberg; Massachusetts Institute of Technology (MIT);
   Massachusetts Institute of Technology (MIT); Massachusetts Institute of
   Technology (MIT)
RP Waheed, NK (通讯作者)，Tufts Univ, Med Ctr, New England Eye Ctr, 800 Washington St, Boston, MA 02111 USA.
EM nadiakwaheed@gmail.com
RI Adhi, Mehreen/AAS-9733-2021; Hornegger, Joachim/H-2465-2017
OI Hornegger, Joachim/0000-0002-1834-8844
FU National Institute of Health [R01-EY011289-28, R01-EY013178-12,
   R01-CA075289-16]; Air Force Office of Scientific Research
   [FA9550-10-1-0551, FA9550-12-1-0499]; Research to Prevent Blindness;
   Tufts University School of Medicine; Deutsche Forschungsgemeinschaft
   [DFG-HO-1791/11-1, DFG-GSC80-SAOT]; Massachusetts Lions Clubs; NATIONAL
   CANCER INSTITUTE [R01CA075289] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R01EY011289, R01EY013178] Funding Source: NIH RePORTER
FX National Institute of Health (R01-EY011289-28, R01-EY013178-12,
   R01-CA075289-16), Air Force Office of Scientific Research
   (FA9550-10-1-0551 and FA9550-12-1-0499), an unrestricted grant from
   Research to Prevent Blindness to the New England Eye Center, Tufts
   University School of Medicine, Massachusetts Lions Clubs, Deutsche
   Forschungsgemeinschaft (DFG-HO-1791/11-1, DFO Training Group 1773,
   DFG-GSC80-SAOT). The sponsors had no role in the design or conduct of
   this research.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Coscas F, 2011, EUR J OPHTHALMOL, V21, P331, DOI 10.5301/EJO.2010.2803
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Gass JDM, 1987, STEREOSCOPIC ATLAS M, V1, P200
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Park SY, 2013, AM J OPHTHALMOL, V156, P557, DOI 10.1016/j.ajo.2013.04.027
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosen RB, 2009, INVEST OPHTH VIS SCI, V50, P851, DOI 10.1167/iovs.08-1855
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Stem RM, 1985, AM J OPHTHALMOL, V100, P560
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yanoff M., 2009, OPHTHALMOLOGY
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 39
TC 52
Z9 53
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2015
VL 159
IS 4
BP 634
EP 643
DI 10.1016/j.ajo.2014.12.012
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE4FV
UT WOS:000351787400003
PM 25528955
OA Green Submitted, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, KY
   Chen, YY
   Sun, XY
   Zhong, QL
   Lin, L
   Gao, Y
   Hong, FL
AF Zhang, Kaiyan
   Chen, Yingying
   Sun, Xuyang
   Zhong, Qionglei
   Lin, Lin
   Gao, Yuan
   Hong, Fanlin
TI Periocular triamcinolone acetonide injection for treating polypoidal
   choroidal vasculopathy concurrent with hemorrhagic retinal detachment
SO MEDICINE
LA English
DT Article
DE hemorrhagic retinal detachment; periocular injection; polypoidal
   choroidal vasculopathy; triamcinolone acetonide
ID DIABETIC MACULAR EDEMA; INTRAVITREAL TRIAMCINOLONE; PHOTODYNAMIC
   THERAPY; DEGENERATION; VERTEPORFIN; MANAGEMENT
AB To investigate the clinical efficiency of periocular triamcinolone acetonide (TA) injection for treating polypoidal choroidal vasculopathy (PCV) concurrent with hemorrhagic retinal detachment (HRD).
   Twenty-two cases confirmed with PCV concurrent with HRD characterized by massive subretinal hemorrhage and exudation presented to our department from January 2015 to May 2017 were included in this study. The initial vision varied from counting finger to 0.2. All cases were randomly divided into TA group (n = 12), which received periocular TA injection per month, and anti-VEGF group (n = 10), which were treated by anti-VEGF intravitreous injection per month. The patients were followed up for 6 months, in which fundus examination and visual acuity along with optical coherence tomography (OCT) were carried out.
   The treatment effect is divided into the following categories. Cure was defined as the elimination of subretinal hemorrhage and exudation accompanied by retinal edema and choroidal neovascularization (CNV) extinction and rise of visual acuity. Improvement was characterized by alleviation of subretinal hemorrhage and exudation accompanied by retinal edema and CNV reduction and rise of visual acuity. Ineffective means remained subretinal hemorrhage and exudation in fundus and no improvement of visual acuity, and polypoid lesions in OCT images. Among the 12 cases in TA group, 1 case was treated by periocular injection of TA twice, and 11 cases were treated by 3 times injection. After that, 3 cases (25%) were cured, 8 cases (66.7%) got improvement, and only 1 case (8.3%) showed no response. Although among 10 cases in the anti-VEGF group, 3 cases were treated by anti-VEGF intravitreous injection twice. Seven cases were treated by 3 times injection. After that, 4 cases (40%) got improvement, and the other 6 case (60%) showed no response. All patients showed no recurrence in the 6-month follow-up. No complications were noticed under periocular injection or intravitreous injection.
   Periocular TA injection is effective for treating PCV concurrent with HRD.
C1 [Zhang, Kaiyan; Chen, Yingying; Sun, Xuyang; Zhong, Qionglei; Lin, Lin; Gao, Yuan; Hong, Fanlin] Hainan Gen Hosp, Dept Ophthalmol, 19 Xiuhua Rd, Haikou 570102, Hainan, Peoples R China.
RP Chen, YY (通讯作者)，Hainan Gen Hosp, Dept Ophthalmol, 19 Xiuhua Rd, Haikou 570102, Hainan, Peoples R China.
EM 372391802@qq.com
FU Hainan Provincial Social Development Special Fund for Science Technology
   Grant [SF201412]; Hainan medical and health research project [14A200031]
FX This study was supported by the Hainan Provincial Social Development
   Special Fund for Science Technology Grant (SF201412) and Hainan medical
   and health research project (14A200031).
CR Athanasiadis Y, 2013, J OCUL PHARMACOL TH, V29, P516, DOI 10.1089/jop.2012.0208
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Carbonniere C, 2017, J FR OPHTALMOL, V40, P177, DOI 10.1016/j.jfo.2016.11.013
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147346
   Ichio Atsushi, 2016, Nippon Ganka Gakkai Zasshi, V120, P429
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim Jae Hui, 2015, Korean J Ophthalmol, V29, P404, DOI 10.3341/kjo.2015.29.6.404
   Kokame GT, 2016, OSLI RETINA, V47, P737, DOI 10.3928/23258160-20160808-07
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lie S, 2010, ACTA OPHTHALMOL, V88, P212, DOI 10.1111/j.1755-3768.2008.01405.x
   Lobo AM, 2010, SEMIN OPHTHALMOL, V25, P283, DOI 10.3109/08820538.2010.518522
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Schwartz SG, 2014, EXPERT OPIN EMERG DR, V19, P397, DOI 10.1517/14728214.2014.938048
   Tsuchihashi T, 2013, CLIN OPHTHALMOL, V7, P615, DOI 10.2147/OPTH.S43566
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Weijtens O, 1997, AM J OPHTHALMOL, V123, P358, DOI 10.1016/S0002-9394(14)70131-X
   Zhao MZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131429
NR 21
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP
PY 2018
VL 97
IS 39
AR e12464
DI 10.1097/MD.0000000000012464
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GZ4NQ
UT WOS:000449373500052
PM 30278530
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wataru, K
   Sugiyama, A
   Yoneyama, S
   Matsubara, M
   Fukuda, Y
   Parikh, R
   Sakurada, Y
AF Wataru, Kikushima
   Sugiyama, Atsushi
   Yoneyama, Seigo
   Matsubara, Mio
   Fukuda, Yoshiko
   Parikh, Ravi
   Sakurada, Yoichi
TI Five-year outcomes of photodynamic therapy combined with intravitreal
   injection of ranibizumab or aflibercept for polypoidal choroidal
   vasculopathy
SO PLOS ONE
LA English
DT Article
ID VISUAL PROGNOSIS; LESION SIZE; EFFICACY; VERTEPORFIN; BEVACIZUMAB;
   THICKNESS; ASSOCIATION; GENOTYPE; SAFETY
AB We report 5-year visual and anatomical outcomes after combination therapy of photodynamic therapy (PDT) and intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy (PCV) and predictive factors for visual outcomes at 5-year and time to recurrence. Medical charts were retrospectively reviewed for 43 consecutive eyes with PCV treated with combination therapy of PDT and intravitreal injection of ranibizumab(n = 13) or aflibercept(n = 30) and completed 5-year follow-up. The variants of ARMS2 A69S and CFH I62V were genotyped using TaqMan assay. Best corrected visual acuity (BCVA) significantly improved at 5-year (P = 0.01) with 20% reduction of subfoveal choroidal thickness irrespective of presence or absence of recurrence. Visual improvement was associated with baseline shorter greatest linear dimension (GLD) (P = 1.0x10(-4)). Mean time to recurrence was 28.6 +/- 23.1 months (95% CI: 21.5-35.7, Median:18.0) and time to recurrence was associated with G allele (protective allele) of ARMS2 A69S and GLD (P = 4.0x10(-4) and 1.0x10(-2), respectively). Multiple regression analysis revealed that time to recurrence extended by 15.5 months when the G allele of ARMS2 A69S increased by one allele (TT: 15.7 +/- 17.0, TG: 30.8 +/- 23.5, GG: 41.1 +/- 22.6 months). The combination therapy resulted in a favorable visual outcome for PCV during 5-year follow-up.
C1 [Wataru, Kikushima; Sugiyama, Atsushi; Yoneyama, Seigo; Matsubara, Mio; Fukuda, Yoshiko; Sakurada, Yoichi] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
   [Parikh, Ravi] NYU, Sch Med, New York, NY USA.
   [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY USA.
C3 University of Yamanashi; New York University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
OI Parikh, Ravi/0000-0003-3369-4224; Sakurada, Yoichi/0000-0002-2894-0454
FU JSPS (Japan Society for the promotion of Science) KAKENHI [18K16921]
FX JSPS (Japan Society for the promotion of Science) KAKENHI Grant Number
   18K16921
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Jain P, 2018, INDIAN J OPHTHALMOL, V66, P1119, DOI 10.4103/ijo.IJO_1222_17
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P389, DOI 10.1007/s10384-019-00683-6
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P100, DOI 10.1007/s10384-018-0636-z
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Sugiyama A, 2018, OPHTHALMOLOGICA, V239, P52, DOI 10.1159/000480439
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1245-4
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 31
TC 10
Z9 11
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 24
PY 2020
VL 15
IS 2
AR e0229231
DI 10.1371/journal.pone.0229231
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LQ8DW
UT WOS:000535229300034
PM 32092094
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kawamura, A
   Yuzawa, M
   Mori, R
   Haruyama, M
   Tanaka, K
AF Kawamura, Akiyuki
   Yuzawa, Mitsuko
   Mori, Ryusaburo
   Haruyama, Miho
   Tanaka, Koji
TI Indocyanine green angiographic and optical coherence tomographic
   findings support classification of polypoidal choroidal vasculopathy
   into two types
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE choroidal neovascularization; choroidal vasculature abnormality;
   indocyanine green angiography; optical coherence tomography; polypoidal
   choroidal vasculopathy
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; LESION SIZE;
   NEOVASCULARIZATION; ASSOCIATION; SUBTYPES
AB Purpose: We assessed the characteristic indocyanine green angiographic (ICGA) and spectral domain optical coherence tomographic (SD-OCT) findings of two types of polypoidal choroidal vasculopathy (PCV), distinguishable by different filling patterns on ICGA. Methods: Thirty-one eyes with PCV were classified into types 1 and 2 based on ICGA findings of either the presence or absence of both a feeder and a draining vessel. Characteristic ICGA findings were evaluated for each type of PCV. Spectral domain optical coherence tomographic images of the 31 eyes were also used to compare the two types of PCV. Results: Both a feeder and a draining vessel were observed in 13 eyes (type 1). Eighteen eyes had neither feeder nor draining vessels (type 2). In PCV type 1, a break in the highly reflective line thought to be Bruch's membrane was detected, corresponding to the feeder vessel in-growth site on SD-OCT. This line was straight. In PCV type 2, the highly reflective line exhibited irregular thickness and had highly reflective substances adhering to its lower portion. It curved downward and became increasingly obscure, ultimately disappearing at a point corresponding to the site at which network vessel filling began. The mean subfoveal choroidal thicknesses in eyes with PCV type 1 and PCV type 2 were 199 +/- 65 and 288 +/- 98m, respectively. Conclusions: Our observations support the existence of two distinct types of PCV. The first type represents choroidal neovascularization, whilst the second type involves choroidal vasculature abnormalities.
C1 [Kawamura, Akiyuki; Yuzawa, Mitsuko; Mori, Ryusaburo; Haruyama, Miho; Tanaka, Koji] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo 1018309, Japan.
C3 Nihon University
RP Yuzawa, M (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, 1-8-13 Surugadai, Tokyo 1018309, Japan.
EM yuzawa.mitsuko@nihon-u.ac.jp
RI Tanaka, Koji/H-3119-2019
OI Tanaka, Koji/0000-0003-3323-4148
FU Research Committee on Chorioretinal Degenerations and Optic Atrophy, The
   Ministry of Health, Welfare and Labor of Japan
FX These results were presented orally at a scientific programme of the
   27th Asian Pacific Academy of Ophthalmology Congress, Busan Korea, April
   13-16 2012. This study was funded in part by the Research Committee on
   Chorioretinal Degenerations and Optic Atrophy, The Ministry of Health,
   Welfare and Labor of Japan (Mitsuko Yuzawa).
CR Bessho H, 2012, MOL VIS, V18, P121
   Bessho H, 2011, MOL VIS, V17, P977
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fadugbagbe AO, 2010, ANN TROP PAEDIATR, V30, P19, DOI 10.1179/146532810X12637745451870
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass JDM, 2004, AM SOC RETINA SPECIA
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Kahn S, 2012, RETINA, V32, P1057
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P680, DOI 10.1016/S0161-6420(98)94024-6
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 34
TC 84
Z9 94
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2013
VL 91
IS 6
BP e474
EP e481
DI 10.1111/aos.12110
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202GG
UT WOS:000323201500010
PM 23848133
DA 2022-11-30
ER

PT J
AU Capasso, C
   Winum, JY
AF Capasso, Clemente
   Winum, Jean-Yves
TI Novel method of treating macular degeneration: a patent evaluation
   (WO2018/107005)
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Article
DE Age-related macular degeneration; AMD cure; botulinum toxin treatment;
   extra-ocular administration
ID MANAGEMENT; THERAPY; DRUG
AB Introduction: Age-related macular degeneration (AMD) is the leading cause of central vision loss in developed countries. Effective therapy for AMD is currently limited to the treatment of the patient with intravitreal injections of anti-VEGF drugs. Areas covered: A method for the management of age-related macular degeneration (AMD) is claimed. It consists of the administration of pure botulinum-toxin or a serogroup of recombinant botulinum-toxins or their peptide fragments or neurotoxin associated with accessory proteins in extra-ocular regions of the eye. The toxin modifies the retinal pigment epithelium, maintaining its structure and function, and delaying the various stages of the macular degeneration. Expert opinion: The botulinum-toxin (BT) is administrated as extra-ocular infusions avoiding the risk of direct intraocular injection and the complications associated with the patients. The possibility to administer BT with accessory proteins (hemagglutinin, monoclonal antibody (anti-VEGF)), makes the novel system interesting for developing combined approaches for AMD treatment. The use of BT (alone or conjugated to other agents) as a method for treating or preventing AMD requires necessarily a patient case report study, as well as the in vitro or in vivo data, for supporting all the claims of the present patent.
C1 [Capasso, Clemente] Natl Res Council CNR, Ist Biosci & Biorisorse, Via Pietro Castellino 111, I-80131 Naples, Italy.
   [Winum, Jean-Yves] Univ Montpellier, ENSCM, UMR CNRS 5247, IBMM, 240 Ave Prof Emile Jeanbrau, F-34296 Montpellier 05, France.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioscienze e
   Biorisorse (IBBR-CNR); Universite de Montpellier
RP Capasso, C (通讯作者)，Natl Res Council CNR, Ist Biosci & Biorisorse, Via Pietro Castellino 111, I-80131 Naples, Italy.; Winum, JY (通讯作者)，Univ Montpellier, ENSCM, UMR CNRS 5247, IBMM, 240 Ave Prof Emile Jeanbrau, F-34296 Montpellier 05, France.
EM clemente.capasso@ibbr.cnr.it; Jean-yves.winum@umontpellier.fr
RI WINUM, Jean-Yves/AAC-9578-2019; Capasso, Clemente/P-3522-2016
OI WINUM, Jean-Yves/0000-0003-3197-3414; Capasso,
   Clemente/0000-0003-3314-2411
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   [Anonymous], 2018, LANCET, V392, P1090, DOI 10.1016/S0140-6736(18)32291-8
   Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Borodic GE, 2018, pA1, Patent No. [WO2018107005 : A1, 2018107005]
   Cai SW, 2018, DRUG DES DEV THER, V12, P3471, DOI 10.2147/DDDT.S177192
   COHEN D, 2018, BMJ-BRIT MED J, V363, DOI DOI 10.1136/BMJ.K4586
   Cohen D, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k4035
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Ehlken C, 2018, GRAEF ARCH CLIN EXP, V256, P105, DOI 10.1007/s00417-017-3849-9
   Ehrenberg M, 2018, CURR EYE RES, V43, P147, DOI 10.1080/02713683.2017.1385088
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Gil-Martinez M, 2020, CURR MED CHEM, V27, P583, DOI 10.2174/0929867326666190726121711
   Jabbari B, 2016, TREMOR OTHER HYPERK, V6, DOI 10.7916/D81836S1
   Li HL, 2017, EXPERT OPIN INV DRUG, V26, P1103, DOI 10.1080/13543784.2017.1369042
   Mastrolorenzo A, 2009, DRUG DESIGN ZINC ENZ, P705
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohamed R, 2019, EYE, V33, P529, DOI 10.1038/s41433-018-0260-7
   Ranibizumab and retinal vein occlusion, 2012, PRESCRIRE INT, V21, P207
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sangroongruangsri S, 2018, EXPERT REV CLIN PHAR, V11, P903, DOI 10.1080/17512433.2018.1507735
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Su YX, 2018, PHOTODIAGN PHOTODYN, V22, P263, DOI 10.1016/j.pdpdt.2018.05.002
   Takahashi Masayo, 2016, Nippon Ganka Gakkai Zasshi, V120, P210
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Vo TA, 2018, EXP EYE RES, V177, P112, DOI 10.1016/j.exer.2018.07.025
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
NR 31
TC 2
Z9 2
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3776
EI 1744-7674
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD OCT 3
PY 2019
VL 29
IS 10
SI SI
BP 749
EP 752
DI 10.1080/13543776.2019.1661991
EA SEP 2019
PG 4
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JF2SJ
UT WOS:000484686800001
PM 31456444
DA 2022-11-30
ER

PT J
AU Wykoff, CC
   Rosenfeld, PJ
   Waheed, NK
   Singh, RP
   Ronca, N
   Slakter, JS
   Staurenghi, G
   Mones, J
   Baumal, CR
   Saroj, N
   Metlapally, R
   Ribeiro, R
AF Wykoff, Charles C.
   Rosenfeld, Philip J.
   Waheed, Nadia K.
   Singh, Rishi P.
   Ronca, Nick
   Slakter, Jason S.
   Staurenghi, Giovanni
   Mones, Jordi
   Baumal, Caroline R.
   Saroj, Namrata
   Metlapally, Ravi
   Ribeiro, Ramiro
TI Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial
   of Complement Inhibitor Pegcetacoplan for Geographic Atrophy
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Complement; Double-layer sign;
   Exudation; Geographic atrophy; Macular neovascularization
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; PROGRESSION;
   OUTCOMES; EYE; RANIBIZUMAB; SECONDARY; FEATURES; ANCHOR; MARINA
AB Objectives: To evaluate clinical characteristics of eyes in which investigator-determined new-onset exudative age-related macular degeneration (eAMD) developed during the FILLY trial.
   Design: Post hoc analysis of the phase 2 study of intravitreal pegcetacoplan in geographic atrophy (GA).
   Subjects: Patients with GA secondary to age-related macular degeneration (AMD), n = 246.
   Intervention: Either 15 mg intravitreal pegcetacoplan or sham given monthly or every other month for 12 months followed by a 6-month off-treatment period.
   Main Outcome Measures: Time of new eAMD onset in the study eye, history of eAMD in the fellow eye, presence of double-layer sign (DLS) on structural OCT in the study eye, changes in retinal anatomic features by structural OCT and fluorescein angiography (FA), and changes in visual acuity.
   Results: Exudation was reported in 26 study eyes across treatment groups over 18 months. Mean time to eAMD diagnosis was 256 days (range, 31-555 days). Overall, a higher proportion of patients with a baseline history of eAMD in the fellow eye (P = 0.016) and a DLS in the study eye (P = 0.0001) demonstrated eAMD. Among study eyes in which eAMD developed, 18 of 26 (69%) had history of fellow-eye eAMD and 19 of 26 (73.1%) had DLS at baseline, compared with 76 of 217 study eyes (35%; P = 0.0007) and 70 of 215 study eyes (32.5%; P < 0.0001), respectively, in which eAMD did not develop. All 21 patients with structural OCT imaging at the time of eAMD diagnosis demonstrated subretinal fluid, intraretinal cysts, or both consistent with exudation. Among 17 patients who underwent FA at eAMD diagnosis, 10 showed detectable macular neovascularization (MNV), all occult lesions. Development of eAMD did not have an appreciable impact on visual acuity, and all patients responded to antievascular endothelial growth factor (VEGF) therapy.
   Conclusions: Intravitreal pegcetacoplan slowed the rate of GA growth and was associated with an unexpected dose-dependent increased incidence of eAMD with no temporal clustering of onset. Exudative AMD seemed to be associated with baseline eAMD in the contralateral eye and a DLS, suggestive of nonexudative MNV, in the study eye. The safety profile of pegcetacoplan was acceptable to proceed to phase 3 studies without adjustments to enrollment criteria. (C) 2021 by the American Academy of Ophthalmology.
C1 [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Waheed, Nadia K.; Baumal, Caroline R.] Tufts Med Ctr, Boston, MA USA.
   [Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Ronca, Nick; Metlapally, Ravi; Ribeiro, Ramiro] Apellis Pharmaceut, Leominster, MA USA.
   [Slakter, Jason S.] NYU, Sch Med, New York, NY USA.
   [Staurenghi, Giovanni] Univ Milano Bicocca, Milan, Italy.
   [Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
   [Saroj, Namrata] All Eyes Consulting LLC, New York, NY USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston; Bascom
   Palmer Eye Institute; University of Miami; Tufts Medical Center;
   Cleveland Clinic Foundation; New York University; University of
   Milano-Bicocca
RP Wykoff, CC (通讯作者)，Houston Methodist Hosp, Blanton Eye Inst, Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM charleswyckoff@gmail.com
RI mones, jordi/CAJ-2963-2022; Staurenghi, Giovanni/K-4388-2017
OI mones, jordi/0000-0003-3685-2160; Staurenghi,
   Giovanni/0000-0002-2299-5251
FU Apellis Pharmaceuticals
FX Supported by Supported by Apellis Pharmaceuticals.
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Gune S, 2020, OPHTHALMOLOGY, V127, P523, DOI 10.1016/j.ophtha.2019.09.030
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P673, DOI 10.1016/j.oret.2020.01.019
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tarique AA, 2015, AM J RESP CELL MOL, V53, P676, DOI 10.1165/rcmb.2015-0012OC
   Wolf-Schnurrbusch UEK, 2009, RETINA-J RET VIT DIS, V29, P966, DOI 10.1097/IAE.0b013e3181a2f40f
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
NR 42
TC 13
Z9 13
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2021
VL 128
IS 9
BP 1325
EP 1336
DI 10.1016/j.ophtha.2021.02.025
EA AUG 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UE3LI
UT WOS:000687793000019
PM 33711380
OA hybrid
DA 2022-11-30
ER

PT J
AU Ornek, K
   Ornek, N
AF Ornek, Kemal
   Ornek, Nurgul
TI Visual recovery from optic atrophy following acute optic neuropathy in
   the fellow eye
SO JOURNAL OF RESEARCH IN MEDICAL SCIENCES
LA English
DT Article
DE Optic atrophy; optic neuropathy; visual recovery
ID IMPROVEMENT; ACUITY
AB The left eye of a 65-year-old male was blind due to optic atrophy and only seeing eye had also dry type age-related macular degeneration. An anterior ischemic optic neuropathy developed in the better seeing eye. Vision recovered in the blind eye in a short time after losing the better eye. Gaining some vision in a blind eye may be an adaptation of visual pathway in such patients.
C1 [Ornek, Kemal; Ornek, Nurgul] Kirikkale Univ, Dept Ophthalmol, Sch Med, Kirikkale, Turkey.
C3 Kirikkale University
RP Ornek, K (通讯作者)，1465 Sokak,16-31 Cukurambar, Ankara, Turkey.
EM kemalornek@hotmail.com
RI Örnek, Kemal/AFL-3613-2022; Örnek, Nurgül/V-1751-2018
OI Örnek, Nurgül/0000-0003-3068-1831
CR Balcer Laura J, 2002, Semin Ophthalmol, V17, P4, DOI 10.1076/soph.17.1.4.10287
   Bissell AJ, 2005, ACTA OPHTHALMOL SCAN, V83, P514, DOI 10.1111/j.1600-0420.2005.00441.x
   Buono LM, 2005, SURV OPHTHALMOL, V50, P15, DOI 10.1016/j.survophthal.2004.10.005
   Chiaretti A, 2011, NEUROREHAB NEURAL RE, V25, P386, DOI 10.1177/1545968310395601
   Fischer QS, 2007, LEARN MEMORY, V14, P277, DOI 10.1101/lm.392107
   Fronius M, 2009, KLIN MONATSBL AUGENH, V226, P634, DOI 10.1055/s-0028-1109374
   Gall C, 2010, NEUROREHABILITATION, V27, P335, DOI 10.3233/NRE-2010-0617
   LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936
   Mashima Y, 2002, JPN J OPHTHALMOL, V46, P660, DOI 10.1016/S0021-5155(02)00562-2
   Mathews Michaela Kunz, 2005, Curr Opin Ophthalmol, V16, P341, DOI 10.1097/01.icu.0000188361.52166.93
   Oyama H, 2012, NAGOYA J MED SCI, V74, P181
   Reed MJ, 1996, VISION RES, V36, P3011, DOI 10.1016/0042-6989(96)00019-3
   TROBE JD, 1980, ARCH OPHTHALMOL-CHIC, V98, P1040, DOI 10.1001/archopht.1980.01020031030003
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ISFAHAN UNIV MED SCIENCES
PI ISFAHAN
PA HEZARJERIB AVE, PO BOX 81745-319, ISFAHAN, 00000, IRAN
SN 1735-1995
J9 J RES MED SCI
JI J. Res. Med. Sci.
PD JUN
PY 2012
VL 17
IS 6
BP 582
EP 583
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 997QW
UT WOS:000308182200018
PM 23626640
DA 2022-11-30
ER

PT J
AU Sun, HP
   Lin, Y
   Pan, CW
AF Sun, Hong-Peng
   Lin, Yi
   Pan, Chen-Wei
TI Iris color and associated pathological ocular complications: a review of
   epidemiologic studies
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE iris color; eye diseases; epidemiology
ID AGE-RELATED MACULOPATHY; BLUE MOUNTAINS EYE; SENILE MACULAR
   DEGENERATION; BODY-MASS INDEX; RISK-FACTORS; VISUAL IMPAIRMENT; UVEAL
   MELANOMA; CHOROIDAL NEOVASCULARIZATION; CARDIOVASCULAR-DISEASE;
   ULTRAVIOLET-RADIATION
AB AIM: To elucidate the associations of iris color with major eye diseases.
   METHODS: A systematic search on Medline with coverage up to August 2013 was conducted. Assessment of the quality of studies based on their levels of evidence was in accordance with the Centre for Evidence-Based Medicine, Oxford, United Kingdom.
   RESULTS: A relationship between darker iris color and an increased risk of age -related cataract has been reported from cross-sectional studies and prospective cohort studies. There was no consistent evidence supporting a major role of iris color in the development or progression of age-related macular degeneration. The association of iris color with ocular uveal melanoma has been confirmed by a meta -analysis of observational studies previously. The etiologic synergism between light iris color and environmental exposure such as UV the exposure of UV radiation was found. There were no studies evaluating the refractive associations with iris color but there may be a possible link between iris color and myopia.
   CONCLUSION: Darker iris color is associated with an increased risk of cataract and a reduced risk of ocular uveal melanoma. The association of iris color with age-related macular degeneration is not confirmed. Ophthalmologists should be aware that the risk of ocular disorders appears to vary by differences in iris color.
C1 [Sun, Hong-Peng; Pan, Chen-Wei] Soochow Univ, Coll Med, Sch Publ Hlth, Suzhou 215123, Jiangsu, Peoples R China.
   [Lin, Yi] Univ Ghent, Fac Med & Hlth Sci, Dept Publ Hlth, B-9000 Ghent, Belgium.
   [Pan, Chen-Wei] Singapore Eye Res Inst, Singapore 168751, Singapore.
C3 Soochow University - China; Ghent University; National University of
   Singapore; Singapore National Eye Center
RP Pan, CW (通讯作者)，Soochow Univ, Coll Med, Sch Publ Hlth, 199 Ren Ai Rd, Suzhou 215123, Jiangsu, Peoples R China.
EM pcwonly@gmail.com
RI Pan, Chen-Wei/L-7174-2019; Pan, Chen-Wei/E-6205-2015
FU China Postdoctoral Science Foundation [2013M531405]
FX Supported by the China Postdoctoral Science Foundation (No.
   2013M531405).
CR Albert Daniel M, 2003, Trans Am Ophthalmol Soc, V101, P217
   Albert DM, 2003, T AM OPHTHAL SOC, V101, P221
   Arnarsson Arsall, 2002, Laeknabladid, V88, P727
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Cumming RG, 2000, AM J OPHTHALMOL, V130, P237, DOI 10.1016/S0002-9394(00)00479-7
   De Leeuw SM, 2001, J PHOTOCH PHOTOBIO B, V61, P106, DOI 10.1016/S1011-1344(01)00168-3
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Echebiri SI, 2010, MIDDLE EAST AFR J OP, V17, P303, DOI 10.4103/0974-9233.71592
   EIBERG H, 1987, CLIN GENET, V31, P186
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Frank RN, 2000, T AM OPHTHAL SOC, V98, P109
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gilmartin B, 2004, CLIN EXP OPHTHALMOL, V32, P305, DOI 10.1111/j.1442-9071.2004.00831.x
   Goiato MC, 2010, CONTACT LENS ANTERIO, V33, P215, DOI 10.1016/j.clae.2010.04.004
   Guenel P, 2001, CANCER CAUSE CONTROL, V12, P451, DOI 10.1023/A:1011271420974
   Hashemi H, 2012, EYE, V26, P1071, DOI 10.1038/eye.2012.94
   Hernandez Camila M., 2010, CATARACTS CAUSES SYM
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   HU DN, 1995, INVEST OPHTH VIS SCI, V36, P931
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Jonas JB, 2006, CLIN EXP OPHTHALMOL, V34, P654, DOI 10.1111/j.1442-9071.2006.01310.x
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2011, AM J OPHTHALMOL, V152, P153, DOI 10.1016/j.ajo.2011.02.016
   LANGLEY RK, 1960, ARCH OPHTHALMOL-CHIC, V63, P473
   Leske MC, 2002, OPHTHALMOLOGY, V109, P1303, DOI 10.1016/S0161-6420(02)01094-1
   Li WJ, 2000, CANCER RES, V60, P3757
   Matta JL, 2010, OCHSNER J, V10, P75
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Meng WH, 2012, MED HYPOTHESES, V78, P778, DOI 10.1016/j.mehy.2012.03.005
   MENON IA, 1992, J OCUL PHARMACOL, V8, P35, DOI 10.1089/jop.1992.8.35
   Mitchell R, 2003, AM J OPHTHALMOL, V135, P384, DOI 10.1016/S0002-9394(02)01967-0
   Morgan I, 2005, PROG RETIN EYE RES, V24, P1, DOI 10.1016/j.preteyeres.2004.06.004
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   MOSS SE, 1987, OPHTHALMOLOGY, V94, P1226
   Diaz YM, 2009, EUR J OPHTHALMOL, V19, P686, DOI 10.1177/112067210901900427
   Nicolas CM, 2003, CLIN EXP OPHTHALMOL, V31, P465, DOI 10.1046/j.1442-9071.2003.00711.x
   OKUNO T, 1991, ANN OCCUP HYG, V35, P1, DOI 10.1093/annhyg/35.1.1
   Pan CW, 2013, AM J OPHTHALMOL, V156, P1021, DOI 10.1016/j.ajo.2013.06.005
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Pan CW, 2012, OPHTHAL PHYSL OPT, V32, P3, DOI 10.1111/j.1475-1313.2011.00884.x
   PITTS DG, 1981, A GRAEF ARCH KLIN EX, V217, P285, DOI 10.1007/BF00429289
   Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210
   Sainz-Gomez C, 2010, EUR J OPHTHALMOL, V20, P442, DOI 10.1177/112067211002000228
   Salomao SR, 2009, AN ACAD BRAS CIENC, V81, P539, DOI 10.1590/S0001-37652009000300017
   SANDBERG MA, 1994, INVEST OPHTH VIS SCI, V35, P2734
   Saw Seang-Mei, 2003, Clin Exp Optom, V86, P289
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schmidt-Pokrzywniak A, 2009, OPHTHALMOLOGY, V116, P340, DOI 10.1016/j.ophtha.2008.09.040
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Stang A, 2005, INT J CANCER, V114, P114, DOI 10.1002/ijc.20690
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vannas AE, 2003, ACTA OPHTHALMOL SCAN, V81, P588, DOI 10.1046/j.1395-3907.2003.0151.x
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   Virgili G, 2007, OPHTHALMOLOGY, V114, P2309, DOI 10.1016/j.ophtha.2007.01.032
   Wakamatsu K, 2008, PIGM CELL MELANOMA R, V21, P97, DOI 10.1111/j.1755-148X.2007.00415.x
   Wang LH, 2013, INVEST OPHTH VIS SCI, V54, P4117, DOI 10.1167/iovs.13-11911
   Weis E, 2006, ARCH OPHTHALMOL-CHIC, V124, P54, DOI 10.1001/archopht.124.1.54
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Younan C, 2002, AM J OPHTHALMOL, V134, P273, DOI 10.1016/S0002-9394(02)01496-4
   Young R. W., 1991, AGE RELATED CATARACT
   Young TL, 2007, ARCH OPHTHALMOL-CHIC, V125, P38, DOI 10.1001/archopht.125.1.38
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
NR 80
TC 12
Z9 13
U1 0
U2 19
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT 18
PY 2014
VL 7
IS 5
BP 872
EP 878
DI 10.3980/j.issn.2222-3959.2014.05.25
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR0PD
UT WOS:000343272900025
PM 25349810
DA 2022-11-30
ER

PT J
AU Rousso, LA
   Rodman, JA
   Sutton, B
   Shechtman, DL
AF Rousso, Leticia A.
   Rodman, Julie A.
   Sutton, Brad
   Shechtman, Diana L.
TI Outer Retinal Tubulation: A Case Series
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE outer retinal tabulation; retinal pigment epithelium; age-related
   macular degeneration; central areolar choroidal dystrophy; cystoid
   macular edema
AB Purpose The advent of spectral domain optical coherence tomography has led to superb imaging capabilities in addition to enhanced visualization of the retinal layers. Such advancements have led to the identification of a variety of new retinal conditions, including outer retinal tubulations (ORTs). ORTs are ovoid hyporeflective spaces located in the outer retina. The pathogenesis is unclear but seems to involve sublethal injury to the photoreceptors leading to a compensatory reorganization of the photoreceptor layer with the neighboring ellipsoid zone resulting in a hyperreflective border surrounding a central lumen. Most ORTs have been linked to wet age-related macular degeneration; however, these peculiar structures are now seen in a myriad of retinal disorders.
   Case Reports Our cases will highlight the wide variety of clinical presentations associated with outer retinal tubulations. The clinical presentations include two cases of wet age-related macular degeneration, a case of presumed ocular histoplasmosis syndrome, a case of central areolar choroidal dystrophy, and a case of pathological myopia.
   Conclusions By correctly differentiating outer retinal tubulations from other masqueraders, unnecessary referrals and interventions can be minimized. Understanding the various disease entities associated with outer retinal tubulation could give further insight into the mechanism and formation of these structures.
C1 [Rousso, Leticia A.; Rodman, Julie A.; Sutton, Brad; Shechtman, Diana L.] Nova Southeastern Univ, Coll Optometry, 3200 South Univ Dr, Ft Lauderdale, FL 33328 USA.
   [Sutton, Brad] Indianapolis Eye Care Ctr, Indianapolis, IN USA.
C3 Nova Southeastern University
RP Rousso, LA (通讯作者)，Nova Southeastern Univ, Coll Optometry, 3200 South Univ Dr, Ft Lauderdale, FL 33328 USA.
EM Lr944@nova.edu
CR Adatia FA, 2015, SURV OPHTHALMOL, V60, P204, DOI 10.1016/j.survophthal.2014.10.002
   Dhingra N, 2010, INDIAN J OPHTHALMOL, V58, P3, DOI 10.4103/0301-4738.58467
   Espina M, 2016, BRIT J OPHTHALMOL, V100, P819, DOI 10.1136/bjophthalmol-2015-307141
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Rodman J Black G Woods A, 2013, J OPTOM, V6, P114
   Weber ML, 2016, DEV OPHTHALMOL, V55, P167, DOI 10.1159/000431194
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 9
TC 0
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAR
PY 2017
VL 94
IS 3
BP 423
EP 431
DI 10.1097/OPX.0000000000001056
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM9KU
UT WOS:000395631200018
PM 28225373
DA 2022-11-30
ER

PT J
AU Georgiannakis, A
   Burgoyne, T
   Lueck, K
   Futter, C
   Greenwood, J
   Moss, SE
AF Georgiannakis, Apostolos
   Burgoyne, Tom
   Lueck, Katharina
   Futter, Clare
   Greenwood, John
   Moss, Stephen E.
TI Retinal Pigment Epithelial Cells Mitigate the Effects of Complement
   Attack by Endocytosis of C5b-9
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MEMBRANE-ATTACK; MACULAR-DEGENERATION; HIGH-RISK;
   MITOCHONDRIAL MORPHOLOGY; POTENTIAL ROLE; ACTIVATION; COMPONENT;
   PROTEINS; REMOVAL
AB Retinal pigment epithelial (RPE) cell death is a hallmark of age-related macular degeneration. The alternative pathway of complement activation is strongly implicated in RPE cell dysfunction and loss in age-related macular degeneration; therefore, it is critical that RPE cells use molecular strategies to mitigate the potentially harmful effects of complement attack. We show that the terminal complement complex C5b-9 assembles rapidly on the basal surface of cultured primary porcine RPE cells but disappears over 48 h without any discernable adverse effects on the cells. However, in the presence of the dynamin inhibitor dynasore, C5b-9 was almost completely retained at the cell surface, suggesting that, under normal circumstances, it is eliminated via the endocytic pathway. In support of this idea, we observed that C5b-9 colocalizes with the early endosome marker EEA1 and that, in the presence of protease inhibitors, it can be detected in lysosomes. Preventing the endocytosis of C5b-9 by RPE cells led to structural defects in mitochondrial morphology consistent with cell stress. We conclude that RPE cells use the endocytic pathway to prevent the accumulation of C5b-9 on the cell surface and that processing and destruction of C5b-9 by this route are essential for RPE cell survival.
C1 [Georgiannakis, Apostolos; Burgoyne, Tom; Lueck, Katharina; Futter, Clare; Greenwood, John; Moss, Stephen E.] UCL, Inst Ophthalmol, Dept Cell Biol, London EC1V9EL, England.
C3 University of London; University College London
RP Moss, SE (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V9EL, England.
EM s.moss@ucl.ac.uk
RI Burgoyne, Thomas/HCI-9054-2022
OI Burgoyne, Thomas/0000-0002-8428-720X; Futter, Clare/0000-0001-5559-9389;
   Greenwood, John/0000-0003-4496-2984
FU Biotechnology and Biological Sciences Research Council; Wellcome Trust
   [093445]; Fight for Sight Ph.D. studentship award; Biotechnology and
   Biological Sciences Research Council [BB/I019707/1] Funding Source:
   researchfish; Medical Research Council [MR/M02282X/1] Funding Source:
   researchfish; Fight for Sight [1833/84] Funding Source: researchfish;
   BBSRC [BB/I019707/1] Funding Source: UKRI; MRC [MR/M02282X/1] Funding
   Source: UKRI
FX The work was supported by grants from the Biotechnology and Biological
   Sciences Research Council and The Wellcome Trust (093445) and by a Fight
   for Sight Ph.D. studentship award (to A.G.)
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Badea TD, 2003, J NEUROIMMUNOL, V142, P58, DOI 10.1016/S0165-5728(03)00261-3
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   BHAKDI S, 1986, J IMMUNOL, V136, P2999
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Boustany NN, 2002, BIOPHYS J, V83, P1691, DOI 10.1016/S0006-3495(02)73937-4
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cybulsky AV, 2005, AM J PHYSIOL-RENAL, V289, pF593, DOI 10.1152/ajprenal.00066.2005
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Eden ER, 2010, NAT CELL BIOL, V12, P267, DOI 10.1038/ncb2026
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEARON DT, 1975, J IMMUNOL, V115, P1357
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GUPTA AK, 1984, BRIT J OPHTHALMOL, V68, P350, DOI 10.1136/bjo.68.5.350
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAMMER CH, 1981, J BIOL CHEM, V256, P3995
   Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   HU VW, 1981, J IMMUNOL, V127, P380
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   LACHMANN PJ, 1970, IMMUNOLOGY, V19, P983
   Lakkaraju A, 2014, ADV EXP MED BIOL, V801, P267, DOI 10.1007/978-1-4614-3209-8_34
   Li WB, 2010, MED SCI MONITOR, V16, pBR17
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lueck K, 2012, INVEST OPHTH VIS SCI, V53, P1406, DOI 10.1167/iovs.11-8889
   Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002
   MANNI JA, 1969, J EXP MED, V130, P1145, DOI 10.1084/jem.130.5.1145
   Martin-Martin N, 2012, INT J BIOCHEM CELL B, V44, P178, DOI 10.1016/j.biocel.2011.10.014
   McElnea EM, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-153
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   MORGAN BP, 1987, J IMMUNOL, V138, P246
   Moskovich O, 2012, J BIOL CHEM, V287, P19904, DOI 10.1074/jbc.M111.333039
   Mouawad F, 2014, J BIOL CHEM, V289, P4206, DOI 10.1074/jbc.M113.506816
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Naughton MA, 1996, EUR J IMMUNOL, V26, P2108, DOI 10.1002/eji.1830260922
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Pilzer D, 2005, SPRINGER SEMIN IMMUN, V27, P375, DOI 10.1007/s00281-005-0004-1
   Pilzer D, 2005, INT IMMUNOL, V17, P1239, DOI 10.1093/intimm/dxh300
   PODACK ER, 1982, P NATL ACAD SCI-BIOL, V79, P574, DOI 10.1073/pnas.79.2.574
   Rawal N, 1998, J BIOL CHEM, V273, P16828, DOI 10.1074/jbc.273.27.16828
   Rohrer B, 2014, ADV EXP MED BIOL, V801, P221, DOI 10.1007/978-1-4614-3209-8_29
   Rus HG, 1996, J IMMUNOL, V156, P4892
   Saleem A, 2015, AM J PHYSIOL-CELL PH, V308, pC319, DOI 10.1152/ajpcell.00253.2014
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schreck SF, 1998, J IMMUNOL, V161, P311
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   SJOHOLM AG, 1975, SCAND J IMMUNOL, V4, P25, DOI 10.1111/j.1365-3083.1975.tb02596.x
   Sonnen Andreas F-P, 2014, Subcell Biochem, V80, P83, DOI 10.1007/978-94-017-8881-6_6
   STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472
   Tegla CA, 2011, IMMUNOL RES, V51, P45, DOI 10.1007/s12026-011-8239-5
   Terman A, 2001, REDOX REP, V6, P15, DOI 10.1179/135100001101535996
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tooze SA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018358
   Tradewell ML, 2011, NEUROBIOL DIS, V42, P265, DOI 10.1016/j.nbd.2011.01.016
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Versey J M, 1975, J Clin Pathol Suppl (Assoc Clin Pathol), V6, P38
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 74
TC 28
Z9 28
U1 1
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 2015
VL 195
IS 7
BP 3382
EP 3389
DI 10.4049/jimmunol.1500937
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA CS0ID
UT WOS:000361741200044
PM 26324770
OA Green Accepted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Nochioka, K
   Okuda, H
   Tatsumi, K
   Morita, S
   Ogata, N
   Wanaka, A
AF Nochioka, Katsunori
   Okuda, Hiroaki
   Tatsumi, Kouko
   Morita, Shoko
   Ogata, Nahoko
   Wanaka, Akio
TI Hedgehog Signaling Components Are Expressed in Choroidal
   Neovascularization in Laser-induced Retinal Lesion
SO ACTA HISTOCHEMICA ET CYTOCHEMICA
LA English
DT Article
DE sonic hedgehog; retina; mouse; choroidal neovascularization
ID SONIC HEDGEHOG; DEPENDENT ANGIOGENESIS; ENDOTHELIAL-CELLS; GENE-THERAPY;
   AGE; INHIBITION; RECEPTOR; VEGF; BOC; PROTEINS
AB Choroidal neovascularization is one of the major pathological changes in age-related macular degeneration, which causes devastating blindness in the elderly population. The molecular mechanism of choroidal neovascularization has been under extensive investigation, but is still an open question. We focused on sonic hedgehog signaling, which is implicated in angiogenesis in various organs. Laser-induced injuries to the mouse retina were made to cause choroidal neovascularization. We examined gene expression of sonic hedgehog, its receptors (patched1, smoothened, cell adhesion molecule down-regulated by oncogenes (Cdon) and biregional Cdon-binding protein (Boc)) and downstream transcription factors (Gli1-3) using real-time RT-PCR. At seven days after injury, mRNAs for Patched1 and Gli1 were upregulated in response to injury, but displayed no upregulation in control retinas. Immunohistochemistry revealed that Patched1 and Gli1 proteins were localized to CD31-positive endothelial cells that cluster between the wounded retina and the pigment epithelium layer. Treatment with the hedgehog signaling inhibitor cyclopamine did not significantly decrease the size of the neovascularization areas, but the hedgehog agonist purmorphamine made the areas significantly larger than those in untreated retina. These results suggest that the hedgehog-signaling cascade may be a therapeutic target for age-related macular degeneration.
C1 [Nochioka, Katsunori; Ogata, Nahoko] Nara Med Univ, Fac Med, Dept Ophthalmol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
   [Okuda, Hiroaki; Tatsumi, Kouko; Morita, Shoko; Wanaka, Akio] Nara Med Univ, Fac Med, Dept Anat & Neurosci, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
C3 Nara Medical University; Nara Medical University
RP Wanaka, A (通讯作者)，Nara Med Univ, Fac Med, Dept Anat & Neurosci, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
EM akiow@naramed-u.ac.jp
RI Wanaka, Akio/ABE-4671-2020; Okuda, Hiroaki/E-9418-2018; Okuda,
   Hiroaki/S-4959-2019; Wanaka, Akio/GPW-8926-2022; Wanaka,
   Akio/AAC-9754-2019
OI Okuda, Hiroaki/0000-0002-6252-9634; Okuda, Hiroaki/0000-0002-6252-9634;
   Wanaka, Akio/0000-0001-9951-9862; Takemura, Shoko/0000-0003-1872-4050
FU Japan Society for the Promotion of Science [26293039, 15K14354]; Takeda
   Science Foundation; Grants-in-Aid for Scientific Research [15K10843]
   Funding Source: KAKEN
FX This work was supported in part by the Japan Society for the Promotion
   of Science (Grant Numbers 26293039 and 15K14354 to AW), and by a
   research grant from the Takeda Science Foundation to AW. We wish to
   thank Dr. Ian Smith (Elite Scientific Editing, UK) for assistance in
   manuscript editing.
CR Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Asai J, 2006, CIRCULATION, V113, P2413, DOI 10.1161/CIRCULATIONAHA.105.603167
   Askou AL, 2014, ACTA OPHTHALMOL, V92, P1, DOI 10.1111/aos.12452
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chung YT, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0084980, 10.1371/journal.pone.0070128]
   Cohen MM, 2010, AM J MED GENET A, V152A, P1875, DOI 10.1002/ajmg.a.32909
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dot C, 2009, MOL VIS, V15, P670
   Fuchs S, 2012, VITAM HORM, V88, P491, DOI 10.1016/B978-0-12-394622-5.00022-5
   Fujii T, 2010, IN VITRO CELL DEV-AN, V46, P487, DOI 10.1007/s11626-009-9270-x
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   He QW, 2013, MOL NEUROBIOL, V47, P976, DOI 10.1007/s12035-013-8396-8
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Izzi L, 2011, DEV CELL, V20, P788, DOI 10.1016/j.devcel.2011.04.017
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kang Jong-Sun, 2007, Sci STKE, V2007, ppe50, DOI 10.1126/stke.4032007pe50
   Kang S, 2013, EXP EYE RES, V112, P125, DOI 10.1016/j.exer.2013.05.006
   Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444
   Kavran JM, 2010, J BIOL CHEM, V285, P24584, DOI 10.1074/jbc.M110.131680
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Lee E, 2010, INVEST OPHTH VIS SCI, V51, P3666, DOI 10.1167/iovs.09-3802
   Liu J, 2013, OPHTHALMOLOGICA, V230, P55, DOI 10.1159/000351660
   Mackie AR, 2012, CIRC RES, V111, P312, DOI 10.1161/CIRCRESAHA.112.266015
   Martinelli DC, 2007, GENE DEV, V21, P1231, DOI 10.1101/gad.1546307
   Morita S, 2015, CELL TISSUE RES, V359, P865, DOI 10.1007/s00441-014-2080-9
   Nagase M, 2006, MICROVASC RES, V71, P85, DOI 10.1016/j.mvr.2005.11.006
   Nagase T, 2005, GENES CELLS, V10, P595, DOI 10.1111/j.1365-2443.2005.00861.x
   Newton Herbert B, 2004, Expert Rev Anticancer Ther, V4, P105, DOI 10.1586/14737140.4.1.105
   Okada A, 2006, NATURE, V444, P369, DOI 10.1038/nature05246
   Olsen CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-43
   Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083
   Renault MA, 2010, J MOL CELL CARDIOL, V49, P490, DOI 10.1016/j.yjmcc.2010.05.003
   Sengupta N, 2010, INVEST OPHTH VIS SCI, V51, P2697, DOI 10.1167/iovs.09-4137
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Surace EM, 2006, MOL THER, V13, P573, DOI 10.1016/j.ymthe.2005.10.010
   Tatsumi K, 2008, J NEUROSCI RES, V86, P3494, DOI 10.1002/jnr.21862
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 47
TC 5
Z9 8
U1 1
U2 3
PU JAPAN SOC HISTOCHEMISTRY & CYTOCHEMISTRY
PI KYOTO
PA C/O NAKANISHI PRINTING CO LTD, SHIMODACHIURI-OGAWA, KAMIGYO-KU, KYOTO,
   602-8048, JAPAN
SN 0044-5991
EI 1347-5800
J9 ACTA HISTOCHEM CYTOC
JI Acta Histochem. Cytochem.
PY 2016
VL 49
IS 2
BP 67
EP 74
DI 10.1267/ahc.15036
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DO2QC
UT WOS:000377623900002
PM 27239075
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Degenring, R
   Vossmerbauemer, U
   Kamppeter, B
AF Jonas, JB
   Degenring, R
   Vossmerbauemer, U
   Kamppeter, B
TI Frequency of cataract surgery after intravitreal injection of
   high-dosage triamcinolone acetonide
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE intravitreal triamcinolone acetonide; cataract; age-related macular
   degeneration; diabetic macular edema; branch retinal vein occlusion
ID INTRAOCULAR-PRESSURE; SYSTEM
AB PURPOSE. To evaluate the frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide in elderly patients.
   METHODS. This clinical interventional case series study included 144 phakic eyes that consecutively received an intravitreal injection of about 20 mg triamcinolone acetonide for diffuse diabetic macular edema (n=42 eyes), exudative age-related macular degeneration (n=98), and branch retinal vein occlusion (n=4). Mean age was 72.3 +/- 8.9 years. Mean follow-up was 11.0 +/- 6.8 months (median, 8.8 months; range, 3 to 35.5 months). Reinjections were carried out in 12 (8.3%) eyes.
   RESULTS. Cataract surgery was performed in 20 (13.9%) eyes 17.4 +/- 9.1 months (median, 12.7 months; range, 8.0 to 35.5 months) after the first intravitreal injection. Out of the 20 eyes undergoing cataract surgery, 19 (95%) eyes had received one intravitreal injection, and 1 (5%) eye had received two previous injections.
   CONCLUSIONS. In the elderly population of patients with exudative age-related macular degeneration, diffuse diabetic macular edema, or branch retinal vein occlusion, intravitreal high-dosage injection of triamcinolone acetonide leads to clinically significant cataract with eventual cataract surgery in about 15% to 20% of eyes within about 1 year after the intravitreal injection.
C1 Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   Univ Heidelberg, Hosp Eye, Med Fac Mannheim, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR Benz MS, 2003, ARCH OPHTHALMOL-CHIC, V121, P271
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2004, EYE, V18, P361, DOI 10.1038/sj.eye.6700654
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   MARAINI G, 1989, OPHTHALMOLOGY, V96, P611
NR 10
TC 45
Z9 48
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2005
VL 15
IS 4
BP 462
EP 464
DI 10.1177/112067210501500407
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 945OD
UT WOS:000230510900007
PM 16001378
DA 2022-11-30
ER

PT J
AU Lu, LL
   Oveson, BC
   Jo, YJ
   Lauer, TW
   Usui, S
   Komeima, K
   Xie, B
   Campochiaro, PA
AF Lu, Lili
   Oveson, Brain C.
   Jo, Young -Joon
   Lauer, Thomas W.
   Usui, Shinichi
   Komeima, Keiichi
   Xie, Bing
   Campochiaro, Peter A.
TI Increased Expression of Glutathione Peroxidase 4 Strongly Protects
   Retina from Oxidative Damage
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
ID CONE CELL-DEATH
AB Oxidative damage contributes to cone cell death in retinitis pigmentosa and death of rods, cones, and retinal pigmented epithelial (RPE) cells in age-related macular degeneration. In this study, we explored the strategy of overexpressing components of the endogenous antioxidant defense system to combat oxidative damage in RPE cells and retina. In transfected cultured RPE cells with increased expression of superoxide dismutase1 (SOD1) or SOD2, there was increased constitutive and stress-induced oxidative damage measured by the level of carbonyl adducts on proteins. In contrast, RPE cells with increased expression of glutathione peroxidase 1 (Gpx1) or Gpx4 did not show an increase in constitutive oxidative damage. An increase in Gpx4, and to a lesser extent Gpx1, reduced oxidative stress-induced RPE cell damage. Co-expression of Gpx4 with SOD1 or 2 partially reversed the deleterious effects of the SODs. Transgenic mice with inducible expression of Gpx4 in photoreceptors were generated, and in three models of oxidative damage-induced retinal degeneration, increased expression of Gpx4 provided strong protection of retinal structure and function. These data suggest that gene therapy approaches to augment the activity of Gpx4 in the retina and RPE should be considered in patients with retinitis pigmentosa or age-related macular degeneration. Antioxid. Redox Signal. 11, 715-724.
C1 [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
OI Xie, Bing/0000-0003-2335-5966
FU NEI [EY05951, P30EY1765]; NATIONAL EYE INSTITUTE [R01EY005951,
   P30EY001765] Funding Source: NIH RePORTER
FX This research is supported by EY05951 and core grant P30EY1765 from the
   NEI and Dr. and Mrs. William Lake. PAC is the George S. and Dolores Dore
   Eccles Professor of Ophthalmology.
CR Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4
   Chang MA, 2000, INVEST OPHTH VIS SCI, V41, P4281
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   Davies SMK, 2001, FREE RADICAL BIO MED, V31, P181, DOI 10.1016/S0891-5849(01)00576-7
   Dong A, 2006, J CELL PHYSIOL, V208, P516, DOI 10.1002/jcp.20683
   Girotti AW, 1998, J LIPID RES, V39, P1529
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7
   Yu DY, 2000, INVEST OPHTH VIS SCI, V41, P3999
NR 16
TC 67
Z9 68
U1 2
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD APR
PY 2009
VL 11
IS 4
BP 715
EP 724
DI 10.1089/ars.2008.2171
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 411TH
UT WOS:000263673000002
PM 18823256
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Cryan, LM
   O'Brien, C
AF Cryan, Lorna M.
   O'Brien, Colm
TI Proteomics as a research tool in clinical and experimental ophthalmology
SO PROTEOMICS CLINICAL APPLICATIONS
LA English
DT Review
DE age-related macular degeneration; glaucoma; retinopathy; tears; uveal
   melanoma
ID RETINAL-PIGMENT EPITHELIUM; IGG ANTIBODY PATTERNS; NORMAL-TENSION
   GLAUCOMA; HUMAN TEAR FLUID; COLLAGEN TYPE-IX; MACULAR DEGENERATION;
   AQUEOUS-HUMOR; UVEAL MELANOMA; MASS-SPECTROMETRY; PSEUDOEXFOLIATION
   SYNDROME
AB It is estimated that 37 million people worldwide suffer from blindness and 124 million people have impaired vision. While the relatively recently developed therapies, antivascular endothelial growth factor inhibitors for the treatment of age-related macular degeneration, and prostaglandin analogues for the treatment of glaucoma are beneficial for some patients, there are many individuals with sight-threatening diseases for whom no effective pharmacological therapy is available. For many of these diseases, the molecular mechanisms remain to be comprehensively elucidated, thus precluding the design of successful therapies against specific pathological targets. The current review summarises recent attempts to elucidate molecular mechanisms of ocular diseases, including diabetic retinal disease, age-related macular degeneration and inherited blindness using proteomic methodologies. A novel hypothesis can be generated from global protein expression analysis of disease tissue, which can then be addressed with cellular and in vivo functional studies. For example, the identification of extracellular carbonic anhydrase from the vitreous of diabetic retinopathy patients using MS based proteomics led to the elucidation of a new pathway involved in intraretinal edema, which could be inhibited by a number of agents targeting different proteins in this pathway in relevant animal models. The potential of protein biomarkers for diagnosis and the identification of novel disease mechanisms are also discussed.
C1 [Cryan, Lorna M.; O'Brien, Colm] Univ Coll Dublin, UCD Conway Inst, Sch Med & Med Sci, Dublin 4, Ireland.
   [O'Brien, Colm] Mater Misericordiae Univ Hosp, Dept Ophthalmol, Dublin 7, Ireland.
C3 University College Dublin; Mater Misericordiae University Hospital;
   University College Dublin
RP Cryan, LM (通讯作者)，Univ Coll Dublin, UCD Conway Inst, Sch Med & Med Sci, Dublin 4, Ireland.
EM lorna.cryan@ucd.ie
OI Cryan, Lorna/0000-0002-2604-7996
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Aroca-Aguilar JD, 2005, J BIOL CHEM, V280, P21043, DOI 10.1074/jbc.M501340200
   Assouti M, 2006, BBA-MOL BASIS DIS, V1762, P54, DOI 10.1016/j.bbadis.2005.09.005
   Azarian SM, 2006, J PROTEOME RES, V5, P521, DOI 10.1021/pr0502323
   Bhattacharya SK, 2005, J BIOL CHEM, V280, P6080, DOI 10.1074/jbc.M411233200
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cooks RG, 2006, SCIENCE, V311, P1566, DOI 10.1126/science.1119426
   Cornett DS, 2007, NAT METHODS, V4, P828, DOI 10.1038/NMETH1094
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Souza GA, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r72
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   FULLARD RJ, 1991, INVEST OPHTH VIS SCI, V32, P2290
   Funding M, 2005, ACTA OPHTHALMOL SCAN, V83, P31, DOI 10.1111/j.1600-0420.2005.00381.x
   Fung KYC, 2004, PROTEOMICS, V4, P3953, DOI 10.1002/pmic.200300849
   Gachon AMF, 1998, BRIT J OPHTHALMOL, V82, P453, DOI 10.1136/bjo.82.4.453
   Gao BB, 2007, NAT MED, V13, P181, DOI 10.1038/nm1534
   Garcia-Ramirez M, 2007, DIABETOLOGIA, V50, P1294, DOI 10.1007/s00125-007-0627-y
   Gartaganis SP, 2004, CURR EYE RES, V28, P5, DOI 10.1076/ceyr.28.1.5.23490
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Golovleva I, 2003, J BIOL CHEM, V278, P12397, DOI 10.1074/jbc.M207300200
   GRAGOUDAS ES, 1991, OPHTHALMOLOGY, V98, P383
   Grus F H, 2002, BMC Ophthalmol, V2, P4, DOI 10.1186/1471-2415-2-4
   Grus FH, 2006, INVEST OPHTH VIS SCI, V47, P968, DOI 10.1167/iovs.05-0685
   Grus FH, 2004, MOL VIS, V10, P132
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Ham BM, 2007, ANAL BIOANAL CHEM, V387, P889, DOI 10.1007/s00216-006-1018-9
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   JANSSEN PT, 1983, INVEST OPHTH VIS SCI, V24, P623
   Joachim SC, 2007, CURR EYE RES, V32, P501, DOI 10.1080/02713680701375183
   Joachim SC, 2007, MOL VIS, V13, P1573
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   KATH R, 1993, CANCER, V72, P2219, DOI 10.1002/1097-0142(19931001)72:7<2219::AID-CNCR2820720725>3.0.CO;2-J
   Khanna H, 2005, J BIOL CHEM, V280, P33580, DOI 10.1074/jbc.M505827200
   Konstas AGP, 2006, EXP EYE RES, V82, P319, DOI 10.1016/j.exer.2005.07.004
   Kremmer S, 2001, CLIN EXP IMMUNOL, V125, P211, DOI 10.1046/j.1365-2249.2001.01578.x
   KUCHLE M, 1994, INVEST OPHTH VIS SCI, V35, P748
   Leonardi A, 2006, CLIN EXP ALLERGY, V36, P777, DOI 10.1111/j.1365-2222.2006.02499.x
   Li N, 2005, J PROTEOME RES, V4, P2052, DOI 10.1021/pr0501970
   Li YX, 2006, BIOCHEM BIOPH RES CO, V339, P797, DOI 10.1016/j.bbrc.2005.11.082
   Lin HJ, 2007, J OCUL PHARMACOL TH, V23, P152, DOI 10.1089/jop.2006.0118
   MACKIE IA, 1984, BRIT J OPHTHALMOL, V68, P321, DOI 10.1136/bjo.68.5.321
   Malvitte L, 2007, BRIT J OPHTHALMOL, V91, P29, DOI 10.1136/bjo.2006.101485
   Missotten GS, 2003, MELANOMA RES, V13, P627, DOI 10.1097/00008390-200312000-00013
   Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264
   Mrugacz M, 2006, J INTERF CYTOK RES, V26, P71, DOI 10.1089/jir.2006.26.71
   Mudhar HS, 2004, HISTOPATHOLOGY, V45, P1, DOI 10.1111/j.1365-2559.2004.01874.x
   Nakajima E, 2006, INVEST OPHTH VIS SCI, V47, P5469, DOI 10.1167/iovs.06-0567
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Nawrot M, 2004, INVEST OPHTH VIS SCI, V45, P393, DOI 10.1167/iovs.03-0989
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Ouchi M, 2005, EXP EYE RES, V81, P176, DOI 10.1016/j.exer.2005.01.020
   Pardo M, 2007, J PROTEOME RES, V6, P2802, DOI 10.1021/pr070021t
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Pflugfelder SC, 2000, INVEST OPHTH VIS SCI, V41, P1316
   Picht G, 2001, GRAEF ARCH CLIN EXP, V239, P199, DOI 10.1007/s004170000252
   Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468
   Quin GJ, 2007, PROTEOMICS, V7, P2636, DOI 10.1002/pmic.200600486
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reyes MR, 1998, J OCUL PHARMACOL TH, V14, P229, DOI 10.1089/jop.1998.14.229
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Rohde E, 1998, ELECTROPHORESIS, V19, P2361, DOI 10.1002/elps.1150191317
   Sack RA, 2005, INVEST OPHTH VIS SCI, V46, P1228, DOI 10.1167/iovs.04-0760
   SACK RA, 1992, INVEST OPHTH VIS SCI, V33, P626
   Sakata M, 1997, CURR EYE RES, V16, P810, DOI 10.1076/ceyr.16.8.810.8992
   SALASAUVERT R, 1995, J CHROMATOGR A, V706, P183, DOI 10.1016/0021-9673(95)00083-Y
   Schlotzer-Schrehardt U, 2001, EXP EYE RES, V73, P765, DOI 10.1006/exer.2001.1084
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Shoji J, 2006, JPN J OPHTHALMOL, V50, P195, DOI 10.1007/s10384-005-0319-4
   Shu X, 2005, HUM MOL GENET, V14, P1183, DOI 10.1093/hmg/ddi129
   Steely HT, 2006, MOL VIS, V12, P372
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tezel G, 2005, INVEST OPHTH VIS SCI, V46, P3177, DOI 10.1167/iovs.05-0208
   Tomosugi N, 2005, J PROTEOME RES, V4, P820, DOI 10.1021/pr0497576
   Tsai PS, 2006, BRIT J OPHTHALMOL, V90, P372, DOI 10.1136/bjo.2005.080846
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vazques J, 1996, J NEUROIMMUNOL, V68, P39
   Virgili G, 2007, OPHTHALMOLOGY, V114, P2309, DOI 10.1016/j.ophtha.2007.01.032
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Warburton S, 2005, MOL VIS, V11, P1122
   Warburton S, 2007, MOL VIS, V13, P318
   Whitlock NA, 2005, INVEST OPHTH VIS SCI, V46, P1085, DOI 10.1167/iovs.04-0042
   Xi QS, 2005, INVEST OPHTH VIS SCI, V46, P4754, DOI 10.1167/iovs.05-0693
   YUN AJ, 1989, INVEST OPHTH VIS SCI, V30, P2012
   Zamora DO, 2007, MOL VIS, V13, P2058
   Zhao HC, 2001, CORNEA, V20, P873, DOI 10.1097/00003226-200111000-00019
   Zhao XJ, 2004, INVEST OPHTH VIS SCI, V45, P4023, DOI 10.1167/iovs.04-0535
   Zhou L, 2004, J PROTEOME RES, V3, P410, DOI 10.1021/pr034065n
   Zuidervaart W, 2006, INVEST OPHTH VIS SCI, V47, P786, DOI 10.1167/iovs.05-0314
NR 91
TC 14
Z9 15
U1 3
U2 15
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1862-8346
J9 PROTEOM CLIN APPL
JI Proteom. Clin. Appl.
PD MAY
PY 2008
VL 2
IS 5
BP 762
EP 775
DI 10.1002/prca.200780094
PG 14
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 305FS
UT WOS:000256163800012
PM 21136873
DA 2022-11-30
ER

PT J
AU Wang, S
   Xu, L
   Jonas, JB
   Wang, YX
   You, QS
   Yang, H
AF Wang, Shuang
   Xu, Liang
   Jonas, Jost B.
   Wang, Ya Xing
   You, Qi Sheng
   Yang, Hua
TI Dyslipidemia and Eye Diseases in the Adult Chinese Population: The
   Beijing Eye Study
SO PLOS ONE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; RETINAL VEIN OCCLUSION; RISK-FACTORS; MACULAR
   DEGENERATION; INTRAOCULAR-PRESSURE; CHOLESTEROL LEVELS;
   CARDIOVASCULAR-DISEASE; PARAPAPILLARY ATROPHY; JAPANESE POPULATION;
   BLOOD-PRESSURE
AB To determine associations between dyslipidemia and ocular diseases, the population-based Beijing Eye Study 2006 examined 3251 subjects (age >= 45 years) who underwent a detailed ophthalmic examination and biochemical blood analysis. Dyslipidemia was defined as any of the following: hypercholesterolemia (total cholesterol concentration >= 5.72 mmol/L ( 220 mg/dL)) or hypertriglyceridemia ( triglyceride concentration >= 1.70 mmol/L (150 mg/dL)) or low high-density lipoprotein-cholesterol (HDL-C concentration <= 0.91 mmol/L (35 mg/dL)). Biochemical blood examinations were available for 2945 (90.6%) subjects. After adjustment for age, gender, habitation region, body mass index, self reported income, blood glucose concentration, diastolic blood pressure and smoking, dyslipidemia was significantly associated with higher intraocular pressure (P<0.001) and beta zone of parapapillary atrophy ( P = 0.03). Dyslipidemia was not significantly associated with the prevalence of glaucoma (P = 0.99), retinal vein occlusions (P = 0.92), diabetic retinopathy (P = 0.49), presence of retinal vascular abnormalities such as focal or general arteriolar narrowing, age-related macular degeneration (P = 0.27), nuclear cataract (P = 0.14), cortical cataract (P = 0.93), and subcapsular cataract (P = 0.67). The results make one conclude that, controlled for systemic and socioeconomic parameters, dyslipidemia was not associated with common ophthalmic disorders including glaucoma and age-related macular degeneration.
C1 [Wang, Shuang; Xu, Liang; Jonas, Jost B.; Wang, Ya Xing; You, Qi Sheng; Yang, Hua] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Wang, S (通讯作者)，Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
EM xlbio@yahoo.cn
RI You, Qisheng/A-3619-2014; You, Qisheng/AAG-7153-2020; wang, YA
   XING/K-9671-2016
OI You, Qisheng/0000-0003-0743-7320; You, Qisheng/0000-0003-0743-7320;
   wang, YA XING/0000-0003-2749-7793
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Cheung N, 2008, INVEST OPHTH VIS SCI, V49, P4297, DOI 10.1167/iovs.08-1826
   Chowdhury T, 2002, EYE, V16, P689, DOI 10.1038/sj.eye.6700205
   Davis MD, 1998, INVEST OPHTH VIS SCI, V39, P233
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   GlacetBernard A, 1996, OPHTHALMOLOGY, V103, P551, DOI 10.1016/S0161-6420(96)30653-2
   Gupta A, 2004, AM J OPHTHALMOL, V137, P675, DOI 10.1016/j.ajo.2003.11.017
   He J, 2004, CIRCULATION, V110, P405, DOI 10.1161/01.CIR.0000136583.52681.0D
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Jia W P, 2002, Obes Rev, V3, P157
   JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002
   JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P2942
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Keen H, 2001, DIABETOLOGIA, V44, pS22, DOI 10.1007/PL00002935
   Klein BE, BR J OPHTHALMOL, V89, P284
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Leung H, 2005, EYE, V19, P861, DOI 10.1038/sj.eye.6701668
   Li YH, 2002, NUTR METAB CARDIOVAS, V12, P118
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liu WW, 2007, OPHTHALMOLOGY, V114, P1795, DOI 10.1016/j.ophtha.2007.03.010
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Memarzadeh F, 2008, AM J OPHTHALMOL, V146, P69, DOI 10.1016/j.ajo.2008.03.015
   Mitchell P, 2005, AM J OPHTHALMOL, V140, P131, DOI 10.1016/j.ajo.2004.12.088
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4
   O'Mahoney PRA, 2008, ARCH OPHTHALMOL-CHIC, V126, P692, DOI 10.1001/archopht.126.5.692
   Paunksnis A, 2005, EUR J OPHTHALMOL, V15, P255, DOI 10.1177/112067210501500213
   Reddy KS, 1998, CIRCULATION, V97, P596
   Rodgers A, 1998, LANCET, V352, P1801
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Stamler J, 2000, JAMA-J AM MED ASSOC, V284, P311, DOI 10.1001/jama.284.3.311
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Wang S, 2006, OPHTHALMOLOGY, V113, P1752, DOI 10.1016/j.ophtha.2006.05.019
   Xu L, 2008, EXP CLIN ENDOCR DIAB, V116, P69, DOI 10.1055/s-2007-985381
   Xu L, 2008, AM J HYPERTENS, V21, P1117, DOI 10.1038/ajh.2008.247
   Xu L, 2008, GRAEF ARCH CLIN EXP, V246, P923, DOI 10.1007/s00417-008-0773-z
   Xu L, 2007, AM J OPHTHALMOL, V144, P541, DOI 10.1016/j.ajo.2007.05.038
   Xu L, 2007, AM J OPHTHALMOL, V144, P461, DOI 10.1016/j.ajo.2007.05.013
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 49
TC 89
Z9 92
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 26
PY 2012
VL 7
IS 3
AR e26871
DI 10.1371/journal.pone.0026871
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 943KB
UT WOS:000304118900001
PM 22128290
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Fujii, GY
   de Juan, E
   Humayun, MS
   Chang, TS
AF Fujii, GY
   de Juan, E
   Humayun, MS
   Chang, TS
TI Limited macular translocation for the management of subfoveal choroidal
   neovascularization after photodynamic therapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NORMAL RETINA; VERTEPORFIN
AB PURPOSE: To report our initial experience of limited macular translocation in patients with subfoveal choroidal neovascularization secondary to age,related macular degeneration following photodynamic therapy with verteporfin.
   DESIGN: Interventional case series.
   METHODS: Retrospective review of four eyes of four consecutive patients with subfoveal choroidal neovascularization secondary to age related macular degeneration who underwent effective limited macular translocation following photodynamic therapy. The mean logarithm of minimal angle of resolution preoperative best,corrected visual acuity was 20/190 (range, 20/150 to 20/200), and in all eyes the visual acuity was 20/150 or worse. The major outcome measures were postoperative visual acuity and complications related to the surgery.
   RESULTS: The mean postoperative follow-up was 6.75 months (range, 6-8 months). Postoperative best,corrected visual acuity improved by 2 or more Snellen lines of visual acuity in three of four eyes (75%) and remained within 1 line in one of four eyes (25%). The mean postoperative best-corrected visual acuity was 20/100 (range, 20/40 to 20/150), and in two of the four eyes (50%) the visual acuity achieved was 20/100 or better. No complication was observed.
   CONCLUSIONS: Limited macular translocation may be a viable option in patients who have previously undergone photodynamic therapy.
C1 Univ So Calif, Doheny Eye Inst, Keck Sch Med, Doheny Retina Inst,Doheny Eye Ctr, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California
RP de Juan, E (通讯作者)，Univ So Calif, Doheny Eye Inst, Keck Sch Med, Doheny Retina Inst,Doheny Eye Ctr, 1450 San Pablo St,Room 3620, Los Angeles, CA 90033 USA.
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
NR 7
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2003
VL 135
IS 1
BP 109
EP 112
DI 10.1016/S0002-9394(02)01854-8
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 632QG
UT WOS:000180233900027
PM 12504715
DA 2022-11-30
ER

PT J
AU De Salvo, G
   Vaz-Pereira, S
   Keane, PA
   Tufail, A
   Liew, G
AF De Salvo, Gabriella
   Vaz-Pereira, Sara
   Keane, Pearse A.
   Tufail, Adnan
   Liew, Gerald
TI Sensitivity and Specificity of Spectral-Domain Optical Coherence
   Tomography in Detecting Idiopathic Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; ANGIOGRAPHY; LESIONS
AB PURPOSE: To evaluate the efficacy of spectral-domain optical coherence tomography (SD OCT) compared to indocyanine green angiography (ICGA) in detecting idiopathic polypoidal choroidal vasculopathy (PCV) and in differentiating between PCV and occult choroidal neovascularization (CNV).
   DESIGN: Retrospective observational case-control study.
   METHODS: SD OCTs of 51 eyes of 44 consecutive patients who presented with 1 or more pigment epithelial detachments (PEDs) attributable to either PCV or occult CNV were retrospectively reviewed by a grader masked to the final diagnosis. A qualitative analysis based on the following tomographic findings was performed: sharp PED peak, PED notch, hyporeflective lumen within hyperreflective lesions adherent to retinal pigment epithelium. The diagnosis based on SD OCT alone was compared with the final diagnosis made using ICGA and fluorescein angiography. Sensitivity and specificity were calculated. Patients with classic CNV and central serous chorioretinopathy were excluded.
   RESULTS: Among 51 eyes of 44 patients, 37 had an ICGA-confirmed diagnosis. of PCV and 14 had occult CNV. SD OCT based on the features above detected 35 of 37 true-positive PCV lesions but missed 2 ICGA-confirmed lesions (false negatives). SD OCT correctly excluded 13 of 14 non-PCV lesions but misidentified 1 PCV lesion (false positive). These data showed a sensitivity of 94.6% and a specificity of 92.9% for the above SD OCT features in identifying PCV lesions.
   CONCLUSIONS: SD OCT based on the features above allowed for good detection of PCV and differentiation between PCV and occult CNV in this selected clinic population. A careful qualitative analysis of the tomographic findings in patients presenting with PEDs may allow ophthalmologists to distinguish between PCV and occult CNV, decreasing the need for ICGA and the risks related to this procedure. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [De Salvo, Gabriella] Moorfields Eye Hosp, Natl Hlth Serv Fdn Trust, Med Retina Dept, London EC1V 2PD, England.
   Moorfields Eye Hosp, Natl Hlth Serv Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London EC1V 2PD, England.
   UCL, Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London
RP De Salvo, G (通讯作者)，Moorfields Eye Hosp, Natl Hlth Serv Fdn Trust, Med Retina Dept, 162 City Rd, London EC1V 2PD, England.
EM gabrydsl@tiscali.it
RI Keane, Pearse/AAE-5709-2019; De Salvo, Gabriella/AAY-5016-2020;
   Vaz-Pereira, Sara/P-5777-2019; Liew, Gerald/AAB-6870-2022
OI Keane, Pearse/0000-0002-9239-745X; Vaz-Pereira,
   Sara/0000-0001-6125-5486; Tufail, Adnan/0000-0001-6131-7640; DE SALVO,
   Gabriella/0000-0002-1185-6942
FU National Institute for Health Research Biomedical Research Centre at
   Moorfields Eye Hospital National Health System Foundation Trust;
   University College London Institute of Ophthalmology, London, United
   Kingdom; National Institute for Health Research [CL-2010-18-004] Funding
   Source: researchfish
FX National Institute for Health Research Biomedical Research Centre at
   Moorfields Eye Hospital National Health System Foundation Trust and
   University College London Institute of Ophthalmology, London, United
   Kingdom.
CR Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ishida T, 2013, INT OPHTHALMOL, V33, P305, DOI 10.1007/s10792-012-9657-7
   Katsimpris JM, 2003, J FR OPHTALMOL, V26, P489
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Ooto S, 2010, GRAEF ARCH CLIN EXP, V248, P1077, DOI 10.1007/s00417-010-1338-5
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 24
TC 85
Z9 86
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2014
VL 158
IS 6
BP 1228
EP 1238
DI 10.1016/j.ajo.2014.08.025
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU8AZ
UT WOS:000345820400018
PM 25152500
DA 2022-11-30
ER

PT J
AU Chan, EW
   Eldeeb, M
   Lingam, G
   Thomas, D
   Bhargava, M
   Chee, CK
AF Chan, Errol W.
   Eldeeb, Mohab
   Lingam, Gopal
   Thomas, Doneal
   Bhargava, Mayuri
   Chee, Caroline K.
TI Quantitative Changes in Pigment Epithelial Detachment Area and Volume
   Predict Retreatment in Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB INJECTIONS; AS-NEEDED REINJECTIONS; RECURRENCE;
   AFLIBERCEPT; SIZE
AB PURPOSE: To determine if changes in pigment epithelial detachment (PED) area and volume predict retreatment in polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective case-control study.
   METHODS: PCV patients on pro re nata (PRN) anti vascular endothelial growth factor (VEGF) therapy with > 1 year follow-up at an academic retina service were included. Monthly anti-VEGF injections were given until a dry macula was achieved, and treatment deferred. Retreatment indication was recurrence of intraretinal or subretinal fluid or new hemorrhage. PED area and volume changes between visits with a dry macula ("D") and immediate preceding visits ("D - 1") were analyzed with an automated optical coherence tomography-based software. Univariate and multivariate analyses were conducted to determine associations between changes in PED parameters and retreatment need at immediate subsequent visits ("D + 1").
   RESULTS: Twenty-two PCV patients (mean age 69.6 years) were included. Of 46 visits D, 11(23.9%) were followed by retreatment at D + 1. An increase in PED area (> 0.43 mm(2)) and volume (> 0.0245 mm(3)) from D - 1 to D was associated with 18.2 (95% CI, 3.7-125.6; P < .001) and 101.9 (95% CI, 9.5-14308.0; P < .001) higher retreatment odds at D + 1, respectively. These associations remained significant after multivariate analyses adjusting for baseline PED area or volume, greatest linear dimension, and type of anti-VEGF agent.
   CONCLUSION: In PCV on PRN anti-VEGF therapy, increases in PED area and volume at one visit, despite achievement of a dry macula, are associated with retreatment at the next visit. Retreatment criteria relying on. intraretinal or subretinal fluid or new hemorrhages may be expanded to include PED changes. Studies are needed to determine if using PED parameters in treatment decisions reduces recurrences. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Chan, Errol W.; Lingam, Gopal; Bhargava, Mayuri; Chee, Caroline K.] Natl Univ Hlth Syst, Dept Ophthalmol, NUHS Tower Block Level 7,1E Kent Ridge Rd, Singapore 119228, Singapore.
   [Eldeeb, Mohab] Montreal Retina Inst, Montreal, PQ, Canada.
   [Thomas, Doneal] McGill Univ, Hlth Ctr Res Inst, CaMos Stat Anal Ctr, Montreal, PQ, Canada.
   [Chan, Errol W.] McGill Univ, Fac Med, Dept Ophthalmol, Retina Serv, Montreal, PQ, Canada.
C3 National University of Singapore; McGill University; McGill University
RP Chee, CK (通讯作者)，Natl Univ Hlth Syst, Dept Ophthalmol, NUHS Tower Block Level 7,1E Kent Ridge Rd, Singapore 119228, Singapore.
EM ophv5@nus.edu.sg
RI Eldeeb, Mohab/AAA-1048-2019
FU NATIONAL UNIVERSITY HEALTH SYSTEM CLINICIAN SCIENTIST PROgram
FX THIS STUDY WAS SUPPORTED BY A NATIONAL UNIVERSITY HEALTH SYSTEM
   CLINICIAN SCIENTIST PROgram Grant awarded to Errol W. Chan in 2014.
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   ClinicalTrials.gov, VIS OUTC PAT SYMPT M
   ClinicalTrials.gov, AFL POL CHOR VASC PL
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kang HM, 2016, GRAEF ARCH CLIN EXP, V254, P1519, DOI 10.1007/s00417-015-3241-6
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 27
TC 7
Z9 7
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2017
VL 177
BP 195
EP 205
DI 10.1016/j.ajo.2016.12.008
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EU3TS
UT WOS:000400954500026
PM 28007451
DA 2022-11-30
ER

PT J
AU Meshi, A
   Lin, TZ
   Dans, K
   Chen, KC
   Amador, M
   Hasenstab, K
   Muftuoglu, IK
   Nudleman, E
   Chao, D
   Bartsch, DU
   Freeman, WR
AF Meshi, Amit
   Lin, Tiezhu
   Dans, Kunny
   Chen, Kevin C.
   Amador, Manuel
   Hasenstab, Kyle
   Muftuoglu, Ilkay Kilic
   Nudleman, Eric
   Chao, Daniel
   Bartsch, Dirk-Uwe
   Freeman, William R.
TI COMPARISON OF RETINAL PATHOLOGY VISUALIZATION IN MULTISPECTRAL SCANNING
   LASER IMAGING
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retinal imaging; scanning laser ophthalmoscope; multispectral imaging;
   multicolor imaging; retinal pathology visualization
ID INDOCYANINE GREEN; ANGIOGRAPHY
AB Purpose: To compare retinal pathology visualization in multispectral scanning laser ophthalmoscope imaging between the Spectralis and Optos devices.
   Methods: This retrospective cross-sectional study included 42 eyes from 30 patients with age-related macular degeneration (19 eyes), diabetic retinopathy (10 eyes), and epiretinal membrane (13 eyes). All patients underwent retinal imaging with a color fundus camera (broad-spectrum white light), the Spectralis HRA-2 system (3-color monochromatic lasers), and the Optos P200 system (2-color monochromatic lasers). The Optos image was cropped to a similar size as the Spectralis image. Seven masked graders marked retinal pathologies in each image within a 5 x 5 grid that included the macula.
   Results: The average area with detected retinal pathology in all eyes was larger in the Spectralis images compared with Optos images (32.4% larger, P < 0.0001), mainly because of better visualization of epiretinal membrane and retinal hemorrhage. The average detection rate of age-related macular degeneration and diabetic retinopathy pathologies was similar across the three modalities, whereas epiretinal membrane detection rate was significantly higher in the Spectralis images.
   Conclusion: Spectralis tricolor multispectral scanning laser ophthalmoscope imaging had higher rate of pathology detection primarily because of better epiretinal membrane and retinal hemorrhage visualization compared with Optos bicolor multispectral scanning laser ophthalmoscope imaging.
C1 [Meshi, Amit; Lin, Tiezhu; Dans, Kunny; Chen, Kevin C.; Amador, Manuel; Muftuoglu, Ilkay Kilic; Bartsch, Dirk-Uwe; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Inst, La Jolla, CA 92093 USA.
   [Lin, Tiezhu] He Univ, He Eye Hosp, Shenyang, Liaoning, Peoples R China.
   [Amador, Manuel] Escuela Super Oftalmol, Inst Barraquer Amer, Bogota, Colombia.
   [Hasenstab, Kyle] Univ Calif San Diego, Dept Ophthalmol, Hamilton Glaucoma Ctr, Shiley Eye Inst, La Jolla, CA 92093 USA.
   [Muftuoglu, Ilkay Kilic] Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Nudleman, Eric; Chao, Daniel] Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Inst, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Istanbul Training & Research Hospital; University of California System;
   University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM wrfreeman@ucsd.edu
RI lin, Tiezhu/AAY-1971-2020; Chen, Kevin/GYU-8963-2022
OI Lotery, Andrew/0000-0001-5541-4305; Amador-Patarroyo, Manuel
   J./0000-0001-6058-5678
FU NIH [EY016323]; UCSD Vision Research Center Core Grant [P30EY022589];
   Research to Prevent Blindness, NY; Heidelberg Engineering; NATIONAL EYE
   INSTITUTE [P30EY022589, R01EY016323] Funding Source: NIH RePORTER
FX Supported in part by an NIH grant EY016323 (D.-U.B.) and an UCSD Vision
   Research Center Core Grant P30EY022589, an unrestricted fund from
   Research to Prevent Blindness, NY (W.R.F).; D.-U. Bartsch has received
   research support from Heidelberg Engineering. The remaining authors have
   no conflicts of interests to disclose.
CR Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   Badal J, 2017, INT OPHTHALMOL
   BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   De Salvo G, 2017, EYE, V31, P127, DOI 10.1038/eye.2016.193
   Espina MP, 2015, RETINA-J RET VIT DIS, V35, P2664, DOI 10.1097/IAE.0000000000000899
   Feng HL, 2017, OSLI RETINA, V48, P810, DOI 10.3928/23258160-20170928-05
   Freeman WR, 1998, ARCH OPHTHALMOL-CHIC, V116, P455, DOI 10.1001/archopht.116.4.455
   Graham KW, 2017, RETINA
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Inoue M, 2013, JAMA OPHTHALMOL, V131, P226, DOI 10.1001/jamaophthalmol.2013.750
   Keane PA, 2014, OPHTHALMOLOGY, V121, P2489, DOI 10.1016/j.ophtha.2014.07.054
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P352, DOI 10.1097/IAE.0000000000001525
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   Reznicek L, 2014, SAUDI J OPHTHALMOL, V28, P134, DOI 10.1016/j.sjopt.2014.03.009
   Silva PS, 2017, OPHTHALMOLOGY, V124, P970, DOI 10.1016/j.ophtha.2017.02.012
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   WEBB RH, 1980, APPL OPTICS, V19, P2991, DOI 10.1364/AO.19.002991
NR 20
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2019
VL 39
IS 7
BP 1333
EP 1342
DI 10.1097/IAE.0000000000002156
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ5AA
UT WOS:000480761900012
PM 29554078
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Streeter, MD
   Rowan, S
   Ray, J
   McDonald, DM
   Volkin, J
   Clark, J
   Taylor, A
   Spiegel, DA
AF Streeter, Matthew D.
   Rowan, Sheldon
   Ray, Jason
   McDonald, David M.
   Volkin, Jonathan
   Clark, Jonathan
   Taylor, Allen
   Spiegel, David A.
TI Generation and Characterization of Anti-Glucosepane Antibodies Enabling
   Direct Detection of Glucosepane in Retinal Tissue
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID GLYCATION END-PRODUCTS; CROSS-LINK; EXTRACELLULAR-MATRIX; MAILLARD
   PROCESSES; SERUM-ALBUMIN; I COLLAGEN; LIPOFUSCIN; LOCALIZATION;
   IDENTIFICATION; ACCUMULATION
AB Although there is ample evidence that the advanced glycation end-product (AGE) glucosepane contributes to age-related morbidities and diabetic complications, the impact of glucosepane modifications on proteins has not been extensively explored due to the lack of sufficient analytical tools. Here, we report the development of the first polyclonal anti-glucosepane antibodies using a synthetic immunogen that contains the core bicydic ring structure of glucosepane. We investigate the recognition properties of these antibodies through ELISAs involving an array of synthetic AGE derivatives and determine them to be both high-affinity and selective in binding glucosepane. We then employ these antibodies to image glucosepane in aging mouse retinae via immunohistochemistry. Our studies demonstrate for the first time accumulation of glucosepane within the retinal pigment epithelium, Brach's membrane, and choroid: all regions of the eye impacted by age-related macular degeneration. Co-localization studies further su est that glucosepane colocalizes with lipofuscin, which has previously been associated with lysosomal dysfunction and has been implicated in the development of age-related macular degeneration, among other diseases. We believe that the anti-glucosepane antibodies described in this study will prove highly useful for examining the role of glycation in human health and disease.
C1 [Streeter, Matthew D.; Ray, Jason; McDonald, David M.; Spiegel, David A.] Yale Univ, Dept Chem, New Haven, CT 06511 USA.
   [Rowan, Sheldon; Volkin, Jonathan; Taylor, Allen] Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Clark, Jonathan] Babraham Inst, Biol Chem Lab, Cambridge CB21 3AT, England.
C3 Yale University; Tufts University; United States Department of
   Agriculture (USDA); UK Research & Innovation (UKRI); Biotechnology and
   Biological Sciences Research Council (BBSRC); Babraham Institute
RP Spiegel, DA (通讯作者)，Yale Univ, Dept Chem, New Haven, CT 06511 USA.
EM david.spiegel@yale.edu
OI Ray, Jason/0000-0002-2675-2679
FU American Diabetes Association Pathway to Stop Diabetes Grant [1-17-
   VSN-04]; SENS Research Foundation; National Institute of Health Yale
   Chemical Biology Training Grant [2T32GM06754 3-17]
FX This work was supported by funding from the American Diabetes
   Association Pathway to Stop Diabetes Grant 1-17- VSN-04 and the SENS
   Research Foundation. J.D.R. was funded by the National Institute of
   Health Yale Chemical Biology Training Grant (2T32GM06754 3-17). The
   authors would also like to thank S. Bhatt and D. McDonald for their help
   in preparing the manuscript and S. Lewis at New England Peptide for his
   helpful advice regarding immunization.
CR Ahmad WQ, 2008, BMB REP, V41, P516, DOI 10.5483/BMBRep.2008.41.7.516
   Bartling B, 2009, FASEB J, V23, P1510, DOI 10.1096/fj.08-122648
   Biemel KM, 2001, J BIOL CHEM, V276, P23405, DOI 10.1074/jbc.M102035200
   Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200
   Chesne S, 2006, BIOCHIMIE, V88, P1467, DOI 10.1016/j.biochi.2006.05.011
   Chiu CJ, 2018, BIOFACTORS, V44, P281, DOI 10.1002/biof.1423
   Collier TA, 2018, J BIOMECH, V67, P55, DOI 10.1016/j.jbiomech.2017.11.021
   Collier TA, 2015, MATRIX BIOL, V48, P78, DOI 10.1016/j.matbio.2015.06.001
   DeGroot J, 2001, EXP CELL RES, V266, P303, DOI 10.1006/excr.2001.5224
   Draghici C, 2015, SCIENCE, V350, P294, DOI 10.1126/science.aac9655
   Finco Alessandra Becker, 2016, Biochem Biophys Rep, V6, P142, DOI 10.1016/j.bbrep.2016.03.011
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Genuth S, 2015, DIABETES, V64, P266, DOI 10.2337/db14-0215
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Lederer MO, 1999, BIOORGAN MED CHEM, V7, P1081, DOI 10.1016/S0968-0896(99)00040-1
   Ling X, 1998, LAB INVEST, V78, P1591
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Monnier VM, 2014, CLIN CHEM LAB MED, V52, P21, DOI 10.1515/cclm-2013-0174
   Morioka Y, 2017, J PHARMACOL SCI, V134, P218, DOI 10.1016/j.jphs.2017.07.005
   Nagai R, 2008, J IMMUNOL METHODS, V332, P112, DOI 10.1016/j.jim.2007.12.020
   Nagai R, 2016, GLYCOCONJUGATE J, V33, P545, DOI 10.1007/s10719-016-9708-9
   Nociari M.M., 2017, LIPOFUSCIN ACCUMULAT, P1
   Rabbani N, 2018, KIDNEY INT, V93, P803, DOI 10.1016/j.kint.2017.11.034
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Sell DR, 2005, J BIOL CHEM, V280, P12310, DOI 10.1074/jbc.M500733200
   Shamsi FA, 1998, J BIOL CHEM, V273, P6928, DOI 10.1074/jbc.273.12.6928
   Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Wang T, 2015, BIOORG MED CHEM LETT, V25, P4881, DOI 10.1016/j.bmcl.2015.06.013
   Wang TN, 2012, J AM CHEM SOC, V134, P8958, DOI 10.1021/ja301994d
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Woods TM, 2012, ORG LETT, V14, P5740, DOI 10.1021/ol302745f
   Xu Hui-Zhuo, 2011, J Ocul Biol Dis Infor, V4, P83, DOI 10.1007/s12177-011-9068-4
   Yamagishi S, 2011, EXP GERONTOL, V46, P217, DOI 10.1016/j.exger.2010.11.007
   Yan SF, 2008, NAT CLIN PRACT ENDOC, V4, P285, DOI 10.1038/ncpendmet0786
   ZYZAK DV, 1995, ARCH BIOCHEM BIOPHYS, V316, P547, DOI 10.1006/abbi.1995.1073
NR 44
TC 2
Z9 2
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD OCT 16
PY 2020
VL 15
IS 10
BP 2655
EP 2661
DI 10.1021/acschembio.0c00093
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA OH4XP
UT WOS:000582580100005
PM 32975399
DA 2022-11-30
ER

PT J
AU Sundaramurthi, H
   Roche, SL
   Grice, GL
   Moran, A
   Dillion, ET
   Campiani, G
   Nathan, JA
   Kennedy, BN
AF Sundaramurthi, Husvinee
   Roche, Sarah L.
   Grice, Guinevere L.
   Moran, Ailis
   Dillion, Eugene T.
   Campiani, Giuseppe
   Nathan, James A.
   Kennedy, Breandan N.
TI Selective Histone Deacetylase 6 Inhibitors Restore Cone Photoreceptor
   Vision or Outer Segment Morphology in Zebrafish and Mouse Models of
   Retinal Blindness
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE HDAC6 inhibitors; tubastatin A; retinal degenerations; Hif-1 alpha;
   proteome profiling
ID VALPROIC ACID TREATMENT; CELL-DEATH; COMPUTATIONAL PLATFORM; MACULAR
   DEGENERATION; RETINITIS-PIGMENTOSA; V-ATPASE; AUTOPHAGY; HDAC6; DISEASE;
   CYTOSCAPE
AB Blindness arising from retinal or macular degeneration results in significant social, health and economic burden. While approved treatments exist for neovascular ('wet') age-related macular degeneration, new therapeutic targets/interventions are needed for the more prevalent atrophic ('dry') form of age-related macular degeneration. Similarly, in inherited retinal diseases, most patients have no access to an effective treatment. Although macular and retinal degenerations are genetically and clinically distinct, common pathological hallmarks can include photoreceptor degeneration, retinal pigment epithelium atrophy, oxidative stress, hypoxia and defective autophagy. Here, we evaluated the potential of selective histone deacetylase 6 inhibitors to preserve retinal morphology or restore vision in zebrafishatp6v0e1(-/-)and mouserd10models. Histone deacetylase 6 inhibitor, tubastatin A-treatedatp6v0e1(-/-)zebrafish show marked improvement in photoreceptor outer segment area (44.7%, p = 0.027) and significant improvement in vision (8-fold,p <= 0.0001). Tubastatin A-treatedrd10/rd10retinal explants show a significantly (p= 0.016) increased number of outer-segment labeled cone photoreceptors.In vitro, ATP6V0E1 regulated HIF-1 alpha activity, but significant regulation of HIF-1 alpha by histone deacetylase 6 inhibition in the retina was not detected. Proteomic profiling identified ubiquitin-proteasome, phototransduction, metabolism and phagosome as pathways, whose altered expression correlated with histone deacetylase 6 inhibitor mediated restoration of vision.
C1 [Sundaramurthi, Husvinee; Moran, Ailis; Kennedy, Breandan N.] Univ Coll Dublin, UCD Conway Inst, Dublin, Ireland.
   [Sundaramurthi, Husvinee; Moran, Ailis; Dillion, Eugene T.; Kennedy, Breandan N.] Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin, Ireland.
   [Sundaramurthi, Husvinee] Univ Coll Dublin, Syst Biol Ireland, Dublin, Ireland.
   [Sundaramurthi, Husvinee] Univ Coll Dublin, UCD Sch Med, Dublin, Ireland.
   [Roche, Sarah L.] Univ Coll Cork, Sch Biochem, Cork, Ireland.
   [Grice, Guinevere L.; Nathan, James A.] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Cambridge, England.
   [Dillion, Eugene T.] Univ Coll Dublin, UCD Conway Inst, Mass Spectrometry Resource, Dublin, Ireland.
   [Campiani, Giuseppe] Univ Siena, Dept Excellence, Dept Biotechnol Chem & Pharm, Siena, Italy.
C3 University College Dublin; University College Dublin; University College
   Dublin; University College Dublin; University College Cork; University
   of Cambridge; University College Dublin; University of Siena
RP Kennedy, BN (通讯作者)，Univ Coll Dublin, UCD Conway Inst, Dublin, Ireland.; Kennedy, BN (通讯作者)，Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin, Ireland.
EM brendan.kennedy@ucd.ie
RI kennedy, Breandan/H-5643-2019
OI kennedy, Breandan/0000-0001-7991-4689; Sundaramurthi,
   Husvinee/0000-0002-0041-0451; Moran, Ailis/0000-0002-8706-9777; Nathan,
   James Alexander/0000-0002-0248-1632
FU European Union's Horizon 2020 Research and Innovation Programme under
   the Marie Sklodowska-Curie grant [666010]; Fighting Blindness MRCG/HRB
   grant [MRCG-2014-3.b]; European Union's Horizon 2020 Research and
   Innovation Programme [734907]; Wellcome Senior Research Fellowship
   [215477/Z/19/Z]; Progetto Dipartimento di Eccellenza 2018-2022
FX This project has received funding from the European Union's Horizon 2020
   Research and Innovation Programme under the Marie Sklodowska-Curie grant
   agreement No. 666010 (TopMed10 -Marie Sklodowska-Curie Actions COFUND
   Programme); Fighting Blindness MRCG/HRB grant MRCG-2014-3.b; European
   Union's Horizon 2020 Research and Innovation Programme under grant
   agreement No. 734907 (3D-NEONET); Wellcome Senior Research Fellowship
   (215477/Z/19/Z); and Progetto Dipartimento di Eccellenza 2018-2022.
CR Barben M, 2018, CELL DEATH DIFFER, V25, P2071, DOI 10.1038/s41418-018-0094-7
   Barben M, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0243-y
   Bassett EA, 2012, TRENDS NEUROSCI, V35, P565, DOI 10.1016/j.tins.2012.05.004
   Benoy V, 2017, NEUROTHERAPEUTICS, V14, P417, DOI 10.1007/s13311-016-0501-z
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bhalla S, 2013, BRIT J OPHTHALMOL, V97, P895, DOI 10.1136/bjophthalmol-2013-303084
   Bibliowicz J, 2011, PROG MOL BIOL TRANSL, V100, P287, DOI 10.1016/B978-0-12-384878-9.00007-8
   Bindea G, 2013, BIOINFORMATICS, V29, P661, DOI 10.1093/bioinformatics/btt019
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bogea TH, 2015, INVEST OPHTH VIS SCI, V56, P7947, DOI 10.1167/iovs.15-16799
   Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614
   Burr SP, 2016, CELL METAB, V24, P740, DOI 10.1016/j.cmet.2016.09.015
   Chen SY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/197946
   Cheng L, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00020
   Clemson CM, 2011, BRIT J OPHTHALMOL, V95, P89, DOI 10.1136/bjo.2009.175356
   Colacurcio DJ, 2016, AGEING RES REV, V32, P75, DOI 10.1016/j.arr.2016.05.004
   Concordet JP, 2018, NUCLEIC ACIDS RES, V46, pW242, DOI 10.1093/nar/gky354
   Cosenza M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082337
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Daiger S. P., 1998, IOVS, V39, pS295
   Daly C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11513-5
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Duan XH, 2018, THERANOSTICS, V8, P5379, DOI 10.7150/thno.28391
   Duncan JL, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.6
   Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Gordon K, 2019, NAT REV DRUG DISCOV, V18, P415, DOI 10.1038/d41573-018-00016-1
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Hoppe G, 2016, P NATL ACAD SCI USA, V113, pE2516, DOI 10.1073/pnas.1523005113
   Howe DG, 2013, NUCLEIC ACIDS RES, V41, pD854, DOI 10.1093/nar/gks938
   Huberman AD, 2011, TRENDS NEUROSCI, V34, P464, DOI 10.1016/j.tins.2011.07.002
   Hull EE, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8797206
   Iraha S, 2016, CLIN OPHTHALMOL, V10, P1375, DOI 10.2147/OPTH.S109995
   Janczura KJ, 2018, P NATL ACAD SCI USA, V115, pE11148, DOI 10.1073/pnas.1805436115
   Kaushal Shalesh, 2006, Trans Am Ophthalmol Soc, V104, P517
   Kawamura N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012086
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Lai JI, 2017, BIOORG MED CHEM LETT, V27, P3289, DOI 10.1016/j.bmcl.2017.06.027
   Lange C, 2011, NEUROBIOL DIS, V41, P119, DOI 10.1016/j.nbd.2010.08.028
   Lee JH, 2015, CELL REP, V12, P1430, DOI 10.1016/j.celrep.2015.07.050
   Leyk J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.415
   Li Y, 2013, FEBS J, V280, P775, DOI 10.1111/febs.12079
   Lin W, 2019, OPHTHALMIC RES, V61, P65, DOI 10.1159/000487486
   Liu HY, 2016, INVEST OPHTH VIS SCI, V57, P1807, DOI 10.1167/iovs.15-18066
   Lopez AMR, 2017, EUR J NEUROSCI, V46, P1663, DOI 10.1111/ejn.13604
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mijaljica D, 2011, AUTOPHAGY, V7, P666, DOI 10.4161/auto.7.6.15812
   Miles AL, 2017, ELIFE, V6, DOI 10.7554/eLife.22693
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moreno ML, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01008
   Narayan DS, 2017, CLIN EXP OPHTHALMOL, V45, P730, DOI 10.1111/ceo.12952
   Nuckels RJ, 2009, INVEST OPHTH VIS SCI, V50, P893, DOI 10.1167/iovs.08-2743
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Olivares-Gonzalez L, 2018, FASEB J, V32, P2438, DOI 10.1096/fj.201700985R
   Pamarthy S, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0811-3
   Park RJ, 2017, NAT GENET, V49, P193, DOI 10.1038/ng.3741
   Park SY, 2020, EXP MOL MED, V52, P204, DOI 10.1038/s12276-020-0382-4
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pinzon-Duarte G, 2000, VISION RES, V40, P3455, DOI 10.1016/S0042-6989(00)00185-1
   Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598
   Ratay ML, 2018, ACTA BIOMATER, V71, P261, DOI 10.1016/j.actbio.2018.03.002
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Richter-Landsberg C, 2013, ACTA NEUROPATHOL, V126, P793, DOI 10.1007/s00401-013-1158-x
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Roche SL, 2018, GLIA, V66, P295, DOI 10.1002/glia.23243
   Roche SL, 2017, SCI REP-UK, V7, DOI 10.1038/srep43067
   Roche SL, 2016, INT J DEV BIOL, V60, P127, DOI 10.1387/ijdb.150400tc
   Rodriguez-Muela N, 2015, CELL DEATH DIFFER, V22, P476, DOI 10.1038/cdd.2014.203
   Ryu HW, 2017, CELL STRESS CHAPERON, V22, P253, DOI 10.1007/s12192-017-0763-3
   Samardzija M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52508-8
   Schoepflin ZR, 2016, J BONE MINER RES, V31, P1287, DOI 10.1002/jbmr.2787
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shine L, 2014, ADV EXP MED BIOL, V801, P97, DOI 10.1007/978-1-4614-3209-8_13
   Simoes-Pires C, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-7
   Singh R, 2015, MOL THER, V23, P1700, DOI 10.1038/mt.2015.141
   Sisk RA, 2012, BRIT J OPHTHALMOL, V96, P1154, DOI 10.1136/bjophthalmol-2012-301950
   Sundaramurthi H, 2019, ADV EXP MED BIOL, V1185, P263, DOI 10.1007/978-3-030-27378-1_43
   Thomas EA, 2018, J NEUROCHEM, V145, P96, DOI 10.1111/jnc.14309
   Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Totan Y, 2017, INDIAN J OPHTHALMOL, V65, P984, DOI 10.4103/ijo.IJO_978_16
   Trachsel-Moncho L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0855-8
   Trifunovic D, 2018, ADV EXP MED BIOL, V1074, P367, DOI 10.1007/978-3-319-75402-4_45
   Trifunovic D, 2016, HUM MOL GENET, V25, P4462, DOI 10.1093/hmg/ddw275
   Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   van Schooneveld MJ, 2011, BRIT J OPHTHALMOL, V95, P153, DOI 10.1136/bjo.2010.194373
   Vent-Schmidt RYJ, 2017, J NEUROSCI, V37, P1039, DOI 10.1523/JNEUROSCI.1647-16.2016
   Wang K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07601
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005
   Yao JY, 2016, AUTOPHAGY, V12, P2439, DOI 10.1080/15548627.2016.1238553
   Zhang H, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/250812
   Zhang L, 2014, J ALZHEIMERS DIS, V41, P1193, DOI 10.3233/JAD-140066
   Ziemka-Nalecz M, 2018, J NEUROPATH EXP NEUR, V77, P855, DOI 10.1093/jnen/nly073
NR 100
TC 10
Z9 10
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD AUG 26
PY 2020
VL 8
AR 689
DI 10.3389/fcell.2020.00689
PG 21
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA NQ0TS
UT WOS:000570581800001
PM 32984302
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Schlecht, A
   Leimbeck, SV
   Jagle, H
   Feuchtinger, A
   Tamm, ER
   Braunger, BM
AF Schlecht, Anja
   Leimbeck, Sarah V.
   Jagle, Herbert
   Feuchtinger, Annette
   Tamm, Ernst R.
   Braunger, Barbara M.
TI Deletion of Endothelial Transforming Growth Factor-beta Signaling Leads
   to Choroidal Neovascularization
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ACTIVATED PROTEIN-KINASE; BASAL LAMINAR
   DEPOSIT; MACULAR DEGENERATION; TGF-BETA; IMMUNOHISTOCHEMICAL
   LOCALIZATION; FENESTRATED ENDOTHELIA; TGF-BETA-1 EXPRESSION;
   DIABETIC-RETINOPATHY; ELECTRON-MICROSCOPY
AB The molecular pathogenesis of choroidal neovascularization (CNV), an angiogenic process that critically contributes to vision loss in age-related macular degeneration, is unclear. Herein, we analyzed the role of transforming growth factor (TGF)-beta signaling for CNV formation by generating a series of mutant mouse models with induced conditional deletion of TGF-beta signaling in the entire eye, the retinal pigment epithelium (RPE), or the vascular endothelium. Deletion of TGF-beta signaling in the eye caused CNV, irrespectively if it was ablated in newborn or 3-week old mice. Areas of CNV showed photoreceptor degeneration, multilayered RPE, basal Lamina deposits, and accumulations of monocytes/macrophages. The changes progressed, leading to marked structural and functional alterations of the retina. Although the specific deletion of TGF-beta signaling in the RPE caused no obvious changes, specific deletion in vascular endothelial cells caused CNV and a phenotype similar to that observed after the deletion in the entire eye. We conclude that impairment of TGF-beta signaling in the vascular endothelium of the eye is sufficient to trigger CNV formation. Our findings highlight the importance of TGF-beta signaling as a key player in the development of ocular neovascularization and indicate a fundamental role of TGF-beta signaling in the pathogenesis of age-related macular degeneration.
C1 [Schlecht, Anja; Leimbeck, Sarah V.; Tamm, Ernst R.; Braunger, Barbara M.] Univ Regensburg, Inst Human Anat & Embryol, Univ Str 31, D-93053 Regensburg, Germany.
   [Jagle, Herbert] Univ Clin Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Feuchtinger, Annette] Helmholtz Zentrum Munich, Res Unit Analyt Pathol, Munich, Germany.
C3 University of Regensburg; University of Regensburg; Helmholtz
   Association; Helmholtz-Center Munich - German Research Center for
   Environmental Health
RP Tamm, ER; Braunger, BM (通讯作者)，Univ Regensburg, Inst Human Anat & Embryol, Univ Str 31, D-93053 Regensburg, Germany.
EM ernst.tamm@ur.de; barbara.braunger@ur.de
RI Tamm, Ernst/AAB-9772-2019; Feuchtinger, Annette/O-4569-2014; Jägle,
   Herbert/GPP-2945-2022; Braunger, Barbara Maria/K-4272-2015
OI Tamm, Ernst/0000-0002-6679-8743; Braunger, Barbara
   Maria/0000-0002-3926-6725
FU German Research Council [FOR1075, TP5, BR 4957/3-1]
FX Supported by German Research Council grants FOR1075 (E.R.T.), TP5
   (E.R.T.), and BR 4957/3-1 (B.M.B.).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Baulmann DC, 2002, MECH DEVELOP, V118, P3, DOI 10.1016/S0925-4773(02)00260-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BILL A, 1980, T OPHTHAL SOC UK, V100, P332
   Boneva SK, 2016, NEUROSCIENCE, V325, P188, DOI 10.1016/j.neuroscience.2016.03.050
   Braunger BM, 2015, AM J PATHOL, V185, P1749, DOI 10.1016/j.ajpath.2015.02.007
   Braunger BM, 2014, INVEST OPHTH VIS SCI, V55, P7499, DOI 10.1167/iovs.14-14872
   Braunger BM, 2013, J NEUROSCI, V33, P14246, DOI 10.1523/JNEUROSCI.0991-13.2013
   Braunger BM, 2013, NEUROBIOL DIS, V50, P1, DOI 10.1016/j.nbd.2012.09.008
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Carmeliet P, 2013, CELL MOL LIFE SCI, V70, P1763, DOI 10.1007/s00018-013-1283-7
   Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046
   Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, NAT RES COUNC GUID C
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Cvetanovic M, 2011, NAT MED, V17, P1445, DOI 10.1038/nm.2494
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418
   Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522
   Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597
   Herrnberger L, 2012, HISTOCHEM CELL BIOL, V138, P709, DOI 10.1007/s00418-012-0987-3
   HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253
   HUME DA, 1984, P NATL ACAD SCI-BIOL, V81, P4174, DOI 10.1073/pnas.81.13.4174
   Jeon SH, 2007, J LEUKOCYTE BIOL, V81, P557, DOI 10.1189/jlb.0806517
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kannan R, 2006, MOL VIS, V12, P1649
   KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137
   Kaufman PL, 2011, ADLERS PHYSL EYE
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kugler M, 2017, HISTOCHEM CELL BIOL, V148, P21, DOI 10.1007/s00418-017-1549-5
   Kugler M, 2015, HISTOCHEM CELL BIOL, V144, P443, DOI 10.1007/s00418-015-1354-y
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Le YZ, 2010, J NEUROCHEM, V112, P1584, DOI 10.1111/j.1471-4159.2010.06573.x
   Lee KS, 2008, EUR RESPIR J, V31, P523, DOI 10.1183/09031936.00125007
   Li FF, 2011, DEV CELL, V20, P291, DOI 10.1016/j.devcel.2011.01.011
   Li ZD, 2005, BIOCHEM BIOPH RES CO, V334, P1049, DOI 10.1016/j.bbrc.2005.07.005
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOEFFLER KU, 1992, ARCH OPHTHALMOL-CHIC, V110, P15
   Ma MM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-117
   Ma YY, 2009, J NEUROSCI RES, V87, P393, DOI 10.1002/jnr.21859
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Monvoisin A, 2006, DEV DYNAM, V235, P3413, DOI 10.1002/dvdy.20982
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Nam EH, 2010, EXP MOL MED, V42, P606, DOI 10.3858/emm.2010.42.9.059
   Nguyen HL, 2011, LAB INVEST, V91, P1554, DOI 10.1038/labinvest.2011.124
   Ohlmann A, 2016, HISTOCHEM CELL BIOL, V146, P769, DOI 10.1007/s00418-016-1461-4
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Park HYL, 2013, AM J PATHOL, V182, P2147, DOI 10.1016/j.ajpath.2013.02.009
   Park SM, 2008, CELL PROLIFERAT, V41, P248, DOI 10.1111/j.1365-2184.2008.00514.x
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313, DOI 10.3109/10520296009114754
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Roussa E, 2009, ADV EXP MED BIOL, V651, P81
   Rousseau B, 2003, EXP EYE RES, V77, P147, DOI 10.1016/S0014-4835(03)00127-1
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schlecht A, 2016, ADV EXP MED BIOL, V854, P495, DOI 10.1007/978-3-319-17121-0_66
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shi X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.282
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   Stan RV, 2012, DEV CELL, V23, P1203, DOI 10.1016/j.devcel.2012.11.003
   Stan RV, 2001, GENOMICS, V72, P304, DOI 10.1006/geno.2000.6489
   Stan RV, 1999, P NATL ACAD SCI USA, V96, P13203, DOI 10.1073/pnas.96.23.13203
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zhu Y, 2004, NEUROSCIENCE, V123, P897, DOI 10.1016/j.neuroscience.2003.10.037
NR 91
TC 19
Z9 19
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2017
VL 187
IS 11
BP 2570
EP 2589
DI 10.1016/j.ajpath.2017.06.018
PG 20
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA FL6UQ
UT WOS:000414382100017
PM 28823871
OA Bronze
DA 2022-11-30
ER

PT J
AU Keane, PA
   Chang, KT
   Liakopoulos, S
   Jivrajka, RV
   Walsh, AC
   Sadda, SR
AF Keane, Pearse A.
   Chang, Karen T.
   Liakopoulos, Sandra
   Jivrajka, Renu V.
   Walsh, Alexander C.
   Sadda, Srinivas R.
TI EFFECT OF RANIBIZUMAB RETREATMENT FREQUENCY ON NEUROSENSORY RETINAL
   VOLUME IN NEOVASCULAR AMD
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography;
   ranibizumab
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; QUANTITATIVE SUBANALYSIS; BEVACIZUMAB AVASTIN;
   SUBGROUP ANALYSIS; VERTEPORFIN; SECONDARY; LUCENTIS; THERAPY
AB Purpose: To determine the characteristics of patients with neovascular age-related macular degeneration who show initial anatomic improvements on optical coherence tomography in response to treatment with ranibizumab, but who subsequently regress toward their anatomic baseline.
   Methods: Data from 50 consecutive patients, receiving ranibizumab therapy for neovascular age-related macular degeneration, were collected. Raw StratusOCT images were analyzed using custom software ("OCTOR"). Changes in volume of neurosensory retina at months 1, 3, and 6 were calculated. Baseline demographic and morphologic characteristics were compared.
   Results: Forty-two patients (84%) showed a reduction in total retinal volume 1 month after initial treatment with ranibizumab. Of the patients that initially showed a reduction, 16 (38%) maintained this reduction through month 6, whereas 26 patients (62%) demonstrated a subsequent increase in retinal volume. Patients who maintained a reduction in edema received 3.75 +/- 1.18 injections of ranibizumab versus 2.96 +/- 1.34 injections for patients who did not (P = 0.049). Regression of initial anatomic improvements was associated with worsening of visual acuity (r = 0.599, P = 0.002).
   Conclusion: Patients receiving fewer injections of ranibizumab appeared less likely to maintain anatomic improvements achieved following commencement of ranibizumab therapy; regression of these improvements was associated with deterioration in visual acuity. RETINA 29:592-600, 2009
C1 [Keane, Pearse A.; Chang, Karen T.; Liakopoulos, Sandra; Jivrajka, Renu V.; Walsh, Alexander C.; Sadda, Srinivas R.] Univ So Calif, Doheny Eye Inst, Doheny Image Reading Ctr, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Liakopoulos, Sandra] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-5000 Cologne 41, Germany.
C3 Doheny Eye Institute; University of Southern California; University of
   Cologne
RP Sadda, SR (通讯作者)，Univ So Calif, Doheny Eye Inst, Doheny Image Reading Ctr, Keck Sch Med, DEI 3623,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
RI Keane, Pearse A/H-1860-2011; Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X
FU NIH [EY03040]; NEI [R01 EY014375]; NATIONAL EYE INSTITUTE [R01EY014375,
   P30EY003040] Funding Source: NIH RePORTER
FX Supported in part by NIH Grant EY03040 and NEI Grant R01 EY014375.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BENZ MS, 2008, INVEST OPHTHALMOL VI, V49
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillen D, 2001, BEST PRACT RES CL GA, V15, P487, DOI 10.1053/bega.2001.0190
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Matsumoto Y, 2007, RETINA-J RET VIT DIS, V27, P426, DOI 10.1097/IAE.0b013e31804a7af2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.OPHTHA.2006.01.027
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 26
TC 14
Z9 15
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2009
VL 29
IS 5
BP 592
EP 600
DI 10.1097/IAE.0b013e31819b17a5
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 445OB
UT WOS:000266059000005
PM 19289984
DA 2022-11-30
ER

PT J
AU Awan, MA
   Tarin, SA
AF Awan, M. A.
   Tarin, S. A.
TI Review of photodynamic therapy
SO SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND
   IRELAND
LA English
DT Review
DE photodynamic; therapy; verteporfin; porfimer
ID PIGMENTED CHOROIDAL MELANOMAS; VERTEPORFIN; NEOVASCULARIZATION
AB Introduction: Photodynamic Therapy (PDT) is an emerging treatment for a variety of conditions including ocular and extra ocular diseases. The porphyrins have been used extensively, as dyes, which are laser-activated to achieve desired clinical effects. Commonly used agents are verteporfin and porfimer sodium. Methods: We performed a literature search of the PubMed database using the medical search headings: photodynamic therapy, photosensitizer verteporfin, visudyne, porfimer sodium and photofrin. We also performed a manual search using references from these articles, review articles and manufacturers' product monographs. Results: Verteporfin and porfimer sodium are commonly used photosensitizing agents with their wide applications in different fields of medicine. Both have well established safety profiles. They are most commonly used in wet age-related macular degeneration, gastrointestinal diseases and bronchial cancers. Conclusion: PDT is a well established treatment entity in ophthalmology and other medical fields. In ophthalmology, it has rekindled interest and hopes in the common yet sight-threatening problem of age-related macular degeneration (AMD). This problem is still considered to be a serious issue as far as management is concerned. However in selective cases of AMD, it has shown success in restoring sight, especially in the 'classic' form of the disease. PDT is also being used to treat a range of solid cancers and non malignant conditions.
C1 Wolverhampton Eye Infirm, Wolverhampton WV3 9QR, England.
RP Awan, MA (通讯作者)，Wolverhampton Eye Infirm, Wolverhampton WV3 9QR, England.
EM dramer_awan@yahoo.co.uk
RI Awan, Muhammad Amer/ABA-5651-2020
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   *AXC PHARM INC, 2003, PHOT PROD MON
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boehncke WH, 2000, ARCH DERMATOL, V136, P271, DOI 10.1001/archderm.136.2.271
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Busetti A, 1999, BRIT J CANCER, V79, P821, DOI 10.1038/sj.bjc.6690131
   Chowdhary RK, 1998, BIOPHARM DRUG DISPOS, V19, P395, DOI 10.1002/(SICI)1099-081X(199809)19:6<395::AID-BDD117>3.0.CO;2-9
   Hendrich C, 2000, KNEE SURG SPORT TR A, V8, P190, DOI 10.1007/s001670050213
   Hoerauf H., 1994, Ophthalmologe, V91, P824
   Husain D, 1997, OPHTHALMOLOGY, V104, P1242, DOI 10.1016/S0161-6420(97)30151-1
   ILER JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Kim RY, 1996, OPHTHALMOLOGY, V103, P2029, DOI 10.1016/S0161-6420(96)30391-6
   Leong S, 1996, PHOTOCHEM PHOTOBIOL, V64, P751, DOI 10.1111/j.1751-1097.1996.tb01830.x
   Levy P, 2002, SLEEP MED REV, V6, P15, DOI 10.1053/smrv.2002.0219
   LUI H, 1994, SEMIN ONCOL, V21, P11
   McCaughan JS, 1999, DRUG AGING, V15, P49, DOI 10.2165/00002512-199915010-00005
   Momma T, 1998, CANCER RES, V58, P5425
   MULRONEY CM, 1994, SEMIN ONCOL, V21, P24
   *NOV OPHTH, 2004, VIS PROD MON
   Obochi MOK, 1997, TRANSPLANTATION, V63, P810, DOI 10.1097/00007890-199703270-00004
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   SchmidtErfurth U, 1997, BRIT J CANCER, V75, P54, DOI 10.1038/bjc.1997.9
   SchmidtErfurth U, 1996, EXP EYE RES, V62, P1, DOI 10.1006/exer.1996.0001
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Senior K, 1998, MOL MED TODAY, V4, P416, DOI 10.1016/S1357-4310(98)01356-2
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   TETSUYA, 1999, PHOTODYNAMICS NEWS, V2, P1461
   Turnbull RC, 2000, J INVEST SURG, V13, P153
   Young LHY, 1996, ARCH OPHTHALMOL-CHIC, V114, P186, DOI 10.1001/archopht.1996.01100130180013
NR 32
TC 38
Z9 40
U1 0
U2 37
PU ROYAL COLLEGE SURGEONS EDINBURGH
PI EDINBURGH
PA NICOLSON ST, EDINBURGH EH8 9DW, SCOTLAND
SN 1479-666X
J9 SURG-J R COLL SURG E
JI Surg. J. R. Coll. Surg. Edinb. Irel.
PD AUG
PY 2006
VL 4
IS 4
BP 231
EP 236
DI 10.1016/S1479-666X(06)80065-X
PG 6
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 069SB
UT WOS:000239467400006
PM 16892841
DA 2022-11-30
ER

PT J
AU Tsai, IL
   Woung, LC
   Tsai, CY
   Kuo, LL
   Liu, SW
   Lin, S
   Wang, IJ
AF Tsai, I. -L.
   Woung, L. -C.
   Tsai, C. -Y.
   Kuo, L. -L.
   Liu, S. -W.
   Lin, S.
   Wang, I. -J.
TI Trends in blind and low vision registrations in Taipei City
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE impairment; low vision; blindness; Taipei City; Taiwan
ID UNREGISTERED VISUAL IMPAIRMENT; CATARACT-SURGERY; PARTIAL SIGHT;
   PREVALENCE; POPULATION; GLAUCOMA; SCOTLAND; PEOPLE; COUNTY; RATES
AB PURPOSE. To determine the overall reported incidence and causes of registrable blindness and low vision in Taipei, Taiwan, that have occurred in the previous 10 years.
   METHODS. Study data were obtained from disability identification registration forms completed between January 1995 and December 2004. Definitions of low vision and blindness were defined by WHO criteria: low vision included visual acuity worse than 6/18 (20/60) to a lower limit of 3/60 (20/400). Blindness was defined as visual acuity worse than 3/60 ( 0/400) in the better eye with best possible correction.
   RESULTS. There were 3151 registrations for visual impairment during the study period. A total of 239 registrations were excluded due to insufficient data. Of the remaining 2912 (1518 males and 1394 females), 640 males and 647 females were legally blind (44.20%). A total of 878 males and 747 females were partially sighted. The six leading causes of low vision and blindness, in decreasing frequency, were glaucoma, optic neuropathy, diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration, and myopic macular degeneration.
   CONCLUSIONS. The proportions of new registrations owing to glaucoma, diabetic retinopathy, age-related macular degeneration, and myopic macular degeneration have changed significantly since 2000; the proportion due to diabetic retinopathy has increased.
C1 [Wang, I. -J.] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Tsai, I. -L.; Tsai, C. -Y.; Kuo, L. -L.; Liu, S. -W.] Taipei City Hosp, Zhongxing Branch, Dept Ophthalmol, Taipei, Taiwan.
   [Woung, L. -C.] Taipei City Hosp, Jen Ai Branch, Dept Ophthalmol, Taipei, Taiwan.
   [Lin, S.] Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA.
C3 National Taiwan University; National Taiwan University Hospital; Taipei
   City Hospital; Taipei City Hospital; University of California System;
   University of California San Francisco
RP Wang, IJ (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan S Rd, Taipei, Taiwan.
EM ijong@ha.mc.ntu.edu.tw
OI WOUNG, LIN-CHUNG/0000-0002-0700-7606; Wang, I-Jong/0000-0002-3045-0614
CR ACLIMANDOS WA, 1988, EYE, V2, P431, DOI 10.1038/eye.1988.78
   Al-Merjan JI, 2005, OPHTHAL EPIDEMIOL, V12, P251, DOI 10.1080/09286580591005813
   Bamashmus MA, 2004, EYE, V18, P257, DOI 10.1038/sj.eye.6700606
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Farber MD, 2003, OPHTHAL EPIDEMIOL, V10, P267, DOI 10.1076/opep.10.4.267.15910
   Foster PJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P1105, DOI 10.1001/archopht.118.8.1105
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   GIBSON JM, 1986, BRIT J OPHTHALMOL, V70, P700, DOI 10.1136/bjo.70.9.700
   GREENBLATT SL, 1988, SOC SCI MED, V26, P393, DOI 10.1016/0277-9536(88)90307-3
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   King AJW, 2000, EYE, V14, P613, DOI 10.1038/eye.2000.152
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   Lin LLK, 2004, ANN ACAD MED SINGAP, V33, P27
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   NICOLOSI A, 1994, INT J EPIDEMIOL, V23, P359, DOI 10.1093/ije/23.2.359
   Pardhan S, 2002, EYE, V16, P572, DOI 10.1038/sj.eye.6700164
   PODOS SM, 1966, AM J OPHTHALMOL, V62, P1039, DOI 10.1016/0002-9394(66)92551-7
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROBINSON JR, 1993, J VISUAL IMPAIR BLIN, V87, P78
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Trautner C, 2001, DIABETOLOGIA, V44, P147, DOI 10.1007/s001250051592
   Zhao J, 1999, Zhonghua Yan Ke Za Zhi, V35, P341
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P506, DOI 10.1016/S0002-9394(98)00275-X
NR 27
TC 6
Z9 7
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2008
VL 18
IS 1
BP 118
EP 124
DI 10.1177/112067210801800120
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 268CW
UT WOS:000253556900020
PM 18203096
DA 2022-11-30
ER

PT J
AU Stewart, WC
   Stewart, JA
   Nelson, LA
AF Stewart, William C.
   Stewart, Jeanette A.
   Nelson, Lindsay A.
TI Ophthalmic community perception of new medication needs
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE ophthalmic; ophthalmology; ocular; eye disease; pharmaceuticals;
   start-up; development; needs; medication; therapies; future; new
   treatments
ID START-UP COMPANIES; DRUG DISCOVERY; CHALLENGES
AB AIM: To survey ophthalmologists (who have participated previously in clinical research) and ophthalmic industry professionals (who have been involved in ocular research and development) to indicate perceived needs for new pharmaceuticals in various ophthalmic subspecialties.
   METHODS: A prospective, industry-based survey was sent to ophthalmologists and ophthalmic industry professionals about the perceived needs for new pharmaceutical products.
   RESULTS: This survey was sent to 559 ophthalmic pharma professionals and ophthalmologists. We received 82 (15%) responses. The results showed that the most commonly perceived need for new pharmaceuticals were dry and wet age-related macular degeneration, glaucoma, diabetic macular edema and dry eye. There was a statistical difference found between response groups (P< 0.0001). Respondents indicated they would express their commitment to a new product they perceived as needed by recommending to colleagues (63%), prescribing (60%), participating as principle investigator in a related clinical trial (52%), advising the company (52%), lecturing on behalf of the product (43%), investing in the product (38%), taking no action (7%) or obtain a position in the company (1%).
   CONCLUSION: Ophthalmic pharma professionals and ophthalmologists perceive the greatest need for new medicines in ophthalmology to be in dry and wet age-related macular degeneration, glaucoma, diabetic macular edema and dry eye.
C1 [Stewart, William C.; Stewart, Jeanette A.; Nelson, Lindsay A.] PRN PharmaFarm LLC, Cheyenne, WY 82001 USA.
RP Stewart, WC (通讯作者)，109 East 17th St,Suite 3407, Cheyenne, WY 82001 USA.
EM info@prnorb.com
CR Book SA, 1978, ESSENTIALS STAT
   Chao W, 2016, OCUL SURF, V14, P264, DOI 10.1016/j.jtos.2015.11.003
   Dahl AA, BLINDNESS
   Downing NS, 2014, JAMA-J AM MED ASSOC, V311, P368, DOI 10.1001/jama.2013.282034
   Gower NJD, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0188-2
   Hwang J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007987
   Kolchinsky P., ENTREPRENEURS GUIDE
   Loss, 2013, SIGHT LOSS VISION PR
   Martin DF, 2015, NEW ENGL J MED, V372, P1260, DOI 10.1056/NEJMe1500351
   National Eye Institute, 2012, VIS RES NEEDS GAPS O
   Riley, 2014, WHAT INVESTORS ARE L
   Sharpe RA, 2015, OPHTHALMIC RES, V54, P6, DOI 10.1159/000377636
   Stewart WC, 2014, REV OPHTHALMOL, P54
   Stewart WC, 2013, REV OPHTHALMOL, P62
   Stewart WC, 2013, ACTA OPHTHALMOL, V91, pe81, DOI 10.1111/j.1755-3768.2012.02443.x
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   UEF Bulletin, 2017, UEF B
   World Health Organization, 2021, BLINDN VIS IMP
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 19
TC 0
Z9 0
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAY 18
PY 2018
VL 11
IS 5
BP 848
EP 851
DI 10.18240/ijo.2018.05.22
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH2QL
UT WOS:000433246500022
PM 29862187
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Sun, TT
   Bai, JH
   Wang, ML
   Liu, L
   Peng, Q
AF Sun, Tingting
   Bai, Jianhao
   Wang, Minli
   Liu, Le
   Peng, Qing
TI Cytokine profiling in patients with polypoidal choroidal vasculopathy
   before and after intravitreal injection of ranibizumab
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Choroidal neovascularization (CNV); polypoidal choroidal vasculopathy
   (PCV); ranibizumab; cytokine
ID MACULAR DEGENERATION; MOLECULAR REGULATION; BONE-MARROW; CHEMOKINES;
   ANGIOGENESIS; CELLS; CCL5/RANTES; EXPRESSION; DIAGNOSIS
AB Objective: This study aims to investigate the cytokines profiling in the aqueous humor of patients with polypoidal choroidal vasculopathy (PCV) before and after intravitreal ranibizumab injection (IVR). Methods: 14 patients clinically diagnosed with PCV and 15 cataract patients of similar age and gender (control group) were included. Throughout the cataract surgery and IVR, aqueous humor samples were collected from the PCV and control groups. Results: The levels of macrophage inflammatory protein 1 beta (MIP-1 beta) and normal T cell expressed and secreted (RANTES) in PCV patients were significantly lower than control subjects (P=0.045 and P=0.004, respectively). The concentration of vascular endothelial growth factor-A (VEGF-A) was significantly higher than the control group (P=0.003). The level of MIP-1 beta was greatly increased in PCV patients compared to prior to IVR (P=0.001). After IVR, the level of VEGF-A in PCV patients were considerably lower compared to before IVR (P=0.001). There was no link between the expression of several cytokines (MCP-1, MIP-1, Eotaxin, G-CSF, IL-8, IL-6, IL-5, IP-10 and IFN-gamma) in the aqueous humor of PCV patients before and after intravitreal ranibizumab injection (IVR). The association between IL-5 expression and central macular thickness (CMT) was discovered before IVR (P=0.02), however, the correlation between several cytokines (MCP-1, MIP-1, Eotaxin, G-CSF, IL-8, IL-6, IL-5, IP-10 and IFN-gamma) was discovered in PCV patients after IVR. Conclusion: Based on our findings, we discovered that the production of neovascularization in PCV patients is driven by both angiogenic and inflammatory factors, with a correlation seen between several cytokines.
C1 [Sun, Tingting; Bai, Jianhao; Wang, Minli; Peng, Qing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.
   [Liu, Le] Tsinghua Univ, Shenzhen Int Grad Sch, Inst Mat Res, Shenzhen 518055, Peoples R China.
C3 Tongji University; Tsinghua University
RP Liu, L; Peng, Q (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.
EM liu.le@sz.tsinghua.edu.cn; pengqing@tongji.edu.cn
FU National Natural Science Foundation of China [81470025]; Three-Year
   Action Plan for Promoting Clinical Skills and Clinical Innovation in
   Municipal Hospitals [SHDC2020CR5014]
FX The National Natural Science Foundation of China (No. 81470025) and the
   Three-Year Action Plan for Promoting Clinical Skills and Clinical
   Innovation in Municipal Hospitals funded this research (No.
   SHDC2020CR5014). All participant information was anonymized and
   de-identified. We plan to share the data collected throughout the
   experiment with the participants as soon as it is published. This paper
   contains all of the data that was generated or analysed throughout the
   investigation.
CR Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Balne PK, 2018, DATA BRIEF, V19, P1570, DOI 10.1016/j.dib.2018.05.085
   Baltus T, 2005, J LEUKOCYTE BIOL, V78, P435, DOI 10.1189/jlb.0305141
   Barcelos LS, 2009, MICROVASC RES, V78, P148, DOI 10.1016/j.mvr.2009.04.009
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen TC, 2011, J BIOL CHEM, V286, P25564, DOI 10.1074/jbc.M111.230540
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Deshauer C, 2015, STRUCTURE, V23, P1066, DOI 10.1016/j.str.2015.03.024
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Guyot Melanie, 2015, Methods Mol Biol, V1332, P3, DOI 10.1007/978-1-4939-2917-7_1
   Honczarenko M, 2002, BLOOD, V100, P2321, DOI 10.1182/blood-2002-01-0248
   Ishikawa K, 2012, LAB INVEST, V92, P91, DOI 10.1038/labinvest.2011.141
   Keophiphath M, 2010, ARTERIOSCL THROM VAS, V30, P39, DOI 10.1161/ATVBAHA.109.197442
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   McColl BK, 2004, APMIS, V112, P463, DOI 10.1111/j.1600-0463.2004.apm11207-0807.x
   Mirabelli-Badenier M, 2011, THROMB HAEMOSTASIS, V105, P409, DOI 10.1160/TH10-10-0662
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Tatara Y, 2009, J MOL CELL CARDIOL, V47, P104, DOI 10.1016/j.yjmcc.2009.03.012
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yao LB, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/181450
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 31
TC 0
Z9 0
U1 1
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2022
VL 14
IS 10
BP 7147
EP 7155
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 6F0RX
UT WOS:000883778800004
PM 36398243
DA 2022-11-30
ER

PT J
AU Roberts, PK
   Schranz, M
   Motschi, A
   Desissaire, S
   Hacker, V
   Pircher, M
   Sacu, S
   Buehl, W
   Hitzenberger, CK
   Schmidt-Erfurth, U
AF Roberts, Philipp Ken
   Schranz, Markus
   Motschi, Alice
   Desissaire, Sylvia
   Hacker, Valentin
   Pircher, Michael
   Sacu, Stefan
   Buehl, Wolf
   Hitzenberger, Christoph Konrad
   Schmidt-Erfurth, Ursula
TI Morphologic and Microvascular Differences Between Macular
   Neovascularization With and Without Subretinal Fibrosis
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography; optical
   coherence tomography angiography
ID OPTICAL-COHERENCE-TOMOGRAPHY; OUTER RETINAL TUBULATION; GROWTH-FACTOR
   THERAPY; CHOROIDAL NEOVASCULARIZATION; DEGENERATION; IDENTIFICATION;
   ANGIOGRAPHY; PROGRESSION; QUANTIFICATION; FEATURES
AB Purpose: To evaluate morphologic and microvascular differences between eyes with and without subretinal fibrosis (SF) caused by neovascular age-related macular degeneration (nAMD). Methods: Patients with nAMD with a minimum history of 12 months of anti-VEGF treatment were prospectively included in this cross-sectional study. Patients were imaged using standard imaging, swept-source optical coherence tomography angiography for quantitative microvascular analysis and polarization-sensitive OCT as an ancillary method for automated SF segmentation. The presence of reticular pseudodrusen, hyperreflective foci (HRF), and outer retinal tubulation (ORT) were also evaluated. Results: Sixty eyes of 60 participants (37 female) with nAMD and a mean 3.1 (+/- 2.7)-year history of anti-VEGF treatment were included, 20 (33%) of which were diagnosed with SF. Eyes with SF had a higher prevalence of ORT (P < 0.001) and a lower prevalence of HRF (P = 0.004) than eyes without SF. Fifty eyes were analyzed quantitatively for microvascular biomarkers. Eyes with SF had a larger greatest vascular caliber (P = 0.001) and greatest linear diameter (P = 0.042), a larger microvascular neovascularization (MNV) area (P = 0.026), larger vessel area (P = 0.037), higher number of vessel junctions (P = 0.025), longer total vessel length (P = 0.027), higher number of vessel endpoints (P = 0.007), and higher endpoint density (P = 0.047). Conclusions: This multimodal imaging approach demonstrated in vivo microvascular and morphological differences in eyes with and without SF. Eyes with SF tend to have larger MNV lesions with thicker vessels and are often associated with the presence of ORT.
C1 [Roberts, Philipp Ken; Schranz, Markus; Hacker, Valentin; Sacu, Stefan; Buehl, Wolf; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Motschi, Alice; Desissaire, Sylvia; Pircher, Michael; Hitzenberger, Christoph Konrad] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Desissaire, Sylvia/0000-0002-7227-8031
FU FWF (Austrian Science Fund) [KLI 749-B]
FX Supported by the FWF (Austrian Science Fund; Grant number KLI 749-B) .
CR Babalola O, 2014, ARCH DERMATOL RES, V306, P1, DOI 10.1007/s00403-013-1417-7
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   Choi M, 2020, AM J OPHTHALMOL, V213, P109, DOI 10.1016/j.ajo.2020.01.012
   Daftarian N, 2019, EXP EYE RES, V184, P286, DOI 10.1016/j.exer.2019.04.027
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   Eastline M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.6
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Grafe MGO, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.13
   Hariri LP, 2019, CLIN CANCER RES, V25, P5242, DOI 10.1158/1078-0432.CCR-19-0566
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678
   Liu Y, 2019, MOL THER-NUCL ACIDS, V17, P113, DOI 10.1016/j.omtn.2019.05.012
   Motschi AR, 2021, BIOMED OPT EXPRESS, V12, P4380, DOI 10.1364/BOE.426650
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Onishi AC, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419840249
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   Roberts PK, 2019, INVEST OPHTH VIS SCI, V60, P304, DOI 10.1167/iovs.18-25189
   Roberts PK, 2017, BRIT J OPHTHALMOL, V101, P1361, DOI 10.1136/bjophthalmol-2016-310004
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sugano Y, 2018, CLIN OPHTHALMOL, V12, P2267, DOI 10.2147/OPTH.S179634
   Sugita M, 2014, BIOMED OPT EXPRESS, V5, P106, DOI 10.1364/BOE.5.000106
   Takeuchi J, 2018, OPHTHALMOLOGICA, V240, P90, DOI 10.1159/000487611
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zeydanli EO, 2021, EUR J OPHTHALMOL, V31, P1192, DOI 10.1177/1120672120925790
   Zhao Z, 2019, OPHTHALMOLOGICA, V242, P178, DOI 10.1159/000497491
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 49
TC 2
Z9 2
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2021
VL 10
IS 14
AR 1
DI 10.1167/tvst.10.14.1
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XL5KQ
UT WOS:000728184200001
PM 34851359
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chino, M
   Yoshikawa, Y
   Kanno, J
   Nagashima, T
   Sakaki, Y
   Katsumoto, T
   Shibuya, M
   Shoji, T
   Makita, J
   Shinoda, K
AF Chino, Minami
   Yoshikawa, Yuji
   Kanno, Junji
   Nagashima, Takamitsu
   Sakaki, Yu
   Katsumoto, Takeshi
   Shibuya, Masayuki
   Shoji, Takuhei
   Makita, Jun
   Shinoda, Kei
TI Development and spontaneous closure of a secondary macular hole
   associated with submacular hemorrhage due to polypoidal choroidal
   vasculopathy: a case report
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Macular hole; Retinal displacement; Spontaneous closure; Submacular
   hemorrhage
ID RANIBIZUMAB; MANAGEMENT; SURGERY
AB BackgroundMacular hole (MH) is a retinal break in the fovea involving partial or complete dehiscence of the neural retinal layers affecting the visual quality by decreasing visual acuity (VA) and visual deformation. We describe a case of secondary MH associated with submacular hemorrhage (SMH) due to polypoidal choroidal vasculopathy (PCV), which showed spontaneous closure.Case presentationA 67-year-old man developed decreased VA in his right eye due to an SMH. The VA was 20/50, and monthly intravitreal injection of aflibercept was administered three times. The SMH gradually decreased, and 10months later the external limiting membrane was found to be perforated, resulting in MH. The old clot disappeared, and the MH remained for 10months. Twenty-three months later, serous retinal detachment (SRD) involving the macula appeared and the MH had disappeared. SRD gradually disappeared, and macular configuration recovered. VA gradually improved and became 20/20 38months later.ConclusionDynamic change of the ultrastructure in an unusual case of secondary-developed and spontaneously closed MH was clearly observed. Although the mechanism was unknown, the small diameter size and exudative PCV are thought to have contributed to the closure.
C1 [Chino, Minami; Yoshikawa, Yuji; Kanno, Junji; Nagashima, Takamitsu; Sakaki, Yu; Katsumoto, Takeshi; Shibuya, Masayuki; Shoji, Takuhei; Makita, Jun; Shinoda, Kei] Saitama Med Univ, Dept Ophthalmol, Fac Med, 38 Moro Hongo, Moroyama, Saitama 3500495, Japan.
   [Nagashima, Takamitsu] Kamishirane Hosp, 2-65-1 Kamishirane, Yokohama, Kanagawa 2410002, Japan.
C3 Saitama Medical University
RP Shinoda, K (通讯作者)，Saitama Med Univ, Dept Ophthalmol, Fac Med, 38 Moro Hongo, Moroyama, Saitama 3500495, Japan.
EM shinodak@med.teikyo-u.ac.jp
RI Shoji, Takuhei/W-1856-2017; Shinoda, Kei/ABC-7993-2020
OI Shoji, Takuhei/0000-0002-5464-2573; Shinoda, Kei/0000-0002-1543-9345
FU Japan Society for the Promotion of Science (JSPS; KAKENHI grant ) [17
   K11430]
FX This study was supported in part by the Japan Society for the Promotion
   of Science (JSPS; KAKENHI grant number: 17 K11430). Funding was provided
   for English editing during manuscript preparation and for the publishing
   fee.
CR Bakri SJ, 2007, GRAEF ARCH CLIN EXP, V245, P609, DOI 10.1007/s00417-006-0349-8
   Benzerroug M, 2008, BRIT J OPHTHALMOL, V92, P217, DOI 10.1136/bjo.2007.122796
   Budoff G, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/5837832
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chen HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep12343
   Cho JH, 2011, CLIN EXP OPTOM, V94, P586, DOI 10.1111/j.1444-0938.2011.00614.x
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Hamano R, 2007, JPN J OPHTHALMOL, V51, P75, DOI 10.1007/s10384-006-0386-1
   Hayashi I, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014230
   Kawaji T, 2019, RETINA-J RET VIT DIS, V39, P84, DOI 10.1097/IAE.0000000000002128
   Kawano K, 2013, EYE, V27, P871, DOI 10.1038/eye.2013.99
   Lee Jennifer, 2019, Am J Ophthalmol Case Rep, V13, P59, DOI 10.1016/j.ajoc.2018.12.006
   Lee Yun Ji, 2019, Korean J Ophthalmol, V33, P198, DOI 10.3341/kjo.2018.0079
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   Liang XD, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/4793764
   McCabe CM, 2000, ARCH OPHTHALMOL-CHIC, V118, P780, DOI 10.1001/archopht.118.6.780
   Oliver A, 2011, OPHTHAL SURG LAS IM, V42, P516, DOI 10.3928/15428877-20110825-01
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Sagara N, 2009, BRIT J OPHTHALMOL, V93, P1337, DOI 10.1136/bjo.2008.149195
   Sato R, 2008, GRAEF ARCH CLIN EXP, V246, P1779, DOI 10.1007/s00417-008-0930-4
   Su D, 2016, JAMA OPHTHALMOL, V134, P604, DOI 10.1001/jamaophthalmol.2016.0020
   Tashimo A, 2003, AM J OPHTHALMOL, V135, P487, DOI 10.1016/S0002-9394(02)02084-6
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Uemoto R, 2008, EUR J OPHTHALMOL, V18, P462, DOI 10.1177/112067210801800326
   Wong R, 2018, RETINA-J RET VIT DIS, V38, P660, DOI 10.1097/IAE.0000000000001705
   Yamashita T, 2002, AM J OPHTHALMOL, V133, P230, DOI 10.1016/S0002-9394(01)01303-4
NR 26
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAR 17
PY 2020
VL 20
IS 1
AR 108
DI 10.1186/s12886-020-01370-8
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW5GU
UT WOS:000521194000003
PM 32183733
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mori, R
   Yuzawa, M
   Akaza, E
   Haruyama, M
AF Mori, Ryusaburo
   Yuzawa, Mitsuko
   Akaza, Eriko
   Haruyama, Miho
TI Treatment results at 1 year of ranibizumab therapy for polypoidal
   choroidal vasculopathy in eyes with good visual acuity
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Ranibizumab; Visual outcome
ID PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION;
   FOLLOW-UP; VERTEPORFIN; EFFICACY; INJECTION; SAFETY
AB To evaluate the efficacy of intravitreal ranibizumab (IVR) for subfoveal polypoidal choroidal vasculopathy (PCV) in eyes with a best corrected visual acuity (BCVA) of 0.6 (logMAR 0.22) or better.
   Fifty eyes with BCVA between 0.6 (logMAR 0.22) and 1.0 (logMAR 0) and subfoveal PCV were treated with IVR for 3 consecutive months. Additional IVR was given at subsequent monthly visits, if needed, up to 11 months after the initial injection. The patients were followed-up prospectively for 12 months, and changes in mean BCVA, central retinal thickness (CRT), serous retinal detachment (SRD), hemorrhage, and number of polypoidal lesions were evaluated.
   Mean BCVA improved significantly at the 3-, 6-, 9-, and 12-month follow-up visits and CRT decreased significantly at 1, 2, 3, 6, 9, and 12 months after the initial treatment as compared with the baseline. SRD was observed in 10 and 21 eyes at 3 and 12 months. Hemorrhage was observed in 6 eyes at 3 months and 3 eyes at 12 months. All polypoidal lesions had completely regressed in 19 % and the size of network vessels was either unchanged or enlarged in 98 % of the eyes at 12 months.
   Based on the maintenance of vision improvement for at least 12 months, IVR for PCV proved useful for eyes with BCVAs of 0.6 (logMAR 0.22) to 1.0 (logMAR 0), despite a low regression rate of polypoidal lesions and minimal network size reduction.
C1 [Mori, Ryusaburo; Yuzawa, Mitsuko; Akaza, Eriko; Haruyama, Miho] Surugadai Nihon Univ Hosp, Dept Ophthalmol, Sch Med, Chiyoda Ku, Tokyo 1018309, Japan.
C3 Nihon University
RP Yuzawa, M (通讯作者)，Surugadai Nihon Univ Hosp, Dept Ophthalmol, Sch Med, Chiyoda Ku, 1-8-13 Surugadai Kanda, Tokyo 1018309, Japan.
EM yuzawa.mitsuko@nihon-u.ac.jp
FU Research Committee on Chorioretinal Degenerations and Optic Atrophy, The
   Ministry of Health and Welfare of Japan
FX This study was funded in part by the Research Committee on Chorioretinal
   Degenerations and Optic Atrophy, The Ministry of Health and Welfare of
   Japan (Mitsuko Yuzawa).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2010, BR J OPHTHALMOL, V150, pe1
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 19
Z9 19
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2013
VL 57
IS 4
BP 365
EP 371
DI 10.1007/s10384-013-0245-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 183SE
UT WOS:000321836700005
PM 23665979
DA 2022-11-30
ER

PT J
AU Bejarano, E
   Taylor, A
AF Bejarano, Eloy
   Taylor, Allen
TI Too sweet: Problems of protein glycation in the eye
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Advanced glycation-end products; Age-related macular degeneration;
   Diabetic retinopathy; Cataracts; Diabetes; Aging; Glycemic index;
   Cornea; Retina; Trabecular meshwork; Vitreous; Retina; Optic nerve
ID ENDOTHELIAL GROWTH-FACTOR; DIETARY GLYCEMIC INDEX; GLYCOSYLATION
   END-PRODUCTS; ADVANCED MAILLARD REACTION; IMIDAZOLIUM CROSS-LINKS;
   NUCLEAR LENS OPACITIES; BOVINE SERUM-ALBUMIN; MACULAR DEGENERATION;
   DIABETIC-RATS; IN-VITRO
AB Laboratory and epidemiological data indicate that high blood sugar levels and/or consuming high glycemia diets are linked to multiple age-related diseases, including age-related macular degeneration, cataract, Parkinson's disease, Alzheimer's disease, diabetic retinopathy, and, apparently glaucoma. High concentrations of blood sugar and perturbations of the systems that regulate blood sugar lead to the accumulation of advanced-glycation end products (AGEs). AGEs are toxic compounds that are formed from the combination of sugars and their meta-bolites with biomolecules in a non-enzymatic biochemical reaction called glycation. In vitro and in vivo data indicate that high sugar consumption is associated with accumulation of AGEs in a variety of human tissues. Hyperglycemia, along with an oxidative environment and limited cell proliferation in many ocular tissues, encourages formation and precludes dilution of AGEs and associated damage by cell division. These circumstances make many eye tissues vulnerable to glycation-derived damage. Here, we summarize research regarding glycation-induced ocular tissue dysfunction and its contribution to the onset and development of eye disorders. We also discuss how management of carbohydrate nutrition may provide a low-cost way to ameliorate the progression of AGEs-related diseases, including age related macular degeneration and some cataracts, as they do for cardiovascular disease and diabetes.
C1 [Bejarano, Eloy; Taylor, Allen] Tufts Univ, USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA)
RP Bejarano, E; Taylor, A (通讯作者)，Tufts Univ, USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.
EM eloy.bejarano@tufts.edu; allen.taylor@tufts.edu
RI Bejarano, Eloy/AAJ-4708-2021
OI Bejarano, Eloy/0000-0001-8390-1581
FU NIH [RO1 EY 13250, RO1 EY21212, RO1 EY26979]; USDA
   [1950-510000-060-03A]; U.S. Department of Agriculture-Agriculture
   Research Service (ARS); USDA AFRI Grant [12212122]; NATIONAL EYE
   INSTITUTE [R01EY026979] Funding Source: NIH RePORTER
FX This work was funded by NIH RO1 EY 13250, RO1 EY21212, RO1 EY26979, USDA
   contract 1950-510000-060-03A U.S. Department of Agriculture-Agriculture
   Research Service (ARS) and USDA AFRI Grant 12212122. The authors declare
   no competing financial interests. We are grateful to Elizabeth Whitcomb,
   Sheldon Rowan, Jonathan Volkin and Opeoluwa Olukorede for critical
   reading and editorial help.
CR Abiko T, 1999, EXP EYE RES, V68, P361, DOI 10.1006/exer.1998.0615
   Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565
   AHMED MU, 1986, J BIOL CHEM, V261, P4889
   Albon J, 2000, BRIT J OPHTHALMOL, V84, P311, DOI 10.1136/bjo.84.3.311
   Amano S, 2001, BRIT J OPHTHALMOL, V85, P52, DOI 10.1136/bjo.85.1.52
   Aragno M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040385
   ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x
   Bejarano Eloy, 2010, Proc Am Thorac Soc, V7, P29, DOI 10.1513/pats.200909-102JS
   Berner AK, 2012, DIABETOLOGIA, V55, P845, DOI 10.1007/s00125-011-2393-0
   BESWICK HT, 1987, BIOCHEM J, V246, P761, DOI 10.1042/bj2460761
   Brummer G, 2011, INVEST OPHTH VIS SCI, V52, P6363, DOI 10.1167/iovs.11-7585
   Caballero B, 2018, AGING CELL, V17, DOI 10.1111/acel.12692
   Cai WW, 2018, CLIN NUTR, V37, P459, DOI 10.1016/j.clnu.2017.01.023
   CASEY EB, 1995, J BIOL CHEM, V270, P20781, DOI 10.1074/jbc.270.35.20781
   Chellan P, 1999, ARCH BIOCHEM BIOPHYS, V368, P98, DOI 10.1006/abbi.1999.1291
   Chiarelli F, 1999, J PEDIATR-US, V134, P486, DOI 10.1016/S0022-3476(99)70208-8
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P1177, DOI 10.1093/ajcn/83.5.1177
   Chiu CJ, 2017, INVEST OPHTH VIS SCI, V58, P1404, DOI 10.1167/iovs.16-20454
   Chiu CJ, 2011, NUTR REV, V69, P231, DOI 10.1111/j.1753-4887.2011.00382.x
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2010, INVEST OPHTH VIS SCI, V51, P2897, DOI 10.1167/iovs.08-2824
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Ciechanover A, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.117
   Clements RS, 1998, J DIABETES COMPLICAT, V12, P28, DOI 10.1016/S1056-8727(97)00051-2
   Curtis TM, 2011, DIABETOLOGIA, V54, P690, DOI 10.1007/s00125-010-1971-x
   Du L, 2017, MOL CELL ENDOCRINOL, V452, P44, DOI 10.1016/j.mce.2017.05.011
   DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481
   Eisermann DJ, 2017, BIOCHEM BIOPH RES CO, V484, P171, DOI 10.1016/j.bbrc.2017.01.043
   Engelen L, 2013, DIABETES OBES METAB, V15, P677, DOI 10.1111/dom.12058
   Farboud B, 1999, MOL VIS, V5, pU1
   Frimat M, 2017, CLIN SCI, V131, P1069, DOI 10.1042/CS20160823
   Frye EB, 1998, J BIOL CHEM, V273, P18714, DOI 10.1074/jbc.273.30.18714
   Gardner TA, 2003, J PATHOL, V201, P328, DOI 10.1002/path.1429
   Gehl Z, 2016, REDOX BIOL, V9, P100, DOI 10.1016/j.redox.2016.07.003
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Hamada Y, 1996, BIOCHEM BIOPH RES CO, V228, P539, DOI 10.1006/bbrc.1996.1695
   HAMMES HP, 1994, DIABETOLOGIA, V37, P32
   HAMMES HP, 1995, DIABETOLOGIA, V38, P656, DOI 10.1007/s001250050333
   Hammes HP, 1998, DIABETOLOGIA, V41, P165, DOI 10.1007/s001250050885
   HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   Hashim Z, 2011, AGE, V33, P377, DOI 10.1007/s11357-010-9177-1
   He CJ, 1999, DIABETES, V48, P1308, DOI 10.2337/diabetes.48.6.1308
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Hollenbach S, 2003, MOL CELL BIOCHEM, V243, P73, DOI 10.1023/A:1021660105893
   Huang JS, 2001, J CELL BIOCHEM, V81, P102, DOI 10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y
   Hudson BI, 2008, J BIOL CHEM, V283, P34457, DOI 10.1074/jbc.M801465200
   Ino-ue M, 1998, BRAIN RES, V800, P319, DOI 10.1016/S0006-8993(98)00512-5
   JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760
   JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K
   JAHNGEN JJ, 1986, CURR EYE RES, V5, P725, DOI 10.3109/02713688609000012
   JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   Ji CH, 2017, MOL CELLS, V40, P441, DOI 10.14348/molcells.2017.0115
   Jono T, 2002, FEBS LETT, V511, P170, DOI 10.1016/S0014-5793(01)03325-7
   Kaji Y, 2000, INVEST OPHTH VIS SCI, V41, P362
   Kandarakis SA, 2015, EXP EYE RES, V137, P1, DOI 10.1016/j.exer.2015.05.017
   Kandarakis SA, 2014, PROG RETIN EYE RES, V42, P85, DOI 10.1016/j.preteyeres.2014.05.002
   Karachalias N, 2003, BIOCHEM SOC T, V31, P1423
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kiland Julie A, 2009, Trans Am Ophthalmol Soc, V107, P146
   Kim J, 2012, EXP MOL MED, V44, P167, DOI 10.3858/emm.2012.44.2.012
   Kim J, 2011, GRAEF ARCH CLIN EXP, V249, P529, DOI 10.1007/s00417-010-1573-9
   Koschinsky T, 1997, P NATL ACAD SCI USA, V94, P6474, DOI 10.1073/pnas.94.12.6474
   Kumar PA, 2007, BIOCHEM J, V408, P251, DOI 10.1042/BJ20070989
   Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810
   Lee OT, 2015, INVEST OPHTH VIS SCI, V56, P2892, DOI 10.1167/iovs.14-15840
   Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414
   LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010
   MALIK NS, 1992, BIOCHIM BIOPHYS ACTA, V1138, P222, DOI 10.1016/0925-4439(92)90041-K
   Marriott BP, 2010, CRIT REV FOOD SCI, V50, P228, DOI 10.1080/10408391003626223
   Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V241, P352, DOI 10.1006/bbrc.1997.7744
   MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690
   Moheimani F, 2010, BBA-MOL BASIS DIS, V1802, P561, DOI 10.1016/j.bbadis.2010.02.007
   Morimoto RI, 2014, J GERONTOL A-BIOL, V69, pS33, DOI 10.1093/gerona/glu049
   Moschos MM, 2017, OPHTHALMIC RES, V58, P81, DOI 10.1159/000464448
   Murata T, 1997, DIABETOLOGIA, V40, P764, DOI 10.1007/s001250050747
   Muthenna P, 2012, BIOCHEM J, V442, P221, DOI 10.1042/BJ20110846
   Nagaraj RH, 2012, AMINO ACIDS, V42, P1205, DOI 10.1007/s00726-010-0778-x
   Nagaraj RH, 1996, DIABETES, V45, P587, DOI 10.2337/diabetes.45.5.587
   Nagaraj RH, 2002, ARCH BIOCHEM BIOPHYS, V402, P110, DOI 10.1016/S0003-9861(02)00067-X
   Nahomi RB, 2013, J BIOL CHEM, V288, P13022, DOI 10.1074/jbc.M112.440214
   NAS, 2017, RED PROC EST DIET GU
   National Health and Medical Research Council (NHMRC), 2013, AUSTR DIET GUID
   NEEPER M, 1992, J BIOL CHEM, V267, P14998
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Ohgami N, 2001, ANN NY ACAD SCI, V947, P350
   Ohgami N, 2002, J DIABETES COMPLICAT, V16, P56, DOI 10.1016/S1056-8727(01)00208-2
   Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200
   Park Cheul Ho, 2012, Korean J Ophthalmol, V26, P123, DOI 10.3341/kjo.2012.26.2.123
   Patil KK, 2016, ARCH BIOCHEM BIOPHYS, V593, P1, DOI 10.1016/j.abb.2016.01.015
   PERRY RE, 1987, EXP EYE RES, V44, P269, DOI 10.1016/S0014-4835(87)80011-8
   Pokupec R, 2003, GRAEF ARCH CLIN EXP, V241, P378, DOI 10.1007/s00417-002-0616-2
   Popkin BM, 2016, LANCET DIABETES ENDO, V4, P174, DOI 10.1016/S2213-8587(15)00419-2
   Queisser MA, 2010, DIABETES, V59, P670, DOI 10.2337/db08-1565
   Rabbani N, 2015, BIOCHEM BIOPH RES CO, V458, P221, DOI 10.1016/j.bbrc.2015.01.140
   Raghavan C, 2015, ADV GLYCATION ENDPRO
   Reber F, 2002, GRAEF ARCH CLIN EXP, V240, P1022, DOI 10.1007/s00417-002-0588-2
   Roehlecke C, 2016, GRAEF ARCH CLIN EXP, V254, P2361, DOI 10.1007/s00417-016-3463-2
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rowan S, 2014, INVEST OPHTH VIS SCI, V55, P492, DOI 10.1167/iovs.13-12413
   Sadowska-Bartosz I, 2014, MOLECULES, V19, P18828, DOI 10.3390/molecules191118828
   SADY C, 1995, BIOCHEM BIOPH RES CO, V214, P793, DOI 10.1006/bbrc.1995.2356
   Sanchez-Aguadero N, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0209-2
   Sato E, 2001, DIABETES CARE, V24, P479, DOI 10.2337/diacare.24.3.479
   Scheijen JLJM, 2018, CLIN NUTR, V37, P919, DOI 10.1016/j.clnu.2017.03.019
   SEBAG J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1472, DOI 10.1001/archopht.1992.01080220134035
   SELL DR, 1991, DIABETES METAB REV, V7, P239, DOI 10.1002/dmr.5610070404
   Semba RD, 2010, J GERONTOL A-BIOL, V65, P963, DOI 10.1093/gerona/glq074
   Shamsi FA, 2000, EXP EYE RES, V70, P369, DOI 10.1006/exer.1999.0800
   SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Shi L, 2013, MOL CELL BIOCHEM, V383, P253, DOI 10.1007/s11010-013-1773-9
   Shi L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066781
   Silva MS, 2013, BIOCHEM J, V453, P1, DOI 10.1042/BJ20121743
   STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918
   Stitt Alan W., 2000, Molecular Cell Biology Research Communications, V3, P380, DOI 10.1006/mcbr.2000.0243
   Stitt AW, 1998, INVEST OPHTH VIS SCI, V39, P2517
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Stitt AW, 1997, AM J PATHOL, V150, P523
   SUAREZ G, 1989, J BIOL CHEM, V264, P3674
   Swamy-Mruthinti S, 1999, CURR EYE RES, V18, P423, DOI 10.1076/ceyr.18.6.423.5271
   SwamyMruthinti S, 1996, EXP EYE RES, V62, P505, DOI 10.1006/exer.1996.0061
   Takahashi A, 2017, DIABETES, V66, P1359, DOI 10.2337/db16-0397
   Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200
   TAYLOR A, 1995, MECH AGEING DEV, V79, P33, DOI 10.1016/0047-6374(94)01541-S
   Taylor A, 2012, AUTOPHAGY, V8, P1404, DOI 10.4161/auto.21150
   Terai N, 2012, OPHTHALMIC RES, V47, P189, DOI 10.1159/000331990
   Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Uribarri J, 2003, AM J KIDNEY DIS, V42, P532, DOI 10.1016/S0272-6386(03)00779-0
   Uribarri J, 2010, J AM DIET ASSOC, V110, P911, DOI 10.1016/j.jada.2010.03.018
   van Deemter M, 2009, EXP EYE RES, V88, P1043, DOI 10.1016/j.exer.2009.01.004
   Villa M, 2017, METABOLISM, V71, P64, DOI 10.1016/j.metabol.2017.03.004
   VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604
   Vlassara H, 2016, DIABETOLOGIA, V59, P2181, DOI 10.1007/s00125-016-4053-x
   Wang MY, 2009, ACTA NEUROPATHOL, V118, P381, DOI 10.1007/s00401-009-0513-4
   Wang P, 2016, BIOSCI BIOTECH BIOCH, V80, P250, DOI 10.1080/09168451.2015.1095065
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Whitcomb EA, 2015, MOL ASPECTS MED, V46, P14, DOI 10.1016/j.mam.2015.08.005
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312
   Zarina S, 2000, MOL CELL BIOCHEM, V210, P29, DOI 10.1023/A:1007015416572
   Zhang Y, 2017, MOL VIS, V23, P228
   Zong H, 2010, DIABETOLOGIA, V53, P2656, DOI 10.1007/s00125-010-1900-z
   Zou CL, 2012, CORNEA, V31, P1455, DOI 10.1097/ICO.0b013e3182490907
NR 154
TC 31
Z9 37
U1 1
U2 17
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2019
VL 178
BP 255
EP 262
DI 10.1016/j.exer.2018.08.017
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HL4RI
UT WOS:000458710400030
PM 30145354
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bench, BJ
   Foulke-Abel, J
   Watanabe, CMH
AF Bench, Bennie J.
   Foulke-Abel, Jennifer
   Watanabe, Coran M. H.
TI Milk, revealed "silent'' chemistry: new mode of cycloretinal synthesis
SO MOLECULAR BIOSYSTEMS
LA English
DT Article
ID PHOTORECEPTOR OUTER SEGMENTS; BOVINE BETA-LACTOGLOBULIN; PIGMENT
   EPITHELIAL-CELLS; MACULAR DEGENERATION; FLUSTRA-FOLIACEA; RETINAL
   LIPOFUSCIN; SELF-CONDENSATION; RABBIT ILEUM; A2E; PHOTOOXIDATION
AB Bovine milk is by far the most commonly consumed milk in the western world. The protein composition in milk consists of casein and whey proteins, of which beta-lactoglobulin (BLG) is the principal constituent of the latter. Here we provide biochemical evidence that this milk protein, in purified form and in pasteurized store-bought milk, promotes the formation of cycloretinal (all-trans retinal dimer), and a variety of other cycloterpenals of biological relevance [Fishkin et al., Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 7091-7096; Fishkin et al., Chirality, 2004, 16, 637-641; Kim et al., Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 19273-19278]. Cycloretinal is an eye metabolite and among several toxic byproducts of the visual cycle firmly established to cause age-related macular degeneration. Experiments in rabbits further demonstrate that BLG/milk can survive the digestive system and promote this reaction in vivo [Caillard et al., Am. J. Physiol., 1994, 266(6), G1053-G1059]. Proteomic studies on age-related macular degeneration patients have detected BLG in the eye of these patients further suggesting that this milk protein could contribute to disease progression [Crabb et al., Proc. Natl. Acad. Sci. U. S. A., 2002, 99(23), 14682-14687].
C1 [Bench, Bennie J.; Foulke-Abel, Jennifer; Watanabe, Coran M. H.] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station
RP Watanabe, CMH (通讯作者)，Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
RI Watanabe, Coran/B-7488-2015
FU Welch Foundation [A-1587]
FX The authors gratefully acknowledge the Welch Foundation (A-1587) for
   financial support of this work.
CR ASATO AE, 1992, TETRAHEDRON LETT, V33, P3105, DOI 10.1016/S0040-4039(00)79825-X
   Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Bench BJ, 2008, BIOORGAN MED CHEM, V16, P7573, DOI 10.1016/j.bmc.2008.07.030
   Bench BJ, 2006, J ORG CHEM, V71, P9458, DOI 10.1021/jo061763t
   Bui TV, 2006, J BIOL CHEM, V281, P18112, DOI 10.1074/jbc.M601380200
   CAILLARD I, 1994, AM J PHYSIOL, V266, pG1053, DOI 10.1152/ajpgi.1994.266.6.G1053
   CHO YJ, 1994, J BIOL CHEM, V269, P11102
   Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Creemers AFL, 2002, J AM CHEM SOC, V124, P6324, DOI 10.1021/ja012368h
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fishkin N, 2004, CHIRALITY, V16, P637, DOI 10.1002/chir.20084
   Fishkin N, 2003, ORG BIOMOL CHEM, V1, P1101, DOI 10.1039/b212213h
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P327, DOI 10.1016/S0167-4838(00)00169-2
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   LOVEGROVE JA, 1993, GUT, V34, P203, DOI 10.1136/gut.34.2.203
   LUGTENBURG J, 1985, PURE APPL CHEM, V57, P753, DOI 10.1351/pac198557050753
   MARCONGENTY D, 1989, AM J PHYSIOL, V256, pG943, DOI 10.1152/ajpgi.1989.256.6.G943
   Peters L, 2004, PLANTA MED, V70, P883, DOI 10.1055/s-2004-832610
   Peters L, 2004, J CHEM ECOL, V30, P1165, DOI 10.1023/B:JOEC.0000030270.65594.f4
   Peters L, 2003, APPL ENVIRON MICROB, V69, P3469, DOI 10.1128/AEM.69.6.3469-3475.2003
   SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079
   Sawyer L, 2000, BBA-PROTEIN STRUCT M, V1482, P136, DOI 10.1016/S0167-4838(00)00160-6
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   TABER DF, 1987, J ORG CHEM, V52, P28, DOI 10.1021/jo00377a005
   Tanumihardjo SA, 2001, J LABELLED COMPD RAD, V44, P365, DOI 10.1002/jlcr.464
   Uchikawa O, 2002, J MED CHEM, V45, P4222, DOI 10.1021/jm0201159
   Valla A, 2007, HELV CHIM ACTA, V90, P512, DOI 10.1002/hlca.200790053
   Warburton S, 2005, MOL VIS, V11, P1122
NR 35
TC 2
Z9 2
U1 1
U2 8
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1742-206X
EI 1742-2051
J9 MOL BIOSYST
JI Mol. Biosyst.
PY 2011
VL 7
IS 1
BP 162
EP 168
DI 10.1039/c0mb00186d
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 691SE
UT WOS:000285100300018
PM 21057693
DA 2022-11-30
ER

PT J
AU Matsubara, M
   Sakurada, Y
   Sugiyama, A
   Fukuda, Y
   Parikh, R
   Kashiwagi, K
AF Matsubara, Mio
   Sakurada, Yoichi
   Sugiyama, Atsushi
   Fukuda, Yoshiko
   Parikh, Ravi
   Kashiwagi, Kenji
TI Response to photodynamic therapy combined with intravitreal aflibercept
   for polypoidal choroidal vasculopathy depending on fellow-eye
   condition:2-year results
SO PLOS ONE
LA English
DT Article
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; MACULAR DEGENERATION; SEVERITY
   SCALE; RANIBIZUMAB; ANGIOGRAPHY; MONOTHERAPY; THICKNESS; EFFICACY;
   DISEASE; SAFETY
AB We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI as well as 2-years of follow-up data. Fellow eyes were divided into 4 groups; Group 0: no drusen, Group 1; pachydrusen, Group 2; soft drusen, Group 3: PCV/fibrovascular scarring. Best-corrected visual acuity improved at 24-months irrespective of groups and there were no significant differences in visual improvement among treated eyes among the 4 groups. Within 2-years, 35 (58.3%) required the retreatment. The need for retreatment including additional injection and the combination therapy was significantly less in Group 1(12.5%) compared to the others (P = 0.0038) and mean number of additional IAI was also less in Group 1 compared to the others (P = 0.017). The retreatment-free period from the initial combination therapy was longest in Group 1 (23.6 +/- 1.1 months) (P = 0.0055, Group 0: 19.1 +/- 6.9, Group 2: 12.8 +/- 7.9, Group 3: 11.5 +/- 9.9). The need for retreatment was significantly different according to fellow-eye condition. Among PCV patients, pachydrusen in fellow eyes appear to be a predictive characteristic for a decreased treatment burden at 2 years.
C1 [Matsubara, Mio; Sakurada, Yoichi; Sugiyama, Atsushi; Fukuda, Yoshiko; Kashiwagi, Kenji] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
   [Parikh, Ravi] NYU, Sch Med, New York, NY USA.
   [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY USA.
C3 University of Yamanashi; New York University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
OI Sakurada, Yoichi/0000-0002-2894-0454; Parikh, Ravi/0000-0003-3369-4224;
   Kashiwagi, Kenji/0000-0001-8506-8503
FU Japan Society for the Promotion of Science KAKENHI [23791972]
FX This work was supported by Japan Society for the Promotion of Science
   KAKENHI Grant Number 23791972 (YS). The funder provided support in the
   form of salaries for authors but did not have any additional role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. Manhattan Retina and Eye Consultants has
   provided a salary for R.P. and did not have any additional role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The specific roles of these authors are
   articulated in the 'author contributions' section.
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Chen L, 2018, INVEST OPHTH VIS SCI, V59, P5237, DOI 10.1167/iovs.18-25124
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Kikushima W, 2017, JPN J OPHTHALMOL, V61, P61, DOI 10.1007/s10384-016-0479-4
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P100, DOI 10.1007/s10384-018-0636-z
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P448, DOI 10.1007/s10384-019-00692-5
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   Sakurada Y, 2018, RETINA-J RET VIT DIS, V38, P1977, DOI 10.1097/IAE.0000000000002294
   Sakurada Y, 2018, GRAEF ARCH CLIN EXP, V256, P99, DOI 10.1007/s00417-017-3847-y
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 38
TC 5
Z9 5
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 11
PY 2020
VL 15
IS 8
AR e0237330
DI 10.1371/journal.pone.0237330
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NE5TX
UT WOS:000562664700039
PM 32780752
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Platania, CBM
   Fisichella, V
   Fidilio, A
   Geraci, F
   Lazzara, F
   Leggio, GM
   Salomone, S
   Drago, F
   Pignatello, R
   Caraci, F
   Bucolo, C
AF Platania, Chiara Bianca Maria
   Fisichella, Vincenzo
   Fidilio, Annamaria
   Geraci, Federica
   Lazzara, Francesca
   Leggio, Gian Marco
   Salomone, Salvatore
   Drago, Filippo
   Pignatello, Rosario
   Caraci, Filippo
   Bucolo, Claudio
TI Topical Ocular Delivery of TGF-beta 1 to the Back of the Eye:
   Implications in Age-Related Neurodegenerative Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE TGF-beta 1; age-related neurodegenerative diseases; retina; liposomes
ID GROWTH-FACTOR-BETA; TGF-BETA; EXTRACELLULAR-MATRIX; FORMULATION;
   RAPAMYCIN; ANTERIOR; DRUG
AB Dysregulation of the transforming growth factor-beta 1 (TGF-beta 1)/selected small mother against decapentaplegic (SMAD) pathway can be implicated in development of age-related macular degeneration (AMD), and the delivery of TGF-beta 1 could be beneficial for AMD. We developed a new ophthalmic formulation of TGF-beta 1 assessing the ocular pharmacokinetic profile of TGF-beta 1 in the rabbit eye. Small unilamellar vesicles (SUV) loaded with TGF-beta 1 were complemented with Annexin V and Ca2+, and the vitreous bioavailability of TGF-beta 1 was assessed after topical ocular administration by a commercial ELISA kit. We detected high levels of TGF-beta 1 (C-max 114.7 +/- 12.40 pg/mL) in the vitreous after 60 min (T-max) from the topical application of the liposomal suspension. Ocular tolerability was also assessed by a modified Draize's test. The new formulation was well tolerated. In conclusion, we demonstrated that the novel formulation was able to deliver remarkable levels of TGF-beta 1 into the back of the eye after topical administration. Indeed, this TGF-beta 1 delivery system may be useful in clinical practice to manage ophthalmic conditions such as age-related macular degeneration, skipping invasive intraocular injections.
C1 [Platania, Chiara Bianca Maria; Fisichella, Vincenzo; Fidilio, Annamaria; Geraci, Federica; Lazzara, Francesca; Leggio, Gian Marco; Salomone, Salvatore; Drago, Filippo; Bucolo, Claudio] Univ Catania, Sch Med, Pharmacol Sect, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy.
   [Leggio, Gian Marco; Salomone, Salvatore; Drago, Filippo; Pignatello, Rosario; Bucolo, Claudio] Univ Catania, Ctr Res Ocular Pharmacol CERFO, I-95123 Catania, Italy.
   [Pignatello, Rosario; Caraci, Filippo] Univ Catania, Dept Drug Sci, I-95125 Catania, Italy.
   [Pignatello, Rosario] Univ Catania, NANO iRes Ctr Ocular Nanotechnol, I-95125 Catania, Italy.
   [Caraci, Filippo] IRCSS Assoc Oasi Maria SS, Inst Res Mental Retardat & Brain Aging, I-94018 Troina, Italy.
C3 University of Catania; University of Catania; University of Catania;
   University of Catania; IRCCS Oasi Maria SS
RP Bucolo, C (通讯作者)，Univ Catania, Sch Med, Pharmacol Sect, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy.; Bucolo, C (通讯作者)，Univ Catania, Ctr Res Ocular Pharmacol CERFO, I-95123 Catania, Italy.
EM chiara.platania@unict.it; vincifisi@hotmail.com; annafidilio@yahoo.it;
   rica2203@hotmail.it; f.lazzara@hotmail.it; gmleggio@me.com;
   salomone@unict.it; f.drago@unict.it; r.pignatello@unict.it;
   carafil@hotmail.com; claudio.bucolo@unict.it
RI Fidilio, Annamaria/GNP-1855-2022; pignatello, rosario/G-3176-2010;
   Leggio, Gian Marco/AHE-1151-2022; Caraci, Filippo/K-2262-2016; Platania,
   Chiara BM/AHE-1140-2022; Drago, Filippo/AAC-5090-2022; Drago,
   Francesco/H-7563-2019
OI Fidilio, Annamaria/0000-0002-9279-0171; pignatello,
   rosario/0000-0002-5937-4192; Leggio, Gian Marco/0000-0002-7280-4871;
   Caraci, Filippo/0000-0002-9867-6054; Bucolo,
   Claudio/0000-0002-4879-4140; Platania, Chiara Bianca
   Maria/0000-0002-8630-5993; Lazzara, Francesca/0000-0002-9825-2104
FU National Grant from Ministry of Education, University and Research
   (MIUR) [PRIN 2015JXE7E8]
FX This work was in part supported by National Grant PRIN 2015JXE7E8 from
   Ministry of Education, University and Research (MIUR).
CR Bevalot F, 2016, FORENSIC TOXICOL, V34, P12, DOI 10.1007/s11419-015-0294-5
   Caraci F, 2008, PHARMACOL RES, V57, P274, DOI 10.1016/j.phrs.2008.02.001
   Caraci F, 2008, NEUROBIOL DIS, V30, P234, DOI 10.1016/j.nbd.2008.01.007
   Caraci F, 2012, CELL TISSUE RES, V347, P291, DOI 10.1007/s00441-011-1230-6
   Chen JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116549
   Cholkar K, 2016, INT J PHARMACEUT, V498, P326, DOI 10.1016/j.ijpharm.2015.12.037
   Cholkar K, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.1
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I
   Cordeiro MF, 2011, EYE, V25, P545, DOI 10.1038/eye.2011.64
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618
   Earla R, 2012, J CHROMATOGR B, V908, P76, DOI 10.1016/j.jchromb.2012.09.014
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Garcia CM, 2004, DEV BRAIN RES, V152, P25, DOI 10.1016/j.devbrainres.2004.05.008
   GIAMBANCO I, 1991, J HISTOCHEM CYTOCHEM, V39, P1189, DOI 10.1177/39.9.1833446
   Giannavola C, 2003, PHARM RES-DORDR, V20, P584, DOI 10.1023/A:1023290514575
   Gunda S, 2015, EUR J DRUG METAB PH, V40, P325, DOI 10.1007/s13318-014-0200-2
   Hoshino T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076306
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Joseph M, 2017, EXPERT OPIN DRUG DEL, V14, P631, DOI 10.1080/17425247.2016.1227783
   Juraskova B, 2010, J NUTR HEALTH AGING, V14, P758, DOI 10.1007/s12603-010-0325-1
   Kenis H, 2004, J BIOL CHEM, V279, P52623, DOI 10.1074/jbc.M409009200
   Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453
   Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060
   Lauzon MA, 2015, CELL SIGNAL, V27, P1025, DOI 10.1016/j.cellsig.2015.02.018
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mocali A, 2004, EXP GERONTOL, V39, P1555, DOI 10.1016/j.exger.2004.07.007
   Pignatello R, 2013, WOODH PUB SER BIOMED, P1, DOI 10.1533/9781908818348.1
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rowe-Rendleman CL, 2014, INVEST OPHTH VIS SCI, V55, P2714, DOI 10.1167/iovs.13-13707
   Saleh M, 2010, J CATARACT REFR SURG, V36, P488, DOI 10.1016/j.jcrs.2009.09.036
   TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171
   Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X
   ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008
   Tuuminen R, 2014, EYE, V28, P1095, DOI 10.1038/eye.2014.137
   Vadlapudi AD, 2014, J OCUL PHARMACOL TH, V30, P49, DOI 10.1089/jop.2013.0157
   Vivien D, 2006, CYTOKINE GROWTH F R, V17, P121, DOI 10.1016/j.cytogfr.2005.09.011
   Walshe TE, 2011, NEUROSCIENCE, V189, P123, DOI 10.1016/j.neuroscience.2011.05.020
   Zambrano R, 2015, NUCLEIC ACIDS RES, V43, pW306, DOI 10.1093/nar/gkv359
NR 41
TC 25
Z9 25
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2017
VL 18
IS 10
AR 2076
DI 10.3390/ijms18102076
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FM0QL
UT WOS:000414671800060
PM 28973964
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Singh, J
   Sharma, M
   Jain, N
   Aftab, I
   Vikram, N
   Singh, T
   Sharma, P
   Sharma, S
AF Singh, Jiya
   Sharma, Mohita
   Jain, Neha
   Aftab, Insha
   Vikram, Naval
   Singh, Tej
   Sharma, Pradeep
   Sharma, Sujata
TI Lactoferrin and its nano-formulations in rare eye diseases
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Corneal diseases; lactoferrin; macular degeneration; nanoparticles;
   retinal diseases; retinitis pigmentosa; retinoblastoma
ID CYCLIN-DEPENDENT KINASES; RETINITIS-PIGMENTOSA; MACULAR DEGENERATION;
   BOVINE LACTOFERRIN; GROWTH ARREST; MOUSE MODEL; IRON; RETINOBLASTOMA;
   PREVALENCE; EXPRESSION
AB Lactoferrin (LF) is an iron-binding glycoprotein released from mucous secreting cells and neutrophils. LF can be used in a broad range of eye diseases related to the retina, cornea, and optic nerve. The retina is particularly affected by oxidative stress inside the photoreceptor being constantly exposed to light which induces accumulation of reactive oxygen species (ROS) in the retinal pigmented epithelium (RPE) causing damage to photoreceptor recycling. Retinitis pigmentosa (RP) and macular degeneration are inherited retinopathies that consist of different disease-causing genes, that cause mutations with highly varied clinical consequences. Age-related macular degeneration is a chronic disease of the retina and one of the major causes of sight loss. This review provides an application of lactoferrin and LF-based nano-formulations or nanoparticles in the field of retinal diseases or corneal diseases such as retinitis pigmentosa, retinoblastoma, age-related macular degeneration (AMD), keratoconus and uveitis. Several studies have found that lactoferrin's antibacterial activity is not limited to its iron sequestration, but also its ability as a nanoparticle that acts as a carrier to deliver drugs by crossing the blood-retina barrier (BRB) and its involvement in cell cycle control, which is not possible by many transferrin proteins.
C1 [Singh, Jiya; Singh, Tej; Sharma, Pradeep; Sharma, Sujata] All India Inst Med Sci, Dept Biophysi, New Delhi 110029, India.
   [Vikram, Naval] All India Inst Med Sci, Dept Med, New Delhi, India.
   [Sharma, Mohita; Aftab, Insha] Tirupati Eye Ctr & Res Inst, Noida, Uttar Pradesh, India.
   [Jain, Neha] LV Prasad Eye Inst, Cornea Inst, KAR Campus, Hyderabad, Telangana, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; All India
   Institute of Medical Sciences (AIIMS) New Delhi; L. V. Prasad Eye
   Institute
RP Sharma, P; Sharma, S (通讯作者)，All India Inst Med Sci, Dept Biophysi, New Delhi 110029, India.
EM pradeepbdk@gmail.com; sujatasharma.aiims@gmail.com
CR Abdelrahman AA, 2015, J PHARM INNOV, V10, P254, DOI 10.1007/s12247-015-9224-7
   Abramson DH, 2004, RETINA-J RET VIT DIS, V24, P828, DOI 10.1097/00006982-200412000-00002
   Aerts I, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-31
   Ahmed F, 2014, INT J BIOL MACROMOL, V70, P572, DOI 10.1016/j.ijbiomac.2014.07.041
   Ali MU, 2017, 3 BIOTECH, V7, DOI 10.1007/s13205-017-0878-3
   Ancona-Lezama D, 2020, INDIAN J OPHTHALMOL, V68, P2356, DOI 10.4103/ijo.IJO_721_20
   [Anonymous], 2015, SUMMARIES GENE LOCUS
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berson EL, 1992, ADLERS PHYSL EYE, P466
   Broaddus E, 2009, BRIT J OPHTHALMOL, V93, P21, DOI 10.1136/bjo.2008.138750
   Cai X, 2010, FASEB J, V24, P1178, DOI 10.1096/fj.09-139147
   CAMPBELL T, 1992, BRIT J CANCER, V65, P19, DOI 10.1038/bjc.1992.4
   Cetinel S, 2015, ASIA-PAC J OPHTHALMO, V4, P381, DOI 10.1097/APO.0000000000000156
   Chantada GL, 2010, PEDIATR BLOOD CANCER, V55, P60, DOI 10.1002/pbc.22503
   Chen JR, 2017, MED HYPOTHESES, V103, P1, DOI 10.1016/j.mehy.2017.03.029
   Cholkar K, 2013, J OCUL PHARMACOL TH, V29, P106, DOI 10.1089/jop.2012.0200
   Cideciyan AV, 1996, VISION RES, V36, P2609, DOI 10.1016/0042-6989(95)00327-4
   Damiens E, 1999, J CELL BIOCHEM, V74, P486, DOI 10.1002/(SICI)1097-4644(19990901)74:3<486::AID-JCB16>3.0.CO;2-6
   DANJO Y, 1994, ACTA OPHTHALMOL, V72, P433
   DeGregori J, 2004, J CELL SCI, V117, P3411, DOI 10.1242/jcs.01189
   DEHOUCK M-P, 1990, Circulation et Metabolisme du Cerveau, V7, P151
   Descamps L, 1996, AM J PHYSIOL-HEART C, V270, pH1149, DOI 10.1152/ajpheart.1996.270.4.H1149
   Devendra J, 2015, J CLIN DIAGN RES, V9, pNC06, DOI 10.7860/JCDR/2015/15797.6670
   Dimaras H, 2008, HUM MOL GENET, V17, P1363, DOI 10.1093/hmg/ddn024
   Dimaras H, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.21
   Dimaras H, 2012, LANCET, V379, P1436, DOI 10.1016/S0140-6736(11)61137-9
   Dong HL, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000339
   DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Durrani OM, 2004, OPHTHALMOLOGICA, V218, P223, DOI 10.1159/000078612
   European Food Safety Authority, 2012, EFSA Journal, V10, P2596
   Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011
   Fujihara T, 1998, J OCUL PHARMACOL TH, V14, P99, DOI 10.1089/jop.1998.14.99
   Gardenghi S, 2014, BLOOD, V123, P1137, DOI 10.1182/blood-2013-08-521625
   Garreis F, 2010, DEV OPHTHALMOL, V45, P16, DOI 10.1159/000315016
   Gesto MI, US Patent, Patent No. [15/551,3862018, 155513862018]
   Godefrooij DA, 2017, AM J OPHTHALMOL, V175, P169, DOI 10.1016/j.ajo.2016.12.015
   Gonzalez-Chavez SA, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.07.020
   Goodnough LT, 2010, BLOOD, V116, P4754, DOI 10.1182/blood-2010-05-286260
   Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014
   Haer-Wigman L, 2015, HUM MOL GENET, V24, P3742, DOI 10.1093/hmg/ddv118
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hood DC, 1996, VISION RES, V36, P1699, DOI 10.1016/0042-6989(95)00246-4
   Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2
   Kanwar JR, 2012, J CANC SCI THER, V4, P31, DOI DOI 10.4172/1948-5956.1000107
   Khan MI, 2011, OPHTHALMOLOGY, V118, P1444, DOI 10.1016/j.ophtha.2010.10.047
   Kim A, 2014, BLOOD, V123, P1129, DOI 10.1182/blood-2013-08-521419
   Kivela T, 2009, BRIT J OPHTHALMOL, V93, P1129, DOI 10.1136/bjo.2008.150292
   Kondapi AK, 2020, NANOMEDICINE-UK, V15, P2071, DOI 10.2217/nnm-2020-0090
   Kruzel ML, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01438
   KUIZENGA A, 1987, INVEST OPHTH VIS SCI, V28, P305
   Kymes SM, 2008, AM J OPHTHALMOL, V145, P611, DOI 10.1016/j.ajo.2007.11.017
   Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5
   Lee V H, 1986, J Ocul Pharmacol, V2, P67, DOI 10.1089/jop.1986.2.67
   Lema I, 2010, MOL VIS, V16, P2055
   Majka G, 2013, ANAL BIOANAL CHEM, V405, P5191, DOI 10.1007/s00216-013-6943-9
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Moneo V, 2003, J CELL BIOCHEM, V89, P484, DOI 10.1002/jcb.10529
   MUSARELLA MA, 1990, GENOMICS, V8, P286, DOI 10.1016/0888-7543(90)90284-2
   Nolen RM, 2020, OPHTHALMIC GENET, V41, P401, DOI 10.1080/13816810.2020.1747090
   ORAM JD, 1968, BIOCHIM BIOPHYS ACTA, V170, P351, DOI 10.1016/0304-4165(68)90015-9
   Ortiz MV, 2016, J CHILD NEUROL, V31, P227, DOI 10.1177/0883073815587943
   Paivonsalo-Hietanen T, 1997, ACTA OPHTHALMOL SCAN, V75, P76
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Pattamatta U, 2009, INVEST OPHTH VIS SCI, V50, P1636, DOI 10.1167/iovs.08-1882
   Ponzini E, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.12.9
   Rageh AA, 2016, CURR EYE RES, V41, P883, DOI 10.3109/02713683.2015.1075220
   Ramasubramanian A., 2012, EPIDEMIOLOGY MAGNITU
   REESE A B, 1963, Trans Am Acad Ophthalmol Otolaryngol, V67, P164
   Riazuddin SA, 2010, AM J HUM GENET, V86, P805, DOI 10.1016/j.ajhg.2010.04.001
   Rice DS, 2004, INVEST OPHTH VIS SCI, V45, P2767, DOI 10.1167/iovs.04-0020
   Rusciano D, 2018, OPHTHALMIC RES, V60, P94, DOI 10.1159/000489093
   Samuel J, 2015, EXP EYE RES, V139, P108, DOI 10.1016/j.exer.2015.07.011
   Schmidt PJ, 2015, J BIOL CHEM, V290, P18975, DOI 10.1074/jbc.R115.650150
   Schvartzman E, 1996, J CLIN ONCOL, V14, P1532, DOI 10.1200/JCO.1996.14.5.1532
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shields CL, 2016, ASIA-PAC J OPHTHALMO, V5, P97, DOI 10.1097/APO.0000000000000172
   Shields JA, 2015, INTRAOCULAR TUMORS A, V3rd
   SHINMOTO H, 1992, BIOSCI BIOTECH BIOCH, V56, P2079, DOI 10.1271/bbb.56.2079
   Sobrino T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13525-7
   Son HJ, 2006, BIOCHEM CELL BIOL, V84, P345, DOI 10.1139/O06-048
   Sorrentino FS, 2016, EYE, V30, P1542, DOI 10.1038/eye.2016.197
   Tzekov RT, 2003, INVEST OPHTH VIS SCI, V44, P3993, DOI 10.1167/iovs.02-1104
   Vorland LH, 1999, APMIS, V107, P971, DOI 10.1111/j.1699-0463.1999.tb01499.x
   Willoughby CE, 2010, CLIN EXP OPHTHALMOL, V38, P2, DOI 10.1111/j.1442-9071.2010.02363.x
   Xiao Y, 2004, CLIN CANCER RES, V10, P8683, DOI 10.1158/1078-0432.CCR-04-0988
NR 87
TC 0
Z9 0
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2022
VL 70
IS 7
BP 2328
EP 2334
DI 10.4103/ijo.IJO_303_22
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4W9JQ
UT WOS:000860471400021
PM 35791114
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gonzalez-Buendia, L
   Delgado-Tirado, S
   An, M
   O'Hare, M
   Amarnani, D
   Whitmore, HAB
   Zhao, G
   Ruiz-Moreno, JM
   Arboleda-Velasquez, JF
   Kim, LA
AF Gonzalez-Buendia, Lucia
   Delgado-Tirado, Santiago
   An, Miranda
   O'Hare, Michael
   Amarnani, Dhanesh
   Whitmore, Hannah A. B.
   Zhao, Guannan
   Ruiz-Moreno, Jose M.
   Arboleda-Velasquez, Joseph F.
   Kim, Leo A.
TI Treatment of Experimental Choroidal Neovascularization via RUNX1
   Inhibition
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
AB Choroidal neovascularization (CNV) is a prevalent cause of vision loss in patients with age-related macular degeneration. Runt-related transcription factor 1 (RUNX1) has been identified as an important mediator of aberrant retinal angiogenesis in proliferative diabetic retinopathy and its modulation has proven to be effective in curbing pathologic angiogenesis in experimental oxygen-induced retinopathy. However, its role in CNV remains to be elucidated. This study demonstrates RUNX1 expression in critical cell types involved in a laser-induced model of CNV in mice. Furthermore, the preclinical efficacy of Ro5-3335, a small molecule inhibitor of RUNX1, in experimental CNV is reported. RUNX1 inhibitor Ro5-3335, aflibercept-an FDA-approved vascular endothelial growth factor (VEGF) inhibitor, or a combination of both, were administered by intravitreal injection immediately after laser injury. The CNV area of choroidal flatmounts was evaluated by immunostaining with isolectin B4, and vascular permeability was analyzed by fluorescein angiography. A single intravitreal injection of Ro5-3335 significantly decreased the CNV area 7 days after laser injury, and when combined with aflibercept, reduced vascular leakage more effectively than aflibercept alone. These data suggest that RUNX1 inhibition alone or in combination with anti-VEGF drugs may be a new therapy upon further clinical validation for patients with neovascular age-related macular degeneration.
C1 [Gonzalez-Buendia, Lucia; Delgado-Tirado, Santiago; An, Miranda; O'Hare, Michael; Amarnani, Dhanesh; Whitmore, Hannah A. B.; Zhao, Guannan; Arboleda-Velasquez, Joseph F.; Kim, Leo A.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02115 USA.
   [Kim, Leo A.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02115 USA.
   [Ruiz-Moreno, Jose M.] Castilla la Mancha Univ, Puerta Hierro Majadahondu Univ Hosp, Dept Ophthalmol, Madrid, Spain.
   [Ruiz-Moreno, Jose M.] Vissum Corp, Alicante, Spain.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Schepens Eye Research Institute; Harvard University; Harvard
   Medical School; Massachusetts Eye & Ear Infirmary; VISSUM
RP Kim, LA (通讯作者)，Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.; Arboleda-Velasquez, JF (通讯作者)，Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM joseph_arboleda@meei.harvard.edu; leo_kim@meei.harvard.edu
RI Gonzalez-Buendia, Lucia/AAC-9445-2022; Kim, Leo/Y-3323-2018
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788; An,
   Miranda/0000-0002-6416-777X; Kim, Leo/0000-0001-9106-6416
FU National Eye Institute (NEI)/NIH [R01EY027739, P30EY003790]; E. Matilda
   Zieger Foundation for the Blind; Karl Kirchgessner Foundation; National
   Institute of Neurological Disorders and Stroke [UH3 NS100121]; National
   Institute on Aging [RF1 NS110048]; Alfonso Martin Escudero Foundation
FX Supported by National Eye Institute (NEI)/NIH grants R01EY027739
   (L.A.K.) and P30EY003790, the E. Matilda Zieger Foundation for the Blind
   (L.A.K.), the Karl Kirchgessner Foundation (L.A.K), National Institute
   of Neurological Disorders and Stroke grant UH3 NS100121 (J.F.A.-V.),
   National Institute on Aging grant RF1 NS110048 (J.F.A.-V.), and the
   Alfonso Martin Escudero Foundation (S.D.-T.).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Delgado-Tirado S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77254-0
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Feng LL, 2017, AM J PATHOL, V187, P2208, DOI 10.1016/j.ajpath.2017.06.015
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lam JD, 2017, DIABETES, V66, P1950, DOI 10.2337/db16-1035
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Okeagu CU, 2021, OPHTHALMOL RETINA, V5, P23, DOI 10.1016/j.oret.2020.09.025
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Whitmore HAB, 2021, FASEB J, V35, DOI 10.1096/fj.202001668R
NR 26
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAR
PY 2021
VL 191
IS 3
BP 418
EP 424
DI 10.1016/j.ajpath.2020.12.005
EA FEB 2021
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA RC0OJ
UT WOS:000632503000001
PM 33345998
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Atchison, EA
   Omar, AF
   Iezzi, R
   Barkmeier, AJ
   Bakri, SJ
AF Atchison, Elizabeth A.
   Omar, Ahmed F.
   Iezzi, Raymond
   Barkmeier, Andrew J.
   Bakri, Sophie J.
TI OUTCOMES OF AN INTRAVITREAL INJECTION CLINIC
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE eye; intravitreal; injection; ranibizumab; bevacizumab; anti-VEGF;
   age-related macular degeneration; retinal vascular disease; ocular;
   choroidal neovascularization; vascular endothelial growth factor
   inhibitors
ID ANTI-VEGF TREATMENT; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   RANIBIZUMAB; SAFETY; THERAPY; DISEASE; TRIAL; EYE
AB Purpose: To examine the safety outcomes of an intravitreal injection-only clinic where patients needing long-term anti-vascular endothelial growth factor therapy are treated with injections at a predetermined interval for a set number of injections without an accompanying clinic visit.
   Methods: This is a retrospective chart review of all patients with exudative macular degeneration treated in an intravitreal injection clinic over a 4-year period. Data on the outcome measures of interest were gathered from electronic medical records.
   Results: There were 556 patients who received 4,386 injections in the injection-only clinic in a total of 1,524 injection cycles. One hundred six cycles were interrupted. The most common causes for interruption were decreased vision in the injected eye (32), decreased vision in the fellow eye (23), flashing lights (6), pain (5), and irritation in the noninjected eye (2). Of patients who had interruption of the cycle, 32 had a new diagnosis (6 corneal abrasions, 6 exudative age-related macular degeneration in fellow eye). There were six instances of conversion to exudative age-related macular degeneration found in the other eye at a routine follow-up visit following the injection clinic.
   Conclusion: An injection-only clinic may provide a reasonable approach to streamline retina practices to ensure that patients receive timely injections.
C1 [Atchison, Elizabeth A.; Omar, Ahmed F.; Iezzi, Raymond; Barkmeier, Andrew J.; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55902 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55902 USA.
EM Bakri.Sophie@mayo.edu
RI Barkmeier, Andrew/AAV-1021-2020
OI Atchison, Elizabeth/0000-0002-5848-9836
FU Research to Prevent Blindness, New York, NY
FX Supported by an unrestricted grant from Research to Prevent Blindness,
   New York, NY.
CR [Anonymous], 2014, R LANG ENV STAT COMP
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Engman SJ, 2011, SEMIN OPHTHALMOL, V26, P380, DOI 10.3109/08820538.2011.622337
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hasler PW, 2015, ACTA OPHTHALMOL, V93, P122, DOI 10.1111/aos.12589
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Michelotti MM, 2014, CLIN OPHTHALMOL, V8, P755, DOI 10.2147/OPTH.S59982
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Panel AAoORV, 2014, PREF PRACT PATT GUID
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 28
TC 8
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2017
VL 37
IS 7
BP 1371
EP 1376
DI 10.1097/IAE.0000000000001372
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY6ZG
UT WOS:000404133400024
PM 27759581
DA 2022-11-30
ER

PT J
AU Pikkel, J
   Chassid, O
   Sharabi-Nov, A
   Beiran, I
AF Pikkel, Joseph
   Chassid, Otzem
   Sharabi-Nov, Adi
   Beiran, Itchak
TI A retrospective evaluation of the effect of hydroxyquinine on RPE
   thickness
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Hydroxychloroquine; Optical
   Coherence Tomography (OCT); Plaquenil; Retinal outer band; Rheumatoid
   arthritis
ID OPTICAL COHERENCE TOMOGRAPHY; HYDROXYCHLOROQUINE RETINOPATHY; MACULAR
   DEGENERATION; ALZHEIMERS-DISEASE; CHLOROQUINE; ARTHRITIS; TOXICITY; EYE
AB To investigate a possible structural difference in the retina of hydroxychloroquine (Plaquenil)-treated patients as an explanation for the protective effect of this medication against age-related macular degeneration (AMD).
   In this retrospective study, we compared the mean thickness of the retinal outer band (consisting of the Bruch's membrane and retinal pigment epithelium layer), as measured by optical coherence tomography (OCT), of 54 eyes of 27 hydroxychloroquine-treated rheumatoid arthritis patients (study group), 40 eyes of 20 healthy similar aged individuals (control group I), and 22 eyes of 11 non-hydroxychloroquine-treated rheumatoid arthritis patients (control group II).
   The mean thicknesses of the outer band of the retinal pigment epithelium layer was 60.4 +/- 7.4, 43.3 +/- 2.7, and 39.7 +/- 3.6 mu m for the study group, control group I, and control group II, respectively. P values for differences in mean thicknesses were < 0.0001 between the study group and each of the control groups, and 0.086 between the two control groups.
   Treatment with hydroxychloroquine was associated with increased thickness of the outer band of the retinal pigment epithelium layer. This finding may explain the protective effect of hydroxychloroquine against age-related macular degeneration (AMD).
C1 [Pikkel, Joseph; Chassid, Otzem] Ziv Med Ctr, Dept Ophthalmol, Safed, Israel.
   [Pikkel, Joseph] Bar Ilan Univ, Fac Med, Safed, Israel.
   [Sharabi-Nov, Adi] Ziv Med Ctr, Res Wing, Safed, Israel.
   [Sharabi-Nov, Adi] Tel Hai Acad Coll, Tel Hai, Israel.
   [Beiran, Itchak] Rambam Med Ctr, Dept Ophthalmol, Haifa, Israel.
   [Beiran, Itchak] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel.
C3 Ziv Medical Center; Bar Ilan University; Ziv Medical Center; Tel Hai
   Academy College; Rambam Health Care Campus; Technion Israel Institute of
   Technology; Technion Israel Institute of Technology; Rappaport Faculty
   of Medicine
RP Chassid, O (通讯作者)，Ziv Med Ctr, Dept Ophthalmol, Safed, Israel.
EM otzem.c@ziv.health.gov.il
RI Pikkel, Joseph/AAZ-2107-2020
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BERNSTEIN H, 1964, ARCH OPHTHALMOL-CHIC, V71, P238
   CAMBIAGGI A, 1957, ARCH OPHTHALMOL-CHIC, V57, P451
   COX NH, 1994, BRIT J DERMATOL, V131, P878, DOI 10.1111/j.1365-2133.1994.tb08593.x
   Coyle JT, 2001, OPHTHALMOLOGY, V108, P243, DOI 10.1016/S0161-6420(00)00400-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HOBBS HE, 1959, LANCET, V2, P478
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   Korah S, 2008, INDIAN J OPHTHALMOL, V56, P511, DOI 10.4103/0301-4738.43379
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425
   RAMSEY MS, 1972, AM J OPHTHALMOL, V73, P229, DOI 10.1016/0002-9394(72)90137-7
   Rodriguez-Padilla JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P775, DOI 10.1001/archopht.125.6.775
NR 13
TC 7
Z9 7
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2013
VL 251
IS 7
BP 1687
EP 1690
DI 10.1007/s00417-012-2256-5
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 164CP
UT WOS:000320386700005
PM 23322085
DA 2022-11-30
ER

PT J
AU Eklund, K
   Sjostrand, J
   Dahlin-Ivanoff, S
AF Eklund, Kajsa
   Sjostrand, Johan
   Dahlin-Ivanoff, Synneve
TI A randomized controlled trial of a health-promotion programme and its
   effect on ADL dependence and self-reported health problems for the
   elderly visually impaired
SO SCANDINAVIAN JOURNAL OF OCCUPATIONAL THERAPY
LA English
DT Article
DE age-related macular degeneration; evaluation; health education;
   longitudinal study; occupational therapy
ID MACULAR DEGENERATION; EDUCATION PROGRAM; RATED HEALTH; FOLLOW-UP;
   POPULATION; WOMEN; GOTHENBURG; RISK
AB Background: Ageing with visual impairment is associated with a high degree of disability whereby age-related macular degeneration in particular causes dependence in activities of daily living (ADL) even at an early stage. Aims: To compare an activity-based, health-pro motion programme with an individual programme, targeting the elderly with age-related macular degeneration concerning the effect on the development of dependence in ADL, general health, and self-reported health problems. Methods: A randomized controlled study with a 28-month follow-up. A total of 229 persons were randomized to the study and 131 (57%) were followed up (individual intervention n =69, health-promotion programme n =62) at 28month. Results: The health-promotion group maintained their ADL level despite a significant decrease in visual acuity, while the individual intervention group increased its dependence in ADL. General health systematically dropped to a lower level in both groups, but participants from the health-promotion group reported fewer health problems. There were significantly fewer reports of tiredness and dizziness among the health-promotion participants. Conclusion: The health-promotion programme seems to have slowed down the disablement process among elderly with decreased vision by enabling them to maintain their ADL level and by reducing self-reported health problems for at least 28 months following intervention.
C1 [Eklund, Kajsa; Dahlin-Ivanoff, Synneve] Gothenburg Univ, Dept Neurol & Physiol, Sahlgrenska Acad, SE-40530 Gothenburg, Sweden.
   [Eklund, Kajsa; Dahlin-Ivanoff, Synneve] Gothenburg Univ, Swedish Inst Hlth Sci, Vardal Inst, SE-40530 Gothenburg, Sweden.
   [Sjostrand, Johan] Gothenburg Univ, Dept Ophthalmol, Sahlgrenska Acad, SE-40530 Gothenburg, Sweden.
C3 University of Gothenburg; University of Gothenburg; University of
   Gothenburg
RP Eklund, K (通讯作者)，Gothenburg Univ, Dept Neurol & Physiol, Sahlgrenska Acad, Box 455, SE-40530 Gothenburg, Sweden.
EM kajsa.Eklund@gu.se
RI Dahlin-Ivanoff, Synneve/U-9819-2018
CR Avlund K, 2003, AGE AGEING, V32, P579, DOI 10.1093/ageing/afg101
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   BRODY BL, 2001, OPHTHALMOLOGY, P1883
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Crews JE, 2001, J VISUAL IMPAIR BLIN, V95, P453, DOI 10.1177/0145482X0109500802
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   Eaton DA, 2003, GERIATRICS, V58, P46
   Eklund K, 2005, DISABIL REHABIL, V27, P1203, DOI 10.1080/09638280500052716
   Eklund K, 2004, DISABIL REHABIL, V26, P401, DOI 10.1080/09638280410001662950
   Eklund Kajsa, 2006, Can J Occup Ther, V73, P272
   Ivanoff SD, 2000, SCAND J OCCUP THER, V7, P148
   IVANOFF SD, 2002, FINDING NEW WAYS INF
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Leinonen R, 2002, ARCH GERONTOL GERIAT, V35, P79, DOI 10.1016/S0167-4943(02)00017-1
   LIANG J, 1986, J GERONTOL, V41, P248, DOI 10.1093/geronj/41.2.248
   Persson LO, 1998, J CLIN EPIDEMIOL, V51, P1095, DOI 10.1016/S0895-4356(98)00101-2
   RODIN J, 1992, J GERONTOL, V47, pP373, DOI 10.1093/geronj/47.6.P373
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SONN U, 1991, SCAND J REHABIL MED, V23, P193
   STEEN B, 1993, Z GERONTOL, V26, P163
   Svensson E, 1998, STAT MED, V17, P2923, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2923::AID-SIM104>3.0.CO;2-#
   VERBRUGGE LM, 1995, AM J PUBLIC HEALTH, V85, P173, DOI 10.2105/AJPH.85.2.173
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 2000, INVEST OPHTH VIS SCI, V41, P49
NR 25
TC 32
Z9 32
U1 1
U2 34
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 1651-2014
J9 SCAND J OCCUP THER
JI Scand. J. Occup. Ther.
PD JUN
PY 2008
VL 15
IS 2
BP 68
EP 74
DI 10.1080/11038120701442963
PG 7
WC Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Rehabilitation
GA 336KQ
UT WOS:000258363100002
PM 17852958
DA 2022-11-30
ER

PT J
AU Skalet, AH
   Miller, AK
   Klein, ML
   Lauer, AK
   Wilson, DJ
AF Skalet, Alison H.
   Miller, Audra K.
   Klein, Michael L.
   Lauer, Andreas K.
   Wilson, David J.
TI CLINICOPATHOLOGIC CORRELATION OF RETINAL ANGIOMATOUS PROLIFERATION
   TREATED WITH RANIBIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; choroidal
   neovascularization; retinal neovascularization; clinicopathologic
   correlation; ranibizumab; retinal angiomatous proliferation
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; INTRAVITREAL
   RANIBIZUMAB; TYPE-3 NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; DIAGNOSIS;
   FEATURES; OCT; RAP
AB Purpose: To describe histopathologic features of an eye with retinal angiomatous proliferation (RAP) secondary to age-related macular degeneration treated with serial ranibizumab injections and to correlate these findings with spectral domain optical coherence tomography.
   Methods: Histopathologic features from serial sections through the globe of a 93-yearold man with age-related macular degeneration were studied and compared with spectral domain optical coherence tomography images obtained 7 weeks before his death.
   Results: The pathologic correlate of ranibizumab-treated RAP was a circumscribed, branching paucicellular vascular complex extending from the inner plexiform layer to Bruch membrane. The histopathologic findings corresponded to an area of hyperreflectivity on spectral domain optical coherence tomography imaging, substantiating the reported tomographic appearance of RAP lesions. A frank anastomosis with choroidal or retinal vasculature was not seen in this treated RAP lesion. There was a lack of retinal pigment epithelium underlying the lesion in an area of retinal pigment epithelium detachment. The elastic portion of Bruch membrane appeared intact. Treatment with ranibizumab over an extended period of time may have been associated with a loss of cellularity of the RAP lesion.
   Conclusion: In a patient with ARMD extensively treated with ranibizumab, color fundus photography, fluorescein angiography and SD-OCT images of RAP correlated histopathologically with a paucicellular intraretinal vascular complex.
C1 [Skalet, Alison H.; Miller, Audra K.; Klein, Michael L.; Lauer, Andreas K.; Wilson, David J.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA.
C3 Oregon Health & Science University
RP Skalet, AH (通讯作者)，3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM skalet@ohsu.edu
OI Miller, Audra/0000-0003-2774-6059
FU Lloyd Research Endowment Faculty Grant; National Institutes of Health
   (Bethesda, MD) [P30 EY010572]; Research to Prevent Blindness (New York,
   NY); NATIONAL EYE INSTITUTE [P30EY010572] Funding Source: NIH RePORTER
FX Supported by a Lloyd Research Endowment Faculty Grant (A. H. Skalet);
   Core Grant P30 EY010572 from the National Institutes of Health
   (Bethesda, MD) and by an unrestricted departmental grant from Research
   to Prevent Blindness (New York, NY).
CR Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P1165, DOI 10.1007/s00417-009-1089-3
   Kramann CA, 2012, ACTA OPHTHALMOL, V90, P487, DOI 10.1111/j.1755-3768.2010.01952.x
   Matsumoto H, 2010, RETINA-J RET VIT DIS, V30, P425, DOI 10.1097/IAE.0b013e3181bd2d95
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Petropoulos IK, 2010, KLIN MONATSBL AUGENH, V227, P309, DOI 10.1055/s-0029-1245221
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P420
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Saito M, 2016, JPN J OPHTHALMOL, V60, P42, DOI 10.1007/s10384-015-0417-x
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 18
TC 9
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2017
VL 37
IS 8
BP 1620
EP 1624
DI 10.1097/IAE.0000000000001672
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FB4JU
UT WOS:000406108700027
PM 28613221
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chew, EY
   Klein, ML
   Clemons, TE
   Agron, E
   Ratnapriya, R
   Edwards, AO
   Fritsche, LG
   Swaroop, A
   Abecasis, GR
AF Chew, Emily Y.
   Klein, Michael L.
   Clemons, Traci E.
   Agron, Elvira
   Ratnapriya, Rinki
   Edwards, Albert O.
   Fritsche, Lars G.
   Swaroop, Anand
   Abecasis, Goncalo R.
CA Age-Related Eye Dis Study Res Grp
TI No Clinically Significant Association between CFH and ARMS2 Genotypes
   and Response to Nutritional Supplements AREDS Report Number 38
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB;
   BLOOD-PRESSURE; EYE DISEASE; VITAMIN-C; AREDS; LOCI; ZINC;
   PHARMACOGENETICS
AB Objective: To determine whether genotypes at 2 major loci associated with late age-related macular degeneration (AMD), complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), influence the relative benefits of Age-Related Eye Disease Study (AREDS) supplements.
   Design: Unplanned retrospective evaluation of a prospective, randomized, placebo-controlled clinical trial of vitamins and minerals for the treatment of AMD.
   Subjects: AREDS participants (mean age, 69 years) who were at risk of developing late AMD and who were randomized to the 4 arms of AREDS supplement treatment.
   Methods: Analyses were performed using the Cox proportional hazards model to predict progression to late AMD (neovascular or central geographic atrophy). Statistical models, adjusted for age, gender, smoking status, and baseline AMD severity, were used to examine the influence of genotypes on the response to therapy with 4 randomly assigned arms of AREDS supplement components: placebo, antioxidants (vitamin C, vitamin E, b-carotene), zinc, or a combination.
   Main Outcome Measures: The influence of the genotype on the relative treatment response to the randomized components of the AREDS supplement, measured as progression to late AMD.
   Results: Of the 1237 genotyped AREDS participants of white ethnicity, late AMD developed in 385 (31.1%) during the mean follow-up of 6.6 years. As previously demonstrated, CFH genotype (P = 0.005), ARMS2 (P< 0.0001), and supplement were associated individually with progression to late AMD. An interaction analysis found no evidence that the relative benefits of AREDS supplementation varied by genotype. Analysis of (1) CFH rs1061170 and rs1410996 combined with ARMS2 rs10490924 with the 4 randomly assigned arms of AREDS supplement and (2) analysis of the combination of CFH rs412852 and rs3766405 with ARMS2 c. 372_815del443ins54 with the AREDS components resulted in no interaction (P = 0.06 and P = 0.45, respectively, before multiplicity adjustment).
   Conclusions: The AREDS supplements reduced the rate of AMD progression across all genotype groups. Furthermore, the genotypes at the CFH and ARMS2 loci did not statistically significantly alter the benefits of AREDS supplements. Genetic testing remains a valuable research tool, but these analyses suggest it provides no benefits in managing nutritional supplementation for patients at risk of late AMD. (C) 2014 by the American Academy of Ophthalmology.
C1 [Chew, Emily Y.; Agron, Elvira] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Klein, Michael L.; Edwards, Albert O.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Ratnapriya, Rinki; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Edwards, Albert O.] Oregon Retina LLP, Eugene, OR USA.
   [Edwards, Albert O.] Univ Oregon, Dept Biol, Eugene, OR 97403 USA.
   [Fritsche, Lars G.; Abecasis, Goncalo R.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Oregon Health & Science University; Emmes Corporation; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   University of Oregon; University of Michigan System; University of
   Michigan
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020; Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Chew, Emily/0000-0003-0999-9802;
   Swaroop, Anand/0000-0002-1975-1141; Ratnapriya,
   Rinki/0000-0002-0469-4631
FU National Eye Institute/National Institutes of Health, Bethesda Maryland
   [HHS-NOI-EY-0-2127]; NATIONAL EYE INSTITUTE [N01EY002127, ZIEEY000487,
   ZIAEY000546, R01EY021532, ZIAEY000475, ZIAEY000489, ZIAEY000485] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL117626] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute/National Institutes of Health,
   (contract no.: HHS-NOI-EY-0-2127), Bethesda Maryland. The sponsor and
   funding organization participated in the design and conduct of the
   study; data collection, management, analysis, and interpretation; and
   the preparation, review, and approval of the manuscript. The NIH holds a
   royalty-bearing license issued to Bausch & Lomb for the Age-Related Eye
   Disease Study Supplement. The Age-Related Eye Disease Study was a
   clinical trial that was conducted before the required clinical trials
   registration.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Emadi A, 2012, PHARMACOGENOMICS, V13, P1257, DOI [10.2217/PGS.12.102, 10.2217/pgs.12.102]
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Westbrook K, 2013, PHARMACOL THERAPEUT, V139, P1, DOI 10.1016/j.pharmthera.2013.03.001
NR 25
TC 62
Z9 62
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2014
VL 121
IS 11
BP 2173
EP 2180
DI 10.1016/j.ophtha.2014.05.008
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS8DM
UT WOS:000344480400022
PM 24974817
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Khatol, P
   Saraf, S
   Jain, A
AF Khatol, Prachi
   Saraf, Shivani
   Jain, Ankit
TI Peroxisome Proliferated Activated Receptors (PPARs): Opportunities and
   Challenges for Ocular Therapy
SO CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LA English
DT Review
DE Peroxisome proliferator-activated receptors (PPARs); diabetic
   retinopathy (DR); choroidal neovascularization (CNV); age-related
   macular degeneration (ARMD)
ID GLYCATION END-PRODUCTS; ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR
   EDEMA; ALDOSE REDUCTASE INHIBITOR; FACTOR-KAPPA-B; AGE-RELATED
   MACULOPATHY; BLOOD-RETINAL BARRIER; OXIDATIVE STRESS; DRUG-DELIVERY;
   CHOROIDAL NEOVASCULARIZATION
AB Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors. They exist in three isoforms (PPAR-alpha, PPAR-beta/delta, and PPAR-Y) in humans, but mainly PPAR-Y, and they are expressed in retinal epithelial pigment. PPARs are involved in mediating numerous pathological implications in eye such as diabetic retinopathy (DR), choroidal neovascularization (CNV), glaucoma, diabetic macular edema, and other retinal diseases. Peroxisome proliferator-activated receptors are key players in various biological pathways like lipid degeneration, immune regulation, and reactive oxygen species regulation, regulation of vascular endothelial growth factor, matrixmetalloproteinase-9, and docosahexaenoic acid pathway. Based on evidence from clinical investigations, the drugs meant for PPARs could be promising candidates for intraocular therapy. Anti-VEGF therapy, including bevacizumab, ranibizumab, and aptamers (pegaptanib), has been approved for wet age-related macular degeneration (ARMD). Recently, researchers have explored the role of PPAR-gamma in ocular pathophysiological processes and PPAR-gamma agonists as novel adjuvants in the treatment of eye diseases. PPAR-gamma exhibits potential benefits to improve or prevent various vision-threatening eye diseases such as age-related macular degeneration (ARMD), diabetic retinopathy (DR), keratitis, and optic neuropathy. However, PPAR-gamma presents challenges and offers opportunities for ocular scientists to bring better outcomes.
C1 [Khatol, Prachi; Saraf, Shivani] Dr Hari Singh Gour Cent Univ, Dept Pharmaceut Sci, Pharmaceut Res Projects Lab, Univ Rd, Sagar 470003, Madhya Pradesh, India.
   [Jain, Ankit] GLA Univ, Inst Pharmaceut Res, 17Km Stone,NH-2,Mathura Delhi Rd,PO Chaumuhan, Mathura 281406, Uttar Pradesh, India.
C3 Dr. Hari Singh Gour University; GLA University
RP Jain, A (通讯作者)，GLA Univ, Inst Pharmaceut Res, 17Km Stone,NH-2,Mathura Delhi Rd,PO Chaumuhan, Mathura 281406, Uttar Pradesh, India.
EM ankitjainsagar@gmail.com
RI Jain, Ankit/S-4534-2019; Jain, Ankit/P-8023-2018
OI Jain, Ankit/0000-0001-8131-1860; Jain, Ankit/0000-0001-8131-1860
CR Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032
   Abu El-Asrar AM, 2009, EXPERT REV OPHTHALMO, V4, P627, DOI 10.1586/EOP.09.52
   Adamis A., 2002, IS DIABETIC RETINOPA
   Adamis AP, 2008, SEM IMM NEW YORK
   Agarwal A, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0652-z
   Agrawal NK, 2014, WORLD J DIABETES, V5, P697, DOI 10.4239/wjd.v5.i5.697
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   Aiello LP, 2005, DIABETES, V54, P2188
   Aizu Y, 2002, NEUROPATHOLOGY, V22, P161, DOI 10.1046/j.1440-1789.2002.00439.x
   Al-Mesallamy HO, 2011, J DIABETES COMPLICAT, V25, P168, DOI 10.1016/j.jdiacomp.2010.06.005
   Allen DA, 2005, J NUTR BIOCHEM, V16, P705, DOI 10.1016/j.jnutbio.2005.06.007
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Aoun P, 2003, INVEST OPHTH VIS SCI, V44, P2999, DOI 10.1167/iovs.02-1060
   Asgary Seddighe, 2002, Journal of Herbal Pharmacotherapy, V2, P47, DOI 10.1080/J157v02n02_05
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Babizhayev MA, 2009, CLIN INTERV AGING, V4, P31
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernardes A, 2013, J MOL BIOL, V425, P2878, DOI 10.1016/j.jmb.2013.05.010
   Bishop-Bailey D., 2008, PPAR RES, P1
   Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Cai JJ, 2012, INVEST OPHTH VIS SCI, V53, P5967, DOI 10.1167/iovs.12-10048
   Caldwelll RB, 2003, DIABETES-METAB RES, V19, P442, DOI 10.1002/dmrr.415
   Cariou B, 2011, DIABETES CARE, V34, P2008, DOI 10.2337/dc11-0093
   Ceriello A, 2001, DIABETOLOGIA, V44, P834
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016/S0140-6736(08)61412-9
   CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302
   Chevallier A., 2016, ENCY HERBAL MED
   Cho WCS, 2006, EUR J PHARMACOL, V550, P173, DOI 10.1016/j.ejphar.2006.08.056
   Choudhary M, 2016, J BIOMOL SCREEN, V21, P1007, DOI 10.1177/1087057116659856
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   Chu J, 2008, DRUG DEVELOP RES, V69, P1, DOI 10.1002/ddr.20222
   Chun SH, 2010, ARCH OPHTHALMOL-CHIC, V128, P146, DOI 10.1001/archophthalmol.2009.363
   Chung P, 2003, NITRIC OXIDE-BIOL CH, V8, P119, DOI 10.1016/S1089-8603(02)00147-7
   Chung SSM, 2005, CURR DRUG TARGETS, V6, P475, DOI 10.2174/1389450054021891
   Ciudin A, 2013, PPAR RES, V2013, DOI 10.1155/2013/686525
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Collins AR, 2001, ARTERIOSCL THROM VAS, V21, P365, DOI 10.1161/01.ATV.21.3.365
   CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552
   Costa V, 2012, BRIT J PHARMACOL, V165, P1, DOI 10.1111/j.1476-5381.2011.01443.x
   Cruz R, 2008, BRIT J OPHTHALMOL, V92, P120, DOI 10.1136/bjo.2007.125179
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Rodriguez-Carrizalez AD, 2016, REDOX REP, V21, P155, DOI 10.1179/1351000215Y.0000000040
   Daniele LL, 2007, J COMP NEUROL, V505, P166, DOI 10.1002/cne.21489
   Decanini A, 2008, DIABETOLOGIA, V51, P1051, DOI 10.1007/s00125-008-0991-2
   Delcourt C, 2009, DIABETES METAB, V35, P431, DOI 10.1016/j.diabet.2009.06.002
   Dietz M, 2012, CHEMMEDCHEM, V7, P1101, DOI 10.1002/cmdc.201100598
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DOBREE JH, 1974, BRIT J OPHTHALMOL, V58, P377, DOI 10.1136/bjo.58.4.377
   Drel VR, 2008, INT J MOL MED, V21, P667
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Emoto M, 2001, DIABETES, V50, P1166, DOI 10.2337/diabetes.50.5.1166
   Erickson Kathryn K., 2007, Angiogenesis, V10, P103, DOI 10.1007/s10456-007-9067-z
   Fangueiro JF, 2015, EUR J PHARM BIOPHARM, V95, P307, DOI 10.1016/j.ejpb.2014.12.023
   Fattal E, 2008, INT J PHARMACEUT, V364, P237, DOI 10.1016/j.ijpharm.2008.06.011
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferre P, 2004, DIABETES, V53, pS43, DOI 10.2337/diabetes.53.2007.S43
   Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426
   Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Ganeshaguru K, 2002, HAEMATOLOGICA, V87, P167
   Gardner T W, 2000, Diabetes Technol Ther, V2, P601
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Geraldes P, 2010, CIRC RES, V106, P1319, DOI 10.1161/CIRCRESAHA.110.217117
   Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251
   Girnun GD, 2002, MOL ENDOCRINOL, V16, P2793, DOI 10.1210/me.2002-0020
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   dos Santos ALG, 2006, J CONTROL RELEASE, V112, P369, DOI 10.1016/j.jconrel.2006.02.010
   Goto SN, 2012, ACTA OPHTHALMOL, V90, P628, DOI 10.1111/j.1755-3768.2010.02066.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gross N, 2013, MOL VIS, V19, P54
   Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638
   Gupta N, 2013, OPEN OPHTHALMOL J, V7, P4, DOI 10.2174/1874364101307010004
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   HAMMES HP, 1995, DIABETOLOGIA, V38, P656, DOI 10.1007/s001250050333
   Harada C, 2006, DIABETES RES CLIN PR, V74, P249, DOI 10.1016/j.diabres.2006.04.017
   Haubner F, 2007, BIOCHEM BIOPH RES CO, V360, P560, DOI 10.1016/j.bbrc.2007.06.044
   Herzlich AA, 2008, PPAR RES, P1
   Hevener AL, 2007, J CLIN INVEST, V117, P1658, DOI 10.1172/JCI31561
   Hotta N, 2008, DIABETIC MED, V25, P818, DOI 10.1111/j.1464-5491.2008.02490.x
   Hunt David W C, 2002, IDrugs, V5, P180
   Jacot JL, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/589813
   Jain GK, 2012, DRUG DISCOV TODAY, V17, P748, DOI 10.1016/j.drudis.2012.03.006
   Javey G, 2012, EXP DIABETES RES, P1
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Kaji Y, 2007, INVEST OPHTH VIS SCI, V48, P858, DOI 10.1167/iovs.06-0495
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   Kaneto H, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/453892
   Kardon R, 2011, OPHTHALMOLOGY, V118, P376, DOI 10.1016/j.ophtha.2010.06.033
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaul K, 2010, CURR DIABETES REV, V6, P294, DOI 10.2174/157339910793360851
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Koh KK, 2008, INT J CARDIOL, V124, P149, DOI 10.1016/j.ijcard.2007.04.080
   Kohno T, 2007, J INVEST DERM SYMP P, V12, P5, DOI 10.1038/sj.jidsymp.5650034
   Konner Jason, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS81
   Korting HC, 2010, DRUG DELIV, P469
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Kuno N, 2011, POLYMERS-BASEL, V3, P193, DOI 10.3390/polym3010193
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lee HB, 2003, J AM SOC NEPHROL, V14, pS241, DOI 10.1097/01.ASN.0000077410.66390.0F
   Lee KJ, 2004, EXP MOL MED, V36, P534, DOI 10.1038/emm.2004.68
   Lian FM, 2016, LANCET DIABETES ENDO, V4, pS23, DOI DOI 10.1016/S2213-8587(16)30378-3
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088203
   Lim JI, 2010, INVEST OPHTH VIS SCI, V51
   Lorenzi M, 2007, EXP DIABETES RES, DOI 10.1155/2007/61038
   Lou J, 2014, INT J NANOMED, V9, P2517, DOI 10.2147/IJN.S60270
   Luo Y, 2006, BRAIN RES, V1110, P55, DOI 10.1016/j.brainres.2006.06.059
   Lutty G, 1999, Mol Vis, V5, P35
   Lutty GA, 1997, AM J PATHOL, V151, P707
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Mansoor S, 2009, PHARM RES-DORDR, V26, P770, DOI 10.1007/s11095-008-9812-z
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   Margolis R, 2008, ACTA OPHTHALMOL, V86, P105, DOI 10.1111/j.1600-0420.2007.00940.x
   Maritim AC, 2003, J NUTR BIOCHEM, V14, P288, DOI 10.1016/S0955-2863(03)00036-6
   Matsumoto K, 2002, DIABETIC MED, V19, P822, DOI 10.1046/j.1464-5491.2002.00799.x
   Milne R, 2013, AMINO ACIDS, V44, P1397, DOI 10.1007/s00726-011-1071-3
   Misra GP, 2009, BIOMATERIALS, V30, P6541, DOI 10.1016/j.biomaterials.2009.08.025
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   Mohamed Q, 2008, EXPERT OPIN EMERG DR, V13, P675, DOI [10.1517/14728210802584035, 10.1517/14728210802584035 ]
   Moore TCB, 2003, INVEST OPHTH VIS SCI, V44, P4457, DOI 10.1167/iovs.02-1063
   Moraes LA, 2006, PHARMACOL THERAPEUT, V110, P371, DOI 10.1016/j.pharmthera.2005.08.007
   Motomura K, 2009, J AGR FOOD CHEM, V57, P7666, DOI 10.1021/jf9007168
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P4342, DOI 10.1167/iovs.06-1473
   Navaratna D, 2007, DIABETES, V56, P2380, DOI 10.2337/db06-1694
   Nissen SE, 2005, JAMA-J AM MED ASSOC, V294, P2581, DOI 10.1001/JAMA.294.20.JOC50147
   O'Brien TP, 2005, CURR MED RES OPIN, V21, P1131, DOI 10.1185/030079905x50651
   Obrosova Irina G., 2005, Current Vascular Pharmacology, V3, P267, DOI 10.2174/1570161054368634
   Olson JA, 1997, DIABETOLOGIA, V40, P1166, DOI 10.1007/s001250050802
   Olukman M, 2010, EXPER DIABET RES, P1
   Omae T, 2011, INVEST OPHTH VIS SCI, V52, P6749, DOI 10.1167/iovs.10-6826
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   ParkSoohyun, 2008, Laboratory Animal Research, V24, P119
   Patel S, 2015, J OCUL PHARMACOL TH, V31, P215, DOI 10.1089/jop.2014.0152
   Patelli F, 2005, RETINA-J RET VIT DIS, V25, P840, DOI 10.1097/00006982-200510000-00004
   Pershadsingh HA, 2008, PPAR RES, V2008, DOI 10.1155/2008/164273
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Petrovic MG, 2010, ACTA OPHTHALMOL, V88, pe311, DOI 10.1111/j.1755-3768.2010.02030.x
   Pirmoradi FN, 2011, LAB CHIP, V11, P2744, DOI 10.1039/c1lc20134d
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   POWELL EDU, 1964, LANCET, V2, P17
   Prager F, 2009, BRIT J OPHTHALMOL, V93, P452, DOI 10.1136/bjo.2008.141085
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Nguyen QD, 2016, LANCET, V388, P1183, DOI 10.1016/S0140-6736(16)31339-3
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Ratner Robert E, 2007, Diab Vasc Dis Res, V4, P214
   Rodrigues GA, 2011, INVEST OPHTH VIS SCI, V52, P890, DOI 10.1167/iovs.10-5715
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Sang DN, 2008, DIABETOLOGIA, V51, P1570, DOI 10.1007/s00125-008-1078-9
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sarayba MA, 2005, EXP EYE RES, V80, P435, DOI 10.1016/j.exer.2004.10.009
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schoonjans K, 1996, J LIPID RES, V37, P907
   Schrader M, 2006, BBA-MOL CELL RES, V1763, P1755, DOI 10.1016/j.bbamcr.2006.09.006
   Sen S, 2016, INDIAN TRADITIONAL M, P125, DOI DOI 10.1007/978-981-10-1542-7_10
   Sheikpranbabu S, 2010, BIOCHIMIE, V92, P1040, DOI 10.1016/j.biochi.2010.05.004
   Sheikpranbabu S, 2010, BIOMATERIALS, V31, P2260, DOI 10.1016/j.biomaterials.2009.11.076
   Shimura M, 2006, OPHTHALMOLOGY, V113, P381, DOI 10.1016/j.ophtha.2005.10.035
   SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405
   Silva PS, 2010, NAT REV ENDOCRINOL, V6, P494, DOI 10.1038/nrendo.2010.122
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Siqueira RC, 2011, CLIN OPHTHALMOL, V5, P1493, DOI 10.2147/OPTH.S25249
   Song MK, 2012, BRIT J PHARMACOL, V165, P4, DOI 10.1111/j.1476-5381.2011.01411.x
   Staels B, 1997, BIOCHIMIE, V79, P95, DOI 10.1016/S0300-9084(97)81497-6
   Sugawara R, 2003, INVEST OPHTH VIS SCI, V44, pU401
   Sun W, 2005, DIABETES, V54, P3418, DOI 10.2337/diabetes.54.12.3418
   Sun W, 2006, DIABETES, V55, P2757, DOI 10.2337/db06-0138
   Suzuki Y, 2011, JPN J OPHTHALMOL, V55, P256, DOI 10.1007/s10384-011-0004-8
   Taban M, 2008, RETINAL PHYS, V5, P17
   Takamura Y, 2015, J OCULAR PHARM THERA, V31
   Tawfik A, 2009, INVEST OPHTH VIS SCI, V50, P878, DOI 10.1167/iovs.08-2005
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tilma KK, 2012, ACTA OPHTHALMOL, V90, P750, DOI 10.1111/j.1755-3768.2011.02185.x
   Treacy MP, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-46
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
   Trudeau K, 2011, INVEST OPHTH VIS SCI, V52, P6348, DOI 10.1167/iovs.11-7282
   TSO MOM, 1977, INVEST OPHTH VIS SCI, V16, P381
   Usui T, 2008, INVEST OPHTH VIS SCI, V49, P4370, DOI 10.1167/iovs.07-0964
   Vicari D., 2008, THESIS
   Villarroel M, 2011, DIABETOLOGIA, V54, P1543, DOI 10.1007/s00125-011-2089-5
   Vincent AM, 2007, ENDOCRINOLOGY, V148, P548, DOI 10.1210/en.2006-0073
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Wang HY, 2008, HEPATOB PANCREAT DIS, V7, P179
   World Health Organization, 2016, GLOB REP DIAB
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Yam Jason C. S., 2007, Hong Kong Medical Journal, V13, P46
   Yamagishi SI, 2007, OPHTHAL RES, V39, P92, DOI 10.1159/000099244
   Yamagishi S, 2011, EXP GERONTOL, V46, P217, DOI 10.1016/j.exger.2010.11.007
   Yamagishi S, 2009, THER APHER DIAL, V13, P534, DOI 10.1111/j.1744-9987.2009.00775.x
   Yasukawa T, 2000, CURR EYE RES, V21, P952, DOI 10.1076/ceyr.21.6.952.6992
   Ye YL, 2009, BIOORGAN MED CHEM, V17, P5722, DOI 10.1016/j.bmc.2009.05.082
   Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624
   Young PW, 1998, J PHARMACOL EXP THER, V284, P751
   Zhang SF, 2015, J ENG-JOE, P1, DOI 10.1049/joe.2014.0349
   Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233
   Zheng L, 2004, DIABETES, V53, P2960, DOI 10.2337/diabetes.53.11.2960
   Zheng L, 2009, FRONT BIOSCI-LANDMRK, V14, P3974, DOI [10.2735/3505, 10.2741/3505]
   Zhou YJ, 2007, LAB INVEST, V87, P488, DOI 10.1038/labinvest.3700532
   Zong H, 2010, DIABETOLOGIA, V53, P2656, DOI 10.1007/s00125-010-1900-z
NR 209
TC 11
Z9 11
U1 0
U2 14
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 0743-4863
EI 2162-660X
J9 CRIT REV THER DRUG
JI Crit. Rev. Ther. Drug Carr. Syst.
PY 2018
VL 35
IS 1
BP 65
EP 97
DI 10.1615/CritRevTherDrugCarrierSyst.2017020231
PG 33
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GI4KI
UT WOS:000434339900002
PM 29611471
DA 2022-11-30
ER

PT J
AU Fu, Y
   Dong, YM
   Gao, QY
AF Fu, Yue
   Dong, Yanmin
   Gao, Qianying
TI Age-related cataract and macular degeneration: Oxygen receptor
   dysfunction diseases
SO MEDICAL HYPOTHESES
LA English
DT Article
ID CAPSULAR VITREOUS BODY; RABBIT EYE; RANIBIZUMAB; BEVACIZUMAB; MECHANISM;
   RELEASE; AMD
AB Age-related cataract and age-related macular degeneration (AMD) is the leading cause of vision impairment and blindness in developing and developed countries, respectively. Oxidative stress and oxidation products have been verified to play important roles in these two aging diseases. Recent research has demonstrated that there are significant oxygen gradients in the eye. Therefore, we propose a new hypothesis that these two diseases could be summarized as oxygen receptor dysfunction diseases of which the main points are as follows. Oxygen in the retinal and choroidal vasculature is transferred into the vitreous cavity by a special switching valve or oxygen receptor that might exist in the internal limiting membrane, vascular endothelium or posterior vitreous surface. It is then transported from the posterior segment to the anterior segment by vitreous collagen fibrilla networks, which work similar to a gas pipeline. Posterior vitreous detachment is the starting point of these two diseases by inducing formation of the local hyperoxia region, which results in the occurrence of age-related cataract and macular degeneration. Thus, an innovative anti-oxidative therapy should be added to the traditional treatment of age related macular degeneration. Some associated experimental and clinical approaches are suggested in our paper to test this hypothesis. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Fu, Yue; Dong, Yanmin; Gao, Qianying] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Gao, QY (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM gaoty@mail.sysu.edu.cn
FU "Twelfth Five-Year" Plan for Science Technology [2012BAI08B02]
FX This study was supported by the "Twelfth Five-Year" Plan for Science &
   Technology Support Grant (2012BAI08B02).
CR Asbell PA, 2005, LANCET, V365, P599
   Bystrom B, 2006, INVEST OPHTH VIS SCI, V47, P777, DOI 10.1167/iovs.05-0367
   Chen JJ, 2011, J BIOMED MATER RES B, V97B, P396, DOI 10.1002/jbm.b.31812
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   CHRISTEN WG, 1993, LANCET, V341, P569, DOI 10.1016/0140-6736(93)90341-D
   COTLIER E, 1977, NEW ENGL J MED, V296, P398
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Filas B, 2013, INVEST OPHTHALMOL VI
   Halfter W, 2008, EYE, V22, P1207, DOI 10.1038/eye.2008.19
   Halfter W, 2000, DEV BIOL, V220, P111, DOI 10.1006/dbio.2000.9649
   Hardarson SH, 2009, INVEST OPHTH VIS SCI, V50, P2308, DOI 10.1167/iovs.08-2576
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lange CA, 2011, AM J OPHTHALMOL, V152, p406e3
   Larkin M, 2001, LANCET, V358, P1347, DOI 10.1016/S0140-6736(01)06463-7
   Lawrence DM, 2002, LANCET, V360, P1307, DOI 10.1016/S0140-6736(02)11363-8
   Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu YQ, 2010, INVEST OPHTH VIS SCI, V51, P1636, DOI 10.1167/iovs.09-4134
   Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555
   Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Shui YB, 2006, INVEST OPHTH VIS SCI, V47, P1571, DOI 10.1167/iovs.05-1475
NR 23
TC 2
Z9 4
U1 0
U2 7
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD SEP
PY 2015
VL 85
IS 3
BP 272
EP 275
DI 10.1016/j.mehy.2015.05.020
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CQ8OP
UT WOS:000360868100008
PM 26049822
DA 2022-11-30
ER

PT J
AU Lee, V
   Rekhi, E
   Kam, JH
   Jeffery, G
AF Lee, Vivian
   Rekhi, Elissa
   Kam, Jaimie Hoh
   Jeffery, Glen
TI Vitamin D rejuvenates aging eyes by reducing inflammation, clearing
   amyloid beta and improving visual function
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Retina; Aging; Macrophage
ID MACULAR DEGENERATION; BRAIN; AGE; MACROPHAGE; MICROGLIA; RODS; CELL
AB Vitamin D-3 plays a key role in immune regulation and may protect against the aging process. A focal point for age-related changes is the outer retina of the eye where there is high metabolic demand resulting in a gradual increase in extracellular deposition, inflammation, and cell loss giving rise to visual decline. Here, we demonstrate that vitamin D-3 administration for only 6 weeks in aged mice significantly impacts on this aging process. Treated mice showed significant reductions in retinal inflammation and levels of amyloid beta (A beta) accumulation, which is a hallmark of aging. They also had significant reductions in retinal macrophage numbers and marked shifts in their morphology. These changes were reflected in a significant improvement in visual function, revealing that vitamin D-3 is a route to avoiding the pace of age-related visual decline. Excess amyloid beta deposition and inflammation are risk factors leading to age-related macular degeneration (AMD), the largest cause of blindness in those older than 50 years in developed countries. Recently, vitamin D-3 has been linked epidemiologically to protection against age-related macular degeneration. Hence, vitamin D-3 enrichment is likely to represent a beneficial route for those at risk. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lee, Vivian; Rekhi, Elissa; Kam, Jaimie Hoh; Jeffery, Glen] UCL, Inst Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM g.jeffery@ucl.ac.uk
FU Biotechnological and Biological Sciences Research Council; Rosetrees
   Trust
FX Supported by the Biotechnological and Biological Sciences Research
   Council and the Rosetrees Trust.
CR AKIYAMA H, 1994, TOHOKU J EXP MED, V174, P295, DOI 10.1620/tjem.174.295
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aparna R, 2008, J CELL BIOCHEM, V104, P1832, DOI 10.1002/jcb.21749
   Baeke F, 2010, CURR OPIN PHARMACOL, V10, P482, DOI 10.1016/j.coph.2010.04.001
   Bar-Yosef O., 2007, RETHINKING HUMAN REV, P207
   Butterfield DA, 2002, J ALZHEIMERS DIS, V4, P193, DOI 10.3233/JAD-2002-4309
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204
   Caspari R, 2004, P NATL ACAD SCI USA, V101, P10895, DOI 10.1073/pnas.0402857101
   Chandra G, 2004, J CLIN IMMUNOL, V24, P249, DOI 10.1023/B:JOCI.0000025446.44146.52
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Francis PJ, 2005, BRIT J OPHTHALMOL, V89, P70, DOI 10.1136/bjo.2004.042416
   Galor O., 2007, NEOLITHIC REVOLUTION
   Graymore C., 1969, EYE
   Guillot X, 2010, JOINT BONE SPINE, V77, P552, DOI 10.1016/j.jbspin.2010.09.018
   Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029
   Holder GE, 2005, BRIT J OPHTHALMOL, V89, P709, DOI 10.1136/bjo.2004.047837
   Holick MF, 2005, J NUTR, V135, p2739S, DOI 10.1093/jn/135.11.2739S
   Janjetovic Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005988
   Kalla R, 2003, GLIA, V41, P50, DOI 10.1002/glia.10176
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kamen DL, 2010, J MOL MED, V88, P441, DOI 10.1007/s00109-010-0590-9
   Kaur C, 2007, ACTA PHARMACOL SIN, V28, P1087, DOI 10.1111/j.1745-7254.2007.00625.x
   Kloss CUA, 2001, EXP NEUROL, V168, P32, DOI 10.1006/exnr.2000.7575
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Lam B.L., 2005, ELECTROPHYSIOLOGY VI
   Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533
   Lips P, 2006, PROG BIOPHYS MOL BIO, V92, P4, DOI 10.1016/j.pbiomolbio.2006.02.016
   Mantel I, 2008, EXP MOL PATHOL, V84, P90, DOI 10.1016/j.yexmp.2007.10.006
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Richards JB, 2007, AM J CLIN NUTR, V86, P1420, DOI 10.1093/ajcn/86.5.1420
   Rosenstiel P, 2001, MICROSC RES TECHNIQ, V54, P18, DOI 10.1002/jemt.1116
   Scholl HPN, 2000, SURV OPHTHALMOL, V45, P29, DOI 10.1016/S0039-6257(00)00125-9
   Skaper SD, 2011, CNS NEUROL DISORD-DR, V10, P44
   Stringer C, 2003, NATURE, V423, P692, DOI 10.1038/423692a
   Szodoray P, 2008, SCAND J IMMUNOL, V68, P261, DOI 10.1111/j.1365-3083.2008.02127.x
   Vanhaeren M, 2006, SCIENCE, V312, P1785, DOI 10.1126/science.1128139
   Walker A, 2010, PHILOS T R SOC B, V365, P3265, DOI 10.1098/rstb.2010.0179
   Yu J, 2011, J ALZHEIMERS DIS, V25, P295, DOI 10.3233/JAD-2011-101986
NR 43
TC 68
Z9 70
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD OCT
PY 2012
VL 33
IS 10
BP 2382
EP 2389
DI 10.1016/j.neurobiolaging.2011.12.002
PG 8
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 996LG
UT WOS:000308088500014
PM 22217419
DA 2022-11-30
ER

PT J
AU Baer, CA
   Rickman, CB
   Srivastava, S
   Malek, G
   Stinnett, S
   Toth, CA
AF Baer, Claxton A.
   Rickman, Catherine Bowes
   Srivastava, Sunil
   Malek, Goldis
   Stinnett, Sandra
   Toth, Cynthia A.
TI RECURRENT CHOROIDAL NEOVASCULARIZATION AFTER MACULAR TRANSLOCATION
   SURGERY WITH 360-DEGREE PERIPHERAL RETINECTOMY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; macula;
   retina; translocation; signaling
ID RETINAL-PIGMENT EPITHELIUM; LASER PHOTOCOAGULATION; GEOGRAPHIC ATROPHY;
   STARGARDT-DISEASE; CIGARETTE-SMOKING; VISUAL FUNCTION; GENE ABCR;
   DEGENERATION; TRANSPLANTATION; MACULOPATHY
AB Purpose: To evaluate the pattern of age-related macular degeneration in the new foveal location after macular translocation surgery with 360 degree peripheral retinectomy for neovascular age-related macular degeneration.
   Methods: Clinical data, fundus photos, and fluorescein angiograms of patients in the Duke Macular Translocation Study were reviewed with 2-year follow-up data.
   Results: With 56 patients completing follow-up, no patient developed de novo choroidal neovascularization (CNV), geographic atrophy, or drusen in the new subfoveal retinal pigment epithelium bed. By 2 years, 14 patients (25%) developed recurrent CNV and 13 of these 14 recurrences clearly arose from the old CNV bed. Of the 13 recurrences clearly arising from the old bed, 12 of them had recurrent CNV that involved the margin of the bed closest to the repositioned fovea. Smokers were 5.3 times (95% confidence interval: 1.2-24) more likely to develop recurrent CNV over 2 years. Despite treatment, median visual acuity for the 14 eyes with recurrent CNV was 20/200 compared with 20/80 in eyes without recurrence.
   Conclusions: Findings in this study support the hypotheses that the development of CNV occurs via a signaling mechanism from the fovea. RETINA 28:1221-1227, 2008
C1 [Baer, Claxton A.; Rickman, Catherine Bowes; Srivastava, Sunil; Malek, Goldis; Stinnett, Sandra; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   [Stinnett, Sandra] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA.
   [Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC USA.
C3 Duke University; Duke University; Duke University; Duke University
RP Baer, CA (通讯作者)，Cabarrus Eye Ctr, 201 LePhillip Court, Concord, NC 28025 USA.
EM cab8b@yahoo.com
RI toth, cynthia a/F-5614-2011; Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Bowes Rickman,
   Catherine/0000-0002-8555-9596; Stinnett, Sandra/0000-0001-7192-0195;
   Malek, Goldis/0000-0003-0026-2388
FU Department of Ophthalmology at Duke University; Heed Fellowship
   Foundation; Ronald G. Michels Fellowship Foundation; NEI [R01 EY11286];
   Research to Prevent Blindness; D. Euan and Angelica H. Baird; NATIONAL
   EYE INSTITUTE [R01EY011286] Funding Source: NIH RePORTER
FX Supported by the Department of Ophthalmology at Duke University, the
   Heed Fellowship Foundation (to C.A.B.), the Ronald G. Michels Fellowship
   Foundation (to C.A.B.), the NEI R01 EY11286 (to C.B.R.), a Career
   Development Award from Research to Prevent Blindness (to C.B.R.), and by
   D. Euan and Angelica H. Baird (to C.A.T.).
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Cahill MT, 2003, ARCH OPHTHALMOL-CHIC, V121, P132
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kent DL, 2003, RETINA-J RET VIT DIS, V23, P152, DOI 10.1097/00006982-200304000-00003
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MAHMOUD TH, 2005, AAO ANN M NEW ORL
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   TOTH CA, 1998, AGE RELATED MACULAR, P353
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
NR 30
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2008
VL 28
IS 9
BP 1221
EP 1227
DI 10.1097/IAE.0b013e31817d5bce
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366IM
UT WOS:000260474200007
PM 18626416
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lee, MY
   Lee, WK
   Baek, J
   Kwon, OW
   Lee, JH
AF Lee, Mee Yon
   Lee, Won Ki
   Baek, Jiwon
   Kwon, Oh Woong
   Lee, Jin Hae
TI Photodynamic Therapy Versus Combination Therapy in Polypoidal Choroidal
   Vasculopathy: Changes of Aqueous Vascular Endothelial Growth Factor
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; NEOVASCULAR MEMBRANES; PIGMENT-EPITHELIUM;
   INTRAVITREAL RANIBIZUMAB; HUMOR LEVELS; VERTEPORFIN; BEVACIZUMAB;
   EXPRESSION; EFFICACY; VEGF
AB PURPOSE: To investigate the influence of photodynamic therapy (PDT) and combination of PDT and ranibizumab on aqueous humor levels of vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV).
   DESIGN: Prospective randomized clinical trial.
   METHOD: We included 20 eyes with treatment-naive PCV and 20 eyes undergoing cataract surgery as controls. PCV eyes were randomized to treatment with PDT alone or to a combination of ranibizumab and PDT on the same day. During 3 months, retreatment was not performed. Aqueous humors were collected at baseline and at 1 week, 1 month, and 3 months after treatment in the PCV group and during cataract surgery in the control group. VEGF levels were measured using multiplex bead immunoassay.
   RESULTS: At baseline, VEGF levels were significantly increased in PCV eyes compared with control eyes. A significant decrease in VEGF levels was found at 1 week after PDT treatment (n = 8) and at all time points after combination treatment (n = 12). With combination treatment, VEGF levels were decreased to values below the detection limit in all eyes at 1 week and 1 month and in 7 of 12 eyes at 3 months. There was no difference in the clinical profiles among the 2 treatment groups at each time point.
   CONCLUSION: Decreased levels of VEGF detected 1 week after PDT for PCV seems to reflect acute damage of vascular endothelial cells, one of the VEGF expression sites in PCV. Concomitant ranibizumab resulted in a further decrease in VEGF to negligible levels, but this result did not affect the clinical results for 3 months. (C) 2013 by Elsevier Inc. All rights reserved.
C1 [Lee, Won Ki; Baek, Jiwon; Lee, Jin Hae] Catholic Univ Korea, Coll Med, Dept Ophthalmol, Seoul St Marys Hosp, Seoul 137701, South Korea.
   [Lee, Mee Yon] Chung Ang Univ, Coll Med, Dept Ophthalmol, Seoul 156756, South Korea.
   [Kwon, Oh Woong] Nune Eye Hosp, Retina Ctr, Seoul, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Chung Ang
   University; Chung Ang University Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Coll Med, Dept Ophthalmol, Seoul St Marys Hosp, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
OI Baek, Jiwon/0000-0001-6736-5379
FU Novartis; Bayer; Allergan; NOVARTIS KOREA, Seoul, South Korea
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following were reported: Won
   Ki Lee: disclosures outside of the submitted work for consultancy
   (Novartis) and payment for lectures (Novartis, Bayer, Allergan); Oh
   Woong Kwon: disclosures outside of the submitted work for consultancy
   (Novartis, Bayer) and payment for lectures (Novartis, Bayer). This
   article was supported by funding from NOVARTIS KOREA, Seoul, South
   Korea. Contributions of authors: design and conduct of the study
   (W.K.L., M.Y.L.); collection (W.K.L., M.Y.L., J.B.L., O.W.K.),
   management (W.K.L., M.Y.L.), analysis (W.K.L., M.Y.L.), and
   interpretation of the data (W.K.L., M.Y.L.); and preparation (W.K.L.,
   M.Y.L.), review, or approval of the manuscript (W.K.L., M.Y.L., J.B.,
   J.H.L., O.W.K.).
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Imasawa M, 2011, JPN J OPHTHALMOL, V55, P241, DOI 10.1007/s10384-011-0006-6
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
NR 30
TC 26
Z9 27
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2013
VL 156
IS 2
BP 343
EP 348
DI 10.1016/j.ajo.2013.04.001
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196BK
UT WOS:000322748200018
PM 23664208
DA 2022-11-30
ER

PT J
AU Velazquez-Villoria, A
   Recalde, S
   Anter, J
   Bezunartea, J
   Hernandez-Sanchez, M
   Garcia-Garcia, L
   Alonso, E
   Ruiz-Moreno, JM
   Araiz-Iribarren, J
   Fernandez-Robredo, P
   Garcia-Layana, A
AF Velazquez-Villoria, Alvaro
   Recalde, Sergio
   Anter, Jaouad
   Bezunartea, Jaione
   Hernandez-Sanchez, Maria
   Garcia-Garcia, Laura
   Alonso, Elena
   Marina Ruiz-Moreno, Jose
   Araiz-Iribarren, Javier
   Fernandez-Robredo, Patricia
   Garcia-Layana, Alfredo
TI Evaluation of 10 AMD Associated Polymorphisms as a Cause of Choroidal
   Neovascularization in Highly Myopic Eyes
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-I; MACULAR DEGENERATION; CANDIDATE GENE; RISK-FACTORS;
   COL1A1 GENE; SUSCEPTIBILITY GENE; PATHOLOGICAL MYOPIA;
   MOLECULAR-GENETICS; REFRACTIVE ERRORS; PREVALENCE
AB Choroidal neovascularization (CNV) commonly occurs in age related macular degeneration and pathological myopia patients. In this study we conducted a case-control prospective study including 431 participants. The aim of this study was to determine the potential association between 10 single nucleotide polymorphisms (SNPs) located in 4 different genetic regions (CFI, COL8A1, LIPC, and APOE), and choroidal neovascularization in age-related macular degeneration and the development of choroidal neovascularization in highly myopic eyes of a Caucasian population. Univariate and multivariate logistic regression analysis adjusted for age, sex and hypertension was performed for each allele, genotype and haplotype frequency analysis. We found that in the univariate analysis that both single-nucleotide polymorphisms in COL8A1 gene (rs13095226 and rs669676) together with age, sex and hypertension were significantly associated with myopic CNV development in Spanish patients (p<0.05). After correcting for multiple testing none of the polymorphisms studied remained significantly associated with myopic CNV (p>0.05); however, analysis of the axial length between genotypes of rs13095226 revealed an important influence of COL8A1 in the development of CNV in high myopia. Furthermore we conducted a meta-analysis of COL8A1, CFI and LIPC genes SNPs (rs669676, rs10033900 and rs10468017) and found that only rs669676 of these SNPs were associated with high myopia neovascularization.
C1 [Velazquez-Villoria, Alvaro; Recalde, Sergio; Bezunartea, Jaione; Hernandez-Sanchez, Maria; Garcia-Garcia, Laura; Alonso, Elena; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Univ Navarra, Ophthalmol Expt Lab, Pamplona, Spain.
   [Velazquez-Villoria, Alvaro; Alonso, Elena; Garcia-Layana, Alfredo] Clin Univ Navarra, Dept Ophthalmol, Pamplona, Spain.
   [Anter, Jaouad] Ctr Invest Biol & Ciber Enfermedades Raras, Dept Celular & Mol Med, Madrid, Spain.
   [Marina Ruiz-Moreno, Jose] Castilla La Mancha Univ, Albacete & Baviera European Inst Retina, Dept Ophthalmol, Alicante, Spain.
   [Araiz-Iribarren, Javier] Univ Basque Country, Surg Clin Inst Ophthalmol, Bilbao, Spain.
   [Araiz-Iribarren, Javier] San Eloy Hosp, Bilbao, Spain.
C3 University of Navarra; University of Navarra; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones
   Biologicas (CIB); University of Basque Country
RP Recalde, S (通讯作者)，Univ Navarra, Ophthalmol Expt Lab, Pamplona, Spain.
EM srecalde@unav.es
RI Recalde, Sergio/D-1815-2017
OI Recalde, Sergio/0000-0002-9328-9725; Ruiz-Moreno, Jose
   M/0000-0001-9636-0788
FU PN I + D + I; ISCIII-Subdireccion General de Redes y Centros de
   Investigacion Cooperativa; European Program FEDER
FX This work has been developed by members of the Spanish Vitreoretinal
   society (SERV), the RETICs: RD07-0062: "Age Related Ocular Diseases,
   Quality of Life, and Vision", and RETICS OFTARED (RD12/0034)
   "Prevention, Early Detection, and Treatment of the Prevalent
   Degenerative and Chronic Ocular Pathology" from the Instituto de Salud
   Carlos III from the Ministerio de Economia y Competitividad, Spain. This
   work has been partly funded by the PN I + D + I 20082011; the
   ISCIII-Subdireccion General de Redes y Centros de Investigacion
   Cooperativa; and the European Program FEDER.; We greatly thank all the
   patients who participated in this study. This work has been developed by
   members of the Spanish Vitreoretinal society (SERV), the RETICs:
   RD07-0062: "Age Related Ocular Diseases, Quality of Life, and Vision",
   and RETICS OFTARED (RD12/0034) "Prevention, Early Detection, and
   Treatment of the Prevalent Degenerative and Chronic Ocular Pathology"
   from the Instituto de Salud Carlos III from the Ministerio de Economia y
   Competitividad, Spain. This work has been partly funded by the PN I + D
   + I 2008-2011; the ISCIII-Subdireccion General de Redes y Centros de
   Investigacion Cooperativa; and the European Program FEDER.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Chan NS, 2015, EYE CONTACT LENS
   Chen SJ, 2012, INVEST OPHTH VIS SCI, V53, P4868, DOI 10.1167/iovs.12-9919
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Dirani M, 2008, INVEST OPHTH VIS SCI, V49, P534, DOI 10.1167/iovs.07-1123
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Feldkamper M, 2003, DEV OPHTHALMOL, V37, P34
   Fernandez-Robredo P, 2008, OPHTHALMOLOGY, V115, P1632, DOI 10.1016/j.ophtha.2008.03.004
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haghighi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112747
   Hammond CJ, 2004, AM J HUM GENET, V75, P294, DOI 10.1086/423148
   Han W, 2006, INVEST OPHTH VIS SCI, V47, P2291, DOI 10.1167/iovs.05-1344
   Hayashi T, 2007, JPN J OPHTHALMOL, V51, P96, DOI 10.1007/s10384-006-0417-y
   He MG, 2009, OPTOMETRY VISION SCI, V86, P40, DOI 10.1097/OPX.0b013e3181940719
   Hrynchak PK, 2013, OPTOMETRY VISION SCI, V90, P1331, DOI 10.1097/OPX.0000000000000069
   Hufnagel SB, 2014, AM J MED GENET A, V164, P2607, DOI 10.1002/ajmg.a.36688
   Ikuno Y, 2008, RETINA-J RET VIT DIS, V28, P1124, DOI 10.1097/IAE.0b013e318174417a
   Inamori Y, 2007, HUM GENET, V122, P151, DOI 10.1007/s00439-007-0388-1
   Kiefer AK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003299
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Leveziel N, 2012, INVEST OPHTH VIS SCI, V53, P5004, DOI 10.1167/iovs.12-9538
   Liang CL, 2007, J HUM GENET, V52, P374, DOI 10.1007/s10038-007-0117-6
   Lin HJ, 2010, EYE, V24, P1093, DOI 10.1038/eye.2009.254
   Lin LL, 2004, ANN ACAD MED SINGAP, V33, P27
   Lopes MC, 2009, INVEST OPHTH VIS SCI, V50, P126, DOI 10.1167/iovs.08-2385
   Lu BY, 2011, INVEST OPHTH VIS SCI, V52, P8258, DOI 10.1167/iovs.11-7914
   Metlapally R, 2009, INVEST OPHTH VIS SCI, V50, P4080, DOI 10.1167/iovs.08-3346
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Miyake M, 2013, INVEST OPHTH VIS SCI, V54, P4208, DOI 10.1167/iovs.13-12280
   Morgan I, 2005, PROG RETIN EYE RES, V24, P1, DOI 10.1016/j.preteyeres.2004.06.004
   Mutti DO, 2007, MOL VIS, V13, P1012
   Nakanishi H, 2010, EYE, V24, P1078, DOI 10.1038/eye.2009.215
   Nakanishi H, 2009, INVEST OPHTH VIS SCI, V50, P544, DOI 10.1167/iovs.08-2425
   NOBLE KG, 1982, OPHTHALMOLOGY, V89, P1099
   Pacella R, 1999, OPTOMETRY VISION SCI, V76, P381, DOI 10.1097/00006324-199906000-00017
   Pan CW, 2012, OPHTHAL PHYSL OPT, V32, P3, DOI 10.1111/j.1475-1313.2011.00884.x
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Percival S P, 1987, Dev Ophthalmol, V14, P42
   Pertile KK, 2008, INVEST OPHTH VIS SCI, V49, P49, DOI 10.1167/iovs.07-0896
   Saw Seang-Mei, 2003, Clin Exp Optom, V86, P289
   Sawada A, 2008, OPHTHALMOLOGY, V115, P363, DOI 10.1016/j.ophtha.2007.03.075
   Scavello GS, 2004, INVEST OPHTH VIS SCI, V45, P2091, DOI 10.1167/iovs.03-0933
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Sergouniotis PI, 2015, EYE, V29, P475, DOI 10.1038/eye.2014.334
   Shih YF, 2006, BRIT J OPHTHALMOL, V90, P546, DOI 10.1136/bjo.2005.081992
   Shuttleworth CA, 1997, INT J BIOCHEM CELL B, V29, P1145, DOI 10.1016/S1357-2725(97)00033-2
   Snead MP, 1999, J MED GENET, V36, P353
   Soubrane G, 2008, SURV OPHTHALMOL, V53, P121, DOI 10.1016/j.survophthal.2007.12.004
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Tang WC, 2007, MOL VIS, V13, P534
   TEIKARI JM, 1991, HUM HERED, V41, P151, DOI 10.1159/000153994
   Terhal PA, 2015, AM J MED GENET A, V167, P461, DOI 10.1002/ajmg.a.36922
   Verhoeven VJM, 2013, NAT GENET, V45, P314, DOI 10.1038/ng.2554
   Vitale S, 2009, ARCH OPHTHALMOL-CHIC, V127, P1632, DOI 10.1001/archophthalmol.2009.303
   Wang PF, 2009, INVEST OPHTH VIS SCI, V50, P1546, DOI 10.1167/iovs.08-2537
   Wolfram C, 2014, BRIT J OPHTHALMOL, V98, P857, DOI 10.1136/bjophthalmol-2013-304228
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Woo W W, 2004, Singapore Med J, V45, P470
   Yu Y, 2015, INT J CLIN EXP PATHO, V8, P11635
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zayats T, 2009, MOL VIS, V15, P213
   Zha Y, 2009, ARCH OPHTHALMOL-CHIC, V127, P541, DOI 10.1001/archophthalmol.2008.623
   Zhang DD, 2011, MOL VIS, V17, P3379
   Zhang X, 2015, EURASIP J AUDIO SPEE, DOI 10.1186/s13636-015-0050-0
NR 73
TC 9
Z9 9
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2016
VL 11
IS 9
AR e0162296
DI 10.1371/journal.pone.0162296
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DW8GC
UT WOS:000383891900010
PM 27643879
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU De Rossi, G
   Vahatupa, M
   Cristante, E
   Arokiasamy, S
   Liyanage, SE
   May, U
   Pellinen, L
   Uusitalo-Jarvinen, H
   Bainbridge, JW
   Jarvinen, TAH
   Whiteford, JR
AF De Rossi, Giulia
   Vahatupa, Maria
   Cristante, Enrico
   Arokiasamy, Samantha
   Liyanage, Sidath E.
   May, Ulrike
   Pellinen, Laura
   Uusitalo-Jarvinen, Hannele
   Bainbridge, James W.
   Jarvinen, Tero A. H.
   Whiteford, James R.
TI Pathological Angiogenesis Requires Syndecan-4 for Efficient
   VEGFA-Induced VE-Cadherin Internalization
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE cadherins; diabetic retinopathy; permeability; syndecans; vascular
   endothelial growth factor A
ID MOLECULAR-MECHANISMS; ENDOTHELIAL-CELLS; MICE; HEPARIN;
   NEOVASCULARIZATION; PHOSPHORYLATION; PROTEOGLYCAN; LOCALIZATION;
   PERMEABILITY; DEFICIENCY
AB Objective:
   VEGFA (Vascular endothelial growth factor A) and its receptor VEGFR2 (vascular endothelial growth factor receptor 2) drive angiogenesis in several pathologies, including diabetic retinopathy, wet age-related macular degeneration, and cancer. Studies suggest roles for HSPGs (heparan sulfate proteoglycans) in this process, although the nature of this involvement remains elusive. Here, we set to establish the role of the HSPG SDC4 (syndecan-4) in pathological angiogenesis.
   Approach and Results:
   We report that angiogenesis is impaired in mice null for SDC4 in models of neovascular eye disease and tumor development. Our work demonstrates that SDC4 is the only SDC whose gene expression is upregulated during pathological angiogenesis and is selectively enriched on immature vessels in retinas from diabetic retinopathy patients. Combining in vivo and tissue culture models, we identified SDC4 as a downstream mediator of functional angiogenic responses to VEGFA. We found that SDC4 resides at endothelial cell junctions, interacts with vascular endothelial cadherin, and is required for its internalization in response to VEGFA. Finally, we show that pathological angiogenic responses are inhibited in a model of wet age-related macular degeneration by targeting SDC4.
   Conclusions:
   We show that SDC4 is a downstream mediator of VEGFA-induced vascular endothelial cadherin internalization during pathological angiogenesis and a potential target for antiangiogenic therapies.
C1 [De Rossi, Giulia; Arokiasamy, Samantha; Whiteford, James R.] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London, England.
   [Vahatupa, Maria; May, Ulrike; Pellinen, Laura; Uusitalo-Jarvinen, Hannele; Jarvinen, Tero A. H.] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.
   [Vahatupa, Maria; May, Ulrike; Pellinen, Laura; Uusitalo-Jarvinen, Hannele; Jarvinen, Tero A. H.] Tampere Univ Hosp, Dept Orthoped, Tampere, Finland.
   [Vahatupa, Maria; May, Ulrike; Pellinen, Laura; Uusitalo-Jarvinen, Hannele; Jarvinen, Tero A. H.] Tampere Univ Hosp, Dept Traumatol, Tampere, Finland.
   [Vahatupa, Maria; May, Ulrike; Pellinen, Laura; Uusitalo-Jarvinen, Hannele; Jarvinen, Tero A. H.] Tampere Univ Hosp, Tampere Eye Ctr, Tampere, Finland.
   [Cristante, Enrico; Liyanage, Sidath E.; Bainbridge, James W.] UCL Inst Ophthalmol, Genet Dept, London, England.
   [De Rossi, Giulia] UCL Inst Ophthalmol, Dept Cell Biol, 11-43 Bath St, London EC1V 9EL, England.
   [Bainbridge, James W.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
C3 University of London; Queen Mary University London; Tampere University;
   Tampere University; Tampere University Hospital; Tampere University;
   Tampere University Hospital; Tampere University; Tampere University
   Hospital; University of London; University College London; University of
   London; University College London; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Whiteford, JR (通讯作者)，Queen Mary Univ London, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.; De Rossi, G (通讯作者)，UCL Inst Ophthalmol, Dept Cell Biol, 11-43 Bath St, London EC1V 9EL, England.
EM giulia.derossi@ucl.ac.uk; j.whiteford@qmul.ac.uk
OI Whiteford, James/0000-0002-8967-7389; Jarvinen,
   Tero/0000-0002-4027-1759; Bainbridge, James/0000-0003-1318-8201; De
   Rossi, Giulia/0000-0001-6163-4590
FU Arthritis Research UK [19207, 21177]; Fight for Sight [1558/59]; Barts
   and The London Charity [MGU0313]; Queen Mary Innovations; William Harvey
   Research Foundation; Macular Society; Dunhill Medical Trust
   [RPGF1906\173]; Academy of Finland; Paivikki and Sakari Sohlberg
   Foundation; Instrumentarium Research Foundation; Diabetes Wellness
   Foundation (DWF); Pirkanmaa Hospital District Research Foundation;
   Tampere Tuberculosis Foundation; Finnish Cultural Foundation; MRC
   [MR/K003003/1] Funding Source: UKRI
FX J.R. Whiteford and G. De Rossi gratefully acknowledge funding from
   Arthritis Research UK (grant no. 19207 and 21177), Fight for Sight
   (grant no. 1558/59), Barts and The London Charity (grant no. MGU0313),
   Queen Mary Innovations, William Harvey Research Foundation, The Macular
   Society and the Dunhill Medical Trust (grant no. RPGF1906\173). T.A.H.
   Jarvinen, M. Vahatupa, and H. Uusitalo-Jarvinen gratefully acknowledge
   funding from the Academy of Finland, Paivikki and Sakari Sohlberg
   Foundation, Instrumentarium Research Foundation, Diabetes Wellness
   Foundation (DWF), Pirkanmaa Hospital District Research Foundation,
   Tampere Tuberculosis Foundation and the Finnish Cultural Foundation.
   J.W. Bainbridge is a National Institute for Health Research (NIHR)
   Research Professor.
CR Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183
   Afratis NA, 2017, FEBS J, V284, P27, DOI 10.1111/febs.13940
   Alexopoulou AN, 2007, INT J BIOCHEM CELL B, V39, P505, DOI 10.1016/j.biocel.2006.10.014
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Arokiasamy S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03031
   Ashikari- Hada S, 2005, J BIOL CHEM, V280, P31508, DOI 10.1074/jbc.M414581200
   Bentley K, 2014, NAT CELL BIOL, V16, P309, DOI 10.1038/ncb2926
   Cao JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02373-8
   Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Cavalheiro RP, 2017, MATRIX BIOL, V63, P23, DOI 10.1016/j.matbio.2016.12.006
   Corti F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09605-z
   Corti F, 2013, J BIOL CHEM, V288, P12712, DOI 10.1074/jbc.M113.452383
   Couchman JR, 2010, ANNU REV CELL DEV BI, V26, P89, DOI 10.1146/annurev-cellbio-100109-104126
   Das S, 2016, ADV HEALTHC MATER, V5, P1008, DOI 10.1002/adhm.201500993
   De Rossi Giulia, 2013, F1000Res, V2, P270, DOI 10.12688/f1000research.2-270.v1
   De Rossi G, 2013, BIOFACTORS, V39, P374, DOI 10.1002/biof.1104
   Dejana E, 2012, CURR OPIN HEMATOL, V19, P218, DOI 10.1097/MOH.0b013e3283523e1c
   Doody KM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4616
   Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559
   Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337
   Filler Renata B, 2007, CSH Protoc, V2007, DOI 10.1101/pdb.prot4837
   Fujita N, 2014, FASEB J, V28, P2455, DOI 10.1096/fj.13-243741
   Gaengel K, 2012, DEV CELL, V23, P587, DOI 10.1016/j.devcel.2012.08.005
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Godmann L, 2020, ANN RHEUM DIS, V79, P481, DOI 10.1136/annrheumdis-2019-216847
   Gondelaud F, 2019, FEBS J, V286, P2994, DOI 10.1111/febs.14828
   Gopal S, 2017, MATRIX BIOL, V60-61, P57, DOI 10.1016/j.matbio.2016.10.006
   Gopal S, 2015, J CELL BIOL, V210, P1199, DOI 10.1083/jcb.201501060
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hakanpaa L, 2018, P NATL ACAD SCI USA, V115, pE6467, DOI 10.1073/pnas.1722317115
   Ishiguro K, 2000, DEV DYNAM, V219, P539, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1081>3.0.CO;2-K
   Jang E, 2012, P NATL ACAD SCI USA, V109, P1679, DOI 10.1073/pnas.1117885109
   Jannaway M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214737
   Jastrebova N, 2010, J BIOL CHEM, V285, P26842, DOI 10.1074/jbc.M109.093542
   Jaszai J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091102
   Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0
   Johns SC, 2016, CIRC RES, V119, P210, DOI 10.1161/CIRCRESAHA.116.308504
   Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200
   Kostelnik KB, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000554
   MACCARANA M, 1993, J BIOL CHEM, V268, P23898
   May U, 2015, SCI REP-UK, V5, DOI 10.1038/srep11663
   Morgan MR, 2013, DEV CELL, V24, P472, DOI 10.1016/j.devcel.2013.01.027
   Okuyama E, 2013, J BIOCHEM, V154, P41, DOI 10.1093/jb/mvt024
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095
   Pulous FE, 2019, CIRC RES, V124, P891, DOI 10.1161/CIRCRESAHA.118.314560
   Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936
   Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Soubrane G, 2017, DEV OPHTHALMOL, V58, P202, DOI 10.1159/000455282
   Stahl A, 2010, AM J PATHOL, V177, P2715, DOI 10.2353/ajpath.2010.100526
   Teleanu RI, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010084
   Vahatupa M, 2020, JOVE-J VIS EXP, DOI 10.3791/61482
   Vahatupa M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00873
   Vahatupa M, 2019, JOVE-J VIS EXP, DOI 10.3791/60445
   Vahatupa M, 2016, INVEST OPHTH VIS SCI, V57, P4898, DOI 10.1167/iovs.16-19212
   WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183
   Xie J, 2012, J MOL CELL CARDIOL, V53, P250, DOI 10.1016/j.yjmcc.2012.04.014
   Xie M, 2019, CELL SIGNAL, V54, P115, DOI 10.1016/j.cellsig.2018.11.022
   Yamamoto H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7429
NR 62
TC 7
Z9 7
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD APR
PY 2021
VL 41
IS 4
BP 1374
EP 1389
DI 10.1161/ATVBAHA.121.315941
PG 16
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA RL9XZ
UT WOS:000639317700020
PM 33596666
OA Green Accepted, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Schwarzer, P
   Kokona, D
   Ebneter, A
   Zinkernagel, MS
AF Schwarzer, Petra
   Kokona, Despina
   Ebneter, Andreas
   Zinkernagel, Martin S.
TI Effect of Inhibition of Colony-Stimulating Factor 1 Receptor on
   Choroidal Neovascularization in Mice
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; MACULAR DEGENERATION;
   INFLAMMATORY CYTOKINES; DENDRITIC CELLS; POLYSIALIC ACID; INNATE
   IMMUNITY; IN-VIVO; MICROGLIA; MACROPHAGES
AB Neovascular age-related macular degeneration is one of the leading causes of blindness. Microglia and macrophages play a critical role in choroidal neovascularization (CNV) and may, therefore, be potential targets to modulate the disease course. This study evaluated the effect of the colony-stimulating factor-1 receptor inhibitor PLX5622 on experimental laser-induced CNV. A 98% reduction of retinal microglia cells was observed in the retina 1 week after initiation of PLX5622 treatment, preventing accumulation of macrophages within the laser site and leading to a reduction of leukocytes within the choroid after CNV induction. Mice treated with PLX5622 had a significantly faster decrease of the CNV lesion size, as revealed by in vivo imaging and immunohistochemistry from day 3 to day 14 compared with untreated mice. Several inflammatory modulators, such as chemokine (C-C motif) ligand 9, granulocyte-macrophage colony-stimulating factor, soluble tumor necrosis factor receptor-I, IL-1 alpha, and matrix metallopeptidase-2, were elevated in the acute phase of the disease when microglia were ablated with PLX5622, whereas other cytokines (eg, interferon-gamma, IL-4, and IL-10) were reduced. Our results suggest that colony-stimulating factor-1 receptor inhibition may be a novel therapeutic target in patients with neovascular age-related macular degeneration.
C1 Univ Bern, Univ Hosp Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   Univ Bern, Dept BioMed Res, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern
RP Zinkernagel, MS (通讯作者)，Univ Bern, Inselspital, Dept Ophthal, CH-3010 Bern, Switzerland.
EM martin.zinkernagel@insel.ch
RI Ebneter, Andreas/C-5226-2017
OI Ebneter, Andreas/0000-0001-6666-2558
FU Swiss RetinAward - Swiss VitreoRetinal Group; Bayer AG
FX Supported by Swiss RetinAward grants (P.S. in 2017; D.K. in 2016),
   supported by the Swiss VitreoRetinal Group in cooperation with Bayer AG.
CR Aderka Dan, 1996, Cytokine and Growth Factor Reviews, V7, P231, DOI 10.1016/S1359-6101(96)00026-3
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arnold T, 2013, VASC CELL, V5, DOI 10.1186/2045-824X-5-4
   Bach LA, 2015, J CELL COMMUN SIGNAL, V9, P189, DOI 10.1007/s12079-015-0288-4
   Bellver-Landete V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08446-0
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Cai JJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-88
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cook EB, 2008, INVEST OPHTH VIS SCI, V49, P3992, DOI 10.1167/iovs.08-1873
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041
   Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09
   Ebneter A, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.10
   Ebneter A, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20474
   Elmore MRP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122912
   Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Eubank TD, 2003, J IMMUNOL, V171, P2637, DOI 10.4049/jimmunol.171.5.2637
   Falk M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109104
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fessler SP, 2004, J VIROL, V78, P13113, DOI 10.1128/JVI.78.23.13113-13121.2004
   FORD AL, 1995, J IMMUNOL, V154, P4309
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Frystyk J, 1997, J CLIN ENDOCR METAB, V82, P3124, DOI 10.1210/jc.82.9.3124
   Funk KE, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1397-4
   GAUTAM S, 1992, J IMMUNOL, V148, P1725
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   Hashimoto D, 2011, J EXP MED, V208, P1069, DOI 10.1084/jem.20101709
   Huang YB, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0011-8
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Karlstetter M, 2017, EMBO MOL MED, V9, P154, DOI 10.15252/emmm.201606627
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kokona D, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1373-4
   Kokona D, 2017, INVEST OPHTH VIS SCI, V58, P2160, DOI 10.1167/iovs.16-20916
   Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Langmann T, 2017, KLIN MONATSBL AUGENH, V234, P657, DOI 10.1055/s-0043-105138
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Lenzo JC, 2012, IMMUNOL CELL BIOL, V90, P429, DOI 10.1038/icb.2011.58
   Liu B, 2007, ONCOGENE, V26, P1811, DOI 10.1038/sj.onc.1209977
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   Liyanage SE, 2016, EXP EYE RES, V151, P160, DOI 10.1016/j.exer.2016.08.007
   Louis C, 2015, J IMMUNOL, V195, P134, DOI 10.4049/jimmunol.1500369
   Lu M, 1999, INVEST OPHTH VIS SCI, V40, P3281
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   MacDonald KPA, 2005, J IMMUNOL, V175, P1399, DOI 10.4049/jimmunol.175.3.1399
   Matsumura N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039890
   Miao H, 2012, MOL VIS, V18, P574
   Mijatovic T, 1997, J BIOL CHEM, V272, P14394, DOI 10.1074/jbc.272.22.14394
   Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1
   Nakai K, 2008, INVEST OPHTH VIS SCI, V49, P3666, DOI 10.1167/iovs.07-1640
   Ohno-Matsui K, 2003, INVEST OPHTH VIS SCI, V44, P5370, DOI 10.1167/iovs.03-0249
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Pabon MM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-9
   Paschalis EI, 2019, J IMMUNOL, V202, P539, DOI 10.4049/jimmunol.1800982
   Paschalis EI, 2018, P NATL ACAD SCI USA, V115, pE11359, DOI 10.1073/pnas.1807123115
   Paschalis EI, 2018, AM J PATHOL, V188, P1580, DOI 10.1016/j.ajpath.2018.03.005
   Patel BV, 2015, AM J PHYSIOL-LUNG C, V309, pL639, DOI 10.1152/ajplung.00140.2015
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Percin GI, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07685-x
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   Priceman SJ, 2010, BLOOD, V115, P1461, DOI 10.1182/blood-2009-08-237412
   Rashid K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00176
   Rho SB, 2008, CARCINOGENESIS, V29, P2106, DOI 10.1093/carcin/bgn206
   Rymo SF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015846
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Schubert SY, 2008, ARTERIOSCL THROM VAS, V28, P97, DOI 10.1161/ATVBAHA.107.157537
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Spangenberg EE, 2016, BRAIN, V139, P1265, DOI 10.1093/brain/aww016
   Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499
   TEVELDE AA, 1990, BLOOD, V76, P1392
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Van Lint P, 2007, J LEUKOCYTE BIOL, V82, P1375, DOI 10.1189/jlb.0607338
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Wheeler DL, 2018, J CLIN INVEST, V128, P931, DOI 10.1172/JCI97229
   Xanthoulea S, 2004, J EXP MED, V200, P367, DOI 10.1084/jem.20040435
   Yamamoto Y, 2015, RETINA-J RET VIT DIS, V35, P344, DOI 10.1097/IAE.0000000000000311
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Zhang CY, 2012, INT J CANCER, V130, P2003, DOI 10.1002/ijc.26201
   Zhang YK, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap8492
   Zhu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094743
NR 96
TC 12
Z9 13
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD FEB
PY 2020
VL 190
IS 2
BP 412
EP 425
DI 10.1016/j.ajpath.2019.10.011
PG 14
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA KF7SB
UT WOS:000509437800012
PM 31783006
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ueta, T
   Inoue, T
   Yuda, K
   Furukawa, T
   Yanagi, Y
   Tamaki, Y
AF Ueta, Takashi
   Inoue, Tatsuya
   Yuda, Kentaro
   Furukawa, Takahisa
   Yanagi, Yasuo
   Tamaki, Yasuhiro
TI Intense Physiological Light Upregulates Vascular Endothelial Growth
   Factor and Enhances Choroidal Neovascularization via Peroxisome
   Proliferator-Activated Receptor gamma Coactivator-1 alpha in Mice
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE angiogenesis; choroidal neovascularization; retinal photoreceptor cell
   outer segment; Ppargc1a protein, mouse
ID RETINAL-PIGMENT EPITHELIUM; PHOTORECEPTOR OUTER SEGMENTS; MACULAR
   DEGENERATION; OXIDATIVE STRESS; VISUAL CYCLE; CELLS; VEGF; PHAGOCYTOSIS;
   EXPRESSION; EYE
AB Objective-Toxicity of intense light to facilitate the development of neovascular age-related macular degeneration has been a health concern although the mechanism remains unclear.
   Methods and Results-Effects of intense, but within physiological range, light on retinal pigment epithelium, a major pathogenic origin of age-related macular degeneration were studied in mice. Intense physiological light upregulated vascular endothelial growth factor (VEGF) expression in retinal pigment epithelium, independent of circadian rhythm, which resulted in enhancement of choroidal neovascularization. In rd1/rd1 mice or Crx(-/-) mice that do not possess outer segment structure, light exposure did not induce VEGF, indicating that VEGF upregulation by light depended on increased outer segment phagocytosis by retinal pigment epithelium. In retinal pigment epithelium cells phagocytosing increased amount of outer segment, peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) not hypoxia-inducible factor-1 alpha was induced, leading to VEGF upregulation. The VEGF upregulation and choroidal neovascularization enhancement were abrogated in PGC-1 alpha(-/-) mice and estrogen-related receptor-alpha(-/-) mice, indicating the involvement of PGC-1 alpha/estrogen-related receptor-alpha pathway.
   Conclusion-Intense physiological light is involved in choroidal neovascularization through excess outer segment phagocytosis and VEGF upregulation mediated by PGC-1 alpha in vivo. (Arterioscler Thromb Vasc Biol. 2012;32:1366-1371.)
C1 [Ueta, Takashi; Inoue, Tatsuya; Yuda, Kentaro; Yanagi, Yasuo; Tamaki, Yasuhiro] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Furukawa, Takahisa] Osaka Biosci Inst, Dept Dev Biol, Suita, Osaka 565, Japan.
   [Furukawa, Takahisa] CREST, JST, Suita, Osaka, Japan.
C3 University of Tokyo; Japan Science & Technology Agency (JST)
RP Ueta, T (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM ueta-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Yanagi, Yasuo/0000-0002-0362-7285
FU Japan Society for the Promotion of Science [20390446, 23659806]
FX T. Ueta was supported by DC2 Research Fellowship for Young Scientists
   from Japan Society for the Promotion of Science. This work was supported
   by Grants-in-Aid for Scientific Research from Japan Society for the
   Promotion of Science to Y. Tamaki (20390446 and 23659806).
CR Akiyama H, 2002, INVEST OPHTH VIS SCI, V43, P1367
   Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395
   Altimus CM, 2010, NAT NEUROSCI, V13, P1107, DOI 10.1038/nn.2617
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   BASINGER S, 1976, SCIENCE, V194, P1074, DOI 10.1126/science.1086510
   Bazan NG, 2007, INVEST OPHTH VIS SCI, V48, P4866, DOI 10.1167/iovs.07-0918
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BESHARSE JC, 1977, SCIENCE, V196, P536, DOI 10.1126/science.300504
   Bobu C, 2009, INVEST OPHTH VIS SCI, V50, P3495, DOI 10.1167/iovs.08-3145
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   EBIHARA S, 1980, PHYSIOL BEHAV, V24, P523, DOI 10.1016/0031-9384(80)90246-2
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591
   Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200
   Ham Jr WT, 1976, NATURE, V260, P153
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Huang WY, 2011, J CLIN INVEST, V121, P2133, DOI 10.1172/JCI46043
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   LERMAN S, 1980, RADIANT ENERGY EYE, P131
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   Morrow EM, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-5
   Moses RA, 1981, ADLERS PHYSL EYE, P357
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 47
TC 19
Z9 19
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JUN
PY 2012
VL 32
IS 6
BP 1366
EP +
DI 10.1161/ATVBAHA.112.248021
PG 18
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 947KH
UT WOS:000304428400008
PM 22516064
OA Bronze
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Tomany, SC
   Cruickshanks, KJ
AF Klein, R
   Klein, BEK
   Tomany, SC
   Cruickshanks, KJ
TI The association of cardiovascular disease with the lone-term incidence
   of ageorelated maculopathy - The Beaver Dam eye study
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; SENILE MACULAR DEGENERATION; RISK-FACTORS;
   VISUAL-ACUITY; 5-YEAR INCIDENCE; POPULATION; HYPERTENSION; CHOLESTEROL;
   SMOKING; ATHEROSCLEROSIS
AB Purpose: To examine the association between cardiovascular disease and its risk factors and the 10-year incidence of age-related maculopathy.
   Design: Population-based cohort study.
   Participants: Persons 43 to 86 years of age at baseline examination from 1988 to 1990, living in Beaver Dam, Wisconsin, of whom 3684 persons participated in a 5-year follow-up examination and 2764 participated in a 10-year follow-up examination.
   Methods: Standardized protocols for physical examination, blood collection, administration of a questionnaire, and stereoscopic color fundus photography to determine age-related maculopathy. The Kaplan-Meier (product-limit) survival approach and discrete linear logistic regression were used in the data analysis.
   Main Outcome Measures: Incidence and progression of age-related maculopathy.
   Results: When age, gender, and history of heavy drinking, smoking, and vitamin use were controlled for, higher systolic blood pressure at baseline was associated with the 10-year incidence of retinal pigment epithelial depigmentation (risk ratio [RR] per 10 mmHg systolic blood pressure, 1.10; 95% confidence interval [CI], 1.01-1.18; P = 0.02) and exudative macular degeneration (RR, 1.22;95%Cl, 1.06-1.41; P = 0.006). Higher pulse pressure at baseline was associated with the incidence of retinal pigment epithelial depigmentation (RR per 10 mmHg, 1.17; 95% Cl, 1.07-1.28; P < 0.001), increased retinal pigment (RR, 1.10; 95% Cl, 1.01-1.19; P = 0.03), exudative macular degeneration (RR, 1.34; 95% Cl, 1.14-1.60; P < 0.001), and progression of age-related maculopathy (RR, 1.08; 95% Cl, 1.01-1.17; P = 0.03). Higher serum high-density lipoprotein cholesterol at baseline was associated with pure geographic atrophy (RR per 10 mg/dl high-density lipoprotein cholesterol, 1.29; 95% Cl, 1.05-1.58; P = 0.01). Physical activity at baseline was associated with the incidence of geographic atrophy (RR in those who worked up a sweat 5 times a week compared with those who did not, 0.12; 95% Cl, 0.02-0.91; P = 0.04) exudative macular degeneration (RR, 0.27; 95% Cl, 0.08-0.87; P = 0.05), and progression of age-related maculopathy (RR, 0.69; 95% Cl, 0.47-1.00; P = 0.05). Neither a history of stroke nor heart attack was associated with the incidence or progression of age-related maculopathy.
   Conclusions: These findings indicate relationships between higher pulse pressure (a presumed indicator of age-related elastin and collagen changes in Bruch's membrane) and systolic blood pressure with an increased 10-year incidence of some lesions defining early age-related maculopathy and exudative macular degeneration. 0 2003 by the American Academy of Ophthalmology.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Wisconsin, Sch Med, Dept Populat Hlth Sci, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,460 WARF, Madison, WI 53726 USA.
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1999, SAS STAT US GUID VER
   AVOLIO AP, 1986, ARTERIOSCLEROSIS, V6, P166, DOI 10.1161/01.ATV.6.2.166
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   CAMERON JD, 1994, AM J PHYSIOL, V266, pH693, DOI 10.1152/ajpheart.1994.266.2.H693
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Heesen WF, 1998, J CARDIOVASC PHARM, V31, P187, DOI 10.1097/00005344-199802000-00003
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAMPOL LM, 1991, ARCH OPHTHALMOL-CHIC, V109, P789, DOI 10.1001/archopht.1991.01080060053022
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   KLENK DC, 1982, CLIN CHEM, V28, P2088
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   LINN S, 1993, AM J PUBLIC HEALTH, V83, P811, DOI 10.2105/AJPH.83.6.811
   LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   OROURKE MF, 1982, ARTERIAL FUNCTION HL, P211
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Safar ME, 1997, J VASC RES, V34, P67, DOI 10.1159/000159204
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stein M. W., 1963, METHODS ENZYMATIC AN, P177
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   1976, PREV MED, V5, P207
NR 55
TC 89
Z9 90
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2003
VL 110
IS 4
BP 636
EP 643
DI 10.1016/S0161-6420(02)01448-3
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 673EE
UT WOS:000182566600018
PM 12689879
DA 2022-11-30
ER

PT J
AU Zhao, XY
   Luo, MY
   Meng, LH
   Zhang, WF
   Li, B
   Wang, EQ
   Liu, SZ
   Yu, WH
   Chen, YX
AF Zhao, Xin-Yu
   Luo, Ming-Yue
   Meng, Li-Hui
   Zhang, Wen-Fei
   Li, Bing
   Wang, Er-Qian
   Liu, Sheng-Zhi
   Yu, Wei-Hong
   Chen, You-Xin
TI THE INCIDENCE, CHARACTERISTICS, MANAGEMENT, PROGNOSIS, AND
   CLASSIFICATION OF BREAKTHROUGH VITREOUS HEMORRHAGE SECONDARY TO
   POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; vitreous hemorrhage; pachychoroid;
   anti-vascular endothelial growth factor; prognosis; pars plana
   vitrectomy
ID VITRECTOMY
AB Purpose: To describe breakthrough vitreous hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). Methods: Patients with the diagnosis of PCV from January 2005 to March 2020 at Peking Union Medical College Hospital were retrospectively reviewed, cases with breakthrough vitreous hemorrhage were analyzed. Subgroup analysis was conducted regarding pachychoroid PCV and nonpachychoroid PCV. Results: Among 722 PCV patients (834 eyes), 103 eyes with breakthrough vitreous hemorrhage (12.4%) were included. Pars plana vitrectomy and proper further interventions could significantly improve the best-corrected visual acuity from logMAR 2.15 +/- 0.48 (Snellen 20/2825) to 1.65 +/- 0.67 (20/893). Hemorrhagic retinal detachment, baseline central macular thickness, and best-corrected visual acuity were factors associated with final best-corrected visual acuity (P < 0.05). In the pachychoroid PCV group, patients were younger, all had hemorrhagic pigment epithelial detachment, with a higher prevalence of choroidal vascular hyperpermeability and hemorrhagic retinal detachment, thicker subfoveal choroidal thickness, and thinner central macular thickness; besides, the initial pars plana vitrectomy were more complicated, more additional surgeries had to be performed. More eyes in the nonpachychoroid PCV group had received anti-vascular endothelial growth factor or photodynamic therapy, mostly fibrovascular pigment epithelial detachment, the best-corrected visual acuity and the status of the fellow eye were significantly worse. For the final ocular status, more eyes in nonpachychoroid PCV group were taking anti-vascular endothelial growth factor monotherapy, whereas more eyes in pachychoroid PCV group were stable. The choroidal parameters of these two groups were all significantly different. Conclusion: Breakthrough vitreous hemorrhage is a troublesome complication of PCV. Pars plana vitrectomy and additional interventions are required for better prognosis. Vitreous hemorrhage secondary to pachychoroid PCV or nonpachychoroid PCV have different characteristics and prognosis.
C1 [Zhao, Xin-Yu; Luo, Ming-Yue; Meng, Li-Hui; Zhang, Wen-Fei; Li, Bing; Wang, Er-Qian; Yu, Wei-Hong; Chen, You-Xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Zhao, Xin-Yu; Luo, Ming-Yue; Meng, Li-Hui; Zhang, Wen-Fei; Li, Bing; Wang, Er-Qian; Yu, Wei-Hong; Chen, You-Xin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Liu, Sheng-Zhi] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Indiana University System;
   Indiana University-Purdue University Indianapolis
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM 478252553@qq.com
RI meng, li/GVT-2063-2022
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Chen LL, 2018, INT J OPHTHALMOL-CHI, V11, P1588, DOI 10.18240/ijo.2018.10.03
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57297-8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li ZX, 2019, INT J OPHTHALMOL-CHI, V12, P1859, DOI 10.18240/ijo.2019.12.07
   Lin HC, 2014, EYE, V28, P797, DOI 10.1038/eye.2014.124
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Narayanan Raja, 2015, Int J Retina Vitreous, V1, P25, DOI 10.1186/s40942-015-0025-4
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhao XY, 2020, RETINA-J RET VIT DIS, V40, P477, DOI 10.1097/IAE.0000000000002389
NR 27
TC 1
Z9 2
U1 5
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2021
VL 41
IS 8
BP 1675
EP 1685
DI 10.1097/IAE.0000000000003098
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5JN
UT WOS:000711803800013
PM 33395221
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Yodoi, Y
   Tsujikawa, A
   Kameda, T
   Otani, A
   Tamura, H
   Mandai, M
   Yoshimura, N
AF Yodoi, Yuko
   Tsujikawa, Akitaka
   Kameda, Takanori
   Otani, Atsushi
   Tamura, Hiroshi
   Mandai, Michiko
   Yoshimura, Nagahisa
TI Central retinal sensitivity measured with the micro perimeter 1 after
   photodynamic therapy for polypoidal choroidal vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; MACULAR DEGENERATION; FUNDUS PERIMETRY;
   MICROPERIMETRY; VERTEPORFIN; NEOVASCULARIZATION; SCOTOMA
AB Purpose: To evaluate central retinal sensitivity and its relation to the symptomatic change noted in central visual disturbance shortly after photodynamic therapy (PDT) in eyes with polypoidal choroidal vasculopathy (PCV).
   Design: Retrospective interventional case series.
   Methods: We reviewed retrospectively 20 eyes of 20 patients who underwent PDT for the treatment of subfoveal PCV. Microperimetry in the macular area was performed with Micro Perimeter 1 (MP1) [Nidek, Vigonza, Italy] before and at one, three, and six months after PDT. Forty measurement points were located within the central 10 degree of the macula.
   Results: After PDT, although most eyes showed a reduction in exudation, the mean posttreatment visual acuity did not change significantly. At one month after PDT, however, retinal sensitivities within the central 2 degree, 6 degree, and 10 degree fields, which were 3.6 +/- 3.1, 5.1 +/- 3.4, and 6.2 +/- 3.6 dB [decibels] at baseline, improved to 5.9 +/- 3.8 (P = .003), 7.1 +/- 3.6 (P = .003), and 8.1 +/- 3.5 dB (P = .004). At one month after treatment, 14 patients (70%) noted subjective improve, ment of the central visual disturbance and mean retinal sensitivity within the central 2 degree, 6 degree, and 10 degree fields had improved more than 2 dB in 11, 10, and eight eyes, respectively. At three and six months after PDT, however, postoperative improvement of the retinal sensitivities was diminished.
   Conclusions: Retinal sensitivity in the macular area of eyes with subfoveal PCV improved shortly after PDT, and may account, at least in part, for the immediate subjective improvement in central vision after PDT.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ Hosp, Translat Res Ctr, Dept Expt Therapeut, Kyoto 606, Japan.
C3 Kyoto University; Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI Mandai, Michiko/E-7986-2011; TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   HIRAMI Y, IN PRESS RETINA
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Jarc-Vidmar M, 2006, EYE, V20, P688, DOI 10.1038/sj.eye.6701949
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Montero JA, 2003, GRAEF ARCH CLIN EXP, V241, P797, DOI 10.1007/s00417-003-0752-3
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okada K, 2006, EYE, V20, P805, DOI 10.1038/sj.eye.6702014
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Sawa M, 2006, JPN J OPHTHALMOL, V50, P111, DOI 10.1007/s10384-005-0292-y
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Varano M, 2005, INVEST OPHTH VIS SCI, V46, P1453, DOI 10.1167/iovs.04-0903
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 34
TC 23
Z9 24
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2007
VL 143
IS 6
BP 984
EP 994
DI 10.1016/j.ajo.2007.01.026
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 177QG
UT WOS:000247167000010
PM 17336913
DA 2022-11-30
ER

PT J
AU Tsujinaka, H
   Fu, J
   Shen, JK
   Yu, Y
   Hafiz, Z
   Kays, J
   McKenzie, D
   Cardona, D
   Culp, D
   Peterson, W
   Gilger, BC
   Crean, CS
   Zhang, JZ
   Kanan, Y
   Yu, WL
   Cleland, JL
   Yang, M
   Hanes, J
   Campochiaro, PA
AF Tsujinaka, Hiroki
   Fu, Jie
   Shen, Jikui
   Yu, Yun
   Hafiz, Zibran
   Kays, Joshua
   McKenzie, David
   Cardona, Delia
   Culp, David
   Peterson, Ward
   Gilger, Brian C.
   Crean, Christopher S.
   Zhang, Jin-Zhong
   Kanan, Yogita
   Yu, Weiling
   Cleland, Jeffrey L.
   Yang, Ming
   Hanes, Justin
   Campochiaro, Peter A.
TI Sustained treatment of retinal vascular diseases with self-aggregating
   sunitinib microparticles
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC-RETINOPATHY SEVERITY; OCCLUSION
   12-MONTH OUTCOMES; LONG-TERM OUTCOMES; CHOROIDAL NEOVASCULARIZATION;
   VEIN OCCLUSION; MACULAR EDEMA; 10-YEAR INCIDENCE; RANIBIZUMAB; VEGF
AB Neovascular age-related macular degeneration and diabetic retinopathy are prevalent causes of vision loss requiring frequent intravitreous injections of VEGF-neutralizing proteins, and under-treatment is common and problematic. Here we report incorporation of sunitinib, a tyrosine kinase inhibitor that blocks VEGF receptors, into a non-inflammatory biodegradable polymer to generate sunitinib microparticles specially formulated to self-aggregate into a depot. A single intravitreous injection of sunitinib microparticles potently suppresses choroidal neovascularization in mice for six months and in another model, blocks VEGF-induced leukostasis and retinal nonperfusion, which are associated with diabetic retinopathy progression. After intravitreous injection in rabbits, sunitinib microparticles self-aggregate into a depot that remains localized and maintains therapeutic levels of sunitinib in retinal pigmented epithelium/choroid and retina for more than six months. There is no intraocular inflammation or retinal toxicity. Intravitreous injection of sunitinib microparticles provides a promising approach to achieve sustained suppression of VEGF signaling and improve outcomes in patients with retinal vascular diseases. Neovascular age-related macular degeneration and diabetic retinopathy are currently treated with repeated intravitreous injections of VEGF neutralizing proteins. Here the authors develop a microparticle-loaded tyrosine kinase inhibitor therapy, which is effective for six months after a single injection in preclinical models.
C1 [Tsujinaka, Hiroki; Fu, Jie; Shen, Jikui; Hafiz, Zibran; Kanan, Yogita; Hanes, Justin; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Ctr Nanomed, Baltimore, MD 21205 USA.
   [Yu, Yun; Kays, Joshua; McKenzie, David; Cardona, Delia; Peterson, Ward; Crean, Christopher S.; Zhang, Jin-Zhong; Yu, Weiling; Cleland, Jeffrey L.; Yang, Ming] Graybug Vis Inc, Redwood City, CA 94065 USA.
   [Culp, David; Gilger, Brian C.] Powered Res LLC, Res Triangle Pk, NC USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Hanes, J; Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Ctr Nanomed, Baltimore, MD 21205 USA.; Yang, M (通讯作者)，Graybug Vis Inc, Redwood City, CA 94065 USA.
EM myang@graybug.com; hanes@jhmi.edu; pcampo@jhmi.edu
RI zhang, jin/GXV-9154-2022; Gilger, Brian/D-8776-2014
OI Gilger, Brian/0000-0002-7771-9166; McKenzie, David/0000-0002-5533-8370;
   Kays, Joshua/0000-0002-9682-6792
CR [Anonymous], 1984, AM J OPHTHALMOL, V98, P271
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Budha NR, 2012, CLIN PHARMACOL THER, V92, P203, DOI 10.1038/clpt.2012.73
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P1783, DOI 10.1016/j.ophtha.2014.03.021
   Campochiaro PA, 2013, OPHTHALMOLOGY, V120, P795, DOI 10.1016/j.ophtha.2012.09.032
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   Cugati S, 2006, ARCH OPHTHALMOL-CHIC, V124, P726, DOI 10.1001/archopht.124.5.726
   Durairaj C, 2012, EXP EYE RES, V98, P23, DOI 10.1016/j.exer.2012.03.004
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Fortmann SD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24197-2
   Fu J, 2019, U.S. Patent, Patent No. [US 2017/0360750, 20170360750]
   Gardiner TA, 2007, MICROCIRCULATION, V14, P25, DOI 10.1080/10739680601072123
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Liu YY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95530
   Long D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120231
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McDonnell P. J, 2019, U.S. Patent, Patent No. 10369107
   Mendel DB, 2013, CLIN CANCER RES, V9, P327
   Motzer RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516, DOI 10.1001/jama.295.21.2516
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Silva PS, 2015, OPHTHALMOLOGY, V122, P2465, DOI 10.1016/j.ophtha.2015.07.034
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sophie R, 2013, AM J OPHTHALMOL, V156, P693, DOI 10.1016/j.ajo.2013.05.039
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Vinores SA, 2007, J NEUROIMMUNOL, V182, P73, DOI 10.1016/j.jneuroim.2006.09.015
   Welsbie DS, 2013, P NATL ACAD SCI USA, V110, P4045, DOI 10.1073/pnas.1211284110
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 52
TC 33
Z9 33
U1 6
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB 4
PY 2020
VL 11
IS 1
AR 694
DI 10.1038/s41467-020-14340-x
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LI5JP
UT WOS:000529522400002
PM 32019921
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, JE
   Shin, JP
   Kim, HW
   Chang, W
   Kim, YC
   Lee, SJ
   Chung, IY
   Lee, JE
AF Lee, Joo Eun
   Shin, Jae Pil
   Kim, Hyun Woong
   Chang, Woohyok
   Kim, Yu Cheol
   Lee, Sang Joon
   Chung, In Young
   Lee, Ji Eun
CA VAULT Study Grp
TI Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal
   vasculopathy: 1-year results of the VAULT study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Polypoidal choroidal
   vasculopathy; Fixed regimen
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; INTRAVITREAL AFLIBERCEPT;
   VEGF-TRAP; RANIBIZUMAB; VERTEPORFIN; BEVACIZUMAB
AB To investigate fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy (PCV).
   This phase IV, prospective, single-arm, interventional case series was conducted in eight centers. Forty treatment-na < ve PCV patients were administered three monthly doses of intravitreal aflibercept (2.0 mg) and an injection every 2 months thereafter. Best-corrected visual acuity (BCVA) and central subfield macular thickness (CSMT) were measured at each visit. Fluorescein and indocyanine green angiography (ICGA) were performed at baseline, 3 and 12 months. The primary outcome measure was the proportion of patients who maintained BCVA (< 15 letters loss) at 12 months. Changes in BCVA, macular appearance, and polypoidal lesion appearance were also examined.
   Thirty-five eyes (87.5 %) had maintained BCVA at 12 months. Average BCVA was significantly higher at 12 months (20/53, 64.2 letters) than at baseline (20/80, 55.1 letters, 9-letter gain; P < .001). Mean CSMT was significantly lower at 12 months (253.6 mu m) than at baseline (365.2 mu m, P < .001). The macula was dry in 32 (76.2 %), 27 (64.3 %), and 24 eyes (60.0 %) at 3, 6, and 12 months respectively. Fourteen eyes (33.3 %) had a fluid recurrence or increase at 6 months, and they had a significantly lower vision gain (P = .005) than other patients at 12 months. Complete polyp regression occurred in 26 eyes (66.7 %) at 12 months.
   Fixed-dosing aflibercept showed favorable outcomes in PCV patients at 12 months. However, some patients had worse outcomes because of fluid recurrence during maintenance dosing, and these patients would require additional treatments.
C1 [Lee, Joo Eun] Inje Univ, Haeundae Paik Hosp, Dept Ophthalmol, Coll Med, Busan, South Korea.
   [Shin, Jae Pil] Kyungpook Natl Univ Hosp, Dept Ophthalmol, Deagu, South Korea.
   [Kim, Hyun Woong] Inje Univ, Coll Med, Dept Ophthalmol, Busan Paik Hosp, Busan, South Korea.
   [Chang, Woohyok] Yeungnam Univ, Dept Ophthalmol, Coll Med, Daegu, South Korea.
   [Chang, Woohyok] Changs Retina Ctr, Daegu, South Korea.
   [Kim, Yu Cheol] Keimyung Univ, Dept Ophthalmol, Dongsan Med Ctr, Sch Med, Daegu, South Korea.
   [Lee, Sang Joon] Kosin Univ, Dept Ophthalmol, Coll Med, Busan, South Korea.
   [Lee, Sang Joon] Kosin Univ, Inst Med, Busan, South Korea.
   [Chung, In Young] Gyeongsang Natl Univ, Dept Ophthalmol, Sch Med, Jinju, South Korea.
   [Lee, Ji Eun] Pusan Natl Univ Hosp, Dept Ophthalmol, 179 Gudeok Ro, Busan 602739, South Korea.
   [Lee, Ji Eun] Pusan Natl Univ, Dept Ophthalmol, Coll Med, Yangsan, South Korea.
   [Lee, Ji Eun] Pusan Natl Univ Hosp, Biomed Res Inst, 179 Gudeok Ro, Busan 602739, South Korea.
C3 Inje University; Kyungpook National University; Kyungpook National
   University Hospital; Inje University; Yeungnam University; Keimyung
   University; Gyeongsang National University; Pusan National University;
   Pusan National University Hospital; Pusan National University; Pusan
   National University; Pusan National University Hospital
RP Lee, JE (通讯作者)，Pusan Natl Univ Hosp, Dept Ophthalmol, 179 Gudeok Ro, Busan 602739, South Korea.; Lee, JE (通讯作者)，Pusan Natl Univ, Dept Ophthalmol, Coll Med, Yangsan, South Korea.; Lee, JE (通讯作者)，Pusan Natl Univ Hosp, Biomed Res Inst, 179 Gudeok Ro, Busan 602739, South Korea.
EM jlee@pusan.ac.kr
RI Lee, Sang Joon/AAG-2448-2019
OI chung, inyoung/0000-0002-4524-6771
FU Bayer Korea (Seoul, Republic of Korea)
FX Bayer Korea (Seoul, Republic of Korea) provided funding and
   investigational drugs for this study.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byon IS, 2014, OSLI RETINA, V45, P534, DOI 10.3928/23258160-20141118-08
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 21
TC 37
Z9 38
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2017
VL 255
IS 3
BP 493
EP 502
DI 10.1007/s00417-016-3489-5
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM0CO
UT WOS:000394986600007
PM 27628062
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Miyata, M
   Ooto, S
   Yamashiro, K
   Tamura, H
   Hata, M
   Ueda-Arakawa, N
   Yoshikawa, M
   Numa, S
   Tsujikawa, A
AF Miyata, Manabu
   Ooto, Sotaro
   Yamashiro, Kenji
   Tamura, Hiroshi
   Hata, Masayuki
   Ueda-Arakawa, Naoko
   Yoshikawa, Munemitsu
   Numa, Shogo
   Tsujikawa, Akitaka
TI Five-year visual outcomes after anti-VEGF therapy with or without
   photodynamic therapy for polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL
   INJECTIONS; RANIBIZUMAB; EFFICACY; SAFETY; MONOTHERAPY
AB Background/aims To evaluate the 5-year visual and anatomical outcomes after anti-vascular endothelial growth factor (VEGF) therapy alone or in combination with photodynamic therapy (PDT), followed by pro re nata (PRN) anti-VEGF therapy with or without PDT, for polypoidal choroidal vasculopathy (PCV). Methods This retrospective, observational study included 61 consecutive patients with treatment-naive symptomatic PCV who were followed for 5 years. Twenty eyes (20 patients) initially received PDT and intravitreal injection of ranibizumab (IVR), followed by a PRN regimen of anti-VEGF therapy with or without PDT (combination group), while 41 eyes (41 patients) initially received only IVR every 3 months, followed by a PRN regimen of anti-VEGF monotherapy (IVR group). Macular atrophy including the fovea was confirmed using colour fundus photography and spectral-domain optical coherence tomography. Results In both groups, the visual acuity (VA) at 1 year was better than the baseline VA, whereas the 3-year, 4-year and 5-year VA values were similar to the baseline VA. There was no significant difference in the 5-year VA, 5-year central retinal thickness and incidence of macular atrophy between the two groups (p= 0.63, 0.72 and 0.06, respectively). In the combination group, the 5-year VA was correlated with the 5-year incidence of macular atrophy (p= 0.02, r= 0.51). Conclusions A PRN regimen for PCV may have a limited effect for the long-term maintenance of improved VA. Macular atrophy may occur more frequently with combination therapy and is possibly associated with the 5-year VA. Thus, combination therapy should be carefully selected for patients susceptible to macular atrophy.
C1 [Miyata, Manabu; Ooto, Sotaro; Yamashiro, Kenji; Tamura, Hiroshi; Hata, Masayuki; Ueda-Arakawa, Naoko; Yoshikawa, Munemitsu; Numa, Shogo; Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
C3 Kyoto University
RP Miyata, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto 6068507, Japan.
EM miyatam@kuhp.kyoto-u.ac.jp
RI Miyata, Manabu/U-9008-2018; TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Miyata, Manabu/0000-0002-7574-1749
FU Japan Society for the Promotion of Science, Tokyo, Japan [26861451];
   Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project
   for Developing Innovation Systems from the Ministry of Education,
   Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
FX This work was supported in part by a grant-in-aid for scientific
   research (number 26861451) from the Japan Society for the Promotion of
   Science, Tokyo, Japan and the Innovative Techno-Hub for Integrated
   Medical Bio-Imaging of the Project for Developing Innovation Systems
   from the Ministry of Education, Culture, Sports, Science and Technology
   (MEXT), Tokyo, Japan. None of these organisations had any role in the
   design or conduct of this research.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Baba T, 2010, BRIT J OPHTHALMOL, V94, P864, DOI 10.1136/bjo.2009.166025
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yodoi Yuko, 2008, International Ophthalmology, V28, P297, DOI 10.1007/s10792-007-9129-7
NR 25
TC 17
Z9 17
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2019
VL 103
IS 5
BP 617
EP 622
DI 10.1136/bjophthalmol-2018-311963
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID7PB
UT WOS:000471873700008
PM 29875231
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Chaikitmongkol, V
   Khunsongkiet, P
   Patikulsila, D
   Ratanasukon, M
   Watanachai, N
   Jumroendararasame, C
   Mayerle, CB
   Han, IC
   Chen, CJ
   Winaikosol, P
   Dejkriengkraikul, C
   Choovuthayakorn, J
   Kunavisarut, P
   Bressler, NM
AF Chaikitmongkol, Voraporn
   Khunsongkiet, Preeyanuch
   Patikulsila, Direk
   Ratanasukon, Mansing
   Watanachai, Nawat
   Jumroendararasame, Chaisiri
   Mayerle, Catherine B.
   Han, Ian C.
   Chen, Connie J.
   Winaikosol, Pawara
   Dejkriengkraikul, Chutikarn
   Choovuthayakorn, Janejit
   Kunavisarut, Paradee
   Bressler, Neil M.
TI Color Fundus Photography, Optical Coherence Tomography, and Fluorescein
   Angiography in Diagnosing Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION
AB PURPOSE: To determine sensitivity and specificity of polypoidal choroidal vasculopathy (PCV) diagnosis using color fundus photography (CFP), optical coherence tomography (OCT), and fundus fluorescein angiography (FFA) without indocyanine green angiography (ICGA).
   DESIGN: Validity analysis.
   METHODS: Treatment-naive eyes with serous/serosanguinous maculopathy undergoing CFP, OCT, FFA, and ICGA imaging before treatment at a university hospital in Thailand (January 1, 2013 to June 30, 2015) were identified. Images of each subject were categorized into 4 sets (set A: CFP; set B: CFP + OCT; set C: CFP + FFA; set D: CFP + OCT + FFA). Six graders, 3 from Thailand (PCV endemic area) and 3 from the United States (nonendemic area), individually reviewed each set (without ICGA), and determined if the presumed diagnosis was PCV. In parallel, 2 other graders confirmed if each case had PCV or not using EVEREST criteria (including ICGA). Sensitivity and specificity of a PCV diagnosis with each set (without ICGA) were analyzed compared with diagnoses including ICGA.
   RESULTS: Of 119 study eyes (113 subjects, 57% male, mean age SD 59.9 +/- 13.8 years), definite PCV diagnosis was 40.3%. Sensitivity of sets A, B, C, D: 0.63 (95% confidence interval [CI]: 0.47-0.76), 0.83 (95% CI: 0.69-0.92), 0.54 (95% CI: 0.39-0.68), 0.67 (95% CI: 0.51-0.79); specificities: 0.93 (95% CI: 0.84-0.97), 0.83 (95% CI: 0.72-0.91), 0.97 (95% CI: 0.89-0.99), 0.92 (95% CI: 0.82-0.97); accuracies: 0.81 (95% CI: 0.73-0.88), 0.83 (95% CI: 0.76-0.90), 0.79 (95% CI: 0.73-0.87), 0.82 (95% CI: 0.74-0.88). Discrepancies between Thai and US graders existed through sets A, C, and D.
   CONCLUSIONS: These data suggest that without ICGA, fundus photography combined with OCT provides high sensitivity and high specificity to diagnose PCV; adding FFA does not improve accuracy. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Chaikitmongkol, Voraporn; Khunsongkiet, Preeyanuch; Patikulsila, Direk; Watanachai, Nawat; Choovuthayakorn, Janejit; Kunavisarut, Paradee] Chiang Mai Univ, Dept Ophthalmol, Retina Div, Chiang Mai, Thailand.
   [Ratanasukon, Mansing] Prince Songkla Univ, Dept Ophthalmol, Retina Div, Hat Yai, Thailand.
   [Jumroendararasame, Chaisiri] Phramongkutklao Coll Med, Dept Ophthalmol, Retina Div, Bangkok, Thailand.
   [Mayerle, Catherine B.; Han, Ian C.; Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   [Chen, Connie J.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
   [Winaikosol, Pawara; Dejkriengkraikul, Chutikarn] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Chiang Mai, Thailand.
C3 Chiang Mai University; Prince of Songkla University; Phramongkutklao
   College of Medicine; Johns Hopkins University; Johns Hopkins Medicine;
   Virginia Mason Medical Center; Chiang Mai University
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, Retina Div, Maumenee 752,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
RI Watanachai, Nawat/AAR-9240-2020
OI Choovuthayakorn, Janejit/0000-0001-5972-0270; Han,
   Ian/0000-0002-2371-727X; watanachai, nawat/0000-0003-3097-8694;
   Chaikitmongkol, Voraporn/0000-0003-0426-7602; kunavisarut,
   paradee/0000-0003-4997-6285
FU RESEARCH COMMITTEE, FACULTY OF MEDICINE, CHIANG MAI University
FX FUNDING OF THIS STUDY WAS PROVIDED BY RESEARCH COMMITTEE, FACULTY OF
   MEDICINE, CHIANG MAI University, and unrestricted donations to Johns
   Hopkins University for retina research.
CR Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Leisenring W, 2000, BIOMETRICS, V56, P345, DOI 10.1111/j.0006-341X.2000.00345.x
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1503
   Tan CS, 2017, JAMA OPHTHALMOL, V135, P1316, DOI 10.1001/jamaophthalmol.2017.4453
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 16
TC 18
Z9 20
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2018
VL 192
BP 77
EP 83
DI 10.1016/j.ajo.2018.05.005
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP9HA
UT WOS:000441226900013
PM 29753852
DA 2022-11-30
ER

PT J
AU Inoue, M
   Arakawa, A
   Yamane, S
   Kadonosono, K
AF Inoue, M.
   Arakawa, A.
   Yamane, S.
   Kadonosono, K.
TI Long-term outcome of intravitreal ranibizumab treatment, compared with
   photodynamic therapy, in patients with polypoidal choroidal vasculopathy
SO EYE
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy;
   ranibizumab; intravitreal injection; vascular endothelial growth factor;
   photodynamic therapy
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; VERTEPORFIN;
   INJECTIONS; VEGF
AB Purpose To evaluate the functional outcomes of patients with polypoidal choroidal vasculopathy (PCV) who underwent intravitreal ranibizumab (IVR) treatment, compared with photodynamic therapy (PDT), after at least 2 years.
   Methods We retrospectively studied all the treatment-naive patients with PCV who were scheduled to undergo IVR or PDT between August 2005 and June 2010. All the patients who had a 2-year or longer follow-up period were included in the study. The best-corrected visual acuity (BCVA) in the two groups was compared before treatment and at 3, 6, 12, 18 and 24 months after the initial treatment. The regression of the polyps was also assessed using indocyanine green angiography.
   Results A total of 77 patients were included in this study. Thirty-three eyes were treated with IVR, and 44 eyes were treated with PDT. Although no significant differences between the two groups were observed at baseline or at 3, 6, and 12 months after treatment, a significantly better BCVA was seen in the IVR group, compared with the PDT group, at 18 and 24 months after treatment (P = 0.035 and P = 0.021, respectively). No significant difference in the rate of polyp regression was observed between the two groups (P = 0.092).
   Conclusion IVR was well tolerated and maintained or improved the vision of patients with PCV, compared with PDT, as evaluated at 2-year follow-up examinations. PDT for the treatment of PCV might result in unfavorable outcomes, with no superiority to achieving the involution of polyps.
C1 [Inoue, M.; Arakawa, A.; Yamane, S.; Kadonosono, K.] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa 2320024, Japan.
C3 Yokohama City University
RP Inoue, M (通讯作者)，Yokohama City Univ, Med Ctr, Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Barbazetto I, 2010, RETINA-J RET VIT DIS, V30, P1376, DOI 10.1097/IAE.0b013e3181dcfb0b
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Inoue M, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329863
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Mataix J, 2009, OPHTHAL SURG LAS IM, V40, P277, DOI 10.3928/15428877-20090430-09
   Rosenfeld PJ, 2006, N ENGL J MED, V355
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 29
TC 32
Z9 36
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2013
VL 27
IS 9
BP 1013
EP 1020
DI 10.1038/eye.2013.179
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 216TK
UT WOS:000324307100004
PM 23970023
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Zeng, FX
   Zhang, M
   Xu, YT
   Xu, HF
AF Zeng, Fanxing
   Zhang, Min
   Xu, Yiting
   Xu, Haifeng
TI ARMS2 interference leads to decrease of proinflammatory mediators
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related maculopathy susceptibility 2; Age-related macular
   degeneration; Retinal pigment epithelium
ID AGE-RELATED MACULOPATHY; COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; MACULAR DEGENERATION; HTRA1;
   SUSCEPTIBILITY; POLYMORPHISM; VARIANT; GENE
AB Age-related macular degeneration (AMD) is a major cause of irreversible blindness among elderly people in developed countries. Many studies suggested that age-related maculopathy susceptibility 2 (ARMS2) is the second major susceptibility gene for AMD. Increasing evidence was found recently that inflammatory processes and oxidative stress may contribute to the pathogenesis of AMD. Meanwhile, the mechanisms underlying the contributions of ARMS2 to the pathogenesis of AMD remain unclear. The purpose of the current study was to elucidate the relationship between the ARMS2 gene and proinflammatory mediators, for further assessment of the associated biologic effects.
   siRNA was used to knock down ARMS2 mRNA, and Western blotting and reverse real-time PCR were used to detect the effect of siRNA on the expression of ARMS2 in ARPE-19 cells. The expressions of C3, C5, IL-6, IL-8, and TNF-alpha after si-RNA knockdown were evaluated by SYBR Green I real-time PCR and ELISA.
   Transcription accumulative indexes (TAI = 2(-delta delta CT)) of ARMS2 by real-time PCR revealed that the transfection rate in the positive control group was 72.0 +/- 2.07 % (P < 0.01). The ratio of absorbance values (by Western blotting) of AMRS2 to beta-actin was 0.85 +/- 0.122, 0.87 +/- 0.143, and 0.61 +/- 0.240 in the blank control group, scrambled ARMS2-siRNA group, and ARMS2-siRNA group respectively (F = 42.5, P < 0.01). The secreted protein levels of C3, C5, IL-6, IL-8, and TNF-alpha were found by ELISA to be reduced by 34.24 +/- 1.81 %, 37.15 +/- 2.02 %, 35.11 +/- 1.75 %, 30.11 +/- 2.19 %, and 34.33 +/- 2.18 % respectively, in the siRNA-ARMS2 group (P < 0.05). Compared with the blank control group, reduced TAI of C3, C5, IL-6, IL-8, and TNF-alpha were detected by real-time PCR in the ARMS2-siRNA group.
   This study produced evidence supporting the notion that the ARMS2 risk allele for AMD is linked directly or indirectly to proinflammatory mediators. More importantly, our data indicate that the change in ARMS2 may affect C3, C5, IL-6, IL-8, and TNF-alpha levels, and this may be one of the mechanisms of AMD development.
C1 [Zeng, Fanxing; Zhang, Min; Xu, Yiting; Xu, Haifeng] Shandong Acad Med Sci, Shandong Eye Inst, Qingdao Eye Hosp, Qingdao 266071, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; University of Jinan
RP Xu, HF (通讯作者)，Shandong Acad Med Sci, Shandong Eye Inst, Qingdao Eye Hosp, 5 Yanerdao Rd, Qingdao 266071, Peoples R China.
EM chxhf@126.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Bessho H, 2011, MOL VIS, V17, P977
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Matsumura N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039890
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Patel AK, 2013, MOL IMMUNOL, V54, P122, DOI 10.1016/j.molimm.2012.11.005
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 32
TC 10
Z9 10
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2013
VL 251
IS 11
BP 2539
EP 2544
DI 10.1007/s00417-013-2442-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239VB
UT WOS:000326052700006
PM 23959158
DA 2022-11-30
ER

PT J
AU Tan, CS
   Ngo, WK
   Chen, JP
   Tan, NW
   Lim, TH
AF Tan, Colin S.
   Ngo, Wei Kiong
   Chen, Jian Ping
   Tan, Nikolle W.
   Lim, Tock Han
CA EVEREST Study Grp
TI EVEREST study report 2: imaging and grading protocol, and baseline
   characteristics of a randomised controlled trial of polypoidal choroidal
   vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; CLINICAL CHARACTERISTICS; JAPANESE PATIENTS; CHINESE
   PATIENTS; FEATURES; VERTEPORFIN; PATTERNS; OUTCOMES
AB Purpose To describe the imaging standards, grading protocol and baseline characteristics of polypoidal choroidal vasculopathy (PCV) from the EVEREST study.
   Methods In a prospective, multicentre study, confocal scanning laser ophthalmoscope indocyanine green angiography (ICGA) was performed using a standardised imaging protocol. All images were graded using standardised, calibrated equipment by fellowship-trained ophthalmologists at the Central Reading Center.
   Results Sixty-one patients with PCV were included in the study. ICGA characteristics included: nodular appearance stereoscopically (56 eyes, 91.8%), hypofluorescent halo (42, 68.9%), abnormal vascular network (54, 88.5%) and pulsation of the polyps (4, 6.6%). Colour fundus photography revealed orange subretinal nodules (34, 55.7%) and massive submacular haemorrhage (8, 13.1%). The mean area of the PCV lesion was 3.11 mm(2) (range, 0.2-10.7 mm(2)). The vascular channels filled within 7.3-32.0 s (mean: 17.9 s) while the mean filling time for polyps was 21.9 s (range, 7.3-40.4 s). Patients with massive submacular haemorrhage were less likely to have abnormal vascular channels seen on ICGA (28.6% vs 83.3% for those without massive haemorrhage, p=0.001).
   Conclusions The imaging and grading protocols and baseline characteristics of a multicentre, randomised controlled trial of PCV are described in detail, and may serve as reference for future randomised, controlled trials on PCV.
C1 [Tan, Colin S.; Tan, Nikolle W.; Lim, Tock Han] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
   [Tan, Colin S.; Ngo, Wei Kiong; Chen, Jian Ping; Tan, Nikolle W.; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
C3 Tan Tock Seng Hospital
RP Lim, TH (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM Tock_Han_Lim@nhg.com.sg
RI Tan, Nikolle/GXH-5775-2022; Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690; Lai, Timothy/0000-0002-7832-6428
FU Novartis Pharma AG, Basel, Switzerland [NCT00674323]
FX This work was supported by Novartis Pharma AG, Basel, Switzerland grant
   number NCT00674323 (clinicaltrials.gov).
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 25
TC 89
Z9 91
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2015
VL 99
IS 5
BP 624
EP 628
DI 10.1136/bjophthalmol-2014-305674
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG5BR
UT WOS:000353305800011
PM 25758601
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ma, IH
   Hsia, Y
   Hsieh, YT
   Ho, TC
   Lai, TT
   Yang, CM
   Yang, CH
AF Ma, I-Hsin
   Hsia, Yun
   Hsieh, Yi-Ting
   Ho, Tzyy-Chang
   Lai, Tso-Ting
   Yang, Chung-May
   Yang, Chang-Hao
TI Real world experience of the treatment outcome between photodynamic
   therapy combined with ranibizumab and aflibercept monotherapy in
   polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; COMBINATION; EFFICACY;
   THICKNESS; SAFETY; BEVACIZUMAB; EVEREST; EYES
AB To provide real-world experiences of treating polypoidal choroidal vasculopathy (PCV) patients with photodynamic therapy (PDT) plus intravitreal injection of ranibizumab or intravitreal injection of aflibercept alone. Retrospective chart review of patients with PCV in a single tertiary referral center in Taiwan. Chart review of PCV patients treated with PDT and injection of ranibizumab or injection of aflibercept. A total of 101 eyes of 101 patients (38 females and 63 males) were reviewed. Of those, 48 and 53 eyes received primary/adjunctive PDT along with injections of ranibizumab or intravitreal injections of aflibercept only, respectively. Initial visual acuity (VA) and central subfield choroidal thickness were similar between the two groups (p > 0.05). In addition, changes in VA at 3, 6, and 12 months post treatment were similar. The central retinal thickness decreased with either treatment (p < 0.01); however, this change did not translate into VA performance (p > 0.05). In the subgroup analysis of pachychoroid and non-pachychoroid patients, better initial VA and post-treatment VA at 3 months and 6 months was noted in the latter group of patients treated with anti-vascular endothelial growth factor monotherapy (p < 0.05). Aflibercept monotherapy is comparable with PDT plus ranibizumab in PCV patients with PCV (pachychoroid and non-pachychoroid patients). In addition, better prognosis regarding VA was observed in non-pachychoroid patients treated with aflibercept monotherapy.
C1 [Ma, I-Hsin; Hsia, Yun; Hsieh, Yi-Ting; Ho, Tzyy-Chang; Lai, Tso-Ting; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Zhongshan S Rd, Taipei 10002, Taiwan.
   [Ma, I-Hsin] Natl Taiwan Univ Hosp, Dept Ophthalmol, Hsin Chu Branch, Hsinchu, Taiwan.
   [Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University Hospital;
   National Taiwan University
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Zhongshan S Rd, Taipei 10002, Taiwan.; Yang, CH (通讯作者)，Natl Taiwan Univ, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
OI YANG, CHUNG-MAY/0000-0003-4082-420X; Hsia, Yun/0000-0001-6972-7732;
   YANG, CHANG-HAO/0000-0002-4328-8716
CR Azuma K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65346-w
   Baer K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46235-3
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Chen LJ, 2020, J FORMOS MED ASSOC, V119, P569, DOI 10.1016/j.jfma.2019.04.012
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Takayama K, 2017, GRAEF ARCH CLIN EXP, V255, P449, DOI 10.1007/s00417-016-3468-x
   Tan CS, 2015, EYE, V29, P1238, DOI 10.1038/eye.2015.101
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yang JY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1609717
   Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1245-4
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeung L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80731-1
   Yoneda A, 2020, EUR J OPHTHALMOL, V30, P1473, DOI 10.1177/1120672119871886
NR 44
TC 2
Z9 2
U1 4
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 11
PY 2021
VL 11
IS 1
AR 20115
DI 10.1038/s41598-021-99634-w
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WF6EU
UT WOS:000706395800101
PM 34635762
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Luviano, DM
   Benz, MS
   Kim, RY
   Fish, RH
   Wong, TP
   Kegley, EN
   Brown, DM
AF Luviano, Damien M.
   Benz, Matthew S.
   Kim, Rosa Y.
   Fish, Richard H.
   Wong, Tien P.
   Kegley, Eric N.
   Brown, David M.
TI Selected Clinical Comparisons of Spectral Domain and Time Domain Optical
   Coherence Tomography
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
AB The authors report four cases where spectral domain optical coherence tomography (SD-OCT) imaged pathology not captured by time domain optical coherence tomography (TD-OCT). These cases include one of angioid streaks, two of juxtafoveal telangiectasia, and one of age-related macular degeneration. In each case, the improved images provided by SD-OCT changed either the management of the patient Or the Counseling of their disease process. [Ophthalmic Surg Lasers Imaging 2009;40:325-328.]
C1 [Luviano, Damien M.; Benz, Matthew S.; Kim, Rosa Y.; Fish, Richard H.; Wong, Tien P.; Kegley, Eric N.; Brown, David M.] Vitreoretinal Consultants, Greater Houston Retina Res Ctr, Houston, TX USA.
RP Benz, MS (通讯作者)，Vitreoretinal Consultants, Greater Houston Retina Res Ctr, 6560 Fannin,Suite 750,Scurlock Tower, Houston, TX USA.
CR Albini TA, 2006, OPHTHAL SURG LAS IM, V37, P120, DOI 10.3928/1542-8877-20060301-07
   Arvas S, 2002, EUR J OPHTHALMOL, V12, P473, DOI 10.1177/112067210201200605
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Paunescu LA, 2006, OPHTHALMOLOGY, V113, P48, DOI 10.1016/j.ophtha.2005.08.016
   Schocket LS, 2006, OPHTHALMOLOGY, V113, P666, DOI 10.1016/j.ophtha.2006.01.003
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
NR 8
TC 4
Z9 4
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2009
VL 40
IS 3
BP 325
EP 328
DI 10.3928/15428877-20090430-20
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 446RY
UT WOS:000266140000020
PM 19485303
DA 2022-11-30
ER

PT J
AU Skondra, D
   Papakostas, TD
   Hunter, R
   Vavvas, DG
AF Skondra, Dimitra
   Papakostas, Thanos D.
   Hunter, Rebecca
   Vavvas, Demetrios G.
TI Near Infrared Autofluorescence Imaging of Retinal Diseases
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Enhanced imaging chorioretinal melanin
ID KOYANAGI-HARADA-DISEASE; CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE
   GREEN ANGIOGRAPHY; FUNDUS AUTOFLUORESCENCE; PSEUDOXANTHOMA ELASTICUM;
   MACULAR DEGENERATION; FLUORESCENCE; LIPOFUSCIN; MELANIN; ABNORMALITIES
AB Near infrared autofluorescence (excitation 787 nm, emission > 800 nm) is a non-invasive imaging technology that provides information on the distribution of melanin within the retinal pigment epithelial cell/choroid complex. This review contains an introduction to near infrared autofluorescence imaging methods. Characteristics of near infrared imaging in a variety of retinal diseases, including age-related macular degeneration, choroidal nevus, retinal degenerations, retinal dystrophies, central serous chorioretinopathy, pseudoxanthoma elasticum and chloroquine retinopathy, are summarized.
C1 [Skondra, Dimitra; Papakostas, Thanos D.; Hunter, Rebecca; Vavvas, Demetrios G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Vavvas, DG (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM vavvas@meei.harvard.edu
OI Vavvas, Demetrios/0000-0002-8622-6478
CR Ayata A, 2009, BRIT J OPHTHALMOL, V93, P79, DOI 10.1136/bjo.2008.141564
   Ayata A, 2009, EUR J OPHTHALMOL, V19, P1094, DOI 10.1177/112067210901900636
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN GC, 1980, OPHTHALMOLOGY, V87, P51
   Chee SP, 2009, AM J OPHTHALMOL, V147, P154, DOI 10.1016/j.ajo.2008.07.044
   De Zaeytijd J, 2010, BRIT J OPHTHALMOL, V94, P479, DOI 10.1136/bjo.2009.162644
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Finger RP, 2009, SURV OPHTHALMOL, V54, P272, DOI 10.1016/j.survophthal.2008.12.006
   Hiraoka T, 2010, CLIN EXP OPHTHALMOL, V38, P669, DOI 10.1111/j.1442-9071.2010.02311.x
   Hu XF, 2003, SURV OPHTHALMOL, V48, P424, DOI 10.1016/S0039-6257(03)00053-5
   Inomata H, 2001, AM J OPHTHALMOL, V131, P607, DOI 10.1016/S0002-9394(00)00851-5
   Issa PC, 2010, OPHTHALMOLOGY, V117, P1406, DOI 10.1016/j.ophtha.2009.11.008
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner S, 2009, BRIT J OPHTHALMOL, V93, P1444, DOI 10.1136/bjo.2008.157198
   Kellner U, 2008, DOC OPHTHALMOL, V116, P119, DOI 10.1007/s10633-007-9105-6
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Koizumi H, 2010, BRIT J OPHTHALMOL, V94, P1499, DOI 10.1136/bjo.2009.164665
   LINCOFF H, 1988, ARCH OPHTHALMOL-CHIC, V106, P61
   Lindner E, 2012, OPHTHALMOLOGICA, V227, P34, DOI 10.1159/000331987
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   MOORTHY RS, 1995, SURV OPHTHALMOL, V39, P265, DOI 10.1016/S0039-6257(05)80105-5
   Oh J, 2012, INVEST OPHTH VIS SCI, V53, P179, DOI 10.1167/iovs.11-8704
   Parodi MB, 2008, RETINA-J RET VIT DIS, V28, P801, DOI 10.1097/IAE.0b013e31816f859d
   Peters S, 2000, OPHTHALMIC RES, V32, P52, DOI 10.1159/000055589
   Piccolino FC, 1996, OPHTHALMOLOGY, V103, P1837
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Rao Narsing A., 2007, International Ophthalmology, V27, P81, DOI 10.1007/s10792-006-9029-2
   Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Schmitz-Valckenberg S, 2011, BRIT J OPHTHALMOL, V95, P1134, DOI 10.1136/bjo.2010.189498
   Sekiryu T, 2010, INVEST OPHTH VIS SCI, V51, P4956, DOI 10.1167/iovs.09-5009
   Sheu SJ, 2003, J CHIN MED ASSOC, V66
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Toju R, 2012, AM J OPHTHALMOL, V153, P314, DOI 10.1016/j.ajo.2011.06.026
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
NR 40
TC 19
Z9 20
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD SEP-NOV
PY 2012
VL 27
IS 5-6
BP 202
EP 208
DI 10.3109/08820538.2012.708806
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 041SD
UT WOS:000311420600018
PM 23163277
DA 2022-11-30
ER

PT J
AU Kvanta, A
   Grudzinska, MK
AF Kvanta, Anders
   Grudzinska, Monika K.
TI Stem cell-based treatment in geographic atrophy: promises and pitfalls
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; embryonic stem cells; induced
   pluripotent stem cells; photoreceptors; retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; AUTOLOGOUS
   TRANSLOCATION; IN-VITRO; RPE; TRANSPLANTATION; DIFFERENTIATION;
   DELIVERY; IMPLANTATION; PROGRESSION
AB Geographic atrophy is a common and untreatable form of advanced age-related macular degeneration. The degeneration primarily affects the retinal pigment epithelium and photoreceptors of the retina and their restoration by cell transplantation seems attractive. Recently, a patient with geographic atrophy was the first human to receive cells derived from human embryonic stem cells. In this short review, the rationale, potential and obstacles for stem cell-derived therapy in geographic atrophy are discussed.
C1 St Erik Eye Hosp, Dept Vitreoretinal Dis, Stockholm, Sweden.
   [Kvanta, Anders] Karolinska Inst, SE-11282 Stockholm, Sweden.
C3 Karolinska Institutet
RP Kvanta, A (通讯作者)，St Eriks Eye Hosp, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
EM anders.kvanta@ki.se
OI Grudzinska Pechhacker, Monika/0000-0001-7007-461X
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Binder S, 2011, BRIT J OPHTHALMOL, V95, P441, DOI 10.1136/bjo.2009.171926
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boucherie C, 2013, STEM CELLS, V31, P408, DOI 10.1002/stem.1268
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Christiansen AT, 2012, STEM CELLS INT, V2012
   Drukker M, 2006, STEM CELLS, V24, P221, DOI 10.1634/stemcells.2005-0188
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   JIANG LQ, 1993, INVEST OPHTH VIS SCI, V34, P3347
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Mazumder MAJ, 2012, J BIOMED MATER RES A, V100A, P1877, DOI 10.1002/jbm.a.34021
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Stout JT, 2011, HUM GENE THER, V22, P531, DOI 10.1089/hum.2011.060
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Treharne AJ, 2011, BRIT J OPHTHALMOL, V95, P768, DOI 10.1136/bjo.2010.184002
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Williams DR, 2011, VISION RES, V51, P1379, DOI 10.1016/j.visres.2011.05.002
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 58
TC 13
Z9 16
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2014
VL 92
IS 1
BP 21
EP 26
DI 10.1111/aos.12185
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292TJ
UT WOS:000329925000005
PM 23890249
DA 2022-11-30
ER

PT J
AU Kimura, S
   Morizane, Y
   Hosokawa, MM
   Shiode, Y
   Doi, S
   Hosogi, M
   Fujiwara, A
   Okanouchi, T
   Inoue, Y
   Shiraga, F
AF Kimura, Shuhei
   Morizane, Yuki
   Hosokawa, Mio Morizane
   Shiode, Yusuke
   Doi, Shinichiro
   Hosogi, Mika
   Fujiwara, Atsushi
   Okanouchi, Toshio
   Inoue, Yasushi
   Shiraga, Fumio
TI Outcomes of vitrectomy combined with subretinal tissue plasminogen
   activator injection for submacular hemorrhage associated with polypoidal
   choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Antivascular endothelial growth factor; Polypoidal choroidal
   vasculopathy; Submacular hemorrhage; Tissue plasminogen activator
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; PNEUMATIC
   DISPLACEMENT; RANIBIZUMAB; BEVACIZUMAB; PHARMACOKINETICS; EFFICACY;
   SAFETY; GAS; AFLIBERCEPT
AB Purpose To examine the outcomes of vitrectomy with subretinal tissue plasminogen activator (tPA) injection and postoperative intravitreal antivascular endothelial growth factor (VEGF) injection for submacular hemorrhage (SMH) associated with polypoidal choroidal vasculopathy (PCV). Study design Retrospective, consecutive case series. Methods Patients who underwent vitrectomy for SMH associated with PCV and who were followed up for at least 12 months were included. Surgery consisted of vitrectomy with subretinal tPA and air tamponade. Postoperative intravitreal anti-VEGF was administered pro re nata. The following were examined: best-corrected visual acuity (BCVA) at baseline, at 1 month, and at the final visit; the percentage of patients requiring anti-VEGF postoperatively; and the number of injections administered. Results This study included 23 eyes of 23 patients (21 men, 2 women) with a mean age of 72.5 +/- 9.0 years. The mean duration from disease onset to surgery was 9.0 +/- 6.6 days. The mean maximum SMH size was 5.8 +/- 4.8 disc diameters. The mean follow-up period was 33 +/- 14 months. The BCVA was significantly improved when compared with baseline 1 month after surgery and at the final visit. Postoperative anti-VEGF was required for 91% of the eyes. In eyes that underwent anti-VEGF therapy until the final visit, the mean injection number was 4.1/year. Conclusions Vitrectomy with subretinal tPA and air tamponade improved visual acuity in patients with SMH associated with PCV. Postoperative intravitreal anti-VEGF injection maintained the improved BCVA throughout a mean period of 33 months.
C1 [Kimura, Shuhei; Morizane, Yuki; Hosokawa, Mio Morizane; Shiode, Yusuke; Doi, Shinichiro; Hosogi, Mika; Fujiwara, Atsushi; Shiraga, Fumio] Okayama Univ, Dept Ophthalmol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
   [Okanouchi, Toshio] Kurashiki Med Ctr, Okayama, Japan.
   [Inoue, Yasushi] Inoue Eye Clin, Okayama, Japan.
C3 Okayama University
RP Morizane, Y (通讯作者)，Okayama Univ, Dept Ophthalmol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
EM moriza-y@okayama-u.ac.jp
CR Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Bressler SB, 2015, RETINA-J RET VIT DIS, V35, P2516, DOI 10.1097/IAE.0000000000000617
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gonzalez-Lopez JJ, 2016, EYE, V30, P929, DOI 10.1038/eye.2016.65
   Haritoglou C, 2013, EYE, V27, P1308, DOI 10.1038/eye.2013.178
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kimura S, 2017, JPN J OPHTHALMOL, V61, P472, DOI 10.1007/s10384-017-0530-0
   Kimura S, 2016, GRAEF ARCH CLIN EXP, V254, P1731, DOI 10.1007/s00417-016-3314-1
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Navarrete-Sanchis J, 2015, GRAEF ARCH CLIN EXP, V253, P713, DOI 10.1007/s00417-014-2745-9
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Okanouchi T, 2016, RETINA-J RET VIT DIS, V36, P1035, DOI 10.1097/IAE.0000000000001029
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Tachi N, 1996, AM J OPHTHALMOL, V122, P258, DOI 10.1016/S0002-9394(14)72018-5
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Treumer F, 2017, GRAEF ARCH CLIN EXP, V255, P1115, DOI 10.1007/s00417-017-3620-2
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
NR 43
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2019
VL 63
IS 5
BP 382
EP 388
DI 10.1007/s10384-019-00679-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IU6NF
UT WOS:000483702300004
PM 31243593
DA 2022-11-30
ER

PT J
AU Tan, PL
   Garrett, ME
   Willer, JR
   Campochiaro, PA
   Campochiaro, B
   Zack, DJ
   Ashley-Koch, AE
   Katsanis, N
AF Tan, Perciliz L.
   Garrett, Melanie E.
   Willer, Jason R.
   Campochiaro, Peter A.
   Campochiaro, Betsy
   Zack, Donald J.
   Ashley-Koch, Allison E.
   Katsanis, Nicholas
TI Systematic Functional Testing of Rare Variants: Contributions of CFI to
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE in vivo testing; complement pathway; rare allele burden
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; GENETIC-VARIANTS;
   FACTOR-I; HIGH-RISK; SUSCEPTIBILITY LOCI; BRUCHS MEMBRANE; SEQUENCING
   DATA; 17Q25 REGIONS; HEART-DISEASE
AB PURPOSE. Genome-wide association (GWAS) and sequencing studies for AMD have highlighted the importance of coding variants at loci that encode components of the complement pathway. However, assessing the contribution of such alleles to AMD, especially when they are rare, remains coarse, in part because of the persistent challenge in establishing their functional relevance. Others and we have shown previously that rare alleles in complement factor I (CFI) can be tested functionally using a surrogate in vivo assay of retinal vascularization in zebrafish embryos. Here, we have implemented and scaled these tools to assess the overall contribution of rare alleles in CFI to AMD.
   METHODS. We performed targeted sequencing of CFI in 731 AMD patients, followed by replication in a second patient cohort of 511 older healthy individuals. Systematic functional testing of all alleles and post-hoc statistical analysis of functional variants was also performed.
   RESULTS. We discovered 20 rare coding nonsynonymous variants, including the previously reported G119R allele. In vivo testing led to the identification of nine variants that alter CFI; six of which are associated with hypoactive complement factor I (FI). Post-hoc analysis in ethnically matched, population controls showed six of these to be present exclusively in cases.
   CONCLUSIONS. Taken together, our data argue that multiple rare and ultra-rare alleles in CFI contribute to AMD pathogenesis; they improve the precision of the assessment of the contribution of CFI to AMD; and they offer a rational route to establishing both causality and direction of allele effect for genes associated with this disorder.
C1 [Tan, Perciliz L.; Garrett, Melanie E.; Willer, Jason R.; Ashley-Koch, Allison E.; Katsanis, Nicholas] Duke Univ, Med Ctr, Ctr Human Dis Modeling, Durham, NC USA.
   [Tan, Perciliz L.; Zack, Donald J.; Katsanis, Nicholas] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   [Campochiaro, Peter A.; Campochiaro, Betsy; Zack, Donald J.] Johns Hopkins Sch Med, Dept Ophthalmol, Neurosci, Baltimore, MD USA.
   [Zack, Donald J.] Johns Hopkins Sch Med, Ctr Stem Cells & Ocular Regenerat Med, Baltimore, MD USA.
   [Zack, Donald J.] Johns Hopkins Sch Med, Dept Mol Biol & Genet, Baltimore, MD USA.
   [Ashley-Koch, Allison E.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Ashley-Koch, Allison E.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA.
   [Ashley-Koch, Allison E.] Duke Univ, Med Ctr, Dept Biostat, Durham, NC USA.
   [Ashley-Koch, Allison E.] Duke Univ, Med Ctr, Dept Bioinformat, Durham, NC USA.
C3 Duke University; Duke University; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine;
   Johns Hopkins University; Johns Hopkins Medicine; Duke University; Duke
   University; Duke University; Duke University
RP Katsanis, N (通讯作者)，300 N Duke St,Suite 47-101, Durham, NC 27701 USA.
EM Nicholas.Katsanis@duke.edu
OI Willer, Jason/0000-0002-5869-3992
FU NIH [5T32EY007143, 5P30EY001765]; Foundation Fighting Blindness; Edward
   N. & Della L. Thome Memorial Foundation Awards Program in Age-Related
   Macular Degeneration Research; Research to Prevent Blindness, Inc.
FX Supported by grants from NIH (5T32EY007143, 5P30EY001765), Foundation
   Fighting Blindness, Edward N. & Della L. Thome Memorial Foundation
   Awards Program in Age-Related Macular Degeneration Research,
   unrestricted funds from Research to Prevent Blindness, Inc., and
   generous gifts from the Guerrieri Family Foundation; funding supported
   the collection of samples.
CR Alvarez Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-114
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Botto M, 2009, MOL IMMUNOL, V46, P2774, DOI 10.1016/j.molimm.2009.04.029
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Frikke-Schmidt R, 2015, INT J EPIDEMIOL, V44, P117, DOI 10.1093/ije/dyu215
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kitambi SS, 2009, MECH DEVELOP, V126, P464, DOI 10.1016/j.mod.2009.01.002
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Nasevicius A, 2000, YEAST, V17, P294, DOI 10.1002/1097-0061(200012)17:4<294::AID-YEA54>3.0.CO;2-5
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qian DG, 2014, EUR J HUM GENET, V22, P1417, DOI 10.1038/ejhg.2014.37
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schlaf G, 2001, MOL IMMUNOL, V38, P231, DOI 10.1016/S0161-5890(01)00045-1
   Schulte EC, 2014, AM J HUM GENET, V95, P85, DOI 10.1016/j.ajhg.2014.06.005
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Soemedi R, 2012, AM J HUM GENET, V91, P489, DOI 10.1016/j.ajhg.2012.08.003
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Rooijen E, 2010, DIS MODEL MECH, V3, P343, DOI 10.1242/dmm.004036
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zeng XXI, 2009, DEV BIOL, V328, P363, DOI 10.1016/j.ydbio.2009.01.035
NR 46
TC 6
Z9 6
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2017
VL 58
IS 3
BP 1570
EP 1576
DI 10.1167/iovs.16-20867
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ4ZA
UT WOS:000398089000027
PM 28282489
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Nili-Ahmadabadi, M
   Espandar, L
   Mansoori, MR
   Karkhane, R
   Riazi, M
   Ardestani, E
AF Nili-Ahmadabadi, Mehdi
   Espandar, Ladan
   Mansoori, Mohammad-Reza
   Karkhane, Reza
   Riazi, Mohammad
   Ardestani, Ehsanollah
TI Therapeutic effect of macular grid photocoagulation in treatment of
   nonexudative age-related macular degeneration
SO ARCHIVES OF IRANIAN MEDICINE
LA English
DT Article
DE laser; macular degeneration; photocoagulation; retinopathy
ID LASER TREATMENT; CHOROIDAL NEOVASCULARIZATION; SOFT DRUSEN; RISK;
   MACULOPATHY; PROGNOSIS
AB Background: To investigate the effect of prophylactic subthreshold laser macular grid photocoagulation on drusen area and to evaluate the visual outcome and incidence of choroidal neovascularization in patients with soft drusen maculopathy.
   Methods: in a nonrandomized nonmasked clinical trial, 18 patients (36 eyes) with bilateral soft drusen maculopathy were studied. For each patient, one eye was treated with 48 subthreshold (invisible end-point) applications of 532-nm KTP-laser in a macular grid pattern and the fellow eye was observed. Soft drusen areas were calculated and compared between the two groups at baseline and follow-up visits at 3, 6, 12, and 30 months of therapy. Best corrected visual acuity was also compared in observed and laser-treated eyes. Reduction of drusen area, change in visual acuity, and rate of CNV were assessed in both groups.
   Results: At baseline, there was no significant difference in the mean drusen surface area between the two groups (P = 0.90). The mean surface area of soft drusen in treated eyes was 6.51 mm(2) after 30 months and 7.58 mm(2) (P = 0.50) in the control eyes. There was a trend towards reduction in the mean soft drusen area after 30 months from baseline in laser-treated eyes (6.51 vs. 6.97 mm(2)). In treated eyes, there was no statistically significant difference between the mean best corrected visual acuity at the baseline (0.28 logMAR) and after 30 months (0.32 logMAR) (P = 0.40).
   Conclusion: Subthreshold macular grid photocoagulation with 532-nm KTP-laser did not seem to reduce drusen surface area significantly and did not improve best corrected visual acuity after 30 months. No exudative lesion developed in laser-treated eyes.
C1 [Nili-Ahmadabadi, Mehdi; Espandar, Ladan; Mansoori, Mohammad-Reza; Karkhane, Reza; Riazi, Mohammad; Ardestani, Ehsanollah] Univ Tehran Med Sci, Dept Ophthalmol, Tehran, Iran.
C3 Tehran University of Medical Sciences
RP Nili-Ahmadabadi, M (通讯作者)，Farabi Hosp, Dept Ophthalmol, Tehran, Iran.
CR [Anonymous], 1998, Ophthalmology, V105, P11
   *CHOR NEOV PREV TR, 1998, CNVPT OPHTHALMOLOGY, V105, P1364
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   *MAL PHOT STUD GRO, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   McCabe FJ, 2002, AGE-RELATED MACULAR DEGENERATION, P325
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
NR 24
TC 3
Z9 4
U1 0
U2 1
PU ACAD MEDICAL SCIENCES I R IRAN
PI TEHRAN
PA PO BOX 19395-5655, TEHRAN, 00000, IRAN
SN 1029-2977
EI 1735-3947
J9 ARCH IRAN MED
JI Arch. Iran. Med.
PD JAN
PY 2007
VL 10
IS 1
BP 14
EP 19
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 272NT
UT WOS:000253866800003
PM 17198447
DA 2022-11-30
ER

PT J
AU Krebs, I
   Haas, P
   Zeiler, F
   Binder, S
AF Krebs, I.
   Haas, P.
   Zeiler, F.
   Binder, S.
TI Optical coherence tomography: limits of the retinal-mapping program in
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB
   AVASTIN; THICKNESS MEASUREMENTS; PHOTODYNAMIC THERAPY; CLINICAL-TRIALS;
   VERTEPORFIN; PEGAPTANIB; PATHOLOGY
AB Aim: The retinal-mapping program of Stratus optical coherence tomography (Carl Zeiss Meditec, Dublin, CA, USA) calculates the retinal volume of the central region between the retinal surface and the retinal pigment epithelium (RPE). This study evaluates the retinal-mapping program for studies dealing with AMD.
   Methods: The scans of both eyes of patients examined from August to October 2006 because of macular degeneration were evaluated retrospectively. Independent examiners tested whether the two lines indicating the retinal surface and the RPE were positioned correctly by the threshold algorithm that corresponded with correct measurements.
   Results: The scans of 233 eyes of 117 patients were evaluated (39.3% were men and 60.7% women, with a mean age of 76.9 years). Overall, in 57.1% both lines were positioned correctly. False-positioned lines were recorded in 9.0% due to low scan quality and in 33.9% due to a doubled or interrupted hyper-reflective band of the RPE. Threshold algorithm misinterpretation was significantly more frequent in occult lesions with and without fibrosis than in non-exudative lesions, and were significantly correlated to distance acuity (p < 0.0001).
   Conclusion: The retinal-mapping program for examination of AMD provided correct results in only 57.1% of eyes. A manual correction of false-positioned lines would be needed to improve accuracy.
C1 [Krebs, I.; Haas, P.; Zeiler, F.; Binder, S.] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krebs, I.; Haas, P.; Zeiler, F.; Binder, S.] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM llse.Krebs@wienkav.at
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Hee MR, 2005, AM J OPHTHALMOL, V140, P350, DOI 10.1016/j.ajo.2005.02.062
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Koozekanani D, 2000, INVEST OPHTH VIS SCI, V41, P1486
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
NR 20
TC 21
Z9 21
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2008
VL 92
IS 7
BP 933
EP 935
DI 10.1136/bjo.2007.128447
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318RL
UT WOS:000257109700015
PM 18577644
DA 2022-11-30
ER

PT J
AU Ting, DSW
   Cheung, GCM
   Lim, LS
   Yeo, IYS
AF Ting, Daniel S. W.
   Cheung, Gemmy C. M.
   Lim, Laurence S.
   Yeo, Ian Y. S.
TI Comparison of swept source optical coherence tomography and spectral
   domain optical coherence tomography in polypoidal choroidal vasculopathy
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; swept source optical coherence
   tomography; polyp
ID MACULAR DEGENERATION; FEATURES
AB Background: Swept source optical coherence tomography (SS-OCT, Topcon Medical System, Japan) is known to have longer wavelength than spectral domain OCT (SD-OCT, Spectralis, Heidelberg Engineering, Germany), allowing a deeper penetration into retina and choroidal layers. This objective of this study was to compare the visibility of retinal and choroidal features in polypoidal choroidal vasculopathy (PCV) using SS-OCT and SD-OCT.
   Design: This study employs prospective comparative observational case series in Singapore National Eye Center.
   Participants: There were 20 eyes (20 patients) with PCV confirmed with indocyanine green angiogram.
   Methods: Six pre-specified OCT parameters (presence of polyps, sharp pigment epithelial detachment [PED] peak, notched PED and visibility of full maximum height of PED, inner segment/outer segment [IS/OS] line and choroid-scleral interface [CSI]) were graded using SS-OCT and SD-OCT.
   Main Outcome Measures: The Kappa statistics between the two imaging modalities were calculated.
   Results: Both SS-OCT and SD-OCT were able to detect polypoidal lesions in the majority of eyes (90% and 85%, respectively). However, SS-OCT had better detection for CSI and IS/OS lines (CSI: 80% vs 45%, P = 0.05; IS/OS line: 65% vs 45%, P = 0.34). For sharp PED peak, notched PED, ability to visualize the full PED height and retinal pigment epithelial line, both OCT machines were able to detect in = 80% of the eyes.
   Conclusion: In conclusion, SS-OCT and SD-OCT appeared to be similarly effective at detecting most features associated with PCV. However, SS-OCT is more superior in detecting the CSI.
C1 [Ting, Daniel S. W.; Cheung, Gemmy C. M.; Lim, Laurence S.; Yeo, Ian Y. S.] Singapore Hlth Serv SingHlth, Singapore Natl Eye Ctr, Singapore, Singapore.
C3 Singapore National Eye Center
RP Ting, DSW (通讯作者)，Singapore Natl Eye Ctr, Ophthalmol, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM daniel.ting45@gmail.com
OI Bidwai, Pooja Vishal/0000-0002-3077-4395; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
CR Abe S., 2010, OPHTHAL SURG LAS IM, V9, P1, DOI DOI 10.3928/15428877-20100215-76.[
   Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Alasil T, 2014, AM J OPHTHALMOL, P634
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lim LS, 2014, EYE, V28, P488, DOI 10.1038/eye.2013.308
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Sayanagi K, 2014, GRAEF ARCH CLIN EXP, V252, P3, DOI 10.1007/s00417-013-2474-5
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Viera AJ, 2005, FAM MED, V37, P360
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 18
TC 34
Z9 35
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2015
VL 43
IS 9
BP 815
EP 819
DI 10.1111/ceo.12580
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB2MJ
UT WOS:000368342700008
PM 26183457
DA 2022-11-30
ER

PT J
AU Wong, IY
   Shi, X
   Gangwani, R
   Zhao, P
   Iu, LP
   Li, Q
   Ng, A
   Li, XX
AF Wong, Ian Y.
   Shi, Xuan
   Gangwani, Rita
   Zhao, Paul
   Iu, Lawrence P.
   Li, Qing
   Ng, Alex
   Li, Xiaoxin
TI 1-year results of combined half-dose photodynamic therapy and
   ranibizumab for polypoidal choroidal vasculopathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age related macular degeneration; Half-dose; Half-fluence; Photodynamic
   therapy; Polypoidal choroidal vasculopathy; Ranibizumab; Verteporfin
ID CENTRAL SEROUS CHORIORETINOPATHY; CONTROLLED-TRIAL; VERTEPORFIN;
   FLUENCE; SAFETY
AB Background: To evaluate the efficacy and safety of half-dose photodynamic therapy (PDT combined with ranibizumab for polypoidal choroidal vasculopathy (PCV). PCV is commonly treated with a combination of anti-vascular endothelial growth factor and standard-dose photodynamic therapy (PDT). Choroidal ischemia and visual loss can be resulted from the standard-dose PDT. Half-dose PDT has proved to produce similar results and safety profile in treating central serous chorioretinopathy. Half-dose PDT may offer an alternative for PCV cases where the damage to choroidal vasculature maybe less. Here, we report the efficacy of treating PCV cases with combination of ranibizumab and half-dose PDT.
   Methods: In this prospective, non-comparative, interventional case series, 19 treatment-naive eyes were treated with combined half-dose PDT and ranibizumab. All subjects were followed up for 12 months with measurement of best-corrected visual acuity (BCVA), central foveal thickness (CFT) by optical coherence tomography. Indocyanine green angiogram (ICG) was performed every 3-monthly, and subjects assessed in terms of polyp regression rates, changes in vision and central foveal thickness, need to repeat half-dose PDT. Subgroup analysis was performed based on ICG features.
   Results: The mean logMAR BCVA improved from 0.64 at baseline to 0.41 at 12 months. The mean CFT improved from 459.6mum at baseline to 384.2mum at 12 months. The difference between baseline BCVA and CFT and that at 12 months were statistically significant (both P = 0.03). Polyp regression rate after one half-dose PDT was 42.1 %. This was 61.5 % in the polyp-only group, while that in the branching-vascular-network (BVN) group was 0 % (P = <0.01).
   Conclusion: Half-dose PDT combined with intravitreal ranibizumab was able to induce high polyp regression rate in PCV cases that had one single polyp.
C1 [Wong, Ian Y.; Gangwani, Rita; Iu, Lawrence P.; Li, Qing; Ng, Alex] Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Shi, Xuan; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Zhao, Paul] Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore.
C3 University of Hong Kong; Peking University; National University of
   Singapore
RP Wong, IY (通讯作者)，Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
EM ianyhwong@gmail.com
RI Iu, Lawrence/K-7441-2019; Ng, Alex Lap-Ki/O-1468-2019
OI Iu, Lawrence/0000-0001-6898-5043; Ng, Alex Lap-Ki/0000-0002-8321-5634
FU Novartis Pharmaceuticals (Hong Kong) Limited
FX Novartis Pharmaceuticals (Hong Kong) Limited sponsored 10 vials of
   verteporfin for this study.
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Liegl R, 2014, OPHTHALMOLOGICA J IN
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Miki A, 2013, JPN J OPHTHALMOL, V57, P301, DOI 10.1007/s10384-013-0237-9
   Nicolo M, 2014, AM J OPHTHALMOL, V157, P1033, DOI 10.1016/j.ajo.2014.01.022
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Wu ZHY, 2011, RETINA-J RET VIT DIS, V31, P1378, DOI 10.1097/FTD.0b013e31820beb02
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 27
TC 13
Z9 13
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 30
PY 2015
VL 15
AR 66
DI 10.1186/s12886-015-0061-8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL5MK
UT WOS:000357003800001
PM 26122636
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ideta, R
   Tasaka, F
   Jang, WD
   Nishiyama, N
   Zhang, GD
   Harada, A
   Yanagi, Y
   Tamaki, Y
   Aida, T
   Kataoka, K
AF Ideta, R
   Tasaka, F
   Jang, WD
   Nishiyama, N
   Zhang, GD
   Harada, A
   Yanagi, Y
   Tamaki, Y
   Aida, T
   Kataoka, K
TI Nanotechnology-based photodynamic therapy for neovascular disease using
   a supramolecular nanocarrier loaded with a dendritic photosensitizer
SO NANO LETTERS
LA English
DT Article
ID POLYION COMPLEX MICELLES; CHARGED BLOCK-COPOLYMERS; CHOROIDAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; PORPHYRINS; ACCUMULATION;
   VERTEPORFIN; DELIVERY
AB Photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD) was evaluated using a supramolecular nanomedical device, that is, a novel dendritic photosensitizer (DP) encapsulated by a polymeric micelle formulation. The characteristic dendritic structure of the DP prevents aggregation of its core sensitizer, thereby inducing a highly effective photochemical reaction. With its highly selective accumulation on choroidal neovascularization (CNV) lesions, this treatment resulted in a remarkably efficacious CNV occlusion with minimal unfavorable phototoxicity.
C1 Univ Tokyo, Grad Sch Engn, Dept Mat Sci & Engn, Bunkyo Ku, Tokyo 1138656, Japan.
   Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Investigat Med, Bunkyo Ku, Tokyo 1130033, Japan.
   Osaka Prefecture Univ, Dept Appl Mat Sci, Sakai, Osaka 5998531, Japan.
   Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
   Santen Pharmaceut Co Ltd, Div Res & Dev, Ikoma, Nara 6300101, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo; Osaka
   Metropolitan University; University of Tokyo; Santen Pharmaceutical Co
   Ltd
RP Kataoka, K (通讯作者)，Univ Tokyo, Grad Sch Engn, Dept Mat Sci & Engn, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
EM kataoka@bmw.t.u-tokyo.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Jang, Woo-Dong/I-7186-2019; Kataoka,
   Kazunori/K-7108-2012; Yanagi, Yasuo/AAF-2670-2020; Nishiyama,
   Nobuhiro/F-1867-2014; Aida, Takuzo/I-9117-2012
OI Jang, Woo-Dong/0000-0002-1281-6037; Kataoka,
   Kazunori/0000-0002-8591-413X; Nishiyama, Nobuhiro/0000-0002-6886-9357;
   Yanagi, Yasuo/0000-0002-0362-7285
CR Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   GROSSWEINER LI, 1982, PHOTOCHEM PHOTOBIOL, V36, P159, DOI 10.1111/j.1751-1097.1982.tb04358.x
   Harada A, 1999, SCIENCE, V283, P65, DOI 10.1126/science.283.5398.65
   HARADA A, 1995, MACROMOLECULES, V28, P5294, DOI 10.1021/ma00119a019
   HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027
   Ideta R, 2004, FEBS LETT, V557, P21, DOI 10.1016/S0014-5793(03)01315-2
   Jang WD, 2005, ANGEW CHEM INT EDIT, V44, P419, DOI 10.1002/anie.200461603
   KWON G, 1994, J CONTROL RELEASE, V29, P17, DOI 10.1016/0168-3659(94)90118-X
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Nishiyama N, 2003, CANCER RES, V63, P8977
   Nishiyama N, 2003, BIOCONJUGATE CHEM, V14, P58, DOI 10.1021/bc025597h
   Pandey R.K., 2000, PORPHYRIN HDB, V6
   Renno RZ, 2001, ADV DRUG DELIVER REV, V52, P63, DOI 10.1016/S0169-409X(01)00195-8
   Sato T, 1999, J AM CHEM SOC, V121, P10658, DOI 10.1021/ja9922983
   Stapert HR, 2000, LANGMUIR, V16, P8182, DOI 10.1021/la000423e
   Tomioka N, 1998, ANGEW CHEM INT EDIT, V37, P1531, DOI 10.1002/(SICI)1521-3773(19980619)37:11<1531::AID-ANIE1531>3.0.CO;2-T
   WORMALD R, 2003, COCHRANE DB SYST REV
   Yanagi Y, 2003, INVEST OPHTH VIS SCI, V44, P751, DOI 10.1167/iovs.02-0222
   Yokoyama M, 1999, J DRUG TARGET, V7, P171, DOI 10.3109/10611869909085500
NR 22
TC 157
Z9 164
U1 1
U2 58
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD DEC
PY 2005
VL 5
IS 12
BP 2426
EP 2431
DI 10.1021/nl051679d
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 998YY
UT WOS:000234357000017
PM 16351191
DA 2022-11-30
ER

PT J
AU Huang, WC
   Cheng, F
   Chen, CC
   Kuo, PH
   Wang, YJ
   Yin, SC
   Tu, CM
   Wu, MH
   Wang, WY
   Chen, SE
AF Huang, Wen-Chia
   Cheng, Felice
   Chen, Chia-Ching
   Kuo, Po-Hsien
   Wang, Yen-Jen
   Yin, Shao-Chan
   Tu, Chia-Mu
   Wu, Ming-Hsi
   Wang, Wen-Yu
   Chen, Sung-En
TI A Novel Eye Drop Formulation for Potential Treatment of Neovascular
   Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE neovascular age-related macular degeneration; eye drops; posterior eye
   delivery
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTIONS; PAZOPANIB;
   MELANIN; MODEL
AB Purpose: Drug delivery to posterior ocular tissues via topical eye drop administration is arduous due to the unique anatomy and physiology of the eye. Therefore, treatments for posterior eye disease have to be administered via intravitreal injection or systemic route, both of which have their drawbacks. Herein, the objective of this work was to demonstrate that a specially designed eye drop formulation could effectively deliver small-molecule vascular endothelial growth factor (VEGF) inhibitor to posterior ocular tissues for antiangiogenic therapy.
   Methods: The unique eye drop formulation, termed ITRI AXN eye drops, was obtained from self-assembly of (2-hydroxypropyl)-beta-cyclodextrin with a VEGF tyrosine kinase inhibitor, a hydrophilic polymer, hypromellose, and a complex stabilizer, caffeine. In vivo ocular pharmacokinetics studies were performed with New Zealand White (NZW) rabbits and Non Human Primates (NHP). The antiangiogenesis effect was evaluated on the Long-Evans rat with laser-induced choroidal neovascularization and pigmented Dutch-Belted rabbits with VEGF-induced retinal neovascularization.
   Results: The successful drug transport from ocular surface to posterior ocular cavity was indicated by a drug biodistribution pattern in pharmacokinetic studies. Excellent drug exposure in the choroid and retina with the concentrations of 900- and 750-fold greater than drug IC50 0.5 hours post the eye drop administration (drug level: 0.8%) was observed on the NHP study. The obtained formulation also demonstrated a comparable antiangiogenic outcome with the intravitreal injection of anti-VEGF antibody on rat and rabbit disease models.
   Conclusions: Our eye drop formulation has demonstrated great promise in antiangiogenic therapy against retinal and choroidal neovascularization in animal models. The results suggest that the aim of this work can be successfully achieved by the novel eye drop formulation.
   Translational Relevance: The preclinical results provide evidence that ITRI AXN eye drops could effectively deliver therapeutics to the choroid and retina for antiangiogenic therapy.
C1 [Huang, Wen-Chia; Cheng, Felice; Chen, Chia-Ching; Kuo, Po-Hsien; Wang, Yen-Jen; Yin, Shao-Chan] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Target Drug & Delivery Technol Div, Dept Drug Delivery Technol, Hsinchu 300, Taiwan.
   [Tu, Chia-Mu; Wu, Ming-Hsi; Wang, Wen-Yu; Chen, Sung-En] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Target Drug & Delivery Technol Div, Dept Preclin Drug Discovery Technol, Hsinchu 300, Taiwan.
C3 Industrial Technology Research Institute - Taiwan; Industrial Technology
   Research Institute - Taiwan
RP Cheng, F (通讯作者)，Ind Technol Res Inst, Biomed Technol & Device Res Labs, Target Drug & Delivery Technol Div, Dept Drug Delivery Technol, Hsinchu 300, Taiwan.
EM itriA00563@itri.org.tw
FU Ministry of Economic Affairs, Republic of China (Taiwan)
   [110-EC-17-A-22-1651]
FX Supported by the Ministry of Economic Affairs, Republic of China
   (Taiwan) with Grant No. 110-EC-17-A-22-1651.
CR Agrahari V, 2016, DRUG DELIV TRANSL RE, V6, P735, DOI 10.1007/s13346-016-0339-2
   Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Boettger MK, 2015, INVEST OPHTH VIS SCI, V56
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Chen Y, 2013, CLIN PHARMACOKINET, V52, P713, DOI 10.1007/s40262-013-0068-3
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Durairaj C, 2012, EXP EYE RES, V98, P23, DOI 10.1016/j.exer.2012.03.004
   EMA, 2015, EUR EU CHMP ASS REP
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Horita S, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.545
   Huang WC, 2019, J DRUG DELIV SCI TEC, V54, DOI 10.1016/j.jddst.2019.101341
   Jakubiak P, 2019, MOL PHARMACEUT, V16, P2549, DOI 10.1021/acs.molpharmaceut.9b00157
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Li Y, 2018, EXP EYE RES, V174, P98, DOI 10.1016/j.exer.2018.05.027
   Loftsson T, 2012, J PHARM SCI-US, V101, P3019, DOI 10.1002/jps.23077
   Manzanares JA, 2016, MOL PHARMACEUT, V13, P1251, DOI 10.1021/acs.molpharmaceut.5b00783
   Mun EA, 2014, MOL PHARMACEUT, V11, P3556, DOI 10.1021/mp500332m
   Ozaki A, 2021, CASE REP OPHTHALM, V12, P48, DOI 10.1159/000510330
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Praphanwittaya P, 2020, J DRUG DELIV SCI TEC, V55, DOI 10.1016/j.jddst.2019.101462
   Rimpela AK, 2018, ADV DRUG DELIVER REV, V126, P23, DOI 10.1016/j.addr.2017.12.008
   Rimpela AK, 2018, J CONTROL RELEASE, V283, P261, DOI 10.1016/j.jconrel.2018.05.034
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
NR 28
TC 0
Z9 0
U1 2
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2021
VL 10
IS 14
AR 23
DI 10.1167/tvst.10.14.23
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XU8BO
UT WOS:000734483600001
PM 34932116
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ferrara, N
   Kerbel, RS
AF Ferrara, N
   Kerbel, RS
TI Angiogenesis as a therapeutic target
SO NATURE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; ANTI-VEGF
   ANTIBODY; CANCER STEM-CELLS; TUMOR ANGIOGENESIS; ENDOGENOUS INHIBITORS;
   VASCULAR-PERMEABILITY; MONOCLONAL-ANTIBODY; PROGENITOR CELLS; IN-VIVO
AB Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis ( promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
C1 Genentech Inc, San Francisco, CA 94080 USA.
   Univ Toronto, Toronto, ON M5G 2M9, Canada.
   Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5G 2M9, Canada.
C3 Roche Holding; Genentech; University of Toronto; University of Toronto;
   Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook
   Health Science Center
RP Ferrara, N (通讯作者)，Genentech Inc, 1DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
RI Yin, ming/F-3737-2012; Xiao, Yang/B-5668-2012
CR ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Bender JG, 2004, DRUG RESIST UPDATE, V7, P289, DOI 10.1016/j.drup.2004.09.001
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bertolini F, 2003, CANCER RES, V63, P4342
   Browder T, 2000, CANCER RES, V60, P1878
   Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871
   DIPIETRO LA, 1997, REGULATION ANGIOGENE, P295
   Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2
   Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Garner Alec, 1994, P1625
   GASPARINI G, 1912, J CLIN ONCOL, P23
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 2005, CANCER RES, V65, P671
   Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   Heinl-Green A, 2005, EUR HEART J, V26, P1327, DOI 10.1093/eurheartj/ehi223
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Herbst RS, 2002, J CLIN ONCOL, V20, P3792, DOI 10.1200/JCO.2002.11.061
   Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891
   Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022
   Jones RJ, 2004, JNCI-J NATL CANCER I, V96, P583, DOI 10.1093/jnci/djh095
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369
   Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858
   Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Klagsbrun M, 2005, CYTOKINE GROWTH F R, V16, P535, DOI 10.1016/j.cytogfr.2005.05.002
   Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   Lederman RJ, 2002, LANCET, V359, P2053, DOI 10.1016/S0140-6736(02)08937-7
   Lewis C, 2005, AM J PATHOL, V167, P627, DOI 10.1016/S0002-9440(10)62038-X
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457
   MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0
   Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098
   Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092
   Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427
   Oliner J, 2004, CANCER CELL, V6, P507, DOI 10.1016/j.ccr.2004.09.030
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959
   Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662
   Peters BA, 2005, NAT MED, V11, P261, DOI 10.1038/nm1200
   Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Prewett M, 1999, CANCER RES, V59, P5209
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702
   RAK J, 1995, CANCER RES, V55, P4575
   Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Samson M, 2004, J CLIN ENDOCR METAB, V89, P4078, DOI 10.1210/jc.2003-032024
   Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023
   Siemann DW, 2004, CANCER-AM CANCER SOC, V100, P2491, DOI 10.1002/cncr.20299
   Simons M, 2005, CIRCULATION, V111, P1556, DOI 10.1161/01.CIR.0000159345.00591.8F
   Smith JK, 2004, ONCOL RES, V14, P175, DOI 10.3727/000000003772462298
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Streubel B, 2004, NEW ENGL J MED, V351, P250, DOI 10.1056/NEJMoa033153
   Sund M, 2005, P NATL ACAD SCI USA, V102, P2934, DOI 10.1073/pnas.0500180102
   Sweeney CJ, 2001, CANCER RES, V61, P3369
   Sweeney CJ, 2003, TRENDS MOL MED, V9, P24, DOI 10.1016/S1471-4914(02)00007-2
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8
   Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8
   Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
   Webb T, 2003, J NATL CANCER I, V95, P774, DOI 10.1093/jnci/95.11.774
   Wey JS, 2005, CANCER-AM CANCER SOC, V104, P427, DOI 10.1002/cncr.21145
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8
   Wood JM, 2000, CANCER RES, V60, P2178
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327
NR 99
TC 2081
Z9 2245
U1 6
U2 360
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 15
PY 2005
VL 438
IS 7070
BP 967
EP 974
DI 10.1038/nature04483
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 993EC
UT WOS:000233934600056
PM 16355214
DA 2022-11-30
ER

PT J
AU Liu, YL
   Li, RC
   Xie, J
   Hu, JH
   Huang, XD
   Ren, F
   Li, LH
AF Liu, Yanli
   Li, Ruichan
   Xie, Jing
   Hu, Jiehua
   Huang, Xudong
   Ren, Fu
   Li, Lihua
TI Protective Effect of Hydrogen on Sodium Iodate-Induced Age-Related
   Macular Degeneration in Mice
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE hydrogen; sirtl; oxidative stress; apoptosis; AMD
ID INDUCED RETINAL DEGENERATION; LIGHT-INDUCED DAMAGE; RICH SALINE;
   OXIDATIVE STRESS; CELL-DEATH; DIABETIC-RATS; BRAIN-INJURY; SIRT1; WATER;
   APOPTOSIS
AB Oxidative stress is one of the main causes of AMD. Hydrogen has anti-oxidative stress and apoptotic effects on retinal injury. However, the effect of hydrogen on AMD is not clear. In this study, fundus radiography, OCT, and FFA demonstrated that HRW reduced the deposition of drusen-like structures in RPE layer, prevented retina from thinning and leakage of ocular fundus vasculature induced by NaIO3. ERG analysis confirmed that HRW effectively reversed the decrease of a-wave and b-wave amplitude in NaIO3-mice. Mechanistically, HRW greatly reduced the oxidative stress reaction through decreased MDA levels, increased SOD production, and decreased ROS content. The OGG1 expression was downregulated which is a marker of oxidative stress. Involvement of oxidative stress was confirmed using oxidative stress inhibitor ALCAR. Moreover, oxidative stress reaction was associated with expression of Sirt1 level and HRW significantly inhibited the downregulation of Sirt1 expression. This result was further confirmed with AICAR which restore Sirt1 expression and activity. In addition, NaIO3-induced retinal damage was related to apoptosis via caspase 8 and caspase 9, but not the caspase 3 pathways, which led to upregulation of Bax and p53, downregulation of BcI-2, and increase in Jc-1-positive cells in mice. However, HRW effectively reversed these effects that apoptosis induced. These results suggest that HRW protects retinal functions against oxidative stress injury through inhibiting downregulation of Sirt1 and reducing retinal apoptosis. Therefore, we speculated that hydrogen administration is a promising treatment for AMD therapy.
C1 [Liu, Yanli; Li, Ruichan; Xie, Jing; Li, Lihua] Taizhou Univ, Dept Cell Biol, Taizhou, Peoples R China.
   [Hu, Jiehua] Naval Univ Engn, Logist Coll, Informat Ctr, Tianjin, Peoples R China.
   [Huang, Xudong] Chengdu Normal Univ, Chem & Life Coll, Chengdu, Sichuan, Peoples R China.
   [Ren, Fu] Jinzhou Med Univ, Biol Anthropol Inst, Jinzhou, Peoples R China.
C3 Taizhou University; Wuhan Naval University of Engineering; Chengdu
   Normal University; Jinzhou Medical University
RP Li, LH (通讯作者)，Taizhou Univ, Dept Cell Biol, Taizhou, Peoples R China.
EM lilihua1018@sina.com
FU Natural Science Foundation of Liaoning Province [201602292]; Liaoning
   BaiQianWan Talents Program [2017101]; Liaoning Distinguished Professor
   Project [LNTP20183501]
FX This study was supported by the Natural Science Foundation of Liaoning
   Province (No. 201602292), Liaoning BaiQianWan Talents Program (No.
   2017101), and Liaoning Distinguished Professor Project (No.
   LNTP20183501).
CR Balaiya S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3187594
   Balmer J, 2015, INT J MOL SCI, V16, P15086, DOI 10.3390/ijms160715086
   Berkowitz BA, 2017, INVEST OPHTH VIS SCI, V58, P3286, DOI 10.1167/iovs.17-21850
   Bjorklund G, 2018, BASIC CLIN PHARMACOL, V122, P539, DOI 10.1111/bcpt.12972
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Chen KY, 2017, CELL PHYSIOL BIOCHEM, V43, P1634, DOI 10.1159/000484024
   Chen T, 2016, EXP EYE RES, V148, P65, DOI 10.1016/j.exer.2016.05.017
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   CHUNG YR, 2017, RES, V2017, DOI DOI 10.1155/2017/1763292
   Du HY, 2016, TRANSPLANTATION, V100, P563, DOI 10.1097/TP.0000000000001052
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ge L, 2017, ONCOTARGET, V8, P42314, DOI 10.18632/oncotarget.15876
   Gu XY, 2018, MOL MED REP, V17, P5402, DOI 10.3892/mmr.2018.8482
   Guo JL, 2017, INT ORTHOP, V41, P2119, DOI 10.1007/s00264-017-3581-4
   Han CF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01654-6
   He X, 2016, CHINESE MED J-PEKING, V129, P2331, DOI 10.4103/0366-6999.190668
   He XF, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15893
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hou M, 2017, CELL PHYSIOL BIOCHEM, V43, P1767, DOI 10.1159/000484063
   Jaliffa C, 2009, INVEST OPHTH VIS SCI, V50, P3562, DOI 10.1167/iovs.08-2817
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Kurokawa R, 2015, MED GAS RES, V5, DOI 10.1186/s13618-015-0034-2
   Li J, 2017, MOL VIS, V23, P149
   Li X, 2017, FRONT PLANT SCI, V8, P1, DOI DOI 10.18632/0NC0TARGET.22237
   Lin CP, 2017, WORLD J GASTROENTERO, V23, P4920, DOI 10.3748/wjg.v23.i27.4920
   Liu FT, 2014, CNS NEUROSCI THER, V20, P778, DOI 10.1111/cns.12258
   Liu S, 2017, EXP THER MED, V14, P5057, DOI 10.3892/etm.2017.5165
   Liu ZB, 2017, EXP BIOL MED, V242, P1534, DOI 10.1177/1535370217725249
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizuno K, 2017, MED GAS RES, V7, P247, DOI 10.4103/2045-9912.222448
   Morigi M, 2015, J CLIN INVEST, V125, P715, DOI 10.1172/JCI77632
   Nakao A, 2010, J CLIN BIOCHEM NUTR, V46, P140, DOI 10.3164/jcbn.09-100
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Qi LS, 2015, INVEST OPHTH VIS SCI, V56, P8268, DOI 10.1167/iovs.15-17034
   Rakoczy EP, 2017, LANCET, V390, P6, DOI 10.1016/S0140-6736(17)31262-X
   Shao AW, 2016, MOL NEUROBIOL, V53, P18, DOI 10.1007/s12035-014-8986-0
   Song HM, 2016, INVEST OPHTH VIS SCI, V57, P2864, DOI 10.1167/iovs.15-18974
   Sun HY, 2011, J HEPATOL, V54, P471, DOI 10.1016/j.jhep.2010.08.011
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
   Takeuchi S, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0165-3
   Tao X, 2017, BIOCHEM BIOPH RES CO, V494, P615, DOI 10.1016/j.bbrc.2017.09.154
   Tian L, 2013, MED GAS RES, V3, DOI 10.1186/2045-9912-3-19
   Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang YX, 2015, TOXINS, V7, P3030, DOI 10.3390/toxins7083030
   Wu MJ, 2017, MED GAS RES, V7, P101, DOI 10.4103/2045-9912.208515
   Xie KL, 2012, SHOCK, V37, P548, DOI 10.1097/SHK.0b013e31824ddc81
   Xin HG, 2014, MOL CELL BIOCHEM, V392, P117, DOI 10.1007/s11010-014-2024-4
   Yang Xi-hua, 2012, Cancer Biology Medicine, V9, P261, DOI 10.7497/j.issn.2095-3941.2012.04.007
   Yang Y, 2013, FREE RADICAL BIO MED, V65, P667, DOI 10.1016/j.freeradbiomed.2013.07.007
   Yao HL, 2018, MOL MED REP, V17, P6681, DOI 10.3892/mmr.2018.8657
   Zeng Y, 2016, EXP EYE RES, V151, P203, DOI 10.1016/j.exer.2016.05.002
   Zeng Y, 2015, BIOCHEM BIOPH RES CO, V468, P167, DOI 10.1016/j.bbrc.2015.10.139
   Zheng TY, 2016, CURR EYE RES, V41, P1068, DOI 10.3109/02713683.2015.1093641
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zieger M, 2016, ONCOTARGET, V7, P9620, DOI 10.18632/oncotarget.7330
NR 57
TC 17
Z9 18
U1 3
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD DEC 4
PY 2018
VL 10
AR 389
DI 10.3389/fnagi.2018.00389
PG 11
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA HC8OA
UT WOS:000452061700001
PM 30564112
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cebeci, Z
   Yilmaz, YC
   Kir, N
AF Cebeci, Zafer
   Yilmaz, Yusuf Cem
   Kir, Nur
TI Real-life experience of ranibizumab therapy for neovascular age-related
   macular degeneration from Turkey
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; visual acuity; ranibizumab; retina; optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; 2.0 MG RANIBIZUMAB; EFFICACY; SAFETY;
   VERTEPORFIN; OUTCOMES; TRIAL; AMD
AB AIM: To report the real-life experience and clinical results of intravitreal ranibizumab injections to neovascular agerelated macular degeneration (nAMD) in a single institution in Turkey.
   METHODS: A total of 101 eyes of 89 patients with nAMD treated with intravitreal ranibizumab injection, followed up for at least 24mo between 2009 and June 2014, which were evaluated retrospectively. A pro re nata (PRN) treatment protocol was performed after the patients had received three, monthly loading injections. Best corrected visual acuity (BCVA) and central macular thickness measurements were evaluated at baseline and 3, 6, 12, 18, and 24mo. Number of injections and visits were also recorded.
   RESULTS: Of the 89 patients, 34 (38.2%) were male and 55 (61.8%) were female and the mean age was 74.0 +/- 9.5 (52-91) y. The mean follow-up period was 24.82 +/- 4.4 (2429) mo. Mean number of visits was 8.4 +/- 1.12 (7-12) in the first year and 6.6 +/- 1.33 (4-12) in the second year. The mean number of injections was 5.8 +/- 1.6 (3-10) and 4.2 +/- 2.2 (0-9) in the first and second year, respectively. The mean BCVA was 59 +/- 15.8 letters at baseline by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean BCVA at 3, 12, and 24mo was 70.3 +/- 15.9, 67.9 +/- 14.3 and 67.3 +/- 16.9 letters, respectively. Improvement in visual acuity for each of the visits from baseline was found to be statistically significant (P<0.01). Visual acuity in 9 eyes at month 3, 7 eyes at month 12, and 13 eyes at month 24 did not change. The mean central macular thickness (CMT) was 437.99 +/- 164.78 mu m at baseline. The mean CMT was 348.05 +/- 138.47 mu m, 349.27 +/- 139.79 mu m, and 344.13 +/- 146.30 mu m at months 3, 12, and 24, respectively. The decrease in CMT for each of the visits from baseline was found to be statistically significant (P<0.01).
   CONCLUSION: Anatomical and functional achievement are obtained in our study, but the mean number of injections and visits are found to be lower than the findings reported in randomized controlled clinical trials in the literature. However, the mean number of injections and visits in our study are compatible with the findings reported in real-life experience studies in the literature.
C1 [Cebeci, Zafer; Yilmaz, Yusuf Cem; Kir, Nur] Istanbul Univ, Dept Ophthalmol, Istanbul Fac Med, TR-34104 Istanbul, Turkey.
C3 Istanbul University
RP Cebeci, Z (通讯作者)，Istanbul Univ, Dept Ophthalmol, Istanbul Fac Med, TR-34104 Istanbul, Turkey.
EM zafceb@gmail.com
RI cebeci, zafer/AAD-5110-2020; Kir, Nur/AAT-9664-2020
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Canan H, 2014, CLIN INTERV AGING, V9, P141, DOI 10.2147/CIA.S56863
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Kiss S, 2014, OSLI RETINA, V45, P285, DOI 10.3928/23258160-20140709-04
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ozkaya A, 2013, ISRN OPHTHALMOL, V2013
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 29
TC 4
Z9 4
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2018
VL 11
IS 2
BP 267
EP 273
DI 10.18240/ijo.2018.02.15
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FV7ZE
UT WOS:000424803700015
PM 29487818
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Park, CH
   Smith, BT
   Oh, M
   Fekrat, S
AF Park, Carl H.
   Smith, Bradley T.
   Oh, Mila
   Fekrat, Sharon
TI Optical coherence tomography following photodynamic therapy with
   verteporfin for subfoveal predominantly classic choroidal
   neovascularization
SO ANNALS OF OPHTHALMOLOGY
LA English
DT Article
AB We characterized the changes in optical coherence tomography following photodynamic therapy (PDT) for subfoveal predominantly classic choroidal neovascularization (CNV) in 26 eyes before, 1 week after, and 3 months after treatment. There appears to be a temporal decrease in central retinal thickness, increase in central retinal pigment epithelium/CNV complex thickness, and decrease in subretinal fluid following PDT, making it a useful adjunct in the management of CNV clue to of age-related macular degeneration.
C1 [Fekrat, Sharon] Duke Univ, Ctr Eye, Albert Eye Res Inst, Durham, NC 27710 USA.
   [Park, Carl H.; Smith, Bradley T.] Thomas Jefferson Univ, Wills Eye Hosp, Philadelphia, PA 19107 USA.
   [Oh, Mila] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
C3 Duke University; Jefferson University; McGill University
RP Fekrat, S (通讯作者)，Duke Univ, Ctr Eye, Albert Eye Res Inst, Box 3802,Erwin Rd, Durham, NC 27710 USA.
EM fekra001@mc.duke.edu
RI Smith, Bradley/ABB-2596-2021
CR [Anonymous], PRELIMINARY PHASE 3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Massin P, 2001, AM J OPHTHALMOL, V132, P599, DOI 10.1016/S0002-9394(01)01015-7
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 17
TC 2
Z9 2
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1530-4086
J9 ANN OPHTHALMOL
JI Ann. Ophthalmol.
PD SUM
PY 2006
VL 38
IS 2
BP 121
EP 125
DI 10.1385/AO:38:2:121
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V49IW
UT WOS:000203335400008
PM 17416941
DA 2022-11-30
ER

PT J
AU Emerich, DF
   Thanos, CG
AF Emerich, Dwaine F.
   Thanos, Christopher G.
TI NT-501: An ophthalmic implant of polymer-encapsulated ciliary
   neurotrophic factor-producing cells
SO CURRENT OPINION IN MOLECULAR THERAPEUTICS
LA English
DT Article
ID MACULAR DEGENERATION; INTRAOCULAR DELIVERY; RETINAL DEGENERATION;
   HUNTINGTONS-DISEASE; FACTOR CNTF; THERAPY; MODEL; RABBIT; MOTOR
AB Neurotech Pharmaceuticals Inc is developing NT-501, an implantable polymeric device containing a genetically modified cell line that secretes ciliary neurotrophic factor, for the potential treatment of retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Phase III clinical trials for RP and a phase II clinical trial for dry AMD are ongoing. A phase I clinical trial showed that NT-501 treatment was well tolerated with variable, but positive improvements in visual acuity.
C1 [Emerich, Dwaine F.] InCytu Inc, Lincoln, RI 02865 USA.
   [Thanos, Christopher G.] Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.
C3 Brown University
RP Emerich, DF (通讯作者)，InCytu Inc, 701 George Washington Highway, Lincoln, RI 02865 USA.
EM emerich@incytu.com
CR AEBISCHER P, 1988, BRAIN RES, V448, P364, DOI 10.1016/0006-8993(88)91278-4
   Aebischer P, 1996, HUM GENE THER, V7, P851, DOI 10.1089/hum.1996.7.7-851
   Bush RA, 2004, INVEST OPHTH VIS SCI, V45, P2420, DOI 10.1167/iovs.03-1342
   BUSH RA, 2004, INVEST OPHTHALMOL VI, V45
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Dejneka NS, 2008, MOL VIS, V14, P997
   Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0
   Emerich DF, 1997, CELL TRANSPLANT, V6, P249, DOI 10.1016/S0963-6897(97)00035-3
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GODDARD MB, 2002, INVEST OPHTHALMOL VI, V43
   Goodwin P, 2008, CURR OPIN OPHTHALMOL, V19, P255, DOI 10.1097/ICU.0b013e3282fc27fc
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ho AC, 2003, RETINA COLOR ATLAS S
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeon Y, 2006, TRANSPL P, V38, P3061, DOI 10.1016/j.transproceed.2006.08.098
   KAUPER KA, 2003, INVEST OPHTHALMOL VI, V44
   KAUPER KA, 2007, INVEST OPHTHALMOL VI, V48
   KAUPER KA, 2006, INVEST OPHTHALMOL VI, V47
   KAUPER KA, 2004, INVEST OPHTHALMOL S2, V45
   KAUPER KA, 2002, INVEST OPHTHALMOL VI, V43
   KAUPER KA, 2005, INVEST OPHTHALMOL S, V46
   LEI B, 2002, INVEST OPHTHALMOL VI, V43
   LEVYJ, 2008, INT OPHTHALMOL
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P5756, DOI 10.1167/iovs.07-0054
   MCGOVERN C, 2007, INVEST OPHTHALMOL VI, V48
   MCGOVERN C, 2005, INVEST OPHTHALMOL VI, V46
   MCGOVERN C, 2008, INVEST OPHTHALMOL VI, V49
   MCGOVERN C, 2006, INVEST OPHTHALMOL VI, V47
   SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   SIEVING PA, 2005, ABSTR SOC NEUR, V35
   SIEVING PA, 2005, INVEST OPHTHALMOL SS, V46
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tao W, 2001, INVEST OPHTH VIS SCI, V42, pS173
   TAO W, 2005, INVEST OPHTHALMOL VI, V46
   TAO W, 2004, INVEST OPHTHALMOL S2, V45
   TAO W, 2003, INVEST OPHTHALMOL VI, V44
   TAO W, 2002, INVEST OPHTHALMOL VI, V43
   TENTE W, 2004, INVEST OPHTHALMOL S2, V45
   TENTE W, 2003, INVEST OPHTHALMOL VI, V44
   Thanos C, 2005, EXPERT OPIN BIOL TH, V5, P1443, DOI 10.1517/14712598.5.11.1443
   Thanos CG, 2004, TISSUE ENG, V10, P1617, DOI 10.1089/ten.2004.10.1617
   THANOS CG, 2003, INVEST OPHTHALMOL VI, V44
   THOMAS CG, 2004, INVEST OPHTHALMOL S2, V45
   WEN R, 2008, INVEST OPHTHALMOL VI, V49
   Wen R, 2006, J NEUROSCI, V26, P13523, DOI 10.1523/JNEUROSCI.4021-06.2006
   Zeiss CJ, 2006, EXP EYE RES, V82, P395, DOI 10.1016/j.exer.2005.07.014
   2008, NCT00063765 EVALUATI
   2008, NCT00447954 STUDY EN
   2007, NCT00447993 STUDY EN
   2008, NCT00277134 PHASE 2
   2007, NCT00447980 STUDY EN
NR 56
TC 65
Z9 67
U1 0
U2 4
PU THOMSON SCIENTIFIC
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND STREET, LONDON, W1T 4JE, ENGLAND
SN 1464-8431
J9 CURR OPIN MOL THER
JI Curr. Opin. Mol. Ther.
PD OCT
PY 2008
VL 10
IS 5
BP 506
EP 515
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 354ZW
UT WOS:000259679400010
PM 18830926
DA 2022-11-30
ER

PT J
AU Nayak, S
   Padhi, TR
   Basu, S
   Das, T
AF Nayak, Sameera
   Padhi, Tapas Ranjan
   Basu, Soumyava
   Das, Taraprasad
TI Pneumatic Displacement and Intra-vitreal Bevacizumab in Management of
   Sub-retinal and Sub-retinal Pigment Epithelial Hemorrhage at Macula in
   Polypoidal Choroidal Vasculopathy (PCV): Rationale and Outcome
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; polypoidal choroidal vasculopathy; sub-retinal hemorrhage;
   sub-retinal pigment epithelial hemorrhage
ID INTRAVITREAL BEVACIZUMAB; SUBMACULAR HEMORRHAGE; PHOTODYNAMIC THERAPY;
   GAS
AB We report three cases of submacular haemorrhage due to polypoidal choroidal vasculopathy (PCV) treated with intravitreal bevacizumab and pneumatic displacement with perfluoropropane (C3F8) gas. The patients were between 45 to 55 years and presented with reduction of vision (20/400 to 20/80) within two weeks of onset of symptoms. The submacular (sub-retinal plus sub-retinal pigment epithelium [RPE]) hemorrhages was confirmed as PCV on indocyanine green angiography and optical coherence tomography in all of them. They were treated with intravitreal bevacizumab (1.25 mg/0.05 ml) and 0.3 ml of 100% C3F8 gas in the affected eye followed by prone positioning for two weeks. The vision and macular anatomy started improving within a week and continued up to three months. These cases demonstrate that pneumatic displacement combined with intravitreal anti-VEGF injection could be a promising option in patients with PCV and sub-macular blood, even when the blood is beneath the RPE.
C1 [Nayak, Sameera; Padhi, Tapas Ranjan; Basu, Soumyava; Das, Taraprasad] LV Prasad Eye Inst, Retina & Vitreous Serv, Bhubaneswar, Orissa, India.
C3 L. V. Prasad Eye Institute
RP Padhi, TR (通讯作者)，LV Prasad Eye Inst, Retina Serv, Bhubaneswar, Orissa, India.
EM drtapasranjan@yahoo.co.in
FU Hyderabad Eye Research Foundation, Hyderabad, India
FX The authors are grateful for support from the Hyderabad Eye Research
   Foundation, Hyderabad, India.
CR Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Pathengay A, 2005, EYE, V19, P929, DOI 10.1038/sj.eye.6701688
NR 6
TC 8
Z9 8
U1 0
U2 3
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD JAN
PY 2015
VL 30
IS 1
BP 53
EP 55
DI 10.3109/08820538.2013.807849
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW7YT
UT WOS:000346478400010
PM 23947424
DA 2022-11-30
ER

PT J
AU Toprak, I
   Yaylali, V
   Yildirim, C
AF Toprak, Ibrahim
   Yaylali, Volkan
   Yildirim, Cem
TI Early deterioration in ellipsoid zone in eyes with non-neovascular
   age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusen; Ellipsoid zone; Optical
   coherence tomography; Photoreceptor; Reflectivity
ID OPTICAL COHERENCE TOMOGRAPHY; DRUSEN; REFLECTIVITY; LAYER
AB The purpose of this study was to investigate the early effects of soft drusen on retinal pigment epithelium (RPE), ellipsoid zone (EZ, photoreceptor inner segment/outer segment junction), and external limiting membrane (ELM) reflectivities using optical coherence tomography (OCT) image analysis. This retrospective comparative study comprised 47 patients with non-neovascular AMD (with intact RPE, EZ, and ELM bands on OCT) and 45 age- and sex-matched healthy controls with normal OCT. A single masked physician performed OCT image analysis using a medical image processing software. Reflectivities of RPE, EZ, and ELM; number of drusen; vertical and horizontal diameters of the largest druse; druse reflectivity; foveal involvement by a druse; and presence of >= 1 large druse (n) were evaluated based on the macular OCT scan. Forty-seven right eyes of 47 patients with non-neovascular AMD and 45 right eyes of 45 healthy subjects were recruited. In the non-neovascular AMD group, absolute EZ and RPE reflectivities were significantly lower compared to those of the control eyes (P < 0.001 and P = 0.001, respectively). Comparing relative reflectivity values, only relative EZ reflectivity (EZ/ELM reflectivity) remained to show a significant difference between the groups (P < 0.001). Correlation analyses revealed no significant relation between the reflectivity values and drusen characteristics (P > 0.05). In eyes with non-neovascular AMD, decreased RPE (only absolute) and EZ (both absolute and relative) reflectivities prior to the disruption of these layers on OCT might indicate early photoreceptor damage. However, lower reflectivity values appear to be independent of the drusen characteristics.
C1 [Toprak, Ibrahim] Servergazi State Hosp, Dept Ophthalmol, Bereketli Beldesi, Denizli, Turkey.
   [Yaylali, Volkan; Yildirim, Cem] Pamukkale Univ, Fac Med, Dept Ophthalmol, Denizli, Turkey.
C3 Servergazi State Hospital; Pamukkale University
RP Toprak, I (通讯作者)，Servergazi State Hosp, Dept Ophthalmol, Bereketli Beldesi, Denizli, Turkey.
EM ibrahimt@doctor.com
RI Toprak, Ibrahim/V-6906-2017
OI Toprak, Ibrahim/0000-0001-6325-7485
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bizheva K, 2006, P NATL ACAD SCI USA, V103, P5066, DOI 10.1073/pnas.0506997103
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Inoue M, 2009, GRAEF ARCH CLIN EXP, V247, P325, DOI 10.1007/s00417-008-0999-9
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Murakami T, 2012, INVEST OPHTH VIS SCI, V53, P1506, DOI 10.1167/iovs.11-9231
   Oh J, 2010, INVEST OPHTH VIS SCI, V51, P1651, DOI 10.1167/iovs.09-4420
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rasband W, 2014, IMAGE J MED IMAGING
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Toprak I, 2014, EYE, V28, P1126, DOI 10.1038/eye.2014.147
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhao WJ, 2014, INT J OPHTHALMOL-CHI, V7, P71, DOI 10.3980/j.issn.2222-3959.2014.01.13
NR 21
TC 9
Z9 9
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD AUG
PY 2017
VL 37
IS 4
BP 801
EP 806
DI 10.1007/s10792-016-0331-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FB2ZC
UT WOS:000406011300005
PM 27591785
DA 2022-11-30
ER

PT J
AU Bakri, SJ
   Kaiser, PK
AF Bakri, SJ
   Kaiser, PK
TI Verteporfin ocular photodynamic therapy
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE choroidal neovascularisation; macular degeneration; ocular
   histoplasmosis; pathologic myopia; photodynamic therapy; verteporfin;
   visudyne
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; HISTOPLASMOSIS SYNDROME; PATHOLOGICAL MYOPIA; HEMANGIOMA;
   PREVALENCE; INFUSION
AB This article reviews the pharmacotherapeutics of verteporfin (Visudyne(R), Novartis Pharma AG) used in ocular photodynamic therapy. The chemistry, pharmacokinetics and pharmacodynamics of the drug are reviewed. The article highlights and summarises the results of the multi-centre, randomised, controlled clinical trials with verteporfin to treat subfoveal choroidal neovascularisation in age-related macular degeneration, ocular histoplasmosis syndrome and pathologic myopia. In addition, the safety profile and side effects of verteporfin are discussed.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM kaiserp@ccf.org
OI Kaiser, Peter/0000-0001-5126-045X
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2000, GRAEF ARCH CLIN EXP, V238, P214, DOI 10.1007/s004170050346
   BERKOW JW, 1984, AM J OPHTHALMOL, V97, P143, DOI 10.1016/S0002-9394(14)76083-0
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borodoker N, 2002, AM J OPHTHALMOL, V133, P211, DOI 10.1016/S0002-9394(01)01341-1
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   Canakis C, 2003, AM J OPHTHALMOL, V136, P750, DOI 10.1016/S0002-9394(03)00397-0
   Hikichi T, 2001, RETINA-J RET VIT DIS, V21, P126, DOI 10.1097/00006982-200104000-00005
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   KAISER PK, IN PRESS ARCH OPHTHA
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Madreperla SA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1606
   Miller, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Porrini G, 2003, OPHTHALMOLOGY, V110, P674, DOI 10.1016/S0161-6420(02)01968-1
   Robertson DM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1155
   Rogers AH, 2003, OPHTHALMOLOGY, V110, P1315, DOI 10.1016/S0161-6420(03)00466-4
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   SCHMIDT ER, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097/00006982-200210000-00003
   *THOMS HLTH, PHYS DESK REF
   Tornambe PE, 2002, ARCH OPHTHALMOL-CHIC, V120, P872
   *VET PHOT THER STU, 2001, OPHTHALMOLOGY, V108, P841
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
NR 41
TC 22
Z9 22
U1 5
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD JAN
PY 2004
VL 5
IS 1
BP 195
EP 203
DI 10.1517/14656566.5.1.195
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 759YG
UT WOS:000187782000019
PM 14680447
DA 2022-11-30
ER

PT J
AU Lenoble, Q
   Corveleyn, X
   Tran, TH
   Rouland, JF
   Boucart, M
AF Lenoble, Quentin
   Corveleyn, Xavier
   Tran, Thi Ha Chau
   Rouland, Jean-Francois
   Boucart, Muriel
TI Can I reach it? A study in age-related macular degeneration and glaucoma
   patients
SO VISUAL COGNITION
LA English
DT Article
DE Glaucoma; AMD; ageing; reachability; perception; cognition
AB Aims: The visual exploration and the ability to correctly locate a target in reaching an object are critical in daily life. We investigate the object reachability judgment in neovascular age-related macular disease (nAMD) and primary open-angle glaucoma patients (POAG). Methods: Sixty-three participants were recruited in 4 groups (15 nAMD, 15 POAG, 18 old controls and 15 young controls). For each trial a cylinder moved between 11 random distances (from the border of their own peripersonal space 0, +/- 3, +/- 6, +/-, +/- 12, +/- 15 cm). Participants had to estimate if they thought that the object was reachable or not. Results: POAG patients estimated that they could reach targets that were farther than their own peripersonal space (increased by 5.8 cm compared to the three other groups: 2.6 cm). The performance of the nAMD group and the normally sighted group were equivalent. Conclusions: The present study highlights the hypothesis of reach and grasps impairments in POAG due to difficulties in the estimation of reachability which is the beginning of any motor action processing. The reachability judgment of the nAMD patients is not affected. We conclude that POAG can modify the perceived peripersonal space of the patients and induce changes in the reachability judgment.
C1 [Lenoble, Quentin; Corveleyn, Xavier; Rouland, Jean-Francois; Boucart, Muriel] Univ Lille, SCALab, UMR CNRS 9193, Lille, France.
   [Corveleyn, Xavier] Univ Cote dAzur, Lab Anthropol & Psychol Cognit & Sociales LAPCOS, Nice, France.
   [Tran, Thi Ha Chau] Lille Catholic Univ, Catholic Hosp, Ophthalmol Dept, Lille, France.
   [Rouland, Jean-Francois] Univ Lille, Claude Huriez Hosp, Ophthalmol Dept, Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute
   for Humanities & Social Sciences (INSHS); Universite de Lille - ISITE;
   Universite de Lille; UDICE-French Research Universities; Universite Cote
   d'Azur; Universite de Lille - ISITE; CHU Lille; Universite de Lille
RP Lenoble, Q (通讯作者)，Pole Rech, Fac Med Lille, 5iem & Ouest,1 Pl Verdun, F-59000 Lille, France.
EM quentin.lenoble@univ-lille.fr
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
FU Centre National de la Recherche Scientifique [PICS-CNRS-2015]; Societe
   Francaise du Glaucome [SFG-2015]
FX This work was supported by Centre National de la Recherche Scientifique
   [grant number PICS-CNRS-2015]; Societe Francaise du Glaucome [grant
   number SFG-2015].
NR 0
TC 1
Z9 1
U1 1
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1350-6285
EI 1464-0716
J9 VIS COGN
JI Vis. Cogn.
PD NOV 26
PY 2019
VL 27
IS 9-10
BP 732
EP 739
DI 10.1080/13506285.2019.1661319
PG 8
WC Psychology, Experimental
WE Social Science Citation Index (SSCI)
SC Psychology
GA 1X0SU
UT WOS:000807175000006
DA 2022-11-30
ER

PT J
AU Chang, AA
   Zhu, M
   Billson, FA
   Chang, AA
   Chang, AA
   Kumar, NL
   Beaumont, PE
AF Chang, AA
   Zhu, M
   Billson, FA
   Chang, AA
   Chang, AA
   Kumar, NL
   Beaumont, PE
TI Indocyanine green localisation in surgically excised choroidal
   neovascular membrane in age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CLINICOPATHOLOGICAL CORRELATION; ANGIOGRAPHY
C1 Univ Sydney, Dept Clin Ophthalmol, Sydney, NSW 2001, Australia.
   Univ Sydney, Save Sight Inst, Sydney, NSW 2001, Australia.
   Sydney Eye Hosp, Sydney, NSW, Australia.
   Sydney Retina Clin, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney
RP Chang, AA (通讯作者)，Univ Sydney, Dept Clin Ophthalmol, GPO Box 4337, Sydney, NSW 2001, Australia.
EM achang@sydneyretina.com.au; achang@sydneyretina.com.au;
   achang@sydneyretina.com.au
CR Chang AA, 1998, OPHTHALMOLOGY, V105, P1060, DOI 10.1016/S0161-6420(98)96008-0
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   CHERRICK GR, 1960, J CLIN INVEST, V39, P592, DOI 10.1172/JCI104072
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   Lafaut BA, 2001, GRAEF ARCH CLIN EXP, V239, P5, DOI 10.1007/s004170000224
   LIM JI, 1995, AM J OPHTHALMOL, V120, P75, DOI 10.1016/S0002-9394(14)73761-4
   MATSUBARA T, 1995, JPN J CLIN OPHTHAL, V49, P25
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 10
TC 9
Z9 10
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB 1
PY 2004
VL 88
IS 2
BP 307
EP 309
DI 10.1136/bjo.2003.024893
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 765UT
UT WOS:000188302800041
PM 14736801
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Schlingemann, RO
AF Schlingemann, RO
TI Role of growth factors and the wound healing response in age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULAR MEMBRANES;
   ENDOTHELIAL-CELLS; FACTOR VEGF; EXPRESSION; ANGIOGENESIS;
   CHORIOCAPILLARIS; DIFFERENTIATION; PATHOGENESIS; LOCALIZATION
AB Growth factors (GF) are important in several stages of the pathogenesis of age-related macular disease (AMD). In choroidal neovascularization (CNV) in exudative AMD, the GF involved are similar to those involved in wound healing of the skin. Like granulation tissue of skin, CNV is characterized by clotting, inflammation, angiogenesis and fibrosis, and like in skin wounds, members of the VEGF, angiopoietin, PDGF and TGF-beta families of GF are expressed. However, several of these GF may also serve physiological functions in the normal eye, where the retinal pigment epithelium (RPE) employs them to provide trophic support to the neuroretina and choriocapillaris, in addition to maintaining an anti-angiogenic state. Derangement of these physiological functions may underlie the initiation of CNV in AMD. Basolateral secretion of VEGF-A by the RPE maintains the choriocapillaris, and is enhanced by hypoxia. Age-related changes in Bruch's membrane lead to impairment of this trophic function and choriocapillaris atrophy, as well as to decreased diffusion of oxygen towards the neuroretina. The resulting outer retina hypoxia may be an important driving force of CNV formation, by stimulating VEGF overexpression by the RPE, in addition to the effects of increased oxidative stress and low-grade inflammation. RPE senescence and hypoxia may also decrease expression of angiogenesis inhibitors such as PEDF, further shifting the balance to a pro-angiogenic state in the aging eye.
C1 Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Ocular Angiogenesis Grp, NL-1105 AZ Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam
RP Schlingemann, RO (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Ocular Angiogenesis Grp, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.
EM r.schlingemann@amc.uva.nl
CR Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Folkman J, 1997, EXS, V79, P1
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREENLEE WF, 1991, RISK ANAL, V11, P565, DOI 10.1111/j.1539-6924.1991.tb00642.x
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hackett SF, 1998, BRAIN RES, V789, P201, DOI 10.1016/S0006-8993(97)01440-6
   Hangai M, 2001, INVEST OPHTH VIS SCI, V42, P1617
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Hinton DR, 2002, EYE, V16, P422, DOI 10.1038/sj.eye.6700190
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672
   Ishida K, 1997, CURR EYE RES, V16, P96, DOI 10.1076/ceyr.16.2.96.5093
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   LAFAUT BA, 2000, B SOC BELGE OPHTALMO, V278, P49
   Li J, 2003, MICROSC RES TECHNIQ, V60, P107, DOI 10.1002/jemt.10249
   Liu XP, 1997, EXP EYE RES, V65, P117, DOI 10.1006/exer.1997.0317
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x
   Luttun A., 2002, NAT MED, V1, P1
   Lutty G, 1999, MOL VIS, V5
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SCHLINGEMANN RO, 1991, AM J PATHOL, V138, P1335
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   THURSTON G, 2003, IN PRESS CELL TISSUE
   TOBE T, 1994, J JPN OPHTHALMOL SOC, V98, P837
   UYAMA M, 1991, Nippon Ganka Gakkai Zasshi, V95, P1145
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
   Zhao J, 2000, Yan Ke Xue Bao, V16, P11
   Zhao SL, 2001, MOL VIS, V7, P277
   Zhao SL, 1997, INT REV CYTOL, V171, P225
NR 75
TC 225
Z9 243
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2004
VL 242
IS 1
BP 91
EP 101
DI 10.1007/s00417-003-0828-0
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 766PU
UT WOS:000188385400015
PM 14685874
DA 2022-11-30
ER

PT J
AU You, QS
   Bartsch, DUG
   Espina, M
   Alam, M
   Camacho, N
   Mendoza, N
   Freeman, WR
AF You, Qi Sheng
   Bartsch, Dirk-Uwe G.
   Espina, Mark
   Alam, Mostafa
   Camacho, Natalia
   Mendoza, Nadia
   Freeman, William R.
TI REPRODUCIBILITY OF MACULAR PIGMENT OPTICAL DENSITY MEASUREMENT BY
   TWO-WAVELENGTH AUTOFLUORESCENCE IN A CLINICAL SETTING
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE macular pigment optical density; age-related macular degeneration;
   autofluorescence; vitamins supplementation
ID VISUAL-ACUITY; LUTEIN; SUPPLEMENTATION; ZEAXANTHIN; DEGENERATION; EYES;
   AMD
AB Purpose: Macular pigment, composed of lutein, zeaxanthin, and meso-zeaxanthin, is postulated to protect against age-related macular degeneration, likely because of filtering blue light and its antioxidant properties. Macular pigment optical density (MPOD) is reported to be associated with macular function evaluated by visual acuity and multifocal electroretinogram. Given the importance of macular pigment, reliable and accurate measurement methods are important. The main purpose of this study is to determine the reproducibility of MPOD measurement by two-wavelength autofluorescence method using scanning laser ophthalmoscopy.
   Methods: Sixty-eight eyes of 39 persons were enrolled in the study, including 11 normal eyes, 16 eyes with wet age-related macular degeneration, 16 eyes with dry age-related macular degeneration, 11 eyes with macular edema due to diabetic mellitus, branch retinal vein occlusion or macular telangiectasia, and 14 eyes with tractional maculopathy, including vitreomacular traction, epiretinal membrane, or macular hole. MPOD was measured with a two-wavelength (488 and 514 nm) autofluorescence method with the Spectralis HRA + OCT after pupil dilation. The measurement was repeated for each eye 10 minutes later. The analysis of variance and Bland-Altman plot were used to assess the reproducibility between the two measurements.
   Results: The mean MPOD at eccentricities of 1 degrees and 2 degrees was 0.36 +/- 0.17 (range: 0.04-0.69) and 0.15 +/- 0.08 (range: -0.03 to 0.35) for the first measurement and 0.35 +/- 0.17 (range: 0.02-0.68) and 0.15 +/- 0.08 (range: -0.01 to 0.33) for the second measurement, respectively. The difference between the 2 measurements was not statistically significant, and the Bland-Altman plot showed 7.4% and 5.9% points outside the 95% limits of agreement, indicating an overall excellent reproducibility. Similarly, there is no significant difference between the first and second measurements of MPOD volume within eccentricities of 1 degrees, 2 degrees, and 6 degrees radius, and the Bland-Altman plot showed 8.8%, 2.9%, and 4.4% points outside the 95% limits of agreement, respectively. The data for the reproducibility did not differ significantly among the various disease and normal eyes.
   Conclusion: Under routine examination conditions with pupil dilation, MPOD measurement by two-wavelength autofluorescence method showed a high reproducibility.
C1 [You, Qi Sheng; Bartsch, Dirk-Uwe G.; Espina, Mark; Alam, Mostafa; Camacho, Natalia; Mendoza, Nadia; Freeman, William R.] Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, San Diego, CA 92103 USA.
   [You, Qi Sheng] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
C3 University of California System; University of California San Diego;
   Capital Medical University
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, San Diego, CA 92103 USA.
EM wrfreeman@ucsd.edu
RI You, Qisheng/AAG-7153-2020
OI You, Qisheng/0000-0003-0743-7320
FU UCSD Vision Research Center Core Grant [P30EY022589]; NIH [EY016323];
   Research to Prevent Blindness, NY; ICO-Retina Research Foundation
   Helmerich Fellowship; National Natural Science Foundation of China
   [81400422]; NATIONAL EYE INSTITUTE [R01EY016323, P30EY022589] Funding
   Source: NIH RePORTER
FX Supported in part by UCSD Vision Research Center Core Grant P30EY022589,
   NIH grant EY016323 (D.-U.B.), an unrestricted grant from Research to
   Prevent Blindness, NY ( W. R. F.) and ICO-Retina Research Foundation
   Helmerich Fellowship and National Natural Science Foundation of China (
   No. 81400422) (Q.-S.Y.).
CR Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Creuzot-Garcher C, 2014, INVEST OPHTH VIS SCI, V55, P2941, DOI 10.1167/iovs.13-13568
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Degli Esposti S, 2012, INVEST OPHTH VIS SCI, V53, P6568, DOI 10.1167/iovs.12-9756
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P8016, DOI 10.1167/iovs.11-7610
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Issa PC, 2009, EXP EYE RES, V89, P25, DOI 10.1016/j.exer.2009.02.006
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Lien EL, 2011, PROG RETIN EYE RES, V30, P188, DOI 10.1016/j.preteyeres.2011.01.001
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Olmedilla-Alonso B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-52
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Zeimer MB, 2010, RETINA-J RET VIT DIS, V30, P1282, DOI 10.1097/IAE.0b013e3181e096dd
NR 25
TC 17
Z9 17
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2016
VL 36
IS 7
BP 1381
EP 1387
DI 10.1097/IAE.0000000000000893
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP6GK
UT WOS:000378595100039
PM 26655614
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lindner, M
   Lambertus, S
   Mauschitz, MM
   Bax, NM
   Kersten, E
   Luning, A
   Nadali, J
   Schmitz-Valckenberg, S
   Schmid, M
   Holz, FG
   Hoyng, CB
   Fleckenstein, M
AF Lindner, Moritz
   Lambertus, Stanley
   Mauschitz, Matthias M.
   Bax, Nathalie M.
   Kersten, Eveline
   Luning, Anna
   Nadali, Jennifer
   Schmitz-Valckenberg, Steffen
   Schmid, Matthias
   Holz, Frank G.
   Hoyng, Carel B.
   Fleckenstein, Monika
TI Differential Disease Progression in Atrophic Age-Related Macular
   Degeneration and Late-Onset Stargardt Disease
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Stargard disease; age-related macular degeneration; fundus
   autofluorescence; retinal pigment epithelium; geographic atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; QUANTITATIVE FUNDUS AUTOFLUORESCENCE;
   GEOGRAPHIC ATROPHY; RETINAL DYSTROPHIES; PERIPHERIN/RDS GENE;
   NATURAL-HISTORY; VISUAL-ACUITY; ABCR GENE; MUTATIONS; INHIBITION
AB PURPOSE. To compare the disease course of retinal pigment epithelium (RPE) atrophy secondary to age-related macula degeneratio (AMD) and late-onset Stargardt disease (STGD1).
   METHODS. Patients were examined longitudinally by fundus autofluorescence, near-infrared reflectance imaging, and best-corrected visual acuity (BCVA). Areas of RPE atrophy were quantified using semi-automated software, and the status of the fovea was evaluated based on autofluorescence and near-infrared reflectance images. Mixed-effects models were used to compare atrophy progression rates. BCVA loss and loss of foveal integrity were analyzed using Turnbull's estimator.
   RESULTS. A total of 151 patients (226 eyes) with RPE atrophy secondary to AMD and 38 patients (66 eyes) with RPE atrophy secondary to late-onset STGD1 were examined for a median time of 2.3 years (interquartile range, 2.7). Mean baseline age was 74.2 years (SD, 7.6) in AMD and 63.4 (SD, 9.9) in late-onset STGD1 (P = 1.1 X 10(-7)). Square root atrophy progression was significantly faster in AMD when compared with late-onset STGD1 (0.28 mm/year [SE, 0.01] vs. 0.23 [SE, 0.03]; P = 0.030). In late-onset STGD1, the median survival of the fovea was significantly longer when compared with eyes with AMD (8.60 vs. 3.35 years; P = 0.005) with a trend to a later BCVA loss of >= 3 lines (5.97 vs. 4.37 years; P = 0.382).
   CONCLUSIONS. These natural history data indicate differential disease progression in AMD versus late-onset STGD1. The results underline the relevance of refined phenotyping in elderly patients presenting with RPE atrophy in regard to prognosis and design of interventional trials.
C1 [Lindner, Moritz; Mauschitz, Matthias M.; Luning, Anna; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Lambertus, Stanley; Bax, Nathalie M.; Kersten, Eveline; Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Nadali, Jennifer; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; Radboud University Nijmegen; University of Bonn
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Monika.Fleckenstein@ukb.uni-bonn.de
RI Lindner, Moritz/AAC-8639-2021; Kersten, Eveline/P-8173-2015; Lambertus,
   Stanley/P-8153-2015
OI Lindner, Moritz/0000-0002-4416-3421; Lambertus,
   Stanley/0000-0001-9600-9592; Bax, Nathalie/0000-0002-1527-0463;
   Fleckenstein, Monika/0000-0001-8321-8037; Schmid,
   Matthias/0000-0002-0788-0317
FU Deutsche Forschungsgemeinschaft, Bonn, Germany [FL 658/4-1, Ho1926/3-1];
   BONFOR Gerok Program, Faculty of Medicine, University of Bonn
   [O-137.0020]; Stichting A.E Deutman Researchfonds Oogheelkunde,
   Nijmegen, The Netherlands; Nederlandse Oogonderzoek Stichting, Nijmegen,
   The Netherlands; Stichting MaculaFonds, the Netherlands; UitZicht
   [2013-25, 2014-3]
FX Supported by the Deutsche Forschungsgemeinschaft, Bonn, Germany, Grants
   FL 658/4-1 and Ho1926/3-1; BONFOR Gerok Program, Faculty of Medicine,
   University of Bonn, Grant O-137.0020; the Stichting A.E Deutman
   Researchfonds Oogheelkunde, Nijmegen, The Netherlands; Nederlandse
   Oogonderzoek Stichting, Nijmegen, The Netherlands; the Stichting
   MaculaFonds, the Netherlands; and by the following foundations that
   contributed through UitZicht (Grants 2013-25 and 2014-3): Stichting
   Maculafonds, Landelijke Stichting voor Blinden en Slechtzienden, and
   Oogfonds. The funding organizations had no role in the design or conduct
   of this research. They provided unrestricted grants.
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Bax NM, 2015, HUM MUTAT, V36, P43, DOI 10.1002/humu.22717
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Boon CJF, 2007, BRIT J OPHTHALMOL, V91, P1504, DOI 10.1136/bjo.2007.115659
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   Chen B, 2010, EXP EYE RES, V91, P143, DOI 10.1016/j.exer.2010.03.021
   Cideciyan AV, 2009, HUM MOL GENET, V18, P931, DOI 10.1093/hmg/ddn421
   de Laat P, 2013, OPHTHALMOLOGY, V120, P2684, DOI 10.1016/j.ophtha.2013.05.013
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P7274, DOI 10.1167/iovs.15-17371
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fujinami K, 2013, AM J OPHTHALMOL, V156, P487, DOI 10.1016/j.ajo.2013.05.003
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Lambertus S, 2016, INVEST OPHTH VIS SCI, V57, P5186, DOI 10.1167/iovs.16-19833
   Lampalizumab Roche., 2013, INVESTOR UPDATE
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   McBain VA, 2012, AM J OPHTHALMOL, V154, P146, DOI 10.1016/j.ajo.2012.01.019
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   TURNBULL BW, 1976, J R STAT SOC B, V38, P290
   van Huet RAC, 2014, INVEST OPHTH VIS SCI, V55, P7467, DOI 10.1167/iovs.13-13825
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 48
TC 17
Z9 17
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20980
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EO8LC
UT WOS:000396939600037
PM 28288486
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Weingessel, B
   Hintermayer, G
   Maca, SM
   Rauch, R
   Vecsei-Marlovits, PV
AF Weingessel, Birgit
   Hintermayer, Gregor
   Maca, Saskia M.
   Rauch, Renate
   Vecsei-Marlovits, Pia Veronika
TI The significance of early treatment of exudative age-related macular
   degeneration: 12 months' results
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE choroidal neovascularization; age-related macular degeneration;
   as-needed; duration of symptoms; ranibizumab; time to first treatment
ID INTRAVITREAL BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   PREVALENCE; THERAPY
AB To assess whether the period between initial symptoms and therapy with ranibizumab in patients with choroidal neovascularization (CNV) influences visual outcome after a follow-up of 12 months.
   Fifty patients with CNV were retrospectively split into three groups depending on the duration of visual symptoms: group I: < 1 month, group II: 1-6 months, and group III: > 6 months. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded at baseline, 2, 6, and 12 months. Patients received two initial intravitreal injections of 0.5 mg ranibizumab at baseline and reinjections as needed.
   The mean time span between initial symptoms and treatment was 66 +/- 63 days. A longer duration of visual symptoms was significantly correlated with a lower BCVA at baseline, but also after 6 and 12 months.
   Shorter duration of visual symptoms prior to treatment is associated with a better visual outcome.
C1 [Weingessel, Birgit; Maca, Saskia M.; Rauch, Renate; Vecsei-Marlovits, Pia Veronika] Hietzing Hosp, Dept Ophthalmol, A-1130 Vienna, Austria.
   [Weingessel, Birgit; Maca, Saskia M.; Rauch, Renate; Vecsei-Marlovits, Pia Veronika] Karl Landsteiner Inst Proc Optimizat & Qual Manag, Vienna, Austria.
   [Hintermayer, Gregor] St Poelten Hosp, Dept Ophthalmol, St Polten, Austria.
C3 Hietzing Hospital
RP Vecsei-Marlovits, PV (通讯作者)，Hietzing Hosp, Dept Ophthalmol, Wolkersbergenstr 1, A-1130 Vienna, Austria.
EM veronika.vecsei-marlovits@wienkav.at
RI Weingessel, Birgit/AAM-6617-2021; Weingessel, Birgit/ABD-5201-2021
OI Weingessel, Birgit/0000-0002-1110-0432
FU Novartis Company
FX This study received a grant from the Novartis Company for a
   site-initiated trial.
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Rauch R, 2011, RETINA, V32, P1260
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schalnus R, 2010, OPHTHALMOLOGICA, V224, P176, DOI 10.1159/000239236
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spitzer MS, 2008, CLIN OPHTHALMOL, V2, P1
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
NR 24
TC 4
Z9 4
U1 0
U2 7
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD NOV
PY 2012
VL 124
IS 21-22
BP 750
EP 755
DI 10.1007/s00508-012-0249-3
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 057AC
UT WOS:000312532900003
PM 23093324
DA 2022-11-30
ER

PT J
AU Lee, WJA
   Cheng, CL
   Lee, CH
   Yang, YHK
   Lin, SJ
   Hsieh, CY
AF Lee, Wan-Ju Annabelle
   Cheng, Ching-Lan
   Lee, Cheng-Han
   Yang, Yea-Huei Kao
   Lin, Swu-Jane
   Hsieh, Cheng-Yang
TI Risks of newly onset hemorrhagic stroke in patients with neovascular
   age-related macular degeneration
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE acute myocardial infarction; neovascular age-related macular
   degeneration; NHIRD; pharmacoepidemiology; stroke; Taiwan
ID INSURANCE RESEARCH DATABASE; CORONARY-ARTERY-DISEASE; ISCHEMIC-STROKE;
   MYOCARDIAL-INFARCTION; NATIONAL-HEALTH; CARDIOVASCULAR-DISEASE;
   HOMOCYSTEINE LEVELS; TAIWAN; ATHEROSCLEROSIS; POPULATION
AB PurposeAge-related macular degeneration (AMD) is an eye disease causing blindness in the elderly. It shares many common possible pathogenic mechanisms with cardiovascular diseases. Many studies have discussed the association between AMD and stroke, but the results were inconsistent. Our aim was to determine the associations between neovascular AMD and the risk of stroke in the Taiwanese population.
   MethodsThis is a retrospective cohort study. We used claims data from National Health Insurance Research Database. Patients aged more than 45years without stroke, myocardial infarction, or any AMD were selected from 2001 to 2008 and followed until 2010. The index date was defined as the date of nAMD diagnosis (ICD-9 code, 362.52). The comparison group was patients without an nAMD diagnosis with age- and sex-matched to nAMD subjects at a ratio of up to 10 to 1. Kaplan-Meier survival analysis and Cox regression analysis were used. The incidence of stroke events (ICD-9 codes, 430-434) and their subtypes (hemorrhagic and ischemic) were primary outcomes. Secondary outcomes included acute myocardial infarction (AMI), composite AMI/stroke, and all-cause mortality.
   ResultsPatients with nAMD had a higher risk of developing stroke, with an adjusted HR of 1.30 (95% CI, 1.01-1.68). A higher risk for hemorrhagic stroke (HR, 1.70, 95% CI, 1.03-2.83) was also found. No significant differences were observed in ischemic stroke, the composite of AMI/stroke, and all-cause mortality.
   ConclusionsPatients with nAMD had a significantly higher risk of developing stroke, which was driven mainly by the increased risk of developing the hemorrhagic subtype.
C1 [Lee, Wan-Ju Annabelle; Cheng, Ching-Lan; Lee, Cheng-Han; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan, Taiwan.
   [Cheng, Ching-Lan; Lee, Cheng-Han; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Sch Pharm, Coll Med, Tainan, Taiwan.
   [Cheng, Ching-Lan; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Hlth Outcome Res Ctr, Tainan, Taiwan.
   [Lee, Cheng-Han] Natl Cheng Kung Univ Hosp, Dept Cardiol, Internal Med, Tainan, Taiwan.
   [Lin, Swu-Jane] Univ Illinois, Chicago, IL USA.
   [Hsieh, Cheng-Yang] Tainan Sin Lau Hosp, Dept Neurol, Tainan, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University; National
   Cheng Kung University; National Cheng Kung University; National Cheng
   Kung University Hospital; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital
RP Yang, YHK (通讯作者)，Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Sch Pharm, 1 Univ Rd,701, Tainan, Taiwan.
EM yhkao@mail.ncku.edu.tw
RI Hsieh, Cheng-Yang/W-4841-2019; Lee, Wan-Ju/AAC-7025-2020
OI Hsieh, Cheng-Yang/0000-0002-8772-4073; Lee, Wan-Ju/0000-0002-9972-8899
CR Cheng CL, 2014, J EPIDEMIOL, V24, P500, DOI 10.2188/jea.JE20140076
   Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fernandez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142968
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hertle E, 2015, THROMB HAEMOST, V115
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Jose PO, 2014, J AM COLL CARDIOL, V64, P2486, DOI 10.1016/j.jacc.2014.08.048
   Kim OJ, 2011, STROKE, V42, P2393, DOI 10.1161/STROKEAHA.110.607739
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Lee CH, 2015, CIRC J, V79, P1107, DOI 10.1253/circj.CJ-14-1227
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Mehta RH, 2014, STROKE, V45, P2263, DOI 10.1161/STROKEAHA.114.005019
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Qiu CX, 2012, NEUROBIOL AGING, V33, P2935, DOI 10.1016/j.neurobiolaging.2012.01.012
   Rempe RG, 2016, J CEREBR BLOOD F MET, V36, P1481, DOI 10.1177/0271678X16655551
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacco RL, 2001, JAMA-J AM MED ASSOC, V285, P2729, DOI 10.1001/jama.285.21.2729
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Taniguchi H, 2015, OPHTHALMOLOGICA, V233, P128, DOI 10.1159/000371716
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   Wang X, 2013, STROKE, V44, P1833, DOI 10.1161/STROKEAHA.113.001326
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wu J, 2016, ANESTH ANALG, V122, P373, DOI 10.1213/ANE.0000000000001048
   Yan T, 2015, NEUROSCI BULL, V31, P717, DOI 10.1007/s12264-015-1567-z
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhou FF, 2015, J STROKE CEREBROVASC, V24, P784, DOI 10.1016/j.jstrokecerebrovasdis.2014.11.005
NR 39
TC 5
Z9 5
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2017
VL 26
IS 10
BP 1277
EP 1285
DI 10.1002/pds.4299
PG 9
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA FI6KV
UT WOS:000412105600017
PM 28856767
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, HS
   Jang, YS
   Han, JI
   Lew, YJ
   Lee, TG
   Kim, CG
   Kim, JW
AF Cho, Han Joo
   Kim, Hyoung Seok
   Jang, Young Seok
   Han, Jung Il
   Lew, Young Ju
   Lee, Tae Gon
   Kim, Chul Gu
   Kim, Jong Woo
TI Effects of Choroidal Vascular Hyperpermeability on Anti-Vascular
   Endothelial Growth Factor Treatment for Polypoidal Choroidal
   Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
   CLINICOPATHOLOGICAL CORRELATION; INTRAVITREAL RANIBIZUMAB; BEVACIZUMAB;
   INJECTIONS; THICKNESS; NETWORK
AB PURPOSE: To evaluate the effect of choroidal vascular hyperpermeability, as determined using indocyanine green angiography (ICGA), on the outcome of anti-vascular endothelial growth factor (VEGF) treatment for polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective comparative series.
   METHODS: Based on the presence of choroidal vascular hyperpermeability on ICGA, 103 eyes (101 patients) with PCV were categorized into 2 subgroups: choroidal vascular hyperpermeability (+) group (41 eyes) and choroidal vascular hyperpermeability (-) group (62 eyes). All subjects were treatment nave and treated by anti-VEGF with initial 3 loading injections per month, followed by an as-needed reinjection. Best-corrected visual acuity (BCVA) and central macular thickness after treatment were compared between the 2 groups at baseline and at 3, 6, 9, and 12 months.
   RESULTS: At 12 months after treatment, mean BCVA was significantly improved from 0.68 logarithm of the minimal angle of resolution (logMAR) (20/95 Snellen equivalent) to 0.50 logMAR (20/63 Snellen equivalent) in the choroidal vascular hyperpermeability () group (P = .01);. however, there was no significant improvement, from 0.79 logMAR (20/123 Snellen equivalent) to 0.74 logMAR (20/109 Snellen equivalent), in the choroidal vascular hyperpermeability ( +) group. In paired comparisons of BCVA between baseline and each follow-up visit, the choroidal vascular hyperpermeability () group showed significant improvement of BCVA at every follow-up visit (P < .05); however, the choroidal vascular hyperpermeability ( +) group did not show significant visual improvement after 9 months (P > .05).
   CONCLUSIONS: The therapeutic response to anti-VEGF treatment for PCV in patients with choroidal vascular hyperpermeability decreased over time. Choroidal vascular hyperpermeability was associated with an inferior visual outcome after intravitreal anti-VEGF treatment for PCV. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Cho, Han Joo; Kim, Hyoung Seok; Jang, Young Seok; Han, Jung Il; Lew, Young Ju; Lee, Tae Gon; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Coll Med, Kims Eye Hosp, Myung Gok Eye Res Inst,Dept Ophthalmol, Seoul, South Korea.
   [Lee, Tae Gon] Kyung Hee Univ, Grad Sch Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital; Kyung Hee University
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4Ga Yeoungdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 25
TC 55
Z9 58
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2013
VL 156
IS 6
BP 1192
EP 1200
DI 10.1016/j.ajo.2013.07.001
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 261OQ
UT WOS:000327674900017
PM 24011522
DA 2022-11-30
ER

PT J
AU Mata, NL
   Lichter, JB
   Vogel, R
   Han, Y
   Bui, TV
   Singerman, LJ
AF Mata, Nathan L.
   Lichter, Jay B.
   Vogel, Roger
   Han, Yun
   Bui, Tam V.
   Singerman, Lawrence J.
TI INVESTIGATION OF ORAL FENRETINIDE FOR TREATMENT OF GEOGRAPHIC ATROPHY IN
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fenretinide; geographic atrophy;
   lipofuscin; N-retinylidene-N-retinylethanolamine; retinal pigment
   epithelium; retinol-binding protein; vitamin A.
ID RETINOL-BINDING-PROTEIN; FUNDUS AUTOFLUORESCENCE PATTERNS; VITAMIN-A;
   BREAST-CANCER; PIGMENT EPITHELIUM; DARK-ADAPTATION; JUNCTIONAL ZONE;
   VISUAL FUNCTION; LIPOFUSCIN; A2E
AB Background: Excessive accumulation of retinol-based toxins has been implicated in the pathogenesis of geographic atrophy (GA). Fenretinide, an orally available drug that reduces retinol delivery to the eye through antagonism of serum retinol-binding protein (RBP), was used in a 2-year trial to determine whether retinol reduction would be effective in the management of geographic atrophy.
   Methods: The efficacy of fenretinide (100 and 300 mg daily, orally) to slow lesion growth in geographic atrophy patients was examined in a 2-year, placebo-controlled double-masked trial that enrolled 246 patients at 30 clinical sites in the United States.
   Results: Fenretinide treatment produced dose-dependent reversible reductions in serum RBP-retinol that were associated with trends in reduced lesion growth rates. Patients in the 300 mg group who achieved serum retinol levels of <1 mu M (<2 mg/dL RBP) showed a mean reduction of 0.33 mm(2) in the yearly lesion growth rate compared with subjects in the placebo group (1.70 mm(2)/year vs. 2.03 mm(2)/year, respectively, P = 0.1848). Retinol-binding protein reductions <2 mg/dL correlated with further reductions in lesion growth rates (r(2) = 0.478). Fenretinide treatment also reduced the incidence of choroidal neovascularization (approximately 45% reduction in incidence rate in the combined fenretinide groups vs. placebo, P = 0.0606). This therapeutic effect was not dose dependent and is consistent with anti-angiogenic properties of fenretinide, which have been observed in other disease states.
   Conclusion: The findings of this study and the established safety profile of fenretinide in chronic dosing regimens warrant further study of fenretinide in the treatment of geographic atrophy. RETINA 33: 498-507, 2013
C1 [Mata, Nathan L.; Lichter, Jay B.; Han, Yun; Bui, Tam V.] ReVis Therapeut Inc, La Jolla, CA 92037 USA.
   [Mata, Nathan L.; Vogel, Roger; Han, Yun; Bui, Tam V.] Sirion Therapeut Inc, Tampa, FL USA.
   [Singerman, Lawrence J.] Retina Associates Cleveland Inc, Cleveland, OH USA.
C3 Retina Associates of Cleveland, Inc.
RP Mata, NL (通讯作者)，ReVis Therapeut Inc, 11099 North Torrey Pines Rd,Suite 290, La Jolla, CA 92037 USA.
EM nathanlmata@gmail.com
FU ReVision Therapeutics Inc; Sirion Therapeutics Inc; Sirion Therapeutics
   and from ReVision Therapeutics
FX This study was supported by ReVision Therapeutics Inc, and Sirion
   Therapeutics Inc. NLM is an employee of ReVision Therapeutics. NLM, JBL,
   YH, TVB are stockholders in ReVision Therapeutics Inc. NLM, RV, YH, TVB
   were employees and stockholders of Sirion Therapeutics Inc. Retina
   Associates of Cleveland received grant support from Sirion Therapeutics
   and from ReVision Therapeutics to defray costs related to the
   fenretinide clinical trial.
CR Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Baglietto L, 2000, CANCER DETECT PREV, V24, P369
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bermann M, 2001, EXP EYE RES, V72, P191
   BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Blaner WS, 2007, CELL METAB, V5, P164, DOI 10.1016/j.cmet.2007.02.006
   BROWN E, 1996, WHONUT9610
   Camerini T, 2001, J CLIN ONCOL, V19, P1664, DOI 10.1200/JCO.2001.19.6.1664
   Caruso RC, 1998, ARCH OPHTHALMOL-CHIC, V116, P759, DOI 10.1001/archopht.116.6.759
   Choudhry N, 2010, SEMIN OPHTHALMOL, V25, P206, DOI 10.3109/08820538.2010.518121
   Conley B, 2000, J CLIN ONCOL, V18, P275, DOI 10.1200/JCO.2000.18.2.275
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P69
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lewis KC, 1996, EUR J CANCER, V32A, P1803, DOI 10.1016/0959-8049(96)00197-9
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Malpeli G, 1996, BBA-PROTEIN STRUCT M, V1294, P48, DOI 10.1016/0167-4838(95)00264-2
   Mariani L, 1996, TUMORI, V82, P444, DOI 10.1177/030089169608200506
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Quadro L, 2004, J LIPID RES, V45, P1975, DOI 10.1194/jlr.M400137-JLR200
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Ribatti D, 2003, CANCER LETT, V197, P181, DOI 10.1016/S0304-3835(03)00105-8
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Sogna I, 2009, RECENT RESULTS CANC, V181, P71
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Taren DL, 2004, J NUTR, V134, P2573, DOI 10.1093/jn/134.10.2573
   Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047
   Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 48
TC 99
Z9 103
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2013
VL 33
IS 3
BP 498
EP 507
DI 10.1097/IAE.0b013e318265801d
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 097DW
UT WOS:000315455200006
PM 23023528
DA 2022-11-30
ER

PT J
AU Robinson, DG
   Margrain, TH
   Dunn, MJ
   Bailey, C
   Binns, AM
AF Robinson, D. Grant
   Margrain, Tom H.
   Dunn, Matt J.
   Bailey, Clare
   Binns, Alison M.
TI Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration:
   A Randomized Clinical Trial
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; light therapy; randomized controlled
   trial
ID MEDIATED DARK-ADAPTATION; CHOROIDAL NEOVASCULAR MEMBRANES; FOVEAL
   FLICKER SENSITIVITY; ENDOTHELIAL GROWTH-FACTOR; EMIXUSTAT HYDROCHLORIDE;
   GEOGRAPHIC ATROPHY; RETINAL FUNCTION; NATURAL-HISTORY; VISUAL FUNCTION;
   COLOR-VISION
AB PURPOSE. To investigate the safety, acceptability, and effectiveness of light therapy on the progression of AMD over 12 months.
   METHODS. This was a phase I/IIa, prospective, proof-of-concept, single-center, unmasked randomized controlled trial. Sixty participants (55 to 88 years) with early AMD in the study eye and neovascular AMD (nAMD) in the fellow eye were recruited from a hospital nAMD clinic. Eligible participants were randomized (ratio 1: 1) to receive light therapy or to an untreated control group. Light therapy was delivered via a light-emitting mask (peak 505 nm, 23 scotopic Td), which was worn each night for 12 months. Co-primary outcome measures were disease progression (onset of nAMD or increased drusen volume beyond test-retest limits) and change in time constant of cone dark adaptation. Other main outcomes included adverse events, compliance, and subjective sleep quality data.
   RESULTS. Disease progression over 12 months was seen in 38.1% (18.1%-61.6% confidence interval [CI]) of intervention participants and 48.3% (29.4%-67.5% CI) of controls (Mantel-Haenszel test, common odds ratio = 0.763, P = 0.495). A significantly larger delay in cone adaptation was observed in the intervention group (1.66 +/- 0.61 minutes) than in the control group (0.66 +/- 0.49 minutes) over the follow-up period. No reported adverse events were deemed to be associated with the intervention.
   CONCLUSIONS. Although acceptable to the patients, light therapy did not have a substantial effect on the progression of early AMD over 12 months. Further investigation is necessary to discover the permanency and cause of the adverse effect of light therapy on dark adaptation.
C1 [Robinson, D. Grant; Margrain, Tom H.; Dunn, Matt J.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, S Glam, Wales.
   [Bailey, Clare] Bristol Eye Hosp, Lower Maudlin St, Bristol, Avon, England.
   [Binns, Alison M.] City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London EC1V 0HB, England.
C3 Cardiff University; Bristol Eye Hospital; City University London
RP Binns, AM (通讯作者)，City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London EC1V 0HB, England.
EM Alison.binns.1@city.ac.uk
FU College of Optometrists, London, UK
FX Supported by a research grant from the College of Optometrists, London,
   UK. The device manufacturer, PolyPhotonix Medical Ltd.,
   Stockton-on-Tees, UK, provided the light masks and technical support for
   the trial free of charge. The sponsor (Cardiff University, Cardiff, UK)
   and the funding organization had no role in the design or conduct of
   this research.
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   Ando K, 1996, BIOL PSYCHIAT, V39, P22, DOI 10.1016/0006-3223(95)00109-3
   Arden GB, 2011, EYE, V25, P1546, DOI 10.1038/eye.2011.264
   Arden GB, 2010, EYE, V24, P1149, DOI 10.1038/eye.2009.328
   Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Carifio J, 2008, MED EDUC, V42, P1150, DOI 10.1111/j.1365-2923.2008.03172.x
   Caruso RC, 1998, ARCH OPHTHALMOL-CHIC, V116, P759, DOI 10.1001/archopht.116.6.759
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Connolly DM, 2006, VISION RES, V46, P1784, DOI 10.1016/j.visres.2005.10.027
   de Winter JFC., 2010, PRACT ASSESS RES EVA, V15, P11, DOI DOI 10.7275/BJ1P-TS64
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Egbewale Bolaji Emmanuel, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P354, DOI 10.1016/S2221-1691(15)30367-1
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Feigl B, 2007, CLIN NEUROPHYSIOL, V118, P887, DOI 10.1016/j.clinph.2006.12.012
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HAGINS WA, 1989, P NATL ACAD SCI USA, V86, P1224, DOI 10.1073/pnas.86.4.1224
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Karakucuk S, 2004, AVIAT SPACE ENVIR MD, V75, P364
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Margrain TH, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-57
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   McKeague C, 2014, OPTOMETRY VISION SCI, V91, P916, DOI 10.1097/OPX.0000000000000318
   McKeague C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-246
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MOSELEY MJ, 1988, OPHTHAL PHYSL OPT, V8, P229, DOI 10.1111/j.1475-1313.1988.tb01043.x
   Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y
   O'Neill-Biba M, 2010, OPHTHAL PHYSL OPT, V30, P705, DOI 10.1111/j.1475-1313.2010.00775.x
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pavlidis M, 2005, OPHTHALMOLOGICA, V219, P404, DOI 10.1159/000088387
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Roberts C, 1999, BRIT MED J, V319, P185, DOI 10.1136/bmj.319.7203.185
   ROBINSON J, 1991, VISION RES, V31, P1837, DOI 10.1016/0042-6989(91)90031-Y
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Sahni JN, 2017, EYE, V31, P97, DOI 10.1038/eye.2016.259
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Stelmack JA, 2007, OPTOMETRY VISION SCI, V84, P705, DOI 10.1097/OPX.0b013e3181339f1a
   Sullivan Gail M, 2013, J Grad Med Educ, V5, P541, DOI 10.4300/JGME-5-4-18
   VINGRYS AJ, 1987, DOC OPHTHALMOL, V66, P171, DOI 10.1007/BF00140454
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   WINN B, 1994, INVEST OPHTH VIS SCI, V35, P1132
NR 72
TC 7
Z9 7
U1 1
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2018
VL 59
IS 11
BP 4531
EP 4541
DI 10.1167/iovs.18-24284
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT6VK
UT WOS:000444658800005
PM 30208421
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Garg, A
   Blumberg, DM
   Al-Aswad, LA
   Oll, M
   Yzer, S
   Forbes, M
   Allikmets, RL
   Bearelly, S
AF Garg, Aakriti
   Blumberg, Dana M.
   Al-Aswad, Lama A.
   Oll, Maris
   Yzer, Suzanne
   Forbes, Max
   Allikmets, Rando L.
   Bearelly, Srilaxmi
TI Associations Between beta-Peripapillary Atrophy and Reticular
   Pseudodrusen in Early Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; beta-peripapillary atrophy;
   normal-tension glaucoma; reticular pseudodrusen; choroidal thinning
ID OPTICAL COHERENCE TOMOGRAPHY; NORMAL-TENSION GLAUCOMA; PARAPAPILLARY
   CHORIORETINAL ATROPHY; CHOROIDAL THICKNESS; GEOGRAPHIC ATROPHY; EYES;
   MACULOPATHY; PREVALENCE; DISEASE; DISK
AB PURPOSE. Choroidal thinning has been associated with reticular pseudodrusen (RPD) and beta-peripapillary atrophy (beta-PPA), which have been linked to normal-tension glaucoma (NTG). This analysis sought to determine whether RPD are independently associated with beta-PPA in early AMD patients. Secondary outcomes included the association of RPD and preexisting diagnosis of glaucoma, cup-to-disc ratio (CDR), subfoveal choroidal thickness (SFCT), and IOP.
   METHODS. This prospective cross-sectional study examined 78 age-and sex-matched early AMD patients: 43 RPD patients (63 eyes) and 35 non-RPD patients (64 eyes). Exclusion criteria included advanced AMD, high myopia, and vitreoretinal conditions/surgery. RPD and nonRPD groups were identified by confocal scanning laser ophthalmoscopy. beta-PPA as well as CDR were graded on digital, nonstereoscopic fundus photos. SFCT was measured on spectraldomain optical coherence tomography for 69 patients (35 RPD and 34 non-RPD). IOP and glaucoma diagnosis were extracted from charts.
   RESULTS. beta-PPA had a greater prevalence in RPD than non-RPD (44% vs. 19%, P = 0.002); however, this relationship was not significant when SFCT was added to the model (P = 0.150). A preexisting diagnosis of glaucoma (P = 0.156), CDR (P = 0.176), and IOP (P = 0.98) was not different between groups.
   CONCLUSIONS. RPD in early AMD are associated with presence of beta-PPA, but choroidal thickness is a confounder in this relationship. Because beta-PPA is a common finding in NTG, focusing on a potential shared pathway between RPD and NTG could improve the understanding of pathophysiology and expand therapies for each condition.
C1 [Garg, Aakriti; Blumberg, Dana M.; Al-Aswad, Lama A.; Oll, Maris; Yzer, Suzanne; Forbes, Max; Allikmets, Rando L.; Bearelly, Srilaxmi] Columbia Univ, Coll Phys & Surg, Ophthalmol, New York, NY USA.
   [Allikmets, Rando L.] Columbia Univ, Coll Phys & Surg, Pathol & Cell Biol, New York, NY USA.
C3 Columbia University; Columbia University
RP Bearelly, S (通讯作者)，635 West 165th St, New York, NY 10032 USA.
EM sb3179@columbia.edu
RI Allikmets, Rando/ABD-4533-2021; Yzer, Suzanne/ABB-6929-2020
OI Garg Shukla, Aakriti/0000-0002-0765-8337; Al-Aswad,
   Lama/0000-0003-2440-9559
FU Doris Duke Charitable Foundation; National Eye Institute; National Eye
   Institute/National Institutes of Health [EY013435, EY019007]; Robert L.
   Burch III Fund, Columbia University; New York Community Trust-Fredrick
   J. and Theresa Dow Wallace Fund
FX Supported by a grant from the Doris Duke Charitable Foundation to
   Columbia University (AG), a National Eye Institute Travel Grant to the
   2014 ARVO Annual Meeting (AG), National Eye Institute/National
   Institutes of Health Grants EY013435 and EY019007 (Core Support for
   Vision Research), Robert L. Burch III Fund, Columbia University (SB),
   and the New York Community Trust-Fredrick J. and Theresa Dow Wallace
   Fund. The funding organizations had no role in the design or conduct of
   this research.
CR Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Alasil T, 2014, AM J OPHTHALMOL, V157, P953, DOI 10.1016/j.ajo.2014.01.014
   Anderson Douglas R, 2003, Curr Opin Ophthalmol, V14, P86
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Ehrlich JR, 2011, EXP EYE RES, V92, P189, DOI 10.1016/j.exer.2011.01.002
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   GEIJSSEN HC, 1990, DOC OPHTHALMOL, V75, P291, DOI 10.1007/BF00164843
   Gieser JP, 2001, RETINA-J RET VIT DIS, V21, P352, DOI 10.1097/00006982-200108000-00010
   Hirooka K, 2012, CLIN EXP OPHTHALMOL, V40, P576, DOI 10.1111/j.1442-9071.2012.02762.x
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P919
   JONAS JB, 1988, INVEST OPHTH VIS SCI, V29, P1151
   JONAS JB, 1992, ARCH OPHTHALMOL-CHIC, V110, P214, DOI 10.1001/archopht.1992.01080140070030
   Jonas JB, 1996, GRAEF ARCH CLIN EXP, V234, P744, DOI 10.1007/BF00189355
   Jonas Jost B, 2005, Curr Opin Ophthalmol, V16, P84, DOI 10.1097/01.icu.0000156135.20570.30
   Kim Jee Hyun, 2014, Korean J Ophthalmol, V28, P473, DOI 10.3341/kjo.2014.28.6.473
   Kim KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127920
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Marsiglia M, 2012, AM AC OPHTH ANN M NO
   Maul EA, 2011, OPHTHALMOLOGY, V118, P1571, DOI 10.1016/j.ophtha.2011.01.016
   Miki A, 2014, OPHTHALMOLOGY, V121, P1350, DOI 10.1016/j.ophtha.2014.01.017
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P3430, DOI 10.1167/iovs.10-6600
   NEVAREZ J, 1988, ARCH OPHTHALMOL-CHIC, V106, P901
   OBrart DPS, 1997, AM J OPHTHALMOL, V123, P657, DOI 10.1016/S0002-9394(14)71078-5
   Park HYL, 2014, J GLAUCOMA, V23, P225, DOI 10.1097/IJG.0000000000000045
   Park KH, 2001, J GLAUCOMA, V10, P95, DOI 10.1097/00061198-200104000-00005
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rhew JY, 2014, J GLAUCOMA, V23, P46, DOI 10.1097/IJG.0b013e31825af772
   Roberts KF, 2012, ARCH OPHTHALMOL-CHIC, V130, P980, DOI 10.1001/archophthalmol.2012.371
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Sugiyama T, 2000, OPHTHALMIC RES, V32, P79, DOI 10.1159/000055594
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Usui S, 2012, AM J OPHTHALMOL, V153, P10, DOI 10.1016/j.ajo.2011.05.037
   Wallsh Josh, 2015, Retin Cases Brief Rep, V9, P88, DOI 10.1097/ICB.0000000000000092
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yin ZQ, 1997, J GLAUCOMA, V6, P23
NR 47
TC 6
Z9 8
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 5
BP 2810
EP 2815
DI 10.1167/iovs.16-20343
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ3DV
UT WOS:000404591500045
PM 28564702
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Zhang, XZ
   Kahende, J
   Fan, AZ
   Barker, L
   Thompson, TJ
   Mokdad, AH
   Li, Y
   Saaddine, JB
AF Zhang, Xinzhi
   Kahende, Jennifer
   Fan, Amy Z.
   Barker, Lawrence
   Thompson, Theodore J.
   Mokdad, Ali H.
   Li, Yan
   Saaddine, Jinan B.
TI Smoking and Visual Impairment Among Older Adults With Age-Related Eye
   Diseases
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; LONG-TERM INCIDENCE; CIGARETTE-SMOKING; MACULAR
   DEGENERATION; RISK-FACTORS; ASSOCIATION; CATARACT; IMPACT; PREVALENCE;
   PEOPLE
AB Introduction
   Tobacco use is the leading preventable cause of death in the United States. Visual impairment, a common cause of disability in the United States, is associated with shorter life expectancy and lower quality of life. The relationship between smoking and visual impairment is not clearly understood. We assessed the association between smoking and visual impairment among older adults with age-related eye diseases.
   Methods
   We analyzed Behavioral Risk Factor Surveillance System data from 2005 through 2008 on older adults with age-related eye diseases (cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy; age >= 50 y, N = 36,522). Visual impairment was defined by self-reported difficulty in recognizing a friend across the street or difficulty in reading print or numbers. Current smokers were respondents who reported having smoked at least 100 cigarettes ever and still smoked at the time of interview. Former smokers were respondents who reported having ever smoked at least 100 cigarettes but currently did not smoke. We used multivariate logistic regressions to examine the association and to adjust for potential confounders.
   Results
   Among respondents with age-related eye diseases, the estimated prevalence of visual impairment was higher among current smokers (48%) than among former smokers (41%, P < .05) and respondents who had never smoked (42%, P < .05). After adjustment for age, sex, race/ethnicity, education, and general health status, current smokers with age-related eye diseases were more likely to have visual impairment than respondents with age-related eye diseases who had never smoked (odds ratio, 1.16, P < .05). Furthermore, respondents with cataract who were current smokers were more likely to have visual impairment than respondents with cataract who had never smoked (predictive margin, 44% vs 40%, P =.03), and the same was true for respondents with age-related macular degeneration (65% of current smokers vs 57% of never smokers, P = .02). This association did not hold true among respondents with glaucoma or diabetic retinopathy.
   Conclusion
   Smoking is linked to self-reported visual impairment among older adults with age-related eye diseases, particularly cataract and age-related macular degeneration. Longitudinal evaluation is needed to assess smoking cessation's effect on vision preservation.
C1 [Zhang, Xinzhi; Kahende, Jennifer] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA.
   [Mokdad, Ali H.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.
   [Fan, Amy Z.; Li, Yan] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30341 USA.
   [Barker, Lawrence; Thompson, Theodore J.; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA.
C3 Centers for Disease Control & Prevention - USA; Institute for Health
   Metrics & Evaluation; University of Washington; University of Washington
   Seattle; Centers for Disease Control & Prevention - USA; Centers for
   Disease Control & Prevention - USA
RP Zhang, XZ (通讯作者)，Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Hwy NE,MS K-10, Atlanta, GA 30341 USA.
EM XZhang4@cdc.gov
RI Mokdad, Ali H./AAD-1232-2022
OI Mokdad, Ali H./0000-0002-4994-3339
CR Adhikari B., 2008, Morbidity and Mortality Weekly Report, V57, P1226
   Bonovas S, 2004, PUBLIC HEALTH, V118, P256, DOI 10.1016/j.puhe.2003.09.009
   CHATURVEDI N, 1995, DIABETES CARE, V18, P785, DOI 10.2337/diacare.18.6.785
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards R, 2008, J GLAUCOMA, V17, P558, DOI 10.1097/IJG.0b013e31815f530c
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Hirai FE, 2007, DIABETES CARE, V30, P1437, DOI 10.2337/dc06-2264
   HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086
   Houston TK, 2006, BMJ-BRIT MED J, V332, P1064, DOI 10.1136/bmj.38779.584028.55
   Jin YP, 2008, CAN J OPHTHALMOL, V43, P407, DOI 10.3129/i08-077
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN BEK, 1993, OPHTHALMOLOGY, V100, P1609
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mokdad AH, 2009, ANNU REV PUBL HEALTH, V30, P43, DOI 10.1146/annurev.publhealth.031308.100226
   MOUTON DP, 1988, S AFR MED J, V74, P399
   Mukesh BN, 2006, ARCH OPHTHALMOL-CHIC, V124, P79, DOI 10.1001/archopht.124.1.79
   Nilsson PM, 2004, DIABETES METAB, V30, P261, DOI 10.1016/S1262-3636(07)70117-9
   Office on Smoking and Health, 2006, HLTH CONS INV EXP TO
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Tan JSL, 2008, OPHTHAL EPIDEMIOL, V15, P155, DOI 10.1080/09286580701840362
   Targher G, 1997, J CLIN ENDOCR METAB, V82, P3619, DOI 10.1210/jc.82.11.3619
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   US Department of Health and Human Services, 2004, HLTH CONS SMOK REP S
   US Department of Health and Human Services Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health, 2007, BEST PRACT COMPR TOB
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Weintraub JM, 2002, AM J EPIDEMIOL, V155, P72, DOI 10.1093/aje/155.1.72
   Wilson GA, 2001, NEW ZEAL MED J, V114, P471
   Zhang XZ, 2007, ARCH OPHTHALMOL-CHIC, V125, P411, DOI 10.1001/archopht.125.3.411
NR 34
TC 31
Z9 32
U1 0
U2 11
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD JUL
PY 2011
VL 8
IS 4
AR A84
PG 8
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA 874OY
UT WOS:000298969100014
PM 21672408
DA 2022-11-30
ER

PT J
AU Sayanagi, K
   Sharma, S
   Kaiser, PK
AF Sayanagi, K.
   Sharma, S.
   Kaiser, P. K.
TI Photoreceptor status after antivascular endothelial growth factor
   therapy in exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VERTEPORFIN PHOTODYNAMIC THERAPY; CENTRAL
   SEROUS CHORIORETINOPATHY; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   BEVACIZUMAB; RANIBIZUMAB; RETINA; EYES; PEGAPTANIB; SAFETY
C1 [Kaiser, P. K.] Cleveland Clin Fdn, Digital OCT Reading Ctr, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Digital OCT Reading Ctr, Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Ko T. H., 2005, OPHTHALMOLOGY, V112, pe1
   MARSHALL J, 1975, BRIT J OPHTHALMOL, V59, P610, DOI 10.1136/bjo.59.11.610
   Murakami T, 2007, AM J OPHTHALMOL, V143, P171, DOI 10.1016/j.ajo.2006.08.030
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Villate N, 2005, AM J OPHTHALMOL, V139, P280, DOI 10.1016/j.ajo.2004.09.029
   Watchtlin J, 2003, GRAEFES ARCH CLIN EX, V241, P218
   Witkin AJ, 2006, AM J OPHTHALMOL, V142, P945, DOI 10.1016/j.ajo.2006.07.024
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 25
TC 53
Z9 57
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2009
VL 93
IS 5
BP 622
EP 626
DI 10.1136/bjo.2008.151977
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 438BE
UT WOS:000265530100014
PM 19208677
DA 2022-11-30
ER

PT J
AU Camacho, P
   Dutra-Medeiros, M
   Cabral, D
   Silva, R
AF Camacho, Pedro
   Dutra-Medeiros, Marco
   Cabral, Diogo
   Silva, Rufino
TI Outer Retina and Choroidal Thickness in Intermediate Age-Related Macular
   Degeneration: Reticular Pseudodrusen Findings
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography; Retinal
   thickness
ID SUBRETINAL DRUSENOID DEPOSITS; BRUCHS MEMBRANE; SD-OCT; EYES;
   REPRODUCIBILITY; REPEATABILITY; MACULOPATHY; PREVALENCE; MORPHOLOGY
AB Purpose: To evaluate outer retina and choroidal thickness in subjects with intermediate age-related macular degenera-tion (iAMD) and to describe associations with the presence of reticular pseudodrusen (RPD). Methods: This was a retro-spective, cross-sectional analysis of 157 consecutive eyes (specifically: 62 eyes classified as having RPD and 95 eyes with drusen >= 125 mu m). Only cases with digital color fundus photographs, red-free, and infrared, obtained and graded according to the Age-Related Eye Disease Study to define iAMD, were used for this study. Outer retina and choroidal thickness were manually segmented and quantified at 12 locations in the horizontal meridian. Results: RPD appeared to be associated with thinning of the outer layers even after adjustment for gender and age. The presence of RPD in iAMD decreased with increase of choroidal thickness (total odds ratio [OR] 0.991, 95% confidence interval [CI] 0.985-0.996; nasal OR 0.992, 95% CI 0.986-0.997), with increased thickness of the myoid zone of the photoreceptors (total OR 0.812, 95% CI 0.688-0.958; nasal OR 0.863, 95% CI 0.755-0.987) and with increased thickness of the outer segment of the photoreceptors (total OR 0.850, 95% CI 0.731-0.989; nasal OR 0.857, 95% CI 0.736-0.989). Conclusions: The greatest differences between eyes with and without RPD are found at the level of the choroidal thickness and at the level of the photoreceptors. (C) 2017 S. Karger AG, Basel
C1 [Camacho, Pedro; Cabral, Diogo] Ophthalmol Inst Dr Gama Pinto, Travessa Larga 2, PT-1169019 Lisbon, Portugal.
   [Dutra-Medeiros, Marco] Cent Lisbon Hosp Ctr, Lisbon, Portugal.
   [Camacho, Pedro; Dutra-Medeiros, Marco] Retina Inst Lisbon, Lisbon, Portugal.
   [Dutra-Medeiros, Marco; Cabral, Diogo] NOVA Med Sch, Lisbon, Portugal.
   [Camacho, Pedro] Lisbon Sch Hlth Technol, Lisbon, Portugal.
   [Silva, Rufino] CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra, Fac Med, Inst Biomed Imaging & Life Sci IBILI, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra
RP Camacho, P (通讯作者)，Ophthalmol Inst Dr Gama Pinto, Travessa Larga 2, PT-1169019 Lisbon, Portugal.
EM pedro.camacho@estesl.ipl.pt
RI Camacho, Pedro/K-8682-2019; Camacho, Pedro/AAD-1757-2020; Cabral,
   Diogo/AAG-3865-2019; Silva, Rufino M/J-2817-2012
OI Camacho, Pedro/0000-0002-2986-5652; Cabral, Diogo/0000-0003-1968-3561;
   Silva, Rufino M/0000-0001-8676-0833; Dutra Medeiros,
   Marco/0000-0003-0421-1211
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, AM AC OPHTH RET VITR
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Camacho P, 2016, ORAL COMMUNICATION 1
   Carneiro A, 2010, AMD AGE RELATED MACU, P33
   Ctori I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129005
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Delcourt C, 2010, AMD AGE RELATED MACU, P13
   Ehnes A, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.1.1
   Eriksson U, 2012, ACTA OPHTHALMOL, V90, P620, DOI 10.1111/j.1755-3768.2011.02112.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Garcia-Martin E, 2011, ACTA OPHTHALMOL, V89, pE23, DOI 10.1111/j.1755-3768.2010.02045.x
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Liu XT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087996
   Loduca AL, 2010, AM J OPHTHALMOL, V150, P849, DOI 10.1016/j.ajo.2010.06.034
   Lutty G, 1999, MOL VIS, V5
   Mansouri K, 2014, AM J OPHTHALMOL, V157, P1022, DOI 10.1016/j.ajo.2014.02.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Rufino S, 2010, AMD AGE RELATED MACU, P129
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schick T, 2015, INVEST OPHTH VIS SCI, V56, P7269, DOI 10.1167/iovs.15-16989
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Silva R, 2015, MANUAL DE RETINA, P3
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Yamashita T, 2012, INVEST OPHTH VIS SCI, V53, P1102, DOI 10.1167/iovs.11-8836
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 53
TC 3
Z9 3
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2018
VL 59
IS 4
BP 212
EP 220
DI 10.1159/000484349
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GG5OD
UT WOS:000432744600005
PM 29237169
DA 2022-11-30
ER

PT J
AU Thumann, G
   Perdikomati-Dahmen, M
   Izsvak, Z
   Ivics, Z
   Layana, AG
   Ronchetti, M
   Petrovski, G
   Scherman, D
   Aranda, P
   Pouillot, S
   Binder, S
   Johnen, S
   Van den Berg, J
AF Thumann, Gabriele
   Perdikomati-Dahmen, Maria
   Izsvak, Zsuzsanna
   Ivics, Zoltan
   Garcia Layana, Alfredo
   Ronchetti, Mattia
   Petrovski, Goran
   Scherman, Daniel
   Aranda, Pablo
   Pouillot, Severine
   Binder, Susanne
   Johnen, Sandra
   Van den Berg, Joost
CA TargetAMD Consortium
TI Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related
   Macular Degeneration (TargetAMD)
SO HUMAN GENE THERAPY CLINICAL DEVELOPMENT
LA English
DT Article
ID SLEEPING-BEAUTY TRANSPOSON; ANTIBIOTIC-RESISTANCE MARKERS; PIGMENT
   EPITHELIAL-CELLS; PLASMIDS FREE; EXPRESSION; PFARS
C1 [Thumann, Gabriele] Univ Geneva, CH-1211 Geneva 4, Switzerland.
   [Perdikomati-Dahmen, Maria] Rhein Westfal TH Aachen, Aachen, Germany.
   [Izsvak, Zsuzsanna] Max Delbruck Ctr Mol Med, Berlin, Germany.
   [Ivics, Zoltan] Paul Ehrlich Inst, Frankfurt, Germany.
   [Garcia Layana, Alfredo] Univ Navarra, E-31080 Pamplona, Spain.
   [Ronchetti, Mattia] IGEA SPA, Rome, Italy.
   [Scherman, Daniel] CNRS, F-75700 Paris, France.
   [Aranda, Pablo] 3P Biopharmaceut SL, Madrid, Spain.
   [Pouillot, Severine] GenoSafe SAS, Evry, France.
   [Binder, Susanne] Rudolf Fdn Hosp, Vienna, Austria.
   [Johnen, Sandra] Univ Klinikum Aachen, Aachen, Germany.
   [Van den Berg, Joost] Stichting Amsterdam Biotherapeut Unit, Amsterdam, Netherlands.
C3 University of Geneva; RWTH Aachen University; Helmholtz Association; Max
   Delbruck Center for Molecular Medicine; Paul Ehrlich Institute;
   University of Navarra; Centre National de la Recherche Scientifique
   (CNRS); UDICE-French Research Universities; Universite Paris Cite; RWTH
   Aachen University; RWTH Aachen University Hospital
RP Thumann, G (通讯作者)，Univ Geneva, CH-1211 Geneva 4, Switzerland.
EM gabriele.thumann@unige.ch
RI Pouillot, Severine/GQI-3574-2022; Johnen, Sandra/ABA-9955-2020
OI Johnen, Sandra/0000-0003-0028-2557; Scherman, Daniel/0000-0003-1207-1298
FU EC [305134]
FX Contract No.: 305134; EC contribution: (sic) 5,976,298; Total costs:
   (sic) 7,769,833.46; Starting date: 01/11/2012; Duration: 48 months
CR Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Ammar I, 2012, NUCLEIC ACIDS RES, V40, P6693, DOI 10.1093/nar/gks317
   Dobias A, 2014, ARVO, V1827, pA0326
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Garcia Garcia L, 2014, EVER, V33, P1764
   Johnen S, 2013, HUM GENE THER, V24, pA139
   Johnen S, 2012, INVEST OPHTH VIS SCI, V53, P4787, DOI 10.1167/iovs.12-9951
   Kropp M, 2014, ESGCT A, VA106, pP156
   Marie C, 2010, J GENE MED, V12, P323, DOI 10.1002/jgm.1441
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   Pastor M, 2013, HUM GENE THER, V24, pA61
   Thumann G, 2010, GENE THER, V17, P181, DOI 10.1038/gt.2009.124
   Thumann G, 2013, HUM GENE THER, V24, pA31
   Walisko O, 2008, MOL THER, V16, P359, DOI 10.1038/sj.mt.6300366
   Wilber A, 2006, MOL THER, V13, P625, DOI 10.1016/j.ymthe.2005.10.014
NR 15
TC 0
Z9 0
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2324-8637
EI 2324-8645
J9 HUM GENE THER CL DEV
JI Hum. Gene Ther. Clin. Dev.
PD JUN 1
PY 2015
VL 26
IS 2
BP 97
EP 100
DI 10.1089/humc.2015.2519
PG 4
WC Biotechnology & Applied Microbiology; Critical Care Medicine; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; General & Internal Medicine;
   Research & Experimental Medicine
GA CS8DD
UT WOS:000362315000012
PM 26086761
OA Green Published
DA 2022-11-30
ER

PT J
AU Lee, JY
   Folgar, FA
   Maguire, MG
   Ying, GS
   Toth, CA
   Martin, DF
   Jaffe, GJ
AF Lee, Joo Yong
   Folgar, Francisco A.
   Maguire, Maureen G.
   Ying, Gui-shuang
   Toth, Cynthia A.
   Martin, Daniel F.
   Jaffe, Glenn J.
CA CATT Res Grp
TI Outer Retinal Tubulation in the Comparison of Age-Related Macular
   Degeneration Treatments Trials (CATT)
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; PHOTORECEPTOR ROSETTES;
   RETINITIS-PIGMENTOSA; RANIBIZUMAB; BEVACIZUMAB; FEATURES
AB Purpose: To determine the prevalence of, risk factors for, and visual acuity (VA) correlations with outer retinal tubulation (ORT) seen on spectral-domain optical coherence tomography (SD OCT) in eyes with neovascular agerelated macular degeneration (AMD) after anti-vascular endothelial growth factor (VEGF) therapy.
   Design: Prospective cohort study within a randomized clinical trial.
   Participants: Patients with SD OCT images at weeks 56 and 104 in the Comparison of AMD Treatments Trials (CATT).
   Methods: Participants in the CATT were assigned randomly to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a monthly or pro re nata (PRN) injection-dosing regimen. A subset of eyes was imaged with SD OCT beginning at week 56. Cirrus 512x128 or Spectralis 20(circle)x20(circle) volume cube scan protocols were used to acquire SD OCT images. Two independent readers at the CATT OCT reading center graded scans, and a senior reader arbitrated discrepant grades. The prevalence of ORT, identified as tubular structures seen on at least 3 consecutive Cirrus B scans or 2 consecutive Spectralis B scans, was determined. The associations of patientspecific and ocular features at baseline and follow-up with ORT were evaluated by univariate and multivariate analyses.
   Main Outcome Measures: Outer retinal tubulations.
   Results: Seven of 69 eyes (10.1%) at 56 weeks and 64 of 368 eyes (17.4%) at week 104 had ORTs. Absence of diabetes, poor VA, blocked fluorescence, geographic atrophy, greater lesion size, and presence of subretinal hyperreflective material at baseline were associated independently with greater risk of ORT at 104 weeks (P < 0.05). Neither drug nor dosing regimen were associated significantly with ORT. The mean VA of eyes with ORT at week 104 (58.5 Early Treatment Diabetic Retinopathy Study letters) was worse than the mean VA of eyes without ORT (68.8 letters; P < 0.0001).
   Conclusion: At 2 years after initiation of anti-VEGF therapy for neovascular AMD, ORTs are present in a substantial proportion of eyes. We identified baseline features that independently predict ORTs. It is important to identify ORTs because eyes with ORTs have worse VA outcomes than those without this finding. (C) 2014 by the American Academy of Ophthalmology.
C1 [Lee, Joo Yong; Folgar, Francisco A.; Toth, Cynthia A.; Jaffe, Glenn J.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Lee, Joo Yong] Univ Ulsan, Dept Ophthalmol, Asan Med Ctr, Seoul, South Korea.
   [Maguire, Maureen G.; Ying, Gui-shuang] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Dept Ophthalmol, Cleveland, OH 44106 USA.
C3 Duke University; University of Ulsan; University of Pennsylvania;
   Cleveland Clinic Foundation
RP Jaffe, GJ (通讯作者)，Duke Eye Ctr, Dept Ophthalmol, Box 3802, Durham, NC 27710 USA.
EM glenn.jaffe@duke.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Maguire, Maureen/0000-0002-4249-2467
FU National Institutes of Health, Bethesda, Maryland [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828]; NATIONAL EYE INSTITUTE
   [U10EY017825, U10EY017826] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health, Bethesda, Maryland
   (cooperative agreement nos.: U10 EY017823, U10 EY017825, U10 EY017826,
   and U10 EY017828).
CR DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Ellabban AA, 2012, EYE, V26, P1086, DOI 10.1038/eye.2012.101
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILAM AH, 1990, OPHTHALMOLOGY, V97, P1620
   Sergouniotis PI, 2012, OPHTHALMOLOGY, V119, P596, DOI 10.1016/j.ophtha.2011.09.017
   Tulvatana W, 1999, ARCH OPHTHALMOL-CHIC, V117, P399, DOI 10.1001/archopht.117.3.399
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 11
TC 38
Z9 44
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2014
VL 121
IS 12
BP 2423
EP 2431
DI 10.1016/j.ophtha.2014.06.013
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU3JR
UT WOS:000345509500027
PM 25064723
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Restrepo, NA
   Spencer, KL
   Goodloe, R
   Garrett, TA
   Heiss, G
   Buzkova, P
   Jorgensen, N
   Jensen, RA
   Matise, TC
   Hindorff, LA
   Klein, BEK
   Klein, R
   Wong, TY
   Cheng, CY
   Cornes, BK
   Tai, ES
   Ritchie, MD
   Haines, JL
   Crawford, DC
AF Restrepo, Nicole A.
   Spencer, Kylee L.
   Goodloe, Robert
   Garrett, Tiana A.
   Heiss, Gerardo
   Buzkova, Petra
   Jorgensen, Neal
   Jensen, Richard A.
   Matise, Tara C.
   Hindorff, Lucia A.
   Klein, Barbara E. K.
   Klein, Ronald
   Wong, Tien Y.
   Cheng, Ching-Yu
   Cornes, Belinda K.
   Tai, E. -Shyong
   Ritchie, Marylyn D.
   Haines, Jonathan L.
   Crawford, Dana C.
TI Genetic Determinants of Age-Related Macular Degeneration in Diverse
   Populations From the PAGE Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; CFH Y402H; ARMS2 A69S; PAGE Study;
   genetic epidemiology
ID COMPLEMENT-FACTOR-H; GENOME-WIDE ASSOCIATION; NUTRITION EXAMINATION
   SURVEY; CARDIOVASCULAR RISK-FACTORS; SINGAPORE MALAY EYE;
   NATIONAL-HEALTH; ATHEROSCLEROSIS RISK; JAPANESE POPULATION; CHINESE
   POPULATION; CIGARETTE-SMOKING
AB PURPOSE. Substantial progress has been made in identifying susceptibility variants for AMD in European populations; however, few studies have been conducted to understand the role these variants play in AMD risk in diverse populations. The present study aims to examine AMD risk across diverse populations in known and suspected AMD complement factor and lipid-related loci.
   METHODS. Targeted genotyping was performed across study sites for AMD and lipid trait-associated single nucleotide polymorphism (SNPs). Genetic association tests were performed at individual sites and then meta-analyzed using logistic regression assuming an additive genetic model stratified by self-described race/ethnicity. Participants included cases with early or late AMD and controls with no signs of AMD as determined by fundus photography. Populations included in this study were European Americans, African Americans, Mexican Americans, and Singaporeans from the Population Architecture using Genomics and Epidemiology (PAGE) study.
   RESULTS. Index variants of AMD, rs1061170 (CFH) and rs10490924 (ARMS2), were associated with AMD at P = 3.05 X 10(-8) and P = 6.36 X 10(-6), respectively, in European Americans. In general, none of the major AMD index variants generalized to our non-European populations with the exception of rs10490924 in Mexican Americans at an uncorrected P value < 0.05. Four lipid-associated SNPS (LPL rs328, TRIB1 rs6987702, CETP rs1800775, and KCTD10/MVK rs2338104) were associated with AMD in African Americans and Mexican Americans (P < 0.05), but these associations did not survive strict corrections for multiple testing.
   CONCLUSIONS. While most associations did not generalize in the non-European populations, variants within lipid-related genes were found to be associated with AMD. This study highlights the need for larger well-powered studies in non-European populations.
C1 [Restrepo, Nicole A.; Goodloe, Robert; Haines, Jonathan L.; Crawford, Dana C.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37232 USA.
   [Spencer, Kylee L.] Heidelberg Univ, Dept Biol & Environm Sci, Tiffin, OH USA.
   [Garrett, Tiana A.; Heiss, Gerardo] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Buzkova, Petra; Jorgensen, Neal] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Jensen, Richard A.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
   [Matise, Tara C.] Rutgers State Univ, Dept Genet, Piscataway, NJ USA.
   [Hindorff, Lucia A.] NHGRI, Div Genom Med, NIH, Bethesda, MD 20892 USA.
   [Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Wong, Tien Y.; Cheng, Ching-Yu; Cornes, Belinda K.; Tai, E. -Shyong] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Y.; Cheng, Ching-Yu] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Wong, Tien Y.; Cheng, Ching-Yu; Tai, E. -Shyong] Natl Univ Hlth Syst, Singapore, Singapore.
   [Cheng, Ching-Yu; Tai, E. -Shyong] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Cheng, Ching-Yu; Tai, E. -Shyong] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
   [Tai, E. -Shyong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
   [Ritchie, Marylyn D.] Penn State Univ, Ctr Syst Genom, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.
   [Crawford, Dana C.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
C3 Vanderbilt University; Heidelberg University USA; University of North
   Carolina; University of North Carolina Chapel Hill; University of
   Washington; University of Washington Seattle; University of Washington;
   University of Washington Seattle; Rutgers State University New
   Brunswick; National Institutes of Health (NIH) - USA; NIH National Human
   Genome Research Institute (NHGRI); University of Wisconsin System;
   University of Wisconsin Madison; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; National University of Singapore;
   National University of Singapore; National University of Singapore;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University -
   University Park; Vanderbilt University
RP Crawford, DC (通讯作者)，Vanderbilt Univ, Ctr Human Genet Res, 2215 Garland Ave,519 Light Hall, Nashville, TN 37232 USA.
EM dana.crawford@case.edu
RI Cheng, Ching-Yu/Y-2229-2019; Crawford, Dana/O-5578-2019; Haines,
   Jonathan/C-3374-2012; Wong, Tien Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Crawford, Dana/0000-0002-6437-6248;
   Haines, Jonathan/0000-0002-4351-4728; Wong, Tien
   Yin/0000-0002-8448-1264; Tai, E Shyong/0000-0003-2929-8966
FU National Human Genome Research Institute (NHGRI); CALiCo [U01HG004803];
   EAGLE [U01HG004798]; MEC [U01HG004802]; WHI [U01HG004790]; Coordinating
   Center [U01HG004801-01]; NHGRI ARRA; National Heart, Lung, and Blood
   Institute (NHLBI) [N01-HC-55015, N01-HC-55016, N01-HC-55018,
   N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022]; NHLBI
   [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103, N01 HC-55222,
   N01-HC-75150, N01-HC-45133, N01-HC-85239, HHSN268201200036C,
   U01HL080295, R01 HL087652, HL105756]; National Institute of Neurological
   Disorders and Stroke; National Medical Research Council [0796/2003,
   IRG07nov013, IRG09nov014, STaR/0003/2008, CG/SERI/2010]; Biomedical
   Research Council of Singapore (BMRC) [03/1/27/18/216, 05/1/36/19/413];
   NMRC [CSA/033/2012]; National Center of Advancing Translational
   Technologies CTSI [UL1TR000124]; National Institute of Diabetes and
   Digestive and Kidney Diseases [DK063491]; Cedars-Sinai Board of
   Governors' Chair in Medical Genetics (JIR); CDC; National Institutes of
   Mental Health; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS
   [N01HC085081, N01HC015103, N01HC055222, N01HC085085, N01HC055022,
   N01HC035129, N01HC045133, N01HC055018, N01HC055021, N01HC075150,
   N01HC085079, N01HC085082, N01HC085084, N01HC085086, N01HC055015,
   N01HC055019, N01HC085083, N01HC085080, N01HC055020, N01HC055016] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [T32EY021453] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [U01HL080295, R41HL055019, R01HL105756,
   R01HL087652, R41HL055018, R42HL055018] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG004802, U01HG007419,
   U01HG004801, U01HG004798, U01HG004803, U01HG004790] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [P30DK063491] Funding Source: NIH RePORTER
FX Supported by: National Human Genome Research Institute (NHGRI; PAGE
   study); U01HG004803 (CALiCo); U01HG004798 (EAGLE); U01HG004802 (MEC);
   U01HG004790 (WHI); U01HG004801-01 (Coordinating Center), and their
   respective NHGRI ARRA supplements;; National Heart, Lung, and Blood
   Institute (NHLBI) contracts N01-HC-55015, N01-HC-55016, N01-HC-55018,
   N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022 (ARIC study);;
   NHLBI contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129,
   N01-HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, N01-HC-85239,
   HHSN268201200036C, Grants U01HL080295, R01 HL087652, and HL105756, with
   additional contribution from the National Institute of Neurological
   Disorders and Stroke (CHS study);; National Medical Research Council
   (Grants 0796/2003, IRG07nov013, IRG09nov014, STaR/0003/2008 and
   CG/SERI/2010) and Biomedical Research Council (Grants 09/1/35/19/616;
   SiMES study), Singapore;; Biomedical Research Council of Singapore (BMRC
   Grant No. 03/1/27/18/216 and 05/1/36/19/413; SP2 study); and; an award
   from NMRC (CSA/033/2012; C-YC).; Handling and genotyping of DNA was
   supported in part by National Center of Advancing Translational
   Technologies CTSI Grant UL1TR000124 and National Institute of Diabetes
   and Digestive and Kidney Diseases Grant DK063491 to the Southern
   California Diabetes Endocrinology Research Center and Cedars-Sinai Board
   of Governors' Chair in Medical Genetics (JIR). See also
   http://www.chs-nhlbi.org/pi.htm. The study participants were derived
   from NHANES, and these studies are supported by the CDC. Assistance with
   phenotype harmonization, SNP selection and annotation, data cleaning,
   data management, integration and dissemination, and general study
   coordination was provided by the PAGE Coordinating Center. The National
   Institutes of Mental Health also contributes to the support for the
   Coordinating Center. The Singapore Tissue Network and the Genome
   Institute of Singapore, Agency for Science, Technology and Research,
   Singapore provided services for tissue archival and genotyping,
   respectively. The authors alone are responsible for the content and
   writing of the paper.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Centers for Disease Control and Prevention, 2004, CTR DIS CONTR PREV P
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MH, 2011, CIRC-CARDIOVASC GENE, V4, P523, DOI 10.1161/CIRCGENETICS.111.959577
   Chang MH, 2009, AM J EPIDEMIOL, V169, P54, DOI 10.1093/aje/kwn286
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cutter J, 2001, B WORLD HEALTH ORGAN, V79, P908
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dumitrescu L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002138
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hughes K, 1997, J EPIDEMIOL COMMUN H, V51, P394, DOI 10.1136/jech.51.4.394
   HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P29, DOI 10.1136/jech.44.1.29
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsson M, 2008, NATURE, V451, P998, DOI 10.1038/nature06742
   Jeganathan VSE, 2009, MICROCIRCULATION, V16, P534, DOI 10.1080/10739680902975222
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keebler ME, 2009, CIRC-CARDIOVASC GENE, V2, P238, DOI 10.1161/CIRCGENETICS.108.829473
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Matise TC, 2011, AM J EPIDEMIOL, V174, P849, DOI 10.1093/aje/kwr160
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nang EEK, 2009, AM J EPIDEMIOL, V169, P1454, DOI 10.1093/aje/kwp076
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neuner B, 2008, OPHTHAL EPIDEMIOL, V15, P148, DOI 10.1080/09286580802105830
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Pendergrass SA, 2010, BIODATA MIN, V3, DOI 10.1186/1756-0381-3-10
   Psaty BM, 2009, CIRC-CARDIOVASC GENE, V2, P73, DOI 10.1161/CIRCGENETICS.108.829747
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Ridker PM, 2009, CIRC-CARDIOVASC GENE, V2, P26, DOI 10.1161/CIRCGENETICS.108.817304
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sabatti C, 2009, NAT GENET, V41, P35, DOI 10.1038/ng.271
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sim X, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001363
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Spencer KL, 2012, ARCH OPHTHALMOL-CHIC, V130, P116, DOI 10.1001/archopthalmol.2011.1370
   Steinberg KK, 1997, EPIDEMIOL REV, V19, P156, DOI 10.1093/oxfordjournals.epirev.a017938
   Tan CE, 1999, DIABETES CARE, V22, P241, DOI 10.2337/diacare.22.2.241
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   US Department of Health and Human Services (DHHS), 1996, CTR DIS CONTR PREV 3
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 84
TC 42
Z9 43
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2014
VL 55
IS 10
DI 10.1167/iovs.14-14246
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT1ZS
UT WOS:000344730500033
PM 25205864
OA Green Published
DA 2022-11-30
ER

PT J
AU Haneef, AS
   Downes, S
AF Haneef, Atikah Shahid
   Downes, Sandra
TI Controlling Fiber Morphology and Scaffold Design for Treatment of Dry
   Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS
LA English
DT Article
DE AMD; Bruch's membrane; electrospinning; fibers; PET
ID MOLECULAR-WEIGHT; POLYSTYRENE FIBERS; NANOFIBERS; HUMIDITY
AB Polystyrene (PS), poly(ethylene terephthalate) (PET), and polyurethane (PU) were electrospun in various solvents, to ascertain the ideal conditions for reproducible scaffold production, in order to develop a synthetic Bruch's membrane. Effects of different environmental factors under laboratory conditions and controlled conditions, with and without 1% NaCl, were investigated. For PS, environmental conditions were more important than NaCl addition in fiber diameter reduction; however, NaCl addition showed reduced fiber size variation. For PET, reduction in fiber diameter on addition of NaCl compared to controlled environmental conditions was observed. Fiber size variation for PET was unaffected by NaCl addition or controlled conditions.
C1 [Haneef, Atikah Shahid; Downes, Sandra] Univ Manchester, Ctr Mat Sci, Sch Mat, Dept Engn & Phys Sci, Manchester M1 7HS, Lancs, England.
C3 University of Manchester
RP Haneef, AS (通讯作者)，Univ Manchester, Ctr Mat Sci, Sch Mat, Dept Engn & Phys Sci, Grosvenor St, Manchester M1 7HS, Lancs, England.
EM atikahhaneef@yahoo.co.uk
OI Haneef, Atikah/0000-0001-7422-9594
CR Abadi FJH, 2014, INT J POLYM MATER PO, V63, P57, DOI 10.1080/00914037.2013.769248
   Agarwal S, 2008, POLYMER, V49, P5603, DOI 10.1016/j.polymer.2008.09.014
   Aghdam RM, 2014, INT J POLYM MATER PO, V63, P229, DOI 10.1080/00914037.2013.800983
   Aytimur A, 2013, POLYM-PLAST TECHNOL, V52, P661, DOI 10.1080/03602559.2012.762662
   Barakat NAM, 2009, POLYMER, V50, P4389, DOI 10.1016/j.polymer.2009.07.005
   Casper CL, 2004, MACROMOLECULES, V37, P573, DOI 10.1021/ma0351975
   Chen JW, 2008, DESALINATION, V233, P48, DOI 10.1016/j.desal.2007.09.026
   De Vrieze S, 2009, J MATER SCI, V44, P1357, DOI 10.1007/s10853-008-3010-6
   Jean-Gilles Riffard, 2010, J Nanotechnol Eng Med, V1, P31008, DOI 10.1115/1.4001744
   Jiang SB, 2012, POLYM-PLAST TECHNOL, V51, P1237, DOI 10.1080/03602559.2012.698686
   Khil M. S., 2003, J BIOMED MATER RES B, V67, P22
   Koski A, 2004, MATER LETT, V58, P493, DOI 10.1016/S0167-577X(03)00532-9
   Koysuren O, 2014, INT J POLYM MATER PO, V63, P337, DOI 10.1080/00914037.2013.845188
   Kumbar SG, 2008, BIOMED MATER, V3, DOI 10.1088/1748-6041/3/3/034002
   Lee KH, 2003, POLYMER, V44, P1287, DOI 10.1016/S0032-3861(02)00820-0
   Luo CJ, 2010, POLYMER, V51, P1654, DOI 10.1016/j.polymer.2010.01.031
   Ma Q., 2010, 38 ANN C N AM THERM
   Piperno S, 2006, APPL SURF SCI, V252, P5583, DOI 10.1016/j.apsusc.2005.12.142
   Senthil T, 2013, POLYM-PLAST TECHNOL, V52, P407, DOI 10.1080/03602559.2012.755546
   Shadi L, 2014, POLYM-PLAST TECHNOL, V53, P254, DOI 10.1080/03602559.2013.844237
   Sigma-Aldrich, DICHL
   Sigma-Aldrich, TETR
   Son WK, 2004, POLYMER, V45, P2959, DOI [10.1016/j.polymer.2004.03.006, 10.1016/j.polymer.2004.02.006]
   Theron SA, 2004, POLYMER, V45, P2017, DOI 10.1016/j.polymer.2004.01.024
   Uyar T, 2008, POLYMER, V49, P5336, DOI 10.1016/j.polymer.2008.09.025
NR 25
TC 1
Z9 1
U1 0
U2 8
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0091-4037
EI 1563-535X
J9 INT J POLYM MATER PO
JI Int. J. Polym. Mater. Polym. Biomat.
PY 2014
VL 63
IS 18
BP 931
EP 940
DI 10.1080/00914037.2014.886231
PG 10
WC Materials Science, Biomaterials; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science; Polymer Science
GA AM8ZB
UT WOS:000340167100002
DA 2022-11-30
ER

PT J
AU Nita, M
   Grzybowski, A
   Ascaso, FJ
   Huerva, V
AF Nita, Malgorzata
   Grzybowski, Andrzej
   Ascaso, Francisco J.
   Huerva, Valentin
TI Age-Related Macular Degeneration in the Aspect of Chronic Low-Grade
   Inflammation (Pathophysiological ParaInflammation)
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; PIGMENT EPITHELIAL-CELLS;
   BRUCHS MEMBRANE; RISK-FACTORS; UP-REGULATION; MOUSE MODEL; DRUSEN;
   PATHOGENESIS; ACTIVATION
AB The products of oxidative stress trigger chronic low-grade inflammation (pathophysiological parainflammation) process in AMD patients. In early AMD, soft drusen contain many mediators of chronic low-grade inflammation such as C-reactive protein, adducts of the carboxyethylpyrrole protein, immunoglobulins, and acute phase molecules, as well as the complement-related proteins C3a, C5a, C5, C5b-9, CFH, CD35, and CD46. The complement system, mainly alternative pathway, mediates chronic autologous pathophysiological parainflammation in dry and exudative AMD, especially in the Y402H gene polymorphism, which causes hypofunction/lack of the protective complement factor H (CFH) and facilitates chronic inflammation mediated by Creactive protein (CRP). Microglial activation induces photoreceptor cells injury and leads to the development of dry AMD. Many autoantibodies (antibodies against alpha beta crystallin, alpha-actinin, amyloid, C1q, chondroitin, collagen I, collagen III, collagen IV, elastin, fibronectin, heparan sulfate, histone H2A, histone H2B, hyaluronic acid, laminin, proteoglycan, vimentin, vitronectin, and aldolase C and pyruvate kinase M2) and overexpression of Fcc receptors play role in immune-mediated inflammation in AMD patients and in animal model. Macrophages infiltration of retinal/choroidal interface acts as protective factor in early AMD (M2 phenotype macrophages); however it acts as proinflammatory and proangiogenic factor in advanced AMD (M1 and M2 phenotype macrophages).
C1 [Nita, Malgorzata] Domest & Specialized Med Ctr Dilmed, PL-40231 Katowice, Poland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Dept Ophthalmol, PL-10082 Olsztyn, Poland.
   [Grzybowski, Andrzej] Jozef Strus Poznan City Hosp, Dept Ophthalmol, PL-61285 Poznan, Poland.
   [Ascaso, Francisco J.] Lozano Blesa Univ Clin Hosp, Dept Ophthalmol, Zaragoza 50009, Spain.
   [Ascaso, Francisco J.] Aragon Hlth Sci Inst, Zaragoza 50009, Spain.
   [Huerva, Valentin] Univ Hosp Arnau de Vilanova, Dept Ophthalmol, Lleida 25198, Spain.
   [Huerva, Valentin] IRB Lleida, Lleida 25198, Spain.
C3 University of Warmia & Mazury; Lozano Blesa University Clinical Hospital
RP Grzybowski, A (通讯作者)，Univ Warmia & Mazury, Dept Ophthalmol, Al Warszawska 30, PL-10082 Olsztyn, Poland.
EM ae.grzybowski@gmail.com
RI Huerva, Valentín/A-6596-2010; Grzybowski, A/E-4486-2010; PUYUELO, FCO.
   JAVIER ASCASO/I-8426-2019
OI Huerva, Valentín/0000-0003-3832-6981; Grzybowski, A/0000-0002-3724-2391;
   
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019
   Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Forrester JV, 2005, BRIT J OPHTHALMOL, V89, P369, DOI 10.1136/bjo.2004.054197
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   FORRESTER JV, 1990, CURR EYE RES, V9, P183, DOI 10.3109/02713689008999440
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1
   GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gul A, 2009, GRAEF ARCH CLIN EXP, V247, P809, DOI 10.1007/s00417-008-1027-9
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harja E, 2008, J CLIN INVEST, V118, P183, DOI 10.1172/JCI32703
   Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Ju WK, 2001, NEUROREPORT, V12, P4075, DOI 10.1097/00001756-200112210-00043
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Li GY, 2008, BRAIN RES, V1188, P35, DOI 10.1016/j.brainres.2007.10.073
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lue LF, 2005, CNS NEUROL DISORD-DR, V4, P249, DOI 10.2174/1568007054038210
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mocellin S, 2004, CYTOKINE GROWTH F R, V15, P61, DOI 10.1016/j.cytogfr.2003.11.001
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murinello S, 2014, INVEST OPHTH VIS SCI, V55, P247, DOI 10.1167/iovs.13-11821
   Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200
   Osborne NN, 2004, INVEST OPHTH VIS SCI, V45, P3787, DOI 10.1167/iovs.04-0147
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2
   Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Vohra RS, 2006, TRENDS CARDIOVAS MED, V16, P60, DOI 10.1016/j.tcm.2005.12.001
   Wang H, 2011, EYE BRAIN, V3, P19, DOI 10.2147/EB.S24951
   Warburton S, 2005, MOL VIS, V11, P1122
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamagishi S, 2007, HORM METAB RES, V39, P845, DOI 10.1055/s-2007-991176
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 115
TC 62
Z9 63
U1 1
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2014
VL 2014
AR 930671
DI 10.1155/2014/930671
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA AP3TI
UT WOS:000342000100001
PM 25214719
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kose, C
   Sevik, U
   Gencalioglu, O
   Ikibas, C
   Kayikicioglu, T
AF Kose, Cemal
   Sevik, Ugur
   Gencalioglu, Okyay
   Ikibas, Cevat
   Kayikicioglu, Temel
TI A Statistical Segmentation Method for Measuring Age-Related Macular
   Degeneration in Retinal Fundus Images
SO JOURNAL OF MEDICAL SYSTEMS
LA English
DT Article
DE Medical image analysis; Statistical segmentation; Retina; Optic disc;
   Macula; Age-related macular degenerations; Automatic diagnosis
ID DIABETIC-RETINOPATHY; AUTOMATED DETECTION; OPTIC DISC; PHOTOGRAPHS;
   DRUSEN
AB Day by day, huge amount of information is collected in medical databases. These databases include quite interesting information that could be exploited in diagnosis of illnesses and medical treatment of patients. Classification of these data is getting harder as the databases are expanded. On the other hand, automated image analysis and processing is one of the most promising areas of computer vision used in medical diagnosis and treatment. In this context, retinal fundus images, offering very high resolutions that are sufficient for most of the clinical cases, provide many indications that could be exploited in diagnosing and screening retinal degenerations or diseases. Consequently, there is a strong demand in developing automated evaluation systems to utilize the information stored in the medical databases. This study proposes an automatic method for segmentation of ARMD in retinal fundus images. The method used in the automated system extracts lesions of the ARMD by employing a statistical method. In order to do this, the statistical segmentation method is first used to extract the healthy area of the macula that is more familiar and regular than the unhealthy parts. Here, characteristic images of the patterns of the macula are extracted and used to segment the healthy textures of an eye. In addition to this, blood vessels are also extracted and then classified as healthy regions. Finally, the inverse image of the segmented image is generated which determines the unhealthy regions of the macula. The performance of the method is examined on various quality retinal fundus images. Segmented images are also compared with consecutive images of the same patient to follow up the changes in the disease.
C1 [Kose, Cemal; Sevik, Ugur; Ikibas, Cevat] Karadeniz Tech Univ, Dept Comp Engn, Fac Engn, TR-61080 Trabzon, Turkey.
   [Gencalioglu, Okyay] Karadeniz Tech Univ, Dept Data Proc Ctr, Fac Med, TR-61080 Trabzon, Turkey.
   [Kayikicioglu, Temel] Karadeniz Tech Univ, Dept Elect & Elect Engn, TR-61080 Trabzon, Turkey.
C3 Karadeniz Technical University; Karadeniz Technical University;
   Karadeniz Technical University
RP Kose, C (通讯作者)，Karadeniz Tech Univ, Dept Comp Engn, Fac Engn, TR-61080 Trabzon, Turkey.
EM ckose@ktu.edu.tr; usevik@ktu.edu.tr; okyaygenc@meds.ktu.edu.tr;
   cikibas@ktu.edu.tr; tkayikci@risc01.ktu.edu.tr
RI KÖSE, Cemal/V-9731-2017; Şevik, Uğur/E-5056-2013
OI KÖSE, Cemal/0000-0002-5982-4771; Şevik, Uğur/0000-0002-2056-9988;
   Ikibas, Cevat/0000-0001-9298-7057
CR Abramoff MD, 2007, INVEST OPHTH VIS SCI, V48, P1665, DOI 10.1167/iovs.06-1081
   Al-Rawi M, 2007, COMPUT BIOL MED, V37, P262, DOI 10.1016/j.compbiomed.2006.03.003
   [Anonymous], 1990, NONLINEAR DIGITAL FI
   Chrastek R, 2005, MED IMAGE ANAL, V9, P297, DOI 10.1016/j.media.2004.12.004
   HART WE, 1994, AUTOMATIC SEGMENTATI
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2009, EXPERT SYST APPL, V36, P1208, DOI 10.1016/j.eswa.2007.11.036
   Kose C, 2006, LECT NOTES COMPUT SC, V4109, P74
   Lalonde M, 2001, IEEE T MED IMAGING, V20, P1193, DOI 10.1109/42.963823
   Li HQ, 2001, 2001 INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, VOL II, PROCEEDINGS, P837, DOI 10.1109/ICIP.2001.958624
   Mendels F., 1999, Proceedings of the First Joint BMES/EMBS Conference. 1999 IEEE Engineering in Medicine and Biology 21st Annual Conference and the 1999 Annual Fall Meeting of the Biomedical Engineering Society (Cat. No.99CH37015), DOI 10.1109/IEMBS.1999.804304
   Narasimha-Iyer H, 2006, IEEE T BIO-MED ENG, V53, P1084, DOI 10.1109/TBME.2005.863971
   Nayak J, 2008, J MED SYST, V32, P107, DOI 10.1007/s10916-007-9113-9
   NIEMEIJER M, 2007, IEEE T BIOMED ENG, V26, P1116
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Osareh A, 2002, INT C PATT RECOG, P743, DOI 10.1109/ICPR.2002.1044865
   Pakin SK, 2002, P SOC PHOTO-OPT INS, V4684, P155, DOI 10.1117/12.467113
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rapantzikos K, 2001, 2001 INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, VOL III, PROCEEDINGS, P1055, DOI 10.1109/ICIP.2001.958308
   Reza AW, 2008, J MED SYST, V32, P147, DOI 10.1007/s10916-007-9117-5
   Shieh YY, 2005, INVEST OPHTH VIS SCI, V46
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   SMITH T, 2004, INVESTIG OPHTHALMOL, V45
   Soliz P, 2002, P SOC PHOTO-OPT INS, V4681, P159, DOI 10.1117/12.466917
   Song JT, 2005, LECT NOTES COMPUT SC, V3645, P492
   Sonka M., 2014, IMAGE PROCESSING ANA
   Stammberger T, 1999, MAGN RESON IMAGING, V17, P1033, DOI 10.1016/S0730-725X(99)00040-5
   Stewart CV, 2005, LECT NOTES COMPUT SC, V3765, P31
   Vermeer KA, 2004, COMPUT BIOL MED, V34, P209, DOI 10.1016/S0010-4825(03)00055-6
   Walter T, 2002, IEEE T MED IMAGING, V21, P1236, DOI 10.1109/TMI.2002.806290
   Xu JA, 2006, COMPUT BIOL MED, V36, P921, DOI 10.1016/j.compbiomed.2005.05.001
NR 32
TC 43
Z9 43
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0148-5598
EI 1573-689X
J9 J MED SYST
JI J. Med. Syst.
PD FEB
PY 2010
VL 34
IS 1
BP 1
EP 13
DI 10.1007/s10916-008-9210-4
PG 13
WC Health Care Sciences & Services; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Medical Informatics
GA 542GE
UT WOS:000273480200001
PM 20192050
DA 2022-11-30
ER

PT J
AU Liu, R
   Wang, T
   Zhang, B
   Qin, L
   Wu, CR
   Li, QS
   Ma, L
AF Liu, Rong
   Wang, Tian
   Zhang, Bao
   Qin, Li
   Wu, Changrui
   Li, Qingshan
   Ma, Le
TI Lutein and Zeaxanthin Supplementation and Association With Visual
   Function in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE lutein; zeaxanthin; age-related macular degeneration; visual function;
   meta-analysis
ID DIETARY SUPPLEMENTATION; CONTRAST SENSITIVITY; OPTICAL-DENSITY; PIGMENT;
   ACUITY; ANTIOXIDANTS; CAROTENOIDS; DAMAGE; MACULOPATHY; PLACEBO
AB PURPOSE. To evaluate the effects of lutein and zeaxanthin on visual function in randomized controlled trials (RCTs) of AMD patients.
   METHODS. Relevant studies were identified by searches on PubMed, EMBASE, Web of Science, and Cochrane Library database up to April 2014. Three investigators independently determined the eligibility of RCTs, which compared lutein and zeaxanthin intervention with placebo. The adjusted weighted mean differences (WMDs) from each study were extracted to calculate a pooled estimate with its corresponding 95% confidence interval (CI). The main outcome measurements included visual acuity (VA), contrast sensitivity (CS), glare recovery time (GRT), and subjective perception of visual quality.
   RESULTS. Eight RCTs involving 1176 AMD patients were included in the meta-analysis. Xanthophyll carotenoids supplementation was associated with significant decrease in logMAR levels compared with the placebo group (WMD, -0.04; 95% CI, -0.06 to -0.03), and during intervention, each 1-mg/day increase in these carotenoids supplementation was related to a 0.003 reduction in logMAR level of VA. Remarkable benefit was also observed at all four spatial frequencies of CS (WMD ranging from 0.08-0.18; all P < 0.05) in contrast to placebo. Furthermore, association was observed between the postintervention increase in macular pigment optical density and improvements in VA (r = -0.58; P = 0.02), and in CS at 12 cycles/degree as well (r = 0.94; P < 0.001).
   CONCLUSIONS. Lutein and zeaxanthin supplementation is a safe strategy for improving visual performance of AMD patients, which mainly showed in a dose-response relationship.
C1 [Liu, Rong; Wang, Tian; Zhang, Bao; Li, Qingshan; Ma, Le] Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China.
   [Qin, Li; Wu, Changrui] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University
RP Ma, L (通讯作者)，Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
EM male@mail.xjtu.edu.cn
OI ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China (Beijing, China)
   [NSFC-81202198, NSFC-81473059]; Natural Science Foundation of Shaanxi
   Province of China [2013JQ4008]; Fundamental Research Funds for the
   Central Universities of China [xjj2012052]
FX Supported by grants from the National Natural Science Foundation of
   China (NSFC-81202198, NSFC-81473059; Beijing, China), the Natural
   Science Foundation of Shaanxi Province of China (2013JQ4008; Xi'an,
   Shaanxi, China), and the Fundamental Research Funds for the Central
   Universities of China (xjj2012052; Xi'an, Shaanxi, China).
CR Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Buhren J, 2006, OPTOMETRY VISION SCI, V83, P290, DOI 10.1097/01.opx.0000216100.93302.2d
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chen XP, 2012, NEUROSCI BULL, V28, P737, DOI 10.1007/s12264-012-1292-9
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Bibiloni MD, 2014, NUTR HOSP, V29, P880, DOI 10.3305/nh.2014.29.4.7078
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hammond BR, 2012, AM J CLIN NUTR, V96, p1207S, DOI 10.3945/ajcn.112.034876
   Han DP, 2013, JAMA OPHTHALMOL, V131, P1124, DOI 10.1001/jamaophthalmol.2013.432
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Horn SD, 2012, ARCH PHYS MED REHAB, V93, pS127, DOI 10.1016/j.apmr.2011.10.031
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lien EL, 2011, PROG RETIN EYE RES, V30, P188, DOI 10.1016/j.preteyeres.2011.01.001
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Siedlecki D, 2014, OPTOMETRY VISION SCI, V91, P240, DOI 10.1097/OPX.0000000000000137
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
NR 44
TC 64
Z9 68
U1 1
U2 41
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2015
VL 56
IS 1
BP 252
EP 258
DI 10.1167/iovs.14-15553
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE0TQ
UT WOS:000351519800027
PM 25515572
DA 2022-11-30
ER

PT J
AU Ferrara, N
AF Ferrara, Napoleone
TI Vascular endothelial growth factor and age-related macular degeneration:
   from basic science to therapy
SO NATURE MEDICINE
LA English
DT Article
ID ANTI-VEGF ANTIBODY; PERMEABILITY FACTOR; TYROSINE KINASE;
   EXTRACELLULAR-MATRIX; NUCLEOTIDE-SEQUENCE; TUMOR ANGIOGENESIS; CELLS
   SECRETE; BLOOD-VESSELS; NEOVASCULARIZATION; RANIBIZUMAB
C1 Genentech Inc, San Francisco, CA USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, San Francisco, CA USA.
EM nf@gene.com
CR ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2006, RETINA, P1075
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FERRARA N, 1987, AM J PHYSIOL, V252, pE304, DOI 10.1152/ajpendo.1987.252.3.E304
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2010, MOL BIOL CELL, V21, P687, DOI 10.1091/mbc.E09-07-0590
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Motiejunaite R, 2008, EXP EYE RES, V86, P171, DOI 10.1016/j.exer.2007.10.013
   Nagy JA, 2006, LAB INVEST, V86, P767, DOI 10.1038/labinvest.3700436
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Presta LG, 1997, CANCER RES, V57, P4593
   Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
NR 56
TC 130
Z9 147
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD OCT
PY 2010
VL 16
IS 10
BP 1107
EP 1111
DI 10.1038/nm1010-1107
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 660LR
UT WOS:000282644800039
PM 20930754
DA 2022-11-30
ER

PT J
AU Sen, P
   Bhende, M
   Sachidanandam, R
   Bansal, N
   Sharma, T
AF Sen, Parveen
   Bhende, Muna
   Sachidanandam, Ramya
   Bansal, Nishat
   Sharma, Tarun
TI Reduced-fluence photodynamic therapy and anti-vascular endothelial
   growth factor for polypoidal choroidal vasculopathy in an Indian
   population
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; photodynamic therapy;
   polypoidal choroidal vasculopathy; reduced fluence
ID EPITHELIUM-DERIVED FACTOR; INTRAVITREAL BEVACIZUMAB; MACULAR
   DEGENERATION; CLINICAL CHARACTERISTICS; JAPANESE PATIENTS; RANIBIZUMAB;
   VERTEPORFIN; ANGIOGRAPHY; MANAGEMENT; EXPRESSION
AB Aims: The aim was to study the efficacy of combined therapy with reduced-fluence photodynamic therapy (RFPDT) and intravitreal bevacizumab/ranibizumab from the Indian subcontinent. Settings and Design: This was a single-center, retrospective interventional study. Methods: Thirty-five eyes of 34 patients diagnosed with polypoidal choroidal vasculopathy were included. All the patients underwent RFPDT, followed by intravitreal bevacizumab/ranibizumab. Statistical Analysis Used: SPSS software, version 17.0 (SPSS Inc., Chicago, IL, USA) was used to compare the logarithm of the minimal angle of resolution visual acuity at presentation and final follow-up. P < 0.05 was considered statistically significant. Results: Regression of polyps after a single session of RFPDT was seen in five eyes; multiple sessions of treatment were required in thirty eyes. An average number of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections given were 4 +/- 1.9 and average number of PDT sessions were 1.2 +/- 0.5. Visual acuity improvement was seen in 21 (60%) eyes (P < 0.001), decrease in visual acuity was seen in 7 (20%) eyes (P = 0.016), and in 7 eyes (20%), vision remained stable. Regression of polypoidal lesions was seen in 80% of cases. No complications of massive subretinal hemorrhage or breakthrough vitreous hemorrhage were noted in our patients. The mean follow-up period was 18 months (range, 12-24 months). Conclusions: RFPDT with anti-VEGF is safe and effective treatment with polyp regression and vision improvement in 80% of cases, without any complication of subretinal hemorrhage/vitreous hemorrhage.
C1 [Sen, Parveen; Bhende, Muna; Bansal, Nishat; Sharma, Tarun] Sankara Nethralaya, Med Res Fdn, Shri Bhagwan Mahavir Vitreoretinal Serv, Dept Vitreoretinal Serv, Madras, Tamil Nadu, India.
   [Sachidanandam, Ramya] Sankara Nethralaya, Med Res Fdn, Dept Optometry, Madras, Tamil Nadu, India.
RP Sen, P (通讯作者)，Sankara Nethralaya, Med Res Fdn, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM parveensen@gmail.com
RI Sen, Parveen/W-4707-2019
CR Anantharaman G, 2010, INDIAN J OPHTHALMOL, V58, P399, DOI 10.4103/0301-4738.67052
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chawla S, 2009, INDIAN J OPHTHALMOL, V57, P155, DOI 10.4103/0301-4738.45511
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kim SW, 2009, OPHTHAL SURG LAS IM, V40, P300, DOI 10.3928/15428877-20090430-14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pai SA, 2009, ACTA OPHTHALMOL, V87, P806, DOI 10.1111/j.1755-3768.2008.01330.x
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 29
TC 3
Z9 3
U1 0
U2 3
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2016
VL 64
IS 12
BP 908
EP 913
DI 10.4103/0301-4738.198856
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ0ZB
UT WOS:000392938700010
PM 28112132
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hinkle, JW
   Mahmoudzadeh, R
   Kuriyan, AE
AF Hinkle, John W.
   Mahmoudzadeh, Raziyeh
   Kuriyan, Ajay E.
TI Cell-based therapies for retinal diseases: a review of clinical trials
   and direct to consumer "cell therapy" clinics
SO STEM CELL RESEARCH & THERAPY
LA English
DT Review
DE Age-related macular degeneration; Cell therapy clinics; Human embryonic
   stem cells; Human umbilical tissue-derived cells; Induced pluripotent
   stem cells; Retinal pigment epithelium; Stargardt's macular dystrophy
ID TISSUE-DERIVED CELLS; EMBRYONIC STEM-CELLS; INTRAVITREAL INJECTION;
   MACULAR DEGENERATION; VISION LOSS; GENERATION; RESOLUTION; SECONDARY;
   SURGERY
AB Background The retinal pigment epithelium (RPE) is implicated in the pathophysiology of many retinal degenerative diseases. This cell layer is also an ideal target for cell-based therapies. Several early phase clinical trials evaluating cell therapy approaches for diseases involving the RPE, such as age-related macular degeneration and Stargardt's macular dystrophy have been published. However, there have also been numerous reports of complications from unproven "cell therapy" treatments marketed by "cell therapy" clinics. This review aims to outline the particular approaches in the different published clinical trials for cell-based therapies for retinal diseases. Additionally, the controversies surrounding experimental treatments offered outside of legitimate studies are presented. Main body Cell-based therapies can be applied to disorders that involve the RPE via a variety of techniques. A defining characteristic of any cell therapy treatment is the cell source used: human embryonic stem cells, induced pluripotent stem cells, and human umbilical tissue-derived cells have all been studied in published trials. In addition to the cell source, various trials have evaluated particular immunosuppression regiments, surgical approaches, and outcome measures. Data from early phase studies investigating cell-based therapies in non-neovascular age-related macular degeneration (70 patients, five trials), neovascular age-related macular degeneration (12 patients, four trials), and Stargardt's macular dystrophy (23 patients, three trials) have demonstrated safety related to the cell therapies, though evidence of significant efficacy has not been reported. This is in contrast to the multiple reports of serious complications and permanent vision loss in patients treated at "cell therapy" clinics. These interventions are marketed directly to patients, funded by the patient, lack Food and Drug Administration approval, and lack significant oversight. Conclusion Currently, there are no proven effective cell-based treatments for retinal diseases, although several trials have investigated potential therapies. These studies reported favorable safety profiles with multiple surgical approaches, with cells derived from multiple sources, and with utilized different immunosuppressive regiments. However, data demonstrating the efficacy and long-term safety are still pending. Nevertheless, "cell therapy" clinics continue to conduct direct-to consumer marketing for non-FDA-approved treatments with potentially blinding complications.
C1 [Hinkle, John W.; Mahmoudzadeh, Raziyeh; Kuriyan, Ajay E.] Thomas Jefferson Univ, Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Kuriyan, AE (通讯作者)，Thomas Jefferson Univ, Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
EM ajay.kuriyan@gmail.com
RI Mahmoudzadeh, Raziyeh/AAD-3047-2019
OI Mahmoudzadeh, Raziyeh/0000-0002-5818-9083; Kuriyan,
   Ajay/0000-0002-2824-3245
CR Alder J, 2012, DEV NEUROBIOL, V72, P755, DOI 10.1002/dneu.20980
   Astellas Institute for Regenerative Medicine, 2017, REPORT NO NCT0146983
   Astellas Institute for Regenerative Medicine, 2017, REPORT NO NCT0134500
   Astellas Institute for Regenerative Medicine, 2017, REPORT NO NCT0134499
   Bracha P, 2017, EXPERT OPIN BIOL TH, V17, P1113, DOI 10.1080/14712598.2017.1346079
   Cao J, 2016, STEM CELLS, V34, P367, DOI 10.1002/stem.2239
   CHABiotech CO. Ltd, 2019, REPORT NO NCT0167482
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Del Priore LV, 2005, ARCH OPHTHALMOL-CHIC, V123, P1156, DOI 10.1001/archopht.123.8.1156-a
   Grisanti S, 2002, JPN J OPHTHALMOL, V46, P36, DOI 10.1016/S0021-5155(01)00464-6
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P384, DOI 10.1016/j.oret.2019.11.011
   Hirano M, 2003, DEV DYNAM, V228, P664, DOI 10.1002/dvdy.10425
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Ikeda F, 2008, OPHTHALMOLOGY, V115, P718, DOI 10.1016/j.ophtha.2007.05.047
   Janssen Research & Development LLC, 2017, REPORT NO NC T012266
   Janssen Research & Development LLC, 2020, REPORT NO NCT0265909
   jCyte Inc, 2021, NCT03073733 JCYTE
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Leung EH, 2016, OSLI RETINA, V47, P600, DOI 10.3928/23258160-20160601-16
   Liu Y, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0053-y
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mead B, 2017, STEM CELL TRANSL MED, V6, P1273, DOI 10.1002/sctm.16-0428
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Moorfields Eye Hospital NHS Foundation Trust, 2019, REPORT NO NCT0169126
   Nirwan RS, 2019, OPHTHALMOLOGY, V126, P1350, DOI 10.1016/j.ophtha.2019.03.019
   Park SS, 2017, PROG RETIN EYE RES, V56, P148, DOI 10.1016/j.preteyeres.2016.10.002
   Parke DW, 2016, OPHTHALMOLOGY, V123, pS62, DOI 10.1016/j.ophtha.2016.07.039
   Regenerative Patch Technologies LLC, 2020, REPORT NO NCT0259069
   Rong AJ, 2018, JAMA OPHTHALMOL, V136, P97, DOI 10.1001/jamaophthalmol.2017.5453
   Saraf SS, 2017, OSLI RETINA, V48, P772, DOI 10.3928/23258160-20170829-16
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Siqueira RC, 2013, BONE MARROW TRANSPL, V48, P612, DOI 10.1038/bmt.2012.185
   Song SJ, 2015, RETINA-J RET VIT DIS, V35, P866, DOI 10.1097/IAE.0000000000000406
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Yin Z, 2018, REPORT NO NCT0274973
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
NR 44
TC 2
Z9 2
U1 1
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD OCT 11
PY 2021
VL 12
IS 1
AR 538
DI 10.1186/s13287-021-02546-9
PG 9
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA WF2EZ
UT WOS:000706125500001
PM 34635174
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xu, L
   Lu, T
   Tuomi, L
   Jumbe, N
   Lu, JF
   Eppler, S
   Kuebler, P
   Damico-Beyer, LA
   Joshi, A
AF Xu, Lu
   Lu, Tong
   Tuomi, Lisa
   Jumbe, Nelson
   Lu, Jianfeng
   Eppler, Steve
   Kuebler, Peter
   Damico-Beyer, Lisa A.
   Joshi, Amita
TI Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related
   Macular Degeneration: A Population Approach
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ANTIBODY FRAGMENT; SINGLE;
   BEVACIZUMAB; CATABOLISM; MODEL; TOLERABILITY; LUCENTIS; PHASE; DRUG
AB PURPOSE. To characterize ranibizumab pharmacokinetics in patients with AMD.
   METHODS. A population approach of nonlinear mixed-effect pharmacokinetic modeling based on concentration-time data from 2993 serum samples from 674 AMD patients enrolled in 5 phase 1 to 3 clinical trials of single or multiple intravitreal (ITV) doses of ranibizumab (0.3-2.0 mg/eye) administered biweekly or monthly for up to 24 months.
   RESULTS. A total of 696 concentration-time records from 229 subjects with one or more measurable total serum ranibizumab concentrations were analyzed. The systemic concentration-time data for ranibizumab were best described by a one-compartment model with first-order absorption into and first-order elimination from the systemic circulation. Vitreous elimination half-life (t(1/2)) was calculated to be 9 days and the intrinsic systemic elimination t(1/2) was calculated to be approximately 2 hours. Following ITV administration, ranibizumab egresses slowly into the systemic circulation, resulting in an apparent serum t(1/2) of 9 days. Systemic-to-vitreous exposure ratio was estimated to be 1: 90,000. With monthly and quarterly ITV regimens, the serum concentrations of ranibizumab at steady-state for both the 0.3 and 0.5 mg/eye dose levels were estimated to be below the range needed to inhibit VEGF-A-induced endothelial cell proliferation in vitro by 50% at all times.
   CONCLUSIONS. Systemic exposure to ranibizumab after ITV injection was very low due to elimination on reaching systemic circulation from the vitreous. Population pharmacokinetic analysis of data from a representative sample of AMD patients did not identify clinically significant sources or correlates of variability in ranibizumab exposure. (ClinicalTrials.gov numbers, NCT00056836, NCT00056823.) (Invest Ophthalmol Vis Sci. 2013;54:1616-1624) DOI:10.1167/iovs.12-10260
C1 [Xu, Lu; Lu, Tong; Tuomi, Lisa; Jumbe, Nelson; Lu, Jianfeng; Eppler, Steve; Kuebler, Peter; Damico-Beyer, Lisa A.; Joshi, Amita] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Damico-Beyer, LA (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM damico.lisa@gene.com
FU Genentech, Inc., South San Francisco, California
FX Supported by Genentech, Inc., South San Francisco, California, member of
   the Roche group.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Beal SL, 2001, J PHARMACOKINET PHAR, V28, P481, DOI 10.1023/A:1012299115260
   Bender B, 2007, ANN M AM ASS PHARM S
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   BRAMBELL FW, 1964, NATURE, V203, P1352, DOI 10.1038/2031352a0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cook DM, 2002, J CLIN ENDOCR METAB, V87, P4508, DOI 10.1210/jc.2002-020480
   Csaky KG, 2007, ANN M ASS RES VIS OP
   Durairaj C, 2009, PHARM RES-DORDR, V26, P1236, DOI 10.1007/s11095-008-9728-7
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   [Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) US Department of Health and Human Services], 1999, GUID IND POP PHARM
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Ghetie V, 2002, IMMUNOL RES, V25, P97, DOI 10.1385/IR:25:2:097
   HART WM, 1992, ADLERS PHYSL EYE
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Karlsson MO, 2007, CLIN PHARMACOL THER, V82, P17, DOI 10.1038/sj.clpt.6100241
   Katakam M, 1997, INT J PHARMACEUT, V152, P53, DOI 10.1016/S0378-5173(97)04920-X
   LARSON SM, 1987, RADIOLOGY, V165, P297, DOI 10.1148/radiology.165.2.3498971
   Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Lowe J, 2010, J PHARMACEUT BIOMED, V52, P680, DOI 10.1016/j.jpba.2010.01.048
   Lu JF, 2008, CANCER CHEMOTH PHARM, V62, P779, DOI 10.1007/s00280-007-0664-8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   MAURICE DM, 1987, AM J PHYSIOL, V252, pF104, DOI 10.1152/ajprenal.1987.252.1.F104
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Morris PE, 2012, CRIT CARE, V16, DOI 10.1186/cc11203
   Renard C, 1997, BRIT J CLIN PHARMACO, V44, P135, DOI 10.1046/j.1365-2125.1997.00654.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   WAGNER JG, 1964, J PHARM SCI, V53, P1392, DOI 10.1002/jps.2600531126
   WAGNER JG, 1983, J PHARM SCI, V72, P838, DOI 10.1002/jps.2600720738
   WOCHNER RD, 1967, J EXP MED, V126, P207, DOI 10.1084/jem.126.2.207
NR 39
TC 139
Z9 140
U1 1
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2013
VL 54
IS 3
BP 1616
EP 1624
DI 10.1167/iovs.12-10260
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117GV
UT WOS:000316942400006
PM 23361508
DA 2022-11-30
ER

PT J
AU Venkatesh, R
   Gadde, SGK
   Pereira, A
   Singh, V
   Sangai, S
   Sridharan, A
   Bavaharan, B
   Jain, N
   Yadav, NK
AF Venkatesh, Ramesh
   Gadde, Santosh Gopi Krishna
   Pereira, Arpitha
   Singh, Vivek
   Sangai, Sajjan
   Sridharan, Akhila
   Bavaharan, Bharathi
   Jain, Nimesh
   Yadav, Naresh Kumar
TI Impact of sub-foveal choroidal thickness on clinical features and
   long-term clinical outcomes in polypoidal choroidal vasculopathy
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Choroidal thickness; Optical
   coherence tomography; Outcome
ID INTRAVITREAL RANIBIZUMAB; SUBTYPES
AB Purpose To study the clinical features and long-term clinical outcomes in polypoidal choroidal vasculopathy (PCV) in eyes with different sub-foveal choroidal thickness (SFCT). Methods In this retrospective, observational comparative study, treatment-naive eyes diagnosed with PCV using the 'EVEREST-2' study criteria were included. The eyes were divided into three groups of thin, medium and thick choroids, based on the SFCT data of total study eyes. Demographic, clinical, imaging features and treatment outcomes between the 3 groups were compared. Results Sixty-three eyes in 63 patients were included. Right eye was involved in 39 (61%) cases and left eye in 24 (39%) cases. Mean age was 68.3 +/- 6.82 years (range 54-85 years). Mean SFCT was 274 mu m (median = 269 mu m), and one standard deviation was 79.2 mu m. Totally, 11, 43 and 9 eyes were included in the thin, medium and thick choroid groups, respectively. The mean SFCT was 161 +/- 24.1 mu m, 275 +/- 39.6 mu m and 412 +/- 26.2 mu m in the thin, medium and thick choroid groups, respectively. There was no statistically significant difference in the clinical and imaging features and treatment outcomes between eyes with thin, medium and thick SFCT. Conclusion Eyes with PCV can have a choroid of varying thicknesses. Clinical, imaging and treatment responses were similar between the three sub-foveal choroidal thickness groups in this study. In future, more studies are required to evaluate the role of the choroidal thickness and its relationship to treatment in PCV.
C1 [Venkatesh, Ramesh; Gadde, Santosh Gopi Krishna; Pereira, Arpitha; Singh, Vivek; Sangai, Sajjan; Sridharan, Akhila; Bavaharan, Bharathi; Jain, Nimesh; Yadav, Naresh Kumar] Narayana Nethralaya, Dept Retina Vitreous, 121-C,Chord Rd,1St R Block, Benguluru 560010, India.
RP Venkatesh, R (通讯作者)，Narayana Nethralaya, Dept Retina Vitreous, 121-C,Chord Rd,1St R Block, Benguluru 560010, India.
EM vramesh80@yahoo.com
OI Venkatesh, Ramesh/0000-0002-4479-9390
CR Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Ho CPS, 2018, INDIAN J OPHTHALMOL, V66, P1727, DOI 10.4103/ijo.IJO_975_18
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Nakai S, 2017, OPHTHALMOLOGICA, V237, P123, DOI 10.1159/000455273
   RAYESS N, 2015, AM J OPHTHALMOL, V159, pE1, DOI DOI 10.1016/j.ajo.2014.09.033
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Takahashi Y, 2018, JPN J OPHTHALMOL, V62, P576, DOI 10.1007/s10384-018-0615-4
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Yang JY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1609717
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
NR 22
TC 0
Z9 1
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JAN
PY 2021
VL 41
IS 1
BP 87
EP 97
DI 10.1007/s10792-020-01555-6
EA AUG 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PY9YP
UT WOS:000562685000003
PM 32844237
DA 2022-11-30
ER

PT J
AU Baghdasarian, SB
   Jneid, H
   Hoogwerf, BJ
AF Baghdasarian, SB
   Jneid, H
   Hoogwerf, BJ
TI Association of dyslipidemia and effects of statins on nonmacrovascular
   diseases
SO CLINICAL THERAPEUTICS
LA English
DT Review
DE statins; hypercholesterolemia; aortic stenosis; dementia; osteoporosis;
   nephropathy; retinopathy; macular degeneration
ID TYPE-2 DIABETES-MELLITUS; COA REDUCTASE INHIBITORS;
   CORONARY-HEART-DISEASE; SERUM-CHOLESTEROL CONCENTRATION; VALVULAR
   AORTIC-STENOSIS; LIPID-LOWERING THERAPY; RISK-FACTORS; SIMVASTATIN
   TREATMENT; ALZHEIMERS-DISEASE; NEPHROTIC SYNDROME
AB Background: Statins have mechanisms of action that expand their effects beyond cholesterol lowering and atherosclerotic medical conditions.
   Objective: This review summarizes clinical evidence for the association of dyslipidemia and the effects of statin use on aortic stenosis, Alzheimer's dementia (AD), osteoporosis, prevention of diabetes mellitus (DM), diabetic retinopathy, age-related macular degeneration, and diabetic/nondiabetic nephropathy.
   Methods: An English-language literature search was conducted using MEDLINE (1966-June 2003). Bibliographies of retrieved articles were reviewed. Search terms included statin, HMG-CoA reductase inhibitors, aortic stenosis, Alzheimer's dementia, osteoporosis, prevention of diabetes, diabetic retinopathy, age-related macular degeneration, diabetic nephropathy, and nondiabetic nephropathy.
   Results: Three retrospective cohort trials have shown an association between statin use and the progression of aortic stenosis; one of these trials observed a 45% decrease in aortic valve area in I year. In AD, one cross-sectional analysis found 60% to 73% lower AD rates in lovastatin or pravastatin recipients (P < 0.001). Of the multiple observational studies on the effect of statins on fracture risk, some have shown a decreased risk, with an odds ratio as low as 0.50 (95% Cl, 0.33-0.76); others have demonstrated no association. A post hoc analysis of the West of Scotland Coronary Prevention Study found a 30% reduction in the development of DM (P = 0.042), but this was not duplicated in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm. A small clinical trial of 6 patients (I I eyes) demonstrated improved retinal hard exudates with pravastatin treatment in patients with diabetic retinopathy. In a cross-sectional analysis, age-related macular degeneration was found to be less common among statin users than nonusers (4% [1/27] vs 22% [76/352]; P = 0.02). Multiple small clinical trials of 19 to 56 patients with diabetic and nondiabetic nephropathy at various stages generated inconsistent results for an association between statin use and decreased albumin excretion rate and decreased rate of decline in glomerular filtration.
   Conclusion: Data of variable quantity and quality support the use of statins as adjuncts in the treatment of nonmacrovascular diseases. (Clin Ther. 2004-126:337-351) Copyright (C) 2004 Excerpta Medica, Inc.
C1 Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Dept Endocrinol, Cleveland, OH 44195 USA.
   Univ Louisville, Div Cardiol, Louisville, KY 40292 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of
   Louisville
RP Baghdasarian, SB (通讯作者)，Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM sarkisbmd@ameritech.net
CR *ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
   [Anonymous], 1999, BMJ-BRIT MED J, V318, P29
   Aronow HD, 2001, LANCET, V357, P1063, DOI 10.1016/S0140-6736(00)04257-4
   ARONOW WS, 1987, AM J CARDIOL, V59, P998, DOI 10.1016/0002-9149(87)91144-1
   Aronow WS, 2001, AM J CARDIOL, V88, P693, DOI 10.1016/S0002-9149(01)01821-5
   Bazzato G., 1992, Nephrology Dialysis Transplantation, V7, P710
   Bianchi S, 2003, AM J KIDNEY DIS, V41, P565, DOI 10.1053/ajkd.2003.50140
   Buemi M, 1999, EUR J PHARMACOL, V370, P201, DOI 10.1016/S0014-2999(99)00122-3
   Buemi M, 2000, CLIN PHARMACOL THER, V67, P427, DOI 10.1067/mcp.2000.105330
   Campeau L, 1997, NEW ENGL J MED, V336, P153
   CAPPELLI P, 1992, NEPHRON, V62, P31, DOI 10.1159/000186991
   Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4
   CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276
   Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004
   Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jc.85.3.1137
   Colhoun HM, 2001, DIABETOLOGIA, V44, pS46, DOI 10.1007/PL00002939
   Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
   COONROD BA, 1993, DIABETES CARE, V16, P1376, DOI 10.2337/diacare.16.10.1376
   CUTHBERT JA, 1981, J IMMUNOL, V126, P2093
   CUTHBERT JA, 1980, J IMMUNOL, V124, P2240
   CUTTS JL, 1989, J CELL PHYSIOL, V139, P550, DOI 10.1002/jcp.1041390314
   Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615
   DUNCAN LJP, 1968, DIABETES, V17, P458, DOI 10.2337/diab.17.7.458
   EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519
   ERNEST I, 1965, AM J MED, V39, P594, DOI 10.1016/0002-9343(65)90082-3
   Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098
   Ferris FL, 1996, DIABETES CARE, V19, P1291, DOI 10.2337/diacare.19.11.1291
   Fratiglioni L, 1999, DRUG AGING, V15, P365, DOI 10.2165/00002512-199915050-00004
   Freeman DJ, 2001, CIRCULATION, V103, P357
   Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x
   Fried LF, 2001, J DIABETES COMPLICAT, V15, P113, DOI 10.1016/S1056-8727(01)00140-4
   Friedhoff LT, 2001, INT J NEUROPSYCHOPH, V4, P127, DOI 10.1017/S1461145701002310
   Ghosh PM, 1997, BBA-MOL CELL RES, V1359, P13, DOI 10.1016/S0167-4889(97)00091-8
   GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018
   GORDON B, 1991, AM J OPHTHALMOL, V112, P385, DOI 10.1016/S0002-9394(14)76244-0
   GRANDALIANO G, 1993, KIDNEY INT, V44, P503, DOI 10.1038/ki.1993.274
   Greco BA, 1997, CONTRIB NEPHROL, V120, P48
   Guijarro C, 1996, MINER ELECTROL METAB, V22, P147
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008
   Harris MI, 1998, DIABETES CARE, V21, pC11, DOI 10.2337/diacare.21.3.C11
   HARROLD BP, 1969, DIABETES, V18, P285, DOI 10.2337/diab.18.5.285
   Hennessy S, 2001, JAMA-J AM MED ASSOC, V285, P1888, DOI 10.1001/jama.285.14.1888
   Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500
   HIDAKA Y, 1992, ATHEROSCLEROSIS, V95, P87, DOI 10.1016/0021-9150(92)90179-K
   HOLMAN RR, 1983, LANCET, V1, P204
   HOMMEL E, 1992, DIABETOLOGIA, V35, P447, DOI 10.1007/BF02342442
   HORTON JC, 1998, HARRISONS PRINCIPLES, P159
   Hunsicker LG, 1997, KIDNEY INT, V51, P1908, DOI 10.1038/ki.1997.260
   INGULLI E, 1991, PEDIATR NEPHROL, V5, P393, DOI 10.1007/BF01453661
   ISHIKAWA SE, 1995, ENDOCRINOLOGY, V136, P1954, DOI 10.1210/en.136.5.1954
   JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092
   KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009
   KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912
   Keefover RW, 1996, NEUROL CLIN, V14, P337, DOI 10.1016/S0733-8619(05)70260-7
   KIM SY, 1995, KIDNEY INT, V48, P363, DOI 10.1038/ki.1995.304
   KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   KLEIN R, 1984, AM J EPIDEMIOL, V119, P54, DOI 10.1093/oxfordjournals.aje.a113725
   KLEIN R, 1989, OPHTHALMOLOGY, V96, P1501
   KREUZER J, 1991, ATHEROSCLEROSIS, V90, P203, DOI 10.1016/0021-9150(91)90116-K
   KROLEWSKI AS, 1994, KIDNEY INT, V45, pS125
   Kureishi Y, 2001, NAT MED, V7, P129
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   LAM KSL, 1995, DIABETOLOGIA, V38, P604, DOI 10.1007/s001250050326
   LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363
   LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z
   LIVANAINEN AM, 1996, AM J CARDIOL, V78, P97
   MAUTNER GC, 1993, AM J CARDIOL, V72, P194, DOI 10.1016/0002-9149(93)90159-A
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   MOHLER ER, 1991, CLIN CARDIOL, V14, P995, DOI 10.1002/clc.4960141210
   Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756-3282(03)00034-6
   MULEC H, 1990, LANCET, V335, P1537, DOI 10.1016/0140-6736(90)93090-C
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   NIELSEN S, 1993, DIABETOLOGIA, V36, P1079, DOI 10.1007/BF02374502
   Novaro GM, 2001, CIRCULATION, V104, P2205, DOI 10.1161/hc4301.098249
   OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523
   ODONNELL MP, 1993, J CLIN INVEST, V91, P83, DOI 10.1172/JCI116204
   ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126
   OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844
   Pedersen TR, 2000, JAMA-J AM MED ASSOC, V284, P1921
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Pitt B, 1999, NEW ENGL J MED, V341, P70, DOI 10.1056/NEJM199907083410202
   RADHAKRISHNAN J, 1993, AM J KIDNEY DIS, V22, P135, DOI 10.1016/S0272-6386(12)70179-8
   RAINE AEG, 1997, KIDNEY HYPERTENSION, P473
   Ravid M, 1998, ARCH INTERN MED, V158, P998, DOI 10.1001/archinte.158.9.998
   Ravid M, 1997, CONTRIB NEPHROL, V120, P39
   Rayner BL, 1996, CLIN NEPHROL, V46, P219
   Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140-6736(00)04042-3
   ROGLER G, 1995, AM J CARDIOL, V76, pA114
   Rosenberg RN, 2000, NEUROLOGY, V54, P2045, DOI 10.1212/WNL.54.11.2045
   Rosenson RS, 1999, LANCET, V353, P983, DOI 10.1016/S0140-6736(98)05917-0
   Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401
   SAMUELSSON O, 1993, NEPHRON, V63, P279, DOI 10.1159/000187210
   SAVILL J, 1994, J AM SOC NEPHROL, V5, P12
   Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711
   SCOTT HD, 2001, COCHRANE DB SYST REV, V4, P3160
   Serne EH, 1999, CIRCULATION, V99, P896, DOI 10.1161/01.CIR.99.7.896
   Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0
   Shavelle DM, 2002, LANCET, V359, P1125, DOI 10.1016/S0140-6736(02)08161-8
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   Shepherd J, 1999, AM J CARDIOL, V84, P1192, DOI 10.1016/S0002-9149(99)00533-0
   Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460
   STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823
   Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735-1097(96)00563-3
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   TERKELTAUB R, 1994, J LEUKOCYTE BIOL, V55, P749, DOI 10.1002/jlb.55.6.749
   The Post Coronary Artery Bypass Graft Trial Investigators, 1997, NEW ENGL J MED, V336, P153
   THOMAS ME, 1993, KIDNEY INT, V44, P1124, DOI 10.1038/ki.1993.358
   Tonolo G, 1997, DIABETES CARE, V20, P1891, DOI 10.2337/diacare.20.12.1891
   TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Ujihara N, 2002, DIABETES RES CLIN PR, V58, P109, DOI 10.1016/S0168-8227(02)00134-1
   Ur E, 2001, CIRCULATION, V104, pE104
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
   van Staa TP, 2001, JAMA-J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850
   VANECK WF, 1959, AM J MED, V27, P196, DOI 10.1016/0002-9343(59)90340-7
   Vrtovsnik F, 1997, KIDNEY INT, V52, P1016, DOI 10.1038/ki.1997.423
   Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Watanabe S, 2001, AM J MED, V110, P584, DOI 10.1016/S0002-9343(01)00679-9
   Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439
   YEARWOOD TL, 1989, CLIN PHYS PHYSIOL M, V10, P11, DOI 10.1088/0143-0815/10/1/002
   ZHANG A, 1995, DIABETES RES CLIN PR, V29, P189, DOI 10.1016/0168-8227(95)01138-2
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   1998, N ENGL J MED, V339, P1349
NR 131
TC 18
Z9 21
U1 0
U2 2
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD MAR
PY 2004
VL 26
IS 3
BP 337
EP 351
DI 10.1016/S0149-2918(04)90031-8
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 811ZQ
UT WOS:000220810200001
PM 15110128
DA 2022-11-30
ER

PT J
AU Tamachi, T
   Kohno, T
   Yamamoto, M
   Hirayama, K
   Kyo, A
   Ueda, N
   Hirabayashi, M
   Shiraki, K
   Honda, S
AF Tamachi, Tomoko
   Kohno, Takeya
   Yamamoto, Manabu
   Hirayama, Kumiko
   Kyo, Akika
   Ueda, Nobuhiko
   Hirabayashi, Michiko
   Shiraki, Kunihiko
   Honda, Shigeru
TI One-Year Results of a Treat-and-Extend Regimen of Intravitreal
   Aflibercept for Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Polypoidal choroidal
   vasculopathy; Treat-and-extend regimen
ID ONE-YEAR OUTCOMES; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   RANIBIZUMAB; EFFICACY; SAFETY
AB Introduction To evaluate 1-year outcomes of intravitreal aflibercept (IVA) using a treat-and-extend (TAE) regimen for polypoidal choroidal vasculopathy (PCV) and identify the factors for patients whose treatment intervals could be extended. Methods Fifty-one eyes of treatment-naive PCV patients treated with IVA using a TAE regimen for at least 1 year were examined retrospectively. All patients received at least three IVA injections every 5 weeks, and the intervals were then extended by 2-week adjustments up to 13 weeks. When retinal exudation recurred, the patient was treated with the same regimen, but with a shortened interval of 5 weeks. The main outcome measures were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) as well as the treatment interval at 1 year. Results The mean logarithm of the minimum angle of resolution BCVA improved from 0.24 +/- 0.32 at baseline to 0.18 +/- 0.31 at 12 months (p = 0.048). The mean CRT decreased from 350.3 +/- 147.7 mu m at baseline to 215.3 +/- 75.0 mu m at 4 months (p < 0.001), after which it was maintained at this level. At 12 months, the administration interval was 5 weeks in eight eyes (15.7%), 7 weeks in six eyes (11.8%), 9 weeks in two eyes (3.9%), 11 weeks in four eyes (7.8%), and 13 weeks in 31 eyes (60.8%). Female sex, a thinner CRT at 6 months, and absence of polypoidal lesions at 12 months were significant factors related to patients whose treatment intervals could be extended without recurrence to 13 weeks. Conclusion IVA using a TAE regimen improved visual and anatomical outcomes in eyes with PCV at 1 year using a protocol to adjust the injection intervals specifically for each patient so as to obtain no retinal exudation.
C1 [Tamachi, Tomoko; Kohno, Takeya; Yamamoto, Manabu; Hirayama, Kumiko; Kyo, Akika; Ueda, Nobuhiko; Shiraki, Kunihiko; Honda, Shigeru] Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Osaka, Japan.
   [Hirabayashi, Michiko] Shiraniwa Hosp, Dept Ophthalmol, Ikoma, Japan.
C3 Osaka Metropolitan University
RP Kohno, T (通讯作者)，Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Osaka, Japan.
EM takeya@med.osaka-cu.ac.jp
RI Kyo, Akika/GQO-8685-2022
CR Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Kato A, 2015, OPHTHALMOLOGICA, V233, P27, DOI 10.1159/000368249
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2020, OPHTHALMOL RETINA, V4, P767, DOI 10.1016/j.oret.2020.03.010
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Mori R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011188
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Morizane-Hosokawa M, 2018, ACTA MED OKAYAMA, V72, P379, DOI 10.18926/AMO/56175
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 26
TC 6
Z9 6
U1 0
U2 2
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD DEC
PY 2020
VL 9
IS 4
BP 1069
EP 1082
DI 10.1007/s40123-020-00312-3
EA OCT 2020
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PA9GG
UT WOS:000577843500001
PM 33058069
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Li, Y
   Andrew, N
   LaHood, BR
AF Li, Ye
   Andrew, Nick
   LaHood, Benjamin R.
TI Evidence-based vitamin supplements for age-related macular degeneration:
   an analysis of available products
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE Age-related macular degeneration; Anti-oxidants; AREDS; supplements;
   vitamins
ID DIETARY FATTY-ACIDS; EYE DISEASE; BETA-CAROTENE; FOLLOW-UP; AREDS; ZINC;
   PROGRESSION
AB Background Vitamin and antioxidant supplementation has been shown to be effective in slowing the progression of AMD. The Age-Related Eye Disease Studies (AREDS) group reported an evidence-based formula in the AREDS 2 trials. Commercially available products carry varying degrees of resemblance to this formula. Methods A review of commercially available supplements in pharmacies and websites across Australasia, the United States, the United Kingdom, and Canada was undertaken. Supplements containing all the ingredients of the AREDS 2 recipe were included. The dose, formulation, and cost of the supplements were reviewed. Results Sixty-six products were reviewed. Forty-three products contained all the AREDS 2 ingredients and were therefore included for analysis. Twenty products contained all ingredients at 100% or more of the recommended dose, and 23 products contained some ingredients at a lower dose. The cost of the products varied from Australian dollar (AUD) $0.12 to AUD $6.72 per day. Seven (35%) products were available online only and 13 (65%) products were available both online and in pharmacies. Eight products were available in the United States pharmacies, five products were available in Canadian pharmacies, three products were available in the United Kingdom pharmacies, and one product was available in Australasian pharmacies. Conclusions Commercially available AMD supplements vary widely in price and resemblance to the AREDS 2 formulation. Clinician awareness of this information is important when counselling patients on which supplement is most suitable. The categorisation of products in Table 1 may assist with patient counselling of vitamin supplementation for AMD.
C1 [Li, Ye] Princess Alexandra Hosp, Dept Ophthalmol, Brisbane, Qld, Australia.
   [Andrew, Nick] Sight Specialists, Dept Ophthalmol, Gold Coast, Australia.
   [LaHood, Benjamin R.] Queen Elizabeth Hosp, Adelaide, SA, Australia.
RP LaHood, BR (通讯作者)，Queen Elizabeth Hosp, Adelaide, SA, Australia.
EM ben@drbenlahood.com
OI Li, Ye/0000-0002-4585-956X
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Arora S, 2004, EYE, V18, P470, DOI 10.1038/sj.eye.6700700
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   Hiscock R, 2012, ANN NY ACAD SCI, V1248, P107, DOI 10.1111/j.1749-6632.2011.06202.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wegmuller R, 2014, J NUTR, V144, P132, DOI 10.3945/jn.113.181487
   Willis MS, 2005, AM J CLIN PATHOL, V123, P125, DOI 10.1309/V6GV-YW2Q-TYD5-C5PJ
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 24
TC 0
Z9 0
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD NOV 17
PY 2022
VL 105
IS 8
BP 836
EP 841
DI 10.1080/08164622.2021.1989264
EA NOV 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5U0PP
UT WOS:000718746200001
PM 34780311
DA 2022-11-30
ER

PT J
AU Thulliez, M
   Angoulvant, D
   Pisella, PJ
   Bejan-Angoulvant, T
AF Thulliez, Marie
   Angoulvant, Denis
   Pisella, Pierre-Jean
   Bejan-Angoulvant, Theodora
TI Overview of Systematic Reviews and Meta-analyses on Systemic Adverse
   Events Associated With Intravitreal Anti-Vascular Endothelial Growth
   Factor Medication Use
SO JAMA OPHTHALMOLOGY
LA English
DT Review
ID DIABETIC MACULAR EDEMA; RETINAL VEIN OCCLUSION; TRIAMCINOLONE ACETONIDE;
   MYOCARDIAL-INFARCTION; RANIBIZUMAB LUCENTIS; BEVACIZUMAB; SAFETY;
   DEGENERATION; SECONDARY; AFLIBERCEPT
AB IMPORTANCE The systemic safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications is still a matter of debate.
   OBJECTIVE This overview of systematic reviews evaluates systemic adverse events associated with intravitreal anti-VEGF treatments in patients with neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion.
   DESIGN, EVIDENCE, AND REPORTING This systematic search of PubMed and the Cochrane Central Register of Controlled Trials database includes meta-analyses and systematic reviews. We describe the summary measures of association between anti-VEGF treatments and outcomes reported in each systematic review.
   MAIN OUTCOMES AND MEASURES The quality of the systematic reviews was assessed with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and A Measurement Tool to Assess Systematic Reviews (AMSTAR) checklist, version 1.
   FINDINGS We retrieved 21 systematic reviews published between January 1, 2011, and June 30, 2016. Of these, 11 analyzed systemic adverse events as the primary outcome. The median (interquartile range) PRISMA and AMSTAR scores were 23 of 27 (15-27) and 8 of 11 (5-11), respectively, but 5 reviews (25%) scored below 20 and 7, respectively. All reviews used an objective scale to assess methodological risk of bias in their included studies, the Cochrane Risk of Bias Tool being the most commonly used (16 reviews [76%]). Anti-VEGF treatments did not increase the risk of systemic adverse events when compared with control regimens; similarly, there was no increase in systematic adverse events when treatment was given on a monthly schedule vs an as-needed regimen. Compared with ranibizumab, bevacizumab did not appear to be associated with an increase in the risk of systemic adverse events in the most recent and exhaustive reviews. Compared with control treatments, ranibizumab may be associated with an increase in the risk of nonocular hemorrhage in patients with age-related macular degeneration.
   CONCLUSIONS AND RELEVANCE This overview of reviews and meta-analyses suggest that anti-VEGF treatments do not increase the risk of systemic adverse events, but that caution might be advisable in older patients with age-related macular degeneration who may be at higher risk of hemorrhagic events when receiving ranibizumab.
C1 [Thulliez, Marie; Pisella, Pierre-Jean] Ctr Hosp Reg Univ, Bretonneau Hosp, Dept Ophthalmol, Tours, France.
   [Angoulvant, Denis] Ctr Hosp Reg Univ, Trousseau Hosp, Dept Cardiol, Tours, France.
   [Angoulvant, Denis] Univ Tours, Unit EA4245, Tours, France.
   [Bejan-Angoulvant, Theodora] Ctr Hosp Reg Univ, Dept Pharmacol, Tours, France.
   [Bejan-Angoulvant, Theodora] CNRS, UMR 7292, Tours, France.
   [Bejan-Angoulvant, Theodora] Univ Tours, Dept Med Res, Genet Immunotherapie Chim & Canc, Tours, France.
C3 CHU Tours; CHU Tours; Universite de Tours; CHU Tours; Centre National de
   la Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Universite de Tours
RP Thulliez, M (通讯作者)，Ctr Hosp Reg Univ, Bretonneau Hosp, Dept Ophthalmol, Tours, France.
EM thulliez.marie@gmail.com
RI Angoulvant, Denis/Q-9743-2019
OI Angoulvant, Denis/0000-0003-0788-8092; Bejan-Angoulvant,
   Theodora/0000-0002-0018-9996
CR Abouammoh MA, 2013, CAN J OPHTHALMOL, V48, P317, DOI 10.1016/j.jcjo.2013.03.004
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   [Anonymous], 1994, BMJ, V308, P1540
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Braithwaite T, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007325.pub3
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheng JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041325
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Etulain J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096402
   Faruque LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101145
   Ford JA, 2012, BMJ-BRIT MED J, V345, P5182
   Ford JA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002269
   Fortin P, 2013, CADTH Technol Overv, V3, pe3203
   Goyal S, 2011, GRAEF ARCH CLIN EXP, V249, P15, DOI 10.1007/s00417-010-1452-4
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247
   Ioannidis JPA, 2016, MILBANK Q, V94, P485, DOI 10.1111/1468-0009.12210
   Jadad AR, 1997, CAN MED ASSOC J, V156, P1411
   Jin EZ, 2015, ANN PHARMACOTHER, V49, P387, DOI 10.1177/1060028014568006
   Jin ZY, 2013, J OCUL PHARMACOL TH, V29, P826, DOI 10.1089/jop.2013.0061
   Martinez-Zapata MJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008721.pub2
   Karim R, 2010, CLIN OPHTHALMOL, V4, P493
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Korobelnik JF, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0035-x
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Liu XD, 2014, INT J OPHTHALMOL-CHI, V7, P1048, DOI 10.3980/j.issn.2222-3959.2014.06.26
   Liu XD, 2014, CHINESE MED J-PEKING, V127, P3471, DOI 10.3760/cma.j.issn.0366-6999.20140080
   Lu Y, 2013, J OCUL PHARMACOL TH, V29, P702, DOI 10.1089/jop.2013.0023
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Michaelides M, 2010, OPHTHALMOLOGY, V117, P1078, DOI 10.1016/j.ophtha.2010.03.045
   Micieli JA, 2010, CAN J OPHTHALMOL, V45, P231, DOI 10.3129/i10-027
   Mikacic I, 2016, DRUG SAFETY, V39, P517, DOI 10.1007/s40264-016-0408-y
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nguyen QD, 2009, OPHTHALMOLOGY, V116
   Poku E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005244
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Regnier SA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007527
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Song WT, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0017-z
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Ueta T, 2014, OPHTHALMOLOGY, V121, P7
   Virgili G, 2014, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD007419.PUB4
   Wang HY, 2012, CURR EYE RES, V37, P661, DOI 10.3109/02713683.2012.675616
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   Wang WJ, 2015, INT J OPHTHALMOL-CHI, V8, P138, DOI 10.3980/j.issn.2222-3959.2015.01.26
   Yanagida Y, 2014, RETINA-J RET VIT DIS, V34, P629, DOI 10.1097/IAE.0000000000000116
   Yilmaz T, 2012, GRAEF ARCH CLIN EXP, V250, P787, DOI 10.1007/s00417-012-2016-6
   Yilmaz T, 2011, ACTA OPHTHALMOL, V89, P709, DOI 10.1111/j.1755-3768.2010.01918.x
   Zarbin MA, 2017, JAMA OPHTHALMOL, V135, P424, DOI 10.1001/jamaophthalmol.2017.0455
   Zhang XL, 2013, INT J OPHTHALMOL-CHI, V6, P546, DOI 10.3980/j.issn.2222-3959.2013.04.26
   Zhang Y, 2013, CURR EYE RES, V38, P578, DOI 10.3109/02713683.2013.767351
   Zhu D, 2013, J OCUL PHARMACOL TH, V29, P523, DOI 10.1089/jop.2012.0278
NR 72
TC 29
Z9 30
U1 1
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2018
VL 136
IS 5
BP 557
EP 566
DI 10.1001/jamaophthalmol.2018.0002
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF3QI
UT WOS:000431870300019
PM 29566105
DA 2022-11-30
ER

PT J
AU Fallah, A
   Sadeghinia, A
   Kahroba, H
   Samadi, A
   Heidari, HR
   Bradaran, B
   Zeinali, S
   Molavi, O
AF Fallah, Asghar
   Sadeghinia, Ali
   Kahroba, Houman
   Samadi, Amin
   Heidari, Hamid Reza
   Bradaran, Behzad
   Zeinali, Sirous
   Molavi, Ommoleila
TI Therapeutic targeting of angiogenesis molecular pathways in
   angiogenesis-dependent diseases
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Anti-angiogenesis; VEGF-VEGFR system receptors; Angiogenesis-dependent
   diseases; Cancer; Anti-angiogenic therapeutics
ID METASTATIC COLORECTAL-CANCER; ENDOTHELIAL GROWTH-FACTOR; DIABETIC
   MACULAR EDEMA; ANTI-VEGF APTAMER; GENE-THERAPY; PERSONALIZED MEDICINE;
   TUMOR ANGIOGENESIS; SYSTEMS BIOLOGY; MONOCLONAL-ANTIBODIES; HEALTH-CARE
AB Angiogenesis is a critical step in the progression of almost all human malignancies and some other life-threatening diseases. Anti-angiogenic therapy is a novel and effective approach for treatment of angiogenesis-dependent diseases such as cancer, diabetic retinopathy, and age-related macular degeneration. In this article, we will review the main strategies developed for anti-angiogenic therapies beside their clinical applications, the major challenges, and the latest advances in the development of anti-angiogenesis-based targeted therapies.
C1 [Fallah, Asghar; Bradaran, Behzad] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran.
   [Fallah, Asghar; Molavi, Ommoleila] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran.
   [Fallah, Asghar; Heidari, Hamid Reza; Molavi, Ommoleila] Tabriz Univ Med Sci, Dept Pharmaceut Biotechnol, Fac Pharm, Tabriz, Iran.
   [Sadeghinia, Ali] Tabriz Univ Med Sci, Dept Pharmaceut Chem, Fac Pharm, Tabriz, Iran.
   [Sadeghinia, Ali] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Kahroba, Houman; Molavi, Ommoleila] Tabriz Univ Med Sci, Mol Med Res Ctr, Tabriz, Iran.
   [Kahroba, Houman] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Mol Med, Tabriz, Iran.
   [Samadi, Amin] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB, Canada.
   [Zeinali, Sirous] Pasteur Inst Iran, Biotechnol Res Ctr, Tehran, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science; Tabriz University of
   Medical Science; Tabriz University of Medical Science; Tabriz University
   of Medical Science; Tabriz University of Medical Science; University of
   Alberta; Le Reseau International des Instituts Pasteur (RIIP); Pasteur
   Institute of Iran
RP Molavi, O (通讯作者)，Tabriz Univ Med Sci, Dept Pharmaceut Biotechnol, Fac Pharm, Tabriz, Iran.
EM omolavi@ualberta.ca
RI ; Heidari, Hamid Reza/M-4362-2017
OI Zeinali, Sirous/0000-0002-2080-9582; Heidari, Hamid
   Reza/0000-0001-7371-4977; Sadeghinia, Ali/0000-0002-7709-6050
CR Abdalla AME, 2018, THERANOSTICS, V8, P533, DOI 10.7150/thno.21674
   Al-Husein B, 2012, PHARMACOTHERAPY, V32, P1095, DOI 10.1002/phar.1147
   Alizadeh N, 2017, BIOMED PHARMACOTHER, V93, P737, DOI 10.1016/j.biopha.2017.07.011
   Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arrieta O, 2017, EXPERT OPIN DRUG SAF, V16, P637, DOI 10.1080/14740338.2017.1313226
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Bandello F., 2017, F1000RESEARCH, V6
   Benny O, 2008, NAT BIOTECHNOL, V26, P799, DOI 10.1038/nbt1415
   Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895
   Bolinger MT, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091498
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, P1722, DOI 10.1016/j.ophtha.2016.04.025
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chen R, 2012, CURR OPIN PHARMACOL, V12, P623, DOI 10.1016/j.coph.2012.07.011
   Chen Z, 2016, NEOPLASMA, V63, P173, DOI 10.4149/201_150704N369
   Chinnasamy D, 2010, J CLIN INVEST, V120, P3953, DOI 10.1172/JCI43490
   Clarke JM, 2014, CANCER TREAT REV, V40, P1065, DOI 10.1016/j.ctrv.2014.07.001
   Curtis TM, 2009, EYE, V23, P1496, DOI 10.1038/eye.2009.108
   Das A, 2016, INDIAN J OPHTHALMOL, V64, P4, DOI 10.4103/0301-4738.178154
   Davis JC, 2009, NAT REV DRUG DISCOV, V8, P279, DOI 10.1038/nrd2825
   de Bono JS, 2010, NATURE, V467, P543, DOI 10.1038/nature09339
   de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51
   De Palma M, 2012, MOL ONCOL, V6, P111, DOI 10.1016/j.molonc.2012.01.011
   Deng HX, 2017, GENE THER, V24, P572, DOI 10.1038/gt.2017.62
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Fagiani E, 2013, CANCER LETT, V328, P18, DOI 10.1016/j.canlet.2012.08.018
   Feldman AL, 2001, J NATL CANCER I, V93, P1014, DOI 10.1093/jnci/93.13.1014
   Ferland-McCollough D, 2017, PHARMACOL THERAPEUT, V171, P30, DOI 10.1016/j.pharmthera.2016.11.008
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Fleetwood F, 2014, SCI REP-UK, V4, DOI 10.1038/srep07518
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Folkman U., 2003, BEGINNING ANGIOGENES
   Folprecht G, 2016, ANN ONCOL, V27, P1273, DOI 10.1093/annonc/mdw176
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gale R, 2017, EYE, V31, DOI 10.1038/eye.2017.53
   Goel S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006486
   Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guijarro-Munoz I, 2013, CURR GENE THER, V13, P282
   Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064
   Henderson D, 2014, BIOTECHNOL J, V9, P1104, DOI 10.1002/biot.201400109
   Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026
   Hillen F, 2007, CANCER METAST REV, V26, P489, DOI 10.1007/s10555-007-9094-7
   Holzer TR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080292
   Hosaka K, 2016, P NATL ACAD SCI USA, V113, pE5618, DOI 10.1073/pnas.1608384113
   Jakka S, 2013, HUGO J, V7, P1
   Ke EE, 2016, TRENDS PHARMACOL SCI, V37, P887, DOI 10.1016/j.tips.2016.09.003
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kim SH, 2006, J CONTROL RELEASE, V116, P123, DOI 10.1016/j.jconrel.2006.05.023
   Kimakova P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071519
   Kimura K, 2007, ATHEROSCLEROSIS, V194, P182, DOI 10.1016/j.atherosclerosis.2006.07.025
   Kubota Yoshiaki, 2012, Keio Journal of Medicine, V61, P47
   Kuczynski EA, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0162-7
   Kuo CH, 2015, HUM GENE THER, V26, P603, DOI 10.1089/hum.2013.220
   Laham-Karam N, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.16
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   Lee J, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006666
   Li J, 2010, ACTA PHARMACOL SIN, V31, P1198, DOI 10.1038/aps.2010.120
   Lu JR, 2017, CANCERS, V9, DOI 10.3390/cancers9070077
   Luo WY, 2011, CANCER GENE THER, V18, P637, DOI 10.1038/cgt.2011.35
   Lupo G, 2017, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00519
   Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x
   Mahendra G, 2005, CANCER GENE THER, V12, P26, DOI 10.1038/sj.cgt.7700754
   Mangoni A. A., 2016, ANTIVEGF INDUCED HYP
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   Mentzer SJ, 2014, ANGIOGENESIS, V17, P499, DOI 10.1007/s10456-014-9428-3
   MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0
   Moserle L, 2014, CANCER DISCOV, V4, P31, DOI 10.1158/2159-8290.CD-13-0199
   Murthy RC, 2003, INVEST OPHTH VIS SCI, V44, P1837, DOI 10.1167/iovs.02-0853
   Nerini IF, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0123-1
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nirmal J, 2016, EXPERT OPIN DRUG DEL, V13, P1625, DOI 10.1080/17425247.2016.1188800
   Niu G, 2010, CURR DRUG TARGETS, V11, P1000, DOI 10.2174/138945010791591395
   Norton KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep36992
   Ohlfest JR, 2005, MOL THER, V12, P778, DOI 10.1016/j.ymthe.2005.07.689
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Parker M, 2014, HUM GENE THER, V25, P408, DOI 10.1089/hum.2013.079
   Pavelic K, 2015, EMBO REP, V16, P133, DOI 10.15252/embr.201439609
   Potente M., 2017, NAT REV MOL CELL BIO
   Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078
   Pritchard DE, 2017, PERS MED, V14, P141, DOI 10.2217/pme-2016-0064
   Ranieri G, 2006, CURR MED CHEM, V13, P1845, DOI 10.2174/092986706777585059
   Ribatti D, 2007, LEUKEMIA, V21, P1606, DOI 10.1038/sj.leu.2404756
   Ribatti D, 2014, VASC CELL, V6, DOI 10.1186/2045-824X-6-8
   Ribatti D, 2012, DEV BIOL, V372, P157, DOI 10.1016/j.ydbio.2012.09.018
   Rouwkema J, 2016, TRENDS BIOTECHNOL, V34, P733, DOI 10.1016/j.tibtech.2016.03.002
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   S. Committee, 2015, CLIN CANC RES S, V21, pS1
   Safi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/801269
   Saharinen P, 2011, TRENDS MOL MED, V17, P347, DOI 10.1016/j.molmed.2011.01.015
   Samant RS, 2011, ONCOTARGET, V2, P122
   Sanz L, 2004, TRENDS IMMUNOL, V25, P85, DOI 10.1016/j.it.2003.12.001
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sha HH, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160332
   Shahneh Fatemeh Zare, 2013, Human Antibodies, V22, P15, DOI 10.3233/HAB-130267
   Shen Z, 2016, MOL THER, V24, P1358, DOI 10.1038/mt.2016.56
   Siavashi V, 2016, ANIM CELLS SYST, V20, P118, DOI 10.1080/19768354.2016.1189961
   Singh Amrita D, 2015, P T, V40, P430
   Smith AJ, 2016, J CELLULAR IMMUNOTHE, V2, P59, DOI DOI 10.1016/j.jocit.2016.08.001
   Stanel SC, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000190
   Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25
   Tabchi S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00052
   Tabernero J, 2014, EUR J CANCER, V50, P320, DOI 10.1016/j.ejca.2013.09.013
   Teven CM, 2014, GENES DIS, V1, P199, DOI 10.1016/j.gendis.2014.09.005
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Trujillo CA, 2007, CLIN OPHTHALMOL, V1, P393
   Ucuzian AA, 2010, J BURN CARE RES, V31, P158, DOI 10.1097/BCR.0b013e3181c7ed82
   van Beijnum J. R., 2017, ANGIOGENESIS, P1
   Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y
   Verdaguer H, 2016, THER ADV MED ONCOL, V8, P230, DOI 10.1177/1758834016635888
   Wang W, 2013, GENE THER, V20, P970, DOI 10.1038/gt.2013.19
   Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744
   Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537
   Wen XY, 2001, HUM GENE THER, V12, P347, DOI 10.1089/10430340150503975
   Weston AD, 2004, J PROTEOME RES, V3, P179, DOI 10.1021/pr0499693
   Xu J., 2017, EXPERT REV ANTICANCE
   Yang HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041214
   Ye W, 2014, MOL THER, V22, P1221, DOI 10.1038/mt.2014.53
   Yong C. S., 2016, IMMUNOL CELL BIOL
   Yun YR, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/218142
   Zhang Q, 2007, CELL RES, V17, P89, DOI 10.1038/sj.cr.7310143
   Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427
   Zhao JP, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085054, 10.1371/journal.pone.0108005]
   Zhou QB, 2016, MOL THER, V24, P1823, DOI 10.1038/mt.2016.108
   Zinser-Sierra JW, 2011, DRUGS R&D, V11, P101, DOI 10.2165/11590440-000000000-00000
NR 137
TC 102
Z9 109
U1 22
U2 121
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2019
VL 110
BP 775
EP 785
DI 10.1016/j.biopha.2018.12.022
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HG3MW
UT WOS:000454879800083
PM 30554116
OA gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Williams, MA
   Craig, D
   Passmore, P
   Silvestri, G
AF Williams, M. A.
   Craig, D.
   Passmore, P.
   Silvestri, G.
TI Retinal drusen: harbingers of age, safe havens for trouble
SO AGE AND AGEING
LA English
DT Review
DE retinal drusen; macular degeneration; vision: ocular; elderly
ID MACULAR DEGENERATION; 5-YEAR INCIDENCE; BRUCHS MEMBRANE; OCULAR DRUSEN;
   RISK-FACTORS; FOLLOW-UP; MACULOPATHY; PREVALENCE; PROGRESSION;
   POPULATION
AB Drusen are small focal extracellular deposits underneath the retina, visible ophthalmoscopically as yellow dots. The more hard drusen there are, the greater the risk of developing soft drusen and retinal pigmentary changes, which in turn increase the risk of developing advanced age-related macular degeneration. Much remains to be discovered about drusen. For the patient with drusen, basic advice on diet and smoking and maintenance of a high level of vigilance for visual changes is appropriate management.
C1 [Williams, M. A.; Craig, D.; Passmore, P.] Queens Univ Belfast, Dept Geriatr Med, Belfast BT9 7BL, Antrim, North Ireland.
   [Williams, M. A.; Silvestri, G.] Royal Hosp Trust, Ctr Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast
RP Williams, MA (通讯作者)，Queens Univ Belfast, Dept Geriatr Med, Whitla Med Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM mikewilliams99@hotmail.com
RI CRAIG, DAVID/C-6232-2009; passmore, anthony/C-9824-2009
OI Silvestri, Giuliana/0000-0001-5662-5374; Williams,
   Michael/0000-0002-5051-5921
FU Dunhill Medical Trust/Royal College of Physicians; Alzheimer's Research
   Trust
FX The first author was supported by a Dunhill Medical Trust/Royal College
   of Physicians Research Fellowship and a grant from the Alzheimer's
   Research Trust.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1998, Ophthalmology, V105, P11
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dentchev T, 2003, MOL VIS, V9, P184
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hogg RE, 2007, OPHTHALMOLOGY, V114, P1027
   INGS S, 2007, NATURAL HIST
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Russell SR, 2004, AM J OPHTHALMOL, V137, P924, DOI 10.1016/j.ajo.2003.12.043
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong TY, 2007, AM J OPHTHALMOL, V144, P117, DOI 10.1016/j.ajo.2007.04.018
NR 62
TC 18
Z9 19
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-0729
EI 1468-2834
J9 AGE AGEING
JI Age Ageing
PD NOV
PY 2009
VL 38
IS 6
BP 648
EP 654
DI 10.1093/ageing/afp136
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 510QQ
UT WOS:000271106000003
PM 19726434
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Donabedian, P
   Dawson, E
   Li, QH
   Chen, JH
AF Donabedian, Patrick
   Dawson, Elizabeth
   Li, Qiuhong
   Chen, Jinghua
TI Gut Microbes and Eye Disease
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Gut microbiome; Glaucoma; Age-related macular degeneration; Diabetic
   retinopathy; Autoimmune uveitis
ID PRIMARY OPEN-ANGLE; HELICOBACTER-PYLORI INFECTION; HEAT-SHOCK PROTEINS;
   OPTIC-NERVE HEAD; DIABETIC-RETINOPATHY; TAUROURSODEOXYCHOLIC ACID; DONOR
   FECES; CELL-DEATH; GLAUCOMA; GLUCOSE
AB Microbial symbionts in the gut are increasingly recognized as having important effects on health and disease, but have only recently begun to be linked to diseases of the eye. We review current research on the intestinal microbiota's relationship to ocular disease, focusing on autoimmune uveitis, diabetic retinopathy, age-related macular degeneration, and primary-open angle glaucoma. We discuss findings and limitations of this exciting new area of ophthalmology research and explore possible future disease-modifying treatments.
C1 [Donabedian, Patrick; Dawson, Elizabeth] Univ Florida, Coll Med, Gainesville, FL USA.
   [Li, Qiuhong; Chen, Jinghua] Univ Florida, Dept Ophthalmol, Gainesville, FL 32611 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Chen, JH (通讯作者)，Univ Florida, Dept Ophthalmol, Gainesville, FL 32611 USA.
EM jinghuachen@ufl.edu
OI Donabedian, Patrick/0000-0003-3636-4378
FU NIH [EY021752, EY024564, P30 EY02172]; American Diabetes Association;
   University of Florida
FX Funding was provided in part by NIH Grants EY021752, EY024564, and
   American Diabetes Association grants to Q.L., and NIH P30 EY02172 and
   Research to Prevent Blindness grants to the University of Florida.
   Funders had no role in study design or manuscript preparation.
CR Ala S, 2020, CASP J INTERN MED, V11, P143, DOI 10.22088/cjim.11.2.143
   Amador-Patarroyo M., 2013, AUTOIMMUNITY BENCH B
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Astafurov K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104416
   Baim AD, 2019, EXP BIOL MED, V244, P419, DOI 10.1177/1535370218813616
   Beli E, 2018, DIABETES, V67, P1867, DOI 10.2337/db18-0158
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bui BV, 2009, J NEUROCHEM, V111, P589, DOI 10.1111/j.1471-4159.2009.06354.x
   Cani PD, 2019, NAT METAB, V1, P34, DOI 10.1038/s42255-018-0017-4
   Cavuoto KM, 2019, OCUL SURF, V17, P384, DOI 10.1016/j.jtos.2019.05.006
   Chakravarthy SK, 2018, INDIAN J MICROBIOL, V58, P457, DOI 10.1007/s12088-018-0746-9
   Chen HY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001578
   Chen HH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05681-9
   Cicciu M, 2016, NEUROEPIDEMIOLOGY, V47, P94, DOI 10.1159/000449517
   Das T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82538-0
   Dave M, 2012, TRANSL RES, V160, P246, DOI 10.1016/j.trsl.2012.05.003
   David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820
   Dehner C, 2019, CURR OPIN RHEUMATOL, V31, P201, DOI 10.1097/BOR.0000000000000574
   Doulberis M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8060894
   Duan FF, 2015, DIABETES, V64, P1794, DOI 10.2337/db14-0635
   Fan Y, 2021, NAT REV MICROBIOL, V19, P55, DOI 10.1038/s41579-020-0433-9
   Fernandez-Sanchez L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177998
   Floyd JL, 2020, OPHTHALMOL THER, V9, P499, DOI 10.1007/s40123-020-00278-2
   Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766
   Fu XY, 2021, OPHTHALMIC RES, V64, P168, DOI 10.1159/000510212
   Gaspar JM, 2013, NEUROSCIENCE, V253, P380, DOI 10.1016/j.neuroscience.2013.08.053
   Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378
   Gong HJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107921
   Gorski A, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03306
   Gurung M, 2020, EBIOMEDICINE, V51, DOI 10.1016/j.ebiom.2019.11.051
   Hacquard S, 2015, CELL HOST MICROBE, V17, P603, DOI 10.1016/j.chom.2015.04.009
   Henein C., 2019, ANN EYE SCI, V4, P10, DOI [10.21037/aes.2019.02.04, DOI 10.21037/AES.2019.02.04]
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Huang XY, 2018, INVEST OPHTH VIS SCI, V59, P1523, DOI 10.1167/iovs.17-22677
   Huang YH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.646348
   Hubens WHG, 2020, EXP EYE RES, V197, DOI 10.1016/j.exer.2020.108077
   Khan R, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.7.19
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008
   Kountouras J, 2002, ARCH INTERN MED, V162, P1237, DOI 10.1001/archinte.162.11.1237
   Kountouras J, 2003, GRAEF ARCH CLIN EXP, V241, P884, DOI 10.1007/s00417-003-0779-5
   Kountouras J, 2001, OPHTHALMOLOGY, V108, P599, DOI 10.1016/S0161-6420(00)00598-4
   Kristensen NB, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0300-5
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Logan RPH, 1996, ALIMENT PHARM THERAP, V10, P3, DOI 10.1046/j.1365-2036.1996.22164001.x
   Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266
   Matijasic M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082668
   Moubayed NMS, 2019, MICROB PATHOGENESIS, V129, P88, DOI 10.1016/j.micpath.2019.01.025
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Nayyar A, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00257-5
   Oshitari T, 2014, BRAIN RES BULL, V101, P18, DOI 10.1016/j.brainresbull.2013.12.002
   Pasquale LR, 2016, OPHTHALMOLOGY, V123, P2318, DOI 10.1016/j.ophtha.2016.07.014
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Polla D, 2017, J GLAUCOMA, V26, P320, DOI 10.1097/IJG.0000000000000465
   Potempa M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000316
   Ramachandran G, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0103
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   ROMANO C, 1995, INVEST OPHTH VIS SCI, V36, P1968
   Rosenbaum JT, 2018, NAT REV RHEUMATOL, V14, P704, DOI 10.1038/s41584-018-0097-2
   Rowan S, 2018, ADV EXP MED BIOL, V1074, P429, DOI 10.1007/978-3-319-75402-4_53
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rullo J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60674-3
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013
   Shibuya E, 2008, INVEST OPHTH VIS SCI, V49, P4453, DOI 10.1167/iovs.07-1575
   Su GL, 2020, GASTROENTEROLOGY, V159, P697, DOI 10.1053/j.gastro.2020.05.059
   Sun KT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74589-6
   Tezel G, 1998, INVEST OPHTH VIS SCI, V39, P2277
   Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511
   Tezel G, 1999, ARCH OPHTHALMOL-CHIC, V117, P917
   Tezel G, 2000, J NEUROSCI, V20, P3552, DOI 10.1523/JNEUROSCI.20-10-03552.2000
   Thursby E, 2017, BIOCHEM J, V474, P1823, DOI 10.1042/BCJ20160510
   Tsirouki T, 2018, OCUL IMMUNOL INFLAMM, V26, P2, DOI 10.1080/09273948.2016.1196713
   van Eden W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01599
   van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037
   Wang CF, 2016, J ETHNOPHARMACOL, V185, P162, DOI 10.1016/j.jep.2016.03.026
   Watstein DM, 2015, METAB ENG, V31, P171, DOI 10.1016/j.ymben.2015.06.007
   Yang JJ, 2001, AM J OPHTHALMOL, V131, P421, DOI 10.1016/S0002-9394(00)00862-X
   Yang T, 2015, HYPERTENSION, V65, P1331, DOI 10.1161/HYPERTENSIONAHA.115.05315
   Zavos C, 2012, OPHTHALMIC RES, V47, P150, DOI 10.1159/000330053
   Zeng J, 2015, INVEST OPHTH VIS SCI, V56, P5238, DOI 10.1167/iovs.15-17059
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zhao D, 2015, OPHTHALMOLOGY, V122, P72, DOI 10.1016/j.ophtha.2014.07.051
   Zhao D, 2014, AM J OPHTHALMOL, V158, P615, DOI 10.1016/j.ajo.2014.05.029
   Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7
   Zhu LP, 2020, FASEB J, V34, P4189, DOI 10.1096/fj.201902496RR
   Zhuang ZC, 2017, SCI REP-UK, V7, DOI 10.1038/srep40414
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zullo A, 2012, DIGEST LIVER DIS, V44, P627, DOI 10.1016/j.dld.2012.03.011
   Zysset-Burri DC, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-00141-0
NR 95
TC 1
Z9 1
U1 3
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD JUN
PY 2022
VL 65
IS 3
BP 245
EP 253
DI 10.1159/000519457
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2E4DS
UT WOS:000812179100001
PM 34915517
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Morizane-Hosokawa, M
   Morizane, Y
   Kimura, S
   Shiode, Y
   Hirano, M
   Doi, S
   Toshima, S
   Hosogi, M
   Fujiwara, A
   Shiraga, F
AF Morizane-Hosokawa, Mio
   Morizane, Yuki
   Kimura, Shuhei
   Shiode, Yusuke
   Hirano, Masayuki
   Doi, Shinichiro
   Toshima, Shinji
   Hosogi, Mika
   Fujiwara, Atsushi
   Shiraga, Fumio
TI Impact of Polyp Regression on 2-year Outcomes of Intravitreal
   Aflibercept Injections: A Treat-and-Extend Regimen for Polypoidal
   Choroidal Vasculopathy
SO ACTA MEDICA OKAYAMA
LA English
DT Article
DE polypoidal choroidal vasculopathy; aflibercept; treat-and-extend
   regimen; polyp regression
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; RANIBIZUMAB; MONOTHERAPY;
   MULTICENTER
AB We conducted intravitreal aflibercept injections (IVAs) for 37 Japanese patients (28 males, 9 females, mean age 73.4 years) with polypoidal choroidal vasculopathy (PCV), with a treat-and-extend regimen (TER). We evaluated the impact of polyp regression after a loading dose (2-mg IVA 1x/month for 3 months) on the patients' 2-year treatment outcomes. Thirty-seven eyes were treated with IVA by a TER for 2 years. We divided the patients into 2 groups based on their polyp status after the loading dose: polyp regression (PR+) (n=19) and no polyp regression (PR-) (n=18). We compared the groups' best-corrected visual acuity (BCVA), central retinal thickness (CRT), recurrence rate, total number of injections, and final treatment interval. Both the BCVA and CRT were significantly improved by the treatment in both groups, with no between-group difference in the amount of change (p=0.769). In the polyp regression (+) group, recurrence was significantly less common (p=0.03), the mean total number of injections was significantly lower (p=0.013), and the mean treatment interval was significantly longer (0.042). Regarding the 2-year outcomes for PCV, the eyes with post-loading-dose polyp regression demonstrated less frequent recurrence and required fewer numbers of injections compared to the eyes without polyp regression.
C1 [Morizane-Hosokawa, Mio; Morizane, Yuki; Kimura, Shuhei; Shiode, Yusuke; Hirano, Masayuki; Doi, Shinichiro; Toshima, Shinji; Hosogi, Mika; Fujiwara, Atsushi; Shiraga, Fumio] Okayama Univ, Dept Ophthalmol, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan.
C3 Okayama University
RP Morizane, Y (通讯作者)，Okayama Univ, Dept Ophthalmol, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan.
EM moriza-y@okayama-u.ac.jp
CR Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Hara C, 2015, RETINA, V36, P37
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Jeng KW, 2014, RETINA-J RET VIT DIS, V34, P1796, DOI 10.1097/IAE.0000000000000182
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Qin VL, 2017, RETINA
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 25
TC 6
Z9 6
U1 0
U2 0
PU OKAYAMA UNIV MED SCHOOL
PI OKAYAMA
PA EDITORIAL OFFICE, ACTA MEDICA OKAYAMA OKAYAMA UNIVERSITY MEDICAL SCHOOL
   2-5-1 SHIKATA-CHO, KITA-KU, OKAYAMA, 700-8558, JAPAN
SN 0386-300X
J9 ACTA MED OKAYAMA
JI Acta Med. Okayama
PD AUG
PY 2018
VL 72
IS 4
BP 379
EP 385
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GR1BJ
UT WOS:000442261200009
PM 30140086
DA 2022-11-30
ER

PT J
AU Kim, J
   Chang, YS
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, J. H.
   Chang, Y. S.
   Kim, J. W.
   Kim, C. G.
   Lee, D. W.
TI Submacular hemorrhage and grape-like polyp clusters: factors associated
   with reactivation of the lesion in polypoidal choroidal vasculopathy
SO EYE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   DEGENERATION; INTRAVITREAL RANIBIZUMAB; NEOVASCULARIZATION; VERTEPORFIN;
   RECURRENCE; THERAPY; MICE
AB Purpose The purpose of this study is to investigate the factors associated with reactivation of the lesion during the first year in patients with polypoidal choroidal vasculopathy (PCV) treated with intravitreal ranibizumab.
   Patients and methods This retrospective observational study included 84 eyes diagnosed with PCV and treated with 3-monthly ranibizumab injections. Only those patients who exhibited complete resolution of fluid after initial treatment and were followed up at least 12 months were included. The baseline characteristics of the patients, including their age and sex, location of the polyps, greatest linear dimensions of the lesions, largest polyp diameter, choroidal vascular hyperpermeability, submacular hemorrhages = 1 disc area in size, presence of grape-like polyp clusters, central foveal thickness, and best-corrected visual acuity were compared between patients with and without reactivation of the lesion.
   Results During the 12-month follow-up period, reactivation of the lesion was observed in 60 patients (71.4%). The first reactivation was noted at a mean duration of 3.9 +/- 1.7 months after the third ranibizumab injection. Cox regression analysis revealed that the absence of submacular hemorrhages = 1 disc area (P = 0.009), presence of grapelike polyp clusters (P = 0.002), and greatest linear dimension of the lesions (P = 0.019) were associated with reactivation of the lesion.
   Conclusion The absence of submacular hemorrhages, presence of grape-like polyp clusters, and large lesion size at diagnosis were associated with a high risk of reactivation of PCV in patients treated with intravitreal ranibizumab. Patients exhibiting these characteristics may require close monitoring.
C1 [Kim, J. H.; Kim, J. W.; Kim, C. G.; Lee, D. W.] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Chang, Y. S.] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, J (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo-Gonzalez C, 2011, AM J OPHTHALMOL, V151, P529, DOI 10.1016/j.ajo.2010.09.021
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Kang HM, 2016, GRAEF ARCH CLIN EXP, V254, P1519, DOI 10.1007/s00417-015-3241-6
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P750, DOI 10.1097/IAE.0b013e31819ed6bd
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee JH, 2016, GRAEF ARCH CLIN EXP, V254, P645, DOI 10.1007/s00417-015-3092-1
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 10
Z9 11
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2017
VL 31
IS 12
BP 1678
EP 1684
DI 10.1038/eye.2017.126
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP7XL
UT WOS:000417853300008
PM 28707675
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wood, E
   Chang, JS
   Flynn, HW
   Kitchens, JW
AF Wood, Edward
   Chang, Jonathan S.
   Flynn, Harry W., Jr.
   Kitchens, John W.
TI Neovascular AMD With Marked Macular Fluid and Rapid Response to
   Anti-VEGF Therapy
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID DEGENERATION; RANIBIZUMAB
AB The authors describe the clinical management and spectral-domain optical coherence tomography (SD-OCT) findings of three unusual cases of neovascular age-related macular degeneration (AMD). Each patient presented with decreased vision and a diagnosis of neovascular AMD, with SD-OCT findings of marked macular fluid. Macular fluid was noted to be subretinal fluid, pigment epithelial detachment, or both. In each case, visual acuity improved and the fluid resolved rapidly with monthly anti-vascular endothelial growth factor therapy.
C1 [Wood, Edward] Univ Kentucky, Coll Med, Lexington, KY USA.
   [Chang, Jonathan S.; Flynn, Harry W., Jr.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Kitchens, John W.] Retinal Associates Kentucky, Lexington, KY USA.
C3 University of Kentucky; Bascom Palmer Eye Institute; University of Miami
RP Chang, JS (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM jchang7@med.miami.edu
OI Wood, Edward/0000-0001-8915-8346; Chang, Jonathan/0000-0001-5693-5065
FU National Institute of Health Center grant [P30-EY014801]; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [P30EY014801] Funding Source:
   NIH RePORTER
FX Supported by National Institute of Health Center grant P30-EY014801 and
   an unrestricted grant to the University of Miami from Research to
   Prevent Blindness.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 7
TC 0
Z9 0
U1 0
U2 4
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2014
VL 45
IS 2
BP 175
EP 178
DI 10.3928/23258160-20140205-02
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AH2VT
UT WOS:000335980800016
PM 24512809
DA 2022-11-30
ER

PT J
AU Ferrara, N
AF Ferrara, Napoleone
TI Vascular Endothelial Growth Factor
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
ID TUMOR ANGIOGENESIS; PERMEABILITY FACTOR; TYROSINE KINASE; CELLS SECRETE;
   IN-VIVO; VEGF; DISORDERS; LETHALITY; RECEPTOR; MITOGEN
AB Vascular endothelial growth factor (VEGF, VEGF-A) is a major regulator of physiological and pathological angiogenesis. Several VEGF inhibitors have been approved by the FDA for the treatment of advanced cancer and neovascular age-related macular degeneration. This brief review provides a historic account of the challenges associated with the discovery of VEGF and the early steps in elucidating the role of this molecule in the regulation of angiogenesis. (Arterioscler Thromb Vasc Biol. 2009;29:789-791.)
C1 [Ferrara, Napoleone] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genencor Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891
   JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHWEIKI D, 1992, NATURE, V359, P845
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
NR 24
TC 355
Z9 388
U1 1
U2 33
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JUN
PY 2009
VL 29
IS 6
BP 789
EP 791
DI 10.1161/ATVBAHA.108.179663
PG 3
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 448DG
UT WOS:000266242700002
PM 19164810
OA Bronze
DA 2022-11-30
ER

PT J
AU Mainolfi, N
   Karki, R
   Liu, F
   Anderson, K
AF Mainolfi, Nello
   Karki, Rajeshri
   Liu, Fang
   Anderson, Karen
TI Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing
   and Redesign
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Vascular endothelial growth factor receptor 2; VEGF; KDR; hinge binding;
   scaffold morphing; amino heterocycles
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; ANTIANGIOGENIC AGENTS;
   KINASE INHIBITORS; POTENT INHIBITORS; TYROSINE KINASE; DISCOVERY;
   RECEPTORS
AB Anti-VEGF therapy is a clinically validated treatment for age-related macular degeneration (AMD). We have recently reported the discovery of oral VEGFR-2 inhibitors that are selectively distributed to the ocular tissues. Herein we report a further development of those compounds and in particular the validation of the hypothesis that aminoheterocycles such as aminoisoxazoles and aminopyrazoles could also function as effective "hinge" binding moieties leading to a new class of KDR (kinase insert domain containing receptor) inhibitors.
C1 [Mainolfi, Nello; Karki, Rajeshri] Novartis Inst Biomed Res, Global Discovery Chem, 100 Technol Sq, Cambridge, MA 02139 USA.
   [Liu, Fang; Anderson, Karen] Novartis Inst Biomed Res, Ophthalmol, 500 Technol Sq, Cambridge, MA 02139 USA.
   [Mainolfi, Nello] Raze Therapeut, 400 Technol Sq, Cambridge, MA 02139 USA.
C3 Novartis; Novartis
RP Mainolfi, N; Karki, R (通讯作者)，Novartis Inst Biomed Res, Global Discovery Chem, 100 Technol Sq, Cambridge, MA 02139 USA.; Mainolfi, N (通讯作者)，Raze Therapeut, 400 Technol Sq, Cambridge, MA 02139 USA.
EM nello@razetx.com; rajeshri.karki@novartis.com
CR [Anonymous], 2005, SCHROD SUIT 2008 IND
   Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687
   Bilodeau MT, 2004, BIOORG MED CHEM LETT, V14, P2941, DOI 10.1016/j.bmcl.2004.03.052
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Gao H, 2004, VISION RES, V44, P349, DOI 10.1016/j.visres.2003.09.027
   Harris PA, 2005, J MED CHEM, V48, P1610, DOI 10.1021/jm049538w
   Hasegawa M, 2007, J MED CHEM, V50, P4453, DOI 10.1021/jm0611051
   Ji N, 2010, TETRAHEDRON LETT, V51, P6799, DOI 10.1016/j.tetlet.2010.10.073
   Johnson L, 2013, SYNTHESIS-STUTTGART, V45, P171, DOI 10.1055/s-0032-1317935
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mainolfi N., ACS MED CHE IN PRESS
   Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21
   McTigue M, 2012, P NATL ACAD SCI USA, V109, P18281, DOI 10.1073/pnas.1207759109
   Meredith EL, 2015, J MED CHEM, V58, P9273, DOI 10.1021/acs.jmedchem.5b01227
   Musumeci F, 2012, J MED CHEM, V55, P10797, DOI 10.1021/jm301085w
   Schenone S, 2007, CURR MED CHEM, V14, P2495, DOI 10.2174/092986707782023622
   TAKASE A, 1991, HETEROCYCLES, V32, P1153, DOI 10.3987/COM-91-5712
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Tripathy R, 2007, BIOORG MED CHEM LETT, V17, P1793, DOI 10.1016/j.bmcl.2006.12.054
   Zhang J, 2011, MINI-REV MED CHEM, V11, P920, DOI 10.2174/138955711797068355
NR 21
TC 16
Z9 16
U1 0
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD APR
PY 2016
VL 7
IS 4
BP 363
EP 367
DI 10.1021/acsmedchemlett.5b00486
PG 5
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA DJ8BI
UT WOS:000374436700006
PM 27096042
OA Green Published
DA 2022-11-30
ER

PT J
AU Reich, SJ
   Bennett, J
AF Reich, SJ
   Bennett, J
TI Gene therapy for ocular neovascularization: a cure in sight
SO CURRENT OPINION IN GENETICS & DEVELOPMENT
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; IN-VIVO TRANSFER;
   ADENOASSOCIATED VIRUS; CHOROIDAL NEOVASCULARIZATION; RETINAL
   NEOVASCULARIZATION; TISSUE INHIBITOR; REPORTER GENE; EXPRESSION; VEGF
AB Recent advances in the field of ocular gene transfer have led researchers pursuing treatment for age-related macular degeneration and diabetic retinopathy to turn to gene therapy for the answer. Viral vector-mediated delivery of both antiangiogenic proteins and molecules that inhibit the eye's endogenous pro-angiogenic factors has successfully diminished the pathology of ocular diseases in rodent models. A gene-therapy solution to the debilitating blindness caused by ocular neovascularization may be on the horizon.
C1 Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Stellar Chance Labs 310, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Reich, SJ (通讯作者)，Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Stellar Chance Labs 310, 422 Curie Blvd, Philadelphia, PA 19104 USA.
EM sreich@mail.med.upenn.edu; jebennet@mail.med.upenn.edu
CR Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   BAINBRIDGE J, 2003, IN PRESS CLIN SCI
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Behling KC, 2002, MOL VIS, V8, P449
   BENNETT J, 1994, INVEST OPHTH VIS SCI, V35, P2535
   Bennett J, 2000, CURR OPIN MOL THER, V2, P420
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dejneka NS, 2001, BIOESSAYS, V23, P662, DOI 10.1002/bies.1092
   Dejneka NS, 2001, GENE THER, V8, P442, DOI 10.1038/sj.gt.3301413
   Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978
   Dudus L, 1999, VISION RES, V39, P2545, DOI 10.1016/S0042-6989(98)00308-3
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Ferry N, 1998, HUM GENE THER, V9, P1975, DOI 10.1089/hum.1998.9.14-1975
   Guy J, 1999, ARCH OPHTHALMOL-CHIC, V117, P929
   Hangai M, 2001, HUM GENE THER, V12, P1311, DOI 10.1089/104303401750270968
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122
   Karakousis PC, 2001, MOL VIS, V7, P154
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2002, EXP EYE RES, V75, P625, DOI 10.1006/exer.2002.2075
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   LI TS, 1994, INVEST OPHTH VIS SCI, V35, P2543
   Lu Ming, 2002, Ophthalmol Clin North Am, V15, P69, DOI 10.1016/S0896-1549(01)00010-4
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052
   Pelzek Christopher, 2002, Ophthalmol Clin North Am, V15, P555, DOI 10.1016/S0896-1549(02)00043-3
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Reichel MB, 1998, GENE THER, V5, P1038, DOI 10.1038/sj.gt.3300691
   Reichel MB, 2001, BRIT J OPHTHALMOL, V85, P341, DOI 10.1136/bjo.85.3.341
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Takagi H, 2003, INVEST OPHTH VIS SCI, V44, P393, DOI 10.1167/iovs.02-0276
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tombran-Tink J, 1996, Mol Vis, V2, P11
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yang GS, 2002, J VIROL, V76, P7651, DOI 10.1128/JVI.76.15.7651-7660.2002
NR 54
TC 17
Z9 21
U1 0
U2 2
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-437X
EI 1879-0380
J9 CURR OPIN GENET DEV
JI Curr. Opin. Genet. Dev.
PD JUN
PY 2003
VL 13
IS 3
BP 317
EP 322
DI 10.1016/S0959-437X(03)00043-1
PG 6
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 691AM
UT WOS:000183582700015
PM 12787796
DA 2022-11-30
ER

PT J
AU Eris, E
   Kocakaya, AE
AF Eris, E.
   Kocakaya, A. E.
TI Comparison of optical coherence tomography angiography and green
   indocyanine angiography in polypoidal choroidal vasculopathy: A
   prospective study
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE ICGA; Indocyanine green angiography; Optical coherence tomography
   angiography; OCTA; PED; Type II PCV; Pigment epithelial detachment;
   Branching vascular network; BVN; Polyp size
AB Purpose. - To compare optical coherence tomography angiography (OCTA) and indocyanine green angiography (ICGA) findings in polypoidal choroidal vasculopathy (PCV) according to polyp type, polyp size and pigment epithelial detachment (PED) size.
   Method. - Seventeen patients with PCV were included this study. The participants were divided into two groups according to ICGA images. Participants who had type I PCV formed group 1, and group 2 was comprised of patients with type II PCV. OCTA was performed for all participants. Polyp detection rates with OCTA and factors affecting this detection were assessed.
   Results. - The mean age of all patients was 68.85 +/- 4.77 years (group 1 70.4 +/- 2.54 years, group 2 67.45 +/- 5.93 years). The rate of polyps seen in OCTA images was statistically significantly correlated with polyp type, polyp size, and PED size (r=0.633, p=0.002; r=0.64, P=0.001 and r=0.59, p < 0.001, respectively). In group 1, the mean polyp size was 230.8 +/- 82.94 mu m, and the mean PED size was 161.3 +/- 73.87 mu m. In group 1, 10 patients with PCV were detected with ICGA, while only 1 (10%) PCV was detected with OCTA. In group 2, the mean polyp size was 387.90 +/- 245.90 mu m, and the mean PED size was 345.18 +/- 276.26 mu m. In group 2, 11 patients with PCV were detected with ICGA, while 8 (72.7%) of these patients were detected using OCTA.
   Conclusions. - OCTA showed a greater percentage of detection of type II PCV than type I PCV. Polyp and PED size are important for the detection of PCV using OCTA. (C) 2019 Published by Elsevier Masson SAS.
C1 [Eris, E.] Beyoglu Eye Training & Res Hosp, Bereketzade Cami Sok, TR-34421 Istanbul, Turkey.
   [Kocakaya, A. E.] Acad Eye Hosp, Denizli, Turkey.
RP Eris, E (通讯作者)，Beyoglu Eye Training & Res Hosp, Bereketzade Cami Sok, TR-34421 Istanbul, Turkey.
EM erdem-eris@hotmail.com
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827
   CARSKI TR, 1978, JAMA-J AM MED ASSOC, V240, P635
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   LIPSON BK, 1989, INT OPHTHALMOL CLIN, V29, P200, DOI 10.1097/00004397-198902930-00011
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   PACURARIU RI, 1982, ANN OPHTHALMOL, V14, P32
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 22
TC 1
Z9 2
U1 0
U2 5
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD SEP
PY 2019
VL 42
IS 7
BP 690
EP 695
DI 10.1016/j.jfo.2019.03.004
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IT0QL
UT WOS:000482551000018
PM 31164300
DA 2022-11-30
ER

PT J
AU Oishi, A
   Kojima, H
   Mandai, M
   Honda, S
   Matsuoka, T
   Oh, H
   Kita, M
   Nagai, T
   Fujihara, M
   Bessho, N
   Uenishi, M
   Kurimoto, Y
   Negi, A
AF Oishi, Akio
   Kojima, Hiroshi
   Mandai, Michiko
   Honda, Shigeru
   Matsuoka, Toshiyuki
   Oh, Hideyasu
   Kita, Mihori
   Nagai, Tomoko
   Fujihara, Masashi
   Bessho, Nobuhiro
   Uenishi, Mamoru
   Kurimoto, Yasuo
   Negi, Akira
TI Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal
   Choroidal Vasculopathy: 12-Month LAPTOP Study Results
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB INJECTION; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; DOSING REGIMEN; EFFICACY; OUTCOMES; NEOVASCULARIZATION;
   MULTICENTER; DIAGNOSIS; SAFETY
AB PURPOSE: To compare the effect of photodynamic therapy (PDT) and intravitreal ranibizumab in patients with polypoidal choroidal vasculopathy (PCV).
   DESIGN: Randomized clinical trial.
   METHODS: SETTING: Multicenter. STUDY POPULATION: Total of 93 patients with treatment-naive PCV. INTERVENTION: Patients were randomized to 2 arms. Patients in the PDT arm underwent a single session of PDT with verteporfin, and patients in the ranibizumab arm received 3 monthly ranibizumab injections at baseline. Additional treatment was performed as needed in each arm. MAIN OUTCOME MEASURES: Primary outcome measurement was the proportion of patients gaining or losing more than 0.2 logarithm of minimal angle of resolution (logMAR) units from baseline. Mean change of logMAR and central retinal thickness (CRT) were also evaluated.
   RESULTS: In the PDT arm (n = 47), 17.0% achieved visual acuity gain, 55.3% had no change, and 27.7% experienced visual acuity loss. The results were 30.4%, 60.9%, and 8.7%, respectively, in the ranibizumab arm (n = 46), significantly better than the PDT arm (P = .039). In the PDT arm, mean CRT improved (366.8 +/- 113.6 mu m to 289.1 +/- 202.3 mu m, P < .001), but logMAR was unchanged (0.57 +/- 0.31 to 0.62 +/- 0.40). The ranibizumab arm demonstrated improvement in both CRT (418.9 +/- 168.6 mu m to 311.2 +/- 146.9 mu m, P < .001) and logMAR (0.48 +/- 0.27 to 0.39 +/- 0.26, P = .003). Mean change of logMAR was also greater in the ranibizumab arm (P = .011).
   CONCLUSION: Intravitreal injection of ranibizumab is more effective than PDT for treatment-naive PCV. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Oishi, Akio; Kojima, Hiroshi; Mandai, Michiko; Kurimoto, Yasuo] Kobe City Med Ctr, Gen Hosp, Kobe, Hyogo 6500047, Japan.
   [Honda, Shigeru; Negi, Akira] Kobe Univ, Kobe, Hyogo 657, Japan.
   [Matsuoka, Toshiyuki; Oh, Hideyasu; Kita, Mihori] Hyogo Kenritsu Amagasaki Hosp, Amagasaki, Hyogo, Japan.
   [Nagai, Tomoko] Steel Mem Hirohata Hosp, Himeji, Hyogo, Japan.
   [Fujihara, Masashi; Bessho, Nobuhiro; Uenishi, Mamoru] Mitsubishi Kobe Hosp, Kobe, Hyogo, Japan.
C3 Kobe City Medical Center General Hospital; Kobe University
RP Oishi, A (通讯作者)，Kobe City Med Ctr, Gen Hosp, Dept Ophthalmol, Chuo Ku, 2-1-1 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; Honda, Shigeru/W-4761-2019
OI Oishi, Akio/0000-0002-0977-9458; 
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [22791706]; Novartis
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. Several of the authors (A.O., H.K.,
   MM., S.H., M.K., M.U., Y.K., A.N.) declared payment for lectures from
   Novartis, but the company had no role in the design or conduct of this
   research. This study was supported in part by the Japan Society for the
   Promotion of Science (JSPS), Tokyo, Japan (Grant-in-Aid for Scientific
   Research, no. 22791706). Contributions of authors: conception and design
   of the study (A.O., MM., S.H.); analysis and interpretation (A.O., M.M.,
   S.H.); writing of the article (A.O.); critical revision of the article
   (MM., S.H., H.O., M.K., Y.K., A.N.); final approval of the article
   (A.O., H.K., M.M., S.H., T.M., H.O., M.K., T.N., M.F., T.B., M.U., Y.K.,
   AN.); data collection (A.O., H.K., M.M., S.H., T.M., H.O., M.K., T.N.,
   M.F., T.B., M.U., Y.K., A.N.); provision of patients or resources (A.O.,
   M.M., S.H., M.K., M.U., Y.K., A.N.); and obtaining funding (A.O.).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Koh A, 2012, RETINA
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 50
TC 107
Z9 118
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2013
VL 156
IS 4
BP 644
EP 651
DI 10.1016/j.ajo.2013.05.024
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 231VT
UT WOS:000325447200002
PM 23876867
DA 2022-11-30
ER

PT J
AU Arias, JD
   Parra, MM
   Hoyos, AT
   Arango, F
   Viteri, EJ
   Arevalo, JF
AF Arias, Juan D.
   Margarita Parra, M.
   Hoyos, Andrea T.
   Arango, Francisco
   Viteri, Eduardo J.
   Arevalo, J. Fernando
TI En face swept-source optical coherence tomography angiography choroidal
   vasculography (CVG) a tool to discriminate choroidal abnormalities in
   polypoidal choroidal vasculopathy
SO EXPERT REVIEW OF MEDICAL DEVICES
LA English
DT Article
DE Choroid; macular degeneration; optical coherence tomography; polyps;
   vasculography
AB Background Swept source optical coherence tomography angiography (SS-OCT-A) choroidal vasculography (CVG) is an imaging method which allows the evaluation of deep choroid details, being a promising too in choroidal pathologies as polypoidal choroidal vasculopathy (PCV). Research design and methods Cross-sectional study performed at FOSCAL International Clinic in Colombia. CVG features in patients with PCV were evaluated using SS-OCT CVG. Results Twenty-two eyes of 21 patients were included. The mean age was 72.7 +/- 6.5 years old (range: 48.6-95.4 years old). Twelve (57.1%) patients were male. The mean number of polyps detected by SS-OCT-A CVG before treatment with anti-VEGF therapy was 2.04 +/- 1.18, which decreased after treatment to 1.18 +/- 0.71. This result was statistically significant (p < 0.05). All polypoidal lesions detected by B-scan were visualized using CVG. Polyp circularity and surrounding reflectivity indicated activity of disease. Conclusion En face SS-OCT-A CVG is an alternative tool to evaluate choroidal structure at different depths without a contrast dye, providing information for the diagnosis and follow-up of patients with PCV. This imaging modality do not pretend to replace gold standard tests in PCV as ICGA, but rather provides choroidal imaging features of PCV, when ICGA is not available.
C1 [Arias, Juan D.] FOSCAL Int Univ Autonoma Bucaramanga, Retina Vitreous & Oncol, Floridablanca, Colombia.
   [Arias, Juan D.; Margarita Parra, M.; Viteri, Eduardo J.] FOSCAL Int Univ Autonoma Bucaramanga, Retina & Vitreous, Floridablanca, Colombia.
   [Hoyos, Andrea T.] Fdn Univ Sanitas, Retina, Vitreous, Bogota, Colombia.
   [Hoyos, Andrea T.] Fdn Univ Sanitas, Retina & Vitreous, Bogota, Colombia.
   [Arango, Francisco] Hosp Mil, Retina, Vitreous, Bogota, Colombia.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Sch Med, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Parra, MM (通讯作者)，FOSCAL Int Univ Autonoma Bucaramanga, Retina & Vitreous, Floridablanca, Colombia.
EM mariamargaritaparrac@gmail.com
OI Arevalo Suarez, Fernando Antonio/0000-0002-4114-5949
CR Arias JD, 2018, OSLI RETINA, V49, P747, DOI 10.3928/23258160-20181002-02
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   Diaz J Daniel, 2018, J Vitreoretin Dis, V2, P146, DOI 10.1177/2474126418771805
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Fujita A, 2020, RETINA-J RET VIT DIS, V40, P2296, DOI 10.1097/IAE.0000000000002760
   Glittenberg C, 2017, SPEKTRUM AUGENHEILKD, V31, P238, DOI 10.1007/s00717-017-0353-x
   Semenova N S, 2020, Vestn Oftalmol, V136, P111, DOI 10.17116/oftalma2020136011111
   Wang YL, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/6837601
NR 9
TC 1
Z9 1
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1743-4440
EI 1745-2422
J9 EXPERT REV MED DEVIC
JI Expert Rev. Med. Devices
PD SEP 2
PY 2021
VL 18
IS 9
BP 903
EP 908
DI 10.1080/17434440.2021.1963230
EA AUG 2021
PG 6
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA UQ7KO
UT WOS:000683183700001
PM 34329562
DA 2022-11-30
ER

PT J
AU Im, E
   Kazlauskas, A
AF Im, Eunok
   Kazlauskas, Andrius
TI The role of cathepsins in ocular physiology and pathology
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE cathepsin; keratoconus; retinal detachment; age-related macular
   degeneration; glaucoma; angiogenesis
ID ENDOTHELIN-CONVERTING ENZYME; CYSTEINE PROTEINASES;
   MOLECULAR-MECHANISMS; DEFICIENT MICE; CYSTATIN-C; PROTEASES;
   LOCALIZATION; EXPRESSION; TISSUES; PROGRESSION
AB Cathepsins are proteases that were originally identified in the lysosome, where they participate in house keeping tasks such as degradation of phagocytosed photoreceptors. More recently, cathepsins have been detected outside of the lysosome, and associated with numerous diseases (keratoconus, retinal detachment, age related macular degeneration, and glaucoma). The most likely mechanism by which cathepsins contribute to ocular pathologies is via degradation of the extracellular matrix, and/or regulation of angiogenesis. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Schepens Eye Research
   Institute
RP Kazlauskas, A (通讯作者)，Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM ak@eri.harvard.edu
FU NEI NIH HHS [R01 EY018344] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY018344] Funding Source: NIH RePORTER
CR Bernstein HG, 1998, NEUROSCI LETT, V240, P135, DOI 10.1016/S0304-3940(97)00946-4
   Blais V, 2002, FEBS LETT, V524, P43, DOI 10.1016/S0014-5793(02)02998-8
   Brookes NH, 2003, EXP EYE RES, V77, P515, DOI 10.1016/S0014-4835(03)00148-9
   de Garavilla L, 2005, J BIOL CHEM, V280, P18001, DOI 10.1074/jbc.M501302200
   Desai SN, 2006, EUR J PHARMACOL, V538, P168, DOI 10.1016/j.ejphar.2006.03.051
   Dibas A, 2005, J OCUL PHARMACOL TH, V21, P288, DOI 10.1089/jop.2005.21.288
   Dibas A, 2005, J OCUL PHARMACOL TH, V21, P196, DOI 10.1089/jop.2005.21.196
   Dong Z, 2001, EUR J BIOCHEM, V268, P6408, DOI 10.1046/j.0014-2956.2001.02607.x
   ELHIFNAWI E, 1995, ANN ANAT, V177, P11, DOI 10.1016/S0940-9602(11)80123-8
   Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187
   Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3
   Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008
   Goulet B, 2004, CELL CYCLE, V3, P986
   GRUBB A, 1984, NEW ENGL J MED, V311, P1547, DOI 10.1056/NEJM198412133112406
   Hamano Y, 2005, BIOCHEM BIOPH RES CO, V333, P292, DOI 10.1016/j.bbrc.2005.05.130
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4
   Kenney MC, 2005, INVEST OPHTH VIS SCI, V46, P823, DOI 10.1167/iovs.04-0549
   Kirsner JB., 1995, INFLAMM BOWEL DIS, V1, P2, DOI DOI 10.1002/ibd.3780010103
   Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6
   Kos J, 1998, ONCOL REP, V5, P1349
   Kure T, 2003, INVEST OPHTH VIS SCI, V44, P137, DOI 10.1167/iovs.01-1058
   Lah TT, 1998, BIOL CHEM, V379, P125
   Lai CM, 2000, INVEST OPHTH VIS SCI, V41, P580
   Ludwig H, 2005, CANCER-AM CANCER SOC, V104, P1794, DOI 10.1002/cncr.21414
   Mackay EA, 1997, EUR J BIOCHEM, V244, P414, DOI 10.1111/j.1432-1033.1997.00414.x
   MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x
   Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737
   NEWMAN DJ, 1994, KIDNEY INT, V47, P20
   Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1
   Obuchowska I, 1999, Klin Oczna, V101, P167
   Obuchowska I, 1997, Klin Oczna, V99, P83
   Obuchowska I, 1996, ACTA BIOCHIM POL, V43, P687
   Ogawa T, 2005, MOL VIS, V11, P380
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Pflugfelder SC, 2005, AM J PATHOL, V166, P61, DOI 10.1016/S0002-9440(10)62232-8
   Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111
   QIAN F, 1989, CANCER RES, V49, P4870
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121
   Riewald M, 2003, CRIT CARE, V7, P123, DOI 10.1186/cc1825
   Sang Q X, 1998, Cell Res, V8, P171
   Schenone M, 2004, CURR OPIN HEMATOL, V11, P272, DOI 10.1097/01.moh.0000130308.37353.d4
   SHERWIN T, 2002, EXP EYE RES, P74
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251
   Sloane BF, 2005, SEMIN CANCER BIOL, V15, P149, DOI 10.1016/j.semcancer.2004.08.001
   Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0
   TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C
   Wasselius J, 2003, GRAEF ARCH CLIN EXP, V241, P934, DOI 10.1007/s00417-003-0782-x
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901
   Wolters P J, 2000, Respir Res, V1, P170, DOI 10.1186/rr29
   Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084
   Zhang D, 2005, INVEST OPHTH VIS SCI, V46, P3031, DOI 10.1167/iovs.04-1510
NR 54
TC 36
Z9 39
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2007
VL 84
IS 3
BP 383
EP 388
DI 10.1016/j.exer.2006.05.017
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 144KG
UT WOS:000244794300002
PM 16893541
DA 2022-11-30
ER

PT J
AU Kikushima, W
   Sakurada, Y
   Yoneyama, S
   Sugiyama, A
   Matsubara, M
   Fukuda, Y
   Kashiwagi, K
AF Kikushima, Wataru
   Sakurada, Yoichi
   Yoneyama, Seigo
   Sugiyama, Atsushi
   Matsubara, Mio
   Fukuda, Yoshiko
   Kashiwagi, Kenji
TI Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year
   remission after an initial combination therapy
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Combination therapy; Visual
   prognosis; Remission
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; VERTEPORFIN; EFFICACY
AB Purpose: To investigate the visual prognosis of patients with polypoidal choroidal vasculopathy (PCV) with a 5-year remission after an initial combination therapy involving photodynamic therapy (PDT) and intravitreal ranibizumab (IVR) or aflibercept injection (IVA).
   Methods: Medical records of 69 consecutive patients with PCV treated with PDT with IVR/IVA were retrospectively reviewed, and 17 eyes were identified with a 5-year remission after the initial combination therapy. The eyes that did not require additional treatment during the 1st-5th year were assigned to the remission group and the eyes requiring additional treatment during the 1st-5th year were assigned to the recurrence group.
   Results: During the 7-year follow-up, the mean logarithm of the minimal angle resolution best-corrected visual acuity (logMAR BCVA) significantly improved from 0.39 +/- 0.27 to 0.17 +/- 0.38 (p=2.9 x 10(-4)) in the remission group, whereas the mean logMAR BCVA was maintained throughout the follow-up period (0.58 +/- 0.27 to 0.60 +/- 0.48) in the recurrence group. In the remission group, only two (11.8%) of the 17 eyes experienced recurrence during the 5th-7th year. Comparison of baseline characteristics between the two groups revealed that a higher proportion of female (p=0.012), better baseline BCVA (p=3.1 x 10(-3)), and lower risk allele frequency in ARMS2 A695 (p=0.029) were observed in the remission group.
   Conclusions: The combination therapy showed a favourable outcome for PCV over a 7-year follow-up, especially in the eyes without recurrence during the 1st-5th year. Physicians should be careful of recurrent exudation in the eyes without recurrence during the 1st-5th years, although the recurrence rate was low.
C1 [Kikushima, Wataru; Sakurada, Yoichi; Yoneyama, Seigo; Sugiyama, Atsushi; Matsubara, Mio; Fukuda, Yoshiko; Kashiwagi, Kenji] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Jain P, 2018, INDIAN J OPHTHALMOL, V66, P1119, DOI 10.4103/ijo.IJO_1222_17
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kikushima W, 2017, JPN J OPHTHALMOL, V61, P61, DOI 10.1007/s10384-016-0479-4
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsubara M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237330
   Miyata M, 2018, BRIT J OPHTHALMOL
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P389, DOI 10.1007/s10384-019-00683-6
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Sugiyama A, 2018, OPHTHALMOLOGICA, V239, P52, DOI 10.1159/000480439
   Wataru K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229231
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yang JY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1609717
   Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1245-4
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
NR 24
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2021
VL 35
AR 102453
DI 10.1016/j.pdpdt.2021.102453
EA AUG 2021
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UR4QR
UT WOS:000696736400006
PM 34303031
OA Bronze
DA 2022-11-30
ER

PT J
AU Alex, D
   Giridhar, A
   Gopalakrishnan, M
   Indu, VP
AF Alex, Divya
   Giridhar, Anantharaman
   Gopalakrishnan, Mahesh
   Indu, V. P.
TI Lateral elongation of flat irregular pigment epithelial detachment: A
   novel optical coherence tomography biomarker in polypoidal choroidal
   vasculopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Branch vascular network; flat irregular pigment epithelial detachment;
   lateral elongation; polypoidal choroidal vasculopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; MACULAR DEGENERATION; JAPANESE;
   SPECTRUM; ANGIOGRAPHY; DIAGNOSIS
AB Purpose: To explore novel Optical Coherence Tomography (OCT) biomarkers and precursor lesions in Polypoidal Choroidal Vasculopathy (PCV). Methods: This retrospective cohort study included 76 treatment naive fellow eyes of PCV. Focus was given to analyse the various morphological changes in the clinically unaffected fellow retina during the follow-up period. Results: 11 fellow eyes (14.47%) developed disease activity in the form of Sub Retinal Fluid (SRF) or Intra Retinal Fluid (IRF) within a mean follow-up of 17 months. All 11 eyes (100%) showed the presence of flat irregular pigment epithelial detachment (FIPED) and a peculiar property of lateral elongation of FIPED during disease activity. A positive correlation with the disease progression was found for the same (P < 0.0001). The mean horizontal dimension of the flat irregular PED at the enrolment was 1984 +/- 376u and the mean expansion of FIPED at SRF formation was 461 +/- 152u. ICG taken at the time of disease activity in the fellow eye revealed branching vascular network (BVN) in 9 (81.8%) eyes, polyps in 7 (63.6%) eyes, a combination of both in 5 (45.4%) eyes. Type one BVN with interconnecting channels showed faster disease progression than type two BVN. Eye tracking ICG illustrated that BVN corresponded to the FIPED in OCT and polypoidal lesions developed at the end of expanding FIPED. Conclusion: Flat irregular pigment epithelial detachment with its characteristic property of lateral elongation may be considered as a precursor lesion for PCV and as a novel OCT biomarker for the disease activity. Fellow eyes with FIPED need close monitoring to identify development of disease activity at the earliest.
C1 [Alex, Divya; Giridhar, Anantharaman; Gopalakrishnan, Mahesh; Indu, V. P.] Giridhar Eye Inst, Dept Vitreoretina Serv, Cochin, Kerala, India.
RP Alex, D (通讯作者)，Giridhar Eye Inst, Ponneth Temple Rd, Cochin, Kerala, India.
EM alex.divya@gmail.com
CR Ayachit G, 2018, INDIAN J OPHTHALMOL, V66, P1022, DOI 10.4103/ijo.IJO_180_18
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Fujimoto H, 2008, OPHTHALMOLOGY, V32, P1829
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Sheth Jay, 2018, Am J Ophthalmol Case Rep, V9, P112, DOI 10.1016/j.ajoc.2018.01.031
   Song IS, 2012, AM J OPHTHALMOL, V154, P366, DOI 10.1016/j.ajo.2012.02.031
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 27
TC 1
Z9 1
U1 0
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JAN
PY 2020
VL 68
IS 1
BP 134
EP 140
DI 10.4103/ijo.IJO_236_19
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NM6TO
UT WOS:000568228500038
PM 31856491
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tatar, O
   Kaiserling, E
   Adam, A
   Gelisken, F
   Shinoda, K
   Volker, M
   Lafaut, BA
   Bartz-Schmidt, KU
   Grisanti, S
AF Tatar, Olcay
   Kaiserling, Edwin
   Adam, Annemarie
   Gelisken, Faik
   Shinoda, Kei
   Volker, Michael
   Lafaut, Bart A.
   Bartz-Schmidt, Karl Ulrich
   Grisanti, Salvatore
TI Consequences of verteporfin photodynamic therapy on choroidal
   neovascular membranes
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; FACTOR VEGF;
   MACULAR DEGENERATION; EXPRESSION; LOCALIZATION; CELLS
AB Objective: To examine the impact of photodynamic therapy (PDT) on angiogenesis in human choroidal neo-vascular membranes with respect to vascular endothelial growth factor (VEGF) expression, proliferation, and vascularization.
   Methods: Retrospective review of an interventional case series of 50 patients (50 eyes) who underwent removal of choroidal neovascular membranes. Choroidal neovascularization was secondary to age-related macular degeneration. Twenty patients were treated with PDT 3 to 655 days before surgery. Choroidal neovascular membranes were stained for CD34, CD105, Ki-67, cytokeratin 18, and VEGF. Thirty choroidal neovascular membranes secondary to age-related macular degeneration without previous treatment were used as controls.
   Results: Specimens without pretreatment disclosed varying degrees of vascularization, proliferative activity, and VEGF-expression by different cells. Specimens treated with PDT 3 days earlier showed mostly occluded vessels, damaged endothelial cells, and low proliferative activity. In contrast, specimens excised at later time points after PDT were highly vascularized and proliferating. This chronology was associated with an impressive VEGF immunoreactivity unique to retinal pigment epithelial cells shortly after PDT that also shifted to other cells at later time points.
   Conclusions: Photodynamic therapy induces selective vascular damage in choroidal neovascular membranes. The effectiveness and selectivity of this treatment, however, seem to be jeopardized by a rebound effect initiated by enhanced VEGF expression in retinal pigment epithelial cells.
C1 Univ Tubingen, Eye Clin, Ctr Ophthalmol, Tubingen, Germany.
   Univ Tubingen, Dept Pathol, Tubingen, Germany.
   Natl Inst Sensory Organs, Lab Visual Physiol, Tokyo, Japan.
   Acad Hosp St Jan, Dept Ophthalmol, Brugge, Belgium.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP Grisanti, S (通讯作者)，Univ Tubingen, Dept Ophthalmol, Div Vitreoretinal Surg, Schleichstr 12-15, D-72076 Tubingen, Germany.
EM salvatore.grisanti@med.uni-tuebingen.de
RI Shinoda, Kei/ABC-7993-2020
OI Shinoda, Kei/0000-0002-1543-9345
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BULA DV, INVEST OPHTHALMOL E, V45
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   *EY STUD GROUP, 2003, RETINA, V110, P979
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   *TREAT AG REL MAC, 2002, ARCH OPHTHALMOL-CHIC, V20, P1443
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
NR 35
TC 30
Z9 35
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2006
VL 124
IS 6
BP 815
EP 823
DI 10.1001/archopht.124.6.815
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 051ZD
UT WOS:000238199300008
PM 16769835
OA Bronze
DA 2022-11-30
ER

PT J
AU Morange, PE
   Tregouet, DA
AF Morange, P. E.
   Tregouet, D. A.
TI Lessons from genome-wide association studies in venous thrombosis
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Review
DE genetics; gwas; epidemiology; risk factor; venous thrombosis
ID VON-WILLEBRAND-FACTOR; PLASMA-LEVELS; PROTEIN-C; GENETIC-VARIATION;
   MESSENGER-RNA; RISK-FACTOR; FACTOR-VIII; EPCR GENE; FACTOR-XI; LOCI
AB From the first genome wide association studies (GWAS) conducted on age-related macular degeneration back in 2005 until now, hundreds of studies have applied this strategy to identify novel genetic loci associated with hundreds of human diseases and related quantitative risk factors. While the GWAS revolution has just started to shift towards the next generation sequencing's burst, it is important to illustrate how the genetics research in venous thrombosis has benefit from the GWAS paradigm.
C1 [Morange, P. E.] INSERM, UMR S 626, F-13258 Marseille, France.
   [Morange, P. E.] Univ Mediterranee, Marseille, France.
   [Tregouet, D. A.] Univ Paris 06, INSERM, UMR S 937, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Aix-Marseille Universite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite
RP Morange, PE (通讯作者)，CHU Timone, Haematol Lab, 24 Rue St Pierre, F-13385 Marseille 05, France.
EM pierre.morange@ap-hm.fr
RI Trégouët, David-Alexandre/P-9210-2019
OI Trégouët, David-Alexandre/0000-0001-9084-7800
CR Anton AI, 2009, HAEMATOL-HEMATOL J, V94, P589, DOI 10.3324/haematol.2008.000604
   Antoni G, 2010, J THROMB HAEMOST, V8, P2671, DOI 10.1111/j.1538-7836.2010.04092.x
   Austin H, 2011, J THROMB HAEMOST, V9, P489, DOI 10.1111/j.1538-7836.2011.04185.x
   BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0
   Bezemer ID, 2008, JAMA-J AM MED ASSOC, V299, P1306, DOI 10.1001/jama.299.11.1306
   Braekkan SK, 2010, J THROMB HAEMOST, V8, P157, DOI 10.1111/j.1538-7836.2009.03498.x
   Buil A, 2010, BLOOD, V115, P4644, DOI 10.1182/blood-2010-01-263038
   Cheng QF, 2010, BLOOD, V116, P3981, DOI 10.1182/blood-2010-02-270918
   Danckwardt S, 2004, BLOOD, V104, P428, DOI 10.1182/blood-2003-08-2894
   De Willige SU, 2004, J THROMB HAEMOST, V2, P1305, DOI 10.1046/j.1538-7836.2004.00855.x
   de Willige SU, 2005, BLOOD, V106, P4176, DOI 10.1182/blood-2005-05-2180
   Dehghan A, 2011, CIRCULATION, V123, P731, DOI 10.1161/CIRCULATIONAHA.110.948570
   EGEBERG O, 1965, THROMB DIATH HAEMOST, V13, P516, DOI 10.1055/s-0038-1656297
   Esmon CT, 2003, J THROMB HAEMOST, V1, P1343, DOI 10.1046/j.1538-7836.2003.00261.x
   Folsom AR, 2002, ARTERIOSCL THROM VAS, V22, P1018, DOI 10.1161/01.ATV.0000017470.08363.AB
   Gailani D, 2007, J THROMB HAEMOST, V5, P1106, DOI 10.1111/j.1538-7836.2007.02446.x
   Gehring NH, 2001, NAT GENET, V28, P389, DOI 10.1038/ng578
   GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385
   Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521
   Houlihan LM, 2010, AM J HUM GENET, V86, P626, DOI 10.1016/j.ajhg.2010.02.016
   Ireland HA, 2009, ARTERIOSCL THROM VAS, V29, P1968, DOI 10.1161/ATVBAHA.109.191551
   Jenkins PV, 2006, TRANSFUSION, V46, P1836, DOI 10.1111/j.1537-2995.2006.00975.x
   KOSTER T, 1994, THROMB HAEMOSTASIS, V71, P719
   KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lanktree MB, 2010, BLOOD, V116, P2160, DOI 10.1182/blood-2010-02-269902
   Li Y, 2009, J THROMB HAEMOST, V7, P1802, DOI 10.1111/j.1538-7836.2009.03544.x
   Meijers JCM, 2000, NEW ENGL J MED, V342, P696, DOI 10.1056/NEJM200003093421004
   Meisinger C, 2009, AM J HUM GENET, V84, P66, DOI 10.1016/j.ajhg.2008.11.015
   Meltzer ME, 2010, BLOOD, V116, P113, DOI 10.1182/blood-2010-02-267740
   Merkulov S, 2008, BLOOD, V111, P1274, DOI 10.1182/blood-2007-06-092338
   Morange PE, 2011, J THROMB HAEMOST, V9, P229, DOI 10.1111/j.1538-7836.2010.04082.x
   Morange PE, 2011, BLOOD, V117, P3692, DOI 10.1182/blood-2010-11-319053
   Morange PE, 2010, AM J HUM GENET, V86, P592, DOI 10.1016/j.ajhg.2010.02.011
   Morange PE, 2010, BRIT J HAEMATOL, V148, P495, DOI 10.1111/j.1365-2141.2009.07975.x
   Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698
   Qu D, 2006, J THROMB HAEMOST, V4, P229, DOI 10.1111/j.1538-7836.2005.01676.x
   Reilly MP, 2011, LANCET, V377, P383, DOI 10.1016/S0140-6736(10)61996-4
   Reiner AP, 2008, J THROMB HAEMOST, V6, P1625, DOI 10.1111/j.1538-7836.2008.03118.x
   Ripatti S, 2010, LANCET, V376, P1393, DOI 10.1016/S0140-6736(10)61267-6
   Rosendaal FR, 2009, J THROMB HAEMOST, V7, P301, DOI 10.1111/j.1538-7836.2009.03394.x
   Saposnik B, 2004, BLOOD, V103, P1311, DOI 10.1182/blood-2003-07-2520
   Saposnik B, 2008, BLOOD, V111, P3442, DOI 10.1182/blood-2007-08-104968
   Schunkert H, 2011, NAT GENET, V43, P333, DOI [10.1038/ng.784, 10.1161/CIRCGENETICS.111.960443]
   SCHWARZ HP, 1984, BLOOD, V64, P1297
   Seligsohn U, 2001, NEW ENGL J MED, V344, P1222, DOI 10.1056/NEJM200104193441607
   Simioni P, 2006, THROMB RES, V117, P523, DOI 10.1016/j.thromres.2005.04.029
   Simioni P, 2009, NEW ENGL J MED, V361, P1671, DOI 10.1056/NEJMoa0904377
   Smith NL, 2010, CIRCULATION, V121, P1382, DOI 10.1161/CIRCULATIONAHA.109.869156
   SMITH NL, 2011, BLOOD
   Snoep JD, 2010, J THROMB HAEMOST, V8, P2377, DOI 10.1111/j.1538-7836.2010.04018.x
   Soranzo N, 2009, BLOOD, V113, P3831, DOI 10.1182/blood-2008-10-184234
   Tang WH, 2010, BLOOD, V116, P5032, DOI 10.1182/blood-2010-05-283739
   Tregouet DA, 2009, BLOOD, V113, P5298, DOI 10.1182/blood-2008-11-190389
   Tripodi A, 2004, BLOOD, V104, P3631, DOI 10.1182/blood-2004-03-1042
   Uitte de Willige S, 2007, J THROMB HAEMOST, V5, P1243
   van de Poel RHL, 2000, BIOCHEMISTRY-US, V39, P14543, DOI 10.1021/bi0006058
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Watkins NA, 2006, J THROMB HAEMOST, V4, P1197, DOI 10.1111/j.1538-7836.2006.01937.x
   Wu O, 2008, J THROMB HAEMOST, V6, P62
   Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693
NR 61
TC 30
Z9 30
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUL
PY 2011
VL 9
SU 1
SI SI
BP 258
EP 264
DI 10.1111/j.1538-7836.2011.04311.x
PG 7
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 796BG
UT WOS:000293024600028
PM 21781262
DA 2022-11-30
ER

PT J
AU Matsui, A
   Kaneko, H
   Kachi, S
   Ye, FX
   Hwang, SJ
   Takayama, K
   Nagasaka, Y
   Sugita, T
   Terasaki, H
AF Matsui, Asako
   Kaneko, Hiroki
   Kachi, Shu
   Ye, Fuxiang
   Hwang, Shiang-Jyi
   Takayama, Kei
   Nagasaka, Yosuke
   Sugita, Tadasu
   Terasaki, Hiroko
TI Expression of Vascular Endothelial Growth Factor by Retinal Pigment
   Epithelial Cells Induced by Amyloid-beta Is Depressed by an Endoplasmic
   Reticulum Stress Inhibitor
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE 4-phenylbutyl phosphonylacetate; Vascular endothelial growth factor;
   Amyloid-beta; Endoplasmic reticulum stress; Age-related macular
   degeneration
ID UNFOLDED PROTEIN RESPONSE; MACULAR DEGENERATION; ER STRESS;
   ALZHEIMERS-DISEASE; SODIUM 4-PHENYLBUTYRATE; DRUSEN; DEATH; GENE;
   INFLAMMATION; RANIBIZUMAB
AB Purpose: Amyloid-beta (A beta) is a 36- to 43-amino-acid peptide that is a constituent of drusen, and it has been demonstrated to upregulate vascular endothelial growth factor (VEGF) expression by retinal pigment epithelial (RPE) cells. This study aimed to determine whether 4-phenylbutyl phosphonylacetate (PBA), a known endoplasmic reticulum (ER) stress inhibitor, can reduce A beta-induced expression of VEGF in RPE cells. Methods: A beta was added to the medium of regularly cultured or polarized ARPE-19 cells, a human RPE cell line, with or without PBA. The levels of VEGF and ER stress markers, namely GRP78/Bip, cleaved caspases 4 and 12 and GADD153/C-EBP homologous protein, were determined by enzyme-linked immunoassay, immunocytochemistry and Western blotting. Results: Exposure of ARPE-19 cells to A beta induced GRP78/Bip expression and activated caspases 4 and 12; however, their expression was decreased by simultaneous exposure to PBA. A beta increased the expression of VEGF both in regularly cultured and polarized ARPE-19 cells, but it was suppressed by PBA. PBA did not cause RPE cell apoptosis. Conclusion: A beta has been suggested to be involved in the development of age-related macular degeneration; therefore, our findings suggest that drugs that target ER stress should be considered for the treatment of age-related macular degeneration. (C) 2015 S. Karger AG, Basel
C1 [Matsui, Asako; Kaneko, Hiroki; Kachi, Shu; Ye, Fuxiang; Hwang, Shiang-Jyi; Takayama, Kei; Nagasaka, Yosuke; Sugita, Tadasu; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan.
   [Ye, Fuxiang] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Ophthalmol, Shanghai 200030, Peoples R China.
C3 Nagoya University; Shanghai Jiao Tong University
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014; Kaneko, Hiroki/AHA-2461-2022
OI Kaneko, Hiroki/0000-0003-0731-6465; Ye, Fuxiang/0000-0003-2550-2173;
   Takayama, Kei/0000-0002-1477-9014
FU Japan Society for the Promotion of Science; Japan Intractable Diseases
   Research Foundation; Takeda Science Foundation; Takeda Medical Research
   Foundation; Yokoyama Foundation for Clinical Pharmacology [YRY1411];
   Uehara Memorial Foundation
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper. This work was
   supported by a Grant-in-Aid for Young Scientists (H.K.) and a
   Grant-in-Aid for Challenging Exploratory Research from the Japan Society
   for the Promotion of Science (H.K.). The study was also supported by the
   Japan Intractable Diseases Research Foundation (H.K.), Takeda Science
   Foundation (H.K.), Takeda Medical Research Foundation (H.K.), Yokoyama
   Foundation for Clinical Pharmacology (YRY1411, H.K.) and The Uehara
   Memorial Foundation (H.K.).
CR Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bian ZM, 2009, INVEST OPHTH VIS SCI, V50, P6006, DOI 10.1167/iovs.09-3628
   Bian ZM, 2008, INVEST OPHTH VIS SCI, V49, P5593, DOI 10.1167/iovs.08-2116
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143
   Dentchev T, 2003, MOL VIS, V9, P184
   Doh SH, 2010, BRAIN RES, V1308, P158, DOI 10.1016/j.brainres.2009.10.025
   DOVER GJ, 1992, NEW ENGL J MED, V327, P569
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Fujii Y, 2010, BRIT J OPHTHALMOL, V94, P1074, DOI 10.1136/bjo.2009.161109
   Gorbatyuk MS, 2010, P NATL ACAD SCI USA, V107, P5961, DOI 10.1073/pnas.0911991107
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Hoozemans JJM, 2005, ACTA NEUROPATHOL, V110, P165, DOI 10.1007/s00401-005-1038-0
   Ijima R, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.6
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaneko H, 2014, BRIT J PHARMACOL, V171, P3754, DOI 10.1111/bph.12737
   Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004
   Koyama Y, 2008, INVEST OPHTH VIS SCI, V49, P2376, DOI 10.1167/iovs.07-1067
   Kubota K, 2006, J NEUROCHEM, V97, P1259, DOI 10.1111/j.1471-4159.2006.03782.x
   Lee K-S, 2010, PLOS ONE, V5, DOI DOI 10.1371/JOURNAL.PONE.0010489
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Maestri NE, 1996, NEW ENGL J MED, V335, P855, DOI 10.1056/NEJM199609193351204
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294
   Oh S, 2005, MECH AGEING DEV, V126, P1292, DOI 10.1016/j.mad.2005.07.006
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Qi X, 2004, MOL PHARMACOL, V66, P899, DOI 10.1124/mol.104.001339
   Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200
   Salminen A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-41
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Ye F, 2015, SCI REP, V5, P7
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 42
TC 15
Z9 15
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 55
IS 1
BP 37
EP 44
DI 10.1159/000440885
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CY3VE
UT WOS:000366337200005
PM 26560903
DA 2022-11-30
ER

PT J
AU Mallikarjun, K
   Narayanan, R
   Raman, R
   Mohamed, A
   Shanmugam, MP
   Apte, RS
   Padhy, SK
AF Mallikarjun, Kushanth
   Narayanan, Raja
   Raman, Rajiv
   Mohamed, Ashik
   Shanmugam, Mahesh P.
   Apte, Rajendra S.
   Padhy, Srikant Kumar
TI Dexamethasone implant improves anatomic response to anti-VEGF therapy in
   treatment-resistant polypoidal choroidal vasculopathy
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Dexamethasone intravitreal implant; Anti-VEGF; Treatment resistance;
   Polypoidal choroidal vasculopathy; Visual acuity; Optical coherence
   tomography; Intravitreal injection
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; RANIBIZUMAB
   MONOTHERAPY; INTRAVITREAL IMPLANT; COMBINATION THERAPY; BEVACIZUMAB;
   NEOVASCULARIZATION; PHARMACOKINETICS; TRIAMCINOLONE; NONRESPONDERS
AB Background A significant proportion of eyes with polypoidal choroidal vasculopathy (PCV) can be resistant to anti-vascular endothelial growth factor (VEGF) injections. We evaluated the efficacy of a combination of dexamethasone intravitreal implant (DXI) and anti-VEGF therapy in eyes resistant to anti-VEGF monotherapy. Methods In this retrospective study, patients with PCV resistant to anti-VEGF injections were additionally injected with a DXI along with an anti-VEGF agent. Best-corrected visual acuity (BCVA), slit-lamp examination, fundus evaluation, and optical coherence tomography (OCT) data were analyzed. Anatomical response on OCT was the primary outcome measure. Change in visual acuity and injection-free interval after DXI were evaluated as secondary outcome measures. Results Twelve eyes of 11 patients were included in the study. Mean age of patients at presentation was 64.7 +/- 9.5 years (range, 49-78.8 years), and there were seven females (63.6%). Median number of anti-VEGF injections prior to DXI was 4 (interquartile range IQR, 3-7). Median follow-up duration after DXI was 32.2 months (IQR, 6.6-41.6 months). Median logMAR BCVA immediately prior to DXI was 0.41 (IQR, 0.30-0.88) and after injection was 0.40 (IQR, 0.30-1.05), which was not significantly different (p = 0.85). Median Central Retinal Thickness (CRT) after DXI was 305.5 mu m (IQR, 249-409 mu m), which was significantly (p = 0.003) lesser than pre-injection thickness of 547 mu m (IQR, 431-771 mu m). Median injection-free interval in these eyes after DXI was 5 months (IQR, 2.8-6.4 months). Kaplan-Meier estimates of first injection after DXI were 27.3% at 3 months, 67.3% at 6 months, and 89.1% at 12 months. Conclusions Dexamethasone implant combined with anti-VEGF treatment can prolong the treatment-free interval in eyes with PCV resistant to anti-VEGF injection while maintaining visual acuity.
C1 [Mallikarjun, Kushanth; Apte, Rajendra S.] Washington Univ, Sch Med, St Louis, MO USA.
   [Narayanan, Raja] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, IHOPE Ctr, Hyderabad, India.
   [Raman, Rajiv] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
   [Mohamed, Ashik] LV Prasad Eye Inst, Ophthalm Biophys, Hyderabad, India.
   [Shanmugam, Mahesh P.] Sankara Eye Hosp, Bengaluru, India.
   [Padhy, Srikant Kumar] LV Prasad Eye Inst, Vitreoretinal Dis, Bhubaneswar, India.
C3 Washington University (WUSTL); L. V. Prasad Eye Institute; L. V. Prasad
   Eye Institute; L. V. Prasad Eye Institute
RP Narayanan, R (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, IHOPE Ctr, Hyderabad, India.
EM narayanan@lvpei.org
RI Narayanan, Raja/AAT-3098-2021
OI Narayanan, Raja/0000-0001-9688-5859
FU Hyderabad Eye Research Foundation and India Alliance DB Wellcome Trust
FX Hyderabad Eye Research Foundation and India Alliance DB Wellcome Trust.
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Giancipoli E, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5612342
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Oliver Alejandro, 2006, Ophthalmol Clin North Am, V19, P345
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Rezar-Dreindl S, 2017, RETINA-J RET VIT DIS, V37, P962, DOI 10.1097/IAE.0000000000001264
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Todorich Bozho, 2017, J Vitreoretin Dis, V1, P65, DOI 10.1177/2474126416683299
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 29
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2022
VL 42
IS 4
BP 1263
EP 1272
DI 10.1007/s10792-021-02113-4
EA NOV 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0L4XW
UT WOS:000716340900001
PM 34755239
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Fagerness, JA
   Maller, JB
   Neale, BM
   Reynolds, RC
   Daly, MJ
   Seddon, JM
AF Fagerness, Jesen A.
   Maller, Julian B.
   Neale, Benjamin M.
   Reynolds, Robyn C.
   Daly, Mark J.
   Seddon, Johanna M.
TI Variation near complement factor I is associated with risk of advanced
   AMD
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE AMD; macular degeneration; genetic association; complement pathway
ID GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION;
   GENE; HAPLOTYPE; DISEASE; VARIANT; SYSTEM; CELLS; SCANS
AB A case-control association study for advanced age-related macular degeneration was conducted to explore several regions of interest identified by linkage. This analysis identified a single nucleotide polymorphism just 3' of complement factor I on chromosome 4 showing significant association (P < 10(-7)). Sequencing was performed on coding exons in linkage disequilibrium with the detected association. No obvious functional variation was discovered that could be the proximate cause of the association, suggesting a noncoding regulatory mechanism.
C1 [Reynolds, Robyn C.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Fagerness, Jesen A.; Maller, Julian B.; Neale, Benjamin M.; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Fagerness, Jesen A.; Maller, Julian B.; Neale, Benjamin M.; Daly, Mark J.] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA USA.
   [Fagerness, Jesen A.; Maller, Julian B.; Neale, Benjamin M.; Daly, Mark J.] MIT, Cambridge, MA 02139 USA.
   [Maller, Julian B.] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   [Neale, Benjamin M.] Kings Coll London, Inst Psychiat, SGDP Ctr, London, England.
C3 Tufts Medical Center; Harvard University; Massachusetts General
   Hospital; Harvard University; Massachusetts Institute of Technology
   (MIT); Broad Institute; Massachusetts Institute of Technology (MIT);
   University of Oxford; University of London; King's College London
RP Seddon, JM (通讯作者)，Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI maller, julian B/A-9323-2009; Daly, Mark J/B-2453-2017
OI Daly, Mark J/0000-0002-0949-8752; Maller, Julian/0000-0002-1565-9559
FU National Institutes of Health [EY11309]; Foundation Fighting Blindness;
   Massachusetts Lions Research Fund; Research to Prevent Blindness;
   Macular Degeneration Research Fund; Ophthalmic Epidemiology and Genetics
   Service; New England Eye Center; Tufts Medical Center; enter for
   Inherited Disease Research; Broad Institute Center for Genotyping and
   Analysis [U54 RR020278]; National Center for Research Resources;
   NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020278] Funding Source: NIH
   RePORTER
FX Funding was provided by the National Institutes of Health grant EY11309;
   the Foundation Fighting Blindness; the Massachusetts Lions Research
   Fund; Research to Prevent Blindness; Macular Degeneration Research Fund
   of the Ophthalmic Epidemiology and Genetics Service, the New England Eye
   Center, Tufts Medical Center; Center for Inherited Disease Research; and
   the Broad Institute Center for Genotyping and Analysis (through grant
   U54 RR020278 from the National Center for Research Resources). We thank
   AREDS participants and investigators and the EMMES Corporation for their
   work on the AREDS Genetic Repository. We also thank Daniel Mirel, Brian
   Galloway (project management); Robb Onofrio, Rob Borowski, Kat Irzene,
   Tony Rachupka (genotyping/sequencing), David Turner, Meg Parker (sample
   management); and Chris Cotsapas (bioinformatics).
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849
   Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200
   Huhtinen HT, 2006, APMIS, V114, P127, DOI 10.1111/j.1600-0463.2006.apm_330.x
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kwan JSH, 2007, STAT GENETICS GENE M, P355
   Landreville S, 2004, INVEST OPHTH VIS SCI, V45, P3997, DOI 10.1167/iovs.04-0084
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Pe'er I, 2008, GENET EPIDEMIOL, V32, P381, DOI 10.1002/gepi.20303
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SULLIVAN PF, 2007, STAT GENETICS GENE M, P355
   VYSE TJ, 1994, GENOMICS, V24, P90, DOI 10.1006/geno.1994.1585
   Wiltshire S, 2006, EUR J HUM GENET, V14, P1209, DOI 10.1038/sj.ejhg.5201678
NR 27
TC 266
Z9 283
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JAN
PY 2009
VL 17
IS 1
BP 100
EP 104
DI 10.1038/ejhg.2008.140
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 382EU
UT WOS:000261588800014
PM 18685559
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Wu, J
   Cui, DM
   Li, HH
   Zeng, JW
AF Wu, Juan
   Cui, Dongmei
   li, Honghui
   Zeng, Junwen
TI Protective effects of NAC and salubrinal on apoptosis of retinal pigment
   epithelial cells induced by all-trans retinoic acid
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE AMD; ATRA; ARPE-19 cells; ERS; ROS; VEGF-A
ID MOUSE MODEL; ENDOPLASMIC-RETICULUM; GEOGRAPHIC ATROPHY; ER STRESS;
   DISEASE; DAMAGE
AB Purpose: Accumulation of endogenous all-trans retinoic acid (ATRA) plays a role in the degeneration of photoreceptor cells and retinal pigment epithelium (RPE) cells, contributing to age-related macular degeneration (AMD). This study attempted to investigate the influence of antioxidant N-acetylcysteine (NAC) and selective endoplasmic reticulum stress (ERS) inhibitor salubrinal on apoptosis of ARPE-19 cells induced by ATRA.
   Methods: The RPE cell line (ARPE-19) was treated with ATRA, ATRA+NAC, ATRA+salubrinal or ATRA+NAC+salubrinal and the control was untreated. After 24 h of cell culture, the levels of apoptosis, multicaspase and reactive oxygen species (ROS) were detected by flow cytometry. Western blot analysis was employed to detect the expression of vascular endothelial growth factor-A (VEGF-A), C/EBP homologous protein (CHOP) and cleaved caspase-3 in the groups.
   Results: The results of flow cytometry showed that NAC and salubrinal decreased the levels of apoptosis, ROS and multicaspase. ATRA increased VEGF-A levels associated with neovascularisation. NAC and salubrinal inhibited an increase in VEGF-A, CHOP and caspase-3 caused by ATRA in ARPE-19 cells.
   Conclusions: In ARPE-19 cells, the levels of ROS and ERS can be increased by ATRA, contributing to apoptosis, which can be effectively inhibited by NAC and salubrinal. Thus, ATRA may play an important role in the prevention, diagnosis and treatment of age-related macular degeneration.
C1 [Wu, Juan; Cui, Dongmei; Zeng, Junwen] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, 54 South Xianlie Rd, Guangzhou 510060, Peoples R China.
   [li, Honghui] Chengdu Air Eye Hosp, Chengdu, Sichuan, Peoples R China.
C3 Sun Yat Sen University
RP Zeng, JW (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, 54 South Xianlie Rd, Guangzhou 510060, Peoples R China.
EM zeng_zoc@163.com
FU National Natural Science Foundation of China [81170872]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: National
   Natural Science Foundation of China (Grant no. 81170872), sponsor name:
   Junwen Zeng.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Chen JT, 2005, J OCUL PHARMACOL TH, V21, P413, DOI 10.1089/jop.2005.21.413
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cui J, 2020, INT J OPHTHALMOL-CHI, V13, P9
   Desideri LF, 2020, DRUG TODAY, V56, P311, DOI 10.1358/dot.2020.56.5.3137164
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Desideri LF, 2020, EXPERT OPIN INV DRUG, V29, P651, DOI 10.1080/13543784.2020.1772754
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Ijima R, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.6
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Li J, 2015, TOXICOL SCI, V143, P196, DOI 10.1093/toxsci/kfu223
   Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Matsui A, 2016, OPHTHALMIC RES, V55, P37, DOI 10.1159/000440885
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Naranmandura H, 2012, TOXICOL APPL PHARM, V260, P241, DOI 10.1016/j.taap.2012.02.017
   Nicolo M, 2020, OPHTHALMOLOGICA, V243, P453, DOI 10.1159/000507711
   Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294
   Oh S, 2005, MECH AGEING DEV, V126, P1292, DOI 10.1016/j.mad.2005.07.006
   Qi X, 2004, MOL PHARMACOL, V66, P899, DOI 10.1124/mol.104.001339
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Sawada O, 2014, EXP EYE RES, V123, P27, DOI 10.1016/j.exer.2014.04.003
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zode GS, 2011, J CLIN INVEST, V121, P3542, DOI 10.1172/JCI58183
NR 33
TC 0
Z9 1
U1 1
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 395
EP 401
AR 11206721211000674
DI 10.1177/11206721211000674
EA MAR 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000678537100001
PM 33726556
DA 2022-11-30
ER

PT J
AU Jung, E
   Jung, W
   Park, SB
   Kim, CS
   Kim, JS
   Kim, J
AF Jung, Eunsoo
   Jung, Wookwon
   Park, Su-Bin
   Kim, Chan-Sik
   Kim, Jin Sook
   Kim, Junghyun
TI EGHB010, a Standardized Extract of Paeoniae Radix and Glycyrrhizae
   Radix, Inhibits VEGF-Induced Tube Formation In Vitro and Retinal
   Vascular Leakage and Choroidal Neovascularization In Vivo
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; TOTAL GLUCOSIDES;
   INTRAVITREAL INJECTION; TARGETING ANGIOGENESIS; ADJUVANT ARTHRITIS;
   OXIDATIVE STRESS; MECHANISMS; PEONY; ENDOPHTHALMITIS
AB EGHB010 is a hot water extract of the rhizome mixture of Paeonia lactiflora Pallas and Glycyrrhiza uralensis Fisch. Choroidal neovascularization (CNV) and vascular leakage are the common pathophysiologies of age-related macular degeneration. In this study, we aimed to evaluate the effect of EGHB010 on retinal vascular leakage and laser-induced CNV in a rat model. Vascular endothelial growth factor-(VEGF-) induced tube formation was assayed in human retinal microvascular endothelial cells. Intravitreal VEGF-induced blood-retinal barrier breakdown was assayed in Sprague-Dawley rats. Experimental CNV was induced by laser photocoagulation in Brown Norway rats. EGHB010 (50 and 100 mg/kg/day) was administered orally for 10 days after laser photocoagulation. Choroidal flat mounts were prepared to measure the lesion size of CNV. Incubation of retinal vascular endothelial cells with EGHB010 (12.5 and 25 mu g/mL) resulted in the inhibition of VEGF-induced tube formation in a dose-dependent manner. VEGF-mediated retinal vascular leakage was blocked by the oral administration of EGHB010. The CNV area was significantly lower in EGHB010-treated rats than in vehicle-treated rats. These results suggest that EGHB010 is a potent antiangiogenic agent. Thus, the oral administration of EGHB010 may have a beneficial effect in the treatment of vascular leakage and CNV in patients with age-related macular degeneration.
C1 [Jung, Eunsoo] Seoul Natl Univ, Res Inst Vet Sci, Lab Toxicol, Seoul, South Korea.
   [Jung, Eunsoo] Seoul Natl Univ, Coll Vet Med, Seoul, South Korea.
   [Jung, Wookwon; Park, Su-Bin; Kim, Junghyun] Chonbuk Natl Univ, Sch Dent, Dept Oral Pathol, Jeonju 54896, South Korea.
   [Kim, Chan-Sik; Kim, Jin Sook; Kim, Junghyun] Korea Inst Oriental Med, Korean Med Convergence Res Div, Daejeon, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU);
   Jeonbuk National University; Korea Institute of Oriental Medicine (KIOM)
RP Kim, J (通讯作者)，Chonbuk Natl Univ, Sch Dent, Dept Oral Pathol, Jeonju 54896, South Korea.; Kim, J (通讯作者)，Korea Inst Oriental Med, Korean Med Convergence Res Div, Daejeon, South Korea.
EM dvmhyun@jbnu.ac.kr
FU Korea Institute of Oriental Medicine [K17810]; Korea Institute of
   Planning and Evaluation for Technology in Food, Agriculture, Forestry
   and Fisheries (IPET) through Agri-Bio Industry Technology Development
   Program - Ministry of Agriculture, Food and Rural Affairs
   [116081-03-2-CG000]
FX This research was supported by Korea Institute of Oriental Medicine
   (Grant no. K17810) and Korea Institute of Planning and Evaluation for
   Technology in Food, Agriculture, Forestry and Fisheries (IPET) through
   Agri-Bio Industry Technology Development Program, funded by Ministry of
   Agriculture, Food and Rural Affairs (Grant no. 116081-03-2-CG000).
CR Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033
   Bensky D., 2004, CHINESE HERBAL MED M, V3rd
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cao LM, 2010, INVEST OPHTH VIS SCI, V51, P6658, DOI 10.1167/iovs.10-5524
   Chang Y, 2009, J ETHNOPHARMACOL, V121, P43, DOI 10.1016/j.jep.2008.09.028
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   Deng H, 2010, J ETHNOPHARMACOL, V127, P781, DOI 10.1016/j.jep.2009.09.053
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gupta SK, 2013, J OCUL PHARMACOL TH, V29, P419, DOI 10.1089/jop.2012.0089
   He JX, 2001, BIOL PHARM BULL, V24, P1395, DOI 10.1248/bpb.24.1395
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Honda S, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/206837
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jung E, 2015, BBA-MOL BASIS DIS, V1852, P2618, DOI 10.1016/j.bbadis.2015.09.010
   Kim JJ, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00020
   Kim KJ, 2013, PHYTOTHER RES, V27, P841, DOI 10.1002/ptr.4800
   KOBAYASHI S, 1995, BIOL PHARM BULL, V18, P1382, DOI 10.1248/bpb.18.1382
   Lee HJ, 2006, CARCINOGENESIS, V27, P2455, DOI 10.1093/carcin/bgl104
   Lee HS, 2007, ARCH TOXICOL, V81, P211, DOI 10.1007/s00204-006-0139-4
   Lee JJ, 2012, MOL VIS, V18, P838
   Lee Y, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/245271
   Meredith EL, 2015, J MED CHEM, V58, P9273, DOI 10.1021/acs.jmedchem.5b01227
   Moss SE, 1998, OPHTHALMOLOGY, V105, P998, DOI 10.1016/S0161-6420(98)96025-0
   Muranaka K, 2005, FEBS LETT, V579, P6084, DOI 10.1016/j.febslet.2005.09.079
   MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567
   Osawa T, 2005, ANN NY ACAD SCI, V1043, P440, DOI 10.1196/annals.1333.050
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Ruma IMW, 2014, INT J ONCOL, V45, P209, DOI 10.3892/ijo.2014.2397
   Sadakane C, 2015, J PHARM SCI-US, V104, P3952, DOI 10.1002/jps.24596
   Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JCI33361, 10.1172/JC133361]
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Szekanecz Z, 2007, NAT CLIN PRACT RHEUM, V3, P635, DOI 10.1038/ncprheum0647
   Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440
   Tanaka J, 2012, PHYTOTHER RES, V26, P214, DOI 10.1002/ptr.3533
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Vinores SA, 1997, HISTOL HISTOPATHOL, V12, P99
   Virgili G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub4
   Xie WK, 2011, MOL VIS, V17, P3512
   Yance DR, 2006, INTEGR CANCER THER, V5, P9, DOI 10.1177/1534735405285562
   Zheng YQ, 2007, INFLAMM RES, V56, P182, DOI 10.1007/s00011-006-6002-5
   Zheng YQ, 2005, INT IMMUNOPHARMACOL, V5, P1560, DOI 10.1016/j.intimp.2005.03.010
   Zhu L, 2005, INFLAMM RES, V54, P211, DOI 10.1007/s00011-005-1345-x
NR 51
TC 1
Z9 1
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2017
VL 2017
AR 1568702
DI 10.1155/2017/1568702
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA FI6ZW
UT WOS:000412146400001
PM 29234364
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Gao, XQ
   Talalay, P
AF Gao, XQ
   Talalay, P
TI Induction of phase 2 genes by sulforaphane protects retinal pigment
   epithelial cells against photooxidative damage
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID MICHAEL REACTION ACCEPTORS; OXIDATIVE DAMAGE; ENZYME INDUCERS;
   GLUTATHIONE; CANCER; NRF2; ISOTHIOCYANATES; EXPRESSION; KEAP1;
   CARCINOGENESIS
AB The retinal pigment epithelial cell (RPE cell) layer protects the photoreceptors of the retina against oxidative stress. The decline of this capacity is believed to be a major factor in the impairment of vision in age-related macular degeneration. Exposure of human adult RPE cells to UV light at predominantly 320-400 nm (UVA light) in the presence of all-trans-retinaidehyde results in photooxidative cytotoxicity. Significant protection of RPE cells was obtained by prior treatment with phase 2 gene inducers, such as the isothiocyanate sulforaphane or a bis-2-hydroxybenzylideneacetone Michael reaction acceptor. The degree of protection was correlated with the potencies of these inducers in elevating cytoprotective glutathione levels and activities of NAD(P)H:quinone oxicloreductase. In embryonic fibroblasts derived from mice in which the genes for the transcription factor Nrf2, the repressor Keapl, or both Nrf2 and Keapl were disrupted, the magnitude of resistance to photooxidative damage paralleled the basal levels of glutathione and NAD(P)H:quinone oxicloreductase in each cell type. Demonstration of protection of RPE cells against photooxidative damage by induction of phase 2 proteins may shed light on the role of oxidative injury in ocular disease. Moreover, the finding that dietary inducers provide indirect antioxidant protection suggests novel strategies for preventing chronic degenerative diseases, such as age-related macular degeneration.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Lewis B & Dorothy Cullman Canc Chemoprotect Ctr, Baltimore, MD 21205 USA.
C3 Johns Hopkins University
RP Talalay, P (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Lewis B & Dorothy Cullman Canc Chemoprotect Ctr, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM ptalalay@jhmi.edu
FU NCI NIH HHS [CA 94076, R01 CA094076] Funding Source: Medline; NATIONAL
   CANCER INSTITUTE [R01CA094076] Funding Source: NIH RePORTER
CR ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bok D, 2002, P NATL ACAD SCI USA, V99, P14619, DOI 10.1073/pnas.242607899
   Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501
   DAVIDSON PC, 1994, INVEST OPHTH VIS SCI, V35, P2843
   Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198
   Dinkova-Kostova AT, 1998, J MED CHEM, V41, P5287, DOI 10.1021/jm980424s
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4
   Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099
   Gao XQ, 2001, P NATL ACAD SCI USA, V98, P15221, DOI 10.1073/pnas.261572998
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Harper WS, 2001, PHOTOCHEM PHOTOBIOL, V73, P71, DOI 10.1562/0031-8655(2001)073<0071:SOATRA>2.0.CO;2
   Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851
   Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X
   Nelson KC, 1999, INVEST OPHTH VIS SCI, V40, P1927
   Nelson KC, 2002, INVEST OPHTH VIS SCI, V43, P3550
   Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   OSTROVSKY MA, 1994, BIOFIZIKA+, V39, P13
   PROCHASKA HJ, 1992, P NATL ACAD SCI USA, V89, P2394, DOI 10.1073/pnas.89.6.2394
   Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Talalay P, 2003, ADV ENZYME REGUL, V43, P121, DOI 10.1016/S0065-2571(02)00038-9
   Talalay P, 2000, BIOFACTORS, V12, P5, DOI 10.1002/biof.5520120102
   Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291
   Winkler BS, 1999, MOL VIS, V5
   Wu BX, 2002, INVEST OPHTH VIS SCI, V43, P3365
   Yang M, 2002, J BIOL CHEM, V277, P3318, DOI 10.1074/jbc.M108946200
   Ye LX, 2002, CLIN CHIM ACTA, V316, P43, DOI 10.1016/S0009-8981(01)00727-6
   Ye LX, 2001, CARCINOGENESIS, V22, P1987, DOI 10.1093/carcin/22.12.1987
   Zhang YS, 1998, CANCER RES, V58, P4632
NR 46
TC 179
Z9 193
U1 3
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 13
PY 2004
VL 101
IS 28
BP 10446
EP 10451
DI 10.1073/pnas.0403886101
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 837TR
UT WOS:000222664200037
PM 15229324
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Do, DV
   Bressler, NM
   Bressler, SB
AF Do, DV
   Bressler, NM
   Bressler, SB
TI Large submacular hemorrhages after verteporfin therapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To report the occurrence of large submacular hemorrhages after photodynamic therapy with vertepor, fin in age-related macular degeneration patients with subfoveal choroidal neovascularization (CNV) composed of occult with no classic CNV in whom the hemorrhage precluded determining if additional therapy should be given within 3 months after initiation of treatment.
   DESIGN: Retrospective, noncomparative case series.
   METHODS: The records of all age-related macular degeneration patients who received verteporfin therapy for subfoveal lesions composed of occult with no classic CNV between February and July 2001 at The Wilmer Eye Institute were reviewed. Subjects who reported either having undergone a procedure to remove intraocular blood before a month 3 follow-up visit, or who had submacular hemorrhage at the month 3 visit that was severe enough to preclude determining if additional verteporfin therapy should be given were identified.
   RESULTS: Fifty-five eyes of 52 patients were reviewed. Five eyes (9% [95% confidence interval, 1.4%-16.6%]) developed submacular hemorrhage that precluded determining if additional verteporfin therapy should be given. Visual acuity 3 months after documentation of the hemorrhage decreased a median of 8.5 lines compared with pretreatment acuity.
   CONCLUSIONS: Even in the absence of acute severe visual acuity decrease, submacular hemorrhage after verteporfin therapy can be associated with severe vision loss and preclude determining if additional therapy should be given. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Johns Hopkins Univ, Sch Med & Hosp, Retinal Vasc Ctr, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Bressler, SB (通讯作者)，Johns Hopkins Univ, Sch Med & Hosp, Retinal Vasc Ctr, Wilmer Ophthalmol Inst, 600 N Wolfe St,229 Maumenee Bldg, Baltimore, MD 21287 USA.
EM sbressler@jhmi.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
NR 1
TC 12
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2004
VL 137
IS 3
BP 558
EP 560
DI 10.1016/j.ajo.2003.08.001
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 804VF
UT WOS:000220325500025
PM 15013883
DA 2022-11-30
ER

PT J
AU Okano, K
   Maeda, A
   Chen, Y
   Chauhan, V
   Tang, J
   Palczewska, G
   Sakai, T
   Tsuneoka, H
   Palczewski, K
   Maeda, T
AF Okano, Kiichiro
   Maeda, Akiko
   Chen, Yu
   Chauhan, Vishal
   Tang, Johnny
   Palczewska, Grazyna
   Sakai, Tsutomu
   Tsuneoka, Hiroshi
   Palczewski, Krzysztof
   Maeda, Tadao
TI Retinal cone and rod photoreceptor cells exhibit differential
   susceptibility to light-induced damage
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE age-related macular degeneration; photoreceptor; retina; retinoid;
   Stargardt's disease; visual cycle
ID CASSETTE TRANSPORTER ABCA4; MEDIATED DARK-ADAPTATION; MACULAR
   DEGENERATION; FUNDUS AUTOFLUORESCENCE; MICE; LIPOFUSCIN; NRL;
   BIOSYNTHESIS; RETINOPATHY; FLUOROPHORE
AB All-trans-retinal and its condensation-products can cause retinal degeneration in a light-dependent manner and contribute to the pathogenesis of human macular diseases such as Stargardts disease and age-related macular degeneration. Although these toxic retinoid by-products originate from rod and cone photoreceptor cells, the contribution of each cell type to light-induced retinal degeneration is unknown. In this study, the primary objective was to learn whether rods or cones are more susceptible to light-induced, all-trans-retinal-mediated damage. Previously, we reported that mice lacking enzymes that clear all-trans-retinal from the retina, ATP-binding cassette transporter 4 and retinol dehydrogenase 8, manifested light-induced retinal dystrophy. We first examined early-stage age-related macular degeneration patients and found retinal degenerative changes in rod-rich rather than cone-rich regions of the macula. We then evaluated transgenic mice with rod-only and cone-like-only retinas in addition to progenies of such mice inbred with Rdh8-/-Abca4-/- mice. Of all these strains, Rdh8-/-Abca4-/-mice with a mixed rodcone population showed the most severe retinal degeneration under regular cyclic light conditions. Intense light exposure induced acute retinal damage in Rdh8-/-Abca4-/- and rod-only mice but not cone-like-only mice. These findings suggest that progression of retinal degeneration in Rdh8-/-Abca4-/- mice is affected by differential vulnerability of rods and cones to light.
C1 [Maeda, Tadao] Case Western Reserve Univ, Sch Med, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Okano, Kiichiro; Maeda, Akiko; Chen, Yu; Palczewski, Krzysztof; Maeda, Tadao] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Palczewska, Grazyna] Polgenix Inc, Cleveland, OH USA.
   [Sakai, Tsutomu; Tsuneoka, Hiroshi] Jikei Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Case Western Reserve University; Case Western Reserve University; Jikei
   University
RP Maeda, T (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Ophthalmol & Visual Sci, 2085 Adelbert Rd,Room 115, Cleveland, OH 44106 USA.
EM txm88@case.edu
FU National Institutes of Health [K08EY019031, K08EY019880, EY009339,
   EY021126, P30 EY11373]; VAMC; Research to Prevent Blindness Foundation;
   Foundation Fighting Blindness; Fight for Sight; Ohio Lions Eye Research
   Foundation; NATIONAL EYE INSTITUTE [K08EY019031, P30EY011373,
   R01EY009339, K08EY019880, R24EY021126] Funding Source: NIH RePORTER
FX We thank Drs L. Webster, H. Fujioka, M. Hitomi, S. Shiose, and K.
   Ishikawa (Case Western Reserve University) and H. Matsuyama and S. Roos,
   (Case Western Reserve University) for technical support. This work was
   supported in part by funding from the National Institutes of Health
   (K08EY019031, K08EY019880, EY009339, EY021126, and P30 EY11373); a VAMC
   Career Development Grant; the Research to Prevent Blindness Foundation;
   Foundation Fighting Blindness; Fight for Sight and the Ohio Lions Eye
   Research Foundation.
CR Allikmets R., 2007, RETINAL DEGENERATION, P105
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Chen JC, 2007, INVEST OPHTH VIS SCI, V48, P2799, DOI 10.1167/iovs.06-0922
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1987, SCIENCE, V236, P579, DOI 10.1126/science.3576186
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Daniele LL, 2005, INVEST OPHTH VIS SCI, V46, P2156, DOI 10.1167/iovs.04-1427
   Feathers KL, 2008, INVEST OPHTH VIS SCI, V49, P1126, DOI 10.1167/iovs.07-1234
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Jacobson SG, 2007, P NATL ACAD SCI USA, V104, P15123, DOI 10.1073/pnas.0706367104
   Jeon CJ, 1998, J NEUROSCI, V18, P8936
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kunchithapautham K, 2009, INVEST OPHTH VIS SCI, V50, P4858, DOI 10.1167/iovs.08-3008
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, 2009, HUM MOL GENET, V18, P2277, DOI 10.1093/hmg/ddp163
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Michael R, 2011, PHILOS T R SOC B, V366, P1278, DOI 10.1098/rstb.2010.0300
   Molday RS, 2007, J BIOENERG BIOMEMBR, V39, P507, DOI 10.1007/s10863-007-9118-6
   Molday RS, 2010, PROG LIPID RES, V49, P476, DOI 10.1016/j.plipres.2010.07.002
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Mustafi D, 2011, FASEB J, V25, P3157, DOI 10.1096/fj.11-186767
   Mustafi D, 2009, PROG RETIN EYE RES, V28, P289, DOI 10.1016/j.preteyeres.2009.05.003
   Nikonov SS, 2005, J GEN PHYSIOL, V125, P287, DOI 10.1085/jgp.200409208
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Palczewski K, 2011, FASEB J, V25, P439, DOI 10.1096/fj.11-0202ufm
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Sakami S, 2011, J BIOL CHEM, V286, P10551, DOI 10.1074/jbc.M110.209759
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Tangelder GJM, 2008, INVEST OPHTH VIS SCI, V49, P2627, DOI 10.1167/iovs.07-0820
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
NR 53
TC 31
Z9 32
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD APR
PY 2012
VL 121
IS 1
BP 146
EP 156
DI 10.1111/j.1471-4159.2012.07647.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 908MQ
UT WOS:000301494900013
PM 22220722
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rohrer, B
   Guo, Y
   Kunchithapautham, K
   Gilkeson, GS
AF Rohrer, Baerbel
   Guo, Yao
   Kunchithapautham, Kannan
   Gilkeson, Gary S.
TI Eliminating complement factor D reduces photoreceptor susceptibility to
   light-induced damage
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID INDUCED RETINAL DEGENERATION; FACTOR-H POLYMORPHISM; 2 APOPTOTIC
   PATHWAYS; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   CELL-DEATH; ROD PHOTORECEPTORS; GENE-EXPRESSION; PHOTIC INJURY; RAT
   RETINAS
AB PURPOSE. Genetic risk factors such as variations in complement factors H ( CFH) and B ( CFB) have been implicated in the etiology of age- related macular degeneration. It has been hypothesized that inadequate control of complement- driven inflammation may be a major factor in disease pathogenesis. The authors tested the involvement of the complement system in an experimental model for oxidative stress- mediated photoreceptor degeneration, the light- damage mouse model.
   METHODS. Changes in gene expression were assessed in BALB/ c retinas in response to constant- light ( CL) exposure using microarrays and real- time PCR. Susceptibility to CL exposure was tested in CFD-/- mice on a BALB/ c background. Eyes were analyzed using electrophysiologic and histologic techniques.
   RESULTS. Genes encoding for proteins involved in complement activation were significantly upregulated after CL. The altered gene profiles were similar to proteins accumulated in drusen and to genes identified in the retina and RPE/ choroid of patients with age- related macular degeneration. Cyclic- light reared CFD-/- and CFD-/- mice had indistinguishable rod function and number; however, after CL challenge, CFD-/- photoreceptors were significantly protected.
   CONCLUSIONS. These results suggest that rod degeneration in the CL- damaged retina involves the activity of the alternative complement pathway and that eliminating the alternative pathway is neuroprotective. Thus, the light damage albino mouse model may be a good model to study complement- mediated photoreceptor degeneration.
C1 Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   Med Univ S Carolina, Div Res, Dept Neurosci, Charleston, SC 29425 USA.
   Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
   Ralph H Johnson VAMC, Med Res Serv, Charleston, SC USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson
   VA Medical Center
RP Rohrer, B (通讯作者)，Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768
FU NCI NIH HHS [R24 CA95841] Funding Source: Medline; NCRR NIH HHS
   [RR16434, C06 RR015455] Funding Source: Medline; NEI NIH HHS [EY13520,
   EY14793] Funding Source: Medline; NATIONAL CANCER INSTITUTE
   [R24CA095841] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCES [P20RR016434, C06RR015455] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R24EY014793, R01EY013520] Funding Source: NIH
   RePORTER
CR Ablonczy Z, 2002, J BIOL CHEM, V277, P40491, DOI 10.1074/jbc.M205507200
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Chen L, 2004, EXP EYE RES, V79, P239, DOI 10.1016/j.exer.2004.05.002
   Chen ST, 2005, NEUROSCIENCE, V130, P397, DOI 10.1016/j.neuroscience.2004.07.054
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Danciger M, 2004, MAMM GENOME, V15, P277, DOI 10.1007/s00335-003-2336-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fearon DT, 1998, SEMIN IMMUNOL, V10, P355, DOI 10.1006/smim.1998.0137
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984
   Holers VM, 2003, CLIN IMMUNOL, V107, P140, DOI 10.1016/S1521-6616(03)00034-2
   Holers VM, 2000, IMMUNOPHARMACOLOGY, V49, P125, DOI 10.1016/S0162-3109(00)80298-2
   Kendziorski CM, 2003, BIOSTATISTICS, V4, P465, DOI 10.1093/biostatistics/4.3.465
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Noell W K, 1987, Prog Clin Biol Res, V247, P469
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohira A, 2003, INVEST OPHTH VIS SCI, V44, P1230, DOI 10.1167/iovs.02-0191
   PENN JS, 1986, EXP EYE RES, V43, P915, DOI 10.1016/0014-4835(86)90070-9
   PENN JS, 1991, PROGR RETINAL RES, P75
   Rattner A, 2006, AM J OPHTHALMOL, V141, P558, DOI 10.1016/j.ajo.2005.10.045
   Rattner A, 2005, J NEUROSCI, V25, P4540, DOI 10.1523/JNEUROSCI.0492-05.2005
   Richards A, 2006, VISUAL NEUROSCI, V23, P91, DOI 10.1017/S0952523806231080
   Roca A, 2004, NEUROSCIENCE, V129, P779, DOI 10.1016/j.neuroscience.2004.08.021
   Rohrer B, 2004, J BIOL CHEM, V279, P41903, DOI 10.1074/jbc.M405085200
   Rohrer B, 2003, EXP EYE RES, V76, P125, DOI 10.1016/S0014-4835(02)00258-0
   Rohrer B, 1999, J NEUROSCI, V19, P8919, DOI 10.1523/JNEUROSCI.19-20-08919.1999
   Tanito M, 2002, NEUROSCI LETT, V326, P142, DOI 10.1016/S0304-3940(02)00314-2
   TAYLOR A, 1993, TOXICOL IND HEALTH, V9, P349, DOI 10.1177/0748233793009001-226
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Xu YY, 2001, P NATL ACAD SCI USA, V98, P14577, DOI 10.1073/pnas.261428398
   Zeng HY, 2005, INVEST OPHTH VIS SCI, V46, P2992, DOI 10.1167/iovs.05-0118
NR 41
TC 75
Z9 94
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2007
VL 48
IS 11
BP 5282
EP 5289
DI 10.1167/iovs.07-0282
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228MU
UT WOS:000250734800055
PM 17962484
DA 2022-11-30
ER

PT J
AU Sears, AE
   Bernstein, PS
   Cideciyan, AV
   Hoyng, C
   Issa, PC
   Palczewski, K
   Rosenfeld, PJ
   Sadda, S
   Schraermeyer, U
   Sparrow, JR
   Washington, I
   Scholl, HPN
AF Sears, Avery E.
   Bernstein, Paul S.
   Cideciyan, Artur V.
   Hoyng, Carel
   Issa, Peter Charbel
   Palczewski, Krzysztof
   Rosenfeld, Philip J.
   Sadda, SriniVas
   Schraermeyer, Ulrich
   Sparrow, Janet R.
   Washington, Ilyas
   Scholl, Hendrik P. N.
TI Towards Treatment of Stargardt Disease: Workshop Organized and Sponsored
   by the Foundation Fighting Blindness
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Review
DE Stargardt disease; geographic atrophy; age-related macular degeneration;
   ABCA4; lipofuscin; A2E, all-trans-retinal
ID RETINAL-PIGMENT EPITHELIUM; QUANTITATIVE FUNDUS AUTOFLUORESCENCE;
   OPTICAL COHERENCE TOMOGRAPHY; SHORT-WAVELENGTH AUTOFLUORESCENCE;
   PHOTORECEPTOR CELL DEGENERATION; MACULAR DEGENERATION; VISUAL CYCLE;
   REDUCED-ILLUMINANCE; SUNLIGHT EXPOSURE; CRYSTAL-STRUCTURE
AB Accumulation of fluorescent metabolic byproducts of the visual (retinoid) cycle is associated with photoreceptor and retinal pigment epithelial cell death in both Stargardt disease and atrophic (nonneovascular) age-related macular degeneration (AMD). As a consequence of this observation, small molecular inhibitors of enzymes in the visual cycle were recently tested in clinical trials as a strategy to protect the retina and retinal pigment epithelium in patients with atrophic AMD.
   To address the clinical translational needs for therapies aimed at both diseases, a workshop organized by the Foundation Fighting Blindness was hosted by the Department of Pharmacology at Case Western Reserve University on February 17, 2017, at the Tinkham Veale University Center, Cleveland, OH, USA. Invited speakers highlighted recent advances in the understanding of the pathophysiology of Stargardt disease, in terms of its clinical characterization and the development of endpoints for clinical trials, and discussed the comparability of therapeutic strategies between atrophic age-related macular degeneration (AMD) and Stargardt disease. Investigators speculated that reducing the concentrations of visual cycle precursor substances and/or their byproducts may provide valid therapeutic options for the treatment of Stargardt disease. Here we review the workshop's presentations in the context of published literature to help shape the aims of ongoing research endeavors and aid the development of therapies for Stargardt disease.
C1 [Sears, Avery E.; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland Ctr Membrane & Struct Biol, Cleveland, OH 44106 USA.
   [Bernstein, Paul S.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
   [Cideciyan, Artur V.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Hoyng, Carel] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Issa, Peter Charbel] Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England.
   [Rosenfeld, Philip J.] Univ Oxford, Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
   [Sadda, SriniVas] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Schraermeyer, Ulrich] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Tubingen, Germany.
   [Sparrow, Janet R.; Washington, Ilyas] Columbia Univ, Edward S Harkness Eye Inst, Med Ctr, New York, NY USA.
   [Scholl, Hendrik P. N.] Univ Basel, Dept Ophthalmol, Basel, Switzerland.
   [Scholl, Hendrik P. N.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Case Western Reserve University; Utah System of Higher Education;
   University of Utah; University of Pennsylvania; Pennsylvania Medicine;
   Radboud University Nijmegen; Oxford University Hospitals NHS Foundation
   Trust; University of Oxford; Bascom Palmer Eye Institute; University of
   Miami; Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Columbia University; University of Basel; Johns Hopkins
   University; Johns Hopkins Medicine
RP Sears, AE (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM aes31@case.edu
RI Cideciyan, Artur V/A-1075-2007; Issa, Peter Charbel/O-2580-2019; Issa,
   Peter Charbel/E-8935-2018
OI Cideciyan, Artur V/0000-0002-2018-0905; Issa, Peter
   Charbel/0000-0002-0351-6673; Issa, Peter Charbel/0000-0002-0351-6673; W,
   I/0000-0002-2238-7918
FU Foundation Fighting Blindness; NATIONAL EYE INSTITUTE [R01EY009339,
   R24EY027283, P30EY019007, P30EY014800] Funding Source: NIH RePORTER
FX The symposium thanks the Foundation Fighting Blindness for support and
   organization, all of the speakers, and the attendees of the symposium.
   In particular we want to thank the organizers (Janet Cheetham, Patricia
   Zilliox). We thank Leslie T. Webster, Jr., Johannes von Lintig and
   members of the Palczewski laboratory for helpful comments on this
   manuscript.
CR Ablonczy Z, 2012, ADV EXP MED BIOL, V723, P75, DOI 10.1007/978-1-4614-0631-0_11
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Chen Y, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag0245
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457
   Cideciyan AV, 2015, INVEST OPHTH VIS SCI, V56, P5946, DOI 10.1167/iovs.15-17698
   Cideciyan AV, 2015, INVEST OPHTH VIS SCI, V56, P3393, DOI 10.1167/iovs.15-16726
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P7274, DOI 10.1167/iovs.15-17371
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P8134, DOI 10.1167/iovs.14-14848
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Kaufman Y, 2011, J BIOL CHEM, V286, P7958, DOI 10.1074/jbc.M110.178640
   Kiser PD, 2015, NAT CHEM BIOL, V11, P409, DOI [10.1038/NCHEMBIO.1799, 10.1038/nchembio.1799]
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Kiser PD, 2009, P NATL ACAD SCI USA, V106, P17325, DOI 10.1073/pnas.0906600106
   Kong X, 2016, OPHTHALMOLOGY, V123, P1887, DOI 10.1016/j.ophtha.2016.05.027
   Lem J, 2004, TRENDS MOL MED, V10, P150, DOI 10.1016/j.molmed.2004.02.009
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Mihai DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.314
   Mihai DM, 2013, MOL VIS, V19, P1677
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   RADDING CM, 1956, J GEN PHYSIOL, V39, P923, DOI 10.1085/jgp.39.6.923
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   Seeliger MW, 1999, INVEST OPHTH VIS SCI, V40, P3
   Sparrow JR, 2015, INVEST OPHTH VIS SCI, V56, P5029, DOI 10.1167/iovs.15-16763
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P2812, DOI 10.1167/iovs.12-11490
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Stone EM, 2017, OPHTHALMOLOGY, V124, P1314, DOI 10.1016/j.ophtha.2017.04.008
   Strauss RW, 2016, AM J OPHTHALMOL, V168, P269, DOI 10.1016/j.ajo.2016.06.003
   Strauss RW, 2016, OPHTHALMOLOGY, V123, P817, DOI 10.1016/j.ophtha.2015.12.009
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Teussink MM, 2015, AM J OPHTHALMOL, V159, P964, DOI 10.1016/j.ajo.2015.02.004
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wu L, 2014, INVEST OPHTH VIS SCI, V55, P1910, DOI 10.1167/iovs.14-13867
   Wu L, 2010, ADV EXP MED BIOL, V664, P533, DOI 10.1007/978-1-4419-1399-9_61
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Zernant J, 2014, HUM MOL GENET, V23, P6797, DOI 10.1093/hmg/ddu396
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
   Zhang N, 2015, HUM MOL GENET, V24, P3220, DOI 10.1093/hmg/ddv073
NR 59
TC 36
Z9 36
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD SEP
PY 2017
VL 6
IS 5
AR 6
DI 10.1167/tvst.6.5.6
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH2HR
UT WOS:000410960400006
PM 28920007
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tibbetts, MD
   Samuel, MA
   Chang, TS
   Ho, AC
AF Tibbetts, Michael D.
   Samuel, Michael A.
   Chang, Tom S.
   Ho, Allen C.
TI Stem cell therapy for retinal disease
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE macular degeneration; pluripotent; retina transplant; retinal dystrophy;
   stem cell
ID PIGMENT EPITHELIUM; MACULAR DEGENERATION; PHOTORECEPTOR DEGENERATION;
   VISUAL FUNCTION; GROWTH-FACTOR; GENE-TRANSFER; TRANSPLANTATION;
   GENERATION; DIFFERENTIATION; MOUSE
AB Purpose of review
   Stem cell therapy holds great promise for the treatment of retinal diseases. This review summarizes recent advances in stem cell biology, outlines ongoing clinical trials and details the obstacles that must be overcome for stem cell therapy to be a viable treatment for retinal disease.
   Recent findings
   Stem cells can now be directed to specific retinal cell fates with high yields and acceptable purity for clinical trials. New stem cell sources have been discovered including induced pluripotent stem cells that can be derived from adult tissues then differentiated into multiple retinal cell types. The initial results of clinical trials of subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelium cells in patients with Stargardt's macular dystrophy and dry age-related macular degeneration showed preliminary safety and possible visual acuity benefits. A phase I trial of intravitreally injected autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy demonstrated no evidence of toxicity with possible visual acuity benefits but no structural or functional changes. Ongoing trials are examining the trophic effects of undifferentiated umbilical cells for the treatment of geographic atrophy in age-related macular degeneration.
   Summary
   Stem cell therapy is a promising treatment under active investigation in multiple retinal diseases. Ongoing clinical trials should yield further insights into the potential for stem cell-based retinal therapies.
C1 [Tibbetts, Michael D.; Ho, Allen C.] Mid Atlantic Retina, Wills Eye Inst Retina Serv, Philadelphia, PA 19107 USA.
   [Samuel, Michael A.; Chang, Tom S.] Retina Inst Calif, Pasadena, CA USA.
RP Tibbetts, MD (通讯作者)，Mid Atlantic Retina, Wills Eye Inst Retina Serv, Suite 1020,840 Walnut St, Philadelphia, PA 19107 USA.
EM michael.tibbetts@gmail.com
OI Ho, Allen/0000-0003-3921-608X
FU Centocor Inc. d/b/a Janssen Research and Development, a division of
   Johnson and Johnson
FX This work was supported in part by research grant funding to Wills Eye
   Retina Research from Centocor Inc. d/b/a Janssen Research and
   Development, a division of Johnson and Johnson. A.C.H., M.A.S., and
   T.S.C. are consultants for Centocor Inc. d/b/a Janssen Research and
   Development, a division of Johnson and Johnson Inc. M.D.T. has no
   disclosures.
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Ali RR, 2011, NATURE, V472, P42, DOI 10.1038/472042a
   Ashtari M, 2011, J CLIN INVEST, V121, P2160, DOI 10.1172/JCI57377
   Atala A, 2012, LANCET
   Baker PS, 2009, CURR OPIN OPHTHALMOL, V20, P175, DOI 10.1097/ICU.0b013e328329b5f2
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Boucherie C, 2011, REGEN MED, V6, P469, DOI [10.2217/RME.11.37, 10.2217/rme.11.37]
   Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799
   Drukker M, 2006, STEM CELLS, V24, P221, DOI 10.1634/stemcells.2005-0188
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Frantz S, 2012, NAT BIOTECHNOL, V30, P12, DOI 10.1038/nbt0112-12
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jonas JB, 2008, ACTA OPHTHALMOL, V86, P225, DOI 10.1111/j.1600-0420.2007.00987.x
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lakowski J, 2011, STEM CELLS, V29, P1391, DOI 10.1002/stem.694
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Rizzo JF, 2011, J NEURO-OPHTHALMOL, V31, P160, DOI 10.1097/WNO.0b013e31821eb79e
   SCHWARTZ SD, 2012, LANCET
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Wilmut I, 2002, NATURE, V419, P583, DOI 10.1038/nature01079
   Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863
   Yang Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013469
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 57
TC 48
Z9 51
U1 1
U2 36
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2012
VL 23
IS 3
BP 226
EP 234
DI 10.1097/ICU.0b013e328352407d
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 933TQ
UT WOS:000303386000010
PM 22450217
DA 2022-11-30
ER

PT J
AU Bearelly, S
   Khanifar, AA
   Lederer, DE
   Lee, JJ
   Ghodasra, JH
   Stinnett, SS
   Cousins, SW
AF Bearelly, Srilaxmi
   Khanifar, Aziz A.
   Lederer, David E.
   Lee, Jane J.
   Ghodasra, Jason H.
   Stinnett, Sandra S.
   Cousins, Scott W.
TI USE OF FUNDUS AUTOFLUORESCENCE IMAGES TO PREDICT GEOGRAPHIC ATROPHY
   PROGRESSION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE geographic atrophy; fundus autofluorescence; age-related macular
   degeneration
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; A2E; ENLARGEMENT;
   PATTERNS
AB Purpose: Fundus autofluorescence imaging has been shown to be helpful in predicting progression of geographic atrophy (GA) secondary to age-related macular degeneration. We assess the ability of fundus autofluorescence imaging to predict rate of GA progression using a simple categorical scheme.
   Methods: Subjects with GA secondary to age-related macular degeneration with fundus autofluorescence imaging acquired at least 12 months apart were included. Rim area focal hyperautofluorescence was defined as percentage of the 500-mu m-wide margin bordering the GA that contained increased autofluorescence. Rim area focal hyperautofluorescence on baseline fundus autofluorescence images was assessed and categorized depending on the extent of rim area focal hyperautofluorescence (Category 1: <= 33%; Category 2: between 33 and 67%; Category 3: >= 67%). Total GA areas at baseline and follow-up were measured to calculate change in GA progression.
   Results: Forty-five eyes of 45 subjects were included; average duration of follow-up was 18.5 months. Median growth rates differed among categories of baseline rim area focal hyperautofluorescence (P = 0.01 among Categories 1, 2, and 3; P = 0.008 for Category 1 compared with Category 3, Jonckheere-Terpstra test).
   Conclusion: A simple categorical scheme that stratifies the amount of increased autofluorescence in the 500-mu m margin bordering GA may be used to differentiate faster and slower progressors. RETINA 31:81-86, 2011
C1 [Bearelly, Srilaxmi] Columbia Univ, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Bearelly, Srilaxmi; Khanifar, Aziz A.; Lederer, David E.; Stinnett, Sandra S.; Cousins, Scott W.] Duke Univ, Ctr Eye, Duke Ctr Macular Dis, Durham, NC USA.
   [Bearelly, Srilaxmi; Khanifar, Aziz A.; Lederer, David E.; Stinnett, Sandra S.; Cousins, Scott W.] Duke Univ, Ctr Eye, Albert Eye Res Inst, Durham, NC USA.
C3 Columbia University; Duke University; Duke University
RP Bearelly, S (通讯作者)，Columbia Univ, Edward S Harkness Eye Inst, 635 W 165th St,Box EI 8, New York, NY 10032 USA.
EM sb3179@columbia.edu
OI Stinnett, Sandra/0000-0001-7192-0195
FU NEI [1K23 EY018895-01]; NIH [P30-EY005722]; NATIONAL EYE INSTITUTE
   [K23EY018895, P30EY005722] Funding Source: NIH RePORTER
FX Supported by NEI 1K23 EY018895-01 and NIH P30-EY005722 Core Grant for
   Vision Research.
CR Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 16
TC 40
Z9 42
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2011
VL 31
IS 1
BP 81
EP 86
DI 10.1097/IAE.0b013e3181e0958b
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 699TG
UT WOS:000285685100012
PM 20890245
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cukras, C
   Flamendorf, J
   Wong, WT
   Ayyagari, R
   Cunningham, D
   Sieving, PA
AF Cukras, Catherine
   Flamendorf, Jason
   Wong, Wai T.
   Ayyagari, Radha
   Cunningham, Denise
   Sieving, Paul A.
TI LONGITUDINAL STRUCTURAL CHANGES IN LATE-ONSET RETINAL DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE late-onset retinal degeneration; fundus autofluorescence; optical
   coherence tomography; retinal atrophy; reticular pseudodrusen
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR MACULAR DISEASE; SUBRETINAL
   DRUSENOID DEPOSITS; ANTERIOR LENS ZONULES; AUTOFLUORESCENCE
   CHARACTERISTICS; PSEUDOXANTHOMA ELASTICUM; GEOGRAPHIC ATROPHY; S163R
   MUTATION; L-ORD; PSEUDODRUSEN
AB Purpose: To characterize longitudinal structural changes in early stages of late-onset retinal degeneration to investigate pathogenic mechanisms.
   Methods: Two affected siblings, both with a S163R missense mutation in the causative gene C1QTNF5, were followed for 8+ years. Color fundus photos, fundus autofluorescence images, near-infrared reflectance fundus images, and spectral domain optical coherence tomography scans were acquired during follow-up.
   Results: Both patients, aged 45 and 50 years, had good visual acuities (>20/20) in the context of prolonged dark adaptation. Baseline color fundus photography demonstrated yellow-white, punctate lesions in the temporal macula that correlated with a reticular pattern on fundus autofluorescence and near-infrared reflectance imaging. Baseline spectral domain optical coherence tomography imaging revealed subretinal deposits that resemble reticular pseudodrusen described in age-related macular degeneration. During follow-up, these affected areas developed confluent thickening of the retinal pigment epithelial layer and disruption of the ellipsoid zone of photoreceptors before progressing to overt retinal pigment epithelium and outer retinal atrophy.
   Conclusion: Structural changes in early stages of late-onset retinal degeneration, revealed by multimodal imaging, resemble those of reticular pseudodrusen observed in age-related macular degeneration and other retinal diseases. Longitudinal follow-up of these lesions helps elucidate their progression to frank atrophy and may lend insight into the pathogenic mechanisms underlying diverse retinal degenerations.
C1 [Cukras, Catherine; Flamendorf, Jason; Wong, Wai T.; Cunningham, Denise; Sieving, Paul A.] NEI, NIH, Bethesda, MD 20892 USA.
   [Ayyagari, Radha] Univ Calif San Diego, Shiley Eye Inst, La Jolla, CA 92093 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of California System; University of California San
   Diego
RP Cukras, C (通讯作者)，NEI, NIH, Bethesda, MD 20892 USA.
EM cukrasc@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016
FU National Eye Institute Intramural Research Program; NIH; Pfizer Inc;
   Doris Duke Charitable Foundation; Alexandria Real Estate Equities, Inc;
   Howard Hughes Medical Institute; NATIONAL EYE INSTITUTE [ZIAEY000554,
   R01EY021237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000077] Funding Source:
   NIH RePORTER
FX Supported by the National Eye Institute Intramural Research Program.
   Portions of this research were made possible through the National
   Institutes of Health (NIH) Medical Research Scholars Program, a
   public-private partnership supported jointly by the NIH, and generous
   contributions to the Foundation for the NIH from Pfizer Inc, The Doris
   Duke Charitable Foundation, The Alexandria Real Estate Equities, Inc and
   Mr. and Mrs. Joel S. Marcus, and the Howard Hughes Medical Institute, as
   well as other private donors.
CR Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Aye KH, 2010, EYE, V24, P1528, DOI 10.1038/eye.2010.71
   Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Ayyagari R, 2000, ARCH OPHTHALMOL-CHIC, V118, P85
   Chavali VRM, 2011, HUM MOL GENET, V20, P2000, DOI 10.1093/hmg/ddr080
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Kishore U, 2004, TRENDS IMMUNOL, V25, P551, DOI 10.1016/j.it.2004.08.006
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5505, DOI 10.1167/iovs.06-0312
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Soumplis V, 2013, ACTA OPHTHALMOL, V91, pE191, DOI 10.1111/aos.12010
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Subrayan V, 2005, AM J OPHTHALMOL, V140, P1127, DOI 10.1016/j.ajo.2005.06.023
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Vincent A, 2012, RETINA-J RET VIT DIS, V32, P1643, DOI 10.1097/IAE.0b013e318240a574
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 34
TC 24
Z9 24
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2016
VL 36
IS 12
BP 2348
EP 2356
DI 10.1097/IAE.0000000000001113
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED6DB
UT WOS:000388944100013
PM 27388725
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cui, JZ
   Hinz, BJ
   Greve, MDJ
   Potter, MJ
   Hornan, D
   Samad, A
   To, E
   Matsubara, JA
AF Cui, JZ
   Hinz, BJ
   Greve, MDJ
   Potter, MJ
   Hornan, D
   Samad, A
   To, E
   Matsubara, JA
TI Expression of neuropilin-1 in choroidal neovascular membranes
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age-related macular degeneration; endothelial cell; retinal pigment
   epithelium; vascular endothelial growth factor; neuropilin-1;
   neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; OCULAR
   NEOVASCULARIZATION; SEMAPHORIN-III; RECEPTOR; ANGIOGENESIS
AB Background: Neovascularization is a serious consequence of several eye diseases, including age-related macular degeneration. Neovascularization is under the control of proangiogenic factors, such as vascular endothelial growth factor and fibroblast growth factor. Recent work in our laboratory has focused on other, novel angiogenic factors, such as neuropilin-1, and their potential role in neovascularization. The purpose of this study was to investigate the role of neuropilin-1 in choroidal neovascularization (CNV).
   Methods: We examined the localization of neuropilin-1 by immunohistochemistry in nine choroidal neovascular membranes (CNVMs) surgically excised from four patients with age-related macular degeneration who had not undergone laser photocoagulation, four with idiopathic CNV and one with ocular histoplasmosis. We also stained the membranes for markers of endothelial and retinal pigment epithelial cells. Controls included omission of primary antibody, use of an irrelevant primary antibody, and neuropilin-1 staining of the posterior sclera, choroid and retina of four healthy donor eyes.
   Results: Neuropilin-1 was present in eight of the nine CNVMs. It was localized mainly to the plasma membrane. The more vascular membranes and those consisting of a larger number of retinal pigment epithelial cells were associated with greater neuropilin-1 staining. Neuropilin-1 was not seen in the posterior segment of the four healthy eyes.
   Interpretation: Neuropilin-1 appears to play an active role in CNV. Further study is needed to establish a causal relation.
C1 Univ British Columbia, Dept Ophthalmol, Vancouver, BC V5Z 3N9, Canada.
   Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2M7, Canada.
   Dalhousie Univ, Dept Ophthalmol, Halifax, NS, Canada.
C3 University of British Columbia; University of Alberta; Dalhousie
   University
RP Matsubara, JA (通讯作者)，Univ British Columbia, Dept Ophthalmol, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM jms@interchange.ubc.ca
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Cui JZ, 2001, AM J OPHTHALMOL, V132, P792, DOI 10.1016/S0002-9394(01)01105-9
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Folkman J, 1997, EXS, V79, P1
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Fuh G, 2000, J BIOL CHEM, V275, P26690
   He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6
   HENKIND P, 1978, AM J OPHTHALMOL, V85, P287, DOI 10.1016/S0002-9394(14)77719-0
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Miao HQ, 2000, CANCER METAST REV, V19, P29, DOI 10.1023/A:1026579711033
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Spaide R F, 1999, Curr Opin Ophthalmol, V10, P177, DOI 10.1097/00055735-199906000-00005
   SPEE C, 1999, INVEST OPHTH VIS SCI, V40, pS1212
   Spraul CW, 2002, GRAEF ARCH CLIN EXP, V240, P227, DOI 10.1007/s00417-002-0441-7
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   WIEDEMANN P, 1992, SURV OPHTHALMOL, V36, P373, DOI 10.1016/0039-6257(92)90115-A
NR 22
TC 7
Z9 7
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2003
VL 38
IS 1
BP 41
EP 45
DI 10.1016/S0008-4182(03)80007-8
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 646KV
UT WOS:000181034900005
PM 12608516
DA 2022-11-30
ER

PT J
AU Izumi-Nagai, K
   Nagai, N
   Ozawa, Y
   Mihara, M
   Ohsugi, Y
   Kurihara, T
   Koto, T
   Satofuka, S
   Inoue, M
   Tsubota, K
   Okano, H
   Oike, Y
   Ishida, S
AF Izumi-Nagai, Kanako
   Nagai, Norihiro
   Ozawa, Yoko
   Mihara, Masahiko
   Ohsugi, Yoshiyuki
   Kurihara, Toshihide
   Koto, Takashi
   Satofuka, Shingo
   Inoue, Makoto
   Tsubota, Kazuo
   Okano, Hideyuki
   Oike, Yuichi
   Ishida, Susumu
TI Interleukin-6 receptor-mediated activation of signal transducer and
   activator of transcription-3 (STAT3) promotes choroidal
   neovascularization
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; RHEUMATOID-ARTHRITIS; TYROSINE KINASE; ANGIOTENSIN-II;
   JOINT DISEASE; RISK-FACTORS; CELL-GROWTH; ANTIBODY
AB Interleukin (IL)-6, a potent proinflammatory cytokine, is suggested to be a risk factor for choroidal neovascularization (CNV) because of its increased levels in the serum of patients with age-related macular degeneration; however, the role of IL-6 in CNV has not been defined. The present study reveals the critical contribution of IL-6 signaling and its downstream STAT3 pathway to the murine model of laser-induced CNV. CNV induction by laser treatment stimulated IL-6 expression in the retinal pigment epithelium-choroid complex, and antibody-based blockade of M-6 receptor or genetic ablation of M-6 led to significant suppression of CNV. CNV generation was accompanied by STAT3 activation in choroidal endothelial cells and macrophages, and M-6 receptor blockade resulted in selectively inhibited phosphorylation of STAT3 but not extracellular signal-regulated kinase 1/2. Consistently, pharmacological blockade of STAT3 pathway also suppressed CNV. in addition, M-6 receptor neutralization led to significant inhibition of the in vivo and in vitro expression of inflammation-related molecules including monocyte chemotactic protein, intercellular adhesion molecule-1, and vascular endothelial growth factor, and of macrophage infiltration into CNV. These results indicate the significant involvement of H,6 receptor-mediated activation of STAT3 inflammatory pathway in CNV generation, suggesting the possibility of M-6 receptor blockade as a therapeutic strategy to suppress CNV associated with age-related macular degeneration.
C1 Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, Tokyo 1608582, Japan.
   Keio Univ, Sch Med, Dept Physiol, Tokyo 1608582, Japan.
   Chugai Pharmaceut Co Ltd, Tokyo, Japan.
   Keio Univ, Sch Med, Lab Retinal Cell Biol, Tokyo 1608582, Japan.
   Keio Univ, Sch Med, Lab Vasc Biol & Metab, Tokyo 1608582, Japan.
C3 Keio University; Keio University; Chugai Pharmaceutical Co., Ltd.; Roche
   Holding; Keio University; Keio University
RP Ishida, S (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ishidasu@sc.itc.keio.ac.jp
RI Ozawa, Yoko/AAH-9888-2020; Okano, Hideyuki/I-7584-2019; Kurihara,
   Toshihide/ABA-7058-2020; ISHIDA, SUSUMU/D-7067-2012
OI Kurihara, Toshihide/0000-0002-5457-2720; 
CR Alonzi T, 1998, CYTOKINE, V10, P13, DOI 10.1006/cyto.1997.0250
   De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fasler-Kan E, 2005, OPHTHALMOLOGICA, V219, P214, DOI 10.1159/000085730
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7
   Hunyady L, 2006, MOL ENDOCRINOL, V20, P953, DOI 10.1210/me.2004-0536
   Iankov I, 2002, LEUKEMIA RES, V26, P363, DOI 10.1016/S0145-2126(01)00132-1
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ito H, 2004, GASTROENTEROLOGY, V126, P989, DOI 10.1053/j.gastro.2004.01.012
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Koh KK, 2005, J AM COLL CARDIOL, V46, P1978, DOI 10.1016/j.jacc.2005.06.082
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Luft FC, 1999, HYPERTENSION, V33, P212, DOI 10.1161/01.HYP.33.1.212
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Naka T, 2002, ARTHRITIS RES, V4, P154, DOI 10.1186/ar400
   Nguyen G, 2004, CURR HYPERTENS REP, V6, P129, DOI 10.1007/s11906-004-0088-3
   Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303
   Nishimoto N, 2003, J RHEUMATOL, V30, P1426
   Nishimoto N, 2005, BLOOD, V106, P2627, DOI 10.1182/blood-2004-12-4602
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ogata A, 1997, J IMMUNOL, V159, P2212
   Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044
   Okazaki M, 2002, IMMUNOL LETT, V84, P231, DOI 10.1016/S0165-2478(02)00202-X
   Ripperger J, 1995, ANN NY ACAD SCI, V762, P252
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SATO K, 1993, CANCER RES, V53, P851
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529-0131(199812)41:12<2117::AID-ART6>3.3.CO;2-G
   Takamiya A, 2001, INVEST OPHTH VIS SCI, V42, P2427
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226
   Wung BS, 2005, J BIOMED SCI, V12, P91, DOI 10.1007/s11373-004-8170-z
   Yamamoto M, 2000, J IMMUNOL, V164, P4878, DOI 10.4049/jimmunol.164.9.4878
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
NR 48
TC 111
Z9 123
U1 0
U2 2
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUN
PY 2007
VL 170
IS 6
BP 2149
EP 2158
DI 10.2353/ajpath.2007.061018
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 174PR
UT WOS:000246955300032
PM 17525280
OA Green Published
DA 2022-11-30
ER

PT J
AU Zweifel, SA
   Engelbert, M
   Laud, K
   Margolis, R
   Spaide, RF
   Freund, KB
AF Zweifel, Sandrine A.
   Engelbert, Michael
   Laud, Ketan
   Margolis, Ron
   Spaide, Richard F.
   Freund, K. Bailey
TI Outer Retinal Tubulation A Novel Optical Coherence Tomography Finding
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTORECEPTOR ROSETTES; RETINITIS-PIGMENTOSA
AB Objective: To describe tubular structures found in the outer retina seen in a variety of retinal disorders.
   Methods: Sixty-nine eyes of 63 patients were examined with spectral-domain optical coherence tomography. Optical coherence tomography C-scans were correlated with their corresponding B-scans. The prevalence, number, size, and shape of the tubular structures were determined.
   Results: Branching tubules were identified in the outer retina of 54 patients with age-related macular degeneration and in 9 patients with other diagnoses. The tubules appeared as round or ovoid hyporeflective spaces with hyperreflective borders on the B-scans, measuring 40 to 140 mu m high and 40 to 2260 mu m wide. Morphologic features ranged from single straight or branching tubules to complex cavitary networks, usually overlying areas of pigment epithelial alteration or subretinal fibrosis. The tubules generally remained stable over time. In a retinal practice specializing in advanced age-related macular degeneration, these structures were identified in 60 of 248 patients (24.2%) seen during a 3-month period.
   Conclusions: Degenerating photoreceptors may become arranged in a circular or ovoid fashion during a process we propose to term outer retinal tubulation. These changes are apparently common in advanced diseases affecting the outer retina and retinal pigment epithelium. This observation has practical implications because these findings can be misinterpreted as intraretinal or subretinal fluid, possibly prompting unnecessary interventions.
C1 [Zweifel, Sandrine A.; Engelbert, Michael; Laud, Ketan; Margolis, Ron; Spaide, Richard F.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Zweifel, Sandrine A.; Engelbert, Michael; Laud, Ketan; Margolis, Ron; Spaide, Richard F.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Engelbert, Michael; Freund, K. Bailey] Columbia Univ, Edward S Harkness Eye Inst, New York, NY USA.
   [Zweifel, Sandrine A.] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Columbia University; University of Zurich; University
   Zurich Hospital
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Spaide, Richard/ABD-7368-2020; Zweifel, Sandrine/AAX-5045-2020; Freund,
   K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc.
FX This study was supported by the Macula Foundation, Inc.
CR Aramant RB, 2002, EXP EYE RES, V75, P115, DOI 10.1006/exer.2002.2001
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gjorloff K, 2001, ACTA OPHTHALMOL SCAN, V79, P366, DOI 10.1034/j.1600-0420.2001.079004366.x
   Manuel M, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-59
   MILAM AH, 1990, OPHTHALMOLOGY, V97, P1620
   PITTLER SJ, 1995, J CELL BIOL, V130, P431, DOI 10.1083/jcb.130.2.431
   Tulvatana W, 1999, ARCH OPHTHALMOL-CHIC, V117, P399, DOI 10.1001/archopht.117.3.399
NR 7
TC 199
Z9 206
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD DEC
PY 2009
VL 127
IS 12
BP 1596
EP 1602
DI 10.1001/archophthalmol.2009.326
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 529YC
UT WOS:000272554300006
PM 20008714
OA Bronze
DA 2022-11-30
ER

PT J
AU Sharma, R
   George, A
   Nimmagadda, M
   Ortolan, D
   Karla, BS
   Qureshy, Z
   Bose, D
   Dejene, R
   Liang, GQ
   Wan, Q
   Chang, J
   Jha, BS
   Memon, O
   Miyagishima, KJ
   Rising, A
   Lal, M
   Hanson, E
   King, R
   Campos, MM
   Ferrer, M
   Amaral, J
   McGaughey, D
   Bharti, K
AF Sharma, Ruchi
   George, Aman
   Nimmagadda, Malika
   Ortolan, Davide
   Karla, Barbosa-Sabanero
   Qureshy, Zoya
   Bose, Devika
   Dejene, Roba
   Liang, Genqing
   Wan, Qin
   Chang, Justin
   Jha, Balendu Shekhar
   Memon, Omar
   Miyagishima, Kiyoharu Joshua
   Rising, Aaron
   Lal, Madhu
   Hanson, Eric
   King, Rebecca
   Campos, Mercedes Maria
   Ferrer, Marc
   Amaral, Juan
   McGaughey, David
   Bharti, Kapil
TI Epithelial phenotype restoring drugs suppress macular degeneration
   phenotypes in an iPSC model
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; FACTOR-KAPPA-B;
   ACTIVATION; CELLS; PROGRESSION; INHIBITION; POLYMORPHISM; ASSOCIATION;
   EXPRESSION
AB Age-related macular degeneration is characterized by lipid-rich drusen deposits underneath the retinal pigment epithelium (RPE). Here the authors report an in vitro iPSC-RPE model for AMD that recapitulates drusen and RPE atrophy, and identify two drugs that reduce drusen deposits and restore RPE epithelial phenotype.
   Age-related Macular Degeneration (AMD), a blinding eye disease, is characterized by pathological protein- and lipid-rich drusen deposits underneath the retinal pigment epithelium (RPE) and atrophy of the RPE monolayer in advanced disease stages - leading to photoreceptor cell death and vision loss. Currently, there are no drugs that stop drusen formation or RPE atrophy in AMD. Here we provide an iPSC-RPE AMD model that recapitulates drusen and RPE atrophy. Drusen deposition is dependent on AMD-risk-allele CFH(H/H) and anaphylatoxin triggered alternate complement signaling via the activation of NF-kappa B and downregulation of autophagy pathways. Through high-throughput screening we identify two drugs, L-745,870, a dopamine receptor antagonist, and aminocaproic acid, a protease inhibitor that reduce drusen deposits and restore RPE epithelial phenotype in anaphylatoxin challenged iPSC-RPE with or without the CFH(H/H) genotype. This comprehensive iPSC-RPE model replicates key AMD phenotypes, provides molecular insight into the role of CFH(H/H) risk-allele in AMD, and discovers two candidate drugs to treat AMD.
C1 [Sharma, Ruchi; Nimmagadda, Malika; Ortolan, Davide; Karla, Barbosa-Sabanero; Qureshy, Zoya; Bose, Devika; Dejene, Roba; Liang, Genqing; Wan, Qin; Chang, Justin; Jha, Balendu Shekhar; Memon, Omar; Miyagishima, Kiyoharu Joshua; Rising, Aaron; Amaral, Juan; Bharti, Kapil] NEI, Ocular & Stem Cell Translat Res Sect, NIH, Bethesda, MD 20892 USA.
   [George, Aman] NEI, Pediat Dev & Genet Ophthalmol Sect, NIH, Bethesda, MD 20892 USA.
   [Lal, Madhu] US FDA, Res Governance Council, White Oak, MD USA.
   [Hanson, Eric] NIAMS, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
   [King, Rebecca; Ferrer, Marc] NIH, Div Preclin Innovat, NCATS, Rockville, MD 20850 USA.
   [Campos, Mercedes Maria] NEI, Histol Core, NIH, Bethesda, MD 20892 USA.
   [McGaughey, David] NIH, Ophthalm Genet & Visual Funct Branch, NEI, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); US Food & Drug Administration (FDA); National
   Institutes of Health (NIH) - USA; NIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health
   (NIH) - USA; NIH National Center for Advancing Translational Sciences
   (NCATS); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Bharti, K (通讯作者)，NEI, Ocular & Stem Cell Translat Res Sect, NIH, Bethesda, MD 20892 USA.
EM Kapil.Bharti@nih.go
RI Ortolan, Davide/AFP-8878-2022; Hanson, Eric/AAE-5511-2022
OI Ortolan, Davide/0000-0002-8236-9391; 
FU NEI Intramural Research Program; NEI animal care facility
FX The authors thank Robert Fariss, NEI Biological Imaging Core. We thank
   Mones Abu from NEI histology core for processing the samples for TEM and
   taking images. The authors would also like to acknowledge the support
   from the NEI animal care facility. This work was supported by funds from
   the NEI Intramural Research Program to Dr. Kapil Bharti.
CR Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   [Anonymous], 2020, R FDN STAT COMP
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bristow LJ, 1997, J PHARMACOL EXP THER, V283, P1256
   Cho MS, 2016, J IMMUNOL, V196, P1412, DOI 10.4049/jimmunol.1501886
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Grebe R, 2019, EXP EYE RES, V181, P252, DOI 10.1016/j.exer.2019.02.018
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hadley Wickham R. F., 2019, dplyr: A Grammar of Data Manipulation
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Nguyen H, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121697
   Ivanova TN, 2008, BRAIN RES, V1207, P111, DOI 10.1016/j.brainres.2008.02.025
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Kleijn A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5623235
   Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Martic I, 2020, MECH AGEING DEV, V190, DOI 10.1016/j.mad.2020.111322
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Parsons N, 2019, MOL IMMUNOL, V108, P8, DOI 10.1016/j.molimm.2019.02.001
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Peng SM, 2011, INVEST OPHTH VIS SCI, V52, P1392, DOI 10.1167/iovs.10-5984
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Prandota J, 2001, Am J Ther, V8, P11, DOI 10.1097/00045391-200101000-00004
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Rohrer B, 2019, MOL VIS, V25, P79
   Rumin J, 2015, BIOTECHNOL BIOFUELS, V8, DOI 10.1186/s13068-015-0220-4
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Salceda R, 2000, CELL CALCIUM, V27, P223, DOI 10.1054/ceca.2000.0111
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sim RB, 2004, BIOCHEM SOC T, V32, P21, DOI 10.1042/BST0320021
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tilborghs S, 2017, CRIT REV ONCOL HEMAT, V120, P141, DOI 10.1016/j.critrevonc.2017.11.001
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Trocoli A, 2011, AM J CANCER RES, V1, P629
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Zhen XC, 2001, MOL PHARMACOL, V60, P857
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhu Y, 2015, MOL VIS, V21, P1122
   Zilberman-Rudenko J, 2016, P NATL ACAD SCI USA, V113, P1612, DOI 10.1073/pnas.1518163113
NR 64
TC 7
Z9 7
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC 15
PY 2021
VL 12
IS 1
AR 7293
DI 10.1038/s41467-021-27488-x
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA XP3WT
UT WOS:000730799500011
PM 34911940
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sun, ZH
   Gong, YY
   Yang, YT
   Huang, Y
   Yu, SQ
   Pei, JQ
   Lin, B
   Zhou, R
   Li, YZ
   Li, YM
   Zhang, JY
   Liu, XL
AF Sun, Zuhua
   Gong, Yuanyuan
   Yang, Yating
   Huang, Ying
   Yu, Suqin
   Pei, Junqing
   Lin, Bing
   Zhou, Rong
   Li, Yingzi
   Li, Yumin
   Zhang, Junyan
   Liu, Xiaoling
TI Efficacy of Initial vs. Delayed Photodynamic Therapy in Combination With
   Conbercept for Polypoidal Choroidal Vasculopathy
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE polypoidal choroidal vasculopathy; photodynamic therapy; conbercept;
   non-inferiority; efficacy
ID MACULAR DEGENERATION; RANIBIZUMAB; VERTEPORFIN
AB Purpose: To compare the efficacy of initial vs. delayed photodynamic therapy (PDT) in combination with intravitreal injection of conbercept (IVC) for polypoidal choroidal vasculopathy (PCV). Design: Multicenter, randomized, non-inferiority clinical trial. Subjects: Naive PCV patients. Methods: Patients were randomized 1:1 into two groups: initial PDT with IVC and delayed PDT with IVC. At baseline, patients in the initial combination group were treated with PDT and IVC within 1 week, while patients in the delayed combination group were treated with IVC alone. PDT and IVC was given PRN during the follow-up in each group. Main Outcome Measures: Non-inferiority of delayed PDT with IVC to initial PDT with IVC for mean change in best-corrected visual acuity from baseline to month 12 (95% CI of the difference entirely above -5 letters). Results: Eighty-six patients were enrolled, with 43 in each group. At month 12, the change of BCVA in initial combination group was equivalent to that in the delayed combination group, with gains of 6.42 +/- 1.89 and 7.49 +/- 2.14 (mean +/- standard error) letters, respectively [delayed group minus initial group: 1.07 letters; 95% confidence interval (CI): -4.62 to 6.76; Pnon-inferiority = 0.0198]. The rates of complete polyp regression were 66.67 and 45.83% in the initial and delayed combination groups, respectively. The difference was not statistically significant (P = 0.386). The mean reductions of CRT were 204.77 +/- 28.79 and 84.14 +/- 30.62 mu m in each group respectively. The difference was statistically significant (P = 0.005). In addition, the mean injection numbers were 3.47 +/- 2.39 and 4.91 +/- 2.65 in each group respectively. The differences were statistically significant (P = 0.010). Conclusions: There was effective in both groups in patients with PCV. The initial combination group showed a more efficient decrease in CRT and polyp regression, along with fewer injections. However, the initial combination group was non-inferior compared with the delayed combination group in terms of the improvement of BCVA.
C1 [Sun, Zuhua; Yang, Yating; Huang, Ying; Pei, Junqing; Lin, Bing; Zhou, Rong; Li, Yingzi; Liu, Xiaoling] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.
   [Sun, Zuhua; Yang, Yating; Huang, Ying; Pei, Junqing; Lin, Bing; Zhou, Rong; Li, Yingzi; Liu, Xiaoling] Wenzhou Med Univ, Hosp Eye, Wenzhou, Peoples R China.
   [Gong, Yuanyuan; Yu, Suqin] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China.
   [Li, Yumin] Zhejiang Univ, Dept Ophthalmol, Sir Run Run Shaw Hosp, Coll Med, Hangzhou, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Shanghai Jiao
   Tong University; Zhejiang University
RP Liu, XL (通讯作者)，Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.; Liu, XL (通讯作者)，Wenzhou Med Univ, Hosp Eye, Wenzhou, Peoples R China.
EM drliuxiaolin@163.com
RI li, Yu/HCI-9086-2022; 俞, 素勤/HDO-8369-2022
OI ZHANG, JUNYAN/0000-0002-7890-3707
FU Science and Technology Project of Wenzhou Science and Technology Bureau
   [Y20160448]; Key Subject of Eye Hospital, Wenzhou Medical University
   [YNZD201601]; Beijing Bethune Charitable Foundation
FX Science and Technology Project of Wenzhou Science and Technology Bureau
   (Y20160448); Key Subject of Eye Hospital, Wenzhou Medical University
   (YNZD201601); IIT project of Research and Development Fund of
   Conbercept, funded by Beijing Bethune Charitable Foundation in 2017. The
   funding sources had no role in the design and conduct of the study;
   collection, management, analysis, and interpretation of the data;
   preparation, review, or approval of the manuscript; and decision to
   submit the manuscript for publication.
CR Adams DM, 2019, AM J PHYS ANTHROPOL, V168, P190, DOI 10.1002/ajpa.23735
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chhablani JK, 2011, RETINA-J RET VIT DIS, V31, P196, DOI 10.1097/IAE.0b013e3181fe924f
   Chi SC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82316-y
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Iesato Y, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0952-6
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ngo WK, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01419-8
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Tan CS, 2015, OSLI RETINA, V46, P786, DOI 10.3928/23258160-20150909-02
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yeung L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80731-1
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
NR 28
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD FEB 9
PY 2022
VL 8
AR 791935
DI 10.3389/fmed.2021.791935
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZH6IZ
UT WOS:000761041400001
PM 35223882
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kowluru, RA
   Kanwar, M
   Chan, PS
   Zhang, JP
AF Kowluru, Renu A.
   Kanwar, Mamta
   Chan, Pooi-See
   Zhang, Jiang Ping
TI Inhibition of retinopathy and retinal metabolic abnormalities in
   diabetic rats with AREDS-Based micronutrients
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; MACULAR DEGENERATION; VITAMIN-E; EXPERIMENTAL
   GALACTOSEMIA; SUPEROXIDE-DISMUTASE; ANTIOXIDANTS; MECHANISM; DAMAGE;
   PEROXYNITRITE; COMPLICATIONS
AB Objectives: To investigate whether the micronutrients that were shown to reduce the risk of development of age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) can have the same effect on the development of diabetic retinopathy in rats, and to understand the possible mechanisms.
   Methods: Streptozotocin-induced diabetic rats received a powdered diet with or without supplemental micronutrients ( ascorbic acid, vitamin E, beta-carotene, zinc, and copper). The retina was used after the rats had diabetes for 12 months to detect vascular histopathology and to measure the biochemical parameters and messenger RNA levels of the genes involved in oxidative and nitrative stress.
   Results: The AREDS-based micronutrients prevented a diabetes-induced increase in the number of retinal acellular capillaries. In the same rats, micronutrients inhibited increases in retinal oxidatively modified DNA and nitrotyrosine and decreases in manganese superoxide dismutase. Diabetes-induced alterations in the messenger RNA expression of mitochondrial electron transport complex III (coenzyme Q cytochrome-c reductase) and inducible nitric oxide synthase were also prevented.
   Conclusion: Age-Related Eye Disease Study-based micronutrients inhibit the development of diabetic retinopathy in rodents by inhibiting oxidative and nitrative stress.
   Clinical Relevance: Micronutrients that slow down the onset and progression of age-related macular degeneration have the potential to inhibit the development of diabetic retinopathy.
C1 [Kowluru, Renu A.; Kanwar, Mamta; Chan, Pooi-See; Zhang, Jiang Ping] Wayne State Univ, Kresge Eye Inst, Detroit, MI 48201 USA.
C3 Wayne State University
RP Kowluru, RA (通讯作者)，Wayne State Univ, Kresge Eye Inst, 4717 St Antoine, Detroit, MI 48201 USA.
EM rkowluru@med.wayne.edu
FU National Institutes of Health [014370, E017313]; Juvenile Diabetes
   Research Foundation [2004-287]; Thomas Foundation; Research to Prevent
   Blindness
FX This study was supported in part by grants 014370 and E017313 from the
   National Institutes of Health, grant 2004-287 from the Juvenile Diabetes
   Research Foundation, the Thomas Foundation, and Research to Prevent
   Blindness.
CR Alper G, 2005, ENDOCR RES, V31, P199, DOI 10.1080/07435800500371805
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Bursell SE, 1999, DIABETES CARE, V22, P1245, DOI 10.2337/diacare.22.8.1245
   Carmo A, 2000, NITRIC OXIDE-BIOL CH, V4, P590, DOI 10.1006/niox.2000.0312
   Cheng HY, 2006, P NATL ACAD SCI USA, V103, P17525, DOI 10.1073/pnas.0605790103
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Cui Y, 2006, EXP EYE RES, V83, P807, DOI 10.1016/j.exer.2006.03.024
   Duzguner V, 2007, FREE RADICAL BIO MED, V42, P1481, DOI 10.1016/j.freeradbiomed.2007.02.021
   ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   HAMMES HP, 1993, INVEST OPHTH VIS SCI, V34, P2092
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   KERN TS, 1994, CURR EYE RES, V13, P863, DOI 10.3109/02713689409015087
   Kowluru RA, 2006, INVEST OPHTH VIS SCI, V47, P1594, DOI 10.1167/iovs.05-1276
   Kowluru RA, 2004, DIABETES, V53, P3233, DOI 10.2337/diabetes.53.12.3233
   Kowluru RA, 1997, FREE RADICAL BIO MED, V22, P587, DOI 10.1016/S0891-5849(96)00347-4
   Kowluru RA, 2003, FREE RADICAL RES, V37, P1169, DOI 10.1080/10715760310001604189
   Kowluru RA, 2001, EXPERT OPIN INV DRUG, V10, P1665, DOI 10.1517/13543784.10.9.1665
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Millen AE, 2004, AM J CLIN NUTR, V79, P865
   Millen AE, 2003, AM J EPIDEMIOL, V158, P225, DOI 10.1093/aje/kwg116
   Moustafa SA, 2004, TOXICOL APPL PHARM, V201, P149, DOI 10.1016/j.taap.2004.05.014
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3
   ROBISON WG, 1995, INVEST OPHTH VIS SCI, V36, P2368
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Stitt AW, 2003, EXP MOL PATHOL, V75, P95, DOI 10.1016/S0014-4800(03)00035-2
   Uriu-Adams Janet Y., 2005, Molecular Aspects of Medicine, V26, P268, DOI 10.1016/j.mam.2005.07.015
   Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122
   Zheng L, 2007, DIABETOLOGIA, V50, P1987, DOI 10.1007/s00125-007-0734-9
   Zheng L, 2007, DIABETES, V56, P337, DOI 10.2337/db06-0789
NR 38
TC 56
Z9 58
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2008
VL 126
IS 9
BP 1266
EP 1272
DI 10.1001/archopht.126.9.1266
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 345XQ
UT WOS:000259031500014
PM 18779489
OA Bronze
DA 2022-11-30
ER

PT J
AU Hata, M
   Tsujikawa, A
   Miyake, M
   Yamashiro, K
   Ooto, S
   Oishi, A
   Nakata, I
   Takahashi, A
   Yoshimura, N
AF Hata, Masayuki
   Tsujikawa, Akitaka
   Miyake, Masahiro
   Yamashiro, Kenji
   Ooto, Sotaro
   Oishi, Akio
   Nakata, Isao
   Takahashi, Ayako
   Yoshimura, Nagahisa
TI Two-year visual outcome of polypoidal choroidal vasculopathy treated
   with photodynamic therapy combined with intravitreal injections of
   ranibizumab
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Photodynamic therapy; Ranibizumab;
   Combined therapy; ARMS2 A69S
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; BEVACIZUMAB;
   VERTEPORFIN; EFFICACY; ASSOCIATION; VEGF
AB Purpose To investigate the 2-year outcomes of photodynamic therapy (PDT) combined with intravitreal injections of ranibizumab for polypoidal choroidal vasculopathy (PCV).
   Methods Ninety-five eyes with subfoveal PCV treated with combined therapy were followed for >= 24 months. The association between visual outcomes and single nucleotide polymorphisms in ARMS2 A69S and CFH I62V genes were examined without adjusting for multiple comparisons.
   Results Visual acuity (VA) improvement was observed at month 3 (P=0.009). The improvement persisted until month 12 (P=0.003), when VA began the decline back to baseline values at month 24. To investigate the factors associated with VA reduction during the second year, patients were divided into those with and those without a second-year VA reduction. Both patients with and without a second-year VA reduction showed similar VA changes over the first year. The first-year VA improvement was not predictive of the VA decline over the second year. Genetic analyses showed no significant difference in the frequency of the A risk allele of CFH I62V between patients with and without a second-year VA reduction. However, patients with the T risk allele of A69S had a higher rate of recurrence and were more likely to experience a reduction in VA during the second year when compared to patients without (P=0.020 and P=0.048, respectively).
   Conclusions PDT combined therapy resulted in significant visual recovery in the first year, which was not sustained during the second year. VA reduction in the second year was affected by genetic factors.
C1 [Hata, Masayuki; Tsujikawa, Akitaka; Miyake, Masahiro; Yamashiro, Kenji; Ooto, Sotaro; Oishi, Akio; Nakata, Isao; Takahashi, Ayako; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; Oishi, Akio/AAE-9996-2020
OI Miyake, Masahiro/0000-0001-7410-3764; Oishi, Akio/0000-0002-0977-9458;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [24249082, 24592625]
FX This research was supported in part by a Grant-in-Aid for Scientific
   Research (24592625, 24249082) from the Japan Society for the Promotion
   of Science (JSPS), Tokyo, Japan.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bessho H, 2011, MOL VIS, V17, P977
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Chen HY, 2012, MOL VIS, V18, P816
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Romano MR, 2010, CLIN OPHTHALMOL, V4, P1237, DOI 10.2147/OPTH.S12577
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 43
TC 21
Z9 24
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2015
VL 253
IS 2
BP 189
EP 197
DI 10.1007/s00417-014-2675-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA6FI
UT WOS:000349004600005
PM 24874746
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Simpson, JM
   Billson, FA
   Luo, W
   Penfold, P
   Chua, W
   Mitchell, P
   Zhu, MD
   Hunyor, ABL
AF Gillies, MC
   Simpson, JM
   Billson, FA
   Luo, W
   Penfold, P
   Chua, W
   Mitchell, P
   Zhu, MD
   Hunyor, ABL
TI Safety of an intravitreal injection of triamcinolone - Results from a
   randomized clinical trial
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CYSTOID MACULAR EDEMA; POSTERIOR SUBTENON INJECTION;
   INTRAOCULAR-PRESSURE; PROLIFERATIVE VITREORETINOPATHY; CRYSTALLINE
   CORTISONE; ADJUNCTIVE TREATMENT; ACETONIDE; NEOVASCULARIZATION; UVEITIS;
   CORTICOSTEROIDS
AB Objective: To determine the safety of a single intravitreal injection of triamcinolone acetonide (4 mg) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration.
   Methods: A double-masked, placebo-controlled, randomized clinical trial was conducted at a public tertiary referral eye hospital. Patients participating had age-related macular degeneration with evidence of choroidal neovascularization, any part of which was classic; age older than 59 years; and best-corrected visual acuity of 20/200 or better. Eyes were assigned to active study treatment or to placebo. Intraocular pressure and cataract grading were performed every 6 months for 3 years. Adverse events, from mild to vision-threatening or life-threatening, were recorded as procedure-related or corticosteroid-related.
   Results: Seventy-five eyes were assigned to study treatment and 76 eyes to placebo. There were no moderate or severe adverse events related to the surgical procedure in either group. Triamcinolone-treated eyes had a significantly increased risk of developing mild or moderate elevation of the intraocular pressure. Topical glaucoma medication reduced intraocular pressure to acceptable levels in all patients. There was significant progression of cataract in the triamcinolone-treated eyes.
   Conclusion: Despite a significant adverse event profile, intravitreal triamcinolone is generally well tolerated by the human eye as long as patients are carefully followed up by their surgeon and treated appropriately, when necessary.
C1 Univ Sydney, Sydney Eye Hosp, Dept Clin Ophthalmol, Save Sight & Eye Hlth Inst, Sydney, NSW 2001, Australia.
   Univ Sydney, Save Sight & Eye Hlth Inst, Dept Clin Ophthalmol, Sydney, NSW 2001, Australia.
   Univ Sydney, Sch Publ Hlth, Sydney, NSW 2001, Australia.
C3 University of Sydney; University of Sydney; University of Sydney
RP Gillies, MC (通讯作者)，Univ Sydney, Sydney Eye Hosp, Dept Clin Ophthalmol, Save Sight & Eye Hlth Inst, GPO Box 4337, Sydney, NSW 2001, Australia.
EM mark@eye.usyd.edu.au
RI gillies, mark c/B-3242-2012; Mitchell, Paul/P-1498-2014
OI Simpson, Judy M/0000-0001-5172-3004
CR Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   CHANDLER DB, 1987, GRAEF ARCH CLIN EXP, V225, P259, DOI 10.1007/BF02150144
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   COLES RS, 1962, AM J OPHTHALMOL, V54, P407, DOI 10.1016/0002-9394(62)93758-3
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   ELLIS PP, 1978, AM J OPHTHALMOL, V85, P352, DOI 10.1016/S0002-9394(14)77728-1
   Giles C L, 1974, Am J Ophthalmol, V77, P438
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   HELM CJ, 1995, AM J OPHTHALMOL, V120, P55, DOI 10.1016/S0002-9394(14)73759-6
   HERSCHLER J, 1976, AM J OPHTHALMOL, V82, P90, DOI 10.1016/0002-9394(76)90669-3
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   KALINA PH, 1995, ARCH OPHTHALMOL-CHIC, V113, P867, DOI 10.1001/archopht.1995.01100070041022
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   McCluskey P, 2000, CLIN EXP OPHTHALMOL, V28, P9, DOI 10.1046/j.1442-9071.2000.00267.x
   MILLS DW, 1986, CAN J OPHTHALMOL, V21, P150
   MORGAN CM, 1988, OPHTHALMOLOGY, V95, P660
   Mueller AJ, 1998, AM J OPHTHALMOL, V125, P158, DOI 10.1016/S0002-9394(99)80085-3
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   SCHINDLER RH, 1982, AM J OPHTHALMOL, V93, P415, DOI 10.1016/0002-9394(82)90130-1
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   STURMAN RM, 1966, AM J OPHTHALMOL, V61, P155, DOI 10.1016/0002-9394(66)90760-4
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
NR 27
TC 225
Z9 245
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2004
VL 122
IS 3
BP 336
EP 340
DI 10.1001/archopht.122.3.336
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 801CY
UT WOS:000220075200004
PM 15006845
OA Bronze
DA 2022-11-30
ER

PT J
AU Blaha, M
   Andrys, C
   Langrova, H
   Studnicka, J
   Drsata, J
   Lanska, M
   Blaha, V
   Zak, P
AF Blaha, M.
   Andrys, C.
   Langrova, H.
   Studnicka, J.
   Drsata, J.
   Lanska, M.
   Blaha, V.
   Zak, P.
TI Changes of the complement system and rheological indicators after
   therapy with rheohemapheresis
SO ATHEROSCLEROSIS SUPPLEMENTS
LA English
DT Article
DE Complement; Rheology; Rheopheresis; Age-related macular degeneration;
   Sudden sensorial hearing loss
ID MACULAR DEGENERATION; DRY FORM; RHEOPHERESIS; RHEOHAEMAPHERESIS;
   POLYMORPHISM; DRUSEN
AB Introduction: In the last 10 years, many studies have been published on the role of the complement system in microcirculation disorders. However, as for the changes of complement components after rheohemapheresis, there is still a lack of detailed data in the literature. Complement changes may play an important role in pathogenesis of some microcirculation disorders, such as age-related macular degeneration and acute hearing loss. The objective of this study was to investigate the effect of rheohemapheresis on the basic complement pathways.
   Patients and methods: 32 patients were treated with rheohemapheresis, including 16 patients (10 men and 6 women) for age-related macular degeneration (AMD), mean age 69.7 +/- 6.06 years (range 62-87 years) and 16 patients (11 men and 5 women) aged 56.4 +/- 11.5 (range 34-73 years) for acute hearing loss.
   Results: Rheohemapheresis led to a significant drop of all three complement-activation pathways in both groups of patients. Moreover, complement factor H was also reduced.
   Conclusion: The observed reduction in all three basic complement activation pathways after rheohemapheresis could be clinically important. The search continues both to find substances which influence complement systems and to develop more effective new drugs that require less frequent administration and that provide improved intraocular therapy for AMD patients. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Blaha, M.; Lanska, M.; Zak, P.] Charles Univ Prague, Fac Med, Dept Internal Med Hematol 4, Hradec Kralove 50005, Czech Republic.
   [Blaha, M.; Andrys, C.; Langrova, H.; Studnicka, J.; Drsata, J.; Lanska, M.; Blaha, V.; Zak, P.] Teaching Hosp, Hradec Kralove, Czech Republic.
   [Andrys, C.] Fac Med, Inst Immunol & Allergol, Hradec Kralove, Czech Republic.
   [Langrova, H.; Studnicka, J.] Fac Med, Dept Ophthalmol, Hradec Kralove, Czech Republic.
   [Drsata, J.] Fac Med, Dept Otorhinolaryngol, Hradec Kralove, Czech Republic.
   [Blaha, V.] Charles Univ Prague, Fac Med, Dept Med Metab Care & Gerontol 3, Hradec Kralove 50005, Czech Republic.
C3 Charles University Prague; University Hospital Hradec Kralove; Charles
   University Prague; Charles University Prague; Charles University Prague;
   Charles University Prague
RP Blaha, M (通讯作者)，Charles Univ Prague, Fac Med, Dept Med 4, Hematol, Sokolskast 580, Hradec Kralove 50005, Czech Republic.
EM blaham@email.cz
RI Studnička, Jan/AAC-4127-2022; Blaha, Vladimir/C-1151-2016; Studnicka,
   Jan/K-2875-2017; Blaha, Milan/H-8955-2016
OI Blaha, Vladimir/0000-0001-8088-9919; Studnicka, Jan/0000-0002-9911-4379;
   Andrys, Ctirad/0000-0001-6489-8786; Langrova, Hana/0000-0001-8488-7208;
   Blaha, Milan/0000-0003-2330-5838
FU Ministry of Health, CZ [IGA NT/14037-3, NT/12287-5, NT/13475-4,
   NT/14265-3]
FX The work was supported by the research tasks of the Ministry of Health,
   CZ, IGA NT/14037-3, NT/12287-5, NT/13475-4, NT/14265-3. Prvouk P37-4,
   12.
CR Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678
   Blaha M, 2013, ATHEROSCLEROSIS SUPP, V14, P179, DOI 10.1016/j.atherosclerosissup.2012.10.023
   Blaha M, 2009, ATHEROSCLEROSIS SUPP, V10, P17, DOI 10.1016/S1567-5688(09)71804-5
   Blaha M, 2009, CLIN HEMORHEOL MICRO, V42, P37, DOI 10.3233/CH-2009-1184
   Blaha M, 2008, AKTUAL NEFROL, V14
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   Borberg H, 2009, TRANSFUS APHER SCI, V41, P49, DOI 10.1016/j.transci.2009.05.013
   Cheyney M, 2014, J MIDWIFERY WOM HEAL, V59, P366, DOI [10.3238/arztebl.2014.0366b, 10.1111/jmwh.12210]
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Drsata J, 2014, J OTORHINOLARYNGOL F, V63, P163
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2007, JAMA-J AM MED ASSOC, V297, P401, DOI 10.1001/jama.297.4.401
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel R, 2010, THER APHER DIAL, V14, P276, DOI 10.1111/j.1744-9987.2010.00807.x
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Mosges R, 2009, EUR ARCH OTO-RHINO-L, V266, P943, DOI 10.1007/s00405-008-0823-5
   Rencova E, 2013, ACTA OPHTHALMOL, V91, pE406, DOI 10.1111/j.1755-3768.2012.02503.x
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Schwartz J, 2013, J CLIN APHERESIS, V28, P145, DOI 10.1002/jca.21276
   Studnicka J, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/135798
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Wang X, 2013, INT J OPHTHALMOL-CHI, V6, P861, DOI 10.3980/j.issn.2222-3959.2013.06.21
NR 27
TC 5
Z9 5
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1567-5688
EI 1878-5050
J9 ATHEROSCLEROSIS SUPP
JI Atheroscler. Suppl.
PD MAY
PY 2015
VL 18
BP 140
EP 145
DI 10.1016/j.atherosclerosissup.2015.02.009
PG 6
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA CH1QI
UT WOS:000353796000022
PM 25936318
DA 2022-11-30
ER

PT J
AU Suh, YW
   Lee, JS
   Heo, H
   Park, SH
   Kim, SH
   Lim, KH
   Moon, NJ
   Lee, SJ
   Park, SH
   Baek, SH
AF Suh, Young-Woo
   Lee, Ji Sung
   Heo, Hwan
   Park, Shin Hae
   Kim, Seung-Hyun
   Lim, Key Hwan
   Moon, Nam Ju
   Lee, Sung Jin
   Park, Song-Hee
   Baek, Seung-Hee
TI Vision Improvement with Refractive Correction Does Not Completely
   Exclude Major Eye Diseases: Analyses of Visually Impaired South Korean
   Population in the Korea National Health and Nutrition Examination Survey
   2009-2011
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; PREVALENCE
AB Purpose. To investigate the association between vision improvement with refractive correction in the visually impaired eyes and the prevalence of ocular comorbidities in the South Korean population. Materials and Methods. The data of 24,620 individuals in the Korea National Health and Nutrition Examination Survey (KNHANES 2009-2011) were reviewed. Visual impairment was defined as a presenting visual acuity < 20/60. The participants with visual impairment in at least one eye were divided into 3 groups according to the best-corrected visual acuity (group 1: < 20/30, group 2: >= 20/30 but < 20/25, and group 3: >= 20/25). The prevalence of ocular comorbidities was estimated and compared between the three groups. Results. Visual impairment in at least one eye was found in 3031 individuals. Groups 1, 2, and 3 comprised 23.5%, 22.2%, and 54.3% of these visually impaired eyes, respectively. The prevalence of cataract, diabetic retinopathy, age-related macular degeneration, corneal opacity, blepharoptosis, and pterygium was similar to or even higher in group 2 compared to group 1. The prevalence of glaucoma and age-related macular degeneration was 5.40% and 11.39%, respectively, in group 2 and 3.31% and 3.76%, respectively, in group 3. Conclusions. Appropriate ophthalmologic examination is necessary even if people exhibit vision improvement after optical correction.
C1 [Suh, Young-Woo; Kim, Seung-Hyun] Korea Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Lee, Ji Sung] Asan Med Ctr, Clin Res Ctr, Seoul, South Korea.
   [Heo, Hwan] Chonnam Natl Univ, Dept Ophthalmol, Med Sch & Hosp, Gwangju, South Korea.
   [Park, Shin Hae] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, Coll Med, Seoul, South Korea.
   [Lim, Key Hwan] Ewha Womans Univ, Sch Med, Dept Ophthalmol, Mokdong Hosp, Seoul, South Korea.
   [Moon, Nam Ju] Chung Ang Univ Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Lee, Sung Jin; Park, Song-Hee] Soonchunhyang Univ, Dept Ophthalmol, Seoul Hosp, Seoul, South Korea.
   [Baek, Seung-Hee] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Samsung;
   University of Ulsan; Asan Medical Center; Chonnam National University;
   Catholic University of Korea; Seoul St. Mary's Hospital; Ewha Womans
   University; Chung Ang University; Chung Ang University Hospital;
   Soonchunhyang University; Konyang University; Konyang University
   Hospital
RP Baek, SH (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
EM drslitlamp@kimeye.com
RI Kim, Seung-Hyun/F-7394-2015
OI Baek, Seung-Hee/0000-0001-5564-1970
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler N. M., JAMA, V291, P1900
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Burr J, 2007, HEALTH TECHNOL ASSES, V11, P1, DOI 10.3310/hta11410
   Colenbrander A., 2002, P 29 INT C OPHTH
   Dandona L, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   FURUSKOG P, 1987, ACTA OPHTHALMOL, V65, P668
   Jin YH., 1997, J KOREAN OPHTHALMOL, V378, P2036
   Kim E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053419
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Park SH, 2015, INVEST OPHTH VIS SCI, V56, P484, DOI 10.1167/iovs.14-14909
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210
   World Health Organization, 1993, INT STAT CLASS DIS I
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
NR 17
TC 2
Z9 2
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2017
VL 2017
AR 3412904
DI 10.1155/2017/3412904
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP6BT
UT WOS:000417708500001
PM 29318038
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Ueda-Arakawa, N
   Ooto, S
   Tsujikawa, A
   Yamashiro, K
   Oishi, A
   Yoshimura, N
AF Ueda-Arakawa, Naoko
   Ooto, Sotaro
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Oishi, Akio
   Yoshimura, Nagahisa
TI SENSITIVITY AND SPECIFICITY OF DETECTING RETICULAR PSEUDODRUSEN IN
   MULTIMODAL IMAGING IN JAPANESE PATIENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE reticular pseudodrusen; age-related macular degeneration; scanning laser
   ophthalmoscopy; fundus autofluorescence; optical coherence tomography
ID SUBRETINAL DRUSENOID DEPOSITS; MACULAR DEGENERATION; FUNDUS
   AUTOFLUORESCENCE; HIGH-RISK; PREVALENCE; DISEASE
AB Purpose: To identify reticular pseudodrusen (RPD) in age-related macular degeneration using multiple imaging modalities, including the blue channel image of fundus photography, infrared reflectance (IR), fundus autofluorescence, near-infrared fundus autofluorescence, confocal blue reflectance, indocyanine green angiography, and spectral-domain optical coherence tomography (SD-OCT), and to compare the sensitivities and specificities of these modalities for detecting RPD.
   Methods: This study included 220 eyes from 114 patients with newly diagnosed age-related macular degeneration. Patients underwent fundus photography, IR, fundus autofluorescence, near-infrared fundus autofluorescence, confocal blue reflectance, indocyanine green angiography, and SD-OCT in both eyes. Eyes were diagnosed with RPD if they showed reticular patterns on at least two of the seven imaging modalities.
   Results: Thirty-seven eyes were diagnosed with RPD. However, SD-OCT and IR had the highest sensitivity (94.6%), and at the same time, SD-OCT had a high specificity (98.4%). The blue channel of color fundus photography, confocal blue reflectance, and indocyanine green angiography had a specificity of 100% but had lower sensitivity than that of SD-OCT and IR.
   Conclusion: For detecting RPD, IR and SD-OCT had the highest sensitivity. Although SD-OCT had the highest sensitivity and specificity, RPD detection should be confirmed using more than one modality for increased accuracy. RETINA 33:490-497, 2013
C1 [Ueda-Arakawa, Naoko; Ooto, Sotaro; Tsujikawa, Akitaka; Yamashiro, Kenji; Oishi, Akio; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
C3 Kyoto University
RP Ooto, S (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM ohoto@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458; Tsujikawa, Akitaka/0000-0003-0779-7799;
   Yamashiro, Kenji/0000-0001-9354-8558
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 16
TC 99
Z9 102
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2013
VL 33
IS 3
BP 490
EP 497
DI 10.1097/IAE.0b013e318276e0ae
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 097DW
UT WOS:000315455200005
PM 23403515
DA 2022-11-30
ER

PT J
AU Feng, LW
   Nie, KL
   Huang, Q
   Fan, W
AF Feng, Liwen
   Nie, Kailai
   Huang, Qing
   Fan, Wei
TI Complement factor H deficiency combined with smoking promotes retinal
   degeneration in a novel mouse model
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Complement factor H; smoking; AMD; animal model; macular degeneration
ID MACULAR DEGENERATION; PIGMENT EPITHELIUM; OXIDATIVE STRESS;
   CIGARETTE-SMOKE; MICE; IMPACT; RISK; ACCUMULATION; POLYMORPHISM;
   ACTIVATION
AB Age-related macular degeneration is the leading cause of blindness in the elderly. The Y402H polymorphism in complement factor H promotes disease-like pathogenesis, and a Cfh(+/-) murine model can replicate this phenotype, but only after two years. We reasoned that by combining CFH deficiency with cigarette smoke exposure, we might be able to accelerate disease progression to facilitate preclinical research in this disease. Wild-type and Cfh(+/-) mice were exposed to nose-only cigarette smoke for three months. Retinal tissue morphology and visual function were evaluated by optical coherence tomography, fundus photography and autofluorescence, and electroretinogram. Retinal pigment epithelial cell phenotype and ultrastructure were evaluated by immunofluorescence staining and transmission electron microscopy. Cfh(+/-) smoking mice showed a dome-like protruding lesion at the ellipsoid zone (drusen-like deposition), many retinal hyper-autofluorescence spots, and a marked decrease in A- and B-wave amplitudes. Compared with non-smoking mice, wild-type and Cfh(+/-) smoking mice showed sub-retinal pigment epithelium complement protein 3 deposition, activation of microglia, metabolic waste accumulation, and impairment of tight junctions. Microglia cells migrated into the photoreceptor outer segment layer in Cfh(+/-) smoking mice showed increased activation. Our results suggest that exposing Cfh(+/-) mice to smoking leads to earlier onset of age-related macular degeneration than in other animal models, which may facilitate preclinical research into the pathophysiology and treatment of this disease.
C1 [Feng, Liwen; Nie, Kailai; Huang, Qing; Fan, Wei] Sichuan Univ, Dept Ophthalmol, West China Hosp, Chengdu 610041, Peoples R China.
   [Feng, Liwen; Nie, Kailai] Sichuan Univ, West China Hosp, Res Lab Ophthalmol & Vis Sci, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Fan, W (通讯作者)，Sichuan Univ, Dept Ophthalmol, West China Hosp, Chengdu 610041, Peoples R China.
EM fanwei55@yahoo.com
OI Feng, liwen/0000-0002-2309-8018
FU National Natural Science Foundation of China [81670869]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This work
   was supported by The National Natural Science Foundation of China
   (81670869 to Wei Fan).
CR Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen J, 2019, ANN MED, V51, P314, DOI 10.1080/07853890.2019.1639809
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Kam JH, 2016, EXP EYE RES, V149, P116, DOI 10.1016/j.exer.2016.07.002
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P461, DOI 10.1080/08820538.2017.1301496
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Pons M, 2010, AM J PATHOL, V177, P1198, DOI 10.2353/ajpath.2010.091108
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   Rowan S, 2014, INVEST OPHTH VIS SCI, V55, P492, DOI 10.1167/iovs.13-12413
   Rutar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093343
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Singaravelu J, 2017, BRAIN STRUCT FUNCT, V222, P2759, DOI 10.1007/s00429-017-1370-x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Wang AL, 2010, VISION RES, V50, P638, DOI 10.1016/j.visres.2009.08.029
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Zeng XX, 2000, VISUAL NEUROSCI, V17, P463, DOI 10.1017/S0952523800173122
NR 52
TC 1
Z9 1
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD JAN
PY 2022
VL 247
IS 2
BP 77
EP 86
AR 15353702211052245
DI 10.1177/15353702211052245
EA NOV 2021
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA YJ5DE
UT WOS:000720857200001
PM 34775843
OA Green Published
DA 2022-11-30
ER

PT J
AU Bhatia, KK
   Graham, MS
   Terry, L
   Wood, A
   Tranos, P
   Trikha, S
   Jaccard, N
AF Bhatia, Kanwal K.
   Graham, Mark S.
   Terry, Louise
   Wood, Ashley
   Tranos, Paris
   Trikha, Sameer
   Jaccard, Nicolas
TI DISEASE CLASSIFICATION OF MACULAR OPTICAL COHERENCE TOMOGRAPHY SCANS
   USING DEEP LEARNING SOFTWARE Validation on Independent, Multicenter Data
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; artificial intelligence; clinical
   decision support; computer-aided diagnosis; deep learning; diabetic
   macular edema; optical coherence tomography
ID DIABETIC-RETINOPATHY; AUTOMATED DETECTION; GLOBAL PREVALENCE; AGE;
   DEGENERATION
AB Purpose: To evaluate Pegasus optical coherence tomography (OCT), a clinical decision support software for the identification of features of retinal disease from macula OCT scans, across heterogenous populations involving varying patient demographics, device manufacturers, acquisition sites, and operators. Methods: Five thousand five hundred and eighty-eight normal and anomalous macular OCT volumes (162,721 B-scans), acquired at independent centers in five countries, were processed using the software. Results were evaluated against ground truth provided by the data set owners. Results: Pegasus-OCT performed with areas under the curve of the receiver operating characteristic of at least 98% for all data sets in the detection of general macular anomalies. For scans of sufficient quality, the areas under the curve of the receiver operating characteristic for general age-related macular degeneration and diabetic macular edema detection were found to be at least 99% and 98%, respectively. Conclusion: The ability of a clinical decision support system to cater for different populations is key to its adoption. Pegasus-OCT was shown to be able to detect age-related macular degeneration, diabetic macular edema, and general anomalies in OCT volumes acquired across multiple independent sites with high performance. Its use thus offers substantial promise, with the potential to alleviate the burden of growing demand in eye care services caused by retinal disease.
C1 [Bhatia, Kanwal K.; Graham, Mark S.; Trikha, Sameer; Jaccard, Nicolas] Visulytix Ltd, Screenworks, London, England.
   [Terry, Louise; Wood, Ashley] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, Wales.
   [Tranos, Paris] Ophthalmica, Ophthalmol & Microsurg Inst, Thessaloniki, Greece.
   [Trikha, Sameer] Kings Coll Hosp NHS Fdn Trust, London, England.
C3 Cardiff University; King's College Hospital NHS Foundation Trust
EM kanwalb@gmail.com
FU Visulytix Ltd.
FX This study was funded by Visulytix Ltd.
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Buolamwini J., 2018, GENDER SHADES INTERS, P77
   Caruana R., 2000, P 13 INT C NEUR INF, P381
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Frcophth AT, 2017, OPHTHALMOLOGY, V124, P343, DOI 10.1016/j.ophtha.2016.11.014
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ilginis T, 2014, BRIT MED BULL, V111, P77, DOI 10.1093/bmb/ldu022
   Kashani AH, 2010, AM J OPHTHALMOL, V149, P496, DOI 10.1016/j.ajo.2009.09.025
   Kavukcuoglu K, 2010, NIPS 10 P 25 INT C N, P1090
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   National Institute for Health and Care Excellence, 2018, TUB NICE GUID 82
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pron G, 2014, Ont Health Technol Assess Ser, V14, P1
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Resnikoff S, 2012, BRIT J OPHTHALMOL, V96, P783, DOI 10.1136/bjophthalmol-2011-301378
   Reznicek L, 2014, BRIT J OPHTHALMOL, V98, P1333, DOI 10.1136/bjophthalmol-2013-304399
   Ribeiro L, 2015, OPHTHALMOLOGICA, V233, P96, DOI 10.1159/000368426
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Simonyan Karen, 2015, INT C LEARN REPR, DOI DOI 10.1016/J.PATCOG.2020.107648
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   van der Heijden AA, 2018, ACTA OPHTHALMOL, V96, P63, DOI 10.1111/aos.13613
   van Ginneken B, 2011, RADIOLOGY, V261, P719, DOI 10.1148/radiol.11091710
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2012, GLOB DAT VIS IMP 201
   Zech JR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002683
NR 37
TC 10
Z9 10
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2020
VL 40
IS 8
BP 1549
EP 1557
DI 10.1097/IAE.0000000000002640
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NA3ZC
UT WOS:000559752400023
PM 31584557
DA 2022-11-30
ER

PT J
AU Raman, R
   Vaghefi, E
   Braakhuis, AJ
AF Raman, Reinlesh
   Vaghefi, Ehsan
   Braakhuis, Andrea J.
TI Food components and ocular pathophysiology: a critical appraisal of the
   role of oxidative mechanisms
SO ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
LA English
DT Review
DE antioxidants; ocular pathology; diet; nutrition; vision
ID AGE-RELATED MACULOPATHY; OPEN-ANGLE GLAUCOMA; NUTRIENT INTAKE; MACULAR
   DEGENERATION; TRABECULAR MESHWORK; ANTIOXIDANT INTAKE; DIETARY-INTAKE;
   SUPPLEMENT USE; ZINC INTAKE; VITAMIN-C
AB Background and Objectives: Three of the major ocular diseases, namely cataracts, age-related macular degeneration and glaucoma are associated with oxidative damage. Disease risk and progression may be reduced through consumption of dietary components. To critically examine the literature on dietary and supplemental intakes of fruit and vegetables, meat, antioxidants (vitamins C, E and A), calcium, folate, iron, and their association with ocular disease. Methods and Study Design: Google Scholar and key references from texts and publications were searched using search terms (eye disease, antioxidants), (vision, nutrition), no date restriction, only articles in English were included. Results: We found probable evidence that dietary intake of fruits and vegetables, and vitamin C lowered incidence of cataracts and age-related macular degeneration. In high supplemental doses, vitamin C increases macular degeneration risk. Vitamin A from food was protective for cataracts and glaucoma, but not in supplemental form. Vitamin A was associated with lower incidence of macular degeneration. We also found probable evidence that higher intakes of meat increased the risk of cataracts and macular degeneration. Dietary calcium and iron appeared protective against glaucoma, but not in supplemental form. Conclusions: While a nutrient rich diet high in fruit and vegetables, and associated antioxidants appeared to be protective, we would caution intake of supplementary antioxidants for those with ocular disease.
C1 [Raman, Reinlesh; Braakhuis, Andrea J.] Univ Auckland, Fac Med & Hlth Sci, Discipline Nutr, Auckland, New Zealand.
   [Vaghefi, Ehsan] Univ Auckland, Fac Med & Hlth Sci, Dept Optometry & Vis Sci, Auckland, New Zealand.
C3 University of Auckland; University of Auckland
RP Braakhuis, AJ (通讯作者)，Univ Auckland, Fac Med & Hlth Sci, Level 2,Room 504-202,85 Pk Rd, Auckland 1023, Grafton, New Zealand.
EM a.braakhuis@auckland.ac.nz
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Agarwal R, 2009, INDIAN J OPHTHALMOL, V57, P257, DOI 10.4103/0301-4738.53049
   ALVARADO J, 1981, INVEST OPHTH VIS SCI, V21, P714
   Appleby PN, 2011, AM J CLIN NUTR, V93, P1128, DOI 10.3945/ajcn.110.004028
   Beebe DC, 2010, OPHTHALMIC RES, V44, P155, DOI 10.1159/000316481
   Boeing H, 2012, EUR J NUTR, V51, P637, DOI 10.1007/s00394-012-0380-y
   Cao GH, 1998, AM J CLIN NUTR, V68, P1081, DOI 10.1093/ajcn/68.5.1081
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Coleman AL, 2008, AM J OPHTHALMOL, V145, P1081, DOI 10.1016/j.ajo.2008.01.022
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   COSTARIDES AP, 1991, OPHTHALMIC RES, V23, P284, DOI 10.1159/000267124
   Bibiloni MD, 2014, NUTR HOSP, V29, P880, DOI 10.3305/nh.2014.29.4.7078
   DelaPaz MA, 1996, INVEST OPHTH VIS SCI, V37, P1849
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Giaconi JA, 2012, AM J OPHTHALMOL, V154, P635, DOI 10.1016/j.ajo.2012.03.048
   GIBLIN FJ, 1984, EXP EYE RES, V38, P87, DOI 10.1016/0014-4835(84)90142-8
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   HANKINSON SE, 1992, BMJ-BRIT MED J, V305, P335, DOI 10.1136/bmj.305.6849.335
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Jacques PF, 1997, AM J CLIN NUTR, V66, P911, DOI 10.1093/ajcn/66.4.911
   JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   Garcia-Medina JJ, 2015, ACTA OPHTHALMOL, V93, P546, DOI 10.1111/aos.12629
   KAHN MG, 1983, INVEST OPHTH VIS SCI, V24, P1283
   Kakigi CLM, 2015, JAMA OPHTHALMOL, V133, P746, DOI 10.1001/jamaophthalmol.2015.0514
   Kang JH, 2003, AM J EPIDEMIOL, V158, P337, DOI 10.1093/aje/kwg167
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   McNeil JJ, 2004, OPHTHALMOLOGY, V111, P75, DOI 10.1016/j.ophtha.2003.04.009
   Mitchell P, 2011, DELOITTE ACCESS EC E
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pham-Huy Lien Ai, 2008, Int J Biomed Sci, V4, P89
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rabin DM, 2013, AGING-US, V5, P51
   Ramdas WD, 2012, EUR J EPIDEMIOL, V27, P385, DOI 10.1007/s10654-012-9672-z
   Ravindran RD, 2011, OPHTHALMOLOGY, V118, P1958, DOI 10.1016/j.ophtha.2011.03.016
   Riley M V, 1990, CLAO J, V16, pS16
   ROBERTSON JM, 1991, AM J CLIN NUTR, V53, pS346, DOI 10.1093/ajcn/53.1.346S
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seth RK, 1999, ANN NUTR METAB, V43, P286, DOI 10.1159/000012796
   Sharma Rajesh K, 2005, BMC Ophthalmol, V5, P25, DOI 10.1186/1471-2415-5-25
   Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024
   Tan AG, 2008, AM J CLIN NUTR, V87, P1899, DOI 10.1093/ajcn/87.6.1899
   Tavani A, 1996, ANN EPIDEMIOL, V6, P41, DOI 10.1016/1047-2797(95)00099-2
   Taylor P, 2009, CLEAR FOCUS EC IMPAC
   Theodoropoulou S, 2014, INT OPHTHALMOL, V34, P59, DOI 10.1007/s10792-013-9795-6
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wang N, 2001, NAT MED, V7, P304, DOI 10.1038/85446
   Wang SY, 2013, EYE, V27, P487, DOI 10.1038/eye.2013.10
   Wang SY, 2013, CURR EYE RES, V38, P1049, DOI 10.3109/02713683.2013.803124
   Wang SY, 2012, INVEST OPHTH VIS SCI, V53, P725, DOI 10.1167/iovs.11-9038
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
NR 61
TC 10
Z9 11
U1 1
U2 7
PU H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI MCKINNON
PA PO BOX 4121, MCKINNON, VIC 3204, AUSTRALIA
SN 0964-7058
EI 1440-6047
J9 ASIA PAC J CLIN NUTR
JI Asia Pac. J. Clin. Nutr.
PY 2017
VL 26
IS 4
BP 572
EP 585
DI 10.6133/apjcn.082016.01
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA EX6WA
UT WOS:000403381600001
PM 28582804
DA 2022-11-30
ER

PT J
AU Herbert, AP
   Uhrin, D
   Lyon, M
   Pangburn, MK
   Barlow, PN
AF Herbert, Andrew P.
   Uhrin, Dusan
   Lyon, Malcolm
   Pangburn, Michael K.
   Barlow, Paul N.
TI Disease-associated sequence variations congregate in a polyanion
   recognition patch on human factor H revealed in three-dimensional
   structure
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; COMPLEMENT FACTOR-H; GROWTH FACTOR/SCATTER
   FACTOR; DECAY-ACCELERATING FACTOR; HEPARIN-BINDING DOMAIN; CONTROL
   PROTEIN MODULE; MACULAR DEGENERATION; ENDOTHELIAL-CELLS;
   CRYSTAL-STRUCTURE; C3B INACTIVATOR
AB Mutations and polymorphisms in the regulator of complement activation, factor H, have been linked to atypical hemolytic uremic syndrome (aHUS), membranoproliferative glomerulonephritis, and age-related macular degeneration. Many aHUS patients carry mutations in the two C-terminal modules of factor H, which normally confer upon this abundant 155-kDa plasma glycoprotein its ability to selectively bind self-surfaces and prevent them from inappropriately triggering the complement cascade via the alternative pathway. In the current study, the three-dimensional solution structure of the C-terminal module pair of factor H has been determined. A binding site for a fully sulfated heparin-derived tetrasaccharide has been delineated using chemical shift mapping and the C3d/C3b-binding site inferred from sequence comparisons and computational docking. The resultant information allows assessment of the likely consequences of aHUS-associated amino acid substitutions in this critical region of factor H. It is striking that, excepting those likely to perturb the three-dimensional structure, aHUS-associated missense mutations congregate in the polyanion-binding site delineated in this study, thus potentially disrupting a vital mechanism for control of complement on self-surfaces in the microvasculature of the kidney. It is intriguing that a single nucleotide polymorphism predisposing to age-related macular degeneration occupies another region of factor H that harbors a polyanion-binding site.
C1 Univ Edinburgh, Dept Chem, Edinburgh Biomol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland.
   Univ Texas Hlth Ctr, Tyler, TX 75708 USA.
   Univ Manchester, Christie Hosp NHS Trust, Canc Res UK Dept Med Oncol, Manchester M20 4BX, Lancs, England.
C3 University of Edinburgh; Cancer Research UK; Christie NHS Foundation
   Trust; Christie Hospital; University of Manchester
RP Barlow, PN (通讯作者)，Univ Edinburgh, Dept Chem, Edinburgh Biomol NMR Unit, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.
EM Paul.Barlow@ed.ac.uk
RI Herbert, Andrew P/C-4755-2008; Barlow, Paul N/G-2853-2011; Herbert, Andy
   P/F-6693-2010
OI Herbert, Andrew P/0000-0002-4549-6965; Herbert, Andy
   P/0000-0002-4549-6965; Lyon, Malcolm/0000-0001-9575-6879
FU Medical Research Council [G0001089] Funding Source: Medline; NIDDK NIH
   HHS [DK 35081] Funding Source: Medline; Wellcome Trust Funding Source:
   Medline; MRC [G0001089] Funding Source: UKRI; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081]
   Funding Source: NIH RePORTER
CR ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389
   Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
   Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911
   Delehedde M, 2002, J BIOL CHEM, V277, P12456, DOI 10.1074/jbc.M111345200
   Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066
   Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116
   FREMEAUXBACCHI V, 2005, J MED GENET, V22, P22
   Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101
   Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j
   Habeck Michael, 2004, Methods Mol Biol, V278, P379
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935
   HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5
   JACKSON P, 1994, METHOD ENZYMOL, V230, P250
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9
   Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KRAULIS PJ, 1994, J MOL BIOL, V243, P696, DOI 10.1016/0022-2836(94)90042-6
   KUHN S, 1995, J IMMUNOL, V155, P5663
   LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147
   Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101
   Lyon M, 2004, J BIOL CHEM, V279, P43560, DOI 10.1074/jbc.M408510200
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1
   Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277
   Neuhaus TJ, 1997, ARCH DIS CHILD, V76, P518, DOI 10.1136/adc.76.6.518
   NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053
   Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3
   NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T
   Olie KH, 2004, PEDIATR NEPHROL, V19, P1173, DOI 10.1007/s00467-004-1565-2
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Pangburn MK, 2002, J IMMUNOL, V169, P4702, DOI 10.4049/jimmunol.169.9.4702
   Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337
   RENAUD C, 1995, PEDIATR NEPHROL, V9, P24, DOI 10.1007/BF00858960
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285
   Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4
   Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19
   Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039
   Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2
   Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, SCIENCE, V193, P1011, DOI 10.1126/science.948757
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 62
TC 83
Z9 84
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 16
PY 2006
VL 281
IS 24
BP 16512
EP 16520
DI 10.1074/jbc.M513611200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 051MR
UT WOS:000238165700041
PM 16533809
OA hybrid
DA 2022-11-30
ER

PT J
AU Chay, JX
   Fenner, BJ
   Finkelstein, EA
   Teo, KYC
   Cheung, CMG
AF Chay, Junxing
   Fenner, Beau J.
   Finkelstein, Eric A.
   Teo, Kelvin Y. C.
   Cheung, Chui Ming Gemmy
TI Real-world cost-effectiveness of anti-VEGF monotherapy and combination
   therapy for the treatment of polypoidal choroidal vasculopathy
SO EYE
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR EDEMA; RANIBIZUMAB;
   BEVACIZUMAB; AFLIBERCEPT; EFFICACY; SAFETY
AB Objectives For patients with polypoidal choroidal vasculopathy (PCV), intravitreal anti-vascular endothelial growth factor (anti-VEGF) combination therapy has been shown to be cost-saving relative to monotherapy in a clinical trial setting. However, whether this also applies to real-world settings is unclear. We aim to compare the real-world functional outcomes and cost-effectiveness of intravitreal anti-VEGF combination therapy relative to monotherapy, to investigate whether combination therapy is truly cost-saving. Methods We used a Markov model to simulate a hypothetical cohort of PCV patients treated at Singapore National Eye Centre. Model parameters were informed by coarsened exact matched estimates of a two-year retrospective study of patients who initiated treatment in 2015. Treatment options included intravitreal aflibercept, bevacizumab, or ranibizumab, as monotherapy or in combination with full-fluence verteporfin photodynamic therapy. Results The two-year logMAR letters gains were significant for combination therapy ( + 10.6, P = 0.006) but not monotherapy (-2.2, P = 0.459). Over 20 years, a PCV patient would cost the health system SGD 48,790 under monotherapy and SGD 61,020 under combination therapy. Quality-adjusted life-years (QALYs) were estimated to be 7.41 for monotherapy and 7.80 for combination therapy. The incremental cost-effectiveness ratio of combination therapy was SGD 31,460/QALY, which is less than the common willingness-to-pay threshold of per capita gross domestic product of Singapore (SGD 88,990/QALY). Sensitivity analysis showed that combination therapy remained incrementally cost-effective, but not cost-saving. Conclusions Our study shows that combination therapy is good value for money but is likely to increase costs when applied in real-world settings.
C1 [Chay, Junxing; Fenner, Beau J.; Finkelstein, Eric A.; Teo, Kelvin Y. C.; Cheung, Chui Ming Gemmy] Duke NUS Med Sch, Singapore, Singapore.
   [Fenner, Beau J.; Teo, Kelvin Y. C.; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Fenner, Beau J.; Teo, Kelvin Y. C.; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Singapore National Eye Center
RP Chay, JX (通讯作者)，Duke NUS Med Sch, Singapore, Singapore.
EM junxing.chay@duke-nus.edu.sg
OI Chay, Junxing/0000-0002-3291-4523; Fenner, Beau/0000-0002-5356-7604
FU Duke-NUS Medical School and Singapore Eye Research Institute
FX This work was supported by Duke-NUS Medical School and Singapore Eye
   Research Institute.
CR Agency for Care Effectiveness, DRUG EV METH PROC GU
   Bro T, 2020, GRAEF ARCH CLIN EXP, V258, P503, DOI 10.1007/s00417-019-04569-8
   Cai S, 2017, CURR OPIN OPHTHALMOL, V28, P636, DOI 10.1097/ICU.0000000000000424
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Deaton A, 2018, SOC SCI MED, V210, P2, DOI 10.1016/j.socscimed.2017.12.005
   Doble B, 2020, JAMA OPHTHALMOL, V138, P251, DOI 10.1001/jamaophthalmol.2019.5628
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Finger RP, 2020, JAMA OPHTHALMOL, V138, P1234, DOI 10.1001/jamaophthalmol.2020.3989
   Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010
   Hykin P, 2019, JAMA OPHTHALMOL, V137, P1256, DOI 10.1001/jamaophthalmol.2019.3305
   Iacus SM, 2012, POLIT ANAL, V20, P1, DOI 10.1093/pan/mpr013
   Jordan-Yu JM, 2021, BRIT J OPHTHALMOL, V105, P1716, DOI 10.1136/bjophthalmol-2020-317537
   Koh A, 2020, RETINA-J RET VIT DIS, V40, P1529, DOI 10.1097/IAE.0000000000002624
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Scott IU, 2017, JAMA-J AM MED ASSOC, V317, P2072, DOI 10.1001/jama.2017.4568
   Singapore Department of Statistics, COMPL LIF TABL 2015
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   StataCorp, 2017, STAT SOFTW REL 15
   TreeAge Software, 2020, TREEAGE PRO
   Wataru K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229231
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 0
Z9 0
U1 0
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2022
VL 36
IS 12
BP 2265
EP 2270
DI 10.1038/s41433-021-01856-9
EA NOV 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6H2ZZ
UT WOS:000721411900001
PM 34811522
DA 2022-11-30
ER

PT J
AU Hytti, M
   Tokarz, P
   Maatta, E
   Piippo, N
   Korhonen, E
   Suuronen, T
   Honkakoski, P
   Kaarniranta, K
   Lahtela-Kakkonen, M
   Kauppinen, A
AF Hytti, M.
   Tokarz, P.
   Maatta, E.
   Piippo, N.
   Korhonen, E.
   Suuronen, T.
   Honkakoski, P.
   Kaarniranta, K.
   Lahtela-Kakkonen, M.
   Kauppinen, A.
TI Inhibition of BET bromodomains alleviates inflammation in human RPE
   cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Inflammation; Bromodomains; Sirtuin 1; Retinal pigment epithelium;
   Age-related macular degeneration
ID NF-KAPPA-B; EPITHELIAL-CELLS; TERMINAL DOMAIN; SIRT1; P53;
   INTERLEUKIN-6; ACTIVATION; CHROMATIN; SURVIVAL; DRUSEN
AB Bromodomain-containing proteins are vital for controlling the expression of many pro-inflammatory genes. Consequently, compounds capable of inhibiting specific bromodomain-facilitated protein-protein interactions would be predicted to alleviate inflammation, making them valuable agents in the treatment of diseases caused by dysregulated inflammation, such as age-related macular degeneration. Here, we assessed the ability of known inhibitors JQ-1, PFI-1, and IBET-151 to protect from the inflammation and cell death caused by etoposide exposure in the human retinal pigment epithelial cell line, ARPE-19. The potential anti-inflammatory effects of the bromodomain inhibitors were assessed by ELISA (enzyme-linked immunosorbent assay) profiling. The involvement of NF-kappa B and SIRT1 in inflammatory signaling was monitored by ELISA and western blotting. Furthermore, SIRT1 was knocked down using a specific siRNA or inhibited by EX-527 to elucidate its role in the inflammatory reaction. The bromodomain inhibitors effectively decreased etoposide-induced release of IL-6 and IL-8. This anti-inflammatory effect was not related to SIRT1 activity, although all bromodomain inhibitors decreased the extent of acetylation of p53 at the SIRT1 deacetylation site. Overall, since bromodomain inhibitors display anti-inflammatory properties in human retinal pigment epithelial cells, these compounds may represent a new way of alleviating the inflammation underlying the onset of age-related macular degeneration. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Hytti, M.; Piippo, N.; Korhonen, E.; Honkakoski, P.; Lahtela-Kakkonen, M.; Kauppinen, A.] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Yliopistonranta 1C, Kuopio 70210, Finland.
   [Hytti, M.; Maatta, E.; Piippo, N.; Korhonen, E.; Kaarniranta, K.] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Yliopistonranta 1C, Kuopio 70210, Finland.
   [Tokarz, P.] Univ Lodz, Dept Mol Genet, Ul Pomorska 141-143, PL-90236 Lodz, Poland.
   [Suuronen, T.] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Yliopistonranta 1C, Kuopio 70210, Finland.
   [Kaarniranta, K.] Kuopio Univ Hosp, Dept Ophthalmol, Puijonlaaksontie 2, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Lodz; University of Eastern Finland; Kuopio University Hospital;
   University of Eastern Finland
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Yliopistonranta 1C, Kuopio 70210, Finland.
EM anu.kauppinen@uef.fi
RI Honkakoski, Paavo/AAJ-1278-2020; Tokarz, Paulina/L-9983-2013; Hytti,
   Maria/AAE-4016-2019
OI Honkakoski, Paavo/0000-0002-4332-3577; Hytti, Maria/0000-0003-2150-6847;
   Korhonen, Eveliina/0000-0002-5360-7258; Kaarniranta,
   Kai/0000-0003-2600-8679; Lahtela-Kakkonen, Maija/0000-0001-7163-7728;
   Tokarz, Paulina/0000-0001-9016-3089
FU Finnish Cultural Foundation - North-Savo; Central Foundations; Academy
   of Finland; Kuopio University Hospital; Alfred Kordelin Foundation;
   Paivikki ja Sakari Sohlbergin Saatio; Emil Aaltonen Foundation; Sokeain
   Ystavat ry; Silma-ja Kudospankkisaatio; Silmasaatio
FX We warmly acknowledge Dr. Ewen MacDonald for the language revision and
   Res. Dir. Emeritus Antero Salminen for his valuable collaboration,
   discussions, and critical review of the manuscript. We also would like
   to thank Dr. Elina Jarho, Dr. Tarja Kokkola, Dr. Piia Kokkonen, and Dr.
   Tiina Suuronen for their collaboration on bromodomain inhibitors. This
   work was financially supported by the Finnish Cultural Foundation -
   North-Savo and Central Foundations, the Academy of Finland, the Kuopio
   University Hospital, the Alfred Kordelin Foundation, the Paivikki ja
   Sakari Sohlbergin Saatio, the Emil Aaltonen Foundation, Sokeain Ystavat
   ry, Silma-ja Kudospankkisaatio, and Silmasaatio. None of the funding
   agencies had an influence on study design or result interpretation.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Banerjee C, 2012, J LEUKOCYTE BIOL, V92, P1147, DOI 10.1189/jlb.0312165
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chen J, 2013, ANGIOGENESIS, V16, P985, DOI 10.1007/s10456-013-9374-5
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Gillum MP, 2011, DIABETES, V60, P3235, DOI 10.2337/db11-0616
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hnilicova J, 2013, MOL BIOL CELL, V24, P3557, DOI 10.1091/mbc.E13-06-0303
   Hou Y, 2014, CELL BIOL INT, V38, P1050, DOI 10.1002/cbin.10294
   Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08
   Hubbard BP, 2014, TRENDS PHARMACOL SCI, V35, P146, DOI 10.1016/j.tips.2013.12.004
   Hubbard BP, 2013, SCIENCE, V339, P1216, DOI 10.1126/science.1231097
   Hytti M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17645
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007
   Kokkola T, 2015, CHEMBIOCHEM, V16, P1997, DOI 10.1002/cbic.201500272
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Miao H, 2012, MOL VIS, V18, P574
   Middleton K, 2014, CRIT REV ONCOL HEMAT, V89, P129, DOI 10.1016/j.critrevonc.2013.08.004
   Morris BJ, 2013, FREE RADICAL BIO MED, V56, P133, DOI 10.1016/j.freeradbiomed.2012.10.525
   Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Peti W, 2013, PROTEIN SCI, V22, P1698, DOI 10.1002/pro.2374
   Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Shimada T, 2014, METABOLISM, V63, P469, DOI 10.1016/j.metabol.2013.12.011
   Sinclair DA, 2014, ANNU REV PHARMACOL, V54, P363, DOI 10.1146/annurev-pharmtox-010611-134657
   Smith SG, 2016, ACS CHEM BIOL, V11, P598, DOI 10.1021/acschembio.5b00831
   Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Wang CY, 2015, TRENDS BIOCHEM SCI, V40, P468, DOI 10.1016/j.tibs.2015.06.002
   Wei W, 2014, SCI WORLD J, DOI 10.1155/2014/750634
   Xiao YJ, 2016, RHEUMATOLOGY, V55, P173, DOI 10.1093/rheumatology/kev312
   Xie J, 2013, PHARMACOL RES, V67, P60, DOI 10.1016/j.phrs.2012.10.010
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 43
TC 17
Z9 17
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JUN 15
PY 2016
VL 110
BP 71
EP 79
DI 10.1016/j.bcp.2016.04.009
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DO4FY
UT WOS:000377738400007
PM 27106081
DA 2022-11-30
ER

PT J
AU Sharpe, RA
   Austin, JP
   Kruft, B
   Nelson, LA
   Stewart, JA
   Stewart, WC
AF Sharpe, R. Allan
   Austin, Jennifer P.
   Kruft, Bonnie
   Nelson, Lindsay A.
   Stewart, Jeanette A.
   Stewart, William C.
TI Description of Ophthalmic Pharmaceutical and Device Start-Up Companies
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Ophthalmic pharmaceuticals; Ophthalmic devices; Start-up; Success;
   Product development
ID MAPRACORAT
AB Aims:To describe the number, type and location of ophthalmic companies and their associated product areas and indications. Methods: A retrospective, non-patient-based, observational review of ophthalmic pharmaceutical and device companies with a new product in development. Data was compiled by Internet searches. Results: We identified 190 companies currently developing ophthalmic products: 134 (71%) were privately held and 56 (29%) publicly held, while 136 (72%) were in the United States and 53 (28%) were outside the United States. There were 436 total products of which 338 (78%) were pharmaceuticals and 98 (22%) devices. With pharmaceuticals we identified 46 separate indications with age-related macular degeneration (n = 75), glaucoma (n = 52) and dry eye (n = 46) as most common; antivascular endothelial growth factor, hormone therapy and anti-inflammatory products were also common classes. With devices there were 30 indications with glaucoma (n = 26), age-related macular degeneration (n = 19) and dry eye (n = 6) as most common; drug delivery, ocular implants and prostheses were less common classes. Conclusions: Ophthalmology as a specialty is benefited by a wide effort in new medicine and device development. However, a concentration of effort into relatively few indications suggests a potential lack of market analysis and possible difficulty for many companies in commercializing their product. (C) 2015 S. Karger AG, Basel
C1 [Sharpe, R. Allan] Med Univ S Carolina, Charleston, SC 29425 USA.
   [Austin, Jennifer P.; Kruft, Bonnie; Nelson, Lindsay A.; Stewart, Jeanette A.; Stewart, William C.] PRN Pharmaceut Res Network LLC, Cheyenne, WY USA.
C3 Medical University of South Carolina
RP Stewart, WC (通讯作者)，109 East 17th St,Suite 3407, Cheyenne, WY 82001 USA.
EM info@prnorb.com
CR Baiula M, 2011, MOL VIS, V17, P3208
   Collier R, 2009, CAN MED ASSOC J, V180, P279, DOI 10.1503/cmaj.082040
   Collins, 2001, GOOD GREAT WHY SOME
   Goodman C S, 1996, Baxter Health Policy Rev, V2, P267
   Peters T., 1982, SEARCH EXCELLENCE LE
   Reichert JM, 2003, NAT REV DRUG DISCOV, V2, P695, DOI 10.1038/nrd1178
   Shafiee A, 2011, INVEST OPHTH VIS SCI, V52, P1422, DOI 10.1167/iovs.10-5598
   Stewart WC, 2013, ACTA OPHTHALMOL, V91, pe496, DOI 10.1111/aos.12041
   Stewart WC, 2013, ACTA OPHTHALMOL, V91, pe81, DOI 10.1111/j.1755-3768.2012.02443.x
   Stewart WC, 2010, AM J OPHTHALMOL, V150, P744, DOI 10.1016/j.ajo.2010.05.039
NR 10
TC 3
Z9 3
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2015
VL 54
IS 1
BP 6
EP 9
DI 10.1159/000377636
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM5ZA
UT WOS:000357766300003
PM 25999058
OA Bronze
DA 2022-11-30
ER

PT J
AU Larson, T
   Coker, J
AF Larson, Tara
   Coker, Janice
TI A descriptive study of lutein and zeaxanthin in optometric practice
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Article
DE Optometry; Macular degeneration; Cataract; Lutein; Zeaxanthin;
   Antioxidants; Patient education
ID MACULAR PIGMENT; VITAMIN-A; CATARACT-EXTRACTION; BETA-CAROTENE; RISK;
   SUPPLEMENTATION
AB PURPOSE: The purpose of this study was to describe the perceptions, recommendations, and educational or informational materials of licensed Wisconsin optometrists on lutein and zeaxanthin and eye health.
   METHODS: A 20-item original survey with letter of consent was mailed to 300 randomly chosen licensed optometrists followed by a reminder postcard II days later. A reminder to complete the survey was published in the Wisconsin Optometric Association newsletter. A total of 127 (42.3%) returned surveys were usable. The survey variables were coded, and data were entered and analyzed using SPSS version 11.5 for Windows (SPSS Inc., Chicago, Illinois).
   RESULTS: Most respondents felt moderately to very informed about the relationship between lutein and zeaxanthin and eye health. Most participants thought the information on lutein and zeaxanthin and eye health was adequate to make recommendations to patients. Most respondents recommended a lutein or zeaxanthin supplement, spinach or other foods rich in lutein and zeaxanthin, a zinc supplement, and a multi-vitamin/mineral supplement to patients with, or at risk of, age-related macular degeneration. About half of respondents who distributed educational or informational materials had materials on lutein and zeaxanthin.
   CONCLUSIONS: Optometrists felt informed about lutein and zeaxanthin and eye health and recommended spinach or antioxidant supplements for age-related macular degeneration. Optometry 2009;80:579-586
C1 [Larson, Tara] Trinity Reg Med Ctr, Ft Dodge, IA 50501 USA.
   [Coker, Janice] Univ Wisconsin Stout, Menomonie, WI USA.
C3 University of Wisconsin System; University of Wisconsin Stout
RP Larson, T (通讯作者)，Trinity Reg Med Ctr, 802 Kenyon Rd, Ft Dodge, IA 50501 USA.
EM tara.larson@sdstate.edu
FU University of Wisconsin-Stout
FX This research was funded in part by the University of Wisconsin-Stout
   Student Research Fund. No funding was obtained from any pharmaceutical
   companies nor do the researchers have any financial interest in their
   products.
CR Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1732, DOI 10.1001/archopht.120.12.1732
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   CAVALLERANO AA, 1994, OPTOMETRIC CLIN PRAC
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   *FOOD DRUG ADM NIH, 2000, NUTR OV, pCH19
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly JP, 2005, ARCH INTERN MED, V165, P281, DOI 10.1001/archinte.165.3.281
   *KEM FOODS, 2002, NEW STUD SHOWS 91 EY
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   MALTBY C, 2003, NATL STUDY SHOWS BIG
   Mares-Perlman JA, 1999, AM J CLIN NUTR, V70, P431
   *NAT EY I, 2006, CLIN STUD DAT AG REL
   Pratt S, 1999, J Am Optom Assoc, V70, P39
   *PREV BLINDN AM, 2000, VIS PROBL US PREV AD
   Redlich CA, 1998, CANCER EPIDEM BIOMAR, V7, P211
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SPERDUTO RD, 1990, ARCH OPHTHALMOL-CHIC, V108, P1403, DOI 10.1001/archopht.1990.01070120051026
   USDA, USDA NAT NUTR DAT ST
   YAMAMOTO ME, 2008, RES SUCCESSFUL APPRO, P81
   YEUM J, 1995, INVEST OPHTH VIS SCI, V36, P2756
NR 29
TC 5
Z9 5
U1 0
U2 4
PU AMER OPTOMETRIC ASSN INC
PI ST LOUIS
PA 243 N LINDBERGH BLVD, ST LOUIS, MO 63141 USA
SN 1529-1839
EI 1558-1527
J9 OPTOMETRY
JI Optometry
PD OCT
PY 2009
VL 80
IS 10
BP 579
EP 586
DI 10.1016/j.optm.2009.03.015
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V18QK
UT WOS:000208019100007
PM 19801342
DA 2022-11-30
ER

PT J
AU Petrus-Reurer, S
   Bartuma, H
   Aronsson, M
   Westman, S
   Lanner, F
   Kvanta, A
AF Petrus-Reurer, Sandra
   Bartuma, Hammurabi
   Aronsson, Monica
   Westman, Sofie
   Lanner, Fredrik
   Kvanta, Anders
TI Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal
   Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Cellular Biology; Issue 131; Retinal Pigment Epithelial Cell; Human
   Embryonic Stem Cell; Large-eyed model; Geographic Atrophy; Suspension
   Subretinal Transplantation; Optical Coherence Tomography; Transvitreal
   Pars Plana
ID DEGENERATION; RABBIT
AB Geographic atrophy (GA), the late stage of dry age-related macular degeneration is characterized by loss of the retinal pigment epithelial (RPE) layer, which leads to subsequent degeneration of vital retinal structures (e.g., photoreceptors) causing severe vision impairment. Similarly, RPE-loss and decrease in visual acuity is seen in long-term follow up of patients with advanced wet age-related macular degeneration (AMD) receiving intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Therefore, on the one hand, it is fundamental to efficiently derive RPE cells from an unlimited source that could serve as replacement therapy. On the other hand, it is important to assess the behavior and integration of the derived cells in a model of the disease entailing surgical and imaging methods as close as possible to those applied in humans. Here, we provide a detailed protocol based on our previous publications that describes the generation of a preclinical model of GA using the albino rabbit eye, for evaluation of the human embryonic stem cell derived retinal pigment epithelial cells (hESC-RPE) in a clinically relevant setting. Differentiated hESC-RPE are transplanted into naive eyes or eyes with NaIO3-induced GA-like retinal degeneration using a 25 G transvitreal pars plana technique. Evaluation of degenerated and transplanted areas is performed by multimodal high-resolution non-invasive real-time imaging.
C1 [Petrus-Reurer, Sandra; Bartuma, Hammurabi; Aronsson, Monica; Westman, Sofie; Kvanta, Anders] Karolinska Inst, Sect Ophtalmol & Vis, Clin Neurosci, Solna, Sweden.
   [Petrus-Reurer, Sandra; Lanner, Fredrik] Karolinska Inst, Div Obstet & Gynecol, Clin Sci Intervent & Technol, Solna, Sweden.
C3 Karolinska Institutet; Karolinska Institutet
RP Petrus-Reurer, S (通讯作者)，Karolinska Inst, Sect Ophtalmol & Vis, Clin Neurosci, Solna, Sweden.; Petrus-Reurer, S (通讯作者)，Karolinska Inst, Div Obstet & Gynecol, Clin Sci Intervent & Technol, Solna, Sweden.
EM sandra.petrus-reurer@ki.se
OI Lanner, Fredrik/0000-0002-2771-7445; Petrus-Reurer,
   Sandra/0000-0002-7051-1741
FU Karolinska Institute; Crown Princess Margareta's Foundation for the
   Visually Impaired; Edwin Jordan Foundation for Ophthalmological
   Research; Swedish Eye Foundation; King Gustav V Foundation; ARMEC
   Lindeberg Foundation; Cronqvist Foundation
FX This study was supported by grants from the Karolinska Institute, the
   Crown Princess Margareta's Foundation for the Visually Impaired, the
   Edwin Jordan Foundation for Ophthalmological Research, the Swedish Eye
   Foundation, the King Gustav V Foundation, the ARMEC Lindeberg
   Foundation, and the Cronqvist Foundation.
CR Bartuma H, 2015, INVEST OPHTH VIS SCI, V56, P2423, DOI 10.1167/iovs.14-16208
   Blanch RJ, 2012, INVEST OPHTH VIS SCI, V53, P2913, DOI 10.1167/iovs.11-8564
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   HUGHES A, 1972, VISION RES, V12, P123, DOI 10.1016/0042-6989(72)90143-5
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Nork TM, 2012, ARCH OPHTHALMOL-CHIC, V130, P65, DOI 10.1001/archophthalmol.2011.295
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
NR 10
TC 8
Z9 8
U1 0
U2 4
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JAN
PY 2018
IS 131
AR e56702
DI 10.3791/56702
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FX5CM
UT WOS:000426095700065
PM 29443034
OA Green Published
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Ohtsuka, H
   Higuchi, M
   Matsushita, T
   Ariga, H
   Kosaka, S
   Matsushita, R
   Takami, K
AF Hikichi, Taiichi
   Ohtsuka, Hideo
   Higuchi, Makoto
   Matsushita, Takuro
   Ariga, Hiroko
   Kosaka, Shoko
   Matsushita, Reiko
   Takami, Kimitaka
TI Improvement of Angiographic Findings of Polypoidal Choroidal
   Vasculopathy After Intravitreal Injection of Ranibizumab Monthly for 3
   Months
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; INDOCYANINE GREEN; JAPANESE PATIENTS; CLINICOPATHOLOGICAL
   CORRELATION; FLUORESCEIN ANGIOGRAPHY; BLACK-WOMEN; VERTEPORFIN;
   NEOVASCULARIZATION
AB PURPOSE: To evaluate the efficacy of 1 intravitreal injection of ranibizumab monthly for 3 months in eyes with polypoidal choroidal vasculopathy (PCV), with attention to changes on indocyanine green angiography (ICGA) with confocal scanning laser ophthalmoscopy (cSLO).
   DESIGN: Prospective, consecutive case series.
   METHODS: Fifty consecutive eyes of 50 patients with symptomatic PCV who had not been treated previously received 1 intravitreal injection of 0.5 mg ranibizumab monthly for 3 months. Changes in ICGA findings with cSLO 3 months after the primary injection were evaluated.
   RESULTS: The mean visual acuity (VA) at baseline (0.25; range, 0.1-0.8) improved to 0.38 (P = .001) 3 months after the primary injection. Nineteen eyes (38%) had an improvement in VA of 0.3 or more logMAR unit, and 5 eyes (10%) had a decrease in VA of 0.3 or more logMAR unit. Polypoidal lesions disappeared on ICGA in 13 eyes (26%) and the number of lesions decreased but did not disappear in 26 eyes (52%), with absorption of the accompanying fluid on optical coherence tomography. The remaining 11 eyes (22%) had unchanged or worsened polypoidal lesions. A branching vascular network remained in all 48 eyes in which the network was detected at baseline. Although resolution of the branching vascular networks or decreased diameter of the branching vascular network occurred in 11 eyes (23%), the branching vascular network was unchanged or worse in 37 eyes (77%).
   CONCLUSION: Although a limitation of this study is the short-term follow-up, polypoidal lesions tended to respond to ranibizumab therapy, but the branching vascular network responded poorly. (Am J Ophthalmol 2010;150:674-682. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Hikichi, Taiichi] Ohtsuka Eye Hosp, Kita Ku, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Kita Ku, Kita 16,Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   [Anonymous], 2005, NIPPON GANKA GAKKAI, V109, P417
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Freeman WR, 1998, ARCH OPHTHALMOL-CHIC, V116, P455, DOI 10.1001/archopht.116.4.455
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Hikichi T, 2009, RETINA-J RET VIT DIS, V29, P395, DOI 10.1097/IAE.0b013e318192f53a
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 38
TC 43
Z9 47
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2010
VL 150
IS 5
BP 674
EP 682
DI 10.1016/j.ajo.2010.05.026
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 679RA
UT WOS:000284177300015
PM 20691424
DA 2022-11-30
ER

PT J
AU Romano, F
   Parrulli, S
   Parodi, MB
   Lupidi, M
   Cereda, M
   Staurenghi, G
   Invernizzi, A
AF Romano, Francesco
   Parrulli, Salvatore
   Battaglia Parodi, Maurizio
   Lupidi, Marco
   Cereda, Matteo
   Staurenghi, Giovanni
   Invernizzi, Alessandro
TI Optical coherence tomography features of the repair tissue following RPE
   tear and their correlation with visual outcomes
SO SCIENTIFIC REPORTS
LA English
DT Article
AB To assess the optical coherence tomography (OCT) features of the repair tissue after retinal pigment epithelial (RPE) tear in neovascular age-related macular degeneration. Retrospective, observational study. Medical and imaging records of patients that developed tears after starting anti-VEGF treatment and with at least 12 months of follow-up were reviewed. OCT reflectivity of the RPE-subretinal hyperreflective tissue (SHT) complex was measured at 6, 12 and 18 months (when available). Reflectivity of the adjacent unaffected RPE-Bruch's membrane was taken as internal reference. Other variables: grade and rip occurrence (early/late); number of intravitreal injections; type of macular neovascularization; sub-macular hemorrhage (SMH) at onset. Forty-nine eyes (age: 76.1 +/- 7.0 years; VA: 0.54 +/- 0.27 LogMAR) were included. Thirty-eight eyes had OCT signs of healing during the follow-up, with 21 showing SMH at baseline. Final VA positively correlated with the number of injections and negatively correlated with the RPE-SHT reflectivity and the presence of SMH (p<0.001). Reflectivity of the RPE-SHT complex was positively associated with time and SMH at baseline (p<0.05). In our study, most eyes showed signs of tissue repair after RPE tear. The reflectivity of repair tissue, the SMH presence and the number of anti-VEGF injections appeared to be major predictors of visual outcomes.
C1 [Romano, Francesco; Parrulli, Salvatore; Cereda, Matteo; Staurenghi, Giovanni; Invernizzi, Alessandro] Univ Milan, Luigi Sacco Hosp, Dept Biomed Sci, Eye Clin, Milan, Italy.
   [Battaglia Parodi, Maurizio] Univ Vita Salute San Raffaele, Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Lupidi, Marco] Univ Perugia, S Maria Della Misericordia Hosp, Sect Ophthalmol, Dept Surg & Biomed Sci, Perugia, Italy.
   [Invernizzi, Alessandro] Univ Sydney, Save Sight Inst, Fac Hlth & Med, Sydney, NSW, Australia.
   [Romano, Francesco] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
C3 University of Milan; Luigi Sacco Hospital; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; Hospital Santa Maria della
   Misericordia; University of Perugia; University of Sydney; University of
   Milan; Luigi Sacco Hospital
RP Romano, F (通讯作者)，Univ Milan, Luigi Sacco Hosp, Dept Biomed Sci, Eye Clin, Milan, Italy.; Romano, F (通讯作者)，Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
EM francesco.romano@unimi.it
CR Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Bloch SB, 2011, ACTA OPHTHALMOL, V89, pe665, DOI 10.1111/j.1755-3768.2010.02023.x
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Giani A, 2011, RETINA-J RET VIT DIS, V31, P942, DOI 10.1097/IAE.0b013e31820a68cc
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   Invernizzi A, 2018, OPHTHALMOLOGY, V125, P237, DOI 10.1016/j.ophtha.2017.08.039
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Moreira CA, 2013, RETINA-J RET VIT DIS, V33, P277, DOI 10.1097/IAE.0b013e318263d139
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Mukai R, 2014, ACTA OPHTHALMOL, V92, pE407, DOI 10.1111/aos.12350
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Oishi A., 2017, RETINA-J RET VIT DIS, V0, P1
   Otani T, 2011, RETINA-J RET VIT DIS, V31, P497, DOI 10.1097/IAE.0b013e3181ed8dae
   Romano F, 2020, BRIT J OPHTHALMOL, V104, P461, DOI 10.1136/bjophthalmol-2019-313980
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Souied EH, 2020, AM J OPHTHALMOL, V214, P151, DOI 10.1016/j.ajo.2020.02.016
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 36
TC 4
Z9 4
U1 1
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 16
PY 2021
VL 11
IS 1
AR 5962
DI 10.1038/s41598-021-85270-x
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QZ1RJ
UT WOS:000630511800008
PM 33727575
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yapici, NB
   Mandalapu, S
   Gibson, KM
   Bi, LR
AF Yapici, Nazmiye B.
   Mandalapu, Srinivas
   Gibson, K. Michael
   Bi, Lanrong
TI Targeted fluorescent probes for detection of oxidative stress in the
   mitochondria
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Mitochondria-targeting; Oxidative stress; Fluorescence probes
ID IMAGING HYDROGEN-PEROXIDE; LIVING CELLS; BETA; ISCHEMIA/REPERFUSION;
   DISORDERS; APOPTOSIS; AUTOPHAGY; FISSION; DISEASE; INJURY
AB Mitochondrial oxidative stress has been implicated in aging, neurodegenerative diseases, diabetes, stroke, ischemia/reperfusion injury, age-related macular degeneration (AMD) and cancer. Recently, we developed two new mitochondria-targeting fluorescent probes, MitoProbes I/II, which specifically localize in mitochondria and employed both in vivo and in vitro for detection of mitochondrial oxidative stress. Here, we report the design and synthesis of these agents, as well as their utility for real-time imaging of mitochondrial oxidative stress in cells. Published by Elsevier Ltd.
C1 [Yapici, Nazmiye B.; Mandalapu, Srinivas; Bi, Lanrong] Michigan Technol Univ, Dept Chem, Houghton, MI 49931 USA.
   [Gibson, K. Michael] Washington State Univ, Coll Pharm, Expt & Syst Pharmacol, Spokane, WA 99201 USA.
C3 Michigan Technological University; Washington State University
RP Bi, LR (通讯作者)，Michigan Technol Univ, Dept Chem, Houghton, MI 49931 USA.
EM Lanrong@mtu.edu
RI Yapici, Nazmiye/AAZ-7848-2021; Bi, Lanrong/B-8133-2012
OI Yapici, Nazmiye/0000-0002-3449-9562; Bi, Lanrong/0000-0001-6624-8314
FU NIH [GM088795-01]; NSF [1048655]; NASA [MSGC R85197]; MIIE [1204010];
   VPR-SI fund [R01386]; Research Excellence Fund [R01121, R01323];
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM088795] Funding
   Source: NIH RePORTER
FX L.B. is grateful to NIH (GM088795-01), NSF (No. 1048655), NASA (# MSGC
   R85197), MIIE (# 1204010), VPR-SI fund (# R01386), and the Research
   Excellence Fund (# R01121 and # R01323). The authors are particularly
   thankful to Dr. Bruce Seely for his ongoing support of our work.
CR Bi W, 2012, J MED CHEM, V55, P4501, DOI 10.1021/jm201381w
   Bi W, 2010, J MED CHEM, V53, P6763, DOI 10.1021/jm100529e
   Bowerman B, 2005, SCIENCE, V308, P1119, DOI 10.1126/science.1113356
   Chen L. B., 1989, METHOD CELL BIOL, V29, P103
   Cho DH, 2009, SCIENCE, V324, P102, DOI 10.1126/science.1171091
   COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908
   Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753
   Dickinson BC, 2013, NAT PROTOC, V8, P1249, DOI 10.1038/nprot.2013.064
   Dickinson BC, 2010, J AM CHEM SOC, V132, P5906, DOI 10.1021/ja1014103
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   GREEN SA, 1990, J AM CHEM SOC, V112, P7337, DOI 10.1021/ja00176a038
   Koide Y, 2007, J AM CHEM SOC, V129, P10324, DOI 10.1021/ja073220m
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Le Droumaguet C, 2010, CHEM SOC REV, V39, P1233, DOI 10.1039/b901975h
   Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230
   Miller RA, 2005, SCIENCE, V308, P1875, DOI 10.1126/science.1114393
   Pajca A., 2006, J AM CHEM SOC, V128, P13497
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Robinson KM, 2006, P NATL ACAD SCI USA, V103, P15038, DOI 10.1073/pnas.0601945103
   Schrier SA, 2011, CURR OPIN OPHTHALMOL, V22, P325, DOI 10.1097/ICU.0b013e328349419d
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Yapici NB, 2012, ORG LETT, V14, P50, DOI 10.1021/ol202816m
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
NR 24
TC 9
Z9 9
U1 3
U2 74
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2015
VL 25
IS 17
BP 3476
EP 3480
DI 10.1016/j.bmcl.2015.07.011
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy; Chemistry
GA CN9XD
UT WOS:000358802900012
PM 26189896
OA Bronze
DA 2022-11-30
ER

PT J
AU Kim, H
   Lee, SC
   Kwon, KY
   Lee, JH
   Koh, HJ
   Byeon, SH
   Kim, SS
   Kim, M
   Lee, CS
AF Kim, Hyesun
   Lee, Sung Chul
   Kwon, Kye Yoon
   Lee, Ji Hwan
   Koh, Hyoung Jun
   Byeon, Suk Ho
   Kim, Sung Soo
   Kim, Min
   Lee, Christopher Seungkyu
TI Subfoveal choroidal thickness as a predictor of treatment response to
   anti-vascular endothelial growth factor therapy for polypoidal choroidal
   vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Polypoidal choroidal
   vasculopathy; Subfoveal choroidal thickness
ID INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
   DIURNAL-VARIATION; VASCULAR HYPERPERMEABILITY; INJECTIONS; RECURRENT
AB To investigate whether subfoveal choroidal thickness predicted treatment response to anti-vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV).
   This retrospective observational case series included 66 eyes of 60 patients who were diagnosed with new-onset PCV and who were followed for a minimum of 6 months. Patients received three monthly intravitreal injections of 0.5 mg ranibizumab or 1.25 mg bevacizumab, at baseline, month 1, and month 2. "Good responders" were defined as those who showed complete resolution of subretinal and/or intraretinal fluid at month 3 after the loading injections, whereas "poor responders" were defined as those who showed persistent retinal fluid on optical coherence tomography (OCT) at month 3 after treatment. Differences in best-corrected visual acuity, indocyanine green angiography, and spectral domain-OCT findings at baseline were analyzed between the two groups.
   The mean patient age was 68.2 +/- 9.7 years, and the mean follow-up period was 27 +/- 21 months. The mean subfoveal choroidal thickness was 273 +/- 117 mu m, and choroidal vascular hyperpermeability was observed in 35 eyes (53.0 %). Thirty-three eyes (50 %) showed good response to treatment, and a thinner subfoveal choroid at baseline significantly correlated with favorable treatment response (P = 0.024). However, there was no significant relationship between treatment response and choroidal vascular hyperpermeability (P = 0.999).
   The subfoveal choroid was found to be significantly thinner among patients who achieved complete resolution of macular exudation after three loading injections of anti-VEGF agents.
C1 [Kim, Hyesun; Lee, Sung Chul; Kwon, Kye Yoon; Lee, Ji Hwan; Koh, Hyoung Jun; Byeon, Suk Ho; Kim, Sung Soo; Kim, Min; Lee, Christopher Seungkyu] Yonsei Univ, Coll Med, Severance Hosp, Inst Vis Res,Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
   [Kim, Hyesun] Siloam Eye Hosp, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Lee, CS (通讯作者)，Yonsei Univ, Coll Med, Severance Hosp, Inst Vis Res,Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM sklee219@yuhs.ac
OI Lee, Ji Hwan/0000-0003-1759-8195; Byeon, suk ho/0000-0001-8101-0830; ,
   Sung Chul/0000-0001-9438-2385; Lee, Christopher/0000-0001-5054-9470;
   Koh, Hyoung Jun/0000-0002-5932-8516; Kim, Min/0000-0003-1873-6959; Kim,
   Sung Soo/0000-0002-0574-7993
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Han YS, 2015, OPHTHALMOLOGICA, V233, P192, DOI 10.1159/000375538
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee SW, 2014, RETINA-J RET VIT DIS, V34, P385, DOI 10.1097/IAE.0b013e3182993f29
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Nishide T, 2013, GRAEF ARCH CLIN EXP, V251, P2415, DOI 10.1007/s00417-013-2419-z
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 24
Z9 24
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2016
VL 254
IS 8
BP 1497
EP 1503
DI 10.1007/s00417-015-3221-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS3IB
UT WOS:000380675200007
PM 26626772
DA 2022-11-30
ER

PT J
AU Yang, M
   Wang, YL
AF Yang, Ming
   Wang, Yanling
TI Recent Advances and the Mechanism of Astaxanthin in Ophthalmological
   Diseases
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID NF-KAPPA-B; OXIDATIVE STRESS; EPITHELIAL-CELLS; UP-REGULATION; IN-VITRO;
   APOPTOSIS; CAROTENOIDS; PROTECTS; INJURY; MICE
AB Astaxanthin (AST) is a naturally occurring carotenoid that has strong antioxidant, anti-inflammatory, and antiapoptosis effects and is used for the prevention of cancer. There is growing evidence that AST has multiple protective effects against various eye diseases. This article reviews the function and the potential mechanism of AST in dry eye syndrome, keratitis, cataract, diabetic retinopathy, age-related macular degeneration, high intraocular pressure, and other ocular diseases. It provides a theoretical basis for the clinical application of AST as a potential nutraceutical.
C1 [Yang, Ming; Wang, Yanling] Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, 95 Yongan Rd, Beijing 100050, Peoples R China.
C3 Capital Medical University
RP Wang, YL (通讯作者)，Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, 95 Yongan Rd, Beijing 100050, Peoples R China.
EM ym8901@sina.com; wangyanlingyy@163.com
OI , Ming/0000-0003-4932-3225
FU library of Beijing Friendship Hospital [2018-2021]
FX All the authors thank the library of Beijing Friendship Hospital for
   assistance with literature search, Capital's Funds for Health
   Improvement and Research (No. 2018-2021).
CR Ahiskali I, 2019, CUTAN OCUL TOXICOL, V38, P227, DOI 10.1080/15569527.2019.1588289
   An Haiyan, 2018, Noncoding RNA Res, V3, P243, DOI 10.1016/j.ncrna.2018.11.003
   AUGUSTIN AJ, 1995, GRAEF ARCH CLIN EXP, V233, P694, DOI 10.1007/BF00164671
   Baccouche B, 2018, CURR EYE RES, V43, P1177, DOI 10.1080/02713683.2018.1484143
   Balietti M, 2016, J SCI FOOD AGR, V96, P615, DOI 10.1002/jsfa.7131
   Bampidis V, 2019, EFSA J, V17, DOI 10.2903/j.efsa.2019.5920
   Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9
   Cai XD, 2019, AM J TRANSL RES, V11, P1884
   Chitchumroonchokchai C, 2004, J NUTR, V134, P3225, DOI 10.1093/jn/134.12.3225
   Cort A, 2010, REGUL TOXICOL PHARM, V58, P121, DOI 10.1016/j.yrtph.2010.05.001
   Davinelli S, 2022, MOLECULES, V27, DOI 10.3390/molecules27020502
   Dong LY, 2013, MAR DRUGS, V11, P960, DOI 10.3390/md11030960
   Edwards JA, 2016, REGUL TOXICOL PHARM, V75, P5, DOI 10.1016/j.yrtph.2015.12.009
   Fakhri S, 2018, PHARMACOL RES, V136, P1, DOI 10.1016/j.phrs.2018.08.012
   Feng YH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00748
   Galasso C, 2018, MAR DRUGS, V16, DOI 10.3390/md16080247
   Grossman MA, 2019, AIDS, V33, P1565, DOI 10.1097/QAD.0000000000002259
   Guo FQ, 2021, EXP CLIN ENDOCR DIAB, V129, P283, DOI 10.1055/a-0865-1754
   Han JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32497-w
   Harada F, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1956104
   Hashimoto H, 2019, J CLIN BIOCHEM NUTR, V65, P47, DOI 10.3164/jcbn.18-110
   Hashimoto H, 2016, J CLIN BIOCHEM NUTR, V59, P10, DOI 10.3164/jcbn.15-137
   Hu JY, 2017, INT J OPHTHALMOL-CHI, V10, P140, DOI 10.18240/ijo.2017.01.23
   Hu JJ, 2018, BIOTECHNOL ADV, V36, P54, DOI 10.1016/j.biotechadv.2017.09.009
   Huang JY, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106455
   Huseyin F, 2019, CUTAN OCUL TOXICOL, V38, P59
   Ibrahim AE, 2019, CUTAN OCUL TOXICOL, V38, P279, DOI 10.1080/15569527.2019.1608227
   Imai A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030281
   Inoue Y, 2017, J PHARMACOL SCI, V134, P147, DOI 10.1016/j.jphs.2017.05.011
   Ishikawa S, 2015, CURR EYE RES, V40, P535, DOI 10.3109/02713683.2014.935445
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Janani R, 2021, EXP EYE RES, V206, DOI 10.1016/j.exer.2021.108555
   Kamath BS, 2008, EUR J PHARMACOL, V590, P387, DOI 10.1016/j.ejphar.2008.06.042
   Katsiougiannis S, 2019, J AUTOIMMUN, V104, DOI 10.1016/j.jaut.2019.102335
   Kavitha K, 2013, BBA-GEN SUBJECTS, V1830, P4433, DOI 10.1016/j.bbagen.2013.05.032
   Khedr M, 2022, SAUDI J BIOL SCI, V29, P831, DOI 10.1016/j.sjbs.2021.10.024
   Kikuchi K, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/9539681
   Kim SH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091320
   Kowshik J, 2019, IUBMB LIFE, V71, P1595, DOI 10.1002/iub.2104
   Kucukodok A, 2019, CAN J OPHTHALMOL, V54, P65, DOI 10.1016/j.jcjo.2018.02.017
   Kumar S, 2019, TROP ANIM HEALTH PRO, V51, P1125, DOI 10.1007/s11250-018-01793-y
   Kuraji M, 2016, J CLIN BIOCHEM NUTR, V59, P79, DOI 10.3164/jcbn.15-150
   Lennikov Anton, 2012, Mol Vis, V18, P455
   Li Y, 2020, J CHEM NEUROANAT, V110, DOI 10.1016/j.jchemneu.2020.101876
   Li YJ, 2019, NANOSCALE, V11, P5580, DOI 10.1039/c9nr00376b
   Li ZR, 2013, MOL VIS, V19, P1656
   Lin CW, 2020, MAR DRUGS, V18, DOI 10.3390/md18080387
   Lin KH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010044
   Ling JW, 2022, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.815075
   Matsuno T, 2010, CHEMINFORM, V22, DOI [10.1002/chin.199114365, DOI 10.1002/CHIN.199114365]
   Matthe E, 2020, RETINA-J RET VIT DIS, V40, P1118, DOI 10.1097/IAE.0000000000002527
   Moroi SE, 2019, CURR OPIN OPHTHALMOL, V30, P187, DOI 10.1097/ICU.0000000000000564
   Mrowicka M, 2017, ACTA OPHTHALMOL, V95, P530, DOI 10.1111/aos.13289
   Musa Y, 2019, INT J OPHTHALMOL-CHI, V12, P930, DOI 10.18240/ijo.2019.06.08
   Naguib YMA, 2000, J AGR FOOD CHEM, V48, P1150, DOI 10.1021/jf991106k
   Najafi H, 2015, AVICENNA J PHYTOMEDI, V5, P576
   Nakajima Y, 2008, J PHARM PHARMACOL, V60, P1365, DOI 10.1211/jpp/60.10.0013
   NAKANO T, 1995, J AGR FOOD CHEM, V43, P1570, DOI 10.1021/jf00054a029
   Norval M, 2011, EYE CONTACT LENS, V37, P176, DOI 10.1097/ICL.0b013e31821d7573
   Odeberg JM, 2003, EUR J PHARM SCI, V19, P299, DOI 10.1016/S0928-0987(03)00135-0
   Ola MS, 2019, NEUROTOX RES, V36, P81, DOI 10.1007/s12640-019-00018-w
   Otsuka T, 2016, CURR EYE RES, V41, P1465, DOI 10.3109/02713683.2015.1127392
   Otsuka T, 2013, J PHARMACOL SCI, V123, P209, DOI 10.1254/jphs.13066FP
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Pauloin T, 2009, MOL VIS, V15, P577
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Postorino EI, 2020, EUR J OPHTHALMOL, V30, P439, DOI 10.1177/1120672119833278
   Renard JP, 2019, J FR OPHTALMOL, V42, P499, DOI 10.1016/j.jfo.2019.03.001
   Renner M, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00254
   Roohbakhsh A, 2017, BIOMED PHARMACOTHER, V91, P31, DOI 10.1016/j.biopha.2017.04.057
   Sahajpal NS, 2019, CURR PROTEIN PEPT SC, V20, P92, DOI 10.2174/1389203719666180928123449
   Saito M, 2012, GRAEF ARCH CLIN EXP, V250, P239, DOI 10.1007/s00417-011-1843-1
   Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6
   Seong H, 2017, CURR EYE RES, V42, P1650, DOI 10.1080/02713683.2017.1344713
   Shimokawa T, 2019, J CLIN BIOCHEM NUTR, V64, P27, DOI 10.3164/jcbn.18-27
   Stewart JS, 2008, FOOD CHEM TOXICOL, V46, P3030, DOI 10.1016/j.fct.2008.05.038
   Tenkate T, 2019, ENVIRON INT, V125, P542, DOI 10.1016/j.envint.2018.10.001
   Tian L, 2022, FRONT NUTR, V8, DOI 10.3389/fnut.2021.796951
   Turrin NP, 2006, MOL NEUROBIOL, V34, P221, DOI 10.1385/MN:34:3:221
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Vurmaz A, 2019, CUTAN OCUL TOXICOL, V38, P182, DOI 10.1080/15569527.2019.1570521
   Wu HJ, 2015, MAR DRUGS, V13, P5750, DOI 10.3390/md13095750
   Wu LW, 2020, BRIT J PHARMACOL, V177, P3760, DOI 10.1111/bph.15099
   Xu Y, 2019, AM J TRANSL RES, V11, P3039
   Yamagishi R, 2014, MOL VIS, V20, P1796
   Yang M, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2020.104372
   Yang Y, 2019, EUR J PHARMACOL, V863, DOI 10.1016/j.ejphar.2019.172667
   Yaqoob Z, 2022, FOOD SCI NUTR, V10, P12, DOI 10.1002/fsn3.2623
   Yeh PT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146438
   Zhang L, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-8078
   Zhang XJ, 2022, NEUROSCIENCE, V490, P89, DOI 10.1016/j.neuroscience.2022.02.030
NR 93
TC 1
Z9 1
U1 3
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD MAY 20
PY 2022
VL 2022
AR 8071406
DI 10.1155/2022/8071406
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1S6FO
UT WOS:000804145200001
PM 35646393
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yang, JW
   Yu, ZY
   Cheng, SJ
   Chung, JHY
   Liu, XA
   Wu, CY
   Lin, SF
   Chen, GY
AF Yang, Jia-Wei
   Yu, Zih-Yu
   Cheng, Sheng-Jen
   Chung, Johnson H. Y.
   Liu, Xiao
   Wu, Chung-Yu
   Lin, Shien-Fong
   Chen, Guan-Yu
TI Graphene Oxide-Based Nanomaterials: An Insight into Retinal Prosthesis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retinal prosthesis; electrodes; nanotechnology; graphene oxide;
   interface
ID ELECTRICAL-STIMULATION; EXTRACELLULAR-MATRIX; CONDUCTING POLYMERS;
   CELL-ADHESION; STEM-CELLS; IN-VITRO; BIOCOMPATIBILITY; PERFORMANCE;
   HYDROGEL; PEPTIDE
AB Retinal prosthesis has recently emerged as a treatment strategy for retinopathies, providing excellent assistance in the treatment of age-related macular degeneration (AMD) and retinitis pigmentosa. The potential application of graphene oxide (GO), a highly biocompatible nanomaterial with superior physicochemical properties, in the fabrication of electrodes for retinal prosthesis, is reviewed in this article. This review integrates insights from biological medicine and nanotechnology, with electronic and electrical engineering technological breakthroughs, and aims to highlight innovative objectives in developing biomedical applications of retinal prosthesis.
C1 [Yang, Jia-Wei; Cheng, Sheng-Jen; Lin, Shien-Fong; Chen, Guan-Yu] Natl Chiao Tung Univ, Dept Elect & Comp Engn, Coll Elect & Comp Engn, Hsinchu 300, Taiwan.
   [Yang, Jia-Wei; Yu, Zih-Yu; Cheng, Sheng-Jen; Lin, Shien-Fong; Chen, Guan-Yu] Natl Chiao Tung Univ, Inst Biomed Engn, Coll Elect & Comp Engn, Hsinchu 300, Taiwan.
   [Chung, Johnson H. Y.; Liu, Xiao] Univ Wollongong, ARC Ctr Excellence Electromech Sci, Intelligent Polymer Res Inst, Wollongong, NSW 2500, Australia.
   [Wu, Chung-Yu] Natl Chiao Tung Univ, Dept Elect Engn, Hsinchu 300, Taiwan.
   [Chen, Guan-Yu] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 300, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; University of Wollongong; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University
RP Chen, GY (通讯作者)，Natl Chiao Tung Univ, Dept Elect & Comp Engn, Coll Elect & Comp Engn, Hsinchu 300, Taiwan.; Chen, GY (通讯作者)，Natl Chiao Tung Univ, Inst Biomed Engn, Coll Elect & Comp Engn, Hsinchu 300, Taiwan.; Chen, GY (通讯作者)，Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 300, Taiwan.
EM jiawei@nctu.edu.tw; zyyu.cm07g@nctu.edu.tw; shengjen@nctu.edu.tw;
   johnsonc@uow.edu.au; xiaol@uow.edu.au; peterwu@mail.nctu.edu.tw;
   linsf5402@nctu.edu.tw; guanyu@nctu.edu.tw
RI Liu, Xiao/GVU-4321-2022; , Johnson/F-9854-2011
OI , Johnson/0000-0003-2449-3607; Cheng, Sheng Jen/0000-0001-5993-1473;
   liu, xiao/0000-0002-1159-9667; Lin, Shien-fong/0000-0003-1270-3961;
   Chen, Guan-Yu/0000-0002-3443-7943
FU Novel Bioengineering and Technological Approaches to Solve Two Major
   Health Problems in Taiwan - Taiwan Ministry of Science and Technology
   Academic Excellence Program [MOST 108-2633-B-009-001]; Higher Education
   Sprout Project of the National Chiao Tung University; Ministry of
   Education (MOE), Taiwan; Australian National Fabrication Facility
   (ANFF)-Materials node; National Chiao Tung University [109W270,
   108W204]; Ministry of Science and Technology [MOST 109-2636-E-009-007-,
   MOST 108-2218-E-080-001-]; National Health Research Institutes
   [NHRI-EX109-10714EC]; Council of Agriculture, Executive Yuan, Taiwan
   [109AS-24.2.1-AD-U2]; ARC industrial transformation training centre in
   additive biomanufacturing [IC160100026]
FX This work was supported in part by the Novel Bioengineering and
   Technological Approaches to Solve Two Major Health Problems in Taiwan,
   sponsored by the Taiwan Ministry of Science and Technology Academic
   Excellence Program, under Grant Number MOST 108-2633-B-009-001, and the
   Higher Education Sprout Project of the National Chiao Tung University
   and Ministry of Education (MOE), Taiwan. J.H.Y.C would like to
   acknowledge funding from the Australian National Fabrication Facility
   (ANFF)-Materials node and support of the ARC industrial transformation
   training centre in additive biomanufacturing (IC160100026). G.Y.C. would
   like to acknowledge financial support from National Chiao Tung
   University (109W270, 108W204), the Ministry of Science and Technology
   (MOST 109-2636-E-009-007-, MOST 108-2218-E-080-001-), the National
   Health Research Institutes (NHRI-EX109-10714EC), and the Council of
   Agriculture, Executive Yuan (109AS-24.2.1-AD-U2), Taiwan.
CR Ahuja AK, 2013, PROG RETIN EYE RES, V36, P1, DOI 10.1016/j.preteyeres.2013.01.002
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Amrollahi-Sharifabadi M, 2018, INT J NANOMED, V13, P4757, DOI 10.2147/IJN.S168731
   Aqrawe Z, 2018, SENSOR ACTUAT B-CHEM, V257, P753, DOI 10.1016/j.snb.2017.11.023
   Aregueta-Robles UA, 2015, IEEE ENG MED BIO, P2600, DOI 10.1109/EMBC.2015.7318924
   Aregueta-Robles Ulises A, 2014, Front Neuroeng, V7, P15, DOI 10.3389/fneng.2014.00015
   Ay SU, 2011, IEEE T BIOMED CIRC S, V5, P535, DOI 10.1109/TBCAS.2011.2170069
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Barriga-Rivera A, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00620
   Bendali A, 2013, ADV HEALTHC MATER, V2, P929, DOI 10.1002/adhm.201200347
   Bloch E, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841418817501
   Boinagrov D, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/2/026008
   BRABYN J, 1985, IEEE ENG MED BIOL, V4, P33, DOI 10.1109/MEMB.1985.5006225
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519
   Chen D, 2012, CHEM REV, V112, P6027, DOI 10.1021/cr300115g
   Chen LN, 2018, MATER TODAY, V21, P38, DOI 10.1016/j.mattod.2017.07.002
   Cheng RM, 2017, MICROCHIM ACTA, V184, P3521, DOI 10.1007/s00604-017-2375-0
   Cheong GLM, 2014, ACTA BIOMATER, V10, P1216, DOI 10.1016/j.actbio.2013.12.032
   Chung-Yu Wu, 2015, 2015 IEEE Biomedical Circuits and Systems Conference (BioCAS), P1, DOI 10.1109/BioCAS.2015.7348318
   Compton OC, 2010, SMALL, V6, P711, DOI 10.1002/smll.200901934
   da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   Devenyi RG, 2018, CAN J OPHTHALMOL, V53, P9, DOI 10.1016/j.jcjo.2017.10.043
   Eda G, 2008, NAT NANOTECHNOL, V3, P270, DOI 10.1038/nnano.2008.83
   Ells AL, 2013, EYE, V27, P525, DOI 10.1038/eye.2012.302
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Feiner R, 2018, NAT REV MATER, V3, DOI 10.1038/natrevmats.2017.76
   Fernandez Eduardo, 2018, Bioelectron Med, V4, P12, DOI 10.1186/s42234-018-0013-8
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Franqui LS, 2019, MAT SCI ENG C-MATER, V100, P363, DOI 10.1016/j.msec.2019.02.066
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Geddes LA, 2003, ANN BIOMED ENG, V31, P879, DOI 10.1114/1.1581292
   Geng L, 2018, CELL PHYSIOL BIOCHEM, V47, P1167, DOI 10.1159/000490213
   Girao AF, 2016, RSC ADV, V6, P49039, DOI 10.1039/c6ra10213a
   Goding J, 2017, MRS COMMUN, V7, P487, DOI 10.1557/mrc.2017.44
   Goding J, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601177
   Goetz GA, 2016, REP PROG PHYS, V79, DOI 10.1088/0034-4885/79/9/096701
   Green RA, 2013, IEEE ENG MED BIO, P6957, DOI 10.1109/EMBC.2013.6611158
   Guo BS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030348
   Gurunathan S, 2016, INT J NANOMED, V11, P1927, DOI 10.2147/IJN.S105264
   Han L, 2018, CHEM MATER, V30, P5561, DOI 10.1021/acs.chemmater.8b01446
   Han L, 2017, SMALL, V13, DOI 10.1002/smll.201601916
   He C, 2015, J MATER CHEM B, V3, P592, DOI 10.1039/c4tb01806k
   Hodgins D, 2008, IEEE PERVAS COMPUT, V7, P14, DOI 10.1109/MPRV.2008.8
   Hong D, 2014, MACROMOL BIOSCI, V14, P314, DOI 10.1002/mabi.201300346
   Hu M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41007-5
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017
   Joo S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13043
   Kang H, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19030536
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Kiew SF, 2016, J CONTROL RELEASE, V226, P217, DOI 10.1016/j.jconrel.2016.02.015
   Kim CL, 2017, NPG ASIA MATER, V9, DOI 10.1038/am.2017.177
   Kim SE, 2016, MICROMACHINES-BASEL, V7, DOI 10.3390/mi7100186
   Kim TH, 2015, ACS NANO, V9, P3780, DOI 10.1021/nn5066028
   Kolodziej CM, 2012, J AM CHEM SOC, V134, P247, DOI 10.1021/ja205524x
   Kotzar G, 2002, BIOMATERIALS, V23, P2737, DOI 10.1016/S0142-9612(02)00007-8
   Langhals NB, 2014, IEEE ENG MED BIO, P1989, DOI 10.1109/EMBC.2014.6944004
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Li DP, 2016, NANOSCALE, V8, P19491, DOI 10.1039/c6nr07249f
   Li JF, 2017, COLLOID SURFACE B, V159, P386, DOI 10.1016/j.colsurfb.2017.07.087
   Li LY, 2016, BIOINTERPHASES, V11, DOI 10.1116/1.4952452
   Li XL, 2008, SCIENCE, V319, P1229, DOI 10.1126/science.1150878
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin PC, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2743939
   Lin TC, 2015, J CHIN MED ASSOC, V78, P501, DOI 10.1016/j.jcma.2015.05.010
   Liu JQ, 2013, ACTA BIOMATER, V9, P9243, DOI 10.1016/j.actbio.2013.08.016
   Liu X, 2011, BIOMATERIALS, V32, P7309, DOI 10.1016/j.biomaterials.2011.06.047
   Liu Y, 2010, LANGMUIR, V26, P6158, DOI 10.1021/la100886x
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Lu H, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1568
   Luo YHL, 2016, PROG RETIN EYE RES, V50, P89, DOI 10.1016/j.preteyeres.2015.09.003
   Luttrull JK, 2012, CURR DIABETES REV, V8, P274, DOI 10.2174/157339912800840523
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantione D, 2017, POLYMERS-BASEL, V9, DOI 10.3390/polym9080354
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Montes-Navajas P, 2013, LANGMUIR, V29, P13443, DOI 10.1021/la4029904
   Muhamad SU, 2017, ELECTROCHIM ACTA, V249, P9, DOI 10.1016/j.electacta.2017.07.174
   Muqit MMK, 2012, ACTA OPHTHALMOL, V90, P155, DOI 10.1111/j.1755-3768.2009.01854.x
   Nanda SS, 2015, CRIT REV SOLID STATE, V40, P291, DOI 10.1080/10408436.2014.1002604
   Newbold C, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/3/036029
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Tran N, 2014, IEEE J SOLID-ST CIRC, V49, P751, DOI 10.1109/JSSC.2014.2298037
   Nichol JW, 2010, BIOMATERIALS, V31, P5536, DOI 10.1016/j.biomaterials.2010.03.064
   Nie ZH, 2008, NAT MATER, V7, P277, DOI 10.1038/nmat2109
   Nurunnabi M, 2015, RSC ADV, V5, P42141, DOI 10.1039/c5ra04756k
   Nyambat B, 2018, J MATER CHEM B, V6, P979, DOI 10.1039/c7tb02480k
   Poellmann MJ, 2011, MACROMOL BIOSCI, V11, P1164, DOI 10.1002/mabi.201100004
   Qi W, 2014, J MATER CHEM B, V2, P5461, DOI 10.1039/c4tb00856a
   Rivnay J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1601649
   Rochford AE, 2020, ADV MATER, V32, DOI 10.1002/adma.201903182
   Sehat AA, 2015, INT J ELECTROCHEM SC, V10, P272
   Sehic A, 2016, AM J PATHOL, V186, P2783, DOI 10.1016/j.ajpath.2016.07.017
   Shen W, 2018, MICROSYST NANOENG, V4, DOI 10.1038/s41378-018-0030-5
   Solanki A, 2013, ADV MATER, V25, P5477, DOI 10.1002/adma.201302219
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Song K, 2016, ADV HEALTHC MATER, V5, P1572, DOI 10.1002/adhm.201600222
   Staples NA, 2018, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00748
   Stronks HC, 2014, EXPERT REV MED DEVIC, V11, P23, DOI 10.1586/17434440.2014.862494
   Tay CY, 2010, EXP CELL RES, V316, P1159, DOI 10.1016/j.yexcr.2010.02.010
   Tian HC, 2014, BIOMATERIALS, V35, P2120, DOI 10.1016/j.biomaterials.2013.11.058
   Tomioka K, 2018, JPN J APPL PHYS, V57, DOI 10.7567/JJAP.57.1002B1
   Walker C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103028
   Wang B, 2019, ACS APPL MATER INTER, V11, P8807, DOI 10.1021/acsami.8b20542
   Wang K, 2011, NANOSCALE RES LETT, V6, DOI 10.1007/s11671-010-9751-6
   Wang XL, 2016, ADV FUNCT MATER, V26, P7634, DOI 10.1002/adfm.201601585
   Wang Y, 2011, TRENDS BIOTECHNOL, V29, P205, DOI 10.1016/j.tibtech.2011.01.008
   Wang Y, 2010, ACS NANO, V4, P1790, DOI 10.1021/nn100315s
   Wang Z, 2012, CHEM COMMUN, V48, P9768, DOI 10.1039/c2cc31974h
   Wise AK, 2011, NEUROTHERAPEUTICS, V8, P774, DOI 10.1007/s13311-011-0070-0
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   Wu CY, 2018, SENSOR MATER, V30, P193, DOI 10.18494/SAM.2018.1664
   Wu KH, 2015, CARBON, V95, P738, DOI 10.1016/j.carbon.2015.08.116
   Xu M, 2016, ACS NANO, V10, P3267, DOI 10.1021/acsnano.6b00539
   Yan C, 2011, BIOMATERIALS, V32, P3931, DOI 10.1016/j.biomaterials.2011.01.078
   Yan L, 2016, ACS APPL MATER INTER, V8, P6834, DOI 10.1021/acsami.5b12843
   Yan L, 2012, CHEM RES TOXICOL, V25, P1265, DOI 10.1021/tx300129f
   Yang JW, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800365
   Yang JW, 2018, ACS APPL MATER INTER, V10, P12497, DOI 10.1021/acsami.8b02225
   Yang K, 2016, ACS APPL MATER INTER, V8, P17763, DOI 10.1021/acsami.6b01804
   Zhang H, 2013, ACS APPL MATER INTER, V5, P1761, DOI 10.1021/am303005j
   Zhang LL, 2010, J MATER CHEM, V20, P5983, DOI 10.1039/c000417k
   Zhao GX, 2018, NPG ASIA MATER, V10, P982, DOI 10.1038/s41427-018-0092-8
   Zheng WF, 2013, ADV HEALTHC MATER, V2, P95, DOI 10.1002/adhm.201200104
   Zhou DC, 2013, ADV INTEL SYS RES, V44, P1
   Zhou K, 2012, ACS APPL MATER INTER, V4, P4524, DOI 10.1021/am3007565
   Zhu BW, 2014, SMALL, V10, P3625, DOI 10.1002/smll.201401207
   Zrenner E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007399
NR 130
TC 16
Z9 16
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2020
VL 21
IS 8
AR 2957
DI 10.3390/ijms21082957
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LR3AC
UT WOS:000535565300299
PM 32331417
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wolkenberg, SE
   Zhao, ZJ
   Thut, C
   Maxwell, JW
   McDonald, TP
   Kinose, F
   Reilly, M
   Lindsley, CW
   Hartman, GD
AF Wolkenberg, Scott E.
   Zhao, Zhijian
   Thut, Catherine
   Maxwell, Jill W.
   McDonald, Terrence P.
   Kinose, Fumi
   Reilly, Michael
   Lindsley, Craig W.
   Hartman, George D.
TI Design, Synthesis, and Evaluation of Novel
   3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin
   Receptor Subtype 2
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PROLIFERATIVE DIABETIC-RETINOPATHY; GROWTH-HORMONE SECRETION; CHOROIDAL
   NEOVASCULARIZATION; ANTAGONISTS; RAT; OCTREOTIDE; ANALOGS; POTENT; CELLS
AB Agonists of somatostatin receptor subtype 2 (sst(2)) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst(2), and these were optimized to provide small molecules with sst(2) binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.
C1 [Wolkenberg, Scott E.; Zhao, Zhijian; Lindsley, Craig W.; Hartman, George D.] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA.
   [Thut, Catherine; Maxwell, Jill W.; McDonald, Terrence P.; Kinose, Fumi] Merck Res Labs, Dept Ophthalm Res, West Point, PA 19486 USA.
   [Reilly, Michael] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA.
C3 Merck & Company; Merck & Company; Merck & Company
RP Wolkenberg, SE (通讯作者)，Merck Res Labs, Dept Med Chem, POB 4, West Point, PA 19486 USA.
EM scott_wolkenberg@merck.com
CR Boehm BO, 2001, HORM METAB RES, V33, P300, DOI 10.1055/s-2001-15282
   Bousquet C, 2001, CHEMOTHERAPY, V47, P30, DOI 10.1159/000049159
   CHENG K, 1993, ENDOCRINOLOGY, V132, P2729, DOI 10.1210/en.132.6.2729
   CLARK RG, 1986, J ENDOCRINOL, V111, P27, DOI 10.1677/joe.0.1110027
   Crider AM, 2003, EXPERT OPIN THER PAT, V13, P1427, DOI 10.1517/13543776.13.9.1427
   DeVita RJ, 1999, BIOORG MED CHEM LETT, V9, P2615, DOI 10.1016/S0960-894X(99)00446-1
   DeVita RJ, 1999, BIOORG MED CHEM LETT, V9, P2621, DOI 10.1016/S0960-894X(99)00447-3
   DeVita RJ, 2001, J MED CHEM, V44, P917, DOI 10.1021/jm000275p
   Florio T, 2003, ENDOCRINOLOGY, V144, P1574, DOI 10.1210/en.2002-220949
   Grant MB, 2000, DIABETES CARE, V23, P504, DOI 10.2337/diacare.23.4.504
   KARALIS K, 1994, J CLIN INVEST, V93, P2000, DOI 10.1172/JCI117193
   Kinose F, 2005, MOL VIS, V11, P366
   Nolt MB, 2008, TETRAHEDRON LETT, V49, P3137, DOI 10.1016/j.tetlet.2008.03.040
   PAINSON JC, 1991, ENDOCRINOLOGY, V128, P2858, DOI 10.1210/endo-128-6-2858
   Palii SS, 2007, EXPERT OPIN INV DRUG, V16, P73, DOI 10.1517/13543784.16.1.73
   Papadaki T, 2003, RETINA-J RET VIT DIS, V23, P800, DOI 10.1097/00006982-200312000-00010
   PATEL YC, 1983, ENDOCRINOLOGY, V112, P220, DOI 10.1210/endo-112-1-220
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Spraul CW, 2002, GRAEF ARCH CLIN EXP, V240, P227, DOI 10.1007/s00417-002-0441-7
   TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562
   Walsh TF, 2000, BIOORG MED CHEM LETT, V10, P443, DOI 10.1016/S0960-894X(00)00024-X
   Weckbecker G, 2003, NAT REV DRUG DISCOV, V2, P999, DOI 10.1038/nrd1255
   Weinstock JV, 2000, EUR J ENDOCRINOL, V143, pS15, DOI 10.1530/eje.0.143S015
   Wolkenberg SE, 2008, CURR OPIN DRUG DISC, V11, P446
   Young JR, 2000, BIOORG MED CHEM LETT, V10, P1723, DOI 10.1016/S0960-894X(00)00318-8
NR 25
TC 22
Z9 42
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD APR 14
PY 2011
VL 54
IS 7
BP 2351
EP 2358
DI 10.1021/jm101501b
PG 8
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 746BJ
UT WOS:000289215700031
PM 21395312
DA 2022-11-30
ER

PT J
AU Raval, V
   Pathengay, A
   Narayanan, R
AF Raval, Vishal
   Pathengay, Avinash
   Narayanan, Raja
TI Bilateral diffuse uveal melanocytic proliferation secondary to thyroid
   carcinoma
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bilateral diffuse uveal melanocytic proliferation; infrared imaging;
   paraneoplastic syndrome; thyroid carcinoma
AB We present a rare case of a bilateral diffuse uveal melanocytic proliferation (BDUMP), which occurred secondary to recurrence of carcinoma of thyroid in a 79-year-old gentleman who was initially misdiagnosed to have age related macular degeneration and/or chronic central serous chorioretinopathy. In spite of being treated with anti-VEGF injection and photodynamic therapy there was progressive loss of vision. Multimodal imaging like autoflourescence, infrared imaging, fluorescein angiography, indocyanine angiography, and OCT angiography helped us in clinching the final diagnosis.
C1 [Raval, Vishal] LV Prasad Eye Inst, Retina & Vitreous Serv, Vijayawada, Andhra Pradesh, India.
   [Pathengay, Avinash] LV Prasad Eye Inst, Retina & Vitreous Serv, Vishakapatnam, Andhra Pradesh, India.
   [Narayanan, Raja] LV Prasad Eye Inst, Retina & Vitreous Serv, KAR Campus, Hyderabad 500034, Telangana, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; L. V. Prasad Eye
   Institute
RP Narayanan, R (通讯作者)，LV Prasad Eye Inst, Retina & Vitreous Serv, KAR Campus, Hyderabad 500034, Telangana, India.
EM narayanan@lvpei.org
RI Raval, Vishal/AAW-3655-2021; Narayanan, Raja/AAT-3098-2021
OI Narayanan, Raja/0000-0001-9688-5859; raval, vishal/0000-0002-8446-2696
CR Chahud F, 2001, AM J SURG PATHOL, V25, P212, DOI 10.1097/00000478-200102000-00009
   GASS JDM, 1990, ARCH OPHTHALMOL-CHIC, V108, P527, DOI 10.1001/archopht.1990.01070060075053
   Klemp K, 2017, ACTA OPHTHALMOL, V95, P439, DOI 10.1111/aos.13481
   Machemer R, 1966, Klin Monbl Augenheilkd, V148, P641
   Mets RB, 2011, ARCH OPHTHALMOL-CHIC, V129, P1235, DOI 10.1001/archophthalmol.2011.277
   Niffenegger John H, 2018, J Clin Exp Ophthalmol, V9, DOI 10.4172/2155-9570.1000740
   O'Neal KD, 2003, SURV OPHTHALMOL, V48, P613, DOI 10.1016/j.survophthal.2003.08.005
   Sahoo NK, 2019, SURV OPHTHALMOL, V64, P30, DOI 10.1016/j.survophthal.2018.09.001
   Shiraki Akihiko, 2018, Am J Ophthalmol Case Rep, V11, P32, DOI 10.1016/j.ajoc.2018.04.014
NR 9
TC 3
Z9 3
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2019
VL 67
IS 12
BP 2094
EP +
DI 10.4103/ijo.IJO_445_19
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KI6MK
UT WOS:000511463500054
PM 31755473
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Foster, A
   Resnikoff, S
AF Foster, A
   Resnikoff, S
TI The impact of Vision 2020 on global blindness
SO EYE
LA English
DT Article
DE blindness; prevalence; Vision 2020
ID VISUAL IMPAIRMENT
AB Introduction Recent data suggest that there are 37 million blind people and 124 million with low vision, excluding those with uncorrected refractive errors. The main causes of global blindness are cataract, glaucoma, corneal scarring (from a variety of causes), age-related macular degeneration, and diabetic retinopathy. Conclusion It would appear that the global Vision 2020 initiative is having an impact to reduce avoidable blindness particularly from ocular infections, but more needs to be done to address cataract, glaucoma, and diabetic retinopathy.
C1 London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   WHO, Prevent Blindness & Deafness Programme, CH-1211 Geneva, Switzerland.
C3 University of London; London School of Hygiene & Tropical Medicine;
   World Health Organization
RP Foster, A (通讯作者)，London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM allenfoster@compuserve.com
RI Resnikoff, Serge/N-2355-2019
OI Resnikoff, Serge/0000-0002-5866-4446; Foster, Allen/0000-0003-2368-4436
CR DANDONA L, CLIN OPHTHALMOLOGY, V5
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Thylefors B, 1999, B WORLD HEALTH ORGAN, V77, P453
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P2203, DOI 10.1016/S0161-6420(00)00459-0
   *WHO, 2004, 282 WHO
   World Health Organization, 2000, WHOPBL9761
NR 10
TC 227
Z9 236
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD OCT
PY 2005
VL 19
IS 10
BP 1133
EP 1135
DI 10.1038/sj.eye.6701973
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 972RC
UT WOS:000232469900016
PM 16304595
OA Bronze
DA 2022-11-30
ER

PT J
AU Liu, L
   Tham, YC
   Wu, JY
   Yue, S
   Cheng, CY
AF Liu, Lei
   Tham, Yih-Chung
   Wu, Jingyang
   Yue, Song
   Cheng, Ching-Yu
TI Photodynamic therapy in combination with ranibizumab versus ranibizumab
   monotherapy for polypoidal choroidal vasculopathy: A systematic review
   and meta-analysis
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Review
DE Photodynamic therapy; Ranibizumab; Polypoidal choroidal vasculopathy;
   Meta-analysis; Systematic review
ID INTRAVITREAL RANIBIZUMAB
AB Purpose: To perform a systematic review and meta-analysis to compare the outcome and serious adverse effects of intravitreal ranibizumab (IVR) monotherapy vs. combined treatment of IVR and photodynamic therapy (PDT) on polypoidal choroidal vasculopathy (PCV).
   Methods: A computerized online search was performed using PubMed, EMBASE, Cochrane Library, Web of Science and China National Knowledge Infrastructure (CNKI) database. The quality of included studies was evaluated according to the Newcastle-Ottawa Scale. Stata 11.0 software was used to do the Meta-analysis.
   Results: After a detailed systematic review, 4 articles (5 study samples) were included for this meta-analysis. PCV eyes treated with PDT combined with IVR achieved better best-corrected visual acuity (BCVA) than IVR monotherapy group throughout a follow-up of 12(th) month (weight mean difference [WMD] in BCVA, 0.132; 95% CI, 0.029-0.234, p = 0.012). Further meta-analysis including studies with 24-month follow up period showed that BCVA at 24(th) month was also better in the combined treatment group than the monotherapy group (WMD in BCVA = 0.234; 95% CI, 0.071-0.398, p = 0.005). There were no significant differences both in serious ocular adverse effects and non-ocular adverse effects (p > 0.05) between two groups.
   Conclusions: Treatment of PCV by PDT combine with IVR is valuable in improving visual acuity and maintaining long term effectiveness. Given the inherent limitations of the included research, future studies are needed to further validate and update the findings in this area.
C1 [Liu, Lei; Wu, Jingyang; Yue, Song] China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Shenyang 110001, Liaoning, Peoples R China.
   [Tham, Yih-Chung; Cheng, Ching-Yu] Singapore Eye Res Inst, Singapore, Singapore.
   [Tham, Yih-Chung; Cheng, Ching-Yu] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Tham, Yih-Chung; Cheng, Ching-Yu] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Tham, Yih-Chung; Cheng, Ching-Yu] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
C3 China Medical University; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; Singapore
   National Eye Center; National University of Singapore
RP Liu, L (通讯作者)，155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM liuleijiao@163.com
RI Cheng, Ching-Yu/Y-2229-2019; Chung, Yih/AIF-2414-2022
OI Cheng, Ching-Yu/0000-0003-0655-885X; Chung, Yih/0000-0002-6752-797X
FU National Natural Science Foundation of China [81300783]
FX This paper was supported by the National Natural Science Foundation of
   China (No. 81300783). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu L, 2015, MOL VIS, V21, P1130
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Wang W., 2014, PLOS ONE, V9
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
   Zhao M, 2017, INT J OPHTHALMOL-CHI, V10, P413, DOI 10.18240/ijo.2017.03.14
NR 18
TC 6
Z9 6
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD DEC
PY 2017
VL 20
BP 215
EP 220
DI 10.1016/j.pdpdt.2017.09.008
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FR3OZ
UT WOS:000418977300038
PM 28935532
DA 2022-11-30
ER

PT J
AU Liu, ZY
   Li, B
   Xia, S
   Chen, YX
AF Liu, Zi-Yang
   Li, Bing
   Xia, Song
   Chen, You-Xin
TI Analysis of choroidal morphology and comparison of imaging findings of
   subtypes of polypoidal choroidal vasculopathy: a new classification
   system
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; spectral-domain optical coherence
   tomography; indocyanine green angiography; subfoveal choroidal thickness
ID MACULAR DEGENERATION; EYES; BINARIZATION; ANGIOGRAPHY; FEATURES; DISEASE
AB AIM: To classify polypoidal choroidal vasculopathy (PCV) into 2 subtypes based on the subfoveal choroidal thickness (SFCT) and to further evaluate their multimodal image features.
   METHODS: A retrospective observational case series study. Sixty-four eyes of 64 patients with PCV were enrolled and classified into 2 groups based on SFCT (thick-choroid group/thin-choroid group). Then further analyze the spectrum domain optical coherence tomography (SD-OCT) and indocyanine green angiography (ICGA) differences of the two subtypes. Imaging analysis included measurement of SFCT, maximum vascular diameter ratio (MVDR), choroidal vascularity index (CVI), central macular thickness (CMT), and the presence of pigment epithelial detachment (PED) on SD-OCT. Polypoidal lesions (polyps) number, branching vascular network (BVN) area, greatest linear dimension (GLD), and the choroidal vascular hyperpermeability (CVH) were analyzed by ICGA.
   RESULTS: The distribution of SFCT was bimodal with two peaks at 195 and 285 mu m, and a trough at 225 mu m. The 225 mu m was taken as the cutoff point for the following classification of thick/thin choroid groups. The PCV eyes in the thick-choroid group presented with greater MVDR, CVI within 3 and 6 mm of the fovea, but lower CMT, less PED, small PED diameters on SD-OCT scans, and fewer polyps, smaller BVN and GLD, but more frequency of CVH on ICGA.
   CONCLUSION: The SFCT at 225 mu m can be used as a readily available indicator for the classification of PCV subtypes. The thick-choroid group presents much apparent enlargement of the choroidal layer and vasculature expansion, which indicates different pathogenesis of the two subtypes.
C1 [Liu, Zi-Yang; Li, Bing; Chen, You-Xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Liu, Zi-Yang] Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, Beijing 100050, Peoples R China.
   [Li, Bing; Chen, You-Xin] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
   [Xia, Song] Guizhou Prov Peoples Hosp, Dept Ophthalmol, Guiyang 550002, Guizhou, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Capital Medical University;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM Chenyx4@pumch.cn
FU Non-profit Central Research Institute Fund of Chinese Academy of Medical
   Sciences [2018PT32029]
FX Supported by the Non-profit Central Research Institute Fund of Chinese
   Academy of Medical Sciences (No.2018PT32029).
CR Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YC, 2019, RETINA
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Giannaccare G, 2019, RETINA, DOI 10.1097/IAE.0000000000002459
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Liu B, 2019, CLIN EXP OPHTHALMOL, V47, P631, DOI 10.1111/ceo.13467
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 27
TC 1
Z9 3
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAY 18
PY 2020
VL 13
IS 5
BP 731
EP 736
DI 10.18240/ijo.2020.05.06
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL9FU
UT WOS:000531859600006
PM 32420219
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Banks, J
AF Banks, Jim
TI Looking Disease in the Eye
SO IEEE PULSE
LA English
DT Article
DE Neurological diseases; Retinopathy; Biomedical imaging; Medical
   diagnosis; Diabetes; Alzheimer's disease; Eyes; Visual systems
AB The eyes are said to be the windows of the soul, but they are increasingly the door to diagnostic information that could transform the lives of millions of people. Age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma are the big three causes of permanent loss of vision, while severe neurological diseases like Alzheimer's and Parkinson's are on the rise. Thanks to new technologies for imaging the eye, the early signs of all of them can be detected earlier.
EM jim_banks@icloud.com
NR 0
TC 0
Z9 0
U1 2
U2 2
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2154-2287
EI 2154-2317
J9 IEEE PULSE
JI IEEE Pulse
PD NOV
PY 2021
VL 12
IS 6
BP 10
EP 13
DI 10.1109/MPULS.2021.3128976
PG 4
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA XY1JV
UT WOS:000736738700006
PM 34968174
DA 2022-11-30
ER

PT J
AU Batliwala, S
   Xavier, C
   Liu, Y
   Wu, HL
   Pang, IH
AF Batliwala, Shehzad
   Xavier, Christy
   Liu, Yang
   Wu, Hongli
   Pang, Iok-Hou
TI Involvement of Nrf2 in Ocular Diseases
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; NRF2-DEPENDENT ANTIOXIDANT FUNCTIONS;
   CHROMOSOMAL DNA FRAGMENTATION; ENDOPLASMIC-RETICULUM STRESS; PRIMARY
   CONGENITAL GLAUCOMA; TRANSCRIPTION FACTOR NRF2; INDUCED-OXIDATIVE
   STRESS; THIOL MIXED DISULFIDES; GLUTAREDOXIN 2 GRX2; MACULAR
   DEGENERATION
AB The human body harbors within it an intricate and delicate balance between oxidants and antioxidants. Any disruption in this checks-and-balances system can lead to harmful consequences in various organs and tissues, such as the eye. This review focuses on the effects of oxidative stress and the role of a particular antioxidant system-the Keap1-Nrf2-ARE pathway-on ocular diseases, specifically age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma. Together, they are the major causes of blindness in the world.
C1 [Batliwala, Shehzad] Univ North Texas Hlth Sci Ctr, Texas Coll Osteopath Med, Ft Worth, Ft Worth, TX 76107 USA.
   [Xavier, Christy; Liu, Yang; Wu, Hongli; Pang, Iok-Hou] Univ North Texas Hlth Sci Ctr, Dept Pharmaceut Sci, Ft Worth, Ft Worth, TX 76107 USA.
   [Liu, Yang; Wu, Hongli; Pang, Iok-Hou] Univ North Texas Hlth Sci Ctr, North Texas Eye Res Inst, Ft Worth, Ft Worth, TX 76107 USA.
RP Wu, HL; Pang, IH (通讯作者)，Univ North Texas Hlth Sci Ctr, Dept Pharmaceut Sci, Ft Worth, Ft Worth, TX 76107 USA.; Wu, HL; Pang, IH (通讯作者)，Univ North Texas Hlth Sci Ctr, North Texas Eye Res Inst, Ft Worth, Ft Worth, TX 76107 USA.
EM hongli.wu@unthsc.edu; iok-hou.pang@unthsc.edu
RI Pang, Iok-Hou/M-4192-2014
OI Pang, Iok-Hou/0000-0002-1458-8824
FU National Eye Institute [R21EY024635]; BrightFocus Foundation for Macular
   Degeneration [M2015180]; NATIONAL EYE INSTITUTE [R21EY024635] Funding
   Source: NIH RePORTER
FX This research is supported by the National Eye Institute (R21EY024635;
   Iok-Hou Pang) and by the BrightFocus Foundation for Macular Degeneration
   (M2015180; Hongli Wu).
CR Aboobaker S, 2016, MIDDLE EAST AFR J OP, V23, P145, DOI 10.4103/0974-9233.164615
   Arnold J. J., 2016, BMJ CLINICAL EVIDENC
   Bakin AV, 2005, FREE RADICAL BIO MED, V38, P375, DOI 10.1016/j.freeradbiomed.2004.10.033
   Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bellner L, 2015, FASEB J, V29, P105, DOI 10.1096/fj.14-256503
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Butterfield DA, 2012, ANTIOXID REDOX SIGN, V17, P1610, DOI 10.1089/ars.2011.4109
   Cabrera Marcela P, 2011, Vet Med Int, V2011, P905153, DOI 10.4061/2011/905153
   Cao YA, 2008, BLOOD, V112, P4494, DOI 10.1182/blood-2007-12-127621
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chandra A, 2016, OPHTHALMIC GENET, V37, P19, DOI 10.3109/13816810.2014.907921
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Clark JI, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0104
   Couto N, 2016, FREE RADICAL BIO MED, V95, P27, DOI 10.1016/j.freeradbiomed.2016.02.028
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cvekl A, 2015, PROG MOL BIOL TRANSL, V134, P129, DOI 10.1016/bs.pmbts.2015.05.001
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Deshpande AD, 2008, PHYS THER, V88, P1254, DOI 10.2522/ptj.20080020
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   El-Osta A, 2008, J EXP MED, V205, P2409, DOI 10.1084/jem.20081188
   Guerrero-Beltran CE, 2012, EXP TOXICOL PATHOL, V64, P503, DOI 10.1016/j.etp.2010.11.005
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   Fernando MR, 2006, FASEB J, V20, P2645, DOI 10.1096/fj.06-5919fje
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   FLORENCE TM, 1995, AUST NZ J OPHTHALMOL, V23, P3, DOI 10.1111/j.1442-9071.1995.tb01638.x
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gao YX, 2015, MOL MED REP, V11, P1442, DOI 10.3892/mmr.2014.2849
   Grossniklaus HE, 2015, PROG MOL BIOL TRANSL, V134, P383, DOI 10.1016/bs.pmbts.2015.06.001
   Ha KN, 2006, INVEST OPHTH VIS SCI, V47, P2709, DOI 10.1167/iovs.05-1322
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hanson SRA, 1999, J BIOL CHEM, V274, P4735, DOI 10.1074/jbc.274.8.4735
   He XQ, 2009, MOL PHARMACOL, V76, P1265, DOI 10.1124/mol.109.058453
   Hejtmancik JF, 2015, PROG MOL BIOL TRANSL, V134, P169, DOI 10.1016/bs.pmbts.2015.04.007
   Hensley K, 2006, ANTIOXID REDOX SIGN, V8, P2075, DOI 10.1089/ars.2006.8.2075
   Higuchi A, 2011, FREE RADICAL BIO MED, V51, P2210, DOI 10.1016/j.freeradbiomed.2011.09.025
   Higuchi Y, 2004, J CELL MOL MED, V8, P455, DOI 10.1111/j.1582-4934.2004.tb00470.x
   Higuchi Y, 2003, BIOCHEM PHARMACOL, V66, P1527, DOI 10.1016/S0006-2952(03)00508-2
   Himori N, 2013, J NEUROCHEM, V127, P669, DOI 10.1111/jnc.12325
   Hollborn M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059603
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   Huang H, 2011, INVEST OPHTH VIS SCI, V52, P1336, DOI 10.1167/iovs.10-5768
   Ildefonso CJ, 2016, INVEST OPHTH VIS SCI, V57, P372, DOI 10.1167/iovs.15-17703
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Ji YH, 2015, MOL CELL BIOCHEM, V401, P87, DOI 10.1007/s11010-014-2294-x
   Johnson DA, 2015, FREE RADICAL BIO MED, V88, P253, DOI 10.1016/j.freeradbiomed.2015.07.147
   Jung KA, 2010, MOLECULES, V15, P7266, DOI 10.3390/molecules15107266
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Koskela A, 2014, MOL VIS, V20, P760
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Kronschlager M, 2012, INVEST OPHTH VIS SCI, V53, P248, DOI 10.1167/iovs.11-8504
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Lenox AR, 2015, NEUROSCI LETT, V609, P30, DOI 10.1016/j.neulet.2015.10.019
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Lime JC, 2016, EXP EYE RES, V145, P432, DOI 10.1016/j.exer.2015.09.007
   Liu H, 2013, INVEST OPHTH VIS SCI, V54, P5236, DOI 10.1167/iovs.13-11664
   Liu XB, 2016, REDOX BIOL, V8, P98, DOI 10.1016/j.redox.2015.12.005
   Liu XB, 2015, INVEST OPHTH VIS SCI, V56, P2821, DOI 10.1167/iovs.14-15876
   Liu YF, 2015, INT J CLIN EXP MED, V8, P15759
   LOU MF, 1995, CURR EYE RES, V14, P951, DOI 10.3109/02713689508995135
   LOU MF, 1989, CURR EYE RES, V8, P883
   Lou MF, 2000, J OCUL PHARMACOL TH, V16, P137, DOI 10.1089/jop.2000.16.137
   Lou MF, 2003, PROG RETIN EYE RES, V22, P657, DOI 10.1016/S1350-9462(03)00050-8
   Lou MF, 1999, EXP EYE RES, V68, P547, DOI 10.1006/exer.1998.0638
   Maessen DEM, 2015, CLIN SCI, V128, P839, DOI 10.1042/CS20140683
   Mailloux RJ, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00068
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200
   Meyer LM, 2009, EXP EYE RES, V89, P833, DOI 10.1016/j.exer.2009.07.020
   Mieyal JJ, 2012, ANTIOXID REDOX SIGN, V16, P471, DOI 10.1089/ars.2011.4454
   Miller OG, 2015, ARCH TOXICOL, V89, P1439, DOI 10.1007/s00204-015-1496-7
   Mishra M, 2014, INVEST OPHTH VIS SCI, V55, P7256, DOI 10.1167/iovs.14-15193
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mitterstiller AM, 2016, CELL MICROBIOL, V18, P1374, DOI 10.1111/cmi.12578
   Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9
   Moshfeghi DM, 2003, CLEV CLIN J MED, V70, P1017, DOI 10.3949/ccjm.70.12.1017
   Murdaugh LS, 2011, J MASS SPECTROM, V46, P90, DOI 10.1002/jms.1865
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Nakagami Y, 2016, CURR EYE RES, V41, P1123, DOI 10.3109/02713683.2015.1078362
   Negi G, 2011, BIOCHEM BIOPH RES CO, V408, P1, DOI 10.1016/j.bbrc.2011.03.087
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Niture SK, 2009, J CELL SCI, V122, P4452, DOI 10.1242/jcs.058537
   Nourooz-Zadeh J, 1999, OPHTHALMIC RES, V31, P273, DOI 10.1159/000055547
   O'Connell MA, 2015, BIOCHEM SOC T, V43, P687, DOI 10.1042/BST20150069
   Pagano G, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/541230
   Palsamy P, 2014, FREE RADICAL BIO MED, V72, P134, DOI 10.1016/j.freeradbiomed.2014.04.010
   Palsamy P, 2014, EXP EYE RES, V121, P26, DOI 10.1016/j.exer.2014.01.021
   Palsamy P, 2012, BIOCHEM BIOPH RES CO, V423, P542, DOI 10.1016/j.bbrc.2012.05.164
   Pan Qing, 2011, Invest Ophthalmol Vis Sci, V52, P1723, DOI 10.1167/iovs.10-5866
   Panicker SG, 2002, INVEST OPHTH VIS SCI, V43, P1358
   Prasad KN, 2016, MECH AGEING DEV, V153, P41, DOI 10.1016/j.mad.2016.01.002
   Radi E, 2014, J ALZHEIMERS DIS, V42, pS125, DOI 10.3233/JAD-132738
   Raghavachari N, 1999, EXP EYE RES, V68, P715, DOI 10.1006/exer.1999.0659
   Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088
   Reisman SA, 2009, TOXICOL SCI, V108, P35, DOI 10.1093/toxsci/kfn267
   Rezaei KA, 2008, INVEST OPHTH VIS SCI, V49, P1665, DOI 10.1167/iovs.07-0959
   RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sacca SC, 2013, MUTAT RES-REV MUTAT, V752, P153, DOI 10.1016/j.mrrev.2013.01.001
   Sacca SC, 2016, J CELL PHYSIOL, V231, P1876, DOI 10.1002/jcp.25305
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Satoh T, 2009, BIOCHEM BIOPH RES CO, V380, P298, DOI 10.1016/j.bbrc.2009.01.063
   Shirao Y, 1998, PROG RETIN EYE RES, V17, P59, DOI 10.1016/S1350-9462(97)00005-0
   Sliwinski Tomasz, 2013, Klin Oczna, V115, P96
   Soley GC, 2003, J GLAUCOMA, V12, P27, DOI 10.1097/00061198-200302000-00005
   Spickett CM, 2015, ANTIOXID REDOX SIGN, V22, P1646, DOI 10.1089/ars.2014.6098
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Sun Y, 2014, INT J MOL MED, V34, P1013, DOI 10.3892/ijmm.2014.1861
   Suzuki T, 2015, FREE RADICAL BIO MED, V88, P93, DOI 10.1016/j.freeradbiomed.2015.06.006
   Synowiec E, 2012, MOL BIOL REP, V39, P2081, DOI 10.1007/s11033-011-0955-3
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511
   Tokarz P, 2016, EUR J PHARMACOL, V776, P167, DOI 10.1016/j.ejphar.2016.02.049
   Upadhyaya B, 2015, EXP EYE RES, V130, P58, DOI 10.1016/j.exer.2014.12.004
   Valavanidis A, 2009, INT J ENV RES PUB HE, V6, P445, DOI 10.3390/ijerph6020445
   Varma SD, 2013, CLIN OPHTHALMOL, V7, P2091, DOI 10.2147/OPTH.S52678
   Vincent AL, 2002, AM J HUM GENET, V70, P448, DOI 10.1086/338709
   Vinson Joe A, 2006, Pathophysiology, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   von Otter M, 2010, MECH AGEING DEV, V131, P105, DOI 10.1016/j.mad.2009.12.007
   Vrensen GFJM, 2016, EXP EYE RES, V145, P100, DOI 10.1016/j.exer.2015.11.009
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang FX, 2016, SCI REP-UK, V6, DOI 10.1038/srep19396
   Wang GM, 1997, EXP EYE RES, V64, P693, DOI 10.1006/exer.1996.0251
   Wang KJ, 2015, BIOCHEM BIOPH RES CO, V468, P541, DOI 10.1016/j.bbrc.2015.10.117
   Wang L, 2008, INVEST OPHTH VIS SCI, V49, P1671, DOI 10.1167/iovs.07-1099
   Wei M, 2015, INVEST OPHTH VIS SCI, V56, P598, DOI 10.1167/iovs.14-15452
   Wei YH, 2011, FREE RADICAL BIO MED, V51, P216, DOI 10.1016/j.freeradbiomed.2011.04.026
   Williamson TP, 2012, NEUROTOXICOLOGY, V33, P272, DOI 10.1016/j.neuro.2012.01.015
   Winkler B S, 1999, Mol Vis, V5, P32
   Wu HL, 2014, J BIOL CHEM, V289, P36125, DOI 10.1074/jbc.M114.620047
   Wu HL, 2011, FREE RADICAL BIO MED, V51, P2108, DOI 10.1016/j.freeradbiomed.2011.09.011
   Wu HL, 2010, BBA-BIOENERGETICS, V1797, P1705, DOI 10.1016/j.bbabio.2010.06.003
   Wu XY, 2016, ENVIRON SCI POLLUT R, V23, P8244, DOI 10.1007/s11356-016-6333-x
   Xu XR, 2016, EUR J PHARMACOL, V770, P1, DOI 10.1016/j.ejphar.2015.11.050
   Xu ZH, 2015, J NEUROCHEM, V133, P233, DOI 10.1111/jnc.13064
   Xu ZH, 2014, DIABETOLOGIA, V57, P204, DOI 10.1007/s00125-013-3093-8
   Yang SP, 2015, MOL MED REP, V12, P1145, DOI 10.3892/mmr.2015.3490
   Yildirim O, 2005, GRAEF ARCH CLIN EXP, V243, P327, DOI 10.1007/s00417-004-1013-9
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
   Yousefi R, 2016, INT J BIOL MACROMOL, V82, P328, DOI 10.1016/j.ijbiomac.2015.10.036
   Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhang J, 2012, INVEST OPHTH VIS SCI, V53, P7276, DOI 10.1167/iovs.12-10482
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P3941, DOI 10.1167/iovs.13-11598
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P244, DOI 10.1167/iovs.12-10854
   Zhong Q, 2011, DIABETES, V60, P1304, DOI 10.2337/db10-0133
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
   Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200
   Zong HL, 2011, CURR DIABETES REP, V11, P244, DOI 10.1007/s11892-011-0198-7
   Zucker SN, 2014, MOL CELL, V53, P916, DOI 10.1016/j.molcel.2014.01.033
NR 174
TC 47
Z9 50
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 1703810
DI 10.1155/2017/1703810
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EQ7AH
UT WOS:000398234400001
PM 28473877
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Chen, YY
   Coorey, NJ
   Zhang, MX
   Zeng, SX
   Madigan, MC
   Zhang, XY
   Gillies, MC
   Zhu, L
   Zhang, T
AF Chen, Yingying
   Coorey, Nathan J.
   Zhang, Meixia
   Zeng, Shaoxue
   Madigan, Michele C.
   Zhang, Xinyuan
   Gillies, Mark C.
   Zhu, Ling
   Zhang, Ting
TI Metabolism Dysregulation in Retinal Diseases and Related Therapies
SO ANTIOXIDANTS
LA English
DT Review
DE retina; metabolism; retinal diseases; gene therapy; lipid metabolism
ID ENDOPLASMIC-RETICULUM STRESS; GLYCATION END-PRODUCTS; DIETARY GLYCEMIC
   INDEX; MACULAR DEGENERATION; OXIDATIVE STRESS; DOCOSAHEXAENOIC ACID;
   DIABETIC-RETINOPATHY; GLUCOSE-METABOLISM; ENERGY-METABOLISM; NMNAT1
   MUTATIONS
AB The human retina, which is part of the central nervous system, has exceptionally high energy demands that requires an efficient metabolism of glucose, lipids, and amino acids. Dysregulation of retinal metabolism disrupts local energy supply and redox balance, contributing to the pathogenesis of diverse retinal diseases, including age-related macular degeneration, diabetic retinopathy, inherited retinal degenerations, and Macular Telangiectasia. A better understanding of the contribution of dysregulated metabolism to retinal diseases may provide better therapeutic targets than we currently have.
C1 [Chen, Yingying; Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610017, Peoples R China.
   [Chen, Yingying; Zeng, Shaoxue; Madigan, Michele C.; Gillies, Mark C.; Zhu, Ling; Zhang, Ting] Univ Sydney, Fac Med & Hlth, Save Sight Inst, Sydney, NSW 2000, Australia.
   [Coorey, Nathan J.] Canberra Hlth Serv, Canberra, ACT 2605, Australia.
   [Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, Macular Dis Res Lab, Chengdu 610017, Peoples R China.
   [Madigan, Michele C.] Univ New South Wales UNSW, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
   [Zhang, Xinyuan] Capital Med Univ, Tongren Hosp, Beijing Tongren Eye Ctr, Dept Ocular Fundus Dis, Beijing 100073, Peoples R China.
   [Zhang, Xinyuan] Beijing Retinal & Choroidal Vasc Study Grp, Beijing 100073, Peoples R China.
C3 Sichuan University; University of Sydney; Sichuan University; University
   of New South Wales Sydney; Capital Medical University
RP Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610017, Peoples R China.; Zhang, T (通讯作者)，Univ Sydney, Fac Med & Hlth, Save Sight Inst, Sydney, NSW 2000, Australia.; Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Macular Dis Res Lab, Chengdu 610017, Peoples R China.
EM 2019324020107@stu.scu.edu.cn; nathan.coorey@gmail.com;
   zhangmeixia@scu.edu.cn; shaoxue.zeng@sydney.edu.au;
   m.madigan@unsw.edu.au; mmzxy2010@163.com; mark.gillies@sydney.edu.au;
   ling.zhu@sydney.edu.au; ting.zhang@sydney.edu.au
OI Zhang, Xinyuan/0000-0002-3372-0798; Chen, Yingying/0000-0003-0817-7612;
   Zhang, Meixia/0000-0002-2633-6819
FU Ophthalmic Research Institute of Australia; National Health and Medical
   Research Council [GNT_1195021]; Lowy Medical Research Institute
FX This research was funded by the Ophthalmic Research Institute of
   Australia (T.Z., M.G.), the National Health and Medical Research Council
   (Investigator Grant GNT_1195021) (M.G.), the Lowy Medical Research
   Institute (M.G., L.Z. and T.Z.).
CR Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Acosta ML, 2005, AM J PHYSIOL-CELL PH, V289, pC1015, DOI 10.1152/ajpcell.00137.2005
   Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Ajith TA, 2020, CLIN EXP PHARMACOL P, V47, P1883, DOI 10.1111/1440-1681.13373
   Akwii RG, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050471
   Alamri A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061387
   Almarhoun M, 2021, BBA-MOL CELL BIOL L, V1866, DOI 10.1016/j.bbalip.2021.158927
   Antonetti DA, 2021, NAT REV ENDOCRINOL, V17, P195, DOI 10.1038/s41574-020-00451-4
   Atsuzawa K, 2010, HISTOCHEM CELL BIOL, V134, P565, DOI 10.1007/s00418-010-0752-4
   Barba I, 2010, INVEST OPHTH VIS SCI, V51, P4416, DOI 10.1167/iovs.10-5348
   BAZAN NG, 1986, PROG LIPID RES, V25, P595, DOI 10.1016/0163-7827(86)90122-0
   Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006
   Bennett LD, 2014, INVEST OPHTH VIS SCI, V55, P4063, DOI 10.1167/iovs.14-13997
   Berdeaux O, 2010, J CHROMATOGR A, V1217, P7738, DOI 10.1016/j.chroma.2010.10.039
   Bonelli R, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00848-4
   Bonelli R, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01788-w
   Butler M, 2021, TRENDS ENDOCRIN MET, V32, P367, DOI 10.1016/j.tem.2021.03.003
   Cahill M, 2001, ACTA OPHTHALMOL SCAN, V79, P596, DOI 10.1034/j.1600-0420.2001.790610.x
   Cappai G, 2011, DIABETOLOGIA, V54, P1539, DOI 10.1007/s00125-011-2099-3
   Caputto BL, 2002, BBA-MOL CELL BIOL L, V1583, P1, DOI 10.1016/S1388-1981(02)00209-3
   Casson RJ, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100881
   Chan CM, 2016, J CELL MOL MED, V20, P1749, DOI 10.1111/jcmm.12893
   Chen LY, 2016, DIABETES, V65, P1099, DOI 10.2337/db15-0661
   Chiang PW, 2012, NAT GENET, V44, P972, DOI 10.1038/ng.2370
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Christen WG, 2020, JAMA OPHTHALMOL, V138, P1280, DOI 10.1001/jamaophthalmol.2020.4409
   Cleghorn WM, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2021.101441
   Coorey NJ, 2012, CLIN EXP OPTOM, V95, P266, DOI 10.1111/j.1444-0938.2012.00741.x
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Daiger S., 1998, INVESTIG OPHTHALMOL, V39
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   DCCT Res Grp, 1994, J PEDIATR-US, V125, P177, DOI 10.1016/S0022-3476(94)70190-3
   Deak F, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00428
   Du JH, 2021, AMINO ACIDS, V53, P1789, DOI 10.1007/s00726-021-02981-1
   Du JH, 2015, METHOD ENZYMOL, V561, P149, DOI 10.1016/bs.mie.2015.04.002
   Duncan JL, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.6
   Eastlake K, 2020, CURR EYE RES, V45, P339, DOI 10.1080/02713683.2019.1648831
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Elsherbiny NM, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01089
   Falk MJ, 2012, NAT GENET, V44, P1040, DOI 10.1038/ng.2361
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fletcher AL, 2012, MOL GENET METAB, V106, P18, DOI 10.1016/j.ymgme.2012.02.015
   Fletcher EL, 2019, DRUG DISCOV TODAY, V24, P1598, DOI 10.1016/j.drudis.2019.03.029
   Fliesler SJ, 1997, INT J BIOCHEM CELL B, V29, P877, DOI 10.1016/S1357-2725(97)00018-6
   Forrester JV, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583687
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fu ZJ, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000618
   Gantner ML, 2019, NEW ENGL J MED, V381, P1422, DOI 10.1056/NEJMoa1815111
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Ge TX, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00365
   Giusto NM, 2010, J LIPID RES, V51, P685, DOI 10.1194/jlr.R001891
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Gurel Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095561
   Haines NR, 2018, J PROTEOME RES, V17, P2421, DOI 10.1021/acs.jproteome.8b00169
   Hammes HP, 2018, DIABETOLOGIA, V61, P29, DOI 10.1007/s00125-017-4435-8
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   Haydinger CD, 2020, CLIN EXP OPHTHALMOL, V48, P1057, DOI 10.1111/ceo.13833
   Hirano AA, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.600777
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   Jadeja RN, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2692794
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Joyal JS, 2018, PROG RETIN EYE RES, V64, P131, DOI 10.1016/j.preteyeres.2017.11.002
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kalloniatis M, 2013, CLIN EXP OPTOM, V96, P310, DOI 10.1111/cxo.12015
   Kananen F, 2021, ACTA OPHTHALMOL, V99, pE1063, DOI 10.1111/aos.14774
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Keen TJ, 2003, EUR J HUM GENET, V11, P420, DOI 10.1038/sj.ejhg.5200981
   Khodabande A, 2019, OPHTHALMOL THER, V8, P155, DOI 10.1007/s40123-019-0170-1
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Kontaxi C, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00056
   Kruger NJ, 2003, CURR OPIN PLANT BIOL, V6, P236, DOI 10.1016/S1369-5266(03)00039-6
   Landowski M, 2022, J OCUL PHARMACOL TH, V38, P3, DOI 10.1089/jop.2021.0067
   Len ACL, 2012, J PROTEOME RES, V11, P537, DOI 10.1021/pr200889t
   Leveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018-016-2318-7
   Li B, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101672
   Li Q, 2002, INVEST OPHTH VIS SCI, V43, P3109
   Li YQ, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01946-y
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Liew G, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0939-3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193947
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   Liu DX, 2017, MOL NEUROBIOL, V54, P5440, DOI 10.1007/s12035-016-0079-9
   Liu JH, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01923-0
   Lorenzi M, 2007, EXP DIABETES RES, DOI 10.1155/2007/61038
   Machkour ZB, 2017, CASE REP OPHTHALMOL, V2017, DOI 10.1155/2017/5395069
   Mao D, 2015, INVEST OPHTH VIS SCI, V56, P5519, DOI 10.1167/iovs.15-16757
   Ventura ALM, 2019, BRAIN RES BULL, V151, P92, DOI 10.1016/j.brainresbull.2018.10.016
   Martis RM, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4594606
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200
   Narayan DS, 2017, CLIN EXP OPHTHALMOL, V45, P730, DOI 10.1111/ceo.12952
   Ng SK, 2015, CLIN EXP OPHTHALMOL, V43, P367, DOI 10.1111/ceo.12462
   Ogurtsova K, 2017, DIABETES RES CLIN PR, V128, P40, DOI 10.1016/j.diabres.2017.03.024
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Ozawa Y, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101779
   Pan WW, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01765-3
   Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102
   Pedley AM, 2017, TRENDS BIOCHEM SCI, V42, P141, DOI 10.1016/j.tibs.2016.09.009
   Petit L, 2018, CELL REP, V23, P2629, DOI 10.1016/j.celrep.2018.04.111
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Rajala RVS, 2010, J LIPID RES, V51, P4, DOI 10.1194/jlr.R000232
   Reichenbach A, 2016, NEUROPHARMACOLOGY, V104, P194, DOI 10.1016/j.neuropharm.2015.05.005
   Villanueva JR, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020094
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Safi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/801269
   Sage AT, 2010, AM J PHYSIOL-ENDOC M, V298, pE499, DOI 10.1152/ajpendo.00507.2009
   Santiago AR, 2020, PHARMACOL THERAPEUT, V210, DOI 10.1016/j.pharmthera.2020.107513
   Sarac O, 2012, OPHTHALMIC GENET, V33, P249, DOI 10.3109/13816810.2012.689412
   Scerri TS, 2017, NAT GENET, V49, P559, DOI 10.1038/ng.3799
   Shaw LC, 2018, INVEST OPHTH VIS SCI, V59, P858, DOI 10.1167/iovs.17-23034
   Sheng L, 2021, DRUG DES DEV THER, V15, P1101, DOI 10.2147/DDDT.S296197
   Sinha T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030674
   Sreekumar PG, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050661
   Stirban A, 2006, DIABETES CARE, V29, P2064, DOI 10.2337/dc06-0531
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Sumarriva K, 2019, INVEST OPHTH VIS SCI, V60, P3119, DOI 10.1167/iovs.19-27321
   Takeuchi M, 2000, J NEUROPATH EXP NEUR, V59, P1094, DOI 10.1093/jnen/59.12.1094
   Tang PH, 2013, PROG RETIN EYE RES, V32, P48, DOI 10.1016/j.preteyeres.2012.09.002
   Tolone A, 2019, GENES-BASEL, V10, DOI 10.3390/genes10060453
   Trapani I, 2019, HUM MOL GENET, V28, pR108, DOI 10.1093/hmg/ddz130
   Trapani I, 2018, TRENDS MOL MED, V24, P669, DOI 10.1016/j.molmed.2018.06.006
   Tyni T, 2002, PEDIATR RES, V52, P595, DOI 10.1203/01.PDR.0000030874.20888.2D
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Viegas FO, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.656000
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2020, OPHTHALMOLOGICA, V243, P9, DOI 10.1159/000502387
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Wu GY, 2020, ADV EXP MED BIOL, V1265, P201, DOI 10.1007/978-3-030-45328-2_12
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wu MY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3420187
   Xue MZ, 2008, DIABETES, V57, P2809, DOI 10.2337/db06-1003
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   Yin J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01697
   Zaitone SA, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118467
   Zhang CH, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/963629
   Zhang R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03103-7
   Zhang T, 2018, MOL NEUROBIOL, V55, P7025, DOI 10.1007/s12035-017-0840-8
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
   Zhong YY, 2021, EUR J NUTR, V60, P3013, DOI 10.1007/s00394-020-02445-4
NR 154
TC 1
Z9 1
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD MAY
PY 2022
VL 11
IS 5
AR 942
DI 10.3390/antiox11050942
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 1O7UO
UT WOS:000801532400001
PM 35624805
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Betzler, BK
   Rim, TH
   Sabanayagam, C
   Cheung, CMG
   Cheng, CY
AF Betzler, Bjorn Kaijun
   Rim, Tyler Hyungtaek
   Sabanayagam, Charumathi
   Cheung, Chui Ming Gemmy
   Cheng, Ching-Yu
TI High-Density Lipoprotein Cholesterol in Age-Related Ocular Diseases
SO BIOMOLECULES
LA English
DT Review
DE age-related macular degeneration; cataract; diabetic retinopathy;
   macular edema; glaucoma; intraocular pressure; visual impairment;
   ageing; high-density lipoprotein; dyslipidaemia
ID TREATMENT DIABETIC-RETINOPATHY; NUTRITION EXAMINATION SURVEY; KOREA
   NATIONAL-HEALTH; OPEN-ANGLE GLAUCOMA; RISK-FACTORS; MACULAR
   DEGENERATION; INTRAOCULAR-PRESSURE; METABOLIC SYNDROME;
   GENETIC-VARIANTS; SERUM-LIPIDS
AB There is limited understanding of the specific role of high-density lipoprotein cholesterol (HDL-C) in the development of various age-related ocular diseases, despite it being a common measurable biomarker in lipid profiles. This literature review summarizes current knowledge of the role of HDL-C, if any, in pathogenesis and progression of four age-related ocular diseases, namely age-related macular degeneration (AMD), age-related cataract, glaucoma, and diabetic retinopathy (DR), and will primarily discuss epidemiological and genetic evidence.
C1 [Betzler, Bjorn Kaijun] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 119228, Singapore.
   [Rim, Tyler Hyungtaek; Sabanayagam, Charumathi; Cheung, Chui Ming Gemmy; Cheng, Ching-Yu] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 169856, Singapore.
   [Rim, Tyler Hyungtaek; Sabanayagam, Charumathi; Cheung, Chui Ming Gemmy; Cheng, Ching-Yu] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program EYE ACP, Singapore 169857, Singapore.
   [Cheng, Ching-Yu] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 119228, Singapore.
C3 National University of Singapore; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Cheng, CY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 169856, Singapore.; Cheng, CY (通讯作者)，Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program EYE ACP, Singapore 169857, Singapore.; Cheng, CY (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 119228, Singapore.
EM bjorn.betzler@u.nus.edu; tyler.rim@snec.com.sg;
   charumathi.sabanayagam@seri.com.sg; gemmy.cheung.c.m@singhealth.com.sg;
   chingyu.cheng@duke-nus.edu.sg
RI Sabanayagam, Charumathi/C-1294-2011; Betzler, Bjorn/AAU-7487-2020;
   Cheng, Ching-Yu/Y-2229-2019
OI Sabanayagam, Charumathi/0000-0002-4042-4719; Betzler,
   Bjorn/0000-0002-4843-7514; Cheng, Ching-Yu/0000-0003-0655-885X; Cheung,
   Chui Ming Gemmy/0000-0003-3358-3516
CR Allard-Ratick M., 2018, EUR HEAR J, V39, P564
   Asztalos BF, 2003, AM J CARDIOL, V91, p12E, DOI 10.1016/S0002-9149(02)03383-0
   Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Benarous R, 2011, INVEST OPHTH VIS SCI, V52, P7464, DOI 10.1167/iovs.11-7598
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Boussageon R, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4169
   Brites F, 2017, BBA CLIN, V8, P66, DOI 10.1016/j.bbacli.2017.07.002
   Bruno Graziella, 2012, Diabetes Care, V35, pe64
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cezario SM, 2015, ARQ BRAS OFTALMOL, V78, P85, DOI 10.5935/0004-2749.20150023
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2014, NAT GENET, V46, P1115, DOI 10.1038/ng.3078
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cikamatana L, 2007, EYE, V21, P465, DOI 10.1038/sj.eye.6702771
   Ciotu I M, 2015, J Med Life, V8, P28
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Connelly MA, 2016, TRANSL RES, V173, P7, DOI 10.1016/j.trsl.2016.01.006
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cugati S, 2006, DIABETES RES CLIN PR, V74, P301, DOI 10.1016/j.diabres.2006.04.002
   Cui Y, 2019, INVEST OPHTH VIS SCI, V60, P761, DOI 10.1167/iovs.18-25247
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286
   Das R, 2015, OPHTHALMOLOGY, V122, P1820, DOI 10.1016/j.ophtha.2015.05.011
   Davidson MH, 2009, CLIN CARDIOL, V32, P482, DOI 10.1002/clc.20559
   Davis MD, 1998, INVEST OPHTH VIS SCI, V39, P233
   De Castro DK, 2007, CLIN EXP OPHTHALMOL, V35, P506, DOI 10.1111/j.1442-9071.2007.01529.x
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Drinkwater JJ, 2019, DIABETES CARE, V42, P288, DOI 10.2337/dc18-1556
   El Hindy N, 2010, J DIABETES, V2, P125, DOI 10.1111/j.1753-0407.2010.00071.x
   Eren Esin, 2014, Open Biochem J, V8, P100, DOI 10.2174/1874091X01408010100
   Eren E, 2015, CLIN CHIM ACTA, V439, P18, DOI 10.1016/j.cca.2014.09.024
   Eren E, 2014, J CLIN DIAGN RES, V8, pCE01, DOI 10.7860/JCDR/2014/7827.4773
   Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gharahkhani P, 2014, NAT GENET, V46, P1120, DOI 10.1038/ng.3079
   Gordon SM, 2010, J PROTEOME RES, V9, P5239, DOI 10.1021/pr100520x
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Haapasalo K, 2015, J BIOL CHEM, V290, P28977, DOI 10.1074/jbc.M115.669226
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hemmingsen Bianca, 2011, BMJ, V343, pd6898, DOI 10.1136/bmj.d6898
   Hennis A, 2004, ARCH OPHTHALMOL-CHIC, V122, P525, DOI 10.1001/archopht.122.4.525
   Hiller R, 2003, OPHTHALMOLOGY, V110, P578, DOI 10.1016/S0161-6420(02)01762-1
   Hirata A, 2018, J CLIN LIPIDOL, V12, P674, DOI 10.1016/j.jacl.2018.01.014
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jacques PF, 2003, AM J CLIN NUTR, V78, P400, DOI 10.1093/ajcn/78.3.400
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim MJ, 2014, CLIN EXP OPHTHALMOL, V42, P825, DOI 10.1111/ceo.12347
   Kim Y.J., 2015, OPTOMETRY VISION SCI, V92, P1
   Kim YH, 2014, EYE, V28, P672, DOI 10.1038/eye.2014.43
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261
   Klein BEK, 1997, AM J OPHTHALMOL, V123, P338, DOI 10.1016/S0002-9394(14)70129-1
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 2002, OPHTHALMOLOGY, V109, P1225, DOI 10.1016/S0161-6420(02)01074-6
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Ko DT, 2016, J AM COLL CARDIOL, V68, P2073, DOI 10.1016/j.jacc.2016.08.038
   Kontush A, 2015, HANDB EXP PHARMACOL, V224, P3, DOI 10.1007/978-3-319-09665-0_1
   Kurtul B.E., 2015, SOFTW TEST VER VAL W, V32, P1, DOI DOI 10.3109/08820538.2015.1068341(
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Li SJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021496
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luo HC, 2015, INVEST OPHTH VIS SCI, V56, P6248, DOI 10.1167/iovs.15-16741
   Lyons TJ, 2004, INVEST OPHTH VIS SCI, V45, P910, DOI 10.1167/iovs.02-0648
   Mackness M, 2015, GENE, V567, P12, DOI 10.1016/j.gene.2015.04.088
   Madsen CM, 2017, EUR HEART J, V38, P2478, DOI 10.1093/eurheartj/ehx163
   Magro CM, 2014, AM J DERMATOPATH, V36, P303, DOI 10.1097/DAD.0b013e31829beaa7
   Maralani HG, 2013, INVEST OPHTH VIS SCI, V54, P641, DOI 10.1167/iovs.12-10980
   Marcus MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029724
   McGwin G, 2004, ARCH OPHTHALMOL-CHIC, V122, P822, DOI 10.1001/archopht.122.6.822
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   Meyer D, 2003, Cardiovasc J S Afr, V14, P60
   Miljanovic B, 2004, DIABETES, V53, P2883, DOI 10.2337/diabetes.53.11.2883
   Misra Anoop, 2003, Am J Cardiovasc Drugs, V3, P325, DOI 10.2165/00129784-200303050-00004
   Morton J, 2012, DIABETES CARE, V35, P2201, DOI 10.2337/dc12-0306
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Park S, 2015, INT J OPHTHALMOL-CHI, V8, P804, DOI 10.3980/j.issn.2222-3959.2015.04.29
   Park YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085068
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Paunksnis A, 2007, EUR J OPHTHALMOL, V17, P605, DOI 10.1177/112067210701700420
   Pillunat LE, 2017, CLIN OPHTHALMOL, V11, P1583, DOI 10.2147/OPTH.S135316
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Raman R, 2010, OPHTHALMOLOGY, V117, P766, DOI 10.1016/j.ophtha.2009.09.005
   Rao V.S., 2010, CHOLESTEROL, V2011, P1
   Rema M, 2006, DIABETIC MED, V23, P1029, DOI 10.1111/j.1464-5491.2006.01890.x
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rezaee F, 2006, PROTEOMICS, V6, P721, DOI 10.1002/pmic.200500191
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Ritch R, 1994, J Glaucoma, V3, P176
   ROSENFELD SI, 1983, J CLIN INVEST, V71, P795, DOI 10.1172/JCI110833
   Rosenson RS, 2016, NAT REV CARDIOL, V13, P48, DOI 10.1038/nrcardio.2015.124
   Rosenson RS, 2013, CIRCULATION, V128, P1256, DOI 10.1161/CIRCULATIONAHA.113.000962
   Rosenson RS, 2011, CLIN CHEM, V57, P392, DOI 10.1373/clinchem.2010.155333
   Rye KA, 2014, CIRC RES, V114, P143, DOI 10.1161/CIRCRESAHA.114.300632
   Sabanayagam C, 2011, INVEST OPHTH VIS SCI, V52, P2397, DOI 10.1167/iovs.10-6373
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sachdev N, 2010, J POSTGRAD MED, V56, P3, DOI 10.4103/0022-3859.62419
   Sacks FM, 2014, CIRCULATION, V129, P999, DOI 10.1161/CIRCULATIONAHA.113.002529
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sasongko MB, 2011, DIABETES CARE, V34, P474, DOI 10.2337/dc10-0793
   Sasso FC, 2019, DIABETES RES CLIN PR, V150, P236, DOI 10.1016/j.diabres.2019.03.028
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Seeree P, 2019, ONCOL LETT, V18, P5173, DOI 10.3892/ol.2019.10874
   Semeraro F, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/582060
   Shon K, 2019, J GLAUCOMA, V28, P550, DOI 10.1097/IJG.0000000000001237
   Simo R, 2009, AM J OPHTHALMOL, V147, P319, DOI 10.1016/j.ajo.2008.08.009
   Skerka C, 1997, J BIOL CHEM, V272, P5627, DOI 10.1074/jbc.272.9.5627
   Sobrin L, 2017, DIABETES, V66, P3130, DOI 10.2337/db17-0398
   Stein JD, 2012, OPHTHALMOLOGY, V119, P2074, DOI 10.1016/j.ophtha.2012.04.029
   Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594
   Sun JK, 2019, OPHTHALMIC RES, V62, P225, DOI 10.1159/000502779
   Tan GS, 2018, OPHTHALMOLOGY, V125, P529, DOI 10.1016/j.ophtha.2017.10.026
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tang YT, 2016, INVEST OPHTH VIS SCI, V57, P1193, DOI 10.1167/iovs.15-18380
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   TSCHOPP J, 1993, J IMMUNOL, V151, P2159
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tsutsumi K, 1999, BIOL PHARM BULL, V22, P37, DOI 10.1248/bpb.22.37
   von Eckardstein A, 2005, CURR OPIN CLIN NUTR, V8, P147, DOI 10.1097/00075197-200503000-00007
   Walldius G, 2006, J INTERN MED, V259, P493, DOI 10.1111/j.1365-2796.2006.01643.x
   Wang C, 2019, CELL CYCLE, V18, P932, DOI 10.1080/15384101.2019.1593645
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wang YX, 2019, INT J OPHTHALMOL-CHI, V12, P510, DOI 10.18240/ijo.2019.03.24
   Watanabe J, 2012, ARTHRITIS RHEUM-US, V64, P1828, DOI 10.1002/art.34363
   Wong J, 2008, ATHEROSCLEROSIS, V196, P180, DOI 10.1016/j.atherosclerosis.2007.03.030
   Wong TY, 2008, OPHTHALMOLOGY, V115, P1869, DOI 10.1016/j.ophtha.2008.05.014
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038701
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yilmaz N, 2016, BOSNIAN J BASIC MED, V16, P21, DOI 10.17305/bjbms.2016.830
   Yilmaz N, 2012, ARCH MED SCI, V8, P138, DOI 10.5114/aoms.2012.27294
   Yokomichi H, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010360
NR 148
TC 11
Z9 11
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD APR
PY 2020
VL 10
IS 4
AR 645
DI 10.3390/biom10040645
PG 20
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA LW9WG
UT WOS:000539492400149
PM 32331355
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, L
   Zhang, XZ
   Li, ML
   Liao, NY
   Wen, F
AF Chen, Ling
   Zhang, Xiongze
   Li, Miaoling
   Liao, Nanying
   Wen, Feng
TI Age-Related Scattered Hypofluorescent Spots on Late-Phase Indocyanine
   Green Angiography as Precursor Lesions of Polypoidal Choroidal
   Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; age-related scattered hypofluorescent
   spots; indocyanine green angiography; ASHS-LIA; basal linear deposits;
   lipid accumulation
ID MACULAR DEGENERATION; GENETIC-VARIANTS; CLINICAL CHARACTERISTICS; BRUCHS
   MEMBRANE; DRUSEN; CLASSIFICATION; ACCUMULATION; MORPHOLOGY; THICKNESS;
   DISEASE
AB PURPOSE. Age-related scattered hypofluorescent spots on late-phase indocyanine green angiography (ASHS-LIA) might represent lipid accumulation in Bruch's membrane in the form of basal linear deposits (BlinD). The present study was conducted to describe the clinical characteristics of polypoidal choroidal vasculopathy (PCV) associated with ASHS-LIA.
   METHODS. Consecutive patients with treatment-naive PCV who underwent color fundus photography (FP), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), and spectral-domain optical coherence tomography (SD-OCT) at the Zhongshan Ophthalmic Center from June 2016 through May 2018, were reviewed. ASHS-LIA and choroidal vascular hyperpermeability (CVH) were evaluated by ICGA. Subfoveal choroidal thickness (SFCT) was assessed by SD-OCT.
   RESULTS. A total of 187 patients were eligible for inclusion in this study (mean, 63.2 6 +/- 7.6 years; range, 41-85 years). Of these patients, 117 (62.6%) showed ASHS-LIA, 57 (30.5%) had bilateral lesions and 70 (37.4%) showed CVH. Moreover, compared with patients without ASHS-LIA, PCV patients with ASHS-LIA were older (P = 0.001), more frequently had bilateral lesions (P = 0.001), and less frequently showed CVH (P = 0.006). SFCT in eyes with ASHS-LIA was significantly greater than that in eyes without ASHS-LIA after adjusting for age, sex, and CVH (P = 0.026). Nevertheless, there was no significant difference in best-corrected visual acuity or lesion characteristics between the two groups.
   CONCLUSIONS. ASHS-LIA, which is very common in PCV patients, might be involved in the pathogenesis of PCV. PCV with ASHS-LIA was more frequently associated with bilateral involvement, less CVH, and a thicker choroid than PCV without ASHS-LIA.
C1 [Chen, Ling; Zhang, Xiongze; Li, Miaoling; Liao, Nanying; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
OI Chen, Ling/0000-0002-5552-4667
FU National Natural Science Foundation of China [81870674]
FX Supported by grants from the National Natural Science Foundation of
   China (grant numbers: 81870674).
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Chen L, 2018, INVEST OPHTH VIS SCI, V59, P5237, DOI 10.1167/iovs.18-25124
   Chen L, 2018, CLIN EXP OPHTHALMOL, V46, P908, DOI 10.1111/ceo.13306
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA., 2018, INVEST OPHTH VIS SCI, V59
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Ethier CR, 2004, ANNU REV BIOMED ENG, P6249
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Jang JW, 2019, RETINA-J RET VIT DIS, V39, P1995, DOI 10.1097/IAE.0000000000002259
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2018, RETINA, V38, P1509
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   McCarty WJ, 2008, J APPL PHYSIOL, V105, P621, DOI 10.1152/japplphysiol.01245.2007
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Shiraki Kunihiko, 1999, International Ophthalmology, V23, P105, DOI 10.1023/A:1026571327117
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Wen XF, 2018, J GENE MED, V20, DOI 10.1002/jgm.3007
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagi Y, 2017, RETINA, V38, P1509
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 51
TC 2
Z9 2
U1 2
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2019
VL 60
IS 6
BP 2102
EP 2109
DI 10.1167/iovs.19-26968
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HZ6RS
UT WOS:000468980600034
PM 31095678
OA gold
DA 2022-11-30
ER

PT J
AU Ngo, WK
   Chee, WK
   Tan, CS
   Lim, TH
AF Ngo, Wei Kiong
   Chee, Wai Kitt
   Tan, Colin S.
   Lim, Tock Han
TI Comparing efficacy of reduced-fluence and standard-fluence photodynamic
   therapy in the treatment of polypoidal choroidal vasculopathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Comparing reduced and standard-fluence photodynamic therapy
ID HEMORRHAGIC COMPLICATIONS; INTRAVITREAL BEVACIZUMAB; MACULAR
   DEGENERATION; RANIBIZUMAB; VERTEPORFIN; EVEREST; OUTCOMES; SAFETY
AB BackgroundThe EVEREST II study reported superior polyp closure rates and visual outcomes using combination standard photodynamic therapy (PDT) with intravitreal ranibizumab in the treatment of polypoidal choroidal vasculopathy (PCV). The optimal PDT protocol remains controversial and it is postulated that less intensive PDT strategies may reduce complications. We aimed to compare the efficacy of reduced and standard-fluence PDT.MethodsCase-control review of 38 consecutive PDT-naive macular PCV patients who underwent verteporfin PDT using one of two PDT regimens at a tertiary referral centre in an Asian population. Comparison of outcomes between standard-fluence PDT (light dose, 50J/cm2; dose rate, 600mW/cm2; wavelength, 689nm PDT applied to the treatment eye for 83s) and reduced-fluence PDT (light dose, 25J/cm2; dose rate, 600mW/cm2; wavelength, 689nm PDT applied to the treatment eye for 42s). Primary outcome measure was best corrected LogMAR visual acuity (VA). Secondary outcome measures included OCT measurements such as central retinal thickness (CRT), height of subfoveal sub-retinal fluid (SRF), central choroid thickness (CCT), mean number of PDT treatments needed, mean number of anti-VEGF injections needed, polyp closure and recurrence rates.ResultsOf these 38 eyes of 38 patients, an equal number of eyes (19 in each arm) were treated with standard-fluence and reduced-fluence PDT. Mean letter gain at 12months for the standard-fluence group was 6.0 compared to 4.3 letters for the reduced-fluence group (p=0.61). Similar results were observed at all time points. There was no statistically significant difference between the retinal and choroidal anatomical OCT outcomes, rates of polyp closure and recurrences between the two PDT regimens.ConclusionsReduced-fluence PDT was comparable to standard-fluence PDT in the treatment of PCV in terms of visual gains, clinical and anatomical OCT outcomes.
C1 [Ngo, Wei Kiong; Chee, Wai Kitt; Tan, Colin S.; Lim, Tock Han] Natl Healthcare Grp Eye Inst, Tan Tock Seng Hosp, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Ngo, Wei Kiong; Tan, Colin S.; Lim, Tock Han] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
C3 Tan Tock Seng Hospital
RP Tan, CS (通讯作者)，Natl Healthcare Grp Eye Inst, Tan Tock Seng Hosp, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.; Tan, CS (通讯作者)，Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
EM colintan_eye@yahoo.com.sg
RI Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Rishi P, 2017, INDIAN J OPHTHALMOL, V65, P712, DOI 10.4103/ijo.IJO_174_17
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Sen P, 2016, INDIAN J OPHTHALMOL, V64, P908, DOI 10.4103/0301-4738.198856
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, OSLI RETINA, V46, P786, DOI 10.3928/23258160-20150909-02
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1900, RETINA, V1, P1
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 25
TC 4
Z9 4
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 15
PY 2020
VL 20
IS 1
DI 10.1186/s12886-020-01419-8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LH3PL
UT WOS:000528699400007
PM 32293353
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Grus, FH
   Joachim, SC
   Pfeiffer, N
AF Grus, Franz H.
   Joachim, Stephanie C.
   Pfeiffer, Norbert
TI Proteomics in ocular fluids
SO PROTEOMICS CLINICAL APPLICATIONS
LA English
DT Review
DE biomarkers; mass spectrometry; ocular fluids; tears
ID TEAR-PROTEIN-PATTERNS; ENDOTHELIAL GROWTH-FACTOR; OPEN-ANGLE GLAUCOMA;
   DIABETIC MACULAR EDEMA; OPTIC-NERVE HEAD; DRY-EYE PATIENTS; PERFORMANCE
   LIQUID-CHROMATOGRAPHY; AQUEOUS-HUMOR DYNAMICS; 2-DIMENSIONAL
   ELECTROPHORESIS; SELDI-TOF
AB The focus of this article is to review recent techniques in proteomic analysis of ocular fluids. These fluids include tears, aqueous humor, and vitreous, they will also be compared to serum analysis. Furthermore, we attempt to summarize some disease correlated biomarkers in ocular fluids that were discovered through different proteomic techniques in eye diseases like dry eye, glaucoma, age-related macular degeneration, uveitis, or diabetic retinopathy. This review is trying to point out the importance of these biomarkers for clinical applications.
C1 Johannes Gutenberg Univ Mainz, Dept Ophthalmol, D-55101 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz
RP Grus, FH (通讯作者)，Johannes Gutenberg Univ Mainz, Dept Ophthalmol, Langenbeckstr 1, D-55101 Mainz, Germany.
EM grus@eye-research.org
RI Pfeiffer, Norbert/AAO-7586-2020; Joachim, Stephanie/AAV-5980-2021
CR An HJ, 2005, J PROTEOME RES, V4, P1981, DOI 10.1021/pr0501620
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Assouti M, 2006, BBA-MOL BASIS DIS, V1762, P54, DOI 10.1016/j.bbadis.2005.09.005
   Barnes S, 2006, LIFE SCI, V78, P2054, DOI 10.1016/j.lfs.2005.12.002
   Berdy GJ, 2000, ACTA OPHTHALMOL SCAN, V78, P32, DOI 10.1034/j.1600-0420.2000.078s230032.x
   Berlau J, 2001, GRAEF ARCH CLIN EXP, V239, P743, DOI 10.1007/s004170100357
   Bleich S, 2004, AM J OPHTHALMOL, V138, P162, DOI 10.1016/j.ajo.2004.02.027
   BREWITT HM, 2001, TROCKENES AUGE KADEN, P33
   BROEKHUYSE RM, 1974, INVEST OPHTH VISUAL, V13, P550
   CHEN CH, 1981, EXP EYE RES, V32, P381, DOI 10.1016/S0014-4835(81)80017-6
   Chen H, 1993, Yan Ke Xue Bao, V9, P113
   Civan MM, 2004, EXP EYE RES, V78, P625, DOI 10.1016/j.exer.2003.09.021
   COUSINS SW, 1991, INVEST OPHTH VIS SCI, V32, P2201
   Curnow SJ, 2005, INVEST OPHTH VIS SCI, V46, P4251, DOI 10.1167/iovs.05-0444
   de Souza GA, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r72
   DENIS P, 1994, FUND CLIN PHARMACOL, V8, P230, DOI 10.1111/j.1472-8206.1994.tb00803.x
   Dogru M, 2001, OPHTHALMOLOGY, V108, P586, DOI 10.1016/S0161-6420(00)00599-6
   DOOREMAL JC, 1873, GRAEFES ARCH CLIN EX, V13, P359
   Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012
   Durham D G, 1970, Trans Am Ophthalmol Soc, V68, P462
   Engwegen JYMN, 2007, LAB INVEST, V87, P161, DOI 10.1038/labinvest.3700503
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   *EUR GLAUC SOC, 2006, TERM GUID GLAUC
   Evans V, 2001, CLIN EXP OPHTHALMOL, V29, P161, DOI 10.1046/j.1442-9071.2001.00408.x
   Evereklioglu C, 2002, JPN J OPHTHALMOL, V46, P203, DOI 10.1016/S0021-5155(01)00501-9
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Fine HF, 2001, AM J OPHTHALMOL, V132, P794, DOI 10.1016/S0002-9394(01)01103-5
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Funatsu H, 2006, OPHTHALMOLOGY, V113, P294, DOI 10.1016/j.ophtha.2005.10.030
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Funding M, 2005, ACTA OPHTHALMOL SCAN, V83, P31, DOI 10.1111/j.1600-0420.2005.00381.x
   Fung KYC, 2004, PROTEOMICS, V4, P3953, DOI 10.1002/pmic.200300849
   GACHON AM, 1982, CURR EYE RES, V2, P301, DOI 10.3109/02713688209000774
   Glasson MJ, 1998, ELECTROPHORESIS, V19, P852, DOI 10.1002/elps.1150190541
   Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9
   Grub M, 2004, OPHTHALMOLOGE, V101, P357, DOI 10.1007/s00347-003-0939-3
   Grus F H, 2002, BMC Ophthalmol, V2, P4, DOI 10.1186/1471-2415-2-4
   Grus FH, 2006, INVEST OPHTH VIS SCI, V47, P968, DOI 10.1167/iovs.05-0685
   Grus FH, 2005, INVEST OPHTH VIS SCI, V46, P863, DOI 10.1167/iovs.04-0448
   Grus FH, 2004, MOL VIS, V10, P132
   Grus FH, 2001, OPHTHALMOLOGICA, V215, P430, DOI 10.1159/000050903
   Grus FH, 2001, EUR J OPHTHALMOL, V11, P19, DOI 10.1177/112067210101100105
   Grus FH, 2001, ELECTROPHORESIS, V22, P1845, DOI 10.1002/1522-2683(200105)22:9<1845::AID-ELPS1845>3.0.CO;2-N
   Grus FH, 2000, OPHTHALMOLOGE, V97, P54, DOI 10.1007/s003470050012
   Grus FH, 1998, EUR J OPHTHALMOL, V8, P90, DOI 10.1177/112067219800800207
   Grus Franz H, 2005, Cont Lens Anterior Eye, V28, P103, DOI 10.1016/j.clae.2005.06.004
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Herber S, 2002, ADV EXP MED BIOL, V506, P623
   Herber S, 2001, ELECTROPHORESIS, V22, P1838, DOI 10.1002/1522-2683(200105)22:9<1838::AID-ELPS1838>3.0.CO;2-7
   Hernandez C, 2006, DIABETES CARE, V29, P2028, DOI 10.2337/dc06-0556
   Hida RY, 2005, CURR EYE RES, V30, P723, DOI 10.1080/02713680591005986
   HOLLY FJ, 1977, SURV OPHTHALMOL, V22, P69, DOI 10.1016/0039-6257(77)90087-X
   Hu DN, 2002, J GLAUCOMA, V11, P406, DOI 10.1097/00061198-200210000-00006
   Hu DN, 2001, J GLAUCOMA, V10, P152, DOI 10.1097/00061198-200106000-00002
   Hu S, 2006, PROTEOMICS, V6, P6326, DOI 10.1002/pmic.200600284
   Janciauskiene S, 2003, DOC OPHTHALMOL, V106, P215, DOI 10.1023/A:1022949121078
   Jin Y, 2005, ELECTROPHORESIS, V26, P2823, DOI 10.1002/elps.200410421
   Joachim S.C., 2006, GRAEFES ARCH CLIN EX
   Joachim SC, 2005, GRAEF ARCH CLIN EXP, V243, P817, DOI 10.1007/s00417-004-1094-5
   Joachim SC, 2003, EUR J OPHTHALMOL, V13, P752, DOI 10.1177/1120672103013009-1003
   JOACHIM SC, ARVO M 2005 SAN DIEG
   JOACHIM SC, DOG M 2006
   JOACHIM SC, 2007, IN PRESS CURR EYE RE
   Jonsson M, 2006, ACTA OPHTHALMOL SCAN, V84, P116, DOI 10.1111/j.1600-0420.2005.00577.x
   Joo WA, 2003, BIOSCI BIOTECH BIOCH, V67, P1574, DOI 10.1271/bbb.67.1574
   KHALIL HA, 1988, AM J OPHTHALMOL, V106, P186, DOI 10.1016/0002-9394(88)90832-X
   KIJLSTRA A, 1983, BRIT J OPHTHALMOL, V67, P199, DOI 10.1136/bjo.67.3.199
   KIJLSTRA A, 1994, ADV EXP MED BIOL, V350, P29
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knepper PA, 2002, INVEST OPHTH VIS SCI, V43, P133
   Koo BS, 2005, J PROTEOME RES, V4, P719, DOI 10.1021/pr0498133
   KRAUSE U, 1969, OPHTHALMOLOGICA, V159, P178, DOI 10.1159/000305901
   KUEHL W, 1971, GRAEFES ARCH OPHTHAL, V182, P76
   LEBRECHT A, 2006, 19 EUR C OBST GYN TU
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lemp Michael A., 1995, CLAO Journal, V21, P221
   Li N, 2005, J PROTEOME RES, V4, P2052, DOI 10.1021/pr0501970
   Lichtenstein SJ, 2005, PEDIATRICS, V116, P270, DOI 10.1542/peds.2005-0875
   Lightman S, 2001, CLIN EXP OPHTHALMOL, V29, P48, DOI 10.1046/j.1442-9071.2001.00375.x
   Lutjen-Drecoll E, 2001, J GLAUCOMA, V10, pS42
   Maatta M, 2006, J GLAUCOMA, V15, P229
   Malvitte L, 2007, BRIT J OPHTHALMOL, V91, P29, DOI 10.1136/bjo.2006.101485
   Maruyama I, 2000, INVEST OPHTH VIS SCI, V41, P1657
   MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q
   Min Seong Hee, 2006, Korean J Ophthalmol, V20, P162
   Missotten GS, 2003, MELANOMA RES, V13, P627, DOI 10.1097/00008390-200312000-00013
   Molloy MP, 1997, ELECTROPHORESIS, V18, P2811, DOI 10.1002/elps.1150181516
   Nilsson SFE, 1997, EYE, V11, P149, DOI 10.1038/eye.1997.43
   Ohashi Y, 2003, AM J OPHTHALMOL, V136, P291, DOI 10.1016/S0002-9394(03)00203-4
   Ouchi M, 2005, EXP EYE RES, V81, P176, DOI 10.1016/j.exer.2005.01.020
   Patel JI, 2006, EXP EYE RES, V82, P798, DOI 10.1016/j.exer.2005.10.002
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Paweletz CP, 2001, DIS MARKERS, V17, P301, DOI 10.1155/2001/674959
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2
   Pflugfelder SC, 2004, AM J OPHTHALMOL, V137, P337, DOI 10.1016/j.ajo.2003.10.036
   PIETSCH RL, 1973, ARCH OPHTHALMOL-CHIC, V90, P94
   Probst K, 2004, BRIT J OPHTHALMOL, V88, P667, DOI 10.1136/bjo.2003.026542
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   QUIGLEY HA, 1993, NEW ENGL J MED, V328, P1097, DOI 10.1056/NEJM199304153281507
   Reitz C, 1998, GRAEF ARCH CLIN EXP, V236, P894, DOI 10.1007/s004170050177
   ROEDL JB, 2006, J NEURAL TRANSM
   Roy MS, 2004, ARCH OPHTHALMOL-CHIC, V122, P546, DOI 10.1001/archopht.122.4.546
   Sack RA, 2005, INVEST OPHTH VIS SCI, V46, P1228, DOI 10.1167/iovs.04-0760
   Schein OD, 1997, AM J OPHTHALMOL, V124, P723, DOI 10.1016/S0002-9394(14)71688-5
   SCHERZ W, 1979, KLIN MONATSBL AUGENH, V174, P188
   SCHIRMER O., 1903, A VONGRAEFES ARCH OP, V56, P197, DOI DOI 10.1007/BF01946264
   Schlotzer-Schrehardt U, 2003, INVEST OPHTH VIS SCI, V44, P1117, DOI 10.1167/iovs.02-0365
   Schmut O, 2002, GRAEF ARCH CLIN EXP, V240, P900, DOI 10.1007/s00417-002-0537-0
   SEBAG J, 2006, DUANES CLIN OPHTHALM, P38
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEN DK, 1977, BRIT J OPHTHALMOL, V61, P216, DOI 10.1136/bjo.61.3.216
   Sethi CS, 2000, BRIT J OPHTHALMOL, V84, P654, DOI 10.1136/bjo.84.6.654
   Shimizu Akira, 2002, Rinsho Byori, V50, P169
   Shoji J, 2006, JPN J OPHTHALMOL, V50, P195, DOI 10.1007/s10384-005-0319-4
   Soltys S. G., 2003, International Journal of Radiation Oncology Biology Physics, V57, pS202, DOI 10.1016/S0360-3016(03)01006-X
   STOLWIJK TR, 1994, ACTA OPHTHALMOL, V72, P357
   TASI PS, 2006, BR J OPHTHALMOL, V90, P372
   TAYLOR AW, 1994, J IMMUNOL, V153, P1080
   Taylor AW, 2003, INVEST OPHTH VIS SCI, V44, P2644, DOI 10.1167/iovs.02-1216
   TAYLOR AW, 1992, CURR EYE RES, V11, P1199, DOI 10.3109/02713689208999545
   Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511
   Tezel G, 1999, ARCH OPHTHALMOL-CHIC, V117, P917
   Toker E, 2004, BRIT J OPHTHALMOL, V88, P384, DOI 10.1136/bjo.2003.028340
   Tomosugi N, 2005, J PROTEOME RES, V4, P820, DOI 10.1021/pr0497576
   Toris CB, 1999, AM J OPHTHALMOL, V127, P407, DOI 10.1016/S0002-9394(98)00436-X
   van Kooij B, 2006, AM J OPHTHALMOL, V142, P192, DOI 10.1016/j.ajo.2006.02.052
   Vesaluoma M, 1998, EYE, V12, P886, DOI 10.1038/eye.1998.224
   Wakabayashi Y, 2006, RETINA-J RET VIT DIS, V26, P432, DOI 10.1097/00006982-200604000-00009
   Yamane K, 2003, MOL CELL PROTEOMICS, V2, P1177, DOI 10.1074/mcp.M300038-MCP200
   Yang JJ, 2001, INVEST OPHTH VIS SCI, V42, P1273
   YOSHIDA Y, 2006, BR J OPHTHALMOL
   Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746
   Zhou L, 2004, J PROTEOME RES, V3, P410, DOI 10.1021/pr034065n
   Zhou L, 2006, ANN ACAD MED SINGAP, V35, P400
NR 136
TC 59
Z9 62
U1 1
U2 20
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1862-8346
EI 1862-8354
J9 PROTEOM CLIN APPL
JI Proteom. Clin. Appl.
PD AUG
PY 2007
VL 1
IS 8
BP 876
EP 888
DI 10.1002/prca.200700105
PG 13
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 203VC
UT WOS:000249001100015
PM 21136741
DA 2022-11-30
ER

PT J
AU Sengupta, S
   Singh, A
   Leopold, HA
   Gulati, T
   Lakshminarayanan, V
AF Sengupta, Sourya
   Singh, Amitojdeep
   Leopold, Henry A.
   Gulati, Tanmay
   Lakshminarayanan, Vasudevan
TI Ophthalmic diagnosis using deep learning with fundus images - A critical
   review
SO ARTIFICIAL INTELLIGENCE IN MEDICINE
LA English
DT Review
DE Fundus photos; Deep learning; Ophthalmology; Image segmentation;
   Classification; Fundus image datasets; Retina
ID OPTIC-NERVE HEAD; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; VESSEL
   SEGMENTATION; EYE DISEASE; AUTOMATED PERIMETRY; GLAUCOMA ANALYSIS;
   LESION DETECTION; RETINAL IMAGES; NEURAL-NETWORK
AB An overview of the applications of deep learning for ophthalmic diagnosis using retinal fundus images is presented. We describe various retinal image datasets that can be used for deep learning purposes. Applications of deep learning for segmentation of optic disk, optic cup, blood vessels as well as detection of lesions are reviewed. Recent deep learning models for classification of diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy are also discussed. Important critical insights and future research directions are given.
C1 [Sengupta, Sourya; Singh, Amitojdeep; Leopold, Henry A.; Lakshminarayanan, Vasudevan] Univ Waterloo, Theoret & Expt Epistemol Lab, Sch Optometry & Vis Sci, Waterloo, ON, Canada.
   [Sengupta, Sourya; Singh, Amitojdeep; Leopold, Henry A.; Lakshminarayanan, Vasudevan] Univ Waterloo, Dept Syst Design Engn, Waterloo, ON, Canada.
   [Gulati, Tanmay] Manipal Inst Technol, Dept Comp Sci & Engn, Manipal, India.
C3 University of Waterloo; University of Waterloo; Manipal Academy of
   Higher Education (MAHE)
RP Sengupta, S (通讯作者)，Univ Waterloo, Theoret & Expt Epistemol Lab, Sch Optometry & Vis Sci, Waterloo, ON, Canada.
EM s28sengu@uwaterloo.ca
FU NSERC, Canada
FX This research was supported by a Discovery Grant from NSERC, Canada to
   Vasudevan Lakshminarayanan.
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Al-Bander B, 2018, BIOMED SIGNAL PROCES, V40, P91, DOI 10.1016/j.bspc.2017.09.008
   Almazroa A, 2018, PROC SPIE, V10579, DOI 10.1117/12.2293584
   Annunziata R, 2016, IEEE T MED IMAGING, V35, P2381, DOI 10.1109/TMI.2016.2570123
   Antal B, 2014, KNOWL-BASED SYST, V60, P20, DOI 10.1016/j.knosys.2013.12.023
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Badar M, 2018, COMM COM INF SC, V894, P313, DOI 10.1007/978-3-319-95921-4_29
   Bengio Y., 2009, P 26 ANN INT C MACHI, P41, DOI DOI 10.1145/1553374.1553380
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Budai A, 2013, INT J BIOMED IMAGING, V2013, DOI 10.1155/2013/154860
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Carmona EJ, 2008, ARTIF INTELL MED, V43, P243, DOI 10.1016/j.artmed.2008.04.005
   Chai YD, 2018, KNOWL-BASED SYST, V161, P147, DOI 10.1016/j.knosys.2018.07.043
   Chakravarty A., 2018, DEEP LEARNING BASED
   Chan GCY, 2017, IEEE I C SIGNAL IMAG, P493, DOI 10.1109/ICSIPA.2017.8120662
   Chen X, 2015, 16TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION (INTERSPEECH 2015), VOLS 1-5, P3511
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   Chudzik Piotr, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P770, DOI 10.1109/EMBC.2018.8512354
   Chudzik Piotr, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P5934, DOI 10.1109/EMBC.2018.8513604
   Cirelan D, 2012, ARXIV2022745
   Ciresan D., 2012, ADV NEURAL INFORM PR, P2843
   Ciresan DC, 2013, LECT NOTES COMPUT SC, V8150, P411, DOI 10.1007/978-3-642-40763-5_51
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Colas E., 2016, ACTA OPHTHALMOL, V94
   Costa P., 2017, ARXIV170108974
   Costagliola C, 2009, EXPERT OPIN PHARMACO, V10, P2663, DOI 10.1517/14656560903300103
   Decenciere E, 2013, IRBM, V34, P196, DOI 10.1016/j.irbm.2013.01.010
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Diaz-Pinto A, 2019, IEEE T MED IMAGING, V38, P2211, DOI 10.1109/TMI.2019.2903434
   Edupuganti VG, 2018, IEEE IMAGE PROC, P2227, DOI 10.1109/ICIP.2018.8451753
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu Huazhu, 2018, IEEE Trans Med Imaging, V37, P2493, DOI 10.1109/TMI.2018.2837012
   Fu HZ, 2016, I S BIOMED IMAGING, P698, DOI 10.1109/ISBI.2016.7493362
   Fumero F., 2011, 2011 24 INT S COMP B, P1, DOI [DOI 10.1109/CBMS.2011.5999143, 10.1109/CBMS.2011.5999143]
   Gajbhiye GO, 2015, ANNU IEEE IND CONF
   Garcia G, 2017, LECT NOTES COMPUT SC, V10614, P635, DOI 10.1007/978-3-319-68612-7_72
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Ghassabi Zeinab, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P5942, DOI 10.1109/EMBC.2018.8513573
   GOLDBAUM MH, 1994, INVEST OPHTH VIS SCI, V35, P3362
   Goodfellow I, 2016, ADAPT COMPUT MACH LE, P1
   Govindaiah Arun, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P702, DOI 10.1109/EMBC.2018.8512379
   Govindaiah A, 2018, I S BIOMED IMAGING, P1525, DOI 10.1109/ISBI.2018.8363863
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Guo YM, 2016, NEUROCOMPUTING, V187, P27, DOI 10.1016/j.neucom.2015.09.116
   Haloi M, 2015, ARXIV PREPRINT ARXIV
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Hogarty DT, 2019, CLIN EXP OPHTHALMOL, V47, P128, DOI 10.1111/ceo.13381
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Horta A, 2017, 2017 16TH IEEE INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS (ICMLA), P716, DOI 10.1109/ICMLA.2017.00-75
   Hou K, 2017, IEEE SYM PARA DISTR, P713, DOI 10.1109/IPDPSW.2017.155
   Huazhu Fu, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P132, DOI 10.1007/978-3-319-46723-8_16
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javanmardi M, 2018, I S BIOMED IMAGING, P554, DOI 10.1109/ISBI.2018.8363637
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Kauppi T, 2007, DIARETDB1 STANDARD D
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khojasteh P, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P5938, DOI 10.1109/EMBC.2018.8513606
   Kingma J., 2014, ARXIV
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443
   Lam C, 2018, INVEST OPHTH VIS SCI, V59, P590, DOI 10.1167/iovs.17-22721
   Leopold HA, 2017, P SPIE MED IMAGING, V10133, P101
   Leopold HA, 2018, DEEP LEARNING METHOD, P329, DOI DOI 10.1201/9781351061223
   Leopold HA, 2019, J IMAGING, V5, DOI 10.3390/jimaging5020026
   Lepetit-Aimon G, 2018, LECT NOTES COMPUT SC, V11039, P201, DOI 10.1007/978-3-030-00949-6_24
   Lim G, 2015, PROC INT C TOOLS ART, P162, DOI 10.1109/ICTAI.2015.36
   Lin GM, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2159702
   Liskowski P, 2016, IEEE T MED IMAGING, V35, P2369, DOI 10.1109/TMI.2016.2546227
   Liu SD, 2018, OPHTHALMOL GLAUCOMA, V1, P15, DOI 10.1016/j.ogla.2018.04.002
   Liu ZF, 2018, J MED IMAG HEALTH IN, V8, P1300, DOI 10.1166/jmihi.2018.2429
   Lowell J, 2004, IEEE T MED IMAGING, V23, P256, DOI 10.1109/TMI.2003.823261
   Maji D, 2016, ARXIV1603
   Maji D, 2015, IEEE ENG MED BIO, P3029, DOI 10.1109/EMBC.2015.7319030
   Maninis Kevis-Kokitsi, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P140, DOI 10.1007/978-3-319-46723-8_17
   Matsuba S, 2019, INT OPHTHALMOL, V39, P1269, DOI 10.1007/s10792-018-0940-0
   Melineeak M, 2015, P VISAPP 10 INT C CO, V1
   Mitra A, 2018, COMPUT METH PROG BIO, V165, P25, DOI 10.1016/j.cmpb.2018.08.003
   Mo J, 2018, NEUROCOMPUTING, V290, P161, DOI 10.1016/j.neucom.2018.02.035
   Ng A, 2011, LECT NOTES STANFORD, V72, P1
   Nicolela MT., 2016, PEARLS GLAUCOMA MANA, P17
   Niemeijer M, 2010, IEEE T MED IMAGING, V29, P185, DOI 10.1109/TMI.2009.2033909
   Oliveira A, 2018, EXPERT SYST APPL, V112, P229, DOI 10.1016/j.eswa.2018.06.034
   Orlando JI, 2018, COMPUT METH PROG BIO, V153, P115, DOI 10.1016/j.cmpb.2017.10.017
   Owen CG, 2009, INVEST OPHTH VIS SCI, V50, P2004, DOI 10.1167/iovs.08-3018
   Pal A, 2018, IEEE IMAGE PROC, P2775, DOI 10.1109/ICIP.2018.8451029
   Perdomo O, 2018, LECT NOTES COMPUT SC, V11039, P319, DOI 10.1007/978-3-030-00949-6_38
   Quellec G, 2017, MED IMAGE ANAL, V39, P178, DOI 10.1016/j.media.2017.04.012
   Rahimy E, 2018, CURR OPIN OPHTHALMOL, V29, P254, DOI 10.1097/ICU.0000000000000470
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roychowdhury S, 2014, IEEE J BIOMED HEALTH, V18, P1717, DOI 10.1109/JBHI.2013.2294635
   Salamat N, 2019, ARTIF INTELL MED, V97, P168, DOI 10.1016/j.artmed.2018.10.009
   Sevastopolsky A., 2017, Pattern Recognition and Image Analysis, V27, P618, DOI 10.1134/S1054661817030269
   Severns ML, 1993, VISUAL OPTICS NONINV, V3, P34
   Shan J, 2016, 2016 IEEE FIRST INTERNATIONAL CONFERENCE ON CONNECTED HEALTH: APPLICATIONS, SYSTEMS AND ENGINEERING TECHNOLOGIES (CHASE), P357, DOI 10.1109/CHASE.2016.12
   Singh A, 2019, PROC SPIE, V11139, DOI 10.1117/12.2529429
   Sivaprasad S, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-458
   Sivaswamy J, 2014, I S BIOMED IMAGING, P53, DOI 10.1109/ISBI.2014.6867807
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   Son J, 2018, LECT NOTES COMPUTER, V11039
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Sun Xu, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P5954, DOI 10.1109/EMBC.2018.8513592
   Takahashi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179790
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Tan JH, 2017, INFORM SCIENCES, V420, P66, DOI 10.1016/j.ins.2017.08.050
   Teikari P, 2018, ARXIV181005874
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
   Wang M, 2018, NEUROCOMPUTING, V312, P135, DOI 10.1016/j.neucom.2018.05.083
   Whitcher JP, 2001, B WORLD HEALTH ORGAN, V79, P214
   Xu J, 2016, IEEE T MED IMAGING, V35, P119, DOI 10.1109/TMI.2015.2458702
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
   Zhang YS, 2018, LECT NOTES COMPUT SC, V11071, P83, DOI 10.1007/978-3-030-00934-2_10
   Zhang Z, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-80
   Zhang Z, 2013, C IND ELECT APPL, P228
   Zhang Z, 2010, IEEE ENG MED BIO, P3065, DOI 10.1109/IEMBS.2010.5626137
   Zheng YF, 2013, INVEST OPHTH VIS SCI, V54, P2171, DOI 10.1167/iovs.12-11393
   Zhixi L, 2018, OPHTHALMOLOGY, V125
NR 119
TC 65
Z9 65
U1 10
U2 48
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0933-3657
EI 1873-2860
J9 ARTIF INTELL MED
JI Artif. Intell. Med.
PD JAN
PY 2020
VL 102
AR 101758
DI 10.1016/j.artmed.2019.101758
PG 13
WC Computer Science, Artificial Intelligence; Engineering, Biomedical;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA KM6NF
UT WOS:000514254100017
PM 31980096
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Coffey, PJ
   Girman, S
   Wang, SM
   Hetherington, L
   Keegan, DJ
   Adamson, P
   Greenwood, J
   Lund, RD
AF Coffey, PJ
   Girman, S
   Wang, SM
   Hetherington, L
   Keegan, DJ
   Adamson, P
   Greenwood, J
   Lund, RD
TI Long-term preservation of cortically dependent visual function in RCS
   rats by transplantation
SO NATURE NEUROSCIENCE
LA English
DT Article
ID PUPILLARY LIGHT REFLEX; DISCRIMINATION
AB Cell transplantation is one way of limiting the progress of retinal degeneration in animal models of blinding diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Here we transplanted a human retinal pigment epithelia] (RPE) cell line into the subretinal space of one such model, the Royal College of Surgeons (RCS) rat, and showed, using head tracking to moving stripes and pattern discrimination in conjunction with single-unit cortical physiology, that cortically mediated vision can be preserved with this treatment.
C1 Univ Utah, Moran Eye Ctr, Dept Ophthalmol, Salt Lake City, UT 84132 USA.
   Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England.
   Univ Coll, Inst Ophthalmol, London EC1V 9EL, England.
C3 Utah System of Higher Education; University of Utah; University of
   Sheffield; University of London; University College London
RP Lund, RD (通讯作者)，Univ Utah, Moran Eye Ctr, Dept Ophthalmol, Salt Lake City, UT 84132 USA.
OI Coffey, Peter/0000-0002-5427-2939; Greenwood, John/0000-0003-4496-2984
CR BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   COWEY A, 1979, EXP BRAIN RES, V35, P443
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   DELCERRO M, 1991, NEUROREPORT, V2, P529, DOI 10.1097/00001756-199109000-00008
   DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73
   Girman SV, 1999, J NEUROPHYSIOL, V82, P301, DOI 10.1152/jn.1999.82.1.301
   KANUGA N, IN PRESS INVEST OPHT
   LAVAIL MM, 1974, VISION RES, V14, P693, DOI 10.1016/0042-6989(74)90066-2
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Sauve Y, 2001, NEUROSCIENCE, V103, P51, DOI 10.1016/S0306-4522(00)00557-1
   TREJO LJ, 1982, VISION RES, V22, P1163, DOI 10.1016/0042-6989(82)90081-5
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
NR 13
TC 168
Z9 179
U1 1
U2 14
PU NATURE AMERICA INC
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1097-6256
J9 NAT NEUROSCI
JI Nat. Neurosci.
PD JAN
PY 2002
VL 5
IS 1
BP 53
EP 56
DI 10.1038/nn782
PG 4
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 507MG
UT WOS:000173031800015
PM 11753416
DA 2022-11-30
ER

PT J
AU Li, ZX
   Hu, YJ
   Atik, A
   Lu, L
   Hu, J
AF Li, Zhi-Xi
   Hu, Yi-Jun
   Atik, Alp
   Lu, Lin
   Hu, Jie
TI Long-term observation of vitrectomy without subretinal hemorrhage
   management for massive vitreous hemorrhage secondary to polypoidal
   choroidal vasculopathy
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; vitreous hemorrhage; vitrectomy;
   visual acuity
ID TISSUE-PLASMINOGEN-ACTIVATOR; SUBMACULAR HEMORRHAGE; MACULAR
   DEGENERATION; OUTCOMES
AB AIM: To describe the long-term observation of vitrectomy without subretinal hemorrhage (SRH) management for massive vitreous hemorrhage (VH) secondary to polypoidal choroidal vasculopathy (PCV).
   METHODS: This is a retrospective, consecutive case series. A total of 86 eyes of 86 patients with >14d of massive VH associated with PCV were included. All patients underwent vitrectomy without SRH management, followed by intravitreal ranibizumab injections and/or photodynamic therapy (PDT) as needed. The main outcome measures were best-corrected visual acuity (BCVA), postoperative adverse events and the recurrence of VH.
   RESULTS: The average follow-up period was 25.5 +/- 9.2mo (range 12-35mo). Mean BCVA at baseline (2.16 +/- 0.39 logMAR) had improved significantly, both 3mo after surgery (1.42 +/- 0.66 logMAR, P< 0.001) and by the last visit (1.23 +/- 0.74 logMAR, P<0.001). The common postoperative complications included macular subretinal fibrosis in 14 eyes (16.3%) and ciliary body detachment in 4 eyes (4.7%). Nineteen eyes (22.1%) received following treatment with ranibizumab injections without/with PDT, and 15 (17.4%) were resolved. Four eyes (4.7%) had recurrent hemorrhage during the follow-up period. In multiple regression analysis, thicker SRH (beta=0.33, P=0.025) in the preoperative B-scan and the presence of foveal subretinal fibrosis (beta=0.28, P= 0.018) in the follow up were associated with poor postoperative BCVA.
   CONCLUSION: Vitrectomy without SRH management for massive VH secondary to PCV improved/stabilized visual function in the long-term observation. Eyes presenting with thicker SRH preoperatively and forming foveal subretinal fibrosis in the follow-up period tended to have worse BCVA.
C1 [Li, Zhi-Xi; Lu, Lin; Hu, Jie] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Hu, Yi-Jun] Cent S Univ, Aier Sch Ophthalmol, Changsha 410000, Hunan, Peoples R China.
   [Atik, Alp] Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3000, Australia.
C3 Sun Yat Sen University; Central South University; Royal Victorian Eye &
   Ear Hospital
RP Hu, J (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM hehujie@126.com
RI Hu, Yijun/J-4044-2016
OI Hu, Yijun/0000-0002-6424-7905
FU National Natural Science Foundation of China [81271009]; Science and
   Technology Planning Project of Guangdong Province, China
   [2017A030303016]
FX Foundations: Supported by the National Natural Science Foundation of
   China (No. 81271009); the Science and Technology Planning Project of
   Guangdong Province, China (No.2017A030303016).
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Choi YJ, 2013, RETINA-J RET VIT DIS, V33, P1365, DOI 10.1097/IAE.0b013e31827b640c
   COLL GE, 1995, RETINA-J RET VIT DIS, V15, P319, DOI 10.1097/00006982-199515040-00009
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   JOHNSON MW, 1992, OPHTHALMOLOGY, V99, P515
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lin HC, 2014, EYE, V28, P797, DOI 10.1038/eye.2014.124
   Lincoff H, 2003, ARCH OPHTHALMOL-CHIC, V121, P91
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Narayanan Raja, 2015, Int J Retina Vitreous, V1, P25, DOI 10.1186/s40942-015-0025-4
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Shin YI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28938-1
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Tao JW, 2019, CURR EYE RES, V44, P219, DOI 10.1080/02713683.2018.1533982
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 27
TC 2
Z9 3
U1 3
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2019
VL 12
IS 12
BP 1859
EP 1864
DI 10.18240/ijo.2019.12.07
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JV3KC
UT WOS:000502264100007
PM 31850169
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Choi, S
   Kang, HM
   Koh, HJ
AF Choi, Seonghee
   Kang, Hae Min
   Koh, Hyoung Jun
TI Clinical characteristics of super stable polypoidal choroidal
   vasculopathy after initial remission with anti-VEGF monotherapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; Polypoidal choroidal
   vasculopathy
ID INTRAVITREAL RANIBIZUMAB INJECTIONS; MACULAR DEGENERATION;
   QUANTITATIVE-ANALYSIS; AFLIBERCEPT TREATMENT; PHOTODYNAMIC THERAPY;
   NEOVASCULARIZATION; RECURRENCE; ANGIOGRAPHY; THICKNESS; REGIMEN
AB Purpose To define a "super stable" subset of polypoidal choroidal vasculopathy (PCV) patients that have a long period of remission following anti-vascular endothelial growth factor (VEGF) therapy.
   Methods Twenty-one eyes that showed no recurrence for over 18 months following anti-VEGF monotherapy were included in the "super stable PCV group" and compared with 37 eyes with recurring disease. Patient demographics, visual acuity, and imaging data from optical coherence tomography (OCT) and fluorescein angiography/indocyanine green angiography were compared between the two groups at baseline and at 3 months after treatment initiation.
   Results The super stable group maintained remission for a mean duration of 31.0 months following a mean of 4.1 anti-VEGF injections. The super stable group was younger at baseline (64.6 +/- 8.8 vs. 71.4 +/- 7.9 years, P < 0.05) with a higher ratio of females (52.4% vs. 24.3%, P < 0.05) compared with the control group. The super stable group had a higher percentage of eyes with a single polyp, as opposed to multiple polyps (66.7% vs. 32.4%, P < 0.05), and the diameter of the largest polyp was smaller (328.4 +/- 98.2 vs. 398.3 +/- 112.2 mu m, P < 0.05). Baseline choroidal thickness was greater in the super stable group (357 +/- 102.7 vs. 293.2 +/- 94.6 mu m, P < 0.05). At 3 months after treatment, OCT features including central retinal thickness, pigment epithelial detachment (PED) size, and presence of subretinal fluid showed superior response in the super stable group. The reduction in PED height was almost 3 times as large in the super stable group (- 250.1 +/- 228.5 mu m vs. - 84.4 +/- 221.1 mu m, P < 0.05). Binary logistic regression further showed that factors such as age, polyp configuration, PED diameter at 3 months, and change in PED height at 3 months were associated with super stable remission.
   Conclusion Identifying super stable PCV patients can prevent overtreatment and lessen treatment burden.
C1 [Choi, Seonghee; Koh, Hyoung Jun] Yonsei Univ, Inst Vis Res, Severance Hosp, Dept Ophthalmol,Coll Med, Seoul, South Korea.
   [Kang, Hae Min] Catholic Kwandong Univ, Int St Marys Hosp, Dept Ophthalmol, Coll Med, Incheon, South Korea.
C3 Yonsei University; Yonsei University Health System; Catholic Kwandong
   University
RP Koh, HJ (通讯作者)，Yonsei Univ, Inst Vis Res, Severance Hosp, Dept Ophthalmol,Coll Med, Seoul, South Korea.
EM HJKOH@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fliney GD, 2017, J OCUL PHARMACOL TH, V33, P604, DOI 10.1089/jop.2017.0013
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kang HM, 2016, GRAEF ARCH CLIN EXP, V254, P1519, DOI 10.1007/s00417-015-3241-6
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nagai N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47738-9
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Wakazono T, 2017, RETINA-J RET VIT DIS, V37, P2062, DOI 10.1097/IAE.0000000000001451
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
NR 32
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2021
VL 259
IS 4
BP 837
EP 846
DI 10.1007/s00417-020-04924-0
EA NOV 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RH0XW
UT WOS:000593446800004
PM 33245428
DA 2022-11-30
ER

PT J
AU Russo, A
   Costagliola, C
   Delcassi, L
   Parmeggiani, F
   Romano, MR
   dell'Omo, R
   Semeraro, F
AF Russo, Andrea
   Costagliola, Ciro
   Delcassi, Luisa
   Parmeggiani, Francesco
   Romano, Mario R.
   dell'Omo, Roberto
   Semeraro, Francesco
TI Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID KETOROLAC TROMETHAMINE 0.5-PERCENT; ENDOTHELIAL GROWTH-FACTOR; SELECTIVE
   CYCLOOXYGENASE-2 INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; INDUCED OCULAR
   INFLAMMATION; EARLY DIABETIC-RETINOPATHY; FACTOR-H POLYMORPHISM;
   OPHTHALMIC SOLUTION; CATARACT-SURGERY; CHOROIDAL NEOVASCULARIZATION
AB Nonsteroidal anti-inflammatory drugs (NSAIDs) are nowadays widely used in ophthalmology to reduce eye inflammation, pain, and cystoid macular edema associated with cataract surgery. Recently, new topical NSAIDs have been approved for topical ophthalmic use, allowing for greater drug penetration into the vitreous. Hence, new therapeutic effects can be achieved, such as reduction of exudation secondary to age-related macular degeneration or diabetic maculopathy. We provide an updated review on the clinical use of NSAIDs for retinal diseases, with a focus on the potential future applications.
C1 [Russo, Andrea; Delcassi, Luisa; Semeraro, Francesco] Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, I-25123 Brescia, Italy.
   [Costagliola, Ciro; dell'Omo, Roberto] Univ Molise, Dept Hlth Sci, Eye Clin, I-86100 Campobasso, Italy.
   [Parmeggiani, Francesco] Univ Ferrara, Dept Ophthalmol, I-44121 Ferrara, Italy.
   [Romano, Mario R.] Ist Clin Humanitas, Eye Clin, I-20089 Milan, Italy.
C3 University of Brescia; University of Molise; University of Ferrara;
   IRCCS Humanitas Research Hospital
RP Russo, A (通讯作者)，Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, Piazzale Spedale Civili 1, I-25123 Brescia, Italy.
EM dott.andrea.russo@gmail.com
RI Costagliola, Ciro/G-5707-2012; dell'Omo, Roberto/K-7328-2016; Semeraro,
   Francesco fs/K-8667-2016; Russo, Andrea/K-8550-2016
OI Costagliola, Ciro/0000-0001-8477-6188; dell'Omo,
   Roberto/0000-0002-7663-8874; Semeraro, Francesco fs/0000-0002-2275-4917;
   Russo, Andrea/0000-0002-1566-3662
CR Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   Reis ADA, 2010, ARQ BRAS OFTALMOL, V73, P338, DOI 10.1590/S0004-27492010000400007
   Ahuja M, 2008, AAPS J, V10, P229, DOI 10.1208/s12248-008-9024-9
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Almeida DRP, 2012, J CATARACT REFR SURG, V38, P1537, DOI 10.1016/j.jcrs.2012.04.034
   [Anonymous], 1991, Ophthalmology, V98, P757
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   BAUDOIN C, 1989, DIABETES, V38, P491
   BLAYDES JE, 1993, J CATARACT REFR SURG, V19, P481, DOI 10.1016/S0886-3350(13)80611-6
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Botting RM, 2010, PHARMACOL REP, V62, P518, DOI 10.1016/S1734-1140(10)70308-X
   Bressler SB, 2013, JAMA OPHTHALMOL, V131, P1033, DOI 10.1001/jamaophthalmol.2013.4154
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bucci FA, 2007, AM J OPHTHALMOL, V144, P146, DOI 10.1016/j.ajo.2007.02.034
   Bucci FA, 2011, ADV THER, V28, P1089, DOI 10.1007/s12325-011-0080-7
   Bucci FA, 2011, CURR MED RES OPIN, V27, P2235, DOI 10.1185/03007995.2011.626018
   BURNETT J, 1983, OPHTHALMIC SURG LAS, V14, P150
   Callanan D, 2008, CLIN OPHTHALMOL, V2, P689
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1249, DOI 10.2147/OPTH.S14092
   Chew Emily Y, 2010, Retina, V30, P459, DOI 10.1097/IAE.0b013e3181bcf1a0
   Chin MS, 2001, INVEST OPHTH VIS SCI, V42, P2338
   Costagliola C, 2005, EXP EYE RES, V81, P610, DOI 10.1016/j.exer.2005.03.020
   Costagliola C, 2008, CURR EYE RES, V33, P477, DOI 10.1080/02713680802100845
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Davies NM, 2004, J PHARM PHARM SCI, V7, P217
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   DEUTSCH TA, 1979, AM J OPHTHALMOL, V87, P536, DOI 10.1016/0002-9394(79)90245-9
   Donnenfeld ED, 2007, OPHTHALMOLOGY, V114, P1653, DOI 10.1016/j.ophtha.2006.12.029
   Du YP, 2004, AM J PHYSIOL-REG I, V287, pR735, DOI 10.1152/ajpregu.00080.2003
   Duong HVQ, 2007, J CATARACT REFR SURG, V33, P1925, DOI 10.1016/j.jcrs.2007.07.017
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elbendary AM, 2011, RETINA-J RET VIT DIS, V31, P2058, DOI 10.1097/IAE.0b013e31822a042a
   ELLIS PP, 1994, J OCUL PHARMACOL, V10, P677, DOI 10.1089/jop.1994.10.677
   Ersoy L, 2013, BRIT J OPHTHALMOL, V97, P862, DOI 10.1136/bjophthalmol-2012-302995
   Flach A J, 1998, Trans Am Ophthalmol Soc, V96, P557
   FLACH AJ, 1987, AM J OPHTHALMOL, V103, P479, DOI 10.1016/S0002-9394(14)74268-0
   FLACH AJ, 1990, OPHTHALMOLOGY, V97, P1253
   FLACH AJ, 1992, SURV OPHTHALMOL, V36, P259, DOI 10.1016/0039-6257(92)90095-B
   FLACH AJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P480
   FLACH AJ, 1991, AM J OPHTHALMOL, V112, P514, DOI 10.1016/S0002-9394(14)76851-5
   Flach Allan Joseph, 2002, International Ophthalmology Clinics, V42, P1
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Gallenga PE, 1997, J CATARACT REFR SURG, V23, P1183
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta Monika, 1997, Indian Journal of Experimental Biology, V35, P844
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hariprasad SM, 2009, CLIN OPHTHALMOL, V3, P147
   Hattori Y, 2007, CURR MED RES OPIN, V23, P1913, DOI 10.1185/030079907X218770
   Heier J, 1999, AM J OPHTHALMOL, V127, P253, DOI 10.1016/S0002-9394(98)00413-9
   Heier JS, 2009, RETINA-J RET VIT DIS, V29, P1310, DOI 10.1097/IAE.0b013e3181b094e6
   Heier JS, 2000, OPHTHALMOLOGY, V107, P2034, DOI 10.1016/S0161-6420(00)00365-1
   Hirneiss C, 2005, GRAEF ARCH CLIN EXP, V243, P768, DOI 10.1007/s00417-005-1126-9
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   Johnson EIM, 1999, CURR EYE RES, V18, P79, DOI 10.1076/ceyr.18.2.79.5386
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Ke TL, 2000, INFLAMMATION, V24, P371, DOI 10.1023/A:1007001131987
   Kern TS, 2007, DIABETES, V56, P373, DOI 10.2337/db05-1621
   Kern TS, 2001, DIABETES, V50, P1636, DOI 10.2337/diabetes.50.7.1636
   Kim SJ, 2008, ARCH OPHTHALMOL-CHIC, V126, P1203, DOI 10.1001/archopht.126.9.1203
   Kim SJ, 2007, OPHTHALMOLOGY, V114, P881, DOI 10.1016/j.ophtha.2006.08.053
   Kim SJ, 2010, EXP EYE RES, V91, P537, DOI 10.1016/j.exer.2010.07.011
   Kim SJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P596, DOI 10.1001/archophthalmol.2010.69
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Kim SJ, 2009, CURR OPIN OPHTHALMOL, V20, P46, DOI 10.1097/ICU.0b013e3283199162
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knudsen ST, 2002, DIABETES CARE, V25, P2328, DOI 10.2337/diacare.25.12.2328
   KRAFF MC, 1982, OPHTHALMOLOGY, V89, P885
   KRAFF MC, 1994, J CATARACT REFR SURG, V20, P138, DOI 10.1016/S0886-3350(13)80153-8
   LANE LS, 1982, OPHTHALMOLOGY, V89, P763
   Lane SS, 2007, J CATARACT REFR SURG, V33, P53, DOI 10.1016/j.jcrs.2006.08.043
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Lobo CL, 2004, J CATARACT REFR SURG, V30, P752, DOI 10.1016/S0886-3350(03)00582-0
   Loewenstein A, 2010, DEV OPHTHALMOL, V47, P148, DOI 10.1159/000320078
   Maldonado RM, 2011, CURR EYE RES, V36, P768, DOI 10.3109/02713683.2011.585734
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   Missotten L, 2001, OPHTHALMOLOGICA, V215, P43, DOI 10.1159/000050825
   MIYAKE K, 1980, BRIT J OPHTHALMOL, V64, P324, DOI 10.1136/bjo.64.5.324
   Miyake K, 2002, SURV OPHTHALMOL, V47, pS203, DOI 10.1016/S0039-6257(02)00294-1
   Miyake K, 2000, JPN J OPHTHALMOL, V44, P58, DOI 10.1016/S0021-5155(99)00176-8
   Monnier Yan, 2005, Current Drug Targets - Inflammation and Allergy, V4, P31, DOI 10.2174/1568010053622975
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Needleman P, 1997, J RHEUMATOL, V24, P6
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   POWELL EDU, 1964, LANCET, V2, P17
   Quaranta L, 2013, SURV OPHTHALMOL, V58, P26, DOI 10.1016/j.survophthal.2012.05.003
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rossetti L, 1998, OPHTHALMOLOGY, V105, P397, DOI 10.1016/S0161-6420(98)93018-4
   Russo A, 2013, BRIT J OPHTHALMOL, V97, P1273, DOI 10.1136/bjophthalmol-2013-303417
   Sawaoka H, 1999, LAB INVEST, V79, P1469
   Schalnus R, 2003, OPHTHALMOLOGICA, V217, P89, DOI 10.1159/000068563
   Schoenberger SD, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/281981
   Schoenberger SD, 2012, INVEST OPHTH VIS SCI, V53, P5906, DOI 10.1167/iovs.12-10410
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Simone JN, 1999, J CATARACT REFR SURG, V25, P699, DOI 10.1016/S0886-3350(99)00023-1
   Sivaprasad S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004239.pub3
   Soheilian M, 2010, RETINA-J RET VIT DIS, V30, P509, DOI 10.1097/IAE.0b013e3181bdfa43
   Solomon KD, 2001, OPHTHALMOLOGY, V108, P331, DOI 10.1016/S0161-6420(00)00543-1
   SOLOMON LD, 1995, J CATARACT REFR SURG, V21, P73, DOI 10.1016/S0886-3350(13)80484-1
   Souza JP, 2006, AM J OPHTHALMOL, V142, P625, DOI 10.1016/j.ajo.2006.05.053
   Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626
   Suzuki M, 2012, EUR J OPHTHALMOL, V22, P495, DOI 10.5301/ejo.5000032
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V325, P461, DOI 10.1016/j.bbrc.2004.10.054
   Tasman W., 1991, DUANES FDN CLIN OPHT
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Ursell PG, 1999, J CATARACT REFR SURG, V25, P1492, DOI 10.1016/S0886-3350(99)00196-0
   Walters T, 2007, J CATARACT REFR SURG, V33, P1539, DOI 10.1016/j.jcrs.2007.05.015
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Warren KA, 2010, RETINA-J RET VIT DIS, V30, P260, DOI 10.1097/IAE.0b013e3181b8628e
   Waterbury LD, 2006, CURR MED RES OPIN, V22, P1133, DOI 10.1185/030079906X112471
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wittpenn JR, 2008, AM J OPHTHALMOL, V146, P554, DOI 10.1016/j.ajo.2008.04.036
   Yamada M, 1999, CURR EYE RES, V19, P300, DOI 10.1076/ceyr.19.4.300.5301
   Yanni SE, 2010, EXP EYE RES, V91, P34, DOI 10.1016/j.exer.2010.03.019
   Yanni SE, 2009, INVEST OPHTH VIS SCI, V50, P5479, DOI 10.1167/iovs.09-3652
   YANNUZZI LA, 1977, AM J OPHTHALMOL, V84, P517, DOI 10.1016/0002-9394(77)90444-5
   YANNUZZI LA, 1981, OPHTHALMOLOGY, V88, P947
   Yilmaz T, 2012, EYE, V26, P252, DOI 10.1038/eye.2011.296
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou JZ, 2012, CURR EYE RES, V37, P416, DOI 10.3109/02713683.2012.661114
   Zweifel SA, 2009, RETINA-J RET VIT DIS, V29, P1527, DOI 10.1097/IAE.0b013e3181b32f4c
NR 128
TC 36
Z9 36
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2013
VL 2013
AR 476525
DI 10.1155/2013/476525
PG 11
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 246HO
UT WOS:000326528900001
PM 24227908
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Moon, SW
   Kim, MS
   Kim, ES
   Yu, SY
   Kwak, HW
AF Moon, Sung Woon
   Kim, Moo Sang
   Kim, Eung Suk
   Yu, Seung-Young
   Kwak, Hyung-Woo
TI Photodynamic Therapy Combined with Intravitreal Injection of Vascular
   Endothelial Growth Factor Antibody for Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Vascular endothelial growth factor antibody; Polypoidal choroidal
   vasculopathy; Photodynamic therapy
ID EPITHELIUM-DERIVED FACTOR; MACULAR DEGENERATION; LASER PHOTOCOAGULATION;
   BEVACIZUMAB AVASTIN; VERTEPORFIN; NEOVASCULARIZATION; RANIBIZUMAB;
   EFFICACY
AB Background/Aims:To evaluate the efficacy of photodynamic therapy (PDT) combined with intravitreal injection of antivascular-endothelial-growth-factor (anti-VEGF) antibody in patients with polypoidal choroidal vasculopathy (PCV). Methods: Twenty-two eyes of 22 patients with PCV followed for 12 months after combination therapy with PDT and anti-VEGF were retrospectively reviewed. Patients received intravitreal anti-VEGF (1.25 mg bevacizumab or 0.5 mg ranibizumab) within 7 days after PDT. Retreatment with PDT and intravitreal anti-VEGF injections, or with intravitreal anti-VEGF alone, was performed when indicated. The main outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT). Results: Mean logMAR BCVA was 0.43 at baseline and 0.45, 0.36, 0.30 and 0.28 at 1, 3,6 and 12 months, respectively, after the initial combination therapy. Mean BCVA was significantly improved at 6 and 12 months after treatment (p < 0.05). Mean CFT was 269.4 mu m at baseline and 180.1, 136.7, 127.5 and 139.6 mu m at 1, 3, 6 and 12 months, respectively, after the initial combination therapy. CFT decreased significantly throughout the follow-up period. At 12 months, mean BCVA improved by 1.5 lines, and mean CFT decreased by 129.8 mu m. Polypoidal lesions disappeared in 7 of the 13 eyes in which indocyanine green angiography was performed at 12 months. No changes in the branching vascular network were observed in any of these 13 eyes. Patients were treated with PDT a mean of 1.3 times and injected with intravitreal anti-VEGF a mean of 3.4 times over the 12-month period. Conclusion: Combined PDT and intravitreal anti-VEGF may improve visual acuity and decrease CFT at 12 months. Large long-term prospective studies are needed to evaluate the efficacy and safety of combination therapy. Copyright (C) 2011 S. Karger AG, Basel
C1 [Moon, Sung Woon; Kim, Eung Suk; Yu, Seung-Young; Kwak, Hyung-Woo] Kyung Hee Univ, Med Ctr, Dept Ophthalmol, Coll Med, Seoul 130702, South Korea.
   [Kim, Moo Sang] Inje Univ, Seoul Paik Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Kyung Hee University; Inje University
RP Yu, SY (通讯作者)，Kyung Hee Univ, Med Ctr, Dept Ophthalmol, Coll Med, 1 Hoegi Dong, Seoul 130702, South Korea.
EM syyu@khu.ac.kr
FU Kyung Hee University [KHU-20081237]
FX This work was supported by a grant from Kyung Hee University in 2008
   (KHU-20081237).
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   KWOK AK, 2002, BR J OPHTHALMOL, V133, P639
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vedantham V, 2005, EYE, V19, P915, DOI 10.1038/sj.eye.6701666
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 33
TC 9
Z9 11
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 3
BP 169
EP 175
DI 10.1159/000323811
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 739CU
UT WOS:000288691000007
PM 21273795
DA 2022-11-30
ER

PT J
AU Falavarjani, KG
   Nguyen, QD
AF Falavarjani, K. Ghasemi
   Nguyen, Q. D.
TI Adverse events and complications associated with intravitreal injection
   of anti-VEGF agents: a review of literature
SO EYE
LA English
DT Article
DE intravitreal injection; anti-vascular endothelial growth factor;
   bevacizumab; ranibizumab; aflibercept; safety
ID PIGMENT EPITHELIAL TEARS; ISCHEMIC OPTIC NEUROPATHY; BEVACIZUMAB
   AVASTIN; INTRAOCULAR-PRESSURE; RANIBIZUMAB LUCENTIS; RETINAL-DETACHMENT;
   HEMORRHAGIC COMPLICATIONS; COATS-DISEASE; SILICONE OIL; ENDOPHTHALMITIS
AB Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.
C1 [Falavarjani, K. Ghasemi] Univ Tehran Med Sci, Rassoul Akram Hosp, Eye Res Ctr, Dept Ophthalmol, Tehran 1445613131, Iran.
   [Nguyen, Q. D.] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA.
C3 Tehran University of Medical Sciences; University of Nebraska System;
   University of Nebraska Medical Center
RP Falavarjani, KG (通讯作者)，Univ Tehran Med Sci, Rassoul Akram Hosp, Eye Res Ctr, Dept Ophthalmol, Sattarkhan Niayesh St, Tehran 1445613131, Iran.
EM drghasemi@yahoo.com
RI Falavarjani, Khalil Ghasemi/I-4029-2019
OI Ghasemi Falavarjani, Khalil/0000-0001-5221-1844
FU Genentech, Inc.; Regeneron, Inc.; Abbott, Inc
FX The University of Nebraska Medical Center, the employer of QDN, has
   received research funding from Genentech, Inc., Regeneron, Inc., and
   Abbott, Inc,. QDN has served on the Steering Committee for clinical
   trials sponsored by Genentech, Inc. and Regeneron, Inc. QDN has served
   on the Scientific Advisory Boards for Santen, Inc. and Bausch and Lomb,
   Inc. KGF has no conflict of interest.
CR Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bohm MRR, 2011, GRAEF ARCH CLIN EXP, V249, P1099, DOI 10.1007/s00417-011-1629-5
   Brouzas D, 2009, CLIN OPHTHALMOL, V3, P457
   Cakmak HB, 2010, STRABISMUS, V18, P18, DOI 10.3109/09273970903567626
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Detorakis Efstathios T, 2012, Ophthalmic Surg Lasers Imaging, V43 Online, pe47, DOI 10.3928/15428877-20120517-03
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   Doshi RR, 2012, RETINA-J RET VIT DIS, V32, P473, DOI 10.1097/IAE.0B013E31822C2958
   Falavarjani KG, 2010, EYE, V24, P717, DOI 10.1038/eye.2009.94
   Falavarjani KG, 2013, RETINA-J RET VIT DIS, V33, P971, DOI 10.1097/IAE.0b013e31826f0675
   Falavarjani KG, 2010, IRAN J OPHTHALMOL, V22, P5
   Arevalo JF, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/584238
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Furino C, 2010, OPHTHAL SURG LAS IM, DOI [10.3928/15428877-20100215-57, DOI 10.3928/15428877-20100215-57]
   Ganssauge M, 2009, GRAEF ARCH CLIN EXP, V247, P1707, DOI 10.1007/s00417-009-1184-5
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Goel Neha, 2011, International Ophthalmology, V31, P183, DOI 10.1007/s10792-011-9436-x
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gower EW, 2011, ARVO M, V52, P6644
   Green-Simms AE, 2011, AM J OPHTHALMOL, V151, P329, DOI 10.1016/j.ajo.2010.08.039
   Higashide T, 2012, GRAEF ARCH CLIN EXP, V250, P603, DOI 10.1007/s00417-011-1865-8
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Honda S, 2008, GRAEF ARCH CLIN EXP, V246, P1061, DOI 10.1007/s00417-008-0786-7
   Hosseini H, 2009, J NEURO-OPHTHALMOL, V29, P160, DOI 10.1097/WNO.0b013e3181a58fd1
   Hu J, 2012, ARCH OPHTHALMOL-CHIC, V130, P1000, DOI 10.1001/archophthalmol.2012.592
   Huang ZL, 2010, OPHTHALMOLOGICA, V224, P86, DOI 10.1159/000235726
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Irigoyen C, 2012, GRAEF ARCH CLIN EXP, V250, P499, DOI 10.1007/s00417-011-1851-1
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Kumar A, 2012, GRAEF ARCH CLIN EXP, V250, P685, DOI 10.1007/s00417-011-1890-7
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lee BJ, 2012, EYE, V26, P903, DOI 10.1038/eye.2012.111
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Lin L, 2010, OPHTHAL SURG LAS IM, V41, P72, DOI 10.3928/15428877-20091230-13
   Loukopoulos V, 2010, KLIN MONATSBL AUGENH, V227, P289, DOI 10.1055/s-0029-1245225
   Manousaridis K, 2012, BRIT J OPHTHALMOL, V96, P179, DOI 10.1136/bjophthalmol-2011-301087
   Mansour AM, 2010, ACTA OPHTHALMOL, V88, P730, DOI 10.1111/j.1755-3768.2009.01535.x
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Mason JO, 2010, RETINA-J RET VIT DIS, V30, P1386, DOI 10.1097/IAE.0b013e3181e09739
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Mezad-Koursh D, 2010, RETINA-J RET VIT DIS, V30, P1051, DOI 10.1097/IAE.0b013e3181cd47ed
   Milder E, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.016
   Modarres M, 2009, EUR J OPHTHALMOL, V19, P848, DOI 10.1177/112067210901900526
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Nazari H, 2010, GRAEF ARCH CLIN EXP, V248, P1713, DOI 10.1007/s00417-010-1430-x
   Nicholson BP, 2010, GRAEF ARCH CLIN EXP, V248, P915, DOI 10.1007/s00417-010-1315-z
   Oshima Y, 2009, OPHTHALMOLOGY, V116, P927, DOI 10.1016/j.ophtha.2008.11.005
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quiroz-Mercado H, 2008, RETINA-J RET VIT DIS, V28, pS19, DOI 10.1097/IAE.0b013e318159ec6b
   Ramasubramanian A, 2012, BRIT J OPHTHALMOL, V96, P356, DOI 10.1136/bjophthalmol-2011-300141
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Shaikh Saad, 2007, Indian Journal of Ophthalmology, V55, P470
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   The Royal College of Ophthalmologists, 2011, STAT BEV AV US MED O
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   van der Reis MI, 2001, RETINA, V31, P1449
   von Hanno T, 2010, ACTA OPHTHALMOL, V88, P263, DOI 10.1111/j.1755-3768.2008.01406.x
   Wen JC, 2011, ARCH OPHTHALMOL-CHIC, V129, P1551, DOI 10.1001/archophthalmol.2011.227
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2010, NEW ENGL J MED, V363, P2135, DOI 10.1056/NEJMcp1003934
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu WC, 2011, OPHTHALMOLOGY, V118, P176, DOI 10.1016/j.ophtha.2010.04.018
   Yeh PT, 2009, RETINA-J RET VIT DIS, V29, P768, DOI 10.1097/IAE.0b013e3181a3b7ef
   Yohendran J, 2010, MIDDLE EAST AFR J OP, V17, P281, DOI 10.4103/0974-9233.65497
   Yu CQ, 2012, CURR OPIN OPHTHALMOL, V23, P19, DOI 10.1097/ICU.0b013e32834cd5a9
NR 87
TC 459
Z9 472
U1 4
U2 72
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2013
VL 27
IS 7
BP 787
EP 794
DI 10.1038/eye.2013.107
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 181WN
UT WOS:000321700800001
PM 23722722
OA Bronze, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Modjtahedi, BS
   Maibach, H
   Park, S
AF Modjtahedi, Bobeck S.
   Maibach, Howard
   Park, Susanna
TI Multifocal bilateral choroidal neovascularization in a patient on
   ipilimumab for metastatic melanoma
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Age related macular degeneration; choroidal neovascularization; drug
   reaction; immunology; ipilimumab; melanoma; T cell
AB Choroidal neovascularization membrane (CNVM) is a significant cause of ocular morbidity. Immunologic mechanisms have been proposed in the development of these lesions in exudative age related macular degeneration. Here, we describe the case of an 81-year-old man receiving ipilimumab, an immune modulating drug that enhances T cell response, for metastatic melanoma who developed three simultaneous CNVM bilaterally. This is the first case of ipilimumab-associated CNVM as well as the first case of an immune modulating drug possibly causing CNVM to our knowledge.
C1 [Modjtahedi, Bobeck S.; Park, Susanna] Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Maibach, Howard] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California San Francisco
RP Park, S (通讯作者)，Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM susanna.park@ucdmc.ucdavis.edu
CR Borodic G, 2011, OPHTHAL PLAST RECONS, V27, pE87, DOI 10.1097/IOP.0b013e3181ef72a1
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Renouf DJ, 2012, J CLIN ONCOL, V30, P3277, DOI 10.1200/JCO.2011.41.5851
   Wong Ryan K, 2012, Retin Cases Brief Rep, V6, P423, DOI 10.1097/ICB.0b013e31824f7130
NR 5
TC 23
Z9 24
U1 0
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1556-9527
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PD OCT
PY 2013
VL 32
IS 4
BP 341
EP 343
DI 10.3109/15569527.2013.781618
PG 3
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA 206NA
UT WOS:000323527300016
PM 23713627
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Tan, CS
   Patalauskaite, R
   Margaron, P
   Lai, TYY
AF Cheung, Chui Ming Gemmy
   Tan, Colin S.
   Patalauskaite, Ramune
   Margaron, Philippe
   Lai, Timothy Y. Y.
TI RANIBIZUMAB WITH OR WITHOUT VERTEPORFIN PHOTODYNAMIC THERAPY FOR
   POLYPOIDAL CHOROIDAL VASCULOPATHY Predictors of Visual and Anatomical
   Response in the EVEREST II Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE predictors; biomarkers; OCT; polyp; age-related macular degeneration;
   imaging; response
ID VASCULAR HYPERPERMEABILITY; MACULAR DEGENERATION; THICKNESS
AB Purpose: To evaluate the demographic and imaging factors at baseline and Month 3 (M3) that predict visual or anatomical responses at Month 12 (M12) in the EVEREST-II study for polypoidal choroidal vasculopathy. Methods: Post-hoc analysis of 322 participants in the EVEREST-II study. Patient factors, best-corrected visual acuity (BCVA), treatment, and imaging parameters at baseline and M3 were evaluated with respect to outcomes at M12 using univariate and multivariable analysis. Results: Younger age (P < 0.001) and lower baseline BCVA (P < 0.001) were associated with higher BCVA gains at M12. Smaller baseline polypoidal lesion area was associated with higher BCVA gains at M12 only in the ranibizumab monotherapy arm (P = 0.008). Central subfield thickness at M3, area of branching vascular network at M3, BCVA at M3, and age were associated with change in BCVA from M3 at M12. Higher odds of fluid-free retina at M12 were associated with lower baseline central subfield thickness (P = 0.006), treatment with combination therapy (baseline and M3 models; P < 0.001), and absence of subretinal fluid at M3 (P < 0.001). Conclusion: Several imaging parameters at baseline and M3 can predict treatment outcome. The interaction between treatment arm and total polypoidal lesion area suggests this feature may assist selecting between initial ranibizumab monotherapy or combination therapy.
C1 [Cheung, Chui Ming Gemmy] Natl Univ Singapore, Singapore Natl Eye Ctr, Duke NUS Med Sch, Singapore Eye Res Inst, Singapore, Singapore.
   [Tan, Colin S.] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Dept Ophthalmol, Singapore, Singapore.
   [Patalauskaite, Ramune] Novartis Ireland Ltd, Dublin, Ireland.
   [Margaron, Philippe] Novartis Pharma AG, Basel, Switzerland.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
C3 National University of Singapore; Singapore National Eye Center; Tan
   Tock Seng Hospital; Novartis; Novartis; Chinese University of Hong Kong
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690
FU National Medical Research Council [NMRC/LCG/0042018]
FX C. M. G. Cheung is supported by National Medical Research Council (Open
   Fund Large Collaborative grant no: NMRC/LCG/0042018).
CR Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Hirakata T, 2016, CLIN OPHTHALMOL, V10, P969, DOI 10.2147/OPTH.S101596
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koh A., 2017, AS PAC VITR RET C DE
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Vaze A, 2018, RETINA-J RET VIT DIS, V38, P1954, DOI 10.1097/IAE.0000000000001815
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
NR 14
TC 3
Z9 3
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2021
VL 41
IS 2
BP 387
EP 392
DI 10.1097/IAE.0000000000002902
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL0VU
UT WOS:000656635200033
PM 33475271
DA 2022-11-30
ER

PT J
AU Wang, J
   Wang, Y
   Li, QM
AF Wang, Jing
   Wang, Yuan
   Li, Qiuming
TI Synthesis of AuNPs using plant polyphenols and their potential treatment
   for age-related macular degeneration
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
ID GOLD NANOPARTICLES; GREEN SYNTHESIS; SILVER NANOPARTICLES; EXTRACT; SIZE
AB The primary idea behind this study is to synthesize Saudi Origanum vulgare L. extract mediated AuNPs and to investigate their efficacy in significantly treating AMD. The biocompatible AuNPs were tested for their radical scavenging efficiency in vitro. Also, The effects of AuNPs in suppressing the angiogenic protein expression and inflammatory cytokine levels were analyzed in ARPE-19 (human retinal pigment epithelium-19) as well as and human umbilical vein endothelium cell lines in vitro. From the ORAC findings, it was evident that the bio synthesized AuNPs have presented momentous anti-oxidative activity in reducing the apoptosis in H2O2 treated ARPE-19 cell lines. In addition, the biocompatible AuNPs exhibited significant potential in suppressing the LPS stimulated inflammatory reaction in ARPE-19 cell lines while demonstrating inhibitory expression of growth factor in ARPE-19 as well as in umbilical vein endothelium cell lines. The experimental findings in this study have suggested that the synthesized AuNPs are biocompatible with significant potential in defending against angiogenesis, apoptosis, and generation of pro-inflammatory cytokines in AMD disease.
C1 [Wang, Jing; Li, Qiuming] Zhengzhou Univ, Dept Ophthalmol, Affiliated Hosp 1, Zhengzhou 45000, Peoples R China.
   [Wang, Yuan] Zhengzhou Univ, Dept Ophthalmol, Zhengzhou Cent Hosp, Zhengzhou 45000, Peoples R China.
C3 Zhengzhou University; Zhengzhou University
RP Li, QM (通讯作者)，1 Jianshe Rd, Zhengzhou 45000, Henan, Peoples R China.
EM qiumingli1221@hotmail.com
RI Wang, Jing/AAR-9645-2021
OI Wang, Jing/0000-0001-8549-852X
CR Ahmed S, 2016, J ADV RES, V7, P17, DOI 10.1016/j.jare.2015.02.007
   Alili L, 2011, BIOMATERIALS, V32, P2918, DOI 10.1016/j.biomaterials.2010.12.056
   Aroma SA, 2012, SPECTROCHIM ACTA A, V85, P99, DOI 10.1016/j.saa.2011.09.035
   Chandran SP, 2006, BIOTECHNOL PROGR, V22, P577, DOI 10.1021/bp0501423
   Cubillana-Aguilera LM, 2011, ULTRASON SONOCHEM, V18, P789, DOI 10.1016/j.ultsonch.2010.10.009
   Deyev S, 2017, BIOCONJUGATE CHEM, V28, P2569, DOI 10.1021/acs.bioconjchem.7b00410
   Francis S, 2017, ENVIRON SCI POLLUT R, V24, P17347, DOI 10.1007/s11356-017-9329-2
   Gan PP, 2012, BIORESOURCE TECHNOL, V113, P132, DOI 10.1016/j.biortech.2012.01.015
   Grzelczak M, 2008, CHEM SOC REV, V37, P1783, DOI 10.1039/b711490g
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Khutale GV, 2017, EUR J PHARM BIOPHARM, V119, P372, DOI 10.1016/j.ejpb.2017.07.009
   Kumar A, 2014, ENVIRON SCI-NANO, V1, P516, DOI 10.1039/c4en00052h
   Kumar VKR, 2010, CHEM-ASIAN J, V5, P887, DOI 10.1002/asia.200900388
   Lee J, 2014, CANCER LETT, V347, P46, DOI 10.1016/j.canlet.2014.02.006
   Lee S, 2008, ANGEW CHEM INT EDIT, V47, P2804, DOI 10.1002/anie.200705240
   Lee SS, 2013, ACS NANO, V7, P9693, DOI 10.1021/nn4026806
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mafune F, 2002, J PHYS CHEM B, V106, P7575, DOI 10.1021/jp020577y
   Makarov VV, 2014, ACTA NATURAE, V6, P35, DOI 10.32607/20758251-2014-6-1-35-44
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Naik RR, 2002, NAT MATER, V1, P169, DOI 10.1038/nmat758
   Narayanan KB, 2008, MATER LETT, V62, P4588, DOI 10.1016/j.matlet.2008.08.044
   Okitsu K, 2001, LANGMUIR, V17, P7717, DOI 10.1021/la010414l
   Qian XM, 2008, NAT BIOTECHNOL, V26, P83, DOI 10.1038/nbt1377
   Sau TK, 2001, J NANOPART RES, V3, P257, DOI 10.1023/A:1017567225071
   Shankar SS, 2004, J COLLOID INTERF SCI, V275, P496, DOI 10.1016/j.jcis.2004.03.003
   Shankar SS, 2004, NAT MATER, V3, P482, DOI 10.1038/nmat1152
   Soshnikova V, 2018, ARTIF CELL NANOMED B, V46, P108, DOI 10.1080/21691401.2017.1296849
   Suganthy N, 2018, ENVIRON SCI POLLUT R, V25, P10418, DOI 10.1007/s11356-017-9789-4
   Suman TY, 2014, SPECTROCHIM ACTA A, V118, P11, DOI 10.1016/j.saa.2013.08.066
   Tolles WM, 1996, NANOTECHNOLOGY, V7, P59, DOI 10.1088/0957-4484/7/2/001
   Wang DD, 2017, ARTIF CELL NANOMED B, V45, P1548, DOI 10.1080/21691401.2016.1260580
   Yuan CG, 2017, IET NANOBIOTECHNOL, V11, P523, DOI 10.1049/iet-nbt.2016.0183
NR 35
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD FEB
PY 2020
VL 55
AR 101377
DI 10.1016/j.jddst.2019.101377
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KS5ZI
UT WOS:000518386500033
DA 2022-11-30
ER

PT J
AU Chang, P
   Tan, A
   Jaffe, GJ
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Chang, Petrus
   Tan, Anna
   Jaffe, Glenn J.
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
CA GAP Study Grp
TI Analysis of Peripapillary Atrophy in Relation to Macular Geographic
   Atrophy in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; fundus
   autofluorescence; scanning laser ophthalmoscopy
ID FUNDUS AUTOFLUORESCENCE PATTERNS; RETINAL-PIGMENT EPITHELIUM;
   RISK-FACTORS; PROGRESSION; POPULATION; SECONDARY; DISEASE
AB PURPOSE. The purpose of this study was to investigate the presence, configuration, and progression of peripapillary atrophy (PPA) relative to macular geographic atrophy (GA) in AMD.
   METHODS. Confocal scanning laser ophthalmoscopy images of 413 eyes of 413 patients with GA secondary to AMD (median age, 77.0 years) were evaluated for the presence and configuration of PPA at baseline. In addition, the progression of PPA and the regression of the shortest linear dimension between PPA and GA ("buffer zone'') were assessed in 164 eyes that had completed 12 months of follow-up.
   RESULTS. At baseline, PPA was present in 357 (86.4%) of 413 eyes, of which 330 eyes (79.9%) were classified as nonconfluent and 27 eyes (6.5%) as confluent PPA. At month 12, eight eyes had transformed from nonconfluent to confluent PPA. The median buffer zone at baseline was significantly smaller in these latter eyes than in eyes where the PPA remained nonconfluent (168.46 vs. 1451.64 mu m; P < 0.001). The mean regression rate of the buffer zone was 163.0 mu m/y (interquartile range, 77.2-281.3).
   CONCLUSIONS. Peripapillary atrophy is highly prevalent in eyes with GA due to AMD. Assessment of the buffer zone in eyes with nonconfluent PPA at baseline may be helpful to identify subjects at risk for the progression to confluent PPA. In future interventional clinical trials, it may be useful to exclude any eyes both with confluent PPA at baseline and at risk for development of confluent PPA over time to improve the accuracy of GA lesion size quantification and its enlargement over time.
C1 [Chang, Petrus; Tan, Anna; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Jaffe, Glenn J.] Duke Univ, Ctr Eye, Ophthalmol, Durham, NC USA.
C3 University of Bonn; Duke University
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
RI Sahel, Jose-Alain/F-3172-2017
OI Sahel, Jose-Alain/0000-0002-4831-1153; Fleckenstein,
   Monika/0000-0001-8321-8037; Russell, Stephen/0000-0003-3776-1367;
   Tufail, Adnan/0000-0001-6131-7640
FU Alcon Research Ltd.; Alcon Laboratories, Inc. (Fort Worth, TX, USA)
FX The GAP Study was sponsored by Alcon Research Ltd. The following Alcon
   Research Ltd. employees contributed to this study as Clinical Trial
   Managers: Alberta Davis, Petra Kozma-Wiebe, and Miguel Martinez.;
   Supported by Alcon Laboratories, Inc. (Fort Worth, TX, USA). The GAP
   Study was funded, designed, and conducted by the sponsor. The primary
   and secondary study objects are not the aim of the current publication
   and have been reported elsewhere. The data presented are additional
   analyses that were conducted without extra funding by the sponsor. The
   manuscript was reviewed and approved by the sponsor.
CR Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Brinkmann CK, 2010, OPHTHALMOLOGE, V107, P999, DOI 10.1007/s00347-010-2158-z
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGE, V107, P1016, DOI 10.1007/s00347-010-2160-5
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 22
TC 3
Z9 3
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 2277
EP 2282
DI 10.1167/iovs.15-18629
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL8XY
UT WOS:000375926700090
PM 27127925
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kindzelskii, AL
   Elner, VM
   Elner, SG
   Yang, DL
   Hughes, BA
   Petty, HR
AF Kindzelskii, AL
   Elner, VM
   Elner, SG
   Yang, DL
   Hughes, BA
   Petty, HR
TI Human, but not bovine, photoreceptor outer segments prime human retinal
   pigment epithelial cells for metabolic activation and massive oxidant
   release in response to lipopolysaccharide and interferon-gamma
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE oxidants; outer segments; RPE activation; pro-inflammatory conditions
ID OXIDATIVE STRESS; GENE-EXPRESSION; PHAGOCYTOSIS; MODEL
AB Reactive oxygen metabolites (ROMs) may contribute to several eye diseases, such as age-related macular degeneration, although the underlying mechanisms are unclear. The present study shows that human photoreceptor outer segments (POS) prime human retinal pigment epithelial (RPE) cells for massive ROM release in response to lipopolysaccharide (LPS) and interferon-gamma. However, no ROM priming of human RPE cells is observed for bovine POS. ROM production appears to be linked with underlying metabolic oscillations involving the hexose monophosphate shunt. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Petty, HR (通讯作者)，Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM hpetty@med.umich.edu
OI Hughes, Bret/0000-0002-6913-4467; Elner, Victor/0000-0001-7708-1898
FU NATIONAL EYE INSTITUTE [R01EY008850, R01EY009441] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   [R01AI051789] Funding Source: NIH RePORTER; NEI NIH HHS [EY07003, EY
   09441, EY08850] Funding Source: Medline; NIAID NIH HHS [AI51789] Funding
   Source: Medline
CR Adachi Y, 1999, J IMMUNOL, V163, P4367
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1047
   ELNER SG, 1991, LAB INVEST, V64, P819
   Elner VM, 1997, EXP EYE RES, V65, P781, DOI 10.1006/exer.1997.0380
   Elner VM, 2003, EXP EYE RES, V76, P321, DOI 10.1016/S0014-4835(02)00310-X
   Hollborn M, 2001, GRAEF ARCH CLIN EXP, V239, P294, DOI 10.1007/s004170100263
   Kindzelskii AL, 2002, J CLIN INVEST, V110, P1801, DOI 10.1172/JCI200215973
   Kindzelskii AL, 1998, BIOPHYS J, V74, P90, DOI 10.1016/S0006-3495(98)77770-7
   Kindzelskii AL, 2002, P NATL ACAD SCI USA, V99, P9207, DOI 10.1073/pnas.132630999
   Laskowski I, 2000, Ann Transplant, V5, P29
   Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8
   Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001
   MCLAREN MJ, 1993, INVEST OPHTH VIS SCI, V34, P317
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   MICELI MV, 1990, INVEST OPHTH VIS SCI, V31, P277
   Olsen LF, 2003, BIOPHYS J, V84, P69, DOI 10.1016/S0006-3495(03)74833-4
   OPHIR A, 1992, OPHTHALMIC SURG LAS, V23, P284
   Petty HR, 2001, IMMUNOL RES, V23, P85, DOI 10.1385/IR:23:1:85
   Rao N A, 1990, Trans Am Ophthalmol Soc, V88, P797
   ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Truscott RJW, 2000, OPHTHALMIC RES, V32, P185, DOI 10.1159/000055612
   Winkler BS, 1999, MOL VIS, V5
   Wu GS, 1999, INVEST OPHTH VIS SCI, V40, P831
NR 27
TC 5
Z9 5
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2004
VL 79
IS 3
BP 431
EP 435
DI 10.1016/j.exer.2004.06.005
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 855KZ
UT WOS:000223973400017
PM 15336507
DA 2022-11-30
ER

PT J
AU Heilig, P
   Rozanova, E
   Godnic-Cvar, J
AF Heilig, P.
   Rozanova, E.
   Godnic-Cvar, J.
TI Retinal light damage
SO SPEKTRUM DER AUGENHEILKUNDE
LA English
DT Review
DE Retinal light damage; age related macular degeneration (AMD);
   nanotoxicology; obstructive sleep apnoe (OSA)
ID AGE-RELATED MACULOPATHY; BLUE-LIGHT; MACULAR DEGENERATION; OPERATING
   MICROSCOPE; INTRAOCULAR-LENS; PHOTOCHEMICAL LESIONS;
   RETINITIS-PIGMENTOSA; OXYGEN DISTRIBUTION; OXIDATIVE STRESS;
   VISIBLE-LIGHT
AB Even moderate exposures of ambient light can impose a threat to human retina and the retinal pigment epithelium - under particular preconditions. Repetitive light-stress implicates reversible phototoxic damage thereby paving the way towards age related macular degeneration (AMD) via temporal summation. Aggravating and interacting prerequisites like genotype/complement factors, smoking, nanomaterials (NM) and obstructive sleep disorders (OSA) as well as other factors "reflective of nature and nurture" [97, 98] eventually impact on the severity of retinal light damage linked to possible formation and progression of AMD.
C1 [Heilig, P.] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Rozanova, E.] Private Hosp Rudolfinerhaus, Vienna, Austria.
   [Godnic-Cvar, J.] Med Univ Vienna, Dept Occupat Med, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Heilig, P (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM peter.heilig@univie.ac.at
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   BARCLAY L, 2008, MAYO CLIN P, V83, P1251
   Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9
   BAUMAL CR, 1998, RETINAL PIGMENT EPIT, P587
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   BOULTON ME, 2000, HUNTERS OCCUPATIONAL, P419
   Busch EM, 1999, VISION RES, V39, P1233, DOI 10.1016/S0042-6989(98)00233-8
   Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457
   Cideciyan AV, 2005, P NATL ACAD SCI USA, V102, P5233, DOI 10.1073/pnas.0408892102
   CROCKETT RS, 1984, CURR EYE RES, V3, P209, DOI 10.3109/02713688408997202
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruts B, 2008, PART FIBRE TOXICOL, V5, DOI 10.1186/1743-8977-5-4
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   DAVIDSON PC, 1993, AM J OPHTHALMOL, V116, P497, DOI 10.1016/S0002-9394(14)71411-4
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   DELINT PJ, 1992, INVEST OPHTH VIS SCI, V33, P2382
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DILLON J, 1991, J PHOTOCH PHOTOBIO B, V10, P23, DOI 10.1016/1011-1344(91)80209-Z
   DOREY CK, 1990, CURR EYE RES, V9, P549, DOI 10.3109/02713689008999595
   Egorov SY, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1117
   Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Foote C.S., 1981, OXYGEN OXY RADICALS, P425
   Frigg R, 2006, EXP EYE RES, V83, P1350, DOI 10.1016/j.exer.2006.07.010
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   GREEN WR, 1991, AM J OPHTHALMOL, V112, P520, DOI 10.1016/S0002-9394(14)76852-7
   Grimm C, 2000, INVEST OPHTH VIS SCI, V41, P3984
   Gu D, 2007, INVEST OPHTH VIS SCI, V48, P4907, DOI 10.1167/iovs.07-0428
   HAM WT, 1982, AM J OPHTHALMOL, V93, P299, DOI 10.1016/0002-9394(82)90529-3
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984
   HECKENLIVELY JR, 1991, ARCH OPHTHALMOL-CHIC, V109, P84, DOI 10.1001/archopht.1991.01080010086038
   HEILIG P, 1979, KLIN MONATSBL AUGENH, V174, P500
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   HOPEROSS MW, 1993, EYE, V7, P29, DOI 10.1038/eye.1993.7
   Jacobson SG, 2008, INVEST OPHTH VIS SCI, V49, P4573, DOI 10.1167/iovs.08-2121
   JAFFE GJ, 1988, OPHTHALMOLOGY, V95, P1130
   JAFFE GJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P445
   JENSEN OL, 1982, ACTA OPHTHALMOL, V60, P568
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kadyan A, 2009, BRIT J OPHTHALMOL, V93, P132
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Koenekoop RK, 2008, OPHTHALMIC GENET, V29, P89, DOI 10.1080/13816810802216480
   Komaromy AM, 2008, ARCH OPHTHALMOL-CHIC, V126, P714, DOI 10.1001/archopht.126.5.714
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366
   KREMERS JJ, 1989, INVEST OPHTH VIS SCI, P1032
   LAVAIL MM, 1987, EXP EYE RES, V44, P877, DOI 10.1016/S0014-4835(87)80050-7
   Lerman S, 1987, CLIN LIGHT DAMAGE EY, P183
   LESSEL M, 1991, DOC OPHTHALMOL, V76, P323, DOI 10.1007/BF00142670
   Li JG, 2008, J NANOSCI NANOTECHNO, V8, P3357, DOI 10.1166/jnn.2008.112
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   Maier R, 2005, INT ARCH OCC ENV HEA, V78, P681, DOI 10.1007/s00420-005-0013-3
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   MARSHALL J, 1985, OPHTHAL PHYSL OPT, V5, P241, DOI 10.1111/j.1475-1313.1985.tb00666.x
   MARSHALL J, 1991, VISION VISUAL DYSFUN, V16, P54
   Mellerio J., 1994, PRINCIPLES PRACTICE, V1, P1326
   MICHELS M, 1992, AM J OPHTHALMOL, V114, P287, DOI 10.1016/S0002-9394(14)71792-1
   MICHELS M, 1990, SURV OPHTHALMOL, V34, P237, DOI 10.1016/0039-6257(90)90025-Q
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1971, SCIENCE, V172, P76, DOI 10.1126/science.172.3978.76
   Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6
   ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5
   ORGANISCIAK DT, 1977, INVEST OPHTH VIS SCI, V16, P188
   Osborne NN, 2006, BRIT J OPHTHALMOL, V90, P237, DOI 10.1136/bjo.2005.082230
   PAUTLER EL, 1989, INHERITED ENV INDUCE, P555
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Pepe IM, 1999, J PHOTOCH PHOTOBIO B, V48, P1, DOI 10.1016/S1011-1344(99)00200-6
   Pitts DG, 1993, ENV VISION, P151
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   RAPP LM, 1992, INVEST OPHTH VIS SCI, V33, P3367
   Reeves JF, 2008, MUTAT RES-FUND MOL M, V640, P113, DOI 10.1016/j.mrfmmm.2007.12.010
   Reinhard J, 2007, VISION RES, V47, P2076, DOI 10.1016/j.visres.2007.04.012
   Reme CE, 1998, RETINAL PIGMENT EPIT, P563
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   RUFFOLO JJ, 1984, INVEST OPHTH VIS SCI, V25, P893
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Seddon JM, 2008, INVEST OPHTH VIS SCI, V50, P2044
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Simonet BM, 2009, ANAL BIOANAL CHEM, V393, P17, DOI 10.1007/s00216-008-2484-z
   Sliney D., 1980, SAFETY LASER OTHER O, P203
   SLINEY DH, 1991, SUSCEPTIBLE VISUAL A, V16, P20
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sorgato MC, 2009, BIOCHEM BIOPH RES CO, V379, P171, DOI 10.1016/j.bbrc.2008.12.026
   Souied EH, 2008, EXP EYE RES, V87, P168, DOI 10.1016/j.exer.2008.04.009
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SYKES SM, 1981, INVEST OPHTH VIS SCI, V20, P425
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   THALER A, 1971, VISION RES, V11, P1217, DOI 10.1016/0042-6989(71)90170-2
   THALER A, 1973, DOCUM OPHTHALMOL P 2, V11, P237
   TSO MOM, 1979, INVEST OPHTH VIS SCI, V18, P447
   TSO MOM, 1989, INVEST OPHTH VIS SCI, V30, P2430
   Tuntivanich N, 2009, INVEST OPHTH VIS SCI, V50, P801, DOI 10.1167/iovs.08-2562
   WERNER JS, 1989, OPHTHALMOLOGY, V96, P1552
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Win-Shwe TT, 2008, NEUROTOXICOLOGY, V29, P940, DOI 10.1016/j.neuro.2008.09.007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhou JL, 2008, PHOTOCHEM PHOTOBIOL, V84, P75, DOI 10.1111/j.1751-1097.2007.00205.x
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 122
TC 1
Z9 1
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-4282
EI 1613-7523
J9 SPEKTRUM AUGENHEILKD
JI Spektrum Augenheilkd.
PY 2009
VL 23
IS 4
BP 240
EP 248
DI 10.1007/s00717-009-0340-y
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 490FQ
UT WOS:000269484700003
DA 2022-11-30
ER

PT J
AU Grewal, PS
   Oloumi, F
   Rubin, U
   Tennant, MTS
AF Grewal, Parampal S.
   Oloumi, Faraz
   Rubin, Uriel
   Tennant, Matthew T. S.
TI Deep learning in ophthalmology: a review
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
AB Deep learning is an emerging technology with numerous potential applications in Ophthalmology. Deep learning tools have been applied to different diagnostic modalities including digital photographs, optical coherence tomography, and visual fields. These tools have demonstrated utility in assessment of various disease processes including cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy. Deep learning techniques are evolving rapidly, and will become more integrated into ophthalmic care. This article reviews the current evidence for deep learning in ophthalmology, and discusses future applications, as well as potential drawbacks.
C1 [Grewal, Parampal S.; Rubin, Uriel; Tennant, Matthew T. S.] Univ Alberta, Dept Ophthalmol & Visual Sci, Edmonton, AB, Canada.
   [Oloumi, Faraz] Aurteen Inc, Calgary, AB, Canada.
C3 University of Alberta
RP Tennant, MTS (通讯作者)，Alberta Retina Consultants, Suite 400,10924 107 Ave, Edmonton, AB, Canada.
EM mtennant@ualberta.ca
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, P5200
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Badrinarayanan V., DEEP CONVOLUTIONAL E
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   Devalla SK, 2018, INVEST OPHTH VIS SCI, V59, P63, DOI 10.1167/iovs.17-22617
   Duda R.O., 2006, PATTERN CLASSIFICATI
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Finally Knight W., MIT TECHNOLOGY REV
   FUKUSHIMA K, 1980, BIOL CYBERN, V36, P193, DOI 10.1007/BF00344251
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Giraffe Lai M., 2015, USING DEEP REINFORCE
   Gulshan V, 2016, JAMA-J AM MED ASSOC, P2202
   Lee A, 2017, OPHTHALMOLOGY, V17, P26
   Lee CS, 2017, BIOMED OPT EXPRESS, P530
   Liu X, 2018, PEER PEER NETW APPL, V11, P1038, DOI 10.1007/s12083-017-0565-5
   Marr B., FORBES
   Muhammad H., 2017, J GLAUCOMA
   Prentasic P, 2015, INT SYMP IMAGE SIG, P188, DOI 10.1109/ISPA.2015.7306056
   Rangayyan R. M., 2005, BIOMED EN S
   Roy AG, 2017, BIOMED OPT EXPRESS, P111
   Schlegl T, 2018, OPHTHALMOLOGY
   Shan J, 2016, IEEE 1 C CONN HLTH A, P357
   Simonyan K., 2015, INT C LEARN REPR ICL
   Szegedy C, 2015, CVPR, P1
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
NR 29
TC 58
Z9 59
U1 1
U2 27
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2018
VL 53
IS 4
BP 309
EP 313
DI 10.1016/j.jcjo.2018.04.019
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GQ3DR
UT WOS:000441541300018
PM 30119782
DA 2022-11-30
ER

PT J
AU Tan, CS
   Ngo, WK
   Lim, LW
   Tan, NW
   Lim, TH
AF Tan, Colin S.
   Ngo, Wei Kiong
   Lim, Louis W.
   Tan, Nikolle W.
   Lim, Tock H.
CA EVEREST Study Grp
TI EVEREST study report 3: diagnostic challenges of polypoidal choroidal
   vasculopathy. Lessons learnt from screening failures in the EVEREST
   study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE EVEREST study; Polypoidal choroidal vasculopathy; Indocyanine green
   angiography; non-PCV; Age-related macular degeneration
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; PIGMENT EPITHELIUM;
   RANIBIZUMAB; VERTEPORFIN; HEMORRHAGE; PATTERNS; FEATURES; LAPTOP; TRIAL
AB Purpose To describe screening failures in the EVEREST study by examining the imaging characteristics that enabled differentiation of polypoidal choroidal vasculopathy (PCV) from cases that were subsequently diagnosed not to be PCV.
   Methods Post-hoc analysis of 34 patients with PCV reported as screening failures from EVEREST study. Standardised con-focal scanning laser indocyanine green angiography (ICGA) images were graded by the Central Reading Centre to confirm PCV diagnosis based on the presence of early focal sub-retinal hyperfluorescence on ICGA and at least one of the following six diagnostic criteria: (1) nodular appearance of polyp(s) on stereoscopic examination, (2) hypofluorescent halo around nodule(s), (3) presence of a branching vascular network, (4) pulsation of polyp(s) on dynamic ICGA, (5) orange subretinal nodules on colour fundus photography, or (6) massive sub-macular haemorrhage (>= 4 disc areas in size). Additional detailed image grading was performed with stereo-imaging and dynamic early-phase ICGA.
   Results Of the 95 screened PCV cases, 34 were excluded: (1) cases not suitable for recruitment as per the study protocol (n = 14), (2) equivocal lesions on ICGA characterised by small hyperfluorescent dots (n=9), and (3) cases that were definitely not PCV (non-PCV, n = 11), identified by definitive diagnoses which included one case each of micro-aneurysm, retinal angiomatous proliferation, retino-choroidal anastomosis, small type-2 choroidal neovascularisation, retinal pigment epithelial (RPE) window defect and disciform scar; two cases of lesions where the choroidal vessel changed its course; and three cases of late-onset RPE staining.
   Conclusions Standardised image grading techniques used in EVEREST study enabled effective differentiation of non-PCV from actual PCV.
C1 [Tan, Colin S.; Tan, Nikolle W.; Lim, Tock H.] Fundus Image Reading Ctr, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Tan, Colin S.; Ngo, Wei Kiong; Lim, Louis W.; Tan, Nikolle W.; Lim, Tock H.] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
C3 Tan Tock Seng Hospital
RP Tan, CS (通讯作者)，Fundus Image Reading Ctr, Natl Healthcare Grp Eye Inst, Singapore, Singapore.; Tan, CS (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM colintan_eye@yahoo.com.sg
RI Tan, Colin S/K-8972-2012; Tan, Nikolle/GXH-5775-2022
OI Tan, Colin S/0000-0003-3088-5690; 
FU Novartis Pharma AG, Basel, Switzerland [NCT00674323]
FX The EVEREST study was funded by Novartis Pharma AG, Basel, Switzerland.
   Grant number NCT00674323 (clinicaltrials.gov). The sponsor had no role
   in the design or conduct of this research.
CR Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 35
TC 23
Z9 23
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2016
VL 254
IS 10
BP 1923
EP 1930
DI 10.1007/s00417-016-3333-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1QL
UT WOS:000387129400008
PM 27142805
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Vishwanathan, R
   Chung, M
   Johnson, EJ
AF Vishwanathan, Rohini
   Chung, Mei
   Johnson, Elizabeth J.
TI A Systematic Review on Zinc for the Prevention and Treatment of
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Review
DE zinc; age-related macular degeneration; systematic review
ID DIETARY ANTIOXIDANTS; ORAL ZINC; MACULOPATHY; RISK; EYE
AB PURPOSE. The objective of this systematic review was to examine the evidence on zinc intake from foods and supplements in the primary prevention and treatment of AMD.
   METHODS. Randomized controlled trials (RCTs), prospective cohort, retrospective cohort, and case-control studies that investigated zinc intake from foods and/or supplements, and AMD in men and women with a mean age of 50 years or older were included. Medline and Cochrane Central were searched from inception to February 2012 and November 2012, respectively. Data extraction and quality appraisal were done on all eligible studies.
   RESULTS. Ten studies were included: four RCTs, four prospective cohort, and two retrospective cohort studies. Age-related Eye Disease Study (AREDS) showed zinc treatment to significantly reduce the risk of progression to advanced AMD. The risk of visual acuity loss was of similar magnitude, but not statistically significant. Two RCTs reported statistically significant increases in visual acuity in early AMD patients and one RCT showed no effect of zinc treatment on visual acuity in advanced AMD patients. Results from six cohort studies on associations between zinc intake and incidence of AMD were inconsistent.
   CONCLUSIONS. Current evidence on zinc intake for the prevention of AMD is inconclusive. Based on the strength of AREDS, we can conclude that zinc treatment may be effective in preventing progression to advanced AMD. Zinc supplementation alone may not be sufficient to produce clinically meaningful changes in visual acuity.
C1 [Vishwanathan, Rohini; Johnson, Elizabeth J.] Tufts Univ, Carotenoids & Hlth Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Chung, Mei] Tufts Univ, Nutr Infect Unit, Dept Publ Hlth & Community Med, Sch Med, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA);
   Massachusetts Department of Public Health; Tufts University
RP Vishwanathan, R (通讯作者)，Tufts Univ, Carotenoids & Hlth Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM rohini.vishwanathan@tufts.edu
FU United States Department of Agriculture [1959051000-073-025]; Bausch
   Lomb, Inc.
FX Support by grants from the United States Department of Agriculture
   1959051000-073-025 and Bausch & Lomb, Inc.
CR Age-Related Eye Dis Study Res Grp, 2000, J NUTR, V130, p1516S, DOI 10.1093/jn/130.5.1516S
   [Anonymous], 2004, PREV BLINDN DAT TABL
   [Anonymous], 2001, DIET REF INT VIT A V
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Cousins RJ, 2006, PRESENT KNOWLEDGE NU, VI, P445
   Dickersin K, 2003, JAMA-J AM MED ASSOC, V290, P516, DOI 10.1001/jama.290.4.516
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Food and Nutrition Board Institute of Medicine National Academies, DIET REF INT DRIS RE
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grover S, 1997, RETINA-J RET VIT DIS, V17, P33, DOI 10.1097/00006982-199701000-00007
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Morris MS, 2007, OPHTHAL EPIDEMIOL, V14, P288, DOI 10.1080/09286580601186759
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   O'Dell BL, 2000, J NUTR, V130, p1432S, DOI 10.1093/jn/130.5.1432S
   Prasad AS, 1998, J AM COLL NUTR, V17, P542, DOI 10.1080/07315724.1998.10718800
   Siepmann M, 2005, INT J CLIN PHARM TH, V43, P562
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Stipanuk M, 1999, HOMOCYSTEINE CYSTEIN
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wells GA., 2011, NEWCASTLE OTTAWA SCA
NR 33
TC 46
Z9 47
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2013
VL 54
IS 6
BP 3985
EP 3998
DI 10.1167/iovs.12-11552
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 173YW
UT WOS:000321120700021
PM 23652490
DA 2022-11-30
ER

PT J
AU Zeng, RP
   Zhang, XZ
   Su, Y
   Li, M
   Wu, KF
   Wen, F
AF Zeng, Renpan
   Zhang, Xiongze
   Su, Yu
   Li, Meng
   Wu, Kunfang
   Wen, Feng
TI The Noninvasive Retro-Mode Imaging Modality of Confocal Scanning Laser
   Ophthalmoscopy in Polypoidal Choroidal Vasculopathy: A Preliminary
   Application
SO PLOS ONE
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   DEGENERATION; FUNDUS AUTOFLUORESCENCE; CHINESE PATIENTS; VISUALIZATION;
   FEATURES; LESIONS; EYES
AB Purpose: To evaluate the validity of the novel and noninvasive retro-mode imaging modality of confocal scanning laser ophthalmoscopy (cSLO) for detecting the morphological features of polypoidal choroidal vasculopathy (PCV).
   Design: Prospective, observational, consecutive case series. Methods: Twenty-six patients (29 eyes) with PCV were enrolled in this study. All patients underwent comprehensive ophthalmologic examinations and imaging studies, including retro-mode imaging, fundus autofluorescence (FAF), fundus photography, fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA) and spectral-domain optical coherence tomography (SD-OCT). We investigated the retro-mode images and compared the results with those of SD-OCT, FFA and ICGA.
   Results: In the 29 PCV eyes, the retro-mode images clearly revealed polypoidal lesions in 27 (93.1%) eyes as well as branching vascular networks in 16 (55.2%) eyes. Others findings, including pigment epithelial detachment (PED) in 20 (69.0%) eyes, neuroretinal detachment (NRD) in 3 (10.3%) eyes, cystoid macular edema (CME) in 3 (10.3%) eyes, drusen in 4 (13.8%) eyes and minute granular changes of the retinal pigment epithelium (RPE) in 12 (41.3%) eyes, were also clearly visualized. When we compared the results with those of SD-OCT, FFA and ICGA, there was no significant difference between ICGA and retro-mode imaging for finding polypoidal lesions and (or) branching choroidal vascular networks (P>0.05). However, the rate of PED detection was significantly better with retro-mode imaging than with the ICGA (P<0.05). The differences were not statistically significant between SD-OCT and retro-mode imaging for detecting PED, NRD, CME, drusen and minute granular RPE changes (P>0.05). The differences were not statistically significant between FFA and retro-mode imaging for detecting PED, NRD, CME (P>0.05).
   Conclusions: The novel and noninvasive retro-mode imaging by cSLO is able to clearly visualize the morphological features of PCV.
C1 [Zeng, Renpan; Zhang, Xiongze; Su, Yu; Li, Meng; Wu, Kunfang; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
RI meng, li/GVT-2063-2022
FU National Natural Science Foundation of China [81271011, 81200705];
   Fundamental Research Funds of State Key Laboratory of Ophthalmology
FX This study was supported by the National Natural Science Foundation of
   China (grant number: 81271011 and 81200705) and the Fundamental Research
   Funds of State Key Laboratory of Ophthalmology. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abe Sachi, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-76
   Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Anastasakis A, 2011, RETINA-J RET VIT DIS, V31, P949, DOI 10.1097/IAE.0b013e3181f441f6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   Katome T, 2012, RETINA-J RET VIT DIS, V32, P1892, DOI 10.1097/IAE.0b013e3182497141
   Katome T, 2012, CLIN EXP OPHTHALMOL, V40, pE120, DOI 10.1111/j.1442-9071.2011.02699.x
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maurizio BP, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-8
   Nagase S, 2012, OPHTHAL SURG LASERS, V43, P5
   Ohkoshi K, 2010, AM J OPHTHALMOL, V150, P856, DOI 10.1016/j.ajo.2010.06.022
   Pilotto E, 2013, GRAEF ARCH CLIN EXP, V251, P27, DOI 10.1007/s00417-012-2031-7
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Shin YU, 2012, AM J OPHTHALMOL, V154, P155, DOI 10.1016/j.ajo.2012.01.023
   Takeda Muneyasu, 2013, Nippon Ganka Gakkai Zasshi, V117, P44
   Tanaka Y, 2010, AM J OPHTHALMOL, V149, P635, DOI 10.1016/j.ajo.2009.10.024
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Vujosevic S, 2012, ACTA OPHTHALMOL, V90, pe374, DOI 10.1111/j.1755-3768.2012.02410.x
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yamamoto M, 2010, CLIN EXP OPHTHALMOL, V38, P27, DOI 10.1111/j.1442-9071.2010.02193.x
   Yamamoto Motoshi, 2009, International Ophthalmology, V29, P503, DOI 10.1007/s10792-008-9274-7
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 30
TC 5
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2013
VL 8
IS 9
AR e75711
DI 10.1371/journal.pone.0075711
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 221YD
UT WOS:000324695900124
PM 24058698
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Kim, M
   Kim, K
   Kim, DG
   Yu, SY
   Kwak, HW
AF Kim, Moosang
   Kim, Kookyoung
   Kim, Do Gyun
   Yu, Seung-Young
   Kwak, Hyung-Woo
TI Two-Year Results of Photodynamic Therapy Combined with Intravitreal
   Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal
   Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Photodynamic therapy; Vascular endothelial growth factor; Polypoidal
   choroidal vasculopathy
ID EPITHELIUM-DERIVED FACTOR; MACULAR DEGENERATION; BEVACIZUMAB AVASTIN;
   VERTEPORFIN; NEOVASCULARIZATION; EFFICACY; RANIBIZUMAB; INJECTION
AB Background/Aims: To evaluate the 2-year efficacy of photodynamic therapy (PDT) combined with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with polypoidal choroidal vasculopathy (PCV). Methods: Twenty-two eyes of 22 patients with PCV followed up for >= 24 months after PDT and anti-VEGF combination therapy were retrospectively reviewed. The patients received intravitreal anti-VEGF (1.25 mg bevacizumab or 0.5 mg ranibizumab) within 7 days after PDT. Eyes were retreated with PDT and anti-VEGF injection, or with only anti-VEGF injection, when indicated. Main outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT). Results: The mean baseline BCVA (0.43 +/- 0.33 logarithm of the minimum angle of resolution, logMAR) was 0.28 +/- 0.24 at 12 months (p < 0.05 vs. baseline) and 0.39 +/- 0.28 at 24 months (not significant). At 24 months, BCVA improved by >= 0.3 logMAR in 27.3% of the eyes, did not significantly decrease in 59.1%, and decreased by >= 0.3 logMAR in 13.6%. The mean CFT was 269.4 +/- 134.5 mu m at baseline and significantly decreased to 139.6 +/- 45.8 mu m (12 months) and 199.6 +/- 72.9 mu m (24 months). PDT was administered 1.45 +/- 0.86 times and anti-VEGF injected 4.45 +/- 1.36 times over the 24-month period. Conclusion: Combined PDT and anti-VEGF injection were effective for 2 years in PCV patients. Visual acuity significantly improved during year 1, but the benefit diminished in year 2. Further investigations are required to determine how to prolong the therapeutic effect of combination therapy for PCV. Copyright (C) 2011 S. Karger AG, Basel
C1 [Kim, Kookyoung; Yu, Seung-Young; Kwak, Hyung-Woo] Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Ophthalmol, Seoul 130702, South Korea.
   [Kim, Moosang] Inje Univ Seoul Paik Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Kim, Do Gyun] Kwandong Univ, Coll Med, Myongji Hosp, Dept Ophthalmol, Goyang, South Korea.
C3 Kyung Hee University; Kyung Hee University Hospital; Inje University;
   Catholic Kwandong University; Myongji Hospital
RP Yu, SY (通讯作者)，Kyung Hee Univ, Med Ctr, Dept Ophthalmol, 1 Hoegi Dong, Seoul 130702, South Korea.
EM syyu@khu.ac.kr
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moon SW, 2011, OPHTHALMOLOGICA, V225, P169, DOI 10.1159/000323811
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Vilaplana D, 2005, Arch Soc Esp Oftalmol, V80, P597
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 29
TC 26
Z9 30
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 226
IS 4
BP 205
EP 213
DI 10.1159/000330793
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 841JQ
UT WOS:000296509000005
PM 21893965
DA 2022-11-30
ER

PT J
AU Yang, LH
   Li, HX
   Zhao, XH
   Pan, Y
AF Yang, Lihong
   Li, Hongxun
   Zhao, Xinheng
   Pan, Ye
TI Association between Cataract Surgery and Age-Related Macular
   Degeneration: A Systematic Review and Meta-Analysis
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID CARDIOVASCULAR RISK-FACTORS; LONG-TERM INCIDENCE; BEAVER DAM; VISUAL
   IMPAIRMENT; MACULOPATHY; DISEASE; HEALTH; EYE; PROGRESSION; OUTCOMES
AB Purpose. We performed a systematic review and meta-analysis to evaluate the association between cataract surgery and the development and progression of AMD. Methods. This meta-analysis was registered at PROSPERO (CRD42017077962). We conducted a systematic literature search in August 2020 in Embase and PubMed and included cohort studies, case-control studies, or randomized controlled trials (RCTs) if they examined the association between cataract surgery and AMD. Odds ratio (OR) was used as a measure of the association with a random effect model. The analysis was further stratified by factors that could affect the outcomes. Results. 15 studies were included in this study. In the overall analysis, cataract surgery was significantly associated with the incidence of late AMD (OR, 1.80; 95% CI, 1.26-2.56; P = 0.001), particularly geographic atrophy (OR, 3.20; 95% CI, 1.90-5.39; P & LE; 0.001). No significant associations were observed between cataract surgery and the incidence of early AMD. Subgroup analysis showed that the OR for incidence of early and late AMD was significantly higher for cataract surgery performed more than 5 years compared with less than 5 years. We also found an increased risk of progression of AMD after cataract surgery performed more than 5 years (OR, 1.97; 95% CI, 1.29-3.01; P = 0.002). Conclusions. Our results suggest that cataract surgery may be associated with an increased risk of late AMD development and AMD progression. In addition, increasing the follow-up time since cataract surgery may further increase the risk for the development and progression of AMD. In the future, prospective multicenter studies with well-designed RCTs are required to confirm our findings.
C1 [Yang, Lihong; Li, Hongxun; Zhao, Xinheng; Pan, Ye] Tianjin Eye Hosp, Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin, Peoples R China.
   [Zhao, Xinheng] Tianjin Med Univ, Clin Coll Ophthalmol, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Li, HX (通讯作者)，Tianjin Eye Hosp, Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin, Peoples R China.
EM 46224382@qq.com; lihongxun_0522@163.com; zhaoxinheng@foxmail.com;
   panye6521@163.com
OI li, hongxun/0000-0002-9550-1304; Zhao, Xinheng/0000-0002-4787-5520
FU Science and Technology Project of Tianjin Health and Health Committee
   [RC20055]; Tianjin Key Medical Discipline (Specialty) Construction
   Project
FX AcknowledgmentsThis study was supported by Science and Technology
   Project of Tianjin Health and Health Committee (grant number RC20055)
   and Tianjin Key Medical Discipline (Specialty) Construction Project.
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Brunner S, 2013, OPHTHALMOLOGICA, V229, P86, DOI 10.1159/000345492
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Casparis H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub3
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ehmann DS, 2017, CURR OPIN OPHTHALMOL, V28, P58, DOI 10.1097/ICU.0000000000000331
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Henderson BA, 2010, SURV OPHTHALMOL, V55, P284, DOI 10.1016/j.survophthal.2009.07.007
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Ho JD, 2018, ACTA OPHTHALMOL, V96, pe213, DOI 10.1111/aos.13511
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   JAVITT JC, 1995, OPHTHALMOLOGY, V102, P1583
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Kim JH, 2015, AM J OPHTHALMOL, V160, P1312, DOI 10.1016/j.ajo.2015.09.012
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein BEK, 2009, ARCH OPHTHALMOL-CHIC, V127, P1528, DOI 10.1001/archophthalmol.2009.258
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Reeves SW, 2003, AM J OPHTHALMOL, V135, P599, DOI 10.1016/S0002-9394(02)02236-5
   Riley AF, 2002, BRIT J OPHTHALMOL, V86, P185, DOI 10.1136/bjo.86.2.185
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stock MV, 2015, INVEST OPHTH VIS SCI, V56, P2536, DOI 10.1167/iovs.14-16069
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Teh BL, 2017, SURV OPHTHALMOL, V62, P346, DOI 10.1016/j.survophthal.2016.12.003
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wong TY, 2000, BRIT J OPHTHALMOL, V84, P1337, DOI 10.1136/bjo.84.12.1337
NR 51
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD MAY 5
PY 2022
VL 2022
AR 6780901
DI 10.1155/2022/6780901
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1I4MT
UT WOS:000797204600001
PM 35573811
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gharbiya, M
   Iannetti, L
   Parisi, F
   De Vico, U
   Mungo, ML
   Marenco, M
AF Gharbiya, Magda
   Iannetti, Ludovico
   Parisi, Francesco
   De Vico, Umberto
   Mungo, Maria Laura
   Marenco, Marco
TI Visual and Anatomical Outcomes of Intravitreal Aflibercept for
   Treatment-Resistant Neovascular Age-Related Macular Degeneration
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID RANIBIZUMAB; BEVACIZUMAB; THERAPY; FLUID; EYES
AB A retrospective chart review of patients with persistent subretinal and/or intraretinal fluid, despite previous treatment with intravitreal ranibizumab (0.5mg), who were switched to aflibercept injections, was performed. Treatment was three monthly aflibercept (2mg) injections followed by dosing on pro re nata basis. Main outcome measures included changes in best corrected visual acuity (BCVA), 1 mm central subfield (CSF) retinal thickness, the height of the pigment epithelial detachment (PED), and subfoveal choroidal thickness on optical coherence tomography at 6 months. Thirty-one eyes of 30 patients were analyzed. The mean number of injections before aflibercept conversion was 34.4 +/- 11.9. After an average of 4.5 aflibercept injections (range 3 to 6) over 6 months, no significant change in BCVA was observed (P > 0.05). Compared with baseline, there was a significant reduction of the CSF retinal thickness (449 +/- 179 versus 269 +/- 145 mu m,P < 0.001), maximum PED height (262 +/- 134 versus 183 +/- 100 mu m, P < 0.001), and choroidal thickness (192 +/- 67 versus 167 +/- 51 mu m, P < 0.01). Stable visual acuity and anatomical improvement were obtained for up to 6 months after aflibercept conversion. However, choroidal thinning related to treatment was observed.
C1 [Gharbiya, Magda; Parisi, Francesco] Univ Roma La Sapienza, Policlin Umberto Hosp 1, I-00161 Rome, Italy.
   [Iannetti, Ludovico] Casa Cura Privata Villa Benedetta, I-00165 Rome, Italy.
   [De Vico, Umberto; Mungo, Maria Laura; Marenco, Marco] Casa Cura Privata Villa Margherita, I-00161 Rome, Italy.
C3 Sapienza University Rome; University Hospital Sapienza Rome
RP Iannetti, L (通讯作者)，Casa Cura Privata Villa Benedetta, 65 Circonvallaz Cornelia, I-00165 Rome, Italy.
EM l.iannetti@policlinicoumberto1.it
RI Gharbiya, Magda/AAS-1182-2021
OI Marenco, Marco/0000-0002-6978-3790; Iannetti,
   Ludovico/0000-0003-1790-3532; Gharbiya, Magda/0000-0002-4991-9689;
   Parisi, Francesco/0000-0002-2516-8331
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2013, GRAEFES ARCH CLIN EX
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Julien S., 2014, BRIT J OPHTHALMOLOGY
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schraermeyer U, 2013, EXPERT OPIN BIOL TH, V13, P157, DOI 10.1517/14712598.2012.748741
   Schraermeyer U, 2012, GRAEF ARCH CLIN EXP, V250, P1303, DOI 10.1007/s00417-012-2055-z
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wykoff C. C., 2014, BRIT J OPHTHALMOLOGY
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 20
TC 45
Z9 48
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 273754
DI 10.1155/2014/273754
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AH5HK
UT WOS:000336158900001
PM 24895562
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Pauleikhoff, D
   Radermacher, M
   Spital, G
   Muller, C
   Brumm, G
   Lommatzsch, A
   Bird, AC
AF Pauleikhoff, D
   Radermacher, M
   Spital, G
   Muller, C
   Brumm, G
   Lommatzsch, A
   Bird, AC
TI Visual prognosis of second eyes in patients with unilateral late
   exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID BRUCHS MEMBRANE; 2ND EYE; HEREDITY; TEARS; RISK
AB Purpose: A prospective longitudinal study was initiated to analyze the correlation between the prognosis for the second eyes of patients with unilateral late exudative AMD and the disease phenotype. Methods: Of the 187 patients with unilateral late exudative AMD recruited, 130 (69.5%) had predominantly classic CNV without pigment epithelium detachment (PED) (CNV group), and 57 (30.5%) had occult CNV with serous PED (PED group). Patients were reexamined by ophthalmoscopy and angiography every 6 months for up to 80 months. The end point was ETDRS visual acuity change of 3 lines or more due to late AMD in the second eye. Results: During follow-up 53 (28.3%) patients reached the end point: 32 (24.6%) in the CNV group and 21 (36.8%) in the PED group. The major prognostic factor for the risk of visual loss in the second eye was the type of late AMD in the first eye (CNV group 6-7% per year, PED group 15-16% per year (P<0.001). There was significant symmetry between the new exudative lesion in the second eye and that in the first, and significant differences in the density and fluorescence of drusen in the second eye between the two groups. Conclusions: Patients with occult CNV with serous PED in the first eye have a significantly higher risk of visual loss in the second eye than patients with CNV without PED. This distinction may be important for future clinical studies. In addition, segregation of AMD by phenotype is necessary in the analysis of genes conferring risk of AMD.
C1 St Franziskus Hosp, Dept Ophthalmol, D-48145 Munster, Germany.
   Moorfields Eye Hosp, London, England.
   Inst Ophthalmol, London, England.
C3 St. Franziskus-Hospital; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London
RP Pauleikhoff, D (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
CR ALTMAN DG, 1999, PRACTICAL STAT MED R, P245
   BIRD AC, 1991, EYE, V5, P1
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   LAVIN MJ, 1990, BR J OPHTHALMOL, V74, P482
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
NR 19
TC 28
Z9 28
U1 0
U2 2
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2002
VL 240
IS 7
BP 539
EP 542
DI 10.1007/s00417-002-0507-6
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 583WJ
UT WOS:000177433600007
PM 12136283
DA 2022-11-30
ER

PT J
AU Moshfeghi, AA
AF Moshfeghi, Andrew A.
TI Endophthalmitis Following Intravitreal Anti-Vascular Endothelial Growth
   Factor Injections for Neovascular Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE anti-VEGF; bevacizumab; ranibizumab; pegaptanib; endophthalmitis;
   intravitreal injection
ID TRIAMCINOLONE ACETONIDE INJECTION; COHERENCE TOMOGRAPHY FINDINGS;
   BEVACIZUMAB AVASTIN THERAPY; PHOTODYNAMIC THERAPY; INTRAOCULAR
   INFLAMMATION; PEGAPTANIB SODIUM; TRIPLE THERAPY; RANIBIZUMAB; SAFETY;
   VERTEPORFIN
AB Endophthalmitis following intravitreal injections of therapeutic medications is a rare but potentially vision-threatening problem. Infectious agents associated with endophthalmitis following injection of vascular endothelial growth factor (VEGF) inhibitors are typically Gram positive organisms with a predominance of Streptococcal and Staphylococcal microbiologic isolates. Patients with infectious endophthalmitis generally present within the first 72 hours following an intravitreal anti-VEGF injection with complaints of pain, redness, and decreased vision. Prompt treatment with a conventional endophthalmitis management approach may mitigate irreversible vision loss; however, poorer outcomes have been reported with more virulent organisms such as those associated with Streptococcal species. As the number of intravitreal injections performed each year continues to increase, ophthalmologists must maintain a rigorous approach to their injection technique and remain vigilant for the signs and symptoms of endophthalmitis.
C1 Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Palm Beach Gardens, FL 33418 USA.
C3 Bascom Palmer Eye Institute
RP Moshfeghi, AA (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 7101 Fairway Dr, Palm Beach Gardens, FL 33418 USA.
EM amoshfeghi@med.miami.edu
FU Palm Beach Community Trust Fund, Palm Beach, FL; Thrombogenics Inc.;
   RetinaSense, LLC; Convene, LLC; Realm Global, LLC
FX This study was funded in part by an unrestricted grant to Dr. Moshfeghi
   from The Palm Beach Community Trust Fund, Palm Beach, FL.; Dr. Moshfeghi
   serves as a compensated consultant and a speaker on behalf of the
   following entities: Genentech, Inc., Carl Zeiss Meditec, Inc., and
   Allergan, Inc.; serves as a compensated consultant to Alimera, Inc.,
   Alcon Inc., Bausch & Lomb, Inc., QLT Inc., and Eyetech, Inc; received
   research funding directed to his employer, the University of Miami, from
   Thrombogenics Inc., and holds an equity position in RetinaSense, LLC,
   Convene, LLC, and Realm Global, LLC.
CR Aggio FB, 2007, EYE, V21, P408, DOI 10.1038/sj.eye.6702683
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Alkuraya Hisham S., 2009, International Ophthalmology, V29, P411, DOI 10.1007/s10792-008-9237-z
   Amato JE, 2005, OCUL IMMUNOL INFLAMM, V13, P245, DOI 10.1080/09273940590928562
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bakri SJ, 2009, AM J OPHTHALMOL, V148, P66, DOI 10.1016/j.ajo.2009.02.013
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Cavalcante LL, 2010, CLIN OPHTHALMOL, V4, P519
   Chen E, 2009, OPHTHAL SURG LAS IM, V40, P192, DOI 10.3928/15428877-20090301-06
   Chen SDM, 2004, BRIT J OPHTHALMOL, V88, P843, DOI 10.1136/bjo.2003.033589
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Forte R, 2011, OPHTHALMIC RES, V45, P129, DOI 10.1159/000318877
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gregori NZ, 2008, RETINA-J RET VIT DIS, V28, P1325, DOI 10.1097/IAE.0b013e318188501f
   Gregori NZ, 2009, RETINA-J RET VIT DIS, V29, P913, DOI 10.1097/IAE.0b013e3181aa8dfe
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jeganathan VSE, 2011, CURR PHARM BIOTECHNO, V12, P369
   Jonas JB, 2008, EYE, V22, P590, DOI 10.1038/eye.2008.10
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2006, CORNEA, V25, P240, DOI 10.1097/01.ico.0000176614.73332.58
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Klein KS, 2009, OPHTHALMOLOGY, V116, P1225, DOI 10.1016/j.ophtha.2009.02.031
   Lee SH, 2010, EYE, V24, P226, DOI 10.1038/eye.2009.86
   Lima LH, 2009, RETINA-J RET VIT DIS, V29, P1213, DOI 10.1097/IAE.0b013e3181b32d27
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Mezad-Koursh D, 2010, RETINA-J RET VIT DIS, V30, P1051, DOI 10.1097/IAE.0b013e3181cd47ed
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2004, AM J OPHTHALMOL, V138, P489, DOI 10.1016/j.ajo.2004.03.025
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schwartz SG, 2009, EXPERT OPIN PHARMACO, V10, P2119, DOI 10.1517/14656560903081752
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Stewart JM, 2011, OCUL IMMUNOL INFLAMM, V19, P32, DOI 10.3109/09273948.2010.520405
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 61
TC 15
Z9 16
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 139
EP 148
DI 10.3109/08820538.2011.570847
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200010
PM 21609227
DA 2022-11-30
ER

PT J
AU Yamagishi, S
   Nakamura, K
   Inoue, H
   Takeuchi, M
AF Yamagishi, S
   Nakamura, K
   Inoue, H
   Takeuchi, M
TI Met72Thr polymorphism of pigment epithelium-derived factor gene and
   susceptibility to age-related macular degeneration
SO MEDICAL HYPOTHESES
LA English
DT Article
ID CULTURED RETINAL PERICYTES; ENDOTHELIAL GROWTH-FACTOR; ANTIOXIDATIVE
   PROPERTIES; NEOVASCULARIZATION; ANGIOGENESIS
AB Age-retated macular degeneration (ARMD) is the most common cause of acquired blindness among the people of occupational age. Although the pathogenesis of ARMD is not fully understood, several studies suggest a possible contribution of a genetic factor in the development and progression of ARMD. Pigment epithetium-derived factor (PEDF), a glycoprotein that belongs to the superfamily of serine protease inhibitors, was first purified from the conditioned media of human retinal pigment epithelial. cells as a factor with potent neuronal differentiating activity in human retinoblastoma cells. Recently, PEN has been shown to be a highly effective inhibitor of angiogenesis in cell culture and animal models. In addition, PEN has been found in the vitreous, and its levels were decreased in angiogenic eye diseases, thus suggesting that a loss of PEN in the eye is functionally important in the pathogenesis of ARMD. A functional amino acid change, a methionine to threonine polymorphism (Met72Thr polymorphism) at codon 72 in exon 3 (T/C polymorphism) of the PEN gene, that results in the formation of BsstSI restriction site, has recently been identified. Since it is well known that a single nucleotide polymorphism and resultant amino acid change often alters the activity or expression level of the target protein, we would like to propose here a novel hypothesis that the Met72Thr polymorphism (T/C polymorphism) of PEN gene may be a genetic marker for ARMD. Are genotype and allele frequencies of the Met72Thr polymorphism (T/C polymorphism) different between the patients with or without ARMD? Is this polymorphism associated with disease severity and progression? If the answer is yes, does this Met72Thr polymorphism regulate the vitreous levels of PEDF? These clinical studies could provide us with information whether this genetic variant of the PEN gene could present an attractive candidate susceptibility gene for ARMD. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Kurume Univ, Sch Med, Dept Med, Kurume, Fukuoka 8300011, Japan.
   Kurume Univ, Sch Med, Radioisotope Inst Basic & Clin Med, Kurume, Fukuoka 830, Japan.
   Hokuriku Univ, Fac Pharmaceut Sci, Dept Pathophysiol Sci, Kanazawa, Ishikawa 92011, Japan.
C3 Kurume University; Kurume University; Hokuriku University
RP Yamagishi, S (通讯作者)，Kurume Univ, Sch Med, Dept Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.
EM shoichi@med.kurume-u.ac.jp
CR Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Koenekoop R, 1999, MOL VIS, V5
   Moreno E, 2004, J BIOL CHEM, V279, P16553, DOI 10.1074/jbc.M400602200
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Thomae BA, 2003, J NEUROCHEM, V87, P809, DOI 10.1046/j.1471-4159.2003.02027.x
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Yamagishi S, 2002, INT J TISSUE REACT, V24, P137
   Yamagishi S, 2002, INT J CLIN PHARM RES, V22, P67
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3
   Yamagishi SI, 2003, MICROVASC RES, V65, P186, DOI 10.1016/S0026-2862(03)00005-0
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   2000, AM J HUM GENET, V67, P487
NR 16
TC 12
Z9 14
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2005
VL 64
IS 6
BP 1202
EP 1204
DI 10.1016/j.mehy.2005.01.017
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 921VG
UT WOS:000228792800031
PM 15823717
DA 2022-11-30
ER

PT J
AU Grunin, M
   Burstyn-Cohen, T
   Hagbi-Levi, S
   Peled, A
   Chowers, I
AF Grunin, Michelle
   Burstyn-Cohen, Tal
   Hagbi-Levi, Shira
   Peled, Amnon
   Chowers, Itay
TI Chemokine Receptor Expression in Peripheral Blood Monocytes from
   Patients with Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACROPHAGE ACTIVATION; CD16(+) MONOCYTES;
   TNF-ALPHA; CCR1; HETEROGENEITY; INVOLVEMENT; PHENOTYPE; DISEASE; RISK
AB PURPOSE. Chemokine signaling and monocytes/macrophages were implicated in the pathogenesis of AMD. We tested the association between chemokines involved in monocyte recruitment and AMD.
   METHODS. Immunophenotyping for white blood cell (WBC) populations including CD14++CD16- and CD14+CD16+ monocytes, CD19+, CD3+, and CD16+ lymphocytes, and chemokine receptors CCR1, CCR2, CCR5, CX(3)CR1, and CXCR4 was performed on peripheral blood from treatment-naive neovascular AMD (NV-AMD) patients and controls. The mRNA level of chemokine receptors in monocytes was measured with quantitative-PCR. Systemic levels of major chemokine ligands CCL2, CCL5, CCL3, and CXCL10 were evaluated by ELISA. Genotyping was performed for risk SNPs for AMD in the CFH, C3, and HTRA1 genes.
   RESULTS. The percentage of WBC subpopulations tested was similar between NV-AMD patients (n = 18) and controls (n = 20). CD14+CD16+ monocyte subpopulation showed a 3.5-fold increased expression of CCR1 (P = 0.039; t-test) and a 2.2-fold increased expression of CCR2 (P = 0.027) in patients compared with controls. Increased CCR1 and CCR2 expression was correlated with each other in patients (R-2 = 0.64, P < 0.0001), but not controls (R-2 = 0.02, P = 0.57). Increased mRNA levels of CCR1 (1.6-fold, P = 0.037) and CCR2 (1.6-fold, P = 0.007) were found in monocytes from NV-AMD patients. Chemokine receptor expression was not correlated with the presence of risk SNPs, and was not associated with blood chemokine levels.
   CONCLUSIONS. CCR1 and CCR2 are coupregulated on the CD14+CD16+ monocyte population in NV-AMD patients. These data implicate CD14+CD16+ monocytes and chemokine signaling in AMD. Additional investigation is needed to elucidate the role of these monocytes and their potential as a biomarker or therapeutic target for AMD. (Invest Ophthalmol Vis Sci. 2012; 53: 5292-5300) DOI:10.1167/iovs.11-9165
C1 [Grunin, Michelle; Hagbi-Levi, Shira; Chowers, Itay] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   [Burstyn-Cohen, Tal] Hadassah Hebrew Univ, Med Ctr, Inst Dent Sci, IL-91120 Jerusalem, Israel.
   [Peled, Amnon] Hadassah Hebrew Univ, Med Ctr, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hadassah University Medical Center
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019; Burstyn-Cohen, Tal/K-8846-2012
OI Grunin, Michelle/0000-0002-3155-2858; Burstyn-Cohen,
   Tal/0000-0002-2324-2921; Hagbi-Levi, Shira/0000-0002-2891-0079
FU Israel Science Foundation (ISF); Israeli Ministry of Health; Israeli
   Ministry of Immigrant Absorption for returning Scientists
FX Supported by grants from the Israel Science Foundation (ISF), the
   Israeli Ministry of Health (IC), and the Israeli Ministry of Immigrant
   Absorption for returning Scientists (TB-C).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557
   Baeten D, 2000, ARTHRITIS RHEUM, V43, P1233, DOI 10.1002/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9
   Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703
   Cherepanoff S, BR J OPHTHALMOL, V94, P918
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Dagkalis A, 2009, IMMUNOLOGY, V128, P25, DOI 10.1111/j.1365-2567.2009.03046.x
   Davies M, 2006, MOL VIS, V12, P467
   Dayyani F, 2004, J LEUKOCYTE BIOL, V75, P207, DOI 10.1189/jlb.0803386
   Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03
   Dong ZM, 2009, CURR PHARM DESIGN, V15, P365, DOI 10.2174/138161209787315783
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fall N, 2007, ARTHRITIS RHEUM-US, V56, P3793, DOI 10.1002/art.22981
   Faucher JL, 2007, CYTOM PART A, V71A, P934, DOI 10.1002/cyto.a.20457
   Frankenberger M, 1996, BLOOD, V87, P373
   Gao W, 2000, J CLIN INVEST, V105, P35, DOI 10.1172/JCI8126
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Gelinas L, 2011, J RENIN-ANGIO-ALDO S, V12, P295, DOI 10.1177/1470320310391332
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heimbeck I, CYTOMETRY A, V77, P823
   Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kataoka K, INVEST OPHTHALMOL VI, V52, P1431
   Katschke KJ, 2001, ARTHRITIS RHEUM, V44, P1022, DOI 10.1002/1529-0131(200105)44:5<1022::AID-ANR181>3.0.CO;2-N
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lederman M, INVEST OPHTHALMOL VI, V51, P53
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303
   Miles EA, 2008, ATHEROSCLEROSIS, V196, P298, DOI 10.1016/j.atherosclerosis.2006.11.002
   Mo FM, INVEST OPHTHALMOL VI, V51, P4226
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Nomiyama H, 2001, INT IMMUNOL, V13, P1021, DOI 10.1093/intimm/13.8.1021
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P255, DOI 10.1007/BF00920031
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   RIVIER A, 1995, CLIN EXP IMMUNOL, V100, P314
   Robertson MJ, 2002, INVEST OPHTH VIS SCI, V43, P2250
   Rottman JB, 2000, EUR J IMMUNOL, V30, P2372, DOI 10.1002/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO;2-D
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SALEH MN, 1995, BLOOD, V85, P2910, DOI 10.1182/blood.V85.10.2910.bloodjournal85102910
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Schlitt A, 2004, THROMB HAEMOSTASIS, V92, P419, DOI 10.1160/TH04-02-0095
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sen A, 2011, INVEST OPHTH VIS SCI, V52, P6940, DOI 10.1167/iovs.11-7834
   Shantsila E, 2011, J THROMB HAEMOST, V9, P1056, DOI 10.1111/j.1538-7836.2011.04244.x
   Shi Y, 2011, INT J INF TECH DECIS, V10, P1, DOI 10.1142/S0219622011004294
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Staples KJ, 2011, IMMUNOBIOLOGY, V216, P832, DOI 10.1016/j.imbio.2010.12.005
   Tallone T, 2011, J CARDIOVASC TRANSL, V4, P211, DOI 10.1007/s12265-011-9256-4
   Trebst C, 2002, E SCHERING RES FDN W, V39, P193
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Weber C, 2001, BLOOD, V97, P1144, DOI 10.1182/blood.V97.4.1144
   Weber C, 2000, J LEUKOCYTE BIOL, V67, P699, DOI 10.1002/jlb.67.5.699
   Xia MSJ, 2010, DATAASSIST DATA ANAL
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85
   Zeng HY, 2011, CURR EYE RES, V36, P264, DOI 10.3109/02713683.2010.535133
   Zeremski M, 2007, J VIRAL HEPATITIS, V14, P675, DOI 10.1111/j.1365-2893.2006.00838.x
   Zeremski M, 2007, JAIDS-J ACQ IMM DEF, V45, P262
   Ziegler-Heitbrock L, 2007, J LEUKOCYTE BIOL, V81, P584, DOI 10.1189/jlb.0806510
   ZieglerHeitbrock HWL, 1996, IMMUNOL TODAY, V17, P424, DOI 10.1016/0167-5699(96)10029-3
   Zimmermann HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011049
NR 81
TC 45
Z9 45
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2012
VL 53
IS 9
BP 5292
EP 5300
DI 10.1167/iovs.11-9165
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004QE
UT WOS:000308695400026
PM 22789920
DA 2022-11-30
ER

PT J
AU Machida, S
   Nishimura, T
   Tamada, K
   Harada, T
   Kurosaka, D
AF Machida, Shigeki
   Nishimura, Tomoharu
   Tamada, Kunifusa
   Harada, Tomomi
   Kurosaka, Daijiro
TI Macular function evaluated by focal macular electroretinograms after
   reduced fluence photodynamic therapy in eyes with polypoidal choroidal
   vasculopathy
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Photodynamic therapy; Reduced fluence; Electroretinogram (ERG); Focal
   ERG; Polypoidal choroidal vasculopathy (PCV)
ID DEGENERATION
AB The purpose of this study was to evaluate the macular function by measuring the focal macular electroretinograms (ERGs) recorded before and after reduced fluence photodynamic therapy (RFPDT) in patients with polypoidal choroidal vasculopathy (PCV). Eleven eyes of 11 patients with PCV were studied. Their ages ranged from 62 to 85 years with a mean of 74.7 +/- 6.9 years. The exposure time for the RFPDT was reduced to 42 s, so that the total energy of the laser was approximately one-half that of the standard PDT. We measured the visual acuity, foveal thickness, and focal macular ERGs before and after the RFPDT. The follow-up period ranged from 13 to 34 months with a mean of 26 months after the treatment. A significant recovery of vision was seen even at 1 week after the RFPDT (P < 0.005), and the visual acuities improved gradually thereafter (P < 0.0005). The foveal thickness was significantly reduced at 1 week after the treatment (P < 0.005) and then continued to become significantly thinner with time (P < 0.0001). A slight recovery of the a-and b-wave amplitudes was seen postoperatively without a transient reduction in the amplitudes. The b-wave amplitude was significantly larger at 3 months after the treatment than at baseline (P < 0.05). Choroidal hypoperfusion did not develop 3 months postoperatively in the indocyanine green angiograms. Exudative changes recurred in 4 (27%) eyes after 1 year and in 9 (82%) eyes during the follow-up period. RFPDT provided short-term benefits in selected patients with PCV with small lesions. The macular function was retained after RFPDT without a transient decrease in visual function. Further study is needed to determine the long-term efficacy of RFPDT for eyes with PCV.
C1 [Machida, Shigeki; Nishimura, Tomoharu; Tamada, Kunifusa; Harada, Tomomi; Kurosaka, Daijiro] Iwate Med Univ, Dept Ophthalmol, Sch Med, Morioka, Iwate 0208505, Japan.
C3 Iwate Medical University
RP Machida, S (通讯作者)，Iwate Med Univ, Dept Ophthalmol, Sch Med, 19-1 Uchimaru, Morioka, Iwate 0208505, Japan.
EM smachida@iwate-med.ac.jp
FU Ministry of Education, Science and Culture in Japan [20592056]
FX This work is supported by Grant-in-Aid for Scientific Research C from
   Ministry of Education, Science and Culture in Japan No. 20592056.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Ishikawa K, 2009, RETINA-J RET VIT DIS, V29, P803, DOI 10.1097/IAE.0b013e31819c631a
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   MIYAKE Y, 1981, JPN J OPHTHALMOL, V25, P438
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 18
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD APR
PY 2012
VL 124
IS 2
BP 91
EP 98
DI 10.1007/s10633-011-9307-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 946ZY
UT WOS:000304397600002
PM 22209990
DA 2022-11-30
ER

PT J
AU Gupta, B
   Jyothi, S
   Sivaprasad, S
AF Gupta, Bhaskar
   Jyothi, Sreedhar
   Sivaprasad, Sobha
TI Current treatment options for retinal angiomatous proliferans (RAP)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; INDOCYANINE GREEN ANGIOGRAPHY;
   BEVACIZUMAB AVASTIN TREATMENT; RANDOMIZED CLINICAL-TRIAL; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   CHORIORETINAL ANASTOMOSES; LASER PHOTOCOAGULATION; VERTEPORFIN
AB Retinal angiomatous proliferation (RAP) accounts for 12-15% of all patients with neovascular age-related macular degeneration (NV-AMD). However, this subtype is often excluded from clinical trials aimed at assessing the efficacy of various treatment options for NV-AMD. Thus, there are no established protocols for the management of RAP. This review of current literature on RAP compares the outcomes of various treatment options for this condition and highlights the lack of clinical trials and paucity of long-term data on this relatively common condition.
C1 [Sivaprasad, Sobha] Kings Coll Hosp London, Laser & Retinal Res Unit, Dept Ophthalmol, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Laser & Retinal Res Unit, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Gupta, Bhaskar/0000-0002-2122-3559
FU Novartis; Pfizer
FX SS has received research grants from Novartis and Pfizer.
CR Amselem L., 2008, Arch Soc Esp Oftalmol, V83, P53
   Bearelly S, 2008, BRIT J OPHTHALMOL, V92, P191, DOI 10.1136/bjo.2007.118760
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Gomez-Ulla F, 2006, OPTOMETRY VISION SCI, V83, P546, DOI 10.1097/01.opx.0000230279.95171.71
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Johnson TM, 2006, RETINA-J RET VIT DIS, V26, P765, DOI 10.1097/01.iae.0000244264.98642.af
   Kang Jae Hoon, 2007, Korean J Ophthalmol, V21, P213, DOI 10.3341/kjo.2007.21.4.213
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P237, DOI 10.1007/s00417-007-0651-0
   Krieglstein TR, 2006, BRIT J OPHTHALMOL, V90, P1357, DOI 10.1136/bjo.2006.092536
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Mahmood S, 2009, EYE, V23, P530, DOI 10.1038/eye.2008.101
   Mantel I, 2006, EUR J OPHTHALMOL, V16, P705, DOI 10.1177/112067210601600507
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Nicolo M, 2006, GRAEF ARCH CLIN EXP, V244, P1336, DOI 10.1007/s00417-006-0306-6
   Panagiotidis D, 2006, EUR J OPHTHALMOL, V16, P326, DOI 10.1177/112067210601600221
   Reche-Frutos J, 2007, EUR J OPHTHALMOL, V17, P979, DOI 10.1177/112067210701700619
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth DB, 2007, RETINA-J RET VIT DIS, V27, P1201, DOI 10.1097/IAE.0b013e3180ed45a6
   Rouvas AA, 2009, RETINA-J RET VIT DIS, V29, P536, DOI 10.1097/IAE.0b013e318196b1de
   Silva RM, 2004, GRAEF ARCH CLIN EXP, V242, P368, DOI 10.1007/s00417-003-0844-0
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SPAIDE RF, 2006, RETINA, V26, P283
   Torrón-Fernández-Blanco C., 2008, Arch Soc Esp Oftalmol, V83, P121
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   2001, AM J OPHTHALMOL, V131, P541
   2007, AM J OPHTHALMOL, V143, P701
NR 37
TC 19
Z9 21
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2010
VL 94
IS 6
BP 672
EP 677
DI 10.1136/bjo.2009.166975
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 601VK
UT WOS:000278093200002
PM 19897475
DA 2022-11-30
ER

PT J
AU Reiter, GS
   Grechenig, C
   Vogl, WD
   Guymer, RH
   Arnold, JJ
   Bogunovic, H
   Schmidt-Erfurth, U
AF Reiter, Gregor S.
   Grechenig, Christoph
   Vogl, Wolf-Dieter
   Guymer, Robyn H.
   Arnold, Jennifer J.
   Bogunovic, Hrvoje
   Schmidt-Erfurth, Ursula
TI ANALYSIS OF FLUID VOLUME AND ITS IMPACT ON VISUAL ACUITY IN THE FLUID
   STUDY AS QUANTIFIED WITH DEEP LEARNING
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; artificial intelligence;
   best-corrected visual acuity; deep learning; fluid quantification;
   intraretinal fluid; optical coherence tomography; subretinal fluid
ID OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF THERAPY; MACULAR DEGENERATION;
   IDENTIFICATION; RANIBIZUMAB; MORPHOLOGY; OUTCOMES
AB Purpose: To investigate quantitative differences in fluid volumes between subretinal fluid (SRF)-tolerant and SRF-intolerant treat-and-extend regimens for neovascular age-related macular degeneration and analyze the association with best-corrected visual acuity. Methods: Macular fluid (SRF and intraretinal fluid) was quantified on optical coherence tomography volumetric scans using a trained and validated deep learning algorithm. Fluid volumes and complete resolution was automatically assessed throughout the study. The impact of fluid location and volumes on best-corrected visual acuity was computed using mixed-effects regression models. Results: Baseline fluid quantifications for 348 eyes from 348 patients were balanced (all P > 0.05). No quantitative differences in SRF/intraretinal fluid between the treatment arms was found at any study-specific time point (all P > 0.05). Compared with qualitative assessment, the proportion of eyes without SRF/intraretinal fluid did not differ between the groups at any time point (all P > 0.05). Intraretinal fluid in the central 1 mm and SRF in the 1-mm to 6-mm macular area were negatively associated with best-corrected visual acuity (-2.8 letters/100 nL intraretinal fluid, P = 0.007 and -0.20 letters/100 nL SRF, P = 0.005, respectively). Conclusion: Automated fluid quantification using artificial intelligence allows objective and precise assessment of macular fluid volume and location. Precise determination of fluid parameters will help improve therapeutic efficacy of treatment in neovascular age-related macular degeneration.
C1 [Reiter, Gregor S.; Grechenig, Christoph; Vogl, Wolf-Dieter; Bogunovic, Hrvoje; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Melbourne, Vic, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
C3 Medical University of Vienna; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Reiter, Gregor/0000-0001-7661-4015
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2014, OPHTHALMOLOGY, V121, P1956, DOI 10.1016/j.ophtha.2014.04.020
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hogarty DT, 2019, CLIN EXP OPHTHALMOL, V47, P128, DOI 10.1111/ceo.13381
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kapoor R, 2019, SURV OPHTHALMOL, V64, P233, DOI 10.1016/j.survophthal.2018.09.002
   Klimscha S, 2017, INVEST OPHTH VIS SCI, V58, P4039, DOI 10.1167/iovs.16-20201
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Riedl S, 2020, RETINA-J RET VIT DIS, V40, P2148, DOI 10.1097/IAE.0000000000002717
   Roberts PK, 2020, JAMA OPHTHALMOL, V138, P945, DOI 10.1001/jamaophthalmol.2020.2457
   Roberts PK, 2019, INVEST OPHTH VIS SCI, V60, P304, DOI 10.1167/iovs.18-25189
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Vogl WD, 2017, INVEST OPHTH VIS SCI, V58, P4173, DOI 10.1167/iovs.17-21878
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 28
TC 22
Z9 22
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2021
VL 41
IS 6
BP 1318
EP 1328
DI 10.1097/IAE.0000000000003023
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2SL
UT WOS:000658826900024
PM 33230065
DA 2022-11-30
ER

PT J
AU Tang, YT
   Wang, XF
   Wang, JC
   Huang, W
   Gao, YP
   Luo, Y
   Lu, Y
AF Tang, Yating
   Wang, Xiaofeng
   Wang, Jiucun
   Huang, Wei
   Gao, Yaping
   Luo, Yi
   Lu, Yi
TI Prevalence and Causes of Visual Impairment in a Chinese Adult Population
   The Taizhou Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; URBAN SOUTHERN CHINA; BLUE MOUNTAINS EYE;
   LOW-VISION; CATARACT-SURGERY; AVOIDABLE BLINDNESS; GEOGRAPHIC REGION;
   REFRACTIVE ERRORS; RAPID ASSESSMENT; SHIHPAI EYE
AB Purpose: To study the current prevalence and causes of low vision and blindness in an adult Chinese population.
   Design: Population-based, cross-sectional study.
   Participants: We used a random cluster sampling method and evaluated 10 234 eligible subjects >= 45 years old (response rate, 78.1%) in the Taizhou Eye Study.
   Methods: Examinations were performed from July 2012 through December 2013.
   Participants underwent a detailed examination, including uncorrected visual acuity, best-corrected visual acuity (BCVA), intraocular pressure, axial length, slit-lamp, and fundus examinations to evaluate the prevalence and primary causes of visual impairment (VI).
   Main Outcome Measures: We defined low vision and blindness according to the World Health Organization (WHO) criteria (low vision: BCVA, <20/63->= 20/400; blindness: BCVA, <20/400 in the better eye) and United States criteria (low vision: BCVA, <20/40->= 20/200; blindness: BCVA, <20/200 in the better eye).
   Results: Using the WHO BCVA criteria, the standardized prevalence of bilateral low vision and blindness were 5.1% and 1.0%, respectively. Using the United States BCVA criteria, the standardized prevalence were 12.8% and 1.5%, respectively. Using the WHO criteria, the primary causes of bilateral low vision and blindness were cataract (59.1% and 48.5%, respectively), myopic macular degeneration (17.6% and 17.2%, respectively), and age-related macular degeneration (11.6% and 10.1%, respectively). The primary causes of monocular low vision were cataract (55.6%), age-related macular degeneration (12.6%), and myopic macular degeneration (8.9%), whereas those of monocular blindness were cataract (46.8%), atrophy of eyeball or prosthetic eye (10.2%), and cornea opacity (7.3%). A further analysis revealed that in adults 45-59 years old, myopic macular degeneration (59.6% and 27.2%, respectively) and cataract (13.8% and 23.4%, respectively) were the leading causes of bilateral and monocular VI. In adults >= 60 years old, cataract (66.8% and 61.2%, respectively) and age-related macular degeneration (12.6% and 11.8%, respectively) were the primary causes of bilateral and monocular VI.
   Conclusions: The prevalence of low vision and blindness in Chinese adults remains a severe public health problem. In the Taizhou Eye Study, cataract was the leading cause of low vision and blindness. Myopic macular degeneration and cataract were the primary causes of VI in adults 45-59 years and >60 years old, respectively. (C) 2015 by the American Academy of Ophthalmology.
C1 [Tang, Yating; Luo, Yi; Lu, Yi] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.
   [Tang, Yating; Luo, Yi; Lu, Yi] Minist Hlth, Myopia Key Lab, Shanghai, Peoples R China.
   [Tang, Yating; Luo, Yi; Lu, Yi] Visual Impairment & Reconstruct Key Lab, Shanghai, Peoples R China.
   [Wang, Xiaofeng; Wang, Jiucun] Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, State Key Lab Genet Engn, Shanghai 200031, Peoples R China.
   [Wang, Xiaofeng; Wang, Jiucun] Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, MOE Key Lab Contemporary Anthropol, Shanghai 200031, Peoples R China.
   [Huang, Wei; Gao, Yaping] Fudan Univ, Inst Biomed Sci, Shanghai 200031, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Fudan University
RP Lu, Y (通讯作者)，Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, 83 Fenyang Rd, Shanghai 200031, Peoples R China.
EM luyieent@126.com
FU Natural Science Foundation of China, Beijing, China [NSFC81270989]; Key
   Projects in the National Science & Technology Pillar Program, Beijing,
   China [2011BAI09B00]; New One Hundred People's Plan of Shanghai Health
   Bureau, Shanghai, China [XBR2011056]; Visual Impairment and
   Reconstruction Key Laboratory of Shanghai, Shanghai, China [12DZ2260500]
FX Supported by the Natural Science Foundation of China, Beijing, China
   (grant no.: NSFC81270989); Key Projects in the National Science &
   Technology Pillar Program, Beijing, China (grant no.: 2011BAI09B00); New
   One Hundred People's Plan of Shanghai Health Bureau, Shanghai, China
   (grant no.: XBR2011056); and Visual Impairment and Reconstruction Key
   Laboratory of Shanghai, Shanghai, China (grant no.: 12DZ2260500).
CR [Anonymous], 2008, LANCET, V372, P1273, DOI [10.1016/S0140-6736(08)61527-5, 10.1016/S0140-6736(08)61348-3]
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BAASANHU J, 1994, B WORLD HEALTH ORGAN, V72, P771
   Cheng CY, 2003, INVEST OPHTH VIS SCI, V44, P4630, DOI 10.1167/iovs.03-0169
   China National Committee on Aging Office, PROSP CHIN ELD NEXT
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Dlugosz Z, 1996, Prz Geogr, V68, P151
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Huang Xiao-bo, 2009, Zhonghua Yan Ke Za Zhi, V45, P786
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Li EY, 2013, OPHTHALMOLOGY, V120, P2176, DOI 10.1016/j.ophtha.2013.04.003
   Li L, 2008, EYE, V22, P1069, DOI 10.1038/eye.2008.53
   Li XF, 2012, OPHTHAL EPIDEMIOL, V19, P272, DOI 10.3109/09286586.2012.700081
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Maignan M, 2009, JAMA-J AM MED ASSOC, V302, P1270, DOI 10.1001/jama.2009.1353
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Murthy GVS, 2001, OPHTHALMOLOGY, V108, P679, DOI 10.1016/S0161-6420(00)00579-0
   Nakamura Y, 2010, OPHTHALMOLOGY, V117, P2315, DOI 10.1016/j.ophtha.2010.03.043
   National Bureau of Statistics of China, PER CAP ANN INC ENG
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Song WL, 2010, ACTA OPHTHALMOL, V88, P669, DOI 10.1111/j.1755-3768.2009.01768.x
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang LH, 2013, INVEST OPHTH VIS SCI, V54, P4117, DOI 10.1167/iovs.13-11911
   Wang Lanming, 2012, Zhongguo Yi Liao Qi Xie Za Zhi, V36, P426
   Wang XF, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-223
   Wang Y, 2011, OPHTHALMOLOGY, V118, P279, DOI 10.1016/j.ophtha.2010.05.026
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   World Health Organization, 2004, GLOB BURD DIS 2004 U
   World Health Organization, PREV BLINDN VIS IMP
   Wu LC, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-10
   Wu M, 2008, OPHTHALMOLOGY, V115, P969, DOI 10.1016/j.ophtha.2007.08.002
   Xiao BX, 2010, BRIT J OPHTHALMOL, V94, P1437, DOI 10.1136/bjo.2009.165308
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   You QS, 2011, OPHTHALMOLOGY, V118, P1069, DOI 10.1016/j.ophtha.2010.09.032
   Zhang YG, 2012, CLIN EXP OPHTHALMOL, V40, P484, DOI 10.1111/j.1442-9071.2011.02682.x
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P409, DOI 10.1016/j.ophtha.2009.11.023
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
   Zhou Q, 2007, OPHTHAL EPIDEMIOL, V14, P399, DOI 10.1080/09286580701331974
   Zou Haidong, 2002, Zhonghua Yan Ke Za Zhi, V38, P744
NR 49
TC 69
Z9 79
U1 2
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2015
VL 122
IS 7
BP 1480
EP 1488
DI 10.1016/j.ophtha.2015.03.022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL0HI
UT WOS:000356621700029
PM 25986897
DA 2022-11-30
ER

PT J
AU D'Souza, HS
   Kapoor, KG
   Wagner, AL
AF D'Souza, Haley S.
   Kapoor, Kapil G.
   Wagner, Alan L.
TI Ziv-aflibercept for Better Regulating Neovascular Age-Related Macular
   Degeneration (ZEBRA): A Prospective, Randomized Trial
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE retina; anti-VEGF; Ziv-aflibercept; neovascular AMD
AB Objective
   The purpose of this study is to determine if ziv-aflibercept is a safe and effective maintenance drug for nAMD.
   Study Design and Methods
   This is a randomized, prospective, single-blinded trial. Inclusion criteria were active nAMD, prior anti-VEGF treatment, and BCVA <= 20/200. The treatment group received ziv-aflibercept. The control group continued their existing anti-VEGF regimen. The main outcome measures were BCVA, CFT, and safety.
   Results
   Mean baseline BCVA was 1.58 +/- 0.44 logMAR and 1.71 +/- 0.39 logMAR in the control (n = 27) and treatment (n = 29) groups, respectively. After 24 months, the mean change in BCVA was 0.11 in the control group (equivalent to a loss of 5 ETDRS letters) and 0.01 logMAR in the treatment group (p = .48). Baseline CFT was 257 +/- 33 mu m and 247 +/- 30 mu m in the control and treatment groups, respectively, and after 24 months mean change in CFT was 26 mu m and -5 mu m (p = .24). There were no ocular or systemic adverse events during the study.
   Conclusion
   Ziv-aflibercept is a safe and effective as a maintenance drug for patients with nAMD. It may represent a cost-effective alternative to aflibercept and second-line therapy for eye resistant bevacizumab or ranibizumab.
C1 [D'Souza, Haley S.; Kapoor, Kapil G.; Wagner, Alan L.] Eastern Virginia Med Sch, Dept Ophthalmol, Norfolk, VA 23501 USA.
   [Kapoor, Kapil G.; Wagner, Alan L.] Wagner & Kapoor Retina Inst, 6160 Kempsville Circle,Suite 250B, Virginia Beach, VA 23462 USA.
C3 Eastern Virginia Medical School
RP Kapoor, KG (通讯作者)，Wagner & Kapoor Retina Inst, 6160 Kempsville Circle,Suite 250B, Virginia Beach, VA 23462 USA.
EM Kaps2003@gmail.com
OI D'Souza, Haley/0000-0002-0938-1650
CR Aleman I, 2019, BRIT J OPHTHALMOL, V103, P1740, DOI 10.1136/bjophthalmol-2018-313313
   Andrade Gabriel Costa de, 2018, Retin Cases Brief Rep, V12, P93, DOI 10.1097/ICB.0000000000000449
   Baghi A, 2017, OPHTHALMOL RETINA, V1, P103, DOI 10.1016/j.oret.2016.08.007
   Barmas-Alamdari D, 2019, SEMIN OPHTHALMOL, V34, P420, DOI 10.1080/08820538.2019.1641526
   Bonyadi MHJ, 2018, OPHTHALMOL RETINA, V2, P428, DOI 10.1016/j.oret.2017.09.010
   Braimah IZ, 2019, INDIAN J OPHTHALMOL, V67, P1109, DOI 10.4103/ijo.IJO_1532_18
   Braimah IZ, 2018, BRIT J OPHTHALMOL, V102, P91, DOI 10.1136/bjophthalmol-2017-310318
   BROWN D, 2006, NEW ENGL J MED, V355
   Browning DJ, 2008, OPHTHALMOLOGY, V115, P533, DOI 10.1016/j.ophtha.2007.06.042
   Chan EW, 2018, ACTA OPHTHALMOL, V96, pe256, DOI 10.1111/aos.13432
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   de Andrade GC, 2018, OSLI RETINA, V49, P245, DOI 10.3928/23258160-20180329-06
   de Andrade GC, 2016, RETINA-J RET VIT DIS, V36, P1640, DOI 10.1097/IAE.0000000000001000
   Dias JRD, 2019, RETINA-J RET VIT DIS, V39, P648, DOI 10.1097/IAE.0000000000002001
   Dias JRD, 2014, OSLI RETINA, V45, P577, DOI 10.3928/23258160-20141118-15
   DIAS JD, 2017, RETINA-J RET VIT DIS, V37
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ebrahimiadib N, 2020, OSLI RETINA, V51, P145, DOI 10.3928/23258160-20200228-03
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Eibl C., 2017, OPHTHALMOLOGICA, V36
   Farah M, 2014, ANG EX DEG ANN M
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   FOROOGHIAN F, 2009, RETINA-J RET VIT DIS, V29
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gokce G, 2016, ARQ BRAS OFTALMOL, V79, P384, DOI 10.5935/0004-2749.20160109
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hsia Ning-Yi, 2015, Taiwan J Ophthalmol, V5, P128, DOI 10.1016/j.tjo.2015.05.001
   Joondeph, 2016, RETINA TODAY, P67
   Lashay A, 2019, OSLI RETINA, V50, P785, DOI 10.3928/23258160-20191119-06
   Mansour AM, 2020, ACTA OPHTHALMOL, V98, pE540, DOI 10.1111/aos.14328
   Mansour AM, 2019, BRIT J OPHTHALMOL, V103, P938, DOI 10.1136/bjophthalmol-2018-312593
   Mansour AM, 2018, BRIT J OPHTHALMOL, V102, P1387, DOI 10.1136/bjophthalmol-2017-311591
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Mansour M., 2017, BRIT J OPHTHALMOL
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   Martin DF, 2015, NEW ENGL J MED, V372, P1260, DOI 10.1056/NEJMe1500351
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oakley CL, 2016, J HYPERTENS, V34, P2099, DOI 10.1097/HJH.0000000000001050
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel, 2018, OPHTHALMOLOGY, V125
   Ramon D, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.23
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Silver J, 2014, JAMA-J AM MED ASSOC, V312, P23, DOI 10.1001/jama.2014.6672
   Singh SR, 2020, SEMIN OPHTHALMOL, V35, P2, DOI 10.1080/08820538.2019.1686528
   Singh SR, 2019, BRIT J OPHTHALMOL, V103, P805, DOI 10.1136/bjophthalmol-2018-312453
   STURNER W Q, 1972, Journal of Forensic Sciences, V17, P387
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yogi Rohit, 2017, Retin Cases Brief Rep, V11, P111, DOI 10.1097/ICB.0000000000000305
NR 55
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD FEB 17
PY 2021
VL 36
IS 1-2
BP 28
EP 34
DI 10.1080/08820538.2021.1884269
EA FEB 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RH9VX
UT WOS:000617595100001
PM 33577373
DA 2022-11-30
ER

PT J
AU Sasaki, M
   Harada, S
   Tsubota, K
   Yasukawa, T
   Takebayashi, T
   Nishiwaki, Y
   Kawasaki, R
AF Sasaki, Mariko
   Harada, Sei
   Tsubota, Kazuo
   Yasukawa, Tsutomu
   Takebayashi, Toru
   Nishiwaki, Yuji
   Kawasaki, Ryo
TI Dietary Saturated Fatty Acid Intake and Early Age-Related Macular
   Degeneration in a Japanese Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; fatty acids; dietary intake
ID FOOD FREQUENCY QUESTIONNAIRE; GENETIC SUSCEPTIBILITY; FISH CONSUMPTION;
   NUTRIENT INTAKE; CANCER-RISK; CHOLESTEROL; MACULOPATHY; METAANALYSIS;
   ASSOCIATION; PROGRESSION
AB PURPOSE. To assess the association of dietary saturated fatty acid (SFA) intake with the presence of early AMD in a Japanese population.
   METHODS. The population-based Tsuruoka Metabolomics Cohort Study enrolled general population individuals aged 35 to 74 years from among participants in annual health check-up programs that included fundus photographs in Tsuruoka, Japan. A total of 4010 individuals participated in the baseline survey. After excluding nonresponders to a dietary survey and participants with suboptimal fundus image quality, 3988 participants (median age, 62.4 years) were included in this cross-sectional analysis. Dietary intake was assessed by a validated food frequency questionnaire. Fatty acids intake was adjusted for total energy intake by the residuals method. The association between fatty acid intake and presence of early AMD was assessed by logistic regression models.
   RESULTS. Median daily SFA intake was 11.3 g (interquartile range, 9.6, 13.0 g). After adjustments for potential confounding factors, participants in the highest quartile of SFA intake were less likely to have early AMD, compared with the lowest quartile (odds ratio, 0.71; 95% confidence interval: 0.52-0.96). A significant trend for decreased risk of early AMD with increasing SFA intake was noted (P = 0.011). There was no significant association between poly-unsaturated fatty acid (PUFA) including n3-PUFA intake and early AMD.
   CONCLUSIONS. We found that increased SFA intake was associated with reduced risk of early AMD in a Japanese population with low SFA intake. Adequate fatty acid intake may be required to maintain retinal homeostasis and prevent AMD.
C1 [Sasaki, Mariko; Tsubota, Kazuo] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Sasaki, Mariko] Tachikawa Hosp, Tokyo, Japan.
   [Sasaki, Mariko] Natl Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo, Japan.
   [Harada, Sei; Takebayashi, Toru] Keio Univ, Sch Med, Dept Prevent Med & Publ Hlth, Tokyo, Japan.
   [Yasukawa, Tsutomu] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Nishiwaki, Yuji] Toho Univ, Dept Environm & Occupat Hlth, Tokyo, Japan.
   [Kawasaki, Ryo] Osaka Univ, Dept Vis Informat Topcon, Grad Sch Med, Osaka, Japan.
C3 Keio University; Tachikawa Hospital; Keio University; Nagoya City
   University; Toho University; Osaka University
RP Sasaki, M (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM mariko.sasaki@a2.keio.jp
RI Takebayashi, Toru/AAB-9356-2019; Kawasaki, Ryo/B-7266-2009; Harada,
   Sei/ABA-5975-2020; Tsubota, Kazuo/M-1915-2013
OI Takebayashi, Toru/0000-0002-8268-8026; Kawasaki,
   Ryo/0000-0002-7492-6303; Harada, Sei/0000-0003-2666-4932; Tsubota,
   Kazuo/0000-0002-8874-7111
FU Ministry of Education, Culture, Sports, Science, and Technology (MEXT),
   Japan (KAKENHI) [17K09150]
FX Partly supported by a Grant-in-Aid for Scientific Research from the
   Ministry of Education, Culture, Sports, Science, and Technology (MEXT),
   Japan (KAKENHI, 17K09150 [MS]).
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Harada S, 2016, ENVIRON HEALTH PREV, V21, P18, DOI 10.1007/s12199-015-0494-y
   Hidaka A, 2015, AM J CLIN NUTR, V102, P1490, DOI 10.3945/ajcn.115.113597
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Imaeda N, 2007, J EPIDEMIOL, V17, P100, DOI 10.2188/jea.17.100
   Iso H, 2005, J EPIDEMIOL, V15, pS24, DOI 10.2188/jea.15.S24
   Iso H, 2003, AM J EPIDEMIOL, V157, P32, DOI 10.1093/aje/kwf166
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kennedy ET, 1999, J AM COLL NUTR, V18, P207, DOI 10.1080/07315724.1999.10718853
   KEYS A, 1957, LANCET, V2, P959
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kuwabara K, 2016, J ATHEROSCLER THROMB, V23, P477, DOI 10.5551/jat.33100
   Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146
   Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mozaffarian D, 2004, AM J CLIN NUTR, V80, P1175, DOI 10.1093/ajcn/80.5.1175
   Mozaffarian D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000252
   Muramatsu K, 2004, B CHIBA COLL HLTH SC, V23, P1
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Sato R, 2013, INVEST OPHTH VIS SCI, V54, P1740, DOI 10.1167/iovs.12-10068
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Siri-Tarino PW, 2010, AM J CLIN NUTR, V91, P535, DOI 10.3945/ajcn.2009.27725
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tokudome Shinkan, 2004, Asian Pac J Cancer Prev, V5, P40
   Tokudome Y, 2005, J EPIDEMIOL, V15, P135, DOI 10.2188/jea.15.135
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamagishi K, 2010, AM J CLIN NUTR, V92, P759, DOI 10.3945/ajcn.2009.29146
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Zhou BF, 2003, J HUM HYPERTENS, V17, P623, DOI 10.1038/sj.jhh.1001605
NR 51
TC 6
Z9 6
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2020
VL 61
IS 3
AR 23
DI 10.1167/iovs.61.3.23
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA8BU
UT WOS:000524168000023
PM 32181798
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Makeyeva, G
   Guymer, RH
   Luu, CD
AF Wu, Zhichao
   Ayton, Lauren N.
   Makeyeva, Galina
   Guymer, Robyn H.
   Luu, Chi D.
TI Impact of Reticular Pseudodrusen on Microperimetry and Multifocal
   Electroretinography in Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; spectral-domain optical coherence tomography; microperimetry;
   multifocal electroretinography
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY; ADAPTIVE
   OPTICS; CLINICAL CHARACTERISTICS; RETINAL FUNCTION; RISK-FACTOR; EYES;
   MACULOPATHY; CLASSIFICATION; SENSITIVITY
AB PURPOSE. To examine the influence of reticular pseudodrusen (RPD) on retinal and visual function in intermediate AMD using multifocal electroretinography (mfERG) and microperimetry.
   METHODS. In a prospective cross-sectional study, microperimetry and mfERG testing, followed by color fundus photography, near-infrared reflectance imaging and spectral-domain optical coherence tomography (SD-OCT) scans were performed in 120 eyes from 60 participants with bilateral intermediate AMD. The number of subfields with pigmentary changes and RPD within the central 3-mm diameter of the Early Treatment of Diabetic Retinopathy Study (ETDRS) grid and drusen cube root volume within the central 3-mm diameter was determined. The influence of these pathological features on microperimetry and mfERG in this region were examined.
   RESULTS. Microperimetric sensitivity was not significantly associated with the presence and extent of RPD (P = 0.068), but with drusen volume and extent of pigmentary changes (P < 0.001 for both). However, the presence and extent of RPD was independently and significantly associated with mfERG implicit time, along with drusen volume and the extent of pigmentary changes (P <= 0.023). The mfERG response amplitude was not significantly associated with the presence and extent of RPD (P = 0.130).
   CONCLUSIONS. The presence and extent of RPD was associated with functional changes on mfERG implicit time, but not mfERG response amplitude or microperimetry. These findings suggest that the presence of RPD in eyes with intermediate AMD has a significant influence on cone-mediated neuroretinal function, without a significant influence on mesopic visual function as determined on microperimetry.
C1 [Wu, Zhichao; Ayton, Lauren N.; Makeyeva, Galina; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Guymer, Robyn/0000-0002-9441-4356;
   Luu, Chi/0000-0002-7604-7097
FU National Health and Medical Research Council (NHMRC) (Canberra, ACT,
   Australia) [1027624]; Macular Disease Foundation Australia (MDFA)
   Research Grant (Sydney, NSW, Australia); Bupa Health Foundation (Sydney,
   NSW, Australia); BrightFocus Foundation (Clarksburg, MD, USA);
   University of Melbourne Early Career Research Grant (Parkville, VIC,
   Australia) [1350114]; Menzies Foundation (East Melbourne, VIC,
   Australia); Victorian Government; NHMRC Centre for Clinical Research
   Excellence Award [529923]
FX Supported by the National Health and Medical Research Council (NHMRC)
   Project Grant (#1027624; Canberra, ACT, Australia), Macular Disease
   Foundation Australia (MDFA) Research Grant (Sydney, NSW, Australia),
   Bupa Health Foundation (Sydney, NSW, Australia), BrightFocus Foundation
   (Clarksburg, MD, USA), a University of Melbourne Early Career Research
   Grant (LNA, #1350114; Parkville, VIC, Australia) and the Menzies
   Foundation (East Melbourne, VIC, Australia). CERA receives Operational
   Infrastructure Support from the Victorian Government and is supported by
   a NHMRC Centre for Clinical Research Excellence Award (#529923).
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2013, RETINA, V33, P1300
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 44
TC 35
Z9 36
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2015
VL 56
IS 3
BP 2100
EP 2106
DI 10.1167/iovs.14-16210
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BF
UT WOS:000352137600088
PM 25736790
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Saleh, GM
   Jackson, H
AF Sivaprasad, S
   Saleh, GM
   Jackson, H
TI Does lesion size determine the success rate of photodynamic therapy for
   age-related macular degeneration?
SO EYE
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; lesion size
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY
AB Photodynamic therapy (PDT) is a new evidence-based treatment modality available for choroidal neovascularisation (CNV) secondary to age-related macular degeneratin (AMD). Eligibility for PDT is based on the morphological classification of the neovascular complex, the benefit being greater in classic with no occult lesions. Lesion size is also shown to be a predictive factor for treatment benefit. This retrospective case series looked at effect of initial and final lesion size on the visual outcome of patients with subfoveal classic with no occult CNV and found that increasing initial and final lesion size is associated with poorer visual outcome.
C1 Royal Princess Univ Hosp, W Kent Eye Ctr, Orpington BR6 8ND, Kent, England.
RP Sivaprasad, S (通讯作者)，Royal Princess Univ Hosp, W Kent Eye Ctr, Orpington BR6 8ND, Kent, England.
EM Senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
NR 6
TC 12
Z9 14
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2006
VL 20
IS 1
BP 43
EP 45
DI 10.1038/sj.eye.6701787
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 999VL
UT WOS:000234418700009
PM 15832188
OA Bronze
DA 2022-11-30
ER

PT J
AU Schwaber, EJ
   Thompson, AC
   Smilnak, G
   Stinnett, SS
   Whitson, HE
   Lad, EM
AF Schwaber, Eric J.
   Thompson, Atalie C.
   Smilnak, Gordon
   Stinnett, Sandra S.
   Whitson, Heather E.
   Lad, Eleonora M.
TI Co-Prevalence of Alzheimer's Disease and Age-Related Macular
   Degeneration Established by Histopathologic Diagnosis
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Age-related macular degeneration; Alzheimer's disease; dementia;
   epidemiology; histopathology
ID APOLIPOPROTEIN-E GENE; COGNITIVE FUNCTION; RISK-FACTORS; DEMENTIA;
   DRUSEN; EPIDEMIOLOGY; ASSOCIATION; MACULOPATHY; EYES; IRON
AB Background: Previous epidemiologic studies have suggested an association between AMD and AD, and several therapeutic agents are being developed based on this principle. However, prior studies have provided conflicting results due in part to their reliance on clinical diagnoses that are not based on gold-standard histopathology.
   Objective: To use histopathologic standards for diagnosis in order to determine the co-prevalence of AD among patients with and without AMD.
   Methods: This is a cross-sectional study of 157 autopsy ocular specimens from patients with and without AMD that were greater than 75 years of age at death. Sarks staging was used to document the severity of AMD, and Braak and Braak staging was used to assess the severity of AD in corresponding brain specimens. The prevalence of AD within different severities of AMD was determined using univariable and multivariable logistic regression.
   Results: 58% of autopsy eyes had AMD. The prevalence of AD was lower in AMD subjects (63%) compared to non-AMD subjects (73%), even when grouped by severity (all p > 0.15). The likelihood of AD was significantly less in AMD subjects, even after adjusting for age and sex in multivariable analysis (OR 0.47, p = 0.049).
   Conclusion: Histopathologic diagnoses fail to support an increase in prevalence of AD among subjects with AMD, even when disease severity is considered.
C1 [Schwaber, Eric J.] Griffin Hosp, Dept Internal Med, Derby, CT USA.
   [Thompson, Atalie C.; Smilnak, Gordon; Stinnett, Sandra S.; Whitson, Heather E.; Lad, Eleonora M.] Duke Univ, Med Ctr, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
   [Whitson, Heather E.] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Lad, EM (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, DUMC 3802, Durham, NC 27710 USA.
EM nora.lad@duke.edu
OI Stinnett, Sandra/0000-0001-7192-0195; Whitson,
   Heather/0000-0002-8417-4846
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b
   Biscetti Leonardo, 2017, Front Biosci (Elite Ed), V9, P174
   BLANKS JC, 1989, BRAIN RES, V501, P364, DOI 10.1016/0006-8993(89)90653-7
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   Blasiak Janusz, 2009, Klin Oczna, V111, P174
   BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
   Chan KY, 2013, LANCET, V381, P2016, DOI 10.1016/S0140-6736(13)60221-4
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Csincsik L, 2018, OPHTHALMIC RES, V59, P182, DOI 10.1159/000487053
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Demirci S, 2015, TURK J MED SCI, V45, P1115, DOI 10.3906/sag-1406-135
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5
   HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804
   Ho CY, 2014, BRAIN PATHOL, V24, P25, DOI 10.1111/bpa.12070
   Hulette CM, 1998, J NEUROPATH EXP NEUR, V57, P1168, DOI 10.1097/00005072-199812000-00009
   Humpel C, 2011, TRENDS BIOTECHNOL, V29, P26, DOI 10.1016/j.tibtech.2010.09.007
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaczmarczyk Kamila, 2007, Klin Oczna, V109, P482
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koronyo Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93621
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Leger F, 2011, J NEUROPATH EXP NEUR, V70, P63, DOI 10.1097/NEN.0b013e31820376cc
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Margeta MA, 2018, GRAEF ARCH CLIN EXP, V256, P2449, DOI 10.1007/s00417-018-4081-y
   Mott RT, 2005, NEUROIMAG CLIN N AM, V15, P755, DOI 10.1016/j.nic.2005.09.003
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ong SS, 2018, JAMA NEUROL, V75, P650, DOI 10.1001/jamaneurol.2018.0602
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Qiu Chengxuan, 2009, Dialogues Clin Neurosci, V11, P111
   Quinn N, 2019, PROG RETIN EYE RES, V68, P83, DOI 10.1016/j.preteyeres.2018.10.001
   Rizzo M, 2000, NEUROPSYCHOLOGIA, V38, P1157, DOI 10.1016/S0028-3932(00)00023-3
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmidt S, 2000, MOL VIS, V6, P287
   Smith MA, 2010, J ALZHEIMERS DIS, V19, P363, DOI 10.3233/JAD-2010-1239
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Thorpe CT, 2012, J AM GERIATR SOC, V60, P644, DOI 10.1111/j.1532-5415.2012.03907.x
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   UHLMANN RF, 1991, J GEN INTERN MED, V6, P126, DOI 10.1007/BF02598307
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   Williams EA, 2017, J NEUROPATH EXP NEUR, V76, P376, DOI 10.1093/jnen/nlx020
   Williams MA, 2015, AM J GERIAT PSYCHIAT, V23, P1290, DOI 10.1016/j.jagp.2015.06.005
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 70
TC 4
Z9 4
U1 0
U2 1
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2020
VL 76
IS 1
BP 207
EP 215
DI 10.3233/JAD-200111
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA MF4TV
UT WOS:000545337600020
PM 32444545
DA 2022-11-30
ER

PT J
AU Meshi, A
   Camacho, N
   Lin, TZ
   Muftuoglu, IK
   Arcinue, CA
   Gaber, R
   You, QS
   Freeman, WR
AF Meshi, Amit
   Camacho, Natalia
   Lin, Tiezhu
   Muftuoglu, Ilkay K.
   Arcinue, Cheryl A.
   Gaber, Raouf
   You, Qi Sheng
   Freeman, William R.
TI Correlates of Good Vision in Eyes With Subfoveal Scars From Neovascular
   Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FOVEAL PHOTORECEPTOR LAYER; VISUAL-ACUITY
   LOSS; TREATMENTS TRIALS; NATURAL-HISTORY; PREDICTORS; ASSOCIATION;
   OUTCOMES; THERAPY
AB BACKGROUND AND OBJECTIVE: To compare subfoveal disciform scars with good and poor vision in patients with neovascular agn-related macular degeneration (nAMD).
   PATIENTS AND METHODS: A retrospective case-control study. Twenty-two eyes of 21 consecutively treated patients with nAMD with subfoveal disciform scar and best-corrected visual acuity (BCVA) of 20/63 or better at the final visit were included. Twenty-one eyes of 21 matched patients with disciform scar and final BCVA less than 20/63 served as controls.
   RESULTS: Subretinal pigment epithelium scar location was more common in the good vision group than in the poor vision group (P < .001). The mean percent disruption of the ellipsoid and the external limiting membrane layers was significantly greater in poor vision eyes than in good vision eyes from scar formation and throughout follow-up (all P < .01).
   CONCLUSION: Preserved photoreceptor layer correlated with good vision in patients with nAMD and subfoveal disciform scar.
C1 [Meshi, Amit; Camacho, Natalia; Lin, Tiezhu; Muftuoglu, Ilkay K.; Arcinue, Cheryl A.; Gaber, Raouf; You, Qi Sheng; Freeman, William R.] Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, Dept Ophthalmol, La Jolla, CA 92037 USA.
   [Camacho, Natalia] Inst Barraquer Amer, Escuela Super Oftalmol, Bogota, Colombia.
   [Lin, Tiezhu] He Univ, He Eye Hosp, Shenyang, Liaoning, Peoples R China.
   [Muftuoglu, Ilkay K.] Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Gaber, Raouf] Tanta Univ, Dept Ophthalmol, Tanta, Egypt.
   [You, Qi Sheng] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
C3 University of California System; University of California San Diego;
   Istanbul Training & Research Hospital; Egyptian Knowledge Bank (EKB);
   Tanta University; Capital Medical University
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, 0946,9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM wrfreeman@ucsd.edu
RI You, Qisheng/AAG-7153-2020; lin, Tiezhu/AAY-1971-2020; Gaber,
   Raouf/GSN-8206-2022
OI You, Qisheng/0000-0003-0743-7320; 
FU UCSD Vision Research Center [P30EY022589]; Research to Prevent
   Blindness, NY
FX This study was supported in part by UCSD Vision Research Center Core
   Grant P30EY022589, an unrestricted fund from Research to Prevent
   Blindness, NY (WRF). The funding organization had no role in the design
   or conduct of this research.
CR Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chhablani JK, 2012, GRAEF ARCH CLIN EXP, V250, P1415, DOI 10.1007/s00417-012-1968-x
   Coco RM, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-82
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   El-Emam S, 2013, RETINA-J RET VIT DIS, V33, P1249, DOI 10.1097/IAE.0b013e31827b6439
   Hartmann KI, 2014, RETINA-J RET VIT DIS, V34, P647, DOI 10.1097/IAE.0000000000000003
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oster SF, 2010, RETINA-J RET VIT DIS, V30, P713, DOI 10.1097/IAE.0b013e3181c596e3
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Otani T, 2010, RETINA-J RET VIT DIS, V30, P774, DOI 10.1097/IAE.0b013e3181c2e0d6
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Riusala AM, 2004, AM J OPHTHALMOL, V138, P245, DOI 10.1016/j.ajo.2004.03.007
   Ryu CL, 2016, RETINA-J RET VIT DIS, V36, P1324, DOI 10.1097/IAE.0000000000000877
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   World Health Organization, 2016, INT STAT CLASS DIS R
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 26
TC 0
Z9 1
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD OCT
PY 2018
VL 49
IS 10
BP 765
EP 774
DI 10.3928/23258160-20181002-04
PG 10
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GY8AM
UT WOS:000448839800018
PM 30395662
DA 2022-11-30
ER

PT J
AU Sauer, L
   Gensure, RH
   Andersen, KM
   Kreilkamp, L
   Hageman, GS
   Hammer, M
   Bernstein, PS
AF Sauer, Lydia
   Gensure, Rebekah H.
   Andersen, Karl M.
   Kreilkamp, Lukas
   Hageman, Gregory S.
   Hammer, Martin
   Bernstein, Paul S.
TI Patterns of Fundus Autofluorescence Lifetimes In Eyes of Individuals
   With Nonexudative Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE FLIO; fluorescence lifetime imaging; AMD; lipofuscin
ID TIME-RESOLVED AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; DRUSEN; PIGMENT;
   PREVALENCE; DISEASE; MACULOPATHY; HYPOTHESIS
AB PURPOSE. To investigate fundus autofluorescence (FAF) lifetimes in patients with nonexudative AMD.
   METHODS. A total of 150 eyes of 110 patients (mean age: 73.2+/-10.7 years) with nonexudative AMD, as well as a healthy group of 57 eyes in 38 subjects (mean age: 66.5+/-8.7 years), were included. Investigations were conducted at the University Eye Clinic in Jena, Germany, as well as the Moran Eye Center in Salt Lake City, Utah, USA, using the Heidelberg Engineering Spectralis-based fluorescence lifetime imaging ophthalmoscope (FLIO). A 308 retinal field centered at the fovea was investigated. FAF decays were detected in short (498-560 nm) and long (560-720 nm, LSC) spectral channels. The mean fluorescence lifetimes (sm) were calculated. Optical coherence tomography scans and fundus photographs were also recorded.
   RESULTS. In patients with nonexudative AMD, FLIO shows a ring-shaped pattern of prolonged sm in the LSC. This pattern occurs in all patients with AMD (including very early stages) and in one-third of the healthy controls. FAF lifetimes were longer with more advanced stages. The presence of drusen is associated with prolonged sm when compared with the healthy fundus, but drusen identification is difficult with FLIO only.
   CONCLUSIONS. FLIO detects a clear pattern of changes within the fundus, which appears to be AMD-associated. These changes are already visible in early AMD stages and not masked by the presence of other coexisting retinal diseases. These findings may be useful for the early diagnosis of AMD and to distinguish AMD from other retinal diseases.
C1 [Sauer, Lydia; Gensure, Rebekah H.; Andersen, Karl M.; Hageman, Gregory S.; Bernstein, Paul S.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Sauer, Lydia; Kreilkamp, Lukas; Hammer, Martin] Univ Hosp Jena, Dept Expt Ophthalmol, Jena, Germany.
   [Andersen, Karl M.] Geisinger Commonwealth Sch Med, Scranton, PA USA.
   [Hageman, Gregory S.] Univ Utah, John A Moran Eye Ctr, Sharon Eccles Steele Ctr Translat Med, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah; Friedrich Schiller
   University of Jena; Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
FU Research to Prevent Blindness; National Institutes of Health [EY11600,
   EY14800]; NATIONAL EYE INSTITUTE [R01EY011600, P30EY014800] Funding
   Source: NIH RePORTER
FX Supported in part by an unrestricted departmental grant from Research to
   Prevent Blindness and National Institutes of Health Grants EY11600 and
   EY14800.
CR Andersen KM, T VIS SCI TECH
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Becker W., 2017, BH TCSPC HDB, V7th
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dysli C, 2018, INVEST OPHTH VIS SCI, V59, P1769, DOI 10.1167/iovs.17-23336
   Dysli C, 2017, RETINA-J RET VIT DIS, V37, P2151, DOI 10.1097/IAE.0000000000001452
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P832, DOI 10.1167/iovs.15-18033
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Klemm M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131640
   Klemm M, 2013, CURR EYE RES, V38, P793, DOI 10.3109/02713683.2013.779723
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sauer L, 2018, OPHTHALMOL RETINA, V2, P587, DOI 10.1016/j.oret.2017.10.008
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, P3094, DOI 10.1167/iovs.18-23886
   Sauer L, 2018, ACTA OPHTHALMOL, V96, P257, DOI 10.1111/aos.13587
   Sauer L, 2017, ACTA OPHTHALMOL, V95, P481, DOI 10.1111/aos.13269
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schmidt J, 2017, ACTA OPHTHALMOL, V95, P33, DOI 10.1111/aos.13174
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P774, DOI 10.1007/s00347-002-0656-3
   Schweitzer D, 2012, INVEST OPHTH VIS SCI, V53, P3376, DOI 10.1167/iovs.11-8970
   Schweitzer D, 2010, ESSENT OPHTHALMOL, P107, DOI 10.1007/978-3-540-85540-8_10
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
NR 45
TC 28
Z9 28
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
BP AMD65
EP AMD77
DI 10.1167/iovs.17-23764
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GN7JZ
UT WOS:000439314600002
PM 30025104
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, EC
   Cho, E
   Jee, D
AF Kim, Eun Chul
   Cho, Eunyoung
   Jee, Donghyun
TI Association Between Blood Cadmium Level and Age-Related Macular
   Degeneration in a Representative Korean Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE cadmium; age-related macular degeneration; sex difference; Korea
ID HUMAN RETINA; GENDER; HEALTH
AB PURPOSE. To investigate the association between blood cadmium level and AMD.
   METHODS. This population-based, cross-sectional study using a nationwide, systemically stratified, multistage, clustered sampling method included 4933 subjects older than 40 years who participated in the Korean National Health and Nutrition Examination Survey (KNHANES) between 2008 and 2012 and had fundus photographs taken. All participants underwent a standardized interview, evaluation of blood cadmium concentrations, and comprehensive ophthalmic examination. A 45 degrees digital fundus photograph was taken from both eyes under physiologic mydriasis, and were graded using the international classification and grading system for AMD.
   RESULTS. Mean blood cadmium levels were 1.47 mu g/L in women and 1.19 mu g/L in men. After adjusting for potential confounders, including age, sex, and smoking status, the odds ratio (OR) for AMD was significantly increased in the highest quintile blood cadmium group (OR, 1.96; 95% confidence interval [CI], 1.17-3.29; P for trend = 0.017). This association between blood cadmium level and AMD was significant in men (OR, 2.11; 95% CI, 1.11-4.02; P for trend = 0.024), but not in women (OR, 1.29; 95% CI, 0.70-2.52; P for trend = 0.158).
   CONCLUSIONS. This study provides the first epidemiologic evidence that higher blood cadmium level is associated with AMD. Results of the present study indicate that an elevated cadmium burden may increase the risk of AMD development.
C1 [Kim, Eun Chul] Catholic Univ Korea, Coll Med, Buchon St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul 137040, South Korea.
   [Cho, Eunyoung] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
   [Cho, Eunyoung] Harvard Univ, Sch Med, Boston, MA USA.
   [Cho, Eunyoung] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA.
   [Jee, Donghyun] Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Ophthalmol & Visual Sci, Seoul 137040, South Korea.
C3 Catholic University of Korea; Harvard University; Brigham & Women's
   Hospital; Harvard University; Harvard Medical School; Brown University;
   Catholic University of Korea
RP Jee, D (通讯作者)，Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Ophthalmol & Visual Sci, 505 Banpo Dong, Seoul 137040, South Korea.
EM donghyunjee@catholic.ac.kr
RI Cho, Eunyoung/AAV-4469-2020
OI Cho, Eunyoung/0000-0001-6594-2582
FU St. Vincent's Hospital, Research Institute of Medical Science Foundation
   [5-2014-B000100101]
FX Supported by funding from St. Vincent's Hospital, Research Institute of
   Medical Science Foundation 2013 (5-2014-B000100101).
CR Akesson A, 2002, AM J PUBLIC HEALTH, V92, P284, DOI 10.2105/AJPH.92.2.284
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bertin G, 2006, BIOCHIMIE, V88, P1549, DOI 10.1016/j.biochi.2006.10.001
   Bhattacharyya MH., 2000, MOL BIOL TOXICOLOGY, P34
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   DeLaPaz MA, 1996, CURR EYE RES, V15, P273, DOI 10.3109/02713689609007621
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Eum KD, 2008, SCI TOTAL ENVIRON, V407, P147, DOI 10.1016/j.scitotenv.2008.08.037
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarup L, 2009, TOXICOL APPL PHARM, V238, P201, DOI 10.1016/j.taap.2009.04.020
   Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kalariya NM, 2009, EXP EYE RES, V89, P494, DOI 10.1016/j.exer.2009.05.011
   Kim K, 2012, ENVIRON RES, V112, P225, DOI 10.1016/j.envres.2011.12.008
   Kim Yangho, 2013, J Prev Med Public Health, V46, P96, DOI 10.3961/jpmph.2013.46.2.96
   Lee MS, 2011, ENVIRON RES, V111, P171, DOI 10.1016/j.envres.2010.10.006
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Park HA, 2013, KOREAN J FAM MED, V34, P79, DOI 10.4082/kjfm.2013.34.2.79
   Satarug S, 2004, TOXICOL LETT, V148, P177, DOI 10.1016/j.toxlet.2003.09.015
   Satarug S, 2004, ENVIRON HEALTH PERSP, V112, P1099, DOI 10.1289/ehp.6751
   TY La, 2014, CURR EYE RES, V55, P1101
   Vahter M, 2007, ENVIRON RES, V104, P85, DOI 10.1016/j.envres.2006.08.003
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
NR 27
TC 17
Z9 17
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2014
VL 55
IS 9
BP 5702
EP 5710
DI 10.1167/iovs.14-14774
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DX
UT WOS:000343146900030
PM 25125608
DA 2022-11-30
ER

PT J
AU Porter, L
   Reynolds, N
   Ellis, JD
AF Porter, L
   Reynolds, N
   Ellis, JD
TI Total parenteral nutrition, vitamin E, and reversible macular
   dysfunction morphologically mimicking age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PATIENT
C1 Dundee Med Sch, Dept Med, Dundee, Scotland.
   Univ Dundee, Ninewells Hosp & Med Sch, Dept Ophthalmol, Dundee DD1 9SY, Scotland.
C3 University of Dundee; University of Dundee
RP Ellis, JD (通讯作者)，Dept Ophthalmol, Dundee DD1 9SY, Scotland.
EM john.ellis@tuht.scot.nhs.uk
RI Porter, Louise/GQP-6108-2022
OI Porter, Louise/0000-0002-7406-0319
CR [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   KAWAKUBO K, 1994, POSTGRAD MED J, V70, P215, DOI 10.1136/pgmj.70.821.215
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1366
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1499
   VINTON NE, 1990, AM J CLIN NUTR, V52, P895, DOI 10.1093/ajcn/52.5.895
   YASSUR Y, 1981, BRIT J OPHTHALMOL, V65, P184, DOI 10.1136/bjo.65.3.184
   ZURDEL J, 2001, MED RADIOLOGY
NR 11
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2005
VL 89
IS 11
BP 1531
EP 1532
DI 10.1136/bjo.2005.074195
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 975HQ
UT WOS:000232652000038
PM 16234469
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Galor, A
   Karp, CL
   Forster, RK
   Dubovy, SR
   Gaunt, ML
   Miller, D
AF Galor, Anat
   Karp, Carol L.
   Forster, Richard K.
   Dubovy, Sander R.
   Gaunt, Morgan L.
   Miller, Darlene
TI Subconjunctival Mycetoma After Sub-Tenon's Corticosteroid Injection
SO CORNEA
LA English
DT Article
DE mycetoma; Exophiala; corticosteroid injection
ID EXOPHIALA-JEANSELMEI KERATITIS; TRIAMCINOLONE ACETONIDE; DERMATITIDIS
   KERATITIS; WANGIELLA-DERMATITIDIS; ENDOPHTHALMITIS; BOYDII
AB Purpose: To describe a case of a subconjunctival mycetoma that developed after a patient received a sub-Tenon's injection of triamcinolone acetonide.
   Methods: Case report.
   Results: A 76-year-old white male presented with a subconjunctival mass in the area of a previous posterior sub-Tenon's corticosteroid injection for wet age-related macular degeneration. Microbiologic and pathologic analysis of the mass revealed the causative organism to be the pigmented fungus Exophiala jeanselmei.
   Conclusion: This is the first published case of an Exophiala-associated subconjunctival mycetoma.
C1 [Galor, Anat; Karp, Carol L.; Forster, Richard K.; Dubovy, Sander R.; Gaunt, Morgan L.; Miller, Darlene] Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Karp, CL (通讯作者)，Univ Miami, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM ckarp@med.miami.edu
RI Miller, Darlene/C-9053-2013
FU Research to Prevent Blindness
FX Supported by Unrestricted grant from Research to Prevent Blindness.
CR ALHEDAITHY SSA, 1993, MYCOSES, V36, P97, DOI 10.1111/j.1439-0507.1993.tb00695.x
   Ben-Simon GJ, 2002, CORNEA, V21, P230, DOI 10.1097/00003226-200203000-00023
   Benaoudia F, 1999, MED MYCOL, V37, P53, DOI 10.1080/02681219980000071
   Chen Jiunn-Liang, 2005, Kaohsiung Journal of Medical Sciences, V21, P286, DOI 10.1016/S1607-551X(09)70203-7
   HAMMER ME, 1983, ANN OPHTHALMOL, V15, P853
   Hofling-Lima AL, 1999, AM J OPHTHALMOL, V128, P512, DOI 10.1016/S0002-9394(99)00192-0
   Oestreicher JH, 1999, OPHTHALMOLOGY, V106, P987, DOI 10.1016/S0161-6420(99)00521-7
   Oh IK, 2007, GRAEF ARCH CLIN EXP, V245, P164, DOI 10.1007/s00417-006-0325-3
   Patel SR, 2006, J CATARACT REFR SURG, V32, P681, DOI 10.1016/j.jcrs.2006.01.040
   PERSAUD V, 1968, BRIT J OPHTHALMOL, V52, P857, DOI 10.1136/bjo.52.11.857
   POSPISIL L, 1990, OPHTHALMOLOGICA, V201, P128, DOI 10.1159/000310140
   Singh R, 2006, ANN OPHTHALMOL, V38, P253, DOI 10.1007/s12009-006-0015-0
   Zeng JS, 2007, J CLIN MICROBIOL, V45, P3713, DOI 10.1128/JCM.02012-06
NR 13
TC 11
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3740
EI 1536-4798
J9 CORNEA
JI Cornea
PD SEP
PY 2009
VL 28
IS 8
BP 933
EP 935
DI 10.1097/ICO.0b013e3181930bb7
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 488QJ
UT WOS:000269364500020
PM 19654518
DA 2022-11-30
ER

PT J
AU Dabir, S
   Bhatt, V
   Bhatt, D
   Rajan, M
   Samant, P
   Munusamy, S
   Webers, CAB
   Berendschot, TTJM
AF Dabir, Supriya
   Bhatt, Vaidehi
   Bhatt, Deepak
   Rajan, Mohan
   Samant, Preetam
   Munusamy, Sivakumar
   Webers, C. A. B.
   Berendschot, T. T. J. M.
TI Need for manual segmentation in optical coherence tomography angiography
   of neovascular age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID BIOMARKERS; ARTIFACTS
AB Purpose
   To compare the characteristics of eyes that had manual vs. automated segmentation of choroidal neovascular membrane (CNVM) using optical coherence tomography angiography (OCTA).
   Methods
   All patients with CNVM underwent OCTA using the Zeiss Angioplex Cirrus 5000. Slabs of the avascular outer retina, outer retina to choriocapillaris (ORCC) region and choriocapillaris were generated. Manual segmentation was done when there were significant segmentation artifacts. Presence of activity of CNVM was adjudged by the presence of subretinal fluid (SRF) on structural OCT and was compared to activity detected on en face OCTA slabs based on well-defined criteria.
   Results
   Eighty-one eyes of 81 patients were recruited of which manual segmentation was required in 46 (57%). Eyes with automated segmentation had significantly more CNVM in the ORCC (75%) whereas those with manual segmentation had deeper CNVM (sub-RPE = 22%, intra-PED = 22%) (p<0.001). Twenty eyes (25%) were found to have active CNVM on both the structural OCT and OCTA while an additional 19 eyes were presumed to have active CNVM on OCTA alone. There was only modest concordance between disease activity detected using structural OCT and OCTA (Kappa = 0.47, 95% CI = 0.30 to 0.64).
   Conclusions
   Manual segmentation of OCTA is required in more than 50% eyes with CNVM and this progressively increases with increasing depth of CNVM location from the ORCC to below the RPE. There is moderate concordance between OCTA and structural OCT in determining CNVM activity.
C1 [Dabir, Supriya; Rajan, Mohan; Munusamy, Sivakumar] Rajan Eye Care Pvt Ltd, Dept Retina, Chennai, Tamil Nadu, India.
   [Bhatt, Vaidehi] Rajiv Gandhi Med Coll, Thana, India.
   [Bhatt, Deepak] UBM Inst, Mumbai, Maharashtra, India.
   [Samant, Preetam] PD Hinduja Hosp & Med Res Ctr, Dept Retina, Mumbai, Maharashtra, India.
   [Webers, C. A. B.; Berendschot, T. T. J. M.] Univ Eye Clin Maastricht, Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC)
RP Dabir, S (通讯作者)，Rajan Eye Care Pvt Ltd, Dept Retina, Chennai, Tamil Nadu, India.
EM supriad@gmail.com
RI Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X; Dabir,
   Supriya/0000-0002-3409-0134
FU Rajan eye care pvt ltd, Chennai; Maastricht University
FX Rajan eye care pvt ltd, Chennai, provided support in the form of
   salaries for authors (Dabir, Rajan, Sivakumar) but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. The specific
   roles of these authors are articulated in the `author contributions'
   section. This does not alter our adherence to PLOS ONE policies on
   sharing data and materials. Maastricht University is funding the article
   processing fees.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Au A, 2019, INVESTIG OPHTHALMOL, DOI [10.1167/iovs.18-26478, DOI 10.1167/I0VS.18-26478]
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P291, DOI 10.1007/s00417-020-04821-6
   Corvi F, 2020, RETINA-J RET VIT DIS, V40, P873, DOI 10.1097/IAE.0000000000002471
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Khurana RN, 2020, OPHTHALMOL RETINA, V4, P1054, DOI 10.1016/j.oret.2020.04.016
   Lauermann JL, 2018, GRAEF ARCH CLIN EXP, V256, P1807, DOI 10.1007/s00417-018-4053-2
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Sambhav K, 2017, SURV OPHTHALMOL, V62, P838, DOI 10.1016/j.survophthal.2017.05.006
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Siggel R, 2020, OPHTHALMOL RETINA, V4, P471, DOI 10.1016/j.oret.2019.11.018
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
NR 19
TC 2
Z9 2
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2020
VL 15
IS 12
AR e0244828
DI 10.1371/journal.pone.0244828
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PP1TW
UT WOS:000605651900106
PM 33382865
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Steinberg, JS
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Steinberg, Julia S.
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Foveal Sparing of Reticular Drusen in Eyes With Early and Intermediate
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; reticular drusen; reticular
   pseudodrusen; subretinal deposits; foveal sparing
ID FUNDUS AUTOFLUORESCENCE PATTERNS; OPTICAL COHERENCE TOMOGRAPHY;
   VISUAL-ACUITY LOSS; BEAVER DAM EYE; GEOGRAPHIC-ATROPHY; LONGITUDINAL
   ANALYSIS; STARGARDT-DISEASE; RISK-FACTOR; PSEUDODRUSEN; MACULOPATHY
AB PURPOSE. To analyze the central distribution of reticular drusen (RDR) in eyes with early and intermediate AMD without soft drusen or pigmentary changes within the central subfield using confocal scanning laser ophthalmoscopy (cSLO) and spectral-domain optical coherence tomography (SD-OCT).
   METHODS. Fifty-two eyes of 46 subjects (median age: 76.3 years, interquartile range [ IQR], 71-80) were examined by simultaneous combined near-infrared cSLO and raster SD-OCT imaging. The appearance and the topographic distribution of RDR were analyzed within the macula area using the Early Treatment Diabetic Retinopathy Study grid. In addition, longitudinal examinations during an observation period of at least 6 months were included (median observation time: 1.5 years, IQR, 0.9-2.8).
   RESULTS. The RDR involvement within the central subfield (46%) was less compared with the surrounding subfields (62%-100%), slices (67%-100%), and zones (94%-100%) (P < 0.001). RDR were typically distributed as one continuous zone around the fovea in an incomplete or complete ring-shaped pattern, whereas the fovea itself was either spared or only a few lesions were present. Over time, the RDR density increased and new RDR lesions occurred at the border of the RDR zone toward a closure of the ring-shaped pattern. Within the fovea, development of RDR was observed in 8 of 28 eyes.
   CONCLUSIONS. The fovea appears to be less vulnerable to RDR development as compared with peripheral macula areas. Factors for initial sparing of the foveal retina are yet unknown but may relate to topographic differences of choroidal blood flow and/or photoreceptor distribution.
C1 [Steinberg, Julia S.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
CR Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Auge J, 2014, OPHTHALMOLOGE, V111, P765, DOI 10.1007/s00347-013-2965-0
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   de Laat P, 2013, OPHTHALMOLOGY, V120, P2684, DOI 10.1016/j.ophtha.2013.05.013
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, JAMA OPHTHALMOL, DOI [10.1001/jamaophthalmol.2015.0477, DOI 10.1001/JAMAOPTHALMOL2015.0477]
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Huet RAC, 2014, INVEST OPHTH VIS SCI, V55, P7467, DOI 10.1167/iovs.13-13825
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 47
TC 21
Z9 21
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2015
VL 56
IS 8
BP 4267
EP 4274
DI 10.1167/iovs.15-16657
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT5WV
UT WOS:000362882700011
PM 26161988
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Luu, CD
   Baird, PN
   Guymer, RH
AF Wu, Zhichao
   Ayton, Lauren N.
   Luu, Chi D.
   Baird, Paul N.
   Guymer, Robyn H.
TI Reticular Pseudodrusen in Intermediate Age-Related Macular Degeneration:
   Prevalence, Detection, Clinical, Environmental, and Genetic Associations
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE reticular pseudodrusen; subretinal drusenoid deposits; drusen;
   age-related macular degeneration
ID NASCENT GEOGRAPHIC ATROPHY; RISK-FACTORS; FELLOW EYE; PROGRESSION;
   DRUSEN; MACULOPATHY
AB PURPOSE. To determine the prevalence of reticular pseudodrusen (RPD) and their detection using multimodal imaging in patients with bilateral large drusen, and examine their clinical, demographic, environmental, and genetic associations.
   METHODS. Three hundred participants with bilateral large drusen (>125 mu m) underwent color fundus photography (CFP), near-infrared reflectance (NIR), fundus autofluorescence (FAF), and spectral-domain optical coherence tomography (SD-OCT) imaging. Demographic information, smoking, and medical history were recorded, and a blood sample was obtained and genotyped to identify the risk alleles of the CFH and ARMS2 genes.
   RESULTS. Reticular pseudodrusen were detected in 28.2% eyes of 29.0% participants using NIR and SD-OCT combined, but CFP and FAF detected only 42% and 89%, respectively, of these eyes with RPD. Participants with RPD were significantly older than those without (P < 0.001), but there was no significant difference in sex distribution, smoking history, cardiovascular factors, and minor allele frequency of the CFH gene (P > 0.173). However, the minor allele frequency of the ARMS2 gene was significantly higher in participants with RPD (P = 0.002). The presence of RPD was also independently associated with the presence of atrophic changes (including nascent geographic atrophy and drusen-associated atrophy detected on SD-OCT; P = 0.043).
   CONCLUSIONS. Reticular pseudodrusen were detected on NIR and SD-OCT in more than a quarter of participants with bilateral large drusen, being often overlooked with CFP. Those with RPD had a higher frequency of the ARMS2 risk variant, and eyes with RPD were more likely to have atrophic changes. These findings are important to consider when managing patients with intermediate AMD.
C1 [Wu, Zhichao; Ayton, Lauren N.; Luu, Chi D.; Baird, Paul N.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Wu, Zhichao; Ayton, Lauren N.; Luu, Chi D.; Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Luu, Chi/0000-0002-7604-7097; Baird,
   Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) [1027624, 1028444];
   Macular Disease Foundation Australia Research Grant; Bupa Health
   Foundation (Australia); BrightFocus Foundation; NHMRC Centre for
   Clinical Research Excellence Award [529923]
FX Supported by National Health and Medical Research Council (NHMRC;
   Project Grant 1027624, Senior Research Fellowship 1028444 [PNB]),
   Macular Disease Foundation Australia Research Grant, Bupa Health
   Foundation (Australia), and BrightFocus Foundation. CERA receives
   operational infrastructure support from the Victorian government and is
   supported by an NHMRC Centre for Clinical Research Excellence Award
   (529923).
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda Arakawa N, 2013, AM J OPHTHALMOL, V155
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 31
TC 47
Z9 47
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2016
VL 57
IS 3
BP 1310
EP 1316
DI 10.1167/iovs.15-18682
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK4BE
UT WOS:000374860600073
PM 26998717
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Keane, PA
   Heussen, FM
   Ouyang, YL
   Mokwa, N
   Walsh, AC
   Tufail, A
   Sadda, SR
   Patel, PJ
AF Keane, Pearse A.
   Heussen, Florian M.
   Ouyang, Yanling
   Mokwa, Nils
   Walsh, Alexander C.
   Tufail, Adnan
   Sadda, Srinivas R.
   Patel, Praveen J.
TI Assessment of Differential Pharmacodynamic Effects Using Optical
   Coherence Tomography in Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; QUANTITATIVE SUBANALYSIS; PHOTODYNAMIC
   THERAPY; RETINAL MORPHOLOGY; DOSING REGIMEN; RANIBIZUMAB; BEVACIZUMAB;
   VERTEPORFIN; PEGAPTANIB; THICKNESS
AB PURPOSE. To use novel OCT parameters in assessing the differential pharmacodynamic effects of bevacizumab (Avastin; Genentech, South San Francisco, CA), pegaptanib (Macugen; OSI Pharmaceuticals, New York, NY), and verteporfin photodynamic therapy (PDT; Novartis, Basel, Switzerland) in a recently completed phase III/IV clinical trial.
   METHODS. Data from 122 patients participating in the Avastin (Bevacizumab) for Choroidal Neovascularization (ABC) trial, were evaluated. OCT scans were analyzed with custom software. Changes in the volume of the neurosensory retina, amount of subretinal fluid (SRF), pigment epithelium detachment (PED), and subretinal tissue (SRT), were calculated over the 54-week trial period.
   RESULTS. Reductions in retinal edema were more than twice as great from bevacizumab as from pegaptanib (-0.82 mm(3) vs. -0.31 mm(3)), whereas SRF reduction was more than three times greater (-0.54 mm(3) vs. -0.15 mm(3)). Both bevacizumab and pegaptanib led to rapid reductions in SRT; however, in those receiving pegaptanib, these improvements were not maintained (at week 54, -0.22 mm(3) vs. +0.18 mm(3)). Acute increases in SRF were seen 1 week after PDT (+0.36 mm(3)) and, across all treatment groups, PED volume tended to remain unchanged or to regress only slowly.
   CONCLUSIONS. In clinical trials, quantitative OCT subanalysis increases the amount of clinically useful information that can be obtained from OCT images. In the emerging era of neovascular AMD therapeutics, the capacity of OCT to provide such detailed pharmacodynamic information in a noninvasive manner is likely to attain increased importance. In future comparative studies, evaluation of SRT may highlight differential effects on vascular proliferation, whereas measurement of PED volume may be useful for the estimation of retinal and subretinal pigment epithelium (RPE) therapeutic penetration. (ClinicalTrials.gov number, ISRCTN83325075.) (Invest Ophthalmol Vis Sci. 2012;53:1152-1161) DOI:10.1167/iovs.11-8130
C1 [Keane, Pearse A.; Tufail, Adnan; Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
   [Keane, Pearse A.; Tufail, Adnan; Patel, Praveen J.] UCL Inst Ophthalmol, London EC1V 2PD, England.
   [Heussen, Florian M.; Ouyang, Yanling; Mokwa, Nils; Walsh, Alexander C.; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Heussen, Florian M.; Ouyang, Yanling; Mokwa, Nils; Walsh, Alexander C.; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Heussen, Florian M.] Charite, Dept Ophthalmol, D-13353 Berlin, Germany.
   [Ouyang, Yanling] Fudan Univ, EENT Eye Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Doheny Eye Institute; University of Southern California; University of
   Southern California; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Fudan University
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM praveen.patel@moorfields.nhs.uk
RI Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X; Tufail, Adnan/0000-0001-6131-7640;
   Heussen, Florian Moritz/0000-0003-0536-9870
FU Deutsche Forschungsgemeinschaft [He 6094/1-1]; National Institutes of
   Health [EY03040]; National Eye Institute [R01 EY014375]; Research to
   Prevent Blindness; Department of Health's NIHR Biomedical Research
   Centre for Ophthalmology at Moorfields Eye Hospital; UCL Institute of
   Ophthalmology; Academy of Medical Sciences (AMS) [AMS-SGCL6-Keane]
   Funding Source: researchfish; National Institute for Health Research
   [CL-2010-18-004] Funding Source: researchfish; NATIONAL EYE INSTITUTE
   [R01EY014375, P30EY003040] Funding Source: NIH RePORTER
FX Supported in part by the Deutsche Forschungsgemeinschaft Grant He
   6094/1-1; National Institutes of Health Grant EY03040, National Eye
   Institute Grant R01 EY014375, and Research to Prevent Blindness. PAK,
   AT, and PJP received a proportion of their funding from the Department
   of Health's NIHR Biomedical Research Centre for Ophthalmology at
   Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views
   expressed in the publication are those of the authors and not
   necessarily those of the Department of Health.
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Alasil T, 2010, OPHTHALMOLOGY, V117, P2379, DOI 10.1016/j.ophtha.2010.03.051
   Audren F, 2004, INVEST OPHTH VIS SCI, V45, P3435, DOI 10.1167/iovs.03-1110
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Dingemanse J, 2007, CLIN PHARMACOKINET, V46, P713, DOI 10.2165/00003088-200746090-00001
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Emerson GG, 2007, RETINA-J RET VIT DIS, V27, P724, DOI 10.1097/IAE.0b013e318042b3c8
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Han IC, 2010, OPHTHALMOLOGY, V117, P1177, DOI 10.1016/j.ophtha.2009.10.029
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2010, BRIT J OPHTHALMOL, V94, P143, DOI 10.1136/bjo.2009.159863
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2010, EYE, V24, P422, DOI 10.1038/eye.2009.309
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane Pearse A, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS85, DOI 10.3928/15428877-20101031-10
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Lloyd R, 2008, CURR OPIN OPHTHALMOL, V19, P190, DOI 10.1097/ICU.0b013e3282f97fa1
   Mager DE, 2009, DRUG METAB PHARMACOK, V24, P16, DOI 10.2133/dmpk.24.16
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   S Liakopoulos, 2008, INVEST OPHTH VIS SCI, V49, P548
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 55
TC 18
Z9 19
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2012
VL 53
IS 3
BP 1152
EP 1161
DI 10.1167/iovs.11-8130
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VT
UT WOS:000302790700011
PM 22281826
OA Green Published
DA 2022-11-30
ER

PT J
AU Carneiro, A
   Falcao, M
   Azevedo, I
   Reis, FF
   Soares, R
AF Carneiro, Angela
   Falcao, Manuel
   Azevedo, Isabel
   Reis, Fernando Falcao
   Soares, Raquel
TI Multiple effects of bevacizumab in angiogenesis: implications for its
   use in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE AMD; angiogenesis; anti-VEGF; Avastin; choroidal neovascularization;
   endothelium; HUVEC
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB; INJECTION; EDEMA; PENETRATION;
   FRAGMENT; CANCER
AB Purpose:
   This study aimed to elucidate the precise effects of bevacizumab in all steps in the neovascularization process in endothelial cells.
   Methods:
   Human umbilical vein endothelial cells (HUVECs) were incubated with bevacizumab at concentrations within the clinically established range or with identical amounts of excipient. Cell cytotoxicity (evaluated by MTT assay), proliferation (by BrdU incorporation assay), apoptosis (by TUNEL assay), migration (by double-chamber assay) and vessel assembly in matrigel-coated plates were assessed in vitro. Mouse plug matrigel assays were performed to confirm in vitro results.
   Results:
   Incubation of HUVECs with bevacizumab did not present cytotoxicity. Concentrations comparable with those after intravitreal doses of bevacizumab significantly reduced proliferation and migration capacity, and increased apoptotic rates in these cells. In addition, bevacizumab led to a significant decrease in the assembly of capillary-like structures on matrigel assay in comparison with excipient-treated cells. Further substantiating these in vitro findings, bevacizumab also inhibited angiogenesis in a mouse plug matrigel assay, as evaluated by haemoglobin content levels.
   Conclusions:
   These results demonstrate that clinical doses of bevacizumab are able to prevent several steps of the angiogenic process. Bevacizumab is thus currently recommended for treating disorders that present augmented angiogenesis.
C1 [Azevedo, Isabel; Soares, Raquel] Univ Porto, Dept Biochem FCT U38, Fac Med, P-4200319 Oporto, Portugal.
   [Carneiro, Angela; Falcao, Manuel; Reis, Fernando Falcao] Univ Porto, Dept Ophthalmol, Fac Med, P-4200319 Oporto, Portugal.
   [Carneiro, Angela; Falcao, Manuel; Reis, Fernando Falcao] Sao Joao Hosp, Dept Ophthalmol, Oporto, Portugal.
C3 Universidade do Porto; Universidade do Porto; Sao Joao Hospital
RP Soares, R (通讯作者)，Univ Porto, Dept Biochem, Fac Med, P-4200319 Oporto, Portugal.
EM raqsoa@med.up.pt
RI Falcao/AAQ-8509-2020; Carneiro, Angela/N-9680-2013; Soares,
   Raquel/L-2349-2013
OI Falcao/0000-0003-4718-0910; Carneiro, Angela/0000-0002-3370-7243;
   Soares, Raquel/0000-0002-9157-5541; Falcao-Reis,
   Fernando/0000-0002-5995-9430
FU Fundacao para a Ciencia e Tecnologia FCT [POCI/BM/55556/04]
FX This study was partially funded by Fundacao para a Ciencia e Tecnologia
   FCT (POCI/BM/55556/04).
CR Costa Carla, 2007, Angiogenesis, V10, P149, DOI 10.1007/s10456-007-9074-0
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Drabkin DL, 1932, J BIOL CHEM, V98, P719
   *EUR MED AG, 2005, SCI DISC
   Ferrara F, 2004, ELECT STUD, V23, P391, DOI 10.1016/s0261-3794(03)00028-3
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kernt M, 2008, ACTA OPHTHALMOL, V86, P456, DOI 10.1111/j.1600-0420.2007.01014.x
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Melo GB, 2007, ACTA OPHTHALMOL SCAN, V85, P461, DOI 10.1111/j.1600-0420.2006.00872.x
   MINNELLA AM, 2007, ACTA OPHTHA IN PRESS
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Rocha A, 2008, J CELL BIOCHEM, V103, P607, DOI 10.1002/jcb.21432
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saif MW, 2006, EXPERT OPIN DRUG SAF, V5, P553, DOI 10.1517/14740338.5.4.553
   Shah MA, 2005, J CLIN ONCOL, V23, P2574, DOI 10.1200/JCO.2005.81.908
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SHIMA C, 2007, ACTA OPHTHA IN PRESS
   Shojaei F, 2007, LAB INVEST, V87, P227, DOI 10.1038/labinvest.3700526
   Soares R, 2004, MOL ENDOCRINOL, V18, P2333, DOI 10.1210/me.2003-0362
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Spandau UHM, 2006, ACTA OPHTHALMOL SCAN, V84, P555, DOI 10.1111/j.1600-0420.2006.00740.x
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Yoeruek E, 2008, ACTA OPHTHALMOL, V86, P322, DOI 10.1111/j.1600-0420.2007.01049.x
   Ziemssen F, 2007, ACTA OPHTHALMOL SCAN, V85, P573, DOI 10.1111/j.1600-0420.2007.00938.x
NR 32
TC 12
Z9 12
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2009
VL 87
IS 5
BP 517
EP 523
DI 10.1111/j.1755-3768.2008.01257.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 473NO
UT WOS:000268214200007
PM 18717653
OA Bronze
DA 2022-11-30
ER

PT J
AU Cohn, AC
   Runciman, J
   Hodgson, LAB
   Caruso, E
   Arnold, JJ
   Chen, FK
   Chakravarthy, U
   Heriot, WJ
   Guymer, RH
   Wu, ZC
AF Cohn, Amy C.
   Runciman, Jim
   Hodgson, Lauren A. B.
   Caruso, Emily
   Arnold, Jennifer J.
   Chen, Fred K.
   Chakravarthy, Usha
   Heriot, Wilson J.
   Guymer, Robyn H.
   Wu, Zhichao
CA LEAD Study Grp
TI Dose Response in the Subthreshold Nanosecond Laser Trial in Early Stages
   of AMD: A LEAD Study Report
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; ATROPHY; RISK
AB BACKGROUND AND OBJECTIVE: To examine the association between treatment parameters and the progression to late age-related macular degeneration (AMD) in the Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study, a randomized, controlled trial of a subthreshold nanosecond laser (SNL) for slowing disease progression in the early stages of AMD.
   PATIENTS AND METHODS: The association between treatment parameters early in the trial period for participants in the SNL arm of the LEAD study and time to develop late AMD during the 3-year trial duration was examined. Parameters included treatment energy at the baseline and 6-month visits and the number of laser spots visible on fundus autofluorescence (FAF) imaging taken at 6 and 12 months (taken as a proxy measure of early, adequate delivery of the laser treatment at the baseline and 6-month visits, respectively).
   RESULTS: A multivariable analysis revealed there were no significant associations between time to develop late AMD and number of FAF-visible laser spots at 6-months (adjusted P = .537) nor laser energy used at baseline (adjusted P = .910). No significant associations were also observed when evaluating FAF-visible spots at 12-months (adjusted P = .107) and the average laser energy used at baseline and 6 months (adjusted P = .558).
   CONCLUSIONS: This study did not find any evidence to suggest that there was a dose response for the effect of laser treatment using these treatment parameters on the progression of AMD.
C1 [Cohn, Amy C.; Hodgson, Lauren A. B.; Caruso, Emily; Guymer, Robyn H.; Wu, Zhichao] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Runciman, Jim] Adelaide Eye & Retina Ctr, Adelaide, SA, Australia.
   [Arnold, Jennifer J.] Marsden Eye Res, Sydney, NSW, Australia.
   [Chen, Fred K.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Inc Lions Eye Inst, Perth, WA, Australia.
   [Chen, Fred K.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Heriot, Wilson J.] Retinol Inst Victoria, Glen Iris, Vic, Australia.
   [Guymer, Robyn H.; Wu, Zhichao] Univ Melbourne, Ophthalmol, Dept Surg, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   Lions Eye Institute; University of Western Australia; Royal Perth
   Hospital; University of Western Australia; University of Melbourne
RP Cohn, AC (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM amycohn1@gmail.com
OI Chen, Fred/0000-0003-2809-9930
FU National Health & Medical Research Council of Australia [APP1027624,
   GNT1103013, APP1104985, APP1054712, APP1142962, GNT1128343]; BUPA Health
   Foundation (Australia); CERA; Ellex R&D Pty Ltd (Adelaide, Australia)
FX Supported by National Health & Medical Research Council of Australia
   (project grant No. APP1027624 [RHG and CDL]); fellowship grants No.
   GNT1103013 (RHG), APP1104985 [ZW], APP1054712 [FKC], APP1142962 [FKC],
   and GNT1128343 [SSW]); and BUPA Health Foundation (Australia) (RHG and
   CDL). The Centre for Eye Research Australia (CERA) receives operational
   infrastructure support from the Victorian Government. Ellex R&D Pty Ltd
   (Adelaide, Australia) provided partial funding of the central
   coordinating center and the in-kind provision of Ellex 2RT laser
   systems, ongoing support of those systems, and the Macular Integrity
   Assessment micro-perimeters for the duration of the study. The web-based
   Research Electronic Data Capture (REDCap) application and open-source
   platform OpenClinica allowed secure electronic data capture. The study
   is sponsored by CERA, an independent medical research institute and a
   not-for-profit company. Dr. Cohn has received personal fees from Bayer
   and Novartis. Dr. Arnold has received personal fees from Alcon,
   Allergan, Bayer, and Novartis. Dr. Chen has received personal fees from
   Bayer, Novartis, Allergan, Heidelberg Engineering, Alcon, and Pfizer, as
   well as research grants from Novartis and Bayer, outside the submitted
   work. Dr. Chakravarthy has received personal fees and research grants
   from Bayer, Novartis, and Roche outside the submitted work. Dr. Heriot
   has received personal fees from Alcon, Bayer and Novartis outside the
   submitted work. Dr. Guymer has received personal fees from Bayer,
   Novartis, Roche Genentech, and Apellis, as well as a research grant from
   Bayer, outside the submitted work. Drs. Runciman, Hodgson, Caruso, and
   Wu report no relevant financial disclosures.
CR Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 17
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL
PY 2021
VL 52
IS 7
BP 380
EP 386
DI 10.3928/23258160-20210628-04
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA TP8YW
UT WOS:000677881000004
PM 34309427
DA 2022-11-30
ER

PT J
AU Stein, JD
   Hanrahan, BW
   Comer, GM
   Sloan, FA
AF Stein, Joshua D.
   Hanrahan, Brian W.
   Comer, Grant M.
   Sloan, Frank A.
TI Diffusion of Technologies for the Care of Older Adults With Exudative
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; CHOROIDAL NEOVASCULARIZATION
   SECONDARY; BEVACIZUMAB AVASTIN; RANIBIZUMAB; THERAPY; SAFETY; TRIAL
AB PURPOSE: To determine patterns of diffusion of diagnostic tests and therapeutic interventions in the United States through 2010 for patients with newly diagnosed exudative macular degeneration (AMD).
   DESIGN: Retrospective longitudinal cohort analysis.
   METHODS: SETTING AND PATIENT POPULATION: A total of 23 941 Medicare beneficiaries with exudative AMD newly diagnosed during 1992-2009. OBSERVATION PROCEDURES: Current Procedural Technology (CPT-4) billing codes were used to identify use of diagnostic tests (optical coherence tomography, fluorescein angiography, and fundus photography) and therapeutic interventions (argon laser photocoagulation, photodynamic therapy, intravitreal corticosteroids, and anti-vascular endothelial growth factor [VEGF] agents) used by these beneficiaries during the first year following diagnosis. MAIN OUTCOME MEASURES: Rates of use of study diagnostic and therapeutic procedures.
   RESULTS: Diffusion was rapid for each successive new diagnostic and treatment modality, with use of newer procedures quickly replacing existing ones. The number of beneficiaries treated with anti-VEGF agents for exudative AMD was considerably greater than for prior innovations, rising from use in 4.0% of beneficiaries in 2004-05 to 62.7% in 2009-10. In each year from first diagnosis years 2006-2009 and in different practice settings, use of bevacizumab exceeded that of ranibizumab (60%-78% vs 33%-47%, respectively). Rates of diffusion of the various therapies were relatively similar in communities throughout the United States irrespective of presence of a major teaching hospital in the vicinity.
   CONCLUSIONS: Newer, more effective therapeutic interventions for exudative AMD diffused rapidly throughout the United States, quickly replacing older, less effective interventions. Although improving patient outcomes, rapid diffusion raises important public policy issues for Medicare and other payers to consider. (Am J Ophthalmol 2013;155:688-696. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Stein, Joshua D.; Comer, Grant M.] Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA.
   [Hanrahan, Brian W.; Sloan, Frank A.] Duke Univ, Dept Econ, Durham, NC 27706 USA.
C3 University of Michigan System; University of Michigan; Duke University
RP Sloan, FA (通讯作者)，213 Social Sci Bldg,Box 90097, Durham, NC 27708 USA.
EM fsloan@duke.edu
OI Stein, Joshua/0000-0003-2937-6987
FU National Eye Institute K23 Mentored Clinician Scientist Award
   [1K23EY019511-01]; Blue Cross Blue Shield of Michigan Foundation;
   National Institute on Aging [5R01AG017473-11]; NATIONAL EYE INSTITUTE
   [K23EY019511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK092926] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017473] Funding Source:
   NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. The authors indicate the following
   funding support and financial disclosures: National Eye Institute K23
   Mentored Clinician Scientist Award (J.D.S.;1K23EY019511-01); Blue Cross
   Blue Shield of Michigan Foundation (J.D.S.); National Institute on Aging
   (5R01AG017473-11). The funding organizations had no role in the design
   or conduct of this research. No conflicting relationship exists for any
   author. Contributions of authors: involved in design and conduct of the
   study (F.S., J.S., BR.); collection, management, analysis, and
   interpretation of the data (F.S., J.S., B.H.); and preparation, review,
   or approval of the manuscript (F.S., J.S., B.H., G.C.).
CR Accreditation Council for Graduate Medical Education, 2012, ACCR OPHTH SPEC PROG
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Association of American Medical Colleges, 2010, MED SCH MEMB DIR 201
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bagchi K, 2008, INFORM MANAGE-AMSTER, V45, P183, DOI 10.1016/j.im.2007.12.005
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Comin D, 2010, AM ECON REV, V100, P2031, DOI 10.1257/aer.100.5.2031
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1358
   Finkelstein A, 2007, Q J ECON, V122, P1, DOI 10.1162/qjec.122.1.1
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gillies MC, 2007, AM J OPHTHALMOL, V144, P134, DOI 10.1016/j.ajo.2007.03.019
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier, 2007, ARCH OPHTHALMOL-CHIC, V125, P138
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oh EH, 2005, INT J TECHNOL ASSESS, V21, P73, DOI 10.1017/S0266462305050099
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   The Trustees of Dartmouth College, 2012, DARTM ATL HLTH CAR D
   Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 29
TC 17
Z9 17
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2013
VL 155
IS 4
BP 688
EP 696
DI 10.1016/j.ajo.2012.10.003
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 118JS
UT WOS:000317022400011
PM 23219066
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hanumunthadu, D
   Lescrauwaet, B
   Jaffe, M
   Sadda, S
   Wiecek, E
   Hubschman, JP
   Patel, PJ
AF Hanumunthadu, Daren
   Lescrauwaet, Benedicte
   Jaffe, Myles
   Sadda, Srinivas
   Wiecek, Emily
   Hubschman, Jean Pierre
   Patel, Praveen J.
TI Clinical Update on Metamorphopsia: Epidemiology, Diagnosis and Imaging
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Optical coherence tomography; metamorphopsia; M-CHARTS; preferential
   hyperacuity perimetry; orientation discrimination threshold
ID PREFERENTIAL HYPERACUITY PERIMETER; QUALITY-OF-LIFE; DIABETIC MACULAR
   EDEMA; CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY;
   EPIRETINAL MEMBRANE; VISUAL-ACUITY; M-CHARTS; SHAPE-DISCRIMINATION;
   PROGNOSTIC-FACTORS
AB Purpose: To discuss the pathophysiology of metamorphopsia, its characterisation using retinal imaging and methods of assessment of patient symptoms and visual function. Methods: A literature search of electronic databases was performed Results: Metamorphopsia has commonly been associated with vitreomacular interface disorders (such as epiretinal membrane) and has also regularly been noted in diseases of the retina and choroid, particularly age-related macular degeneration and central serous chorioretinopathy. Developments in optical coherence tomography retinal imaging have enabled improved imaging of the foveal microstructure and have led to the localisation of the pathophysiology of metamorphopsia within the retinal layers of the macula. Alteration of alignment of inner and outer retinal layers at various retinal loci has been identified using multimodal imaging in patients with metamorphopsia in a range of conditions. Although the Amsler Grid assessment of metamorphopsia is a useful clinical indicator, new emerging methods of metamorphopsia assessment with psychophysical tests such as M-CHARTS and preferential hyperacuity perimetry, have been developed. Conclusions: It appears that there is a complex relationship between visual acuity and metamorphopsia symptoms that vary between retinal conditions. Although metamorphopsia has traditionally been challenging to measure in the clinic, advances in technology promise more robust, easy-to-use tests. It is possible that home assessment of metamorphopsia, particularly in conditions such as age-related macular degeneration, may help to guide the need for further clinic evaluation and consideration of treatment.
C1 [Hanumunthadu, Daren; Patel, Praveen J.] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Hanumunthadu, Daren; Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
   [Lescrauwaet, Benedicte] Xintera Bv, Ghent, Belgium.
   [Jaffe, Myles] Innova Med Commun LLC, Tustin, CA USA.
   [Sadda, Srinivas] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA USA.
   [Wiecek, Emily] Boston Childrens Hosp, Dept Ophthalmol, Boston, MA USA.
   [Wiecek, Emily] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Hubschman, Jean Pierre] Univ Calif Los Angeles, Stein Eye Inst, Retina Div, Los Angeles, CA USA.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Doheny Eye Institute; University of California System; University of
   California Los Angeles; Harvard University; Boston Children's Hospital;
   Harvard University; Harvard Medical School; University of California
   System; University of California Los Angeles
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England.
EM praveen.patel1@nhs.net
CR Achiron A, 2015, ACTA OPHTHALMOL, V93, pE649, DOI 10.1111/aos.12735
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Bae K, 2016, AM J OPHTHALMOL, V169, P179, DOI 10.1016/j.ajo.2016.06.041
   Bae S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0170-4
   Bae SW, 2013, INDIAN J OPHTHALMOL, V61, P172, DOI 10.4103/0301-4738.112162
   Bae SH, 2013, AM J OPHTHALMOL, V155, P109, DOI 10.1016/j.ajo.2012.07.007
   Bahrami B, 2016, DIABETOLOGIA, V59, P1594, DOI 10.1007/s00125-016-3974-8
   Bormann Caroline, 2020, Retin Cases Brief Rep, V14, P377, DOI 10.1097/ICB.0000000000000717
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Carpineto P, 2019, RETINA-J RET VIT DIS, V39, P1061, DOI 10.1097/IAE.0000000000002546
   Chen TY, 2018, CURR EYE RES, V43, P1151, DOI 10.1080/02713683.2018.1481515
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Claessens D, 2019, KLIN MONATSBL AUGENH, V236, P877, DOI 10.1055/s-0043-125080
   dell'Omo R, 2013, INVEST OPHTH VIS SCI, V54, P7803, DOI 10.1167/iovs.13-12817
   Dell'Omo R, 2012, RETINA-J RET VIT DIS, V32, P719, DOI 10.1097/IAE.0b013e31822c293e
   Di Antonio L, 2015, EUR J OPHTHALMOL, V25, P68, DOI 10.5301/ejo.5000496
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Falkner-Radler CI, 2010, OPHTHALMOLOGY, V117, P798, DOI 10.1016/j.ophtha.2009.08.034
   Fink W, 2004, J BIOMED OPT, V9, P149, DOI 10.1117/1.1625952
   Francisconi CLM, 2019, J VITREORETIN DIS, V3, P297, DOI [10.1177/2474126419856461, DOI 10.1177/2474126419856461]
   Fu HJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185070
   Fujita K, 2014, RETINA-J RET VIT DIS, V34, P964, DOI 10.1097/IAE.0000000000000027
   Ghaffari-Rafi A, 2020, AM J CASE REP, V21, DOI 10.12659/AJCR.923441
   Ichikawa Y, 2018, EYE, V32, P400, DOI 10.1038/eye.2017.201
   Ichikawa Y, 2018, AM J OPHTHALMOL, V193, P20, DOI 10.1016/j.ajo.2018.06.001
   Ichikawa Y, 2017, RETINA-J RET VIT DIS, V37, P673, DOI 10.1097/IAE.0000000000001232
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khanna RK, 2021, GRAEF ARCH CLIN EXP, V259, P1723, DOI 10.1007/s00417-020-05064-1
   Kim JW, 2016, ACTA OPHTHALMOL, V94, pE54, DOI 10.1111/aos.12795
   Kinoshita T, 2016, GRAEF ARCH CLIN EXP, V254, P1041, DOI 10.1007/s00417-015-3147-3
   Kinoshita T, 2015, CLIN OPHTHALMOL, V9, P225, DOI 10.2147/OPTH.S76847
   Kinoshita T, 2012, INVEST OPHTH VIS SCI, V53, P3592, DOI 10.1167/iovs.12-9493
   Kroyer K, 2005, INVEST OPHTH VIS SCI, V46, P1017, DOI 10.1167/iovs.04-0952
   Lina G, 2016, EYE, V30, P40, DOI 10.1038/eye.2015.171
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Manabe K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186737
   Manabe K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153817
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mao JB, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01429-6
   Matsumoto C, 2003, INVEST OPHTH VIS SCI, V44, P4012, DOI 10.1167/iovs.03-0117
   Matsuoka Y, 2012, INVEST OPHTH VIS SCI, V53, P3054, DOI 10.1167/iovs.11-9153
   McGowan G, 2016, RETINA-J RET VIT DIS, V36, P703, DOI 10.1097/IAE.0000000000000778
   Murakami T, 2018, RETINA-J RET VIT DIS, V38, P684, DOI 10.1097/IAE.0000000000001588
   Murakami T, 2016, GRAEF ARCH CLIN EXP, V254, P2191, DOI 10.1007/s00417-016-3382-2
   Nakano E, 2019, GRAEF ARCH CLIN EXP, V257, P1873, DOI 10.1007/s00417-019-04393-0
   Ng HJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.34
   Nguyen JH, 2016, OPHTHALMOLOGY, V123, P1500, DOI 10.1016/j.ophtha.2016.03.022
   Nowacka B, 2016, DOC OPHTHALMOL, V132, P111, DOI 10.1007/s10633-016-9531-4
   Nowomiejska K, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-13
   Okamoto F, 2009, AM J OPHTHALMOL, V147, P869, DOI 10.1016/j.ajo.2008.11.018
   Ooto S, 2011, OPHTHALMOLOGY, V118, P873, DOI 10.1016/j.ophtha.2010.08.032
   Osaka R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204015
   Park SH, 2021, RETINA-J RET VIT DIS, V41, P931, DOI 10.1097/IAE.0000000000002955
   Patel PJ, 2019, EYE, V33, P435, DOI 10.1038/s41433-018-0230-0
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P7012, DOI 10.1167/iovs.11-7517
   Querques G, 2011, BRIT J OPHTHALMOL, V95, P986, DOI 10.1136/bjo.2010.190942
   Reznicek L, 2013, ACTA OPHTHALMOL, V91, pE529, DOI 10.1111/aos.12153
   Rossetti A, 2010, EYE, V24, P1808, DOI 10.1038/eye.2010.138
   Saito Y, 2000, ARCH OPHTHALMOL-CHIC, V118, P41
   Saleh M, 2018, OPHTHALMOLOGICA, V240, P121, DOI 10.1159/000486164
   Schawkat M, 2020, GRAEF ARCH CLIN EXP, V258, P57, DOI 10.1007/s00417-019-04498-6
   Simunovic MP, 2015, RETINA-J RET VIT DIS, V35, P1285, DOI 10.1097/IAE.0000000000000581
   Takabatake M, 2018, RETINA-J RET VIT DIS, V38, P2118, DOI 10.1097/IAE.0000000000001831
   Tanikawa A, 2018, JPN J OPHTHALMOL, V62, P280, DOI 10.1007/s10384-018-0581-x
   Terasaki H, 2019, INVEST OPHTH VIS SCI, V60
   Tozer Kevin R, 2013, Retin Cases Brief Rep, V7, P57, DOI 10.1097/ICB.0b013e318263d3ee
   Uji A, 2014, AM J OPHTHALMOL, V157, P227, DOI 10.1016/j.ajo.2013.09.008
   van de Put MAJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120543
   Von Helmholtz H, HELMHOLTZS TREATISE
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Watanabe A, 2009, OPHTHALMOLOGY, V116, P1788, DOI 10.1016/j.ophtha.2009.04.046
   Wiecek E, 2015, ACTA OPHTHALMOL, V93, pE318, DOI 10.1111/aos.12559
   Wiecek E, 2015, OPHTHALMOLOGY, V122, P431, DOI 10.1016/j.ophtha.2014.09.006
   Wiecek E, 2014, J VISION, V14, DOI 10.1167/14.14.1
   Wilkinson F, 1998, VISION RES, V38, P3555, DOI 10.1016/S0042-6989(98)00039-X
   Williams MA, 2009, AGE AGEING, V38, P648, DOI 10.1093/ageing/afp136
   Xu KY, 2018, CAN J OPHTHALMOL, V53, P168, DOI 10.1016/j.jcjo.2017.08.006
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
   Zhou CD, 2017, BRIT J OPHTHALMOL, V101, P725, DOI 10.1136/bjophthalmol-2016-309097
NR 81
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC 2
PY 2021
VL 46
IS 12
BP 1777
EP 1791
DI 10.1080/02713683.2021.1912779
EA MAY 2021
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XV0SU
UT WOS:000651252300001
PM 33825600
DA 2022-11-30
ER

PT J
AU Nashine, S
   Subramaniam, SR
   Chwa, M
   Nesburn, A
   Kuppermann, BD
   Federoff, H
   Kenney, MC
AF Nashine, Sonali
   Subramaniam, Sudhakar R.
   Chwa, Marilyn
   Nesburn, Anthony
   Kuppermann, Baruch D.
   Federoff, Howard
   Kenney, M. Cristina
TI PU-91 drug rescues human age-related macular degeneration RPE cells;
   implications for AMD therapeutics
SO AGING-US
LA English
DT Article
DE age-related macular degeneration (AMD); RPE; PGC-1 alpha; mitochondria;
   FDA-approved drugs
ID ACTIVATED RECEPTOR-GAMMA; PEROXISOME PROLIFERATOR; CORNEAL
   NEOVASCULARIZATION; TRANSCRIPTION FACTOR; MITOCHONDRIAL-DNA; OXIDATIVE
   STRESS; NEURON APOPTOSIS; MOUSE MODEL; PGC-1-ALPHA; INHIBITION
AB Since mitochondria! dysfunction is implicated in the pathogenesis of AMD, this study is based on the premise that repurposing of mitochondria-stabilizing FDA-approved drugs such as PU-91, might rescue AMD RPE cells from AMD mitochondria-induced damage. The PU-91 drug upregulates PGC-1 alpha which is a critical regulator of mitochondrial biogenesis. Herein, we tested the therapeutic potential of PU-91 drug and examined the additive effects of treatment with PU-91 and esterase inhibitors i.e., EI-12 and EI-78, using the in vitro transmitochondrial AMD cell model. This model was created by fusing platelets obtained from AMD patients with Rho(0) i.e., mitochondria-deficient, ARPE-19 cell lines. The resulting AMD RPE cell lines have identical nuclei but differ in their mitochondrial DNA content, which is derived from individual AMD patients. Briefly, we report significant improvement in cell survival, mitochondrial health, and antioxidant potential in PU-91-treated AMD RPE cells compared to their untreated counterparts. In conclusion, this study identifies PU-91 as a therapeutic candidate drug for AMD and repurposing of PU-91 will be a smoother transition from lab bench to clinic since the pharmacological profiles of PU-91 have been examined already.
C1 [Nashine, Sonali; Chwa, Marilyn; Nesburn, Anthony; Kuppermann, Baruch D.; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Subramaniam, Sudhakar R.; Federoff, Howard] Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA.
   [Nesburn, Anthony] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine; Cedars
   Sinai Medical Center; University of California System; University of
   California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.; Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM mkenney@uci.edu
RI NASHINE, SONALI/AAG-1474-2020
FU 2017 Genentech/ARVO AMD Translational Research Fellowship; RPB (Research
   to Prevent Blindness) pilot research grant; Arnold and Mabel Beckman
   Foundation; UCI School of Medicine; Discovery Eye Foundation; Guenther
   Foundation; Beckman Initiative for Macular Research; Max Factor Family
   Foundation; Iris and B. Gerald Cantor Foundation; RPB; 2016 RPB pilot
   research grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [UL1TR001414] Funding Source: NIH RePORTER
FX This research work was supported by the 2017 Genentech/ARVO AMD
   Translational Research Fellowship, RPB (Research to Prevent Blindness)
   pilot research grant, Arnold and Mabel Beckman Foundation, UCI School of
   Medicine, Discovery Eye Foundation, Guenther Foundation, Beckman
   Initiative for Macular Research, Polly and Michael Smith, Max Factor
   Family Foundation, Iris and B. Gerald Cantor Foundation; research was
   supported in part by an unrestricted grant from RPB. SN is a recipient
   of the 2017 Genentech/ARVO AMD Translational Research Fellowship and the
   2016 RPB pilot research grant.
CR Adler R, 1999, MOL VIS, V5
   Beckman JS, 2001, TRENDS NEUROSCI, V24, pS15, DOI 10.1016/S0166-2236(00)01981-0
   Carta AR, 2011, NEUROSCIENCE, V194, P250, DOI 10.1016/j.neuroscience.2011.07.046
   Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002
   Ciron C, 2012, HUM MOL GENET, V21, P1861, DOI 10.1093/hmg/ddr618
   Corona JC, 2015, NEUROCHEM RES, V40, P308, DOI 10.1007/s11064-014-1377-0
   Cousins SW, 2015, RETINA TODAY, P83
   Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012
   Ding LX, 2014, AM J PATHOL, V184, P2709, DOI 10.1016/j.ajpath.2014.06.021
   Ellis DZ, 2017, INVEST OPHTH VIS SCI, V58, P2755, DOI 10.1167/iovs.16-19199
   Escribano L, 2009, BIOCHEM BIOPH RES CO, V379, P406, DOI 10.1016/j.bbrc.2008.12.071
   Estevez AG, 1998, J NEUROSCI, V18, P923
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Guo XX, 2014, AM J PATHOL, V184, P1017, DOI 10.1016/j.ajpath.2013.12.012
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   He MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084800
   Hertel M, 2002, EUR J NEUROSCI, V15, P1707, DOI 10.1046/j.1460-9568.2002.01992.x
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Indo HP, 2015, J CLIN BIOCHEM NUTR, V56, P1, DOI 10.3164/jcbn.14-42
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Johri A, 2013, FREE RADICAL BIO MED, V62, P37, DOI 10.1016/j.freeradbiomed.2013.04.016
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kan MY, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-73
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X
   Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200
   Lieven CJ, 2003, ANTIOXID REDOX SIGN, V5, P641, DOI 10.1089/152308603770310310
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Markovets AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021682
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   McGill JK, 2006, CELL, V127, P465, DOI 10.1016/j.cell.2006.10.023
   Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5
   Modenese A, 2019, INT ARCH OCC ENV HEA, V92, P1, DOI 10.1007/s00420-018-1355-y
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nashine S, 2019, AGING-US, V11, P1177, DOI 10.18632/aging.101820
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Okada AK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08372-5
   Pearsall EA, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0451-x
   Qiao H, 2001, OPHTHALMOLOGICA, V215, P401, DOI 10.1159/000050897
   Radhakrishnan SK, 2010, MOL CELL, V38, P17, DOI 10.1016/j.molcel.2010.02.029
   Rao JJ, 2012, MOL CELL BIOCHEM, V367, P9, DOI 10.1007/s11010-012-1313-z
   Rona-Voros K, 2010, CURR DRUG TARGETS, V11, P1262, DOI 10.2174/1389450111007011262
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   Sarayba MA, 2005, EXP EYE RES, V80, P435, DOI 10.1016/j.exer.2004.10.009
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Sweeney G, 2016, ANAT CELL BIOL, V49, P1, DOI 10.5115/acb.2016.49.1.1
   Telegina D V, 2016, Adv Gerontol, V29, P424
   Uchiyama M, 2013, MOL VIS, V19, P2135
   Usui T, 2008, INVEST OPHTH VIS SCI, V49, P4370, DOI 10.1167/iovs.07-0964
   Ventura-Clapier R, 2008, CARDIOVASC RES, V79, P208, DOI 10.1093/cvr/cvn098
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431
   Wang B, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0065-1
   Wigdal SS, 2002, J NEUROCHEM, V82, P1029, DOI 10.1046/j.1471-4159.2002.01049.x
   Yamanaka O, 2009, INVEST OPHTH VIS SCI, V50, P187, DOI 10.1167/iovs.08-2282
   Zheng B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001059
   Zhu JM, 2015, INT J OPHTHALMOL-CHI, V8, P52, DOI 10.3980/j.issn.2222-3959.2015.01.09
   Zhu JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068935
NR 69
TC 5
Z9 5
U1 1
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD SEP 15
PY 2019
VL 11
IS 17
BP 6691
EP 6713
DI 10.18632/aging.102179
PG 23
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA JA6UU
UT WOS:000487978100011
PM 31477635
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU El Matri, L
   Bouraoui, R
   Chebil, A
   Kort, F
   Bouladi, M
   Limaiem, R
   Landoulsi, H
AF El Matri, Leila
   Bouraoui, Rym
   Chebil, Ahmed
   Kort, Fedra
   Bouladi, Mejda
   Limaiem, Rym
   Landoulsi, Hana
TI Bevacizumab Injection in Patients with Age-Related Macular Degeneration
   Associated with Poor Initial Visual Acuity
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; AVASTIN
AB Purpose. To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with neovascular AMD and initial low visual acuity. Methods. Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated with intravitreal bevacizumab injection. Results. Mean followup was 14.1 months +/- 7.1 (range: 5 to 24 months). Mean logMAR vision at baseline was 1.38 logMAR +/- 0.33, at 6 months was 1.14 logMAR +/- 0.37 (P = 0.001) and at 12 months was 1.22 logMar +/- 0.33 (P = 0.004). Mean baseline central retinal thickness was 431 mu m +/- 159.7 at 6 months was 293.43 mu m +/- 122.79 (P = 10(-4)) and at 12 months was 293.1 mu m +/- 130 (P = 0.004). Visual acuity improved in both patients with or without prior PDT treatment. Conclusions. Intravitreal bevacizumab injection may increase the chance of visual acuity gain in neovascular AMD even in cases with initial low visual acuity.
C1 [El Matri, Leila; Bouraoui, Rym; Chebil, Ahmed; Kort, Fedra; Bouladi, Mejda; Limaiem, Rym; Landoulsi, Hana] Hedi Rais Inst Ophthalmol, Dept Ophthalmol B, Bab Saadoun Tunis 1006, Tunisia.
C3 Universite de Tunis-El-Manar; Institut Hedi Raies d'ophtalmologie de
   Tunis
RP El Matri, L (通讯作者)，Hedi Rais Inst Ophthalmol, Dept Ophthalmol B, Blvd 9 Avril, Bab Saadoun Tunis 1006, Tunisia.
EM leila.elmatri@rns.tn
OI bouladi, mejda/0000-0002-6300-4434
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Galbinur T, 2009, BRIT J OPHTHALMOL, V93, P1351, DOI 10.1136/bjo.2009.158931
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 7
TC 4
Z9 4
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 861384
DI 10.1155/2012/861384
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979DT
UT WOS:000306795800001
PM 22174999
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Rubin, GS
   Feely, M
AF Rubin, Gary S.
   Feely, Mary
TI The Role of Eye Movements During Reading in Patients with Age-Related
   Macular Degeneration (AMD)
SO NEURO-OPHTHALMOLOGY
LA English
DT Article
CT International Interdisciplinary Symposium on Neuro Ophthalmology and Low
   Vision - From Eye to Mind
CY OCT 24-25, 2008
CL Tubingen, GERMANY
DE Age-related macular degeneration (AMD); reading; eye movements;
   scotomas; saccades
ID LOW-VISION; PERCEPTUAL SPAN; SIMULATED SCOTOMAS; LETTER-RECOGNITION;
   PERIPHERAL-VISION; DISEASE; FIXATION; SPEED; PSYCHOPHYSICS; PERFORMANCE
AB AMD patients often have particular difficulty reading, even when the text is magnified to compensate for reduced visual acuity. This study explores whether reading performance can be explained by eye movement factors. Forty patients with advanced AMD were tested with a high-speed video eye tracker to evaluate fixation stability and saccadic eye movements. Reading speed was measured for standardized texts viewed at the critical print size. Visual acuity and contrast sensitivity were unrelated to reading speed, but fixation stability, proportion of regressive saccades and size of forward saccades were all significantly associated with reading performance, accounting for 74% of the variance. The implications of these findings for low-vision training programmes are discussed.
C1 [Rubin, Gary S.] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   UCL, Biomed Res Ctr Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London; University of London;
   University College London
RP Rubin, GS (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM g.rubin@ucl.ac.uk
CR BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Cheong AMY, 2008, VISION RES, V48, P577, DOI 10.1016/j.visres.2007.11.022
   Chung STL, 2004, VISION RES, V44, P695, DOI 10.1016/j.visres.2003.09.028
   Crossland MD, 2006, VISION RES, V46, P590, DOI 10.1016/j.visres.2005.05.015
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Fine EM, 1999, VISION RES, V39, P1039, DOI 10.1016/S0042-6989(98)00208-9
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Habel A., PRIMARY CAUSES UNPUB
   Hahn GA, 2006, BRIT J OPHTHALMOL, V90, P480, DOI 10.1136/bjo.2005.087379
   LEAT SJ, 1990, OPHTHAL PHYSL OPT, V10, P8, DOI 10.1111/j.1475-1313.1990.tb01098.x
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Legge GE, 2001, VISION RES, V41, P725, DOI 10.1016/S0042-6989(00)00295-9
   MCCONKIE GW, 1975, PERCEPT PSYCHOPHYS, V17, P578, DOI 10.3758/BF03203972
   Petre KL, 2000, OPTOMETRY VISION SCI, V77, P34, DOI 10.1097/00006324-200001000-00011
   POLLATSEK A, 1981, BRAIN LANG, V14, P174, DOI 10.1016/0093-934X(81)90073-0
   RAYNER K, 1975, COGNITIVE PSYCHOL, V7, P65, DOI 10.1016/0010-0285(75)90005-5
   RUBIN GS, 2005, INT C SERIES, V1282, P699
   Scherlen AC, 2008, VISION RES, V48, P1870, DOI 10.1016/j.visres.2008.06.005
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   TRAUZETTELKLOSINSKI S, 1994, NEURO-OPHTHALMOLOGY, V14, P15, DOI 10.3109/01658109409019482
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 26
TC 37
Z9 37
U1 1
U2 24
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0165-8107
J9 NEURO-OPHTHALMOLOGY
JI Neuro-Ophthalmol.
PY 2009
VL 33
IS 3
BP 120
EP 126
AR PII 912466732
DI 10.1080/01658100902998732
PG 7
WC Clinical Neurology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA 459KE
UT WOS:000267100000007
DA 2022-11-30
ER

PT J
AU Delcourt, C
   Souied, E
   Sanchez, A
   Bandello, F
AF Delcourt, Cecile
   Souied, Eric
   Sanchez, Alice
   Bandello, Francesco
CA STARs Survey Grp
TI Development and Validation of a Risk Score for Age-Related Macular
   Degeneration: The STARS Questionnaire
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; epidemiology; risk factors
ID BLUE MOUNTAINS EYE; CATARACT-SURGERY; CIGARETTE-SMOKING; 10-YEAR
   INCIDENCE; REFRACTIVE ERROR; 5-YEAR INCIDENCE; BEIJING EYE; BEAVER DAM;
   MACULOPATHY; ASSOCIATION
AB PURPOSE. To develop and validate a risk score for AMD based on a simple self-administered questionnaire.
   METHODS. Risk factors having shown the most consistent associations with AMD were included in the STARS (Simplified Thea AMD Risk-Assessment Scale) questionnaire. Two studies were conducted, one in Italy (127 participating ophthalmologists) and one in France (80 participating ophthalmologists). During 1 week, participating ophthalmologists invited all their patients aged 55 years or older to fill in the STARS questionnaire. Based on fundus examination, early AMD was defined by the presence of soft drusen and/or pigmentary abnormalities and late AMD by the presence of geographic atrophy and/or neovascular AMD.
   RESULTS. The Italian and French samples consisted of 12,639 and 6897 patients, respectively. All 13 risk factors included in the STARS questionnaire showed significant associations with AMD in the Italian sample. The area under the receiving operating characteristic curve for the STARS risk score, derived from the multivariate logistic regression in the Italian sample, was 0.78 in the Italian sample and 0.72 in the French sample. In both samples, less than 10% of patients without AMD were classified at high risk, and less than 13% of late AMD cases were classified as low risk, with a more intermediate situation in early AMD cases.
   CONCLUSIONS. STARS is a new, simple self-assessed questionnaire showing good discrimination of risk for AMD in two large European samples. It might be used by ophthalmologists in routine clinical practice or as a self-assessment for risk of AMD in the general population.
C1 [Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team LEHA,UMR 1219, Bordeaux, France.
   [Souied, Eric] Univ Paris Est, Hop Inter Communal Creteil, Creteil, France.
   [Sanchez, Alice] Biostatem, Castries, France.
   [Bandello, Francesco] Univ Vita Salute, Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele
RP Delcourt, C (通讯作者)，Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, UMR 1219, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM cecile.delcourt@u-bordeaux.fr
RI bandello, francesco/AAH-2405-2019; Delcourt, Cecile/I-2627-2013
OI bandello, francesco/0000-0003-3238-9682; Delcourt,
   Cecile/0000-0002-2099-0481
FU Laboratoires Thea (Clermont-Ferrand, France)
FX Supported by Laboratoires Thea (Clermont-Ferrand, France). The sponsor
   participated in all steps of this study (design, data collection, data
   management, data analysis, interpretation of the data, preparation, and
   review of the manuscript).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   COLE TJ, 1993, J R STAT SOC C-APPL, V42, P261
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Lazreg S, 2016, OPHTHALMIC RES, V56, P145, DOI 10.1159/000446844
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rosenthal T, 2014, J AM SOC HYPERTENS, V8, P171, DOI 10.1016/j.jash.2013.12.007
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2010, GRAEF ARCH CLIN EXP, V248, P721, DOI 10.1007/s00417-009-1233-0
NR 35
TC 6
Z9 6
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2017
VL 58
IS 14
BP 6399
EP 6407
DI 10.1167/iovs.17-21819
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY4GV
UT WOS:000426781300048
PM 29260196
OA gold
DA 2022-11-30
ER

PT J
AU de Sisternes, L
   Jonna, G
   Moss, J
   Marmor, MF
   Leng, T
   Rubin, DL
AF de Sisternes, Luis
   Jonna, Gowtham
   Moss, Jason
   Marmor, Michael F.
   Leng, Theodore
   Rubin, Daniel L.
TI Automated intraretinal segmentation of SD-OCT images in normal and
   age-related macular degeneration eyes
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; NERVE-FIBER LAYER; RETINAL LAYERS;
   THICKNESS; DRUSEN; CLASSIFICATION; INNER; REPEATABILITY; PERFORMANCE;
   DETACHMENT
AB This work introduces and evaluates an automated intra-retinal segmentation method for spectral-domain optical coherence (SD-OCT) retinal images. While quantitative assessment of retinal features in SD-OCT data is important, manual segmentation is extremely time-consuming and subjective. We address challenges that have hindered prior automated methods, including poor performance with diseased retinas relative to healthy retinas, and data smoothing that obscures image features such as small retinal drusen. Our novel segmentation approach is based on the iterative adaptation of a weighted median process, wherein a three-dimensional weighting function is defined according to image intensity and gradient properties, and a set of smoothness constraints and pre-defined rules are considered. We compared the segmentation results for 9 segmented outlines associated with intra-retinal boundaries to those drawn by hand by two retinal specialists and to those produced by an independent state-of-the-art automated software tool in a set of 42 clinical images (from 14 patients). These images were obtained with a Zeiss Cirrus SD-OCT system, including healthy, early or intermediate AMD, and advanced AMD eyes. As a qualitative evaluation of accuracy, a highly experienced third independent reader blindly rated the quality of the outlines produced by each method. The accuracy and image detail of our method was superior in healthy and early or intermediate AMD eyes (98.15% and 97.78% of results not needing substantial editing) to the automated method we compared against. While the performance was not as good in advanced AMD (68.89%), it was still better than the manual outlines or the comparison method (which failed in such cases). We also tested our method's performance on images acquired with a different SD-OCT manufacturer, collected from a large publicly available data set (114 healthy and 255 AMD eyes), and compared the data quantitatively to reference standard markings of the internal limiting membrane and inner boundary of retinal pigment epithelium, producing a mean unsigned positioning error of 6.04 +/- 7.83 mu m (mean under 2 pixels). Our automated method should be applicable to data from different OCT manufacturers and offers detailed layer segmentations in healthy and AMD eyes. (C) 2017 Optical Society of America
C1 [de Sisternes, Luis; Rubin, Daniel L.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.
   [de Sisternes, Luis] Carl Zeiss Meditec inc, Dublin, CA 94568 USA.
   [Jonna, Gowtham] Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, Bronx, NY 10467 USA.
   [Moss, Jason] Retina Inst Calif, Pasadena, CA 91105 USA.
   [Marmor, Michael F.; Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Stanford, CA 94303 USA.
   [Rubin, Daniel L.] Stanford Univ, Dept Med Biomed Informat Res, Stanford, CA 94305 USA.
C3 Stanford University; Carl Zeiss AG; Yeshiva University; Albert Einstein
   College of Medicine; Stanford University; Stanford University
RP Rubin, DL (通讯作者)，Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.; Leng, T (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst Stanford, Stanford, CA 94303 USA.; Rubin, DL (通讯作者)，Stanford Univ, Dept Med Biomed Informat Res, Stanford, CA 94305 USA.
EM tedleng@stanford.edu; dlrubin@stanford.edu
RI Leng, Theodore/AAQ-7459-2020
FU Bio-X Interdisciplinary Initiatives Program of Stanford University;
   Spectrum-SPADA innovation grant of Stanford University, Clinical and
   Translational Science Award (CTSA) program - National Center for
   Advancing Translational Sciences at the National Institutes of Health
   (NIH) [UL1 TR001085]
FX This work was supported by a grant from the Bio-X Interdisciplinary
   Initiatives Program of Stanford University, and a Spectrum-SPADA
   innovation grant of Stanford University, part of the Clinical and
   Translational Science Award (CTSA) program funded by the National Center
   for Advancing Translational Sciences (Grant: UL1 TR001085) at the
   National Institutes of Health (NIH).
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   BROWNRIGG DRK, 1984, COMMUN ACM, V27, P807, DOI 10.1145/358198.358222
   Buades A, 2005, PROC CVPR IEEE, P60, DOI 10.1109/cvpr.2005.38
   Buades A, 2006, IEEE T IMAGE PROCESS, V15, P1499, DOI 10.1109/TIP.2006.871137
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chiu S. J., 2012, DATASET SD OCT RETIN
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   de Sisternes L, 2015, INVEST OPHTH VIS SCI, V56, P4631, DOI 10.1167/iovs.14-16344
   de Sisternes L, 2015, INVEST OPHTH VIS SCI, V56, P3415, DOI 10.1167/iovs.14-16345
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   DErrico J., SURFACE FITTING USIN
   Dufour P. A., 2012, OCT SEGMENTATION APP
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Ehnes A, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.1.1
   Fang LY, 2013, IEEE T MED IMAGING, V32, P2034, DOI 10.1109/TMI.2013.2271904
   Farsiu S., WORLDS LARGEST ANNOT
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Ishikawa H, 2002, GRAEF ARCH CLIN EXP, V240, P362, DOI 10.1007/s00417-002-0461-3
   Ishikawa H, 2009, INVEST OPHTH VIS SCI, V50, P1344, DOI 10.1167/iovs.08-2703
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133
   Lee HJ, 2015, INVEST OPHTH VIS SCI, V56, P4554, DOI 10.1167/iovs.15-16949
   Lee HJ, 2015, AM J OPHTHALMOL, V160, P283, DOI 10.1016/j.ajo.2015.05.015
   Lee JR, 2010, INVEST OPHTH VIS SCI, V51, P6424, DOI 10.1167/iovs.09-5130
   Lee K., IOWA REFERENCE ALGOR
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Matt G, 2011, EYE, V25, P511, DOI 10.1038/eye.2010.216
   Mayer M., 2016, OPTICAL COHERENCE TO
   Mayer MA, 2010, BIOMED OPT EXPRESS, V1, P1358, DOI 10.1364/BOE.1.001358
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   Parrilli S., 2010, IEEE GEOSC REM SENS
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Teng, 2013, CASEREL OPEN SOURCE
   Vermeer KA, 2011, BIOMED OPT EXPRESS, V2, P1743, DOI 10.1364/BOE.2.001743
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Yin L, 1996, IEEE T CIRCUITS-II, V43, P157, DOI 10.1109/82.486465
NR 52
TC 24
Z9 24
U1 0
U2 6
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAR 1
PY 2017
VL 8
IS 3
BP 1926
EP 1949
DI 10.1364/BOE.8.001926
PG 24
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA EN3YA
UT WOS:000395942600047
PM 28663874
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Markham, A
AF Markham, Anthony
TI Brolucizumab: First Approval
SO DRUGS
LA English
DT Article
ID AFLIBERCEPT; HAWK
AB Brolucizumab (Beovu) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Based primarily on the results of the phase III HAWK and HARRIER trials brolucizumab was recently approved in the US for the treatment of wet AMD. This article summarizes the milestones in the development of brolucizumab leading to this first approval.
C1 [Markham, Anthony] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.
RP Markham, A (通讯作者)，Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.
EM dru@adis.com
CR Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2018, INVEST OPHTH VIS SCI, V59
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Nimz EL, 2016, INVEST OPHTH VIS SCI, V57
   Novartis, 2019, BEOVU BROL DBLL INJ
   Singh RP, 2019, INVEST OPHTH VIS SCI, V60
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
NR 9
TC 42
Z9 42
U1 0
U2 9
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD DEC
PY 2019
VL 79
IS 18
BP 1997
EP 2000
DI 10.1007/s40265-019-01231-9
PG 4
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA JT2MQ
UT WOS:000500830300008
PM 31768932
DA 2022-11-30
ER

PT J
AU Vujosevic, S
   Pucci, P
   Casciano, M
   Longhin, E
   Convento, E
   Bini, S
   Midena, E
AF Vujosevic, Stela
   Pucci, Porzia
   Casciano, Margerita
   Longhin, Evelyn
   Convento, Enrica
   Bini, Silvia
   Midena, Edoardo
TI Long-term longitudinal modifications in mesopic microperimetry in early
   and intermediate age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Early age-related macular degeneration; Intermediate age-related macular
   degeneration; Microperimetry; Retinal sensitivity; Fixation; OCT
ID LUMINANCE VISUAL-ACUITY
AB To evaluate functional changes (retinal sensitivity and fixation characteristics) determined by microperimetry in patients with early and intermediate AMD over 6 years.
   Prospective, longitudinal follow-up (FU) study of 16 patients (29 eyes) with early and intermediate AMD (AREDS 2 and AREDS 3 classification). All eyes underwent: complete ophthalmic examination with best corrected visual acuity (BCVA) determination, color fundus photo (CFP), optical coherence tomography and microperimetry. All CFP were evaluated by two retinal specialists masked to functional data for changes in severity of clinical features over the course of FU.
   Of 17 eyes graded as AREDS 2 at baseline, 14 (82.35 %) remained stable, and 3 (18.75 %) progressed to AREDS 3. Of 12 eyes graded as AREDS 3 at baseline, 10 remained stable (83.33 %), and 2 (16.67 %) progressed to AREDS 4. Mean BCVA significantly deteriorated in both AREDS 2 (p = 0.006) and AREDS 3 (p = 0.016), with greater decrease in AREDS 3 (p = 0.01)6. Mean retinal sensitivity (RS) significantly decreased over time in both AREDS 2 (p < 0.0001) and AREDS 3 group (p = 0.002), with greater decrease in AREDS 3 (p = 0.006). The mean number of dense scotomas did not change in AREDS 2 (p = 0.3), but significantly increased in the AREDS 3 group (p = 0.035). Points with decreased RS were located in all but the central point (p < 0.0001 for all), without significant differences in number among rings. In the AREDS 2 group, fixation stability remained unchanged. In the AREDS 3 group, four eyes deteriorated from stable to unstable fixation at FU (p = 0.045).
   A significant deterioration in RS is reported in early and intermediate AMD eyes, whereas fixation stability changed only in intermediate AMD (AREDS 3) over long-term follow-up. Microperimetry examination can become a new functional biomarker in early and intermediate AMD patients.
C1 [Vujosevic, Stela; Pucci, Porzia; Casciano, Margerita; Longhin, Evelyn; Convento, Enrica; Bini, Silvia; Midena, Edoardo] Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
   [Midena, Edoardo] IRCCS, Fdn GB Bietti, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.; Midena, E (通讯作者)，IRCCS, Fdn GB Bietti, Rome, Italy.
EM edoardo.midena@unipd.it
RI Bini, Silvia/AAB-4226-2020; Bini, Silvia/AAM-9984-2021; Midena,
   Edoardo/AAB-6010-2020; Vujosevic, Stela/AAI-4874-2020
OI Vujosevic, Stela/0000-0001-6773-9967
FU GB Bietti Foundation; Ministry of Health and Fondazione Roma
FX This research was financially supported, as the GB Bietti Foundation is
   concerned, by the Ministry of Health and Fondazione Roma.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Amore FM, 2013, OPHTHAL PHYSL OPT, V33, P611, DOI 10.1111/opo.12048
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Klyce SD, 2015, J REFRACT SURG, V31, P690, DOI 10.3928/1081597X-20150928-02
   Kroisamer JS, 2014, MICROPERIMETRY MULTI, P13
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 19
TC 19
Z9 19
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2017
VL 255
IS 2
BP 301
EP 309
DI 10.1007/s00417-016-3466-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK8ET
UT WOS:000394157400010
PM 27582087
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Burlutsky, G
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Burlutsky, George
   Mitchell, Paul
TI Age-related macular degeneration and risk of total and cause-specific
   mortality over 15 years
SO MATURITAS
LA English
DT Article
DE Age-related macular degeneration; Blue Mountains Eye Study; Mortality;
   Cardiovascular disease; Ischemic heart disease
ID BLUE MOUNTAINS EYE; VISUAL IMPAIRMENT PROJECT; 5-YEAR INCIDENCE;
   MYOCARDIAL-INFARCTION; OLDER-PEOPLE; MACULOPATHY; STROKE; PREVALENCE;
   DISEASE; AUSTRALIA
AB Objective: We aimed to investigate the independent association between AMD and risk of ischemic heart disease (IHD), stroke, and cardiovascular (CVD) mortality, and all-cause mortality over 15 years.
   Methods: 3654 participants aged 49+ years at baseline were followed over 15 years. AMD was assessed from retinal photographs. Deaths and cause of death were confirmed by data linkage with the Australian National Death Index. Hazard ratios (HRs) and 95% confidence intervals (Cls) were assessed using Cox models.
   Results: 71.4% (n = 162) and 34.6% (n = 1037) of participants with any AMD and no AMD, respectively, died over 15 years. After multivariable-adjustment, no significant associations were observed between AMD and total- and cause-specific mortality in the overall cohort. However, among men, late AMD at baseline was associated with an increased risk of all-cause mortality (n=22; 95.7%), 15 years later: multivariable-adjusted HR, 1.80(95% CI 1.04-3.11). Women with late AMD had 2-fold increased risk of stroke mortality (n =15; 28.9%), HR 2.10 (95% CI 1.08-4.06). Early-stage AMD was not associated with mortality risk.
   Conclusion: Late AMD independently predicted all-cause mortality in men and stroke mortality in women, over 15 years. Although underlying mechanisms are unclear, these findings indicate that late AMD is a marker of biological aging. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Gopinath, Bamini; Liew, Gerald; Burlutsky, George; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Dept Ophthalmol, Westmead, NSW 2145, Australia.
C3 University of Sydney; Westmead Institute for Medical Research
RP Gopinath, B (通讯作者)，Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Gopinath, Bamini/K-4286-2019; Mitchell, Paul/P-1498-2014; Liew,
   Gerald/AAB-6870-2022
OI Gopinath, Bamini/0000-0003-3573-359X; 
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120, 457349]; Westmead Millennium Institute; Blackmores Dr
   Paul Beaumont; Macular Disease Foundation of Australia Fellowship
FX The Blue Mountains Eye Study was funded by the Australian National
   Health and Medical Research Council (Grant Nos. 974159, 991407, 211069,
   262120, 457349), and Westmead Millennium Institute. Bamini Gopinath is
   supported by a Blackmores Dr Paul Beaumont and Macular Disease
   Foundation of Australia Fellowship.
CR Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bi P, 2005, DIABETES RES CLIN PR, V70, P270, DOI 10.1016/j.diabres.2005.03.035
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gopinath B, 2011, AM J CLIN NUTR, V93, P1073, DOI 10.3945/ajcn.110.009977
   Gorelick PB, 1999, JAMA-J AM MED ASSOC, V281, P1112, DOI 10.1001/jama.281.12.1112
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Kardys I, 2006, EUR HEART J, V27, P1331, DOI 10.1093/eurheartj/ehl018
   KARLSON BW, 1994, AM HEART J, V128, P477, DOI 10.1016/0002-8703(94)90620-3
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Kulmala J, 2008, AGING CLIN EXP RES, V20, P25
   Magliano D, 2003, AUST NZ J PUBL HEAL, V27, P649, DOI 10.1111/j.1467-842X.2003.tb00615.x
   Mitchell P, 1985, Aust Fam Physician, V14, P757
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   World Health Organization, 2004, INT STAT CLASS DIS H
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 38
TC 10
Z9 10
U1 0
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD FEB
PY 2016
VL 84
BP 63
EP 67
DI 10.1016/j.maturitas.2015.11.001
PG 5
WC Geriatrics & Gerontology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA DB0OJ
UT WOS:000368207100011
PM 26596903
DA 2022-11-30
ER

PT J
AU Smith, DH
   Fenn, P
   Drummond, M
AF Smith, DH
   Fenn, P
   Drummond, M
TI Cost effectiveness of photodynamic therapy with verteporfin for age
   related macular degeneration: the UK case
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
AB Aim: To estimate the potential cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK setting.
   Methods: Using data from a variety of sources a Markov model was built to produce estimates of the cost effectiveness (incremental cost per quality adjusted life year (QALY) and incremental cost per vision year gained) of PDT for two cohorts of patients (one with starting visual acuity (VA) of 20/40 and one at 20/100) with predominantly classic choroidal neovascular disease over a 2 year and 5 year time horizon. A government perspective and a treatment cost only perspective were considered. Probabilistic and one way sensitivity analyses were undertaken.
   Results: From the government perspective, over the 2 year period, the expected incremental cost effectiveness ratios range from pound286 000 (starting VA 20/100) to pound76 000 (starting VA 20/40) per QALY gained and from pound14 000 (20/100) to pound34 000 (20/40) per vision year gained. A 5 year perspective yields incremental ratios less than pound5000 for vision years gained and from pound9000 ( 20/40) to pound30 000 (20/100) for QALYs gained. Without societal or NHS cost offsets included, the 2 year incremental cost per vision year gained ranges from pound20 000 (20/100) to pound40 000 (20/40), and the 2 year incremental cost per QALY gained ranges from pound412 000 (20/100) to pound90 000 (20/40). The 5 year time frame shows expected costs of pound7000 (20/40) to pound10 000 (20/100) per vision year gained and from pound38 000 (20/40) to pound69 000 (20/100) per QALY gained.
   Conclusion: This evaluation suggests that early treatment (that is, treating eyes at less severe stages of disease) with PDT leads to increased efficiency. When considering only the cost of therapy, treating people at lower levels of visual acuity would probably not be considered cost effective. However, a broad perspective that incorporates other NHS treatment costs and social care costs suggests that over a long period of time, PDT may yield reasonable value for money.
C1 Kaiser Permanente NW, Ctr Hlth Res, Portland, OR 97211 USA.
   Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.
   Univ Nottingham, Sch Business, Nottingham NG7 2RD, England.
C3 Kaiser Permanente; University of York - UK; University of Nottingham
RP Smith, DH (通讯作者)，Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97211 USA.
EM David.Smith@kpchr.org
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   *HM TREAS GREAT BR, 1991, EC APPR CENTR GOV TE
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   MEADS C, 2002, CLIN EFFECTIVENESS
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   *NAT I CLIN EXC, FIN APPR DET PHOT TH
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   SMITH D, 2002, CHE DISCUSSION PAPER
NR 15
TC 46
Z9 46
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2004
VL 88
IS 9
BP 1107
EP 1112
DI 10.1136/bjo.2003.023986
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 846YN
UT WOS:000223355700003
PM 15317697
OA Green Published, Green Submitted, Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Grzybowski, A
   Kanclerz, P
   Tuuminen, R
AF Grzybowski, Andrzej
   Kanclerz, Piotr
   Tuuminen, Raimo
TI Multifocal intraocular lenses and retinal diseases
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Cataract surgery; Contrast
   sensitivity; Diabetic retinopathy; Multifocal intraocular lens;
   Refractive lens exchange
ID SPATIAL CONTRAST SENSITIVITY; AGE-RELATED-CHANGES; VISUAL PERFORMANCE;
   BILATERAL IMPLANTATION; RANDOMIZED-TRIAL; EXTENDED RANGE; OUTCOMES;
   CATARACT; VISION; MONOVISION
AB Purpose Multifocal intraocular lenses (MIOLs) are often discouraged in patients with or at risk of retinal disorders (including diabetic retinopathy, age-related macular degeneration, and epiretinal membranes), as MIOLs are believed to reduce contrast sensitivity (CS). Concerns with MIOLs have also been raised in individuals with visual field defects, fixation instability or eccentric preferred retinal locations. The aim of this study is to review the influence of MIOL on quality of vision in patients with retinal diseases. Methods We reviewed the PubMed and Web of Science databases to identify relevant studies using the following keywords: multifocal intraocular lens, cataract surgery, cataract extraction, lens exchange, diabetic retinopathy, age-related macular degeneration, and contrast sensitivity. Results Studies evaluating CS in MIOLs present conflicting results: MIOLs either did not influence CS or resulted in worse performance under low-illuminance conditions and higher spatial frequencies when compared to monofocal IOLs. Nevertheless, MIOLs preserved CS levels within the age-matched normal range. Two studies reported that patients with concurrent retinal diseases receiving a MIOL, both unilaterally and bilaterally, reported a significant improvement in visual-related outcomes. Individuals with a monofocal IOL in one eye and a MIOL in the fellow eye reported greater subjective satisfaction with the MIOL. Conclusion We were unable to find evidence suggesting that patients with retinal diseases should be advised against MIOLs. Nevertheless, more research is needed to address the aforementioned concerns and to optimize the use of MIOLs in eyes with retinal disease.
C1 [Grzybowski, Andrzej] Univ Warmia & Mazury, Dept Ophthalmol, Olsztyn, Poland.
   [Grzybowski, Andrzej] Fdn Ophthalmol Dev, Inst Res Ophthalmol, Poznan, Poland.
   [Kanclerz, Piotr] Hygeia Clin, Gdansk, Poland.
   [Tuuminen, Raimo] Univ Helsinki, Fac Med, Helsinki Retina Res Grp, Helsinki, Finland.
   [Tuuminen, Raimo] Kymenlaakso Cent Hosp, Dept Ophthalmol, Kotka, Finland.
C3 University of Warmia & Mazury; University of Helsinki
RP Grzybowski, A (通讯作者)，Univ Warmia & Mazury, Dept Ophthalmol, Olsztyn, Poland.; Grzybowski, A (通讯作者)，Fdn Ophthalmol Dev, Inst Res Ophthalmol, Poznan, Poland.
EM ae.grzybowski@gmail.com
RI Kanclerz, Piotr/L-7620-2018
OI Kanclerz, Piotr/0000-0002-8036-7691; Grzybowski,
   Andrzej/0000-0002-3724-2391
CR Alio JL, 2017, SURV OPHTHALMOL, V62, P611, DOI 10.1016/j.survophthal.2017.03.005
   Allen ED, 1996, J CATARACT REFR SURG, V22, P446, DOI 10.1016/S0886-3350(96)80040-X
   Altemir-Gomez I, 2019, EUR J OPHTHALMOL
   Andersen GJ, 2012, WIRES COGN SCI, V3, P403, DOI 10.1002/wcs.1167
   ARDEN GB, 1978, INVEST OPHTH VIS SCI, V171, P23
   Aychoua N, 2013, JAMA OPHTHALMOL, V131, P481, DOI 10.1001/jamaophthalmol.2013.2368
   Braga-Mele R, 2014, J CATARACT REFR SURG, V40, P313, DOI 10.1016/j.jcrs.2013.12.011
   BURTON KB, 1993, VISION RES, V33, P939, DOI 10.1016/0042-6989(93)90077-A
   Cillino S, 2008, OPHTHALMOLOGY, V115, P1508, DOI 10.1016/j.ophtha.2008.04.017
   CRASSINI B, 1988, PERCEPTION, V17, P315, DOI 10.1068/p170315
   de Vries NE, 2011, J CATARACT REFR SURG, V37, P859, DOI 10.1016/j.jcrs.2010.11.032
   DEREFELDT G, 1979, ACTA OPHTHALMOL, V57, P679
   Dyrda A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8285637
   ELLIOTT D, 1990, VISION RES, V30, P541, DOI 10.1016/0042-6989(90)90066-T
   ELLIOTT DB, 1987, OPHTHAL PHYSL OPT, V7, P415, DOI 10.1111/j.1475-1313.1987.tb00771.x
   Gayton JL, 2012, J CATARACT REFR SURG, V38, P415, DOI 10.1016/j.jcrs.2011.12.022
   Gil MA, 2014, EUR J OPHTHALMOL, V24, P44, DOI 10.5301/ejo.5000335
   Grzybowski A., 2020, CURRENT CONCEPTS OPH, P55, DOI [10.1007/ 978-3-030-25389-9_3, DOI 10.1007/978-3-030-25389-9_3, 10.1007/978-3-030-25389-9_3]
   Grzybowski A, 2019, GRAEF ARCH CLIN EXP, V257, P1091, DOI 10.1007/s00417-019-04270-w
   Grzybowski A, 2019, GRAEF ARCH CLIN EXP, V257, P855, DOI 10.1007/s00417-018-04210-0
   Haaskjold E, 1998, J CATARACT REFR SURG, V24, P653, DOI 10.1016/S0886-3350(98)80260-5
   Harman FE, 2008, OPHTHALMOLOGY, V115, P993, DOI 10.1016/j.ophtha.2007.08.042
   HIGGINS KE, 1988, J OPT SOC AM A, V5, P2173, DOI 10.1364/JOSAA.5.002173
   Hohberger B, 2007, GRAEF ARCH CLIN EXP, V245, P1805, DOI 10.1007/s00417-007-0662-x
   Ji J, 2013, EXP THER MED, V5, P277, DOI 10.3892/etm.2012.740
   Kamath GG, 2000, J CATARACT REFR SURG, V26, P576, DOI 10.1016/S0886-3350(99)00457-5
   Kamlesh MS, 2001, CAN J OPHTHALMOL, V36, P197, DOI 10.1016/S0008-4182(01)80040-5
   Karatepe AS, 2017, TURK OFTALMOL DERG, V47, P80, DOI 10.4274/tjo.93763
   Klein B E, 1996, Ophthalmic Epidemiol, V3, P47, DOI 10.3109/09286589609071600
   KLINE DW, 1983, J GERONTOL, V38, P211, DOI 10.1093/geronj/38.2.211
   Labiris G, 2015, J CATARACT REFR SURG, V41, P53, DOI 10.1016/j.jcrs.2014.06.015
   Leyland MD, 2002, EYE, V16, P481, DOI 10.1038/sj.eye.6700077
   Maxwell A, 2017, J CATARACT REFR SURG, V43, P29, DOI 10.1016/j.jcrs.2016.10.026
   MCGRATH C, 1981, Q J EXP PHYSIOL CMS, V66, P253, DOI 10.1113/expphysiol.1981.sp002554
   Mencucci R, 2018, GRAEF ARCH CLIN EXP, V256, P1913, DOI 10.1007/s00417-018-4052-3
   Montes-Mico R, 2004, OPHTHALMOLOGY, V111, P85, DOI 10.1016/S0161-6420(03)00862-5
   MORRISON JD, 1985, Q J EXP PHYSIOL CMS, V70, P249, DOI 10.1113/expphysiol.1985.sp002907
   MORRISON JD, 1993, EYE, V7, P20, DOI 10.1038/eye.1993.5
   NAMEDA N, 1989, OPTOMETRY VISION SCI, V66, P760, DOI 10.1097/00006324-198911000-00007
   Nio YK, 2000, OPHTHAL PHYSL OPT, V20, P323, DOI 10.1016/S0275-5408(99)00103-9
   Nomura H, 2003, JPN J OPHTHALMOL, V47, P299, DOI 10.1016/S0021-5155(03)00011-X
   Oen F. T. S., 1994, Annals Academy of Medicine Singapore, V23, P322
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   Palmer AM, 2008, J REFRACT SURG, V24, P257, DOI 10.3928/1081597X-20080301-07
   Pedrotti E, 2018, J CATARACT REFR SURG, V44, P156, DOI 10.1016/j.jcrs.2017.11.011
   Pedrotti E, 2018, INT OPHTHALMOL, V38, P1709, DOI 10.1007/s10792-017-0652-x
   PERCIVAL SPB, 1993, J CATARACT REFR SURG, V19, P26, DOI 10.1016/S0886-3350(13)80275-1
   Plaza-Puche AB, 2016, EUR J OPHTHALMOL, V26, P612, DOI 10.5301/ejo.5000777
   Prakash G, 2011, EYE, V25, P1187, DOI 10.1038/eye.2011.150
   Rosen E, 2016, J CATARACT REFR SURG, V42, P310, DOI 10.1016/j.jcrs.2016.01.014
   ROSS JE, 1985, BRIT J OPHTHALMOL, V69, P51, DOI 10.1136/bjo.69.1.51
   SEKULER R, 1980, SCIENCE, V209, P1255, DOI 10.1126/science.7403884
   Sen HN, 2004, J CATARACT REFR SURG, V30, P2483, DOI 10.1016/j.jcrs.2004.04.049
   Sia DIT, 2013, ACTA OPHTHALMOL, V91, P312, DOI 10.1111/j.1755-3768.2011.02379.x
   SLOANE ME, 1988, J OPT SOC AM A, V5, P2181, DOI 10.1364/JOSAA.5.002181
   STEINERT RF, 1992, OPHTHALMOLOGY, V99, P853
   Tan NA, 2014, EUR J OPHTHALMOL, V24, P693, DOI 10.5301/ejo.5000425
   TULUNAYKEESEY U, 1988, J OPT SOC AM A, V5, P2191, DOI 10.1364/JOSAA.5.002191
   Wang SY, 2017, EUR J OPHTHALMOL, V27, P387, DOI 10.5301/ejo.5000978
   Wilkins MR, 2013, OPHTHALMOLOGY, V120, P2449, DOI 10.1016/j.ophtha.2013.07.048
   Yamauchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068236
   YATES JT, 1987, AM J OPTOM PHYS OPT, V64, P519
   Zeng MB, 2007, CLIN EXP OPHTHALMOL, V35, P355, DOI 10.1111/j.1442-9071.2007.01452.x
   Zhao GQ, 2010, J CATARACT REFR SURG, V36, P282, DOI 10.1016/j.jcrs.2009.08.037
NR 64
TC 16
Z9 16
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2020
VL 258
IS 4
BP 805
EP 813
DI 10.1007/s00417-020-04603-0
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KU2JY
UT WOS:000519535900013
PM 31955239
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JH
   Yu, YS
   Park, KH
   Kang, HJ
   Lee, HY
   Kim, KW
AF Kim, Jeong Hun
   Kim, Jin Hyoung
   Yu, Young Suk
   Park, Kyu Hyung
   Kang, Hye Jin
   Lee, Ho-Young
   Kim, Kyu-Won
TI Antiangiogenic effect of deguelin on choroidal neovascularization
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID BRONCHIAL EPITHELIAL-CELLS; ORNITHINE-DECARBOXYLASE; ANGIOGENESIS;
   INHIBITION; ROTENONE; MACULOPATHY; MECHANISMS; APOPTOSIS
AB Age-related macular degeneration is the leading cause of blindness in the elderly. Choroidal neovascularization (CNV) leads to severe vision loss in patients of age-related macular degeneration. Previously, we have demonstrated that deguelin, isolated from plants in the Mundulea sericea family, is a chemopreventive agent. This study evaluates the antiangiogenic effect of deguelin on CNV. The toxicity of deguelin was evaluated through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in human umbilical vein endothelial cells (HUVECs) as well as histological examination and terminal deoxynucleotidyl transferase dUTP nick-end labeling staining in the deguelin-injected retina. Antiangiogenic activity of deguelin was evaluated by in vitro tube formation assay of HUVECs and in vivo angiogenesis of chick chorioallantoic membrane (CAM). In C57BL/6 mice with laser-induced CNV, deguelin or phosphate-buffered saline was injected intravitreously. CNV lesions were examined by fluorescence angiography and vessel counting in cross-sections. Deguelin showed no effect on cell viability of HUVECs and no retinal toxicity in a concentration range of 0.01 to 1 mu M. Deguelin effectively inhibited in vitro tube formation of HUVECs and in vivo angiogenesis of CAM. Interestingly, deguelin significantly reduced CNV and its leakage in mouse model of laser photocoagulation-induced CNV. Our data suggests that deguelin is a potent inhibitor of CNV and may be applied in the treatment of other vasoproliferative retinopathies such as retinopathy of prematurity and diabetic retinopathy.
C1 [Kim, Jeong Hun; Kim, Jin Hyoung; Yu, Young Suk; Park, Kyu Hyung] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 151744, South Korea.
   [Kim, Jeong Hun; Kim, Jin Hyoung; Yu, Young Suk] Seoul Natl Univ Hosp, Clin Res Inst, Seoul Artificial Eye Ctr, Seoul 151744, South Korea.
   [Park, Kyu Hyung] Bundang Seoul Natl Univ Hosp, Songnam, South Korea.
   [Kang, Hye Jin; Kim, Kyu-Won] Seoul Natl Univ, Coll Pharm, NeuroVasc Coordinat Res Ctr, Seoul, South Korea.
   [Kang, Hye Jin; Kim, Kyu-Won] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul, South Korea.
   [Lee, Ho-Young] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University (SNU); University of Texas System; UTMD Anderson
   Cancer Center
RP Yu, YS (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 151744, South Korea.
EM ysyu@snu.ac.kr
RI Yu, Young Suk/J-5551-2012; Park, Kyu Hyung/J-5481-2012; Kim, Kyu
   Won/AAJ-7213-2020; Kim, Jeong Hun/J-2748-2012
OI Lee, Ho-Young/0000-0001-7556-9312
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ANZEVENO PB, 1979, J ORG CHEM, V44, P2578, DOI 10.1021/jo01328a056
   Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Fang NB, 1998, P NATL ACAD SCI USA, V95, P3380, DOI 10.1073/pnas.95.7.3380
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerhauser C, 1997, CANCER RES, V57, P3429
   GERHAUSER C, 1995, NAT MED, V1, P260, DOI 10.1038/nm0395-260
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Lee HY, 2005, J NATL CANCER I, V97, P1695, DOI 10.1093/jnci/dji377
   Lee HY, 2004, BIOCHEM PHARMACOL, V68, P1119, DOI 10.1016/j.bcp.2004.05.033
   Lee HY, 2004, CLIN CANCER RES, V10, P1074, DOI 10.1158/1078-0432.CCR-0833-3
   MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298
   Oh SH, 2007, J NATL CANCER I, V99, P949, DOI 10.1093/jnci/djm007
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Srivastava P, 2007, FEBS J, V274, P4788, DOI 10.1111/j.1742-4658.2007.06004.x
NR 20
TC 30
Z9 30
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD FEB
PY 2008
VL 324
IS 2
BP 643
EP 647
DI 10.1124/jpet.107.132720
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 255CB
UT WOS:000252633200025
PM 17967937
DA 2022-11-30
ER

PT J
AU Gibson, JM
AF Gibson, J. M.
TI 25th RCOphth Congress, President's Session paper: 25 years of progress
   in medical retina
SO EYE
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN PHOTODYNAMIC
   THERAPY; INDOCYANINE GREEN VIDEOANGIOGRAPHY; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; LASER PHOTOCOAGULATION; INTRAVITREAL
   TRIAMCINOLONE; CONTROLLED TRIAL; RANIBIZUMAB; PHOTOGRAPHY
AB The quarter century since the foundation of the Royal College of Ophthalmologists has coincided with immense change in the subspecialty of medical retina, which has moved from being the province of a few dedicated enthusiasts to being an integral, core part of ophthalmology in every eye department. In age-related macular degeneration, there has been a move away from targeted, destructive laser therapy, dependent on fluorescein angiography to intravitreal injection therapy of anti-growth factor agents, largely guided by optical coherence tomography. As a result of these changes, ophthalmologists have witnessed a marked improvement in visual outcomes for their patients with wet age-related macular degeneration (AMD), while at the same time developing and enacting entirely novel ways of delivering care. In the field of diabetic retinopathy, this period also saw advances in laser technology and a move away from highly destructive laser photocoagulation treatment to gentler retinal laser treatments. The introduction of intravitreal therapies, both steroids and anti-growth factor agents, has further advanced the treatment of diabetic macular oedema. This era has also seen in the United Kingdom the introduction of a coordinated national diabetic retinopathy screening programme, which offers an increasing hope that the burden of blindness from diabetic eye disease can be lessened. Exciting future advances in retinal imaging, genetics, and pharmacology will allow us to further improve outcomes for our patients and for ophthalmologists specialising in medical retina, the future looks very exciting but increasingly busy.
C1 Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
C3 Aston University
RP Gibson, JM (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
EM j.m.gibson@aston.ac.uk
OI Gibson, Jonathan M/0000-0002-9281-5244
FU Novartis Pharmaceuticals UK Ltd; Bayer PLC
FX The author has received travel re-imbursement and honoraria for
   attending advisory boards and conferences from Novartis Pharmaceuticals
   UK Ltd, Bayer PLC, Alimera Sciences, and Allergan Limited. He has
   received research funding from Novartis Pharmaceuticals UK Ltd and Bayer
   PLC.
CR Al-Husainy S, 2005, EYE, V19, P312, DOI 10.1038/sj.eye.6701480
   Al-Hussainy S, 2008, EYE, V22, P96, DOI 10.1038/sj.eye.6703026
   [Anonymous], 1990, Diabet Med, V7, P360
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P271
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   [Anonymous], 1987, Int Ophthalmol Clin, V27, P265
   [Anonymous], 2008, EXCELLENCE NIFHACTA
   Arden GB, 1995, EYE, V9, P686, DOI 10.1038/eye.1995.180
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin Albert, 2009, Retina, V29, pS8, DOI 10.1097/IAE.0b013e3181ad253d
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   Beck RW, 2009, ARCH OPHTHALMOL-CHIC, V127, P245, DOI 10.1001/archophthalmol.2008.610
   Bhatnagar Ajay, 2010, Ophthalmic Surg Lasers Imaging, V41 Online, pe1, DOI 10.3928/15428877-20101124-09
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURNSCOX CJ, 1985, BMJ-BRIT MED J, V290, P1052, DOI 10.1136/bmj.290.6474.1052
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P745
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1434
   Denniston AKO, 2005, DIABETIC MED, V22, P665, DOI 10.1111/j.1464-5491.2005.01484.x
   Dodson PM, 1998, EYE, V12, P1
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Ergun E, 2004, ARCH OPHTHALMOL-CHIC, V122, P37, DOI 10.1001/archopht.122.1.37
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   FINE SL, 1983, OPHTHALMOLOGY, V90, P531
   Foulds W S, 1983, Health Bull (Edinb), V41, P318
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   FUNG WE, 1991, AM J OPHTHALMOL, V112, P349, DOI 10.1016/S0002-9394(14)76743-1
   GIBSON JM, 1989, BRIT J OPHTHALMOL, V73, P687, DOI 10.1136/bjo.73.8.687
   GILLIES MC, 1993, BRIT J OPHTHALMOL, V77, P759, DOI 10.1136/bjo.77.12.759
   Gillow JT, 1999, BRIT J OPHTHALMOL, V83, P1083, DOI 10.1136/bjo.83.9.1083
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   GUYER DR, 1993, CURR OPIN OPHTHALMOL, V4, P3, DOI 10.1097/00055735-199306000-00002
   Haller JA, 2010, OPHTHALMOLOGY, V117, pe3, DOI [DOI 10.1016/j.ophtha.2010.03.032, 10.1016/j.ophtha.2010.03.032]
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Harding S, 2003, DIABETIC MED, V20, P965, DOI 10.1111/j.1464-5491.2003.01077.x
   HARDING SP, 1995, BMJ-BRIT MED J, V311, P1131, DOI 10.1136/bmj.311.7013.1131
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   HOPEROSS MW, 1994, ACTA OPHTHALMOL, V72, P134
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Jain A, 2008, ARCH OPHTHALMOL-CHIC, V126, P78, DOI 10.1001/archophthalmol.2007.29
   James M, 2000, BRIT MED J, V320, P1627, DOI 10.1136/bmj.320.7250.1627
   Jude EB, 1998, DIABETIC MED, V15, P143, DOI 10.1002/(SICI)1096-9136(199802)15:2<143::AID-DIA531>3.0.CO;2-U
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kaiser PK, 2009, OPHTHALMOLOGY, V1164, p55e1
   KIRKPATRICK JNP, 1993, BRIT J OPHTHALMOL, V77, P766, DOI 10.1136/bjo.77.12.766
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P7
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   KLEIN R, 1989, OPHTHALMOLOGY, V96, P1501
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   KOHNER EM, 1978, T OPHTHAL SOC UK, V98, P299
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   MACCUISH AC, 1993, EYE, V7, P254, DOI 10.1038/eye.1993.59
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Michaelides M, 2010, OPHTHALMOLOGY, V117, P1078
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Michels S, 2005, RETINA-J RET VIT DIS, V25, P697, DOI 10.1097/00006982-200509000-00003
   Mookhtiar M, 2012, EYE, V26, P619, DOI 10.1038/eye.2011.345
   MOSS SE, 1989, INVEST OPHTH VIS SCI, V30, P823
   Muqit MMK, 2010, ARCH OPHTHALMOL-CHIC, V128, P525, DOI 10.1001/archophthalmol.2010.60
   OWENS DR, 1991, DIABETIC MED, V8, pS4, DOI 10.1111/j.1464-5491.1991.tb02148.x
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   ROSENBERG N, 1986, ARCH OPHTHALMOL-CHIC, V104, P34
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnisky CJ, 2010, RETINA-J RET VIT DIS, V30, P548, DOI 10.1097/IAE.0b013e3181bcf1b8
   RYDER REJ, 1985, BRIT MED J, V291, P1256, DOI 10.1136/bmj.291.6504.1256
   Scanlon PH, 2003, BRIT J OPHTHALMOL, V87, P1258, DOI 10.1136/bjo.87.10.1258
   Scanlon PH, 2003, DIABETIC MED, V20, P467, DOI 10.1046/j.1464-5491.2003.00954.x
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   SINGERMAN LJ, 1989, RETINA-J RET VIT DIS, V9, P247, DOI 10.1097/00006982-198909040-00002
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243
   The Diabetic Retinopathy Study Research Group, 1987, INT OPHTHALMOL CLIN, V27, P239, DOI DOI 10.1097/00004397-198702740-00004
   TORNAMBE PE, 1992, RETINA-J RET VIT DIS, V12, P305, DOI 10.1097/00006982-199212040-00003
   ULBIG MW, 1993, BRIT J OPHTHALMOL, V77, P218, DOI 10.1136/bjo.77.4.218
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 2010, AM J OPHTHALMOL, V149, P361, DOI 10.1016/j.ajo.2009.11.017
NR 97
TC 4
Z9 4
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2014
VL 28
IS 9
BP 1041
EP 1052
DI 10.1038/eye.2014.141
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AP4QX
UT WOS:000342064400001
PM 24993325
OA Green Published, Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Rex, TS
AF Rex, Tonia S.
TI Rescue of sight by gene therapy - Closer than it may appear
SO OPHTHALMIC GENETICS
LA English
DT Review
DE retina; gene therapy; retinoblastoma; AMD; retinal degeneration
ID EPITHELIUM-DERIVED FACTOR; ADENOVIRUS-MEDIATED DELIVERY; RETINAL
   DEGENERATION; MOUSE MODEL; CHOROIDAL NEOVASCULARIZATION; PHOTORECEPTOR
   DEGENERATION; REPLACEMENT THERAPY; ADENOASSOCIATED VIRUS;
   IMMUNE-RESPONSE; RESTORES VISION
AB This review will cover the state of the field in retinal degeneration and gene therapy with a focus on the great strides that have been made in retina gene therapy. Topics ranging from the development of animal models to clinical trials (for the treatment of Leber congenital amaurosis, age-related macular degeneration, and retinoblastoma) will be discussed. In addition, the results of gene therapy studies targeting the photoreceptors will be presented. Finally, strategies and progress in overcoming the challenges of photoreceptor-directed gene therapy will be presented.
C1 Univ Penn, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Rex, TS (通讯作者)，Univ Tennessee, Ctr Hlth Sci, Hamilton Eye Inst, 930 Madison Ave,Ste 750, Memphis, TN 38163 USA.
EM trex@utmem.edu
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Anand V, 2002, MOL THER, V5, P125, DOI 10.1006/mthe.2002.0525
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333
   Bennett J, 2003, GENE THER, V10, P977, DOI 10.1038/sj.gt.3302030
   Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649
   Buch PK, 2006, MOL THER, V14, P700, DOI 10.1016/j.ymthe.2006.05.019
   Budzynski E, 2006, OPHTHALMIC GENET, V27, P123, DOI 10.1080/13816810600977192
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cashman SM, 2005, GENE THER, V12, P1223, DOI 10.1038/sj.gt.3302512
   Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042
   Chevez-Barrios P, 2000, AM J PATHOL, V157, P1405, DOI 10.1016/S0002-9440(10)64653-6
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   FARBER DB, 1994, PROG RETIN EYE RES, V13, P31, DOI 10.1016/1350-9462(94)90004-3
   FRANCKE U, 1976, MED PEDIATR ONCOL, V2, P379, DOI 10.1002/mpo.2950020404
   Gao GP, 2005, CURR GENE THER, V5, P285, DOI 10.2174/1566523054065057
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gorbatyuk M, 2007, EXP EYE RES, V84, P44, DOI 10.1016/j.exer.2006.08.014
   Gorbatyuk MS, 2005, MOL VIS, V11, P648
   GOVERDHANA S, 2006, CURR GENE THER, V6, P421
   Haire SE, 2006, INVEST OPHTH VIS SCI, V47, P3745, DOI 10.1167/iovs.06-0086
   Hurwitz MY, 1999, HUM GENE THER, V10, P441, DOI 10.1089/10430349950018887
   Imai D, 2005, J CELL PHYSIOL, V202, P570, DOI 10.1002/jcp.20155
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Jomary C, 1997, GENE THER, V4, P683, DOI 10.1038/sj.gt.3300440
   Kiang AS, 2005, MOL THER, V12, P555, DOI 10.1016/j.ymthe.2005.03.028
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kumar-Singh R, 1998, HUM MOL GENET, V7, P1893, DOI 10.1093/hmg/7.12.1893
   Lebherz C, 2005, HUM GENE THER, V16, P178, DOI 10.1089/hum.2005.16.178
   LEONARD KC, 2007, PLOS MED, V2, P1
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358
   MillingtonWard S, 1997, HUM MOL GENET, V6, P1415, DOI 10.1093/hmg/6.9.1415
   Min SH, 2005, MOL THER, V12, P644, DOI 10.1016/j.ymthe.2005.06.002
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Narfstrom K, 2003, J HERED, V94, P31, DOI 10.1093/jhered/esg015
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Palfi A, 2006, HUM MUTAT, V27, P260, DOI 10.1002/humu.20287
   Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001
   Pang JJ, 2005, MOL VIS, V11, P152
   Pawlyk BS, 2005, INVEST OPHTH VIS SCI, V46, P3039, DOI 10.1167/iovs.05-0371
   Rakoczy PE, 2003, ADV EXP MED BIOL, V533, P431
   RASMUSSEN H, 2001, HUM GENE THER, V2, P2029
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Reich SJ, 2003, HUM GENE THER, V14, P37, DOI 10.1089/10430340360464697
   Rex TS, 2004, HUM GENE THER, V15, P960, DOI 10.1089/hum.2004.15.960
   Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Sarra GM, 2001, HUM MOL GENET, V10, P2353, DOI 10.1093/hmg/10.21.2353
   Schlichtenbrede FC, 2003, J GENE MED, V5, P757, DOI 10.1002/jgm.401
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Sullivan JM, 2002, MOL VIS, V8, P102
   Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   Williams ML, 2006, PLOS MED, V3, P904, DOI 10.1371/journal.pmed.0030201
NR 65
TC 5
Z9 6
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2007
VL 28
IS 3
BP 127
EP 133
DI 10.1080/13816810701503707
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 218JG
UT WOS:000250011200003
PM 17896310
DA 2022-11-30
ER

PT J
AU Schilling, OK
   Wahl, HW
   Horowitz, A
   Reinhardt, JP
   Boerner, K
AF Schilling, Oliver K.
   Wahl, Hans-Werner
   Horowitz, Amy
   Reinhardt, Joann P.
   Boerner, Kathrin
TI The Adaptation Dynamics of Chronic Functional Impairment: What We Can
   Learn From Older Adults With Vision Loss
SO PSYCHOLOGY AND AGING
LA English
DT Article
DE adaptation to vision loss; functional ability; perceived vision loss;
   visual acuity
ID PSYCHOSOCIAL ADAPTATION; VISUAL IMPAIRMENT; DEPRESSION; MODEL; SCALE
AB This study used vision loss due to age-related macular degeneration to learn about adaptation processes related to chronic functional impairment, focusing on Horowitz and Reinhardt's (1998) concept of Adaptation to Age-related Vision Loss (AVL) as the outcome. We hypothesized that impacts of visual acuity on AVL are mediated by perceived functional vision losses and functional abilities, and tested for "adaptive" weakening of this impact with ongoing loss. Longitudinal data covering a one-year interval from samples with age-related macular degeneration gathered in New York (N = 361) and Heidelberg (Germany, N = 90) were used. We analyzed the hypothesized causal structure by modeling latent change scores, and checked if those with low, medium, and high levels of vision loss at baseline differ in the relations between one-year change scores. Results confirmed that impacts of vision loss on AVL are mediated by decline in functional ability. However, under the most severe levels of vision loss at baseline, functional decline showed only a minor impact on AVL change not explained by a lack of further decline in vision. Findings confirm the effectiveness of adaptation in terms of reduced reactivity to functional losses across increasing level of chronic impairment. Thus, adaptation, weakening the impact of chronic functional impairment on psychological outcomes over time with disease progression, deserves consideration in the study of psychological consequences of chronic physical health conditions in old age.
C1 [Schilling, Oliver K.; Wahl, Hans-Werner] Heidelberg Univ, Dept Psychol Ageing Res, Inst Psychol, D-69115 Heidelberg, Germany.
   [Horowitz, Amy; Reinhardt, Joann P.; Boerner, Kathrin] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA.
   [Horowitz, Amy; Reinhardt, Joann P.; Boerner, Kathrin] Jewish Home Lifecare, New York, NY USA.
C3 Ruprecht Karls University Heidelberg; Icahn School of Medicine at Mount
   Sinai
RP Schilling, OK (通讯作者)，Heidelberg Univ, Dept Psychol Ageing Res, Inst Psychol, Bergheimer Str 58, D-69115 Heidelberg, Germany.
EM oliver.schilling@psychologie.uni-heidelberg.de
RI Boerner, Kathrin/M-1504-2019
FU NATIONAL EYE INSTITUTE [R01EY012563] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064437] Funding Source: NIH
   RePORTER; NEI NIH HHS [R01EY12563] Funding Source: Medline; NIMH NIH HHS
   [R01 MH064437] Funding Source: Medline
CR Baltes P.B., 1990, SUCCESSFUL AGING PER, P1, DOI [DOI 10.1017/CBO9780511665684.003, 10.1017/CBO9780511665684.003]
   BEVAN W, 1965, J PSYCHOL, V59, P73, DOI 10.1080/00223980.1965.9916779
   Boerner K, 2007, HUM DEV, V50, P171, DOI 10.1159/000103358
   BRANDTSTADTER J, 1990, PSYCHOL AGING, V5, P58, DOI 10.1037/0882-7974.5.1.58
   Brandtstadter J., 2006, HDB CHILD PSYCHOL, V1, P516
   BRENNAN M, 2003, J GERONTOLOGICAL SOC, V40, P54
   Brickman P., 1971, ADAPTATION LEVEL THE, P287, DOI DOI 10.3389/FPSYG.2018.01158
   Burmedi D., 2002, VISUAL IMPAIRMENT RE, V4, P47
   Diener E, 2006, AM PSYCHOL, V61, P305, DOI 10.1037/0003-066X.61.4.305
   Diener E, 1999, PSYCHOL BULL, V125, P276, DOI 10.1037//0033-2909.125.2.276
   Fauth EB, 2008, EUR J AGEING, V5, P161, DOI 10.1007/s10433-008-0092-6
   Gilbert DT, 1998, J PERS SOC PSYCHOL, V75, P617, DOI 10.1037/0022-3514.75.3.617
   GURALNIK JM, 1995, NIH PUB
   HECKHAUSEN J, 1995, PSYCHOL REV, V102, P284, DOI 10.1037/0033-295X.102.2.284
   HELSON H, 1948, PSYCHOL REV, V55, P297, DOI 10.1037/h0056721
   HOLZ FG, 2003, AGE RELATED MACULAR
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Horowitz A, 1998, J VISUAL IMPAIR BLIN, V92, P30, DOI 10.1177/0145482X9809200106
   HOROWITZ A, 1991, J GERONTOL SOC WORK, V17, P37, DOI 10.1300/J083v17n03_04
   HOROWITZ A, 2002, GERONTECHNOLOGY, V1, P262, DOI DOI 10.4017/GT.2002.01.04.005.00
   HOROWITZ A, 2006, J GERONTOLOGY SOCIAL, V65, P274
   Horowitz A, 2000, LIGHTHOUSE HDB VISIO, V2, P1089
   HOROWITZ A, 1996, 5 ANN INT C LOW VIS
   Horowitz A, 2007, J VISUAL IMPAIR BLIN, V101, P146, DOI 10.1177/0145482X0710100303
   Lacey HP, 2008, HEALTH PSYCHOL, V27, P669, DOI 10.1037/0278-6133.27.6.669
   Lawton M.P., 1973, PSYCHOL ADULT DEV AG, P619, DOI DOI 10.1037/10044-020
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   Lazarus R.S., 1984, STRESS APPRAISAL COP
   Lucas RE, 2003, J PERS SOC PSYCHOL, V84, P527, DOI 10.1037/0022-3514.84.3.527
   MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4
   Muthen L., 2017, MPLUS, V8th ed.
   ORR AL, 1992, VISION AGING CROSSRO, P3
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Raykov T, 2008, STRUCT EQU MODELING, V15, P603, DOI 10.1080/10705510802339015
   REINHARDT JP, 2001, APPL DEV SCI, V15, P76, DOI DOI 10.1207/S1532480XADS0502_3
   Rovner BW, 2007, INT J GERIATR PSYCH, V22, P789, DOI 10.1002/gps.1742
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147
   Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23, DOI DOI 10.1002/0470010940
   Schilling OK, 2006, PSYCHOL AGING, V21, P703, DOI 10.1037/0882-7974.21.4.703
   Shrout PE, 2002, PSYCHOL METHODS, V7, P422, DOI 10.1037//1082-989X.7.4.422
   Smith DM, 2009, HEALTH PSYCHOL, V28, P787, DOI 10.1037/a0016624
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   Ubel PA, 2005, HEALTH PSYCHOL, V24, pS57, DOI 10.1037/0278-6133.24.4.S57
   Vaillant G. E., 1995, ADAPTATION LIFE
   VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1
   Wahl HW, 2007, J GERONTOL B-PSYCHOL, V62, pP90, DOI 10.1093/geronb/62.2.P90
   Wahl HW, 1999, J GERONTOL B-PSYCHOL, V54, pP304, DOI 10.1093/geronb/54B.5.P304
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   Wahl HW, 2003, EUR PSYCHOL, V8, P168, DOI 10.1027//1016-9040.8.3.168
   Whitbourne SK, 1996, AGING INDIVIDUAL PHY
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
NR 52
TC 19
Z9 20
U1 1
U2 10
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0882-7974
EI 1939-1498
J9 PSYCHOL AGING
JI Psychol. Aging
PD MAR
PY 2011
VL 26
IS 1
BP 203
EP 213
DI 10.1037/a0021127
PG 11
WC Gerontology; Psychology, Developmental
WE Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychology
GA 737TJ
UT WOS:000288590800022
PM 21142375
DA 2022-11-30
ER

PT J
AU Xu, L
   Xie, XW
   Wang, YX
   Jonas, JB
AF Xu, L.
   Xie, X. W.
   Wang, Y. X.
   Jonas, J. B.
TI Ocular and systemic factors associated with diabetes mellitus in the
   adult population in rural and urban China. The Beijing Eye Study
SO EYE
LA English
DT Article
DE diabetes mellitus; optic disc; intraocular pressure; peripapillary
   atrophy; retinal vessel diameter; Beijing Eye Study
ID AGE-RELATED MACULOPATHY; OPTIC DISC MORPHOLOGY; RISK-FACTORS; MACULAR
   DEGENERATION; CARDIOVASCULAR-DISEASE; PREVALENCE; CHINESE;
   ATHEROSCLEROSIS; ABNORMALITIES; COMMUNITIES
AB Purpose To assess ocular and systemic factors associated with diabetes mellitus in the adult population in rural and urban China.
   Methods The Beijing Eye Study 2006, a population-based, cross-sectional cohort study, included 3251 subjects aged 45 years and more (participation rate: 73.2%). Blood samples were available for 2960 (91.0%) subjects. Diabetes mellitus was defined by a fasting plasma glucose concentration >= 7.0 mmol/l or by a self-reported history diagnosis of diabetes.
   Results Diabetes mellitus was found in 381 (12.9%) subjects. In binary regression analysis, the presence of diabetes mellitus was significantly associated with body mass index, systolic blood pressure, triglyceride concentrations, intraocular pressure, cylindrical refractive dioptre, presence of arteriolar sheathing, rural vs urban region, lower best-corrected visual acuity, lower highdensity lipoprotein level, and lower diastolic blood pressure. It was not statistically associated with age, presence of cataract (nuclear, cortical, or subcapsular), size of the optic disc, neuroretinal rim, a zone and beta zone of peripapillary atrophy, retinal artery and vein diameters, arteriovenous nicking, focal or general narrowing, refractive error, prevalence of glaucoma, and early or late stage of age-related macular degeneration.
   Conclusions In a population-based setting, diabetes mellitus was not associated with optic disc, rim and peripapillary atrophy measurements, retinal vessel diameters, arteriovenous nicking, focal or general retinal artery narrowing, and prevalence of age-related macular degeneration. Although diabetes mellitus was significantly correlated with higher intraocular pressure, it was not associated with glaucoma.
C1 [Xu, L.; Xie, X. W.; Wang, Y. X.; Jonas, J. B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, J. B.] Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou Lane, Beijing 100005, Peoples R China.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
FU National Key Laboratory Fund, Beijing, China.
FX Supported by the National Key Laboratory Fund, Beijing, China.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Gu D, 2003, DIABETOLOGIA, V46, P1190, DOI 10.1007/s00125-003-1167-8
   Hayreh SS, 2001, OPHTHALMOLOGY, V108, P1586, DOI 10.1016/S0161-6420(01)00649-2
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jia WP, 2007, DIABETOLOGIA, V50, P286, DOI 10.1007/s00125-006-0503-1
   JONAS JB, 1993, INVEST OPHTH VIS SCI, V34, P2260
   JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P401
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Liu WW, 2007, OPHTHALMOLOGY, V114, P1795, DOI 10.1016/j.ophtha.2007.03.010
   Morgan WH, 1998, INVEST OPHTH VIS SCI, V39, P1419
   Pan XR, 1997, DIABETES CARE, V20, P1664, DOI 10.2337/diacare.20.11.1664
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   Wang S, 2006, OPHTHALMOLOGY, V113, P1752, DOI 10.1016/j.ophtha.2006.05.019
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Xu L, 2006, OPHTHALMOLOGY, V113, P747, DOI 10.1016/j.ophtha.2006.01.026
   Xu L, 2006, OPHTHALMOLOGY, V113, pe1
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
NR 26
TC 17
Z9 17
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD MAR
PY 2009
VL 23
IS 3
BP 676
EP 682
DI 10.1038/sj.eye.6703104
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 418AL
UT WOS:000264119500031
PM 18259206
OA Bronze
DA 2022-11-30
ER

PT J
AU Majid, MA
   Smith, VA
   Matthews, FJ
   Newby, AC
   Dick, AD
AF Majid, M. A.
   Smith, V. A.
   Matthews, F. J.
   Newby, A. C.
   Dick, A. D.
TI Tissue inhibitor of metalloproteinase-3 differentially binds to
   components of Bruch's membrane
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SORSBYS-FUNDUS-DYSTROPHY; RETINAL-PIGMENT EPITHELIUM; MEDIATED GENE
   DELIVERY; CELL-DEATH; TIMP-3; LOCALIZATION; APOPTOSIS; EXPRESSION;
   INVASION
AB Background: Sorsby's fundus dystrophy ( SFD) is caused by mutations in tissue inhibitor of metalloproteinase ( TIMP)-3 and, with the exception of early onset, is similar to age-related macular degeneration. The pathological features of this condition relate to the accumulation of TIMP-3 in Bruch's membrane.
   Aims: To compare the extracellular membrane-binding characteristics of wild-type and four SFD-mutant TIMP-3s.
   Methods: COS-7 cells were transfected with wild-type, Ser-181, Gly-167, Ser-156 and Tyr-168 SFD-mutant TIMP- 3 cDNA. The TIMP-3 proteins subsequently synthesised were harvested, analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, semiquantified by ELISA and used in binding assays on the basis of the retention of the wild-type and SFD-mutant TIMP-3 proteins by components of Bruch's membrane.
   Results: SFD-mutant TIMP-3s could not be distinguished from wild-type TIMP- 3 by the extents to which they aggregated or adhered to type-I collagen, type-IV collagen, fibronectin, laminin, elastin, chondroitin sulphates A, B and C, and heparin sulphate. Of these macromolecules, the wild-type and SFD- mutant TIMP-3s exhibited greatest affinity for elastin and laminin.
   Conclusion: The similarity in the physical and extracellular membrane-binding characteristics of wild-type and SFD-mutant TIMP-3s indicates that these properties are not responsible for the difference in timing of onset of SFD and age-related macular degeneration.
C1 Univ Bristol, Bristol Eye Hosp, Acad Unit Ophthalmol, Bristol BS1 2LX, Avon, England.
   Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS8 1TH, Avon, England.
C3 Bristol Eye Hospital; University of Bristol; Bristol Royal Infirmary;
   University of Bristol
RP Smith, VA (通讯作者)，Univ Bristol, Bristol Eye Hosp, Acad Unit Ophthalmol, Lower Maudlin St, Bristol BS1 2LX, Avon, England.
EM Val.Smith@bristol.ac.uk
RI Matthews, Fiona/O-6932-2015
OI Matthews, Fiona/0000-0002-1728-2388; Dick, Andrew/0000-0002-0742-3159
CR Ahonen M, 1998, CANCER RES, V58, P2310
   Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X
   Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584
   Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805
   Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200
   CAPON MRC, 1988, EYE, V2, P114, DOI 10.1038/eye.1988.23
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   FARISS RN, 1997, AM J PATHOL, V16, P102
   HAMILTON WK, 1989, OPHTHALMOLOGY, V96, P1755
   Jomary C, 1997, NEUROREPORT, V8, P2169, DOI 10.1097/00001756-199707070-00015
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KAMEI M, 1997, DEGENERATIVE DIS RET
   Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835
   Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8
   Majid MA, 2002, BRIT J OPHTHALMOL, V86, P97, DOI 10.1136/bjo.86.1.97
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   WILLENBROCK F, 1994, AM J RESP CRIT CARE, V150, pS165, DOI 10.1164/ajrccm/150.6_Pt_2.S165
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
NR 30
TC 3
Z9 3
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2006
VL 90
IS 10
BP 1310
EP 1315
DI 10.1136/bjo.2006.097246
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 084HX
UT WOS:000240525100025
PM 16837541
OA Green Published
DA 2022-11-30
ER

PT J
AU Gambrelle, J
   Missotten, G
   Delhoum, S
   Desjardins, L
AF Gambrelle, J.
   Missotten, G.
   Delhoum, S.
   Desjardins, L.
TI Intravitreal injection of anti-VEGF and diagnosis of primary intraocular
   central nervous system lymphoma
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Primary intraocular central nervous; system lymphoma; Ranibizumab;
   Vitreous biopsy
AB We report a case of primary intraocular central nervous system (CNS) lymphoma in a patient previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections for age-related macular degeneration (AMD). An 88-year-old woman, with past medical history significant for bilateral age-related macular degeneration (AMD) treated with intravitreal ranibizumab injections for 1 year, was referred to our department for bilateral vitritis diagnosed 10 days after the last anti-VEGF injection. A complete uveitis work-up including aqueous humour analysis, brain MRI and vitreous biopsy enabled us to confirm the diagnosis of primary intraocular CNS lymphoma. To the best of our knowledge, this is the first report of the diagnosis of primary intraocular CNS lymphoma in a patient treated with anti-VEGF for AMD. The differential diagnosis of vitritis in elderly patients is relatively broad. Endophthalmitis and uveitis have been described after anti-VEGF injections. In such a situation, there is actually a risk of missing the diagnosis of intraocular lymphoma in the mistaken belief that the observed vitritis may be a reaction to administered anti-VEGFs. If no direct time-relationship with the anti-VEGF injections can be found, a classic vitritis work-up should be performed. Our observation suggests that ranibizumab, at the dosage used for AMD, does not impede the spread of CNS lymphoma in the eye nor interfere with cytological diagnosis. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Gambrelle, J.; Delhoum, S.] CHU Brest, Serv Ophtalmol, F-29609 Brest, France.
   [Missotten, G.] Catholic Univ Louvain, Serv Ophtalmol, B-1348 Louvain, Belgium.
   [Desjardins, L.] Inst Curie, Serv Ophtalmol, F-75005 Paris, France.
C3 CHU Brest; Universite Catholique Louvain; UDICE-French Research
   Universities; PSL Research University Paris; UNICANCER; Institut Curie
RP Gambrelle, J (通讯作者)，CHU Brest, Serv Ophtalmol, 2 Ave Foch, F-29609 Brest, France.
EM joel.gambrelle@hotmail.fr
CR Fardeau C, 2009, AM J OPHTHALMOL, V147, P886, DOI 10.1016/j.ajo.2008.12.025
   Itty S, 2009, RETINA-J RET VIT DIS, V29, P129, DOI 10.1097/IAE.0b013e318192f574
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Ruan J, 2009, ANN ONCOL, V20, P413, DOI 10.1093/annonc/mdn666
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
NR 5
TC 3
Z9 3
U1 0
U2 8
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD MAY
PY 2013
VL 36
IS 5
BP 431
EP 434
DI 10.1016/j.jfo.2012.11.005
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 197CQ
UT WOS:000322827000011
PM 23306179
DA 2022-11-30
ER

PT J
AU Strittmatter, K
   Pomeroy, H
   Marneros, AG
AF Strittmatter, Karin
   Pomeroy, Hayley
   Marneros, Alexander G.
TI Targeting Platelet-Derived Growth Factor Receptor beta(+) Scaffold
   Formation Inhibits Choroidal Neovascularization
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID VEGF; THERAPY
AB Neovascular age-related macular degeneration is among the most common causes of irreversible blindness and manifests with choroidal neovascularization (CNV). Anti-vascular endothelial growth factor-A therapies are only partially effective and their chronic administration may impair functions of the choriocapillaris and retina. Thus, novel therapeutic targets are needed urgently. We have observed in a laser-induced model of CNV that a platelet-derived growth factor receptor beta positive (PDGFR beta(+)) scaffold is formed before infiltration of neovessels into this scaffold to form CNV lesions, and that this scaffold limits the extent of neovascularization. Based on these observations we hypothesized that ablation of proliferating PDGFR beta(+) cells to prevent the formation of this scaffold might inhibit CNV growth and present a novel therapeutic approach for neovascular age-related macular degeneration. To test this hypothesis we targeted proliferating PDGFR beta(+) cells through independent distinct approaches after laser injury: i) by using an inducible genetic model to inhibit specifically proliferating PDGFR beta cells, ii) by treating mice with a neutralizing anti-PDGFR beta antibody, iii) by administering an anti-PDGF-AB/BB aptamer, and iv) by using small chemical inhibitor approaches. The results show that therapeutic targeting of proliferating PDGFR beta(+) cells potently inhibits the formation of the pericyte-like scaffold, with concomitant attenuation of CNV. Moreover, we show that early inhibition of PDGFR beta cell proliferation before neovessel formation is sufficient to inhibit scaffold formation and neovascularization.
C1 [Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, CNY 149,Rm 3-216,13th St, Charlestown, MA 02129 USA.
   Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School
RP Marneros, AG (通讯作者)，Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, CNY 149,Rm 3-216,13th St, Charlestown, MA 02129 USA.
EM amarneros@mgh.harvard.edu
OI Marneros, Alexander/0000-0003-3866-020X; Pomeroy,
   Hayley/0000-0002-7924-8046
FU Ophthotech Corporation
FX Supported by a grant from Ophthotech Corporation.
CR Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kang S, 2013, EXP EYE RES, V112, P125, DOI 10.1016/j.exer.2013.05.006
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nakamura K, 2006, CANCER RES, V66, P9134, DOI 10.1158/0008-5472.CAN-05-4290
   Patel S, 2009, RETINA-J RET VIT DIS, V29, pS45, DOI 10.1097/IAE.0b013e3181ad22d5
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
NR 15
TC 22
Z9 22
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUL
PY 2016
VL 186
IS 7
BP 1890
EP 1899
DI 10.1016/j.ajpath.2016.02.018
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA DP8OV
UT WOS:000378758400016
PM 27338108
OA Bronze
DA 2022-11-30
ER

PT J
AU Ku, CS
   Teo, SM
   Naidoo, N
   Sim, X
   Teo, YY
   Pawitan, Y
   Seielstad, M
   Chia, KS
   Salim, A
AF Ku, Chee-Seng
   Teo, Shu-Mei
   Naidoo, Nasheen
   Sim, Xueling
   Teo, Yik-Ying
   Pawitan, Yudi
   Seielstad, Mark
   Chia, Kee-Seng
   Salim, Agus
TI Copy number polymorphisms in new HapMap III and Singapore populations
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE Affymetrix SNP Array 6.0; Birdsuite software; copy number polymorphisms;
   International HapMap III populations; Southeast Asian populations
ID DELETION POLYMORPHISM; HUMAN GENOME; STRUCTURAL VARIATION;
   PROSTATE-CANCER; COMMON; GENE; EXPRESSION; VARIANTS; DISEASE; RISK
AB Copy number variations can be identified using newer genotyping arrays with higher single nucleotide polymorphisms (SNPs) density and copy number probes accompanied by newer algorithms. McCarroll et al. (2008) applied these to the HapMap II samples and identified 1316 copy number polymorphisms (CNPs). In our study, we applied the same approach to 859 samples from three Singapore populations and seven HapMap III populations. Approximately 50% of the 1291 autosomal CNPs were found to be polymorphic only in populations of non-African ancestry. Pairwise comparisons among the 10 populations showed substantial differences in the CNPs frequencies. Additionally, 698 CNPs showed significant differences with false discovery rate (FDR) < 0.01 among the 10 populations and these loci overlap with known disease-associated or pharmacogenetic-related genes such as CFHR3 and CFHR1 (age related macular degeneration), GSTTI (metabolism of various carcinogenic compounds and cancers) and UGT2B17 (prostate cancer and graft-versus-host disease). The correlations between CNPs and genome-wide association studies-SNPs were investigated and several loci, which were previously unreported, that may potentially be implicated in complex diseases and traits were found; for example, childhood acute lymphoblastic leukaemia, age-related macular degeneration, breast cancer, response to antipsychotic treatment, rheumatoid arthritis and type-1 diabetes. Additionally, we also found 5014 novel copy number loci that have not been reported previously by McCarroll et al. (2008) in the 10 populations. Journal of Human Genetics (2011) 56, 552-560; doi:10.1038/jhg.2011.54; published online 16 June 2011
C1 [Ku, Chee-Seng; Salim, Agus] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth MD3, Ctr Mol Epidemiol, Singapore 117597, Singapore.
   [Ku, Chee-Seng; Teo, Shu-Mei; Naidoo, Nasheen; Sim, Xueling; Teo, Yik-Ying; Chia, Kee-Seng; Salim, Agus] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117597, Singapore.
   [Teo, Shu-Mei] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117597, Singapore.
   [Teo, Yik-Ying] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117597, Singapore.
   [Teo, Yik-Ying] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore, Singapore.
   [Pawitan, Yudi; Chia, Kee-Seng] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Seielstad, Mark] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
C3 National University of Singapore; National University of Singapore;
   National University of Singapore; National University of Singapore;
   Agency for Science Technology & Research (A*STAR); A*STAR - Genome
   Institute of Singapore (GIS); Karolinska Institutet; University of
   California System; University of California San Francisco
RP Ku, CS (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth MD3, Ctr Mol Epidemiol, 16 Med Dr, Singapore 117597, Singapore.
EM g0700040@nus.edu.sg; ephaguss@nus.edu.sg
RI Salim, Agus/P-1407-2014; Seielstad, Mark/T-7841-2019; Sim,
   Xueling/AAZ-6652-2020
OI Salim, Agus/0000-0003-3999-7701; Sim, Xueling/0000-0002-1233-7642; Teo,
   Shu Mei/0000-0002-4563-7836; Seielstad, Mark/0000-0001-5783-1401;
   Naidoo, Nasheen/0000-0001-8613-4808
FU Yong Loo Lin School of Medicine; Life Science Institute; Office of
   Deputy President (Research and Technology), National University of
   Singapore; Genome Institute of Singapore; Agency for Science, Technology
   and Research, Singapore
FX This study was supported by the Yong Loo Lin School of Medicine, the
   Life Science Institute and the Office of Deputy President (Research and
   Technology), National University of Singapore. We also acknowledge the
   technical and financial support of the Genome Institute of Singapore and
   Agency for Science, Technology and Research, Singapore.
CR Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516
   Freeman JL, 2006, GENOME RES, V16, P949, DOI 10.1101/gr.3677206
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Karypidis AH, 2008, PHARMACOGENOMICS J, V8, P147, DOI 10.1038/sj.tpj.6500449
   Kidd JM, 2008, NATURE, V453, P56, DOI 10.1038/nature06862
   Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504
   Korn JM, 2008, NAT GENET, V40, P1253, DOI 10.1038/ng.237
   Ku CS, 2010, HUM MUTAT, V31, P851, DOI 10.1002/humu.21287
   Lewandowska U, 2009, J PHYSIOL PHARMACOL, V60, P47
   McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238
   McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215
   McCarroll SA, 2009, NAT GENET, V41, P1341, DOI 10.1038/ng.490
   Mei TS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-147
   Park H, 2010, NAT GENET, V42, P400, DOI 10.1038/ng.555
   Park J, 2006, CANCER EPIDEM BIOMAR, V15, P1473, DOI 10.1158/1055-9965.EPI-06-0141
   Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918
   Teo YY, 2009, GENOME RES, V19, P2154, DOI 10.1101/gr.095000.109
   Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287
   Yim SH, 2010, HUM MOL GENET, V19, P1001, DOI 10.1093/hmg/ddp564
NR 20
TC 1
Z9 1
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
J9 J HUM GENET
JI J. Hum. Genet.
PD AUG
PY 2011
VL 56
IS 8
BP 552
EP 560
DI 10.1038/jhg.2011.54
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 811WB
UT WOS:000294246100003
PM 21677662
OA Bronze
DA 2022-11-30
ER

PT J
AU Nan, RD
   Gor, J
   Perkins, SJ
AF Nan, Ruodan
   Gor, Jayesh
   Perkins, Stephen J.
TI Implications of the progressive self-association of wild-type human
   factor H6 for complement regulation and disease
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE factor H; oligomerisation; X-ray scattering; analytical
   ultracentrifugation; age-related macular degeneration
ID HEMOLYTIC-UREMIC SYNDROME; HEPARIN-BINDING DOMAIN; C-TERMINAL DOMAINS;
   X-RAY; NEUTRON-SCATTERING; PROTEIN BETA-1H; FACTOR-I; IDENTIFICATION;
   POLYMORPHISM; MUTATIONS
AB Factor H (FH) is a major regulator of complement alternative pathway activation. It is composed of 20 short complement regulator (SCR) domains and is genetically associated as a risk factor for age-related macular degeneration. Previous studies on FH suggested that it existed in monomeric and dimeric forms. Improved X-ray scattering and analytical ultracentrifugation methodology for wild-type FH permitted a clarification of these oligomeric properties. Data at lower concentrations revealed a dependence of the X-ray radius of gyration values on concentration that corresponded to the weak self-association of FH. Global sedimentation equilibrium fits indicated that a monomer-dimer equilibrium best described the data up to 1.3 mg/ml with a fitted dissociation constant K-D of 28 mu M and that higher oligomers formed at increased concentrations. The KD showed that about 85-95% of serum FH will be monomeric in the absence of other factors. Size-distribution analyses in sedimentation velocity experiments showed that monomeric FH was the major species but that as many as six oligomeric forms co-existed with it. The data were explained in terms of two weak dimerisation sites recently identified in the SCR-6/8 and SCR-16/20 fragments of FH with similar KD values. These observations indicate a mechanism for the progressive self-association of FH and may be relevant for complement regulation and the formation of drusen deposits that are associated with age-related macular degeneration. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Nan, Ruodan; Gor, Jayesh; Perkins, Stephen J.] UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England.
C3 University of London; University College London
RP Perkins, SJ (通讯作者)，UCL, Dept Biochem & Mol Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.
EM s.perkins@medsch.uct.ac.uk
FU Biotechnology and Biological Sciences Research Council [BB/E013104/1]
   Funding Source: Medline; BBSRC [BB/E013104/1] Funding Source: UKRI
CR Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011
   BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Dragon-Durey MA, 2005, SPRINGER SEMIN IMMUN, V27, P359, DOI 10.1007/s00281-005-0003-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FARROW GA, 1990, AUA TODAY, V3, P1
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Law SKA, 1995, COMPLEMENT
   McRorie D. K., 1993, SELF ASSOCIATING SYS
   Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8
   Okemefuna AI, 2008, J MOL BIOL, V375, P80, DOI 10.1016/j.jmb.2007.09.026
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Perkins SJ, 1998, INT J BIOL MACROMOL, V22, P1, DOI 10.1016/S0141-8130(97)00088-3
   Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Perkins SJ, 2008, METHOD CELL BIOL, V84, P375, DOI 10.1016/S0091-679X(07)84013-1
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X
   Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
NR 44
TC 33
Z9 33
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD JAN 25
PY 2008
VL 375
IS 4
BP 891
EP 900
DI 10.1016/j.jmb.2007.11.015
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 261RP
UT WOS:000253098000001
PM 18054958
DA 2022-11-30
ER

PT J
AU Koch, R
   Schmidt, M
   Gebauer, S
   Busse, H
   Uhlig, CE
AF Koch, Raphael
   Schmidt, Matthias
   Gebauer, Sabine
   Busse, Holger
   Uhlig, Constantin E.
TI Intravitreal treatment in patients with exudative age-related macular
   degeneration and visual acuity <= 0.05
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; VERTEPORFIN PHOTODYNAMIC
   THERAPY; RANIBIZUMAB; BEVACIZUMAB; TRIAMCINOLONE; CANADA
AB Background: To investigate intravitreal treatment efficiencies in patients suffering from exudative ARMD with a BCVA <= 0.05.
   Methods: Retrospective analysis: Analysis parameters were lesion type, BCVA at baseline and at follow-up, the intravitreal drug used, and its application frequency. Patients were divided into: 1) following injections of bevacizumab, triamcinolone, their combination, or ranibizumab regardless of their lesion subtype, 2) or by lesion subtype. Statistical tests were performed using Wilcoxon signed-rank tests, Kruskal-Wallis tests and multivariable logistic regressions.
   Results: Seventy four eyes of 74 patients were analyzed. Follow-up was at 12.0 to 15.7 weeks. Median difference of BCVA (logMAR) between baseline and follow-up was 0.000 (-0.030, 0.175) in classic (p = 0.105), 0.000 (-1.15, 0.20) in occult (p = 0.005), -0.200 (-1.20, 0.60) in cases with subretinal fluid (p = 0.207), 0.000 (-0.60, 0.30) in pigment epithelial detachment (p = 0.813), and 0.050 (-0.40, 0.70) in Junius Kuhnt maculopathy (p = 0.344). BCVA increased >= 0.2 logMAR in 4 (24 %) classic, 9 (47 %) occult, 6 (33 %) pigment epithelial detachment, 6 (55 %) subretinal fluid, in 29 (39 %) eyes regardless of the lesion type, and reached a BCVA = 0.05 in 7 (9 %) of those with a baseline BCVA <0.05.
   Conclusions: Results indicate that in patients with ARMD and a BCVA lower 0.05, intravitreal treatment may improve visual acuity, most probably in cases with occult lesions.
C1 [Koch, Raphael] Univ Munster, Inst Biostat & Clin Res, D-48149 Munster, Germany.
   [Schmidt, Matthias; Gebauer, Sabine; Busse, Holger; Uhlig, Constantin E.] Univ Munster, Med Ctr, Dept Ophthalmol, D-48149 Munster, Germany.
C3 University of Munster; University of Munster
RP Uhlig, CE (通讯作者)，Univ Munster, Med Ctr, Dept Ophthalmol, Albert Schweitzer Campus 1,Bldg D15, D-48149 Munster, Germany.
EM uhligc@uni-muenster.de
RI Koch, Raphael/A-7857-2013
OI Koch, Raphael/0000-0002-5581-5122
CR Bach M, 1998, KLIN MONATSBL AUGENH, V212, P190, DOI 10.1055/s-2008-1034863
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Clement FM, 2009, JAMA-J AM MED ASSOC, V302, P1437, DOI 10.1001/jama.2009.1409
   Cruess A, 2009, CAN J OPHTHALMOL, V44, P548, DOI 10.3129/i09-140
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Framme C, 2009, KLIN MONATSBL AUGENH, V226, P154, DOI 10.1055/s-0028-1109173
   Galbinur T, 2009, BRIT J OPHTHALMOL, V93, P1351, DOI 10.1136/bjo.2009.158931
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P370, DOI 10.1089/jop.2006.22.370
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Martin DF, 2011, OPHTHALMOLOGY, V119, P1388
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2008, N ENGL J M, V355, P1419
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sorensen TL, 2011, ACTA OPHTHALMOL, V89, pE97, DOI 10.1111/j.1755-3768.2010.01899.x
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Tao Y, 2010, RETINA-J RET VIT DIS, V30, P1426, DOI 10.1097/IAE.0b013e3181d5e964
NR 28
TC 1
Z9 1
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD OCT 21
PY 2015
VL 15
AR 138
DI 10.1186/s12886-015-0123-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT8XJ
UT WOS:000363099900001
PM 26490832
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tsai, CY
   Woung, LC
   Chou, P
   Yang, CS
   Sheu, MM
   Wu, JR
   Chuang, TL
   Tung, TH
AF Tsai, CY
   Woung, LC
   Chou, P
   Yang, CS
   Sheu, MM
   Wu, JR
   Chuang, TL
   Tung, TH
TI The current status of visual disability in the elderly population of
   Taiwan
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE blindness; disease prevalence; population-based study; the elderly;
   visual disability; visual impairment
ID DIABETIC-RETINOPATHY; CATARACT-SURGERY; OLDER AMERICANS; IMPAIRMENT;
   BLINDNESS; PREVALENCE; EYE; AUSTRALIA; VISION; ACUITY
AB Purpose: This study was conducted to explore the prevalence and the associated factors of visual impairment and blindness among the elderly Taiwanese population.
   Methods: A nationwide population-based visual health care screening program of elderly people aged 65 years or older was conducted between I July 2002 and 31 December 2002 in Taiwan. Based on the same standardized protocol used by the Bureau of Health Promotion, Department of Health, and a stratified random sampling design, 3160 out of 5000 elderly subjects were selected by a two-stage visual care screening method. The overall response rate was 63.2%.
   Results: The mean age of the elderly participants was 72.4 +/- 5.1 years. ne overall prevalence of glaucoma, corneal diseases, trauma, cataracts, myopic or diabetic retinopathy, and age-related macular degeneration among the elderly population was 2.1 %, 6.3%, 0.9%, 60.2%, 7.5%, and 2.9%, respectively. The overall prevalence of visual disability (visual acuity of the better eye < 0.5) was 17.7%, including 17.1% with visual impairment and 0.6% with blindness. Based on logistic regression, the significant independent factors of visual disability (visual impairment plus blindness) were sex (male vs. female, odds ratio (OR) = 0.627 95% confidence interval (CI), 0.51-0.76), age (70-74 years vs. 65-69 years, OR = 1.60,95% CI, 1.24-2.06; 75-79 years vs. 65-69 years, OR 2.527 95% CI, 1.92-3.32, >= 80yrs vs. 65-69vrs. OR 4.86, 95 % CI, 3.52-6.70), corneal diseases (OR 2.26, 95 % CI, 1.61-3.16), myopic or diabetic retinopathy (OR = 1.69 95% CI, 1.20-2.39), age-related macular degeneration (OR = 4.96, 95% CI, 3.16-7.78) and cataract (OR = 3.40, 95% CI, 2.67-4.33).
   Conclusions: The geographic difference in the prevalence of vision-related eye disease, visual impairment, and blindness point to the importance of taking actions that suit local circumstances. Our results also revealed that visual impairment and blindness are important visual health problems in the elderly Taiwanese population. Age-related macular degeneration, cataracts, corneal diseases, myopic or diabetic retinopathy, female sex, and aging were the leading causes of visual disability. Further organized preventive strategies for eye care are recommended in this population.
C1 Cheng Hsin Rehabil Med Ctr, Dept Med Res & Educ, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.
   Taipei City Hosp, Dept Ophthalmol, Zhongxing Branch, Taipei, Taiwan.
   Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   Buddhist Tzu Chi Gen Hosp, Dept Ophthalmol, Hualien, Taiwan.
   Bur Hlth Promot, Dept Hlth, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; Taipei City Hospital; National Taiwan University; National
   Taiwan University Hospital; Taipei Veterans General Hospital; Buddhist
   Tzu Chi General Hospital; Hualien Tzu Chi Hospital
RP Tung, TH (通讯作者)，Cheng Hsin Rehabil Med Ctr, Dept Med Res & Educ, Taipei 112, Taiwan.
EM ch2876@chgh.org.tw
OI WOUNG, LIN-CHUNG/0000-0002-0700-7606
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   *CHIN MED ASS, 2004, MED STAT
   *DEP HLTH, 2001, HLTH VIT STAT VIT ST
   *DRS RES GROUP, 1987, INDICATIONS PHOTOCOA, V27, P239
   FAIRCHILD JM, 1994, MED J AUSTRALIA, V160, P757, DOI 10.5694/j.1326-5377.1994.tb125943.x
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V38, P557
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   Liu J H, 2001, Ophthalmic Epidemiol, V8, P339
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   ROHAN TE, 1989, BMJ-BRIT MED J, V299, P1198, DOI 10.1136/bmj.299.6709.1198
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   THLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Thylefors B, 1999, LANCET, V354, P44
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P506, DOI 10.1016/S0002-9394(98)00275-X
NR 20
TC 24
Z9 24
U1 0
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR-APR
PY 2005
VL 49
IS 2
BP 166
EP 172
DI 10.1007/s10384-004-0164-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 916TU
UT WOS:000228409900018
PM 15838737
DA 2022-11-30
ER

PT J
AU Tabandeh, H
   Boscia, F
   Sborgia, A
   Ciraci, L
   Dayani, P
   Mariotti, C
   Furino, C
   Flynn, HW
AF Tabandeh, Homayoun
   Boscia, Francesco
   Sborgia, Alessandra
   Ciraci, Lorenza
   Dayani, Pouya
   Mariotti, Cesare
   Furino, Claudio
   Flynn, Harry W., Jr.
TI ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS Office-Based
   Setting and Operating Room Setting
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; diabetic retinopathy; endophthalmitis;
   intravitreal injection; macular edema; retinal vein occlusion;
   ranibizumab; bevacizumab; triamcinolone
ID BLEB-ASSOCIATED ENDOPHTHALMITIS; BEVACIZUMAB AVASTIN INJECTION;
   GROWTH-FACTOR AGENTS; MACULAR DEGENERATION; ANTIMICROBIAL RESISTANCE;
   TOPICAL ANTIBIOTICS; RANIBIZUMAB; OUTCOMES; FLORA; RISK
AB Purpose: To report on the occurrence of endophthalmitis after intravitreal injections (IVI) in two different settings: office-based and operating room.
   Methods: Consecutive case series. Retrospective review of all patients who underwent IVI by 2 physicians between January 2009 and December 2011. Group A underwent IVI in the examination room in office-based setting and Group B underwent IVI in the operating room.
   Results: A total of 11,710 IVIs were performed during the study period. Group A: A total of 8,647 IVIs performed including 2,041 ranibizumab, 6,169 bevacizumab, and 437 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (5,376), diabetic macular edema (1,587), retinal vein occlusion (1,068), and miscellaneous diagnosis (616). Group B: A total of 3,063 IVIs performed including 683 ranibizumab, 2,364 bevacizumab, and 16 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (1,836), diabetic macular edema (771), retinal vein occlusion (189), and miscellaneous diagnosis (267). A total of 5 cases (0.043%) of clinically suspected endophthalmitis occurred in 11,710 injections. Three cases (0.035%) occurred in Group A, and 2 cases (0.065%) occurred in Group B.
   Conclusion: The rate of clinically suspected endophthalmitis after IVIs is low whether the procedure is performed in the office or operating room setting. The findings have implications in terms of the patient convenience, efficiency, and cost of administrating these treatments.
C1 [Tabandeh, Homayoun; Dayani, Pouya] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   [Boscia, Francesco; Sborgia, Alessandra; Ciraci, Lorenza; Furino, Claudio] Univ Bari, Dept Ophthalmol, Bari, Italy.
   [Mariotti, Cesare] Polytech Univ Ancona, Dept Ophthalmol, Ancona, Italy.
   [Flynn, Harry W., Jr.] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Retina Vitreous Associates Medical Group; Universita degli Studi di Bari
   Aldo Moro; Bascom Palmer Eye Institute
RP Tabandeh, H (通讯作者)，Retina Vitreous Associates Med Grp, 9001 Wilshire Blvd,Suite 301, Beverly Hills, CA 90211 USA.
EM tabandeh@att.net
RI Boscia, Francesco/AAC-7729-2022
OI Flynn, Harry/0000-0002-9990-7467; Boscia, Francesco/0000-0002-5478-060X
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Alabiad CR, 2011, AM J OPHTHALMOL, V152, P999, DOI 10.1016/j.ajo.2011.05.026
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Bhatt SS, 2011, RETINA-J RET VIT DIS, V31, P2032, DOI 10.1097/IAE.0b013e31820f4b4f
   Bhavsar AR, 2012, ARCH OPHTHALMOL-CHIC, V130, P809, DOI 10.1001/archophthalmol.2012.227
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2004, OPHTHALMOLOGY, V111, P1495, DOI 10.1016/j.ophtha.2004.01.028
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   Doshi RR, 2012, RETINA-J RET VIT DIS, V32, P473, DOI 10.1097/IAE.0B013E31822C2958
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green-Simms AE, 2011, AM J OPHTHALMOL, V151, P329, DOI 10.1016/j.ajo.2010.08.039
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Jacobs DJ, 2011, CLIN OPHTHALMOL, V5, P739, DOI 10.2147/OPTH.S17975
   Kim SJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P1180, DOI 10.1001/archophthalmol.2011.213
   Klein KS, 2009, OPHTHALMOLOGY, V116, P1225, DOI 10.1016/j.ophtha.2009.02.031
   Leng T, 2011, RETINA-J RET VIT DIS, V31, P344, DOI 10.1097/IAE.0b013e3181e09810
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Milder E, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.016
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Moss JM, 2010, OPHTHALMOLOGY, V117, P2141, DOI 10.1016/j.ophtha.2010.02.030
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Song A, 2002, OPHTHALMOLOGY, V109, P985, DOI 10.1016/S0161-6420(02)00965-X
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1769
   Wen JC, 2011, ARCH OPHTHALMOL-CHIC, V129, P1551, DOI 10.1001/archophthalmol.2011.227
NR 37
TC 57
Z9 58
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2014
VL 34
IS 1
BP 18
EP 23
DI 10.1097/IAE.0000000000000008
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6CZ
UT WOS:000336958700005
PM 24362413
DA 2022-11-30
ER

PT J
AU Monaghan-Benson, E
   Hartmann, J
   Vendrov, AE
   Budd, S
   Byfield, G
   Parker, A
   Ahmad, F
   Huang, W
   Runge, M
   Burridge, K
   Madamanchi, N
   Hartnett, ME
AF Monaghan-Benson, Elizabeth
   Hartmann, John
   Vendrov, Aleksandr E.
   Budd, Steve
   Byfield, Grace
   Parker, Augustus
   Ahmad, Faisal
   Huang, Wei
   Runge, Marschall
   Burridge, Keith
   Madamanchi, Nageswara
   Hartnett, M. Elizabeth
TI The Role of Vascular Endothelial Growth Factor-Induced Activation of
   NADPH Oxidase in Choroidal Endothelial Cells and Choroidal
   Neovascularization
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; MACULAR DEGENERATION;
   OXIDATIVE DAMAGE; NAD(P)H OXIDASE; ANIMAL-MODEL; FACTOR-A; PREVALENCE;
   EXPRESSION; VARIANT
AB Rac1, a subunit of NADPH oxidase, plays an important role in directed endothelial cell motility. We reported previously that Rac1 activation was necessary for choroidal endothelial cell migration across the retinal pigment epithelium, a critical step in the development of vision-threatening neovascular age-related macular degeneration. Here we explored the roles of Rac1 and NADPH oxidase activation in response to vascular endothelial growth factor treatment in vitro and in a model of laser-induced choroidal neovascularization. We found that vascular endothelial growth factor induced the activation of Rac1 and of NADPH oxidase in cultured human choroidal endothelial cells. Further, vascular endothelial growth factor led to heightened generation of reactive oxygen species from cultured human choroidal endothelial cells, which was prevented by the NADPH oxidase inhibitors, apocynin and diphenyleneiodonium, or the antioxidant, N-acetyl-L-cysteine. In a model of laser-induced injury, inhibition of NADPH oxidase with apocynin significantly reduced reactive oxygen species levels as measured by dihydroethidium fluorescence and the volume of laser-induced choroidal neovascularization. Mice lacking functional p47phox, a subunit of NADPH oxidase, had reduced dihydroethidium fluorescence and choroidal neovascularization compared with wild-type controls. Taken together, these results indicate that vascular endothelial growth factor activates Rac1 upstream from NADPH oxidase in human choroidal endothelial cells and increases generation of reactive oxygen species, contributing to choroidal neovascularization. These steps may contributed to the pathology of neovascular age-related macular degeneration. (Am J Pathol 2010, 177:2091-2102; DOI: 10.2353/ajpath.2010.090878)
C1 [Monaghan-Benson, Elizabeth; Burridge, Keith; Hartnett, M. Elizabeth] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Monaghan-Benson, Elizabeth; Burridge, Keith] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA.
   [Hartmann, John; Budd, Steve; Byfield, Grace; Parker, Augustus; Ahmad, Faisal; Huang, Wei; Hartnett, M. Elizabeth] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC USA.
   [Vendrov, Aleksandr E.; Runge, Marschall; Burridge, Keith; Madamanchi, Nageswara; Hartnett, M. Elizabeth] Univ N Carolina, McAllister Heart Inst, Chapel Hill, NC USA.
   [Vendrov, Aleksandr E.; Runge, Marschall; Madamanchi, Nageswara] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Hartnett, ME (通讯作者)，Univ Utah, Dept Ophthalmol, Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM me.hartnett@hsc.utah.edu
RI Ariel, Pablo/AGJ-4118-2022; Vendrov, Aleksandr/A-4115-2010; Vendrov,
   Aleksandr E./ABF-1266-2021; Vendrov, Aleksandr E./AHE-8649-2022
OI Vendrov, Aleksandr/0000-0003-4971-8040; Vendrov, Aleksandr
   E./0000-0003-4971-8040; Madamanchi, Nageswara/0000-0003-0590-0908;
   Ahmad, Faisal/0000-0002-3945-3643
FU National Institutes of Health [R01-EY015130, R01-EY017011, P01-HL080166,
   HL-57352, AG-024282]; Research to Prevent Blindness; American Cancer
   Society [PF-09-119-01-CSM]; NATIONAL EYE INSTITUTE [P30EY014800,
   R01EY015130, R01EY017011] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL057352, P01HL080166] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [P01AG024282] Funding Source: NIH
   RePORTER
FX Supported by the National Institutes of Health (grants R01-EY015130 to
   M.E.H., principle investigator [PI]; R01-EY017011 to M.E.H., PI;
   P01-HL080166 to KB., PI; HL-57352 to M.S.R. and N.M., PIs; and AG-024282
   to M.S.R.), Research to Prevent Blindness, and the American Cancer
   Society (grant PF-09-119-01-CSM to E.M-B.).
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Haruta M, 2009, P NATL ACAD SCI USA, V106, P9397, DOI 10.1073/pnas.0808940106
   Heumuller S, 2008, HYPERTENSION, V51, P211, DOI 10.1161/HYPERTENSIONAHA.107.100214
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339
   JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saito Y, 2007, MOL VIS, V13, P840
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sreekumar PG, 2006, BIOCHEM BIOPH RES CO, V346, P1200, DOI 10.1016/j.bbrc.2006.06.021
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   TIELSCH JM, 1994, VISION PROBLEMS US, P1
   Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Vendrov AE, 2007, ARTERIOSCL THROM VAS, V27, P2714, DOI 10.1161/ATVBAHA.107.152629
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   1993, ARCH OPHTHALMOL, V111, P104
NR 61
TC 41
Z9 43
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT
PY 2010
VL 177
IS 4
BP 2091
EP 2102
DI 10.2353/ajpath.2010.090878
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 658NG
UT WOS:000282496100050
PM 20802176
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Nashine, S
   Kenney, MC
AF Nashine, Sonali
   Kenney, M. Cristina
TI Effects of Mitochondrial-Derived Peptides (MDPs) on Mitochondrial and
   Cellular Health in AMD
SO CELLS
LA English
DT Review
DE MDPs; mitochondrial-derived peptides; Humanin; HNG; SHLPs; MOTS-c;
   Age-related Macular Degeneration (AMD); neuroprotection; RPE;
   mitochondria
ID RETINAL-PIGMENT EPITHELIUM; HUMANIN PEPTIDE; NEUROPROTECTIVE FACTOR;
   MACULAR DEGENERATION; PROGRESSIVE STAGES; APOPTOSIS; DEATH; CELLS;
   PROTEOMICS; ANALOGS
AB Substantive evidence demonstrates the contribution of mitochondrial dysfunction in the etiology and pathogenesis of Age-related Macular Degeneration (AMD). Recently, extensive characterization of Mitochondrial-Derived Peptides (MDPs) has revealed their cytoprotective role in several diseases, including AMD. Here we summarize the varied effects of MDPs on cellular and mitochondrial health, which establish the merit of MDPs as therapeutic targets for AMD. We argue that further research to delve into the mechanisms of action and delivery of MDPs may advance the field of AMD therapy.
C1 [Nashine, Sonali; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.; Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM snashine@uci.edu; mkenney@uci.edu
FU Arnold and Mabel Beckman foundation; NEI [R01 EY0127363]; Discovery Eye
   Foundation; Iris and B. Gerald Cantor Foundation; Research to Prevent
   Blindness; UCI School of Medicine; Institute for Clinical and
   Translational Science (ICTS) at University of California Irvine; 2017
   Genentech/ ARVO AMD Translational Research Fellowship; 2016 RPB pilot
   research grant
FX This work is supported by Arnold and Mabel Beckman foundation, NEI R01
   EY0127363, Discovery Eye Foundation, Polly and Michael Smith, Edith and
   Roy Carver, Iris and B. Gerald Cantor Foundation, Unrestricted
   Departmental Grant from Research to Prevent Blindness, UCI School of
   Medicine, and support of the Institute for Clinical and Translational
   Science (ICTS) at University of California Irvine. S.N. is a recipient
   of the 2017 Genentech/ ARVO AMD Translational Research Fellowship and
   the 2016 RPB pilot research grant.
CR Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Bachar AR, 2010, CARDIOVASC RES, V88, P360, DOI 10.1093/cvr/cvq191
   Brand MD, 2013, BRIT J DERMATOL, V169, P1, DOI 10.1111/bjd.12208
   Cardamone MD, 2018, MOL CELL, V69, P757, DOI 10.1016/j.molcel.2018.01.037
   Chin YP, 2013, ENDOCRINOLOGY, V154, P3739, DOI 10.1210/en.2012-2004
   Chistiakov DA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/238463
   CLAYTON DA, 1992, J INHERIT METAB DIS, V15, P439, DOI 10.1007/BF01799602
   Cobb LJ, 2016, AGING-US, V8, P796, DOI 10.18632/aging.100943
   Colon E, 2006, J CELL PHYSIOL, V208, P373, DOI 10.1002/jcp.20672
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Fuku N, 2015, AGING CELL, V14, P921, DOI 10.1111/acel.12389
   Gong Zhenwei, 2018, Oncotarget, V9, P10832, DOI 10.18632/oncotarget.24396
   Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627
   Gurunathan S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184439
   Hashimoto Y, 2005, LIFE SCI, V77, P3092, DOI 10.1016/j.lfs.2005.03.031
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   Hashimoto Y, 2009, MOL BIOL CELL, V20, P2864, DOI 10.1091/mbc.E09-02-0168
   Holt IJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012971
   Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100
   Jia Y, 2015, APOPTOSIS, V20, P551, DOI 10.1007/s10495-015-1105-5
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim KH, 2018, CELL METAB, V28, P516, DOI 10.1016/j.cmet.2018.06.008
   Kim SJ, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.14171
   Kim SJ, 2018, AGING-US, V10, P1239, DOI 10.18632/aging.101463
   Kim SJ, 2016, ONCOTARGET, V7, P46899, DOI 10.18632/oncotarget.10380
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Knapp A., 2012, J CELL SCI THERAPY, V3, P128, DOI DOI 10.4172/2157-7013.1000128
   Lee C, 2016, FREE RADICAL BIO MED, V100, P182, DOI 10.1016/j.freeradbiomed.2016.05.015
   Lee C, 2014, AGING CELL, V13, P958, DOI 10.1111/acel.12243
   Li X, 2013, NEURAL REGEN RES, V8, P2573, DOI 10.3969/j.issn.1673-5374.2013.27.009
   Li Z, 2020, NANOMED-NANOTECHNOL, V24, DOI 10.1016/j.nano.2019.102111
   Luciano F, 2005, J BIOL CHEM, V280, P15825, DOI 10.1074/jbc.M413062200
   Lue YH, 2015, ENDOCRINOLOGY, V156, P4511, DOI 10.1210/en.2015-1542
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   McCusker MM, 2016, CLIN DERMATOL, V34, P276, DOI 10.1016/j.clindermatol.2015.11.009
   Mehta HH, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1549-7
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Moretti E, 2010, FERTIL STERIL, V94, P2888, DOI 10.1016/j.fertnstert.2010.04.075
   Muzumdar RH, 2010, ARTERIOSCL THROM VAS, V30, P1940, DOI 10.1161/ATVBAHA.110.205997
   Muzumdar RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006334
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Njomen E, 2015, PROTEIN PEPTIDE LETT, V22, P869, DOI 10.2174/0929866522666150728114955
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Oh YK, 2011, ATHEROSCLEROSIS, V219, P65, DOI 10.1016/j.atherosclerosis.2011.06.038
   Okada AK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08372-5
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797
   Tajima H, 2002, NEUROSCI LETT, V324, P227, DOI 10.1016/S0304-3940(02)00199-4
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Widmer RJ, 2013, AM J PHYSIOL-HEART C, V304, pH393, DOI 10.1152/ajpheart.00765.2012
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Xu XS, 2008, BRAIN RES, V1227, P12, DOI 10.1016/j.brainres.2008.06.018
   Yamagishi Y, 2003, PEPTIDES, V24, P585, DOI 10.1016/S0196-9781(03)00106-2
   Yang L, 2014, SCI REP-UK, V4, DOI 10.1038/srep04089
   Yen K, 2013, J MOL ENDOCRINOL, V50, pR11, DOI 10.1530/JME-12-0203
   Zacharias DG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031065
   Zhang X, 2012, LIFE SCI, V91, P199, DOI 10.1016/j.lfs.2012.07.010
NR 60
TC 13
Z9 15
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD MAY
PY 2020
VL 9
IS 5
DI 10.3390/cells9051102
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LW7RF
UT WOS:000539340200036
PM 32365540
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tienaho, J
   Karonen, M
   Muilu-Makela, R
   Kaseva, J
   de Pedro, N
   Vicente, F
   Genilloud, O
   Aapola, U
   Uusitalo, H
   Vuolteenaho, K
   Franzen, R
   Wahala, K
   Karp, M
   Santala, V
   Sarjala, T
AF Tienaho, Jenni
   Karonen, Maarit
   Muilu-Makela, Riina
   Kaseva, Janne
   de Pedro, Nuria
   Vicente, Francisca
   Genilloud, Olga
   Aapola, Ulla
   Uusitalo, Hannu
   Vuolteenaho, Katriina
   Franzen, Robert
   Wahala, Kristiina
   Karp, Matti
   Santala, Ville
   Sarjala, Tytti
TI Bioactive Properties of the Aqueous Extracts of Endophytic Fungi
   Associated with Scots Pine (Pinus sylvestris) Roots
SO PLANTA MEDICA
LA English
DT Article
DE Acephala applanate; antibacterial; antioxidant; Coniochaeta mutabilis;
   endophytic fungi; Humicolopsis cephalosporioides; Leotimycetidae;
   Phialocephala fortinii; Sordariomycetidae
ID EPITHELIAL-CELL LINE; ANTIOXIDANT ACTIVITY; PEPTIDES; STRESS;
   METABOLITE; BACTERIA; DROUGHT
AB Despite the continuing interest in various plant and natural products, only a small portion of the biologically active compounds from nature has been discovered and exploited. In this study, antioxidant and antibacterial properties of aqueous fractions of three endophytic fungi isolated from the roots of 8-year-old Scots pines (Pinus sylvestris) growing on a drained peatland were investigated. The endophytic fungi species were Acephala applanata, Phialocephala fortinii, and Humicolopsis cephalosporioides/Coniochaeta mutabilis. The bioactivities were examined using hydrogen peroxide scavenging and oxygen radical absorbance capacity tests as well as sensitive Escherichia coli-based biosensors, which produce a luminescent signal in the presence of substances with oxidative or genotoxic properties. In addition, cell models for Parkinson's disease, age-related macular degeneration, and osteoarthritis were used to evaluate the potential for pharmaceutical applications. The aqueous extracts of fungi and 19 out of 42 fractions were found to be active in one or more of the tests used. However, no activity was found in the age-related macular degeneration and osteoarthritis cell model tests. Additionally, bioactivity data was connected with metabolites putatively annotated, and out of 330 metabolites, 177 were interesting in view of the bioactivities investigated. A majority of these were peptides and all three fungal species shared a highly similar metabolome. We propose that Scots pine endophytic fungi are a rich source of interesting metabolites, and synergistic effects may cause the bioactivities, as they were found to vary after the fractionation process.
C1 [Tienaho, Jenni; Karp, Matti; Santala, Ville] Tampere Univ, Fac Nat Sci & Engn, Korkeakoulunkatu 8, Tampere 33101, Finland.
   [Tienaho, Jenni; Muilu-Makela, Riina; Sarjala, Tytti] Nat Resources Inst Finland Luke, Prod Syst Unit, Biomass Characterizat & Properties Grp, Espoo, Finland.
   [Karonen, Maarit] Univ Turku, Dept Chem, Nat Chem Res Grp, Turku, Finland.
   [Kaseva, Janne] Nat Resources Inst Finland Luke, Nat Resources Unit, Appl Stat Methods Grp, Jokioinen, Finland.
   [de Pedro, Nuria; Vicente, Francisca; Genilloud, Olga] Fdn MEDINA, Avda Conocimiento, Granada, Spain.
   [Aapola, Ulla; Uusitalo, Hannu] Tampere Univ, Fac Med & Hlth Technol, Dept Ophthalmol, Tampere, Finland.
   [Uusitalo, Hannu] Tampere Univ Hosp, Tays Eye Ctr, Tampere, Finland.
   [Vuolteenaho, Katriina] Tampere Univ, Fac Med & Hlth Technol, Immunopharmacol Res Grp, Tampere, Finland.
   [Vuolteenaho, Katriina] Tampere Univ Hosp, Tampere, Finland.
   [Franzen, Robert] Aalto Univ, Sch Chem Engn, Dept Chem & Mat Sci, Espoo, Finland.
   [Wahala, Kristiina] Univ Helsinki, Dept Biochem & Dev Biol, Helsinki, Finland.
   [Wahala, Kristiina] Univ Helsinki, Dept Chem, Helsinki, Finland.
C3 Tampere University; Natural Resources Institute Finland (Luke);
   University of Turku; Natural Resources Institute Finland (Luke); Tampere
   University; Tampere University; Tampere University Hospital; Tampere
   University; Tampere University; Tampere University Hospital; Aalto
   University; University of Helsinki; University of Helsinki
RP Tienaho, J (通讯作者)，Tampere Univ, Fac Nat Sci & Engn, Korkeakoulunkatu 8, Tampere 33101, Finland.
EM jenni.tienaho@tuni.fi
RI Kaseva, Janne/GLT-5462-2022
OI Kaseva, Janne/0000-0002-8167-5434; Vuolteenaho,
   Katriina/0000-0003-0017-1291; Muilu-Makela, Riina/0000-0003-4879-5482;
   Tienaho, Jenni/0000-0002-7089-7832; Santala, Ville/0000-0002-9084-931X;
   Aapola, Ulla/0000-0001-7691-3170; Franzen, Robert/0000-0002-4845-2976;
   Wahala, Kristiina/0000-0003-4082-8622
FU COST Action [FA1103]; European Regional Development Fund [A71142]; town
   of Parkano and SASKY municipal education and training consortium;
   Natural Resources Institute Finland; Tampere University of Technology;
   Kone Foundation
FX We thank Anneli Kaenmaki, Hanna Leppalammi, and Eeva Pihlajaviita for
   proficient and competent laboratory assistance. We also thank COST
   Action FA1103: Endophytes in Biotechnology and Agriculture for the
   short-term scientific mission funding of Jenni Tienaho. This study has
   been financially supported by the European Regional Development Fund
   (project code A71142) as well as the town of Parkano and SASKY municipal
   education and training consortium. Natural Resources Institute Finland
   and Tampere University of Technology are also warmly acknowledged for
   their financial support. In addition, Jenni Tienaho is grateful to Kone
   Foundation for a personal grant.
CR Aapola U, 2011, INVESTIG OPHTHALMOL, V52, P5656
   Apak R, 2013, PURE APPL CHEM, V85, P957, DOI 10.1351/PAC-REP-12-07-15
   Bartolome A, 2006, PROC SPIE, V6098, DOI 10.1117/12.643950
   Belkin S, 1996, ENVIRON TOXIC WATER, V11, P179, DOI 10.1002/(SICI)1098-2256(1996)11:3<179::AID-TOX2>3.0.CO;2-6
   Bondaryk M, 2017, J FUNGI, V3, P1
   Carrasco-Castilla J, 2012, FOOD CHEM, V135, P1789, DOI 10.1016/j.foodchem.2012.06.016
   CHEN HM, 1995, J AGR FOOD CHEM, V43, P574, DOI 10.1021/jf00051a004
   de Pedro N, 2016, PHARMACOLOGIA, V7, P361
   de Pedro N, 2016, NEUROPHARMACOLOGY, V101, P538, DOI 10.1016/j.neuropharm.2015.09.029
   Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Firakova S, 2007, BIOLOGIA, V62, P251, DOI 10.2478/s11756-007-0044-1
   GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595
   Hernandez-Ledesma B, 2005, J AGR FOOD CHEM, V53, P588, DOI 10.1021/jf048626m
   Jaleel CA, 2007, COLLOID SURFACE B, V60, P201, DOI 10.1016/j.colsurfb.2007.06.010
   JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kombrink A, 2019, ISME J, V13, P588, DOI 10.1038/s41396-018-0293-8
   Koskimaki JJ, 2016, NAT CHEM BIOL, V12, P332, DOI [10.1038/NCHEMBIO.2043, 10.1038/nchembio.2043]
   Li X, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26183-0
   Mannerstrom M, 2002, TOXICOL IN VITRO, V16, P193, DOI 10.1016/S0887-2333(01)00113-8
   Miller G, 2010, PLANT CELL ENVIRON, V33, P453, DOI 10.1111/j.1365-3040.2009.02041.x
   Obata T, 2012, CELL MOL LIFE SCI, V69, P3225, DOI 10.1007/s00018-012-1091-5
   Osugi A, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0214-5
   Pirttila AM, 2011, FOR SCI, V80, P139, DOI 10.1007/978-94-007-1599-8_8
   Pocsi I, 2004, ADV MICROB PHYSIOL, V49, P1, DOI 10.1016/S0065-2911(04)49001-8
   Prior RL, 2003, J AGR FOOD CHEM, V51, P3273, DOI 10.1021/jf0262256
   RIES S, 1990, PLANT GROWTH REGUL, V9, P263, DOI 10.1007/BF00045289
   Saiga A, 2003, J AGR FOOD CHEM, V51, P3661, DOI 10.1021/jf021156g
   Salas CE, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/102129
   Sanchez A, 2017, FOOD QUAL SAF-OXFORD, V1, P29, DOI 10.1093/fqsafe/fyx006
   Shashidhar MG, 2013, J FUNCT FOODS, V5, P1013, DOI 10.1016/j.jff.2013.04.018
   Stone JK, 2000, BOOK SOIL P, P3
   Strobel G, 2004, J NAT PROD, V67, P257, DOI 10.1021/np030397v
   Tabachnick B.G., 2007, USING MULTIVARIATE S, V5
   Tan RX, 2001, NAT PROD REP, V18, P448, DOI 10.1039/b100918o
   Tienaho J, 2019, MOLECULES, V24, DOI 10.3390/molecules24122330
   Tienaho J, 2015, J MICROBIOL METH, V118, P78, DOI 10.1016/j.mimet.2015.08.018
   Vollmer AC, 1997, APPL ENVIRON MICROB, V63, P2566, DOI 10.1128/AEM.63.7.2566-2571.1997
   Vuolteenaho K, 2007, SCAND J RHEUMATOL, V36, P247, DOI 10.1080/03009740701483014
   WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967
   Watt K, 2007, PHYTOTHER RES, V21, P1193, DOI 10.1002/ptr.2238
   Willfor SM, 2003, J AGR FOOD CHEM, V51, P7600, DOI 10.1021/jf030445h
   Yeo D, 2005, APPL CLUSTERING TECH
NR 44
TC 2
Z9 2
U1 1
U2 20
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD SEP
PY 2020
VL 86
IS 13/14
BP 1009
EP 1024
DI 10.1055/a-1185-4437
PG 16
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA NR8EH
UT WOS:000571792100011
PM 32521558
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhou, JL
   Gao, XQ
   Cai, BL
   Sparrow, JR
AF Zhou, Jilin
   Gao, Xiangqun
   Cai, Bolin
   Sparrow, Janet R.
TI Indirect antioxidant protection against photooxidative processes
   initiated in retinal pigment epithelial cells by a lipofuscin pigment
SO REJUVENATION RESEARCH
LA English
DT Article
ID AGE-RELATED MACULOPATHY; OXIDANT-INDUCED APOPTOSIS; MITOCHONDRIAL-DNA
   DAMAGE; LIGHT-INDUCED DAMAGE; MACULAR DEGENERATION; BLUE-LIGHT; FUNDUS
   FLAVIMACULATUS; OXIDATIVE DAMAGE; PHASE-2 ENZYMES; A2E-LADEN RPE
AB Oxidative mechanisms are considered to contribute to the aging changes in retinal pigment epithelial (RPE) cells that underlie the pathogenesis of age-related macular degeneration. An important source of oxidative damage is likely to be the photoreactive pigments that progressively accumulate and constitute the lipofuscin of retinal pigment epithelial cells. Evidence for a link between RPE lipofuscin and cellular dysfunction is also provided by the understanding of disease progression in Stargardt disease. Using a culture model previously used to demonstrate photooxidative damage to retinal pigment epithelial cells that have accumulated the lipofuscin fluorophore A(2)E, it was shown that the propensity for cell death is increased under conditions that deplete cellular levels of glutathione. Additionally, sulforaphane, a phytochemical and inducer of phase 2 enzymes, protected RPE cells that accumulated A2E and were irradiated at 430 nm. The protection afforded by sulforaphane was paralleled by elevated levels of glutathione and increases in the activities of the phase 2 enzymes NAD(P)H:quinone reductase and glutathione-S-transferases. Moreover, transcriptional induction of NAD(P)H:quinone reductase was indicated by the increases in mRNA determined by real time RT-PCR. There has been considerable interest in the intake of carotenoids and antioxidant vitamins and the related incidence of age-related macular degeneration. The present results indicate that the indirect antioxidant activity of plant-derived phase 2 inducers also may be potentially important.
C1 Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Columbia University; Johns Hopkins University; Columbia University
RP Sparrow, JR (通讯作者)，Columbia Univ, Dept Ophthalmol, 630 W 168th St, New York, NY 10032 USA.
EM jrs88@columbia.edu
FU NATIONAL EYE INSTITUTE [R01EY012951] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY 12951] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ayalasomayajula SP, 2002, EUR J PHARMACOL, V449, P213, DOI 10.1016/S0014-2999(02)02043-5
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Busch EM, 1999, PHOTOCHEM PHOTOBIOL, V70, P353, DOI 10.1562/0031-8655(1999)070<0353:TEOTSO>2.3.CO;2
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DEVASAGAYAM TPA, 1991, J PHOTOCH PHOTOBIO B, V9, P105, DOI 10.1016/1011-1344(91)80008-6
   Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Gao XQ, 2001, P NATL ACAD SCI USA, V98, P15221, DOI 10.1073/pnas.261572998
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   HAM WTJ, 1986, CRC OPTICAL RAD VISU, P43
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jiang S, 2002, INVEST OPHTH VIS SCI, V43, P2546
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Lois N, 1999, INVEST OPHTH VIS SCI, V40, P2668
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X
   Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445
   Nelson KC, 1999, INVEST OPHTH VIS SCI, V40, P1927
   Nelson KC, 2002, INVEST OPHTH VIS SCI, V43, P3550
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   PROCHASKA HJ, 1992, P NATL ACAD SCI USA, V89, P2394, DOI 10.1073/pnas.89.6.2394
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Singhal SS, 1999, INVEST OPHTH VIS SCI, V40, P2652
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S
   Talalay P, 2000, BIOFACTORS, V12, P5, DOI 10.1002/biof.5520120102
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Winkler BS, 1999, MOL VIS, V5
   Zhang YS, 1998, CANCER RES, V58, P4632
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 58
TC 24
Z9 25
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD SUM
PY 2006
VL 9
IS 2
BP 256
EP 263
DI 10.1089/rej.2006.9.256
PG 8
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 046RE
UT WOS:000237827900016
PM 16706653
DA 2022-11-30
ER

PT J
AU Yang, JY
   Yuan, MZ
   Xia, S
   Chen, YX
AF Yang, Jingyuan
   Yuan, Mingzhen
   Xia, Song
   Chen, Youxin
TI Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor
   Monotherapy and Combination Therapy for Various Subtypes of Polypoidal
   Choroidal Vasculopathy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; RANIBIZUMAB MONOTHERAPY;
   CLASSIFICATION; EFFICACY; SAFETY; INFARCTION; DIAGNOSIS; EVEREST
AB The purpose of this study was to compare 6-year visual outcomes of antivascular endothelial growth factor (anti-VEGF) monotherapy and initial combination therapy of photodynamic therapy (PDT) and anti-VEGF therapy for polypoidal choroidal vasculopathy (PCV) in a Chinese population and to investigate imaging biomarkers associated with visual outcomes. Forty-eight treatment-naive PCV eyes of 46 patients were reviewed retrospectively, which underwent anti-VEGF monotherapy or initial combination therapy. PCV was classified into 2 subtypes. Mean best-corrected visual acuity (BCVA) using logarithm of minimal angle resolution and imaging morphological features was compared. No significant differences of mean BCVA changes were noticed between anti-VEGF monotherapy and combination therapy in either subtype 1 PCV or subtype 2 PCV during 6-year period (all P values >0.05). Compared with BCVA at baseline, the mean BCVA at 72 months deteriorated significantly in eyes with subtype 1 PCV (P<0.001), while the mean BCVA at 72 months remained stable in eyes with subtype 2 PCV (P=0.941). In subtype 2 PCV eyes with continuous retina pigment epithelium, the mean changes of BCVA in eyes treated with anti-VEGF monotherapy were better than those in eyes treated with combination therapy (P=0.020). Anti-VEGF monotherapy and combination therapy for various subtypes of PCV had comparable long-term visual outcomes in most cases in real world. Imaging biomarkers which correlate with visual outcomes and treatment response should be included in the classification of PCV and validated in real world.
C1 [Yang, Jingyuan; Yuan, Mingzhen; Chen, Youxin] Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing 100730, Peoples R China.
   [Xia, Song] Guizhou Prov Peoples Hosp, Dept Ophthalmol, Guiyang 550002, Guizhou, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing 100730, Peoples R China.
EM yangjingyuan90@126.com; yuanmingzhenpumc@sohu.com; xiasongpumch@126.com;
   chenyx@pumch.cn
OI Chen, Youxin/0000-0002-7231-5058
FU National Natural Science Foundation of China (NSFC) [81670879]
FX The authors thank Chenxi Zhang, Ruoan Han, Yuelin Wang, and Shan Wu for
   helping them to collect the data and supporting their work. This work
   was supported by the National Natural Science Foundation of China (NSFC)
   (81670879).
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chung M, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700028
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Jang JW, 2019, RETINA-J RET VIT DIS, V39, P1995, DOI 10.1097/IAE.0000000000002259
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim SW, 2009, OPHTHAL SURG LAS IM, V40, P300, DOI 10.3928/15428877-20090430-14
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lo Giudice G, 2008, EUR J OPHTHALMOL, V18, P652, DOI 10.1177/112067210801800429
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 32
TC 3
Z9 3
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD DEC 16
PY 2019
VL 2019
AR 1609717
DI 10.1155/2019/1609717
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KX8HH
UT WOS:000522115500001
PM 31949949
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Holekamp, NM
AF Holekamp, Nancy M.
TI Moving From Clinic to Home: What the Future Holds for Ophthalmic
   Telemedicine
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; DIABETIC-RETINOPATHY; MONITORING-SYSTEM; GLOBAL
   PREVALENCE; METAANALYSIS; CHALLENGES; TRIAL
AB PURPOSE: To describe the expanding role of telemedicine in healthcare, the key criteria required for a successful device and program implementation, and the current and future role of home monitoring in ophthalmology.
   DESIGN: Expert perspective.
   METHODS: Analysis with real-world interpretation of home monitoring technologies, including current adoption barriers and expanded future demands based on demographic and market forces.
   RESULTS: Remote patient monitoring represents a paradigm shift in the way physicians care for patients. Success depends on meeting several criteria, among which are a recognized value proposition to the physician, robust device performance validation, ease of use for the patient, reliability of connectivity, safe and secure data transmission, and economic feasibility. Ophthalmic diseases, such as age-related macular degeneration, glaucoma, and diabetic retinopathy, are ideal candidates for home monitoring practice integration. Established home monitoring technology is already facilitating early detection and improved visual outcomes for patients with age-related macular degeneration. Future innovation currently underway or on the horizon will continue to evolve and expand the footprint of telemedicine within ophthalmology.
   CONCLUSION: Home monitoring has the potential to enhance the patient-physician relationship and to positively impact visual acuity outcomes in ophthalmic diseases. Advances in technology, demographic shifts, market changes, and patient demand for personalized medicine will require physicians to embrace technology in new and diverse ways, perhaps facilitating widespread adoption of home monitoring technology platforms. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Holekamp, Nancy M.] Pepose Vis Inst, 1815 Clarkson Rd, Chesterfield, MO 63017 USA.
   [Holekamp, Nancy M.] Washington Univ, Sch Med, St Louis, MO USA.
C3 Washington University (WUSTL)
RP Holekamp, NM (通讯作者)，Pepose Vis Inst, 1815 Clarkson Rd, Chesterfield, MO 63017 USA.
EM nholekamp@gmail.com
FU ALLERGAN, DUBLIN, Ireland; Genentech, South San Francisco, California;
   Alimera Sciences, Inc, Alpharetta, Georgia; Neurotech Pharmaceuticals,
   Cumberland, Rhode Island; Ophthotech Corporation, New York, New York;
   Ohr Pharmaceuticals, Inc, New York, New York
FX NANCY M. HOLEKAMP: ALLERGAN, DUBLIN, Ireland (consultant, speaker,
   research support); Genentech, South San Francisco, California
   (consultant, speaker, research support); Regeneron Pharmaceuticals, Inc,
   Tarrytown, New York (consultant, speaker); Novartis, Basel, Switzerland
   (consultant); Roche, Basel, Switzerland (consultant); Shire, Dublin,
   Ireland (consultant); Katalyst Surgical, Chesterfield, Missouri
   (consultant, equity investor); Alimera Sciences, Inc, Alpharetta,
   Georgia (research support); Neurotech Pharmaceuticals, Cumberland, Rhode
   Island (research support); Ophthotech Corporation, New York, New York
   (research support); Ohr Pharmaceuticals, Inc, New York, New York
   (research support). The author attests that she meets the current ICMJE
   criteria for authorship.
CR Benjamin EM., 2002, CLIN DIABETES, V20, P45, DOI [10.2337/diaclin.20.1.45, DOI 10.2337/DIACLIN.20.1.45]
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Chew EY, 2016, RETINA-J RET VIT DIS, V36, P1542, DOI 10.1097/IAE.0000000000000940
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hazin R, 2011, AM J OPHTHALMOL, V152, P723, DOI 10.1016/j.ajo.2011.06.022
   Hickey KT, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0327-y
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   Ittoop SM, 2016, ADV THER, V33, P1679, DOI 10.1007/s12325-016-0388-4
   Krishnaswamy U, 2015, J POSTGRAD MED, V61, P223, DOI 10.4103/0022-3859.166509
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Mansouri K, 2015, CLIN EXP OPHTHALMOL, V43, P787, DOI 10.1111/ceo.12567
   Mariacher S, 2016, EXP EYE RES, V151, P54, DOI 10.1016/j.exer.2016.07.016
   Ogedegbe Gbenga, 2006, J Clin Hypertens (Greenwich), V8, P174, DOI 10.1111/j.1524-6175.2006.04872.x
   Pare G, 2007, J AM MED INFORM ASSN, V14, P269, DOI 10.1197/jamia.M2270
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Sharma P, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007758
   Skaggs Julie B, 2017, N C Med J, V78, P121, DOI 10.18043/ncm.78.2.121
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Uhlig K, 2013, ANN INTERN MED, V159, P185, DOI 10.7326/0003-4819-159-3-201308060-00008
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhao F, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00236
NR 24
TC 23
Z9 23
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2018
VL 187
BP XXVIII
EP XXXV
DI 10.1016/j.ajo.2017.11.003
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ1IP
UT WOS:000427330400004
PM 29137959
DA 2022-11-30
ER

PT J
AU Yao, Y
   Shao, J
   Sun, W
   Zhu, J
   Fu, DH
   Guan, HJ
   Liu, QH
AF Yao, Yong
   Shao, Jun
   Sun, Wei
   Zhu, Jing
   Fu, Dong Hong
   Guan, Huaijing
   Liu, Qinghuai
TI Prevalence of blindness and causes of visual impairment among adults
   aged 50 years or above in southern Jiangsu Province of China
SO PAKISTAN JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Blindness; Epidemiology; Eye diseases; Low Vision
ID EYE; URBAN; POPULATION
AB Objective: The prevalence of blindness and low vision among adults aged = 50 years in southern Jiangsu Province were surveyed and estimated.
   Methods: Cluster sampling was employed from January to September 2010 to randomly select 6,722 individuals aged = 50 years in 28 clusters from southern Jiangsu Province. The survey was preceded by a pilot study, which refined operational methods and conducted quality assurance evaluation. Eligible individuals were registered for visual acuity measurement and eye examination.
   Results: A total of 6,155 individuals were recruited, and a response rate of 91.50% was obtained. The prevalence of bilateral blindness and low vision were found to be 0.76% and 1.37%, respectively. Subjects with monocular blindness and low vision were 3.27% and 3.48%, respectively. Among the individuals evaluated, 201 were detected to have monocular blindness and 47 with bilateral blindness. In addition, 55 of the 201 subjects with monocular blindness were found to suffer from low vision of the other eye. Among the 295 subjects with blind eyes, 116 (39.32%), 31 (10.51%), and 28 (9.49%) were caused by cataract, high myopia macular degeneration, and atrophic eyeballs, respectively. In the 437 subjects with low-vision eyes, 223 (51.03%), 41 (9.38%), and 41 (9.38%) had cataract, high myopia macular degeneration, and age-related macular degeneration, respectively.
   Conclusions: Blindness and low vision are caused by descending cataract, age-related macular degeneration, high myopia macular degeneration, and atrophic eyeballs.
C1 [Yao, Yong; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
   [Yao, Yong; Shao, Jun; Zhu, Jing; Fu, Dong Hong] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Ophthalmol, Wuxi 214023, Peoples R China.
   [Sun, Wei] Suzhou Municipal Hosp, Dept Ophthalmol, Suzhou 215008, Peoples R China.
   [Guan, Huaijing] Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong 226001, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nantong
   University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964
CR Al Ghamdi AH, 2012, BRIT J OPHTHALMOL, V96, P1168, DOI 10.1136/bjophthalmol-2012-301874
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Cheng JW, 2013, OPHTHALMIC RES, V49, P1, DOI 10.1159/000327144
   Fotouhi A, 2004, BRIT J OPHTHALMOL, V88, P740, DOI 10.1136/bjo.2003.031153
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Huang Xiao-bo, 2009, Zhonghua Yan Ke Za Zhi, V45, P786
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Lu HH, 2012, J CHEM THERMODYN, V48, P48, DOI 10.1016/j.jct.2011.11.016
   Luo Rong, 2012, Zhonghua Yan Ke Za Zhi, V48, P530
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Resnikoff S, 2012, INDIAN J OPHTHALMOL, V60, P387, DOI 10.4103/0301-4738.100532
   Silva R, 2012, OPHTHALMOLOGICA, V228, P197, DOI 10.1159/000339893
   Snell-Bergeon JK, 2012, DIABETES TECHNOL THE, V14, pS51, DOI 10.1089/dia.2012.0031
   Studnicka J, 2012, Cesk Slov Oftalmol, V68, P61
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P409, DOI 10.1016/j.ophtha.2009.11.023
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
   Zhou Q, 2007, OPHTHAL EPIDEMIOL, V14, P399, DOI 10.1080/09286580701331974
NR 18
TC 12
Z9 13
U1 0
U2 5
PU PROFESSIONAL MEDICAL PUBLICATIONS
PI SADDAR
PA PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO
   BOX 8766, SADDAR, KARACHI 00000, PAKISTAN
SN 1682-024X
J9 PAK J MED SCI
JI Pak. J. Med. Sci.
PD SEP-OCT
PY 2013
VL 29
IS 5
BP 1203
EP 1207
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 230GB
UT WOS:000325323800025
PM 24353720
DA 2022-11-30
ER

PT J
AU Cao, LN
   Wang, H
   Wang, F
AF Cao, Lining
   Wang, Hao
   Wang, Fang
TI Amyloid-beta-induced matrix metalloproteinase-9 secretion is associated
   with retinal pigment epithelial barrier disruption
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; barrier integrity; tight junction;
   matrix metalloproteinase-9; GM6001; 4-aminophenylmercuric acetate; RNA
   interference
ID BLOOD-BRAIN-BARRIER; MACULAR DEGENERATION; TIGHT JUNCTIONS; MATRIX
   METALLOPROTEINASES; COMPLEMENT ACTIVATION; PROTEINS; PERMEABILITY;
   EXPRESSION; MECHANISM; CYTOKINES
AB Local and chronic inflammation induced by amyloid-beta (A beta) plays a central role in the development of age-related macular degeneration. The retina is an immune-privileged site due to local tissue barrier. Yet, the manner by which immune cells pass through this barrier and accumulate in the retina remains unclear. Matrix metalloproteinases (MMPs) induce barrier disruption via proteolysis of epithelial tight junction (TJ) proteins. We hypothesized that A beta-induced MMP secretion causes disruption of epithelial barrier integrity. To test this hypothesis, human adult retinal pigment epithelial (haRPE) cells were exposed to A beta, and the expression of MMP-2 and MMP-9 was detected using gelatin zymography. To demonstrate the key role of MMPs in modulating epithelial barrier structure, the MMP agonist 4-aminophenylmercuric acetate (APMA), an MMP inhibitor (GM6001) and siRNA against MMP-9 were employed for comparison. We found that MMP-9, secreted by A beta- or APMA-stimulated cells, mediated low transepithelial electrical resistance (TER) and high transepithelial permeability by disrupting TJ proteins. However, these alterations were reduced by the MMP inhibitor GM6001 or by silencing of the MMP-9 gene. Our findings suggest that the degradation of TJ proteins such as zonula occludens-1, occludin and F-actin by MMP-9 secreted by A beta-stimulated cells constitutes an important mechanism in the breakdown of the barrier which contributes to chronic inflammation in the retina of age-related macular degeneration.
C1 [Cao, Lining; Wang, Hao; Wang, Fang] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai 200092, Peoples R China.
C3 Tongji University
RP Wang, F (通讯作者)，Shanghai Tenth Peoples Hosp, Dept Ophthalmol, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
EM 18917683335@163.com
FU Science and Technology Commission of Shanghai [11JC1409900]
FX This study was supported by the Science and Technology Commission of
   Shanghai (11JC1409900). We gratefully thank the Biochemistry and
   Molecular Biology Institute of Shanghai Tenth People's Hospital for the
   technological support, the Xiaoqing Liu's Laboratory of Tongji
   University for the experimental facilities and equipment and Xiujuan Shi
   for the excellent technical assistance.
CR Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Ecker SM, 2012, MOL VIS, V18, P1658
   Feng SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020599
   Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251
   Grolla AA, 2013, NEUROBIOL AGING, V34, P511, DOI 10.1016/j.neurobiolaging.2012.05.005
   Huet E, 2011, AM J PATHOL, V179, P1278, DOI 10.1016/j.ajpath.2011.05.036
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jeong S, 2012, AM J PATHOL, V180, P2028, DOI 10.1016/j.ajpath.2012.01.025
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kobayashi T, 2000, IUBMB LIFE, V50, P221
   Kook SY, 2012, J NEUROSCI, V32, P8845, DOI 10.1523/JNEUROSCI.6102-11.2012
   Kuchibhotla KV, 2009, SCIENCE, V323, P1211, DOI 10.1126/science.1169096
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Liu J, 2012, J NEUROSCI, V32, P3044, DOI 10.1523/JNEUROSCI.6409-11.2012
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Manicone AM, 2008, SEMIN CELL DEV BIOL, V19, P34, DOI 10.1016/j.semcdb.2007.07.003
   Martins T, 2011, BRAIN RES, V1411, P28, DOI 10.1016/j.brainres.2011.07.013
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Peng SM, 2012, INVEST OPHTH VIS SCI, V53, P5016, DOI 10.1167/iovs.11-8311
   Pflugfelder SC, 2005, AM J PATHOL, V166, P61, DOI 10.1016/S0002-9440(10)62232-8
   STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y
   Suzuki T, 2011, J BIOL CHEM, V286, P31263, DOI 10.1074/jbc.M111.238147
   Thibault O, 2007, AGING CELL, V6, P307, DOI 10.1111/j.1474-9726.2007.00295.x
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
NR 37
TC 12
Z9 15
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAY
PY 2013
VL 31
IS 5
BP 1105
EP 1112
DI 10.3892/ijmm.2013.1310
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 131MF
UT WOS:000317997100013
PM 23525277
OA Bronze
DA 2022-11-30
ER

PT J
AU Tortajada, A
   Pinto, S
   Martinez-Ara, J
   Lopez-Trascasa, M
   Sanchez-Corral, P
   de Cordoba, SR
AF Tortajada, Agustin
   Pinto, Sheila
   Martinez-Ara, Jorge
   Lopez-Trascasa, Margarita
   Sanchez-Corral, Pilar
   Rodriguez de Cordoba, Santiago
TI Complement factor H variants I890 and L1007 while commonly associated
   with atypical hemolytic uremic syndrome are polymorphisms with no
   functional significance
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE complement factor H; hemolytic uremic syndrome; disease-associated
   mutations
ID MACULAR DEGENERATION; ALTERNATIVE PATHWAY; SIALIC-ACID; SUSCEPTIBILITY
   GENE; ENDOTHELIAL-CELLS; BINDING-AFFINITY; PROTEIN BETA-1H; C3B
   INACTIVATOR; MUTATIONS; SURFACE
AB Mutations and polymorphisms in the gene-encoding factor H (CFH) are associated with atypical hemolytic uremic syndrome, dense deposit disease, and age-related macular degeneration. Many of these CFH genetic variations disrupt the regulatory role of factor H, supporting the concept that dysregulation of complement is a unifying pathogenic feature of these disorders. Evidence of a causal relationship with the disease is, however, not available for all CFH genetic variations found in patients, which is a potential cause of misinterpretations with important consequences for the patients and their relatives. CFH I890 and L1007 are two genetic variations repeatedly associated with atypical hemolytic uremic syndrome and also found in patients with dense deposit disease and age-related macular degeneration. Here we report an extensive genetic and functional analysis of these CFH variants. Our results indicate that I890 and L1007 segregate together as part of a distinct and relatively infrequent CFH haplotype in Caucasians. Extensive analysis of the S890/V1007 (control) and I890/L1007 (disease-associated) factor H protein variants failed to provide evidence that these amino acid changes have functional implications. Thus, the presence of the I890 and L1007 variants in healthy individuals and their high frequency in sub-Saharan African and African-American populations strongly suggest that I890 and L1007 are rare factor H polymorphisms unrelated to disease. Kidney International (2012) 81, 56-63; doi:10.1038/ki.2011.291; published online 31 August 2011
C1 [Tortajada, Agustin; Pinto, Sheila; Rodriguez de Cordoba, Santiago] CSIC, Ctr Invest Biol, Dept Med Celular & Mol, Madrid 28040, Spain.
   [Tortajada, Agustin; Pinto, Sheila; Lopez-Trascasa, Margarita; Sanchez-Corral, Pilar; Rodriguez de Cordoba, Santiago] Ciber Enfermedades Raras, Madrid, Spain.
   [Martinez-Ara, Jorge] Hosp Univ La Paz, Serv Nefrol, Madrid, Spain.
   [Lopez-Trascasa, Margarita; Sanchez-Corral, Pilar] Hosp Univ La Paz, Unidad Invest, Madrid, Spain.
   [Lopez-Trascasa, Margarita; Sanchez-Corral, Pilar] Hosp Univ La Paz, Unidade Inmunol, Madrid, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de
   Investigaciones Biologicas (CIB); CIBER - Centro de Investigacion
   Biomedica en Red; CIBERER; Hospital Universitario La Paz; Hospital
   Universitario La Paz; Hospital Universitario La Paz
RP de Cordoba, SR (通讯作者)，CSIC, Ctr Invest Biol, Dept Med Celular & Mol, Ramiro Maeztu 9, Madrid 28040, Spain.
EM SRdeCordoba@cib.csic.es
RI Tortajada, Agustín/H-2857-2015; de Cordoba, Santiago
   Rodriguez/K-6727-2014; Sánchez-Corral, Pilar/GLR-0387-2022;
   López-Trascasa, Margarita/L-2699-2014; kavukcu, salih/B-3417-2012
OI Tortajada, Agustín/0000-0002-2131-2594; de Cordoba, Santiago
   Rodriguez/0000-0001-6401-1874; López-Trascasa,
   Margarita/0000-0001-8594-282X; 
FU Spanish Ministerio de Ciencia e Innovacion [SAF2008-00226, PS09/00268,
   PS09/00122]; Ciber de Enfermedades Raras; Fundacion Renal Inigo Alvarez
   de Toledo
FX We are grateful to the patients and their relatives for their
   participation in this study, as well as to the physicians: Dr Jimenez
   (Nephrology, Hospital Universitario La Paz, Madrid), Dr Carreras,
   (Nephrology, Hospital de Bellvitge, Barcelona), Dr Zamora (Paediatric
   Nephrology, Hospital la Fe, Valencia), and Dr Serrano (Intensive Care
   Unit, Hospital Nino Jesus, Madrid). We thank the members of Secugen SL
   and the DNA sequencing laboratory at the CIB for invaluable technical
   assistance with patient sequencing and genotyping. This work was funded
   by the Spanish Ministerio de Ciencia e Innovacion (SAF2008-00226 to
   SRdeC, PS09/00268 to PS-C and PS09/00122 to ML-T), the Ciber de
   Enfermedades Raras, and the Fundacion Renal Inigo Alvarez de Toledo.
CR Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fakhouri F, 2010, NAT REV NEPHROL, V6, P494, DOI 10.1038/nrneph.2010.85
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hakobyan S, 2010, KIDNEY INT, V78, P782, DOI 10.1038/ki.2010.275
   Heinen S, 2007, J AM SOC NEPHROL, V18, P506, DOI 10.1681/ASN.2006091069
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Martinez-Barricarte R, 2010, J CLIN INVEST, V120, P3702, DOI 10.1172/JCI43343
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Noris M, 2005, J AM SOC NEPHROL, V16, P1177, DOI 10.1681/ASN.2005010086
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   PANGBURN MK, 1983, J IMMUNOL, V131, P1930
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROTHER U, 1982, J IMMUNOL METHODS, V51, P101, DOI 10.1016/0022-1759(82)90386-6
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, SCIENCE, V193, P1011, DOI 10.1126/science.948757
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 47
TC 31
Z9 32
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD JAN
PY 2012
VL 81
IS 1
BP 56
EP 63
DI 10.1038/ki.2011.291
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA 869XP
UT WOS:000298633600008
PM 21881555
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Ladas, ID
   Kotsolis, AI
   Rouvas, AA
   Brouzas, D
   Moschos, MM
AF Ladas, Ioannis D.
   Kotsolis, Athanasios I.
   Rouvas, Alexandros A.
   Brouzas, Dimitrios
   Moschos, Marilita M.
TI Efficacy of photodynamic therapy in the management of occult choroidal
   Neovascularization associated with serous pigment epithelium detachment
SO OPHTHALMOLOGICA
LA English
DT Article
DE occult choroidal neovascularization; serous pigment; epithelium
   detachment; photodynamic therapy; age-related macular degeneration
ID NATURAL-HISTORY
AB Aims: To evaluate the efficacy of photodynamic therapy (PDT) in the treatment of subfoveal occult choroidal neovascularization (CNV) associated with serous pigment epithelium detachment (PED) in eyes with age-related macular degeneration. Methods: Hundred and fifty-three patients ( 161 eyes) with subfoveal occult CNV due to age-related macular degeneration, were divided into two groups. The first group (70 patients, 75 eyes) included eyes with occult CNV associated with serous PED of at least 1 disc diameter in size and the second (83 patients, 86 eyes) eyes with late leakage of undetermined source. All the patients were treated with PDT. The follow-up time ranged from 12 to 48 months. Results: At the last examination, in the first group, the visual acuity (VA) improved or remained stable in 17 (22.7%) and decreased in 58 (77.3%). In the second group, the VA improved or remained stable in 37 (43%) and decreased in 49 (57%). The difference in the change (decrease) in the VA between the two groups was statistically very significant (p = 0.0075). Retinal pigment epithelium tear occurred in 15 eyes (20%) of the first group. Conclusion: Our study showed that the visual prognosis of eyes treated with PDT due to subfoveal occult CNV associated with serous PED is not favorable. We believe that the distinction between the two forms of occult CNV is essential, as they carry a different prognosis. Copyright (c) 2007 S. Karger AG, Basel.
C1 Univ Athens, Sch Med, Dept Ophthalmol, GR-11527 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens
RP Kotsolis, AI (通讯作者)，11 Zefiron Str, GR-15342 Athens, Greece.
EM thanoskotsolis@hotmail.com
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brancato R, 2000, RETINA-J RET VIT DIS, V20, P134, DOI 10.1097/00006982-200003000-00004
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CANTRILL HL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1074
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Fossarello M, 2004, EUR J OPHTHALMOL, V14, P568, DOI 10.1177/112067210401400620
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   LIM JI, 1994, AM J OPHTHALMOL, V112, P465
   Mennel S, 2005, AM J OPHTHALMOL, V140, P758, DOI 10.1016/j.ajo.2005.04.041
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
NR 20
TC 7
Z9 9
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2007
VL 221
IS 5
BP 313
EP 319
DI 10.1159/000104761
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 207BF
UT WOS:000249225900005
PM 17728553
DA 2022-11-30
ER

PT J
AU Dimitrov, PN
   Mukesh, BN
   McCarty, CA
   Taylor, HR
AF Dimitrov, PN
   Mukesh, BN
   McCarty, CA
   Taylor, HR
TI Five-year incidence of bilateral cause-specific visual impairment in the
   Melbourne visual impairment project
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER-DAM EYE; AGE-RELATED MACULOPATHY;
   CATARACT-SURGERY; ACUITY; POPULATION; PREVALENCE; AUSTRALIA; BLINDNESS;
   SERVICES
AB PURPOSE. To describe the age-, gender-, and cause-specific 5-year incidence of bilateral visual impairment in participants in the Melbourne Visual Impairment Project, Victoria, Australia.
   METHODS. Participants aged 40 years and older were recruited from Melbourne, Victoria, Australia, by random cluster sampling. The mean age of the 3271 (83% of the eligible) participants was 59 +/- 12 (SD) years. Of the participants, 54% were female. The initial baseline study (1992-1994) was followed by a 5-year incidence study (1997-1999). At both time points of the study, participants underwent a standardized testing procedure. Distance and near vision was tested using logarithm of the minimum angle of resolution (logMAR) charts, followed by refraction if needed. Visual fields were assessed by the 24-2 Humphrey field test (FastPac, Humphrey Field Analyzer; Carl Zeiss Meditec, Dublin, CA). Also, intraocular pressure, ocular motility, dilated ophthalmoscopy, and photography of the lens and the fundus were conducted. Furthermore, an interview included demographic characteristics, history of eye disease, medical history, and medication use. For classification of visual impairment, both visual acuity (VA) and visual fields (VF) examination results were used. Four levels of bilateral presenting visual impairment were defined: mild (VA, < 20/40 -20/60, and/or VF, homonymous hemianopia), moderate (VA, <20/ 60-20/200, and/or VF, constriction <20degrees to 10degrees from fixation), severe (VA, <20/200 -10/200, and/or VF, constriction < 10degrees to 5degrees from fixation), and profound (VA, <10/200, and/or VF, constriction <5degrees from fixation). For all participants found to be visually impaired, the major cause was identified.
   RESULTS. Of the 3040 people eligible to attend follow-up 2594 (85%) participated. Data were available for 2530 (98%) participants. In 105 participants (4.22%; 95% confidence limit 2.58 - 5.85) some degree of visual impairment developed. The main causes were undercorrected refractive error (59%), age-related macular degeneration, cataract and neuro-ophthalmic disorders (7% each), glaucoma (3%), and diabetic retinopathy (1%). The main cause of severe and profound visual impairment was age-related macular degeneration (37%).
   CONCLUSIONS. Undercorrected refractive error was the primary cause of new cases of visual impairment in this population. Further research is needed to understand the origin of this and to develop appropriate prevention measures. Age-related macular degeneration is the primary cause of severe or profound vision loss in Australia. This disease requires further investigation for effective cure and preventive strategies.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA.
   Peter MacCallum Canc Inst, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Marshfield
   Clinic; Peter Maccallum Cancer Center
RP Dimitrov, PN (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM dimitrov@unimelb.edu.au
OI McCarty, Catherine/0000-0003-1089-0142; Taylor, Hugh/0000-0002-9437-784X
CR [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   *AUSTR BUR STAT, 1996, PROJ POP AUSTR STAT
   *AUSTR BUR STAT, 2000, 2000 CENS POP HOUS C
   BAHRAM R, 1996, OPHTHALMOLOGY, V103, P1721
   BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESLOW NE, 1987, STAT METHODS CANC RE, V2, P52
   *BUR IMM RES, 1990, AUSTR POP TREND PROS
   Cochran WG., 1977, SAMPLING TECHNIQUES, P249
   EVANS J, 1995, CAUSES BLINDNESS PAR
   Ivers RQ, 1999, AM J PUBLIC HEALTH, V89, P85, DOI 10.2105/AJPH.89.1.85
   Keeffe JE, 1998, AUST NZ J OPHTHALMOL, V26, pS16, DOI 10.1111/j.1442-9071.1998.tb01360.x
   Keeffe JE, 1996, AUST NZ J OPHTHALMOL, V24, P313, DOI 10.1111/j.1442-9071.1996.tb01601.x
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Liou HL, 1999, AM J OPHTHALMOL, V127, P590, DOI 10.1016/S0002-9394(98)00449-8
   Livingston P M, 1997, Ophthalmic Epidemiol, V4, P73
   Livingston P M, 1994, Aust J Public Health, V18, P7
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   LIVINGSTON PM, 1994, DEV OPHTHALMOL, V26, P1
   LlewellynJones RH, 1997, MED J AUSTRALIA, V167, P416, DOI 10.5694/j.1326-5377.1997.tb126648.x
   LORD SR, 1994, J AM GERIATR SOC, V42, P1110, DOI 10.1111/j.1532-5415.1994.tb06218.x
   McCarty CA, 2003, AM J OPHTHALMOL, V136, P10, DOI 10.1016/S0002-9394(02)01844-5
   McCarty CA, 1999, BRIT J OPHTHALMOL, V83, P62, DOI 10.1136/bjo.83.1.62
   McCarty CA, 1998, BRIT J OPHTHALMOL, V82, P410, DOI 10.1136/bjo.82.4.410
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4
   Newland H S, 1996, Ophthalmic Epidemiol, V3, P97, DOI 10.3109/09286589609080114
   SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Taylor H, 1988, LENS RES, V5, P175
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   WEIGH LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wensor MD, 1998, OPHTHALMOLOGY, V105, P733, DOI 10.1016/S0161-6420(98)94031-3
   WEST SK, 1988, INVEST OPHTH VIS SCI, V29, P73
   World Health Organization, 1977, INT CLASS DIS
   WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226
NR 47
TC 59
Z9 65
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2003
VL 44
IS 12
BP 5075
EP 5081
DI 10.1167/iovs.02-0457
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 747JJ
UT WOS:000186801200004
PM 14638700
DA 2022-11-30
ER

PT J
AU Ito, A
   Maruyama-Inoue, M
   Kitajima, Y
   Sato, S
   Inoue, T
   Yamane, S
   Kadonosono, K
AF Ito, Arisa
   Maruyama-Inoue, Maiko
   Kitajima, Yoko
   Sato, Shimpei
   Inoue, Tatsuya
   Yamane, Shin
   Kadonosono, Kazuaki
TI Comparison of one-year results of photodynamic therapy combined with
   ranibizumab or aflibercept for treating polypoidal choroidal
   vasculopathy
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; VERTEPORFIN;
   BEVACIZUMAB; EFFICACY
AB Purpose To compare the 1-year visual outcomes and anatomical responses of patients who received photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) injections with those of patients who received PDT combined with intravitreal aflibercept (IVA) injections for treating polypoidal choroidal vasculopathy (PCV). Methods We retrospectively studied all treatment-naive patients with PCV who received PDT combined with either IVR or IVA. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), the number of additional injections, and the presence of polypoidal lesions, as indicated by indocyanine green angiography (ICGA), during 1 year were evaluated. Results Forty-four eyes were assessed at the 1-year follow-up examination. Of these, 23 were treated with PDT combined with IVR (PDT/IVR group), and 21 were treated with PDT combined with IVA (PDT/IVA group). In both groups, BCVA was shown to be significantly improved 1 year after the initial treatment. CMT and CCT were also significantly decreased after 1 year. There were no significant differences in the changes in BCVA or CMT between the two groups. However, the change in CCT in the PDT/IVA group was significantly larger than that of the PDT/IVR group (P< 0.001). The mean number of additional injections was 0.78 +/- 0.21 in the PDT/IVR group and 0.57 +/- 0.21 in the PDT/IVA group with no significant difference between the two groups (P= 0.45). The polyp regression rate at 12 months was 78.2% in the PDT/IVR group and 78.9% in the PDT/IVA group with no significant difference between the two groups. Conclusions PDT combined with either IVR or IVA was well tolerated and appeared to improve both vision and anatomy in patients with PCV. PDT/IVA may have a more pronounced effect on macular choroidal thickness at 1-year follow-up.
C1 [Ito, Arisa; Maruyama-Inoue, Maiko; Inoue, Tatsuya; Yamane, Shin; Kadonosono, Kazuaki] Yokohama City Univ, Dept Ophthalmol, Med Ctr, Yokohama, Kanagawa, Japan.
   [Kitajima, Yoko; Sato, Shimpei] Kanto Rosai Hosp, Dept Ophthalmol, Kawasaki, Kanagawa, Japan.
C3 Yokohama City University
RP Maruyama-Inoue, M (通讯作者)，Yokohama City Univ, Dept Ophthalmol, Med Ctr, Yokohama, Kanagawa, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Choi EY, 2020, OPHTHALMOLOGICA, V243, P136, DOI 10.1159/000501724
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, JPN J OPHTHALMOL, V61, P61, DOI 10.1007/s10384-016-0479-4
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Takada K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181598
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 25
TC 7
Z9 7
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2020
VL 15
IS 6
AR e0235213
DI 10.1371/journal.pone.0235213
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MF9GS
UT WOS:000545646600034
PM 32579608
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Badia, A
   Salas, A
   Duarri, A
   Ferreira-de-Souza, B
   Zapata, MA
   Fontrodona, L
   Garcia-Arumi, J
AF Badia, Anna
   Salas, Anna
   Duarri, Anna
   Ferreira-de-Souza, Barbara
   Zapata, Miguel Angel
   Fontrodona, Laura
   Garcia-Arumi, Jose
TI Transcriptomics analysis of Ccl2/Cx3cr1/Crb1(rd8) deficient mice
   provides new insights into the pathophysiology of progressive retinal
   degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Retinal degeneration; Oxidative stress; Chemokine signaling; Mouse
   model; Photoreceptors; Atrophy
AB Chronic oxidative stress and immune dysregulation are key mechanisms involved in the pathogenesis of most retinal degenerative diseases, including age-related macular degeneration. The Ccl2(-/-)/Cx3cr1(-/-)/Crb1(rd8/rd8) mouse model develops a progressive degeneration phenotype, with photoreceptor atrophy, drusen-like lesions or pigment alterations at an early age; however, the role of oxidative stress and immune function in the pathogenesis of the model is poorly understood. We performed a comprehensive characterization of the Ccl2(-/-) /Cx3cr1(-/-)/Crb1(rd8/rd8) mouse to evaluate how these pathways influence pathogenesis. We generated a Ccl2(-/-)/Cx3cr1(-/-) double-knockout(DKO) mouse on a C57BL/6N background (with the rd8 mutation of the Crb1 gene), assessed its retina status and function during 9 months in both in vivo and post-mortem analysis, and performed a comprehensive transcriptomic analysis. DKOrd8 mice presented focal retinal lesions with increased infiltration of microglia and involvement of Muller cells. Lesions progressed to thinning of the photoreceptor nuclear layer, causing a loss in retinal function. Transcriptomics analysis revealed major differential expression of genes involved in oxidative stress and neuronal function, in particular genes related to the mitochondrial electron transport chain and antioxidant cellular response. Our results suggest that alterations in chemokine signaling combined with the rd8 mutation in Ccl2(-/-)/Cx3cr1(-/-)/Crb1(rd8/rd8) mice involve early changes in several pathways associated with age-related macular degeneration, highlighting the relevance of these processes in the pathological retinal degeneration in the DKOrd8 model.
C1 [Badia, Anna; Salas, Anna; Duarri, Anna; Ferreira-de-Souza, Barbara; Zapata, Miguel Angel; Fontrodona, Laura; Garcia-Arumi, Jose] Vall dHebron Res Inst VHIR, Ophthalmol Res, Barcelona, Spain.
   [Garcia-Arumi, Jose] Hosp Univ Vall dHebron, Dept Ophthalmol, Barcelona, Spain.
C3 Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron;
   Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall
   d'Hebron
RP Badia, A (通讯作者)，Vall dHebron Res Inst, Passeig Vall dHebron 119-129,Collserola Bldg, Barcelona 08035, Spain.
EM annabadia02@gmail.com; anna_salas_torras@hotmail.com;
   anna.duarri@vhir.org; ferreiradesouza.b@gmail.com;
   zapatavictori@hotmail.com; lfontrodona@gmail.com;
   jgarcia.arumi@gmail.com
RI ; Duarri, Anna/K-2811-2017
OI Zapata, Miguel Angel/0000-0002-0096-4569; Duarri,
   Anna/0000-0003-4075-5478; Garcia-Arumi, Jose/0000-0001-8827-1160
FU Instituto de Salud Carlos III [PI14/00999]; Fundacio Josep Palau Francas
FX This study was funded by a grant from Instituto de Salud Carlos III
   (PI14/00999) and a predoctoral grant from Fundacio Josep Palau Francas.
CR Aredo B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0221-4
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Eastlake K, 2016, GLIA, V64, P495, DOI 10.1002/glia.22942
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Feng CY, 2017, MOL VIS, V23, P765
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fu SH, 2015, DIABETES, V64, P3554, DOI 10.2337/db15-0180
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   He Y, 2010, ADV EXP MED BIOL, V664, P165, DOI 10.1007/978-1-4419-1399-9_20
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Kohno H, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0408-3
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luhmann UFO, 2015, HUM MOL GENET, V24, P128, DOI 10.1093/hmg/ddu424
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mecca C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010318
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Nadal-Nicolas FM, 2018, NEUROBIOL AGING, V61, P146, DOI 10.1016/j.neurobiolaging.2017.09.021
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saddala MS, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0199-1
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Verardo MR, 2008, INVEST OPHTH VIS SCI, V49, P3659, DOI 10.1167/iovs.07-1474
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Wang G., 2014, INVEST OPHTH VIS SCI, P2221
   Wu TH, 2002, INVEST OPHTH VIS SCI, V43, P2834
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Zhang J, 2013, SYNAPSE, V67, P515, DOI 10.1002/syn.21674
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhou T, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00077
   Zhou YD, 2011, EXP EYE RES, V93, P636, DOI 10.1016/j.exer.2011.07.017
NR 51
TC 6
Z9 6
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2021
VL 203
AR 108424
DI 10.1016/j.exer.2020.108424
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG8GX
UT WOS:000617820900005
PM 33373623
DA 2022-11-30
ER

PT J
AU Mojana, F
   Brar, M
   Cheng, LY
   Bartsch, DUG
   Freeman, WR
AF Mojana, Francesca
   Brar, Manpreet
   Cheng, Lingyun
   Bartsch, Dirk-Uwe G.
   Freeman, William R.
TI LONG-TERM SD-OCT/SLO IMAGING OF NEURORETINA AND RETINAL PIGMENT
   EPITHELIUM AFTER SUBTHRESHOLD INFRARED LASER TREATMENT OF DRUSEN
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE spectral domain OCT-SLO; subthreshold laser; autofluorescence;
   photoreceptors; age-related macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; DIABETIC MACULAR EDEMA; CENTRAL SEROUS
   CHORIORETINOPATHY; DIODE-LASER; MICROPULSE PHOTOCOAGULATION; GRID
   PHOTOCOAGULATION; DEGENERATION; RETINOPATHY
AB Purpose: The purpose of this study was to determine the long-term effect of subthreshold diode laser treatment for drusen in patients with nonexudative age-related macular degeneration with spectral domain optical coherence tomography combined with simultaneous scanning laser ophthalmoscope.
   Methods: Eight eyes of four consecutive age-related macular degeneration patients with bilateral drusen previously treated with subthreshold diode laser were imaged with spectral domain optical coherence tomography/scanning laser ophthalmoscope. Abnormalities in the outer retinal layers' reflectivity as seen with spectral domain optical coherence tomography/scanning laser ophthalmoscope were retrospectively analyzed and compared with color fundus pictures, and autofluorescence images were acquired immediately before and after the laser treatment.
   Results: A focal discrete disruption in the reflectivity of the outer retinal layers was noted in 29% of the laser lesions. The junction in between the inner and outer segment of the photoreceptor was more frequently affected, with associated focal damage of the outer nuclear layer. Defects of the retinal pigment epithelium were occasionally detected. These changes did not correspond to threshold burns on color fundus photography but corresponded to focal areas of increased autofluorescence in the majority of the cases.
   Conclusion: Subthreshold diode laser treatment causes long-term disruption of the retinal photoreceptor layer as analyzed by spectral domain optical coherence tomography/scanning laser ophthalmoscope. The concept that subthreshold laser treatment can achieve a selected retinal pigment epithelium effect without damage to rods and cones may be flawed.
   RETINA 31: 235-242, 2011
C1 [Mojana, Francesca; Brar, Manpreet; Cheng, Lingyun; Bartsch, Dirk-Uwe G.; Freeman, William R.] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, San Diego, CA 92103 USA.
C3 University of California System; University of California San Diego
RP Freeman, WR (通讯作者)，UCSD, Dept Ophthalmol, Shiley Eye Ctr, Joan & Irwin Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
FU RPB Physician Scientist award; National Eye Institute NIH-NEI [EY16323];
   NIH [EY07366]; NATIONAL EYE INSTITUTE [R01EY016323, R01EY007366] Funding
   Source: NIH RePORTER
FX Research to Prevent Blindness (RPB, Inc), New York, NY; Dr. W. R. F. is
   the recipient of an RPB Physician Scientist award and support to
   Department. National Eye Institute NIH-NEI grant EY16323 (D.-U.G.B.) NIH
   grant EY07366 (W.R.F.); Dr D.-U.G.B. has received discounted products
   and specialized software from OPKO Instrumentation/OTI, Inc; Dr. W. R.
   F. has been consultant for OPKO. The other authors declare that they
   have no financial interest.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Bessho K, 2005, RETINA-J RET VIT DIS, V25, P981, DOI 10.1097/00006982-200512000-00005
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Chen SN, 2008, OPHTHALMOLOGY, V115, P2229, DOI 10.1016/j.ophtha.2008.08.026
   Colome J, 2007, OPHTHAL SURG LAS IM, V38, P484, DOI 10.3928/15428877-20071101-07
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Friberg T R, 2001, Semin Ophthalmol, V16, P19, DOI 10.1076/soph.16.1.19.4217
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Gellermann W, 2004, J BIOMED OPT, V9, P75, DOI 10.1117/1.1628240
   KO TH, 1922, OPHTHALMOLOGY, V112
   Lanzetta P, 2001, Semin Ophthalmol, V16, P8, DOI 10.1076/soph.16.1.8.4216
   Lanzetta P, 2008, EUR J OPHTHALMOL, V18, P934, DOI 10.1177/112067210801800613
   Lanzetta P, 2008, OPHTHALMOLOGY, V115, P216, DOI 10.1016/j.ophtha.2007.08.007
   Liem ATA, 1996, SURV OPHTHALMOL, V41, P37, DOI 10.1016/S0039-6257(97)81994-7
   Luttrull JK, 2008, EYE, V22, P607, DOI 10.1038/sj.eye.6702725
   Luttrull JK, 2006, OPHTHAL SURG LAS IM, V37, P370, DOI 10.3928/15428877-20060901-03
   Mainster M A, 1999, Semin Ophthalmol, V14, P200
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parodi MB, 2006, OPHTHALMOLOGY, V113, P2237, DOI 10.1016/j.ophtha.2006.05.056
   Pollack JS, 1998, ARCH OPHTHALMOL-CHIC, V116, P1633, DOI 10.1001/archopht.116.12.1633
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Roider J, 2000, BRIT J OPHTHALMOL, V84, P40, DOI 10.1136/bjo.84.1.40
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Sivaprasad S, 2007, CLIN EXP OPHTHALMOL, V35, P640, DOI 10.1111/j.1442-9071.2007.01566.x
   Squirrell DM, 2008, RETINA-J RET VIT DIS, V28, P615, DOI 10.1097/IAE.0b013e31815ee567
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
NR 29
TC 15
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2011
VL 31
IS 2
BP 235
EP 242
DI 10.1097/IAE.0b013e3181ec80ad
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 711JG
UT WOS:000286586500004
PM 21157398
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, K
   Yang, J
   Feuer, W
   Gregori, G
   Kim, ES
   Rosenfeld, PJ
   Yu, SY
AF Kim, Kiyoung
   Yang, Jin
   Feuer, William
   Gregori, Giovanni
   Kim, Eung Suk
   Rosenfeld, Philip J.
   Yu, Seung-Young
TI A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with
   Indocyanine Green Angiography and Swept-Source Optical Coherence
   Tomography Angiography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SPECTRAL-DOMAIN; MACULAR DEGENERATION; OCT ANGIOGRAPHY; DIAGNOSIS;
   NEOVASCULARIZATION; DIFFERENTIATION; SPECIFICITY; SENSITIVITY;
   DEFINITION; EVEREST
AB PURPOSE: Indocyanine green angiography (ICGA) was compared with swept-source optical coherence tomography angiography (SS-OCTA) for the detection of polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective, cross-sectional.
   METHODS: Patients with treatment-naive PCV based on ICGA imaging underwent same-day SS-OCTA imaging at Kyung Hee University Medical Center between April 2017 and November 2018. ICGA and SS-OCTA images were graded independently. SS-OCTA images were graded using both flow and structural information. Images were graded for the number of polypoidal lesions and the total lesion area, which included both the polypoidal lesions and the branching vascular networks (BVNs).
   RESULTS: A total of 31 eyes from 30 patients were enrolled. Polypoidal lesions were identified in all eyes using both modalities, and there was agreement on the number of polypoidal lesions in 17 eyes (55%). In 12 eyes (39%), SS-OCTA graders identified a greater number of polypoidal lesions, and in 2 eyes (6%) ICGA graders identified more lesions. There was no significant difference in the lesion area measurements (standard deviation = 1.09, P = .08). The lesion with the largest difference in area measurements resulted from focal areas of atrophy, misdiagnosed as polypoidal lesions on ICGA, and a low-lying serous retinal pigment epithelial detachment erroneously identified as part of the BVN by ICGA graders. SS-OCTA imaging correctly diagnosed the focal areas of atrophy and the serous retinal pigment epitheial detachment.
   CONCLUSIONS: SS-OCTA imaging was comparable to ICGA for the diagnosis of treatment-naive PCV. However, SS-OCTA might be better than ICGA in correctly identifying both polypoidal lesions and BVNs in treatment-naive PCV. ((C) 2020 Elsevier Inc. All rights reserved.)
C1 [Kim, Kiyoung; Kim, Eung Suk; Yu, Seung-Young] Kyung Hee Univ, Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Yang, Jin; Feuer, William; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Kyung Hee University; Bascom Palmer Eye Institute; University of Miami
RP Yu, SY (通讯作者)，Kyung Hee Univ Hosp, Dept Ophthalmol, 23 Kyungheedae Ro, Seoul 02447, South Korea.
EM syyu@khu.ac.kr
RI KIM, KIYOUNG/GWM-6103-2022
OI Rosenfeld, Philip/0000-0002-4068-6671; Feuer,
   William/0000-0002-9442-3076
CR Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Cheung CMG, 2019, JAMA OPHTHALMOL, V137, P667, DOI 10.1001/jamaophthalmol.2019.0583
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   de Carlo TE, 2018, OPHTHALMOLOGICA, V239, P103, DOI 10.1159/000481540
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Fujita A, 2020, RETINA-J RET VIT DIS, V40, P2296, DOI 10.1097/IAE.0000000000002760
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2016, OSLI RETINA, V47, P737, DOI 10.3928/23258160-20160808-07
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Motulsky EH, 2018, OSLI RETINA, V49, P878, DOI 10.3928/23258160-20181101-09
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sengupta S, 2015, AM J OPHTHALMOL, V160, P203, DOI 10.1016/j.ajo.2015.03.023
   Seong San, 2019, Korean J Ophthalmol, V33, P54, DOI 10.3341/kjo.2018.0048
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P614, DOI 10.1111/ceo.13464
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Teo KYC, 2019, ASIA-PAC J OPHTHALMO, V8, P165, DOI 10.22608/APO.201909
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 45
TC 11
Z9 11
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2020
VL 217
BP 240
EP 251
DI 10.1016/j.ajo.2020.05.017
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NW3NW
UT WOS:000574918000026
PM 32445699
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Higuchi, M
   Matsushita, T
   Kosaka, S
   Matsushita, R
   Takami, K
   Ohtsuka, H
   Ariga, H
AF Hikichi, Taiichi
   Higuchi, Makoto
   Matsushita, Takuro
   Kosaka, Shoko
   Matsushita, Reiko
   Takami, Kimitaka
   Ohtsuka, Hideo
   Ariga, Hiroko
TI One-Year Results of Three Monthly Ranibizumab Injections and As-Needed
   Reinjections for Polypoidal Choroidal Vasculopathy in Japanese Patients
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB;
   DOSING REGIMEN; VERTEPORFIN; NEOVASCULARIZATION; OUTCOMES; FLUID
AB PURPOSE: To investigate the 1-year outcomes of monthly intravitreal injections of ranibizumab for 3 months followed by an as-needed reinjection schedule to treat polypoidal choroidal vasculopathy (PCV) in Japanese patients.
   DESIGN: Prospective, consecutive case series.
   METHODS: Eighty-five eyes of 82 consecutive Japanese patients with naive symptomatic PCV received monthly intravitreal injections of ranibizumab for 3 months followed by an as-needed reinjection schedule. Eighty-one eyes (95%) followed for 1 year were studied.
   RESULTS: A mean of 4.2 +/- 1.3 (mean +/- standard deviation) injections were administered over 1 year. Twenty-three of 81 eyes (28%) did not require additional injections and 32 eyes (40%) required only 1 injection after the 3 monthly injections. The mean (+/- standard error) logarithm of minimal angle of resolution (logMAR) visual acuity (VA) at baseline was 0.59 +/- 0.37 and improved to 0.37 +/- 0.30 (P = .001). Thirty eyes (37%) and 5 eyes (6%), respectively, had improved and decreased VA of 0.3 or more logMAR unit. Indocyanine green angiography showed that the polypoidal lesions resolved in 21 eyes (26%) and 32 eyes (40%) 3 months and 1 year after the first injection, respectively. Abnormal choroidal vessels remained in all eyes.
   CONCLUSIONS: Monthly injections of ranibizumab for 3 months to treat PCV improved the VA, and a reinjection schedule based on need maintained the improved VA. The polypoidal lesions tended to improve over 1 year, whereas abnormal choroidal vessels remained in all eyes. Further long-term follow-up is needed to determine the efficacy of ranibizumab therapy for PCV. (Am J Ophthalmol 2012;154:117-124. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Hikichi, Taiichi] Ohtsuka Eye Hosp, Kita Ku, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Kita Ku, Kita 16,Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Ahlers C, 2009, INVEST OPHTH VIS SCI, V50, P3417, DOI 10.1167/iovs.08-2759
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Barbazetto I, 2010, RETINA-J RET VIT DIS, V30, P1376, DOI 10.1097/IAE.0b013e3181dcfb0b
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
NR 41
TC 63
Z9 68
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2012
VL 154
IS 1
BP 117
EP 124
DI 10.1016/j.ajo.2011.12.019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 966XX
UT WOS:000305871800017
PM 22465366
DA 2022-11-30
ER

PT J
AU Kikushima, W
   Sakurada, Y
   Sugiyama, A
   Tanabe, N
   Kume, A
   Iijima, H
AF Kikushima, Wataru
   Sakurada, Yoichi
   Sugiyama, Atsushi
   Tanabe, Naohiko
   Kume, Atsuki
   Iijima, Hiroyuki
TI Comparison of initial treatment between 3-monthly intravitreal
   aflibercept monotherapy and combined photodynamic therapy with single
   intravitreal aflibercept for polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Photodynamic therapy; Aflibercept;
   Retreatment-free period
ID VERTEPORFIN; RANIBIZUMAB
AB To compare the efficacy of two different initial treatment modalities on visual outcome, need for retreatment, and angiographic improvement during 12-month follow-up for polypoidal choroidal vasculopathy (PCV).
   A retrospective medical chart review was performed for 66 eyes from 66 patients with treatment-na < ve PCV. Visual and angiographic improvements and the incidence of retreatment for recurrence or residual pathology were compared between two groups that underwent either intravitreal aflibercept injection (IAI) monotherapy (n = 33) or combined photodynamic therapy (PDT) with IAI (n = 33).
   Best-corrected visual acuity improved significantly (P < 0.001) in both groups at each of the 3-monthly visits during the 12-month follow-up period, with no difference between groups at 12 months (P = 0.56). The relative risk of the need for retreatment was significantly lower in the combined PDT and IAI group than in the IAI monotherapy group (P = 0.007). Angiographic regression of polypoidal vascular lesions occurred more frequently in the combined PDT group than in the IAI monotherapy group at 3 (87.5 % vs 56.7 %) and 12 months (68.8 % vs 60.0 %) (p = 0.0065 and p = 0.47 respectively).
   The combination of PDT with IAI as the initial treatment for PCV may be superior to IAI monotherapy in terms of disease-stabilizing efficacy, but with equivalent visual gain at 12 months.
C1 [Kikushima, Wataru; Sakurada, Yoichi; Sugiyama, Atsushi; Tanabe, Naohiko; Kume, Atsuki; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 9
TC 25
Z9 25
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2017
VL 255
IS 2
BP 311
EP 316
DI 10.1007/s00417-016-3467-y
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK8ET
UT WOS:000394157400011
PM 27534663
DA 2022-11-30
ER

PT J
AU Park, YG
   Kang, S
   Roh, YJ
AF Park, Young Gun
   Kang, Seungbum
   Roh, Young Jung
TI Effects of three consecutive monthly intravitreal injection of
   ranibizumab for polypoidal choroidal vasculopathy in Korea
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE ranibizumab; polypoidal choroidal vasculopathy; intravitral injection
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; BEVACIZUMAB; EFFICACY;
   NEOVASCULARIZATION; VERTEPORFIN; FEATURES; OUTCOMES
AB AIM: To evaluate the efficacy and safety of three consecutive monthly injections of intravitreal ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV) in Korea.
   METHODS: A retrospective chart review of 25 patients (27 eyes) with PCV was conducted. Patients received three initial monthly intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12mo from January 2010 to October 2011. Reinjection of ranibizumab after three initial monthly loading was administered on an as -needed basis, guided by the optical coherence tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICGA). The main outcomes were the changes of the mean best corrected Snellen visual acuity (VA), central macular thickness (CMT) by OCT, the changes of polyps and branching vascular network by FA and ICGA, and total number of injections received by patients during the 12mo.
   RESULTS: The mean best corrected Snellen visual acuities at baseline, 1, 3, 6 and 12mo after primary injection were 0.77 +/- 0.59, 0.76 +/- 0.53, 0.70 +/- 0.47, 0.63 +/- 0.43, 0.61 +/- 0.43, 0.62 +/- 0.42 logMAR, respectively, and showed significant improvement at 3, 6, 12mo (P=0.003, P=0.002, P=0.018, Wilcoxon signed-rank test). The mean CMT at baseline, 1, 2, 3, 6, and 12mo was 312.41 +/- 66.38 mu m, 244.59 +/- 71.47 mu m, 232.32 +/- 69.41 mu m, 226.69 +/- 69.03 mu m, 228.62 +/- 37.07 mu m, 227.59 +/- 51.01 mu m respectively, and showed significant reduction (all P<0.001, Wilcoxon signed -rank test). Polypoidal lesions resolved on ICGA in 3 eyes (11.1%) and a branching vascular network remained in all 24 eyes (88.9%). A total of 106 injections were given in the 12-month period, which equaled to a mean of 3.92 (range, 3-6) times. Sixteen of the 27 treated eyes had additional 1.56 +/- 0.91 injections. The others (11 eyes) had just 3 consecutive injections.
   CONCLUSION: An initial loading dose of three monthly ranibizumab injections is a safe and effective method in treating PCV, with visual and anatomical improvement over one year follow-up.
C1 [Park, Young Gun; Roh, Young Jung] Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Ophthalmol, Seoul 150713, South Korea.
   [Kang, Seungbum] Catholic Univ Korea, Daejeon St Marys Hosp, Dept Ophthalmol, Taejon 301010, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP Roh, YJ (通讯作者)，Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Ophthalmol, 62 Yeouido Dong, Seoul 150713, South Korea.
EM shy9172@naver.com
CR Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Chhablani JK, 2011, RETINA-J RET VIT DIS, V31, P196, DOI 10.1097/IAE.0b013e3181fe924f
   Chhablani JK., 2011, RETINA, V31, P197
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ishikawa K, 2011, GRAEF ARCH CLIN EXP, V249, P273, DOI 10.1007/s00417-010-1548-x
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Romano MR, 2010, CLIN OPHTHALMOL, V4, P1237, DOI 10.2147/OPTH.S12577
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 1
Z9 1
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2015
VL 8
IS 2
BP 315
EP 320
DI 10.3980/j.issn.2222-3959.2015.02.18
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CF7RN
UT WOS:000352754100019
PM 25938048
DA 2022-11-30
ER

PT J
AU Lechanteur, YTE
   van de Ven, JPH
   Smailhodzic, D
   Boon, CJF
   Klevering, BJ
   Fauser, S
   Groenewoud, JMM
   van der Wilt, GJ
   den Hollander, AI
   Hoyng, CB
AF Lechanteur, Yara T. E.
   van de Ven, Johannes P. H.
   Smailhodzic, Dzenita
   Boon, Camiel J. F.
   Klevering, B. Jeroen
   Fauser, Sascha
   Groenewoud, Joannes M. M.
   van der Wilt, Gert-Jan
   den Hollander, Anneke I.
   Hoyng, Carel B.
TI Genetic, Behavioral, and Sociodemographic Risk Factors for Second Eye
   Progression in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULARIZATION SECONDARY; TOLL-LIKE
   RECEPTOR-3; GEOGRAPHIC ATROPHY; APOLIPOPROTEIN-E; FELLOW EYES; FACTOR-B;
   ASSOCIATION; VARIANTS; SUSCEPTIBILITY
AB PURPOSE. This study was conducted to investigate the correlation of genetic, sociodemographic, and behavioral risk factors with second eye progression to end-stage AMD.
   METHODS. One hundred and eight patients with end-stage AMD in one or both eyes were included in a retrospective time-to-event analysis of the onset of end-stage AMD in the second eye. Multivariate Cox regression survival analysis was performed for sex, age, smoking, body mass index (BMI), education, and 16 single nucleotide polymorphisms (SNPs) associated with AMD.
   RESULTS. Except for education, all sociodemographic and behavioral risk factors analyzed were significantly associated with a more rapid progression toward second eye involvement. Hazard ratios (HRs) were 2.6 (95% confidence interval [CI], 1.4-5.0) for female sex; 5.0 (95% CI, 2.0-12.5) for age >80; 2.2 (95% CI, 1.1-4.1) for BMI >30; and 4.4 (95% CI, 1.4-14.3) for >40 pack years, compared with the referent groups. Carriers of the lipoprotein lipase (LPL; rs12678919) risk alleles were at risk for more rapid progression to end-stage AMD in the second eye compared with the referent wild-type genotype (HR 2.0; 95% CI, 1.0-3.6). For complement factor I (CFI; rs10033900), homozygous carriers of the risk allele progressed faster than wild-type individuals (HR 2.2; 95% CI, 1.1-4.3).
   CONCLUSIONS. Sociodemographic, behavioral, and genetic risk factors are associated with the rate of second eye progression toward end-stage AMD. The findings of this study underline the importance of lifestyle factors and the complement pathway in AMD progression and suggest a role of the high-density-lipoprotein metabolism in second eye progression. (Invest Ophthalmol Vis Sci. 2012;53:5846-5852) DOI:10.1167/iovs.11-7731
C1 [Lechanteur, Yara T. E.; van de Ven, Johannes P. H.; Smailhodzic, Dzenita; Boon, Camiel J. F.; Klevering, B. Jeroen; den Hollander, Anneke I.; Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands.
   [Fauser, Sascha] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50931 Cologne, Germany.
   [Groenewoud, Joannes M. M.; van der Wilt, Gert-Jan] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & Hlth Technol Assessment, NL-6500 HB Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; University of Cologne; Radboud University
   Nijmegen; Radboud University Nijmegen
RP Hoyng, CB (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM C.Hoyng@ohk.umcn.nl
RI Lehtimäki, Terho/AAD-1094-2022; Hollander, Anneke den/N-4911-2014;
   Lechanteur, Yara/ABB-6875-2020; Klevering, B.J./L-4434-2015; Groenewoud,
   Hans JMM/R-3588-2017; Hoyng, C.B./H-8050-2014; van der Wilt,
   G.J./H-8120-2014; Boon, CJF/P-7534-2014
OI Lehtimäki, Terho/0000-0002-2555-4427; Lechanteur,
   Yara/0000-0003-0951-4625; Groenewoud, Hans JMM/0000-0002-4974-150X; van
   der Wilt, G.J./0000-0002-5856-762X; Boon, CJF/0000-0002-6737-7932
FU MD fonds; Oogfonds; Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid
FX Supported by MD fonds, Oogfonds, and Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawkins JR, 2002, HUM MUTAT, V19, P543, DOI 10.1002/humu.10060
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuczmarski MF, 2001, J AM DIET ASSOC, V101, P28, DOI 10.1016/S0002-8223(01)00008-6
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Meng HD, 2010, J AM GERIATR SOC, V58, P412, DOI 10.1111/j.1532-5415.2009.02713.x
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shields Margot, 2008, Health Rep, V19, P61
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Vailas LI, 1998, J GERONTOL A-BIOL, V53, pM481, DOI 10.1093/gerona/53A.6.M481
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 57
TC 17
Z9 18
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2012
VL 53
IS 9
BP 5846
EP 5852
DI 10.1167/iovs.11-7731
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004QE
UT WOS:000308695400095
PM 22815349
DA 2022-11-30
ER

PT J
AU Chen, L
   Ma, B
   Liu, X
   Hao, Y
   Yang, XG
   Liu, M
AF Chen, Li
   Ma, Bo
   Liu, Xuan
   Hao, Yang
   Yang, Xiaogang
   Liu, Ming
TI H2O2 induces oxidative stress damage through the BMP-6/SMAD/hepcidin
   axis
SO DEVELOPMENT GROWTH & DIFFERENTIATION
LA English
DT Article
DE bone morphogenetic protein-6; H2O2; Hepcidin; neovascular age-related
   macular degeneration
ID IRON; BMP6; EXPRESSION; HEPCIDIN; REGULATOR
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness in elderly individuals worldwide. Oxidative stress injury to retinal pigment epithelial (RPE) cells plays a major role in the pathogenesis of AMD. The purpose of this study was to observe the correlation between Hepcidin and neovascular age-related macular degeneration (nAMD) and to further observe whether oxidative stress can inhibit Hepcidin expression through relevant signaling pathways to produce oxidative damage. We compared the concentrations of Hepcidin in the aqueous humor of nAMD patients and a control group and found that the concentration of Hepcidin was lower in nAMD patients. Through PCR and western blotting, we observed that H2O2 can significantly inhibit the expression of Bone morphogenetic protein-6 (BMP-6) and Hepcidin and increase the intracellular iron concentration in RPE cells, while BMP-6 can reverse the inhibition of Hepcidin and the increase in iron concentration caused by H2O2. In addition, alterations in smad1 and smad5 expression were examined, and pretreatment with BMP-6 was demonstrated to reduce H2O2-induced activation of smad1 and smad5. The effects of BMP-6 were attenuated by smad1 and smad5 siRNA, further verifying that oxidative stress inhibits the expression of Hepcidin by inhibiting activation of the BMP/SMAD signaling pathway. To some extent, this study verified that oxidative stress injury plays a role in nAMD by affecting the level of hepcidin, which lays a foundation for exploring new methods to treat nAMD.
C1 [Chen, Li; Ma, Bo; Liu, Xuan; Hao, Yang] Xi An Jiao Tong Univ, Dept Ophthalmol, Affiliated Hosp 1, Xian, Peoples R China.
   [Yang, Xiaogang; Liu, Ming] Xian 1 Hosp, Dept Ophthalmol, Xian, Peoples R China.
   [Yang, Xiaogang; Liu, Ming] Shaanxi Inst Ophthalmol, Xian, Peoples R China.
C3 Xi'an Jiaotong University
RP Liu, M (通讯作者)，Xian 1 Hosp, Dept Ophthalmol, Shaanxi Inst Ophthalmol, 30 Fenxiang,Nanda St, Xian 710002, Shaanxi, Peoples R China.
EM liuming24900@163.com
OI chen, li/0000-0003-1054-8021
FU Xi'an Science and Technology Project [201805097YX5SF31]; Institutional
   Science Foundation of first affiliated hospital of Xi'an Jiaotong
   University [2018MS-34]; Shaanxi Provincial Key Research and Development
   Project [S2018-YF-YBSF-0809]
FX Xi'an Science and Technology Project, Grant/Award Number: No.
   201805097YX5SF31 (5); Institutional Science Foundation of first
   affiliated hospital of Xi'an Jiaotong University, Grant/Award Number:
   2018MS-34; Shaanxi Provincial Key Research and Development Project,
   Grant/Award Number: S2018-YF-YBSF-0809
CR Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335
   Barcellini W, 2019, BRIT J HAEMATOL, V185, P523, DOI 10.1111/bjh.15811
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen L, 2018, INT J MOL MED, V42, P1096, DOI 10.3892/ijmm.2018.3675
   Goh JB, 2015, SCI REP-UK, V5, DOI 10.1038/srep13986
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Haynes T, 2007, P NATL ACAD SCI USA, V104, P20380, DOI 10.1073/pnas.0708202104
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Latour C, 2017, BLOOD, V130, P2339, DOI 10.1182/blood-2017-07-795658
   Liu J, 2019, SHOCK, V51, P780, DOI 10.1097/SHK.0000000000001182
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320
   Naylor RM, 2013, CLIN PHARMACOL THER, V93, P105, DOI 10.1038/clpt.2012.193
   Oahalou A, 2014, RETINA-J RET VIT DIS, V34, P108, DOI 10.1097/IAE.0b013e31828e6985
   Pathanapitoon Kessara, 2005, Journal of the Medical Association of Thailand, V88, P228
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Poli M, 2017, MOLECULES, V22, DOI 10.3390/molecules22040598
   Powers JM, 2019, HEMATOL ONCOL CLIN N, V33, P393, DOI 10.1016/j.hoc.2019.01.006
   Rauber MR, 2019, AN ACAD BRAS CIENC, V91, DOI 10.1590/0001-3765201920180286
   Sheetz M, 2019, BRIT J CLIN PHARMACO, V85, P935, DOI 10.1111/bcp.13877
   Wang BS, 2018, BRIT J OPHTHALMOL, V102, P220, DOI 10.1136/bjophthalmol-2017-310333
   Yu AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048501
   Zhao LL, 2014, AM J PATHOL, V184, P2862, DOI 10.1016/j.ajpath.2014.07.008
NR 23
TC 4
Z9 4
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1592
EI 1440-169X
J9 DEV GROWTH DIFFER
JI Dev. Growth Diff.
PD FEB
PY 2020
VL 62
IS 2
BP 139
EP 146
DI 10.1111/dgd.12650
EA FEB 2020
PG 8
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA KK8XN
UT WOS:000510556000001
PM 32012242
OA Bronze
DA 2022-11-30
ER

PT J
AU Bae, K
   Cho, GE
   Yoon, JM
   Kang, SW
AF Bae, Kunho
   Cho, Ga Eun
   Yoon, Je Moon
   Kang, Se Woong
TI Optical Coherence Tomographic Features and Prognosis of Pneumatic
   Displacement for Submacular Hemorrhage
SO PLoS One
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; SUBRETINAL HEMORRHAGE;
   INTRAVITREAL INJECTION; NATURAL-HISTORY; EXPANSILE GAS; MANAGEMENT;
   LESIONS
AB Purpose
   To identify prognostic factors, including optical coherence tomographic features, of visual outcome in exudative age-related macular degeneration with submacular hemorrhage treated with pneumatic displacement.
   Methods
   This retrospective interventional case series included 37 eyes with exudative age-related macular degeneration and submacular hemorrhage, all of which underwent pneumatic displacement. The best-corrected visual acuity (BCVA) was measured at diagnosis and at 3 and 6 months after treatment. In addition to demographic and funduscopic parameters, tomographic features such as reflectance of the submacular hemorrhage were analyzed with regard to BCVA at 6 months.
   Results
   After pneumatic displacement and a subsequent treatment such as laser or anti-vascular endothelial growth factor therapy, the BCVA at 3 and 6 months improved significantly (P < 0.001, respectively). Higher baseline BCVA (P < 0.001), shorter symptom duration (P = 0.007), and younger age (P = 0.014) were significant positive prognostic factors on regression analysis. Among optical coherence tomography characteristics, reflectance of the submacular hemorrhage, the shortest radius of the submacular hemorrhage centered on the fovea, and defects in the ellipsoid zone, and external limiting membrane affected the BCVA at 6 months (P < 0.05).
   Conclusion
   A favorable visual outcome was demonstrated after initial pneumatic displacement and subsequent treatment for submacular hemorrhage. The submacular hemorrhages exhibiting lower reflectance on optical coherence tomography and a smaller shortest radius from the foveal center were found to be good candidates for pneumatic displacement.
C1 [Bae, Kunho; Cho, Ga Eun; Yoon, Je Moon; Kang, Se Woong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
EM swkang@skku.edu
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kokame GT, 2000, AM J OPHTHALMOL, V129, P546, DOI 10.1016/S0002-9394(99)00474-2
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 25
TC 6
Z9 7
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 19
PY 2016
VL 11
IS 12
AR e0168474
DI 10.1371/journal.pone.0168474
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EI9QC
UT WOS:000392842600064
PM 27992524
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Hamel, CP
   Meunier, I
   Arndt, C
   Ben Salah, S
   Lopez, S
   Bazalgette, C
   Bazalgette, C
   Zanlonghi, X
   Arnaud, B
   Defoort-Dellhemmes, S
   Puech, B
AF Hamel, Christian P.
   Meunier, Isabelle
   Arndt, Carl
   Ben Salah, Safouane
   Lopez, Severine
   Bazalgette, Christian
   Bazalgette, Cecile
   Zanlonghi, Xavier
   Arnaud, Bernard
   Defoort-Dellhemmes, Sabine
   Puech, Bernard
TI Extensive Macular Atrophy with Pseudodrusen-like Appearance: A New
   Clinical Entity
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ONSET RETINAL DEGENERATION; GEOGRAPHIC ATROPHY; CHOROIDAL
   NEOVASCULARIZATION; PIGMENT-EPITHELIUM; VISUAL FUNCTION; DYSTROPHY;
   EYES; ENLARGEMENT; DEPOSITS; FORM
AB PURPOSE: To describe a previously unreported clinical entity of progressive extensive macular atrophy and pseudodrusen-like appearance in middle-aged patients.
   DESIGN: Clinical, electrophysiologic, and molecular retrospective study.
   METHODS: The database of an outpatient clinic unit for genetic sensory diseases was screened for patients older than 40 years with uncharacterized macular dystrophy. Patients with extensive macular atrophy and pseudo drusen-like appearance were included.
   RESULTS: Eighteen patients of 45 records (40%) matched the inclusion criteria. Bilateral polycyclic well. delineated chorioretinal atrophy extending to the temporal vascular arcades, with a larger vertical axis and without sparing of the fovea featured the macular lesion. The pseudodrusen-like appearance was widespread throughout the posterior pole and the peripheral retina. In the extreme periphery, paving stone lesions were located mostly in the inferior quadrants. In contrast to age-related macular degeneration, a rapid progression of the atrophy was observed with an early involvement of the foveal zone, thus leading to a severe visual loss. All the patients except 2 were legally blind at the end of the follow,up. Unlike age-related macular degeneration, in none of these patients did choroidal neovascularization develop. In all patients, the scotopic and photopic electroretinography responses were reduced.
   CONCLUSIONS: Extensive macular atrophy with pseudo drusen should be considered as a possible pattern of severe macular dystrophy occurring in the middle-aged adult. (Am J Ophthalmol 2009;147:609-620. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Hamel, Christian P.] Hop St Eloi, Inst Neurosci Montpellier, INSERM, U583, F-34091 Montpellier 5, France.
   [Hamel, Christian P.; Meunier, Isabelle; Arndt, Carl; Ben Salah, Safouane; Lopez, Severine; Bazalgette, Christian; Bazalgette, Cecile; Arnaud, Bernard] Ctr Hosp Reg & Univ, Ctr Reference Malad Sensorielles Genet, Montpellier, France.
   [Hamel, Christian P.] Univ Montpellier I, Montpellier, France.
   [Zanlonghi, Xavier] Clin Sourdille, Nantes, France.
   [Defoort-Dellhemmes, Sabine; Puech, Bernard] Ctr Hosp Reg & Univ Lille, Serv Exploratat Vis Neuroophtalmol, F-59037 Lille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; CHU de Montpellier; Universite de
   Montpellier; CHU de Montpellier; Universite de Montpellier; Universite
   de Lille - ISITE; CHU Lille
RP Hamel, CP (通讯作者)，Hop St Eloi, Inst Neurosci Montpellier, INSERM, U583, BP 74103,80 Rue Augustin Fliche, F-34091 Montpellier 5, France.
EM christian.hamel@inserm.fr
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   CARR RE, 1965, ARCH OPHTHALMOL-CHIC, V73, P32
   COHEN Y, 1994, BRIT J OPHTHALMOL, V78, P437
   Felbor U, 1997, AM J HUM GENET, V60, P57
   FERRY AP, 1972, ARCH OPHTHALMOL-CHIC, V88, P39
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   FRANK HR, 1974, AM J OPHTHALMOL, V78, P903, DOI 10.1016/0002-9394(74)90800-9
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hoyng CB, 1996, GRAEF ARCH CLIN EXP, V234, P87, DOI 10.1007/BF00695246
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klevering BJ, 2002, BRIT J OPHTHALMOL, V86, P91, DOI 10.1136/bjo.86.1.91
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Lotery Andrew John, 1998, Documenta Ophthalmologica, V97, P103, DOI 10.1023/A:1002024028861
   Maguire MG, 1996, RETINA-J RET VIT DIS, V16, P167, DOI 10.1097/00006982-199616020-00019
   Marmor MF, 1996, AM J OPHTHALMOL, V122, P382, DOI 10.1016/S0002-9394(14)72065-3
   Meunier I, 2004, ARCH OPHTHALMOL-CHIC, V122, P1566, DOI 10.1001/archopht.122.10.1566
   Michaelides M, 2006, SURV OPHTHALMOL, V51, P232, DOI 10.1016/j.survophthal.2006.02.007
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   NOBLE KG, 1977, AM J OPHTHALMOL, V84, P310, DOI 10.1016/0002-9394(77)90670-5
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   ROTHMAN RJ, 1994, ANN OPHTHALMOL, V26, P25
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Small K W, 1997, Mol Vis, V3, P1
   SORSBY A, 1955, Br J Ophthalmol, V39, P385, DOI 10.1136/bjo.39.7.385
   Styles CJ, 2003, EYE, V17, P530, DOI 10.1038/sj.eye.6700408
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0
NR 35
TC 29
Z9 30
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2009
VL 147
IS 4
BP 609
EP 620
DI 10.1016/j.ajo.2008.10.022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 424KW
UT WOS:000264566600009
PM 19181301
DA 2022-11-30
ER

PT J
AU Skerka, C
   Zipfel, PF
AF Skerka, Christine
   Zipfel, Peter F.
TI Complement factor H related proteins in immune diseases
SO VACCINE
LA English
DT Article
DE CFHR; Factor H family; HUS; AMD
ID HEMOLYTIC-UREMIC SYNDROME; MACULAR DEGENERATION; BINDING-PROTEIN; GENES;
   HEPARIN; FHR-4; AUTOANTIBODIES; RECOGNITION; MUTATIONS; FAMILY
AB The complement system is a powerful part of the host innate immune defense and is aimed to damage and eliminate microbes and modified self-cells. To protect host cells and biological surfaces from damage mediated by complement activation products a tight control of the complement system is necessary. Imbalances in complement regulation contribute to tissue injury and can result in autoimmune diseases Such as hemolytic Uremic syndrome (HUS), membranoproliferative glomerulonephritis (MPGN) or age related macular degeneration (AMD). Disease associated mutations have been identified in several complernent regulators or components, such as members of the factor H protein family, This group includes the major alternative pathway regulator, complement factor H (CFH) and five complement factor H related proteins (CFHR). Homozygous chromosomal deletion of a genomic 84 kb, chromosomal fragment which includes the genes CFHR1/CFHR3 is a risk factor for hemolytic uremic syndrome (HUS) at young age and is predominantly associated with the generation of autoantibodies to CFH, leading to a specific type of HUS. called DEAP (deficiency of CFHR. and autoantibody positive)-HUS. The same deletion however is protective to the development of age related macular degeneration (AMD) in elderly people. Thus CFHR1 and CFHR3 proteins, and likely also the other members of this gene family are linked to human diseases. We here summarize the current knowledge about the role or association of CFHR1 and CFHR3 in the human diseases HUS and AMD. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Skerka, Christine; Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
   [Skerka, Christine; Zipfel, Peter F.] Univ Jena, Jena, Germany.
C3 Hans Knoll Institute (HKI); Friedrich Schiller University of Jena
RP Skerka, C (通讯作者)，Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11, D-07745 Jena, Germany.
EM christine.skerka@hki-jena.de
FU Deutsche Forschungsgerneinschaft, Kidneeds; NIH and ProRetina
FX Conflict of interest statement: The authors declare no conflict of
   interest.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534
   GASSER C, 1955, Schweiz Med Wochenschr, V85, P905
   Haupt K, 2007, J INFECT DIS, V196, P124, DOI 10.1086/518509
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jokiranta TS, 2007, MOL IMMUNOL, V44, P3889, DOI 10.1016/j.molimm.2007.06.003
   Jozsi M, 2005, EUR J HUM GENET, V13, P321, DOI 10.1038/sj.ejhg.5201324
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Kotarsky H, 2001, MOL MICROBIOL, V41, P817, DOI 10.1046/j.1365-2958.2001.02496.x
   KOZIOLEK MJ, 2008, KIDNEY INT
   Kunert A, 2007, J IMMUNOL, V179, P2979, DOI 10.4049/jimmunol.179.5.2979
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200
   Montero MIM, 2007, IEEE T POWER ELECTR, V22, P229, DOI 10.1109/TPEL.2006.886616
   Monteferrante G, 2007, MOL IMMUNOL, V44, P1704, DOI 10.1016/j.molimm.2006.08.004
   Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Park CT, 1996, J BIOL CHEM, V271, P18054, DOI 10.1074/jbc.271.30.18054
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   SKERKA C, 1991, J BIOL CHEM, V266, P12015
   SKERKA C, 1992, J IMMUNOL, V148, P3313
   SKERKA C, 1993, J BIOL CHEM, V268, P2904
   Skerka C, 1997, J BIOL CHEM, V272, P5627, DOI 10.1074/jbc.272.9.5627
   STUHLINGER W, 1974, LANCET, V2, P788
   TIMMANN C, 1991, J IMMUNOL, V146, P1265
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 37
TC 56
Z9 56
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD DEC 30
PY 2008
VL 26
BP I9
EP I14
DI 10.1016/j.vaccine.2008.11.021
PG 6
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA 402HT
UT WOS:000263005500003
PM 19388158
DA 2022-11-30
ER

PT J
AU Yu, Y
   Li, LC
   Lin, S
   Hu, JM
AF Yu, Yang
   Li, Licheng
   Lin, Shu
   Hu, Jianmin
TI Update of application of olfactory ensheathing cells and stem
   cells/exosomes in the treatment of retinal disorders
SO STEM CELL RESEARCH & THERAPY
LA English
DT Review
DE Retinal disorders; Olfactory ensheathing cells; Stem cells; Exosomes
ID INDUCED CHOROIDAL NEOVASCULARIZATION; MOUSE MODEL; DIABETIC-RETINOPATHY;
   PIGMENT EPITHELIUM; EXTRACELLULAR VESICLES; RETINITIS-PIGMENTOSA;
   GANGLION-CELLS; ANIMAL-MODEL; GENE-THERAPY; MACULAR DEGENERATION
AB Age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa and other retinal disorders are the main causes of visual impairment worldwide. In the past, these retinal diseases, especially dry age-related macular degeneration, proliferative diabetic retinopathy and retinitis pigmentosa, were treated with traditional surgery and drugs. However, the effect was moderate. In recent years, researchers have used embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, olfactory ensheathing cells and other stem cells to conduct experiments and found that stem cells can inhibit inflammation, regulate immune response, secrete neurotrophic factors, and differentiate into retinal cells to replace and promote restoration of the damaged parts. These stem cells have the potential to treat retinal diseases. Whether it is in animal experiments or clinical trials, the increase in the number of retinal cells, maintenance of function and improvement of visual function all reflect the advanced of stem cells to treat retinal diseases, but its risk preserves the donor's hidden pathogenic genes, immune rejection and tumorigenicity. With the development of exosomes study, researchers have discovered that exosomes come from a wide range of sources and can be secreted by almost all types of cells. Using exosomes with stem cell to treat retinal diseases is more effective than using stem cells alone. This review article summarizes the recent advances in the application of olfactory ensheathing cells and stem cells/exosomes in the treatment of retinal disorders.
C1 [Yu, Yang; Li, Licheng; Hu, Jianmin] Fujian Med Univ, Fujian Prov Univ, Affiliated Hosp 2, Dept Ophthalmol,Engn Res Ctr Assist Technol Visua, Quanzhou 362000, Fujian, Peoples R China.
   [Lin, Shu] Fujian Med Univ, Affiliated Hosp 2, Ctr Neurol & Metab Res, Quanzhou 362000, Fujian, Peoples R China.
   [Lin, Shu] Garvan Inst Med Res, Diabet & Metab Div, 384 Victoria St, Sydney, NSW 2010, Australia.
   [Hu, Jianmin] Fujian Med Univ, Sch Med Technol & Engn, Fuzhou 350004, Fujian, Peoples R China.
C3 Fujian Medical University; Fuzhou University; Fujian Medical University;
   Garvan Institute of Medical Research; Fujian Medical University
RP Hu, JM (通讯作者)，Fujian Med Univ, Fujian Prov Univ, Affiliated Hosp 2, Dept Ophthalmol,Engn Res Ctr Assist Technol Visua, Quanzhou 362000, Fujian, Peoples R China.; Lin, S (通讯作者)，Fujian Med Univ, Affiliated Hosp 2, Ctr Neurol & Metab Res, Quanzhou 362000, Fujian, Peoples R China.; Lin, S (通讯作者)，Garvan Inst Med Res, Diabet & Metab Div, 384 Victoria St, Sydney, NSW 2010, Australia.; Hu, JM (通讯作者)，Fujian Med Univ, Sch Med Technol & Engn, Fuzhou 350004, Fujian, Peoples R China.
EM shulin1956@126.com; doctorhjm@163.com
OI Li, Licheng/0000-0001-7195-3624; lin, shu/0000-0002-4239-2028
FU National Natural Science Foundation of China [81970791]; Science and
   Technology Bureau of Quanzhou [2020CT003]
FX This work was supported by National Natural Science Foundation of China
   (Grant Number 81970791), Science and Technology Bureau of Quanzhou
   (Grant Number 2020CT003).
CR Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08-0180
   Adackapara CA, 2008, RETINA-J RET VIT DIS, V28, P103, DOI 10.1097/IAE.0b013e31809862aa
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arrigo A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13071102
   Au E, 2003, GLIA, V41, P224, DOI 10.1002/glia.10160
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Ballios BG, 2015, STEM CELL REP, V4, P1031, DOI 10.1016/j.stemcr.2015.04.008
   Baranov PY, 2014, TISSUE ENG PT A, V20, P1465, DOI [10.1089/ten.tea.2013.0361, 10.1089/ten.TEA.2013.0361]
   Berson EL, 2018, JAMA OPHTHALMOL, V136, P490, DOI 10.1001/jamaophthalmol.2018.0590
   Bian BSJ, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1748931
   Boruch AV, 2001, GLIA, V33, P225, DOI 10.1002/1098-1136(200103)33:3<225::AID-GLIA1021>3.3.CO;2-P
   Bressler SB, 2018, RETINA-J RET VIT DIS, V38, P1896, DOI 10.1097/IAE.0000000000002302
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buckley Kathleen, 2011, Insight, V36, P10
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chao JR, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.4
   Chen SY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0846-9
   Chen XJ, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.12.14
   Chen XJ, 2020, MOL THER-NUCL ACIDS, V19, P339, DOI 10.1016/j.omtn.2019.11.016
   Chou RH, 2014, CELL TRANSPLANT, V23, P567, DOI 10.3727/096368914X678508
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   CUMMINGS DM, 1995, DEV BRAIN RES, V88, P148, DOI 10.1016/0165-3806(95)00091-Q
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Dinculescu Astra, 2021, Int Ophthalmol Clin, V61, P109, DOI 10.1097/IIO.0000000000000378
   Dinculescu A, 2014, ADV EXP MED BIOL, V801, P711, DOI 10.1007/978-1-4614-3209-8_89
   Du SW, 2022, TRENDS NEUROSCI, V45, P78, DOI 10.1016/j.tins.2021.10.008
   Feit-Leichman RA, 2005, INVEST OPHTH VIS SCI, V46, P4281, DOI 10.1167/iovs.04-1361
   Ferrington DA, 2021, ADV EXP MED BIOL, V1256, P237, DOI 10.1007/978-3-030-66014-7_10
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Fujiwara K, 2017, INVEST OPHTH VIS SCI, V58, P2534, DOI 10.1167/iovs.17-21612
   Gong LH, 2008, CLIN EXP OPHTHALMOL, V36, P666, DOI 10.1111/j.1442-9071.2008.01857.x
   Gonzalez-Cordero A, 2018, HUM GENE THER, V29, P1124, DOI 10.1089/hum.2018.027
   Gumerson JD, 2022, GENE THER, V29, P81, DOI 10.1038/s41434-021-00258-6
   He GH, 2018, INT J OPHTHALMOL-CHI, V11, P559, DOI 10.18240/ijo.2018.04.04
   He XY, 2021, STEM CELL REP, V16, P1805, DOI 10.1016/j.stemcr.2021.06.002
   Helfenstein T, 2011, INT J EXP PATHOL, V92, P40, DOI 10.1111/j.1365-2613.2010.00753.x
   Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694
   Huo SJ, 2012, CURR EYE RES, V37, P749, DOI 10.3109/02713683.2012.697972
   Huo SJ, 2011, BRAIN RES, V1382, P238, DOI 10.1016/j.brainres.2010.12.079
   Jiang Q, 2020, J CLIN INVEST, V130, P3833, DOI 10.1172/JCI123353
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kalloniatis M, 2016, EXP EYE RES, V150, P106, DOI 10.1016/j.exer.2015.10.019
   Ke YF, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02034-6
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kern TS, 2010, MOL VIS, V16, P1629
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Koster C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137234
   Kumar S, 2010, EXP EYE RES, V91, P530, DOI 10.1016/j.exer.2010.07.010
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Li BN, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1368-9
   Li JY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.737242
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Li Y, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107714
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lingam S, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02539-8
   Liu Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0661-8
   Liu ZP, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02395-6
   Lo Sicco C, 2017, STEM CELL TRANSL MED, V6, P1018, DOI 10.1002/sctm.16-0363
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Luthy K, 2019, BRAIN, V142, P2319, DOI 10.1093/brain/awz175
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Ma MM, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2019.107899
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1
   Martinez B, 2021, NEURAL REGEN RES, V16, P621, DOI 10.4103/1673-5374.295271
   Massengill Michael T, 2021, Int Ophthalmol Clin, V61, P79, DOI 10.1097/IIO.0000000000000383
   Mathew B, 2019, BIOMATERIALS, V197, P146, DOI 10.1016/j.biomaterials.2019.01.016
   Mead B, 2018, INVEST OPHTH VIS SCI, V59, P5473, DOI 10.1167/iovs.18-25310
   Mead B, 2017, STEM CELL TRANSL MED, V6, P1273, DOI 10.1002/sctm.16-0428
   Mead B, 2016, CYTOTHERAPY, V18, P487, DOI 10.1016/j.jcyt.2015.12.002
   Mellough CB, 2012, STEM CELLS, V30, P673, DOI 10.1002/stem.1037
   Michalakis S, 2014, ADV EXP MED BIOL, V801, P733, DOI 10.1007/978-1-4614-3209-8_92
   Michelet F, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-1568-3
   Miki T, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13003
   Minkelyte K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051186
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moisseiev E, 2017, CURR EYE RES, V42, P1358, DOI 10.1080/02713683.2017.1319491
   Mookherjee S, 2015, HUM MOL GENET, V24, P6446, DOI 10.1093/hmg/ddv354
   Murrell W, 2005, DEV DYNAM, V233, P496, DOI 10.1002/dvdy.20360
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716
   Olivares AM, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0913-0
   Olvera-Montano O, 2019, DRUG DES DEV THER, V13, P3813, DOI 10.2147/DDDT.S219350
   Ong SS, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122078
   Ortiz-Virumbrales M, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01975-2
   Pan DY, 2019, J CHEM NEUROANAT, V96, P134, DOI 10.1016/j.jchemneu.2019.01.006
   Panni P, 2013, NEUROSCI LETT, V539, P65, DOI 10.1016/j.neulet.2013.01.052
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Peng BY, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/7806435
   Peng YQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194004
   Qiu C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207730
   Qiu G, 2006, EXP EYE RES, V83, P141, DOI 10.1016/j.exer.2005.11.014
   Radtke C, 2009, BRAIN RES, V1254, P10, DOI 10.1016/j.brainres.2008.11.036
   RAMONCUETO A, 1993, EUR J NEUROSCI, V5, P1172, DOI 10.1111/j.1460-9568.1993.tb00971.x
   Reshamwala R, 2020, NEURAL REGEN RES, V15, P2016, DOI 10.4103/1673-5374.282218
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Safwat A, 2018, J Circ Biomark, V7, p1849454418807827, DOI 10.1177/1849454418807827
   Sakami S, 2014, HUM MOL GENET, V23, P1723, DOI 10.1093/hmg/ddt561
   Sancho-Pelluz J, 2019, CELL MOL LIFE SCI, V76, P3657, DOI 10.1007/s00018-019-03090-9
   Scalinci SZ, 2011, CLIN OPHTHALMOL, V5, P691, DOI 10.2147/OPTH.S21161
   Schmack I, 2009, MOL VIS, V15, P146
   Seyedrazizadeh SZ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01702-x
   Shaw LC, 2011, CURR DIABETES REP, V11, P265, DOI 10.1007/s11892-011-0197-8
   Sherpa RD, 2021, ANIM MODEL EXP MED, V4, P189, DOI 10.1002/ame2.12177
   Shi XZ, 2010, BRAIN RES, V1317, P257, DOI 10.1016/j.brainres.2009.12.061
   Shibuya S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073542
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Straub LG, 2019, DIABETOLOGIA, V62, P2094, DOI 10.1007/s00125-019-4937-7
   Strom SC, 2016, HUM IMMUNOL, V77, P734, DOI 10.1016/j.humimm.2016.07.002
   Stronks HC, 2014, EXPERT REV MED DEVIC, V11, P23, DOI 10.1586/17434440.2014.862494
   Su ZD, 2013, GLIA, V61, P490, DOI 10.1002/glia.22450
   Sun LF, 2021, ADV BIOL-GER, V5, DOI 10.1002/adbi.202100906
   Sun LF, 2020, CLIN EXP OPHTHALMOL, V48, P1085, DOI 10.1111/ceo.13806
   Teare KA, 2003, NEUROREPORT, V14, P2171, DOI 10.1097/00001756-200312020-00008
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Triolo G, 2013, OPHTHALMIC RES, V50, P160, DOI 10.1159/000351681
   Ubink R, 2000, J COMP NEUROL, V423, P13, DOI 10.1002/1096-9861(20000717)423:1<13::AID-CNE2>3.0.CO;2-P
   Vila N, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0592-2
   Wang YH, 2020, J FR OPHTALMOL, V43, P718, DOI 10.1016/j.jfo.2020.02.003
   Wang YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02955-3
   Wang ZS, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.921184
   Winkler PA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040882
   Woodhall E, 2001, MOL BRAIN RES, V88, P203, DOI 10.1016/S0169-328X(01)00044-4
   Wu KC, 2019, INVEST OPHTH VIS SCI, V60, P1265, DOI 10.1167/iovs.18-24166
   Wu MM, 2010, CELL TRANSPLANT, V19, P159, DOI 10.3727/096368910X492625
   Xiang L, 2017, P NATL ACAD SCI USA, V114, P6376, DOI 10.1073/pnas.1618757114
   Xie J, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00341
   Xie J, 2017, CELL TRANSPLANT, V26, P967, DOI 10.3727/096368917X694994
   Xue LY, 2017, ONCOTARGET, V8, P93087, DOI 10.18632/oncotarget.21857
   Yang PJ, 2018, ACTA PHARMACOL SIN, V39, P1305, DOI 10.1038/aps.2018.22
   Yin DP, 2016, NEURAL REGEN RES, V11, P1006, DOI 10.4103/1673-5374.184505
   Yoshizawa K, 2012, J TOXICOL PATHOL, V25, P27, DOI 10.1293/tox.25.27
   Yu B, 2016, SCI REP-UK, V6, DOI 10.1038/srep34562
   Zhai W, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00052
   Zhang CJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.12
   Zhang W, 2019, INVEST OPHTH VIS SCI, V60, P294, DOI 10.1167/iovs.18-25617
   Zhong H, 2015, GENE THER, V22, P619, DOI 10.1038/gt.2015.42
   Ziegler MD, 2011, EXP NEUROL, V229, P109, DOI 10.1016/j.expneurol.2011.01.007
NR 142
TC 1
Z9 1
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JAN 10
PY 2022
VL 13
IS 1
AR 11
DI 10.1186/s13287-021-02685-z
PG 14
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA YE3NK
UT WOS:000741034600005
PM 35012635
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Li, Y
   Zou, X
   Gao, J
   Cao, K
   Feng, ZH
   Liu, JK
AF Li, Yuan
   Zou, Xuan
   Gao, Jing
   Cao, Ke
   Feng, Zhihui
   Liu, Jiankang
TI APR3 modulates oxidative stress and mitochondrial function in ARPE-19
   cells
SO FASEB JOURNAL
LA English
DT Article
DE phase II enzymes; nuclear factor (erythroid-derived 2)-like 2;
   age-related macular degeneration; apoptosis
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; MOLECULAR-MECHANISMS;
   ANTIOXIDANT RESPONSE; TRANSCRIPTION FACTOR; GLUTATHIONE GSH; NRF2; RPE;
   DEPLETION; DYSFUNCTION
AB Impairment of retinal pigment epithelial (RPE) cells is considered a key contributor to the development of age-related macular degeneration. Apoptosis-related protein 3 (APR3) was recently discovered after treatment with all-trans retinoic acid, a pivotal molecule in RPE cells. However, the function of APR3 remains poorly understood. In the present study, we found that APR3 could interact with nuclear factor (erythroid-derived 2)-like 2, which is a regulator of phase II enzymes, and that knockdown of APR3 promoted nuclear factor (erythroid-derived 2)-like 2 nuclear translocation and activated expression of phase II enzymes, which was accompanied by improved redox status and mitochondrial activity. Overexpression of APR3 revealed its mitochondrial localization and induced a robust production of reactive oxygen species that was accompanied by impaired mitochondrial oxygen consumption, complex activity, and lower ATP content, resulting in significant changes in mitochondrial structure, which may contribute to cell apoptosis. High doses of all-trans retinoic acid treatment were found to significantly induce APR3 expression, increase reactive oxygen species levels, and decrease ATP content, which were abolished by knockdown of APR3. These results indicate that APR3 plays a vital role in regulating redox status and mitochondrial activity and thus suggest APR3 might be a potential novel target for study of treatment of age-related macular degeneration.Li, Y., Zou, X., Gao, J., Cao, K., Feng, Z., Liu, J. APR3 modulates oxidative stress and mitochondrial function in ARPE-19 cells.
C1 [Li, Yuan; Gao, Jing; Cao, Ke; Feng, Zhihui; Liu, Jiankang] Xi An Jiao Tong Univ, Ctr Mitochondrial Biol & Med, Key Lab Biomed Informat Engn, Minist Educ,Sch Life Sci & Technol, Xian, Shaanxi, Peoples R China.
   [Li, Yuan; Gao, Jing; Cao, Ke; Feng, Zhihui; Liu, Jiankang] Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian, Shaanxi, Peoples R China.
   [Zou, Xuan] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; University of
   Texas System; University of Texas Southwestern Medical Center Dallas
RP Feng, ZH; Liu, JK (通讯作者)，Xi An Jiao Tong Univ, 28 West Xianning Rd, Xian 710049, Shaanxi, Peoples R China.
EM zhfeng@mail.xjtu.edu.cn; j.liu@mail.xjtu.edu.cn
RI Zou, Xuan/A-6452-2015; Liu, Jiankang/A-1610-2011; Feng,
   Zhihui/E-7408-2011
OI Feng, Zhihui/0000-0002-2448-6565
FU National Basic Research Program [2015CB553602, 2014CB548200]; National
   Natural Science Foundation of China [81571050, 31570777, 91439113]
FX The authors thank X. Wang (School of Life Science and Technology, Xi'an
   Jiaotong University) for his technical support for immunofluorescence
   staining. This study was supported by the National Basic Research
   Program (2015CB553602, 2014CB548200) and the National Natural Science
   Foundation of China (81571050, 31570777, 91439113). The authors declare
   no conflicts of interest.
CR Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071
   Beard KM, 2003, MOL CELL BIOCHEM, V252, P331, DOI 10.1023/A:1025544309616
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Botta D, 2008, DRUG METAB REV, V40, P465, DOI [10.1080/03602530802186587, 10.1080/03602530802186587 ]
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Carreno H, 2013, NEUROTOXICOL TERATOL, V40, P35, DOI 10.1016/j.ntt.2013.06.001
   Chang YC, 2016, J PHARMACOL SCI, V132, P262, DOI 10.1016/j.jphs.2016.11.002
   Cvekl A, 2009, EXP EYE RES, V89, P280, DOI 10.1016/j.exer.2009.04.012
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dickman ED, 1997, DEVELOPMENT, V124, P3111
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Han S, 2016, MOL MED REP, V13, P3121, DOI 10.3892/mmr.2016.4926
   Hao JJ, 2010, J NUTR BIOCHEM, V21, P634, DOI 10.1016/j.jnutbio.2009.03.012
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   Li WG, 2009, MOL CARCINOGEN, V48, P91, DOI 10.1002/mc.20465
   Li X, 2008, FREE RADICAL BIO MED, V44, P1465, DOI 10.1016/j.freeradbiomed.2008.01.004
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   SASTRE J, 1989, LIFE SCI, V45, P183, DOI 10.1016/0024-3205(89)90293-2
   SMAALAND R, 1992, BRIT J CANCER, V66, P39, DOI 10.1038/bjc.1992.213
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Tokarz P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060898
   Townsend DM, 2003, BIOMED PHARMACOTHER, V57, P145, DOI 10.1016/S0753-3322(03)00043-X
   Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960
   Wang HB, 2016, MOL VIS, V22, P189
   Wang XH, 2014, NAT COMMUN, V5, P1, DOI 10.1038/ncomms3957
   White CC, 2003, ANAL BIOCHEM, V318, P175, DOI 10.1016/S0003-2697(03)00143-X
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zeevalk GD, 2007, EXP NEUROL, V203, P512, DOI 10.1016/j.expneurol.2006.09.004
   Zhao LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124978
   Zhu F, 2000, BIOTECHNIQUES, V29, P310, DOI 10.2144/00292st06
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
   Zou X, 2011, FEBS LETT, V585, P2410, DOI 10.1016/j.febslet.2011.06.024
NR 47
TC 1
Z9 1
U1 0
U2 24
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2018
VL 32
IS 11
BP 5851
EP 5861
DI 10.1096/fj.201800001RR
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA GW7TC
UT WOS:000447172000008
PM 29792731
OA Bronze
DA 2022-11-30
ER

PT J
AU Joachim, N
   Mitchell, P
   Kifley, A
   Rochtchina, E
   Hong, T
   Wang, JJ
AF Joachim, Nichole
   Mitchell, Paul
   Kifley, Annette
   Rochtchina, Elena
   Hong, Thomas
   Wang, Jie Jin
TI Incidence and Progression of Geographic Atrophy Observations from a
   Population-based Cohort
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; BLUE MOUNTAINS EYE; BEAVER DAM EYE; LONG-TERM
   INCIDENCE; MACULAR DEGENERATION; RISK-FACTORS; 10-YEAR INCIDENCE; 5-YEAR
   INCIDENCE; INFLAMMATORY MARKERS; VISUAL IMPAIRMENT
AB Purpose: To examine early age-related macular degeneration (AMD) lesion characteristics and risk factors associated with the long-term development and progression of geographic atrophy (GA).
   Design: Population-based cohort.
   Participants: Of 3654 participants aged >= 49 years in the Blue Mountains Eye Study, 75.8%, 76.7%, and 56.1% of survivors attended the 5-, 10-, and 15-year follow-up examinations, respectively.
   Methods: Retinal photographs were taken at each visit. Incident GA was confirmed using a side-by-side grading method. Computer planimetry was used to measure the area involved by GA. Fast and slow/normal progression rates were defined as GA area enlargement by >= 2 and <2 mm(2)/year, respectively. Incident GA was estimated using the Kaplan-Meier product-limit method. Early AMD lesion characteristics were assessed for association with GA incidence using eye-specific data and generalized estimating equation models adjusting for age, current smoking, and presence of risk alleles of the complement factor H (CFH) or age-related maculopathy susceptibility 2 (ARMS2) genes, genotyped or imputed using genome-wide scan data.
   Main Outcome Measures: Incidence and progression of GA.
   Results: By excluding 41 subjects with GA at baseline, of 2503 participants at risk of GA, incident pure GA (without coexisting neovascular AMD lesions) was confirmed in 57 participants, with a 15-year incidence of 3.6%. Baseline early AMD lesion characteristics associated with GA incidence included drusen type (soft indistinct: odds ratio [OR], 59.0; 95% confidence interval [CI], 20.4-171.0; reticular drusen: OR, 13.9; 95% CI, 4.0-47.6); drusen location within a 500-mm radius of the fovea (OR, 15.1; 95% CI, 7.4-30.8); drusen area greater than 375 mm in diameter (OR, 10.1; 95% CI, 4.0-25.6); presence of retinal pigment epithelial depigmentation (OR, 9.0; 95% CI, 4.1-19.8); or hyperpigmentation (OR, 12.0; 95% CI, 6.1-23.5), referenced to subjects with no or hard drusen only. Fast progression was more frequent among current smokers at baseline, subjects with the CFH or ARMS2 risk genotypes, and pseudophakic eyes.
   Conclusions: Early AMD lesion characteristics (type, location, area involved) were strongly associated with higher long-term risk of developing GA independent of age, smoking, and AMD genetic susceptibility from the CFH or ARMS2 genes. Known AMD risk factors also were more frequently present among quickly progressing GA cases.
C1 [Joachim, Nichole; Mitchell, Paul; Kifley, Annette; Rochtchina, Elena; Hong, Thomas; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Joachim, Nichole; Mitchell, Paul; Kifley, Annette; Rochtchina, Elena; Hong, Thomas; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Centre for Eye Research Australia; University of
   Melbourne
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
FU National Health and Medical Research Council, Australia [974159, 211069,
   457349]
FX Supported by the National Health and Medical Research Council, Australia
   (Grants 974159, 211069, 457349). The National Health and Medical
   Research Council had no role in the design or conduct of this research.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 41
TC 44
Z9 45
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2013
VL 120
IS 10
BP 2042
EP 2050
DI 10.1016/j.ophtha.2013.03.029
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 227CQ
UT WOS:000325086400021
PM 23706948
DA 2022-11-30
ER

PT J
AU Lee, JH
   Kong, M
   Sohn, JH
   Cho, BJ
   Choi, KY
   Lee, SM
AF Lee, Jung-Hwa
   Kong, Mingui
   Sohn, Joon-Hong
   Cho, Beom-Jin
   Choi, Kee-Yong
   Lee, Sang-Mok
TI Analysis of Korean Retinal Specialists' Opinions on Implanting
   Diffractive Multifocal Intraocular Lenses in Eyes with Underlying
   Retinal Diseases
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE cataract; multifocal intraocular lenses; retinal diseases; macular
   degeneration; diabetic retinopathy; guidelines; surveys and
   questionnaires
ID OPTICAL COHERENCE TOMOGRAPHY; CATARACT-SURGERY; IMPLANTATION;
   PRESBYOPIA; IMPACT
AB Multifocal intraocular lenses (MF-IOLs) are increasingly implanted as the need for good near- and intermediate-distance vision increases. Although retinal disease is known to be a relative contraindication for MF-IOL implantation, there are no detailed guidelines for MF-IOL implantation with respect to the type and severity of retinal diseases/statuses. In this study, because retinal diseases can affect the performance of MF-IOLs, we analyzed the opinions of 111 retinal specialists, who were members of the Korean Retina Society, on the implantation of diffractive MF-IOLs in eyes with 15 retinal diseases/statuses using a web-based survey. For each underlying condition, retinal specialists were asked to rate their approval regarding implantation of MF-IOLs on a scale from 1 (completely disapprove) to 7 (completely approve), under the assumption that there were no known contraindications except for a given retinal disease/status. As a result, retinal specialists disapproved MF-IOL implantation (median value of Likert score < 4) in the eyes with wet age-related macular degeneration, dry age-related macular degeneration with geographic atrophy, proliferative diabetic retinopathy, nonproliferative diabetic retinopathy with macular edema, previous macula-off retinal detachment, previous retinal vein occlusion, and epiretinal membrane, but the scores varied by disease/status. The factors that affected the specialists' opinions were the type of practice and the frequency of MF-IOL implantation (p = 0.013 and p = 0.021, respectively; one-way ANOVA).
C1 [Lee, Jung-Hwa; Kong, Mingui; Sohn, Joon-Hong; Cho, Beom-Jin; Choi, Kee-Yong; Lee, Sang-Mok] Han Gil Eye Hosp, Dept Ophthalmol, 35 Bupyeong Daero, Incheon 21388, South Korea.
   [Kong, Mingui; Cho, Beom-Jin; Lee, Sang-Mok] Catholic Kwandong Univ, Dept Ophthalmol, Coll Med, 24 Beomil Ro 579 Beon Gil, Kangnung 25601, South Korea.
C3 Catholic Kwandong University
RP Lee, SM (通讯作者)，Han Gil Eye Hosp, Dept Ophthalmol, 35 Bupyeong Daero, Incheon 21388, South Korea.; Lee, SM (通讯作者)，Catholic Kwandong Univ, Dept Ophthalmol, Coll Med, 24 Beomil Ro 579 Beon Gil, Kangnung 25601, South Korea.
EM bibacoomon@naver.com; eyedockong@gmail.com; jhsohn19@nate.com;
   chobjn@empal.com; cky104@empal.com; lsm10003@gmail.com
OI Lee, Sang-Mok/0000-0002-9018-8216
FU National Research Foundation (NRF) of Korea [NRF-2017R1D1A1B03031577]
FX The authors appreciate the members of the Korean Retina Society, who
   enthusiastically participated in this survey, and former President Won
   Ki Lee, for encouraging cooperation among members. This research was
   supported by a research grant (NRF-2017R1D1A1B03031577 to S.-M.L.) from
   the National Research Foundation (NRF) of Korea.
CR Ahmad BU, 2014, RETINA-J RET VIT DIS, V34, P1046, DOI 10.1097/IAE.0000000000000237
   Alio JL, 2017, SURV OPHTHALMOL, V62, P611, DOI 10.1016/j.survophthal.2017.03.005
   Berdahl J, 2020, CLIN OPHTHALMOL, V14, P3439, DOI 10.2147/OPTH.S269597
   Braga-Mele R, 2014, J CATARACT REFR SURG, V40, P313, DOI 10.1016/j.jcrs.2013.12.011
   Chen TY, 2016, BRIT J OPHTHALMOL, V100, P1530, DOI 10.1136/bjophthalmol-2015-307135
   Chung Jin Kwon, 2019, Korean J Ophthalmol, V33, P451, DOI 10.3341/kjo.2019.0064
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   de Vries NE, 2013, J CATARACT REFR SURG, V39, P268, DOI 10.1016/j.jcrs.2012.12.002
   Dias-Santos A, 2015, INT OPHTHALMOL, V35, P43, DOI 10.1007/s10792-014-0016-8
   Farid M, 2014, AM J OPHTHALMOL, V158, P227, DOI 10.1016/j.ajo.2014.04.017
   Grzybowski A, 2020, GRAEF ARCH CLIN EXP, V258, P805, DOI 10.1007/s00417-020-04603-0
   Hadayer A, 2017, INT J OPHTHALMOL-CHI, V10, P1008, DOI 10.18240/ijo.2017.06.27
   Inoue M, 2009, J CATARACT REFR SURG, V35, P1239, DOI 10.1016/j.jcrs.2009.04.016
   Kawamura R, 2008, J CATARACT REFR SURG, V34, P1048, DOI 10.1016/j.jcrs.2008.01.031
   Klein BR, 2016, J CATARACT REFR SURG, V42, P537, DOI 10.1016/j.jcrs.2016.01.036
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Lee JY, 2021, RETINA-J RET VIT DIS, V41, P2491, DOI 10.1097/IAE.0000000000003255
   Logothetis HD, 2019, EYE, V33, P1635, DOI 10.1038/s41433-019-0460-9
   Montes-Mico R, 2004, OPHTHALMOLOGY, V111, P85, DOI 10.1016/S0161-6420(03)00862-5
   Pham TQ, 2004, CLIN EXP OPHTHALMOL, V32, P383, DOI 10.1111/j.1442-9071.2004.00842.x
   Rementeria-Capelo LA, 2021, J GLAUCOMA, V30, P300, DOI 10.1097/IJG.0000000000001743
   Riley AF, 2002, BRIT J OPHTHALMOL, V86, P185, DOI 10.1136/bjo.86.2.185
   Tanabe H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72473-x
   Watanabe T, 2020, CLIN OPHTHALMOL, V14, P3279, DOI 10.2147/OPTH.S272341
   Yoshino M, 2010, CLIN OPHTHALMOL, V4, P467
NR 25
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2022
VL 11
IS 7
AR 1836
DI 10.3390/jcm11071836
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0M1XD
UT WOS:000781954000001
PM 35407444
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Dithmer, M
   Fuchs, S
   Shi, Y
   Schmidt, H
   Richert, E
   Roider, J
   Klettner, A
AF Dithmer, Michaela
   Fuchs, Sabine
   Shi, Yang
   Schmidt, Harald
   Richert, Elisabeth
   Roider, Johann
   Klettner, Alexa
TI Fucoidan Reduces Secretion and Expression of Vascular Endothelial Growth
   Factor in the Retinal Pigment Epithelium and Reduces Angiogenesis In
   Vitro
SO PLOS ONE
LA English
DT Article
ID HUMAN PERIPHERAL-BLOOD; MACULAR DEGENERATION; CELLS; PHAGOCYTOSIS;
   ACTIVATION; MECHANISMS; INGESTION; APOPTOSIS; ANTITUMOR; SURVIVAL
AB Fucoidan is a polysaccharide isolated from brown algae which is of current interest for anti-tumor therapy. In this study, we investigated the effect of fucoidan on the retinal pigment epithelium (RPE), looking at physiology, vascular endothelial growth factor (VEGF) secretion, and angiogenesis, thus investigating a potential use of fucoidan for the treatment of exudative age-related macular degeneration. For this study, human RPE cell line ARPE-19 and primary porcine RPE cells were used, as well as RPE/choroid perfusion organ cultures. The effect of fucoidan on RPE cells was investigated with methyl thiazolyl tetrazolium - assay, trypan blue exclusion assay, phagocytosis assay and a wound healing assay. VEGF expression was evaluated in immunocytochemistry and Western blot, VEGF secretion was evaluated in ELISA. The effect of fucoidan on angiogenesis was tested in a Matrigel assay using calcein-AM vital staining, evaluated by confocal laser scanning microcopy and quantitative image analysis. Fucoidan displays no toxicity and does not diminish proliferation or phagocytosis, but reduces wound healing in RPE cells. Fucoidan decreases VEGF secretion in RPE/choroid explants and RPE cells. Furthermore, it diminishes VEGF expression in RPE cells even when co-applied with bevacizumab. Furthermore, fucoidan reduces RPE-supernatant- and VEGF-induced angiogenesis of peripheral endothelial cells. In conclusion, fucoidan is a non-toxic agent that reduces VEGF expression and angiogenesis in vitro and may be of interest for further studies as a potential therapy against exudative age-related macular degeneration.
C1 [Dithmer, Michaela; Richert, Elisabeth; Roider, Johann; Klettner, Alexa] Univ Kiel, Dept Ophthalmol, Univ Med Ctr, Kiel, Germany.
   [Fuchs, Sabine; Shi, Yang] Univ Kiel, Univ Med Ctr, Kiel, Germany.
   [Schmidt, Harald] MetaPhysiol, Essenheim, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，Univ Kiel, Dept Ophthalmol, Univ Med Ctr, Kiel, Germany.
EM aklettner@auge.uni-kiel.de
RI Klettner, Alexa Karina/M-8344-2018
OI Klettner, Alexa/0000-0002-2709-1059
FU DFG [KL2425]; Hermann Wacker Fond
FX This study has been partly supported by a DFG research grand (KL2425)
   and the Hermann Wacker Fond. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abe S, 2013, J FOOD SCI, V78, pT648, DOI 10.1111/j.1750-3841.2012.02966.x
   Aisa Y, 2005, AM J HEMATOL, V78, P7, DOI 10.1002/ajh.20182
   Araya N, 2011, ANTIVIR THER, V16, P89, DOI 10.3851/IMP1699
   Azuma K, 2012, MAR DRUGS, V10, P2337, DOI 10.3390/md10102337
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Cai H, 2006, MOL VIS, V12, P1
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Cumashi A, 2007, GLYCOBIOLOGY, V17, P541, DOI 10.1093/glycob/cwm014
   Fitton JH, 2011, MAR DRUGS, V9, P1731, DOI 10.3390/md9101731
   Fuchs S, 2007, TISSUE ENG, V13, P2577, DOI 10.1089/ten.2007.0022
   Fuchs S, 2006, BIOMATERIALS, V27, P5399, DOI 10.1016/j.biomaterials.2006.06.015
   Fuchs S, 2009, BIOMATERIALS, V30, P1329, DOI 10.1016/j.biomaterials.2008.11.028
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hodge W, 2010, CAN J OPHTHALMOL, V45, P223, DOI 10.3129/i10-047
   Irhimeh MR, 2007, EXP HEMATOL, V35, P989, DOI 10.1016/j.exphem.2007.02.009
   Johnson JD, 2003, J LEUKOCYTE BIOL, V74, P810, DOI 10.1189/jlb.0303092
   Kim EJ, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-96
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2013, MOL VIS, V19, P281
   Klettner A, 2012, OXID STRESS APPL BAS, P277, DOI 10.1007/978-1-61779-606-7_13
   Klettner A, 2011, OPHTHALMIC RES, V46, P88, DOI 10.1159/000323271
   Klettner A, 2010, CUTAN OCUL TOXICOL, V29, P122, DOI 10.3109/15569521003745685
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Koyanagi S, 2003, BIOCHEM PHARMACOL, V65, P173, DOI 10.1016/S0006-2952(02)01478-8
   Li N, 2005, FOOD CHEM TOXICOL, V43, P421, DOI 10.1016/j.fct.2004.12.001
   Liu RM, 2005, ANTICANCER RES, V25, P2129
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Matou S, 2002, THROMB RES, V106, P213, DOI 10.1016/S0049-3848(02)00136-6
   Miller DW, 2003, OPHTHALMOLOGE, V100, P92, DOI 10.1007/s00347-002-0760-4
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Minuth WW, 1999, EXP NEPHROL, V7, P394
   Miura Y, 2010, OPHTHAL RES, V43, P122, DOI 10.1159/000252979
   Myers SP, 2010, BIOL-TARGETS THER, V4, P33
   Narazaki M, 2008, BLOOD, V111, P4126, DOI 10.1182/blood-2007-09-112474
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rasband W., 2015, IMAGEJ
   Riou D, 1996, ANTICANCER RES, V16, P1213
   de Souza MCR, 2007, J APPL PHYCOL, V19, P153, DOI 10.1007/s10811-006-9121-z
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tissot B, 2003, BBA-PROTEINS PROTEOM, V1651, P5, DOI 10.1016/S1570-9639(03)00230-9
   Wiencke AK, 2003, ACTA OPHTHALMOL SCAN, V81, P170, DOI 10.1034/j.1600-0420.2003.00030.x
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 52
TC 52
Z9 56
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2014
VL 9
IS 2
AR e89150
DI 10.1371/journal.pone.0089150
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AB3RA
UT WOS:000331706700128
PM 24558482
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Awh, CC
   Hawken, S
   Zanke, BW
AF Awh, Carl C.
   Hawken, Steven
   Zanke, Brent W.
TI Treatment Response to Antioxidants and Zinc Based on CFH and ARMS2
   Genetic Risk Allele Number in the Age-Related Eye Disease Study
SO OPHTHALMOLOGY
LA English
DT Article
ID HIGH-DOSE SUPPLEMENTATION; MACULAR DEGENERATION; CLINICAL-TRIAL;
   BETA-CAROTENE; VISION LOSS; VITAMIN-C; ASSOCIATION; VARIANT; MAP
AB Objective: To evaluate the impact of complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) risk alleles on the observed response to components of the Age-Related Eye Disease Study (AREDS) formulation.
   Design: Genetic and statistical subgroup analysis of a randomized, prospective clinical trial.
   Participants: White patients from the AREDS with category 3 or 4 age-related macular degeneration (AMD) with available DNA (n = 989).
   Methods: Four genotype groups based on CFH and ARMS2 risk allele number were defined. Progression to advanced AMD was analyzed by genotype and treatment using Cox proportionate hazards estimates and 7-year events.
   Main Outcome Measures: The effect of predefined genotype group on treatment-specific progression to advanced AMD.
   Results: Patients with 2 CFH risk alleles and no ARMS2 risk alleles progressed more with zinc-containing treatment compared with placebo, with a hazard ratio (HR) of 3.07 (P = 0.0196) for zinc and 2.73 (P = 0.0418) for AREDS formulation (AF). Seven-year treatment-specific progression rates were: placebo, 17.0%; zinc, 43.2% (P = 0.023); and AF, 40.2% (P = 0.039). Patients with 0 or 1 CFH risk alleles and 1 or 2 ARMS2 risk alleles benefited from zinc-containing treatment compared with placebo, with an HR of 0.514 for zinc (P = 0.012) and 0.569 for AF (P = 0.0254). Seven-year treatment-specific AMD progression rates were as follows: placebo, 43.3%; zinc, 25.2% (P = 0.020); and AF, 27.3% (P = 0.011). Zinc and AF treatment each interacted statistically with these 2 genotype groups under a Cox model, with P values of 0.000999 and 0.00366, respectively. For patients with 0 or 1 CFH risk alleles and no ARMS2 risk alleles, neither zinc-containing treatment altered progression compared with placebo, but treatment with antioxidants decreased progression (HR, 0.380; P = 0.034). Seven-year progression with placebo was 22.6% and with antioxidants was 9.17% (P = 0.033). For patients with 2 CFH risk alleles and 1 or 2 ARMS2 risk alleles, no treatment was better than placebo (48.4%).
   Conclusions: The benefit of the AREDS formulation seems the result of a favorable response by patients in only 1 genotype group, balanced by neutral or unfavorable responses in 3 genotype groups. (C) 2015 by the American Academy of Ophthalmology.
C1 [Awh, Carl C.] Tennessee Retina, PC, Nashville, TN 37203 USA.
   [Hawken, Steven; Zanke, Brent W.] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
   [Zanke, Brent W.] Univ Ottawa, Dept Epidemiol, Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
   [Zanke, Brent W.] Univ Ottawa, Div Hematol, Dept Med, Ottawa, ON, Canada.
   [Zanke, Brent W.] Arctic Grp Companies, Toronto, ON, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; Ottawa Hospital Research Institute; University of Ottawa
RP Awh, CC (通讯作者)，Tennessee Retina, PC, Centennial Profess Plaza,345 23rd Ave North, Nashville, TN 37203 USA.
EM carlawh@gmail.com
CR Age related eye disease study research group, 2001, ARCH OPHTHALMOL, V119, P1439
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Awh CC, 2014, OPHTHALMOLOGY
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lengyel I, 2008, EXPERT REV OPHTHALMO, V3, P1, DOI 10.1586/17469899.3.1.1
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
NR 20
TC 64
Z9 64
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2015
VL 122
IS 1
BP 162
EP 169
DI 10.1016/j.ophtha.2014.07.049
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX1XK
UT WOS:000346737000033
PM 25200399
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Yeo, I
   Li, X
   Mathur, R
   Lee, SY
   Chan, CM
   Wong, D
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Yeo, Ian
   Li, Xiang
   Mathur, Ranjana
   Lee, Shu Yen
   Chan, Choi Mun
   Wong, Doric
   Wong, Tien Yin
TI Argon Laser With and Without Anti-Vascular Endothelial Growth Factor
   Therapy for Extrafoveal Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; INTRAVITREAL BEVACIZUMAB; JAPANESE PATIENTS; CHINESE PATIENTS;
   CLINICOPATHOLOGICAL CORRELATION; RANIBIZUMAB; VERTEPORFIN;
   PHOTOCOAGULATION
AB PURPOSE: To describe the clinical characteristics and outcome of eyes with extrafoveal polypoidal choroidal vasculopathy (PCV) treated with argon laser.
   DESIGN: Prospective cohort, noninterventional study.
   METHODS: A prospective study of Asian patients with extrafoveal PCV, confirmed on indocyanine green angiography and treated with argon laser with and without anti-vascular endothelial growth factor (VEGF) therapy. Patients were followed-up over 12 months with visual, angiographic, and structural outcomes recorded.
   RESULTS: Of the 93 eyes with PCV at baseline, 33 eyes (35.5%) in 31 patients had extrafoveal involvement and were treated with argon laser. Foveal involvement with fluid or blood at baseline was apparent in 23 eyes (69.7%), despite the extrafoveal location of 1 or more polyps. Of these 33 eyes, 12 (36.4%) also received anti-VEGF injections (median, 2.5 injections) over the 12-month period. Two eyes received photodynamic therapy rescue during subsequent follow-up and were excluded for visual outcome analysis. In the remaining 31 eyes, mean visual acuity improved from 0.57 logarithm of the minimal angle of resolution (logMAR) units (range, 0.00 to 2.0 logMAR; standard deviation, 0.51 logMAR) at baseline to 0.39 logMAR (range, 0.00 to 2.0 logMAR; standard deviation, 0.43 logMAR) at month 12 (P = .01), with a mean gain in visual acuity of 9.0 letters at month 12. Stable or improved vision (defined as losing 5 letters or fewer) was achieved in 28 eyes (90.3%). Use of anti-VEGF was associated with significantly thicker central subfield at baseline (347.6 vs 258.1 mu m; P = .02) and resulted in similar vision and OCT results at month 3 and 12 compared with eyes that did not receive anti-VEGF.
   CONCLUSIONS: Argon laser treatment with selected use of anti-VEGF therapy achieves stable or improved visual outcome in most eyes with extrafoveal PCV, including eyes with fluid or blood affecting the fovea at presentation. (Am J Ophthalmol 2013;155:295-304. (c) 2013 by Elsevier Inc. All rights reserved.)
C1 [Cheung, Chui Ming Gemmy; Li, Xiang; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Li, Xiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Wong, Damon/0000-0003-4601-9121;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [NMRC/NIG/1003/2009]; Biomedical
   Research Council [10/1/35/19/671]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. Publication
   of this article was supported by National Medical Research Council Grant
   NMRC/NIG/1003/2009 and Biomedical Research Council Grant No.
   10/1/35/19/671. Involved in Design and conduct of study (C.M.G.C.,
   T.Y.W.); Collection (C.M.G.C., I.Y., R.M., S.Y.L., C.M.C., D.W.,
   T.Y.W.), management (C.M.G.C., T.Y.W.), analysis (C.M.G.C., X.L.), and
   interpretation (C.M.G.C., X.L., TYW) of data; and Preparation, review,
   and approval of manuscript (C.M.G.C., I.Y., R.M., S.Y.L., C.M.C., D.W.,
   T.Y.W.).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cheung CM, GRAEFES ARCH CLIN EX
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pantaleoni FB, 2007, ACTA OPHTHALMOL SCAN, V85, P456, DOI 10.1111/j.1600-0420.2006.00742.x
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 59
TC 24
Z9 24
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2013
VL 155
IS 2
BP 295
EP 304
DI 10.1016/j.ajo.2012.08.002
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 078YQ
UT WOS:000314137400013
PM 23111181
DA 2022-11-30
ER

PT J
AU Bohley, M
   Dillinger, AE
   Tamm, ER
   Goepferich, A
AF Bohley, Marilena
   Dillinger, Andrea E.
   Tamm, Ernst R.
   Goepferich, Achim
TI Targeted drug delivery to the retinal pigment epithelium: Untapped
   therapeutic potential for retinal diseases
SO DRUG DISCOVERY TODAY
LA English
DT Review
DE Retinal pigment epithelium; RPE; Retinal diseases; Retinopathy of
   prematurity; Diabetic retinopathy; Age-related macular degeneration;
   Targeted drug delivery; Nanotherapy
ID DIABETIC-RETINOPATHY; DNA NANOPARTICLES; GENE-EXPRESSION; BRUCHS
   MEMBRANE; GROWTH-FACTORS; RPE; EYE; SYSTEM; MECHANISMS; RECEPTORS
AB The retinal pigment epithelium (RPE) plays a crucial part in sight-threatening diseases. In this review, we shed light on the pivotal implication of the RPE in age-related macular degeneration, diabetic retinopathy and retinopa-thy of prematurity; and explain why a paradigm shift toward targeted RPE therapy is needed to efficiently fight these retinal diseases. We provide guidance for the devel-opment of RPE-specific nanotherapeutics by giving a comprehensive overview of the possibilities and challenges of drug delivery to the RPE and highlight successful nanotherapeutic approaches targeting the RPE.
C1 [Bohley, Marilena; Goepferich, Achim] Univ Regensburg, Dept Pharmaceut Technol, D-93053 Regensburg, Germany.
   [Dillinger, Andrea E.; Tamm, Ernst R.] Univ Regensburg, Dept Human Anat & Embryol, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Bohley, M (通讯作者)，Univ Regensburg, Dept Pharmaceut Technol, D-93053 Regensburg, Germany.
EM marilena.bohley@chemie.uni-regensburg.de
FU German Research Foundation (DFG) [GO 565/18-1]
FX Financial support from the German Research Foundation (DFG) , Grant
   Number GO 565/18-1, is gratefully acknowledged.
CR Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296
   Bhattacharya M, 2017, J CONTROL RELEASE, V251, P37, DOI 10.1016/j.jconrel.2017.02.013
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   BUNTMILAM AH, 1985, INVEST OPHTH VIS SCI, V26, P1377
   Caceres PS, 2020, CURR OPIN CELL BIOL, V62, P37, DOI 10.1016/j.ceb.2019.08.001
   Campochiaro PA, 1996, PROG RETIN EYE RES, V15, P547, DOI 10.1016/1350-9462(96)00012-2
   Cheloni R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022188
   Chen P, 2019, J CELL PHYSIOL, V234, P21915, DOI 10.1002/jcp.28755
   Chrzanowska M, 2018, INT J OPHTHALMOL-CHI, V11, P1856, DOI 10.18240/ijo.2018.11.19
   Couvreur P, 2013, ADV DRUG DELIVER REV, V65, P21, DOI 10.1016/j.addr.2012.04.010
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Delgado D, 2012, HUM GENE THER, V23, P345, DOI 10.1089/hum.2011.115
   Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Gan L, 2013, BIOMATERIALS, V34, P5978, DOI 10.1016/j.biomaterials.2013.04.035
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Giannaccini M, 2017, SCI REP-UK, V7, DOI 10.1038/srep43092
   Giannaccini M, 2014, INT J MOL SCI, V15, P1590, DOI 10.3390/ijms15011590
   Han ZC, 2014, ADV EXP MED BIOL, V801, P719, DOI 10.1007/978-1-4614-3209-8_90
   Hartnett ME, 2015, OPHTHALMOLOGY, V122, P200, DOI 10.1016/j.ophtha.2014.07.050
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Hennig R, 2015, J CONTROL RELEASE, V220, P265, DOI 10.1016/j.jconrel.2015.10.033
   Hernandez C, 2017, J ENDOCRINOL INVEST, V40, P925, DOI 10.1007/s40618-017-0648-4
   Himawan E, 2019, DRUG DISCOV TODAY, V24, P1637, DOI 10.1016/j.drudis.2019.03.004
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Huang D, 2018, BIOMATERIALS, V168, P10, DOI 10.1016/j.biomaterials.2018.03.034
   Huang XN, 2019, DRUG DISCOV TODAY, V24, P1510, DOI 10.1016/j.drudis.2019.05.005
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang JJ, 2021, FUND CLIN PHARMACOL, V35, P4, DOI 10.1111/fcp.12561
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kambhampati SP, 2021, J CONTROL RELEASE, V335, P527, DOI 10.1016/j.jconrel.2021.05.035
   Kambhampati SP, 2015, INVEST OPHTH VIS SCI, V56, P4413, DOI 10.1167/iovs.14-16250
   Kaur IP, 2014, J CONTROL RELEASE, V193, P100, DOI 10.1016/j.jconrel.2014.05.031
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kelley RA, 2018, INT J NANOMED, V13, P1361, DOI 10.2147/IJN.S157000
   Kickova E., 2021, PHARMACEUTICS, V14
   Kim HM, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010108
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim H, 2009, PHARM RES-DORDR, V26, P329, DOI 10.1007/s11095-008-9745-6
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Kim JH, 2011, BIOMATERIALS, V32, P1865, DOI 10.1016/j.biomaterials.2010.11.030
   Kim SJ, 2018, SURV OPHTHALMOL, V63, P618, DOI 10.1016/j.survophthal.2018.04.002
   King GL, 2000, NEW ENGL J MED, V342, P349, DOI 10.1056/NEJM200002033420511
   Koirala A, 2013, HUM MOL GENET, V22, P1632, DOI 10.1093/hmg/ddt013
   Kolar GR, 2017, J INTERN MED, V281, P25, DOI 10.1111/joim.12528
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Li QQ, 2021, INT J PHARMACEUT, V596, DOI 10.1016/j.ijpharm.2021.120226
   Li QQ, 2021, MOL PHARMACEUT, V18, P506, DOI 10.1021/acs.molpharmaceut.0c00224
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Lynch SK, 2017, VISION RES, V139, P101, DOI 10.1016/j.visres.2017.03.003
   Maharaj A. S., 2008, INVEST OPHTH VIS SCI, V49, P5836
   Maminishkis A, 2002, INVEST OPHTH VIS SCI, V43, P3555
   Nakanishi M, 2016, INVEST OPHTH VIS SCI, V57, P2213, DOI 10.1167/iovs.15-17934
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pavan B, 2018, DRUG DISCOV TODAY, V23, P1672, DOI 10.1016/j.drudis.2018.06.009
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Peynshaert K, 2019, CURR EYE RES, V44, P465, DOI 10.1080/02713683.2019.1565890
   Peynshaert K, 2018, ADV DRUG DELIVER REV, V126, P44, DOI 10.1016/j.addr.2017.09.007
   Puras G, 2013, EUR J PHARM BIOPHARM, V83, P131, DOI 10.1016/j.ejpb.2012.09.010
   Quinn GE, 2016, EYE BRAIN, V8, P31, DOI 10.2147/EB.S94436
   Ramsay E, 2019, EUR J PHARM BIOPHARM, V143, P18, DOI 10.1016/j.ejpb.2019.08.008
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Rezapour J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61706-8
   Rivera JC, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0943-1
   Ryals RC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241006
   Senanayake PD, 2006, EXP EYE RES, V83, P235, DOI 10.1016/j.exer.2005.10.034
   Singh R, 2020, NANOMED-NANOTECHNOL, V28, DOI 10.1016/j.nano.2020.102205
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stan RV, 2012, DEV CELL, V23, P1203, DOI 10.1016/j.devcel.2012.11.003
   Storm T, 2020, J CELL SCI, V133, DOI 10.1242/jcs.238279
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6
   Tavakoli S, 2020, J CONTROL RELEASE, V328, P952, DOI 10.1016/j.jconrel.2020.10.028
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tisi A, 2020, EXP EYE RES, V199, DOI 10.1016/j.exer.2020.108169
   Tisi A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071617
   Tram NK, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00199
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Vellonen KS, 2016, MOL PHARMACEUT, V13, P2906, DOI 10.1021/acs.molpharmaceut.5b00729
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Wei Y, 2009, MOL VIS, V15, P1243
   Wong LL, 2019, ADV EXP MED BIOL, V1185, P125, DOI 10.1007/978-3-030-27378-1_21
   World Health Organization, 2000, PROGR PREV BLINDN DE
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu QG, 2013, J CONTROL RELEASE, V167, P76, DOI 10.1016/j.jconrel.2013.01.018
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang Y, 2003, MOL VIS, V9, P465
   Zhu CN, 2002, INVEST OPHTH VIS SCI, V43, P3075
NR 112
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD SEP
PY 2022
VL 27
IS 9
BP 2497
EP 2509
DI 10.1016/j.drudis.2022.05.024
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 4X1GD
UT WOS:000860597600009
PM 35654389
DA 2022-11-30
ER

PT J
AU Kondo, N
   Honda, S
   Kuno, S
   Negi, A
AF Kondo, Naoshi
   Honda, Shigeru
   Kuno, Shin-ichi
   Negi, Akira
TI Coding Variant I62V in the Complement Factor H Gene Is Strongly
   Associated with Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; JAPANESE POPULATION; CHINESE PATIENTS;
   POLYMORPHISMS; CFH; HAPLOTYPE; HTRA1; RISK; SUSCEPTIBILITY; INCREASES
AB Purpose: To investigate whether variants in the complement factor H (CFH) gene are associated with polypoidal choroidal vasculopathy (PCV).
   Design: Cross-sectional study.
   Participants: A case-control group of 130 PCV subjects and 173 unrelated controls.
   Methods: We conducted an association analysis between CFH variants and PCV in a Japanese population, genotyping 12 tag single nucleotide polymorphisms (SNPs)-including rs3753394, rs800292 (I62V), and rs1061170 (Y402H)-that are highly representative of the common genetic variation in the CFH region. Genotyping was performed using TaqMan technology.
   Main Outcome Measures: Allele and haplotype frequencies of the CFH variants.
   Results: A highly significant association with PCV was observed across the CFH region. The strongest association was observed at I62V (P = 1.7 x 10(-7)). Six other SNPs (rs3753394, rs6680396, rs1410996, rs2284664, rs1329428, and rs1065489) also showed significant association (10(-3) < p < 10(-6)). These associations became nonsignificant after accounting for rs800292 in a conditional logistic regression analysis. A significant omnibus haplotype association was detected in the entire CFH region (omnibus P = 1.6 x 10(-5) at 7 degrees of freedom). Conditional haplotype-based likelihood ratio tests revealed that the significant omnibus haplotype association disappeared when it was estimated conditional on I62V (omnibus P = 0.20, 6 degrees of freedom, post-I62V dependency), whereas the omnibus haplotype association remained significant when it was estimated conditional on any SNP other than I62V. These findings indicate that multiple observed effects were caused by linkage disequilibrium with I62V, and that this variant fully accounts for the association signals observed at the set of SNPs examined at this locus.
   Conclusions: The present study provides evidence that the complement pathway plays a substantial role in the pathogenesis of PCV. The nonsynonymous variant I62V is a plausible candidate for a causal polymorphism leading to the development of PCV, given its potential for functional consequences on the CFH protein and our own statistical evidence.
   Financial Disclosure(s): The authors have to proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:304-310 (C) 2009 by the American Academy of Ophthalmology.
C1 [Kondo, Naoshi; Honda, Shigeru; Negi, Akira] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo 6500017, Japan.
   [Kuno, Shin-ichi] Fdn Biomed Res & Innovat, Transplantat Res Informat Ctr, Kobe, Hyogo, Japan.
   [Kuno, Shin-ichi] Kobe Univ, Grad Sch Med, Clin Genome Informat Ctr, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Institute for Biomedical Research & Innovation (IBRI);
   Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Organ Therapeut, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education, Science, and Culture, Tokyo, Japan [17591836]
FX Supported by a Grant-in Aid (C) 17591836 from the Ministry of Education,
   Science, and Culture, Tokyo, Japan. The funding organization had no role
   in the design or conduct of this research.
CR Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Okamoto H, 2006, MOL VIS, V12, P156
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Purcell S, 2007, BIOINFORMATICS, V23, P255, DOI 10.1093/bioinformatics/btl580
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 45
TC 66
Z9 73
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2009
VL 116
IS 2
BP 304
EP 310
DI 10.1016/j.ophtha.2008.11.011
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 403QW
UT WOS:000263098100021
PM 19187823
DA 2022-11-30
ER

PT J
AU Takahashi, J
AF Takahashi, Jun
TI Stem cells and regenerative medicine for neural repair
SO CURRENT OPINION IN BIOTECHNOLOGY
LA English
DT Review
ID DOPAMINE NEURONS; PRECLINICAL EFFICACY; ANALYSIS REVEALS;
   CLINICAL-TRIALS; TRANSPLANTATION; PROGENITORS; GENERATION; SAFETY;
   MODEL; TUMORIGENICITY
AB Clinical trials of cell-based therapies that use pluripotent stem cells (PSC) have already started for several neurological diseases including spinal cord injury and age-related macular degeneration. Regarding future PSC-based clinical trials for other neurological diseases, these trials have been instrumental at recognizing first, the difference between research cell lines and clinical cell lines of a stem cell product, second, the selection of an appropriate animal model for pre clinical study, third, criteria and the quality control of donor cells, and fourth, the mode of action of the grafts.
C1 [Takahashi, Jun] Kyoto Univ, Ctr iPS Cell Res & Applicat, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
C3 Kyoto University
RP Takahashi, J (通讯作者)，Kyoto Univ, Ctr iPS Cell Res & Applicat, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM jbtaka@cira.kyoto-u.ac.jp
FU Network Program for Realization of Regenerative Medicine from the Japan
   Agency for Medical Research and Development (AMED)
FX I thank Dr. Peter Karagiannis (CiRA) for critical reading of the
   manuscript. is supported by a grant from the Network Program for
   Realization of Regenerative Medicine from the Japan Agency for Medical
   Research and Development (AMED).
CR Amir H, 2017, STEM CELLS, V35, P872, DOI 10.1002/stem.2550
   Amps K, 2011, NAT BIOTECHNOL, V29, P1132, DOI 10.1038/nbt.2051
   Anderson AJ, 2017, STEM CELL REP, V8, P249, DOI 10.1016/j.stemcr.2016.12.018
   Assinck P, 2017, NAT NEUROSCI, V20, P637, DOI 10.1038/nn.4541
   Avery S, 2013, STEM CELL REP, V1, P379, DOI 10.1016/j.stemcr.2013.10.005
   Bar S, 2017, CELL REP, V19, P957, DOI 10.1016/j.celrep.2017.04.020
   Barker RA, 2015, NAT REV NEUROL, V11, P492, DOI 10.1038/nrneurol.2015.123
   Barker RA, 2013, LANCET NEUROL, V12, P84, DOI 10.1016/S1474-4422(12)70295-8
   Bye CR, 2015, P NATL ACAD SCI USA, V112, pE1946, DOI 10.1073/pnas.1501989112
   Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102
   Cyranoski D, 2017, NATURE, V546, P15, DOI 10.1038/546015a
   Doi D, 2014, STEM CELL REP, V2, P337, DOI 10.1016/j.stemcr.2014.01.013
   Doi D, 2012, STEM CELLS, V30, P935, DOI 10.1002/stem.1060
   Evans JR, 2012, PROG BRAIN RES, V200, P169, DOI 10.1016/B978-0-444-59575-1.00008-9
   Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121
   Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002
   Garitaonandia I, 2016, SCI REP-UK, V6, DOI 10.1038/srep34478
   Gonzalez R, 2016, CELL TRANSPLANT, V25, P1945, DOI 10.3727/096368916X691682
   Gonzalez R, 2015, CELL TRANSPLANT, V24, P681, DOI 10.3727/096368915X687769
   Gonzalez R, 2013, SCI REP-UK, V3, DOI 10.1038/srep01463
   Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805
   Grealish S, 2014, CELL STEM CELL, V15, P653, DOI 10.1016/j.stem.2014.09.017
   Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235
   Hooshmand MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005871
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kee N, 2017, CELL STEM CELL, V20, P29, DOI 10.1016/j.stem.2016.10.003
   Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005
   Kikuchi T, 2017, NATURE, V548, P592, DOI 10.1038/nature23664
   Kirkeby A, 2017, CELL STEM CELL, V20, P135, DOI 10.1016/j.stem.2016.09.004
   Kirkeby A, 2012, CELL REPORTS, V1, P703, DOI 10.1016/j.celrep.2012.04.009
   Kriks S, 2011, NATURE, V480, P547, DOI 10.1038/nature10648
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   La Manno G, 2016, CELL, V167, P566, DOI 10.1016/j.cell.2016.09.027
   Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Manley NC, 2017, STEM CELL TRANSL MED, V6, P1917, DOI 10.1002/sctm.17-0065
   Marsh SE, 2017, STEM CELL REP, V8, P235, DOI 10.1016/j.stemcr.2016.12.019
   Merkle FT, 2017, NATURE, V545, P229, DOI 10.1038/nature22312
   Morizane A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00926-5
   Nakagawa M, 2010, P NATL ACAD SCI USA, V107, P14152, DOI 10.1073/pnas.1009374107
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720
   Ono Y, 2007, DEVELOPMENT, V134, P3213, DOI 10.1242/dev.02879
   Politis M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000976
   Priest CA, 2015, REGEN MED, V10, P939, DOI 10.2217/rme.15.57
   Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Steinbeck JA, 2015, NAT BIOTECHNOL, V33, P204, DOI 10.1038/nbt.3124
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Xi JJ, 2012, STEM CELLS, V30, P1655, DOI 10.1002/stem.1152
   Yoshihara M, 2017, CELL REP, V21, P308, DOI 10.1016/j.celrep.2017.09.060
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 54
TC 26
Z9 28
U1 2
U2 17
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0958-1669
EI 1879-0429
J9 CURR OPIN BIOTECH
JI Curr. Opin. Biotechnol.
PD AUG
PY 2018
VL 52
BP 102
EP 108
DI 10.1016/j.copbio.2018.03.006
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA GQ9CL
UT WOS:000442063400015
PM 29621691
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Noolandi, J
   Peterman, MC
   Huie, P
   Lee, C
   Blumenkranz, MS
   Fishman, HA
AF Noolandi, J
   Peterman, MC
   Huie, P
   Lee, C
   Blumenkranz, MS
   Fishman, HA
TI Towards a neurotransmitter-based retinal prosthesis using an inkjet
   print-head
SO BIOMEDICAL MICRODEVICES
LA English
DT Article
DE retinal prosthesis; neurotransmitters; inkjet printing; age-related
   macular degeneration
ID CELLS; RELEASE; CALCIUM
AB Electronic chips that provide a patterned stimulus to cells in the retina may provide a viable treatment for age-related macular degeneration. A surrogate MEMS device, in the form of a print-head from a desktop printer, has been used to eject a pattern of neurotransmitters (bradykinin) onto living rat pheochromocytoma (PC12) cells. Fluorescent calcium imaging was used to measure the patterned stimulation of individual cells. The chemical stimulation of cells by directed microfluidic delivery may have applications in retinal prosthetic devices, and in other prosthetic implants in the nervous system.
C1 Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA.
   Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.
   Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Stanford University
RP Fishman, HA (通讯作者)，Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA.
EM hfishman@stanford.edu
RI Noolandi, Jaan/D-7450-2015
CR APPELL KC, 1989, BIOCHEM J, V263, P11, DOI 10.1042/bj2630011
   Bui JD, 1999, J NEUROSCI METH, V89, P9, DOI 10.1016/S0165-0270(99)00032-1
   Fink CC, 2000, BIOPHYS J, V79, P163, DOI 10.1016/S0006-3495(00)76281-3
   GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424
   Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730
   Humayun M S, 2001, Trans Am Ophthalmol Soc, V99, P271
   Kawase T, 2001, ADV MATER, V13, P1601, DOI 10.1002/1521-4095(200111)13:21<1601::AID-ADMA1601>3.0.CO;2-X
   Liu X, 1999, IEEE Trans Rehabil Eng, V7, P315, DOI 10.1109/86.788468
   Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P2073
   Peterman MC, 2003, INVEST OPHTH VIS SCI, V44, P3144, DOI 10.1167/iovs.02-1097
   Peterman MC, 2002, MATER RES SOC SYMP P, V729, P149
   Rizzo JF, 2001, OPHTHALMOLOGY, V108, P13, DOI 10.1016/S0161-6420(00)00430-9
   SCHOBER A, 1993, BIOTECHNIQUES, V15, P324
   Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123
   Stieglitz T, 1997, P ANN INT IEEE EMBS, V19, P2307, DOI 10.1109/IEMBS.1997.758825
   STIEGLITZ T, 1999, ANN INT C IEEE ENG M, V1, P474
   Vastag B, 2002, JAMA-J AM MED ASSOC, V288, P1833, DOI 10.1001/jama.288.15.1833
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
NR 18
TC 17
Z9 19
U1 1
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387-2176
EI 1572-8781
J9 BIOMED MICRODEVICES
JI Biomed. Microdevices
PD SEP
PY 2003
VL 5
IS 3
BP 195
EP 199
DI 10.1023/A:1025704124504
PG 5
WC Engineering, Biomedical; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Science & Technology - Other Topics
GA 722CR
UT WOS:000185358300003
DA 2022-11-30
ER

PT J
AU Zhan, ZY
   Sun, LM
   Jin, CJ
   Yang, Y
   Hu, ADN
   Tang, M
   Wang, ZR
   Ding, XY
AF Zhan, Zongyi
   Sun, Limei
   Jin, Chenjin
   Yang, Yu
   Hu, Andina
   Tang, Miao
   Wang, Zhirong
   Ding, Xiaoyan
TI Comparison between non-visualized polyps and visualized polyps on
   optical coherence tomography angiography in polypoidal choroidal
   vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Optical coherence tomography
   angiography; Non-visualized polyp; Visualized polyp
ID OCT ANGIOGRAPHY; DIAGNOSIS; EVEREST
AB Purpose To determine the underlying reasons for the non-visualization of polyps on en face optical coherence tomography angiography (OCTA) in patients with polypoidal choroidal vasculopathy (PCV). Methods A cross-sectional study of consecutive treatment-naive 30 eyes with active PCV was included. Results of fundus photography, fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), spectral domain optical coherence tomography (SD-OCT), and en face OCTA were analyzed. Results A total of 64 active polyps were found on FFA and ICGA in 30 eyes. On OCTA, 42/64 (65.6%) polyps were visualized, while 22/64 (34.4%) polyps were non-visualized. There were no significant differences in the size (P = 0.723) and filling time of polyps (P = 0.558) between the two groups. However, polypoidal lesions were less common in the non-visualized group (P < 0.001). The height of the polyps on SD-OCT was 243.95 +/- 114.24 mu m in the non-visualized group, which was higher than those (188.00 +/- 87.93 mu m) in the visualized group (P = 0.048). Moreover, more pulsatile polyps (72.7%) were found in the non-visualized group than those (2.4%) in the visualized group (P < 0.001). Four of the 22 polyps in the non-visualized group (18.2%) were located under a thick subretinal hemorrhage, and two of 22 invisible polyps (9.6%) located under and parallel to the retinal vessel in the inner layer of retina. Conclusions Our results revealed that the height of the polyps, and not the size and pulsation of the polyps, correlated with the visualization of the polyps on OCTA. Polyps that were pulsating in early ICGA were difficult to be visualized on OCTA, which is the most possible reason for the non-visualization. Coverage with thick subretinal hemorrhage or retina vessels was another reason for the non-visualization of the polyps in active PCV on OCTA.
C1 [Zhan, Zongyi; Sun, Limei; Jin, Chenjin; Yang, Yu; Hu, Andina; Tang, Miao; Wang, Zhirong; Ding, Xiaoyan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510000, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Ding, XY (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510000, Guangdong, Peoples R China.
EM dingziaoyan@gzzoc.com
OI Zhan, Zongyi/0000-0002-6621-1172
CR [Anonymous], 2017, B ENG GEOL ENV
   Bradley PD, 2016, INVEST OPHTH VIS SCI, V57, P626, DOI 10.1167/iovs.15-18034
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Fukuyama H, 2018, OPHTHALMOL RETINA, V2, P803, DOI 10.1016/j.oret.2017.11.016
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Puliafito CA, 2014, OSLI RETINA, V45, P360, DOI 10.3928/23258160-20140925-01
   Seong San, 2019, Korean J Ophthalmol, V33, P54, DOI 10.3341/kjo.2018.0048
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Srour M, 2016, DEV OPHTHALMOL, V56, P71, DOI 10.1159/000442781
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 2
Z9 2
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2019
VL 257
IS 11
BP 2349
EP 2356
DI 10.1007/s00417-019-04445-5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JI6YO
UT WOS:000493612800002
PM 31446460
DA 2022-11-30
ER

PT J
AU Liu, L
   Gao, SS
   Bailey, ST
   Huang, D
   Li, DW
   Jia, YL
AF Liu, Li
   Gao, Simon S.
   Bailey, Steven T.
   Huang, David
   Li, Dengwang
   Jia, Yali
TI Automated choroidal neovascularization detection algorithm for optical
   coherence tomography angiography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID AMPLITUDE-DECORRELATION ANGIOGRAPHY; MOTION-CORRECTION; HUMAN RETINA;
   PERFUSION
AB Optical coherence tomography angiography has recently been used to visualize choroidal neovascularization (CNV) in participants with age-related macular degeneration. Identification and quantification of CNV area is important clinically for disease assessment. An automated algorithm for CNV area detection is presented in this article. It relies on denoising and a saliency detection model to overcome issues such as projection artifacts and the heterogeneity of CNV. Qualitative and quantitative evaluations were performed on scans of 7 participants. Results from the algorithm agreed well with manual delineation of CNV area. (C)2015 Optical Society of America
C1 [Liu, Li; Gao, Simon S.; Bailey, Steven T.; Huang, David; Jia, Yali] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Liu, Li; Li, Dengwang] Shandong Normal Univ, Coll Phys & Elect, Jinan, Peoples R China.
C3 Oregon Health & Science University; Shandong Normal University
RP Liu, L (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
EM jiaya@ohsu.edu
OI Li, Dengwang/0000-0001-5126-3888; Bailey, Steven/0000-0003-4949-1464;
   Liu, Li/0000-0002-2347-3017; Gao, Simon/0000-0002-7020-037X; Jia,
   Yali/0000-0002-2784-1905
FU NIH [R01 EY023285, R01 EY024544, DP3 DK104397, T32 EY23211]; CTSA
   [UL1TR000128]; NSFC [61471226, 61201441]; Research to Prevent Blindness;
   NATIONAL EYE INSTITUTE [T32EY023211, P30EY010572, R01EY024544] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [DP3DK104397] Funding Source: NIH RePORTER
FX This work was supported by NIH grants R01 EY023285, R01 EY024544, DP3
   DK104397, T32 EY23211; CTSA grant UL1TR000128; NSFC (Grant No. 61471226
   and No. 61201441); and an unrestricted grant from Research to Prevent
   Blindness. Financial interests: Yali Jia and David Huang have a
   significant financial interest in Optovue. David Huang also has a
   financial interest in Carl Zeiss Meditec. These potential conflicts of
   interest have been reviewed and managed by Oregon Health & Science
   University. Yali Jia, David Huang and Li Liu have potential patent
   interest in the subject of this article. Other authors do not have
   financial interest in the subject of this article.
CR An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   Borji A, 2013, IEEE T PATTERN ANAL, V35, P185, DOI 10.1109/TPAMI.2012.89
   Da Chen, 2015, Scale Space and Variational Methods in Computer Vision. 5th International Conference, SSVM 2015. Proceedings: LNCS 9087, P270, DOI 10.1007/978-3-319-18461-6_22
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Gao SS, 2015, OPT LETT, V40, P2305, DOI 10.1364/OL.40.002305
   Goferman S, 2012, IEEE T PATTERN ANAL, V34, P1915, DOI 10.1109/TPAMI.2011.272
   Grulkowski I, 2009, OPT EXPRESS, V17, P23736, DOI 10.1364/OE.17.023736
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang YP, 2015, BIOMED OPT EXPRESS, V6, P1195, DOI 10.1364/BOE.6.001195
   Itti L, 1998, IEEE T PATTERN ANAL, V20, P1254, DOI 10.1109/34.730558
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kuehlewein L., 2015, EYE LOND
   Law MWK, 2008, LECT NOTES COMPUT SC, V5305, P368, DOI 10.1007/978-3-540-88693-8_27
   Lee J, 2007, COMPUT METH PROG BIO, V88, P26, DOI 10.1016/j.cmpb.2007.07.005
   Liu GJ, 2011, OPT EXPRESS, V19, P3657, DOI 10.1364/OE.19.003657
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Lumbroso B., 2015, CLIN OCT ANGIOGRAPHY
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Tan O, 2008, OPHTHALMOLOGY, V115, P949, DOI 10.1016/j.ophtha.2007.08.011
   Tomasi C, 1998, SIXTH INTERNATIONAL CONFERENCE ON COMPUTER VISION, P839, DOI 10.1109/ICCV.1998.710815
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
NR 32
TC 78
Z9 80
U1 1
U2 10
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD SEP 1
PY 2015
VL 6
IS 9
BP 3564
EP 3575
DI 10.1364/BOE.6.003564
PG 12
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA CQ8VR
UT WOS:000360888400039
PM 26417524
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Toh, T
   Borthwick, JH
AF Toh, Tze'Yo
   Borthwick, James H.
TI Acute retinal necrosis post intravitreal injection of triamcinolone
   acetonide
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE acute retinal necrosis; macular degeneration; triamcinolone
AB Although few data exist on the complication of intravitreal injection of triamcinolone acetonide (IVTA) in human eyes, it is generally thought to be well-tolerated. The commonest reported adverse events are raised intraocular pressure and progression of cataract. Acute retinal necrosis, as far as the authors are aware, has not been reported to be associated with IVTA in the literature before. The authors hereby report such a case in a patient who has IVTA as an adjunct to photodynamic therapy of choroidal neovascularization secondary to age-related macular degeneration.
C1 Christchurch Hosp, Dept Ophthalmol, Christchurch, New Zealand.
C3 Christchurch Hospital New Zealand
RP Toh, T (通讯作者)，Christchurch Hosp, Dept Ophthalmol, Christchurch, New Zealand.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   HOLLAND GN, 1994, AM J OPHTHALMOL, V117, P663, DOI 10.1016/S0002-9394(14)70075-3
   Jonas JB, 2004, AM J OPHTHALMOL, V137, P560, DOI 10.1016/j.ajo.2003.08.012
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Walters G, 2001, CURR OPIN OPHTHALMOL, V12, P191, DOI 10.1097/00055735-200106000-00008
NR 8
TC 12
Z9 15
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAY-JUN
PY 2006
VL 34
IS 4
BP 380
EP 382
DI 10.1111/j.1442-9071.2006.01229.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 048NX
UT WOS:000237954900020
PM 16764663
DA 2022-11-30
ER

PT J
AU Ferrington, DA
   Fisher, CR
   Kowluru, RA
AF Ferrington, Deborah A.
   Fisher, Cody R.
   Kowluru, Renu A.
TI Mitochondrial Defects Drive Degenerative Retinal Diseases
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   OXIDATIVE STRESS; TRANSCRIPTION FACTOR; PROGRESSIVE STAGES; DNA DAMAGE;
   PHOTOBIOMODULATION; PROTECTION; TRANSPORT
AB Mitochondrial dysfunction is involved in the pathology of two major blinding retinal diseases, diabetic retinopathy (DR) and age-related macular degeneration (AMD). These diseases accumulate mitochondrial defects in distinct retinal subcellular structures, the vascular/neural network in DR and the retinal pigment epithelium (RPE) in AMD. These mitochondrial defects cause a metabolic crisis that drives disease. With no treatments to stop these diseases, coupled with an increasing population suffering from AMD and DR, there is an urgent need to develop new therapeutics targeting the mitochondria to prevent or reverse disease-specific pathology.
C1 [Ferrington, Deborah A.; Fisher, Cody R.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Ferrington, Deborah A.; Fisher, Cody R.] Univ Minnesota, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   [Kowluru, Renu A.] Wayne State Univ, Ophthalmol Vis & Anat Sci, Detroit, MI 48202 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   Wayne State University
RP Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.; Ferrington, DA (通讯作者)，Univ Minnesota, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.; Kowluru, RA (通讯作者)，Wayne State Univ, Ophthalmol Vis & Anat Sci, Detroit, MI 48202 USA.
EM ferri013@umn.edu; rkowluru@med.wayne.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU National Institutes of Health [T32 AG029796, NEI EY028554, EY026012,
   EY014370, EY017313, EY022230]; VitroRetinal Surgery Foundation
   Fellowship; Elaine and Robert Larson Endowed Research Chair; Research to
   Prevent Blindness
FX We acknowledge the contributions of laboratory associates (past and
   present) to the work cited in this review, Nikhil S. Sahajpal for his
   help in preparing the initial draft, Jorge Polanco for help with
   developing figures, and Parvathy Hariharan for editorial assistance.
   National Institutes of Health (T32 AG029796), VitroRetinal Surgery
   Foundation Fellowship to C.R.F.; National Institutes of Health (NEI
   EY028554 and EY026012), Elaine and Robert Larson Endowed Research Chair,
   Anonymous Benefactor for Macular Degeneration Research, Lindsay Family
   Foundation to D.A.F.; National Institutes of Health (EY014370, EY017313,
   and EY022230) and The Thomas Foundation to R. A.K.; and an unrestricted
   grant from Research to Prevent Blindness to the WSU's Ophthalmology
   Department.
CR Alam NM, 2015, DIS MODEL MECH, V8, P701, DOI 10.1242/dmm.020248
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Birk AV, 2014, BRIT J PHARMACOL, V171, P2017, DOI 10.1111/bph.12468
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   Cheng Y, 2018, DIABETES, V67, P291, DOI 10.2337/db17-0803
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Devi TS, 2019, BIOL OPEN, V8, DOI 10.1242/bio.038521
   Devi TS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.190
   Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Duraisamy AJ, 2019, BBA-MOL BASIS DIS, V1865, P1617, DOI 10.1016/j.bbadis.2019.03.013
   Duraisamy AJ, 2018, INVEST OPHTH VIS SCI, V59, P4831, DOI 10.1167/iovs.18-24548
   Duraisamy AJ, 2017, INVEST OPHTH VIS SCI, V58, P6440, DOI 10.1167/iovs.17-22706
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fu DX, 2016, DIABETOLOGIA, V59, P2251, DOI 10.1007/s00125-016-4058-5
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Grazioli S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00832
   Haider SZ, 2019, NEUROSCIENCE, V406, P140, DOI 10.1016/j.neuroscience.2019.02.026
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Kanki T, 2004, MOL CELL BIOL, V24, P9823, DOI 10.1128/MCB.24.22.9823-9834.2004
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   Karst SG, 2018, JAMA OPHTHALMOL, V136, P315, DOI 10.1001/jamaophthalmol.2017.6135
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim MK, 2018, INVEST OPHTH VIS SCI, V59, P572, DOI 10.1167/iovs.17-22692
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Kowluru RA, 2019, DIABETES, V68, P241, DOI 10.2337/dbi18-0016
   Kowluru RA, 2017, FREE RADICAL BIO MED, V103, P155, DOI 10.1016/j.freeradbiomed.2016.12.030
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Kowluru RA, 2014, DIABETOLOGIA, V57, P1047, DOI 10.1007/s00125-014-3194-z
   Kowluru RA, 2011, DIABETES, V60, P3023, DOI 10.2337/db11-0816
   Kumar B, 2015, INVEST OPHTH VIS SCI, V56, P2985, DOI 10.1167/iovs.15-16466
   Kusuhara S, 2018, DIABETES METAB J, V42, P364, DOI 10.4093/dmj.2018.0182
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Madsen-Bouterse SA, 2010, ANTIOXID REDOX SIGN, V13, P797, DOI 10.1089/ars.2009.2932
   Madsen-Bouterse SA, 2010, FREE RADICAL RES, V44, P313, DOI 10.3109/10715760903494168
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   McLaughlin T, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060906
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Mishra M, 2019, MOL NEUROBIOL, V56, P88, DOI 10.1007/s12035-018-1086-9
   Mishra M, 2017, BBA-MOL BASIS DIS, V1863, P1761, DOI 10.1016/j.bbadis.2017.04.024
   Mishra M, 2015, INVEST OPHTH VIS SCI, V56, P5133, DOI 10.1167/iovs.15-16937
   Mishra M, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15020
   Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036
   Mohammad G, 2019, INVEST OPHTH VIS SCI, V60, P3943, DOI 10.1167/iovs.19-27602
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olivares AM, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0913-0
   Ploumi C, 2017, FEBS J, V284, P183, DOI 10.1111/febs.13820
   Remor AP, 2011, BBA-MOL BASIS DIS, V1812, P1460, DOI 10.1016/j.bbadis.2011.06.017
   Reyes-Reveles J, 2017, J BIOL CHEM, V292, P8038, DOI 10.1074/jbc.M116.770784
   ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857
   Roy S, 2017, AM J PATHOL, V187, P9, DOI 10.1016/j.ajpath.2016.08.022
   Santos JM, 2013, DIABETES-METAB RES, V29, P204, DOI 10.1002/dmrr.2384
   Santos JM, 2011, FREE RADICAL BIO MED, V51, P1849, DOI 10.1016/j.freeradbiomed.2011.08.017
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Tang J, 2014, BRIT J OPHTHALMOL, V98, P1013, DOI 10.1136/bjophthalmol-2013-304477
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tewari S., 2012, INVEST OPHTH VIS SCI, V53, P5422
   Tewari S, 2012, ANTIOXID REDOX SIGN, V17, P492, DOI 10.1089/ars.2011.4333
   Tien T, 2017, INVEST OPHTH VIS SCI, V58, P2915, DOI 10.1167/iovs.16-21355
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zheng YF, 2012, INDIAN J OPHTHALMOL, V60, P428, DOI 10.4103/0301-4738.100542
   Zhong Q, 2011, INVEST OPHTH VIS SCI, V52, P8739, DOI 10.1167/iovs.11-8045
NR 80
TC 41
Z9 41
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD JAN
PY 2020
VL 26
IS 1
SI SI
BP 105
EP 118
DI 10.1016/j.molmed.2019.10.008
PG 14
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA KH4KP
UT WOS:000510615900010
PM 31771932
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Monaghan, M
   Greiser, U
   Wall, JG
   O'Brien, T
   Pandit, A
AF Monaghan, Michael
   Greiser, Udo
   Wall, J. Gerard
   O'Brien, Timothy
   Pandit, Abhay
TI Interference: an alteRNAtive therapy following acute myocardial
   infarction
SO TRENDS IN PHARMACOLOGICAL SCIENCES
LA English
DT Review
DE gene therapy; myocardial infarction; non-viral gene delivery; ligand;
   siRNA; RNAi; microRNA
ID IMPROVES CARDIAC-FUNCTION; INFLAMMATORY RESPONSE; ENDOTHELIAL-CELLS;
   ANTIBODY FRAGMENT; GENE DELIVERY; HEART; MICRORNAS; HYPERTROPHY;
   DYSFUNCTION; IMMUNOLIPOSOMES
AB A complex cascade of genomic and proteomic interactions follows myocardial infarction (MI) irrespective of the intervention employed. A potential pharmacological intervention gaining momentum is RNAi therapy. RNAi therapy has been successfully clinically used in the treatment of age-related macular degeneration and cancer, but its translation to the coronary care unit is lacking despite the existence of preclinical proof of concept. Here we review current RNAi approaches and tissue-specific delivery systems that exhibit candidacy as future pharmacological interventions following MI and considerations for improved non-viral delivery to the infarcted myocardium.
C1 [Monaghan, Michael; Wall, J. Gerard; Pandit, Abhay] Natl Univ Ireland, Network Excellence Funct Biomat, Galway, Ireland.
   [Greiser, Udo; O'Brien, Timothy] Natl Univ Ireland, Regenerat Med Inst, Natl Ctr Biomed Engn Sci, Galway, Ireland.
   [Wall, J. Gerard] Natl Univ Ireland, Sch Nat Sci, Galway, Ireland.
C3 Ollscoil na Gaillimhe-University of Galway; Ollscoil na
   Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of
   Galway
RP Pandit, A (通讯作者)，Natl Univ Ireland, Network Excellence Funct Biomat, Galway, Ireland.
EM abhay.pandit@nuigalway.ie
RI Pandit, Abhay/B-6187-2008; Monaghan, Michael/N-8866-2013; Monaghan,
   Michael/AAB-8457-2022; O'Brien, Timothy/N-7112-2014
OI Pandit, Abhay/0000-0002-6292-4933; Monaghan,
   Michael/0000-0002-5530-4998; Monaghan, Michael/0000-0002-5530-4998;
   O'Brien, Timothy/0000-0001-9028-5481; Wall, Gerard/0000-0003-4603-4276
FU Science Foundation Ireland [07/SRC/B1163]
FX This work was supported by Science Foundation Ireland under Grant No.
   07/SRC/B1163. We acknowledge Mr Anthony Sloan for editorial assistance.
CR Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001
   Arnold AS, 2007, J HYPERTENS, V25, P197, DOI 10.1097/01.hjh.0000254374.73241.ab
   Audouy SAL, 2002, PHARM RES-DORDR, V19, P1599, DOI 10.1023/A:1020989709019
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Buhler P, 2008, CANCER IMMUNOL IMMUN, V57, P43, DOI 10.1007/s00262-007-0348-6
   Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154
   Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582
   Clark PR, 1999, CURR OPIN MOL THER, V1, P158
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   DeVincenzo J, 2010, P NATL ACAD SCI USA, V107, P8800, DOI 10.1073/pnas.0912186107
   Dong SM, 2009, J BIOL CHEM, V284, P29514, DOI 10.1074/jbc.M109.027896
   Duisters RF, 2009, CIRC RES, V104, P170, DOI 10.1161/CIRCRESAHA.108.182535
   Emdin M, 2009, EUR J HEART FAIL, V11, P331, DOI 10.1093/eurjhf/hfp035
   Fattal E, 2006, ADV DRUG DELIVER REV, V58, P1203, DOI 10.1016/j.addr.2006.07.020
   Fiedler J, 2011, CIRCULATION, V124, P720, DOI 10.1161/CIRCULATIONAHA.111.039008
   Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5
   Frangogiannis NG, 2012, CIRC RES, V110, P159, DOI 10.1161/CIRCRESAHA.111.243162
   Frederick JR, 2010, CIRCULATION, V122, pS107, DOI 10.1161/CIRCULATIONAHA.109.930404
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Hajitou A, 2006, TRENDS CARDIOVAS MED, V16, P80, DOI 10.1016/j.tcm.2006.01.003
   Hillis GS, 1998, HEART, V79, P429, DOI 10.1136/hrt.79.5.429
   Holladay CA, 2012, BIOMATERIALS, V33, P1303, DOI 10.1016/j.biomaterials.2011.10.019
   Hu SJ, 2011, CIRCULATION, V124, pS27, DOI 10.1161/CIRCULATIONAHA.111.017954
   Hu SJ, 2010, CIRCULATION, V122, pS124, DOI 10.1161/CIRCULATIONAHA.109.928424
   Hu XJ, 2007, PROTEIN EXPRES PURIF, V52, P194, DOI 10.1016/j.pep.2006.08.009
   Huang M, 2008, CIRCULATION, V118, pS226, DOI 10.1161/CIRCULATIONAHA.107.760785
   JAIN RK, 1988, CANCER RES, V48, P7022
   Jayawardena TM, 2012, CIRC RES, V110, P1465, DOI 10.1161/CIRCRESAHA.112.269035
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kido M, 2005, J AM COLL CARDIOL, V46, P2116, DOI 10.1016/j.jacc.2005.08.045
   Kim SH, 2008, BIOMATERIALS, V29, P4439, DOI 10.1016/j.biomaterials.2008.07.047
   Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418
   Krishnamurthy P, 2010, FASEB J, V24, P2484, DOI 10.1096/fj.09-149815
   Kumar MNVR, 2004, EXPERT OPIN BIOL TH, V4, P1213, DOI 10.1517/14712598.4.8.1213
   Landa N, 2008, CIRCULATION, V117, P1388, DOI 10.1161/CIRCULATIONAHA.107.727420
   Landmesser U, 2005, NAT CLIN PRACT CARD, V2, P628, DOI 10.1038/ncpcardio0371
   Lau S, 2012, MOL PHARMACEUT, V9, P71, DOI 10.1021/mp2002522
   Li LH, 2012, AM J PHYSIOL-HEART C, V302, pH2112, DOI 10.1152/ajpheart.00339.2011
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Liu C, 2003, AM J PATHOL, V163, P1859, DOI 10.1016/S0002-9440(10)63545-6
   Matkovich SJ, 2010, CIRC RES, V106, P166, DOI 10.1161/CIRCRESAHA.109.202176
   Mezzaroma E, 2011, P NATL ACAD SCI USA, V108, P19725, DOI 10.1073/pnas.1108586108
   Monaghan M, 2011, ADV DRUG DELIVER REV, V63, P197, DOI 10.1016/j.addr.2011.01.006
   Montgomery RL, 2011, CIRCULATION, V124, P1537, DOI 10.1161/CIRCULATIONAHA.111.030932
   Morgan PE, 2011, J APPL PHYSIOL, V111, P566, DOI 10.1152/japplphysiol.00200.2011
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Nam HY, 2010, BIOMATERIALS, V31, P8081, DOI 10.1016/j.biomaterials.2010.07.025
   Natarajan R, 2007, AM J PHYSIOL-HEART C, V293, pH1571, DOI 10.1152/ajpheart.00291.2007
   Nolte A, 2011, MOL MED, V17, P1213, DOI 10.2119/molmed.2011.00143
   Pansri P, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-6
   Perez L, 2006, BIOTECHNOL APPL BIOC, V43, P39, DOI 10.1042/BA20050073
   Qian L, 2011, J EXP MED, V208, P549, DOI 10.1084/jem.20101547
   Rao PK, 2009, CIRC RES, V105, P585, DOI 10.1161/CIRCRESAHA.109.200451
   Scott RC, 2007, BIOTECHNOL BIOENG, V96, P795, DOI 10.1002/bit.21233
   Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795
   Sugano M, 2005, FASEB J, V19, P2054, DOI 10.1096/fj.05-4020fje
   Suh W, 2002, MOL THER, V6, P664, DOI 10.1006/mthe.2002.0721
   Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981
   Tan PH, 2003, J GENE MED, V5, P311, DOI 10.1002/jgm.358
   Tepe G, 2001, ATHEROSCLEROSIS, V157, P383, DOI 10.1016/S0021-9150(00)00753-X
   Theoharis S, 2009, J IMMUNOL METHODS, V343, P79, DOI 10.1016/j.jim.2008.12.005
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105
   van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103
   van Rooij E, 2009, DEV CELL, V17, P662, DOI 10.1016/j.devcel.2009.10.013
   Van Tassell BW, 2010, J CARDIOVASC PHARM, V55, P385, DOI 10.1097/FJC.0b013e3181d3da24
   Voinea M, 2005, PHARM RES-DORDR, V22, P1906, DOI 10.1007/s11095-005-7247-3
   Volkel T, 2004, BBA-BIOMEMBRANES, V1663, P158, DOI 10.1016/S0005-2736(04)00085-9
   Wang D, 1997, BIOCONJUGATE CHEM, V8, P878, DOI 10.1021/bc970071w
   Wang J, 2012, J CELL MOL MED, V16, P2150, DOI 10.1111/j.1582-4934.2012.01523.x
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684
   Writing Group M, 2012, CIRCULATION, V125, P188, DOI [DOI 10.1161/CIR.0b013e3182456d46, 10.1161/CIR.0b013e3182456d46]
   Yin C, 2009, CIRC RES, V104, P572, DOI 10.1161/CIRCRESAHA.108.193250
NR 76
TC 7
Z9 8
U1 0
U2 8
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0165-6147
EI 1873-3735
J9 TRENDS PHARMACOL SCI
JI Trends Pharmacol. Sci.
PD DEC
PY 2012
VL 33
IS 12
BP 635
EP 645
DI 10.1016/j.tips.2012.09.003
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 050KW
UT WOS:000312053200003
PM 23068432
DA 2022-11-30
ER

PT J
AU Jones, M
   Mitchell, P
   Wang, JJ
   Sue, C
AF Jones, M
   Mitchell, P
   Wang, JJ
   Sue, C
TI MELAS A3243G mitochondrial DNA mutation and age related maculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; PREVALENCE
AB DESIGN: Case report.
   METHODS: Hair follicles were collected from 3557 persons aged 49 years or older during the Blue Mountains Eye Study. General health measures were assessed and a detailed eye examination was performed, including stereo retinal photography of the macula, and other retinal fields. ARM was graded according to international classification. Polymerase chain reaction and restriction fragment length polymorphism analysis was performed to detect the MELAS A3243G mutation in 570 subjects identified to have signs of Early or Late ARM, as well as in age, and gender matched controls.
   RESULTS: Only one participant with Early ARM, mild hearing loss, hypertension, ischemic heart disease, and asthma was found to have the MELAS A3243G mutation.
   CONCLUSIONS: The MELAS A3243G mutation appears to be a very rare cause of typical ARM in the general population. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Sydney, Dept Neurogenet, Kolling Inst, Sydney, NSW 2006, Australia.
   Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Save Sight & Westmead Millennium Inst, Westmead, NSW 2145, Australia.
C3 University of Sydney; Kolling Institute of Medical Research; University
   of Sydney
RP Mitchell, P (通讯作者)，Westmead Hosp, FRACO Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Wang, Jie Jin/P-1499-2014; wang, jie/GRS-0942-2022; Mitchell,
   Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
NR 6
TC 24
Z9 25
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2004
VL 138
IS 6
BP 1051
EP 1053
DI 10.1016/j.ajo.2004.06.026
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 882TC
UT WOS:000225960200025
PM 15629304
DA 2022-11-30
ER

PT J
AU Brunel, JM
   Salmi, C
   Loncle, C
   Vidal, N
   Letourneux, Y
AF Brunel, JM
   Salmi, C
   Loncle, C
   Vidal, N
   Letourneux, Y
TI Squalamine: A polyvalent drug of the future?
SO CURRENT CANCER DRUG TARGETS
LA English
DT Review
DE squalamine; aminosterol; cancer; age-related macular degeneration (AMD);
   appetite suppression; weight reduction
ID VASCULAR-PERMEABILITY FACTOR; STEREOSELECTIVE-SYNTHESIS; PLUS
   CARBOPLATIN; PHASE-I; ANGIOGENESIS; AMINOSTEROL; GROWTH; SHARK;
   NEOVASCULARIZATION; EXPRESSION
AB The purpose of this mini-review is to summarize and highlight the different advances in our understanding of the antimicrobial and antiangiogenic activity of squalamine, a cationic steroid isolated in 1993 from the dogfish shark Squalus Acanthias. Indeed, squalamine has shown to be useful for the treatment of important diseases such as cancers (lung, ovarian, brain and others), age-related macular degeneration (AMD) and the control of body weight in man. All these results led to a question: could we consider squalamine as a polyvalent drug of the future?
C1 Univ Paul Cezanne, IMRN, INRA, Lab SESNAB,Fac St Jerome,UMR 1111, F-13397 Marseille, France.
C3 INRAE; UDICE-French Research Universities; Aix-Marseille Universite
RP Brunel, JM (通讯作者)，Univ Paul Cezanne, IMRN, INRA, Lab SESNAB,Fac St Jerome,UMR 1111, Case 342,Av Escadrille Normandie Niemen, F-13397 Marseille, France.
EM bruneljm@yahoo.fr
OI jean michel, brunel/0000-0002-9355-8980
CR Ahima RS, 2002, DIABETES, V51, P2099, DOI 10.2337/diabetes.51.7.2099
   Akhter S, 1999, AM J PHYSIOL-CELL PH, V276, pC136, DOI 10.1152/ajpcell.1999.276.1.C136
   Bax R, 2001, CLIN MICROBIOL INFEC, V7, P316, DOI 10.1046/j.1198-743x.2001.00239.x
   Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503
   Bhargava P, 2001, CLIN CANCER RES, V7, P3912
   BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q
   Brunel JM, 2003, EUR J ORG CHEM, V2003, P3897, DOI 10.1002/ejoc.200300167
   Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8
   Cho JJ, 2002, MAR BIOTECHNOL, V4, P521, DOI 10.1007/s10126-002-0064-3
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Folkman J, 1985, Important Adv Oncol, P42
   Genaidy M, 2002, RETINA-J RET VIT DIS, V22, P772, DOI 10.1097/00006982-200212000-00014
   Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48
   Hao D, 2003, CLIN CANCER RES, V9, P2465
   Herbst RS, 2003, CLIN CANCER RES, V9, P4108
   Higgins RD, 2000, INVEST OPHTH VIS SCI, V41, P1507
   Kinney WA, 2000, ORG LETT, V2, P2921, DOI 10.1021/ol0059495
   Li D, 2002, ONCOGENE, V21, P2805, DOI 10.1038/sj.onc.1205410
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195
   MOORE KS, 1993, P NATL ACAD SCI USA, V90, P1354, DOI 10.1073/pnas.90.4.1354
   MORIARTY RM, 1994, TETRAHEDRON LETT, V35, P8103, DOI 10.1016/0040-4039(94)88254-1
   MORIARTY RM, 1995, TETRAHEDRON LETT, V36, P5139
   Ozols RF, 1999, SEMIN ONCOL, V26, P84
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Rao MN, 2000, J NAT PROD, V63, P631, DOI 10.1021/np990514f
   Russo TA, 1998, FEMS MICROBIOL LETT, V162, P311, DOI 10.1016/S0378-1097(98)00139-6
   Savage P. B., 2002, Current Medicinal Chemistry - Anti-Infective Agents, V1, P293, DOI 10.2174/1568012023354776
   Savage PB, 2002, EUR J ORG CHEM, V2002, P759
   Savage PB, 2002, FEMS MICROBIOL LETT, V217, P1
   Schiller JH, 1999, CLIN CANCER RES, V5, P4287
   Selinsky BS, 1998, BBA-BIOMEMBRANES, V1370, P218, DOI 10.1016/S0005-2736(97)00265-4
   Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873
   Sills AK, 1998, CANCER RES, V58, P2784
   STONE R, 1993, SCIENCE, V259, P1125, DOI 10.1126/science.8438163
   Teicher BA, 1998, ANTICANCER RES, V18, P2567
   WEHRLI SL, 1993, STEROIDS, V58, P370, DOI 10.1016/0039-128X(93)90040-T
   Williams JI, 1999, CANC DRUG DISC DEV, V3, P153
   Williams JI, 2001, CLIN CANCER RES, V7, P724
   Young T L, 1997, J AAPOS, V1, P105, DOI 10.1016/S1091-8531(97)90008-2
   Zasloff M, 2001, INT J OBESITY, V25, P689, DOI 10.1038/sj.ijo.0801599
   ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U
   ZASLOFF M, 1994, PHYLOGENET PERSPECT, P31
   Zhou XD, 2002, TETRAHEDRON, V58, P10293, DOI 10.1016/S0040-4020(02)01413-8
   Zhou XD, 2001, TETRAHEDRON LETT, V42, P2537, DOI 10.1016/S0040-4039(01)00191-5
NR 45
TC 44
Z9 48
U1 0
U2 20
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD JUN
PY 2005
VL 5
IS 4
BP 267
EP 272
DI 10.2174/1568009054064642
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 939VH
UT WOS:000230100100003
PM 15975047
DA 2022-11-30
ER

PT J
AU Josefsen, LB
   Boyle, RW
AF Josefsen, Leanne B.
   Boyle, Ross W.
TI Unique Diagnostic and Therapeutic Roles of Porphyrins and
   Phthalocyanines in Photodynamic Therapy, Imaging and Theranostics
SO THERANOSTICS
LA English
DT Review
DE tetrapyrrolic photosensitisers; phototherapy; imaging; nanoagents;
   theranostics
ID MESOPOROUS SILICA NANOPARTICLES; INDUCED PROTOPORPHYRIN IX; WALLED
   CARBON NANOTUBES; ENZYME PRODRUG THERAPY; HUMAN SERUM-ALBUMIN;
   FLUORESCENCE BRONCHOSCOPIC SURVEILLANCE; OPTICAL COHERENCE TOMOGRAPHY;
   IN-VIVO BIODISTRIBUTION; BRAIN-TUMOR RESECTION; BASAL-CELL CARCINOMA
AB Porphyrinic molecules have a unique theranostic role in disease therapy; they have been used to image, detect and treat different forms of diseased tissue including age-related macular degeneration and a number of different cancer types. Current focus is on the clinical imaging of tumour tissue; targeted delivery of photosensitisers and the potential of photosensitisers in multimodal biomedical theranostic nanoplatforms. The roles of porphyrinic molecules in imaging and pdt, along with research into improving their selective uptake in diseased tissue and their utility in theranostic applications are highlighted in this Review.
C1 [Josefsen, Leanne B.; Boyle, Ross W.] Univ Hull, Dept Chem, Kingston Upon Hull HU6 7RX, Yorks, England.
C3 University of Hull
RP Boyle, RW (通讯作者)，Univ Hull, Dept Chem, Kingston Upon Hull HU6 7RX, Yorks, England.
EM R.W.Boyle@hull.ac.uk
CR Ackroyd R, 2001, PHOTOCHEM PHOTOBIOL, V74, P656, DOI 10.1562/0031-8655(2001)074<0656:THOPAP>2.0.CO;2
   AGARWAL ML, 1991, CANCER RES, V51, P5993
   AICHER A, 1993, OPT ENG, V32, P342, DOI 10.1117/12.60747
   Ali H, 1999, CHEM REV, V99, P2379, DOI 10.1021/cr980439y
   Allison RR, 2004, PHOTODIAGN PHOTODYN, V1, P263, DOI 10.1016/S1572-1000(04)00084-5
   Allison R, 2011, PHOTODIAGN PHOTODYN, V8, P231, DOI 10.1016/j.pdpdt.2011.03.342
   Almdal K, 2006, POLYM ADVAN TECHNOL, V17, P790, DOI 10.1002/pat.786
   Alvarez-Mico X, 2007, CARBOHYD RES, V342, P440, DOI 10.1016/j.carres.2006.11.017
   Alves E, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-70
   Anderson HL, 1999, CHEM COMMUN, P2323, DOI 10.1039/a904209a
   Andersson-Engels S., 1995, Bioimaging, V3, P134
   ANDERSSON-ENGELS S, 1991, Lasers in Medical Science, V6, P415, DOI 10.1007/BF02042464
   Arduini M, 2005, LANGMUIR, V21, P9314, DOI 10.1021/la050785s
   AULER H., 1942, Z. Krebsforsck, V53, P65, DOI 10.1007/BF01792783
   AVELINE BM, 1995, J PHOTOCH PHOTOBIO B, V30, P161, DOI 10.1016/1011-1344(95)07174-Z
   Aylott JW, 2003, ANALYST, V128, P309, DOI 10.1039/b302174m
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   BAGSHAWE KD, 1989, BRIT J CANCER, V60, P275, DOI 10.1038/bjc.1989.270
   Balaji T, 2005, ANALYST, V130, P1162, DOI 10.1039/b503261j
   BALCHUM OJ, 1982, RECENT RES CANCER, V82, P97
   Ball DJ, 1998, J PHOTOCH PHOTOBIO B, V45, P28, DOI 10.1016/S1011-1344(98)00156-0
   Banfi S, 2006, J MED CHEM, V49, P3293, DOI 10.1021/jm050997m
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barratt G, 2003, CELL MOL LIFE SCI, V60, P21, DOI 10.1007/s000180300002
   Barrett JF, 2004, EXPERT OPIN THER TAR, V8, P515, DOI 10.1517/14728222.8.6.515
   BASES R, 1958, CANCER, V11, P259, DOI 10.1002/1097-0142(195803/04)11:2<259::AID-CNCR2820110206>3.0.CO;2-2
   Bell A G., 1880, AM J SCI, V20, P305, DOI DOI 10.2475/AJS.S3-20.118.305
   Ben Amor T, 1998, PHOTOCHEM PHOTOBIOL, V67, P206, DOI 10.1562/0031-8655(1998)067&lt;0206:PARCAP&gt;2.3.CO;2
   Bennett JJ, 2001, NAT MED, V7, P859, DOI 10.1038/89991
   Berard V, 2006, J NUCL MED, V47, P1119
   Betz CS, 2002, INT J CANCER, V97, P245, DOI 10.1002/ijc.1596
   Bharali DJ, 2005, P NATL ACAD SCI USA, V102, P11539, DOI 10.1073/pnas.0504926102
   Bhawalkar J D, 1997, J Clin Laser Med Surg, V15, P201
   Birchler M, 1999, NAT BIOTECHNOL, V17, P984, DOI 10.1038/13679
   Biris AS, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3119145
   Birkert O, 2000, ANAL BIOCHEM, V282, P200, DOI 10.1006/abio.2000.4615
   Bogaards A, 2005, PHOTOCH PHOTOBIO SCI, V4, P438, DOI 10.1039/b414829k
   Bogaards A, 2004, LASER SURG MED, V35, P181, DOI 10.1002/lsm.20088
   Bombelli C, 2008, MOL PHARMACEUT, V5, P672, DOI 10.1021/mp800037d
   Bonneau S, 2004, BIOCHEM PHARMACOL, V68, P1443, DOI 10.1016/j.bcp.2004.06.014
   Bonneau S, 2008, EXPERT OPIN THER PAT, V18, P1011, DOI 10.1517/13543776.18.9.1011
   BONNETT R, 1995, CHEM SOC REV, V24, P19, DOI 10.1039/cs9952400019
   Bonnett R, 2001, TETRAHEDRON, V57, P9513, DOI 10.1016/S0040-4020(01)00952-8
   Borle F, 2003, PHOTOCHEM PHOTOBIOL, V78, P377, DOI 10.1562/0031-8655(2003)078<0377:EOTPTF>2.0.CO;2
   Botteman MF, 2003, PHARMACOECONOMICS, V21, P1315, DOI 10.1007/BF03262330
   Bourre L, 2002, J PHOTOCH PHOTOBIO B, V67, P23, DOI 10.1016/S1011-1344(02)00279-8
   Bourre L, 2010, PHOTOCH PHOTOBIO SCI, V9, P1613, DOI 10.1039/c0pp00146e
   Boyle RW, 1996, PHOTOCHEM PHOTOBIOL, V64, P469, DOI 10.1111/j.1751-1097.1996.tb03093.x
   Brasseur N, 1995, PHOTOCHEM PHOTOBIOL, V62, P1058
   BRASSEUR N, 1994, J MED CHEM, V37, P415, DOI 10.1021/jm00029a014
   Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3
   BRUNNER H, 1995, CHEM BER-RECL, V128, P173, DOI 10.1002/cber.19951280215
   Bullous AJ, 2011, PHOTOCH PHOTOBIO SCI, V10, P721, DOI 10.1039/c0pp00266f
   Buriankova L, 2011, PHOTOCHEM PHOTOBIOL, V87, P56, DOI 10.1111/j.1751-1097.2010.00847.x
   Burns A, 2006, CHEM SOC REV, V35, P1028, DOI 10.1039/b600562b
   Camerin M, 2010, EUR J CANCER, V46, P1910, DOI 10.1016/j.ejca.2010.02.037
   Candau F, 1999, ADV COLLOID INTERFAC, V79, P149, DOI 10.1016/S0001-8686(98)00077-3
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Carcenac M, 2001, BRIT J CANCER, V85, P1787, DOI 10.1054/bjoc.2001.2170
   Carcenac M, 1999, PHOTOCHEM PHOTOBIOL, V70, P930, DOI 10.1562/0031-8655(1999)070<0930:PPABSO>2.3.CO;2
   Castano AP, 2005, PHOTODIAGN PHOTODYN, V2, P1, DOI 10.1016/S1572-1000(05)00030-X
   Castano AP, 2005, PHOTODIAGN PHOTODYN, V2, P91, DOI 10.1016/S1572-1000(05)00060-8
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4
   Cauchon N, 2006, PHOTOCHEM PHOTOBIOL, V82, P1712, DOI 10.1562/2005-12-13-RA-752
   Celli JP, 2010, CHEM REV, V110, P2795, DOI 10.1021/cr900300p
   Chan JK, 2002, GYNECOL ONCOL, V87, P64, DOI 10.1006/gyno.2002.6793
   Chen B, 2006, CRIT REV EUKAR GENE, V16, P279, DOI 10.1615/CritRevEukarGeneExpr.v16.i4.10
   Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b
   Chen X, 2004, BIOCHEMISTRY-US, V43, P10918, DOI 10.1021/bi049272v
   Chen Y, 2005, J MED CHEM, V48, P3692, DOI 10.1021/jm050039k
   Chen ZP, 1998, PHOTOCHEM PHOTOBIOL, V67, P56, DOI 10.1111/j.1751-1097.1998.tb05165.x
   Cheng SH, 2010, J MATER CHEM, V20, P6149, DOI 10.1039/c0jm00645a
   Cheng SH, 2009, J MATER CHEM, V19, P1252, DOI 10.1039/b816636f
   Cheng Y, 2011, J AM CHEM SOC, V133, P2583, DOI 10.1021/ja108846h
   Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246
   Cho SJ, 2006, NANOTECHNOLOGY, V17, P640, DOI 10.1088/0957-4484/17/3/004
   Choi Y, 2006, CANCER RES, V66, P7225, DOI 10.1158/0008-5472.CAN-06-0448
   Chung TH, 2007, BIOMATERIALS, V28, P2959, DOI 10.1016/j.biomaterials.2007.03.006
   COHEN S, 1990, BIOCHEM J, V270, P325, DOI 10.1042/bj2700325
   Collard P, 1976, DEV MICROBIOLOGY, P52
   COLLIER RJ, 1984, SCI AM, V251, P56, DOI 10.1038/scientificamerican0784-56
   Collins-Gold L., 2000, MOD DRUG DISCOVERY, V3, P44
   Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2
   Cook MJ, 2002, CHEM REC, V2, P225, DOI 10.1002/tcr.10028
   Corbin IR, 2006, NEOPLASIA, V8, P488, DOI 10.1593/neo.05835
   CORTESE DA, 1982, AM REV RESPIR DIS, V126, P1087
   Coulter CV, 2000, FREE RADICAL BIO MED, V28, P1547, DOI 10.1016/S0891-5849(00)00255-0
   Couvreur P, 2002, CRIT REV THER DRUG, V19, P99, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i2.10
   Crespo-Biel O, 2006, DALTON T, P2737, DOI 10.1039/b517699a
   Cubeddu R, 1997, LASER MED SCI, V12, P200, DOI 10.1007/BF02765100
   Cubeddu R, 2000, PHOTOCHEM PHOTOBIOL, V72, P690, DOI 10.1562/0031-8655(2000)072<0690:FIDPTO>2.0.CO;2
   Cullum BM, 2000, TRENDS BIOTECHNOL, V18, P388, DOI 10.1016/S0167-7799(00)01477-3
   CUOMO V, 1990, BRIT J CANCER, V62, P966, DOI 10.1038/bjc.1990.418
   da Silva EFF, 2012, J PHYS CHEM B, V116, P445, DOI 10.1021/jp206739y
   DaCosta RS, 1997, P SOC PHOTO-OPT INS, V2975, P98, DOI 10.1117/12.275463
   DAUBRESSE C, 1994, J COLLOID INTERF SCI, V168, P222, DOI 10.1006/jcis.1994.1412
   Davila G W, 2001, Surg Oncol Clin N Am, V10, P557
   de la Torre G, 2007, CHEM COMMUN, P2000, DOI 10.1039/b614234f
   De La Zerda A, 2008, NAT NANOTECHNOL, V3, P557, DOI 10.1038/nnano.2008.231
   de la Zerda A, 2011, CONTRAST MEDIA MOL I, V6, P346, DOI 10.1002/cmmi.455
   de la Zerda A, 2010, NANO LETT, V10, P2168, DOI 10.1021/nl100890d
   Decreau R, 1999, J PHOTOCH PHOTOBIO B, V48, P48, DOI 10.1016/S1011-1344(99)00008-1
   Detty MR, 2004, J MED CHEM, V47, P3897, DOI 10.1021/jm040074b
   DING L, 1990, NEW J CHEM, V14, P421
   Dong DZ, 2004, HUM GENE THER, V15, P553, DOI 10.1089/104303404323142006
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931
   Dozzo P, 2005, J MED CHEM, V48, P357, DOI 10.1021/jm049277q
   Dresco PA, 1999, LANGMUIR, V15, P1945, DOI 10.1021/la980971g
   Duan WB, 2005, ORG BIOMOL CHEM, V3, P2384, DOI 10.1039/b504334d
   Duncan R, 2005, MATER TODAY, V8, P16, DOI 10.1016/S1369-7021(05)71032-4
   Durmus M, 2011, DYES PIGMENTS, V91, P153, DOI 10.1016/j.dyepig.2011.02.007
   Duska LR, 2002, GYNECOL ONCOL, V85, P125, DOI 10.1006/gyno.2001.6580
   Ebihara A, 2003, LASER SURG MED, V32, P17, DOI 10.1002/lsm.10137
   EDELSON RL, 1988, SCI AM, V259, P68, DOI 10.1038/scientificamerican0888-68
   Ehrlich P, 1913, LANCET, V2, P445
   Eichhorn H, 2000, J PORPHYR PHTHALOCYA, V4, P88, DOI 10.1002/(SICI)1099-1409(200001/02)4:1<88::AID-JPP208>3.0.CO;2-6
   El-Laithy HM, 2003, AAPS PHARMSCITECH, V3, P1
   Erathodiyil N, 2008, CHEM-EUR J, V14, P3118, DOI 10.1002/chem.200701361
   Ethirajan M, 2011, CHEM SOC REV, V40, P340, DOI 10.1039/b915149b
   Euliss LE, 2006, CHEM SOC REV, V35, P1095, DOI 10.1039/b600913c
   Fabris C, 2006, J PHOTOCH PHOTOBIO B, V83, P48, DOI 10.1016/j.jphotobiol.2005.12.006
   Fahmy TM, 2005, MATER TODAY, V8, P18, DOI 10.1016/S1369-7021(05)71033-6
   Ferrand Y, 2003, BIOORG MED CHEM LETT, V13, P833, DOI 10.1016/S0960-894X(03)00002-7
   FIGGE FHJ, 1948, P SOC EXP BIOL MED, V68, P640
   Firnau G, 1984, Prog Clin Biol Res, V170, P629
   Fisher WG, 1997, PHOTOCHEM PHOTOBIOL, V66, P141, DOI 10.1111/j.1751-1097.1997.tb08636.x
   Flynn T, 2005, NANOMED-NANOTECHNOL, V1, P47, DOI 10.1016/j.nano.2004.11.010
   FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x
   FREITAS I, 1990, J PHOTOCH PHOTOBIO B, V7, P359, DOI 10.1016/1011-1344(90)85169-W
   Freitas RA, 2005, NANOMED-NANOTECHNOL, V1, P2, DOI 10.1016/j.nano.2004.11.003
   Fritsch C, 1998, PHOTOCHEM PHOTOBIOL, V68, P218
   Funkhouser J, 2002, CURR DRUG DISCOV, V2, P17
   Alvarez MG, 2004, PHOTODIAGN PHOTODYN, V1, P335, DOI 10.1016/S1572-1000(04)00068-7
   Galanzha EI, 2008, CYTOM PART A, V73A, P884, DOI 10.1002/cyto.a.20587
   Galanzha EI, 2008, LASER SURG MED, P81
   Galanzha EI, 2007, WORLD J GASTROENTERO, V13, P192, DOI 10.3748/wjg.v13.i2.192
   Galanzha EI, 2009, J BIOPHOTONICS, V2, P725, DOI 10.1002/jbio.200910078
   Galanzha EI, 2009, NAT NANOTECHNOL, V4, P855, DOI [10.1038/nnano.2009.333, 10.1038/NNANO.2009.333]
   Galanzha EI, 2009, CANCER RES, V69, P7926, DOI 10.1158/0008-5472.CAN-08-4900
   Galanzha EI, 2009, J BIOPHOTONICS, V2, P528, DOI 10.1002/jbio.200910046
   GAMALY EG, 1995, PHYS REV B, V52, P2083, DOI 10.1103/PhysRevB.52.2083
   Geng YY, 2003, P SOC PHOTO-OPT INS, V5060, P63, DOI 10.1117/12.510132
   George JE, 2005, LASER SURG MED, V36, P383, DOI 10.1002/lsm.20185
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   Gibbs-Strauss SL, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3065543
   Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X
   Giuliani F, 2010, ANTIMICROB AGENTS CH, V54, P637, DOI 10.1128/AAC.00603-09
   Giuntini F, 2011, PHOTOCH PHOTOBIO SCI, V10, P759, DOI 10.1039/c0pp00366b
   Glickson JD, 2009, ADV EXP MED BIOL, V645, P227, DOI [10.1007/978-0-387-95998-9_35, 10.1007/978-0-387-85998-9_35]
   GOMER CJ, 1979, CANCER RES, V39, P146
   GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196
   Goslinski T, 2011, J PHOTOCH PHOTOBIO C, V12, P304, DOI 10.1016/j.jphotochemrev.2011.09.005
   Gref R, 2003, BIOMATERIALS, V24, P4529, DOI 10.1016/S0142-9612(03)00348-X
   GREGORIE HB, 1968, ANN SURG, V167, P820, DOI 10.1097/00000658-196806000-00002
   Gu HW, 2005, CHEM COMMUN, P4270, DOI 10.1039/b507779f
   Guldi DM, 2005, ADV MATER, V17, P871, DOI 10.1002/adma.200400641
   Guo YY, 2007, CHEM MATER, V19, P6071, DOI 10.1021/cm7028454
   Haider MA, 2007, RADIOLOGY, V244, P196, DOI 10.1148/radiol.2441060398
   HASAN T, 1986, P NATL ACAD SCI USA, V83, P4604, DOI 10.1073/pnas.83.13.4604
   HAYATA Y, 1982, CHEST, V82, P10, DOI 10.1378/chest.82.1.10
   Hazarika P, 2010, ANAL CHEM, V82, P9150, DOI 10.1021/ac1023205
   Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818
   Hewett J, 2001, PHOTOCHEM PHOTOBIOL, V73, P278, DOI 10.1562/0031-8655(2001)073<0278:TAOACM>2.0.CO;2
   Hirohara S, 2010, BIOORGAN MED CHEM, V18, P1526, DOI 10.1016/j.bmc.2010.01.006
   Hirsch FR, 2001, CLIN CANCER RES, V7, P5
   Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100
   Hofmann B, 1999, JMRI-J MAGN RESON IM, V9, P336, DOI 10.1002/(SICI)1522-2586(199902)9:2<336::AID-JMRI28>3.0.CO;2-3
   Hongrapipat J, 2008, MOL PHARMACEUT, V5, P696, DOI 10.1021/mp800006e
   Howard AG, 2005, ANALYST, V130, P1432, DOI 10.1039/b506242j
   HSIANG Y, 1993, LASER SURG MED, V13, P271, DOI 10.1002/lsm.1900130303
   HSIANG YN, 1993, PHOTOCHEM PHOTOBIOL, V57, P670, DOI 10.1111/j.1751-1097.1993.tb02935.x
   Huang L, 2010, ANTIMICROB AGENTS CH, V54, P3834, DOI 10.1128/AAC.00125-10
   Huang Z, 2006, LASER SURG MED, V38, P672, DOI 10.1002/lsm.20375
   Hudson R, 2005, BRIT J CANCER, V92, P1442, DOI 10.1038/sj.bjc.6602517
   Hughes GA, 2005, NANOMED-NANOTECHNOL, V1, P22, DOI 10.1016/j.nano.2004.11.009
   Huh AJ, 2011, J CONTROL RELEASE, V156, P128, DOI 10.1016/j.jconrel.2011.07.002
   Huh YM, 2005, J AM CHEM SOC, V127, P12387, DOI 10.1021/ja052337c
   Hulchanskyy TY, 2007, NANO LETT, V7, P2835, DOI 10.1021/nl0714637
   HUNG J, 1991, LASER SURG MED, V11, P99, DOI 10.1002/lsm.1900110203
   IKEDA S, 1968, Keio Journal of Medicine, V17, P1
   Iqbal Z, 2009, TETRAHEDRON LETT, V50, P5681, DOI 10.1016/j.tetlet.2009.07.127
   Jaffer FA, 2005, JAMA-J AM MED ASSOC, V293, P855, DOI 10.1001/jama.293.7.855
   Jaffer FA, 2006, J AM COLL CARDIOL, V47, P1328, DOI 10.1016/j.jacc.2006.01.029
   Jaffer FA, 2006, MOL IMAGING, V5, P85, DOI 10.2310/7290.2006.00009
   Jang J, 2004, J MATER CHEM, V14, P2872, DOI 10.1039/b405607h
   Jankun J, 2011, INT J ONCOL, V39, P949, DOI 10.3892/ijo.2011.1110
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jimenez-Banzo A, 2008, FREE RADICAL BIO MED, V44, P1926, DOI 10.1016/j.freeradbiomed.2008.02.011
   Jin HL, 2012, BIOCONJUGATE CHEM, V23, P33, DOI 10.1021/bc200233n
   Jin I, 2008, ARCH DERMATOL RES, V300, P161, DOI 10.1007/s00403-007-0820-3
   JORI G, 1979, TUMORI, V65, P425, DOI 10.1177/030089167906500402
   JORI G, 1993, INT J BIOCHEM, V25, P1369, DOI 10.1016/0020-711X(93)90684-7
   Jori G, 1996, J PHOTOCH PHOTOBIO B, V36, P87, DOI 10.1016/S1011-1344(96)07352-6
   Josefsen LB, 2010, PHOTOCH PHOTOBIO SCI, V9, P801, DOI 10.1039/c0pp00004c
   Josefsen Leanne B, 2008, Met Based Drugs, V2008, P276109, DOI 10.1155/2008/276109
   JUNGHEIM LN, 1994, CHEM REV, V94, P1553, DOI 10.1021/cr00030a004
   Juzeniene A, 2006, BRIT J DERMATOL, V155, P791, DOI 10.1111/j.1365-2133.2006.07484.x
   Kaestner L, 2003, PHOTOCH PHOTOBIO SCI, V2, P660, DOI 10.1039/b211348a
   Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102
   Karrer S, 1997, ARCH DERMATOL RES, V289, P132, DOI 10.1007/s004030050168
   Kato H, 2012, FLEXIBLE BRONCHOSCOP, DOI [10.1002/9781444346428.ch20, DOI 10.1002/9781444346428.CH20]
   Kato H, 2004, PHOTODIAGN PHOTODYN, V1, P49, DOI 10.1016/S1572-1000(04)00008-0
   Keating PB, 1999, P INT C APPL LAS LAS, P253
   Kelkar SS, 2011, BIOCONJUGATE CHEM, V22, P1879, DOI 10.1021/bc200151q
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   KENNEDY JC, 1992, J PHOTOCH PHOTOBIO B, V14, P275, DOI 10.1016/1011-1344(92)85108-7
   KENNEDY JC, 1990, J PHOTOCH PHOTOBIO B, V6, P143, DOI 10.1016/1011-1344(90)85083-9
   Kereiakes DJ, 2003, CIRCULATION, V108, P1310, DOI 10.1161/01.CIR.0000087602.91755.19
   Keren S, 2008, P NATL ACAD SCI USA, V105, P5844, DOI 10.1073/pnas.0710575105
   KESSEL D, 1984, PHOTOCHEM PHOTOBIOL, V39, P851, DOI 10.1111/j.1751-1097.1984.tb08871.x
   KESSEL D, 1982, CANCER RES, V42, P1703
   Khlebtsov B, 2006, NANOTECHNOLOGY, V17, P5167, DOI 10.1088/0957-4484/17/20/022
   Khurana M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2965545
   Kikuchi K, 2004, CURR OPIN CHEM BIOL, V8, P182, DOI 10.1016/j.cbpa.2004.02.007
   Kim GJ, 2005, MATER TODAY, V8, P28, DOI 10.1016/S1369-7021(05)71034-8
   Kim JW, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2206875
   Kim JW, 2007, LASER SURG MED, V39, P622, DOI 10.1002/lsm.20534
   Kim JW, 2009, NAT NANOTECHNOL, V4, P688, DOI 10.1038/nnano.2009.231
   Kim S, 2007, J AM CHEM SOC, V129, P2669, DOI 10.1021/ja0680257
   KIMEL S, 1994, P SOC PHOTO-OPT INS, V2078, P205, DOI 10.1117/12.168654
   KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591
   Kirkali Z, 2005, UROLOGY, V66, P4, DOI 10.1016/j.urology.2005.07.062
   Kochevar IE, 2000, METHOD ENZYMOL, V319, P20
   Koenig F, 1999, BJU INT, V83, P129, DOI 10.1046/j.1464-410X.1999.00917.x
   Konan YN, 2003, EUR J PHARM BIOPHARM, V55, P115, DOI 10.1016/S0939-6411(02)00128-5
   Konan YN, 2003, EUR J PHARM SCI, V18, P241, DOI 10.1016/S0928-0987(03)00017-4
   Konan YN, 2002, J PHOTOCH PHOTOBIO B, V66, P89, DOI 10.1016/S1011-1344(01)00267-6
   Kopelman R, 2005, J MAGN MAGN MATER, V293, P404, DOI 10.1016/j.jmmm.2005.02.061
   KORBELIK M, 1993, PHOTOCHEM PHOTOBIOL, V57, P846, DOI 10.1111/j.1751-1097.1993.tb09222.x
   Kostron H, 2006, WIEN MED WOCHENSCHR, V156, P338, DOI 10.1007/s10354-006-0305-6
   Krasnovsky AA, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1065, DOI 10.1134/S0006297907100057
   Krieg RC, 2002, PHOTOCHEM PHOTOBIOL, V76, P518, DOI 10.1562/0031-8655(2002)076<0518:MCOTCS>2.0.CO;2
   Kriegmair M, 2002, J UROLOGY, V168, P475, DOI 10.1016/S0022-5347(05)64661-7
   KRIEGMAIR M, 1994, UROLOGY, V44, P836, DOI 10.1016/S0090-4295(94)80167-3
   Kriegmair M, 1996, J UROLOGY, V155, P105, DOI 10.1016/S0022-5347(01)66559-5
   Kruft BI, 2011, PHOTOCHEM PHOTOBIOL, V87, P1204, DOI 10.1111/j.1751-1097.2011.00993.x
   Kruijt B, 2006, LASER MED SCI, V21, P208, DOI 10.1007/s10103-006-0399-5
   Kubler AC, 1999, LASER SURG MED, V25, P60, DOI 10.1002/(SICI)1096-9101(1999)25:1<60::AID-LSM8>3.0.CO;2-X
   Kuijpers Danielle I, 2006, J Drugs Dermatol, V5, P642
   Kullberg M, 2005, MED HYPOTHESES, V64, P468, DOI 10.1016/j.mehy.2004.07.033
   Kuo Phillip H, 2008, J Am Coll Radiol, V5, P29, DOI 10.1016/j.jacr.2007.08.014
   Kuruppuarachchi M, 2011, MOL PHARMACEUT, V8, P920, DOI 10.1021/mp200023y
   KYRIAZIS GA, 1973, AM J OBSTET GYNECOL, V117, P375, DOI 10.1016/0002-9378(73)90041-0
   Lam M, 2011, CLIN EXP DERMATOL, V36, P645, DOI 10.1111/j.1365-2230.2010.03989.x
   Lam M, 2011, PHOTOCHEM PHOTOBIOL, V87, P904, DOI 10.1111/j.1751-1097.2011.00938.x
   Lam S, 1998, CHEST, V113, P696, DOI 10.1378/chest.113.3.696
   LAM S, 1993, J THORAC CARDIOV SUR, V105, P1035, DOI 10.1016/S0022-5223(19)33775-4
   LAM S, 1990, CHEST, V97, P333, DOI 10.1378/chest.97.2.333
   LAM S, 1993, P SOC PHOTO-OPT INS, V1881, P160, DOI 10.1117/12.146306
   Lang K, 2004, COORDIN CHEM REV, V248, P321, DOI 10.1016/j.ccr.2004.02.004
   Lange N, 1999, BRIT J CANCER, V80, P185, DOI 10.1038/sj.bjc.6690338
   Lapointe D, 1999, J NUCL MED, V40, P876
   Lee PPS, 2005, TETRAHEDRON LETT, V46, P1551, DOI 10.1016/j.tetlet.2004.12.137
   Lee P, 2009, CLIN CANCER RES, V15, P4700, DOI 10.1158/1078-0432.CCR-08-1644
   Letfullin RR, 2006, NANOMEDICINE-UK, V1, P473, DOI 10.2217/17435889.1.4.473
   Leunig A, 2000, LARYNGOSCOPE, V110, P78, DOI 10.1097/00005537-200001000-00015
   Leunig A, 1996, AM J SURG, V172, P674, DOI 10.1016/S0002-9610(96)00312-1
   Levy JG, 1994, INT PHOTODYNAMICS, V1, P3
   Levy L, 2002, CHEM MATER, V14, P3715, DOI 10.1021/cm0203013
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235
   Li CY, 2006, ANALYST, V131, P388, DOI 10.1039/b514510d
   LI D, 1992, BIOCHEM PHARMACOL, V44, P1675, DOI 10.1016/0006-2952(92)90486-3
   Li GL, 2005, BIOCONJUGATE CHEM, V16, P32, DOI 10.1021/bc049807x
   Li ZZ, 2006, J CONTROL RELEASE, V111, P81, DOI 10.1016/j.jconrel.2005.10.020
   Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705
   Linstead RP, 1934, J CHEM SOC, P1016, DOI 10.1039/jr9340001016
   LIPSON RL, 1961, J THORAC CARDIOV SUR, V42, P623, DOI 10.1016/S0022-5223(19)32560-7
   LIPSON RL, 1961, J NATL CANCER I, V26, P1
   LITVACK F, 1985, AM J CARDIOL, V56, P667, DOI 10.1016/0002-9149(85)91032-X
   Liu GL, 2006, NAT NANOTECHNOL, V1, P47, DOI 10.1038/nnano.2006.51
   Liu TWB, 2011, THERANOSTICS, V1, P354, DOI 10.7150/thno/v01p0354
   Liu Z, 2008, P NATL ACAD SCI USA, V105, P1410, DOI 10.1073/pnas.0707654105
   Liu Z, 2007, ACS NANO, V1, P50, DOI 10.1021/nn700040t
   Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144
   Lo PC, 2007, PHOTODIAGN PHOTODYN, V4, P117, DOI 10.1016/j.pdpdt.2007.03.001
   Loewen G, 2007, THORAX, V62, P335, DOI 10.1136/thx.2006.068999
   Loning M, 2004, CANCER-AM CANCER SOC, V100, P1650, DOI 10.1002/cncr.20155
   Lovell JF, 2011, NAT MATER, V10, P324, DOI [10.1038/NMAT2986, 10.1038/nmat2986]
   Lovell JF, 2010, CHEM REV, V110, P2839, DOI 10.1021/cr900236h
   Lovell JF, 2009, J PHYS CHEM B, V113, P3203, DOI 10.1021/jp810324v
   Lu CW, 2007, NANO LETT, V7, P149, DOI 10.1021/nl0624263
   Lu J, 2007, SMALL, V3, P1341, DOI 10.1002/smll.200700005
   Ludicke F, 2003, BRIT J CANCER, V88, P1780, DOI 10.1038/sj.bjc.6600958
   Lutsenko SV, 1999, TUMOR BIOL, V20, P218, DOI 10.1159/000030066
   Ma B, 2003, J PORPHYR PHTHALOCYA, V7, P500, DOI 10.1142/S108842460300063X
   Ma GXB, 1997, SYNTHETIC COMMUN, V27, P2445
   MA LW, 1994, INT J CANCER, V57, P883, DOI 10.1002/ijc.2910570618
   MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328
   Maisch T, 2009, MINI-REV MED CHEM, V9, P974, DOI 10.2174/138955709788681582
   Major A, 1999, IEEE J SEL TOP QUANT, V5, P1168, DOI 10.1109/2944.796343
   Malatesti N, 2006, INT J ONCOL, V28, P1561
   Mantareva V, 1997, J PHOTOCH PHOTOBIO B, V40, P258, DOI 10.1016/S1011-1344(97)00066-3
   Mantareva V, 2007, BIOORGAN MED CHEM, V15, P4829, DOI 10.1016/j.bmc.2007.04.069
   Mantareva V, 2011, PHOTOCH PHOTOBIO SCI, V10, P91, DOI 10.1039/b9pp00154a
   Mantareva V, 2010, CR ACAD BULG SCI, V63, P77
   MARGARON P, 1992, J PHOTOCH PHOTOBIO B, V14, P187, DOI 10.1016/1011-1344(92)85097-E
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   MARTIN A, 1995, ARCH DERMATOL RES, V287, P665
   Martin M, 1996, P SOC PHOTO-OPT INS, V2924, P153, DOI 10.1117/12.260752
   Martins J, 2004, PHOTOCHEM PHOTOBIOL, V80, P267, DOI 10.1562/2004-03-26-RA-124.1
   Mason C, 2004, BIOSENS BIOELECTRON, V20, P414, DOI 10.1016/j.bios.2004.03.035
   Maxwell DJ, 2002, J AM CHEM SOC, V124, P9606, DOI 10.1021/ja025814p
   McCann TE, 2011, NMR BIOMED, V24, P561, DOI 10.1002/nbm.1590
   McCarthy JR, 2006, SMALL, V2, P983, DOI 10.1002/smll.200600139
   McCarthy JR, 2005, NANO LETT, V5, P2552, DOI 10.1021/nl0519229
   McWilliams A, 2003, AM J RESP CRIT CARE, V168, P1167, DOI 10.1164/rccm.200301-144OC
   Mehnert CP, 1997, CHEM COMMUN, P2215, DOI 10.1039/a705104b
   Metzger SW, 1999, J VAC SCI TECHNOL A, V17, P2623, DOI 10.1116/1.581921
   Meyyappan M, 2003, PLASMA SOURCES SCI T, V12, P205, DOI 10.1088/0963-0252/12/2/312
   Milgrom L.R, 1997, COLOURLIFE INTRO C
   Mitsunaga M, 2012, BIOCONJUGATE CHEM, V23, P604, DOI 10.1021/bc200648m
   Mitsunaga M, 2011, NAT MED, V17, P1685, DOI 10.1038/nm.2554
   Moffat Bradford A, 2003, Mol Imaging, V2, P324, DOI 10.1162/153535003322750664
   Moghissi K, 2004, CURR OPIN PULM MED, V10, P256, DOI 10.1097/01.mcp.0000128434.57020.6a
   Moghissi K, 2008, PHOTODIAGN PHOTODYN, V5, P238, DOI 10.1016/j.pdpdt.2009.01.008
   Moghissi K, 2008, PHOTODIAGN PHOTODYN, V5, P235, DOI 10.1016/j.pdpdt.2009.01.006
   Moghissi K, 2007, THORAX, V62, P391, DOI 10.1136/thx.2006.061143
   Moore JV, 1998, EUR J NUCL MED, V25, P1248, DOI 10.1007/s002590050292
   Moreira LM, 2008, AUST J CHEM, V61, P741, DOI 10.1071/CH08145
   MORGAN AR, 1988, CANCER RES, V48, P194
   Morgan J, 2001, ADV DRUG DELIVER REV, V49, P71, DOI 10.1016/S0169-409X(01)00126-0
   MORGAN J, 1994, PHOTOCHEM PHOTOBIOL, V60, P486, DOI 10.1111/j.1751-1097.1994.tb05139.x
   Muller S, 1996, J PHOTOCH PHOTOBIO B, V35, P167, DOI 10.1016/S1011-1344(96)07294-6
   Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97
   Nakanishi T, 2001, J CONTROL RELEASE, V74, P295, DOI 10.1016/S0168-3659(01)00341-8
   NEAVE V, 1988, NEUROSURGERY, V23, P307, DOI 10.1227/00006123-198809000-00004
   Nedosekin DA, 2010, CYTOM PART A, V77A, P1049, DOI 10.1002/cyto.a.20977
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Ng KK, 2011, ACCOUNTS CHEM RES, V44, P1105, DOI 10.1021/ar200017e
   NiculescuDuvaz I, 1997, ADV DRUG DELIVER REV, V26, P151, DOI 10.1016/S0169-409X(97)00032-X
   Nikolaev P, 1999, CHEM PHYS LETT, V313, P91, DOI 10.1016/S0009-2614(99)01029-5
   Niyogi S, 2002, ACCOUNTS CHEM RES, V35, P1105, DOI 10.1021/ar010155r
   Nonaka T, 2011, J HEPATO-BIL-PAN SCI, V18, P592, DOI 10.1007/s00534-011-0377-6
   Nyman ES, 2004, J PHOTOCH PHOTOBIO B, V73, P1, DOI 10.1016/j.jphotobiol.2003.10.002
   O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631
   O'Donovan C, 2005, J MATER CHEM, V15, P2946, DOI 10.1039/b501748c
   O'Reilly RK, 2006, CHEM SOC REV, V35, P1068, DOI 10.1039/b514858h
   Oar MA, 2006, CHEM MATER, V18, P3682, DOI 10.1021/cm0606070
   Ochsner M, 1996, J PHOTOCH PHOTOBIO B, V32, P3, DOI 10.1016/1011-1344(95)07209-8
   Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3
   OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x
   Olivo M, 2004, INT J ONCOL, V25, P37
   PAGNAN A, 1989, INT J TISSUE REACT, V11, P93
   PALCIC B, 1991, CHEST, V99, P742, DOI 10.1378/chest.99.3.742
   Palumbo A, 2011, BRIT J CANCER, V104, P1106, DOI 10.1038/bjc.2011.78
   Pan D, 2008, J AM CHEM SOC, V130, P9186, DOI 10.1021/ja801482d
   Pan DPJ, 2010, FUTURE MED CHEM, V2, P471, DOI 10.4155/FMC.10.5
   Pande AN, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2186337
   Pandey SK, 2005, J MED CHEM, V48, P6286, DOI 10.1021/jm050427m
   Papkovsky DB, 2005, J FLUORESC, V15, P569, DOI 10.1007/s10895-005-2830-x
   Pardridge WM, 1998, J PHARMACOL EXP THER, V286, P548
   Patito IA, 2001, BIOL CELL, V93, P285, DOI 10.1016/S0248-4900(01)01118-2
   Paunov VN, 2007, J MATER CHEM, V17, P609, DOI 10.1039/b615865j
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Pegaz B, 2005, J PHOTOCH PHOTOBIO B, V80, P19, DOI 10.1016/j.jphotobiol.2005.02.003
   PENG Q, 1990, INT J CANCER, V46, P719, DOI 10.1002/ijc.2910460428
   PENG Q, 1990, INT J CANCER, V45, P972, DOI 10.1002/ijc.2910450533
   Phelps ME, 2000, P NATL ACAD SCI USA, V97, P9226, DOI 10.1073/pnas.97.16.9226
   Phillips D, 2011, PURE APPL CHEM, V83, P733, DOI 10.1351/PAC-CON-11-01-05
   Pierard P, 2000, CHEST, V117, P779, DOI 10.1378/chest.117.3.779
   Plaetzer K, 2009, LASER MED SCI, V24, P259, DOI 10.1007/s10103-008-0539-1
   Policard A, 1924, CR SOC BIOL, V91, P1423
   POLLOCK ME, 1987, J AM COLL CARDIOL, V9, P639, DOI 10.1016/S0735-1097(87)80059-1
   Pramanik M, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3147407
   Pramanik M, 2009, PHYS MED BIOL, V54, P3291, DOI 10.1088/0031-9155/54/11/001
   Ragas X, 2010, J MED CHEM, V53, P7796, DOI 10.1021/jm1009555
   Rao AM, 1997, SCIENCE, V275, P187, DOI 10.1126/science.275.5297.187
   RASSMUSSENTAXDAL DS, 1955, CANCER, V8, P78, DOI 10.1002/1097-0142(1955)8:1<78::AID-CNCR2820080109>3.0.CO;2-L
   REBEIZ CA, 1990, PHOTOCHEM PHOTOBIOL, V52, P1099, DOI 10.1111/j.1751-1097.1990.tb08451.x
   Reddy GR, 2006, CLIN CANCER RES, V12, P6677, DOI 10.1158/1078-0432.CCR-06-0946
   Redondo P, 2008, ARCH DERMATOL, V144, P115, DOI 10.1001/archdermatol.2007.3
   REED MWR, 1989, SURGERY, V106, P94
   Resch-Genger U, 2008, NAT METHODS, V5, P763, DOI 10.1038/NMETH.1248
   Ribeiro AO, 2006, TETRAHEDRON LETT, V47, P9177, DOI 10.1016/j.tetlet.2006.10.155
   Riedl CR, 2001, J UROLOGY, V165, P1121, DOI 10.1016/S0022-5347(05)66442-7
   Rockson SG, 2000, CIRCULATION, V102, P591
   Rockson SG, 2000, CIRCULATION, V102, P2322, DOI 10.1161/01.CIR.102.19.2322
   Rosca ID, 2005, CARBON, V43, P3124, DOI 10.1016/j.carbon.2005.06.019
   ROSENBERGER V, 1993, PHOTOCHEM PHOTOBIOL, V58, P627, DOI 10.1111/j.1751-1097.1993.tb04943.x
   Roy I, 2003, J AM CHEM SOC, V125, P7860, DOI 10.1021/ja0343095
   Roy I, 2005, P NATL ACAD SCI USA, V102, P279, DOI 10.1073/pnas.0408039101
   Ruck A, 1998, MINIM INVASIV THER, V7, P503, DOI 10.3109/13645709809152895
   Samkoe KS, 2009, P PHOTOOPTICAL INSTR, V7164, p71640D
   Schieweck K, 1993, P PHOTOOPTICAL INSTR, V2078, P107
   Schwiertz J, 2009, BIOMATERIALS, V30, P3324, DOI 10.1016/j.biomaterials.2009.02.029
   SEE KL, 1984, PHOTOCHEM PHOTOBIOL, V39, P631, DOI 10.1111/j.1751-1097.1984.tb03902.x
   Sekkat N, 2012, MOLECULES, V17, P98, DOI 10.3390/molecules17010098
   SESSLER JL, 1994, ACCOUNTS CHEM RES, V27, P43, DOI 10.1021/ar00038a002
   SESSLER JL, 1987, J ORG CHEM, V52, P4394, DOI 10.1021/jo00228a048
   Sharma SK, 1996, ADV DRUG DELIVER REV, V22, P369, DOI 10.1016/S0169-409X(96)00440-1
   Sharman WM, 2004, ADV DRUG DELIVER REV, V56, P53, DOI 10.1016/j.addr.2003.08.015
   Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9
   Shi JY, 2011, THERANOSTICS, V1, P363, DOI 10.7150/thno/v01p0363
   Shin JH, 2006, ANALYST, V131, P609, DOI 10.1039/b600129g
   SHOPOVA M, 1994, J PHOTOCH PHOTOBIO B, V23, P35, DOI 10.1016/1011-1344(93)06983-A
   Si D, 2012, ANAL CHEM, V84, P978, DOI 10.1021/ac202521e
   Silva JN, 2006, BIO-MED MATER ENG, V16, pS147
   Smetana Z, 1998, J PHOTOCH PHOTOBIO B, V44, P77, DOI 10.1016/S1011-1344(98)00124-9
   Smith K, 2011, IMMUNOLOGY, V132, P256, DOI 10.1111/j.1365-2567.2010.03359.x
   Smith S, 2003, SENSORS MAG, P20
   Smyth CM, 2002, EUR RESPIR J, V19, P458, DOI 10.1183/09031936.02.00103702
   Sobolev A. S., 1997, INT PHOTODYN, V1, P2
   SOKOLOV VV, 1995, P SOC PHOTO-OPT INS, V2325, P364
   Song LP, 2007, INT J NANOMED, V2, P767
   Sortino S, 2012, J MATER CHEM, V22, P301, DOI 10.1039/c1jm13288a
   SPIKES JD, 1986, PHOTOCHEM PHOTOBIOL, V43, P691, DOI 10.1111/j.1751-1097.1986.tb05648.x
   STABLES GI, 1995, CANCER TREAT REV, V21, P311, DOI 10.1016/0305-7372(95)90035-7
   Standish BA, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2744068
   Standish BA, 2007, GASTROINTEST ENDOSC, V66, P326, DOI 10.1016/j.gie.2007.02.040
   Staneloudi C, 2007, IMMUNOLOGY, V120, P512, DOI 10.1111/j.1365-2567.2006.02522.x
   STARK DD, 1988, RADIOLOGY, V168, P297, DOI 10.1148/radiology.168.2.3393649
   Stefflova K, 2007, FRONT BIOSCI-LANDMRK, V12, P4709, DOI 10.2741/2420
   Stepp H, 2007, J ENVIRON PATHOL TOX, V26, P157, DOI 10.1615/JEnvironPatholToxicolOncol.v26.i2.110
   Sternberg ED, 1998, TETRAHEDRON, V54, P4151, DOI 10.1016/S0040-4020(98)00015-5
   Stringer MR, 2008, PHOTODIAGN PHOTODYN, V5, P148, DOI 10.1016/j.pdpdt.2008.06.002
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Stylli SS, 2004, J CLIN NEUROSCI, V11, P584, DOI 10.1016/j.jocn.2004.02.001
   Sugiyama M, 2004, J NUCL MED, V45, P1754
   Sutro CJ, 1933, ARCH PATHOL, V16, P346
   Sutton JM, 2002, BIOCONJUGATE CHEM, V13, P249, DOI 10.1021/bc015547x
   Suzuki Y, 1999, J CHROMATOGR A, V839, P85, DOI 10.1016/S0021-9673(99)00189-2
   Svanberg K, 1998, ACTA RADIOL, V39, P2
   Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031
   Syrigos KN, 1999, ANTICANCER RES, V19, P605
   Szeimies RM, 1996, J PHOTOCH PHOTOBIO B, V34, P67, DOI 10.1016/1011-1344(95)07275-6
   Tammela J, 2004, CURR OPIN OBSTET GYN, V16, P5, DOI 10.1097/00001703-200402000-00003
   TAN WH, 1995, SENSOR ACTUAT B-CHEM, V28, P157, DOI 10.1016/0925-4005(95)80042-5
   Tanaka M, 2012, PHOTOCHEM PHOTOBIOL, V88, P227, DOI 10.1111/j.1751-1097.2011.01005.x
   TANG G, 1993, NEUROSURGERY, V32, P438, DOI 10.1227/00006123-199303000-00016
   Tang W, 2008, BIOCHEM BIOPH RES CO, V369, P579, DOI 10.1016/j.bbrc.2008.02.066
   Taquet JP, 2007, CURR MED CHEM, V14, P1673, DOI 10.2174/092986707780830970
   Tartaj P, 2003, J PHYS D APPL PHYS, V36, pR182, DOI 10.1088/0022-3727/36/13/202
   Tavares A, 2010, MAR DRUGS, V8, P91, DOI 10.3390/md8010091
   Thote AJ, 2005, NANOMED-NANOTECHNOL, V1, P85, DOI 10.1016/j.nano.2004.12.001
   Tome JPC, 2005, BIOORGAN MED CHEM, V13, P3878, DOI 10.1016/j.bmc.2005.04.015
   Trewyn BG, 2007, CHEM COMMUN, P3236, DOI 10.1039/b701744h
   TROMBERG BJ, 1990, PHOTOCHEM PHOTOBIOL, V52, P375, DOI 10.1111/j.1751-1097.1990.tb04193.x
   Tsuchida T, 1997, PHOTOCHEM PHOTOBIOL, V66, P224, DOI 10.1111/j.1751-1097.1997.tb08647.x
   UNSOLD E, 1990, Lasers in Medical Science, V5, P309, DOI 10.1007/BF02032660
   Vahabi S, 2011, LASER PHYS, V21, P2132, DOI 10.1134/S1054660X11210213
   Vallet-Regi M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   VANLIER JE, 1991, NATO ADV SCI I A-LIF, V216, P85
   Vargas A, 2004, INT J PHARMACEUT, V286, P131, DOI 10.1016/j.ijpharm.2004.07.029
   Vedachalam S, 2011, MEDCHEMCOMM, V2, P371, DOI 10.1039/c0md00175a
   Vince RV, 2011, PHOTOCH PHOTOBIO SCI, V10, P515, DOI 10.1039/c0pp00267d
   VINOGRADOV SA, 1994, BIOPHYS J, V67, P2048, DOI 10.1016/S0006-3495(94)80688-5
   Vo-Dinh T, 2001, SENSOR ACTUAT B-CHEM, V74, P2, DOI 10.1016/S0925-4005(00)00705-X
   von Tappeiner H., 1900, MUENCH MED WCHSCHR, V47, P5
   Voss R, 2005, J MATER CHEM, V15, P4010, DOI 10.1039/b507084h
   Vrouenraets MB, 2001, CANCER RES, V61, P1970
   Wang GP, 2005, CHEM COMMUN, P4276, DOI 10.1039/b508075d
   Wang SY, 2011, LASER SURG MED, V43, P686, DOI 10.1002/lsm.21113
   Weigel TL, 2000, ANN SURG ONCOL, V7, P176, DOI 10.1007/BF02523650
   Weigel TL, 2001, ANN THORAC SURG, V71, P967, DOI 10.1016/S0003-4975(00)02523-6
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   Weizman E, 2000, J PHOTOCH PHOTOBIO B, V59, P92, DOI 10.1016/S1011-1344(00)00143-3
   Wen LX, 2005, PEST MANAG SCI, V61, P583, DOI 10.1002/ps.1032
   Wentworth P, 1996, P NATL ACAD SCI USA, V93, P799, DOI 10.1073/pnas.93.2.799
   Westermann P, 1998, INT J CANCER, V76, P842, DOI 10.1002/(SICI)1097-0215(19980610)76:6<842::AID-IJC13>3.0.CO;2-4
   WHEELER BL, 1984, J AM CHEM SOC, V106, P7404, DOI 10.1021/ja00336a019
   Whitacre CM, 2000, CLIN CANCER RES, V6, P2021
   Whitacre CM, 2002, CANCER LETT, V179, P43, DOI 10.1016/S0304-3835(01)00853-9
   Wieder ME, 2006, PHOTOCH PHOTOBIO SCI, V5, P727, DOI 10.1039/b602830f
   Wiegell SR, 2006, J AM ACAD DERMATOL, V54, P647, DOI 10.1016/j.jaad.2005.12.033
   WILSON B C, 1988, Lasers in Medical Science, V3, P71, DOI 10.1007/BF02593792
   Winsborrow BG, 1997, PHOTOCHEM PHOTOBIOL, V66, P847, DOI 10.1111/j.1751-1097.1997.tb03236.x
   WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0
   Witjes JA, 2007, NAT CLIN PRACT UROL, V4, P542, DOI 10.1038/ncpuro0917
   WOHRLE D, 1993, J PHOTOCH PHOTOBIO B, V21, P155, DOI 10.1016/1011-1344(93)80178-C
   Wolfe LA, 1999, BIOCONJUGATE CHEM, V10, P38, DOI 10.1021/bc980057z
   Woodburn KW, 1997, P SOC PHOTO-OPT INS, V2970, P44, DOI 10.1117/12.275065
   Woodburn KW, 1998, J INVEST DERMATOL, V110, P746, DOI 10.1046/j.1523-1747.1998.00182.x
   WRENN FR, 1951, SCIENCE, V113, P525, DOI 10.1126/science.113.2940.525
   Wu P, 2008, ANGEW CHEM INT EDIT, V47, P5022, DOI 10.1002/anie.200705363
   Wu SH, 2008, CHEMBIOCHEM, V9, P53, DOI 10.1002/cbic.200700509
   Xiang LZ, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3078809
   Yan F, 2003, PHOTOCHEM PHOTOBIOL, V78, P587, DOI 10.1562/0031-8655(2003)078<0587:TEOMIS>2.0.CO;2
   Yang KW, 2011, PHOTOCH PHOTOBIO SCI, V10, P1593, DOI 10.1039/c1pp05100h
   Yang VXD, 2003, LASER SURG MED, V32, P224, DOI 10.1002/lsm.10131
   Yim EKF, 2005, NANOMED-NANOTECHNOL, V1, P10, DOI 10.1016/j.nano.2004.11.008
   Yourre TA, 2003, SEMICONDUCTORS+, V37, P807, DOI 10.1134/1.1592855
   Yu GQ, 2005, CLIN CANCER RES, V11, P3543, DOI 10.1158/1078-0432.CCR-04-2582
   Yu KG, 2009, CHINESE CHEM LETT, V20, P411, DOI 10.1016/j.cclet.2008.11.030
   Yu MK, 2012, THERANOSTICS, V2, P3, DOI 10.7150/thno.3463
   Yudasaka M, 1997, CHEM PHYS LETT, V278, P102, DOI 10.1016/S0009-2614(97)00952-4
   Zaak D, 2001, UROLOGY, V57, P690, DOI 10.1016/S0090-4295(00)01053-0
   Zagal JH, 2010, COORDIN CHEM REV, V254, P2755, DOI 10.1016/j.ccr.2010.05.001
   Zahr AS, 2005, LANGMUIR, V21, P403, DOI 10.1021/la0478595
   ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P204, DOI 10.1111/j.1751-1097.1993.tb09550.x
   Zavaleta C, 2008, NANO LETT, V8, P2800, DOI 10.1021/nl801362a
   Zguris JC, 2005, LANGMUIR, V21, P4168, DOI 10.1021/la0470176
   Zhang HD, 2005, J MATER CHEM, V15, P3181, DOI 10.1039/b503336e
   Zhang P, 2007, J AM CHEM SOC, V129, P4526, DOI 10.1021/ja0700707
   Zhang XZ, 2006, J NUCL MED, V47, P492
   Zhang ZH, 2009, ANGEW CHEM INT EDIT, V48, P9171, DOI 10.1002/anie.200903112
   Zhao XJ, 2004, P NATL ACAD SCI USA, V101, P15027, DOI 10.1073/pnas.0404806101
   Zeng HS, 1999, PROC SPIE, V3863, P275, DOI 10.1117/12.364398
   Zhao B, 2005, J AM CHEM SOC, V127, P8197, DOI 10.1021/ja042924i
   ZHARKOVA NN, 1995, P SOC PHOTO-OPT INS, V2325, P400
   Zharov VP, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2793746
   Zharov VP, 2005, NANOMED-NANOTECHNOL, V1, P326, DOI 10.1016/j.nano.2005.10.006
   Zharov VP, 2011, NAT PHOTONICS, V5, P110, DOI [10.1038/nphoton.2010.280, 10.1038/NPHOTON.2010.280]
   Zharov VP, 2006, BIOPHYS J, V90, P619, DOI 10.1529/biophysj.105.061895
   Zharov VP, 2005, LASER SURG MED, V37, P219, DOI 10.1002/lsm.20223
   Zharov VP, 2005, J PHYS D APPL PHYS, V38, P2571, DOI 10.1088/0022-3727/38/15/007
   Zharov VP, 2003, APPL PHYS LETT, V83, P4897, DOI 10.1063/1.1632546
   Zheng G, 2007, P NATL ACAD SCI USA, V104, P8989, DOI 10.1073/pnas.0611142104
   Zheng X, 2009, ANGEW CHEM INT EDIT, V48, P2148, DOI 10.1002/anie.200804804
   Zhong W, 2009, BRIT J CANCER, V101, P2015, DOI 10.1038/sj.bjc.6605436
   Zhu HG, 2005, J AM CHEM SOC, V127, P13448, DOI 10.1021/ja052188y
   Zhu YF, 2005, MICROPOR MESOPOR MAT, V85, P75, DOI 10.1016/j.micromeso.2005.06.015
   Zilberstein J, 2001, PHOTOCHEM PHOTOBIOL, V73, P257, DOI 10.1562/0031-8655(2001)073<0257:ATOSMT>2.0.CO;2
   Zimmermann A, 2001, PHOTOCHEM PHOTOBIOL, V74, P611, DOI 10.1562/0031-8655(2001)074<0611:MMPDOM>2.0.CO;2
   ZUK MM, 1994, PHOTOCHEM PHOTOBIOL, V59, P66, DOI 10.1111/j.1751-1097.1994.tb05002.x
NR 518
TC 422
Z9 431
U1 23
U2 458
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2012
VL 2
IS 9
BP 916
EP 966
DI 10.7150/thno.4571
PG 51
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 021LH
UT WOS:000309885800010
PM 23082103
OA gold, Green Submitted, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Caras, IW
   Collins, LR
   Creasey, AA
AF Caras, Ingrid W.
   Collins, Lila R.
   Creasey, Abla A.
TI A stem cell JOURNEY IN OPHTHALMOLOGY: From the bench to the clinic
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; CYSTOID MACULAR EDEMA; RETINITIS-PIGMENTOSA;
   SURVIVAL; TRANSPLANTATION; MANAGEMENT; THERAPY
AB Debilitating diseases of the eye represent a large unmet medical need potentially addressable with stem cell-based approaches. Over the past decade, the California Institute for Regenerative Medicine (CIRM) has funded and supported the translation, from early research concepts to human trials, of therapeutic stem cell approaches for dry age-related macular degeneration, retinitis pigmentosa, and limbal stem cell deficiency. This article chronicles CIRM's journey in the ophthalmology field and discusses some key challenges and questions that were addressed along the way as well as questions that remain.
C1 [Caras, Ingrid W.; Collins, Lila R.; Creasey, Abla A.] Calif Inst Regenerat Med, 1999 Harrison St,Suite 1650, Oakland, CA 94612 USA.
RP Caras, IW (通讯作者)，Calif Inst Regenerat Med, 1999 Harrison St,Suite 1650, Oakland, CA 94612 USA.
EM icaras@cirm.ca.gov
OI Collins, Lila/0000-0002-1322-6901; Caras, Ingrid/0000-0002-8902-808X
CR Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Chan E, 2016, CORNEA, V35, P1483, DOI 10.1097/ICO.0000000000000914
   Deng SX, 2020, CORNEA, V39, P1291, DOI 10.1097/ICO.0000000000002358
   Deng SX, 2019, CORNEA, V38, P364, DOI 10.1097/ICO.0000000000001820
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Francis PJ, 2009, INVEST OPHTH VIS SCI, V50, P3425, DOI 10.1167/iovs.08-2908
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   HUANG AJW, 1991, INVEST OPHTH VIS SCI, V32, P96
   Huckfeldt RM, 2017, SEMIN OPHTHALMOL, V32, P43, DOI 10.1080/08820538.2016.1228404
   Ivanova E, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126747
   Jones MK, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800213
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Le QH, 2018, CORNEA, V37, P1067, DOI 10.1097/ICO.0000000000001631
   Le QH, 2018, OCUL SURF, V16, P58, DOI 10.1016/j.jtos.2017.11.002
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lu B, 2010, INVEST OPHTH VIS SCI, V51, P2269, DOI 10.1167/iovs.09-4526
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   Pellegrini G, 2018, STEM CELL TRANSL MED, V7, P146, DOI 10.1002/sctm.17-0003
   Rama P, 2010, NEW ENGL J MED, V363, P147, DOI 10.1056/NEJMoa0905955
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Strong S, 2017, BRIT J OPHTHALMOL, V101, P31, DOI 10.1136/bjophthalmol-2016-309376
   VINORES SA, 1995, HISTOL HISTOPATHOL, V10, P913
   Wang SK, 2019, P NATL ACAD SCI USA, V116, P10140, DOI 10.1073/pnas.1901787116
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
NR 29
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD DEC
PY 2021
VL 10
IS 12
BP 1581
EP 1587
DI 10.1002/sctm.21-0239
EA SEP 2021
PG 7
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XH8GW
UT WOS:000695154100001
PM 34515419
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rahimy, E
AF Rahimy, Ehsan
TI Deep learning applications in ophthalmology
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; artificial intelligence; deep
   learning; diabetic retinopathy; glaucoma; machine learning;
   telemedicine; teleretinal screening
ID OPTICAL COHERENCE TOMOGRAPHY; MEDICAL IMAGE-ANALYSIS;
   DIABETIC-RETINOPATHY; RETINAL IMAGES; MACULAR EDEMA; VALIDATION; SYSTEM;
   SEGMENTATION; INTEGRATION; ALGORITHM
AB Purpose of reviewTo describe the emerging applications of deep learning in ophthalmology.Recent findingsRecent studies have shown that various deep learning models are capable of detecting and diagnosing various diseases afflicting the posterior segment of the eye with high accuracy. Most of the initial studies have centered around detection of referable diabetic retinopathy, age-related macular degeneration, and glaucoma.SummaryDeep learning has shown promising results in automated image analysis of fundus photographs and optical coherence tomography images. Additional testing and research is required to clinically validate this technology.
C1 [Rahimy, Ehsan] Palo Alto Med Fdn, Dept Ophthalmol, 795 El Camino Real, Palo Alto, CA 94301 USA.
C3 Palo Alto Medical Foundation Research Institute
RP Rahimy, E (通讯作者)，Palo Alto Med Fdn, Dept Ophthalmol, 795 El Camino Real, Palo Alto, CA 94301 USA.
EM erahimy@gmail.com
OI Rahimy, Ehsan/0000-0001-8446-7078
CR Abramoff MD, 2013, JAMA OPHTHALMOL, V131, P351, DOI 10.1001/jamaophthalmol.2013.1743
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Ambrosio R, 2017, J REFRACT SURG, V33, P434, DOI 10.3928/1081597X-20170426-02
   American Academy of Ophthalmology, INT CLIN DIAB RET DI
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714
   Bresnick GH, 2000, OPHTHALMOLOGY, V107, P19, DOI 10.1016/S0161-6420(99)00010-X
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Cabitza F, 2017, JAMA-J AM MED ASSOC, V318, P517, DOI 10.1001/jama.2017.7797
   Campbell JP, 2016, JAMA OPHTHALMOL, V134, P651, DOI 10.1001/jamaophthalmol.2016.0611
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   ElTanboly A, 2017, MED PHYS, V44, P914, DOI 10.1002/mp.12071
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Frcophth AT, 2017, OPHTHALMOLOGY, V124, P343, DOI 10.1016/j.ophtha.2016.11.014
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hansen AB, 2004, ACTA OPHTHALMOL SCAN, V82, P666, DOI 10.1111/j.1600-0420.2004.00350.x
   Haritoglou C, 2014, RETINA-J RET VIT DIS, V34, P157, DOI 10.1097/IAE.0b013e318295f6de
   Hidalgo IR, 2017, CORNEA, V36, P689, DOI 10.1097/ICO.0000000000001194
   Hoff T, 2011, HEALTH CARE MANAGE R, V36, P338, DOI 10.1097/HMR.0b013e31821826a1
   Krause J, 2018, OPHTHALMOLOGY
   Kuo S, 2005, AM J PREV MED, V29, P396, DOI 10.1016/j.amepre.2005.08.010
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Liu XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168606
   Muhammad H, 2017, J GLAUCOMA, V26, P1086, DOI 10.1097/IJG.0000000000000765
   Philip S, 2007, BRIT J OPHTHALMOL, V91, P1512, DOI 10.1136/bjo.2007.119453
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Puget J.F., 2016, WHAT IS MACHINE LEAR
   Schlegl T., 2017, OPHTHALMOLOGY
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Shen DG, 2017, ANNU REV BIOMED ENG, V19, P221, DOI [10.1146/annurev-bioeng-071516044442, 10.1146/annurev-bioeng-071516-044442]
   Solanki K, 2015, INVEST OPHTH VIS SCI, V56
   Squirrell DM, 2003, J ROY SOC MED, V96, P273, DOI 10.1258/jrsm.96.6.273
   Tan E, 2017, J EUR ACAD DERMATOL, V31, P717, DOI 10.1111/jdv.14012
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
NR 39
TC 56
Z9 62
U1 2
U2 71
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2018
VL 29
IS 3
BP 254
EP 260
DI 10.1097/ICU.0000000000000470
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC0AF
UT WOS:000429436700010
PM 29528860
DA 2022-11-30
ER

PT J
AU Crabb, JW
AF Crabb, John W.
TI The Proteomics of Drusen
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID GLYCATION END-PRODUCTS; COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR;
   RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; BRUCHS MEMBRANE;
   AMYLOID-BETA; OXIDATIVE STRESS; BASAL DEPOSITS; MALATTIA LEVENTINESE
AB The formation of extracellular deposits known as drusen below the macular region of the retina correlates with increased risk of severe visual loss from age-related macular degeneration (AMD). Inflammation and complement dysregulation contribute to AMD progression; however, disease mechanisms remain incompletely defined. Multiple genetic and environmental factors influence AMD pathology, and although immune system processes play a central role, multiple molecular mechanisms appear to be involved. Drusen proteomics, including the analyses of constituent proteins, oxidative protein modifications, and pattern recognition receptors, provide a foundation for deciphering mechanisms of drusen biogenesis and AMD pathology.
C1 Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Crabb, JW (通讯作者)，Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
EM crabbj@ccf.org
FU NIH [EY021840, EY022134, EY14239, EY15638]; Ohio Biomedical Research
   Technology [05-29]; Foundation Fighting Blindness; Research to Prevent
   Blindness (RPB); Cleveland Clinic Foundation; NATIONAL EYE INSTITUTE
   [R21EY021840, R21EY022134, R24EY015638, R01EY014239] Funding Source: NIH
   RePORTER
FX Supported in part by NIH grants EY021840, EY022134, EY14239, EY15638,
   Ohio Biomedical Research Technology Transfer grant 05-29, a Research
   Center grant from The Foundation Fighting Blindness, an unrestricted
   grant from Research to Prevent Blindness (RPB), an RPB Senior
   Investigator Award, a Steinbach Award, and The Cleveland Clinic
   Foundation.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   ALVAREZ RA, 1994, INVEST OPHTH VIS SCI, V35, P402
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bok D, 2002, P NATL ACAD SCI USA, V99, P14619, DOI 10.1073/pnas.242607899
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Chen X, 2007, CURR MOL MED, V7, P735
   CHIO KS, 1969, SCIENCE, V166, P1535, DOI 10.1126/science.166.3912.1535
   Crabb JW, 2012, OXID STRESS APPL BAS, P65, DOI 10.1007/978-1-61779-606-7_3
   Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dentchev T, 2003, MOL VIS, V9, P184
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Elgawish A, 1996, J BIOL CHEM, V271, P12964, DOI 10.1074/jbc.271.22.12964
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Farboud B, 1999, MOL VIS, V5, pU1
   Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FRIGUET B, 1994, J BIOL CHEM, V269, P21639
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Goh SY, 2008, J CLIN ENDOCR METAB, V93, P1143, DOI 10.1210/jc.2007-1817
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG MF, 1976, INVEST OPHTH VISUAL, V15, P443
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagenow K, 2009, J IMMUNOL, V183, P874, DOI 10.4049/jimmunol.0900966
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hazen SL, 2008, J BIOL CHEM, V283, P15527, DOI 10.1074/jbc.R700054200
   Herold K, 2007, J LEUKOCYTE BIOL, V82, P204, DOI 10.1189/jlb.1206751
   Hirata C, 1997, BIOCHEM BIOPH RES CO, V236, P712, DOI 10.1006/bbrc.1997.7036
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JIANG HX, 1994, J IMMUNOL, V152, P5050
   Jiang Kailun, 2012, J Clin Exp Ophthalmol, V3, P208
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531
   Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Matsue H, 2003, J IMMUNOL, V171, P3010, DOI 10.4049/jimmunol.171.6.3010
   Michaelides M, 2006, INVEST OPHTH VIS SCI, V47, P3085, DOI 10.1167/iovs.05-1600
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Okamoto T, 2002, MICROVASC RES, V63, P186, DOI 10.1006/mvre.2001.2371
   Panigrahi S, 2013, CIRC RES, V112, P103, DOI 10.1161/CIRCRESAHA.112.274241
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt AM, 2009, CURR OPIN INVEST DR, V10, P672
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tombran-Tink J, 2007, RETINAL DEGENERATION, P213
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Urata Y, 2002, FREE RADICAL BIO MED, V32, P688, DOI 10.1016/S0891-5849(01)00823-1
   Verhasselt V, 1998, EUR J IMMUNOL, V28, P3886
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WANG N, 1992, CURR EYE RES, V11, P783, DOI 10.3109/02713689209000751
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zahringer U, 2008, IMMUNOBIOLOGY, V213, P205, DOI 10.1016/j.imbio.2008.02.005
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 123
TC 48
Z9 49
U1 1
U2 14
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD JUL
PY 2014
VL 4
IS 7
DI 10.1101/cshperspect.a017194
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AW8NB
UT WOS:000346518000008
PM 24799364
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Boon, CJF
   van de Ven, JPH
   Hoyng, CB
   den Hollander, AI
   Klevering, BJ
AF Boon, Camiel J. F.
   van de Ven, Johannes P. H.
   Hoyng, Carel B.
   den Hollander, Anneke I.
   Klevering, B. Jeroen
TI Cuticular drusen: Stars in the sky
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Cuticular drusen; Drusen; Age-related macular degeneration; Complement
   system; Genetics
ID HEMOLYTIC-UREMIC SYNDROME; AGE-RELATED MACULOPATHY; COMPLEMENT FACTOR-H;
   BASAL LAMINAR DRUSEN; OPTICAL COHERENCE TOMOGRAPHY; GLOMERULONEPHRITIS
   TYPE-II; DENSE DEPOSIT DISEASE; CAROLINA MACULAR DYSTROPHY; SORSBY
   FUNDUS DYSTROPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY
AB Cuticular drusen is a specific clinical subtype of age-related macular degeneration (AMD). This subtype of AMD has an earlier age at onset, a stronger familial component, and genetic factors play a more prominent role in its development than in the general AMD population. In this review, we describe the clinical characteristics and differential diagnosis of cuticular drusen, as well as systemic associations including membranoproliferative glomerulonephritis type II. We discuss recent genetic and pathophysiological insights, and future therapeutic perspectives are highlighted. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Boon, Camiel J. F.; van de Ven, Johannes P. H.; Hoyng, Carel B.; den Hollander, Anneke I.; Klevering, B. Jeroen] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands.
   [Boon, Camiel J. F.] Univ Oxford, John Radcliffe Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England.
   [Boon, Camiel J. F.] Leiden Univ, Dept Ophthalmol, Med Ctr, Leiden, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; University of Oxford; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University - Excl LUMC;
   Radboud University Nijmegen
RP Boon, CJF (通讯作者)，Radboud Univ Nijmegen Med Ctr, Inst Ophthalmol 400, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM C.Boon@ohk.umcn.nl
RI Hollander, Anneke den/N-4911-2014; Klevering, B.J./L-4434-2015; Hoyng,
   C.B./H-8050-2014; Boon, CJF/P-7534-2014
OI Boon, CJF/0000-0002-6737-7932
FU Netherlands Organisation for Scientific Research [016.096.309]; Niels
   Stensen Fellowship Award
FX This work was supported by the Netherlands Organisation for Scientific
   Research (grant 016.096.309). Camiel J.F. Boon was supported by a Niels
   Stensen Fellowship Award.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Agbeko RS, 2010, PEDIATR CRIT CARE ME, V11, P561, DOI 10.1097/PCC.0b013e3181d900ba
   Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Albig AR, 2004, DNA CELL BIOL, V23, P367, DOI 10.1089/104454904323145254
   Alchi B, 2010, PEDIATR NEPHROL, V25, P1409, DOI 10.1007/s00467-009-1322-7
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Awan MA, 2008, CLIN EXP OPTOM, V91, P476, DOI 10.1111/j.1444-0938.2008.00268.x
   BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S
   Barbazetto IA, 2007, OPHTHALMIC GENET, V28, P192, DOI 10.1080/13816810701538596
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109
   Berger SP, 2007, SEMIN IMMUNOPATHOL, V29, P375, DOI 10.1007/s00281-007-0090-3
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOK D, 1993, J CELL SCI, P189
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2007, BRIT J OPHTHALMOL, V91, P1504, DOI 10.1136/bjo.2007.115659
   Boon CJF, 2009, PROG RETIN EYE RES, V28, P187, DOI 10.1016/j.preteyeres.2009.04.002
   Boon CJF, 2009, RETINA-J RET VIT DIS, V29, P835, DOI 10.1097/IAE.0b013e31819d4fda
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   BOUDREAULT G, 1983, CAN J OPHTHALMOL, V18, P325
   Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Calabria G., 2002, ADV OPHTHALMOL, V105, P41
   Callewaert B, 2013, HUM MUTAT, V34, P111, DOI 10.1002/humu.22165
   CAMERON JS, 1983, AM J MED, V74, P175, DOI 10.1016/0002-9343(83)90606-X
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   COHEN Y, 1994, BRIT J OPHTHALMOL, V78, P437
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   D'souza Y, 2008, BRIT J OPHTHALMOL, V92, P950, DOI 10.1136/bjo.2007.130138
   D'Souza Y.B., 2010, J CANADIEN OPHTALMOL, V45, P297
   DAHA MR, 1979, J IMMUNOL, V123, P755
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Laat P., 2013, OPHTHALMOLOGY, DOI DOI 10.1016/J.0PHTHA.2013.05.013
   DEUTMAN AF, 1969, ARCH OPHTHALMOL-CHIC, V81, P305, DOI 10.1001/archopht.1969.00990010307001
   Dolz-Marco R., 2012, Arch Soc Esp Oftalmol, V87, P55, DOI 10.1016/j.oftal.2011.09.004
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 1998, AM J OPHTHALMOL, V126, P417, DOI 10.1016/S0002-9394(98)00097-X
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elahi E, 2006, J INVEST DERMATOL, V126, P1506, DOI 10.1038/sj.jid.5700247
   Ergun E, 2004, RETINA-J RET VIT DIS, V24, P399, DOI 10.1097/00006982-200406000-00010
   Evans K, 1997, ARCH OPHTHALMOL-CHIC, V115, P904, DOI 10.1001/archopht.1997.01100160074012
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fakhouri F, 2010, J AM SOC NEPHROL, V21, P859, DOI 10.1681/ASN.2009070706
   Farah SE, 2009, OPHTHAL SURG LAS IM, V40, P416, DOI 10.3928/15428877-20096030-13
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Finger RP, 2010, RETINA-J RET VIT DIS, V30, P1455, DOI 10.1097/IAE.0b013e3181e09829
   Finger RP, 2009, SURV OPHTHALMOL, V54, P272, DOI 10.1016/j.survophthal.2008.12.006
   FISHMAN GA, 1976, ARCH OPHTHALMOL-CHIC, V94, P231
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   GEHRS KM, 1995, RETINA-J RET VIT DIS, V15, P305, DOI 10.1097/00006982-199515040-00007
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Guigui B, 2009, EYE, V23, P2115, DOI 10.1038/eye.2009.239
   Guigui B, 2013, RETINA-J RET VIT DIS, V33, P1346, DOI 10.1097/IAE.0b013e318283127d
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2002, OPHTHALMOLOGY, V109, P164, DOI 10.1016/S0161-6420(01)00947-2
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Hassenstein A, 2003, KLIN MONATSBL AUGENH, V220, P492
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hogg RE, 2012, RETINA-J RET VIT DIS, V32, P1950, DOI 10.1097/IAE.0b013e31824dadf1
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P859, DOI 10.1136/bjo.65.12.859
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Karampelas M, 2012, OPHTHALMOLOGE, V109, P791, DOI 10.1007/s00347-012-2550-y
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kiernan DF, 2011, OPHTHALMOLOGY, V118, P1435, DOI 10.1016/j.ophtha.2010.10.041
   KIM Y, 1979, LAB INVEST, V40, P474
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Klevering BJ, 2002, BRIT J OPHTHALMOL, V86, P91, DOI 10.1136/bjo.86.1.91
   Kniazeva M, 2000, AM J OPHTHALMOL, V130, P197, DOI 10.1016/S0002-9394(00)00585-7
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Lai TYY, 2007, INVEST OPHTH VIS SCI, V48, P5212, DOI 10.1167/iovs.07-0660
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lerche W., 1975, PIGMENT EPITHELIUM C, P439
   Leys A, 1991, Eur J Ophthalmol, V1, P17
   LEYS A, 1991, PEDIATR NEPHROL, V5, P189, DOI 10.1007/BF01095950
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003
   Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   Maugeri A, 2004, INVEST OPHTH VIS SCI, V45, P4263, DOI 10.1167/iovs.04-0078
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   Meunier I, 2004, ARCH OPHTHALMOL-CHIC, V122, P1566, DOI 10.1001/archopht.122.10.1566
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Michaelides M, 2003, INVEST OPHTH VIS SCI, V44, P2178, DOI 10.1167/iovs.02-1094
   Michaelides M, 2008, ARCH OPHTHALMOL-CHIC, V126, P320, DOI 10.1001/archopht.126.3.320
   Michaelides M, 2006, INVEST OPHTH VIS SCI, V47, P3085, DOI 10.1167/iovs.05-1600
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Muller H., 1856, ARCH OPHTHALMOL-CHIC, V2, P1
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Nguyen AD, 2004, CIRC RES, V95, P1067, DOI 10.1161/01.RES.0000149568.85071.FB
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Orth SR, 1998, NEW ENGL J MED, V338, P1202, DOI 10.1056/NEJM199804233381707
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pilli S, 2011, RETINA-J RET VIT DIS, V31, P812, DOI 10.1097/IAE.0b013e318207d112
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Querques Giuseppe, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-94
   Querques G, 2013, GRAEF ARCH CLIN EXP, V251, P705, DOI 10.1007/s00417-012-2106-5
   Querques G, 2011, GRAEF ARCH CLIN EXP, V249, P1617, DOI 10.1007/s00417-011-1702-0
   Rath PP, 2008, BRIT J OPHTHALMOL, V92, P623, DOI 10.1136/bjo.2007.131177
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenberg T, 2010, MOL VIS, V16, P2659
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Russell SR, 2004, AM J OPHTHALMOL, V137, P924, DOI 10.1016/j.ajo.2003.12.043
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Saihan Z, 2009, MOL VIS, V15, P1218
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schneider R, 2010, J MOL BIOL, V401, P605, DOI 10.1016/j.jmb.2010.06.039
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Schwertz R, 2001, PEDIAT ALLERG IMM-UK, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sergouniotis PI, 2012, OPHTHALMOLOGY, V119, P596, DOI 10.1016/j.ophtha.2011.09.017
   Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328
   Servais A, 2011, HUM PATHOL, V42, P1305, DOI 10.1016/j.humpath.2010.11.023
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Sivaprasad S, 2008, AM J OPHTHALMOL, V146, P228, DOI 10.1016/j.ajo.2008.03.024
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Small K W, 1998, Trans Am Ophthalmol Soc, V96, P925
   SMALL KW, 1991, BRIT J OPHTHALMOL, V75, P401, DOI 10.1136/bjo.75.7.401
   SMALL KW, 1989, OPHTHALMOLOGY, V96, P1747
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Souied EH, 2006, AM J OPHTHALMOL, V141, P404, DOI 10.1016/j.ajo.2005.09.001
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Stefko ST, 2000, AM J OPHTHALMOL, V130, P203, DOI 10.1016/S0002-9394(00)00562-6
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sullivan KM, 2007, LAB INVEST, V87, P818, DOI 10.1038/labinvest.3700594
   Temel RE, 2007, J LIPID RES, V48, P1618, DOI 10.1194/jlr.M700109-JLR200
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   ULBIG MRW, 1993, AM J OPHTHALMOL, V116, P410, DOI 10.1016/S0002-9394(14)71397-2
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   van der Schaft T.L., 1993, ARCH CLIN EXP OPHTHA, V231, P470
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Voo I, 2001, AM J OPHTHALMOL, V132, P933, DOI 10.1016/S0002-9394(01)01184-9
   Walker PD, 2007, MODERN PATHOL, V20, P605, DOI 10.1038/modpathol.3800773
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Westra D, 2010, NEPHROL DIAL TRANSPL, V25, P2195, DOI 10.1093/ndt/gfq010
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 241
TC 43
Z9 43
U1 0
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2013
VL 37
BP 90
EP 113
DI 10.1016/j.preteyeres.2013.08.003
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 264VI
UT WOS:000327908700005
PM 24028794
DA 2022-11-30
ER

PT J
AU Hou, XW
   Wang, Y
   Wu, Q
   Ke, CF
   Pan, CW
AF Hou, Xiao-Wen
   Wang, Ying
   Wu, Qian
   Ke, Chaofu
   Pan, Chen -Wei
TI A review of study designs and data analyses in metabolomics studies in
   myopia
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Review
DE Metabolomics; Myopia; Metabolites; Metabolomics technology
ID TEAR-FILM; CHOROIDAL NEOVASCULARIZATION; AQUEOUS-HUMOR; RISK;
   ASSOCIATION; KERATOCYTE; THICKNESS; BURDEN; ONSET
AB Metabolomics analyzes the entire range of small molecule metabolites in biological systems to reveal the response signals that are transmitted from "genetics and environment", which could help us understand complex phenotypes of diseases. Metabolomics has been successfully applied to the study of eye diseases including age -related macular degeneration, glaucoma, and diabetic retinopathy. In this review, we summarize the findings of myopic metabolomics and discuss them from a design and analysis perspective. Finally, we provide new ideas for the future development of myopia metabolomics research based on the broader ocular metabolomics study.
C1 [Hou, Xiao-Wen; Wang, Ying; Wu, Qian; Ke, Chaofu; Pan, Chen -Wei] Soochow Univ, Med Coll, Sch Publ Hlth, Suzhou, Peoples R China.
   [Pan, Chen -Wei] Soochow Univ, Med Coll, Sch Publ Hlth, 199 Ren Ai Rd, Suzhou 215123, Peoples R China.
C3 Soochow University - China; Soochow University - China
RP Pan, CW (通讯作者)，Soochow Univ, Med Coll, Sch Publ Hlth, 199 Ren Ai Rd, Suzhou 215123, Peoples R China.
EM pcwonly@gmail.com
FU National Key R & D Program of China [2021YFC2702100, 2021YFC2702103,
   2021YFC2702104]; National Natural Science Foundation of China [82122059,
   81973061]
FX Fundings This work was supported by the National Key R & D Program of
   China (2021YFC2702100, 2021YFC2702103, and 2021YFC2702104) and the
   National Natural Science Foundation of China (82122059 and 81973061) .
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Ackermann K, 2006, CHRONOBIOL INT, V23, P369, DOI 10.1080/07420520500464379
   Artal P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016823
   Asakuma T, 2012, OPHTHALMOLOGY, V119, P1760, DOI 10.1016/j.ophtha.2012.02.034
   Baba K, 2015, INVEST OPHTH VIS SCI, V56, P4753, DOI 10.1167/iovs.15-17124
   Barbas-Bernardos C, 2016, J PHARMACEUT BIOMED, V127, P18, DOI 10.1016/j.jpba.2016.03.032
   Benito A, 2011, J CATARACT REFR SURG, V37, P1481, DOI 10.1016/j.jcrs.2011.03.036
   Brennan NA, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100923
   Cheng CY, 2013, AM J HUM GENET, V93, P264, DOI 10.1016/j.ajhg.2013.06.016
   Chua SYL, 2016, OPHTHAL PHYSL OPT, V36, P388, DOI 10.1111/opo.12305
   Craig A, 2006, ANAL CHEM, V78, P2262, DOI 10.1021/ac0519312
   D'Souza S, 2014, INVEST OPHTH VIS SCI, V55, P3396, DOI 10.1167/iovs.14-14113
   Dai LL, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107737
   Du B, 2020, EXP EYE RES, V199, DOI 10.1016/j.exer.2020.108182
   Fini ME, 1999, PROG RETIN EYE RES, V18, P529, DOI 10.1016/S1350-9462(98)00033-0
   Gieger C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000282
   Govindarajan B, 2010, EXP EYE RES, V90, P655, DOI 10.1016/j.exer.2010.02.014
   Grochowski ET, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113464
   Heazell AEP, 2008, PLACENTA, V29, P691, DOI 10.1016/j.placenta.2008.05.002
   Hou XW, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.13
   Houten SM, 2009, ANN MED, V41, P402, DOI 10.1080/07853890902729794
   Itoh R, 1999, CORNEA, V18, P440, DOI 10.1097/00003226-199907000-00009
   Izquierdo-Garcia JL, 2011, PROG NUCL MAG RES SP, V59, P263, DOI 10.1016/j.pnmrs.2011.02.001
   Ji YH, 2017, EXP EYE RES, V159, P147, DOI 10.1016/j.exer.2017.03.004
   Kaddurah-Daouk R, 2008, ANNU REV PHARMACOL, V48, P653, DOI 10.1146/annurev.pharmtox.48.113006.094715
   Kandel H, 2017, CLIN EXP OPHTHALMOL, V45, P677, DOI 10.1111/ceo.12954
   Katajamaa M, 2007, J CHROMATOGR A, V1158, P318, DOI 10.1016/j.chroma.2007.04.021
   Ke CF, 2021, EYE, V35, P817, DOI 10.1038/s41433-020-0968-z
   Kearney S, 2017, OPHTHAL PHYSL OPT, V37, P557, DOI 10.1111/opo.12396
   Khamar P, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107936
   King-Smith PE, 2000, INVEST OPHTH VIS SCI, V41, P3348
   Kunikata H, 2017, SCI REP-UK, V7, DOI 10.1038/srep41984
   Lauwen S, 2017, INVEST OPHTH VIS SCI, V58, pBIO88, DOI 10.1167/iovs.17-21809
   Lawton KA, 2008, PHARMACOGENOMICS, V9, P383, DOI 10.2217/14622416.9.4.383
   Li J, 2020, EUR HEART J, V41, P2645, DOI 10.1093/eurheartj/ehaa209
   Liu K, 2020, J PROTEOME RES, V19, P699, DOI 10.1021/acs.jproteome.9b00574
   Lommen A., 2002, CHEM-ING-TECH, V74, P696
   Luan HM, 2019, MASS SPECTROM REV, V38, P22, DOI 10.1002/mas.21553
   Modjtahedi BS, 2018, OPHTHALMOLOGY, V125, P628, DOI 10.1016/j.ophtha.2018.01.033
   Morgan IG, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.5.3
   Mun JJ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00008
   Mutti DO, 2002, INVEST OPHTH VIS SCI, V43, P3633
   Najjar RP, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87201-2
   Nickla DL, 2016, EXP EYE RES, V146, P189, DOI 10.1016/j.exer.2016.03.003
   Ohno-Matsui K, 2012, INVEST OPHTH VIS SCI, V53, P6046, DOI 10.1167/iovs.12-10161
   Omali NB, 2012, BIOFOULING, V28, P697, DOI 10.1080/08927014.2012.702763
   Pieragostino D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071349
   Pool R, 2020, TWIN RES HUM GENET, V23, P145, DOI 10.1017/thg.2020.53
   Snytnikova OA, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1545-y
   Snytnikova OA, 2017, METABOLOMICS, V13, DOI 10.1007/s11306-016-1144-0
   Ting DSW, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0812-9
   Urbanczyk-Wochniak E, 2003, EMBO REP, V4, P989, DOI 10.1038/sj.embor.embor944
   Wang XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071403
   Want EJ, 2010, NAT PROTOC, V5, P1005, DOI 10.1038/nprot.2010.50
   Wild CP, 2013, ENVIRON MOL MUTAGEN, V54, P480, DOI 10.1002/em.21777
   Wilson SE, 1998, INVEST OPHTH VIS SCI, V39, P220
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
   Yang JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03075-3
   Yanshole VV, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1495-4
   Zetterberg H, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0448-1
   Zhou B, 2012, MOL BIOSYST, V8, P470, DOI 10.1039/c1mb05350g
   Zhu XJ, 2018, REDOX BIOL, V19, P179, DOI 10.1016/j.redox.2018.08.012
NR 64
TC 0
Z9 0
U1 10
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD OCT 15
PY 2022
VL 655
AR 114850
DI 10.1016/j.ab.2022.114850
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 5A4CZ
UT WOS:000862837500009
PM 35970413
DA 2022-11-30
ER

PT J
AU Papay, JA
   Elsner, AE
AF Papay, Joel A.
   Elsner, Ann E.
TI Near-infrared polarimetric imaging and changes associated with normative
   aging
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND
   VISION
LA English
DT Article
ID RETINAL BIREFRINGENCE; SUBRETINAL STRUCTURES; SPATIAL-DISTRIBUTION;
   IMPROVED CONTRAST; POLARIZATION; FIXATION
AB With aging, the human retina undergoes cell death and additional structural changes that can increase scattered light. We quantified the effect of normative aging on multiply scattered light returning from the human fundus. As expected, there was an increase of multiply scattered light associated with aging, and this is consistent with the histological changes that occur in the fundus of individuals before developing age-related macular degeneration. This increase in scattered light with aging cannot be attributed to retinal reflectivity, anterior segment scatter, or pupil diameter. (C) 2018 Optical Society of America
C1 [Papay, Joel A.; Elsner, Ann E.] Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
C3 Indiana University System; Indiana University Bloomington
RP Elsner, AE (通讯作者)，Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
EM aeelsner@indiana.edu
FU National Eye Institute (NEI) [EY007624]; NATIONAL EYE INSTITUTE
   [P30EY003790] Funding Source: NIH RePORTER
FX National Eye Institute (NEI) (EY007624).
CR Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   BRINK HBK, 1988, J OPT SOC AM A, V5, P49, DOI 10.1364/JOSAA.5.000049
   Bueno JM, 2001, VISION RES, V41, P2687, DOI 10.1016/S0042-6989(01)00167-5
   Bueno JM, 2010, VISION RES, V50, P2439, DOI 10.1016/j.visres.2010.09.005
   Burns SA, 2003, INVEST OPHTH VIS SCI, V44, P4061, DOI 10.1167/iovs.03-0124
   Cense B, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201700134
   Chui TYP, 2012, INVEST OPHTH VIS SCI, V53, P3545, DOI 10.1167/iovs.11-8694
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Elsner AE, 2008, VISION RES, V48, P2578, DOI 10.1016/j.visres.2008.04.031
   Hunter DG, 1999, APPL OPTICS, V38, P1273, DOI 10.1364/AO.38.001273
   Irsch K, 2014, OPT EXPRESS, V22, P7972, DOI 10.1364/OE.22.007972
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Mellem-Kairala MB, 2005, INVEST OPHTH VIS SCI, V46, P1099, DOI 10.1167/iovs.04-0574
   Miura M, 2005, AM J OPHTHALMOL, V140, P1014, DOI 10.1016/j.ajo.2005.06.033
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Twietmeyer KM, 2008, OPT EXPRESS, V16, P21339, DOI 10.1364/OE.16.021339
   van den Berg TJTP, 2018, OPHTHAL PHYSL OPT, V38, P6, DOI 10.1111/opo.12426
   VANBLOKLAND GJ, 1985, J OPT SOC AM A, V2, P72, DOI 10.1364/JOSAA.2.000072
   VanNasdale DA, 2009, J VIS, V9, P1
   VanNasdale DA, 2018, OPTOMETRY VISION SCI, V95, P277, DOI 10.1097/OPX.0000000000001197
   VanNasdale DA, 2015, INVEST OPHTH VIS SCI, V56, P284, DOI 10.1167/iovs.14-14459
   VanNasdale DA, 2012, OPTOMETRY VISION SCI, V89, P667, DOI 10.1097/OPX.0b013e31824eeb25
   VanNasdale DA, 2011, VISION RES, V51, P2263, DOI 10.1016/j.visres.2011.08.017
   Weber A, 2007, EYE, V21, P353, DOI 10.1038/sj.eye.6702203
   Weber A, 2004, OPT EXPRESS, V12, P5178, DOI 10.1364/OPEX.12.005178
NR 31
TC 3
Z9 3
U1 0
U2 3
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1084-7529
EI 1520-8532
J9 J OPT SOC AM A
JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis.
PD SEP 1
PY 2018
VL 35
IS 9
BP 1487
EP 1495
DI 10.1364/JOSAA.35.001487
PG 9
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA GS1EV
UT WOS:000443260200001
PM 30183002
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lane, M
   Ferrara, D
   Louzada, RN
   Fujimoto, JG
   Seddon, JM
AF Lane, Mark
   Ferrara, Daniela
   Louzada, Ricardo Noguera
   Fujimoto, James G.
   Seddon, Johanna M.
TI Diagnosis and Follow-Up of Nonexudative Choroidal Neovascularization
   With Multiple Optical Coherence Tomography Angiography Devices: A Case
   Report
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION
AB Nonexudative choroidal neovascularization (CNV) is a new phenomenon that has only recently been described in the literature with the advent of optical coherence tomography angiography (OCTA) imaging. The authors present a 1-year longitudinal follow-up of a nonexudative CNV lesion secondary to age-related macular degeneration. This report describes the appearance of the lesion on two commercially available spectraldomain OCTA devices and one prototype sweptsource OCTA device. Management of these cases is still debatable. Watchful waiting with regular follow-up using serial OCTA to monitor disease progression has been valuable in this case.
C1 [Lane, Mark; Ferrara, Daniela; Louzada, Ricardo Noguera; Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Lane, Mark] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England.
   [Louzada, Ricardo Noguera] Univ Fed Goias, Goiania, Go, Brazil.
   [Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
C3 Tufts University; University of Birmingham; Universidade Federal de
   Goias; Massachusetts Institute of Technology (MIT); Massachusetts
   Institute of Technology (MIT); Tufts Medical Center; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Institutes of Health [R01-EY011309]; National Institute for
   Health Research [R01-EY011289-29, R44-EY022864-3, R01-CA075289-16]; Air
   Force Office of Scientific Research [FA9550-15-1-0473,
   FA9550-12-1-0499]; Champalimaud Foundation; Massachusetts Lions Eye
   Research Fund, New Bedford, MA; Age-Related Macular Degeneration
   Research Fund, Ophthalmic Epidemiology and Genetics Service, Tufts
   Medical Center, Tufts University School of Medicine, Boston; Birdshot
   Uveitis Society/Fight for Sight [24BU151]; CAPES Foundation, Ministry of
   Education of Brazil, Brasilia, DF, Brazil; NATIONAL CANCER INSTITUTE
   [R01CA075289] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY011289, R01EY011309, R44EY022864] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health (R01-EY011309); the
   National Institute for Health Research (R01-EY011289-29, R44-EY022864-3,
   R01-CA075289-16); the Air Force Office of Scientific Research
   (FA9550-15-1-0473 and FA9550-12-1-0499); the Champalimaud Foundation;
   the Massachusetts Lions Eye Research Fund, New Bedford, MA; and the
   Age-Related Macular Degeneration Research Fund, Ophthalmic Epidemiology
   and Genetics Service, Tufts Medical Center, Tufts University School of
   Medicine, Boston.; Dr. Lane was supported by a joint award from the
   Birdshot Uveitis Society/Fight for Sight (24BU151). Dr. Louzada is
   supported by CAPES Foundation, Ministry of Education of Brazil,
   Brasilia, DF, Brazil. Dr. Ferrara is an employee of Genentech and has
   stock/stock options with Roche. Dr. Fujimoto receives royalties from
   intellectual property owned by the Massachusetts Institute of Technology
   and licensed to Carl Zeiss Meditec and Optovue. Dr. Seddon has received
   a research grant from Novartis unrelated to this project.
CR Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Povazay B, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2773728
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
NR 6
TC 5
Z9 5
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD AUG
PY 2016
VL 47
IS 8
BP 778
EP 781
DI 10.3928/23258160-20160808-13
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3GQ
UT WOS:000393101000013
PM 27548457
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Bourla, DH
   Dotan, A
   Weinberger, D
   Bourla, N
   Kremer, I
AF Bourla, Dan H.
   Dotan, Assaf
   Weinberger, Dov
   Bourla, Nirit
   Kremer, Israel
TI Consecutive Appearance of Corneal Subepithelial Infiltrates After
   Intravitreous Bevacizumab Injections
SO CORNEA
LA English
DT Article
DE infiltrates; subepithelial; bevacizumab
ID GENE-EXPRESSION; ADENOVIRUS; INTERLEUKIN-8; KERATITIS
AB Purpose: To report a case of corneal subepithelial infiltrates appearing after intravitrcous bevacizumab injections.
   Methods: A review of the patient's history and clinical examination findings in a patient who had epidemic keratoconjunctivitis more then 20 years before treatment with bevacizumab for age-related macular degeneration.
   Results: After the third and fourth bevacizumab injections, the patient presented with unilateral corneal subepithelial infiltrates. The infiltrates were accompanied by mild anterior chamber reaction and resolved with topical steroid treatment.
   Conclusions: Treatment with intravitreous bevacizumab may precipitate an immune response leading to the appearance of corneal subepithelial infiltrates.
C1 [Bourla, Dan H.; Dotan, Assaf; Weinberger, Dov; Kremer, Israel] Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel.
   [Weinberger, Dov; Kremer, Israel] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Bourla, Nirit] Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel.
C3 Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine;
   Chaim Sheba Medical Center
RP Bourla, DH (通讯作者)，Rabin Med Ctr, Campus Beilinson, IL-49100 Petah Tiqwa, Israel.
EM danb2@clalit.org.il
CR Chintakuntlawar AV, 2007, INVEST OPHTH VIS SCI, V48, P781, DOI 10.1167/iovs.06-1036
   Chodosh J, 2000, INVEST OPHTH VIS SCI, V41, P783
   COPPENS I, 1988, INT OPHTHALMOL, V12, P201, DOI 10.1007/BF00133933
   CUBITT CL, 1993, INVEST OPHTH VIS SCI, V34, P3199
   ELNER VM, 1991, AM J PATHOL, V139, P977
   FERRICK MR, 1991, INVEST OPHTH VIS SCI, V32, P1534
   HODGE W, 1995, CORNEA, V14, P324, DOI 10.1097/00003226-199505000-00016
   HOLLAND EJ, 1991, AM J OPHTHALMOL, V112, P414, DOI 10.1016/S0002-9394(14)76250-6
   JONES BR, 1958, P ROY SOC MED, V51, P13
   Kaye SB, 2005, J MED VIROL, V77, P227, DOI 10.1002/jmv.20440
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   MATOBA AY, 1987, OPHTHALMOLOGY, V94, P1669
   MIZEL SB, 1989, FASEB J, V3, P2379, DOI 10.1096/fasebj.3.12.2676681
   MONDINO BJ, 1986, GRAEF ARCH CLIN EXP, V224, P313, DOI 10.1007/BF02143077
   Sancho-Tello M, 2009, OPHTHALMIC RES, V41, P28, DOI 10.1159/000162263
   TROUSDALE MD, 1995, INVEST OPHTH VIS SCI, V36, P2740
NR 16
TC 1
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD JUN
PY 2010
VL 29
IS 6
BP 686
EP 687
DI 10.1097/ICO.0b013e3181ba0cc7
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 604GD
UT WOS:000278265000019
PM 20458242
DA 2022-11-30
ER

PT J
AU Saornil, MA
AF Saornil, MA
TI Iris colour and uveal melanoma
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE iris; colour; melanoma; uvea
ID OCULAR MELANOMA; EYE COLOR; RISK-FACTORS; RADIATION; CATARACT
AB Iris pigmentation has several physiologic functions, including protection of the underlying tissues from ultraviolet radiation and a protective role in various diseases, such as age-related macular degeneration, cataract and uveal melanoma. Uveal melanoma has been reported to be more prevalent among white people with light irides. It has been suggested that the increased risk may be due to the lack of pigmentation, which allows greater light transmission to the uvea. In this article the author reviews the association between iris colour and ocular disease, particularly uveal melanoma.
C1 Univ Valladolid, Inst Univ Oftalmobiol Aplicada, Registry Ocular Pathol Miguel N Burnier, E-47005 Valladolid, Spain.
   Univ Valladolid, Hosp Clin, Ocular Oncol Unit, Dept Ophthalmol, E-47005 Valladolid, Spain.
C3 Universidad de Valladolid; Universidad de Valladolid
RP Saornil, MA (通讯作者)，Univ Valladolid, Inst Univ Oftalmobiol Aplicada, Registry Ocular Pathol Miguel N Burnier, Ramon & Cajal 7, E-47005 Valladolid, Spain.
EM saornil@ioba.med.uva.es
CR Bergman L, 2002, INVEST OPHTH VIS SCI, V43, P2579
   Bito LZ, 1997, ARCH OPHTHALMOL-CHIC, V115, P659, DOI 10.1001/archopht.1997.01100150661017
   Cumming RG, 2000, AM J OPHTHALMOL, V130, P237, DOI 10.1016/S0002-9394(00)00479-7
   EGAN KM, 1988, SURV OPHTHALMOL, V32, P239, DOI 10.1016/0039-6257(88)90173-7
   Frudakis T, 2003, GENETICS, V165, P2071
   GALLAGHER RP, 1985, J NATL CANCER I, V74, P775
   Guenel P, 2001, CANCER CAUSE CONTROL, V12, P451, DOI 10.1023/A:1011271420974
   HILLER R, 1982, AM J EPIDEMIOL, V115, P674, DOI 10.1093/oxfordjournals.aje.a113350
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   Imesch PD, 1997, SURV OPHTHALMOL, V41, pS117, DOI 10.1016/S0039-6257(97)80018-5
   JENSEN OA, 1963, ACTA OPHTHALMOL, P17
   KLIMAN GH, 1985, AM J OPHTHALMOL, V100, P547, DOI 10.1016/0002-9394(85)90679-8
   Li WJ, 2000, CANCER RES, V60, P3757
   López Caballero C, 2003, Arch Soc Esp Oftalmol, V78, P99
   Marks R, 2000, CLIN EXP DERMATOL, V25, P459, DOI 10.1046/j.1365-2230.2000.00693.x
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Mitchell R, 2003, AM J OPHTHALMOL, V135, P384, DOI 10.1016/S0002-9394(02)01967-0
   MUINOS Y, 2003, OPHTHALMIC RES S1, V35, P177
   Regan S, 1999, ARCH OPHTHALMOL-CHIC, V117, P811
   ROOTMAN J, 1984, AM J OPHTHALMOL, V98, P558, DOI 10.1016/0002-9394(84)90240-X
   SAHEL JA, 2000, PRINCIPLES PRACTICE, V6, P5067
   SANDRA C, 2003, OPHTHALMOLOGY, V110, P1526
   SEDDON JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1274, DOI 10.1001/archopht.1990.01070110090031
   Singh AD, 2003, OPHTHALMOLOGY, V110, P956, DOI 10.1016/S0161-6420(03)00078-2
   Sumich P, 1998, ARCH OPHTHALMOL-CHIC, V116, P645, DOI 10.1001/archopht.116.5.645
   TAYLOR AI, 1967, HUM BIOL, V39, P316
   TUCKER MA, 1985, NEW ENGL J MED, V313, P789, DOI 10.1056/NEJM198509263131305
   Vajdic CM, 2001, INT J CANCER, V92, P906, DOI 10.1002/ijc.1281
   Younan C, 2002, AM J OPHTHALMOL, V134, P273, DOI 10.1016/S0002-9394(02)01496-4
NR 29
TC 11
Z9 11
U1 0
U2 6
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2004
VL 39
IS 4
BP 448
EP 452
DI 10.1016/S0008-4182(04)80018-8
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 831XB
UT WOS:000222228900017
PM 15328594
DA 2022-11-30
ER

PT J
AU Sardell, RJ
   Nittala, MG
   Adams, LD
   Laux, RA
   Bailey, JNC
   Fuzzell, D
   Fuzzell, S
   Reinhart-Mercer, L
   Caywood, LJ
   Horst, V
   Mackay, T
   Dana, D
   Sadda, SR
   Scott, WK
   Stambolian, D
   Haines, JL
   Pericak-Vance, MA
AF Sardell, Rebecca J.
   Nittala, Muneeswar G.
   Adams, Larry D.
   Laux, Renee A.
   Bailey, Jessica N. Cooke
   Fuzzell, Denise
   Fuzzell, Sarada
   Reinhart-Mercer, Lori
   Caywood, Laura J.
   Horst, Violet
   Mackay, Tine
   Dana, Debbie
   Sadda, SriniVas R.
   Scott, William K.
   Stambolian, Dwight
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
TI Heritability of Choroidal Thickness in the Amish
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; EYES; ASSOCIATION;
   PROGRESSION; SEVERITY
AB Purpose: To evaluate the heritability of choroidal thickness and its relationship to age-related macular degeneration (AMD).
   Design: Cohort study.
   Participants: Six hundred eighty-nine individuals from Amish families with early or intermediate AMD.
   Methods: Ocular coherence tomography was used to quantify choroidal thickness, and fundus photography was used to classify eyes into categories using a modified Clinical Age-Related Maculopathy Staging (CARMS) system. Repeatability and heritability of choroidal thickness and its phenotypic and genetic correlations with the AMD phenotype (CARMS category) were estimated using a generalized linear mixed model (GLMM) approach that accounted for relatedness, repeated measures (left and right eyes), and the effects of age, gender, and refraction.
   Main Outcome Measures: Heritability of choroidal thickness and its phenotypic and genetic correlation with the AMD phenotype (CARMS category).
   Results: Phenotypic correlation between choroidal thickness and CARMS category was moderate (Spearman's rank correlation, rs = -0.24; n = 1313 eyes) and significant (GLMM posterior mean, -4.27; 95% credible interval [CI], -7.88 to -0.79; P = 0.02) after controlling for relatedness, age, gender, and refraction. Eyes with advanced AMD had thinner choroids than eyes without AMD (posterior mean, -73.8; 95% CI, -94.7 to -54.6; P < 0.001; n = 1178 eyes). Choroidal thickness was highly repeatable within individuals (repeatability, 0.78; 95% CI, 0.68 to 0.89) and moderately heritable (heritability, 0.40; 95% CI, 0.14 to 0.51), but did not show significant genetic correlation with CARMS category, although the effect size was moderate (genetic correlation, -0.18; 95% CI, -0.49 to 0.16). Choroidal thickness also varied with age, gender, and refraction. The CARMS category showed moderate heritability (heritability, 0.49; 95% CI, 0.26 to 0.72).
   Conclusions: We quantify the heritability of choroidal thickness for the first time, highlighting a heritable, quantitative trait that is measurable in all individuals regardless of AMD affection status, and moderately phenotypically correlated with AMD severity. Choroidal thickness therefore may capture variation not captured by the CARMS system. However, because the genetic correlation between choroidal thickness and AMD severity was not significant in our data set, genes associated with the 2 traits may not overlap substantially. Future studies should therefore test for genetic variation associated with choroidal thickness to determine the overlap in genetic basis with AMD. (C) 2016 by the American Academy of Ophthalmology.
C1 [Sardell, Rebecca J.; Adams, Larry D.; Reinhart-Mercer, Lori; Caywood, Laura J.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 319, Miami, FL 33136 USA.
   [Nittala, Muneeswar G.; Sadda, SriniVas R.] Univ Calif Los Angeles, Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA USA.
   [Laux, Renee A.; Bailey, Jessica N. Cooke; Fuzzell, Denise; Fuzzell, Sarada; Haines, Jonathan L.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Horst, Violet; Mackay, Tine; Dana, Debbie; Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Penn, Dept Genet, Philadelphia, PA 19104 USA.
C3 University of Miami; Doheny Eye Institute; University of California
   System; University of California Los Angeles; Case Western Reserve
   University; University of Pennsylvania; University of Pennsylvania
RP Pericak-Vance, MA (通讯作者)，Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 319, Miami, FL 33136 USA.
EM mpericak@med.miami.edu
RI Haines, Jonathan/C-3374-2012; Cooke Bailey, Jessica
   Nicole/AFQ-5925-2022; Nittala, Muneeswar/AAT-7533-2020; Bailey, Jessica
   Cooke/Q-5062-2019
OI Haines, Jonathan/0000-0002-4351-4728; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Bailey, Jessica Cooke/0000-0002-4001-8702;
   Scott, William/0000-0001-9336-6404
FU Optos; Carl Zeiss Meditec; NATIONAL EYE INSTITUTE [T32EY023194,
   R01EY023164] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): S.R.S.: Consultant
   - Optosplc (Dunfermline, Scotland); Carl Zeiss Meditec HQ (Jena,
   Germany); Alcon (Fort Worth, TX); Allergan HQ (Parsippany-Troy Hills,
   NJ); Genentech (San Francisco CA); Regeneron (Tarrytown, NY); Novartis
   (Basel, Switzerland); Financial support - Optos; Carl Zeiss Meditec;
   Board member - Allergan; Genentech
CR Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Charlesworth J, 2010, INVEST OPHTH VIS SCI, V51, P3509, DOI 10.1167/iovs.09-4786
   Chen JH, 2012, MOL VIS, V18, P765
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freeman EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055573
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Glahn DC, 2012, BIOL PSYCHIAT, V71, P6, DOI 10.1016/j.biopsych.2011.08.022
   Gorin MB, 2014, J CLIN MED, V3, P1335, DOI 10.3390/jcm3041335
   Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636
   Hadfield JD, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i02
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   McCourt Emily A, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS28, DOI 10.3928/15428877-20101031-14
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Plummer M., 2006, R NEWS, V6, P7, DOI DOI 10.1159/000323281
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tenesa A, 2013, NAT REV GENET, V14, P139, DOI 10.1038/nrg3377
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Wang Chih-Ping, 2015, Taiwan J Ophthalmol, V5, P169, DOI 10.1016/j.tjo.2015.10.002
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
NR 43
TC 18
Z9 19
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2016
VL 123
IS 12
BP 2537
EP 2544
DI 10.1016/j.ophtha.2016.09.001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3YZ
UT WOS:000389539900021
PM 27771146
OA Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU He, SK
   Li, XH
   Chan, N
   Hinton, DR
AF He, Shikun
   Li, Xiaohua
   Chan, Nymph
   Hinton, David R.
TI Review: Epigenetic mechanisms in ocular disease
SO MOLECULAR VISION
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; HISTONE DEACETYLASE ACTIVITY; GENE-EXPRESSION;
   DNA METHYLATION; UVEAL MELANOMA; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; RETINITIS-PIGMENTOSA; VALPROIC ACID; MYOFIBROBLAST
   TRANSDIFFERENTIATION
AB Epigenetics has become an increasingly important area of biomedical research. Increasing evidence shows that epigenetic alterations influence common pathologic responses including inflammation, ischemia, neoplasia, aging, and neurodegeneration. Importantly, epigenetic mechanisms may have a pathogenic role in many complex eye diseases such as corneal dystrophy, cataract, glaucoma, diabetic retinopathy, ocular neoplasia, uveitis, and age-related macular degeneration. The emerging emphasis on epigenetic mechanisms in studies of eye disease may provide new insights into the pathogenesis of complex eye diseases and aid in the development of novel treatments for these diseases.
C1 [He, Shikun; Chan, Nymph; Hinton, David R.] Univ So CA, Keck Sch Med, Dept Pathol, Los Angeles, CA USA.
   [He, Shikun; Hinton, David R.] Univ So CA, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
   [He, Shikun; Hinton, David R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Li, Xiaohua] Henan Eye Inst, Zhengzhou, Peoples R China.
C3 Doheny Eye Institute
RP Hinton, DR (通讯作者)，Univ So Calif, Dept Pathol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90089 USA.
EM dhinton@usc.edu
FU National Eye Institute, Bethesda, MD [EY03040]; Department of
   Ophthalmology of the Keck School of Medicine from Research to Prevent
   Blindness, Inc. New York, NY; Arnold and Mabel Beckman Foundation;
   National Natural Science Foundation of China [81100650]; NATIONAL EYE
   INSTITUTE [P30EY003040] Funding Source: NIH RePORTER
FX We thank Susan Clark for her editorial review of the manuscript. This
   work was supported by Core Grant EY03040 from the National Eye
   Institute, Bethesda, MD; an unrestricted grant to the Department of
   Ophthalmology of the Keck School of Medicine from Research to Prevent
   Blindness, Inc. New York, NY; and the Arnold and Mabel Beckman
   Foundation (S. H., N.C., D.R.H.). Funding was also provided by the Youth
   Fund of the National Natural Science Foundation of China (grant
   #81100650; X.L.).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Baer-Dubowska W, 2011, PHARMACOL REP, V63, P293, DOI 10.1016/S1734-1140(11)70498-4
   Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   Bayarsaihan D, 2011, J DENT RES, V90, P9, DOI 10.1177/0022034510378683
   Bell JT, 2011, TRENDS GENET, V27, P116, DOI 10.1016/j.tig.2010.12.005
   Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P526, DOI 10.1167/iovs.09-3903
   Bloom DC, 2010, BBA-GENE REGUL MECH, V1799, P246, DOI 10.1016/j.bbagrm.2009.12.001
   Brunmeir R, 2009, INT J DEV BIOL, V53, P275, DOI 10.1387/ijdb.082649rb
   Buysschaert I, 2008, J CELL MOL MED, V12, P2533, DOI 10.1111/j.1582-4934.2008.00515.x
   Calipel A, 2011, MOL CANCER RES, V9, P1187, DOI 10.1158/1541-7786.MCR-10-0437
   Calvanese V, 2012, ADV EXP MED BIOL, V741, P231, DOI 10.1007/978-1-4614-2098-9_16
   Catania A, 2006, BIOCHEM BIOPH RES CO, V343, P544, DOI 10.1016/j.bbrc.2006.03.013
   Chen LJ, 2012, MOL VIS, V18, P1629
   Chen SL, 2010, AM J PHYSIOL-ENDOC M, V298, pE127, DOI 10.1152/ajpendo.00432.2009
   Clemson CM, 2011, BRIT J OPHTHALMOL, V95, P89, DOI 10.1136/bjo.2009.175356
   Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Damiani D, 2008, J NEUROSCI, V28, P4878, DOI 10.1523/JNEUROSCI.0828-08.2008
   Danaher RJ, 2005, J NEUROVIROL, V11, P306, DOI 10.1080/13550280590952817
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Dratviman-Storobinsky O, 2012, INVEST OPHTHALMOL VI
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Farthing CR, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000116
   Feinberg AP, 2010, NAT BIOTECHNOL, V28, P1049, DOI 10.1038/nbt1010-1049
   Fernandez-Morera JL, 2010, TISSUE ANTIGENS, V76, P431, DOI 10.1111/j.1399-0039.2010.01587.x
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Glubb DM, 2011, WIRES SYST BIOL MED, V3, P299, DOI 10.1002/wsbm.125
   Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009
   He SY, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-21
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Huber LC, 2007, ARTHRITIS RHEUM-US, V56, P3523, DOI 10.1002/art.22948
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jackson John K., 2005, Angiogenesis, V8, P229, DOI 10.1007/s10456-005-9018-5
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Junemann A, 2009, ACTA OPHTHALMOL, V87, ps244
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052
   Kovacs B, 2011, INVEST OPHTH VIS SCI, V52, P4402, DOI 10.1167/iovs.10-6879
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Landreville S, 2012, CLIN CANCER RES, V18, P408, DOI 10.1158/1078-0432.CCR-11-0946
   Lee D, 2012, ANN NY ACAD SCI, V1271, P118, DOI 10.1111/j.1749-6632.2012.06745.x
   Lee SI, 2011, P NATL ACAD SCI USA, V108, P10426, DOI 10.1073/pnas.1106141108
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Liu Ru, 2009, Zhonghua Yan Ke Za Zhi, V45, P631
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Maat W, 2007, INVEST OPHTH VIS SCI, V48, P486, DOI 10.1167/iovs.06-0781
   Mann J, 2010, GASTROENTEROLOGY, V138, P705, DOI 10.1053/j.gastro.2009.10.002
   Mazzio EA, 2012, EPIGENETICS-US, V7, P119, DOI 10.4161/epi.7.2.18764
   McArthur K, 2011, DIABETES, V60, P1314, DOI 10.2337/db10-1557
   Merhavi E, 2007, INVEST OPHTH VIS SCI, V48, P4403, DOI 10.1167/iovs.07-0272
   Moulin AP, 2008, BRIT J OPHTHALMOL, V92, P281, DOI 10.1136/bjo.2007.127035
   Negahban Kambiz, 2002, Curr Opin Ophthalmol, V13, P419, DOI 10.1097/00055735-200212000-00013
   Olynik Brendan M., 2012, Frontiers in Genetics, V3, P81, DOI 10.3389/fgene.2012.00081
   Ospelt C, 2011, AUTOIMMUN REV, V10, P519, DOI 10.1016/j.autrev.2011.04.001
   Pang MY, 2010, J PHARMACOL EXP THER, V335, P266, DOI 10.1124/jpet.110.168385
   Pelzel HR, 2012, INVEST OPHTH VIS SCI, V53, P1428, DOI 10.1167/iovs.11-8872
   Pelzel HR, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-62
   Peng CH, 2010, SENSORS-BASEL, V10, P6172, DOI 10.3390/s100606172
   Perez-Perri JI, 2011, INT J MOL SCI, V12, P4705, DOI 10.3390/ijms12074705
   Petkova TD, 2011, VISION RES, V51, P260, DOI 10.1016/j.visres.2010.09.022
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234
   Qureshi IA, 2011, CURR NEUROL NEUROSCI, V11, P464, DOI 10.1007/s11910-011-0210-2
   Raffoux E, 2010, ONCOTARGET, V1, P34, DOI 10.18632/oncotarget.106
   Rao Rajesh C, 2011, Int Ophthalmol Clin, V51, P117, DOI 10.1097/IIO.0b013e31822d6966
   Rodriguez-Rodero S, 2010, DISCOV MED, V10, P225
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Sahni JN, 2011, CURR GENOMICS, V12, P276, DOI 10.2174/138920211795860062
   Saied MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033213
   Saika S, 2007, ARCH OPHTHALMOL-CHIC, V125, P647, DOI 10.1001/archopht.125.5.647
   Saito Yoshimasa, 2012, Frontiers in Genetics, V3, P194, DOI 10.3389/fgene.2012.00194
   Sancho-Pelluz J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.4
   Schonrock N, 2012, CIRC RES, V111, P1349, DOI 10.1161/CIRCRESAHA.112.268953
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Shen Y, 2006, HUM MOL GENET, V15, P2623, DOI 10.1093/hmg/ddl188
   Silingardi D, 2010, EUR J NEUROSCI, V31, P2185, DOI 10.1111/j.1460-9568.2010.07261.x
   Sivamurthy N, 2001, SURGERY, V130, P204, DOI 10.1067/msy.2001.115823
   Smith ZD, 2012, NATURE, V484, P339, DOI 10.1038/nature10960
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Villeneuve LM, 2010, AM J PHYSIOL-RENAL, V299, pF14, DOI 10.1152/ajprenal.00200.2010
   Viola T, 2011, CELL MOL LIFE SCI, V68, P1131, DOI 10.1007/s00018-010-0600-7
   Volkmar M, 2012, EMBO J, V31, P1405, DOI 10.1038/emboj.2011.503
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wang SS, 2008, P NATL ACAD SCI USA, V105, P7738, DOI 10.1073/pnas.0802857105
   Webster ALH, 2013, CAN J CARDIOL, V29, P46, DOI 10.1016/j.cjca.2012.10.023
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weiland M, 2012, RNA BIOL, V9, P850, DOI 10.4161/rna.20378
   Wu JH, 2012, OPHTHALMIC RES, V47, P195, DOI 10.1159/000331992
   Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733
   Zhong Q, 2010, J CELL BIOCHEM, V110, P1306, DOI 10.1002/jcb.22644
   Zhou P, 2011, MOL VIS, V17, P2717
   Zhou XT, 2012, MOL VIS, V18, P1312
   Zhu HQ, 2010, J BIOL CHEM, V285, P9429, DOI 10.1074/jbc.M109.071274
NR 102
TC 51
Z9 56
U1 0
U2 29
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 21
PY 2013
VL 19
BP 665
EP 674
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 110BQ
UT WOS:000316417500003
PM 23559860
DA 2022-11-30
ER

PT J
AU Singerman, L
AF Singerman, Lawrence
TI COMBINATION THERAPY USING THE SMALL INTERFERING RNA BEVASIRANIB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor agents; bevasiranib; combination therapy; small interfering RNA
ID SIRNA
AB Bevasiranib, the first small interfering RNA agent developed for the treatment of neovascular age-related macular degeneration, has demonstrated clinical promise. Injected intravitreally, this small interfering RNA acts by inducing catalytic destruction of messenger RNA to silence gene expression. Bevasiranib targets the production of vascular endothelial growth factor (VEGF) protein. It does not affect existing VEGF protein, suggesting that it may offer a synergistic effect when given in combination with anti-VEGF treatments, such as ranibizumab. The safety of bevasiranib has been supported by preclinical and clinical research. RETINA 29:S49-S50, 2009
C1 [Singerman, Lawrence] Retina Associates Cleveland, Case Univ Sch Med, Cleveland, OH 44122 USA.
   [Singerman, Lawrence] Cleveland Clin Educ Fdn, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Singerman, Lawrence] Bascom Palmer Eye Inst, Dept Clin Ophthalmol, Miami, FL 33136 USA.
C3 Case Western Reserve University; Retina Associates of Cleveland, Inc.;
   Cleveland Clinic Foundation; Bascom Palmer Eye Institute
RP Singerman, L (通讯作者)，Retina Associates Cleveland, Case Univ Sch Med, 3401 Enterprise Pkwy, Cleveland, OH 44122 USA.
EM lsingerman@retina-assoc.com
CR *AM AC OPHTH, 2005, AM AC OPHTH M CHIC I
   Dejneka NS, 2008, MOL VIS, V14, P997
   Karagiannis TC, 2005, CANCER GENE THER, V12, P787, DOI 10.1038/sj.cgt.7700857
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Reich S, 2003, MOL VIS, V9, P210
NR 5
TC 45
Z9 55
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S49
EP S50
DI 10.1097/IAE.0b013e3181ad2341
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700018
PM 19553802
DA 2022-11-30
ER

PT J
AU Lyons, RJ
   Ahmad, S
   Ansari, S
   Foote, JE
   Jain, N
AF Lyons, Riley J.
   Ahmad, Samera
   Ansari, Sana
   Foote, Jenelle E.
   Jain, Nieraj
TI Pentosan Polysulfate-Associated Macular Disease in Patients With
   Interstitial Cystitis
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
AB Recent studies have implicated long-term pentosan polysulfate use with vision loss from a newly described macular condition. Affected patients report difficulty with reading and adjusting to dim lighting, and they occasionally develop severe visual disability. Macular changes resemble those seen in age-related macular degeneration, potentially leading to misdiagnosis. The objectives of this Current Commentary are to summarize studies evaluating the association between pentosan polysulfate use and macular disease, to educate pentosan polysulfate prescribers about the clinical manifestations of this condition, and to provide recommendations for screening at-risk patients.
C1 [Lyons, Riley J.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA USA.
   [Lyons, Riley J.; Jain, Nieraj] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Lyons, Riley J.] Midtown Urol, Atlanta, GA USA.
C3 Emory University; Emory University
RP Jain, N (通讯作者)，Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
EM nieraj.jain@emory.edu
OI Ansari, Sana/0000-0002-3265-168X
FU Foundation Fighting Blindness Career Development Award
   [CD-C-0918-0748-EEC]
FX Supported by a Foundation Fighting Blindness Career Development Award
   CD-C-0918-0748-EEC (Nieraj Jain).
CR American Urological Association, 2014, DIAGN TREATM INT CYS
   [Anonymous], 2015, ELM PAT FLYER
   Giusto LL, 2018, EXPERT OPIN PHARMACO, V19, P1097, DOI 10.1080/14656566.2018.1491968
   Hanif AM, 2019, JAMA OPHTHALMOL, V137, P1275, DOI 10.1001/jamaophthalmol.2019.3392
   Hanif AM, 2019, OPHTHALMOLOGY, V126, P1464, DOI 10.1016/j.ophtha.2019.04.024
   Hanif Adam M, 2019, Int Ophthalmol Clin, V59, P173, DOI 10.1097/IIO.0000000000000262
   Hanno PM, 2015, J UROLOGY, V193, P1545, DOI 10.1016/j.juro.2015.01.086
   Jain N, 2020, BRIT J OPHTHALMOL, V104, P1093, DOI 10.1136/bjophthalmol-2019-314765
   Nickel JC, 2015, J UROLOGY, V193, P857, DOI 10.1016/j.juro.2014.09.036
   Patnaik SS, 2017, ARCH GYNECOL OBSTET, V295, P1341, DOI 10.1007/s00404-017-4364-2
   Pearce WA, 2018, OPHTHALMOLOGY, V125, P1793, DOI 10.1016/j.ophtha.2018.04.026
   Vora RA, 2020, OPHTHALMOLOGY, V127, P835, DOI 10.1016/j.ophtha.2020.01.017
NR 12
TC 6
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD MAY
PY 2020
VL 135
IS 5
BP 1091
EP 1094
DI 10.1097/AOG.0000000000003794
PG 4
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA NP5II
UT WOS:000570209400018
PM 32282604
DA 2022-11-30
ER

PT J
AU Namavari, A
   Zheng, F
   Motulsky, EH
   Dias, JRD
   Gregori, G
   Rosenfeld, PJ
AF Namavari, Abed
   Zheng, Fang
   Motulsky, Elie H.
   Dias, Joao R. de Oliveira
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI Swept-Source OCT Angiography Identifies Choroidal Neovascularization
   Arising From a Choroidal Nevus
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; MACULAR DEGENERATION; MEMBRANE
AB Swept-source optical coherence tomography angiography (SS-OCTA) was used to diagnose choroidal neovascularization (CNV) arising from a choroidal nevus. A 61-year-old woman initially presented with submacular hemorrhage. She was diagnosed with neovascular age-related macular degeneration (AMD) and received three injections of bevacizumab (Avastin; Genentech, South San Francisco, CA). At a follow-up visit, SS-OCTA showed that the CNV appeared to arise from an adjacent choroidal nevus. This is the first report of using SS-OCTA to diagnose CNV associated with a choroidal nevus masquerading as neovascular AMD.
C1 [Namavari, Abed; Zheng, Fang; Motulsky, Elie H.; Dias, Joao R. de Oliveira; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Zheng, Fang] Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
C3 Bascom Palmer Eye Institute; University of Miami; Tianjin Medical
   University
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
FU Carl Zeiss Meditec (Dublin, CA); National Eye Institute Center
   [P30EY014801]; Carl Zeiss Meditec; Apellis; Genentech; Astellas
   Institute for Regenerative Medicine; Tyrogenex
FX This research was supported by grants from Carl Zeiss Meditec (Dublin,
   CA) and the National Eye Institute Center Core Grant (P30EY014801) to
   the Department of Ophthalmology, University of Miami Miller School of
   Medicine. The funding organization had no role in the design or conduct
   of this research.; Drs. Gregori and Rosenfeld received research support
   from Carl Zeiss Meditec. Dr. Gregori and the University of Miami co-own
   a patent that is licensed to Carl Zeiss Meditec. Dr. Rosenfeld also
   received additional research support from Apellis, Genentech, Astellas
   Institute for Regenerative Medicine, and Tyrogenex; is a consultant to
   Acucela, Boehringer-Ingelheim, Carl Zeiss Meditec, Cell Cure
   Neurosciences, Chengdu Kanghong Biotech, F. Hoffmann-La Roche Ltd.,
   Genentech, Healios K.K, Hemera Biosciences, Isarna Pharmaceuticals,
   MacRegen Inc., Ocudyne, Ocunexus Therapeutics, Tyrogenex, and Unity
   Biotechnology; and has equity interests in Apellis, Digisight, and
   Ocudyne. The remaining authors report no relevant financial disclosures.
CR Amer R, 2017, SURV OPHTHALMOL, V62, P723, DOI 10.1016/j.survophthal.2017.05.001
   Hanhart J, 2017, CASE REP OPHTHALM, V8, P108, DOI 10.1159/000458516
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Papastefanou VP, 2013, BRIT J OPHTHALMOL, V97, P1014, DOI 10.1136/bjophthalmol-2013-303234
   Pellegrini M, 2018, RETINA-J RET VIT DIS, V38, P1338, DOI 10.1097/IAE.0000000000001730
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
NR 9
TC 1
Z9 1
U1 1
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2018
VL 49
IS 5
BP 360
EP 363
DI 10.3928/23258160-20180501-10
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GG9DF
UT WOS:000433000200010
PM 29772047
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Sparrow, JR
   Fishkin, N
   Zhou, JL
   Cai, BL
   Jang, YP
   Krane, S
   Itagaki, Y
   Nakanishi, K
AF Sparrow, JR
   Fishkin, N
   Zhou, JL
   Cai, BL
   Jang, YP
   Krane, S
   Itagaki, Y
   Nakanishi, K
TI A2E, a byproduct of the visual cycle
SO VISION RESEARCH
LA English
DT Article
DE aging; atrophy; lipofuscin; retinal pigment epithelium; retinoids
ID RETINAL-PIGMENT EPITHELIUM; LYSOSOMAL DEGRADATIVE FUNCTIONS;
   LIGHT-INDUCED DAMAGE; LIPOFUSCIN FLUOROPHORE; FUNDUS AUTOFLUORESCENCE;
   MACULAR DEGENERATION; STARGARDT-DISEASE; ABC TRANSPORTER; GEOGRAPHIC
   ATROPHY; OUTER SEGMENTS
AB A substantial portion of the lipofuscin that accumulates with age and in some retinal disorders in retinal pigment epithelial (RPE) cells, forms as a consequence of light-related vitamin A recycling. Major constituents of RPE lipofuscin are the di-retinal conjugate A2E and its photoisomers. That the accretion of A2E has consequences for the cell, with the adverse effects of A2E being attributable to its amphiphilic structure and its photoreactivity, is consistent with evidence of an association between atrophic age-related macular degeneration (AMD) and excessive lipofuscin accumulation. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   Columbia Univ, Dept Chem, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Sparrow, JR (通讯作者)，Columbia Univ, Dept Ophthalmol, 630 W 168th St, New York, NY 10032 USA.
EM jrs88@columbia.edu
RI Cerviño, Alejandro/L-5853-2014; Jang, Young Pyo/AAJ-8782-2020
OI Cerviño, Alejandro/0000-0001-8014-3279; Jang, Young
   Pyo/0000-0001-5865-9228; Krane, Sonja/0000-0002-6525-8067
FU NEI NIH HHS [EY 12951] Funding Source: Medline; NIGMS NIH HHS [GM 36564]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012951] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [R01GM036564] Funding Source: NIH RePORTER
CR Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bermann M, 2001, EXP EYE RES, V72, P191
   BUNTING JR, 1992, PHOTOCHEM PHOTOBIOL, V55, P81, DOI 10.1111/j.1751-1097.1992.tb04212.x
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Dai JW, 1999, BIOPHYS J, V77, P3363, DOI 10.1016/S0006-3495(99)77168-7
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Delaey E, 2000, J PHOTOCH PHOTOBIO B, V55, P27, DOI 10.1016/S1011-1344(00)00021-X
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DELORI RC, 1995, RETINAL PIGMENT EPIT, V62, P37
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   ELDRED GE, 1989, FREE RADICAL BIO MED, V7, P157, DOI 10.1016/0891-5849(89)90007-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1982, SCIENCE, V216, P757, DOI 10.1126/science.7079738
   FAULKNER DJ, 1984, VISION RES, V24, P221, DOI 10.1016/0042-6989(84)90124-X
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fishkin N, 2003, ORG BIOMOL CHEM, V1, P1101, DOI 10.1039/b212213h
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   Imamoto Y, 2000, BIOCHEMISTRY-US, V39, P15225, DOI 10.1021/bi0018685
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   KATZ ML, 1986, MECH AGEING DEV, V35, P291, DOI 10.1016/0047-6374(86)90131-4
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   KATZ ML, 1987, MECH AGEING DEV, V39, P81, DOI 10.1016/0047-6374(87)90088-1
   Krieg M, 1996, BIOCHEM PHARMACOL, V51, P1461, DOI 10.1016/0006-2952(96)00087-1
   Lai CC, 1999, INVEST OPHTH VIS SCI, V40, P2141
   Liem ATA, 1996, SURV OPHTHALMOL, V41, P37, DOI 10.1016/S0039-6257(97)81994-7
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Lois N, 1999, INVEST OPHTH VIS SCI, V40, P2668
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   MOLDAY RS, 1979, J BIOL CHEM, V254, P4653
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415
   PARISH EJ, 1998, RRD ORG CHEM 1, V2, P95
   Raucher D, 2001, J CELL SCI, V114, P3759
   Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414
   Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sun H, 2001, J BIOENERG BIOMEMBR, V33, P523, DOI 10.1023/A:1012883306823
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tornow RP, 1998, ACTA ANAT, V162, P163
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 75
TC 208
Z9 221
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD DEC
PY 2003
VL 43
IS 28
BP 2983
EP 2990
DI 10.1016/S0042-6989(03)00475-9
PG 8
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 749WC
UT WOS:000186951700003
PM 14611934
OA Bronze
DA 2022-11-30
ER

PT J
AU Fischer, C
   Mazzone, M
   Jonckx, B
   Carmeliet, P
AF Fischer, Christian
   Mazzone, Massimiliano
   Jonckx, Bart
   Carmeliet, Peter
TI FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic
   therapy?
SO NATURE REVIEWS CANCER
LA English
DT Review
ID ENDOTHELIAL-GROWTH-FACTOR; INHIBITS TUMOR-GROWTH; RETINAL VASCULAR
   DEVELOPMENT; RECEPTOR TYROSINE KINASE; FACTOR-B; BONE-MARROW;
   UP-REGULATION; FACTOR-I; PROGNOSTIC VALUE; DOWN-REGULATION
AB Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic. After numerous patients with cancer or age-related macular degeneration have been treated with these drugs, they have now become part of the standard range of therapeutic tools. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity. Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment.
C1 [Mazzone, Massimiliano; Jonckx, Bart; Carmeliet, Peter] VIB, Flanders Inst Biotechnol, Vesalius Res Ctr, B-3000 Louvain, Belgium.
   [Fischer, Christian] Charite, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany.
   [Mazzone, Massimiliano; Jonckx, Bart; Carmeliet, Peter] Katholieke Univ Leuven, Vesalius Res Ctr, B-3000 Louvain, Belgium.
C3 Flanders Institute for Biotechnology (VIB); Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin; KU
   Leuven
RP Carmeliet, P (通讯作者)，VIB, Flanders Inst Biotechnol, Vesalius Res Ctr, B-3000 Louvain, Belgium.
EM peter.carmeliet@med.kuleuven.be
RI Carmeliet, Peter/AAQ-5140-2020
OI Carmeliet, Peter/0000-0001-7961-1821; Mazzone,
   Massimiliano/0000-0001-8824-4015
CR Aase K, 2001, CIRCULATION, V104, P358, DOI 10.1161/01.CIR.104.3.358
   Abraham D, 2000, CIRC RES, V87, P644, DOI 10.1161/01.RES.87.8.644
   Adini A, 2002, CANCER RES, V62, P2749
   Afuwape AO, 2003, GENE THER, V10, P1950, DOI 10.1038/sj.gt.3302104
   Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.0.CO;2-E
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Babiak A, 2004, CARDIOVASC RES, V61, P789, DOI 10.1016/j.cardiores.2003.12.014
   Bae DG, 2005, CLIN CANCER RES, V11, P2651, DOI 10.1158/1078-0432.CCR-04-1564
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005
   Bando H, 2005, BRIT J CANCER, V92, P553, DOI 10.1038/sj.bjc.6602374
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002
   Bellik L, 2005, BRIT J PHARMACOL, V146, P568, DOI 10.1038/sj.bjp.0706347
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bhardwaj S, 2003, HUM GENE THER, V14, P1451, DOI 10.1089/104303403769211664
   Bjorndahl M, 2004, CIRC RES, V94, P1443, DOI 10.1161/01.RES.0000129194.61747.bf
   Burris H, 2008, ONCOLOGIST, V13, P289, DOI 10.1634/theoncologist.2007-0134
   Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069
   Carlo-Stella C, 2007, STEM CELLS, V25, P252, DOI 10.1634/stemcells.2006-0020
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chang YT, 2008, PANCREAS, V37, P145, DOI 10.1097/MPA.0b013e318164548a
   Chen CN, 2004, CANCER LETT, V213, P73, DOI 10.1016/j.canlet.2004.05.020
   Cianfarani F, 2006, AM J PATHOL, V169, P1167, DOI 10.2353/ajpath.2006.051314
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   De Bandt M, 2003, J IMMUNOL, V171, P4853, DOI 10.4049/jimmunol.171.9.4853
   De Ceuninck F, 2004, BIOCHEM BIOPH RES CO, V323, P960, DOI 10.1016/j.bbrc.2004.08.184
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   Dineen SP, 2008, CANCER RES, V68, P4340, DOI 10.1158/0008-5472.CAN-07-6705
   Donnini S, 1999, J PATHOL, V189, P66, DOI 10.1002/(SICI)1096-9896(199909)189:1<66::AID-PATH390>3.0.CO;2-X
   Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104
   Eggert A, 2000, CLIN CANCER RES, V6, P1900
   El-Mousawi M, 2003, J BIOL CHEM, V278, P46681, DOI 10.1074/jbc.M308681200
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4
   Failla CM, 2000, J INVEST DERMATOL, V115, P388, DOI 10.1046/j.1523-1747.2000.00085.x
   Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246
   Feeney SA, 2003, INVEST OPHTH VIS SCI, V44, P839, DOI 10.1167/iovs.02-0040
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Fiedler J, 2005, BIOCHEM BIOPH RES CO, V334, P561, DOI 10.1016/j.bbrc.2005.06.116
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106
   Fragoso R, 2006, BLOOD, V107, P1608, DOI 10.1182/blood-2005-06-2530
   Fragoso R, 2008, EXP HEMATOL, V36, P1329, DOI 10.1016/j.exphem.2008.04.023
   Franco M, 2006, CANCER RES, V66, P3639, DOI 10.1158/0008-5472.CAN-05-3295
   Fujii T, 2008, ATHEROSCLEROSIS, V200, P51, DOI 10.1016/j.atherosclerosis.2007.12.012
   Gargioli C, 2008, NAT MED, V14, P973, DOI 10.1038/nm.1852
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Ghanem MA, 2003, J CLIN PATHOL, V56, P107, DOI 10.1136/jcp.56.2.107
   Gigante B, 2006, FASEB J, V20, P970, DOI 10.1096/fj.05-4481fje
   Gigante Bruna, 2004, Angiogenesis, V7, P277, DOI 10.1007/s10456-004-4179-1
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064
   Gille J, 2007, INT J CANCER, V120, P1899, DOI 10.1002/ijc.22531
   Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795
   Green CJ, 2001, CANCER RES, V61, P2696
   Gunningham SP, 2001, CANCER RES, V61, P3206
   Hagedorn A, 2005, EXP TOXICOL PATHOL, V57, P149, DOI 10.1016/j.etp.2005.04.005
   Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   Hatva E, 1996, AM J PATHOL, V148, P763
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Hiratsuka S, 2001, CANCER RES, V61, P1207
   HO MC, 2007, CANC LETT, V251, P43
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hollborn M, 2006, GRAEF ARCH CLIN EXP, V244, P732, DOI 10.1007/s00417-005-0154-9
   Hu QL, 2004, CANCER-AM CANCER SOC, V100, P1884, DOI 10.1002/cncr.20187
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ikuta T, 2000, GENES CELLS, V5, P913, DOI 10.1046/j.1365-2443.2000.00376.x
   Itokawa T, 2002, MOL CANCER THER, V1, P295
   Jackson MW, 2002, CANCER RES, V62, P854
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kakehashi A, 2008, DIABETES RES CLIN PR, V79, P438, DOI 10.1016/j.diabres.2007.10.018
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kami J, 2008, JPN J OPHTHALMOL, V52, P91, DOI 10.1007/s10384-007-0506-6
   Kanda M, 2008, J SURG ONCOL, V98, P190, DOI 10.1002/jso.21095
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114
   Kato H, 2002, ANTICANCER RES, V22, P3977
   Kearney JB, 2004, BLOOD, V103, P4527, DOI 10.1182/blood-2003-07-2315
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kerber M, 2008, CANCER RES, V68, P7342, DOI 10.1158/0008-5472.CAN-07-6241
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Khurana R, 2005, CIRCULATION, V111, P2828, DOI 10.1161/CIRCULATIONAHA.104.495887
   Kolakowski S, 2006, J CARDIAC SURG, V21, P559, DOI 10.1111/j.1540-8191.2006.00296.x
   Kreuter M, 2006, LEUKEMIA, V20, P1950, DOI 10.1038/sj.leu.2404384
   Lacal PM, 2008, EUR J CANCER, V44, P1914, DOI 10.1016/j.ejca.2008.06.032
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Larcher F, 2003, MOL CARCINOGEN, V37, P83, DOI 10.1002/mc.10126
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Xu L, 2007, MOL CANCER RES, V5, P873, DOI 10.1158/1541-7786.MCR-06-0141
   Leppanen P, 2005, CIRCULATION, V112, P1347, DOI 10.1161/CIRCULATIONAHA.105.534107
   Li B, 2006, FASEB J, V20, P1495, DOI 10.1096/fj.05-5137fje
   Li XR, 2001, GROWTH FACTORS, V19, P49, DOI 10.3109/08977190109001075
   Li X, 2008, ARTERIOSCL THROM VAS, V28, P1614, DOI 10.1161/ATVBAHA.107.158725
   Lijnen HR, 2006, DIABETES, V55, P2698, DOI 10.2337/db06-0526
   Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278
   Lin YL, 2007, J LEUKOCYTE BIOL, V82, P1473, DOI 10.1189/jlb.0307164
   Louzier V, 2003, AM J PHYSIOL-LUNG C, V284, pL926, DOI 10.1152/ajplung.00247.2002
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Luttun A, 2002, BIOCHEM BIOPH RES CO, V295, P428, DOI 10.1016/S0006-291X(02)00677-0
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Maes C, 2006, J CLIN INVEST, V116, P1230, DOI 10.1172/JCI26772
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   Malik AK, 2006, BLOOD, V107, P550, DOI 10.1182/blood-2005-05-2047
   Marcellini M, 2006, AM J PATHOL, V169, P643, DOI 10.2353/ajpath.2006.051041
   Marrony S, 2003, BONE, V33, P426, DOI 10.1016/S8756-3282(03)00195-9
   Maru Y, 1998, ONCOGENE, V16, P2585, DOI 10.1038/sj.onc.1201786
   Matsumoto K, 2003, ANTICANCER RES, V23, P4953
   Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272
   Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2
   Mohammed KA, 2007, AM J PHYSIOL-LUNG C, V292, pL559, DOI 10.1152/ajplung.00075.2006
   Mould AW, 2008, RHEUMATOLOGY, V47, P263, DOI 10.1093/rheumatology/kem369
   Mould AW, 2005, CIRC RES, V97, P60, DOI 10.1161/01.RES.0000182631.33638.77
   Mould AW, 2003, ARTHRITIS RHEUM-US, V48, P2660, DOI 10.1002/art.11232
   Murakami M, 2008, ARTERIOSCL THROM VAS, V28, P658, DOI 10.1161/ATVBAHA.107.150433
   Murakami M, 2006, BLOOD, V108, P1849, DOI 10.1182/blood-2006-04-016030
   Mylona E, 2007, GYNECOL ONCOL, V104, P557, DOI 10.1016/j.ygyno.2006.09.031
   Nagura S, 2001, HUM PATHOL, V32, P10, DOI 10.1053/hupa.2001.21139
   Nash AD, 2006, PULM PHARMACOL THER, V19, P61, DOI 10.1016/j.pupt.2005.02.007
   Neufeld G, 2002, ADV EXP MED BIOL, V515, P81
   Niki T, 2000, CLIN CANCER RES, V6, P2431
   Nomura M, 1998, J NEURO-ONCOL, V40, P123, DOI 10.1023/A:1006198422718
   Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103
   Odorisio T, 2006, J DERMATOL SCI, V41, P11, DOI 10.1016/j.jdermsci.2005.08.008
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Osada H, 2004, ANTICANCER RES, V24, P547
   Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Parr C, 2005, EUR J CANCER, V41, P2819, DOI 10.1016/j.ejca.2005.07.022
   Pavco PA, 2000, CLIN CANCER RES, V6, P2094
   Persico MG, 1999, CURR TOP MICROBIOL, V237, P31
   Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72
   PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415
   PLATE KH, 1993, CANCER RES, V53, P5822
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Ponticelli S, 2008, J BIOL CHEM, V283, P34250, DOI 10.1074/jbc.M806607200
   Rafii S, 2003, ANN NY ACAD SCI, V996, P49, DOI 10.1111/j.1749-6632.2003.tb03232.x
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Reichelt M, 2003, CLIN EXP OPHTHALMOL, V31, P61, DOI 10.1046/j.1442-9071.2003.00602.x
   Ribatti D, 2008, ANGIOGENESIS, V11, P215, DOI 10.1007/s10456-008-9114-4
   Rini BI, 2008, J CLIN ONCOL, V26, P3743, DOI 10.1200/JCO.2007.15.5416
   Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3
   Roncal C, 2008, J PATHOL, V216, P236, DOI 10.1002/path.2408
   Roy H, 2005, HUM GENE THER, V16, P1422, DOI 10.1089/hum.2005.16.1422
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Sasso FC, 2005, J AM COLL CARDIOL, V46, P827, DOI 10.1016/j.jacc.2005.06.007
   Sato YF, 2008, ARTERIOSCL THROM VAS, V28, P604, DOI 10.1161/ATVBAHA.108.162032
   Sawano A, 1996, CELL GROWTH DIFFER, V7, P213
   Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785
   Schoenfeld Jonathan, 2004, Angiogenesis, V7, P143, DOI 10.1007/s10456-004-1677-0
   Scholz D, 2003, J MOL CELL CARDIOL, V35, P177, DOI 10.1016/S0022-2828(02)00304-8
   Schomber T, 2007, CANCER RES, V67, P10840, DOI 10.1158/0008-5472.CAN-07-1034
   Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1
   SEETHARAM L, 1995, ONCOGENE, V10, P135
   Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423
   Seto T, 2006, LUNG CANCER-J IASLC, V53, P91, DOI 10.1016/j.lungcan.2006.02.009
   Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592
   Shibuya M, 2002, BIOL CHEM, V383, P1573, DOI 10.1515/BC.2002.177
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808
   Shintani S, 2004, ORAL ONCOL, V40, P13, DOI 10.1016/S1368-8375(03)00127-1
   Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Silvestre JS, 2003, CIRC RES, V93, P114, DOI 10.1161/01.RES.0000081594.21764.44
   Sowter HM, 1997, LAB INVEST, V77, P607
   Sun YJ, 2006, DEV BIOL, V289, P329, DOI 10.1016/j.ydbio.2005.10.016
   Tayade C, 2007, J IMMUNOL, V178, P4267, DOI 10.4049/jimmunol.178.7.4267
   Taylor AP, 2007, MOL CANCER THER, V6, P524, DOI 10.1158/1535-7163.MCT-06-0461
   Taylor AP, 2003, INT J CANCER, V105, P158, DOI 10.1002/ijc.11059
   Thomas S, 2000, J AM SOC NEPHROL, V11, P1236, DOI 10.1681/ASN.V1171236
   Tirziu D, 2007, J CLIN INVEST, V117, P3188, DOI 10.1172/JCI32024
   Tomanek RJ, 2006, CIRC RES, V98, P947, DOI 10.1161/01.RES.0000216974.75994.da
   Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
   VIGLIETTO G, 1995, ONCOGENE, V11, P1569
   Wafai R, 2009, J VASC RES, V46, P45, DOI 10.1159/000139132
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wanstall JC, 2002, CARDIOVASC RES, V55, P361, DOI 10.1016/S0008-6363(02)00440-6
   Wei SC, 2005, GUT, V54, P666, DOI 10.1136/gut.2004.050831
   Willett CG, 2005, J CLIN ONCOL, V23, P8136, DOI 10.1200/JCO.2005.02.5635
   Wirzenius M, 2007, J EXP MED, V204, P1431, DOI 10.1084/jem.20062642
   Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603
   Wu Y, 2006, CLIN CANCER RES, V12, P6573, DOI 10.1158/1078-0432.CCR-06-0831
   Wu Y, 2006, INT J CANCER, V119, P1519, DOI 10.1002/ijc.21865
   Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797
   Xu L, 2006, CANCER RES, V66, P3971, DOI 10.1158/0008-5472.CAN-04-3085
   Xu XY, 2001, J THORAC CARDIOV SUR, V121, P735, DOI 10.1067/mtc.2001.112340
   Yao YG, 2005, FEBS LETT, V579, P1227, DOI 10.1016/j.febslet.2005.01.017
   Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172
   Zhang Lijian, 2005, World J Surg Oncol, V3, P68, DOI 10.1186/1477-7819-3-68
   Zhao QW, 2004, ARTERIOSCL THROM VAS, V24, P2284, DOI 10.1161/01.ATV.0000147161.42956.80
   Ziche M, 1997, LAB INVEST, V76, P517
NR 208
TC 450
Z9 468
U1 2
U2 48
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-175X
EI 1474-1768
J9 NAT REV CANCER
JI Nat. Rev. Cancer
PD DEC
PY 2008
VL 8
IS 12
BP 942
EP 956
DI 10.1038/nrc2524
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 375QA
UT WOS:000261127200014
PM 19029957
DA 2022-11-30
ER

PT J
AU Nagy, V
   Agocs, A
   Deli, J
AF Nagy, V.
   Agocs, A.
   Deli, J.
TI In Vitro and In Vivo Transformations of Lutein
SO MINI-REVIEWS IN ORGANIC CHEMISTRY
LA English
DT Article
DE Lutein; anhydroluteins; 3 '-epilutein; 3-oxolutein
ID PAPRIKA CAPSICUM-ANNUUM; FATTY-ACID ESTERS; HUMAN PLASMA;
   ABSOLUTE-CONFIGURATION; STRUCTURAL ELUCIDATION; LIQUID-CHROMATOGRAPHY;
   SPECTROSCOPIC CHARACTERIZATION; OXIDATION-PRODUCTS; CALTHA-PALUSTRIS;
   PROCESSED FOODS
AB Lutein ((all-E,3R,3'R,6'R)-beta,epsilon-carotene-3,3'-diol) is the main carotenoid that can be found in light-harvesting complexes of higher plants and it is also involved in human diet. In the extracts of human plasma the 3'-epimer of lutein, several geometrical isomers, dehydration and oxidation products of lutein have been identified. It was also established that lutein reduces the risk of AMD (age-related macular degeneration). This mini review focuses on the in vitro and in vivo transformations of lutein.
C1 [Nagy, V.; Agocs, A.; Deli, J.] Univ Pecs, Sch Med, Dept Biochem & Med Chem, H-7624 Pecs, Hungary.
C3 University of Pecs
RP Deli, J (通讯作者)，Univ Pecs, Sch Med, Dept Biochem & Med Chem, Szigeti Ut 12, H-7624 Pecs, Hungary.
EM jozsef.deli@aok.pte.hu
RI Nagy, Veronika/C-6324-2008
OI Nagy, Veronika/0000-0002-9019-7980; Deli, Jozsef/0000-0002-0625-6117
FU Hungarian Research Fund [OTKA K 60121]
FX This work was supported by the Hungarian Research Fund OTKA K 60121.
CR BARANYAI M, 1984, ACTA CHIM HUNG, V116, P153
   BARANYAI M, 1981, TETRAHEDRON, V37, P203, DOI 10.1016/S0040-4020(01)97736-1
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BUCHECKE.R, 1974, HELV CHIM ACTA, V57, P631, DOI 10.1002/hlca.19740570317
   BUCHECKER R, 1979, HELV CHIM ACTA, V62, P2817, DOI 10.1002/hlca.19790620831
   BUCHECKER R, 1978, HELV CHIM ACTA, V61, P1962, DOI 10.1002/hlca.19780610603
   CADOSCH H, 1974, HELV CHIM ACTA, V57, P1466, DOI 10.1002/hlca.19740570522
   DABBAGH AG, 1974, Z PFLANZENPHYSIOL, V72, P177, DOI 10.1016/S0044-328X(74)80128-5
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Deli J, 2004, BIOORG MED CHEM LETT, V14, P925, DOI 10.1016/j.bmcl.2003.12.012
   Deli J, 2001, TETRAHEDRON LETT, V42, P1395, DOI 10.1016/S0040-4039(00)02268-1
   DELI J, 1988, PHYTOCHEMISTRY, V27, P547, DOI 10.1016/0031-9422(88)83139-X
   DELI J, 1994, CHIMIA, V48, P102
   EUGSTER CH, 1979, PURE APPL CHEM, V51, P463, DOI 10.1351/pac197951030463
   Feltl L, 2005, CURR ANAL CHEM, V1, P93
   HAGER A, 1970, ARCH MIKROBIOL, V71, P132, DOI 10.1007/BF00417739
   Hentschel P, 2006, J CHROMATOGR A, V1112, P285, DOI 10.1016/j.chroma.2005.12.082
   KARASHIMA K, 1970, INT J BIOCHEM, V1, P523
   KAYSER H, 1975, J COMP PHYSIOL, V104, P27, DOI 10.1007/BF02482835
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   KHACHIK F, 1988, J AGR FOOD CHEM, V36, P929, DOI 10.1021/jf00083a010
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2003, J NAT PROD, V66, P67, DOI 10.1021/np020376l
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khachik F, 1999, J AGR FOOD CHEM, V47, P455, DOI 10.1021/jf980823w
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   KHACHIK F, 1995, J CHROMATOGR B, V670, P219, DOI 10.1016/0378-4347(95)00169-7
   KHACHIK F, 1988, J AGR FOOD CHEM, V36, P938, DOI 10.1021/jf00083a011
   KHACHIK F, 1992, J CHROMATOGR-BIOMED, V582, P153, DOI 10.1016/0378-4347(92)80314-G
   KHACHIK F, 1992, ANAL CHEM, V64, P2111, DOI 10.1021/ac00042a016
   Khachik F, 2007, J NAT PROD, V70, P220, DOI 10.1021/np060575v
   Liaaen-Jensen S., 1966, ACTA CHEM SCAND, V20, P1703
   Linden A, 2004, HELV CHIM ACTA, V87, P1254, DOI 10.1002/hlca.200490115
   MARKIFISCHER E, 1990, HELV CHIM ACTA, V73, P1205, DOI 10.1002/hlca.19900730508
   MATSUNO T, 1986, COMP BIOCHEM PHYS B, V83, P335, DOI 10.1016/0305-0491(86)90377-9
   MATSUNO T, 1985, COMP BIOCHEM PHYS B, V80, P779, DOI 10.1016/0305-0491(85)90461-4
   MATSUNO T, 1986, COMP BIOCHEM PHYS B, V85, P77, DOI 10.1016/0305-0491(86)90224-5
   MAYER H, 1980, HELV CHIM ACTA, V83, P1451
   Molnar P, 2006, HELV CHIM ACTA, V89, P667, DOI 10.1002/hlca.200690067
   Molnar P, 2005, CHEM BIODIVERS, V2, P928, DOI 10.1002/cbdv.200590070
   Molnar P, 2004, CHROMATOGRAPHIA, V60, pS101, DOI 10.1365/s10337-004-0291-z
   Molnar P, 2004, HELV CHIM ACTA, V87, P2169, DOI 10.1002/hlca.200490196
   Molnar P, 2004, HELV CHIM ACTA, V87, P2159, DOI 10.1002/hlca.200490195
   Molnar P, 2006, LETT ORG CHEM, V3, P723, DOI 10.2174/157017806779025933
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   WILSTATTER R, 1907, LIEBIGSS ANN CHEM, V355, P1
   Yokota T, 2003, BIOSCI BIOTECH BIOCH, V67, P2644, DOI 10.1271/bbb.67.2644
   Young A. J, 1993, CAROTENOIDS PHOTOSYN
   Zechmeister L, 1943, J AM CHEM SOC, V65, P1951, DOI 10.1021/ja01250a040
   ZECHMEISTER L, 1956, ARCH BIOCHEM BIOPHYS, V61, P243, DOI 10.1016/0003-9861(56)90337-X
   ZECHMEISTER L, 1958, FORTSCHR CHEM ORG NA, V15, P15
NR 53
TC 1
Z9 1
U1 0
U2 22
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-193X
J9 MINI-REV ORG CHEM
JI Mini-Rev. Org. Chem.
PD AUG
PY 2009
VL 6
IS 3
BP 211
EP 219
DI 10.2174/157019309788922711
PG 9
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 482UA
UT WOS:000268913100005
DA 2022-11-30
ER

PT J
AU Teo, KYC
   Jordan-Yu, JM
   Tan, ACS
   Yeo, IYS
   Mathur, R
   Chan, CM
   Wong, TY
   Chakravarthy, U
   Cheung, CMG
AF Teo, Kelvin Yi Chong
   Jordan-Yu, Janice Marie
   Tan, Anna C. S.
   Yeo, Ian Y. S.
   Mathur, Ranjana
   Chan, Choi Mun
   Wong, Tien Yin
   Chakravarthy, Usha
   Cheung, Chui Ming Gemmy
TI Efficacy of a novel personalised aflibercept monotherapy regimen based
   on polypoidal lesion closure in participants with polypoidal choroidal
   vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TREAT-AND-EXTEND; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; SAFETY; TRIAL
AB Purpose To compare the efficacy of aflibercept using a personalised versus fixed regimen in treatment-naive participants with polypoidal choroidal vasculopathy (PCV).
   Design A 52-week, randomised, open-label, non-inferiority, single-centre study that included participants with symptomatic PCV. Participants were randomised (3:1 ratio) to receive either personalised (n=40) or fixed 8-weekly treatment regimen (n=13). The personalised regimen allowed for either early treat and extend (T&E) after week 12 or late T&E with 3 additional 4-weekly aflibercept injections until week 24 in participants with residual polypoidal lesions (PL) on indocyanine green angiography (ICGA) at week 12.
   Main outcomes and measures Non-inferiority of personalised to fixed regimen for mean change in best-corrected visual acuity (BCVA) from baseline to week 52 (non-inferiority margin: -5 letters). The key secondary outcomes include reduction in central subfield thickness (CSFT) on optical coherence tomography and the anatomical closure of PL on ICGA.
   Results Of the 53 participants, the mean (SD) age was 69.2 (8.1) years, 19 (35.8 %) were male. Personalised group was non-inferior to fixed for the primary end point (+8.1 vs +7.9 letters at week 52, respectively; difference 0.16, 95% CI -2.8 to 2.4, p=0.79). There was greater reduction in mean CSFT (SD) in the personalised versus fixed group (-248.8 (169.9) vs -164.8 (148.9) mu m, p=0.03). Closure of PL occurred in 21 (55.2%) and 5 (41.6%) of study eyes in personalised and fixed groups, respectively at week 52 (p=0.41).
   Conclusions Personalised regimen achieved non-inferior BCVA gain and numerically higher PL closure compared with fixed regimen.
C1 [Teo, Kelvin Yi Chong; Jordan-Yu, Janice Marie; Tan, Anna C. S.; Yeo, Ian Y. S.; Mathur, Ranjana; Chan, Choi Mun; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Med Retina, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Jordan-Yu, Janice Marie; Tan, Anna C. S.; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Retina Res Grp, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Tan, Anna C. S.; Yeo, Ian Y. S.; Mathur, Ranjana; Chan, Choi Mun; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Chakravarthy, Usha] Queens Univ Belfast, Ophthalmol & Vis Sci, Belfast, Antrim, North Ireland.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore; Queens
   University Belfast
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Med Retina, Singapore, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Teo, Kelvin/0000-0002-7458-7081
FU National Medical Research Council Singapore Open Fund Large
   Collaborative Grant [NMRC/LCG/004/2018]; Bayer
FX National Medical Research Council Singapore Open Fund Large
   Collaborative Grant: NMRC/LCG/004/2018. This study was in investigator
   initiated study with partial funding supported by Bayer (no funding or
   grant number). Bayer was not involved in the study design, data
   collection, data interpretation and drafting of this manuscript.
CR Azuma K, 2018, CLIN OPHTHALMOL, V12, P1589, DOI 10.2147/OPTH.S172115
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Browning DJ, 2018, JAMA OPHTHALMOL, V136, P794, DOI 10.1001/jamaophthalmol.2018.1799
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Calugaru D, 2018, GRAEF ARCH CLIN EXP, V256, P221, DOI 10.1007/s00417-017-3784-9
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Gan A, 2020, OPHTHALMOL RETINA
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Pak KY, 2017, RETINA-J RET VIT DIS, V37, P561, DOI 10.1097/IAE.0000000000001195
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 24
TC 9
Z9 9
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2022
VL 106
IS 7
BP 987
EP 993
DI 10.1136/bjophthalmol-2020-318354
EA FEB 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2L7SE
UT WOS:000726953300001
PM 33574033
DA 2022-11-30
ER

PT J
AU Liu, L
   Ma, J
   Duan, P
   Liu, Y
   Yin, ZQ
AF Liu, Ling
   Ma, Jie
   Duan, Ping
   Liu, Yong
   Yin, Zheng Qin
TI Practicability confirmation by meta-analysis of intravitreal ranibizumab
   compared to photodynamic therapy to treat polypoidal choroidal
   vasculopathy
SO MOLECULAR VISION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; BEVACIZUMAB; NEOVASCULARIZATION; VERTEPORFIN; COMBINATION;
   INJECTIONS; EFFICACY; FEATURES
AB Purpose: The literatures show that photodynamic therapy (PDT) and intravitreal ranibizumab (IVR) have their own specific advantages in treating polypoidal choroidal vasculopathy (PCV). Using a meta-analysis, we want to provide some suggestions for the clinical application of the two treatments to PCV patients through a comparison of the functional outcomes in a follow-up period after administration.
   Methods: A comprehensive literature search was performed using several databases to assemble the controlled trials of IVR and PDT. The program of RevMan version 5.0 was used to analyze the data. The effects of two treatments on PCV were evaluated by comparing weighted mean differences (WMDs) in the change of LogMar visual acuity, central retinal thickness (CRT), and the deterioration ratio for the proportions of patients with visual reductions from the baseline. Data with homogeneity among studies were analyzed using a fixed-effect meta-analysis model; otherwise, a random-effect model was applied to data with heterogeneity.
   Results: Five studies are included covering 260 cases in total in this study. The outcomes of IVR treatment compared to PDT appear to significantly improve vision, decrease the central retinal thickness (CRT), and reduce the invalidation rate. The LogMar visual acuity shifts from 0.6 to 0.3 in the following 24 months and the improvement rate of visual acuity ranges from 60-70% in IVR treated patients. However, the visual acuity improvement is moderate in the PDT group. These analyses indicate that IVR is an applicable treatment in PCV patients, although PDT is able to yield about a 35% visual acuity improvement in a short-term follow-up. Our 3-D mesh modal also confirms that IVR is able to yield better effects to treat PCV than PDT.
   Conclusions: The analysis in this study suggests that IVR has a significant effect on the improvement of visual acuity when treating patients with PCV. Our findings clearly document that IVR can be used as a more effective therapy for long-term administration in PCV.
C1 [Liu, Ling; Duan, Ping; Liu, Yong; Yin, Zheng Qin] Third Mil Med Univ, Key Lab Visual Damage & Repair Chongqing, Southwest Hosp, Southwest Eye Hosp, Chongqing 400038, Peoples R China.
   [Ma, Jie] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst,Massachusetts Eye & Ear, Boston, MA USA.
C3 Army Medical University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute
RP Yin, ZQ (通讯作者)，Third Mil Med Univ, Key Lab Visual Damage & Repair Chongqing, Southwest Hosp, Southwest Eye Hosp, Chongqing 400038, Peoples R China.
EM qinzyin@ailiyun.com
FU National Basic Research Program of China (973 Program) [2013CB967002];
   National Natural Science Foundation of China [81470671]
FX This study was supported by the National Basic Research Program of China
   (973 Program, 2013CB967002 to ZQY) and the National Natural Science
   Foundation of China (No. 81470671 to YL). Yong Liu
   (liu_yong2012@yahoo.com) and Zheng Qin Yin (qinzyin@aliyun.com) are
   co-corresponding authors for this paper.
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Centre TNC, 2012, COCHRANE COLLABORATI
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fine Howard F, 2008, Retin Cases Brief Rep, V2, P15, DOI 10.1097/ICB.0b013e318159e7e9
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2013, AM J OPHTHALMOL, V155, P713, DOI 10.1016/j.ajo.2012.10.010
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Li HT, 2004, RETINA-J RET VIT DIS, V24, P629, DOI 10.1097/00006982-200408000-00026
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Mieler WF, 2001, RETINA, V21, P396
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 39
TC 4
Z9 4
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 3
PY 2015
VL 21
BP 1130
EP 1141
PG 12
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA CS5ID
UT WOS:000362110600001
PM 26539025
DA 2022-11-30
ER

PT J
AU Kabedi, NN
   Kayembe, DL
   Mwanza, JC
AF Kabedi, N. N.
   Kayembe, D. L.
   Mwanza, J. C.
TI Effect of intravitreal injection of bevacizumab in treated and untreated
   eyes of Black African patients with polypoidal choroidal vasculopathy
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Anti-VEGF; Bevacizumab; Black
   african; Fellow eye
ID PHOTODYNAMIC THERAPY; MG BEVACIZUMAB; PHARMACOKINETICS; RANIBIZUMAB;
   MANAGEMENT; DIAGNOSIS; EFFICACY; AVASTIN
AB Objective. - To evaluate the response of polypoidal choroidal vasculopathy (PCV) in eyes treated with intravitreal bevacizumab (BVZ) and untreated fellow eyes in black Africans.
   Methods. - We studied 22 eyes (12 patients) divided into 12 treated and 10 untreated eyes from January 2017 to January 2020. Treated eyes received 1 monthly injection of BVZ 2.5 mg for 3 months, with optional additional injections depending on the patient's course. Both groups of eyes were evaluated at presentation and then at 3, 6, 9, and 12 months after treatment. Outcome measures were visual acuity (VA) and ophthalmoscopic and OCT findings.
   Results. - The mean age of the patients was 66.3 +/- 5.6 years. In treated eyes, VA remained stable from 0.10 +/- 0.12 at baseline to 0.20 +/- 0.30 at month 12, P = 0.84. VA was stable in 83.3% and improved in 16.7% of eyes. On OCT, 41.7% of eyes showed decreased and another 41.7% disappearance of subretinal fluid (SRF) at 12 months. Pigment epithelial detachment (PED) height decreased in 9 eyes (75.0%) but remained unchanged in 3 eyes (25%). In untreated eyes, no difference was observed between the baseline (0.53 +/- 0.42) and 12-month VA (0.58 +/- 0.40), P = 0.82. VA improved in 2 eyes, decreased in one eye, and remained unchanged in 7 eyes. OCT lesions remained stable in 6 eyes. The PED enlarged in one eye but remained stable in 3 other eyes.
   Conclusion. - Intravitreal injection of BVZ 2.5 mg led to stabilization of VA, resorption of SRF, and reduction in the size of the PED in the majority of eyes with PCV but was ineffective on the polyps. The one-year prognosis in untreated eyes with PCV was favorable and marked by functional and structural stability. (C) 2021 Elsevier Masson SAS. All rights reserved.
C1 [Kabedi, N. N.; Kayembe, D. L.; Mwanza, J. C.] Univ Kinshasa, Sch Med, Dept Ophthalmol, Kinshasa, DEM REP CONGO.
   [Mwanza, J. C.] Univ N Carolina, Dept Ophthalmol, Sch Med, Chapel Hill, NC 27515 USA.
C3 Universite de Kinshasa; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine
RP Mwanza, JC (通讯作者)，Univ N Carolina, Dept Ophthalmol, Sch Med, Chapel Hill, NC 27515 USA.
EM jean-claude_mwanza@med.unc.edu
CR Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Chen CH, 2011, J OCUL PHARMACOL TH, V27, P395, DOI 10.1089/jop.2011.0023
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Chhablani JK, 2013, INDIAN J OPHTHALMOL, V61, P136, DOI 10.4103/0301-4738.109390
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dow ER, 2019, J VITREORETINAL DIS, V3, P438
   Gamulescu MA, 2010, J OCUL PHARMACOL TH, V26, P213, DOI 10.1089/jop.2009.0126
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2019, JPN J OPHTHALMOL, V63, P437, DOI 10.1007/s10384-019-00687-2
   Guyomarch J, 2008, J FR OPHTALMOL, V31, P579, DOI 10.1016/S0181-5512(08)75458-5
   Ho CPS, 2018, INDIAN J OPHTHALMOL, V66, P1727, DOI 10.4103/ijo.IJO_975_18
   Isildak H, 2018, CASE REP OPHTHALMOL, V2018, DOI 10.1155/2018/8561895
   Kabedi NN, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4103871
   Kal A, 2016, ADV OPHTHALMOL VIS S, V4, P60
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lew Y, 2007, INVEST OPHTHALMOL VI, V48, P3352
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Meyer CH, 2012, ACTA OPHTHALMOL, V90, P68, DOI 10.1111/j.1755-3768.2009.01842.x
   Michalska-Malecka K, 2016, CLIN INTERV AGING, V11, P357, DOI 10.2147/CIA.S93820
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Oluleye TS, 2013, CLIN OPHTHALMOL, V7, P1373, DOI 10.2147/OPTH.S47511
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P914, DOI 10.1001/jamaophthalmol.2019.1947
   Park UC, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0631-z
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 40
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD DEC
PY 2021
VL 44
IS 10
BP 1505
EP 1515
DI 10.1016/j.jfo.2021.06.012
EA NOV 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YJ0TJ
UT WOS:000744251400014
PM 34776295
DA 2022-11-30
ER

PT J
AU Ghoshal, R
   Sharanjeet-Kaur, S
   Fadzil, NM
   Ghosh, S
   Ngah, N
   Abd Aziz, RA
AF Ghoshal, Rituparna
   Sharanjeet-Kaur, Sharanjeet
   Fadzil, Norliza Mohamad
   Ghosh, Somnath
   Ngah, NorFariza
   Abd Aziz, Roslin Azni
TI Baseline Optical Coherence Tomography Parameters That May Influence 6
   Months Treatment Outcome of Polypoidal Choroidal Vasculopathy Eyes with
   Combination Therapy: A Short-Term Pilot Study
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE combination therapy; polypoidal choroidal vasculopathy; optical
   coherence tomography
ID EXTERNAL LIMITING MEMBRANE; PHOTODYNAMIC THERAPY; RETINAL MORPHOLOGY;
   VISUAL-ACUITY; DEGENERATION; RANIBIZUMAB; PREDICTORS
AB Although optical coherence tomography (OCT) parameters have assisted in the diagnosis of polypoidal choroidal vasculopathy (PCV), its potential to evaluate treatment outcomes has not been established. The purpose of this pilot study was to evaluate baseline OCT parameters that may influence treatment outcome in PCV eyes with combination therapy. In this single-centered, prospective study, patients were recruited with at least one treatment-naive PCV eye and treated with combination therapy of intravitreal anti-vascular endothelial growth factor and photodynamic therapy. Best-corrected distance and near visual acuity (DVA and NVA), and contrast sensitivity (CS) were recorded at baseline and six months after treatment. OCT parameters were determined. Twenty-six eyes of 26 patients aged between 51 to 83 years were evaluated. In eyes that had disrupted external limiting membrane (ELM), photoreceptors inner and outer segment (IS-OS) junction at 1000 micron of fovea at baseline showed low mean visual functions after 6 months of treatment. Eyes with foveal sub-retinal fluid (SRF) and polyp at central 1000 micron of fovea at baseline showed significantly worse DVA and CS after six months. Thus, the presence of foveal SRF, foveal polyp, disrupted ELM, and IS-OS junction at baseline significantly influenced the six months' visual outcome in PCV eyes treated with combination therapy.
C1 [Ghoshal, Rituparna; Sharanjeet-Kaur, Sharanjeet; Fadzil, Norliza Mohamad] Univ Kebangsaan Malaysia, Fac Hlth Sci, Optometry & Vis Sci Program, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.
   [Ghoshal, Rituparna] CT Univ, Dept Optometry, Ferozepur Rd, Ludhiana 142024, Punjab, India.
   [Ghosh, Somnath] Brainware Univ, Dept Allied Hlth Sci, Kalkata 700125, W Bengal, India.
   [Ngah, NorFariza; Abd Aziz, Roslin Azni] Hosp Shah Alam, Dept Ophthalmol, Seksyen 7, Shah Alam 40000, Malaysia.
C3 Universiti Kebangsaan Malaysia
RP Sharanjeet-Kaur, S (通讯作者)，Univ Kebangsaan Malaysia, Fac Hlth Sci, Optometry & Vis Sci Program, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.
EM rituparna4ab@yahoo.co.in; sharanjeet@ukm.edu.my;
   norlizafadzil@ukm.edu.my; somnath4ab@yahoo.co.in;
   drfarizangah@gmail.com; roslinazni@gmail.com
OI Kaur, Sharanjeet/0000-0003-0734-5151
CR Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Buari Noor Halilah, 2014, J Optom, V7, P210, DOI 10.1016/j.optom.2013.12.009
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Ghoshal R, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052581
   Ghoshal R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176379
   Ghoshal R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176378
   Ghoshal R, 2018, SAINS MALAYS, V47, P2447, DOI 10.17576/jsm-2018-4710-21
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Keane PA, 2011, SAUDI J OPHTHALMOL, V25, P145, DOI 10.1016/j.sjopt.2011.01.003
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Landa G, 2012, EYE, V26, P61, DOI 10.1038/eye.2011.237
   Marco A.B.F., 2015, REV OPHTHALMOL, VXXII, P78
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nazima SA, 2016, MED HEALTH-KUALA LUM, V11, P245, DOI 10.17576/MH.2016.1102.13
   Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Saxena S, 2014, CLIN OPHTHALMOL, V8, P2507, DOI 10.2147/OPTH.S72132
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharanjeet-Kaur S., 2018, MALAYS J PUBLIC HLTH, V1, P124
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Wakabayashi T, 2010, OPHTHALMOLOGY, V117, P1815, DOI 10.1016/j.ophtha.2010.01.017
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wojtkowski M, 2010, APPL OPTICS, V49, pD30, DOI 10.1364/AO.49.000D30
   Zhang Yi, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V37, P165
NR 34
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD MAY
PY 2021
VL 18
IS 10
AR 5378
DI 10.3390/ijerph18105378
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA SI6MC
UT WOS:000654941000001
PM 34070071
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Calonge, N
   Petitti, DB
   DeWitt, TG
   Dietrich, AJ
   Gregory, KD
   Grossman, D
   Isham, G
   LeFevre, ML
   Leipzig, RM
   Marion, LN
   Melnyk, B
   Moyer, VA
   Ockene, JK
   Sawaya, GF
   Schwartz, JS
   Wilt, T
AF Calonge, Ned
   Petitti, Diana B.
   DeWitt, Thomas G.
   Dietrich, Allen J.
   Gregory, Kimberly D.
   Grossman, David
   Isham, George
   LeFevre, Michael L.
   Leipzig, Rosanne M.
   Marion, Lucy N.
   Melnyk, Bernadette
   Moyer, Virginia A.
   Ockene, Judith K.
   Sawaya, George F.
   Schwartz, J. Sanford
   Wilt, Timothy
CA US Preventive Serv Task Force
TI Screening for Impaired Visual Acuity in Older Adults: US Preventive
   Services Task Force Recommendation Statement
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID INTRAOCULAR-LENS IMPLANTATION; RANDOMIZED-TRIAL; UNITED-STATES;
   CATARACT-EXTRACTION; PREVALENCE; PEOPLE; VISION; FALLS
AB Description: Update of the 1996 U. S. Preventive Services Task Force (USPSTF) recommendation statement on screening for visual impairment.
   Methods: The USPSTF reviewed evidence published since its last review on screening adults 65 years or older in the primary care setting for visual acuity impairment associated with uncorrected refractive errors, cataracts, and age-related macular degeneration.
   Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for visual acuity for the improvement of outcomes in older adults. (I statement).
C1 [Calonge, Ned] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
   [Petitti, Diana B.] Arizona State Univ, Phoenix, AZ USA.
   [DeWitt, Thomas G.] Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA.
   [Dietrich, Allen J.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA.
   [Gregory, Kimberly D.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Grossman, David] Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA.
   [Isham, George] Hlth Partners, Minneapolis, MN USA.
   [LeFevre, Michael L.] Univ Missouri, Sch Med, Columbia, MO USA.
   [Leipzig, Rosanne M.] Mt Sinai Sch Med, New York, NY USA.
   [Marion, Lucy N.] Med Coll Georgia, Sch Nursing, Augusta, GA 30912 USA.
   [Melnyk, Bernadette] Arizona State Univ, Coll Nursing & Hlth Innovat, Phoenix, AZ USA.
   [Moyer, Virginia A.] Univ Texas Hlth Sci Ctr, Houston, TX USA.
   [Ockene, Judith K.] Univ Massachusetts, Sch Med, Worcester, MA USA.
   [Sawaya, George F.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Schwartz, J. Sanford] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Schwartz, J. Sanford] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
   [Wilt, Timothy] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA.
   [Wilt, Timothy] Univ Minnesota, Dept Med, Denver, CO USA.
   [US Preventive Serv Task Force] Agcy Healthcare Res & Qual, Rockville, MD USA.
C3 Colorado Department of Public Health & Environment; Arizona State
   University; Arizona State University-Downtown Phoenix; Cincinnati
   Children's Hospital Medical Center; Dartmouth College; Cedars Sinai
   Medical Center; Group Health Cooperative; University of Missouri System;
   University of Missouri Columbia; Icahn School of Medicine at Mount
   Sinai; University System of Georgia; Augusta University; Arizona State
   University; Arizona State University-Downtown Phoenix; University of
   Texas System; University of Texas Health Science Center Houston;
   University of Massachusetts System; University of Massachusetts
   Worcester; University of California System; University of California San
   Francisco; University of Pennsylvania; University of Pennsylvania; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Minneapolis VA Health Care System; University of Minnesota System;
   Agency for Healthcare Research & Quality
RP Calonge, N (通讯作者)，Colorado Dept Publ Hlth & Environm, Denver, CO USA.
RI Melnyk, Bernadette J/E-9868-2013
FU Agency for Healthcare Research and Quality
FX The USPSTF is an independent, voluntary body. The U. S. Congress
   mandates that the Agency for Healthcare Research and Quality support the
   operations of the USPSTF.
CR ACOG Committee on Gynecologic Practice, 2006, Obstet Gynecol, V108, P1615
   *AM AC OPHTH PREF, 2005, PREF PRACT PATT GUID
   *AM OPT ASS CONS P, 2005, OPT CLIN PRACT GUID
   Centers for Disease Control and Prevention, 2006, IMPR NAT VIS HLTH CO
   Chou R., 2009, AHRQ PUBLICATION
   Chou R, 2009, ANN INTERN MED, V151, P44, DOI 10.7326/0003-4819-151-1-200907070-00008
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cumming RG, 2007, J AM GERIATR SOC, V55, P175, DOI 10.1111/j.1532-5415.2007.01046.x
   Eekhof JAH, 2000, FAM PRACT, V17, P329, DOI 10.1093/fampra/17.4.329
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Lord SR, 2002, J AM GERIATR SOC, V50, P1760, DOI 10.1046/j.1532-5415.2002.50502.x
   McGwin G, 2003, OPHTHALMIC EPIDEMIOL, V10, P107, DOI 10.1076/opep.10.2.107.13900
   Meads C, 2003, Health Technol Assess, V7, pv
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Moore AA, 1997, AM J MED, V102, P371, DOI 10.1016/S0002-9343(97)00089-2
   MURRAY A, SYSTEMATIC REV SAFET
   Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P228, DOI 10.1001/archopht.1994.01090140104032
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033
   Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3
   Smeeth L, 2003, BMJ-BRIT MED J, V327, P1027, DOI 10.1136/bmj.327.7422.1027
   *US PREV SERV TASK, 1996, SCREEN VIS IMP GUID
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Vitale S, 2006, JAMA-J AM MED ASSOC, V295, P2158, DOI 10.1001/jama.295.18.2158
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
NR 27
TC 14
Z9 15
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUL 7
PY 2009
VL 151
IS 1
BP 37
EP U56
DI 10.7326/0003-4819-151-1-200907070-00007
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 470BF
UT WOS:000267946100005
PM 19581645
OA Green Published
DA 2022-11-30
ER

PT J
AU Kong, M
   Kim, SM
   Ham, DI
AF Kong, Mingui
   Kim, Sung Min
   Ham, Don-Il
TI Comparison of clinical features and 3-month treatment response among
   three different choroidal thickness groups in polypoidal choroidal
   vasculopathy
SO PLOS ONE
LA English
DT Article
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB;
   RANIBIZUMAB THERAPY
AB Eyes with polypoidal choroidal vasculopathy (PCV) were recently reported to have various choroidal thickness, and choroidal thickness might be associated with visual outcome in the treatment of many retinal disorders. The range of subfoveal choroidal thickness (SFCT), clinical features, and 3-month treatment response among three groups having different range of SFCT were investigated in PCV eyes. In 78 treatment-naive eyes with PCV, SFCT was measured using optical coherence tomography. Eyes were classified into thin, medium, and thick groups, using mean and one standard deviation of SFCT. Clinical features and imaging findings were compared among the three groups. Some eyes were treated with three consecutive monthly injection of anti-vascular endothelial growth factor (VEGF) as an initial treatment. They were also classified into three thickness groups, and the short-term post-treatment improvement in visual acuity and central retinal thickness were compared among groups. The mean SFCT was 271.9 +/- 135.6 mu m. Twelve, 53, and 13 eyes were classified into thin (<136.3 mu m), medium (136.3-407.5 mu m), and thick (>407.5 mu m) groups, respectively. The thin group showed older age, lower visual acuity, and a higher prevalence of fundus tessellation than the other two groups (P<0.05). In multiple linear regression analyses, baseline BCVA was correlated with baseline SFCT. Forty-six eyes completed three consecutive anti-VEGF treatments. The thin group showed no visual improvement after treatment (P = 0.141), unlike the other two groups showing visual improvement (P<0.05). Eyes with PCV have a broad range of SFCT, and PCV eyes with a thin choroid manifest worse visual function than eyes with a medium or thick choroid.
C1 [Kong, Mingui] Hangil Eye Hosp, Incheon, South Korea.
   [Kong, Mingui] Catholic Kwandong Univ, Coll Med, Dept Ophthalmol, Incheon, South Korea.
   [Kim, Sung Min; Ham, Don-Il] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Catholic Kwandong University; Sungkyunkwan University (SKKU); Samsung
   Medical Center
RP Ham, DI (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
EM oculus@naver.com
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Balaratnasingam C, 2015, RETINA
   Byon IS, 2014, OSLI RETINA, V45, P534, DOI 10.3928/23258160-20141118-08
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim JH, 2013, EYE, V27, P809, DOI 10.1038/eye.2013.78
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Nishide T, 2013, GRAEF ARCH CLIN EXP, V251, P2415, DOI 10.1007/s00417-013-2419-z
   Ouyang YL, 2011, INVEST OPHTH VIS SCI, V52, P7019, DOI 10.1167/iovs.11-8046
   Rayess N, 2015, AM J OPHTHALMOL, V159, P85, DOI 10.1016/j.ajo.2014.09.033
   Sakurada Y, 2016, RETINA
   Shin J.Y., 2015, ACTA OPHTHALMOL
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yan YN, 2015, OPHTHALMOLOGY
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 9
Z9 10
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 8
PY 2017
VL 12
IS 9
AR e0184058
DI 10.1371/journal.pone.0184058
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FG2YO
UT WOS:000410001100060
PM 28886052
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Tholen, P
   Brown, CN
   Keil, C
   Bayir, A
   Zeng, HH
   Haase, H
   Thompson, RB
   Lengyel, I
   Yucesan, G
AF Tholen, Patrik
   Brown, Connor N.
   Keil, Claudia
   Bayir, Ali
   Zeng, Hui-Hui
   Haase, Hajo
   Thompson, Richard B.
   Lengyel, Imre
   Yucesan, Gundog
TI A 2,7-dichlorofluorescein derivative to monitor microcalcifications
SO MOLECULAR SYSTEMS DESIGN & ENGINEERING
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN-2; BREAST-CANCER; BISPHOSPHONATES;
   DIFFERENTIATION; FLUOROPHORES; MECHANISM; INSIGHTS; HISTORY
AB Herein, we report the crystal structure of 2,7-dichlorofluorescein methyl ester (DCF-ME) and its fluorescence response to hydroxyapatite binding. The reported fluorophore is very selective for staining the bone matrix and provides turn-on fluorescence upon hydroxyapatite binding. The reported fluorophore can readily pass the cell membrane of the C2C12 cell line, and it is non-toxic for the cell line. The reported fluorophore DCF-ME may find applications in monitoring bone remodeling and microcalcification as an early diagnosis tool for breast cancer and age-related macular degeneration.
C1 [Brown, Connor N.; Lengyel, Imre] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast BT9 7BL, Antrim, North Ireland.
   [Tholen, Patrik; Keil, Claudia; Haase, Hajo; Yucesan, Gundog] Tech Univ Berlin, Inst Food Chem & Toxicol, Gustav Meyer Allee 25, D-13355 Berlin, Germany.
   [Bayir, Ali] Yildiz Tech Univ, Dept Chem, TR-31220 Istanbul, Turkey.
   [Zeng, Hui-Hui; Thompson, Richard B.] Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA.
C3 Queens University Belfast; Technical University of Berlin; Yildiz
   Technical University; University System of Maryland; University of
   Maryland Baltimore
RP Yucesan, G (通讯作者)，Tech Univ Berlin, Inst Food Chem & Toxicol, Gustav Meyer Allee 25, D-13355 Berlin, Germany.
EM yuecesan@tu-berlin.de
RI Haase, Hajo/B-9280-2009; Lengyel, Imre/B-5217-2009; Yucesan,
   Gundog/C-4330-2018
OI Haase, Hajo/0000-0002-1622-8718; Lengyel, Imre/0000-0001-7467-2174;
   Yucesan, Gundog/0000-0002-5105-7280
FU DFG; Department for Education of Northern Ireland; Belfast Association
   for the Blind; U.S. National Eye Institute [RO1 EY 030443]
FX G. Y. would like to thank the DFG for funding his work. C. N. B. would
   like to thank the Department for Education of Northern Ireland for his
   PhD studentship. I. L. would like to thank the Belfast Association for
   the Blind for supporting his research. R. B. T. and H.-H. Z. thank the
   U.S. National Eye Institute RO1 EY 030443 for their support. The authors
   thank Professor Ki Tae Nam (Department of Materials Science and
   Engineering, Seoul National University, Seoul, 151-744, South Korea;
   E-mail: nkitae@snu.ac.kr) for the generous gift of synthetic HAP and WHT
   nanocrystals.
CR Alford R, 2009, MOL IMAGING, V8, P341, DOI 10.2310/7290.2009.00031
   Ali MA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51186-w
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bhushan KR, 2007, ANGEW CHEM INT EDIT, V46, P7969, DOI 10.1002/anie.200701216
   Borisov SM, 2009, TALANTA, V79, P1322, DOI 10.1016/j.talanta.2009.05.041
   Cho CH, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.208
   Choi W, 2019, NATURE, V576, P163, DOI 10.1038/s41586-019-1781-3
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   COLSMAN MR, 1990, J AM CHEM SOC, V112, P2349, DOI 10.1021/ja00162a040
   Cox RF, 2012, BRIT J CANCER, V106, P525, DOI 10.1038/bjc.2011.583
   Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0
   Dolomanov OV, 2009, J APPL CRYSTALLOGR, V42, P339, DOI 10.1107/S0021889808042726
   Dreses-Werringloer U, 2008, CELL, V133, P1149, DOI 10.1016/j.cell.2008.05.048
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Heining E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025163
   Hyun H, 2014, ANGEW CHEM INT EDIT, V53, P10668, DOI 10.1002/anie.201404930
   Jang HL, 2016, ADV HEALTHC MATER, V5, P128, DOI 10.1002/adhm.201400824
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Keil C, 2021, CHEMBIOCHEM, V22, P1925, DOI 10.1002/cbic.202100031
   Korolev AV, 2001, ORGANOMETALLICS, V20, P3367, DOI 10.1021/om010395a
   Levitskaia TG, 2000, J AM CHEM SOC, V122, P554, DOI 10.1021/ja992760j
   Lotsari A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06570-x
   Maares M, 2018, METALLOMICS, V10, P979, DOI 10.1039/c8mt00064f
   MELOAN S N, 1985, Journal of Histotechnology, V8, P11
   Pazianas Michael, 2014, Bonekey Rep, V3, P529, DOI 10.1038/bonekey.2014.24
   Morgan MP, 2005, J MAMMARY GLAND BIOL, V10, P181, DOI 10.1007/s10911-005-5400-6
   Omarjee L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52808-z
   POSNER AS, 1975, ACCOUNTS CHEM RES, V8, P273, DOI 10.1021/ar50092a003
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Rangayyan RM, 2007, J FRANKLIN I, V344, P312, DOI 10.1016/j.jfranklin.2006.09.003
   Rizwan A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29330-9
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Sheldrick GM, 2014, SHELXS 2014 PROGRAM
   Sim AM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35454-9
   Song RY, 2017, MOL MED REP, V16, P4483, DOI 10.3892/mmr.2017.7183
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Vermeer JAF, 2013, BONE, V57, P242, DOI 10.1016/j.bone.2013.08.007
   Waich K, 2008, TALANTA, V77, P66, DOI 10.1016/j.talanta.2008.05.058
   Walkup GK, 2000, J AM CHEM SOC, V122, P5644, DOI 10.1021/ja000868p
   Wang ZT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4797
   YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0
   Zhang XA, 2008, J AM CHEM SOC, V130, P15788, DOI 10.1021/ja807156b
   Zorlu Y, 2020, CHEM-EUR J, V26, P11129, DOI 10.1002/chem.202001613
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2058-9689
J9 MOL SYST DES ENG
JI Mol. Syst. Des. Eng.
PD OCT 31
PY 2022
VL 7
IS 11
BP 1415
EP 1421
DI 10.1039/d2me00185c
EA OCT 2022
PG 7
WC Chemistry, Physical; Engineering, Chemical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Science & Technology - Other Topics; Materials
   Science
GA 5U1TU
UT WOS:000869871300001
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ferrara, N
AF Ferrara, Napoleone
TI VEGF-A: a critical regulator of blood vessel growth
SO EUROPEAN CYTOKINE NETWORK
LA English
DT Review
DE VEGF; VPF; angiogenesis; tumor
ID VASCULAR-PERMEABILITY FACTOR; ENDOTHELIAL-CELL; TUMOR ANGIOGENESIS;
   IN-VIVO; BEVACIZUMAB; THERAPY; INHIBITION; SURVIVAL; CANCER;
   NEOVASCULARIZATION
AB Angiogenesis is required for a variety of normal and pathological, proliferative processes. Numerous regulators of angiogenesis have been identified and characterized over the last decades. Among these, vascular endothelial growth factor (VEGF)-A appears especially important in normal development and in disease processes. Several VEGF inhibitors have been approved by the FDA for the treatment of tumors or the neovascular form of age-related macular degeneration. This article examines the molecular and biological characteristics of VEGF and also discusses preclinical and clinical studies with VEGF inhibitors and the lessons learned from these studies.
C1 [Ferrara, Napoleone] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Broxmeyer HE, 1995, INT J HEMATOL, V62, P203
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017
   Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289
   EHRMANN RL, 1968, J NATL CANCER I, V41, P1329
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342
   Gerber HP, 2007, P NATL ACAD SCI USA, V104, P3478, DOI 10.1073/pnas.0611492104
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 2005, CANCER RES, V65, P671
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111
   Hamilton W.J., 1962, HUMAN EMBRYOLOGY
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Korsisaari N, 2008, CLIN CANCER RES, V14, P249, DOI 10.1158/1078-0432.CCR-07-1552
   Korsisaari N, 2007, P NATL ACAD SCI USA, V104, P10625, DOI 10.1073/pnas.0704213104
   Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520
   Lang L, 2008, GASTROENTEROLOGY, V134, P379, DOI 10.1053/j.gastro.2007.12.038
   Lee John T, 2003, Curr Opin Investig Drugs, V4, P757
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Manley PW, 2002, EXPERT OPIN INV DRUG, V11, P1715, DOI 10.1517/13543784.11.12.1715
   Maragoudakis ME, 2000, GEN PHARMACOL-VASC S, V35, P225, DOI 10.1016/S0306-3623(01)00111-2
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x
   Presta LG, 1997, CANCER RES, V57, P4593
   Red-Horse K, 2007, DEV CELL, V12, P181, DOI 10.1016/j.devcel.2007.01.013
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SENGER DR, 1990, CANCER RES, V50, P1774
   Shojaei F, 2008, TRENDS CELL BIOL, V18, P372, DOI 10.1016/j.tcb.2008.06.003
   Shojaei F, 2008, P NATL ACAD SCI USA, V105, P2640, DOI 10.1073/pnas.0712185105
   Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Smith JK, 2004, ONCOL RES, V14, P175, DOI 10.3727/000000003772462298
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   Tejada ML, 2006, CLIN CANCER RES, V12, P2676, DOI 10.1158/1078-0432.CCR-05-1770
   Yu LL, 2008, INVEST OPHTH VIS SCI, V49, P522, DOI 10.1167/iovs.07-1175
NR 94
TC 221
Z9 256
U1 0
U2 23
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
EI 1952-4005
J9 EUR CYTOKINE NETW
JI Eur. Cytokine Netw.
PD DEC
PY 2009
VL 20
IS 4
BP 158
EP 163
DI 10.1684/ecn.2009.0170
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 540PM
UT WOS:000273347200002
PM 20167554
DA 2022-11-30
ER

EF